PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	SONNEX, C; SCHOLEFIELD, JH; KOCJAN, G; KELLY, G; WHATRUP, C; MINDEL, A; NORTHOVER, JMA				SONNEX, C; SCHOLEFIELD, JH; KOCJAN, G; KELLY, G; WHATRUP, C; MINDEL, A; NORTHOVER, JMA			ANAL HUMAN PAPILLOMAVIRUS INFECTION IN HETEROSEXUALS WITH GENITAL WARTS - PREVALENCE AND RELATION WITH SEXUAL-BEHAVIOR	BRITISH MEDICAL JOURNAL			English	Article							MEN		UNIV COLL & MIDDLESEX HOSP SCH MED,ACAD DEPT GENITOURINARY MED,LONDON W1,ENGLAND; ST MARKS HOSP,IMPERIAL CANC RES FUND,COLORECTAL CANC UNIT,LONDON EC1,ENGLAND; UNIV COLL & MIDDLESEX HOSP SCH MED,DEPT HISTOPATHOL,LONDON W1,ENGLAND									FRAZER IH, 1986, LANCET, V2, P657; GOORNEY BP, 1987, GENITOURIN MED, V63, P216; ORIEL JD, 1971, BRIT J VENER DIS, V47, P1; ORIEL JD, 1971, BR J VENER DIS, V47, P273; SONNEX C, 1991, GENITOURIN MED, V67, P21	5	30	32	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1991	303	6812					1243	1243		10.1136/bmj.303.6812.1243	http://dx.doi.org/10.1136/bmj.303.6812.1243			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GQ342	1747648	Bronze, Green Published			2022-12-01	WOS:A1991GQ34200027
J	THORNTON, JG; ONWUDE, JL				THORNTON, JG; ONWUDE, JL			PREECLAMPSIA - DISCORDANCE AMONG IDENTICAL-TWINS	BRITISH MEDICAL JOURNAL			English	Article							PREECLAMPSIA; GENETICS				THORNTON, JG (corresponding author), ST JAMES UNIV HOSP,DEPT OBSTET & GYNAECOL,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND.		ONWUDE, JOSEPH LOZE/ABA-4929-2021; Thornton, Jim/B-8336-2008; ONWUDE, JOSEPH Loze/AAH-2903-2022; ONWUDE, JOSEPH Loze/AFM-0527-2022; ONWUDE, JOSEPH LOZE/ABF-7876-2021	Thornton, Jim/0000-0001-9764-6876; 				ARNGRIMSSON R, 1990, BRIT J OBSTET GYNAEC, V97, P762, DOI 10.1111/j.1471-0528.1990.tb02569.x; CHESLEY LC, 1986, BRIT J OBSTET GYNAEC, V93, P898, DOI 10.1111/j.1471-0528.1986.tb08006.x; KASRIEL J, 1976, J BIOSOC SCI, V8, P263, DOI 10.1017/S0021932000010737; THOMPSON B, 1988, TWINNING TWINS, P253; THORNTON JG, 1990, LANCET, V336, P1319, DOI 10.1016/0140-6736(90)93004-9	5	65	66	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1991	303	6812					1241	1242		10.1136/bmj.303.6812.1241	http://dx.doi.org/10.1136/bmj.303.6812.1241			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GQ342	1747646	Bronze, Green Published			2022-12-01	WOS:A1991GQ34200025
J	AELONY, Y; KING, R; BOUTIN, C				AELONY, Y; KING, R; BOUTIN, C			THORACOSCOPIC TALC POUDRAGE PLEURODESIS FOR CHRONIC RECURRENT PLEURAL EFFUSIONS	ANNALS OF INTERNAL MEDICINE			English	Article							CORYNEBACTERIUM-PARVUM; SYMPTOMATIC TREATMENT; TETRACYCLINE; MESOTHELIOMA; DIAGNOSIS	Objective: To assess the effectiveness of thoracoscopic talc poudrage for the treatment of chronic pleural effusions. Design: Prospective evaluation. Setting: Kaiser-Permanente Hospital. Patients: Forty-seven consecutive patients with recalcitrant pleural effusions, referred for thoracoscopy. Intervention: Patients received general or local anesthesia; 42 had a 7-mm rigid thoracoscopic examination followed by insufflation of 5 mL of talc. Patients then had chest-tube drainage. Measurements: We recorded clinical characteristics, final diagnosis, procedure-related pain and morbidity, days of hospitalization, patient-reported degree of symptom relief, and chest roentgenographic results at 1, 3, and 12 months. All patients were followed for 16 months or until death. Main Results: Of 39 evaluable patients, all reported prolonged relief of effusion-related dyspnea. Radiographic results confirmed the elimination of pleural effusions in 34 patients (87%), including all 11 with benign conditions and 23 of 28 (82%) with malignancies. Treatment failed in three patients because of entrapped lung and in two patients with mesotheliomas whose effusions recurred more than a year after treatment. No procedure-related mortality or morbidity was found. Ambulatory patients required hospitalization for a mean of 3.9 days (range, 2 to 11 days). Mild pain was reported by some patients. The mean duration of chest-tube drainage was 2.7 days (range, 1 to 9 days). Patients with malignant disease lived an average of 12.4 months (range, 1 to 61 months) after the procedure. Conclusions: Thoracoscopic talc poudrage is an effective pleural sclerosing technique and is relatively painless.	HOP CONCEPTION, F-13386 MARSEILLE 5, FRANCE	Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	AELONY, Y (corresponding author), SO CALIF PERMANENTE MED GRP, DEPT INTERNAL MED, 25825 S VERMONT, HARBOR CITY, CA 90710 USA.							ANTONY VB, 1987, AM REV RESPIR DIS, V135, P775, DOI 10.1164/arrd.1987.135.4.775; BONIFACE E, 1989, REV MAL RESPIR, V6, P133; BOUTIN C, 1981, AM REV RESPIR DIS, V124, P588; Boutin C, 1991, PRACTICAL THORACOSCO; BOUTIN C, 1990, LUNG S, P1113; Boutin C, 1985, REV MAL RESPIR, V2, P374; BOUTIN C, 1985, PLEURA HLTH DISEASE; BRANDT HJ, 1985, ATLAS DIAGNOSTIC THO; CANTO A, 1985, MED CLIN-BARCELONA, V84, P806; CHRETIEN J, 1983, DISEASES PLEURA, P152; DAVIDSON AC, 1988, THORAX, V43, P327, DOI 10.1136/thx.43.4.327; DUNKEL TB, 1986, MINN MED, V69, P717; ELMES PC, 1976, Q J MED, V45, P427; FENTIMAN IS, 1987, CANCER TREAT REV, V14, P107, DOI 10.1016/0305-7372(87)90043-0; Frank W, 1989, Pneumologie, V43, P80; GAENSLER EA, 1964, NEW ENGL J MED, V270, P1319, DOI 10.1056/NEJM196406182702501; Gust R, 1989, Pneumologie, V43, P85; HAUPT GJ, 1960, JAMA-J AM MED ASSOC, V73, P173; HAUSHEER FH, 1985, SEMIN ONCOL, V12, P54; JONES DP, 1989, CHEST S, V96, pS276; LADJIMI S, 1989, REV MAL RESPIR, V6, P147; LANDVATER L, 1988, CHEST, V93, P1196, DOI 10.1378/chest.93.6.1196; LANGE P, 1988, THORAX, V43, P559, DOI 10.1136/thx.43.7.559; LEAHY BC, 1985, EUR J RESPIR DIS, V66, P50; LIGHT RW, 1972, ANN INTERN MED, V77, P507, DOI 10.7326/0003-4819-77-4-507; LIGHT RW, 1983, PLEURAL DISEASES, P84; LIGHT RW, 1983, PLEURAL DISEASES, P86; LIGHT RW, 1983, PLEURAL DISEASES, P77; MARTINI N, 1975, CANCER, V35, P734, DOI 10.1002/1097-0142(197503)35:3<734::AID-CNCR2820350328>3.0.CO;2-N; MUIR J F, 1987, American Review of Respiratory Disease, V135, pA244; NG TK, 1984, MED J AUSTRALIA, V140, P452, DOI 10.5694/j.1326-5377.1984.tb108157.x; RINALDO JE, 1983, J THORAC CARDIOV SUR, V85, P523; ROSSI GA, 1987, AM REV RESPIR DIS, V135, P885, DOI 10.1164/arrd.1987.135.4.885; SHERMAN S, 1988, CHEST, V93, P533, DOI 10.1378/chest.93.3.533; SHERMAN S, 1987, SOUTH MED J, V80, P716, DOI 10.1097/00007611-198706000-00013; TSANG V, 1990, THORAX, V45, P369, DOI 10.1136/thx.45.5.369; TZENG E, 1990, CHEST, V98, P890, DOI 10.1378/chest.98.4.890; Viskum K, 1981, Poumon Coeur, V37, P25; WEISSBERG D, 1980, ANN THORAC SURG, V29, P205, DOI 10.1016/S0003-4975(10)61868-1; Weissberg D, 1981, Poumon Coeur, V37, P291; WOOTEN S A, 1987, American Review of Respiratory Disease, V135, pA245	41	74	75	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1991	115	10					778	782		10.7326/0003-4819-115-10-778	http://dx.doi.org/10.7326/0003-4819-115-10-778			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP800	1929026				2022-12-01	WOS:A1991GP80000006
J	ALIPERTI, G; EDMUNDOWICZ, SA; SOPER, NJ; ASHLEY, SW				ALIPERTI, G; EDMUNDOWICZ, SA; SOPER, NJ; ASHLEY, SW			COMBINED ENDOSCOPIC SPHINCTEROTOMY AND LAPAROSCOPIC CHOLECYSTECTOMY IN PATIENTS WITH CHOLEDOCHOLITHIASIS AND CHOLECYSTOLITHIASIS	ANNALS OF INTERNAL MEDICINE			English	Note							COMMON BILE-DUCT; EXPLORATION	Eighteen symptomatic patients with cholecystolithiasis and choledocholithiasis were prospectively evaluated to assess the efficacy of endoscopic sphincterotomy combined with laparoscopic cholecystectomy as definitive management of simultaneous gallbladder and bile duct stones. The endoscopic management of bile duct stones was successful in all 18 patients. Seventeen patients later had laparoscopic cholecystectomy, and one required conventional cholecystectomy (5.6%; 95% CI, 0.1% to 27.3%). Mean (+/- SE) duration of postoperative hospitalization (1.6 +/- 1.0 days), total hospital stay (5.0 +/- 3.5 days), and length of convalescence (9.3 +/- 6.6 days) were significantly reduced (P < 0.01 for each) compared with similar measures from a group of 12 consecutive patients treated with conventional cholecystectomy and bile duct exploration (8.3 +/- 4.3, 14.1 +/- 12.6, and 41.7 +/- 10.9 days, respectively). Outcomes in our patients compared favorably with those in patients described in published series of cholecystectomy and bile duct exploration. We found that endoscopic sphincterotomy combined with laparoscopic cholecystectomy is effective in the treatment of patients with simultaneous gallbladder and bile duct stones. Length of hospital stay and degree of postoperative disability were significantly reduced among our patients compared with those having standard cholecystectomy and bile duct exploration.			ALIPERTI, G (corresponding author), WASHINGTON UNIV, SCH MED, GASTROENTEROL CLIN SECT, 1 BARNES HOSP PLAZA, ST LOUIS, MO 63110 USA.			Edmundowicz, Steven/0000-0002-6541-3485				COTTON PB, 1991, GASTROINTEST ENDOSC, V37, P94, DOI 10.1016/S0016-5107(91)70637-8; CRANLEY B, 1980, BRIT J SURG, V67, P869, DOI 10.1002/bjs.1800671210; FRAZEE RC, 1989, SURG GYNECOL OBSTET, V168, P513; NORRBY S, 1988, ACTA CHIR SCAND, V154, P113; REDDICK E J, 1989, Surgical Endoscopy, V3, P131, DOI 10.1007/BF00591357; SHERIDAN WG, 1987, BRIT J SURG, V74, P1095, DOI 10.1002/bjs.1800741208; SIVAK MV, 1989, AM J SURG, V158, P228, DOI 10.1016/0002-9610(89)90256-0; SMITH PC, IN PRESS SURGERY; SOPER NJ, 1991, SURGERY, V109, P342; VELLACOTT KD, 1979, BRIT J SURG, V66, P389, DOI 10.1002/bjs.1800660605	10	60	60	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1991	115	10					783	785		10.7326/0003-4819-115-10-783	http://dx.doi.org/10.7326/0003-4819-115-10-783			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP800	1834001				2022-12-01	WOS:A1991GP80000007
J	ANDERSON, MP; BERGER, HA; RICH, DP; GREGORY, RJ; SMITH, AE; WELSH, MJ				ANDERSON, MP; BERGER, HA; RICH, DP; GREGORY, RJ; SMITH, AE; WELSH, MJ			NUCLEOSIDE TRIPHOSPHATES ARE REQUIRED TO OPEN THE CFTR CHLORIDE CHANNEL	CELL			English	Article							CYSTIC-FIBROSIS GENE; TRANSMEMBRANE CONDUCTANCE REGULATOR; DEPENDENT PROTEIN-KINASE; NUCLEOTIDE-BINDING FOLD; ADENYLATE KINASE; ATP-BINDING; MULTIDRUG RESISTANCE; ESCHERICHIA-COLI; TYROSINE KINASE; BETA-SUBUNIT	The CFTR Cl- channel contains two predicted nucleotide-binding domains (NBD1 and NBD2); therefore, we examined the effect of ATP on channel activity. Once phosphorylated by cAMP-dependent protein kinase (PKA), channels required cytosolic ATP to open. Activation occurred by a PKA-independent mechanism. ATP-gamma-S substituted for ATP in PKA phosphorylation, but it did not open the channel. Several hydrolyzable nucleotides (ATP > GTP > ITP almost-equal-to UTP > CTP) reversibly activated phosphorylated channels, but nonhydrolyzable analogs and Mg2+-free ATP did not. Studies of CFTR mutants indicated that ATP controls channel activity independent of the R domain and suggested that hydrolysis of ATP by NBD1 may be sufficient for channel opening. The finding that nucleoside triphosphates regulate CFTR begins to explain why CF-associated mutations in the NBDs block Cl- channel function.	GENZYME CORP,FRAMINGHAM,MA 01701; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Sanofi-Aventis; Genzyme Corporation; University of Iowa	ANDERSON, MP (corresponding author), UNIV IOWA,COLL MED,DEPT INTERNAL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242, USA.			Anderson, Matthew/0000-0003-4602-1811; Welsh, Michael/0000-0002-1646-6206; Berger, Herbert/0000-0003-4383-2643				AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; AMES GF, 1989, J BIOL CHEM, V264, P3998; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHENG HC, 1986, J BIOL CHEM, V261, P989; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, IN PRESS CELL; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; CORNWELL MM, 1987, FASEB J, V1, P51, DOI 10.1096/fasebj.1.1.2886389; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FLOCKHART DA, 1984, EUR J BIOCHEM, V140, P289, DOI 10.1111/j.1432-1033.1984.tb08100.x; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FRY DC, 1985, BIOCHEMISTRY-US, V24, P4680, DOI 10.1021/bi00338a030; FRY DC, 1988, BIOCHEMISTRY-US, V27, P3588, DOI 10.1021/bi00410a009; GLYNN IM, 1971, PHYSIOLOGY, V218, P239; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; Innis M. A., 1990, PCR PROTOCOLS GUIDE, P3; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KRUG F, 1973, J BIOL CHEM S, V24, P1203; LEMAIRE S, 1974, CAN J BIOCHEM CELL B, V52, P137, DOI 10.1139/o74-021; MACKETT M, 1985, DNA CLONING PRACTICA, P191; MANDEL KG, 1986, AM J PHYSIOL, V250, pC486, DOI 10.1152/ajpcell.1986.250.3.C486; MOOS C, 1960, ARCH BIOCHEM BIOPHYS, V88, P183, DOI 10.1016/0003-9861(60)90220-4; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; NAKANO H, 1987, J ANTIBIOT, V40, P706, DOI 10.7164/antibiotics.40.706; PAI EF, 1977, J MOL BIOL, V114, P37, DOI 10.1016/0022-2836(77)90281-9; PARSONAGE D, 1988, J BIOL CHEM, V263, P4740; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; QUINTON PM, 1990, NATURE, V347, P226, DOI 10.1038/347226a0; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; REINSTEIN J, 1988, BIOCHEMISTRY-US, V27, P4712, DOI 10.1021/bi00413a020; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SASAKI N, 1985, J BIOL CHEM, V260, P9793; SCHULTZ SG, 1981, AM J PHYSIOL, V241, pF579, DOI 10.1152/ajprenal.1981.241.6.F579; SECRIST JP, 1990, J BIOL CHEM, V265, P20394; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YANAGIHARA N, 1991, J NEUROCHEM, V56, P294, DOI 10.1111/j.1471-4159.1991.tb02595.x; YOUNT RG, 1971, BIOCHEMISTRY-US, V10, P2490, DOI 10.1021/bi00789a010	64	484	493	1	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1991	67	4					775	784		10.1016/0092-8674(91)90072-7	http://dx.doi.org/10.1016/0092-8674(91)90072-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GQ407	1718606				2022-12-01	WOS:A1991GQ40700014
J	BUCHSBAUM, DG; BUCHANAN, RG; CENTOR, RM; SCHNOLL, SH; LAWTON, MJ				BUCHSBAUM, DG; BUCHANAN, RG; CENTOR, RM; SCHNOLL, SH; LAWTON, MJ			SCREENING FOR ALCOHOL-ABUSE USING CAGE SCORES AND LIKELIHOOD RATIOS	ANNALS OF INTERNAL MEDICINE			English	Article							HEALTH-MAINTENANCE-ORGANIZATION; DIAGNOSTIC INTERVIEW SCHEDULE; GENERAL-PRACTICE; QUESTIONNAIRE; RECOGNITION; PREVALENCE; CONSUMPTION; POPULATION; VALIDATION; SERVICES	Objective: To assess the performance of the CAGE (acronym referring to four questions, see below) questionnaire in discriminating between medicine outpatients with and without an alcohol abuse or dependence disorder. Design: A cross-sectional design of a sample of consecutive patients who received both the alcohol module of the diagnostic interview schedule and the CAGE (Cut down, Annoyed, Guilty, Eye-opener) screening questionnaire. Setting: The outpatient medical practice of an urban university teaching hospital. Patients: All patients 18 years or older who signed a consent form approved by the university's institutional review board. Measurement: Calculation of the sensitivity, specificity, receiver operating characteristic (ROC) curve, and likelihood ratio for CAGE Scores of 0 to 4. Results: Thirty-six percent of the sample group met criteria for a history of alcohol abuse or dependence. A CAGE score of 2 or more was associated with a sensitivitY and specificity of 74% and 91%. The calculated area under the ROC curve was 0.89, whereas the likelihood ratios for CAGE scores of 0 to 4 were 0.14, 1.5, 4.5, 13, and 100, respectively. These ratios were associated with posterior probabilities for an abuse or dependence disorder of 7%, 46%, 72%, 88%, and 98%, respectively. Conclusion: Clinicians can improve their ability to estimate a patient's risk for an alcohol abuse or dependence disorder using likelihood ratios for CAGE scores.			BUCHSBAUM, DG (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, BOX 102, RICHMOND, VA 23298 USA.							BERESFORD TP, 1988, PREV MED, V17, P653, DOI 10.1016/0091-7435(88)90058-8; BUCHSBAUM DG, 1991, ALCOHOL ALCOHOLISM, V26, P215, DOI 10.1093/oxfordjournals.alcalc.a045103; BUSH B, 1987, AM J MED, V82, P231, DOI 10.1016/0002-9343(87)90061-1; CENTOR RM, 1989, 13TH P ANN S COMP AP; CLEARY PD, 1988, AM J MED, V85, P466; COULEHAN JL, 1987, ARCH INTERN MED, V147, P349, DOI 10.1001/archinte.147.2.349; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; FAGAN TJ, 1975, NEW ENGL J MED, V293, P257; Ford D E, 1990, J Gen Intern Med, V5, pS37, DOI 10.1007/BF02600839; GART JJ, 1988, BIOMETRICS, V44, P323, DOI 10.2307/2531848; GILL JS, 1986, NEW ENGL J MED, V315, P1041, DOI 10.1056/NEJM198610233151701; HELZER JE, 1987, ARCH GEN PSYCHIAT, V44, P1069; HOLDER HD, 1986, JAMA-J AM MED ASSOC, V256, P1456, DOI 10.1001/jama.256.11.1456; HSIAO JK, 1989, ARCH GEN PSYCHIAT, V46, P664; KING M, 1986, PSYCHOL MED, V16, P213, DOI 10.1017/S0033291700002658; KLATSKY AL, 1981, ANN INTERN MED, V95, P139, DOI 10.7326/0003-4819-95-2-139; KOOPMAN PAR, 1984, BIOMETRICS, V40, P513, DOI 10.2307/2531405; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; MOORE RD, 1989, JAMA-J AM MED ASSOC, V261, P403, DOI 10.1001/jama.261.3.403; PAUKER SG, 1980, NEW ENGL J MED, V302, P1109, DOI 10.1056/NEJM198005153022003; POSES RM, 1986, ANN INTERN MED, V105, P586, DOI 10.7326/0003-4819-105-4-586; PUDDEY IB, 1987, LANCET, V1, P647; REIFF S, 1981, ALCOHOL CLIN EXP RES, V5, P559, DOI 10.1111/j.1530-0277.1981.tb05361.x; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; ROBINSON KS, 1987, CLIN RES, V35, pA92; ROGHMANN KJ, 1981, J STUD ALCOHOL, V42, P312, DOI 10.15288/jsa.1981.42.312; SCHWARTZ WB, 1981, NEW ENGL J MED, V305, P917, DOI 10.1056/NEJM198110153051604; SKINNER HA, 1984, ANN INTERN MED, V101, P847, DOI 10.7326/0003-4819-101-6-847; WALLACE P, 1985, BRIT MED J, V290, P1949, DOI 10.1136/bmj.290.6486.1949; 1987, DIAGNOSTIC STATISTIC	30	264	264	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1991	115	10					774	777		10.7326/0003-4819-115-10-774	http://dx.doi.org/10.7326/0003-4819-115-10-774			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP800	1929025				2022-12-01	WOS:A1991GP80000005
J	DESBOIS, C; AUBERT, D; LEGRAND, C; PAIN, B; SAMARUT, J				DESBOIS, C; AUBERT, D; LEGRAND, C; PAIN, B; SAMARUT, J			A NOVEL MECHANISM OF ACTION FOR V-ERBA - ABROGATION OF THE INACTIVATION OF TRANSCRIPTION FACTOR AP-1 BY RETINOIC ACID AND THYROID-HORMONE RECEPTORS	CELL			English	Article							RAT GROWTH-HORMONE; NEGATIVE REGULATION; RESPONSIVE ELEMENT; C-ERBA; GLUCOCORTICOID RECEPTOR; RETROVIRAL VECTORS; GENE-TRANSCRIPTION; FUNCTIONAL DOMAINS; JUN; EXPRESSION	Ligand-activated retinoic acid receptor-alpha (RAR-alpha) and c-ErbA-alpha repress the AP-1-mediated transcriptional activation of the interstitial collagenase gene promoter by specifically decreasing the activity of the AP-1 transcription factor. On the other hand, the v-ErbA oncoprotein fails to repress the AP-1 activity and acts as a dominant negative oncoprotein by overcoming the repression of the AP-1 activity induced by RAR-alpha and c-ErbA-alpha. This maintenance by v-ErbA of a fully active AP-1 complex is correlated with the abrogation by this same oncogene product of the growth-inhibitory response of chicken embryo fibroblasts to retinoic acid treatment. This new mechanism of action of v-ErbA together with its previously discovered dominant repressor effect on transcription of thyroid hormone-activated target genes may explain the contribution of the v-erbA oncogene to sarcomatogenic and leukemogenic transformation.	ECOLE NORMALE SUPER LYON,INRA,BIOL MOLEC & CELLULAIRE LAB,CNRS,UMR49,F-69364 LYONS 07,FRANCE	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); INRAE	DESBOIS, C (corresponding author), UNIV CLAUDE BERNARD LYON 1,FAC MED ALEXIS CARREL,CNRS,UMR30,F-69372 LYONS 08,FRANCE.		Samarut, Jacques/AAD-2587-2019; Aubert, dominique/AAH-5854-2019; Morris, Christelle/M-8168-2014; Pain, Bertrand/A-7686-2015	Morris, Christelle/0000-0003-1575-4609; Aubert, Denise/0000-0002-1442-3384; Pain, Bertrand/0000-0002-1210-8444				AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; CLARK SD, 1987, J CLIN INVEST, V80, P1280, DOI 10.1172/JCI113203; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DESBOIS C, 1991, IN PRESS ONCOGENE; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DIAZ JJ, 1989, ONCOL RES, V1, P163; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1988, MOL ENDOCRINOL, V2, P902, DOI 10.1210/mend-2-10-902; FRISCH SM, 1987, P NATL ACAD SCI USA, V84, P2600, DOI 10.1073/pnas.84.9.2600; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GREEN S, 1986, NATURE, V324, P615, DOI 10.1038/324615a0; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; JANSSON M, 1987, ONCOGENE, V1, P167; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KOENIG RJ, 1987, P NATL ACAD SCI USA, V84, P5670, DOI 10.1073/pnas.84.16.5670; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; Oppenheimer J. H., 1983, MOL BASIS THYROID HO; PAIN B, 1990, New Biologist, V2, P284; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PRIVALSKY ML, 1988, MOL CELL BIOL, V8, P4510, DOI 10.1128/MCB.8.10.4510; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SAUS J, 1988, J BIOL CHEM, V263, P6742; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SPORN MB, 1991, MOL ENDOCRINOL, V5, P3, DOI 10.1210/mend-5-1-3; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; URIER G, 1989, EMBO J, V8, P1447, DOI 10.1002/j.1460-2075.1989.tb03527.x; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	58	161	163	1	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1991	67	4					731	740		10.1016/0092-8674(91)90068-A	http://dx.doi.org/10.1016/0092-8674(91)90068-A			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GQ407	1682056				2022-12-01	WOS:A1991GQ40700010
J	EPSTEIN, DJ; VEKEMANS, M; GROS, P				EPSTEIN, DJ; VEKEMANS, M; GROS, P			SPLOTCH (SP2H), A MUTATION AFFECTING DEVELOPMENT OF THE MOUSE NEURAL-TUBE, SHOWS A DELETION WITHIN THE PAIRED HOMEODOMAIN OF PAX-3	CELL			English	Article							DEVELOPING EXCRETORY SYSTEM; CONSERVED LINKAGE; GENES; BOX; EXPRESSION; DROSOPHILA; DOMAIN; MUTANT	The molecular basis of the mouse mutation splotch (Sp), which is associated with spina bifida and exencephaly, was analyzed at three of its alleles, Sp, Sp2H, and Sp(r). We mapped the paired box gene Pax-3 within the Inha to Akp3 interval, near or at the Sp locus on chromosome 1, and found Pax-3 to be deleted in heterozygous Sp(r)/+ mice. Analysis of genomic DNA and cDNA clones constructed from Sp2H/Sp2H embryos identified a deletion of 32 nucleotides in the Pax-3 mRNA transcript and gene. This deletion maps within the paired homeodomain of PAX-3 and is predicted to create a truncated protein as a result of a newly created termination codon at the deletion breakpoint. Our study provides evidence for a causal link between deletion of the paired homeodomain of Pax-3 and the Sp2H mutation, and infers that Pax-3 plays a key role in normal neural development.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL H3G 1Y6,QUEBEC,CANADA	McGill University	EPSTEIN, DJ (corresponding author), MCGILL UNIV,DEPT BIOL,MONTREAL H3G 1Y6,QUEBEC,CANADA.							ARIAS S, 1978, CYTOGENET CELL GENET, V22, P291, DOI 10.1159/000130956; ASHER JH, 1990, J MED GENET, V27, P618, DOI 10.1136/jmg.27.10.618; ASHER JH, 1991, AM J HUM GENET, V48, P43; AUERBACH R, 1954, J EXP ZOOL, V127, P305, DOI 10.1002/jez.1401270206; BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; Beechey CV, 1986, MOUSE NEWS LETT, V75, P28; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BOPP D, 1989, EMBO J, V8, P3447, DOI 10.1002/j.1460-2075.1989.tb08509.x; BURRI M, 1989, EMBO J, V8, P1183, DOI 10.1002/j.1460-2075.1989.tb03490.x; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COPP AJ, 1990, PROG NEUROBIOL, V35, P363, DOI 10.1016/0301-0082(90)90037-H; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; DICKIE MM, 1964, J HERED, V55, P97, DOI 10.1093/oxfordjournals.jhered.a107317; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; Edmonds L D, 1990, MMWR CDC Surveill Summ, V39, P19; EPSTEIN DJ, 1991, GENOMICS, V10, P89, DOI 10.1016/0888-7543(91)90488-Z; EVANS EP, 1988, MOUSE NEWS LETT, V81, P66; FRANZ T, 1990, ACTA ANAT, V138, P246; FRANZ T, 1989, ANAT EMBRYOL, V1806, P4577; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HIRSCH MR, 1990, MOL CELL BIOL, V10, P1959, DOI 10.1128/MCB.10.5.1959; ISHIKIRIYAMA S, 1989, AM J MED GENET, V33, P505, DOI 10.1002/ajmg.1320330419; JOSTES B, 1990, MECH DEVELOP, V33, P27, DOI 10.1016/0925-4773(90)90132-6; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; Le Douarin N, 1980, Curr Top Dev Biol, V16, P31; MALO D, 1991, GENOMICS, V10, P356, DOI 10.1016/0888-7543(91)90320-E; MALO D, 1990, GENOMICS, V6, P697, DOI 10.1016/0888-7543(90)90507-Q; MCKUSICK VA, 1990, MENDELIAN INHERITANC, P976; MOASE CE, 1990, TERATOLOGY, V42, P171, DOI 10.1002/tera.1420420208; MOASE CE, 1989, TERATOLOGY, V40, P67, DOI 10.1002/tera.1420400109; MOASE CE, 1991, IN PRESS DEVELOPMENT; MORRISSEY D, 1991, GENE DEV, V5, P1684, DOI 10.1101/gad.5.9.1684; NORNES HO, 1990, DEVELOPMENT, V109, P797; OLSON E, 1990, GENOMICS, V8, P427, DOI 10.1016/0888-7543(90)90028-S; PLACHOV D, 1990, DEVELOPMENT, V110, P643; RUSSELL WL, 1947, GENETICS, V32, P107; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLEIF R, 1988, SCIENCE, V241, P1182, DOI 10.1126/science.2842864; SCHURR E, 1990, GENOMICS, V8, P477, DOI 10.1016/0888-7543(90)90034-R; SKOW LC, 1988, BIOCHEM GENET, V26, P557, DOI 10.1007/BF02399601; SNELL GD, 1954, HEREDITY, V8, P271, DOI 10.1038/hdy.1954.23; STEEL KP, 1989, DEVELOPMENT, V107, P453; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594	46	620	628	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1991	67	4					767	774		10.1016/0092-8674(91)90071-6	http://dx.doi.org/10.1016/0092-8674(91)90071-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GQ407	1682057				2022-12-01	WOS:A1991GQ40700013
J	EYSTER, ME; ALTER, HJ; ALEDORT, LM; QUAN, S; HATZAKIS, A; GOEDERT, JJ				EYSTER, ME; ALTER, HJ; ALEDORT, LM; QUAN, S; HATZAKIS, A; GOEDERT, JJ			HETEROSEXUAL COTRANSMISSION OF HEPATITIS-C VIRUS (HCV) AND HUMAN-IMMUNODEFICIENCY-VIRUS (HIV)	ANNALS OF INTERNAL MEDICINE			English	Article							NON-B-HEPATITIS; NON-A; HEPATOCELLULAR-CARCINOMA; III ANTIBODIES; LIVER-DISEASE; BELLE-GLADE; HEMOPHILIACS; PREVALENCE; AIDS; FLORIDA	Objectives: To determine the prevalence of antibodies to hepatitis C virus (HCV) in female sexual partners of multitransfused men with hemophilia and to compare the frequency of transmission of HCV and human immunodeficiency virus (HIV). Study Design: Cross-sectional measurement of HCV and HIV antibodies. Setting: Ten hemophilia treatment centers. Patients: A total of 234 female sexual partners of 231 multitransfused men with hemophilia. Measurements and Main Results: The prevalence of antibodies to HCV (anti-HCV) among female sexual partners of HCV-Positive men was 5 of 194 (2.6%). Anti-HIV prevalence among female sexual partners of HIV-positive men was 25 of 196 (12.8%). Five (3%) of the 164 female sexual partners of HIV-positive/HCV-positive men were infected with HCV compared with none of the 30 female sexual partners of HIV-negative/HCV-positive men. Twenty-one (13%) of the 164 female sexual partners of HIV-positive/HCV-positive men were infected with HIV compared with 4 (13%) of 32 female sexual partners of HIV-positive/HCV-indeterminate men. The co-infected men were five times more likely to transmit both viruses than would be expected by chance (P = 0.01). When a single virus was transmitted to a female sexual partner, it was more often HIV than HCV (18 of 164 compared with 2 of 164, P = 0.001; odds ratio, 8.5; 95% Cl, 2.2 to 33.1). Conclusions: The higher prevalence of HCV in female sexual partners of men with hemophilia than in blood donor and other low-risk groups suggests that there is a low level of sexual transmission. Male to female sexual transmission of HCV is less efficient than that of HIV. The frequency of HCV transmission to sexual partners is five times higher when HIV is also transmitted, suggesting that HIV may be a cofactor for the sexual transmission of HCV.			EYSTER, ME (corresponding author), PENN STATE UNIV, MILTON S HERSHEY MED CTR, DEPT MED, DIV HEMATOL, BOX 850, HERSHEY, PA 17033 USA.			, M. Elaine Eyster/0000-0001-8248-6793	NCI NIH HHS [N01-CP-85649] Funding Source: Medline; DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP085649] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics)		ALEDORT LM, 1985, BLOOD, V66, P367; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1975, LANCET, V2, P838, DOI 10.1016/S0140-6736(75)90234-2; ALTER HJ, 1991, IN PRESS 1990 INT S; ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; BIANCHI L, 1987, SEMIN LIVER DIS, V7, P203, DOI 10.1055/s-2008-1040577; BRUIX J, 1989, LANCET, V2, P1004; CASTRO KG, 1988, SCIENCE, V239, P193, DOI 10.1126/science.3336781; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COLOMBO M, 1989, LANCET, V2, P1006; DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P439; ESTEBAN JI, 1989, LANCET, V2, P294; EVATT BL, 1985, NEW ENGL J MED, V312, P483, DOI 10.1056/NEJM198502213120805; EVERHART JE, 1990, ANN INTERN MED, V112, P544, DOI 10.7326/0003-4819-112-7-544; EYSTER ME, 1985, JAMA-J AM MED ASSOC, V253, P2219, DOI 10.1001/jama.253.15.2219; GIOVANNINI M, 1990, LANCET, V335, P1166, DOI 10.1016/0140-6736(90)91174-9; GOEDERT JJ, 1987, AIDS RES HUM RETROV, V3, P355, DOI 10.1089/aid.1987.3.355; GOEDERT JJ, 1988, 4 INT C AIDS STOCKH, P264; KITCHEN LW, 1984, NATURE, V312, P367, DOI 10.1038/312367a0; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MAKRIS M, 1990, LANCET, V335, P1117, DOI 10.1016/0140-6736(90)91124-S; MELBYE M, 1990, BRIT MED J, V301, P210, DOI 10.1136/bmj.301.6745.210; RAGNI MV, 1986, BLOOD, V67, P592; ROSENBLUM LS, 1990, J INFECT DIS, V161, P407, DOI 10.1093/infdis/161.3.407; RUMI MG, 1990, ANN INTERN MED, V112, P379, DOI 10.7326/0003-4819-112-5-379; SCHRAMM W, 1989, BLUT, V59, P390, DOI 10.1007/BF00321210; VANDERPOEL CL, 1991, LANCET, V337, P317, DOI 10.1016/0140-6736(91)90942-I; VANDERPOEL CL, 1989, LANCET, V2, P297; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q; 1987, 51 US DEP HLTH HUM S, P19; 1989, 1ST P INT S HEP C VI, P31	32	281	287	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1991	115	10					764	768		10.7326/0003-4819-115-10-764	http://dx.doi.org/10.7326/0003-4819-115-10-764			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP800	1656825				2022-12-01	WOS:A1991GP80000003
J	GRAY, JT; CELANDER, DW; PRICE, CM; CECH, TR				GRAY, JT; CELANDER, DW; PRICE, CM; CECH, TR			CLONING AND EXPRESSION OF GENES FOR THE OXYTRICHA TELOMERE-BINDING PROTEIN - SPECIFIC SUBUNIT INTERACTIONS IN THE TELOMERIC COMPLEX	CELL			English	Article							TERMINAL TRANSFERASE-ACTIVITY; TETRAHYMENA TRANSFER-RNASGLN; SIZED DNA-MOLECULES; MACRONUCLEAR DNA; NUCLEOPROTEIN COMPLEXES; ANTICODON MUTATIONS; CILIATE EVOLUTION; GLUTAMINE CODONS; DRAMATIC EVENTS; 3' TERMINUS	Telomeres of Oxytricha nova macronuclear chromosomes consist of a repeated T4G4 sequence, single-stranded at the 3' terminus, bound by a heterodimeric protein. The cloning of genes for the two polypeptides and their separate expression in E. coli have enabled evaluation of their individual contributions to DNA binding. The 56 kd alpha-subunit binds single-stranded DNA by itself, one polypeptide per T4G4 block; multiple subunits can coat a (T4G4)n multimer. The derived amino acid sequence of alpha does not reveal any known DNA-binding motif, so it appears to represent a novel type of DNA-binding protein. The previously cloned 41 kd beta-subunit does not by itself protect DNA from methylation, but is required along with alpha to recreate the pattern of methylation protection indicative of telomeres in vivo. The unusual ability of the protein to engage in two different interactions with the same telomeric DNA sequence might provide the versatility necessary for diverse telomere functions.			GRAY, JT (corresponding author), UNIV COLORADO, HOWARD HUGHES MED INST, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA.		Gray, John T/D-2916-2016	Gray, John T/0000-0002-1888-4612; PRICE, Carolyn/0000-0002-7865-2303				AGARD DA, 1983, NATURE, V302, P676, DOI 10.1038/302676a0; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; COREN JS, 1991, MOL CELL BIOL, V11, P2282, DOI 10.1128/MCB.11.4.2282; DANCIS BM, 1979, J THEOR BIOL, V78, P211, DOI 10.1016/0022-5193(79)90265-0; DILLON JR, 1985, RECOMBINANT DNA METH; DODD IB, 1990, NUCLEIC ACIDS RES, V18, P5019, DOI 10.1093/nar/18.17.5019; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOTTSCHLING DE, 1984, CELL, V38, P501, DOI 10.1016/0092-8674(84)90505-1; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GRESLIN AF, 1989, P NATL ACAD SCI USA, V86, P6264, DOI 10.1073/pnas.86.16.6264; HANYU N, 1986, EMBO J, V5, P1307, DOI 10.1002/j.1460-2075.1986.tb04360.x; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; HENDERSON ER, 1989, MOL CELL BIOL, V9, P345, DOI 10.1128/MCB.9.1.345; HERRICK G, 1987, GENE DEV, V1, P1047, DOI 10.1101/gad.1.10.1047; HICKE BJ, 1990, P NATL ACAD SCI USA, V87, P1481, DOI 10.1073/pnas.87.4.1481; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAWRENCE CB, 1988, COMPUT APPL BIOSCI, V4, P25; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LIU ZP, 1991, GENE DEV, V5, P49, DOI 10.1101/gad.5.1.49; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; McClintock B, 1942, P NATL ACAD SCI USA, V28, P458, DOI 10.1073/pnas.28.11.458; McClintock B, 1941, GENETICS, V26, P234; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Muller HJ., 1938, COLLECT NET, V13, P181; NIELSEN H, 1986, EMBO J, V5, P2711, DOI 10.1002/j.1460-2075.1986.tb04555.x; PATTERSON B, 1991, CELL, V64, P181, DOI 10.1016/0092-8674(91)90219-O; Prescott D.M., 1983, Modern Cell Biology, V2, P329; PRICE CM, 1987, GENE DEV, V1, P783, DOI 10.1101/gad.1.8.783; PRICE CM, 1989, BIOCHEMISTRY-US, V28, P769, DOI 10.1021/bi00428a053; QUIRES CH, 1988, J BIOL CHEM, V263, P16297; RAGHURAMAN MK, 1989, CELL, V59, P719, DOI 10.1016/0092-8674(89)90018-4; RAGHURAMAN MK, 1989, NUCLEIC ACIDS RES, V17, P4235, DOI 10.1093/nar/17.11.4235; RAGHURAMAN MK, 1990, NUCLEIC ACIDS RES, V18, P4543, DOI 10.1093/nar/18.15.4543; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; SWANTON MT, 1980, CHROMOSOMA, V77, P217, DOI 10.1007/BF00329546; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; WU M, 1986, P NATL ACAD SCI USA, V83, P8674, DOI 10.1073/pnas.83.22.8674; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAHLER AM, 1988, NUCLEIC ACIDS RES, V16, P6953, DOI 10.1093/nar/16.14.6953; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	47	142	161	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 15	1991	67	4					807	814		10.1016/0092-8674(91)90075-A	http://dx.doi.org/10.1016/0092-8674(91)90075-A			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GQ407	1840510				2022-12-01	WOS:A1991GQ40700017
J	GUBERSKI, DL; THOMAS, VA; SHEK, WR; LIKE, AA; HANDLER, ES; ROSSINI, AA; WALLACE, JE; WELSH, RM				GUBERSKI, DL; THOMAS, VA; SHEK, WR; LIKE, AA; HANDLER, ES; ROSSINI, AA; WALLACE, JE; WELSH, RM			INDUCTION OF TYPE-I DIABETES BY KILHAM RAT VIRUS IN DIABETES-RESISTANT BB/WOR RATS	SCIENCE			English	Article							MELLITUS	Type I diabetes mellitus is an autoimmune disease resulting from the interaction of genetic and environmental factors. A virus that was identified serologically as Kilham's rat virus (KRV) was isolated from a spontaneously diabetic rat and reproducibly induced diabetes in naive diabetes-resistant (DR) BB/Wor rats. Viral antigen was not identified in pancreatic islet cells, and beta-cell cytolysis was not observed until after the appearance of lymphocytic insulitis. KRV did not induce diabetes in major histocompatibility complex-concordant and discordant non-BB rats and did not accelerate diabetes in diabetes-prone BB/Wor rats unless the rats had been reconstituted with DR spleen cells. This model of diabetes may provide insight regarding the interagation of viruses and autoimmune disease.	UNIV MASSACHUSETTS, MED CTR, DEPT PATHOL, WORCESTER, MA 01655 USA; UNIV MASSACHUSETTS, MED CTR, DEPT MED, WORCESTER, MA 01655 USA; CHARLES RIVER LAB, WILMINGTON, MA 01887 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019155, N01DK072287, T32DK007302, R37DK019155] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK19155, DK7-2287, DK07302] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BUTLER L, 1988, FRONTIERS DIABETES R, V2, P74; CERRA MA, 1991, LAB ROBOTICS AUTOMAT, V2, P119; COLLE E, 1986, DIABETES, V35, P454, DOI 10.2337/diabetes.35.4.454; FORREST IM, 1969, PEDIATRICS, V44, P445; GAMBLE DR, 1969, BRIT MED J, V3, P627, DOI 10.1136/bmj.3.5671.627; GUBERSKI DL, UNPUB; JACOBY RO, 1987, ARCH VIROL, V95, P251, DOI 10.1007/BF01310784; LEITER EH, 1988, PATHOLOGY ENDOCRINE, P85; LIKE AA, 1991, DIABETES, V40, P259, DOI 10.2337/diabetes.40.2.259; LIKE AA, 1990, AM J PATHOL, V136, P565; LIKE AA, 1986, J IMMUNOL, V136, P3254; LIKE AA, 1985, J IMMUNOL, V134, P1583; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; NAKHOODA AF, 1977, DIABETES, V26, P100, DOI 10.2337/diabetes.26.2.100; OLDSTONE MBA, 1991, CELL, V65, P319, DOI 10.1016/0092-8674(91)90165-U; ROSSINI AA, 1985, ANNU REV IMMUNOL, V3, P289; SIMPSON RW, 1984, SCIENCE, V223, P1425, DOI 10.1126/science.6701529; THOMAS VA, 1991, DIABETES, V40, P255, DOI 10.2337/diabetes.40.2.255; YOON JW, 1979, NEW ENGL J MED, V300, P1173, DOI 10.1056/NEJM197905243002102; YOON JW, 1991, CURR TOP MICROBIOL I, V160, P95	20	160	162	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 15	1991	254	5034					1010	1013		10.1126/science.1658938	http://dx.doi.org/10.1126/science.1658938			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP883	1658938				2022-12-01	WOS:A1991GP88300046
J	HEALD, A; FLEPP, M; CHAVE, JP; MALINVERNI, R; RUTTIMANN, S; GABRIEL, V; RENOLD, C; SUGAR, A; HIRSCHEL, B				HEALD, A; FLEPP, M; CHAVE, JP; MALINVERNI, R; RUTTIMANN, S; GABRIEL, V; RENOLD, C; SUGAR, A; HIRSCHEL, B			TREATMENT FOR CEREBRAL TOXOPLASMOSIS PROTECTS AGAINST PNEUMOCYSTIS-CARINII PNEUMONIA IN PATIENTS WITH AIDS	ANNALS OF INTERNAL MEDICINE			English	Article							PYRIMETHAMINE; CLINDAMYCIN	Objective: To determine whether long-term maintenance treatment for toxoplasmosis protects against Pneumocystis carinii Pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Design: Cohort study. Setting: Switzerland. Patients: A total of 453 patients with human immunodeficiency virus (HIV) entered the Swiss HIV Cohort Study. Ninety-nine patients with cerebral toxoplasmosis but no previous or simultaneous P. carinii pneumonia were compared with 240 patients with AIDS and other severe opportunistic infections (Centers for Disease Control [CDC] stage IVC1 infection other than toxoplasmosis and P. carinii pneumonia) as well as with 114 patients receiving inhaled pentamidine in a study of primary pneumocystis prophylaxis in patients infected with HIV. Measurements: Life-table analysis for P. carinii-free survival. Main Results: Six of 99 (6%) patients with toxoplasmosis, 50 of 240 (21%) patients with other severe opportunistic infections, and 8 of 114 (6%) patients receiving inhaled pentamidine developed P. carinii pneumonia. Life-table analysis showed that the incidence of pneumonia was substantially lower in patients with toxoplasmosis compared with that in patients with other severe opportunistic infections and was similar to the incidence in patients receiving pentamidine as prophylaxis. Analysis of the medication records from patients with toxoplasmosis showed that pyrimethamine and sulfonamides were administered 50% of the time; pyrimethamine and clindamycin, 25% of the time; and pyrimethamine alone, 9.9% of the time but that only one of the six patients with toxoplasmosis who developed P. carinii pneumonia received pyrimethamine and sulfonamides in the month before diagnosis. Conclusion: Patients with cerebral toxoplasmosis have a low risk for subsequently developing P. carinii pneumonia. This decreased risk is probably the result of chronic suppressive treatment with pyrimethamine and sulfonamides.	UNIV GENEVA, DIV MALAD INFECT, 24 RUE MICHELI CREST, CH-1211 GENEVA 4, SWITZERLAND; MED POLIKLIN BERN, BERN, SWITZERLAND; MED POLIKLIN, BASEL, SWITZERLAND; CHU VAUDOIS, CH-1011 LAUSANNE, SWITZERLAND	University of Geneva; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)								CAMPOS N, 1988, COMPUT METH PROG BIO, V27, P223, DOI 10.1016/0169-2607(88)90086-7; GIRARD PM, 1989, LANCET, V1, P1459; HIRSCHEL B, 1991, NEW ENGL J MED, V324, P1079, DOI 10.1056/NEJM199104183241602; HUGHES WT, 1978, J PEDIATR-US, V92, P285, DOI 10.1016/S0022-3476(78)80028-6; JACQUIER P, 1989, CONTRIBUTION ETUDE T; KIRBY HB, 1971, ANN INTERN MED, V75, P505, DOI 10.7326/0003-4819-75-4-505; KOVACS JA, 1989, J INFECT DIS, V160, P312, DOI 10.1093/infdis/160.2.312; QUEENER SF, 1988, ANTIMICROB AGENTS CH, V32, P807, DOI 10.1128/AAC.32.6.807; SANDE MA, 1990, MED MANAGEMENT AIDS, P241; STURCHLER D, 1987, SCHWEIZ MED WSCHR, V117, P161; [No title captured]	11	28	28	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1991	115	10					760	763		10.7326/0003-4819-115-10-760	http://dx.doi.org/10.7326/0003-4819-115-10-760			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP800	1929023				2022-12-01	WOS:A1991GP80000002
J	HO, PS; KAGAWA, TF; TSENG, K; SCHROTH, GP; ZHOU, GW				HO, PS; KAGAWA, TF; TSENG, K; SCHROTH, GP; ZHOU, GW			PREDICTION OF A CRYSTALLIZATION PATHWAY FOR Z-DNA HEXANUCLEOTIDES	SCIENCE			English	Article							CRYSTAL-STRUCTURE; BASE-PAIRS; MOLECULAR-STRUCTURE; B-DNA; TRANSITION; FRAGMENT	Crystallization of macromolecules for structural studies has long been a hit-or-miss process. The crystallization of hexanucleotides as Z-DNA was studied, and it was shown that the cation concentration for crystal formation could be predicted from solvation free energy (SFE) calculations. Solution studies on the conformation and solubilities of the hexanucleotides showed that a critical concentration of the DNA in the Z-conformation must be present in solution to effect crystallization. The SFE calculations therefore predict the propensity of the hexanucleotides to adopt the left-handed conformation and the driving force required to reach this critical concentration relative to the intrinsic solubility of Z-DNA for crystallization.			HO, PS (corresponding author), OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331, USA.		Ho, Pui/AAF-8838-2020; Ho, Pui S/F-6186-2014	Ho, Pui/0000-0002-8082-4311; Ho, Pui S/0000-0002-8082-4311				COLL M, 1988, NUCLEIC ACIDS RES, V16, P8695, DOI 10.1093/nar/16.17.8695; COLL M, 1986, J BIOMOL STRUCT DYN, V4, P157, DOI 10.1080/07391102.1986.10506337; FUJII S, 1982, NUCLEIC ACIDS RES, V10, P7879, DOI 10.1093/nar/10.23.7879; HO PS, 1988, J PHYS CHEM-US, V92, P939, DOI 10.1021/j100315a017; JOVIN TM, 1987, ANNU REV PHYS CHEM, V38, P521, DOI 10.1146/annurev.physchem.38.1.521; KAGAWA TF, 1989, BIOCHEMISTRY-US, V28, P6642, DOI 10.1021/bi00442a017; Tseng K. T., UNPUB; WANG AHJ, 1979, NATURE, V282, P680, DOI 10.1038/282680a0; WANG AHJ, 1984, CELL, V37, P321, DOI 10.1016/0092-8674(84)90328-3; ZHOU GW, 1990, BIOCHEMISTRY-US, V29, P7229, DOI 10.1021/bi00483a010	10	12	12	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1991	254	5034					1003	1006		10.1126/science.1948069	http://dx.doi.org/10.1126/science.1948069			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP883	1948069				2022-12-01	WOS:A1991GP88300044
J	JORGENSEN, WL				JORGENSEN, WL			RUSTING OF THE LOCK AND KEY MODEL FOR PROTEIN-LIGAND BINDING	SCIENCE			English	Editorial Material							3-DIMENSIONAL STRUCTURE; COMPLEX; ANTIBODY; RESOLUTION; ANTIGEN; PEPTIDE				JORGENSEN, WL (corresponding author), YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511, USA.		/AAW-1187-2021					AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BENNETT WS, 1984, CRC CR REV BIOCH MOL, V15, P291, DOI 10.3109/10409238409117796; BLOW DM, 1976, ACCOUNTS CHEM RES, V9, P145, DOI 10.1021/ar50100a004; COLMAN PM, 1987, NATURE, V326, P358, DOI 10.1038/326358a0; CRUMPTON MJ, 1966, BIOCHEM J, V100, P223, DOI 10.1042/bj1000223; HUBBARD SJ, 1991, J MOL BIOL, V220, P507, DOI 10.1016/0022-2836(91)90027-4; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; KIM PS, 1982, J MOL BIOL, V162, P187, DOI 10.1016/0022-2836(82)90168-1; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; ROSEN MK, 1990, SCIENCE, V248, P863, DOI 10.1126/science.1693013; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; VANDUYNE GD, 1991, J AM CHEM SOC, V113, P7433, DOI 10.1021/ja00019a057; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WEBER C, 1991, SCIENCE, V252, P6574; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722	16	178	186	2	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1991	254	5034					954	955		10.1126/science.1719636	http://dx.doi.org/10.1126/science.1719636			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP883	1719636				2022-12-01	WOS:A1991GP88300031
J	LIN, HY; HARRIS, TL; FLANNERY, MS; ARUFFO, A; KAJI, EH; GORN, A; KOLAKOWSKI, LF; LODISH, HF; GOLDRING, SR				LIN, HY; HARRIS, TL; FLANNERY, MS; ARUFFO, A; KAJI, EH; GORN, A; KOLAKOWSKI, LF; LODISH, HF; GOLDRING, SR			EXPRESSION CLONING OF AN ADENYLATE-CYCLASE COUPLED CALCITONIN RECEPTOR	SCIENCE			English	Article							G-PROTEINS	A calcitonin receptor complementary DNA (cDNA) was cloned by expression of a cDNA library from a porcine kidney epithelial cell line in COS cells. The 482-amino acid receptor has high affinity for salmon calcitonin (dissociation constant K(d) almost-equal-to 6 nM) and is functionally coupled to increases in intracellular cyclic adenosine monophosphate (cAMP). The receptor shows no sequence similarity to other reported G protein-coupled receptors but is homologous to the parathyroid hormone-parathyroid hormone-related peptide (PTH-PTHrP) receptor, indicating that the receptors for these hormones, which regulate calcium homeostasis, represent a new family of G protein-coupled receptors.	WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, MED SERV, ARTHRIT UNIT, BOSTON, MA 02114 USA; NEW ENGLAND DEACONESS HOSP, BOSTON, MA 02215 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital					NHLBI NIH HHS [HL-41484] Funding Source: Medline; NIADDK NIH HHS [AM 03564] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [P01AM003564] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTWOOD TK, 1991, GENE, V98, P153, DOI 10.1016/0378-1119(91)90168-B; CHAKRABORTY M, 1991, SCIENCE, V251, P1078, DOI 10.1126/science.1847755; COPP DH, 1962, ENDOCRINOLOGY, V70, P638, DOI 10.1210/endo-70-5-638; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GOLDRING SR, 1978, BIOCHEM BIOPH RES CO, V83, P434, DOI 10.1016/0006-291X(78)91009-4; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KLEIN P, 1985, BIOCHIM BIOPHYS ACTA, V815, P468, DOI 10.1016/0005-2736(85)90375-X; KOWALSKI LF, UNPUB; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; LOREAU N, 1978, J ENDOCRINOL, V76, P533, DOI 10.1677/joe.0.0760533; MURAD F, 1970, Proceedings of the National Academy of Sciences of the United States of America, V65, P446, DOI 10.1073/pnas.65.2.446; Sambrook J., 1989, MOL CLONING LAB MANU; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; ZAIDI M, 1990, J ENDOCRINOL, V126, P473, DOI 10.1677/joe.0.1260473	19	433	469	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 15	1991	254	5034					1022	1024		10.1126/science.1658940	http://dx.doi.org/10.1126/science.1658940			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP883	1658940				2022-12-01	WOS:A1991GP88300050
J	LO, YJ; POO, MM				LO, YJ; POO, MM			ACTIVITY-DEPENDENT SYNAPTIC COMPETITION INVITRO - HETEROSYNAPTIC SUPPRESSION OF DEVELOPING SYNAPSES	SCIENCE			English	Article							MOTOR UNIT SIZE; SKELETAL-MUSCLE; POLYNEURONAL INNERVATION; RAT MUSCLE; NEUROMUSCULAR-JUNCTIONS; EMBRYONIC NEURON; NEWBORN RATS; ELIMINATION; ACETYLCHOLINE; MECHANISMS	The development and stability of synaptic connections in the nervous system are influenced by the pattern of electrical activity and the competitive interaction between the adjacent nerve terminals. To investigate this influence, a culture system of nerve and muscle cells has been developed in which a single embryonic muscle cell is coinnervated by two spinal neurons. The effect of electrical activity on the synaptic efficacy was examined after repetitive electrical stimulation was applied to one or both neurons. Brief tetanic stimulation of one neuron resulted in immediate functional suppression of the synapse made by the unstimulated neuron innervating the same muscle cell. This heterosynaptic suppression was largely absent when the tetanic stimulation was applied concurrently to both neurons. This result demonstrates that activity-dependent synaptic competition can be studied in vitro at a cellular level.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Columbia University					NINDS NIH HHS [NS 22764] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022764] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BETZ WJ, 1989, J PHYSIOL-LONDON, V417, P25; BROW H, 1990, ANN REV NEUROSCI, V13, P475; BROWN MC, 1976, J PHYSIOL-LONDON, V261, P387, DOI 10.1113/jphysiol.1976.sp011565; BUCHANAN J, 1989, J NEUROSCI, V9, P1544; CALLAWAY EM, 1987, NATURE, V328, P357; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; DECKER ER, 1990, J NEUROSCI, V10, P3413; DUNIA R, MOTONEURONAL PLASTIC; EVERS J, 1989, J NEUROSCI, V9, P1523; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hebb DO, 1949, ORG BEHAVIOR, P62; HERRERA AA, 1990, J NEUROBIOL, V21, P73, DOI 10.1002/neu.480210106; HERRERA AA, 1990, J NEUROBIOL, V21, P21; HUBEL DH, 1965, J NEUROPHYSIOL, V28, P1041, DOI 10.1152/jn.1965.28.6.1041; KUFFLER D, 1977, BRAIN RES, V138, P353, DOI 10.1016/0006-8993(77)90752-1; LOMO T, 1980, TRENDS NEUROSCI, V3, P126, DOI 10.1016/0166-2236(80)90047-8; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MAGCHIELSE T, 1986, DEV BRAIN RES, V25, P211, DOI 10.1016/0165-3806(86)90210-5; NELSON PG, 1989, SCIENCE, V244, P585, DOI 10.1126/science.2717942; NELSON PG, 1990, J NEUROBIOL, V21, P138, DOI 10.1002/neu.480210110; OBRIEN RAD, 1978, J PHYSIOL-LONDON, V282, P571, DOI 10.1113/jphysiol.1978.sp012482; POO M, 1989, J NEUROBIOL, V21, P157; PURVES D, 1990, PRINCIPLES NEURAL DE, V5, P745; REDFERN PA, 1970, J PHYSIOL-LONDON, V209, P701, DOI 10.1113/jphysiol.1970.sp009187; RIBCHESTER RR, 1983, J PHYSIOL-LONDON, V344, P89, DOI 10.1113/jphysiol.1983.sp014926; RIBCHESTER RR, 1984, J PHYSIOL-LONDON, V347, P497, DOI 10.1113/jphysiol.1984.sp015078; RICH MM, 1989, J NEUROSCI, V9, P1781, DOI 10.1523/jneurosci.09-05-01781.1989; RIDGE RMAP, 1984, J NEUROSCI, V4, P2614; SPITZER NC, 1976, P NATL ACAD SCI USA, V73, P1641, DOI 10.1073/pnas.73.5.1641; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; STRYKER MP, 1986, J NEUROSCI, V6, P2117; SUN YA, 1987, P NATL ACAD SCI USA, V84, P2540, DOI 10.1073/pnas.84.8.2540; Tabti N., 1991, CULTURING NERVE CELL, P137; THOMPSON W, 1983, NATURE, V302, P614, DOI 10.1038/302614a0; VANESSEN DC, 1990, J NEUROBIOL, V21, P223, DOI 10.1002/neu.480210115; VANESSEN DC, 1982, NEURONAL DEV, P333; XIE ZP, 1986, P NATL ACAD SCI USA, V83, P7069, DOI 10.1073/pnas.83.18.7069; YOUNG SH, 1983, NATURE, V305, P634, DOI 10.1038/305634a0; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	39	137	139	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1991	254	5034					1019	1022		10.1126/science.1658939	http://dx.doi.org/10.1126/science.1658939			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP883	1658939				2022-12-01	WOS:A1991GP88300049
J	MULLER, F; WICKY, C; SPICHER, A; TOBLER, H				MULLER, F; WICKY, C; SPICHER, A; TOBLER, H			NEW TELOMERE FORMATION AFTER DEVELOPMENTALLY REGULATED CHROMOSOMAL BREAKAGE DURING THE PROCESS OF CHROMATIN DIMINUTION IN ASCARIS-LUMBRICOIDES	CELL			English	Article							GERM-LINE; DNA; SEQUENCE; ORGANIZATION; GENOME	During the process of chromatin diminution, which takes place in all presomatic cells of the early Ascaris embryo, the heterochromatic termini of the chromosomes are lost. Here we show that the newly formed ends of the reduced somatic chromosomes carry tandem repeats of the telomeric sequence TTAGGC. Comparison of a cloned somatic telomere with the corresponding germline chromosomal region revealed that these telomeric repeats are not present at or near the chromosomal breakage site. They are most likely added by a telomerase-mediated event. Chromosomal breakage, which precedes the telomere addition process, takes place within a short, specific chromosomal region (CBR); however, it does not occur at a single locus, but rather at many different sites. Altogether, our data show that chromatin diminution in Ascaris is a complex molecular process that includes site-specific chromosomal breakage, new telomere formation, and DNA degradation.			MULLER, F (corresponding author), UNIV FRIBOURG,INST ZOOL,CH-1700 FRIBOURG,SWITZERLAND.			Wicky, Chantal/0000-0002-0034-4992				AEBY P, 1986, EMBO J, V5, P3353, DOI 10.1002/j.1460-2075.1986.tb04650.x; ALLSHIRE RC, 1988, NATURE, V332, P656, DOI 10.1038/332656a0; BACK E, 1984, NUCLEIC ACIDS RES, V12, P1313, DOI 10.1093/nar/12.3.1313; BAROIN A, 1987, NUCLEIC ACIDS RES, V15, P1717, DOI 10.1093/nar/15.4.1717; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Boveri T., 1910, ZUGLEICHEIN BEITRAG, P131; Boveri T, 1887, ANAT ANZEIGER, V2, P688; BOWERI T, 1910, ANAT ANZEIGER, V3, P131; ETTER A, 1991, P NATL ACAD SCI USA, V88, P1593, DOI 10.1073/pnas.88.5.1593; FORNEY JD, 1988, MOL CELL BIOL, V8, P251, DOI 10.1128/MCB.8.1.251; GREIDER CW, 1990, BIOESSAYS, V12, P363, DOI 10.1002/bies.950120803; Maniatis T., 1982, MOL CLONING; MORITZ KB, 1976, NATURE, V259, P55, DOI 10.1038/259055a0; MULLER F, 1982, NUCLEIC ACIDS RES, V10, P7493, DOI 10.1093/nar/10.23.7493; PIMPINELLI S, 1989, TRENDS GENET, V5, P310, DOI 10.1016/0168-9525(89)90114-5; PONZI M, 1985, EMBO J, V4, P2991, DOI 10.1002/j.1460-2075.1985.tb04034.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TARTOF KD, 1991, CELL, V65, P201, DOI 10.1016/0092-8674(91)90153-P; TOBLER H, 1972, DEV BIOL, V27, P190, DOI 10.1016/0012-1606(72)90097-8; TOBLER H, 1985, EXPERIENTIA, V41, P1311, DOI 10.1007/BF01952073; TOBLER H, 1986, CELL DIFFER, V13, P2; YAO MC, 1990, CELL, V63, P763, DOI 10.1016/0092-8674(90)90142-2; Yao MC, 1989, MOBILE DNA, P715; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	24	116	131	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1991	67	4					815	822		10.1016/0092-8674(91)90076-B	http://dx.doi.org/10.1016/0092-8674(91)90076-B			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GQ407	1934070				2022-12-01	WOS:A1991GQ40700018
J	NOWAK, MA; ANDERSON, RM; MCLEAN, AR; WOLFS, TFW; GOUDSMIT, J; MAY, RM				NOWAK, MA; ANDERSON, RM; MCLEAN, AR; WOLFS, TFW; GOUDSMIT, J; MAY, RM			ANTIGENIC DIVERSITY THRESHOLDS AND THE DEVELOPMENT OF AIDS	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1 REVERSE-TRANSCRIPTASE; ZIDOVUDINE; DISEASE; TYPE-1; INFECTION; EVOLUTION; MUTATIONS; NEUTRALIZATION; REPLICATION	Longitudinal studies of patients infected with HIV-1 reveal a long and variable incubation period between infection and the development of AIDS. Data from a small number of infected patients show temporal changes in the number of genetically distinct strains of the virus throughout the incubation period, with a slow but steady rise in diversity during the progression to disease. A mathematical model of the dynamic interaction between viral diversity and the human immune system suggests the existence of an antigen diversity threshold, below which the immune system is able to regulate viral population growth but above which the virus population induces the collapse of the CD4+ lymphocyte population. The model suggests that antigenic diversity is the cause, not a consequence, of immunodeficiency disease. The model is compared with available data, and is used to assess how the timing of the application of chemotherapy or immunotherapy influences the rate of progress to disease.	DEPT VIROL, HUMAN RETROVIRUS LAB, 1105 AZ AMSTERDAM, NETHERLANDS; UNIV LONDON IMPERIAL COLL SCI & TECHNOL, DEPT BIOL, LONDON SW7 2AZ, ENGLAND	Imperial College London	NOWAK, MA (corresponding author), UNIV OXFORD, DEPT ZOOL, S PARKS RD, OXFORD OX1 3PS, ENGLAND.		Nowak, Martin A/A-6977-2008	Anderson, Roy/0000-0002-9528-3175				ANDERS RF, 1986, PARASITE IMMUNOL, V8, P529, DOI 10.1111/j.1365-3024.1986.tb00867.x; ANDERSON RM, 1989, CELL TO CELL SIGNALLING : FROM EXPERIMENTS TO THEORETICAL MODELS, P335; ANDERSON RM, 1991, J ANIM ECOL, V60, P1, DOI 10.2307/5443; ASJO B, 1986, LANCET, V2, P660; BALFE P, 1990, J VIROL, V64, P6221, DOI 10.1128/JVI.64.12.6221-6233.1990; BIGGAR RJ, 1990, AIDS, V4, P1059, DOI 10.1097/00002030-199011000-00002; CASTRO BA, 1988, AIDS, V2, pS17, DOI 10.1097/00002030-198800001-00004; CHENGMAYER C, 1990, J VIROL, V64, P4390, DOI 10.1128/JVI.64.9.4390-4398.1990; DEWOLF F, IN PRESS VIROLOGY; DEWOLF F, 1991, LANCET, V337, P389; DOUGHERTY JP, 1988, J VIROL, V62, P2817, DOI 10.1128/JVI.62.8.2817-2822.1988; DOURNON E, 1988, LANCET, V2, P1297; EIGEN M, 1977, NATURWISSENSCHAFTEN, V64, P541, DOI 10.1007/BF00450633; EIGEN M, 1971, NATURWISSENSCHAFTEN, V58, P465, DOI 10.1007/BF00623322; EIGEN M, 1989, ADV CHEM PHYS, V75, P149; FENYO EM, 1989, AIDS, V3, pS5, DOI 10.1097/00002030-198901001-00002; FENYO EM, 1988, J VIROL, V62, P4414; FISCHL MA, 1989, JAMA-J AM MED ASSOC, V262, P2405; FISHER AG, 1988, NATURE, V334, P444, DOI 10.1038/334444a0; GAINES H, 1990, AIDS, V4, P995, DOI 10.1097/00002030-199010000-00008; GOODENOW M, 1989, J ACQ IMMUN DEF SYND, V2, P344; GORY RF, 1989, LANCET S1, V3, P683; HAASE AT, 1986, NATURE, V322, P130, DOI 10.1038/322130a0; HAMMING RW, 1986, CODING INFORMATION T; HAVERKOS HW, 1987, J INFECT DIS, V156, P251, DOI 10.1093/infdis/156.1.251; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LEIDER JM, 1988, J VIROL, V62, P3084, DOI 10.1128/JVI.62.9.3084-3091.1988; LEVY JA, 1990, AIDS, V4, P1051, DOI 10.1097/00002030-199011000-00001; LO SC, 1989, AM J TROP MED HYG, V41, P364, DOI 10.4269/ajtmh.1989.41.364; LOONEY DJ, 1988, SCIENCE, V241, P357, DOI 10.1126/science.3388046; LULLEY R, 1983, J GEN VIROL, V64, P1433; MAY RM, 1981, THEORETICAL ECOLOGY, pCH11; MCKEETING JA, 1989, AIDS, V4, P535; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; NOWAK M, 1989, J THEOR BIOL, V137, P375, DOI 10.1016/S0022-5193(89)80036-0; NOWAK M, 1990, NATURE, V347, P522, DOI 10.1038/347522a0; NOWAK MA, 1990, AIDS, V4, P1095, DOI 10.1097/00002030-199011000-00007; NOWAK MA, IN PRESS MATH BIOSCI; PARRY N, 1990, NATURE, V347, P569, DOI 10.1038/347569a0; PECKHAM CS, 1991, LANCET, V337, P253; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; RATNER L, 1989, AIDS RES HUM RETROV, V5, P115, DOI 10.1089/aid.1989.5.115; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; SAAG MS, 1988, NATURE, V334, P440, DOI 10.1038/334440a0; SHRODA T, 1991, NATURE, V349, P167; VICKERMAN K, 1978, NATURE, V273, P613, DOI 10.1038/273613a0; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WAINHOBSON S, 1989, AIDS, V3, pS13, DOI 10.1097/00002030-198901001-00003; WOLFS TFW, 1990, P NATL ACAD SCI USA, V87, P9938, DOI 10.1073/pnas.87.24.9938; WOLFS TFW, IN PRESS VIROLOGY	52	446	453	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 15	1991	254	5034					963	969		10.1126/science.1683006	http://dx.doi.org/10.1126/science.1683006			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP883	1683006				2022-12-01	WOS:A1991GP88300033
J	OKAMOTO, T; MURAYAMA, Y; HAYASHI, Y; INAGAKI, M; OGATA, E; NISHIMOTO, I				OKAMOTO, T; MURAYAMA, Y; HAYASHI, Y; INAGAKI, M; OGATA, E; NISHIMOTO, I			IDENTIFICATION OF A GS ACTIVATOR REGION OF THE BETA-2-ADRENERGIC RECEPTOR THAT IS AUTOREGULATED VIA PROTEIN KINASE-A-DEPENDENT PHOSPHORYLATION	CELL			English	Article							BETA-ADRENERGIC-RECEPTOR; MANNOSE 6-PHOSPHATE RECEPTOR; GTP-BINDING PROTEINS; GROWTH FACTOR-II; ADENYLATE-CYCLASE; PHOSPHOLIPID-VESICLES; DISTINCT PATHWAYS; PERTUSSIS-TOXIN; LYMPHOMA-CELLS; BASIC RESIDUES	We have localized a G protein activator region of the human beta-2-adrenergic receptor to region beta-III-2 (from Arg259 to Lys273). The synthetic beta-III-2, corresponding to the C-terminal end of the third cytoplasmic loop, activates G(s) at nanomolar concentrations and weakly activates G(i). Beta-III-2 activates adenylyl cyclase at nanomolar concentrations in wild-type S49 lymphoma membranes, but not in membranes of unc mutant S49 cells, in which G(s) is uncoupled from beta-adrenergic stimulation. Phosphorylation of beta-III-2 by cAMP-dependent protein kinase A, which is involved in the desensitization of the beta-adrenergic receptor from G(s), drastically reduces the effect of beta-III-2 on G(s) while potentiating its action on G(i), resulting in a total loss of adenylyl cyclase-stimulating activity. These findings indicate that this receptor sequence is a multipotential G protein activator whose G protein specificity is regulated by protein kinase A.	SUNTORY BIOMED CTR,TOKYO,GUMMA 37005,JAPAN; AICHI CANC CTR,RES INST,EXPTL RADIOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Suntory Holdings Ltd; Aichi Cancer Center	OKAMOTO, T (corresponding author), UNIV TOKYO,SCH MED,DEPT INTERNAL MED 4,LIFE SCI LAB,BUNKYO KU,TOKYO 113,JAPAN.		Inagaki, Masaki/B-9920-2016					ABRAMSON SN, 1985, J BIOL CHEM, V260, P4580; ASANO T, 1984, J BIOL CHEM, V259, P9351; Beavo J A, 1974, Methods Enzymol, V38, P299; BENOVIC JL, 1985, J BIOL CHEM, V260, P7094; BLAKE AD, 1987, BIOCHEM BIOPH RES CO, V147, P168, DOI 10.1016/S0006-291X(87)80102-X; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; CERIONE RA, 1985, J BIOL CHEM, V260, P1493; CHEUNG AH, 1991, FEBS LETT, V279, P277, DOI 10.1016/0014-5793(91)80167-2; CLARK RB, 1986, BIOCHEM J, V235, P399, DOI 10.1042/bj2350399; FERAMISCO JR, 1980, J BIOL CHEM, V255, P4240; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HILDEBRANDT JD, 1982, J BIOL CHEM, V257, P4723; HOUSE C, 1987, J BIOL CHEM, V262, P772; INAGAKI M, 1985, J BIOL CHEM, V260, P2922; KATADA T, 1987, FEBS LETT, V213, P353, DOI 10.1016/0014-5793(87)81521-1; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUHN H, 1981, BIOCHEMISTRY-US, V20, P2410; MORISHITA R, 1990, BIOCHEM BIOPH RES CO, V172, P249, DOI 10.1016/S0006-291X(05)80201-3; MORISHITA R, 1989, BIOCHEM BIOPH RES CO, V161, P1280, DOI 10.1016/0006-291X(89)91381-8; MURAYAMA Y, 1990, J BIOL CHEM, V265, P17456; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; PALM D, 1989, FEBS LETT, V254, P89, DOI 10.1016/0014-5793(89)81015-4; ROSS EM, 1977, P NATL ACAD SCI USA, V74, P3715, DOI 10.1073/pnas.74.9.3715; RUBENSTEIN RC, 1987, J BIOL CHEM, V262, P16655; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; STRADER CD, 1987, J BIOL CHEM, V262, P16439; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; WEISS ER, 1988, J BIOL CHEM, V263, P6150; WONG SKF, 1990, J BIOL CHEM, V265, P6219	38	256	266	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1991	67	4					723	730		10.1016/0092-8674(91)90067-9	http://dx.doi.org/10.1016/0092-8674(91)90067-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GQ407	1657404				2022-12-01	WOS:A1991GQ40700009
J	OTTING, G; LIEPINSH, E; WUTHRICH, K				OTTING, G; LIEPINSH, E; WUTHRICH, K			PROTEIN HYDRATION IN AQUEOUS-SOLUTION	SCIENCE			English	Article							NUCLEAR MAGNETIC-RESONANCE; PANCREATIC TRYPSIN-INHIBITOR; SOLVENT SATURATION; WATER-MOLECULES; SPIN DIFFUSION; RELAXATION; NMR; SPECTROSCOPY; OXYTOCIN; CRYSTALS	High-resolution proton nuclear magnetic resonance studies of protein hydration in aqueous solution show that there are two qualitatively different types of hydration sites. A well-defined, small number of water molecules in the interior of the protein are in identical locations in the crystal structure and in solution, and their residence times are in the range from about 10(-2) to 10(-8) second. Hydration of the protein surface in solution is by water molecules with residence times in the subnanosecond range, even when they are located in hydration sites that contain well-ordered water in the x-ray structures of protein single crystals.			OTTING, G (corresponding author), SWISS FED INST TECHNOL,INST MOLEK BIOL & BIOPHYS,CH-8093 ZURICH,SWITZERLAND.		Otting, Gottfried/H-8413-2014	Otting, Gottfried/0000-0002-0563-0146				ABRAGAM A, 1961, PRINCIPLES NUCLEAR M; AYANT Y, 1977, J PHYS-PARIS, V38, P325, DOI 10.1051/jphys:01977003803032500; BERNDT K, UNPUB; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Blundell T.L., 1976, PROTEIN CRYSTALLOGRA; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BRYANT RG, 1980, BIOPHYS J, V32, P3, DOI 10.1016/S0006-3495(80)84912-5; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P567; DEISENHOFER J, 1975, ACTA CRYSTALLOGR B, V31, P238, DOI 10.1107/S0567740875002415; FUJIWARA T, 1985, J CHEM PHYS, V83, P3110, DOI 10.1063/1.449217; GILLEN KT, 1972, J CHEM PHYS, V57, P5117, DOI 10.1063/1.1678198; GLICKSON JD, 1976, BIOCHEMISTRY-US, V15, P1111, DOI 10.1021/bi00650a025; GLICKSON JD, 1975, PEPTIDES CHEM STRUCT, P787; HALLE B, 1981, J AM CHEM SOC, V103, P500, DOI 10.1021/ja00393a004; HRUBY VJ, 1981, TOPICS MOL PHARM, P100; KALK A, 1976, J MAGN RESON, V24, P343, DOI 10.1016/0022-2364(76)90115-3; KOENIG SH, 1988, BIOPHYS J, V53, P91, DOI 10.1016/S0006-3495(88)83069-8; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; MARANI R, UNPUB; MEIBOOM S, 1961, J CHEM PHYS, V34, P375, DOI 10.1063/1.1700960; MESSERLE BA, 1989, J MAGN RESON, V85, P608, DOI 10.1016/0022-2364(89)90252-7; OTTING G, 1991, J AM CHEM SOC, V113, P4363, DOI 10.1021/ja00011a068; OTTING G, 1991, Journal of Biomolecular NMR, V1, P209, DOI 10.1007/BF01877232; OTTING G, 1989, J AM CHEM SOC, V111, P1871, DOI 10.1021/ja00187a050; OTTING G, 1990, WATER IONS BIOMOLECU, P141; OTTING G, 1991, WATER IONS BIOMOLECU, V113, P4363; PITNER TP, 1974, NATURE, V250, P582, DOI 10.1038/250582a0; POLNASZEK CF, 1984, J CHEM PHYS, V81, P4038, DOI 10.1063/1.448147; Richards F. M., 1991, Scientific American, V264, P34; RICHARZ R, 1980, BIOCHEMISTRY-US, V19, P5189, DOI 10.1021/bi00564a006; RICHMOND TJ, 1984, J MOL BIOL, V178, P63, DOI 10.1016/0022-2836(84)90231-6; SAENGER W, 1987, ANNU REV BIOPHYS BIO, V16, P93; Schulz G.E., 1979, PRINCIPLES PROTEIN S; SOLOMON I, 1955, PHYS REV, V99, P559, DOI 10.1103/PhysRev.99.559; STOESZ JD, 1978, FEBS LETT, V91, P320, DOI 10.1016/0014-5793(78)81201-0; TEETER MM, 1984, P NATL ACAD SCI-BIOL, V81, P6014, DOI 10.1073/pnas.81.19.6014; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WLODAWER A, 1984, J MOL BIOL, V180, P301, DOI 10.1016/S0022-2836(84)80006-6; WLODAWER A, 1987, J MOL BIOL, V198, P469, DOI 10.1016/0022-2836(87)90294-4; WOOD SP, 1986, SCIENCE, V232, P633, DOI 10.1126/science.3008332; WUTHRICH K, 1989, SCIENCE, V243, P45, DOI 10.1126/science.2911719; WUTHRICH K, 1989, ACCOUNTS CHEM RES, V22, P36, DOI 10.1021/ar00157a006; Wuthrich K., 1986, NMR PROTEINS NUCL AC	43	749	758	0	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1991	254	5034					974	980		10.1126/science.1948083	http://dx.doi.org/10.1126/science.1948083			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP883	1948083				2022-12-01	WOS:A1991GP88300035
J	REBAY, I; FLEMING, RJ; FEHON, RG; CHERBAS, L; CHERBAS, P; ARTAVANISTSAKONAS, S				REBAY, I; FLEMING, RJ; FEHON, RG; CHERBAS, L; CHERBAS, P; ARTAVANISTSAKONAS, S			SPECIFIC EGF REPEATS OF NOTCH MEDIATE INTERACTIONS WITH DELTA AND SERRATE - IMPLICATIONS FOR NOTCH AS A MULTIFUNCTIONAL RECEPTOR	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; GAMMA-CARBOXYGLUTAMIC ACID; NEURONAL PRECURSOR CELLS; NEUROGENIC LOCUS NOTCH; DROSOPHILA-MELANOGASTER; TRANSMEMBRANE PROTEIN; NEGATIVE COMPLEMENTATION; GENETIC INTERACTIONS; LDL RECEPTOR; FACTOR-IX	The neurogenic loci Notch and Delta, which both encode EGF-homologous transmembrane proteins, appear to function together in mediating cell-cell communication and have been shown to interact at the cell surface in vitro. To examine the role of the EGF repeats in this interaction, we performed an extensive deletion mutagenesis of the extracellular domain of Notch. We find that of the 36 EGF repeats of Notch, only two, 11 and 12, are both necessary and sufficient to mediate interactions with Delta. Furthermore, this Delta binding ability is conserved in the corresponding two repeats from the Xenopus Notch homolog. We report a novel molecular interaction between Notch and Serrate, another EGF-homologous transmembrane protein containing a region of striking similarity to Delta, and show that the same two EGF repeats of Notch also constitute a Serrate binding domain. These results suggest that Notch may act as a multifunctional receptor whose 36 EGF repeats form a tandem array of discrete ligand-binding units, each of which may potentially interact with several different proteins during development.	YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06511; INDIANA UNIV,DEPT BIOL,PROGRAM MOLEC CELLULAR & DEV BIOL,BLOOMINGTON,IN 47405	Yale University; Indiana University System; Indiana University Bloomington	REBAY, I (corresponding author), YALE UNIV,DEPT CELL BIOL,HOWARD HUGHES MED INST,NEW HAVEN,CT 06511, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026084, R37NS026084] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM20093, GM37813] Funding Source: Medline; NINDS NIH HHS [NS26084] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALTON AK, 1989, DEV GENET, V10, P261, DOI 10.1002/dvg.1020100315; APPELLA E, 1987, J BIOL CHEM, V262, P4437; APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; ARTAVANISTSAKON.S, 1991, IN PRESS, V7, P427; ARTAVANISTSAKONAS S, 1988, TRENDS GENET, V4, P95, DOI 10.1016/0168-9525(88)90096-0; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BAKER NE, 1990, SCIENCE, V250, P1370, DOI 10.1126/science.2175046; BOUROUIS M, 1983, EMBO J, V2, P1099, DOI 10.1002/j.1460-2075.1983.tb01552.x; BRAND M, 1990, ROUX ARCH DEV BIOL, V198, P275, DOI 10.1007/BF00377394; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; DAVIS LD, 1991, IN PRESS J BIOL CHEM; DELACONCHA A, 1988, GENETICS, V118, P499; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; ENGEL J, 1989, FEBS LETT, V251, P1, DOI 10.1016/0014-5793(89)81417-6; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; FOSTER GG, 1975, GENETICS, V81, P99; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HANDFORD PA, 1990, EMBO J, V9, P479; HARTLEY DA, 1987, EMBO J, V6, P3407, DOI 10.1002/j.1460-2075.1987.tb02664.x; HAYS TS, 1989, MOL CELL BIOL, V9, P875, DOI 10.1128/MCB.9.3.875; JACKMAN RW, 1986, P NATL ACAD SCI USA, V83, P8834, DOI 10.1073/pnas.83.23.8834; JOHANSEN KM, 1989, J CELL BIOL, V109, P2427, DOI 10.1083/jcb.109.5.2427; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIDD S, 1989, GENE DEV, V3, P1113, DOI 10.1101/gad.3.8.1113; KOMORIYA A, 1984, P NATL ACAD SCI-BIOL, V81, P1351, DOI 10.1073/pnas.81.5.1351; KOPCZYNSKI CC, 1989, DEVELOPMENT, V107, P623; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; LINDSLEY PL, 1968, PUBLICATION NUMBER C, V627; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; Maniatis T, 1989, DECONTAMINATION DILU; MARKOPOULOU K, 1989, J NEUROGENET, V6, P11, DOI 10.3109/01677068909107097; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; MORITA T, 1984, J BIOL CHEM, V259, P5698; MOSS RE, 1985, THESIS HARVARD U; PEARSON CA, 1988, EMBO J, V7, P2977, DOI 10.1002/j.1460-2075.1988.tb03160.x; PORTIN P, 1975, GENETICS, V81, P121; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; ROTHBERG JM, 1988, CELL, V55, P1047, DOI 10.1016/0092-8674(88)90249-8; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; SHEPARD SB, 1989, GENETICS, V122, P429; SUGO T, 1984, J BIOL CHEM, V259, P5705; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; THOMAS U, 1991, DEVELOPMENT, V111, P749; VASSIN H, 1985, J NEUROGENET, V2, P291, DOI 10.3109/01677068509102325; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; WELSHONS WJ, 1965, SCIENCE, V150, P1122, DOI 10.1126/science.150.3700.1122; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; XU T, 1990, GENE DEV, V4, P464, DOI 10.1101/gad.4.3.464; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	60	655	710	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1991	67	4					687	699		10.1016/0092-8674(91)90064-6	http://dx.doi.org/10.1016/0092-8674(91)90064-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GQ407	1657403				2022-12-01	WOS:A1991GQ40700006
J	SMITH, WC; HARLAND, RM				SMITH, WC; HARLAND, RM			INJECTED XWNT-8 RNA ACTS EARLY IN XENOPUS EMBRYOS TO PROMOTE FORMATION OF A VEGETAL DORSALIZING CENTER	CELL			English	Article							MESODERM-INDUCING FACTOR; MESSENGER-RNA; CELL LINEAGE; AMPHIBIAN DEVELOPMENT; LAEVIS EMBRYOS; GROWTH-FACTOR; INDUCTION; EXPRESSION; AXIS; PATTERN	Expression cloning from a pool of gastrula cDNAs identified the Wnt family member Xwnt-8 as having dorsal axis-inducing activity in Xenopus embryos. Microinjected Xwnt-8 mRNA was able to rescue the development of a dorsally complete anterior-posterior axis in embryos ventralized by exposure to UV light. Axis induction was observed in embryos injected in either marginal or vegetal blastomeres at the 32-cell stage. Vegetal blastomeres receiving Xwnt-8 mRNA contributed progeny not to the induced dorsal axis, but to the endoderm, a result consistent with Xwnt-8 causing cells to act as a Nieuwkoop center (the vegetal-inducing component of normal dorsal axis formation), rather than as a Spemann organizer (the induced dorsal marginal zone component that directly forms the dorsal mesoderm). Xwnt-8, which is normally expressed ventrally in midgastrula and neurula embryos, appears to mimic, when injected, maternally encoded dorsal mesoderm-inducing factors that act early in development.			SMITH, WC (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720, USA.							AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BOTERENBROOD EC, 1973, ROUX ARCH DEV BIOL, V173, P319, DOI 10.1007/BF00575837; CHRISTIAN JL, 1991, DEV BIOL, V143, P230, DOI 10.1016/0012-1606(91)90073-C; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; CONDIE BG, 1987, DEVELOPMENT, V101, P93; COOKE J, 1987, DEVELOPMENT, V99, P197; DALE L, 1985, J EMBRYOL EXP MORPH, V89, P289; DALE L, 1987, DEVELOPMENT, V100, P279; DALE L, 1987, DEVELOPMENT, V99, P527; Dawid I.B., 1990, Current Topics in Developmental Biology, V24, P261, DOI 10.1016/S0070-2153(08)60090-3; ELINSON RP, 1988, DEV BIOL, V128, P185, DOI 10.1016/0012-1606(88)90281-3; FRANK D, 1991, IN PRESS DEVELOPMENT; GERHART J, 1986, ANNU REV CELL BIOL, V2, P201, DOI 10.1146/annurev.cb.02.110186.001221; GERHART J, 1989, DEVELOPMENT, V107, P37; Gerhart J, 1980, BIOL REGULATION DEV, V2; GIMLICH RL, 1986, DEV BIOL, V115, P340, DOI 10.1016/0012-1606(86)90254-X; GIMLICH RL, 1984, DEV BIOL, V104, P117, DOI 10.1016/0012-1606(84)90042-3; GIMLICH RL, 1983, NATURE, V306, P471, DOI 10.1038/306471a0; GREEN JBA, 1990, DEVELOPMENT, V108, P173; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HARLAND R, 1985, J CELL BIOL, V101, P1094, DOI 10.1083/jcb.101.3.1094; HARLAND RM, 1991, IN PRESS METH CELL B, V36; HAUSEN P, 1991, EARLY DEV XENOPUS; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; HEMMATIBRIVANLOU A, 1991, DEVELOPMENT, V111, P715; JONES EA, 1987, DEVELOPMENT, V101, P557; KAGEURA H, 1990, DEV BIOL, V142, P432, DOI 10.1016/0012-1606(90)90365-P; KAO KR, 1989, DEV BIOL, V132, P81, DOI 10.1016/0012-1606(89)90207-8; KAO KR, 1986, NATURE, V322, P371, DOI 10.1038/322371a0; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KELLER RE, 1975, DEV BIOL, V42, P222, DOI 10.1016/0012-1606(75)90331-0; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MCMAHON AP, 1991, ADV DEV BIOL, V1, P31; MOODY SA, 1987, DEV BIOL, V122, P300, DOI 10.1016/0012-1606(87)90296-X; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; NIEUWKOOP PD, 1973, ADV MORPHOGEN, V10, P2; NOMA Y, 1986, NATURE, V319, P640, DOI 10.1038/319640a0; NOORDERMEER J, 1989, NUCLEIC ACIDS RES, V17, P11, DOI 10.1093/nar/17.1.11; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; ROSA F, 1988, DEV BIOL, V129, P114, DOI 10.1016/0012-1606(88)90166-2; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; Sambrook J., 1989, MOL CLONING LAB MANU; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SCHARF SR, 1983, DEV BIOL, V99, P75, DOI 10.1016/0012-1606(83)90255-5; SLACK JMW, 1988, DEVELOPMENT, V103, P581; SMITH JC, 1987, DEVELOPMENT, V99, P3; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH JC, 1989, DEVELOPMENT, V105, P665; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; SOKOL S, 1991, CELL, V67; Spemann H., 1938, EMBRYONIC DEV INDUCT; STEWART RM, 1990, DEVELOPMENT, V109, P363; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VINCENT JP, 1986, DEV BIOL, V113, P484, DOI 10.1016/0012-1606(86)90184-3; VIZE PD, 1991, METHOD CELL BIOL, V36, P361; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7	59	543	557	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1991	67	4					753	765		10.1016/0092-8674(91)90070-F	http://dx.doi.org/10.1016/0092-8674(91)90070-F			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GQ407	1657405				2022-12-01	WOS:A1991GQ40700012
J	SOKOL, S; CHRISTIAN, JL; MOON, RT; MELTON, DA				SOKOL, S; CHRISTIAN, JL; MOON, RT; MELTON, DA			INJECTED WNT RNA INDUCES A COMPLETE BODY AXIS IN XENOPUS EMBRYOS	CELL			English	Article							MESODERM INDUCTION; GROWTH-FACTORS; AMPHIBIAN DEVELOPMENT; INT-1 PROTOONCOGENE; LAEVIS EMBRYOS; ACTIVIN-A; PATTERN; TRANSCRIPTION; EMBRYOGENESIS; EXPRESSION	Studies in Xenopus have shown that growth factors of the TGF-beta and Wnt oncogene families can mimic aspects of dorsal axis formation. Here we directly compare the inductive properties of two Wnt proteins by injecting synthetic mRNA into developing embryos. The results show that Wnt-1 and Xwnt-8 can induce a new and complete dorsal axis and can rescue the development of axis-deficient, UV-irradiated embryos. In contrast, activin mRNA injection induces only a partial dorsal axis that lacks anterior structures. These studies demonstrate that the mechanism of Wnt-induced axis duplication results from the creation of an independent Spemann organizer. The relationship between the properties of the endogenous dorsal inducer and the effects of Wnts and activins is discussed.	UNIV WASHINGTON,SCH MED,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	SOKOL, S (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.		Young, Richard A/F-6495-2012; Moon, Randall T/B-1743-2014; Moon, Randall/M-5605-2019	Young, Richard A/0000-0001-8855-8647; Moon, Randall T/0000-0002-9352-1408; Moon, Randall/0000-0002-9352-1408; Sokol, Sergei/0000-0002-3963-9202				ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; CHRISTIAN JL, 1991, DEV BIOL, V143, P230, DOI 10.1016/0012-1606(91)90073-C; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; COOKE J, 1989, DEVELOPMENT, V107, P229; COOKE J, 1987, DEVELOPMENT, V101, P893; DALE L, 1987, DEVELOPMENT, V99, P527; ELINSON RP, 1989, DEV GROWTH DIFFER, V31, P423; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GERHART J, 1989, DEVELOPMENT, V107, P37; GIMLICH RL, 1984, DEV BIOL, V104, P117, DOI 10.1016/0012-1606(84)90042-3; Hamburger V, 1988, HERITAGE EXPT EMBRYO; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; JONES EA, 1987, DEVELOPMENT, V101, P557; KAGEURA H, 1990, DEV BIOL, V142, P432, DOI 10.1016/0012-1606(90)90365-P; KAO KR, 1986, NATURE, V322, P371, DOI 10.1038/322371a0; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; MCMAHON AP, 1989, DEVELOPMENT, V107, P161; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MOHUN TJ, 1984, NATURE, V311, P715; MOODY SA, 1987, DEV BIOL, V119, P560, DOI 10.1016/0012-1606(87)90059-5; MORATA G, 1977, DEV BIOL, V56, P227, DOI 10.1016/0012-1606(77)90266-4; NAKAMURA O, 1970, P JPN ACAD, V46, P546, DOI 10.2183/pjab1945.46.546; NAKAMURA O, 1978, ORG MILESTONE HALF C, P179; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V163, P298, DOI 10.1007/BF00577017; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; NIEUWKOOP PD, 1969, ROUX ARCH DEVEL BIOL, V62, P341; NOORDERMEER J, 1989, NUCLEIC ACIDS RES, V17, P11, DOI 10.1093/nar/17.1.11; NUSSE R, 1988, TRENDS GENET, V4, P291, DOI 10.1016/0168-9525(88)90172-2; NUSSE R, 1991, CELL, V64, P231, DOI 10.1016/0092-8674(91)90633-A; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; OGI K-I, 1967, Science Reports of the Tohoku University Fourth Series (Biology), V33, P239; OLSON DJ, 1991, SCIENCE, V252, P1173, DOI 10.1126/science.252.5009.1173; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PATERNO GD, 1989, DEVELOPMENT, V106, P79; Roberts AB, 1990, GROWTH FACTORS, V3, P277, DOI 10.3109/08977199009003670; ROSA F, 1988, SCIENCE, V239, P783, DOI 10.1126/science.3422517; Ruiz i Altaba A, 1989, Nature, V341, P33; SCHARF SR, 1980, DEV BIOL, V79, P181, DOI 10.1016/0012-1606(80)90082-2; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH JC, 1989, DEVELOPMENT, V105, P665; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; Spemann H., 1938, EMBRYONIC DEV INDUCT; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VIZE PD, 1991, XENOPUS LAEVIS PRACT; WHITMAN M, 1989, ANNU REV CELL BIOL, V5, P93; YISRAELI JK, 1990, DEVELOPMENT, V108, P289	54	460	469	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1991	67	4					741	752		10.1016/0092-8674(91)90069-B	http://dx.doi.org/10.1016/0092-8674(91)90069-B			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GQ407	1834344				2022-12-01	WOS:A1991GQ40700011
J	STEFANOVA, I; HOREJSI, V; ANSOTEGUI, IJ; KNAPP, W; STOCKINGER, H				STEFANOVA, I; HOREJSI, V; ANSOTEGUI, IJ; KNAPP, W; STOCKINGER, H			GPI-ANCHORED CELL-SURFACE MOLECULES COMPLEXED TO PROTEIN TYROSINE KINASES	SCIENCE			English	Article							GLYCOSYL-PHOSPHATIDYLINOSITOL; CYTOPLASMIC DOMAINS; MEMBRANE; CD4; PHOSPHORYLATION; P56LCK	Binding of ligand or antibody to certain cell-surface proteins that are anchored to the membrane by glycophosphatidylinositol (GPI) can cause activation of leukocytes. However, it is not known how these molecules, which lack intracellular domains, can transduce signals. The GPI-linked human molecules CD59, CD55, CD48, CD24, and CD14 as well as the mouse molecules Thy-1 and Ly-6 were found to associate with protein tyrosine kinases, key regulators of cell activation and signal transduction. A protein tyrosine kinase associated with the GPI-linked proteins CD59, CD55, and CD48 in human T cells, and with Thy-1 in mouse T cells was identified as p56lck, a protein tyrosine kinase related to Src. This interaction of GPI-linked molecules with protein tyrosine kinases suggests a potential mechanism of signal transduction in cells.	CZECHOSLOVAK ACAD SCI, INST MOLEC GENET, CS-14220 PRAGUE 4, CZECHOSLOVAKIA; KAROLINSKA INST, S-10401 STOCKHOLM 60, SWEDEN	Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Karolinska Institutet	STEFANOVA, I (corresponding author), UNIV VIENNA, VIENNA INT RES COOPERAT CTR SFI, INST IMMUNOL, BRUNNER STR 59, A-1235 VIENNA, AUSTRIA.		Horejsi, Vaclav/G-3113-2014; Stockinger, Hannes/E-5173-2011	Horejsi, Vaclav/0000-0003-4925-0142; Stockinger, Hannes/0000-0001-6404-4430				ANSOTEGUI IJ, 1991, SCAND J IMMUNOL, V33, P375, DOI 10.1111/j.1365-3083.1991.tb01784.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; FISCHER GF, 1990, J IMMUNOL, V144, P638; HOREJSI V, 1991, ADV IMMUNOL, V49, P75; HSI ED, 1989, J BIOL CHEM, V264, P10836; HURLEY TR, 1989, ONCOGENE, V4, P265; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; LOW MG, 1989, FASEB J, V3, P1600, DOI 10.1096/fasebj.3.5.2522071; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MUNOZ G, 1990, ANAL BIOCHEM, V190, P233, DOI 10.1016/0003-2697(90)90185-C; ROBINSON PJ, 1991, IMMUNOL TODAY, V12, P35, DOI 10.1016/0167-5699(91)90110-F; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; STEFANOVA I, 1989, MOL IMMUNOL, V26, P153, DOI 10.1016/0161-5890(89)90097-7; STEFANOVA I, UNPUB; TAMURA GS, 1984, ANAL BIOCHEM, V136, P458, DOI 10.1016/0003-2697(84)90244-6; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2	17	871	887	2	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 15	1991	254	5034					1016	1019		10.1126/science.1719635	http://dx.doi.org/10.1126/science.1719635			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP883	1719635				2022-12-01	WOS:A1991GP88300048
J	WAGNER, JL; HERDMAN, RC; WADHWA, S				WAGNER, JL; HERDMAN, RC; WADHWA, S			COST-EFFECTIVENESS OF COLORECTAL-CANCER SCREENING IN THE ELDERLY	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							OCCULT BLOOD-TEST; LARGE BOWEL; CONVENIENT APPROXIMATION; FLEXIBLE SIGMOIDOSCOPY; LIFE EXPECTANCY; POLYPS; CARCINOMA; SENSITIVITY; STAGE; RISK	Objective: To assess the cost effectiveness of a periodic program of colorectal cancer screening in the elderly. Design: A model was constructed of four strategies for the periodic screening of persons 65 to 85 years of age. The effect of each strategy on life expectancy and health care costs was estimated under assumptions that were uniformly unfavorable to screening. Cost and added years of life were discounted at 5% per year. Cost per year of life gained from screening was calculated for each screening strategy. Data Sources: Assumptions used in the model were based on a review of pertinent studies; those studies with results more unfavorable to screening were given more weight. Strengths and weaknesses of studies are discussed. Main Results: A program of annual fecal occult blood testing (FOBT) in the elderly would detect at least 17% of the expected cases of cancer and could cost $35 000 per year of life saved. Screening schedules that include periodic sigmoidoscopy would prevent more cases of cancer but could cost between $43 000 and $47 000 per year of life gained. These estimates are based on uncertain assumptions, but results were not extremely sensitive to further relaxation of the values of the most uncertain assumptions. In no case did the cost per year of life gained from annual FOBT exceed $55 000 or did the cost per year of life gained from FOBT with sigmoidoscopy every 5 years exceed $61 000. Conclusions: Although colorectal cancer screening is costly in the aggregate, its potential medical benefits make it a reasonably cost-effective preventive intervention for the elderly.			WAGNER, JL (corresponding author), US OFF TECHNOL ASSESSMENT, WASHINGTON, DC USA.							AHLQUIST D, 1991, Gastroenterology, V100, pA346; AHLQUIST DA, 1989, CANCER, V63, P1826; AHLQUIST DA, 1990, GASTROENTEROLOGY, V100, pA1; ALLISON JE, 1985, DIGEST DIS SCI, V30, P860, DOI 10.1007/BF01309517; ARMINSKI T. C., 1964, DIS COLON RECTUM, V7, P249, DOI 10.1007/BF02630528; BANG KM, 1986, J OCCUP ENVIRON MED, V28, P709, DOI 10.1097/00043764-198608000-00033; BARRY MJ, 1987, GASTROENTEROLOGY, V93, P301, DOI 10.1016/0016-5085(87)91019-5; BECK JR, 1982, AM J MED, V73, P883, DOI 10.1016/0002-9343(82)90786-0; BECK JR, 1982, AM J MED, V73, P889, DOI 10.1016/0002-9343(82)90787-2; BERG JW, 1970, CANCER, V25, P1076, DOI 10.1002/1097-0142(197005)25:5<1076::AID-CNCR2820250511>3.0.CO;2-L; Blatt LJ., 1961, DIS COLON RECTUM, V4, P277; CHAPMAN I, 1963, ANN SURG, V157, P223, DOI 10.1097/00000658-196302000-00007; CORREA P, 1977, CANCER, V39, P2258; DEMERS RY, 1985, PREV MED, V14, P55, DOI 10.1016/0091-7435(85)90020-9; EDDY D, 1987, BREAST CANCER SCREEN; EDDY DM, 1990, ANN INTERN MED, V113, P373, DOI 10.7326/0003-4819-113-5-373; EDDY DM, 1987, GASTROENTEROLOGY, V92, P682, DOI 10.1016/0016-5085(87)90018-7; EDDY DM, 1980, SCREENING CANCER THE; ENGLAND WL, 1989, MED DECIS MAKING, V9, P3, DOI 10.1177/0272989X8900900103; FENOGLIO CM, 1974, CANCER, V34, P819, DOI 10.1002/1097-0142(197409)34:3+<819::AID-CNCR2820340706>3.0.CO;2-S; FIELDING LP, 1989, LANCET, V1, P595; FLEISCHER DE, 1989, JAMA-J AM MED ASSOC, V261, P580, DOI 10.1001/jama.261.4.580; GNAUCK R, 1984, CA-CANCER J CLIN, V34, P134, DOI 10.3322/canjclin.34.3.134; GOODWIN JS, 1986, J AM GERIATR SOC, V34, P20, DOI 10.1111/j.1532-5415.1986.tb06335.x; GRINNELL RS, 1964, ANN SURG, V159, P132, DOI 10.1097/00000658-196401000-00023; HAYWARD RSA, 1991, ANN INTERN MED, V114, P758, DOI 10.7326/0003-4819-114-9-758; HOFF G, 1986, SCAND J GASTROENTERO, V21, P853, DOI 10.3109/00365528609011130; HOFF G, 1987, SCAND J GASTROENTERO, V22, P769, DOI 10.3109/00365528708991912; HOLMES FF, 1981, J AM GERIATR SOC, V29, P55, DOI 10.1111/j.1532-5415.1981.tb01227.x; Hughes L E, 1968, Aust N Z J Surg, V38, P30; IRVIN TT, 1988, BRIT J SURG, V75, P419, DOI 10.1002/bjs.1800750508; KRONBORG O, 1975, BR J SURG S, V72, pS26; KUNE GA, 1987, BRIT J SURG, V74, P1064, DOI 10.1002/bjs.1800741135; MACRAE FA, 1982, GASTROENTEROLOGY, V82, P891; MANDEL JS, 1989, GASTROENTEROLOGY, V97, P597, DOI 10.1016/0016-5085(89)90629-X; MILLER AB, 1990, INT J CANCER, V46, P761, DOI 10.1002/ijc.2910460502; MOR V, 1988, J AM GERIATR SOC, V36, P873, DOI 10.1111/j.1532-5415.1988.tb05778.x; MORSON B, 1974, P ROY SOC MED, V67, P451, DOI 10.1177/00359157740676P115; NEUGUT AI, 1985, CANCER, V55, P1586, DOI 10.1002/1097-0142(19850401)55:7<1586::AID-CNCR2820550729>3.0.CO;2-I; OTT DJ, 1989, COLON CANCER DIAGNOS; RANSOHOFF DF, 1991, ANN INTERN MED, V114, P177, DOI 10.7326/0003-4819-114-3-177; RESTREPO C, 1981, DIS COLON RECTUM, V24, P29, DOI 10.1007/BF02603446; RHOADS GG, 1987, JAMA-J AM MED ASSOC, V258, P3254, DOI 10.1001/jama.1987.03400220053020; RIBET A, 1980, LANCET, V1, P417; RICKERT RR, 1979, CANCER-AM CANCER SOC, V43, P1847, DOI 10.1002/1097-0142(197905)43:5<1847::AID-CNCR2820430538>3.0.CO;2-L; ROBERTS SD, 1980, ANN INTERN MED, V92, P243, DOI 10.7326/0003-4819-92-2-243; SEIDMAN H, 1985, CA-CANCER J CLIN, V35, P36, DOI 10.3322/canjclin.35.1.36; SELBY JV, 1989, JAMA-J AM MED ASSOC, V261, P595; SIMON JB, 1985, GASTROENTEROLOGY, V88, P820, DOI 10.1016/0016-5085(85)90158-1; STEMMERMANN GN, 1973, CANCER-AM CANCER SOC, V31, P1260, DOI 10.1002/1097-0142(197305)31:5<1260::AID-CNCR2820310535>3.0.CO;2-N; STEVENSON G, 1989, COLON CANCER DIAGNOS; SUGARBAKER PH, 1985, CANCER PRINCIPLES PR; WILLIAMS AR, 1982, GUT, V23, P835, DOI 10.1136/gut.23.10.835; WILLIAMS CB, 1982, ENDOSCOPY, V14, P74, DOI 10.1055/s-2007-1021584; WINAWER SJ, 1980, CANCER, V45, P2959, DOI 10.1002/1097-0142(19800615)45:12<2959::AID-CNCR2820451212>3.0.CO;2-E; WINDELER J, 1987, INT J COLORECTAL DIS, V2, P223, DOI 10.1007/BF01649510; 1989, ANN REPORT C; 1988, BASIC CLIN PERSPECTI; 1979, OTA PUBLICATION H, V96; 1990, OTA BPH65 PUBL; 1990, CANCER LETT, V11, P3; 1989, NIH892789 PUBL; 1990, OTA PUBLICATION H, V416	63	123	124	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1991	115	10					807	817		10.7326/0003-4819-115-10-807	http://dx.doi.org/10.7326/0003-4819-115-10-807			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP800	1929029				2022-12-01	WOS:A1991GP80000011
J	WANG, XF; LIN, HY; NGEATON, E; DOWNWARD, J; LODISH, HF; WEINBERG, RA				WANG, XF; LIN, HY; NGEATON, E; DOWNWARD, J; LODISH, HF; WEINBERG, RA			EXPRESSION CLONING AND CHARACTERIZATION OF THE TGF-BETA TYPE-III RECEPTOR	CELL			English	Article							TRANSFORMING GROWTH-FACTOR; MEMBRANE PROTEOGLYCAN; MOLECULAR-CLONING; GLYCOSAMINOGLYCAN CHAINS; EXTRACELLULAR-MATRIX; CELL PROLIFERATION; DOMAIN-STRUCTURE; LIGAND-BINDING; 2 FORMS; INHIBITION	The rat TGF-beta type III receptor cDNA has been cloned by overexpression in COS cells. The encoded receptor is an 853 amino acid protein with a large N-terminal extracellular domain containing at least one site for glycosaminoglycan addition, a single hydrophobic transmembrane domain, and a 41 amino acid cytoplasmic tail with no obvious signaling motif. Introduction of the cDNA into COS cells and L6 myoblasts induces expression of a heterogenously glycosylated 280-330 kd protein characteristic of the type III receptor that binds TGF-beta-1 specifically. In L6 myoblasts lacking the endogenous type III receptor, expression of the recombinant receptor leads to an increase in the amount of ligand bound and cross-linked to surface type II TGF-beta receptors. This indicates that the type III receptor may regulate the ligand-binding ability or surface expression of the type II receptor.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)	WANG, XF (corresponding author), WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA.			Downward, Julian/0000-0002-2331-4729	NATIONAL CANCER INSTITUTE [R35CA039826] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007287] Funding Source: NIH RePORTER; NCI NIH HHS [R35-CA39826] Funding Source: Medline; NHLBI NIH HHS [HL-41484] Funding Source: Medline; NIGMS NIH HHS [T 32 GM07287-16] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BERNFIELD M, 1991, IN PRESS ANN NY ACAD; BOYD FT, 1989, J BIOL CHEM, V264, P2272; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; CARR BI, 1986, CANCER RES, V46, P2330; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; CHEIFETZ S, 1989, J BIOL CHEM, V264, P12025; CHEIFETZ S, 1986, J BIOL CHEM, V261, P9972; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; FANGER BO, 1986, BIOCHEMISTRY-US, V25, P3083, DOI 10.1021/bi00359a003; FRATERSCHRODER M, 1986, BIOCHEM BIOPH RES CO, V137, P295, DOI 10.1016/0006-291X(86)91209-X; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; GRAYCAR JL, 1989, MOL ENDOCRINOL, V3, P1977, DOI 10.1210/mend-3-12-1977; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; KEHRL JH, 1986, J IMMUNOL, V137, P3855; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KERR LD, 1988, J BIOL CHEM, V263, P1699; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LEMISCHKA IR, 1981, J MOL BIOL, V151, P101, DOI 10.1016/0022-2836(81)90223-0; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; LIN HY, 1991, IN PRESS SCIENCE; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASSAGUE J, 1985, J BIOL CHEM, V260, P7059; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; Moses H. L., 1985, CANC CELLS, V3, P65; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P421; ROBERTS CJ, 1988, J BIOL CHEM, V263, P4586; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEGARINI PR, 1988, J BIOL CHEM, V263, P8366; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; SEGARINI PR, 1987, J BIOL CHEM, V262, P14655; SHIPLEY GD, 1986, CANCER RES, V46, P2068; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	66	588	619	0	6	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 15	1991	67	4					797	805		10.1016/0092-8674(91)90074-9	http://dx.doi.org/10.1016/0092-8674(91)90074-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GQ407	1657407				2022-12-01	WOS:A1991GQ40700016
J	WINK, DA; KASPRZAK, KS; MARAGOS, CM; ELESPURU, RK; MISRA, M; DUNAMS, TM; CEBULA, TA; KOCH, WH; ANDREWS, AW; ALLEN, JS; KEEFER, LK				WINK, DA; KASPRZAK, KS; MARAGOS, CM; ELESPURU, RK; MISRA, M; DUNAMS, TM; CEBULA, TA; KOCH, WH; ANDREWS, AW; ALLEN, JS; KEEFER, LK			DNA DEAMINATING ABILITY AND GENOTOXICITY OF NITRIC-OXIDE AND ITS PROGENITORS	SCIENCE			English	Article							ESCHERICHIA-COLI; POINT MUTATIONS; 5-METHYLCYTOSINE; MACROPHAGES; NITROSATION; ACTIVATION; RATS; HYPOMETHYLATION; NUCLEOTIDES; CYTOSINE	Nitric oxide (NO), a multifaceted bioregulatory agent and an environmental pollutant, can also cause genomic alterations. In vitro, NO deaminated deoxynucleosides, deoxynucleotides, and intact DNA at physiological pH. That similar DNA damage can also occur in vivo was tested by treating Salmonella typhimurium strain TA1535 with three NO-releasing compounds, including nitroglycerin. All proved mutagenic. Observed DNA sequence changes were > 99% C --> T transitions in the hisG46 (CCC) target codon, consistent with a cytosine-deamination mechanism. Because exposure to endogenously and exogenously produced NO is extensive, this mechanism may contribute to the incidence of deamination-related genetic disease and cancer.	NCI,FREDERICK CANC RES & DEV CTR,COMPARAT CARCINOGENESIS NATL LAB,FREDERICK,MD 21701; US FDA,ROCKVILLE,MD 20852; GLAXO INC,RES TRIANGLE PK,NC 27709; US FDA,WASHINGTON,DC 20204; NCI,FREDERICK CANC RES & DEV CTR,PRI DYNCORP,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; US Food & Drug Administration (FDA); GlaxoSmithKline; US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Keefer, Larry K/N-3247-2014	Keefer, Larry K/0000-0001-7489-9555; Azad, Mahan/0000-0002-8633-3513	OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74102] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BROWN TC, 1987, CELL, V50, P945, DOI 10.1016/0092-8674(87)90521-6; CEBULA TA, 1990, MUTAT RES, V229, P79, DOI 10.1016/0027-5107(90)90010-2; COPPER DN, 1990, HUM GENET, V85, P55; COULONDRE C, 1978, NATURE, V274, P775, DOI 10.1038/274775a0; EHRLICH M, 1990, MUTAT RES, V238, P277, DOI 10.1016/0165-1110(90)90019-8; FEDERN H, 1986, CHROMATOGRAPHIA, V22, P287, DOI 10.1007/BF02268776; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FREDERICO LA, 1990, BIOCHEMISTRY-US, V29, P2532, DOI 10.1021/bi00462a015; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HIRSCHHORN R, 1990, P NATL ACAD SCI USA, V87, P6171, DOI 10.1073/pnas.87.16.6171; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; JI XB, 1988, APPL ENVIRON MICROB, V54, P1791, DOI 10.1128/AEM.54.7.1791-1794.1988; KASPRZAK KS, 1990, CARCINOGENESIS, V11, P647, DOI 10.1093/carcin/11.4.647; KOCHETKOV NK, 1972, ORGANIC CHEM NUCLE B, P362; KOSAKA H, 1989, CARCINOGENESIS, V10, P563, DOI 10.1093/carcin/10.3.563; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; LEAF CD, 1991, CARCINOGENESIS, V12, P537, DOI 10.1093/carcin/12.3.537; LINDAHL T, 1990, MUTAT RES, V238, P305, DOI 10.1016/0165-1110(90)90022-4; LOEB LA, 1990, MUTAT RES, V238, P297, DOI 10.1016/0165-1110(90)90021-3; MARAGOS CM, IN PRESS J MED CHEM; MARLETTA MA, 1988, CHEM RES TOXICOL, V1, P249, DOI 10.1021/tx00005a001; MARON DM, 1983, MUTAT RES, V113, P173, DOI 10.1016/0165-1161(83)90010-9; MONCADA S, 1990, NITRIC OXIDE L ARGIN; MOSCHEL RC, 1989, TETRAHEDRON LETT, V30, P1467, DOI 10.1016/S0040-4039(00)99492-9; NGUYEN T, IN PRESS P NATL ACAD; NGUYEN TT, 1991, P AM ASS CANCER RES, V32; PATTINSON JK, 1990, BLOOD, V76, P2242; PERUTZ MF, 1990, BIOPHYS CHEM, V37, P25, DOI 10.1016/0301-4622(90)88004-C; RALT D, 1988, J BACTERIOL, V170, P359, DOI 10.1128/jb.170.1.359-364.1988; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; SAGHER D, 1983, BIOCHEMISTRY-US, V22, P4518, DOI 10.1021/bi00288a026; SHAPIRO HS, 1966, BIOCHEMISTRY-US, V5, P3012, DOI 10.1021/bi00873a034; SHAPIRO R, 1966, BIOCHEMISTRY-US, V5, P2358, DOI 10.1021/bi00871a026; SHIVAPURKAR N, 1984, CARCINOGENESIS, V5, P989, DOI 10.1093/carcin/5.8.989; Singer B., 1983, MOL BIOL MUTAGENS CA; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; TANNENBAUM SR, 1991, AM J CLIN NUTR, V53, pS247, DOI 10.1093/ajcn/53.1.247S; WALLACE SS, 1988, ENVIRON MOL MUTAGEN, V12, P431, DOI 10.1002/em.2860120411; Williams D. L. H., 1988, NITROSATION; WINK DA, 1991, P AM ASS CANCER RES, V32; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501; 1977, WHO ENV HLTH CRITERI, V4	47	1119	1158	0	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1991	254	5034					1001	1003		10.1126/science.1948068	http://dx.doi.org/10.1126/science.1948068			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP883	1948068				2022-12-01	WOS:A1991GP88300043
J	WONG, MMY; FOSKETT, JK				WONG, MMY; FOSKETT, JK			OSCILLATIONS OF CYTOSOLIC SODIUM DURING CALCIUM OSCILLATIONS IN EXOCRINE ACINAR-CELLS	SCIENCE			English	Article							MANDIBULAR SALIVARY-GLAND; AGONIST-INDUCED ACTIVATION; NA+/H+ EXCHANGE; INTRACELLULAR PH; SECRETION; AMILORIDE; FLUID	In acinar cells from rat salivary glands, cholinergic agonists cause oscillations in cytoplasmic free calcium concentration, which then drive oscillations of cell volume that reflect oscillating cell solute content and fluid secretion. By quantitative fluorescence ratio microscopy of an intracellular indicator dye for sodium, it has now been shown that large amplitude oscillations of sodium concentration were associated with the calcium and cell volume oscillations. Both calcium and sodium oscillations were dependent on the continued presence of calcium in the extracellular medium and were abolished by the specific sodium-potassium adenosine triphosphatase inhibitor ouabain. Thus, calcium oscillations in salivary acinar cells, by modulating the activities of ion transport pathways in the plasma membrane, can cause significant oscillations of monovalent ions that may in turn feed back to regulate calcium oscillations and fluid secretion.	HOSP SICK CHILDREN,RES INST,DIV CELL BIOL,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Foskett, Kevin/R-2549-2019	Foskett, J. Kevin/0000-0002-8854-0268				BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; CASE RM, 1984, J PHYSIOL-LONDON, V349, P619, DOI 10.1113/jphysiol.1984.sp015177; DISSING S, 1990, AM J PHYSIOL, V259, pG1044, DOI 10.1152/ajpgi.1990.259.6.G1044; FOSKETT JK, 1988, AM J PHYSIOL, V255, pC566, DOI 10.1152/ajpcell.1988.255.4.C566; FOSKETT JK, 1990, AM J PHYSIOL, V259, pC998; FOSKETT JK, 1991, J BIOL CHEM, V266, P14535; FOSKETT JK, 1989, SCIENCE, V244, P1582, DOI 10.1126/science.2500708; FOSKETT JK, 1991, J BIOL CHEM, V266, P2778; FOSKETT JK, IN PRESS AM J PHYSL; JACOB R, 1990, BIOCHIM BIOPHYS ACTA, V1052, P427, DOI 10.1016/0167-4889(90)90152-4; LAU KR, 1990, J PHYSIOL-LONDON, V425, P407, DOI 10.1113/jphysiol.1990.sp018111; MANGANEL M, 1989, J MEMBRANE BIOL, V111, P191, DOI 10.1007/BF01871782; MANGANEL M, 1990, J BIOL CHEM, V265, P4284; MARTINEZ JR, 1989, EUR J PHARMACOL, V164, P335, DOI 10.1016/0014-2999(89)90474-3; MELVIN JE, 1988, J BIOL CHEM, V263, P19564; MINTA A, 1989, J BIOL CHEM, V264, P19449; NOVAK I, 1989, PFLUG ARCH EUR J PHY, V414, P68, DOI 10.1007/BF00585628; PIRANI D, 1987, PFLUG ARCH EUR J PHY, V408, P178, DOI 10.1007/BF00581349; POULSEN JH, 1987, J DENT RES, V66, P608, DOI 10.1177/00220345870660024401; SMAJE LH, 1986, PFLUEGERS ARCH, V406, P4925; SOLTOFF SP, 1989, J GEN PHYSIOL, V93, P285, DOI 10.1085/jgp.93.2.285; STEWARD MC, 1989, PFLUG ARCH EUR J PHY, V414, P200, DOI 10.1007/BF00580964; TURNER RJ, 1986, J MEMBRANE BIOL, V94, P143, DOI 10.1007/BF01871194; Wong M, UNPUB	24	60	60	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1991	254	5034					1014	1016		10.1126/science.1948071	http://dx.doi.org/10.1126/science.1948071			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP883	1948071				2022-12-01	WOS:A1991GP88300047
J	WUTHRICH, K; VONFREYBERG, B; WEBER, C; WIDER, G; TRABER, R; WIDMER, H; BRAUN, W				WUTHRICH, K; VONFREYBERG, B; WEBER, C; WIDER, G; TRABER, R; WIDMER, H; BRAUN, W			RECEPTOR-INDUCED CONFORMATION CHANGE OF THE IMMUNOSUPPRESSANT CYCLOSPORINE-A	SCIENCE			English	Editorial Material							NUCLEAR-MAGNETIC-RESONANCE; CIS-TRANS ISOMERASE; 2D H-1-NMR SPECTRA; DOUBLE-HALF-FILTER; NMR-SPECTROSCOPY; BINDING-PROTEIN; CYCLOPHILIN		SANDOZ PHARMA AG,PRAKLIN FORSCH,CH-4002 BASEL,SWITZERLAND	Novartis; Sandoz	WUTHRICH, K (corresponding author), SWISS FED INST TECHNOL,INST MOLEK BIOL & BIOPHYS,CH-8093 ZURICH,SWITZERLAND.		Braun, Werner/A-6642-2012	Wider, Gerhard/0000-0001-9366-7645				BOREL JF, 1986, CICLOSPORIN; FESIK SW, 1988, NATURE, V332, P865, DOI 10.1038/332865a0; FESIK SW, 1988, BIOCHEMISTRY-US, V27, P8297, DOI 10.1021/bi00422a001; FESIK SW, 1991, BIOCHEMISTRY-US, V30, P6575; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; GRIFFEY RH, 1987, Q REV BIOPHYS, V19, P51, DOI 10.1017/S0033583500004029; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; KALLEN J, 1991, NATURE, V353, P276, DOI 10.1038/353276a0; KAWAMUKAI M, 1989, J BACTERIOL, V171, P4525, DOI 10.1128/JB.171.8.4525-4529.1989; KESSLER H, 1990, HELV CHIM ACTA, V73, P1818, DOI 10.1002/hlca.19900730703; KOLETSKY AJ, 1986, J IMMUNOL, V137, P1054; Lautz J, 1987, J Comput Aided Mol Des, V1, P219, DOI 10.1007/BF01677046; LAUTZ J, 1990, BIOPOLYMERS, V29, P1969; LOOSLI HR, 1985, HELV CHIM ACTA, V68, P682, DOI 10.1002/hlca.19850680319; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MOORE JM, 1991, NATURE, V351, P248, DOI 10.1038/351248a0; OTTING G, 1986, J MAGN RESON, V70, P500, DOI 10.1016/0022-2364(86)90144-7; OTTING G, 1989, J MAGN RESON, V85, P586, DOI 10.1016/0022-2364(89)90249-7; OTTING G, 1990, Q REV BIOPHYS, V23, P39, DOI 10.1017/S0033583500005412; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WEBER C, 1991, BIOCHEMISTRY-US, V30, P6563, DOI 10.1021/bi00240a029; WENGER RM, 1985, ANGEW CHEM INT EDIT, V24, P77, DOI 10.1002/anie.198500773; WIDER G, 1990, J AM CHEM SOC, V112, P9015, DOI 10.1021/ja00180a076; WIDER G, 1991, J AM CHEM SOC, V113, P4676, DOI 10.1021/ja00012a044; WUTHRICH K, 1991, FEBS LETT, V285, P237, DOI 10.1016/0014-5793(91)80808-G	27	78	78	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1991	254	5034					953	954		10.1126/science.1948082	http://dx.doi.org/10.1126/science.1948082			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP883	1948082				2022-12-01	WOS:A1991GP88300030
J	YANG, XH; SEOW, KT; BAHRI, SM; OON, SH; CHIA, W				YANG, XH; SEOW, KT; BAHRI, SM; OON, SH; CHIA, W			2 DROSOPHILA RECEPTOR-LIKE TYROSINE PHOSPHATASE GENES ARE EXPRESSED IN A SUBSET OF DEVELOPING AXONS AND PIONEER NEURONS IN THE EMBRYONIC CNS	CELL			English	Article							HOMOPHILIC ADHESION MOLECULE; LEUKOCYTE-COMMON ANTIGEN; PROTO-ONCOGENE HOMOLOG; FASCICLIN-I; IMMUNOGLOBULIN SUPERFAMILY; SIGNAL TRANSDUCTION; KINASE-ACTIVITY; PHOSPHORYLATION; GRASSHOPPER; SEQUENCE	Two Drosophila receptor-like tyrosine phosphatase genes, DPTP99A and DPTP10D, were characterized. Protein products of these genes show distinct expression patterns specific to subsets of developing CNS axons. DPTP99A expression coincides with the onset of axonogenesis and is expressed in several pioneer neurons, including aCC and RP2, which pioneer the intersegmental nerve; its proteins are transiently expressed in the intersegmental and segmental nerves, arguing for a role in the establishment of these nerves. Both genes produce complex sets of transcripts, owing to the alternative utilization of exons and polyadenylation sites. Each gene produces alternative protein forms, which differ in their C-terminal tails. The deduced proteins possess extracellular FN-III repeats and intracellular PTPase domain(s). We discuss the implications of these results and the role of protein tyrosine dephosphorylation in axon outgrowth and guidance.			YANG, XH (corresponding author), NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, DROSOPHILA NEUROBIOL LAB, SINGAPORE 0511, SINGAPORE.							ALEXANDER D R, 1990, New Biologist, V2, P1049; BASTIANI MJ, 1987, CELL, V48, P745, DOI 10.1016/0092-8674(87)90072-9; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; DOE CQ, 1988, NATURE, V333, P376, DOI 10.1038/333376a0; DOE CQ, 1988, SCIENCE, V239, P170, DOI 10.1126/science.2892267; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; ELKINS T, 1990, J CELL BIOL, V110, P1825, DOI 10.1083/jcb.110.5.1825; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GOODMAN CS, 1984, SCIENCE, V225, P1271, DOI 10.1126/science.6474176; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HENKEMEYER MJ, 1988, MOL CELL BIOL, V8, P843, DOI 10.1128/MCB.8.2.843; HENKEMEYER MJ, 1987, CELL, V51, P821, DOI 10.1016/0092-8674(87)90105-X; HOFFMANN FM, 1983, CELL, V35, P393, DOI 10.1016/0092-8674(83)90172-1; HORTSCH M, 1990, NEURON, V4, P697, DOI 10.1016/0896-6273(90)90196-M; HORTSCH M, 1990, J BIOL CHEM, V265, P15104; HSU S, 1988, NEUROSCI LETT, V85, P169; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LANDER AD, 1989, TRENDS NEUROSCI, V12, P189, DOI 10.1016/0166-2236(89)90070-2; MAHER PA, 1985, P NATL ACAD SCI USA, V82, P6576, DOI 10.1073/pnas.82.19.6576; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; MANESS PF, 1990, CIBA F SYMP, V150, P57; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; ROHRSCHNEIDER LR, 1984, J VIROL, V51, P547, DOI 10.1128/JVI.51.2.547-552.1984; SAMBROOK J, 1989, MOL CLONNING LABORAT; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SEEGER MA, 1988, CELL, V55, P589, DOI 10.1016/0092-8674(88)90217-6; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THOMAS JB, 1984, NATURE, V310, P203, DOI 10.1038/310203a0; TONKS NK, 1989, TRENDS BIOCHEM SCI, V14, P497, DOI 10.1016/0968-0004(89)90184-9; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	52	174	181	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 15	1991	67	4					661	673		10.1016/0092-8674(91)90062-4	http://dx.doi.org/10.1016/0092-8674(91)90062-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GQ407	1657401				2022-12-01	WOS:A1991GQ40700004
J	YU, GL; BLACKBURN, EH				YU, GL; BLACKBURN, EH			DEVELOPMENTALLY PROGRAMMED HEALING OF CHROMOSOMES BY TELOMERASE IN TETRAHYMENA	CELL			English	Article							TERMINAL TRANSFERASE-ACTIVITY; SACCHAROMYCES-CEREVISIAE; EUPLOTES-CRASSUS; MACRONUCLEAR DNA; OXYTRICHA-NOVA; SEQUENCE; YEAST; THERMOPHILA; CLONING; RNA	Healing of a broken chromosome end in eukaryotes involves acquisition of a telomere. During macronuclear development in ciliated protozoans, germline chromosomes are fragmented into linear subchromosomes, whose ends are healed by de novo addition of telomeres. We showed previously that the ribonucleoprotein enzyme telomerase elongates preexisting telomeres by synthesizing one telomeric DNA strand, using a template sequence in the RNA moiety of the enzyme. By marking telomerase with a mutation in the telomerase RNA template, which causes synthesis of novel telomeric sequences, we now show that in the ciliate Tetrahymena, telomerase directly adds telomeric DNA onto nontelomeric sequences during developmentally controlled chromosome healing. Unexpectedly, one telomerase RNA template mutation converted telomerase from an enzyme that normally synthesizes precisely templated sequences to a less precise polymerase that sometimes synthesizes irregular telomeric repeats in vivo.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIGMS NIH HHS [GM26259, GM32565] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032565, R37GM026259, R01GM026259] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAIRD SE, 1989, GENE DEV, V3, P585, DOI 10.1101/gad.3.5.585; BAROIN A, 1987, NUCLEIC ACIDS RES, V15, P1717, DOI 10.1093/nar/15.4.1717; BLACKBURN EH, 1990, SCIENCE, V249, P489, DOI 10.1126/science.2200120; BLACKBURN EH, 1989, GENOME, V31, P553, DOI 10.1139/g89-104; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BROWN WRA, 1989, NATURE, V338, P774, DOI 10.1038/338774a0; Bruns P.J., 1986, P27; BUDARF M, 1987, NUCLEIC ACIDS RES, V15, P6273, DOI 10.1093/nar/15.15.6273; BUDARF ML, 1986, J BIOL CHEM, V261, P363; CHALLONER PB, 1986, NUCLEIC ACIDS RES, V14, P6299, DOI 10.1093/nar/14.15.6299; CHENG JF, 1989, NUCLEIC ACIDS RES, V17, P6109, DOI 10.1093/nar/17.15.6109; CHIOU S, 1981, P NATL ACAD SCI USA, V78, P2263; CROSS SH, 1989, NATURE, V338, P771, DOI 10.1038/338771a0; EMERY HS, 1981, CELL, V26, P411, DOI 10.1016/0092-8674(81)90210-5; FORNEY JD, 1988, MOL CELL BIOL, V8, P251, DOI 10.1128/MCB.8.1.251; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1991, MOL CELL BIOL, V11, P4572, DOI 10.1128/MCB.11.9.4572; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HERRICK G, 1987, J PROTOZOOL, V34, P429, DOI 10.1111/j.1550-7408.1987.tb03207.x; JACQUES JP, 1991, GENE DEV, V5, P707, DOI 10.1101/gad.5.5.707; Karrer K.M., 1986, P85; KING BO, 1982, CELL, V31, P177, DOI 10.1016/0092-8674(82)90417-2; KISS GB, 1981, MOL CELL BIOL, V1, P535, DOI 10.1128/MCB.1.6.535; KLOBUTCHER LA, 1984, CELL, V36, P1045, DOI 10.1016/0092-8674(84)90054-0; LARSON DD, 1986, CELL, V47, P229, DOI 10.1016/0092-8674(86)90445-9; Maniatis T., 1982, MOL CLONING; McDonald B.B., 1973, P287; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Orias E., 1986, P45; PAN W, 1991, Acta Genetica Sinica, V18, P127; PENNOCK DG, 1988, MOL CELL BIOL, V8, P2681, DOI 10.1128/MCB.8.7.2681; PONZI M, 1985, EMBO J, V4, P2991, DOI 10.1002/j.1460-2075.1985.tb04034.x; RIETHMAN HC, 1989, P NATL ACAD SCI USA, V86, P6240, DOI 10.1073/pnas.86.16.6240; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; SHAMPAY J, 1988, P NATL ACAD SCI USA, V85, P534, DOI 10.1073/pnas.85.2.534; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SHIPPENLENTZ D, 1989, MOL CELL BIOL, V9, P2761, DOI 10.1128/MCB.9.6.2761; SPANGLER EA, 1988, NUCLEIC ACIDS RES, V16, P5569, DOI 10.1093/nar/16.12.5569; SZOSTAK JW, 1982, CELL, V29, P245, DOI 10.1016/0092-8674(82)90109-X; WANG SS, 1990, MOL CELL BIOL, V10, P4415, DOI 10.1128/MCB.10.8.4415; YAO MC, 1987, CELL, V48, P779, DOI 10.1016/0092-8674(87)90075-4; YOKOYAMA R, 1986, NUCLEIC ACIDS RES, V14, P2109, DOI 10.1093/nar/14.5.2109; YU GL, 1989, P NATL ACAD SCI USA, V86, P8487, DOI 10.1073/pnas.86.21.8487; ZAHLER AM, 1988, NUCLEIC ACIDS RES, V16, P6953, DOI 10.1093/nar/16.14.6953	45	191	210	0	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1991	67	4					823	832		10.1016/0092-8674(91)90077-C	http://dx.doi.org/10.1016/0092-8674(91)90077-C			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GQ407	1934071				2022-12-01	WOS:A1991GQ40700019
J	BI, E; LUTKENHAUS, J				BI, E; LUTKENHAUS, J			FTSZ RING STRUCTURE ASSOCIATED WITH DIVISION IN ESCHERICHIA-COLI	NATURE			English	Article							CELL-DIVISION; DNA-REPLICATION; INHIBITOR SULA; BEHAVIOR; MUTANTS; PROTEIN; SEPTUM; SHAPE; LOCUS	GENES for cell division have been identified in Escherichia coli by the isolation of conditional lethal mutations that block cell division, but do not affect DNA replication or segregation 1. Of these genes, ftsZ is of great interest as it acts earliest in the division pathway 2,3, is essential 4, its level dictates the frequency of division 5,6, and it is thought to be the target of two cell-division inhibitors 7-9, SulA, produced in response to DNA damage 10, and MinCD, which prevents division at old sites 11. Here we have used immunoelectronmicroscopy to localize the FtsZ protein to the division site. The results suggest that FtsZ self-assembles into a ring structure at the future division site and may function as a cytoskeletal element. The formation of this ring may be the point at which division is regulated.			BI, E (corresponding author), UNIV KANSAS,MED CTR,DEPT MICROBIOL MOLEC GENET & IMMUNOL,KANSAS CITY,KS 66103, USA.							BEALL B, 1991, GENE DEV, V5, P447, DOI 10.1101/gad.5.3.447; BEGG KJ, 1985, J BACTERIOL, V163, P615, DOI 10.1128/JB.163.2.615-622.1985; BI E, 1990, J BACTERIOL, V172, P2765, DOI 10.1128/jb.172.5.2765-2768.1990; BI E, 1990, J BACTERIOL, V172, P5602, DOI 10.1128/jb.172.10.5602-5609.1990; BI E, 1990, J BACTERIOL, V172, P5610, DOI 10.1128/jb.172.10.5610-5616.1990; BI E, IN PRESS PROKARYOTIC; BURTON P, 1983, MOL GEN GENET, V190, P309, DOI 10.1007/BF00330656; CASAREGOLA S, 1990, MOL MICROBIOL, V4, P505, DOI 10.1111/j.1365-2958.1990.tb00617.x; CORTON JC, J BACTERIOL, V169, P1; DAI K, 1991, J BACTERIOL, V172, P3500; DEBOER PAJ, 1989, CELL, V56, P641, DOI 10.1016/0092-8674(89)90586-2; DEBOER PAJ, 1990, P NATL ACAD SCI USA, V87, P1129, DOI 10.1073/pnas.87.3.1129; HUISMAN O, 1981, NATURE, V290, P797, DOI 10.1038/290797a0; ITO K, 1981, CELL, V24, P707, DOI 10.1016/0092-8674(81)90097-0; JAFFE A, 1986, J BACTERIOL, V165, P66, DOI 10.1128/jb.165.1.66-71.1986; NIKI H, 1991, EMBO J, V10, P183, DOI 10.1002/j.1460-2075.1991.tb07935.x; ROBIN A, 1990, J BACTERIOL, V172, P1392, DOI 10.1128/jb.172.3.1392-1399.1990; SCHROEDER TE, 1973, P NATL ACAD SCI USA, V70, P1688, DOI 10.1073/pnas.70.6.1688; TASCHNER PEM, 1988, J BACTERIOL, V170, P1533, DOI 10.1128/jb.170.4.1533-1540.1988; TEATHER RM, 1974, J BACTERIOL, V118, P407, DOI 10.1128/JB.118.2.407-413.1974; WARD JE, 1984, J BACTERIOL, V157, P815, DOI 10.1128/JB.157.3.815-820.1984; WARD JE, 1985, CELL, V42, P399; WIENTJES FB, 1989, J BACTERIOL, V171, P3412, DOI 10.1128/jb.171.6.3412-3419.1989	23	1129	1166	1	98	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 14	1991	354	6349					161	164		10.1038/354161a0	http://dx.doi.org/10.1038/354161a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP880	1944597				2022-12-01	WOS:A1991GP88000064
J	GRAY, WA; CAPONE, RJ; MOST, AS				GRAY, WA; CAPONE, RJ; MOST, AS			UNSUCCESSFUL EMERGENCY MEDICAL RESUSCITATION - ARE CONTINUED EFFORTS IN THE EMERGENCY DEPARTMENT JUSTIFIED	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOSPITAL CARDIAC-ARREST; CARDIOPULMONARY RESUSCITATION; SURVIVAL; DEATH; DEFIBRILLATION; EXPERIENCE; OUTCOMES; CPR	Background. The majority of attempts to resuscitate victims of prehospital cardiopulmonary arrest are unsuccessful, and patients are frequently transported to the emergency department for further resuscitation efforts. We evaluated the efficacy and costs of continued hospital resuscitation for patients in whom resuscitation efforts outside the hospital have failed. Methods. We reviewed the records of 185 patients presenting to our emergency department after an initially unsuccessful, but ongoing, resuscitation for a prehospital arrest (cardiac, respiratory, or both) by an emergency medical team. Prehospital and hospital characteristics of treatment for the arrest were identified, and the patients' outcomes in the emergency room were ascertained. The hospital course and the hospital costs for the patients who were revived were determined. Results. Over a 19-month period, only 16 of the 185 patients (9 percent) were successfully resuscitated in the emergency department and admitted to the hospital. A shorter duration of prehospital resuscitation was the only characteristic of the resuscitation associated with an improved outcome in the emergency department. No patient survived until hospital discharge, and all but one were comatose throughout hospitalization. The mean stay in the hospital was 12.6 days (range, 1 to 132), with an average of 2.3 days (range, 1 to 11) in an intensive care unit. The total hospital cost for the 16 patients admitted was $180,908 (range per patient, $1,984 to $95,144). Conclusions. In general, continued resuscitation efforts in the emergency department tor victims of cardiopulmonary arrest in whom prehospital resuscitation has tailed are not worthwhile, and they consume precious institutional and economic resources without gain.	BROWN UNIV,PROGRAM MED,PROVIDENCE,RI 02912; UNIV ROCHESTER,MED CTR,DIV CARDIOL,ROCHESTER,NY 14642	Brown University; University of Rochester	GRAY, WA (corresponding author), RHODE ISL HOSP,DIV CARDIOL,593 EDDY ST,PROVIDENCE,RI 02903, USA.							APRAHAMIAN C, 1986, ANN EMERG MED, V15, P445, DOI 10.1016/S0196-0644(86)80185-8; BACHMAN JW, 1986, JAMA-J AM MED ASSOC, V256, P477, DOI 10.1001/jama.256.4.477; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; BLACKHALL LJ, 1987, NEW ENGL J MED, V317, P1281, DOI 10.1056/NEJM198711123172009; BRETT AS, 1986, NEW ENGL J MED, V315, P1347, DOI 10.1056/NEJM198611203152109; COBB LA, 1980, MOD CONC CARDIOV DIS, V49, P31; CUMMINS RO, 1985, AM J EMERG MED, V3, P114, DOI 10.1016/0735-6757(85)90032-4; CUMMINS RO, 1985, JAMA-J AM MED ASSOC, V253, P2408, DOI 10.1001/jama.253.16.2408; EINARSSON O, 1989, J INTERN MED, V225, P129, DOI 10.1111/j.1365-2796.1989.tb00052.x; EISENBERG M, 1979, AM J PUBLIC HEALTH, V69, P30, DOI 10.2105/AJPH.69.1.30; Hallstorm AP, 1983, EMERG HLTH SERV Q, V1, P41; HALLSTROM AP, 1985, CRIT CARE MED, V13, P927, DOI 10.1097/00003246-198511000-00019; KELLERMANN AL, 1988, ANN EMERG MED, V17, P589, DOI 10.1016/S0196-0644(88)80398-6; KOUWENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064, DOI 10.1001/jama.1960.03020280004002; McIntyre KM, 1983, TXB ADV CARDIAC LIFE; MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199; MYERBURG RJ, 1982, JAMA-J AM MED ASSOC, V247, P1485, DOI 10.1001/jama.247.10.1485; MYERBURG RJ, 1980, AM J MED, V68, P568, DOI 10.1016/0002-9343(80)90307-1; OROURKE PP, 1986, CRIT CARE MED, V14, P466, DOI 10.1097/00003246-198605000-00006; ROTH R, 1984, ANN EMERG MED, V13, P237, DOI 10.1016/S0196-0644(84)80470-9; SAPHIR R, 1968, MEDICINE, V47, P73, DOI 10.1097/00005792-196801000-00004; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; SHIMAZU S, 1983, J TRAUMA, V23, P213, DOI 10.1097/00005373-198303000-00006; STULTS KR, 1984, NEW ENGL J MED, V310, P219, DOI 10.1056/NEJM198401263100403; TAFFET GE, 1988, JAMA-J AM MED ASSOC, V260, P2069, DOI 10.1001/jama.260.14.2069; Talbott J., 1965, FUNDAMENTALS CARDIOP, P1; THOMPSON RG, 1979, ANN INTERN MED, V90, P437; TOMLINSON T, 1988, NEW ENGL J MED, V318, P43, DOI 10.1056/NEJM198801073180109; TRESCH DD, 1981, ARCH INTERN MED, V141, P1154, DOI 10.1001/archinte.141.9.1154; TWEED WA, 1984, CAN MED ASSOC J, V131, P429; WEAVER WD, 1976, CIRCULATION, V54, P895, DOI 10.1161/01.CIR.54.6.895; WEAVER WD, 1984, CIRCULATION, V69, P943, DOI 10.1161/01.CIR.69.5.943; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; WEAVER WD, 1986, ANN EMERG MED, V15, P1181; 1983, EUTHANASIA AIDING SU; 1980, JAMA-J AM MED ASSOC, V24, P453	36	202	204	1	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 14	1991	325	20					1393	1398		10.1056/NEJM199111143252001	http://dx.doi.org/10.1056/NEJM199111143252001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP524	1922249				2022-12-01	WOS:A1991GP52400001
J	HYAMS, KC; BOURGEOIS, AL; MERRELL, BR; ROZMAJZL, P; ESCAMILLA, J; THORNTON, SA; WASSERMAN, GM; BURKE, A; ECHEVERRIA, P; GREEN, KY; KAPIKIAN, AZ; WOODY, JN				HYAMS, KC; BOURGEOIS, AL; MERRELL, BR; ROZMAJZL, P; ESCAMILLA, J; THORNTON, SA; WASSERMAN, GM; BURKE, A; ECHEVERRIA, P; GREEN, KY; KAPIKIAN, AZ; WOODY, JN			DIARRHEAL DISEASE DURING OPERATION-DESERT-SHIELD	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TOXIGENIC ESCHERICHIA-COLI; TRAVELERS DIARRHEA; NORWALK VIRUS; SOUTH-KOREA; TRIMETHOPRIM; SHIGELLA; ANTIGEN; SULFAMETHOXAZOLE; GASTROENTERITIS; CHILDREN	Background. Under combat conditions infectious disease can become a major threat to military forces. During Operation Desert Shield, there were numerous outbreaks of diarrhea among the U.S. forces. To evaluate the causes of and risk factors for diarrheal disease, we collected clinical and epidemiologic data from U.S. troops stationed in northeastern Saudi Arabia. Methods. Between September and December 1990, stool cultures for enteric pathogens were obtained from 432 military personnel who presented with diarrhea, cramps, vomiting, or hematochezia. In addition, a questionnaire was administered to 2022 soldiers in U.S. military units located in various regions of Saudi Arabia. Results. A bacterial enteric pathogen was identified in 49.5 percent of the troops with gastroenteritis. Enterotoxigenic Escherichia coli and Shigella sonnei were the most common bacterial pathogens. Of 125 E. coli infections, 39 percent were resistant to trimethoprim-sulfamethoxazole, 63 percent to tetracycline, and 48 percent to ampicillin. Of 113 shigella infections, 85 percent were resistant to trimethoprim-sulfamethoxazole, 68 percent to tetracycline, and 21 percent to ampicillin. All bacterial isolates were sensitive to norfloxacin and ciprofloxacin. After an average of two months in Saudi Arabia, 57 percent of the surveyed troops had at least one episode of diarrhea, and 20 percent reported that they were temporarily unable to carry out their duties because of diarrheal symptoms. Vomiting was infrequently reported as a primary symptom, but of 11 military personnel in whom vomiting was a major symptom, 9 (82 percent) had serologic evidence of infection with the Norwalk virus. Conclusions. Gastroenteritis caused by enterotoxigenic E coli and shigella resistant to a number of drugs was a major problem that frequently interfered with the duties of U.S. troops during Operation Desert Shield.	ARMED FORCES RES INST MED SCI,BANGKOK,THAILAND; NIH,INFECT DIS LAB,BETHESDA,MD 20892; USN,MED RES & DEV COMMAND,BETHESDA,MD 20814; USN,MED RES INST DETACHMENT,LIMA,PERU; USN,ENVIRONM & PREVENT MED UNIT 7,NAPLES,ITALY; USA,MED DEPT ACT,PREVENT MED SERV,FT CAMPBELL,KY; USN,MED RES UNIT 3,DIV EPIDEMIOL,CAIRO,EGYPT; WILLIAM BEAUMONT ARMY MED CTR,DEPT PEDIAT,EL PASO,TX 79920	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS); National Institutes of Health (NIH) - USA; United States Department of Defense; United States Navy; Naval Medical Research Center (NMRC); Naval Medical Research Unit - No. 3 (NAMRU-3); United States Department of Defense; United States Navy; William Beaumont Army Medical Center	HYAMS, KC (corresponding author), USN,MED RES INST,DIV EPIDEMIOL,12300 WASHINGTON AVE,ROCKVILLE,MD 20852, USA.							AUGUST MJ, 1987, J CLIN MICROBIOL, V25, P2233, DOI 10.1128/JCM.25.11.2233-2235.1987; BAUER AW, 1966, AM J CLIN PATHOL, V45, P493; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CHATKAEOMORAKOT A, 1987, PEDIATR INFECT DIS J, V6, P735, DOI 10.1097/00006454-198708000-00008; CHUGH TD, 1985, J HYG-CAMBRIDGE, V95, P391, DOI 10.1017/S0022172400062811; COHEN D, 1991, LANCET, P993; DANIELL FD, 1985, MIL MED, V150, P171, DOI 10.1093/milmed/150.4.171; DAVIS H, 1988, AM J EPIDEMIOL, V128, P1312, DOI 10.1093/oxfordjournals.aje.a115084; DEAN AG, 1972, J INFECT DIS, V125, P407, DOI 10.1093/infdis/125.4.407; DUPONT HL, 1989, J INFECT DIS, V159, P1126, DOI 10.1093/infdis/159.6.1126; ECHEVERRIA P, 1979, AM J EPIDEMIOL, V109, P493, DOI 10.1093/oxfordjournals.aje.a112706; ECHEVERRIA P, 1979, J INFECT DIS, V139, P215, DOI 10.1093/infdis/139.2.215; ECHEVERRIA P, 1978, AM J EPIDEMIOL, V108, P68; ECHEVERRIA P, 1990, GENE PROBES BACTERIA, P95; ERICSSON CD, 1990, JAMA-J AM MED ASSOC, V263, P257, DOI 10.1001/jama.263.2.257; ERICSSON CD, 1987, ANN INTERN MED, V106, P216, DOI 10.7326/0003-4819-106-2-216; GARY GW, 1985, J CLIN MICROBIOL, V22, P274, DOI 10.1128/JCM.22.2.274-278.1985; GARY GW, 1987, J CLIN MICROBIOL, V25, P2001, DOI 10.1128/JCM.25.10.2001-2003.1987; GASSER RA, 1991, NEW ENGL J MED, V324, P859, DOI 10.1056/NEJM199103213241229; GOLDFIELD EC, 1991, REV INFECT DIS S3, V13, pS197; GOODMAN LJ, 1990, ARCH INTERN MED, V150, P541, DOI 10.1001/archinte.150.3.541; GRIFFIN MR, 1982, AM J EPIDEMIOL, V115, P178, DOI 10.1093/oxfordjournals.aje.a113289; HABERBERGER RL, 1991, MIL MED, V156, P27, DOI 10.1093/milmed/156.1.27; HEGGERS JP, 1978, MIL MED, V143, P390; Kapikian AZ, 1990, VIROLOGY, P1353; KAPIKIAN AZ, 1975, PERSPECT VIROL, V9, P9; KAPIKIAN AZ, 1990, VIROLOGY, V1, P671; KELLY MT, 1985, MANUAL CLIN MICROBIO, P00263; MARTIN DL, 1986, AM J EPIDEMIOL, V124, P299, DOI 10.1093/oxfordjournals.aje.a114388; MELDMAN IJ, 1978, BACTERIOLOGY ANAL MA; MIDTHUN K, 1989, J CLIN MICROBIOL, V27, P2799, DOI 10.1128/JCM.27.12.2799-2804.1989; MIKHAIL IA, 1990, J CLIN MICROBIOL, V28, P956, DOI 10.1128/JCM.28.5.956-961.1990; Morris G. K., 1985, MANUAL CLIN MICROBIO, P302; MURRAY BE, 1986, REV INFECT DIS, V8, pS172; OLDFIELD EC, 1987, AM J TROP MED HYG, V37, P616, DOI 10.4269/ajtmh.1987.37.616; OPRANDY JJ, 1988, J CLIN MICROBIOL, V26, P92, DOI 10.1128/JCM.26.1.92-95.1988; PAZZAGLIA G, 1982, MIL MED, V147, P27, DOI 10.1093/milmed/147.1.27; QUIN NE, 1982, MIL MED, V147, P728, DOI 10.1093/milmed/147.9.728; SACK DA, 1977, JOHNS HOPKINS MED J, V141, P63; SACK DA, 1975, INFECT IMMUN, V11, P334, DOI 10.1128/IAI.11.2.334-336.1975; SCOTT DA, 1990, AM J TROP MED HYG, V42, P160, DOI 10.4269/ajtmh.1990.42.160; SERENY B, 1955, Acta Microbiol Acad Sci Hung, V2, P293; TAYLOR DN, 1991, ANN INTERN MED, V114, P731, DOI 10.7326/0003-4819-114-9-731; TAYLOR WR, 1982, NEW ENGL J MED, V306, P1093, DOI 10.1056/NEJM198205063061807; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x; YOLKEN RH, 1986, MANUAL CLIN LABORATO, P573; YOUSIF AA, 1989, J BAHRAIN MED SOC, V1, P52	47	218	226	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 14	1991	325	20					1423	1428		10.1056/NEJM199111143252006	http://dx.doi.org/10.1056/NEJM199111143252006			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP524	1656260				2022-12-01	WOS:A1991GP52400006
J	JAVITT, JC; MCBEAN, AM; NICHOLSON, GA; BABISH, JD; WARREN, JL; KRAKAUER, H				JAVITT, JC; MCBEAN, AM; NICHOLSON, GA; BABISH, JD; WARREN, JL; KRAKAUER, H			UNDERTREATMENT OF GLAUCOMA AMONG BLACK-AMERICANS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OPEN-ANGLE GLAUCOMA; ARGON-LASER TRABECULOPLASTY; FOLLOW-UP; RETINOPATHY; POPULATION; BLINDNESS; WHITES; CARE	Background. Cross-sectional studies and those using national data sets estimate that glaucoma-related blindness is between six and eight times more common among black Americans than among whites. Community-based studies have found that glaucoma is four to six times more prevalent among blacks. It is not known why blacks with glaucoma are more likely to become blind than whites with glaucoma. Methods. To investigate the possibility that under-treatment of glaucoma is an important factor contributing to this higher rate of blindness, we studied the population-based rates of incisional and laser surgery tor open-angle glaucoma among blacks and whites in a 5 percent random sample of Medicare claims for 1986 through 1988. Results. For all U.S. census divisions combined, the rate of surgery for glaucoma among black Medicare beneficiaries was 2.2 times higher than the rate among white beneficiaries (95 percent confidence interval, 2.1 to 2.3). We calculated an expected rate of treatment among blacks on the basis of the rate of treatment among whites and the assumption that glaucoma is four times more prevalent among blacks - a conservative estimate. The observed rate of glaucoma surgery among blacks was 45 percent lower than the expected rate we calculated, which may in part account for the excess rate of blindness among blacks. The magnitude of this difference in treatment rates varied from 29 percent in the Middle Atlantic states to 50 percent in the South Atlantic states. Conclusions. Older black Americans are not receiving potentially sight-saving care for open-angle glaucoma at the same rate as older white Americans.	GEORGETOWN UNIV,DEPT COMMUNITY & FAMILY MED,PROGRAM TECHNOL ASSESSMENT,WASHINGTON,DC 20057; HLTH CARE FINANCING ADM,BUR HLTH STAND QUAL,OFF PROGRAM ASSESSMENT,BALTIMORE,MD; HLTH CARE FINANCING ADM,OFF RES,BALTIMORE,MD	Georgetown University	JAVITT, JC (corresponding author), CTR SIGHT,WORTHEN CTR EYE CARE RES,3800 RESERVOIR RD NW,WASHINGTON,DC 20007, USA.		Javitt, Jonathan/AAJ-5574-2021	Javitt, Jonathan/0000-0003-2371-1609	NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR006758, R01RR006758] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY008805, R21EY007744] Funding Source: NIH RePORTER; NCRR NIH HHS [S10 RR0 6758] Funding Source: Medline; NEI NIH HHS [R21 EY07744, R01 EY08805] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		[Anonymous], HCFA COMMON PROCEDUR; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; DASBACH EJ, 1991, MED CARE, V29, P20, DOI 10.1097/00005650-199101000-00003; EISENBERG JM, 1979, ANN INTERN MED, V90, P957, DOI 10.7326/0003-4819-90-6-957; FISHER E, IN PRESS AM J PUBLIC; FORD E, 1989, AM J PUBLIC HEALTH, V79, P437, DOI 10.2105/AJPH.79.4.437; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HILLER R, 1975, AM J OPHTHALMOL, V80, P62, DOI 10.1016/0002-9394(75)90870-3; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; JAVITT JC, 1991, OPHTHALMOLOGY, V98, P1565; JAVITT JC, 1990, OPHTHALMOLOGY, V97, P483, DOI 10.1016/S0161-6420(90)32573-3; JAVITT JC, 1989, OPHTHALMOLOGY, V96, P255; KAHN HA, 1973, DHEW NIH73427 NAT EY; KRUPIN T, 1986, OPHTHALMOLOGY, V93, P811; Lave J, 1983, Health Care Financ Rev, V5, P93; LESKE MC, 1989, BRIT J OPHTHALMOL, V73, P365, DOI 10.1136/bjo.73.5.365; MARTIN MJ, 1985, AM J OPHTHALMOL, V99, P383, DOI 10.1016/0002-9394(85)90001-7; MASON RP, 1989, OPHTHALMOLOGY, V96, P1363; MAYER WJ, 1989, AM J PUBLIC HEALTH, V79, P772, DOI 10.2105/AJPH.79.6.772; MILLER RD, 1981, OPHTHALMIC SURG LAS, V12, P46; PODGOR MJ, 1983, AM J EPIDEMIOL, V118, P206, DOI 10.1093/oxfordjournals.aje.a113628; ROBERTS J, 1977, VITAL HLTH STATI 201, V11; ROOS LL, 1990, JAMA-J AM MED ASSOC, V263, P2453, DOI 10.1001/jama.263.18.2453; SCHWARTZ AL, 1985, ARCH OPHTHALMOL-CHIC, V103, P1482; STROGATZ DS, 1990, AM J PUBLIC HEALTH, V80, P290, DOI 10.2105/AJPH.80.3.290; TIELSCH JM, 1991, JAMA-J AM MED ASSOC, V266, P369, DOI 10.1001/jama.266.3.369; TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048; WELSH NH, 1972, BRIT J OPHTHALMOL, V56, P32, DOI 10.1136/bjo.56.1.32; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; WENNEKER MB, 1990, JAMA-J AM MED ASSOC, V264, P1255, DOI 10.1001/jama.264.10.1255; 1977, CPT4 AM MED ASS; 1986, INT CLASSIFICATION D; 1990, HCFA03301 HLTH CAR F, V2	33	98	98	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 14	1991	325	20					1418	1422		10.1056/NEJM199111143252005	http://dx.doi.org/10.1056/NEJM199111143252005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GP524	1922253				2022-12-01	WOS:A1991GP52400005
J	JULIER, C; HYER, RN; DAVIES, J; MERLIN, F; SOULARUE, P; BRIANT, L; CATHELINEAU, G; DESCHAMPS, I; ROTTER, JI; FROGUEL, P; BOITARD, C; BELL, JI; LATHROP, GM				JULIER, C; HYER, RN; DAVIES, J; MERLIN, F; SOULARUE, P; BRIANT, L; CATHELINEAU, G; DESCHAMPS, I; ROTTER, JI; FROGUEL, P; BOITARD, C; BELL, JI; LATHROP, GM			INSULIN-IGF2 REGION ON CHROMOSOME-11P ENCODES A GENE IMPLICATED IN HLA-DR4-DEPENDENT DIABETES SUSCEPTIBILITY	NATURE			English	Article							WIEDEMANN-BECKWITH SYNDROME; MELLITUS; DNA; SEQUENCE; LOCUS; IDDM; INHERITANCE; LINKAGE; HLA	A CLASS of alleles at the VNTR (variable number of tandem repeat) locus in the 5' region of the insulin gene (INS) on chromosome 11p is associated with increased risk of insulin-dependent diabetes mellitus (IDDM) 1-6, but family studies have failed to demonstrate linkage 5,7. INS is thought to contribute to IDDM susceptibility but this view has been difficult to reconcile with the lack of linkage evidence 6-8. We thus investigated polymorphisms of INS and neighbouring loci in random diabetics, IDDM multiplex families and controls. HLA-DR4-positive diabetics showed an increased risk associated with common variants at polymorphic sites in a 19-kilobase segment spanned by the 5' INS VNTR and the third intron of the gene for insulin-like growth factor II (IGF2). As INS is the major candidate gene from this region, diabetic and control sequences were compared to identify all INS polymorphisms that could contribute to disease susceptibility. In multiplex families the IDDM-associated alleles were transmitted preferentially to HLA-DR4-positive diabetic offspring from heterozygous parents. The effect was strongest in paternal meioses, suggesting a possible role for maternal imprinting. Our results strongly support the existence of a gene or genes affecting HLA-DR4 IDDM susceptibility which is located in a 19-kilobase region of INS-IGF2. Our results also suggest new ways to map susceptibility loci in other common diseases.	JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC IMMUNOL GRP,OXFORD OX3 9DU,ENGLAND; CTR ETUD POLYMORHISME HUMAIN,F-75010 PARIS,FRANCE; HOP ST LOUIS,SERV ENDOCRINOL,F-75010 PARIS,FRANCE; HOP NECKER ENFANTS MALAD,INSERM,U25,F-75730 PARIS 15,FRANCE; CEDARS SINAI MED CTR,DIV MED GENET,LOS ANGELES,CA 90048; UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90024	University of Oxford; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			FROGUEL, Philippe/O-6799-2017; JULIER, Cécile/M-9824-2017; Briant, Laurence/AAB-9281-2021	FROGUEL, Philippe/0000-0003-2972-0784; JULIER, Cécile/0000-0002-1538-0240; Briant, Laurence/0000-0002-1995-3501	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEECHEY CV, 1990, MOUSE GENOME, V87, P64; BELL G I, 1985, American Journal of Human Genetics, V37, pA188; BELL GI, 1980, NATURE, V284, P26, DOI 10.1038/284026a0; BELL GI, 1982, NATURE, V295, P31, DOI 10.1038/295031a0; BELL GI, 1984, DIABETES, V33, P176, DOI 10.2337/diabetes.33.2.176; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BELL GI, 1987, CIBA F S, V130; BELL GI, 1990, MOL BIOL ISLETS LANG; BIDWELL JL, 1988, TRANSPLANTATION, V45, P640, DOI 10.1097/00007890-198803000-00027; BROWN KW, 1990, AM J HUM GENET, V46, P1000; COX NJ, 1988, AM J HUM GENET, V43, P495; COX NJ, 1989, GENET EPIDEMIOL, V6, P65, DOI 10.1002/gepi.1370060113; COX NJ, 1988, AM J HUM GENET, V42, P167; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DIXON WJ, 1988, BMDP STATISTICAL SOF; FERNS GAA, 1986, J MED GENET, V23, P210, DOI 10.1136/jmg.23.3.210; GRUNT JA, 1972, YALE J BIOL MED, V45, P15; HITMAN GA, 1985, DIABETOLOGIA, V28, P218; HITMAN GA, 1990, J MED GENET, V27, P97; HYER RN, 1991, AM J HUM GENET, V48, P243; KOUFOS A, 1989, AM J HUM GENET, V44, P711; OWERBACH D, 1990, DIABETES, V39, P1504, DOI 10.2337/diabetes.39.12.1504; PETTENATI MJ, 1986, HUM GENET, V74, P143, DOI 10.1007/BF00282078; SPIELMAN RS, 1989, GENET EPIDEMIOL, V6, P43, DOI 10.1002/gepi.1370060111; SURES I, 1980, SCIENCE, V208, P57, DOI 10.1126/science.6927840; THOMSON G, 1989, GENET EPIDEMIOL, V6, P155, DOI 10.1002/gepi.1370060129; THOMSON G, 1988, AM J HUM GENET, V43, P799; ULLRICH A, 1980, SCIENCE, V209, P612, DOI 10.1126/science.6248962; ULLRICH A, 1982, NUCLEIC ACIDS RES, V10, P2225, DOI 10.1093/nar/10.7.2225; WARRAM JH, 1984, NEW ENGL J MED, V311, P149, DOI 10.1056/NEJM198407193110304; 1990, CYTOGENET CELL GENET, V55, P1; 1989, CYTOGENET CELL GENET, V51, P1	32	367	372	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 14	1991	354	6349					155	159		10.1038/354155a0	http://dx.doi.org/10.1038/354155a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP880	1944595				2022-12-01	WOS:A1991GP88000062
J	MOHR, G; LAMBOWITZ, AM				MOHR, G; LAMBOWITZ, AM			INTEGRATION OF A GROUP-I INTRON INTO A RIBOSOMAL-RNA SEQUENCE PROMOTED BY A TYROSYL-TRANSFER RNA-SYNTHETASE	NATURE			English	Article							NEUROSPORA MITOCHONDRIA; INVOLVEMENT; INVITRO	GROUP I and II introns are mobile elements that propagate by insertion into different genes 1. Some introns of both types self-splice in vitro by transesterification reactions catalysed by the intron RNA 2. These transesterifications are reversible 3-5, and it has been suggested that reverse splicing followed by reverse transcription and recombination with genomic DNA may be a mechanism for intron transposition 6-7. In vivo the splicing of many, if not all, group I and II introns requires protein factors, which may facilitate correct folding of the intron RNAs 8. Here we show that the Neurospora mitochondrial large rRNA intron, a group I intron that is not self-splicing in vitro 9, undergoes reverse splicing in a reaction promoted by the CYT-18 protein, the Neurospora mitochondrial tyrosyl-tRNA synthetase, which is required for splicing the intron in vivo 10. In contrast to known RNA-catalysed reverse splicing reactions, this protein-assisted reverse splicing is sufficiently rapid to compete with forward splicing at low RNA concentrations under physiologically relevant conditions, including high GTP and low Mg2+ concentrations. Our results indicate that proteins that promote splicing could contribute to intron mobility by promoting reverse splicing in vivo.	OHIO STATE UNIV,DEPT MOLEC GENET,484 W 12TH AVE,COLUMBUS,OH 43210; OHIO STATE UNIV,CTR BIOTECHNOL,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University				Mohr, Georg/0000-0002-6411-0685				AKINS RA, 1987, CELL, V50, P331, DOI 10.1016/0092-8674(87)90488-0; AUGUSTIN S, 1990, NATURE, V343, P383, DOI 10.1038/343383a0; BARTEL DP, 1991, MOL CELL BIOL, V11, P3390, DOI 10.1128/MCB.11.6.3390; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CECH TR, 1985, INT REV CYTOL, V3, P3; COLLINS RA, 1985, J MOL BIOL, V184, P413, DOI 10.1016/0022-2836(85)90291-8; GARRIGA G, 1986, CELL, V46, P669, DOI 10.1016/0092-8674(86)90342-9; GUO QB, 1991, J BIOL CHEM, V266, P1809; KITTLE JD, 1991, GENE DEV, V5, P109; KUIPER MTR, 1988, CELL, V55, P693, DOI 10.1016/0092-8674(88)90228-0; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; LAMBOWITZ AM, 1989, CELL, V56, P323, DOI 10.1016/0092-8674(89)90232-8; MAJUMDER AL, 1989, MOL CELL BIOL, V9, P2089, DOI 10.1128/MCB.9.5.2089; MORL M, 1990, CELL, V60, P629, DOI 10.1016/0092-8674(90)90666-3; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; WOODSON SA, 1991, BIOCHEMISTRY-US, V30, P2042, DOI 10.1021/bi00222a006; WOODSON SA, 1989, CELL, V57, P335, DOI 10.1016/0092-8674(89)90971-9	17	23	26	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 14	1991	354	6349					164	167		10.1038/354164a0	http://dx.doi.org/10.1038/354164a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP880	1658660				2022-12-01	WOS:A1991GP88000065
J	SAKAI, K; MIYASHITA, Y				SAKAI, K; MIYASHITA, Y			NEURAL ORGANIZATION FOR THE LONG-TERM-MEMORY OF PAIRED ASSOCIATES	NATURE			English	Article							INFERIOR TEMPORAL NEURONS; CORTEX; MONKEY; LOBECTOMY; CORRELATE; STIMULUS; MACAQUE	MOST of our long-term memories of episodes or objects are organized so that we can retrieve them by association. Clinical neuropsychologists assess human memory by the paired-associate learning test, in which a series of paired words or figures is presented and the subject is then asked to retrieve the other pair member associated with each cue 1. Patients with lesions of the temporal lobe show marked impairment in this test 2-6. In our study, we trained monkeys in a pair-association task 7 using a set of computer-generated paired patterns. We found two types of task-related neurons in the anterior temporal cortex. One type selectively responded to both pictures of the paired associates. The other type, which had the strongest response to one picture during the cue presentation, exhibited increasing activity during the delay period when the associate of that picture was used as a cue. These results provide new evidence that single neurons acquire selectivity for visual patterns through associative learning. They also indicate neural mechanisms for storage and retrieval in the long-term memory of paired associates.			SAKAI, K (corresponding author), UNIV TOKYO,SCH MED,DEPT PHYSIOL,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN.		Rohlf, F J/A-8710-2008; Miyashita, Yasushi/B-7171-2019	Miyashita, Yasushi/0000-0003-3496-8637				ARTOLA A, 1987, NATURE, V330, P649, DOI 10.1038/330649a0; BRUCE CJ, 1985, J NEUROPHYSIOL, V53, P603, DOI 10.1152/jn.1985.53.3.603; Darley, 1967, BRAIN MECH UNDERLY, P122; DESIMONE R, 1984, J NEUROSCI, V4, P2051; FREGNAC Y, 1988, NATURE, V333, P367, DOI 10.1038/333367a0; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; GOLDSTEIN LH, 1988, CORTEX, V24, P41, DOI 10.1016/S0010-9452(88)80016-9; GROSS CG, 1972, J NEUROPHYSIOL, V35, P96, DOI 10.1152/jn.1972.35.1.96; INSAUSTI R, 1987, J COMP NEUROL, V264, P356, DOI 10.1002/cne.902640306; JONES MK, 1974, NEUROPSYCHOLOGIA, V12, P21, DOI 10.1016/0028-3932(74)90023-2; MAURITZ KH, 1986, EXP BRAIN RES, V61, P229; MEYER V, 1955, J NEUROL NEUROSUR PS, V18, P44, DOI 10.1136/jnnp.18.1.44; Milner B, 1972, Clin Neurosurg, V19, P421; MIYASHITA Y, 1988, NATURE, V331, P68, DOI 10.1038/331068a0; MIYASHITA Y, 1988, NATURE, V335, P817, DOI 10.1038/335817a0; MURRAY E A, 1988, Society for Neuroscience Abstracts, V14, P2; PERRETT DI, 1982, EXP BRAIN RES, V47, P329; PETRIDES M, 1985, NEUROPSYCHOLOGIA, V23, P601, DOI 10.1016/0028-3932(85)90062-4; ROLLS ET, 1989, J NEUROSCI, V9, P1835; SCHWARTZ EL, 1983, P NATL ACAD SCI-BIOL, V80, P5776, DOI 10.1073/pnas.80.18.5776; Snedecor GW, 1989, STAT METHODS, P97; Squire L. R., 1984, MEMORY CONSOLIDATION, P185; WEBSTER MJ, 1991, J NEUROSCI, V11, P1095; Wechsler D., 1987, WMS R WECHSLER MEMOR; ZAHN CT, 1972, IEEE T COMPUT, VC 21, P269, DOI 10.1109/TC.1972.5008949	25	513	517	0	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 14	1991	354	6349					152	155		10.1038/354152a0	http://dx.doi.org/10.1038/354152a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP880	1944594				2022-12-01	WOS:A1991GP88000061
J	SLOANE, DL; LEUNG, R; CRAIK, CS; SIGAL, E				SLOANE, DL; LEUNG, R; CRAIK, CS; SIGAL, E			A PRIMARY DETERMINANT FOR LIPOXYGENASE POSITIONAL SPECIFICITY	NATURE			English	Article							LOW-DENSITY-LIPOPROTEIN; HUMAN RETICULOCYTE 15-LIPOXYGENASE; MOLECULAR-CLONING; SUBSTRATE-SPECIFICITY; HUMAN 5-LIPOXYGENASE; IRON ENVIRONMENT; EXPRESSION; PROTEIN; CDNA; 12-LIPOXYGENASE	THE three mammalian lipoxygenases are named according to the carbon position (5, 12 or 15) at which they catalyse the oxygenation of arachidonic acid 1; they are implicated in inflammatory disorders, for example 15-lipoxygenase is induced in atherosclerosis 2 and can oxidize low-density lipoprotein to its atherogenic form 3,4. To identify what determines this positional specificity, we have exchanged conserved differences in the isoforms of 12- and 15-lipoxygenases. Substitution of methionine with valine at position 418 of human 15-lipoxygenase results in an enzyme that performs 12- and 15-lipoxygenation equally. This effect can be mimicked by incubating wild-type 15-lipoxygenase with a synthetically altered substrate which has its doubly allylic methylene carbons shifted by one carbon relative to arachidonic acid. Other mutations at the neighbouring amino acids 416 and 417 give an enzyme which performs 12- and 15-lipoxygenation in a ratio of 15:1. These results indicate that this region might position the substrate in the active site.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco								BALCAREK JM, 1988, J BIOL CHEM, V263, P13937; BRYANT RW, 1982, J BIOL CHEM, V257, P6050; CRAIK CS, 1985, SCIENCE, V228, P291, DOI 10.1126/science.3838593; DEMARZO N, IN PRESS AM J PHYSL; DIXON RAF, 1988, P NATL ACAD SCI USA, V85, P416, DOI 10.1073/pnas.85.2.416; DUNHAM WR, 1990, EUR J BIOCHEM, V190, P611, DOI 10.1111/j.1432-1033.1990.tb15616.x; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FUNK CD, 1990, P NATL ACAD SCI USA, V87, P5638, DOI 10.1073/pnas.87.15.5638; HAMBERG M, 1967, J BIOL CHEM, V242, P5329; KUHN H, 1990, J BIOL CHEM, V265, P16300; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MATSUMOTO T, 1988, P NATL ACAD SCI USA, V85, P26, DOI 10.1073/pnas.85.1.26; NAVARATNAM S, 1988, BIOCHIM BIOPHYS ACTA, V956, P70, DOI 10.1016/0167-4838(88)90299-3; NGUYEN T, IN PRESS J BIOL CHEM; PISTORIUS EK, 1974, J BIOL CHEM, V249, P3183; PONDER JW, 1987, J MOL BIOL, V1939, P7751; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBATA D, 1988, J BIOL CHEM, V263, P6816; SIGAL E, 1988, BIOCHEM BIOPH RES CO, V157, P457, DOI 10.1016/S0006-291X(88)80271-7; SIGAL E, 1990, J BIOL CHEM, V265, P5113; SLOANE DL, 1990, BIOMED BIOCHIM ACTA, V49, pS11; SPARROW CP, 1988, J LIPID RES, V29, P745; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; WELLS JA, 1987, P NATL ACAD SCI USA, V84, P5167, DOI 10.1073/pnas.84.15.5167; WILKS HM, 1988, SCIENCE, V242, P1541, DOI 10.1126/science.3201242; YLAHERTTUALA S, 1990, P NATL ACAD SCI USA, V87, P6959, DOI 10.1073/pnas.87.18.6959; YOSHIMOTO T, 1990, P NATL ACAD SCI USA, V87, P2142, DOI 10.1073/pnas.87.6.2142	28	189	192	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 14	1991	354	6349					149	152		10.1038/354149a0	http://dx.doi.org/10.1038/354149a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP880	1944593				2022-12-01	WOS:A1991GP88000060
J	SOMMER, A; TIELSCH, JM; KATZ, J; QUIGLEY, HA; GOTTSCH, JD; JAVITT, JC; MARTONE, JF; ROYALL, RM; WITT, KA; EZRINE, S				SOMMER, A; TIELSCH, JM; KATZ, J; QUIGLEY, HA; GOTTSCH, JD; JAVITT, JC; MARTONE, JF; ROYALL, RM; WITT, KA; EZRINE, S			RACIAL-DIFFERENCES IN THE CAUSE-SPECIFIC PREVALENCE OF BLINDNESS IN EAST BALTIMORE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLAUCOMA; IMPAIRMENT; RACE	Background. Bilateral blindness unrelated to simple refractive error is twice as prevalent among blacks as among whites, although the difference narrows among the elderly. The reasons for this race- and age-related pattern are uncertain. Methods and Results. A randomly selected, stratified, multistage cluster sample of 2395 blacks and 2913 whites 40 years of age and older in East Baltimore underwent detailed ophthalmic examinations by a single team. We identified 64 subjects who were blind in both eyes. The leading causes of blindness were unoperated senile cataract (accounting for blindness in 27 of the total of 128 eyes), primary open-angle glaucoma (17 eyes), and age-related macular degeneration (16 eyes). Together, these three disorders accounted for 47 percent of all blindness in this sample. Unoperated cataract accounted for 27 percent of all blindness among blacks, among whom it was four times more common than among whites; whites were almost 50 percent more likely than blacks to have undergone cataract extraction before the age of 80 (P < 0.002). Primary open-angle glaucoma accounted for 19 percent of all blindness among blacks; it was six times as frequent among blacks as among whites and began 10 years earlier, on average. By contrast, age-related macular degeneration resulting in blindness was limited to whites, among whom it was the leading cause of blindness (prevalence, 2.7 per 1000; 95 percent confidence interval, 1.2 to 5.4); it affected 3 percent of all white subjects 80 years of age or older. Conclusions. The pattern of blindness in urban Baltimore appears to be different among blacks and whites. Whites are far more likely to have age-related macular degeneration, and blacks to have primary open-angle glaucoma. The high rate of unoperated cataracts among younger blacks and among elderly subjects of both races suggests that health services are underused. Half of all blindness in this urban population is probably preventable or reversible.	JOHNS HOPKINS UNIV HOSP,WILMER OPHTHALMOL INST,DANA CTR PREVENT OPHTHALMOL,BALTIMORE,MD 21205; SURVEY RES ASSOCIATES INC,BALTIMORE,MD; JOHNS HOPKINS UNIV HOSP,WILMER OPHTHALMOL INST,GLAUCOMA SERV,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV HOSP,WILMER OPHTHALMOL INST,CORNEAL SERV,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	SOMMER, A (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOSTAT,1041 HYG BLDG,615 N WOLFE ST,BALTIMORE,MD 21205, USA.		Javitt, Jonathan/AAJ-5574-2021	Javitt, Jonathan/0000-0003-2371-1609; Katz, Joanne/0000-0002-5997-7823; Tielsch, James/0000-0002-1151-060X	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004060] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY003605] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-04060] Funding Source: Medline; NEI NIH HHS [EY-03605, EY-05091] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		[Anonymous], 1981, OPHTHALMOLOGY, V88, P583; Cairns L, 1984, Trans Am Ophthalmol Soc, V82, P166; EDERER F, 1986, AM J PUBLIC HEALTH, V76, P160, DOI 10.2105/AJPH.76.2.160; FERRIS FL, 1982, AM J OPHTHALMOL, V94, P97, DOI 10.1016/0002-9394(82)90198-2; GANLEY JP, 1983, VITAL HLTH STATI 228, V11; GOLDSTEIN H, 1980, RES SERIES AM F BLIN, V26; GRANT WM, 1982, OPHTHALMOLOGY, V89, P991; JAVITT JC, 1989, OPHTHALMOLOGY, V96, P255; KAHN HA, 1973, DHEW NIH73427 NAT EY; KAHN HA, 1989, STATISTICAL METHODS; KIRCHNER C, 1979, VISUAL IMPAIRMENT BL, V73, P151; KOSOKO O, 1986, OPHTHALMOLOGY, V93, P882; Leibowitz H M, 1980, Surv Ophthalmol, V24, P335; MARTIN MJ, 1985, AM J OPHTHALMOL, V99, P383, DOI 10.1016/0002-9394(85)90001-7; MASON RP, 1989, OPHTHALMOLOGY, V96, P1363; PEARSON ES, 1958, BIOMETR TABLES ST, V1, P203; SOMMER A, 1991, ARCH OPHTHALMOL-CHIC, V109, P1090, DOI 10.1001/archopht.1991.01080080050026; SOMMER A, 1977, AM J OPHTHALMOL, V83, P334, DOI 10.1016/0002-9394(77)90729-2; SOMMER A, 1984, ARCH OPHTHALMOL-CHIC, V102, P1766; STARK WJ, 1989, ARCH OPHTHALMOL-CHIC, V107, P1441, DOI 10.1001/archopht.1989.01070020515030; Taylor J M, 1981, Ophthalmology, V88, p41A; TIELSCH JM, 1991, JAMA-J AM MED ASSOC, V266, P369, DOI 10.1001/jama.266.3.369; TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048; TIELSCH JM, 1991, ARCH OPHTHALMOL-CHIC, V109, P637, DOI 10.1001/archopht.1991.01080050051027; WILSON R, 1985, ANN OPHTHALMOL, V17, P653; 1985, ARCH OPHTHALMOL-CHIC, V103, P1796; 1983, NIH832469 DEP HLTH H, P12; 1980, VISION PROBLEMS S	28	551	578	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 14	1991	325	20					1412	1417		10.1056/NEJM199111143252004	http://dx.doi.org/10.1056/NEJM199111143252004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP524	1922252	Bronze			2022-12-01	WOS:A1991GP52400004
J	SPAINK, HP; SHEELEY, DM; VANBRUSSEL, AAN; GLUSHKA, J; YORK, WS; TAK, T; GEIGER, O; KENNEDY, EP; REINHOLD, VN; LUGTENBERG, BJJ				SPAINK, HP; SHEELEY, DM; VANBRUSSEL, AAN; GLUSHKA, J; YORK, WS; TAK, T; GEIGER, O; KENNEDY, EP; REINHOLD, VN; LUGTENBERG, BJJ			A NOVEL HIGHLY UNSATURATED FATTY-ACID MOIETY OF LIPO-OLIGOSACCHARIDE SIGNALS DETERMINES HOST SPECIFICITY OF RHIZOBIUM	NATURE			English	Article							LEGUMINOSARUM BV VICIAE; SYM PLASMID PRL1JI; ROOT EXUDATE; NODULATION REGION; NOD GENE; MELILOTI; PROTEIN; ENCODES; NODULES; MUTANTS	In Rhizobium leguminosarum biovar viciae, the nodABC and nodFEL operons are involved in the production of lipo-oligosaccharide signals which mediate host specificity. The structure of these metabolites and those produced in nod mutants links the nodE and nodL genes to specific chemical features of the signal molecules. A nodE-determined, highly unsaturated fatty acid and a nodL-determined O-acetyl substituent are essential for the ability of the signals to induce nodule meristems on the host plant Vicia sativa.	HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; COMPLEX CARBOHYDRATE RES CTR,ATHENS,GA 30602; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	SPAINK, HP (corresponding author), LEIDEN UNIV,DEPT PLANT MOLEC BIOL,NONNENST 3,2311 VJ LEIDEN,NETHERLANDS.		Geiger, Otto/F-6356-2019; Spaink, Herman P./S-3586-2017	Geiger, Otto/0000-0002-7794-1568; Spaink, Herman P./0000-0003-4128-9501				BARKER SA, 1958, J CHEM SOC, V451, P2218; BIBB MJ, 1989, EMBO J, V8, P2727, DOI 10.1002/j.1460-2075.1989.tb08414.x; Breitmaier E., 1987, CARBON 13 NMR SPECTR; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DEMAAGD RA, 1989, J BACTERIOL, V171, P6764, DOI 10.1128/jb.171.12.6764-6770.1989; DOWNIE JA, 1983, EMBO J, V2, P947, DOI 10.1002/j.1460-2075.1983.tb01526.x; DOWNIE JA, 1990, MOL GEN GENET, V222, P81, DOI 10.1007/BF00283027; DOWNIE JA, 1989, MOL MICROBIOL, V3, P1649, DOI 10.1111/j.1365-2958.1989.tb00150.x; ECONOMOU A, 1990, EMBO J, V9, P349, DOI 10.1002/j.1460-2075.1990.tb08117.x; FINAN TM, 1985, CELL, V40, P869, DOI 10.1016/0092-8674(85)90346-0; GEIGER O, 1991, J BACTERIOL, V173, P2872, DOI 10.1128/JB.173.9.2872-2878.1991; HAHN MG, IN PRESS MOL PLANT P, pCH2; HOOYKAAS PJJ, 1982, PLASMID, V8, P73, DOI 10.1016/0147-619X(82)90042-7; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; LONG SR, 1989, CELL, V56, P203, DOI 10.1016/0092-8674(89)90893-3; MUSSO RE, 1973, BIOCHEMISTRY-US, V12, P553, DOI 10.1021/bi00727a031; RECOURT K, 1991, PLANT MOL BIOL, V16, P841, DOI 10.1007/BF00015076; RECOURT K, 1991, THESIS U LEIDEN; ROCHE P, 1991, J BIOL CHEM, V266, P10933; ROCHE P, 1991, ADV MOL GENETICS PLA, V1, P119; SCHWEDOCK J, 1990, NATURE, V348, P644, DOI 10.1038/348644a0; SHEARMAN CA, 1986, EMBO J, V5, P647, DOI 10.1002/j.1460-2075.1986.tb04262.x; SHEELEY DM, 1991, ANAL BIOCHEM, V193, P240, DOI 10.1016/0003-2697(91)90016-M; SPAINK HP, 1989, EMBO J, V8, P2811, DOI 10.1002/j.1460-2075.1989.tb08427.x; SPAINK HP, 1987, PLANT MOL BIOL, V9, P27, DOI 10.1007/BF00017984; SPAINK HP, 1991, ADV MOL GENETICS PLA, V1, P142; SPAINK HP, IN PRESS MOL PL MICR; STELLNER K, 1973, ARCH BIOCHEM BIOPHYS, V155, P464, DOI 10.1016/0003-9861(73)90138-0; TRUCHET G, 1989, PROTOPLASMA, V149, P82, DOI 10.1007/BF01322980; TRUCHET G, 1991, NATURE, V351, P670, DOI 10.1038/351670a0; TRUCHET G, 1980, DIFFERENTIATION, V16, P163, DOI 10.1111/j.1432-0436.1980.tb01072.x; VANBRUSSEL AAN, 1986, J BACTERIOL, V165, P517, DOI 10.1128/jb.165.2.517-522.1986; VANBRUSSEL AAN, 1990, J BACTERIOL, V172, P5394, DOI 10.1128/jb.172.9.5394-5401.1990; WIJFFELMAN CA, 1985, ARCH MICROBIOL, V143, P225, DOI 10.1007/BF00411240	34	452	468	2	39	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 14	1991	354	6349					125	130		10.1038/354125a0	http://dx.doi.org/10.1038/354125a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP880	1944592				2022-12-01	WOS:A1991GP88000051
J	TIMSIT, Y; VILBOIS, E; MORAS, D				TIMSIT, Y; VILBOIS, E; MORAS, D			BASE-PAIRING SHIFT IN THE MAJOR GROOVE OF (CA)N TRACTS BY B-DNA CRYSTAL-STRUCTURES	NATURE			English	Article							A-DNA; SEQUENCES; CONFORMATION; REFINEMENT; HYDRATION; MUTATION; MISMATCH; EXCHANGE	THE crystal packing of the B-DNA dodecamer d(ACCGGCGCCACA). d(TGTGGCGCCGGT) is characterized by the reciprocal fit of double helices with specific base-backbone interactions in the major groove. Cooling the crystals below -10-degrees-C stabilizes a new conformational state with a long-range sequence-dependent one-step shift in the major-groove base pairing. The tilt of the bases leads to the disruption of the Watson-Crick pairing in the major groove and to the formation of interactions with the 5' neighbour of their complement. This alteration propagates along the helical axis over more than half a turn. As a result, the molecular structure is normal when seen from the minor groove side and mismatched in the major groove. Comparison with a parent isomorphous dodecamer structure corresponding to the codon 10-13 of the c-Ha-ras proto-oncogene shows that this new structural feature is sequence dependent and clearly favoured by (CA)n tracts. As(CA)n tracts of DNA are involved both in recombination and in transcription, this new recognition pattern should be considered in the analysis of the various processes involving the reading of the genetic information.			TIMSIT, Y (corresponding author), INST BIOL MOLEC & CELLULAIRE,CRISTALLOG BIOL LAB,15 RUE DESCARTES,F-67000 STRASBOURG,FRANCE.		Timsit, Youri/AAL-2412-2021	Timsit, Youri/0000-0003-0601-7201				BOLSHOY A, 1991, P NATL ACAD SCI USA, V88, P2312, DOI 10.1073/pnas.88.6.2312; CHEUNG S, 1984, P NATL ACAD SCI-BIOL, V81, P3665, DOI 10.1073/pnas.81.12.3665; COLL M, 1987, P NATL ACAD SCI USA, V84, P8385, DOI 10.1073/pnas.84.23.8385; COWIE A, 1988, MOL CELL BIOL, V8, P3122, DOI 10.1128/MCB.8.8.3122; FUCHS RPP, 1981, NATURE, V294, P657, DOI 10.1038/294657a0; HUNTER WN, 1987, NUCLEIC ACIDS RES, V15, P6589, DOI 10.1093/nar/15.16.6589; HUNTER WN, 1986, NATURE, V320, P552, DOI 10.1038/320552a0; JAIN S, 1989, BIOCHEMISTRY-US, V28, P2360, DOI 10.1021/bi00432a002; JARMAN AP, 1989, TRENDS GENET, V5, P367, DOI 10.1016/0168-9525(89)90171-6; KENNARD O, 1985, J BIOMOL STRUCT DYN, V3, P205, DOI 10.1080/07391102.1985.10508412; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; LU P, 1983, J BIOMOL STRUCT DYN, V1, P509, DOI 10.1080/07391102.1983.10507458; MCNAMARA PT, 1990, J BIOMOL STRUCT DYN, V8, P529, DOI 10.1080/07391102.1990.10507827; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; PRIVE GG, 1987, SCIENCE, V238, P498, DOI 10.1126/science.3310237; PRIVE GG, 1991, J MOL BIOL, V217, P177, DOI 10.1016/0022-2836(91)90619-H; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; RODGERS J, 1983, NATURE, V305, P101; SHEN SH, 1981, CELL, V26, P191, DOI 10.1016/0092-8674(81)90302-0; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; SUSSMAN JL, 1977, ACTA CRYSTALLOGR A, V33, P800, DOI 10.1107/S0567739477001958; TIMSIT Y, 1989, NATURE, V341, P459, DOI 10.1038/341459a0; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TRECO D, 1986, MOL CELL BIOL, V6, P3934, DOI 10.1128/MCB.6.11.3934; USDIN K, 1989, J BIOL CHEM, V264, P20736; WEBSTER GD, 1990, P NATL ACAD SCI USA, V87, P6693, DOI 10.1073/pnas.87.17.6693; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8	27	97	97	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 14	1991	354	6349					167	170		10.1038/354167a0	http://dx.doi.org/10.1038/354167a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP880	1944598				2022-12-01	WOS:A1991GP88000066
J	ARAL, SO; MOSHER, WD; CATES, W				ARAL, SO; MOSHER, WD; CATES, W			SELF-REPORTED PELVIC INFLAMMATORY DISEASE IN THE UNITED-STATES, 1988	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEXUALLY-TRANSMITTED DISEASES; BEHAVIOR; RISK; CHLAMYDIA	Objective. - To assess any changes in the characteristics of women with self-reported pelvic inflammatory disease (PID) between 1982 and 1988 and to evaluate the role of additional behavioral factors. In 1982, PID was a frequent problem among American women of reproductive age, occurring in one in seven. It was also more common among older (greater-than-or-equal-to 30 years) than younger women, more common among blacks than among whites, and more common among formerly married women than among those currently married. Design. - We analyzed data on self-reported PID from the cycle IV National Survey of Family Growth, conducted in 1988. Sample. - The survey was conducted with a multistage probability sample of 8450 women. Results. - The findings from 1982 were all replicated. Additional variables available in 1988 show that PID is more common among women with multiple (two or more) sexual partners (10% to 22%) compared with those with only one lifetime partner (7%) and among women who report a history of sexually transmitted disease (STD) (26%) compared with those with no STD history (10%). Controlling for other variables, age, race, vaginal douching, age at first intercourse, STD history, and number of lifetime partners emerged as independent predictors of self-reported PID among American women of reproductive age. Conclusion. - PID is still a widely prevalent condition among American women; PID is associated with a variety of risk factors for STD. Prevention of lower genital tract infection is crucial to avoiding PID and its sequelae.	CTR DIS CONTROL,NATL CTR HLTH STAT,NATL SURVEY FAMILY GROWTH,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	ARAL, SO (corresponding author), CTR DIS CONTROL,CTR PREVENT SERV,DIV STD HIV PREVENT,MAILSTOP E-44,ATLANTA,GA 30333, USA.							ARAL SO, 1985, AM J PUBLIC HEALTH, V75, P1216, DOI 10.2105/AJPH.75.10.1216; ARAL SO, 1989, SEX TRANSM DIS, V16, P173, DOI 10.1097/00007435-198910000-00003; ARAL SO, 1990, CURR OPIN INFECT DIS, V3, P20, DOI 10.1097/00001432-199002000-00004; ARAL SO, 1991, SEX TRANSM DIS, V18, P10, DOI 10.1097/00007435-199101000-00003; ARAL SO, 1990, SEXUALLY TRANSMITTED, P19; ARAL SO, 1991, SEX TRANSM DIS, V17, P208; BACHRACH CA, 1985, VITAL HLTH STAT 98, V2; CATES W, 1990, EPIDEMIOL REV, V12, P199, DOI 10.1093/oxfordjournals.epirev.a036054; CATES W, 1990, CURR OPIN INFECT DIS, V3, P10, DOI 10.1097/00001432-199002000-00003; NEWTON W, 1985, J REPROD MED, V30, P82; PADIAN N, 1990, SEX TRANSM DIS, V17, P200, DOI 10.1097/00007435-199010000-00010; ROLFS RT, 1979, IN PRESS AM J OBSTET; TEISALA K, 1988, ARCH GYNECOL OBSTET, V243, P225, DOI 10.1007/BF00932272; WASHINGTON AE, 1985, JAMA-J AM MED ASSOC, V253, P2246, DOI 10.1001/jama.253.15.2246; WOLNERHANSSEN P, 1990, JAMA-J AM MED ASSOC, V263, P1936, DOI 10.1001/jama.263.14.1936; WONNACOTT TH, 1984, INTRO STATISTICS BUS, P106; 1991, MMWR-MORBID M   SRR5, V40, P1; 1990, JAMA-J AM MED ASSOC, V263, P2344; 1989, 1989 CTR DIS CONTR D	19	96	99	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	1991	266	18					2570	2573		10.1001/jama.266.18.2570	http://dx.doi.org/10.1001/jama.266.18.2570			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN660	1942402				2022-12-01	WOS:A1991GN66000033
J	BURROWS, A				BURROWS, A			THE MAN WHO DIDNT KNOW HE HAD CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	1991	266	18					2550	2550						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN660	1942391				2022-12-01	WOS:A1991GN66000009
J	NIGHTINGALE, SL				NIGHTINGALE, SL			DIDANOSINE (DDI) APPROVED FOR ADVANCED HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	1991	266	18					2528	2528						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN660	1942388				2022-12-01	WOS:A1991GN66000006
J	WASHINGTON, AE; KATZ, P				WASHINGTON, AE; KATZ, P			COST OF AND PAYMENT SOURCE FOR PELVIC INFLAMMATORY DISEASE - TRENDS AND PROJECTIONS, 1983 THROUGH 2000	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFERTILE WOMEN; UNITED-STATES	Pelvic inflammatory disease (PID) and its sequelae affect millions of women in the United States at substantial costs. To estimate these total costs annually and to determine payment sources, we analyzed data from local, state, and national sources. Direct costs for PID and PID-associated ectopic pregnancy and infertility were estimated to be $2.7 billion, and indirect costs were estimated to be $1.5 billion, for a total cost of $4.2 billion in 1990. Overall, private insurance covered the largest portion of the direct costs of PID (41%), followed by public payment sources (30%). However, the proportion of payments made by private insurance appears to be decreasing, while that by public payment sources is increasing. In the year 2000, costs associated with PID are projected to approach $10 billion if the current PID incidence persists, with an increasing proportion of this expense burdening public institutions. Prevention of PID is needed both to reduce human suffering and to contain rising costs.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94109; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94109	University of California System; University of California San Francisco; University of California System; University of California San Francisco	WASHINGTON, AE (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,CTR REPROD HLTH POLICY RES,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94109, USA.				NIAID NIH HHS [AI24768] Funding Source: Medline; PHS HHS [282-88-0018] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024768] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLENDON RJ, 1986, NEW ENGL J MED, V314, P1160, DOI 10.1056/NEJM198605013141806; CATES W, 1990, EPIDEMIOL REV, V12, P199, DOI 10.1093/oxfordjournals.epirev.a036054; FORREST J, 1989, NEED AVAILABILITY FI; GUMP DW, 1983, AM J OBSTET GYNECOL, V146, P153, DOI 10.1016/0002-9378(83)91044-X; HIRSCH MB, 1987, FERTIL STERIL, V47, P618; METHOD MW, 1987, J REPROD MED, V32, P759; NETTLEMAN MD, 1989, SEX TRANSM DIS, V16, P36, DOI 10.1097/00007435-198901000-00008; Rice D P, 1985, Health Care Financ Rev, V7, P61; ROLFS RT, 1990, SEP P CTR DIS CONTR; SCHIFF RL, 1986, NEW ENGL J MED, V314, P552, DOI 10.1056/NEJM198602273140905; SWEET RL, 1990, INFECT DIS FEMALE GE, P241; WASHINGTON AE, 1991, JAMA-J AM MED ASSOC, V266, P2574, DOI 10.1001/jama.266.18.2574; WASHINGTON AE, 1984, JAMA-J AM MED ASSOC, V251, P2529, DOI 10.1001/jama.251.19.2529; WASHINGTON AE, 1986, JAMA-J AM MED ASSOC, V255, P1735, DOI 10.1001/jama.255.13.1735; WASHINGTON AE, 1985, J ADOLESCENT HEALTH, V6, P298, DOI 10.1016/S0197-0070(85)80067-X; WESTROM L, 1981, BRIT MED J, V282, P15, DOI 10.1136/bmj.282.6257.15; WESTROM L, 1980, AM J OBSTET GYNECOL, V138, P880, DOI 10.1016/0002-9378(80)91077-7; 1987, PHS871589 US DEP HLT; 1989, PATIENT DISCHARGE DA; 1989, INT CLASSIFICATION D; 1989, SOCIOECONOMIC CHARAC; 1989, STATISTICAL ABSTRACT; 1991, MMWR-MORBID MORTAL W, V40, pS1; 1988, SEXUALLY TRANSMITTED; 1990, MMWR-MORBID MORTAL W, V39, P401	25	153	158	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	1991	266	18					2565	2569		10.1001/jama.266.18.2565	http://dx.doi.org/10.1001/jama.266.18.2565			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN660	1942401				2022-12-01	WOS:A1991GN66000032
J	BAETEN, CGMI; KONSTEN, J; SPAANS, F; VISSER, R; HABETS, AMMC; BOURGEOIS, IM; WAGENMAKERS, AJM; SOETERS, PB				BAETEN, CGMI; KONSTEN, J; SPAANS, F; VISSER, R; HABETS, AMMC; BOURGEOIS, IM; WAGENMAKERS, AJM; SOETERS, PB			DYNAMIC GRACILOPLASTY FOR TREATMENT OF FECAL INCONTINENCE	LANCET			English	Article							FECAL INCONTINENCE; NEOANAL SPHINCTER; GRACILIS MUSCLE; SKELETAL-MUSCLE; CONSTRUCTION; TRANSFORMATION; TRANSPOSITION; NEOSPHINCTER; STIMULATION; NEORECTUM	Serious faecal incontinence due to anal sphincter damage should be treated by surgery. Graciloplasty has had limited success because the gracilis is a fast-twitch muscle and fatigues quickly. A favourable outcome in a patient who had dynamic (electrically stimulated) graciloplasty encouraged us to further assess this procedure. Gracilis muscle transposition was done in ten patients with complete anal incontinence due to anal atresia, sphincter damage, or neurogenic causes, and who had had several other unsuccessful treatments. 6 weeks after muscle transposition, intramuscular leads were implanted and connected to an implantable electric stimulator. Eight patients became continent, one patient still has a diverting colostomy, and a fistula developed in the other patient. Anal sphincter pressure improved from 35 mm Hg without stimulation to 62 mm Hg with stimulation at 8 weeks (mean increase 28 mm Hg [95% confidence interval 18, 36), p < 0.01). Retention time of a phosphate enema increased from 22 to 281 s (mean increase 259 s (82, 436], p < 0.01). Defaecography showed that the new sphincter was functioning. Defaecation was possible when the stimulator was turned "off" with a magnet. Dynamic graciloplasty can restore continence and it improves quality of life in faecally incontinent patients for whom other treatments have been unsuccessful.	UNIV LIMBURG HOSP,DEPT CLIN NEUROPHYSIOL,6202 AZ MAASTRICHT,NETHERLANDS; BAKKEN RES CTR,MAASTRICHT,NETHERLANDS; UNIV LIMBURG,DEPT HUMAN BIOL,6200 MD MAASTRICHT,NETHERLANDS	Maastricht University; Maastricht University Medical Centre (MUMC); Medtronic Bakken Research Center B.V.; Hasselt University; Maastricht University	BAETEN, CGMI (corresponding author), UNIV LIMBURG HOSP,DEPT SURG,POB 5800,6202 AZ MAASTRICHT,NETHERLANDS.		Wagenmakers, Anton/H-7625-2014	Wagenmakers, Anton/0000-0003-1916-3822				BAETEN C, 1988, DIS COLON RECTUM, V31, P134, DOI 10.1007/BF02562646; BAETEN CGMI, 1990, BRIT J SURG, V77, P473, DOI 10.1002/bjs.1800770433; CARPENTIER A, 1986, BIOMECHANICAL CARDIA, P85; CAVINA E, 1990, INT J COLORECTAL DIS, V5, P6, DOI 10.1007/BF00496141; CHACHQUES JC, 1986, BIOMECHANICAL CARDIA, P59; CHRISTIANSEN J, 1990, BRIT J SURG, V77, P1039, DOI 10.1002/bjs.1800770928; CORMAN ML, 1979, DIS COLON RECTUM, V22, P290, DOI 10.1007/BF02609307; EDSTROM L, 1986, MUSCLE NERVE, V9, P104, DOI 10.1002/mus.880090203; EISENBERG BR, 1984, CELL TISSUE RES, V238, P221; HALLAN RI, 1990, BRIT J SURG, V77, P208, DOI 10.1002/bjs.1800770226; HAVENITH MG, 1990, HISTOCHEMISTRY, V93, P497, DOI 10.1007/BF00266407; LEIGH RJ, 1982, LANCET, V1, P1349; PETTE D, 1984, MED SCI SPORT EXER, V16, P517; PICKRELL KL, 1952, ANN SURG, V135, P853, DOI 10.1097/00000658-195206000-00010; SALMONS S, 1981, MUSCLE NERVE, V4, P94, DOI 10.1002/mus.880040204; WILLIAMS NS, 1989, BRIT J SURG, V76, P1191, DOI 10.1002/bjs.1800761124; WILLIAMS NS, 1990, ANN ROY COLL SURG, V72, P108	17	177	182	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 9	1991	338	8776					1163	1165		10.1016/0140-6736(91)92030-6	http://dx.doi.org/10.1016/0140-6736(91)92030-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP034	1682590				2022-12-01	WOS:A1991GP03400002
J	BERKELEY, MIKB; MOFFAT, MAJ; RUSSELL, D				BERKELEY, MIKB; MOFFAT, MAJ; RUSSELL, D			SURVEILLANCE OF ANTIBODY TO RUBELLA-VIRUS IN GRAMPIAN - CLOSING THE IMMUNITY GAP	BRITISH MEDICAL JOURNAL			English	Article							PREGNANCY	Objectives - To identify causes for the continuing deficit of rubella immunity in women of childbearing age with a view to further reducing the risk of the congenital rubella syndrome. Design - A questionnaire was sent to the general practitioner and a laboratory follow up study conducted in a one year cohort of women found on screening to have inadequate protection against rubella. Setting - Virus laboratory of the department of medical microbiology, Aberdeen, serving the health board areas of Grampian, Orkney, and Shetland. Patients - 239 women whose concentration of antibodies to rubella virus was either absent or below standard (15 000 IU/l) and whose general practitioner could be contacted to supply a history of infection, immunisation, pregnancy, and antibody testing. Main outcome measures - Whether rubella vaccination was given and whether those vaccinated were tested for seroconversion. Results - Only 122 (55%) of the women for whom information was available received the recommended vaccine; only 74 (61%) of these were tested for seroconversion. Oversight was the reason given for not vaccinating 64 (65%) of the women who remained at risk. Women who were pregnant when tested were significantly less likely to receive vaccine (odds ratio 3.36) than women who were not pregnant, and even if vaccinated were less likely to have a follow up antibody test (odds ratio 1.94). Conclusion - Once women are identified as being unprotected against rubella they are often over-looked and not vaccinated. Prompting mechanisms aimed at general practitioners, such as the one recently set up in Grampian, should reduce the immunity gap and help to eradicate rubella in pregnancy.	UNIV ABERDEEN,DEPT MED MICROBIOL,MED BLDG,ABERDEEN AB9 2ZD,SCOTLAND; UNIV ABERDEEN,DEPT PUBL HLTH,ABERDEEN AB9 2ZD,SCOTLAND	University of Aberdeen; University of Aberdeen								COOK GA, 1987, COMMUNITY MED, V9, P254; EDMOND E, 1986, BRIT J OBSTET GYNAEC, V93, P563, DOI 10.1111/j.1471-0528.1986.tb07954.x; FREESTONE DS, 1972, POSTGRAD MED J, V48, P30; MILLER CL, 1985, BRIT MED J, V291, P1398, DOI 10.1136/bmj.291.6506.1398; MILLER E, 1991, REV COMMUNICABLE DIS, V4, pR33; Morgan-Capner P, 1991, CDR (Lond Engl Rev), V1, pR57; TOOKEY PA, 1988, PUBLIC HLTH, V102, P58; 1988, DHSS PLCMO8819 DEP H; 1972, DHSS1772 DEP HLTH SO; 1983, CMO838 CHIEF MED OFF; 1970, DHSS970 DEP HLTH SOC	11	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1991	303	6811					1174	1176		10.1136/bmj.303.6811.1174	http://dx.doi.org/10.1136/bmj.303.6811.1174			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP488	1747615	Green Published, Bronze			2022-12-01	WOS:A1991GP48800024
J	CHITTY, LS; HUNT, GH; MOORE, J; LOBB, MO				CHITTY, LS; HUNT, GH; MOORE, J; LOBB, MO			EFFECTIVENESS OF ROUTINE ULTRASONOGRAPHY IN DETECTING FETAL STRUCTURAL ABNORMALITIES IN A LOW-RISK POPULATION	BRITISH MEDICAL JOURNAL			English	Article							MALFORMATIONS; DIAGNOSIS	Objective - To review the efficacy of routine prenatal ultrasonography for detecting fetal structural abnormalities. Design - Retrospective study of the ultrasonographic findings and outcome of all pregnancies in women scanned in 1988-9. Setting - Maternity ultrasonography department of a district general hospital. Subjects - 8785 fetuses. Main outcome measures - Correlation of prenatal ultrasonographic findings with outcome in the neonate. Results - 8733 babies were born during 1988-9, and 52 pregnancies were terminated after a fetal malformation was identified. 8432 (95%) of the fetuses were examined by ultrasonography in the second trimester. 130 fetuses (1.5%) were found to have an abnormality at birth or after termination of pregnancy, 125 of which had been examined in the second trimester. In 93 cases the abnormality was detected before 24 weeks (sensitivity 74.4%, 95% confidence interval to 66.7% to 82.1%. Two false positive diagnoses occurred, in both cases the pregnancies were not terminated and apparently normal infants were born. This gives a specificity of 99.98% (99.9% to 99.99%). The positive predictive value of ultrasonography in the second trimester was 97.9% (92.6% to 99.7%). Of the 125 abnormalities, 87 were lethal or severely disabling; 72 of the 87 were detected by the routine screening programme (sensitivity 82.8%, 73.2% to 90.0%). Conclusion - Routine fetal examination by ultrasonography in a low risk population detects many fetal structural abnormalities but can present several dilemmas in counselling.	LUTON & DUNSTABLE HOSP,LUTON LU4 0DZ,BEDS,ENGLAND; INST CHILD HLTH,DEPT CLIN GENET,LONDON WC1 1EH,ENGLAND	University of London; University College London				chitty, lyn/0000-0002-4857-7138				ASH P, 1977, LANCET, V1, P849; BENACERRAF BR, 1988, RADIOLOGY, V169, P858, DOI 10.1148/radiology.169.3.3055042; BENACERRAF BR, 1987, AM J OBSTET GYNECOL, V156, P573, DOI 10.1016/0002-9378(87)90053-6; BENACERRAF BR, 1991, ULTRASOUND OBST GYN, V1, P66, DOI 10.1046/j.1469-0705.1991.01010066.x; CAMPBELL S, 1983, PRENATAL DIAGNOSIS, P325; CHITTY LS, 1991, ULTRASOUND OBST GYN, V1, P115, DOI 10.1046/j.1469-0705.1991.01020115.x; CHITTY LS, 1989, ARCH DIS CHILD, V64, P1036, DOI 10.1136/adc.64.7.1036; CHITTY LS, 1990, LANCET, P875; DEWALS P, 1984, EUROCAT GUIDE, P65; Gardner MJ, 1989, STAT CONFIDENCE, P28; JONES LJ, 1988, SMITHS RECOGNISABLE, P662; LEVI S, 1989, LANCET, V1, P678; NICOLAIDES KH, 1987, BAILLIERE CLIN OB GY, V1, P591, DOI 10.1016/S0950-3552(87)80008-1; PERSSON PH, 1983, AM J OBSTET GYNECOL, V146, P942, DOI 10.1016/0002-9378(83)90970-5; ROSENDAHL H, 1989, OBSTET GYNECOL, V73, P947; SAARIKEMPPAINEN A, 1990, LANCET, P387	16	221	231	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1991	303	6811					1165	1169		10.1136/bmj.303.6811.1165	http://dx.doi.org/10.1136/bmj.303.6811.1165			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP488	1747613	Bronze, Green Published			2022-12-01	WOS:A1991GP48800022
J	DECOCK, KM; SELIK, RM; SORO, B; GAYLE, H; COLEBUNDERS, RL				DECOCK, KM; SELIK, RM; SORO, B; GAYLE, H; COLEBUNDERS, RL			FOR DEBATE - AIDS SURVEILLANCE IN AFRICA - A REAPPRAISAL OF CASE DEFINITIONS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CLINICAL CASE-DEFINITION; HIV INFECTION; IVORY-COAST; TUBERCULOSIS; ABIDJAN; UGANDA; EPIDEMIC; KINSHASA; FOLLOW; ZAIRE		PROJET RETRO CI, ABIDJAN, COTE IVOIRE; INST NATL SANTE PUBL, ABIDJAN, COTE IVOIRE; ROYAL INST TROP MED, ANTWERP, BELGIUM	Institute of Tropical Medicine (ITM)	DECOCK, KM (corresponding author), CTR DIS CONTROL, CTR INFECT DIS, DIV HIV AIDS, MAIL STOP E-50, 1600 CLIFTON RD NE, ATLANTA, GA 30333 USA.							BACCHETTI P, 1989, NATURE, V338, P251, DOI 10.1038/338251a0; BRAUN MM, 1990, IN PRESS AM REV RESP; CHIN J, 1990, AIDS (London), V4, pS277, DOI 10.1097/00002030-199001001-00045; COLEBUNDERS R, 1987, LANCET, V1, P492; COLEBUNDERS RL, 1989, AM REV RESPIR DIS, V139, P1082, DOI 10.1164/ajrccm/139.5.1082; COLEBUNDERS RL, 1989, J INFECT DIS, V160, P902, DOI 10.1093/infdis/160.5.902; DECOCK KM, 1990, SCIENCE, V249, P793, DOI 10.1126/science.2167515; DECOCK KM, 1990, AIDS, V4, P443, DOI 10.1097/00002030-199005000-00010; DECOCK KM, 1991, BMJ-BRIT MED J, V302, P496, DOI 10.1136/bmj.302.6775.496; DECOCK KM, 1989, LANCET, V2, P408; DONDERO TJ, 1988, PUBLIC HEALTH REP, V103, P213; GILKS CF, 1990, LANCET, V336, P545, DOI 10.1016/0140-6736(90)92096-Z; HOWLETT WP, 1989, AIDS, V3, P289, DOI 10.1097/00002030-198905000-00007; LAST JM, 1989, DICT EPIDEMIOLOGY, P9; MAMUN KZ, 1989, AIDS, V3, P323, DOI 10.1097/00002030-198905000-00017; NUNN P, 1990, 6TH INT C AIDS SAN F; PETERMAN TA, 1990, AM J PUBLIC HEALTH, V80, P401, DOI 10.2105/AJPH.80.4.401; PITCHENIK AE, 1990, ANN INTERN MED, V113, P89, DOI 10.7326/0003-4819-113-2-89; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SATO PA, 1989, AIDS, V3, pS301, DOI 10.1097/00002030-198901001-00043; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SERWADDA D, 1985, LANCET, V2, P849, DOI 10.1016/S0140-6736(85)90122-9; SORO B, 1990, 6TH INT C AIDS SAN F; WABWIREMANGEN F, 1989, AIDS, V3, P462, DOI 10.1097/00002030-198907000-00013; WEYER J, 1987, INFECTION, V15, P413, DOI 10.1007/BF01647217; WIDYWIRSKI R, 1988, JAMA-J AM MED ASSOC, V260, P3286, DOI 10.1001/jama.260.22.3286; 1987, MMWR, V36, pS1; 1986, WKLY EPIDEMIOL REC, V61, P69; 1990, EPIDEMIOLOGICAL B, V4, P9; 1986, WKLY EPIDEMIOL REC, V61, P72; 1989, MMWR, V38, P561; 1988, MMWR, V37, pS1	32	38	38	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 9	1991	303	6811					1185	1188		10.1136/bmj.303.6811.1185	http://dx.doi.org/10.1136/bmj.303.6811.1185			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP488	1747620	Bronze, Green Published			2022-12-01	WOS:A1991GP48800030
J	GILKS, CF				GILKS, CF			WHAT USE IS A CLINICAL CASE DEFINITION FOR AIDS IN AFRICA	BRITISH MEDICAL JOURNAL			English	Article							ZAIRE; TUBERCULOSIS; INFECTION		KENYA GOVT MED RES CTR,NAIROBI,KENYA	Kenya Medical Research Institute			Gilks, Charles/B-4184-2012	Gilks, Charles/0000-0002-8953-3123				BROWN C, 1991, AIDS, V5, P89, DOI 10.1097/00002030-199101000-00013; COLEBUNDERS R, 1987, LANCET, V1, P492; COLEBUNDERS RL, 1989, J INFECT DIS, V160, P902, DOI 10.1093/infdis/160.5.902; DECOCK KM, 1990, SCIENCE, V249, P793, DOI 10.1126/science.2167515; DECOCK KM, 1988, AIDS, V2, P219; GILKES CF, IN PRESS Q J MED; GILKS CF, 1990, LANCET, V336, P545, DOI 10.1016/0140-6736(90)92096-Z; GILKS CF, 1990, AIDS, V4, P981, DOI 10.1097/00002030-199010000-00006; GILKS CF, 1991, IN PRESS TROPICAL DO; GILKS CF, IN PRESS AIDS; HARRIES AD, 1990, LANCET, V335, P387, DOI 10.1016/0140-6736(90)90216-R; LUCAS SB, 1990, T ROY SOC TROP MED H, V84, P34, DOI 10.1016/0035-9203(90)90453-L; MANN JM, 1986, LANCET, V2, P707; REEVE PA, 1989, BRIT MED J, V298, P1567, DOI 10.1136/bmj.298.6687.1567; ROSE G, 1978, BRIT MED J, V2, P873, DOI 10.1136/bmj.2.6141.873; SWAI ABM, 1989, LANCET, V2, P976; WABWIREMANGEN F, 1989, AIDS, V3, P462, DOI 10.1097/00002030-198907000-00013; WIDIWIRSKI R, 1988, JAMA-J AM MED ASSOC, V260, P3286; 1987, MMWR S1, V36, pS4; 1986, WEEKLY EPIDEMIOLOGIC, V61, P69	20	19	20	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1991	303	6811					1189	1190		10.1136/bmj.303.6811.1189	http://dx.doi.org/10.1136/bmj.303.6811.1189			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP488	1747621	Bronze, Green Published			2022-12-01	WOS:A1991GP48800031
J	HJORTDAHL, P; BORCHGREVINK, CF				HJORTDAHL, P; BORCHGREVINK, CF			CONTINUITY OF CARE - INFLUENCE OF GENERAL-PRACTITIONERS KNOWLEDGE ABOUT THEIR PATIENTS ON USE OF RESOURCES IN CONSULTATIONS	BRITISH MEDICAL JOURNAL			English	Article								Objective - To examine the relation between general practitioners' knowledge about their patients and the use of resources in consultations. Design - A cross sectional evaluation of consultations. Setting and subjects - A representative sample of 133 Norwegian general practitioners were each asked to record 30 consecutive consultations. 131 did so, and of 3990 possible registrations, 3918 (98%) were evaluated. Main outcome measures - The influence, as assessed by the doctor, of accumulated knowledge on the use of laboratory tests, expectant management, prescriptions, sickness certification, referrals, and time spent in the consultation. Results - Accumulated knowledge was a substantial factor in saving time, especially in consultations with children, the elderly, patients with psychosocial problems. and those with chronic diseases. It also influenced the overall use of laboratory tests, expectant management, sickness certification, and referrals, and to a lesser degree the use of medication. Conclusion - The findings imply strong but complex associations between accumulated knowledge and the use of resources in the consultation.			HJORTDAHL, P (corresponding author), UNIV OSLO,DEPT GEN PRACTICE,N-0264 OSLO 2,NORWAY.							ANDREWS FM, 1984, PUBLIC OPIN QUART, V48, P409, DOI 10.1086/268840; Bentsen B G, 1986, Scand J Prim Health Care, V4, P43, DOI 10.3109/02813438609013970; CARTWRIGHT A, 1976, J R COLL GEN PRACT, V26, P895; Hjortdahl P, 1990, Fam Med, V22, P361; Hosmer D, 2013, APPL LOGISTIC REGRES; MCWHINNEY I, 1982, J FAM PRACTICE, V15, P847; McWhinney IR, 1989, TXB FAMILY MED; MOSSEY JM, 1982, AM J PUBLIC HEALTH, V72, P800, DOI 10.2105/AJPH.72.8.800; Nylenna M, 1985, Scand J Prim Health Care, V3, P155, DOI 10.3109/02813438509013938; NYLENNA M, 1986, FAM PRACT, V3, P240, DOI 10.1093/fampra/3.4.240; ODOWD TC, 1988, BRIT MED J, V297, P528, DOI 10.1136/bmj.297.6647.528; Polanyi M, 1967, TACIT DIMENSION; ROSENBERG EE, 1985, FAM PRACT, V2, P23, DOI 10.1093/fampra/2.1.23; RUTLE O, 1983, 11983 STAT I FOLK RA; Schon Donald A., 2017, REFLECTIVE PRACTITIO; SHELDON M, 1985, DECISION MAKING GENE; YAFFE MJ, 1985, MED CARE, V23, P1276, DOI 10.1097/00005650-198511000-00006; 1989, WORKING PATIENTS; 1988, JAMA-J AM MED ASSOC, V260, P1272	19	119	120	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1991	303	6811					1181	1184		10.1136/bmj.303.6811.1181	http://dx.doi.org/10.1136/bmj.303.6811.1181			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GP488	1747619	Green Published, Bronze			2022-12-01	WOS:A1991GP48800029
J	KOTEN, JW; DENOTTER, W				KOTEN, JW; DENOTTER, W			ARE OMENTAL MILKY SPOTS AN INTESTINAL THYMUS	LANCET			English	Note								It is suggested that omental milky spots in young children, which in later life gradually transform into fatty tissue and only reappear during intraperitoneal infection, might influence the development of gastrointestinal immunity.	ACAD ZIEKENHUIS,DEPT EXPTL PATHOL,HEIDELBERGLAAN 100,3584 CX UTRECHT,NETHERLANDS									Dux K., 1988, OMENTUM RES CLIN APP, P19; Liebermann-Meffert D, 1983, GREATER OMENTUM ANAT, P1; LIEBERMANNMEFFE.D, 1991, 4TH INT S BIOL IMM S; SHIMOTSUMA M, 1989, ACTA ANAT, V136, P211; SHIMOTSUMA M, 1991, 4TH INT S BIOL IMM S	5	21	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 9	1991	338	8776					1189	1190		10.1016/0140-6736(91)92043-2	http://dx.doi.org/10.1016/0140-6736(91)92043-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP034	1682602				2022-12-01	WOS:A1991GP03400015
J	LAAKSO, M; KESANIEMI, A; KERVINEN, K; JAUHIAINEN, M; PYORALA, K				LAAKSO, M; KESANIEMI, A; KERVINEN, K; JAUHIAINEN, M; PYORALA, K			RELATION OF CORONARY HEART-DISEASE AND APOLIPOPROTEIN-E PHENOTYPE IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DENSITY LIPOPROTEIN CHOLESTEROL; E POLYMORPHISM; APOPROTEIN-E; ARTERY DISEASE; INCREASED FREQUENCY; C-PEPTIDE; SERUM; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; ASSOCIATION	Objectives - To examine the relation between coronary heart disease and the apolipoprotein E phenotypes in patients with non-insulin dependent diabetes mellitus. Design - Cross sectional study. Setting - District around Kuopio University Central Hospital, East Finland. Subjects - 138 men with non-insulin dependent diabetes and 64 men without diabetes as controls. Main outcome measure - Apolipoprotein E phenotype, electrocardiographic abnormalities, other signs of coronary heart disease. Results - The prevalences of definite myocardial infarction and ischaemic electrocardiographic changes were highest in the diabetic men with the phenotypes E4/4 or E4/3 (25% (95% confidence interval 18% to 32%) and 50% (42% to 58%) respectively), although the difference between the phenotype groups was not significant. The prevalence of angina pectoris was 69% (61% to 77%) in men with the phenotypes E4/4 or E4/3 (p = 0.005 compared with other phenotypes), 41% (33% to 49%) in men with phenotype E3/3, and 47% (39% to 55%) in those with phenotypes E2/2 or E2/3. Similarly, the simultaneous presence of angina pectoris and ischaemic electrocardiographic changes was highest in the diabetic men with the phenotypes E4/4 or E4/3 (42% v 22% in those with E3/3 and 29% in those with E2/2, E2/3; p = 0.038). Overall, the prevalence of any evidence of coronary heart disease among the diabetic subjects with the phenotypes E4/4 or E4/3 was 81%(p = 0.01 compared with other phenotypes), 58% in those with phenotype E3/3, and 53% in those with phenotypes E2/2 or E3/3. Conclusion - Apolipoprotein E phenotypes E4/4 and E4/3 modulate the risk of coronary heart disease in men with non-insulin dependent diabetes.	UNIV OULU, DEPT MED, SF-90100 OULU 10, FINLAND; NATL PUBL HLTH INST, DEPT BIOCHEM, SF-00280 HELSINKI 28, FINLAND	University of Oulu; Finland National Institute for Health & Welfare	LAAKSO, M (corresponding author), KUOPIO UNIV, CENT HOSP, DEPT MED, SF-70210 KUOPIO, FINLAND.							ASSMANN G, 1984, CLIN CHEM, V30, P641; BASU SK, 1982, J BIOL CHEM, V257, P9788; CUMMING AM, 1984, CLIN GENET, V25, P310; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; EHNHOLM C, 1986, J LIPID RES, V27, P227; ETO M, 1986, DIABETES, V35, P1374, DOI 10.2337/diabetes.35.12.1374; ETO M, 1987, DIABETES, V36, P1301, DOI 10.2337/diabetes.36.11.1301; ETO M, 1986, CLIN GENET, V29, P477; FRIER BM, 1977, DIABETES, V26, P369; GREGG RE, 1981, SCIENCE, V211, P584, DOI 10.1126/science.7455696; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HEDING LG, 1975, DIABETOLOGIA, V11, P541, DOI 10.1007/BF01222104; HUI DY, 1980, J BIOL CHEM, V255, P1775; IMARI Y, 1988, METABOLISM, V37, P1134, DOI 10.1016/0026-0495(88)90189-8; JAUHIAINEN M, 1983, CLIN CHEM, V29, P1731; KESANIEMI YA, 1987, J CLIN INVEST, V80, P578, DOI 10.1172/JCI113107; KUUSI T, 1989, ARTERIOSCLEROSIS, V9, P237, DOI 10.1161/01.ATV.9.2.237; LAAKSO M, 1985, ARTERIOSCLEROSIS, V5, P653, DOI 10.1161/01.ATV.5.6.653; LAAKSO M, 1987, AM J EPIDEMIOL, V125, P611, DOI 10.1093/oxfordjournals.aje.a114574; LAAKSO M, 1988, DIABETES CARE, V11, P449, DOI 10.2337/diacare.11.6.449; LENZEN HJ, 1986, CLIN CHEM, V32, P778; LEREN TP, 1985, CLIN GENET, V27, P458; MADSBAD S, 1979, BRIT MED J, V2, P1257, DOI 10.1136/bmj.2.6200.1257; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MENZEL HJ, 1983, ARTERIOSCLEROSIS, V3, P310, DOI 10.1161/01.ATV.3.4.310; MENZEL HJ, 1986, ELECTROPHORESIS, V7, P492, DOI 10.1002/elps.1150071103; PENTTILA IM, 1981, SCAND J CLIN LAB INV, V41, P353, DOI 10.3109/00365518109092057; PEPE MG, 1986, J IMMUNOL, V136, P3716; PYORALA K, 1987, Diabetes Metabolism Reviews, V3, P463; PYORALA K, 1985, CARDIOLOGY, V72, P35, DOI 10.1159/000173839; RIEPPONEN P, 1987, SCAND J CLIN LAB INV, V47, P739; Rose G.A., 1982, CARDIOVASCULAR SURVE; SIEDEL J, 1981, J CLIN CHEM CLIN BIO, V19, P838; SING CF, 1985, AM J HUM GENET, V37, P268; UTERMANN G, 1984, HUM GENET, V65, P237, DOI 10.1007/BF00286509; UTERMANN G, 1984, HUM GENET, V65, P232, DOI 10.1007/BF00286508; WANG K, 1986, ACTA ACAD MED SINICA, V8, P198; 1980, WHO TECH REP SER, P646; WHOMNC821	39	71	72	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 9	1991	303	6811					1159	1162		10.1136/bmj.303.6811.1159	http://dx.doi.org/10.1136/bmj.303.6811.1159			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP488	1747611	Green Published, Bronze			2022-12-01	WOS:A1991GP48800020
J	MCMILLAN, SA; HAUGHTON, DJ; BIGGART, JD; EDGAR, JD; PORTER, KG; MCNEILL, TA				MCMILLAN, SA; HAUGHTON, DJ; BIGGART, JD; EDGAR, JD; PORTER, KG; MCNEILL, TA			PREDICTIVE VALUE FOR CELIAC-DISEASE OF ANTIBODIES TO GLIADIN, ENDOMYSIUM, AND JEJUNUM IN PATIENTS ATTENDING FOR JEJUNAL BIOPSY	BRITISH MEDICAL JOURNAL			English	Article							CELIAC-DISEASE; DERMATITIS-HERPETIFORMIS; ANTIGLIADIN ANTIBODIES; SCREENING-TEST; IGA; DIAGNOSIS; GLUTEN; SENSITIVITY; MULTICENTER; CHILDREN	Objective - To investigate the extent to which the detection of antibodies to gliadin, endomysium, and jejunum predicts the eventual diagnosis of coeliac disease according to the revised ESPGAN diagnostic criteria in a group of patients in whom there is a high suspicion of coeliac disease. Design - Clinical assessment and laboratory analysis of patients with suspected coeliac disease. Setting - Gastroenterology department of teaching hospital. Patients - 96 adults with suspected coeliac disease attending for jejunal biopsy. Main outcome measures - Diagnosis of coeliac disease with the revised criteria of the European Society of Paediatric Gastroenterology and Nutrition in patients with and without antibodies associated with coeliac disease. Results - 28 patients had a clinical diagnosis of coeliac disease, seven of other gastrointestinal diseases, and 12 of miscellaneous diseases; 49 had no diagnosis. Gliadin IgA detected by ELISA was found in all patients with coeliac disease and none of those without, giving a sensitivity, specificity, positive and negative predictive values, and predictive efficiency of 100% for diagnosing coeliac disease within the group. Endomysial IgA was found in 25 (89%) patients with coeliac disease and jejunal IgA in 21 (75%); neither IgA was found in patients without coeliac disease. Conclusion - Detection of gliadin IgA by ELISA and to a lesser extent the endomysial IgA should allow better selection of patients for jejunal biopsy and thus make diagnosing coeliac disease simpler and more efficient.	QUEENS UNIV BELFAST,BELFAST BT7 1NN,ANTRIM,NORTH IRELAND	Queens University Belfast	MCMILLAN, SA (corresponding author), BELFAST CITY HOSP,REG IMMUNOL LAB,BELFAST BT9 7AD,ANTRIM,NORTH IRELAND.			Edgar, John David Moore/0000-0003-2969-4475				ASCHER H, 1990, J PEDIATR GASTR NUTR, V10, P443, DOI 10.1097/00005176-199005000-00005; BURGINWOLFF A, 1989, EUR J PEDIATR, V148, P496, DOI 10.1007/BF00441541; CHORZELSKI TP, 1984, BRIT J DERMATOL, V111, P395, DOI 10.1111/j.1365-2133.1984.tb06601.x; DIAS J, 1987, LANCET, V2, P157; ELEWAUT A, 1989, CLIN CHIM ACTA, V183, P285, DOI 10.1016/0009-8981(89)90362-8; GALLEN RS, 1986, MANUAL CLIN LABORATO, P966; GRODZINSKY E, 1990, INT ARCH ALLER A IMM, V92, P119, DOI 10.1159/000235201; GUANDALINI S, 1989, ARCH DIS CHILD, V64, P1320, DOI 10.1136/adc.64.9.1320; HALLSTROM O, 1989, GUT, V30, P1225, DOI 10.1136/gut.30.9.1225; KARPATI S, 1990, LANCET, P1335; KELLY J, 1987, ARCH DIS CHILD, V62, P469, DOI 10.1136/adc.62.5.469; KOLETZKO S, 1988, EUR J PEDIATR, V148, P113, DOI 10.1007/BF00445915; KUMAR V, 1989, IMMUNOL INVEST, V18, P533, DOI 10.3109/08820138909112261; MCNEISH AS, 1979, ARCH DIS CHILD, V54, P783, DOI 10.1136/adc.54.10.783; SCOTT H, 1990, SCAND J GASTROENTERO, V25, P287, DOI 10.1080/00365521.1990.12067105; UNSWORTH DJ, 1981, ARCH DIS CHILD, V56, P864, DOI 10.1136/adc.56.11.864; VOLTA U, 1990, CLIN EXP IMMUNOL, V80, P192, DOI 10.1111/j.1365-2249.1990.tb05232.x; WALKERSMITH JA, 1990, ARCH DIS CHILD, V65, P909, DOI 10.1136/adc.65.8.909; WATSON RGP, 1986, ULSTER MED J, V55, P160; 1991, LANCET, P590	20	122	122	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1991	303	6811					1163	1165		10.1136/bmj.303.6811.1163	http://dx.doi.org/10.1136/bmj.303.6811.1163			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP488	1747612	Green Published, Bronze			2022-12-01	WOS:A1991GP48800021
J	WILLIAMS, RB; BURDGE, AH; JONES, SL				WILLIAMS, RB; BURDGE, AH; JONES, SL			SKIN BIOPSY IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article											WILLIAMS, RB (corresponding author), MAELOR GEN HOSP,WREXHAM LL13 7TD,CLWYD,WALES.							Brundel K H, 1990, Derm Beruf Umwelt, V38, P54; Paver R D, 1990, Aust Fam Physician, V19, P699	2	23	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1991	303	6811					1179	1180		10.1136/bmj.303.6811.1179	http://dx.doi.org/10.1136/bmj.303.6811.1179			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP488	1747617	Bronze, Green Published			2022-12-01	WOS:A1991GP48800027
J	WOTHERSPOON, AC; ORTIZHIDALGO, C; FALZON, MR; ISAACSON, PG				WOTHERSPOON, AC; ORTIZHIDALGO, C; FALZON, MR; ISAACSON, PG			HELICOBACTER-PYLORI-ASSOCIATED GASTRITIS AND PRIMARY B-CELL GASTRIC LYMPHOMA	LANCET			English	Note							CAMPYLOBACTER-PYLORI; IMMUNE-RESPONSE; MUCOSA; TISSUE	Although lymphoid tissue is absent in normal gastric mucosa, primary lymphomas arise in the stomach and most of these recapitulate the features of mucosa-associated lymphoid tissue (MALT). Gastric lymphoid tissue is known to be acquired in response to local infection by Helicobacter pylori, and we have confirmed this in 450 patients with H pylori-associated gastritis of whom 125 showed mucosal lymphoid follicles. In 8 patients, B lymphocytes infiltrated epithelium, which is a feature characteristic of MALT. We also examined 110 cases of gastric MALT lymphoma and found H pylori infection in 101 of these (92%). We conclude that gastric MALT is acquired in H pylori infection and that this provides the necessary background in which MALT lymphoma might develop.	UNIV COLL & MIDDLESEX SCH MED,DEPT HISTOPATHOL,UNIV ST,LONDON WC1E 6JJ,ENGLAND	University of London; University College London								CHAN JKC, 1990, AM J PATHOL, V136, P1153; CRABTREE JE, 1991, LANCET, P332; HYJEK E, 1988, HUM PATHOL, V19, P766, DOI 10.1016/S0046-8177(88)80259-4; HYJEK E, 1988, HUM PATHOL, V19, P1315, DOI 10.1016/S0046-8177(88)80287-9; ISAACSON PG, 1987, HISTOPATHOLOGY, V11, P445, DOI 10.1111/j.1365-2559.1987.tb02654.x; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; SHALLCROSS TM, 1989, CAMPYLOBACTER PYLORI, P155; SPENCER JO, 1986, GUT, V27, P405, DOI 10.1136/gut.27.4.405; STOLTE M, 1989, J CLIN PATHOL, V42, P1269, DOI 10.1136/jcp.42.12.1269; WYATT JI, 1988, SCAND J GASTROENTERO, V23, P44, DOI 10.3109/00365528809091712; WYATT JI, 1991, SEMIN DIAGN PATHOL, V8, P137	11	1537	1580	2	30	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 9	1991	338	8776					1175	1176		10.1016/0140-6736(91)92035-Z	http://dx.doi.org/10.1016/0140-6736(91)92035-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP034	1682595				2022-12-01	WOS:A1991GP03400007
J	CUNNINGHAM, BC; ULTSCH, M; DEVOS, AM; MULKERRIN, MG; CLAUSER, KR; WELLS, JA				CUNNINGHAM, BC; ULTSCH, M; DEVOS, AM; MULKERRIN, MG; CLAUSER, KR; WELLS, JA			DIMERIZATION OF THE EXTRACELLULAR DOMAIN OF THE HUMAN GROWTH-HORMONE RECEPTOR BY A SINGLE HORMONE MOLECULE	SCIENCE			English	Article							MONOCLONAL-ANTIBODIES; SCANNING MUTAGENESIS; PROLACTIN RECEPTOR; ESCHERICHIA-COLI; SUPERFAMILY; FAMILY	Human growth hormone (hGH) forms a 1:2 complex with the extracellular domain of its receptor-binding protein (hGHbp) as studied by crystallization, size exclusion chromatography, calorimetry, and a previously undescribed fluorescence quenching assay. These and other experiments with protein engineered variants of hGH have led to the identification of the binding determinants for two distinct but adjacent sites on hGH for the hGHbp, and the data indicated that there are two overlapping binding sites on the hGHbp for hGH. Furthermore, the binding of hGH to the hGHbp occurred sequentially; a first hGHbp molecule bound to site 1 on hGH and then a second hGHbp bound to site 2. Hormone-induced receptor dimerization is proposed to be relevant to the signal transduction mechanism for the hGH receptor and other related cytokine receptors.	GENENTECH INC,DEPT PROT ENGN,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT MED & ANALYT CHEM,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT PROT CHEM,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech			Wells, Jim A/O-9854-2016	Clauser, Karl/0000-0002-1052-9456				ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; BARNARD R, 1985, BIOCHEM J, V231, P459, DOI 10.1042/bj2310459; BARNARD R, 1984, ENDOCRINOLOGY, V115, P1805, DOI 10.1210/endo-115-5-1805; BASS S, 1990, PROTEINS, V8, P309, DOI 10.1002/prot.340080405; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BEWLEY TA, 1970, ARCH BIOCHEM BIOPHYS, V138, P338, DOI 10.1016/0003-9861(70)90315-2; BINDER L, 1990, MOL ENDOCRINOL, V4, P7; CLARK RD, UNPUB; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CUNNINGHAM BA, UNPUB; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1990, SCIENCE, V247, P1461, DOI 10.1126/science.2321008; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEVOS B, UNPUB; DUKOVICH M, 1987, NATURE, V327, P518, DOI 10.1038/327518a0; ELBERG G, 1990, J BIOL CHEM, V265, P14770; FENDLEY B, UNPUB; FUH G, 1990, J BIOL CHEM, V265, P3111; GRIEP MA, 1988, BIOCHEMISTRY-US, V27, P5210, DOI 10.1021/bi00414a040; GUNTHER N, 1990, J BIOL CHEM, V265, P22082; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; LAX I, 1991, J BIOL CHEM, V266, P13828; LOWMAN HB, 1991, J BIOL CHEM, V260, P10982; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McPherson A., 1989, PREPARATION ANAL PRO; MULKERRIN MG, UNPUB; OLSON KB, UNPUB; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; TESHIGAWARA K, 1987, J EXP MED, V165, P223, DOI 10.1084/jem.165.1.223; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	32	840	891	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1991	254	5033					821	825		10.1126/science.1948064	http://dx.doi.org/10.1126/science.1948064			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN833	1948064				2022-12-01	WOS:A1991GN83300034
J	IMBERTI, L; SOTTINI, A; BETTINARDI, A; PUOTI, M; PRIMI, D				IMBERTI, L; SOTTINI, A; BETTINARDI, A; PUOTI, M; PRIMI, D			SELECTIVE DEPLETION IN HIV-INFECTION OF T-CELLS THAT BEAR SPECIFIC T-CELL RECEPTOR-V-BETA SEQUENCES	SCIENCE			English	Article							STAPHYLOCOCCAL ENTEROTOXINS; SUPERANTIGENS; INDUCTION; MURINE; CHAIN	The mechanism of T cell depletion during infection with the human immunodeficiency virus (HIV) is unclear. Examination of the repertoire of T cell receptor V (variable) regions m persons infected with HIV revealed the absence of a common set of V-beta-regions, whereas V-alpha usage was normal. The lack of these V-beta-segments did not appear to correlate with opportunistic infections. The selective elimination of T cells that express a defined set of V-beta-sequences may indicate the presence of an HIV-encoded superantigen, similar to those encoded by the long terminal repeat of the mouse mammary tumor virus.	OSPED CIVILE,DIV MALATTIE INFETT 1,BRESCIA,ITALY	Hospital Spedali Civili Brescia	IMBERTI, L (corresponding author), UNIV BRESCIA,SCH MED,INST CHEM,CNR,CONSORZIO BIOTECNOL,P SPEDALI CIVILI 1,I-25123 BRESCIA,ITALY.		Puoti, Massimo/AAA-6580-2020	Imberti, Luisa/0000-0002-2075-8391; Puoti, Massimo/0000-0003-3278-7138				ACHAORBEA H, 1991, NATURE, V350, P207, DOI 10.1038/350207a0; BACCALA R, 1991, P NATL ACAD SCI USA, V88, P2908, DOI 10.1073/pnas.88.7.2908; CERNY A, 1990, J EXP MED, V171, P315, DOI 10.1084/jem.171.1.315; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; CHOI YW, 1991, NATURE, V350, P203, DOI 10.1038/350203a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS MM, 1985, ANNU REV IMMUNOL, V3, P537, DOI 10.1146/annurev.iy.03.040185.002541; DYASON PJ, 1991, NATURE, V349, P531; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; HERMAN A, 1990, J EXP MED, V172, P709, DOI 10.1084/jem.172.3.709; HUGIN AW, 1991, SCIENCE, V252, P424, DOI 10.1126/science.1850169; JANEWAY C, 1991, NATURE, V349, P459, DOI 10.1038/349459a0; JANEWAY CA, 1990, CELL, V63, P659, DOI 10.1016/0092-8674(90)90130-7; KAPPLER J, 1989, SCIENCE, V244, P811, DOI 10.1126/science.2524876; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; MACDONALD HR, 1988, J EXP MED, V167, P2005, DOI 10.1084/jem.167.6.2005; MANTERO G, 1991, CLIN CHEM, V37, P422; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; SOTTINI A, 1991, EUR J IMMUNOL, V21, P461, DOI 10.1002/eji.1830210231; STROMINGER JL, 1989, SCIENCE, V244, P943, DOI 10.1126/science.2658058; WILSON RK, 1988, IMMUNOL REV, V101, P149, DOI 10.1111/j.1600-065X.1988.tb00736.x; WOODLAND DL, 1991, NATURE, V349, P529, DOI 10.1038/349529a0	23	349	355	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1991	254	5033					860	862		10.1126/science.1948066	http://dx.doi.org/10.1126/science.1948066			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN833	1948066				2022-12-01	WOS:A1991GN83300046
J	LEVINE, B; HARDWICK, JM; TRAPP, BD; CRAWFORD, TO; BOLLINGER, RC; GRIFFIN, DE				LEVINE, B; HARDWICK, JM; TRAPP, BD; CRAWFORD, TO; BOLLINGER, RC; GRIFFIN, DE			ANTIBODY-MEDIATED CLEARANCE OF ALPHAVIRUS INFECTION FROM NEURONS	SCIENCE			English	Article							AGE-DEPENDENT RESISTANCE; CENTRAL NERVOUS-SYSTEM; SINDBIS VIRUS; VIRAL-INFECTION; IMMUNE-RESPONSE; MICE; ENCEPHALITIS; PATHOGENESIS; ENCEPHALOMYELITIS; LYMPHOCYTES	Humoral immunity is important for protection against viral infection and neutralization of extracellular virus, but clearance of virus from infected tissues is thought to be mediated solely by cellular immunity. However, in a SCID mouse model of persistent alphavirus encephalomyelitis, adoptive transfer of hyperimmune serum resulted in clearance of infectious virus and viral RNA from the nervous system, whereas adoptive transfer of sensitized T lymphocytes had no effect on viral replication. Three monoclonal antibodies to two different epitopes on the E2 envelope glycoprotein mediated viral clearance. Treatment of alphavirus-infected primary cultured rat neurons with these monoclonal antibodies to E2 resulted in decreased viral protein synthesis, followed by gradual termination of mature infectious virion production. Thus, antibody can mediate clearance of alphavirus infection from neurons by restricting viral gene expression.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Crawford, Thomas/E-6307-2012	Bollinger, Robert/0000-0002-6798-6834	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029234, T32NS007000] Funding Source: NIH RePORTER; NINDS NIH HHS [NS29234, T32-NS-07000] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALLAS ZK, 1986, J IMMUNOL, V137, P2380; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; FROSHAUER S, 1988, J CELL BIOL, V107, P2075, DOI 10.1083/jcb.107.6.2075; FUJINAMI RS, 1989, J VIROL, V63, P2081, DOI 10.1128/JVI.63.5.2081-2087.1989; GRIFFIN DE, 1976, J INFECT DIS, V133, P456, DOI 10.1093/infdis/133.4.456; GRIFFIN DE, 1973, CELL IMMUNOL, V9, P426, DOI 10.1016/0008-8749(73)90057-9; JACKSON AC, 1987, LAB INVEST, V56, P418; JACKSON AC, 1988, LAB INVEST, V58, P503; JOHNSON RT, 1972, J INFECT DIS, V125, P257, DOI 10.1093/infdis/125.3.257; LEVINE B, UNPUB; MAUERHOFF T, 1988, J NEUROIMMUNOL, V18, P271, DOI 10.1016/0165-5728(88)90049-5; MCFARLAND HF, 1974, J IMMUNOL, V113, P173; MCKINNEY RE, 1987, REV INFECT DIS, V9, P334; MENDOZA QP, 1988, J GEN VIROL, V70, P3015; MOMBURG F, 1986, EUR J IMMUNOL, V16, P551, DOI 10.1002/eji.1830160516; OLDSTONE MBA, 1986, NATURE, V321, P239, DOI 10.1038/321239a0; OLMSTED RA, 1986, VIROLOGY, V148, P245, DOI 10.1016/0042-6822(86)90322-3; PERRY LL, 1991, J VIROL, V65, P3429, DOI 10.1128/JVI.65.7.3429-3434.1991; SCHMALJOHN AL, 1982, NATURE, V297, P70, DOI 10.1038/297070a0; SCHMALJOHN AL, 1983, VIROLOGY, V130, P305; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SHERMAN LA, 1990, J VIROL, V64, P2041, DOI 10.1128/JVI.64.5.2041-2046.1990; STANLEY J, 1986, J VIROL, V58, P107, DOI 10.1128/JVI.58.1.107-115.1986; TRAPP BD, 1989, J CELL BIOL, V109, P2417, DOI 10.1083/jcb.109.5.2417; TYLER KL, 1989, J EXP MED, V170, P887, DOI 10.1084/jem.170.3.887	25	324	328	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1991	254	5033					856	860		10.1126/science.1658936	http://dx.doi.org/10.1126/science.1658936			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN833	1658936				2022-12-01	WOS:A1991GN83300045
J	OTOOLE, TE; MANDELMAN, D; FORSYTH, J; SHATTIL, SJ; PLOW, EF; GINSBERG, MH				OTOOLE, TE; MANDELMAN, D; FORSYTH, J; SHATTIL, SJ; PLOW, EF; GINSBERG, MH			MODULATION OF THE AFFINITY OF INTEGRIN-ALPHA-IIB-BETA-3 (GPIIB-IIIA) BY THE CYTOPLASMIC DOMAIN OF ALPHA-IIB	SCIENCE			English	Article							MEMBRANE GLYCOPROTEIN-IIB; FIBRINOGEN RECEPTOR; PLATELET ACTIVATION; MONOCLONAL-ANTIBODY; ADHESION; BINDING; EXPRESSION; INTEGRINS; SEQUENCE; SUBUNITS	Intracellular signaling alters integrin adhesive functions in inflammation, immune responses, hemostasis, thrombosis, and retinal development. By truncating the cytoplasmic domain of alpha-IIb, the affinity of integrin alpha-IIb-beta-3, for ligand was increased. Reconstitution with the cytoplasmic domain from integrin alpha-5 did not reverse the increased affinity. Thus, the cytoplasmic domain of the alpha-subunit of GPIIb-IIIa controls ligand binding affinity, which suggests mechanisms for inside-out transmembrane signaling through integrins. These findings imply the existence of hitherto unappreciated hereditary and acquired thrombotic disorders in humans.	SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA; UNIV PENN, CTR CANC, PHILADELPHIA, PA 19104 USA	Scripps Research Institute; University of Pennsylvania			O'Toole, Timothy/I-4172-2013		NHLBI NIH HHS [HL16411, HL28235, HL 39150] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411, R01HL039150, R01HL028235] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BRASS LF, 1986, J BIOL CHEM, V261, P6838; COLLER BS, 1983, J CLIN INVEST, V72, P325, DOI 10.1172/JCI110973; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FROJMOVIC MM, 1991, BLOOD, V78, P369; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KUNICKI TJ, 1981, J CLIN INVEST, V67, P717, DOI 10.1172/JCI110088; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOFTUS JC, 1988, J BIOL CHEM, V263, P11025; Maniatis T., 1982, MOL CLONING; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MCEVER RP, 1983, J BIOL CHEM, V258, P5269; MUNKER R, 1991, HEMATOLOGY BASIC PRI, P817; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEUGEBAUER KM, 1991, NATURE, V350, P68, DOI 10.1038/350068a0; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1989, BLOOD, V74, P14; PLOW EF, 1981, J BIOL CHEM, V256, P9477; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SHATTIL SJ, 1987, J BIOL CHEM, V262, P992; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHAW LM, 1990, J CELL BIOL, V110, P2167, DOI 10.1083/jcb.110.6.2167; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; SUZUKI S, 1987, J BIOL CHEM, V262, P14080; TAMURA RN, IN PRESS P NATL ACAD; TAUB R, 1989, J BIOL CHEM, V264, P259; WOODS VL, 1986, J BIOL CHEM, V261, P5242	30	311	316	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1991	254	5033					845	847		10.1126/science.1948065	http://dx.doi.org/10.1126/science.1948065			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN833	1948065				2022-12-01	WOS:A1991GN83300041
J	RANDAZZO, PA; NORTHUP, JK; KAHN, RA				RANDAZZO, PA; NORTHUP, JK; KAHN, RA			ACTIVATION OF A SMALL GTP-BINDING PROTEIN BY NUCLEOSIDE DIPHOSPHATE KINASE	SCIENCE			English	Article							ADENYLATE-CYCLASE; NUCLEOTIDE BINDING; ADP-RIBOSYLATION; ESCHERICHIA-COLI; GS-ALPHA; TUMOR-METASTASIS; CHOLERA-TOXIN; 2 FORMS; EXPRESSION; NM23	Genes that encode nucleoside diphosphate kinases (NDKs) have been implicated as regulators of mammalian tumor metastasis and development in Drosophila melanogaster. However, the cellular pathways through which NDKs function am not known. One potential mechanism of regulation is phosphorylation of guanosine diphosphate (GDP) bound to regulatory guanosine triphosphate (GTP) binding proteins. NDK-catalyzed phosphorylation of bound GDP was investigated for the adenosine diphosphate ribosylation factor (ARF), a 21-kilodalton GTP-binding protein that functions in the protein secretion pathway. Bovine liver NDK, recombinant human NDK, and the protein product of the mouse gene nm23-1, which suppresses the metastatic potential of certain tumor cells, used ARF-GDP as a substrate, thereby allowing rapid and efficient production of activated ARF (ARF-GTP) in the absence of nucleotide exchange. These data are consistent with the proposed function of NDK as an activator of a small GTP-binding protein and provide a mechanism of activation for a regulatory GTP-binding protein that is independent of nucleotide exchange.	NCI,DIV CENT RES,BIOL CHEM LAB,BETHESDA,MD 20892; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06514	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Yale University			Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601				BERG P, 1953, NATURE, V172, P1008, DOI 10.1038/1721008a0; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; CHENG YC, 1971, BIOCHEMISTRY-US, V10, P2139; COLOMB MG, 1969, BIOCHEMISTRY-US, V8, P1926, DOI 10.1021/bi00833a024; GARCES E, 1969, BIOCHEMISTRY-US, V8, P633, DOI 10.1021/bi00830a026; GOFFEAU A, 1967, J BIOL CHEM, V242, P1845; GRAZIANO MP, 1987, J BIOL CHEM, V262, P11375; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HENNESSY C, 1991, J NATL CANCER I, V83, P281, DOI 10.1093/jnci/83.4.281; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KIKKAWA S, 1990, J BIOL CHEM, V265, P21536; KIMURA N, 1979, J BIOL CHEM, V254, P3451; KIMURA N, 1983, J BIOL CHEM, V258, P2278; KREBS HA, 1953, BIOCHIM BIOPHYS ACTA, V12, P172, DOI 10.1016/0006-3002(53)90136-X; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MOURAD N, 1966, J BIOL CHEM, V241, P271; OHTSUKI K, 1985, BIOCHEM INT, V11, P719; OHTSUKI K, 1987, BIOCHEM BIOPH RES CO, V148, P300, DOI 10.1016/0006-291X(87)91110-7; Parks R. E., 1973, ENZYMES, V8, P307, DOI 10.1016/S1874-6047(08)60069-4; RANDAZZO PA, UNPUB; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; RULKA C, UNPUB; SCHLEIFER LS, 1982, J BIOL CHEM, V257, P20; SEDMARK J, 1971, J BIOL CHEM, V246, P53; SERAFINI T, IN PRESS CELL; STEEG PS, 1988, CANCER RES, V48, P6550; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; UESAKA H, 1987, BIOCHEM BIOPH RES CO, V143, P552, DOI 10.1016/0006-291X(87)91389-1; WEISS O, 1989, J BIOL CHEM, V264, P21066; WILDMAN D, UNPUB	35	76	77	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1991	254	5033					850	853		10.1126/science.1658935	http://dx.doi.org/10.1126/science.1658935			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN833	1658935				2022-12-01	WOS:A1991GN83300043
J	SHAANAN, B; LIS, H; SHARON, N				SHAANAN, B; LIS, H; SHARON, N			STRUCTURE OF A LEGUME LECTIN WITH AN ORDERED N-LINKED CARBOHYDRATE IN COMPLEX WITH LACTOSE	SCIENCE			English	Article							X-RAY-DIFFRACTION; 3-DIMENSIONAL STRUCTURE; CONCANAVALIN-A; CRYSTAL-STRUCTURE; ERYTHRINA-CORALLODENDRON; SACCHARIDE-BINDING; FC-FRAGMENT; OLIGOSACCHARIDES; RECOGNITION; RESOLUTION	The three-dimensional structure of the lactose complex of the Erythrina corallodendron lectin (EcorL), a dimer of N-glycosylated subunits, was determined crystallographically and refined at 2.0 angstrom resolution to an R value of 0.19. The tertiary structure of the subunit is similar to that of other legume lectins, but interference by the bulky N-linked heptasaccharide, which is exceptionally well ordered in the crystal, forces the EcorL dimer into a drastically different quaternary structure. Only the galactose moiety of the lactose ligand resides within the combining site. The galactose moiety is oriented differently from ligands in the mannose-glucose specific legume lectins and is held by hydrophobic interactions with Ala88, Tyr106, Phe131, and Ala218, and by seven hydrogen bonds, four of which are to the conserved Asp89, Asn133, and NH of Gly107. The specificity of legume lectins toward the different C-4 epimers appears to be associated with extensive variations in the outline of the variable parts of the binding sites.	WEIZMANN INST SCI, DEPT BIOPHYS, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science	SHAANAN, B (corresponding author), NIADDKD, MOLEC BIOL LAB, BETHESDA, MD 20892 USA.		Shaanan, Boaz/F-1202-2012	Shaanan, Boaz/0000-0001-8925-4362				ADAR R, 1989, FEBS LETT, V257, P81, DOI 10.1016/0014-5793(89)81791-0; AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; ARANGO R, 1990, FEBS LETT, V264, P109, DOI 10.1016/0014-5793(90)80777-G; ASHFORD D, 1987, EUR J BIOCHEM, V166, P311, DOI 10.1111/j.1432-1033.1987.tb13516.x; ASHWELL G, 1974, ADV ENZYMOL RAMB, V41, P99; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BECKER JW, 1975, J BIOL CHEM, V250, P1513; BECKER JW, 1991, T AM CRYSTALLOGR ASS, V25, P37; BODE W, 1989, BIOCHEMISTRY-US, V28, P1951, DOI 10.1021/bi00431a001; BOURNE Y, 1990, PROTEINS, V8, P365, DOI 10.1002/prot.340080410; BOURNE Y, 1990, J MOL BIOL, V214, P571, DOI 10.1016/0022-2836(90)90199-V; BOUWSTRA JB, 1990, EUR J BIOCHEM, V190, P113, DOI 10.1111/j.1432-1033.1990.tb15553.x; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; BRISSON JR, 1983, BIOCHEMISTRY-US, V22, P3680, DOI 10.1021/bi00284a022; Brunger AT, 1988, CRYSTALLOGRAPHIC COM, V3, P126; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Davies D R, 1975, Contemp Top Mol Immunol, V4, P127; DEBOECK H, 1984, ARCH BIOCHEM BIOPHYS, V234, P297, DOI 10.1016/0003-9861(84)90352-7; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DELBAERE LT, 1991, T AM CRYSTALLOGR ASS, V25, P51; DELBAERE LTJ, 1990, CAN J CHEM, V68, P1116, DOI 10.1139/v90-172; DEREWENDA Z, 1989, EMBO J, V8, P2189, DOI 10.1002/j.1460-2075.1989.tb08341.x; EDELMAN GM, 1972, P NATL ACAD SCI USA, V69, P2580, DOI 10.1073/pnas.69.9.2580; EINSPAHR H, 1986, J BIOL CHEM, V261, P6518; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FUJINAGA M, 1987, J APPL CRYSTALLOGR, V20, P517, DOI 10.1107/S0021889887086102; HARDMAN KD, 1982, J MOL BIOL, V157, P69, DOI 10.1016/0022-2836(82)90513-7; HARDMAN KD, 1972, BIOCHEMISTRY-US, V11, P4910, DOI 10.1021/bi00776a006; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; HOMANS SW, 1987, BIOCHEMISTRY-US, V26, P6553, DOI 10.1021/bi00394a040; HOMANS SW, 1987, BIOCHEMISTRY-US, V26, P6571, DOI 10.1021/bi00395a001; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; LIS H, 1985, PHYTOCHEMISTRY, V24, P2803, DOI 10.1016/0031-9422(85)80004-2; LOONTIENS FG, UNPUB; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; REEKE GN, 1975, J BIOL CHEM, V250, P1525; REEKE GN, 1988, CURR TOP MICROBIOL, V139, P35; REEKE GN, 1986, SCIENCE, V234, P1108, DOI 10.1126/science.3775378; ROSEN SD, 1990, AM J RESP CELL MOL, V3, P397, DOI 10.1165/ajrcmb/3.5.397; SAPER MA, 1987, J MOL BIOL, V193, P823, DOI 10.1016/0022-2836(87)90363-9; SHAANAN B, UNPUB; SHARON N, 1990, FASEB J, V4, P3198, DOI 10.1096/fasebj.4.14.2227211; SHARON N, 1989, SCIENCE, V246, P227, DOI 10.1126/science.2552581; SKEHEL JJ, 1984, P NATL ACAD SCI-BIOL, V81, P1779, DOI 10.1073/pnas.81.6.1779; SUCK D, 1984, EMBO J, V3, P2423, DOI 10.1002/j.1460-2075.1984.tb02149.x; SUTTON BJ, 1983, BIOCHEM SOC T, V11, P130, DOI 10.1042/bst0110130; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; WEIS WI, 1990, J MOL BIOL, V212, P737, DOI 10.1016/0022-2836(90)90234-D; WILLIAMS RL, 1987, J BIOL CHEM, V262, P16020; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; WRIGHT CS, 1990, J MOL BIOL, V215, P635, DOI 10.1016/S0022-2836(05)80174-3	54	265	268	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 8	1991	254	5033					862	866		10.1126/science.1948067	http://dx.doi.org/10.1126/science.1948067			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN833	1948067				2022-12-01	WOS:A1991GN83300047
J	WEST, JW; NUMANN, R; MURPHY, BJ; SCHEUER, T; CATTERALL, WA				WEST, JW; NUMANN, R; MURPHY, BJ; SCHEUER, T; CATTERALL, WA			A PHOSPHORYLATION SITE IN THE NA+ CHANNEL REQUIRED FOR MODULATION BY PROTEIN-KINASE-C	SCIENCE			English	Article							SODIUM-CHANNEL; RAT-BRAIN; ALPHA-SUBUNIT; GATING PROPERTIES; SKELETAL-MUSCLE; MESSENGER-RNAS; EXPRESSION; INACTIVATION; ACTIVATION; SEQUENCE	Voltage-gated sodium channels are responsible for generation of action potentials in excitable cells. Activation of protein kinase C slows inactivation of sodium channels and reduces peak sodium currents. Phosphorylation of a single residue, serine 1506, that is located in the conserved intracellular loop between domains III and IV and is involved in inactivation of the sodium channel, is required for both modulatory effects. Mutant sodium channels lacking this phosphorylation site have normal functional properties in unstimulated cells but do not respond to activation of protein kinase C. Phosphorylation of this conserved site in sodium channel alpha-subunits may regulate electrical activity in a wide range of excitable cells.			WEST, JW (corresponding author), UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015751, R01NS025704] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07270] Funding Source: Medline; NINDS NIH HHS [NS25704, NS15751] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AULD VJ, 1990, P NATL ACAD SCI USA, V87, P323, DOI 10.1073/pnas.87.1.323; AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; BECKH S, 1989, EMBO J, V8, P3611, DOI 10.1002/j.1460-2075.1989.tb08534.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLEGG C, 1977, J BIOL CHEM, V262, P13111; COSTA MRC, 1984, CELL MOL NEUROBIOL, V4, P291, DOI 10.1007/BF00733592; GOLDIN AL, 1986, P NATL ACAD SCI USA, V83, P7503, DOI 10.1073/pnas.83.19.7503; GORDON D, 1987, P NATL ACAD SCI USA, V84, P8682, DOI 10.1073/pnas.84.23.8682; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARTSHORNE RP, 1984, J BIOL CHEM, V259, P1667; Hille B, 1984, IONIC CHANNELS EXCIT; KACZMAREK LK, 1987, TRENDS NEUROSCI, V10, P30, DOI 10.1016/0166-2236(87)90122-6; KALLEN RG, 1990, NEURON, V4, P233, DOI 10.1016/0896-6273(90)90098-Z; KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; NUMANN R, 1991, SCIENCE, V254, P115, DOI 10.1126/science.1656525; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; SARAO R, IN PRESS NUCLEIC ACI; SCHEUER T, 1990, SCIENCE, V247, P854, DOI 10.1126/science.2154850; SCHEUER T, 1991, Biophysical Journal, V59, p262A; SHEARMAN MS, 1989, PHARMACOL REV, V41, P211; SIGEL E, 1988, P NATL ACAD SCI USA, V85, P6192, DOI 10.1073/pnas.85.16.6192; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; VASSILEV P, 1989, P NATL ACAD SCI USA, V86, P8147, DOI 10.1073/pnas.86.20.8147; VASSILEV PM, 1988, SCIENCE, V241, P1658, DOI 10.1126/science.2458625; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836	29	237	241	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1991	254	5033					866	868		10.1126/science.1658937	http://dx.doi.org/10.1126/science.1658937			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN833	1658937				2022-12-01	WOS:A1991GN83300048
J	BISCHOFF, FR; PONSTINGL, H				BISCHOFF, FR; PONSTINGL, H			CATALYSIS OF GUANINE-NUCLEOTIDE EXCHANGE ON RAN BY THE MITOTIC REGULATOR RCC1	NATURE			English	Article							CHROMOSOME CONDENSATION; HUMAN-GENE; PROTEIN; ONSET; CLONING; MUTANT; CDNA; DNA; GDP	THE product of the gene RCC1 (regulator of chromosome condensation) in a BHK cell line is involved in the control of mitotic events 1. Homologous genes have been found in Xenopus 2, Drosophila 3 and yeast 4,5. A human genomic DNA fragment and complementary DNA that complement a temperature-sensitive mutation of RCC1 in BHK21 cells 6,7 encode a protein of relative molecular mass 45,000 (M(r) 45K) which is located in the nucleus and binds to chromatin 8. We have recently isolated a protein from HeLa cells that strongly binds an anti-RCC1 antibody and has the same molecular mass, DNA-binding properties, and amino-acid sequence as the 205 residues already identified 9. HeLa cell RCC1 is complexed to a protein of M(r) 25K (ref. 9). We have shown 10 that this 25K protein has a sequence homologous to the translated reading frame of TC4, a cDNA found by screening a human teratocarcinoma cDNA library with oligonucleotides coding for a ras consensus sequence 11, and that the protein binds GDP and GTP. We have referred to this protein as the Ran protein (ras-related nuclear protein). In addition to the fraction of Ran protein complexed to RCC1, a 25-fold molar excess of the protein over RCC1 was found in the nucleoplasm of HeLa cells. Here we show that RCC1 specifically catalyses the exchange of guanine nucleotides on the Ran protein but not on the protein c-Ha-ras p2l (p21ras).	DEUTSCH KREBSFORSCHUNGSZENTRUM,MOLEC BIOL MITOSIS PROJECT,NEUENHEIMER FELD 280,W-6900 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)								AEBI M, 1990, MOL GEN GENET, V224, P72, DOI 10.1007/BF00259453; BISCHOFF FR, 1990, P NATL ACAD SCI USA, V87, P8617, DOI 10.1073/pnas.87.21.8617; BISCHOFF FR, IN PRESS P NATN ACAD; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHARDIN P, 1991, CANCER CELL-MON REV, V3, P117; CLARK KL, 1989, MOL CELL BIOL, V9, P2682, DOI 10.1128/MCB.9.6.2682; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; FRASCH M, 1991, EMBO J, V10, P1225, DOI 10.1002/j.1460-2075.1991.tb08064.x; JOHN J, 1988, J BIOL CHEM, V263, P11792; KAI R, 1986, MOL CELL BIOL, V6, P2027, DOI 10.1128/MCB.6.6.2027; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; NISHITANI H, 1990, J BIOCHEM-TOKYO, V107, P228, DOI 10.1093/oxfordjournals.jbchem.a123031; OHTSUBO M, 1987, GENE DEV, V1, P585, DOI 10.1101/gad.1.6.585; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; WEST M, 1990, FEBS LETT, V259, P245, DOI 10.1016/0014-5793(90)80019-F; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667	20	559	571	1	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1991	354	6348					80	82		10.1038/354080a0	http://dx.doi.org/10.1038/354080a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN829	1944575				2022-12-01	WOS:A1991GN82900063
J	BLAKELY, RD; BERSON, HE; FREMEAU, RT; CARON, MG; PEEK, MM; PRINCE, HK; BRADLEY, CC				BLAKELY, RD; BERSON, HE; FREMEAU, RT; CARON, MG; PEEK, MM; PRINCE, HK; BRADLEY, CC			CLONING AND EXPRESSION OF A FUNCTIONAL SEROTONIN TRANSPORTER FROM RAT-BRAIN	NATURE			English	Article							IMIPRAMINE BINDING-SITES; TRITIATED IMIPRAMINE; DEPRESSED-PATIENTS; UPTAKE INHIBITOR; GABA TRANSPORTER; LIGAND-BINDING; POLYMERASE; PLATELETS; DOPAMINE; PROTEIN	SELECTIVE antagonism of serotonin (5-hydroxytryptamine, 5HT) and noradrenaline transport by antidepressants is a key element in the 'amine' hypothesis of affective disorders 1. Uptake 2,3 and/or transport sites 4-5 of 5HT have been reported to be reduced in platelets of patients suffering from depression and in post-mortem brain samples of depressed patients 6 and suicide victims 7. To date there has been little molecular information available on the structure and regulation of 5HT transporters. Using the polymerase chain reaction 8 with degenerate oligonucleotides 9 derived from two highly conserved regions of the transporters for noradrenaline 10 and gamma-aminobutyric acid 11 (GABA), we have identified a large family of related gene products expressed in rodent brain. One of these products hybridizes to a single 3.7-kilobase RNA restricted to rat midbrain and brainstem, where it is highly enriched within the serotonergic raphe complex. Transfection with a single 2.3-kilobase brainstem complementary DNA clone is sufficient to confer expression of a Na+-dependent 5HT transporter upon non-neural cells, with transport selectively and potently antagonized by 5HT uptake-specific antidepressants, including paroxetine, citalopram and fluoxetine.	EMORY UNIV, SCH MED, PROGRAM NEUROSCI, ATLANTA, GA 30322 USA; DUKE UNIV, SCH MED, DEPT NEUROBIOL, DURHAM, NC 27710 USA; DUKE UNIV, SCH MED, DEPT CELL BIOL & MED, DURHAM, NC 27710 USA	Emory University; Duke University; Duke University	BLAKELY, RD (corresponding author), EMORY UNIV, SCH MED, DEPT ANAT & CELL BIOL, ATLANTA, GA 30322 USA.							ANDERSEN PH, 1989, EUR J PHARMACOL, V166, P493, DOI 10.1016/0014-2999(89)90363-4; ASHTON H, 1987, BRIAN SYSTEMS DISORD, P283; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BRILEY MS, 1980, SCIENCE, V209, P303, DOI 10.1126/science.7384806; COOL DR, 1991, J BIOL CHEM, V266, P15750; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FREMEAU RT, 1991, P NATL ACAD SCI USA, V88, P3772, DOI 10.1073/pnas.88.9.3772; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; FULLER RW, 1990, ANN NY ACAD SCI, V600, P68, DOI 10.1111/j.1749-6632.1990.tb16873.x; GRAHAM D, 1989, BIOCHEM PHARMACOL, V38, P3819, DOI 10.1016/0006-2952(89)90591-1; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HINSON JP, 1989, J ENDOCRINOL, V121, P253, DOI 10.1677/joe.0.1210253; HOLZWARTH MA, 1985, NEUROENDOCRINOLOGY, V41, P230, DOI 10.1159/000124182; HYTTEL J, 1977, PSYCHOPHARMACOLOGY, V51, P225, DOI 10.1007/BF00431629; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOE BK, 1976, J PHARMACOL EXP THER, V199, P649; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LASSEN J B, 1978, European Journal of Pharmacology, V47, P351; LEMBERGER L, 1978, CLIN PHARMACOL THER, V23, P421; MARCUSSON JO, 1989, PSYCHOPHARMACOLOGY, V99, P17, DOI 10.1007/BF00634446; MAXWELL RA, 1978, HDB PSYCHOPHARMACOLO, P83; MELTZER HY, 1981, ARCH GEN PSYCHIAT, V38, P1322; NELSON H, 1990, FEBS LETT, V269, P181, DOI 10.1016/0014-5793(90)81149-I; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PAUL SM, 1981, ARCH GEN PSYCHIAT, V38, P1315; PERRY EK, 1983, BRIT J PSYCHIAT, V142, P188, DOI 10.1192/bjp.142.2.188; RATHE R, 1985, J MOL BIOL, V183, P1; RICHELSON E, 1990, MAYO CLIN PROC, V65, P1227, DOI 10.1016/S0025-6196(12)62747-5; RITZ MC, 1990, LIFE SCI, V46, P635, DOI 10.1016/0024-3205(90)90132-B; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU; STANLEY M, 1982, SCIENCE, V216, P1337, DOI 10.1126/science.7079769; Steinbusch H. W., 1983, CHEM NEUROANATOMY, P131; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; SURANYICADOTTE BE, 1985, LIFE SCI, V36, P795, DOI 10.1016/0024-3205(85)90201-2; VERHOFSTAD AAJ, 1983, NEUROSCIENCE, V10, P1443, DOI 10.1016/0306-4522(83)90125-2; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17	39	710	727	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 7	1991	354	6348					66	70		10.1038/354066a0	http://dx.doi.org/10.1038/354066a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN829	1944572				2022-12-01	WOS:A1991GN82900059
J	CHOI, HK; TONG, L; MINOR, W; DUMAS, P; BOEGE, U; ROSSMANN, MG; WENGLER, G				CHOI, HK; TONG, L; MINOR, W; DUMAS, P; BOEGE, U; ROSSMANN, MG; WENGLER, G			STRUCTURE OF SINDBIS VIRUS CORE PROTEIN REVEALS A CHYMOTRYPSIN-LIKE SERINE PROTEINASE AND THE ORGANIZATION OF THE VIRION	NATURE			English	Article							SEMLIKI FOREST VIRUS; ALPHA-LYTIC PROTEASE; AMINO-ACID-SEQUENCE; CAPSID PROTEIN; RNA VIRUSES; NONSTRUCTURAL PROTEINS; CYSTEINE PROTEASES; MOSAIC-VIRUS; RESOLUTION; ALPHAVIRUSES	Sindbis virus consists of a nucleocapsid core surrounded by a lipid membrane through which penetrate 80 glycoprotein trimers. The structure of the core protein comprising the coat surrounding the genomic RNA has been determined. The polypeptide fold from residue 114 to residue 264 is homologous to that of chymotrypsin-like serine proteinases with catalytic residues His 141, Asp 163 and Ser 215 of the core protein positioned as in other serine proteinases. The C-terminal tryptophan remains in the P1 substrate site subsequent to the autocatalytic cis cleavage of the capsid protein, thus rendering the proteinase inactive. Model building of the Sindbis core protein dimer shows that the nucleocapsid is likely to have T = 4 quasisymmetry.	PURDUE UNIV, DEPT BIOL SCI, W LAFAYETTE, IN 47907 USA; UNIV ALBERTA, DEPT BIOCHEM, EDMONTON T6G 2H7, ALBERTA, CANADA; UNIV GIESSEN, INST VIROL, W-6300 GIESSEN, GERMANY	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Alberta; Justus Liebig University Giessen			Minor, Wladek/F-3096-2014	Minor, Wladek/0000-0001-7075-7090; Tong, Liang/0000-0002-0563-6468				ABADZAPATERO C, 1980, NATURE, V286, P33, DOI 10.1038/286033a0; AHLQUIST P, 1985, J VIROL, V53, P536, DOI 10.1128/JVI.53.2.536-542.1985; ALIPERTI G, 1978, VIROLOGY, V90, P366, DOI 10.1016/0042-6822(78)90321-5; ANDINO R, 1990, CELL, V63, P369, DOI 10.1016/0092-8674(90)90170-J; ANTHONY RP, 1991, J VIROL, V65, P1187, DOI 10.1128/JVI.65.3.1187-1194.1991; BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872; BIRKTOFT JJ, 1972, J MOL BIOL, V68, P187, DOI 10.1016/0022-2836(72)90210-0; BODE W, 1978, J MOL BIOL, V118, P99, DOI 10.1016/0022-2836(78)90246-2; BOEGE U, 1989, J MOL BIOL, V208, P79, DOI 10.1016/0022-2836(89)90089-2; BOEGE U, 1983, EUR J BIOCHEM, V133, P415, DOI 10.1111/j.1432-1033.1983.tb07479.x; BOEGE U, 1981, VIROLOGY, V113, P293, DOI 10.1016/0042-6822(81)90156-2; BONE R, 1987, BIOCHEMISTRY-US, V26, P7609, DOI 10.1021/bi00398a012; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; CONNOLLY ML, 1985, J MOL GRAPHICS, V3, P19, DOI 10.1016/0263-7855(85)80009-6; COOMBS K, 1987, J MOL BIOL, V195, P359, DOI 10.1016/0022-2836(87)90657-7; COOMBS K, 1987, VIRUS RES, V7, P131, DOI 10.1016/0168-1702(87)90075-X; COOMBS K, 1984, VIRUS RES, V1, P297, DOI 10.1016/0168-1702(84)90018-2; COOMBS KM, 1989, J VIROL, V63, P883, DOI 10.1128/JVI.63.2.883-891.1989; DESSENS JT, 1991, VIROLOGY, V184, P738, DOI 10.1016/0042-6822(91)90444-G; ENZMANN PJ, 1979, VIROLOGY, V95, P501, DOI 10.1016/0042-6822(79)90504-X; FREEMAN R, 1981, J MICROSC-OXFORD, V122, P275, DOI 10.1111/j.1365-2818.1981.tb01267.x; FUJINAGA M, 1985, J MOL BIOL, V184, P479, DOI 10.1016/0022-2836(85)90296-7; FULLER SD, 1987, EMBO J, V6, P1099, DOI 10.1002/j.1460-2075.1987.tb04864.x; FULLER SD, 1987, CELL, V48, P923, DOI 10.1016/0092-8674(87)90701-X; GORBALENYA AE, 1989, FEBS LETT, V243, P103, DOI 10.1016/0014-5793(89)80109-7; HAHN CS, 1990, J VIROL, V64, P3069, DOI 10.1128/JVI.64.6.3069-3073.1990; HAHN CS, 1988, P NATL ACAD SCI USA, V85, P5997, DOI 10.1073/pnas.85.16.5997; HAHN CS, 1985, P NATL ACAD SCI USA, V82, P4648, DOI 10.1073/pnas.82.14.4648; HAMMERLE T, 1991, J BIOL CHEM, V266, P5412; Harrison S. C., 1986, TOGAVIRIDAE FLAVIVIR, P21; HARRISON SC, 1978, NATURE, V276, P368, DOI 10.1038/276368a0; HASELOFF J, 1984, P NATL ACAD SCI-BIOL, V81, P4358, DOI 10.1073/pnas.81.14.4358; HORZINEK M, 1969, J VIROL, V4, P514, DOI 10.1128/JVI.4.4.514-520.1969; Kaariainen L, 1978, Curr Top Microbiol Immunol, V82, P15; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KEAN KM, 1991, VIROLOGY, V181, P609, DOI 10.1016/0042-6822(91)90894-H; KRAULIS P, IN PRESS J APPL CRYS; KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413; Liljas A., 1974, ANNU REV BIOCHEM, V43, P475; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCKENNA R, UNPUB NATURE; MELANCON P, 1987, J VIROL, V61, P1301, DOI 10.1128/JVI.61.5.1301-1309.1987; METSIKKO K, 1990, J VIROL, V64, P4678; NAMBA K, 1986, SCIENCE, V231, P1401, DOI 10.1126/science.3952490; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; ROSSMANN MG, 1975, J BIOL CHEM, V250, P7525; ROSSMANN MG, IN PRESS J APPL CRYS; SCHEEFERS H, 1980, P NATL ACAD SCI-BIOL, V77, P7277, DOI 10.1073/pnas.77.12.7277; Schlesinger, 1986, TOGAVIRIDAE FLAVIVIR, P35, DOI 10.1007/978-1-4757-0785-4_3; Schlesinger S., 1986, TOGAVIRIDAE FLAVIVIR, P121, DOI [10.1007/978-1-4757-0785-4_5, DOI 10.1007/978-1-4757-0785-4_5]; SCUPHAM RK, 1977, J VIROL, V22, P568; SHOPE RE, 1980, TOGAVIRUSES BIOL STR, P47; SIMMONS DT, 1974, J MOL BIOL, V86, P397, DOI 10.1016/0022-2836(74)90027-8; SIMONS K, 1984, ADV PROTEIN CHEM, V36, P79, DOI 10.1016/S0065-3233(08)60296-X; STRAUSS EG, 1984, VIROLOGY, V133, P92, DOI 10.1016/0042-6822(84)90428-8; STRAUSS JH, 1988, ANNU REV MICROBIOL, V42, P657, DOI 10.1146/annurev.mi.42.100188.003301; Strauss JH, 1990, SEMIN VIROL, V1, P347; TSAO J, 1991, SCIENCE, V251, P1456, DOI 10.1126/science.2006420; ULMANEN I, 1979, VIROLOGY, V99, P265, DOI 10.1016/0042-6822(79)90006-0; VALEGARD K, 1990, NATURE, V345, P36, DOI 10.1038/345036a0; VANSTEEG H, 1984, EUR J BIOCHEM, V138, P473; VAUX DJT, 1988, NATURE, V336, P36, DOI 10.1038/336036a0; VOGEL RH, 1986, NATURE, V320, P533, DOI 10.1038/320533a0; VONBONSDORFF CH, 1975, J VIROL, V16, P141, DOI 10.1128/JVI.16.1.141-145.1975; WEISS B, 1989, J VIROL, V63, P5310, DOI 10.1128/JVI.63.12.5310-5318.1989; WENGLER G, 1984, VIROLOGY, V132, P401, DOI 10.1016/0042-6822(84)90045-X; WENGLER G, 1982, VIROLOGY, V118, P401, DOI 10.1016/0042-6822(82)90359-2	68	261	267	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 7	1991	354	6348					37	43		10.1038/354037a0	http://dx.doi.org/10.1038/354037a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN829	1944569				2022-12-01	WOS:A1991GN82900049
J	GUTHRIE, PB; SEGAL, M; KATER, SB				GUTHRIE, PB; SEGAL, M; KATER, SB			INDEPENDENT REGULATION OF CALCIUM REVEALED BY IMAGING DENDRITIC SPINES	NATURE			English	Article							LONG-TERM POTENTIATION; SYNAPTIC TRANSMISSION; PYRAMIDAL CELLS; HIPPOCAMPAL; NEURONS; ACCUMULATION; 4-AMINOPYRIDINE; STIMULATION; ENHANCEMENT; MICROSCOPY	THE dendritic spine is a basic structural unit of neuronal organization. It is assumed to be a primary locus of synaptic plasticity, and to undergo long-term morphological and functional changes 1-6, at least some of which are regulated by intracellular calcium concentrations 7-11. It is known that physiological stimuli can cause marked increases in intracellular calcium levels in hippocampal dendritic shafts 12,13, but it is completely unknown to what extent such changes in the dendrites would also be seen by calcium-sensing structures within spines. Will calcium levels in all spines change in parallel with the dendrite or will there be a heterogeneous response? This study, through direct visualization and measurement of intracellular calcium concentrations in individual living spines, demonstrates that experimentally evoked changes in calcium concentrations in the dendritic shaft ([Ca2+]d) are frequently not parallelled in the spine ([Ca2+]s). This isolation is not caused by a physical diffusion barrier. This report provides, to our knowledge, the first direct demonstration of autonomous spine function.	COLORADO STATE UNIV, DEPT ANAT & NEUROBIOL, PROGRAM NEURONAL GROWTH & DEV, FT COLLINS, CO USA; WEIZMANN INST SCI, CTR NEUROSCI, IL-76100 REHOVOT, ISRAEL	Colorado State University; Weizmann Institute of Science			SEGAL, MENAHEM/K-1577-2012					ANDREWS SB, 1988, P NATL ACAD SCI USA, V85, P1682, DOI 10.1073/pnas.85.5.1682; BENTLEY D, 1991, J NEUROSCI, V11, P1300; Brown T. H., 1989, NEURAL MODELS PLASTI, P266; BUCKLE PJ, 1982, J PHYSIOL-LONDON, V326, P109, DOI 10.1113/jphysiol.1982.sp014180; CONNOR JA, 1986, P NATL ACAD SCI USA, V83, P6179, DOI 10.1073/pnas.83.16.6179; COSS RG, 1985, BEHAV NEURAL BIOL, V44, P151, DOI 10.1016/S0163-1047(85)90170-0; FIFKOVA E, 1989, ANN NY ACAD SCI, V568, P131; FIFKOVA E, 1985, CELL MOL NEUROBIOL, V5, P47, DOI 10.1007/BF00711085; FIFKOVA E, 1983, BRAIN RES, V266, P163, DOI 10.1016/0006-8993(83)91322-7; FIFKOVA E, 1977, J NEUROCYTOL, V6, P211, DOI 10.1007/BF01261506; GAMBLE E, 1987, SCIENCE, V236, P1311, DOI 10.1126/science.3495885; HARRIS KM, 1989, J NEUROSCI, V9, P2982; HOLMES WR, 1990, J NEUROPHYSIOL, V63, P1148, DOI 10.1152/jn.1990.63.5.1148; KAWATO M, 1983, J THEOR BIOL, V103, P507, DOI 10.1016/0022-5193(83)90280-1; LEVRAM V, 1987, BIOPHYS J, V52, P571, DOI 10.1016/S0006-3495(87)83246-0; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MATTSON MP, 1990, DEV BRAIN RES, V52, P201, DOI 10.1016/0165-3806(90)90236-R; MATTSON MP, 1988, J NEUROSCI RES, V20, P331, DOI 10.1002/jnr.490200307; MILLER JP, 1985, BRAIN RES, V325, P325, DOI 10.1016/0006-8993(85)90333-6; PONGRACZ F, 1985, NEUROSCIENCE, V15, P933, DOI 10.1016/0306-4522(85)90244-1; REGEHR WG, 1990, NATURE, V345, P807, DOI 10.1038/345807a0; REGEHR WG, 1989, NATURE, V341, P533, DOI 10.1038/341533a0; SEGAL M, 1984, J NEUROSCI, V4, P604; SEGAL M, 1987, BRAIN RES, V414, P285, DOI 10.1016/0006-8993(87)90008-4; SEGEV I, 1988, J NEUROPHYSIOL, V60, P499, DOI 10.1152/jn.1988.60.2.499; SHEPHERD GM, 1985, P NATL ACAD SCI USA, V82, P2192, DOI 10.1073/pnas.82.7.2192; SMITH SJ, 1983, NATURE, V304, P350, DOI 10.1038/304350a0; TSIEN RY, 1985, CELL CALCIUM, V6, P145, DOI 10.1016/0143-4160(85)90041-7; WICKENS J, 1988, PROG NEUROBIOL, V31, P507, DOI 10.1016/0301-0082(88)90013-5; WILLIAMS S, 1989, NEURON, V3, P583, DOI 10.1016/0896-6273(89)90268-7; WINSLOW RL, 1989, P NATL ACAD SCI USA, V86, P387, DOI 10.1073/pnas.86.1.387	32	216	217	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 7	1991	354	6348					76	80		10.1038/354076a0	http://dx.doi.org/10.1038/354076a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN829	1944573				2022-12-01	WOS:A1991GN82900062
J	HOUGHTEN, RA; PINILLA, C; BLONDELLE, SE; APPEL, JR; DOOLEY, CT; CUERVO, JH				HOUGHTEN, RA; PINILLA, C; BLONDELLE, SE; APPEL, JR; DOOLEY, CT; CUERVO, JH			GENERATION AND USE OF SYNTHETIC PEPTIDE COMBINATORIAL LIBRARIES FOR BASIC RESEARCH AND DRUG DISCOVERY	NATURE			English	Article							SOLID-PHASE SYNTHESIS; ANTIGENIC DETERMINANT; LIGANDS; PROTEIN; ACID	EXISTING methods for the synthesis and screening of large numbers of peptides are limited by their inability to generate and screen the requisite number (millions) of individual peptides 1-4 and/or their inability to generate unmodified free peptides in quantities able to interact in solution 4-8. We have circumvented these limitations by developing synthetic peptide combinatorial libraries composed of mixtures of free peptides in quantities which can be used directly in virtually all existing assay systems. The screening of these heterogeneous libraries, along with an iterative selection and synthesis process, permits the systematic identification of optimal peptide ligands. Starting with a library composed of more than 34 million hexa-peptides, we present here the precise identification of an antigenic determinant recognized by a monoclonal antibody as well as the straightforward development of new potent antimicrobial peptides.			HOUGHTEN, RA (corresponding author), TORREY PINES INST MOLEC STUDIES,3550 GEN ATOM COURT,SAN DIEGO,CA 92121, USA.		Abrams, William R/A-5782-2008					APPEL JR, 1990, J IMMUNOL, V144, P976; BLONDELLE S E, 1991, Peptide Research, V4, P12; BLONDELLE SE, 1991, BIOCHEMISTRY-US, V30, P4671, DOI 10.1021/bi00233a006; BOMAN HG, 1981, TRENDS BIOCHEM SCI, V6, P306, DOI 10.1146/annurev.mi.41.100187.000535; Cuervo J H, 1988, Pept Res, V1, P81; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; GEYSEN HM, 1986, MOL IMMUNOL, V23, P709, DOI 10.1016/0161-5890(86)90081-7; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; GISIN BF, 1972, ANAL CHIM ACTA, V58, P248, DOI 10.1016/S0003-2670(00)86882-8; HOUGHTEN R, 1986, Patent No. 4631211; HOUGHTEN RA, 1986, INT J PEPT PROT RES, V27, P673; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HOUGHTEN RA, 1988, VACCINES 88, P9; HOUGHTEN RA, 1987, PEPTIDE CHEM, P769; HOUGHTEN RA, 1986, VACCINES 86 NEW APPR, P21; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; PINILLA C, 1991, PEPTIDES 1990, P860; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SELSTED ME, 1983, J BIOL CHEM, V258, P4485; TAM JP, 1983, J AM CHEM SOC, V105, P6442, DOI 10.1021/ja00359a014; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	25	1121	1446	4	104	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1991	354	6348					84	86		10.1038/354084a0	http://dx.doi.org/10.1038/354084a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN829	1719428				2022-12-01	WOS:A1991GN82900065
J	KODISH, E; LANTOS, J; STOCKING, C; SINGER, PA; SIEGLER, M; JOHNSON, FL				KODISH, E; LANTOS, J; STOCKING, C; SINGER, PA; SIEGLER, M; JOHNSON, FL			BONE-MARROW TRANSPLANTATION FOR SICKLE-CELL DISEASE - A STUDY OF PARENTS DECISIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							APLASTIC-ANEMIA; CHILDREN; SURVIVAL; MORTALITY; LEUKEMIA; QUALITY; CANCER; LIFE	Background. Bone marrow transplantation has been shown to cure sickle cell disease, but it carries a 15 percent mortality risk. To determine whether parents would accept this risk to cure their children of sickle cell disease, we interviewed parents of children with sickle cell disease who were being followed in a university hospital clinic. Methods. We assessed parents' attitudes by using questions based on the standard reference-gamble paradigm. After we gave them descriptions of bone marrow transplantation and graft-versus-host disease (GVHD), the parents were presented with a series of hypothetical situations. In the first situation, bone marrow transplantation was described as offering certain (100 percent) survival with cure of sickle cell disease. In subsequent descriptions, the mortality rate associated with bone marrow transplantation was increased by 5 percent increments. The parents indicated the highest mortality risk at which they would consent to the procedure in order to cure their children. Results. In order to obtain a cure for their children, 36 of 67 parents (54 percent) were willing to accept some risk of short-term mortality, 25 of 67 (37 percent) were willing to accept at least the 15 percent short-term mortality risk we estimate to be the current figure for bone marrow transplantation, and 8 of 67 (12 percent) were willing to accept a short-term mortality risk of 50 percent or more. Nine parents (13 percent) said they would accept both a mortality risk of 15 percent or more and an additional 15 percent risk of GVHD. The parents' decisions were not related to the clinical severity of their children's illness. Conclusions. At current rates of mortality and morbidity with bone marrow transplantation, a substantial minority of the parents of children with sickle cell disease may consent to bone marrow transplantation for their children. Parental attitudes should be factored into decisions about whether to off er bone marrow transplantation to children with sickle cell disease.	UNIV TORONTO,CTR BIOETH,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV CHICAGO,PRITZKER SCH MED,CTR CLIN MED ETH,CHICAGO,IL 60637; UNIV TORONTO,DEPT MED,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University of Chicago; University of Toronto	KODISH, E (corresponding author), UNIV CHICAGO,PRITZKER SCH MED,DEPT PEDIAT,BOX 97,5841 S MARYLAND AVE,CHICAGO,IL 60637, USA.							BEUTLER E, 1983, HEMATOLOGY, P583; BRIGGS NC, 1986, TRANSFUSION, V26, P324, DOI 10.1046/j.1537-2995.1986.26486262738.x; DURBIN M, 1988, PEDIATRICS, V82, P774; FORMAN SJ, 1990, HEMATOL ONCOL CLIN N, V4, P517, DOI 10.1016/S0889-8588(18)30476-3; FROBERG DG, 1989, J CLIN EPIDEMIOL, V42, P459, DOI 10.1016/0895-4356(89)90136-4; Galimberti M, 1989, Prog Clin Biol Res, V309, P223; HARTH SC, 1990, BRIT MED J, V300, P1372, DOI 10.1136/bmj.300.6736.1372; JOHNSON FL, 1984, NEW ENGL J MED, V311, P780, DOI 10.1056/NEJM198409203111207; JOHNSON FL, 1985, AM J PEDIAT HEMATOL, V7, P254; KODISH E, 1990, CLIN RES, V38, P694; LEIKIN SL, 1989, PEDIATRICS, V84, P500; LOCASCIULLI A, 1990, BONE MARROW TRANSPL, V6, P211; LUCARELLI G, 1990, NEW ENGL J MED, V322, P417, DOI 10.1056/NEJM199002153220701; MCGLAVE P, 1990, SEMIN HEMATOL, V27, P23; MCNEIL BJ, 1978, NEW ENGL J MED, V299, P1397, DOI 10.1056/NEJM197812212992506; MCNEIL BJ, 1981, NEW ENGL J MED, V305, P982, DOI 10.1056/NEJM198110223051704; OR R, 1988, HEMOGLOBIN, V12, P609, DOI 10.3109/03630268808991651; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; PLATT OS, 1987, HEMATOLOGY INFANCY C, P655; SARNAIK SA, 1982, AM J PEDIAT HEMATOL, V4, P386; SINGER PA, 1991, J CLIN ONCOL, V9, P328, DOI 10.1200/JCO.1991.9.2.328; SPRINKLE RH, 1986, AM J PEDIAT HEMATOL, V8, P105; STORB R, 1984, SEMIN HEMATOL, V21, P27; VERMYLEN C, 1988, LANCET, V1, P1427; 1986, ETHICS REGULATION CL, P1; 29TH WORLD MED ASS T; 1983, FED REGISTER, V48, P9814	27	106	106	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 7	1991	325	19					1349	1353		10.1056/NEJM199111073251905	http://dx.doi.org/10.1056/NEJM199111073251905			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN470	1922237				2022-12-01	WOS:A1991GN47000005
J	KUMAR, KN; TILAKARATNE, N; JOHNSON, PS; ALLEN, AE; MICHAELIS, EK				KUMAR, KN; TILAKARATNE, N; JOHNSON, PS; ALLEN, AE; MICHAELIS, EK			CLONING OF CDNA FOR THE GLUTAMATE-BINDING SUBUNIT OF AN NMDA RECEPTOR COMPLEX	NATURE			English	Article							FUNCTIONAL EXPRESSION; PROTEIN; FAMILY; HOMOLOGY; SEQUENCE; BRAIN; SHOWS	THE amino acids L-glutamic and L-aspartic acids form the most widespread excitatory transmitter network in mammalian brain 1,2. The excitation produced by L-glutamic acid is important in the early development of the nervous system 3,4, Synaptic plasticity and memory formation 5-6, seizures 7,8 and neuronal degeneration 9,10. The receptors activated by L-glutamic acid are a target for therapeutic intervention in neurodegenerative diseases, brain ischaemia and epilepsy. There are two types of receptors for the excitatory amino acids, those that lead to the opening of cation-selective channels and those that activate phospholipase C (ref. 11). The receptors activating ion channels are NMDA (N-methyl-D-aspartate) and kainate/AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate)-sensitive receptors. The complementary DNAs for the kainate/AMPA receptor 12,13 and for the metabotropic receptor 14 have been cloned. We report here on the isolation and characterization of a protein complex of four major proteins that represents an intact complex of the NMDA receptor ion channel and on the cloning of the cDNA for one ot the subunits of this receptor complex, the glutamate-binding protein.	UNIV KANSAS,DEPT PHARMACOL & TOXICOL,2099 CONSTANT AVE,W CAMPUS,LAWRENCE,KS 66047; UNIV KANSAS,CTR BIOMED RES,LAWRENCE,KS 66047	University of Kansas; University of Kansas								BALAZS R, 1988, NEUROSCI LETT, V87, P80, DOI 10.1016/0304-3940(88)90149-8; CHAPMAN AG, 1987, EUR J PHARMACOL, V139, P91, DOI 10.1016/0014-2999(87)90501-2; CHEN JW, 1988, J BIOL CHEM, V263, P417; CHOI DW, 1987, J NEUROSCI, V7, P369; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; COTMAN CW, 1987, TRENDS NEUROSCI, V10, P273, DOI 10.1016/0166-2236(87)90172-X; DESCHENES RJ, 1989, J BIOL CHEM, V264, P11865; EATON MJ, 1990, J BIOL CHEM, V265, P16196; FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x; FRANSSON LA, 1987, TRENDS BIOCHEM SCI, V12, P406, DOI 10.1016/0968-0004(87)90197-6; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; GEAN DW, 1988, NEUROPHARMACOLOGY, V27, P557; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; HEIJNE GV, 1986, NUCLEIC ACIDS RES, V14, P4683; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KUMAR KN, 1991, J BIOL CHEM, V266, P14947; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LY AM, 1991, BIOCHEMISTRY-US, V30, P4307, DOI 10.1021/bi00231a029; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MATTSON MP, 1988, J NEUROSCI, V8, P2087; MATTSON MP, IN PRESS BRAIN RES; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SEYER JM, 1977, BIOCHEMISTRY-US, V16, P1158, DOI 10.1021/bi00625a020; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; TATE SS, 1981, MOL CELL BIOCHEM, V39, P357, DOI 10.1007/BF00232585; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; WEILOCH T, 1985, SCIENCE, V230, P681	32	153	163	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1991	354	6348					70	73		10.1038/354070a0	http://dx.doi.org/10.1038/354070a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN829	1719427				2022-12-01	WOS:A1991GN82900060
J	LAM, KS; SALMON, SE; HERSH, EM; HRUBY, VJ; KAZMIERSKI, WM; KNAPP, RJ				LAM, KS; SALMON, SE; HERSH, EM; HRUBY, VJ; KAZMIERSKI, WM; KNAPP, RJ			A NEW TYPE OF SYNTHETIC PEPTIDE LIBRARY FOR IDENTIFYING LIGAND-BINDING ACTIVITY	NATURE			English	Article							PHAGE	OUR aim was to improve techniques for drug development by facilitating the identification of small molecules that bind with high affinity to acceptor molecules (for example, cell-surface receptors, enzymes, antibodies) and so to mimic or block their interaction with the natural ligand 1,2. Previously such small molecules have been characterized individually on a serial basis. The systematic synthesis and screening of peptide libraries of defined structure represents a new approach. For relatively small libraries, predetermined sequence variations on solid-phase supports have been used 3,4, and large libraries have been produced using a bacteriophage vector into which random oligodeoxynucleotide sequences have been introduced 5-8, but these techniques have severe limitations. Here we investigate an alternative approach to synthesis and screening of peptide libraries. Our simple methodology greatly enhances the production and rapid evaluation of random libraries of millions of peptides so that acceptor-binding ligands of high affinity can be rapidly identified and sequenced, on the basis of a 'one-bead, one-peptide' approach.	UNIV ARIZONA,FAC SCI,DEPT CHEM,TUCSON,AZ 85721; SELECTIDE CORP,TUCSON,AZ 85737; COLL MED TUCSON,DEPT INTERNAL MED,TUCSON,AZ 85724	University of Arizona; Sanofi-Aventis	LAM, KS (corresponding author), COLL MED TUCSON,ARIZONA CANC CTR,TUCSON,AZ 85724, USA.							CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; HRUBY V, 1990, BIOCHEM J, V268, P246; HRUBY VJ, 1991, CURR OPIN BIOTECH, V2, P599, DOI 10.1016/0958-1669(91)90086-K; NIALL HD, 1972, CHEM BIOL PEPTIDES, P695; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028	9	1697	2515	5	195	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1991	354	6348					82	84		10.1038/354082a0	http://dx.doi.org/10.1038/354082a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN829	1944576				2022-12-01	WOS:A1991GN82900064
J	MORIYOSHI, K; MASU, M; ISHII, T; SHIGEMOTO, R; MIZUNO, N; NAKANISHI, S				MORIYOSHI, K; MASU, M; ISHII, T; SHIGEMOTO, R; MIZUNO, N; NAKANISHI, S			MOLECULAR-CLONING AND CHARACTERIZATION OF THE RAT NMDA RECEPTOR	NATURE			English	Article							AMINO-ACID RECEPTORS; GLUTAMATE RECEPTOR; XENOPUS OOCYTES; FUNCTIONAL EXPRESSION; PROTEIN-KINASE; ACETYLCHOLINE-RECEPTOR; BRAIN; SEQUENCE; CHANNEL; KAINATE	A complementary DNA encoding the rat NMDA receptor has been cloned and characterized. The single protein encoded by the cDNA forms a receptor-channel complex that has electrophysiological and pharmacological properties characteristic of the NMDA receptor. This protein has a significant sequence similarity to the AMPA/kainate receptors and contains four putative transmembrane segments following a large extracellular domain. The NMDA receptor messenger RNA is expressed in neuronal cells throughout the brain regions, particularly in the hippocampus, cerebral cortex and cerebellum.	KYOTO UNIV,DEPT MORPHOL BRAIN SCI,KYOTO 606,JAPAN	Kyoto University	MORIYOSHI, K (corresponding author), KYOTO UNIV,FAC MED,INST IMMUNOL,KYOTO 606,JAPAN.		Shigemoto, Ryuichi/E-3628-2013	Shigemoto, Ryuichi/0000-0001-8761-9444				BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; CHANGEUX JP, 1987, TRENDS PHARMACOL SCI, V8, P459, DOI 10.1016/0165-6147(87)90039-3; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; GREGOR P, 1989, NATURE, V342, P689, DOI 10.1038/342689a0; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HONORE T, 1989, EUR J PHARM-MOLEC PH, V172, P239, DOI 10.1016/0922-4106(89)90054-0; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; IKIN AF, 1990, BIOCHEMISTRY-US, V29, P2290, DOI 10.1021/bi00461a012; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEONARD JP, 1990, NEURON, V4, P53, DOI 10.1016/0896-6273(90)90443-J; LODGE D, 1990, TRENDS PHARMACOL SCI, V11, P81, DOI 10.1016/0165-6147(90)90323-Z; LY AM, 1991, BIOCHEMISTRY-US, V30, P4307, DOI 10.1021/bi00231a029; MADISON DV, 1991, REV NEUROSCI, V14, P379; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MONAGHAN DT, 1985, J NEUROSCI, V5, P2909; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; NOHNO T, 1986, MOL GEN GENET, V205, P260, DOI 10.1007/BF00430437; SAITO M, 1989, BRAIN RES, V481, P16, DOI 10.1016/0006-8993(89)90480-0; SAKIMURA K, 1990, FEBS LETT, V272, P73, DOI 10.1016/0014-5793(90)80452-O; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOEPP D, 1990, TRENDS PHARMACOL SCI, V11, P508, DOI 10.1016/0165-6147(90)90052-A; SONDERS MS, 1990, J BIOL CHEM, V265, P6776; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; VERDOORN TA, 1988, MOL PHARMACOL, V34, P298; VERDOORN TA, 1987, SCIENCE, V238, P1114, DOI 10.1126/science.2825347; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WADA K, 1989, NATURE, V342, P684, DOI 10.1038/342684a0; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0; YOUNG AB, 1990, TRENDS PHARMACOL SCI, V11, P126, DOI 10.1016/0165-6147(90)90199-I	44	1724	1764	1	41	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1991	354	6348					31	37		10.1038/354031a0	http://dx.doi.org/10.1038/354031a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN829	1834949				2022-12-01	WOS:A1991GN82900048
J	MULLER, W; CONNOR, JA				MULLER, W; CONNOR, JA			DENDRITIC SPINES AS INDIVIDUAL NEURONAL COMPARTMENTS FOR SYNAPTIC CA2+ RESPONSES	NATURE			English	Article							LONG-TERM POTENTIATION; HIPPOCAMPAL PYRAMIDAL CELLS; EXCITATORY AMINO-ACIDS; SYNAPSES; BLOCK	THE possibility that postsynaptic spines on neuronal dendrites are discrete biochemical compartments for Ca2+-activated processes involved in synaptic plasticity 1-6 is a widely proposed concept that has eluded experimental demonstration. Using microfluorometry on CA3 neurons in hippocampal slices, we show here that with weak presynaptic stimulation of associative/commissural fibres, Ca2+ accumulates in single postsynaptic spines but not in the parent dendrite. Stronger stimulation also promotes changes in dendrites. The NMDA-receptor antagonist AP-5 blocks changes in Ca2+ in spines. Sustained steep Ca2+ gradients between single spines and the parent dendrite, often lasting several minutes, develop with repeated stimulation. The observed compartmentalization allows for the specificity 7,8, cooperativity 9 and associativity 10-14 displayed by memory models such as long-term potentiation.			MULLER, W (corresponding author), ROCHE INST MOLEC BIOL,ROCHE RES CTR,DEPT NEUROSCI,340 KINGSLAND ST,NUTLEY,NJ 07110, USA.							BARRIONUEVO G, 1983, P NATL ACAD SCI-BIOL, V80, P7347, DOI 10.1073/pnas.80.23.7347; BROWN TH, 1990, ANNU REV NEUROSCI, V13, P475, DOI 10.1146/annurev.ne.13.030190.002355; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; CONNOR JA, 1988, SCIENCE, V240, P649, DOI 10.1126/science.2452481; COTMAN CW, 1988, ANNU REV NEUROSCI, V11, P61, DOI 10.1146/annurev.ne.11.030188.000425; DINGLEDINE R, 1983, J PHYSIOL-LONDON, V343, P385, DOI 10.1113/jphysiol.1983.sp014899; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARRIS EW, 1986, NEUROSCI LETT, V70, P132, DOI 10.1016/0304-3940(86)90451-9; HARRIS KM, 1989, J NEUROSCI, V9, P2982; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; KELSO SR, 1986, P NATL ACAD SCI USA, V83, P5326, DOI 10.1073/pnas.83.14.5326; LEVY WB, 1979, BRAIN RES, V175, P233, DOI 10.1016/0006-8993(79)91003-5; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MCNAUGHTON BL, 1978, BRAIN RES, V157, P277, DOI 10.1016/0006-8993(78)90030-6; MULLER W, 1991, NEURON, V6, P901, DOI 10.1016/0896-6273(91)90230-W; MULLER W, 1988, EXP BRAIN RES, V72, P287; REGEHR WG, 1989, NATURE, V341, P533, DOI 10.1038/341533a0; TANK DW, 1988, SCIENCE, V242, P773, DOI 10.1126/science.2847315; TSIEN RY, 1989, ANNU REV NEUROSCI, V12, P227, DOI 10.1146/annurev.neuro.12.1.227; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039	23	413	418	1	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1991	354	6348					73	76		10.1038/354073a0	http://dx.doi.org/10.1038/354073a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN829	1682815				2022-12-01	WOS:A1991GN82900061
J	NEGLIA, JP; MEADOWS, AT; ROBISON, LL; KIM, TH; NEWTON, WA; RUYMANN, FB; SATHER, HN; HAMMOND, GD				NEGLIA, JP; MEADOWS, AT; ROBISON, LL; KIM, TH; NEWTON, WA; RUYMANN, FB; SATHER, HN; HAMMOND, GD			2ND NEOPLASMS AFTER ACUTE LYMPHOBLASTIC-LEUKEMIA IN CHILDHOOD	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CANCER STUDY-GROUP; ACUTE LYMPHOCYTIC-LEUKEMIA; MALIGNANT NEOPLASMS; CHILDREN; THERAPY; RADIOTHERAPY; CHEMOTHERAPY; PROPHYLAXIS; SURVIVAL; SARCOMAS	Background. Effective forms of treatment for acute lymphoblastic leukemia (ALL) in childhood now result in survival rates above 70 percent at five years, but the treatments are potentially carcinogenic. To determine the magnitude of this risk and identify possible risk factors for the development of second neoplasms, we studied a large cohort of children treated for ALL. Methods and Results. We undertook a retrospective cohort study of 9720 children who had been given a diagnosis of ALL between June 1972 and August 1988 and had been treated according to the therapeutic protocols of the Children's Cancer Study Group. The median follow-up was 4.7 years (range, 2 months to 16 years). We found that 43 second neoplasms occurred among the children in the cohort, including 24 neoplasms of the central nervous system, 10 new leukemias and lymphomas, and 9 other neoplasms. This represented a 7-fold excess of all cancers and a 22-fold excess of neoplasms of the central nervous system. The estimated cumulative proportion of children in whom a second neoplasm developed was 2.53 percent 15 years after diagnosis (95 percent confidence limits, 1.74 percent and 3.38 percent). An even higher risk, particularly of central nervous system tumors, was evident in children five years of age or less at the time of the diagnosis of ALL (P = 0.012). All central nervous system neoplasms developed in children who had previously undergone irradiation. There was no association with exposure to cyclophosphamide or anthracyclines. Conclusions. There is a substantial excess of second neoplasms, especially of the central nervous system, among children treated for ALL. Children five years old or younger and those receiving radiation are at higher risk, especially for second tumors arising in the central nervous system.	CHILDRENS CANC STUDY GRP,440 E HUNTINGTON DR,SUITE 300,POB 60012,ARCADIA,CA 91066; CHILDRENS HOSP,COLUMBUS,OH 43205; UNIV SO CALIF,SCH MED,LOS ANGELES,CA 90033; UNIV MINNESOTA,SCH MED,MINNEAPOLIS,MN 55455; ABBOTT NW HOSP,MINNEAPOLIS,MN; CHILDRENS HOSP PHILADELPHIA,PHILADELPHIA,PA	University System of Ohio; Ohio State University; Nationwide Childrens Hospital; University of Southern California; University of Minnesota System; University of Minnesota Twin Cities; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia			Robison, Leslie/N-8122-2018	Neglia, Joseph/0000-0002-5525-0598	NATIONAL CANCER INSTITUTE [K08CA001240] Funding Source: NIH RePORTER; NCI NIH HHS [CA 01240] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albo V, 1985, P AN M AM SOC CLIN, V4, P172; BAILAR JC, 1964, BIOMETRICS, V20, P639; BRESLOW N, 1974, BIOMETRICS, V30, P89, DOI 10.2307/2529620; COCCIA PF, 1983, LEUKEMIA RES ADV CEL, P241; FARWELL J, 1984, NEW ENGL J MED, V311, P749, DOI 10.1056/NEJM198409203111201; FRIED M, 1987, CANCER, V60, P2548, DOI 10.1002/1097-0142(19871115)60:10<2548::AID-CNCR2820601033>3.0.CO;2-H; GAYNON PS, 1988, AM J PEDIAT HEMATOL, V10, P42; Goldes J, 1984, Pediatr Dermatol, V1, P295, DOI 10.1111/j.1525-1470.1984.tb01132.x; HAMMOND G D, 1986, Cancer, V58, P407, DOI 10.1002/1097-0142(19860715)58:2+<407::AID-CNCR2820581302>3.0.CO;2-U; HAWKINS MM, 1987, BRIT J CANCER, V56, P339, DOI 10.1038/bjc.1987.200; Kalbfleisch JD, 1980, STATISTICAL ANAL FAI, P14; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LABOTKA RJ, 1983, CANCER, V52, P846, DOI 10.1002/1097-0142(19830901)52:5<846::AID-CNCR2820520517>3.0.CO;2-B; LI FP, 1982, JAMA-J AM MED ASSOC, V247, P2692, DOI 10.1001/jama.247.19.2692; LITTMAN P, 1987, INT J RADIAT ONCOL, V13, P1443, DOI 10.1016/0360-3016(87)90308-7; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALONE M, 1986, CANCER, V57, P1979, DOI 10.1002/1097-0142(19860515)57:10<1979::AID-CNCR2820571016>3.0.CO;2-R; MANTEL N, 1974, J AM STAT ASSOC, V69, P81, DOI 10.2307/2285503; MEADOWS AT, 1977, CANCER, V40, P1903, DOI 10.1002/1097-0142(197710)40:4+<1903::AID-CNCR2820400822>3.0.CO;2-E; MEADOWS AT, 1989, NEW ENGL J MED, V321, P1830; MEADOWS AT, 1985, J CLIN ONCOL, V3, P532, DOI 10.1200/JCO.1985.3.4.532; MIKE V, 1982, LANCET, V2, P1326; MILLER DR, 1983, CANCER, V51, P1041, DOI 10.1002/1097-0142(19830315)51:6<1041::AID-CNCR2820510612>3.0.CO;2-G; MOSIJCZUK AD, 1981, AM J DIS CHILD, V135, P313, DOI 10.1001/archpedi.1981.02130280003002; NESBIT ME, 1982, CANCER RES, V42, P674; ORTEGA JA, 1977, CANCER RES, V37, P535; Parkin D. M, 1988, IARC SCI PUBLICATION, V87; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; PINKEL D, 1987, CANCER, V59, P1683, DOI 10.1002/1097-0142(19870515)59:10<1683::AID-CNCR2820591002>3.0.CO;2-G; PRATT C B, 1988, Pediatric Research, V23, p345A; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; R&DEG;rth M., 1991, P AN M AM SOC CLIN, V10, P221; RIMM IJ, 1987, CANCER, V59, P1506, DOI 10.1002/1097-0142(19870415)59:8<1506::AID-CNCR2820590819>3.0.CO;2-P; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; STEINHERZ PG, 1986, J CLIN ONCOL, V4, P744, DOI 10.1200/JCO.1986.4.5.744; SULLIVAN MP, 1982, BLOOD, V60, P948; SUSSMAN A, 1990, CANCER CAUSE CONTROL, V1, P75, DOI 10.1007/BF00053186; TUCKER MA, 1987, NEW ENGL J MED, V317, P588, DOI 10.1056/NEJM198709033171002; ZARRABI MH, 1983, CANCER, V52, P1712, DOI 10.1002/1097-0142(19831101)52:9<1712::AID-CNCR2820520927>3.0.CO;2-I; 1989, NIH8292789 NCI PUBL	40	434	442	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 7	1991	325	19					1330	1336		10.1056/NEJM199111073251902	http://dx.doi.org/10.1056/NEJM199111073251902			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN470	1922234	Bronze			2022-12-01	WOS:A1991GN47000002
J	SCHLOTTERER, C; AMOS, B; TAUTZ, D				SCHLOTTERER, C; AMOS, B; TAUTZ, D			CONSERVATION OF POLYMORPHIC SIMPLE SEQUENCE LOCI IN CETACEAN SPECIES	NATURE			English	Article							DNA; EVOLUTION	LENGTH polymorphisms within simple-sequence loci occur ubiquitously in non-coding eukaryotic DNA and can be highly informative in the analysis of natural populations 1-4. Simple-sequence length polymorphisms (SSLP) in the long-finned pilot whale Globicephala melas (Delphinidae) have provided useful information on the mating system as well as on the genetic structure of populations 5. We have therefore tested whether the polymerase chain reaction primers designed for Globicephala could also be used to uncover variability in other whale species. Homologous loci could indeed be amplified from a diverse range of whales, including all toothed (Odontoceti) and baleen whales (Mysticeti) tested. Cloning and sequencing these loci from 11 different species revealed an unusually high conservation of sequences flanking the simple-sequence stretches, averaging 3.2% difference over 35-40 Myr. This represents the lowest divergence rate for neutral nucleotide positions found for any species group so far and raises the possible need for a re-evaluation of the age of the modern whales. On the other hand, the high conservation of non-coding sequences in whales simplifies the application of SSLP DNA fingerprinting in cetacean species, as primers designed for one species will often uncover variability in other species.	UNIV MUNICH,INST GENET,W-8000 MUNICH 19,GERMANY; UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 3EH,ENGLAND	University of Munich; University of Cambridge			Tautz, Diethard/H-8436-2014; Schlötterer, Christian/Q-5264-2019; Tautz, Diethard/D-4304-2011; Schlötterer, Christian/G-6326-2010	Tautz, Diethard/0000-0002-0460-5344; Schlötterer, Christian/0000-0003-4710-6526; Schlötterer, Christian/0000-0003-4710-6526				Amos W., 1991, REP INT WHAL COMMN, P255; BARNES LG, 1985, MAR MAMMAL SCI, V1, P15, DOI 10.1111/j.1748-7692.1985.tb00530.x; BULMER M, 1987, NATURE, V325, P728, DOI 10.1038/325728a0; FORDYCE RE, 1980, PALAEOGEOGR PALAEOCL, V31, P319, DOI 10.1016/0031-0182(80)90024-3; HOELZEL AR, 1988, NATURE, V333, P305, DOI 10.1038/333305a0; HOELZEL AR, 1991, REP INT WHALING COMM, V13, P171; LI WH, 1987, J MOL EVOL, V25, P330, DOI 10.1007/BF02603118; LITT M, 1989, AM J HUM GENET, V44, P397; MOORE SS, 1991, GENOMICS, V10, P654, DOI 10.1016/0888-7543(91)90448-N; PENTREATH RJ, 1979, 3RD P NEA SEM MAR EC; SAKAI RK, 1988, SCIENCE, V239, P487; TAUTZ D, 1990, BIOESSAYS, V12, P44, DOI 10.1002/bies.950120111; TAUTZ D, 1984, NUCLEIC ACIDS RES, V12, P4127, DOI 10.1093/nar/12.10.4127; TAUTZ D, 1986, NATURE, V322, P652, DOI 10.1038/322652a0; TAUTZ D, 1989, NUCLEIC ACIDS RES, V17, P6463, DOI 10.1093/nar/17.16.6463; WEBER JL, 1989, AM J HUM GENET, V44, P388; WILSON AC, 1987, TRENDS GENET, V3, P241, DOI 10.1016/0168-9525(87)90257-5	17	292	320	1	32	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1991	354	6348					63	65		10.1038/354063a0	http://dx.doi.org/10.1038/354063a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN829	1944571				2022-12-01	WOS:A1991GN82900058
J	HEALY, B				HEALY, B			INVASIVE MANAGEMENT OF PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION INCREASES RISK OF HEMORRHAGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							1991, ANN INTERN MED, V115, P256	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1991	266	17					2341	2341						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM790	1920737				2022-12-01	WOS:A1991GM79000006
J	HEALY, B				HEALY, B			RESULTS OF RADIAL KERATOTOMY EVALUATED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							1991, OPHTHALMOLOGY, V98, P1164	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1991	266	17					2341	2341						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM790	1920737				2022-12-01	WOS:A1991GM79000007
J	HEALY, B				HEALY, B			TL-201 ABNORMALITIES FOUND INDICATIVE OF ISCHEMIA IN HYPERTROPHIC CARDIOMYOPATHY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							1991, CIRCULATION, V83, P1660	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1991	266	17					2341	2341						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM790	1920737				2022-12-01	WOS:A1991GM79000008
J	HONIGMAN, B; LOWENSTEIN, SR; MOORE, EE; ROWEDER, K; PONS, P				HONIGMAN, B; LOWENSTEIN, SR; MOORE, EE; ROWEDER, K; PONS, P			THE ROLE OF THE PNEUMATIC ANTISHOCK GARMENT IN PENETRATING CARDIAC WOUNDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LIFE SUPPORT; MAST SUIT; TRAUMA; TROUSERS; RESUSCITATION; EMERGENCY; TAMPONADE	Objective. - To determine the impact of the pneumatic antishock garment on survival in patients with cardiac wounds. Design. - A retrospective review of a 6.5-year experience in a population of patients with gunshot or stab wounds to the heart (N = 70). Setting. - The city and county of Denver, Colo, where all patients were transported by paramedic ambulances to Denver General Hospital, an urban, level 1 trauma center. Patients. - All patients were analyzed, including those transported to the emergency department with no vital signs at the trauma scene. Only patients with definite penetrating cardiac injuries were included. Methods. - Paramedic trip sheets and emergency department, operating room, in-hospital, and autopsy records were reviewed. Demographic, clinical outcome, and treatment data were collected. A multiple logistic regression model was developed to determine which characteristics and treatment variables were independently predictive of patient outcome. The ability of each independent variable to predict outcome was determined by calculating adjusted odds ratios (ORs) and 95% confidence intervals (Cls). Results. - Seventy patients (31 gunshot and 39 stab wounds) had a revised trauma score of 2.8 +/- 4.0 (mean +/- SD; range, 0-1 2; median, 0). Thirty-two (46%) had cardiac tamponade. Overall, 21 (30%) of the patients survived. In the logistic model, the presence of cardiac tamponade (OR, 9.1; 95% Cl, 1.5 to 56. 1) and a higher revised trauma score were associated with higher survival. Inflation of the pneumatic antishock garment was associated with sevenfold lower survival (adjusted OR, 0.14; 95% Cl, 0.02 to 0.86); the effect was negative across all trauma score groups. Conclusion. - Survival in patients with penetrating cardiac wounds is highly associated with anatomic and physiologic factors, while application of the pneumatic antishock garment appears to be detrimental.	UNIV COLORADO,HLTH SCI CTR,EMERGENCY MED RES CTR,DENVER,CO 80262; DENVER GEN HOSP,DEPT SURG,DENVER,CO 80204; DENVER GEN HOSP,DEPT EMERGENCY MED,DENVER,CO 80204	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Denver Health Medical Center; Denver Health Medical Center	HONIGMAN, B (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT SURG,EMERGENCY MED & TRAUMA SECT,4200 E 9TH AVE,DENVER,CO 80262, USA.							BICKELL WH, 1985, ANN EMERG MED, V14, P218, DOI 10.1016/S0196-0644(85)80443-1; BIVINS HG, 1982, ANN EMERG MED, V11, P409, DOI 10.1016/S0196-0644(82)80036-X; Carrasquilla C, 1972, Ann Thorac Surg, V13, P208; CHAMPION HR, 1988, TRAUMA; Civetta J M, 1976, JACEP, V5, P581, DOI 10.1016/S0361-1124(76)80216-X; COGBILL TH, 1983, J TRAUMA, V23, P453, DOI 10.1097/00005373-198306000-00002; COPASS MK, 1984, AM J SURG, V148, P20, DOI 10.1016/0002-9610(84)90284-8; DAVIS JW, 1981, ANN EMERG MED, V10, P185, DOI 10.1016/S0196-0644(81)80158-8; DEMETRIADES D, 1986, ANN SURG, V203, P315, DOI 10.1097/00000658-198603000-00018; IVATURY RR, 1988, J TRAUMA, V27, P1066; JACOBS LM, 1984, J TRAUMA, V24, P8, DOI 10.1097/00005373-198401000-00002; JONES EW, 1982, ARCH SURG-CHICAGO, V96, P671; KABACK KR, 1984, JAMA-J AM MED ASSOC, V252, P2598, DOI 10.1001/jama.252.18.2598; KARREL R, 1982, ANN EMERG MED, V11, P504; MACKERSIE RC, 1984, J TRAUMA, V24, P882, DOI 10.1097/00005373-198410000-00003; MATTOX KL, 1989, J TRAUMA, V29, P1104, DOI 10.1097/00005373-198908000-00007; MATTOX KL, 1986, J TRAUMA, V26, P779, DOI 10.1097/00005373-198609000-00002; MORENO C, 1986, J TRAUMA, V26, P821, DOI 10.1097/00005373-198609000-00007; PALAFOX BA, 1981, J TRAUMA, V21, P55, DOI 10.1097/00005373-198101000-00012; PONS PT, 1985, J TRAUMA, V25, P828, DOI 10.1097/00005373-198509000-00003; RANSOM K, 1978, J AM COLL EMERG PHYS, V7, P15; Schlesselman J.J., 1982, CASE CONTROL STUDIES; SMITH JP, 1985, J TRAUMA, V25, P65, DOI 10.1097/00005373-198501000-00011; SUGG WL, 1968, J THORAC CARDIOV SUR, V56, P531, DOI 10.1016/S0022-5223(19)42812-2; TRINKLE JK, 1974, ANN THORAC SURG, V17, P230, DOI 10.1016/S0003-4975(10)65641-X; TRUNKEY DD, 1984, J TRAUMA, V24, P86, DOI 10.1097/00005373-198401000-00017; WECHSLER AS, 1974, J THORAC CARDIOVASC, V69, P847; 1985, INJURY AM CONTINUING	28	12	12	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1991	266	17					2398	2401		10.1001/jama.266.17.2398	http://dx.doi.org/10.1001/jama.266.17.2398			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM790	1920746				2022-12-01	WOS:A1991GM79000026
J	SALTZ, BL; WOERNER, MG; KANE, JM; LIEBERMAN, JA; ALVIR, JMJ; BERGMANN, KJ; BLANK, K; KOBLENZER, J; KAHANER, K				SALTZ, BL; WOERNER, MG; KANE, JM; LIEBERMAN, JA; ALVIR, JMJ; BERGMANN, KJ; BLANK, K; KOBLENZER, J; KAHANER, K			PROSPECTIVE-STUDY OF TARDIVE-DYSKINESIA INCIDENCE IN THE ELDERLY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREVALENCE; MOVEMENTS; AGE	Objectives. - To investigate the incidence of tardive dyskinesia in elderly individuals beginning treatment with antipsychotic drugs and to identify risk factors for the development of tardive dyskinesia in the elderly. Design. - A cohort of previously neuroleptic-naive patients was identified at the time of initiation of antipsychotic drug treatment. Patients were evaluated at baseline and followed up at 3-month intervals for periods ranging from 3 to 119 weeks. Setting. - Subjects were recruited from the psychiatric and geriatric medical services of two medical centers, a geriatric institute, and three nursing homes in the metropolitan area of New York City, NY. Patients. - Two hundred fifteen individuals older than 55 years have entered the study thus far. Preliminary data are presented for 160 patients who were followed up for at least 1 month. Their age range was 57 to 99 years (mean, 77 years). Seventy-two percent were women and 87% were white. Sixty-seven percent of patients had a diagnosis of organic mental syndrome and 42% had a psychiatric diagnosis. Interventions. - A naturalistic, longitudinal, repeated assessment paradigm was employed. Assessments included abnormal involuntary movements, extrapyramidal signs, psychiatric symptoms, and medical and drug treatment histories. Main Outcome Measure. - The incidence of tardive dyskinesia was determined using a standardized rating instrument and survival analysis. Results. - The incidence of neuroleptic-induced dyskinesia was 31% (95% confidence interval, 20%, 42%) after 43 weeks of cumulative neuroleptic treatment. Psychiatric (as opposed to organic) diagnosis and presence of extrapyramidal signs early in treatment were associated with increased tardive dyskinesia vulnerability.	LONG ISL JEWISH MED CTR,DEPT NEUROL,NEW HYDE PK,NY 11042; PARKER JEWISH GERIATR CTR,NEW HYDE PK,NY; YESHIVA UNIV ALBERT EINSTEIN COLL MED,BRONX,NY 10461; BETH ISRAEL MED CTR,DEPT PSYCHIAT,NEW YORK,NY 10003	Northwell Health; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Beth Israel Deaconess Medical Center	SALTZ, BL (corresponding author), LONG ISL JEWISH MED CTR,HILLSIDE HOSP,DEPT PSYCHIAT,BOX 38,GLEN OAKS,NY 11004, USA.		Lieberman, Jeffrey/AAY-8239-2020		NIMH NIH HHS [MH-41960, MH-40015, MH-32369] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH032369, P50MH041960, P30MH041960, R01MH040015, R01MH032369] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BARNES TRE, 1983, J NEUROL NEUROSUR PS, V46, P540, DOI 10.1136/jnnp.46.6.540; BENEDETTI J, 1985, BMDP STATISTICAL SOF, P557; BOURGEOIS M, 1980, J NERV MENT DIS, V168, P177, DOI 10.1097/00005053-198003000-00009; BRANDON S, 1971, BRIT J PSYCHIAT, V118, P171, DOI 10.1192/bjp.118.543.171; CASEY DE, 1985, J CLIN PSYCHIAT, V46, P42; CHACKO RC, 1985, J CLIN PSYCHIAT, V46, P55; CRANE GE, 1974, ARCH GEN PSYCHIAT, V30, P314; DEGKWITZ R, 1969, PSYCHOTROPIC SIGNS D; DELWAIDE PJ, 1977, ACTA NEUROL SCAND, V56, P256; FINCH CE, 1973, BRAIN RES, V52, P261, DOI 10.1016/0006-8993(73)90663-X; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GARDOS G, 1983, TARDIVE DYSKINESIA A; GUY W, 1976, ADM76338 NAT I MENT; HOPKINS A, 1985, BMDP STATISTICAL SOF, P576; JESTE DV, 1982, UNDERSTANDING TREATI; JONES M, 1969, PSYCHOTROPIC DRUGS D, P53; KANE JM, 1982, ARCH GEN PSYCHIAT, V39, P473; KANE JM, 1982, PSYCHOPHARMACOLOGY, V77, P105, DOI 10.1007/BF00431929; KANE JM, 1986, DRUG DEVELOP RES, P41; KARSON CN, 1990, AM J PSYCHIAT, V147, P1646; LIEBERMAN J, 1984, PSYCHOPHARMACOL BULL, V20, P382; PRIEN RF, 1973, J AM GERIATR SOC, V21, P546; RABINS P, 1984, COMPR PSYCHIAT, V25, P290, DOI 10.1016/0010-440X(84)90060-9; RASKIND M, 1979, J AM GERIATR SOC, V27, P459, DOI 10.1111/j.1532-5415.1979.tb01727.x; SALZMAN C, 1987, PSYCHOPHARMACOLOGY 3, P1167; SCHOOLER NR, 1982, ARCH GEN PSYCHIAT, V39, P486; Simpson G M, 1970, Acta Psychiatr Scand Suppl, V212, P11; SIMPSON GM, 1979, PSYCHOPHARMACOLOGY, V64, P171, DOI 10.1007/BF00496058; SIRIS SG, 1982, ELECTROCONVULSIVE TH; SMITH JM, 1980, ARCH GEN PSYCHIAT, V37, P1368; SPIKER DG, 1985, AM J PSYCHIAT, V142, P430; TOENNIESSEN LM, 1985, ARCH GEN PSYCHIAT, V42, P278; UHRBRAND I, 1960, PSYCHOPHARMACOLOGIA, V1, P408; WOERNER MG, 1988, PSYCHOPHARMACOL BULL, V24, P112; WOERNER MG, 1991, J CLIN PSYCHOPHARM, V11, P34; YASSA R, 1985, PSYCHOSOMATICS, V26, P305, DOI 10.1016/S0033-3182(85)72863-0; 1987, DIAGNOSTIC STATISTIC	37	150	150	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1991	266	17					2402	2406						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GM790	1681122				2022-12-01	WOS:A1991GM79000027
J	STLOUIS, ME; CONWAY, GA; HAYMAN, CR; MILLER, C; PETERSEN, LR; DONDERO, TJ				STLOUIS, ME; CONWAY, GA; HAYMAN, CR; MILLER, C; PETERSEN, LR; DONDERO, TJ			HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION IN DISADVANTAGED ADOLESCENTS - FINDINGS FROM THE UNITED-STATES-JOB-CORPS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MILITARY SERVICE; SEROPREVALENCE; APPLICANTS; EPIDEMIC; RISK	Objective. - To describe the human immunodeficiency virus (HIV) epidemic among socially and educationally disadvantaged young persons in the United States. Design. - We analyzed demographic and geographic findings from the screening of Job Corps students for antibody to HIV. Setting. - The Job Corps is a federal training program for disadvantaged, out-of-school youth. Population Screened. - Residential students aged 16 to 21 years who entered the Job Corps from October 1987 through February 1990. Main Outcome Measure. - Rates of observed HIV infection in entering students, stratified by demographic and geographic features. Results. - Of 137 209 Job Corps students screened, 488 were HIV seropositive (3.6 per 1000), a seroprevalence rate higher than that among military applicants of the same age. Overall seroprevalence was slightly higher in male (3.7 per 1000) than in female (3.2 per 1000) Job Corps students, but among those students aged 16 and 17 years, seroprevalence was higher among females (2.3 per 1000) than among males (1.5 per 1000) (P < .05). For students aged 16 to 21 years, seroprevalence increased with year of age: 1.8 per 1000 per year for males and 0.7 per 1 000 per year for females. Among those aged 21 years, HIV prevalence was 8.9 per 1000. For black and Hispanic students from large Northeastern cities, seroprevalence increased by 4.3 per 1000 per year of age and reached 24.8 per 1000 (one of 40) in students aged 21 years. However, among students from rural areas and small towns, HIV seroprevalence was disproportionately high in the Southeast. Compared with recently described US patients with the acquired immunodeficiency syndrome, HIV-infected students who entered the Job Corps were much more likely to be female. Conclusions. - These findings show that disadvantaged, out-of-school adolescents are at high risk for HIV infection. The screening results identified surprisingly high seroprevalence in the southeastern United States and demonstrated a marked shift in the HIV epidemic to young women. Controlling the HIV epidemic among teenagers must include interventions that will reach adolescents early and outside of the formal educational system.	CTR DIS CONTROL,CTR INFECT DIS,DIV HIV AIDS,HIV SEROEPIDEMIOL BRANCH,1600 CLIFTON RD,ATLANTA,GA 30333; US DEPT LABOR,EMPLOYMENT AND TRAINING ADM,OFF JOB CORPS,WASHINGTON,DC 20210	Centers for Disease Control & Prevention - USA; United States Department of Labor								BELL T, 1984, SEXUALLY TRANSMITTED, P73; BRUNDAGE JF, 1990, J ACQ IMMUN DEF SYND, V3, P1168; BURKE DS, 1990, JAMA-J AM MED ASSOC, V263, P2074, DOI 10.1001/jama.263.15.2074; BURKE DS, 1987, NEW ENGL J MED, V317, P131, DOI 10.1056/NEJM198707163170302; EDLIN B, 1991, 7TH INT C AIDS FLOR, V2; FULLILOVE RE, 1990, JAMA-J AM MED ASSOC, V263, P851, DOI 10.1001/jama.263.6.851; GAYLE HD, 1990, NEW ENGL J MED, V323, P1538, DOI 10.1056/NEJM199011293232206; HEIN K, 1989, J PEDIATR-US, V114, P144, DOI 10.1016/S0022-3476(89)80622-5; KOMINSKI R, 1990, DEMOGRAPHY, V27, P303, DOI 10.2307/2061455; QUINN TC, 1988, NEW ENGL J MED, V318, P197, DOI 10.1056/NEJM198801283180401; SELIK RM, 1988, AM J PUBLIC HEALTH, V78, P1539, DOI 10.2105/AJPH.78.12.1539; STLOUIS ME, 1990, NEW ENGL J MED, V323, P213, DOI 10.1056/NEJM199007263230401; WENDELL D, 1990, 6TH INT C AIDS SAN F; 1990, MMWR, V39, P385; 1990, AIDS 2ND DECADE, P147; 1990, JOB CORPS BRIEF PROG; 1990, HIV AIDS SURVEILLANC, P1; 1989, SAS STAT USERS GUIDE, V2, P1351; 1990, MMWR, V39, P395; 1989, MMWR, V38, P1; 1988, SEXUALLY TRANSMITTED	21	106	106	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1991	266	17					2387	2391		10.1001/jama.266.17.2387	http://dx.doi.org/10.1001/jama.266.17.2387			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GM790	1920745				2022-12-01	WOS:A1991GM79000024
J	WALKER, RM				WALKER, RM			DNR IN THE OR - RESUSCITATION AS AN OPERATIVE RISK	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ETHICAL CHALLENGE; CARDIAC-ARREST; ANESTHESIA; WITNESSES; CARE	Should do-not-resuscitate (DNR) orders be routinely rescinded when terminally ill patients undergo palliative surgery? If so, patients will be forced to balance the benefits of palliative surgery against the risks of unwanted resuscitation. If physicians are required to honor intraoperative DNR orders, they may feel unacceptably restrained from correcting adverse effects for which they feel responsible. This dilemma has been overlooked by DNR policies. This article argues for the permissibility of honoring intraoperative DNR orders. The patient's right to refuse treatment outweighs physicians' concerns about professional scrutiny over intraoperative deaths. Physicians' moral concerns about hastening patient death are important but may be assuaged by (1) emphasizing patients' acceptance of operative mortality risk; (2) viewing matters as analogous to surgery on Jehovah's Witnesses who refuse lifesaving transfusion; (3) viewing the patient's intraoperative death as a double effect, that is, an unintended negative effect that is linked to the performance of a good act (palliation); and (4) distinguishing this from assisted suicide.			WALKER, RM (corresponding author), UNIV S FLORIDA, COLL MED, DEPT INTERNAL MED, DIV MED ETH & HUMANITIES, 12901 BRUCE B DOWNS BLVD, TAMPA, FL 33612 USA.							Beauchamp T.L., 1989, PRINCIPLES BIOMEDICA, V3rd; BENSON KT, 1989, ANESTH ANALG, V69, P647; CANTOR NL, 1987, LEGAL FRONTIERS DEAT; COHEN MM, 1988, JAMA-J AM MED ASSOC, V260, P2859, DOI 10.1001/jama.260.19.2859; COHEN MM, 1988, J CLIN EPIDEMIOL, V41, P83, DOI 10.1016/0895-4356(88)90012-1; DIXON JL, 1981, JAMA-J AM MED ASSOC, V246, P2471, DOI 10.1001/jama.246.21.2471; EMANUEL EJ, 1988, AM J MED, V84, P291, DOI 10.1016/0002-9343(88)90428-7; FRADER J, 1988, NEONATAL ANESTHESIA, pCH12; FRIED C, 1976, NEW ENGL J MED, V295, P390, DOI 10.1056/NEJM197608122950711; GILLON R, 1986, BRIT MED J, V292, P193, DOI 10.1136/bmj.292.6514.193; HARRIS TJB, 1983, ANAESTHESIA, V38, P989, DOI 10.1111/j.1365-2044.1983.tb12031.x; Katz Jay, 1984, SILENT WORLD DOCTOR; KEATS AS, 1983, COMPLICATIONS ANESTH, pCH1; LEDERER DH, 1987, HASTINGS CENT REP, V17, P18, DOI 10.2307/3563178; LONGO WE, 1988, DIS COLON RECTUM, V31, P842, DOI 10.1007/BF02554846; MAY W, 1978, ENCY BIOETHICS, P316; MCGRATH PC, 1989, ANN SURG, V209, P284, DOI 10.1097/00000658-198903000-00006; MEISEL A, 1986, CRIT CARE MED, V14, P239, DOI 10.1097/00003246-198603000-00016; Miles S., 1988, PROTOCOLS ELECTIVE U; MILES SH, 1989, NEW ENGL J MED, V321, P48, DOI 10.1056/NEJM198907063210110; OLSSON GL, 1988, ACTA ANAESTH SCAND, V32, P653, DOI 10.1111/j.1399-6576.1988.tb02804.x; PEATFIELD RC, 1977, LANCET, V1, P1223; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; SCOTT NB, 1988, BRIT J SURG, V75, P299; THOMAS JM, 1983, CAN MED ASSOC J, V128, P1153; TRUOG RD, 1991, ANESTHESIOLOGY, V74, P606, DOI 10.1097/00000542-199103000-00030; YOUNGNER SJ, 1987, HASTINGS CENT REP, V17, P24, DOI 10.2307/3562438; 1991, ACCREDITATION MANUAL, P77; 1987, GUIDELINES TERMINATI; 1985, CONN MED, V49, P367	30	63	64	1	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1991	266	17					2407	2412		10.1001/jama.266.17.2407	http://dx.doi.org/10.1001/jama.266.17.2407			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM790	1717723				2022-12-01	WOS:A1991GM79000028
J	WEINTRAUB, M; SINGH, S; BYRNE, L; MAHARAJ, K; GUTTMACHER, L				WEINTRAUB, M; SINGH, S; BYRNE, L; MAHARAJ, K; GUTTMACHER, L			CONSEQUENCES OF THE 1989 NEW-YORK-STATE TRIPLICATE BENZODIAZEPINE PRESCRIPTION REGULATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ABUSE	Objective. - Comparison of psychoactive medication prescribing and Medicaid expenditures before (1987 through 1988) and after (1989 through 1990) institution of the New York State triplicate benzodiazepine regulations. Data Sources. - The National Prescription Audit (IMS America, Plymouth Meeting, Pa), New York State Medicaid, and Blue Cross/Blue Shield of the Rochester (NY) Area. Results. - From 1988 to 1989, New York State benzodiazepine prescribing decreased by 44%, 60%, and 30% as assessed by IMS America, Medicaid, and Blue Cross/Blue Shield, respectively. Prescribing of the following alternative sedative-hypnotics increased in New York State compared with decreases nationally (IMS America data): meprobamate, + 125% vs - 9%; methyprylon, + 84% vs - 15%; ethchlorvynol, + 29% vs - 18%; butabarbital, + 31 % vs - 15%; hydroxyzine, + 15% vs - 1.1 %; and chloral hydrate, + 136% vs - 0.4%. increased prescribing of alternatives was also seen in the Medicaid and Blue Cross/Blue Shield data. Medicaid benzodiazepine expenditures decreased 52% from 1988 to 1989 ($21.7 million to $10.4 million). Alternative sedative expenditures increased 115% ($3.9 million to $8.4 million). Total Medicaid psychoactive medication expenditures remained nearly constant ($46.7 million to $45.6 million). Conclusion. - Although the triplicate regulations have decreased benzodiazepine prescribing, an undesirable increase has occurred in the prescribing of less acceptable medications. The wider public health, patient care, and financial implications of triplicate benzodiazepine regulations are of concern and require further study before other jurisdictions undertake similar programs.	UNIV ROCHESTER,SCH MED & DENT,DEPT PSYCHIAT,ROCHESTER,NY 14642	University of Rochester	WEINTRAUB, M (corresponding author), UNIV ROCHESTER,SCH MED & DENT,DEPT COMMUNITY & PREVENT MED,BOX 644,601 ELMWOOD AVE,ROCHESTER,NY 14642, USA.							BLACKWELL B, 1973, JAMA-J AM MED ASSOC, V223, P798, DOI 10.1001/jama.1973.03220070052017; BRAHAMS D, 1990, LANCET, V336, P1372, DOI 10.1016/0140-6736(90)92914-4; EADIE JL, 1988, DEC AM MED ASS NAT S; FINKLE BS, 1979, JAMA-J AM MED ASSOC, V242, P429, DOI 10.1001/jama.242.5.429; KAUFMAN A, 1972, J AMER MED ASSOC, V221, P1504, DOI 10.1001/jama.221.13.1504; KUNIN CM, 1973, ANN INTERN MED, V79, P555, DOI 10.7326/0003-4819-79-4-555; MADDALONI M A, 1990, Veterinary and Human Toxicology, V32, P355; MARKS J, 1985, BENZODIAZEPINES USE; PRESCOTT LP, 1983, BENZODIAZEPINES MOL, P252; RALL T W, 1990, P345; ROACHE JD, 1987, J PHARMACOL EXP THER, V243, P978; RODOS JJ, 1990, J AM OSTEOPATH ASSOC, V90, P26; SHENFIELD GM, 1980, BRIT MED J, V281, P651, DOI 10.1136/bmj.281.6241.651; WOODS JH, 1988, JAMA-J AM MED ASSOC, V260, P3476, DOI 10.1001/jama.260.23.3476; 1987, NEW YORK STAT R 0831; 1990, NEW YORK STATES REGU; 1989, EPIDEMIOL NOTES, P4; 1982, WHO6TH REP; 1990, EPIDEMIOL NOTES, P5; 1990, BENZODIAZEPINE DEPEN	20	123	127	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1991	266	17					2392	2397		10.1001/jama.266.17.2392	http://dx.doi.org/10.1001/jama.266.17.2392			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM790	1681121				2022-12-01	WOS:A1991GM79000025
J	CHAN, A; SHINDE, R; CHOW, CC; COCKRAM, CS; SWAMINATHAN, R				CHAN, A; SHINDE, R; CHOW, CC; COCKRAM, CS; SWAMINATHAN, R			INVIVO AND INVITRO SODIUM-PUMP ACTIVITY IN SUBJECTS WITH THYROTOXIC PERIODIC PARALYSIS	BRITISH MEDICAL JOURNAL			English	Article							OUABAIN-BINDING-SITES; NA+,K+-ATPASE ACTIVITY; RUBIDIUM CHLORIDE; CATION-TRANSPORT; SKELETAL-MUSCLE; THYROID-HORMONE; ATPASE ACTIVITY; GRAVES-DISEASE; POTASSIUM PUMP; HYPERTHYROIDISM	Objective - To examine whether sodium pump activity plays a part in the pathogenesis of thyrotoxic periodic paralysis. Design - Measurement of platelet sodium-potassium ATPase and in vivo sodium pump activities in healthy subjects and thyrotoxic subjects with and without paralysis. Setting - University hospital in Hong Kong. Subjects - 21 healthy subjects, 23 untreated thyrotoxic subjects, 13 untreated men with periodic paralysis, seven treated thyrotoxic subjects, and six treated men with periodic paralysis. Main outcome measures - Platelet Na+, K+-ATPase activity and plasma rubidium concentration after oral loading. Results - Median (range) platelet Na+, K+-ATPase activity in thyrotoxic subjects was 253 (169-821) mu-mol inorganic phosphate/h/g protein-significantly higher than that in healthy subjects (134 (81-180) mu-mol/h/g protein; p < 0.001). Na+, K+-ATPase activity in those with periodic paralysis was 374 (195-11%) mu-mol/h/g protein, again significantly higher than that in healthy subjects (p < 0.001) and that in other thyrotoxic subjects (p < 0.01) despite similar degrees of hyperthyroidism. Activities in treated thyrotoxic subjects with and without periodic paralysis were 148 (110-234) and 131 (86-173) mu-mol/h/g protein respectively. Mean (95% confidence interval) plasma rubidium concentration five hours after oral administration in thyrotoxic subjects (7.0 (6.6 to 7.5) mu-mol/l) was significantly lower than in healthy subjects (10.2 (9.5 to 10.9) mu-mol/l; p < 0.001) and higher than in those with periodic paralysis (6.0 (5.7 to 6.3) mu-mol/l; p < 0.01). Conclusions - Sodium pump activity in untreated subjects with periodic paralysis is higher than in other thyrotoxic subjects, and this may be responsible for the hypokalaemia.	CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT CHEM PATHOL,SHA TIN,HONG KONG; CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT MED,SHA TIN,HONG KONG	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital								ARNOTT RD, 1982, J CLIN ENDOCR METAB, V54, P1150, DOI 10.1210/jcem-54-6-1150; ARUMANAYAGAM M, 1990, J CLIN ENDOCR METAB, V71, P260, DOI 10.1210/jcem-71-1-260; ARUMANAYAGAM M, 1990, METABOLISM, V39, P952, DOI 10.1016/0026-0495(90)90307-X; ASANO Y, 1976, J CLIN INVEST, V57, P368, DOI 10.1172/JCI108288; BARON DN, 1985, CLIN SCI, V68, P143, DOI 10.1042/cs0680143; BERNSTEIN JC, 1970, J PHARMACOL EXP THER, V174, P323; BOON NA, 1984, CLIN SCI, V66, P569, DOI 10.1042/cs0660569; DALY JA, 1972, CLIN CHEM, V18, P263; ENGEL AG, 1972, MAYO CLIN PROC, V47, P919; FEELY J, 1981, POSTGRAD MED J, V57, P238, DOI 10.1136/pgmj.57.666.238; FIEVE RR, 1971, PSYCHOPHARMACOLOGIA, V20, P307, DOI 10.1007/BF00403562; HABER RS, 1984, ENDOCRINOLOGY, V115, P291, DOI 10.1210/endo-115-1-291; HALLIS KF, 1985, CLIN CHEM, V31, P274; HAWKINS BR, 1985, CLIN ENDOCRINOL, V23, P245, DOI 10.1111/j.1365-2265.1985.tb00220.x; ISMAILBEIGI F, 1988, AM ZOOL, V28, P363; KHAN FA, 1987, CLIN SCI, V72, P171, DOI 10.1042/cs0720171; KJELDSEN K, 1984, LANCET, V2, P8; LAM KSL, 1989, AUST NZ J MED, V19, P6, DOI 10.1111/j.1445-5994.1989.tb01664.x; LIN MH, 1978, J BIOL CHEM, V253, P723; MARX A, 1989, MUSCLE NERVE, V12, P810, DOI 10.1002/mus.880121005; MCFADZEAN AJ, 1967, BMJ-BRIT MED J, V1, P451, DOI 10.1136/bmj.1.5538.451; OH VMS, 1990, CLIN SCI, V78, P199, DOI 10.1042/cs0780199; OKINAKA S, 1957, J CLIN ENDOCR METAB, V17, P1454, DOI 10.1210/jcem-17-12-1454; RUBYTHON EJ, 1983, CLIN SCI, V64, P441, DOI 10.1042/cs0640441; SCHIZUME K, 1966, METABOLISM, V15, P138; TURAIHI K, 1989, METABOLISM, V38, P773, DOI 10.1016/0026-0495(89)90065-6; YEO PPB, 1978, BRIT MED J, V2, P930, DOI 10.1136/bmj.2.6142.930; YEUNG RTT, 1974, AM J MED, V57, P584, DOI 10.1016/0002-9343(74)90010-2; YEUNG RTT, 1987, OXFORD TXB MED, V10, P48	29	126	133	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1991	303	6810					1096	1099		10.1136/bmj.303.6810.1096	http://dx.doi.org/10.1136/bmj.303.6810.1096			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN209	1660744	Bronze, Green Published			2022-12-01	WOS:A1991GN20900020
J	DINNING, G; DOUGHTY, RW; REID, MM; LLOYD, HL				DINNING, G; DOUGHTY, RW; REID, MM; LLOYD, HL			POTASSIUM CONCENTRATIONS IN IRRADIATED BLOOD	BRITISH MEDICAL JOURNAL			English	Article									ROYAL VICTORIA INFIRM,DEPT HAEMATOL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND; REG TRANSFUS CTR,NEWCASTLE TYNE NE2 4NQ,ENGLAND	Newcastle University - UK								BUTTON LN, 1981, TRANSFUSION, V21, P419, DOI 10.1046/j.1537-2995.1981.21481275998.x; LEITMAN SF, 1985, TRANSFUSION, V25, P293, DOI 10.1046/j.1537-2995.1985.25485273804.x; RAMIREZ AM, 1987, TRANSFUSION, V27, P444, DOI 10.1046/j.1537-2995.1987.27587320546.x; RIVET C, 1989, TRANSFUSION, V29, P185, DOI 10.1046/j.1537-2995.1989.29289146841.x; 1989, LANCET, V1, P529	5	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1991	303	6810					1110	1110		10.1136/bmj.303.6810.1110	http://dx.doi.org/10.1136/bmj.303.6810.1110			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN209	1747580	Bronze, Green Published			2022-12-01	WOS:A1991GN20900024
J	DOROZYNSKI, A				DOROZYNSKI, A			CRIMINAL CHARGES OVER HIV IN FRENCH BLOOD-TRANSFUSIONS	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1991	303	6810					1091	1091						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GN209	1747576				2022-12-01	WOS:A1991GN20900016
J	DUNEA, G				DUNEA, G			BURNING DOWN THEIR HOUSES	BRITISH MEDICAL JOURNAL			English	Editorial Material											DUNEA, G (corresponding author), COOK CTY HOSP,CHICAGO,IL 60612, USA.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1991	303	6810					1141	1141						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN209	1747602				2022-12-01	WOS:A1991GN20900076
J	HANDEL, J; TRIPP, JH				HANDEL, J; TRIPP, JH			VITAMIN-K PROPHYLAXIS AGAINST HEMORRHAGIC-DISEASE OF THE NEWBORN IN THE UNITED-KINGDOM	BRITISH MEDICAL JOURNAL			English	Article									POSTGRAD MED SCH,DEPT CHILD HLTH,EXETER EX2 5SQ,ENGLAND	University of Exeter								Lehmann JL, 1944, LANCET, V1, P493; MCNINCH AW, 1985, ARCH DIS CHILD, V60, P814, DOI 10.1136/adc.60.9.814; MCNINCH AW, 1991, BRIT MED J, V303, P1105, DOI 10.1136/bmj.303.6810.1105; TRIPP JH, 1987, ARCH DIS CHILD, V62, P436, DOI 10.1136/adc.62.5.436	4	23	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1991	303	6810					1109	1109		10.1136/bmj.303.6810.1109	http://dx.doi.org/10.1136/bmj.303.6810.1109			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN209	1747579	Green Published			2022-12-01	WOS:A1991GN20900023
J	HANNINGTONKIFF, JG				HANNINGTONKIFF, JG			DOES FAILED NATURAL OPIOID MODULATION IN REGIONAL SYMPATHETIC-GANGLIA CAUSE REFLEX SYMPATHETIC DYSTROPHY	LANCET			English	Article							ENKEPHALIN	Early features of reflex sympathetic dystrophy in a limb resemble the general effects of autonomic arousal associated with opioid withdrawal. It is suggested that natural opioid peptide modulation in regional sympathetic ganglia normally rises to prevent excessive autonomic activity in an injured limb. After an injury (especially a trivial one) to a susceptible subject, this localised increase in opioid modulation may fail or may rapidly wane so that autonomic features of opioid withdrawal appear in the affected limb. Florid dystrophic changes may then occur because of passive complications of disuse associated with pain, or as a result of more active processes. Preservation of an appropriate opioid bias in the regional sympathetic ganglia might be an important factor in the successful management and prevention of reflex sympathetic dystrophy.			HANNINGTONKIFF, JG (corresponding author), FRIMLEY PK HOSP,CTR PAIN RELIEF,PORTSMOUTH RD,CAMBERLEY GU16 5UJ,SURREY,ENGLAND.							AN HS, 1988, J HAND SURG-AM, V13A, P458, DOI 10.1016/S0363-5023(88)80032-7; ARIAS LM, 1989, REGION ANESTH, V14, P90; Crile GW, 1913, LANCET, V2, P7; DIGIULIO AM, 1978, NEUROPHARMACOLOGY, V17, P989, DOI 10.1016/0028-3908(78)90144-2; HANNINGTONKIFF JG, 1990, J ROY SOC MED, V83, P373, DOI 10.1177/014107689008300612; HANNINGTONKIFF JG, 1988, LANCET, V1, P1404; HELEN P, 1984, NEUROSCIENCE, V12, P907, DOI 10.1016/0306-4522(84)90178-7; Janig W, 1990, PAIN SYMPATHETIC NER, P17; KONISHI S, 1981, NATURE, V294, P80, DOI 10.1038/294080a0; MAYS KS, 1981, J NEUROL NEUROSUR PS, V44, P189, DOI 10.1136/jnnp.44.2.189; NEELY J C, 1956, Br J Ophthalmol, V40, P636, DOI 10.1136/bjo.40.10.636; RIOS L, 1983, EUR J PHARMACOL, V86, P277; ROBERTS WJ, 1986, PAIN, V24, P297, DOI 10.1016/0304-3959(86)90116-8; SCHULTZBERG M, 1979, NEUROSCIENCE, V4, P249, DOI 10.1016/0306-4522(79)90087-3; THOREN P, 1990, MED SCI SPORT EXER, V22, P417; WALL PD, 1979, PAIN, V7, P103, DOI 10.1016/0304-3959(79)90002-2	16	27	27	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 2	1991	338	8775					1125	1127		10.1016/0140-6736(91)91974-Y	http://dx.doi.org/10.1016/0140-6736(91)91974-Y			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM784	1682552				2022-12-01	WOS:A1991GM78400014
J	MCNINCH, AW; TRIPP, JH				MCNINCH, AW; TRIPP, JH			HEMORRHAGIC-DISEASE OF THE NEWBORN IN THE BRITISH-ISLES - 2 YEAR PROSPECTIVE-STUDY	BRITISH MEDICAL JOURNAL			English	Article								Objective - To determine the incidence of haemorrhagic disease of the newborn in the British Isles, study risk factors, and examine the effect of vitamin K prophylaxis. Design - Prospective survey of all possible cases of haemoffhagic disease of the newborn as reported by consultant paediatricians using the monthly notification cards of the British Paediatric Surveillance Unit and a follow up questionnaire for each case to validate the diagnosis and accrue further data. Setting - Britain (England, Scotland, and Wales) and Ireland (Northern Ireland and the Irish Republic) during December 1987 to March 1990. Patients - 27 infants classified as having confirmed (n = 25) or probable (n = 2) haemoffhagic disease of the newborn. Results - 24 of the 27 infants were solely breast fed. 10 suffered intracranial haemorrhage; two of these died and there was clinical concern about the remainder. 20 infants had received no vitamin K prophylaxis, and seven had received oral prophylaxis. Relative risk ratios for these groups compared with babies who had received intramuscular vitamin K were 81:1 and 13:1 respectively. Six infants had hepatitis (alpha-1 antitrypsin deficiency in four), unsuspected until presentation with haemorrhagic disease of the newborn, of whom four had received oral prophylaxis. One other baby had prolonged jaundice. One mother had taken phenytoin during pregnancy. Conclusions - All newborn infants should receive vitamin K prophylaxis. Intramuscular vitamin K is more effective than oral prophylactic regimens currently used in the British Isles.	POSTGRAD MED SCH,DEPT CHILD HLTH,EXETER EX2 5SQ,ENGLAND	University of Exeter	MCNINCH, AW (corresponding author), ROYAL DEVON & EXETER HOSP,EXETER EX2 5DW,DEVON,ENGLAND.							DAM H, 1952, ADV PEDIATR, V5, P129; EKELUND H, 1991, ACTA PAEDIATR SCAND, V80, P966, DOI 10.1111/j.1651-2227.1991.tb11763.x; GOLDING J, 1990, BRIT J CANCER, V62, P304, DOI 10.1038/bjc.1990.283; Hall S M, 1988, Arch Dis Child, V63, P344; HANAWA Y, 1990, Acta Paediatrica Japonica, V32, P51; HANDEL J, 1991, BRIT MED J, V303, P1109, DOI 10.1136/bmj.303.6810.1109; MARTIN J, 1988, INFANT FEEDING 1985; MOUNTAIN KR, 1970, LANCET, V1, P265; SUTHERLAND JM, 1967, AM J DIS CHILD, V113, P524, DOI 10.1001/archpedi.1967.02090200056003; TONZ O, 1988, SCHWEIZ MED WSCHR, V118, P1747; TRIPP JH, 1987, ARCH DIS CHILD, V62, P426; VONKRIES R, 1988, EUR J PEDIATR, V147, P106; 1988, BPSU3RD BRIT PAED SU	13	132	135	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1991	303	6810					1105	1109		10.1136/bmj.303.6810.1105	http://dx.doi.org/10.1136/bmj.303.6810.1105			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN209	1747578	Green Published, Bronze			2022-12-01	WOS:A1991GN20900022
J	BARTEL, DP; ZAPP, ML; GREEN, MR; SZOSTAK, JW				BARTEL, DP; ZAPP, ML; GREEN, MR; SZOSTAK, JW			HIV-1 REV REGULATION INVOLVES RECOGNITION OF NON-WATSON-CRICK BASE-PAIRS IN VIRAL-RNA	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; BACTERIOPHAGE-T4 DNA-POLYMERASE; MESSENGER-RNA; TARGET SEQUENCE; RIBOSOMAL-RNA; TRANS-ACTIVATOR; SECONDARY STRUCTURE; RIBONUCLEIC-ACID; XENOPUS OOCYTES; BINDING-SITES	We have used an iterative in vitro genetic selection to identify the important structural features of the viral RNA element bound by the Rev protein of human immunodeficiency virus type 1 (HIV-1). Functional Rev-binding RNAs were selected from a pool of 10(13) variants of the wild-type Rev-binding domain. Bases conserved among the binding species define a 20 nucleotide core binding element. Covariation of some of these conserved bases indicates that the Rev-binding element is a stem-bulge-stem with a G:G base pair in the bulge. Mutational studies show that this non-Watson-Crick base pair is required for Rev binding in vitro and Rev responsiveness in vivo. We propose that the G:G base pair distorts the sugar-phosphate backbone of viral RNA and that this distortion is a critical determinant of recognition by Rev.	UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester	BARTEL, DP (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114, USA.							AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BROWN BD, 1990, GENE DEV, V4, P1925, DOI 10.1101/gad.4.11.1925; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2601, DOI 10.1021/bi00280a002; COCHRANE AW, 1990, P NATL ACAD SCI USA, V87, P1198, DOI 10.1073/pnas.87.3.1198; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; DAYTON ET, 1989, SCIENCE, V246, P1625, DOI 10.1126/science.2688093; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; GREEN R, 1990, NATURE, V347, P406, DOI 10.1038/347406a0; GUTELL RR, 1990, P NATL ACAD SCI USA, V87, P663, DOI 10.1073/pnas.87.2.663; HAMMARSKJOLD ML, 1989, J VIROL, V63, P1959; HEAPHY S, 1990, CELL, V60, P685, DOI 10.1016/0092-8674(90)90671-Z; HOLLAND SM, 1990, J VIROL, V64, P5966, DOI 10.1128/JVI.64.12.5966-5975.1990; HOPE TJ, 1990, P NATL ACAD SCI USA, V87, P7787, DOI 10.1073/pnas.87.19.7787; HOPE TJ, 1990, J VIROL, V64, P5360, DOI 10.1128/JVI.64.11.5360-5366.1990; HUANG XJ, 1991, J VIROL, V65, P2131, DOI 10.1128/JVI.65.4.2131-2134.1991; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683; LEVITT M, 1969, NATURE, V224, P759, DOI 10.1038/224759a0; LIN YS, 1989, NATURE, V340, P656, DOI 10.1038/340656a0; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; OAKES MI, 1990, J MOL BIOL, V211, P907, DOI 10.1016/0022-2836(90)90083-X; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; OLSEN HS, 1990, SCIENCE, V247, P845, DOI 10.1126/science.2406903; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; ROSEN CA, 1988, P NATL ACAD SCI USA, V85, P2071, DOI 10.1073/pnas.85.7.2071; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; STERN S, 1988, J MOL BIOL, V201, P683, DOI 10.1016/0022-2836(88)90467-6; SUGIMOTO N, 1987, BIOCHEMISTRY-US, V26, P4554, DOI 10.1021/bi00388a058; THIESEN HJ, 1990, NUCLEIC ACIDS RES, V18, P3203, DOI 10.1093/nar/18.11.3203; TRAUB W, 1982, NUCLEIC ACIDS RES, V10, P2701, DOI 10.1093/nar/10.8.2701; TUERK C, 1990, J MOL BIOL, V213, P749, DOI 10.1016/S0022-2836(05)80261-X; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; TUERK C, 1988, P NATL ACAD SCI USA, V85, P1364, DOI 10.1073/pnas.85.5.1364; WOESE CR, 1983, MICROBIOL REV, V47, P621, DOI 10.1128/MMBR.47.4.621-669.1983; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467; YISRAELI JK, 1990, DEVELOPMENT, V108, P289; ZAPP ML, 1991, P NATL ACAD SCI USA, V88, P7734, DOI 10.1073/pnas.88.17.7734; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	49	373	403	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1991	67	3					529	536		10.1016/0092-8674(91)90527-6	http://dx.doi.org/10.1016/0092-8674(91)90527-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GN664	1934059				2022-12-01	WOS:A1991GN66400009
J	BELLIVEAU, JW; KENNEDY, DN; MCKINSTRY, RC; BUCHBINDER, BR; WEISSKOFF, RM; COHEN, MS; VEVEA, JM; BRADY, TJ; ROSEN, BR				BELLIVEAU, JW; KENNEDY, DN; MCKINSTRY, RC; BUCHBINDER, BR; WEISSKOFF, RM; COHEN, MS; VEVEA, JM; BRADY, TJ; ROSEN, BR			FUNCTIONAL MAPPING OF THE HUMAN VISUAL-CORTEX BY MAGNETIC-RESONANCE-IMAGING	SCIENCE			English	Article							POSITRON-EMISSION TOMOGRAPHY; CEREBRAL BLOOD-VOLUME; HUMAN-BRAIN; COMPUTED-TOMOGRAPHY; COGNITIVE NEUROSCIENCE; STRIATE CORTEX; INSTANT IMAGES; FLOW; CONTRAST; NMR	Knowledge of regional cerebral hemodynamics has widespread application for both physiological research and clinical assessment because of the well-established interrelation between physiological function, energy metabolism, and localized blood supply. A magnetic resonance technique was developed for quantitative imaging of cerebral hemodynamics, allowing for measurement of regional cerebral blood volume during resting and activated cognitive states. This technique was used to generate the first functional magnetic resonance maps of human task activation, by using a visual stimulus paradigm. During photic stimulation, localized increases in blood volume (32 +/- 10 percent, n = 7 subjects) were detected in the primary visual cortex. Center-of-mass coordinates and linear extents of brain activation within the plane of the calcarine fissure are reported.	MASSACHUSETTS GEN HOSP,CTR NMR,DEPT RADIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,CTR NMR,DEPT NEUROL,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital			Cohen, Mark S/C-6610-2011; Kennedy, David N/H-3627-2012	Cohen, Mark S/0000-0001-6731-4053; 	NCI NIH HHS [R01-CA40303, P01-CA48729] Funding Source: Medline; NHLBI NIH HHS [R01-HL39810] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040303, P01CA048729] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039810] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREASEN NC, 1988, SCIENCE, V239, P1381, DOI 10.1126/science.3279509; AXEL L, 1983, INVEST RADIOL, V18, P94, DOI 10.1097/00004424-198301000-00018; AXEL L, 1980, RADIOLOGY, V137, P679, DOI 10.1148/radiology.137.3.7003648; Belliveau J W, 1991, J Neuroimaging, V1, P36; BELLIVEAU JW, 1990, MAGNET RESON MED, V14, P538, DOI 10.1002/mrm.1910140311; CAVINESS VS, 1989, BRAIN DEV-JPN, V11, P1; CHURCHLAND PS, 1988, SCIENCE, V242, P741, DOI 10.1126/science.3055294; COHEN MS, 1991, MAGN RESON IMAGING, V9, P1, DOI 10.1016/0730-725X(91)90094-3; FISEL CR, 1991, MAGNET RESON MED, V17, P336, DOI 10.1002/mrm.1910170206; FOX PT, 1984, J NEUROPHYSIOL, V51, P1109, DOI 10.1152/jn.1984.51.5.1109; FOX PT, 1986, NATURE, V323, P806, DOI 10.1038/323806a0; FOX PT, 1985, ANN NEUROL, V17, P303, DOI 10.1002/ana.410170315; FOX PT, 1987, J NEUROSCI, V7, P913; GAZZANIGA MS, 1989, SCIENCE, V245, P947, DOI 10.1126/science.2672334; KENNEDY DN, 1989, IEEE T MED IMAGING, V8, P1, DOI 10.1109/42.20356; KENT TA, 1989, AM J NEURORADIOL, V10, P335; KOSSLYN SM, 1988, SCIENCE, V240, P1621, DOI 10.1126/science.3289115; Lassen N. A., 1983, HDB PHYSL 2, VIII, P21; LASSEN NA, 1984, J CEREBR BLOOD F MET, V4, P633, DOI 10.1038/jcbfm.1984.90; MANSFIELD P, 1977, J PHYS C SOLID STATE, V10, pL55, DOI 10.1088/0022-3719/10/3/004; MINTUN MA, 1989, J CEREBR BLOOD F MET, V9, P96, DOI 10.1038/jcbfm.1989.13; MOONEN CTW, 1990, SCIENCE, V250, P53, DOI 10.1126/science.2218514; MOSELEY ME, 1990, 1990 P SOC MAGN RES, P56; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; PHELPS ME, 1981, SCIENCE, V211, P1445, DOI 10.1126/science.6970412; PHELPS ME, 1985, SCIENCE, V228, P799, DOI 10.1126/science.2860723; POSNER MI, 1988, SCIENCE, V240, P1627, DOI 10.1126/science.3289116; PYKETT IL, 1987, MAGNET RESON MED, V5, P563; Raichle M. E., 1987, HDB PHYSL NERVOUS SY, V1, P643; ROSEN B R, 1989, Magnetic Resonance Quarterly, V5, P263; ROSEN BR, 1990, MAGNET RESON MED, V14, P249, DOI 10.1002/mrm.1910140211; RZEDZIAN RR, 1987, AM J ROENTGENOL, V149, P245, DOI 10.2214/ajr.149.2.245; SAKAI F, 1985, J CEREBR BLOOD F MET, V5, P207, DOI 10.1038/jcbfm.1985.27; SANDMAN CA, 1984, SCIENCE, V224, P1355, DOI 10.1126/science.6729458; SOKOLOFF L, 1985, BRAIN IMAGING BRAIN; STARMER CF, 1970, J APPL PHYSIOL, V28, P219, DOI 10.1152/jappl.1970.28.2.219; Talairach J, 1967, ATLAS ANATOMIE STERE; Talairach J., 1988, COPLANAR STEREOTAXIC, P5; THOMPSON HK, 1964, CIRC RES, V14, P502, DOI 10.1161/01.RES.14.6.502; VILLRINGER A, 1988, MAGNET RESON MED, V6, P164, DOI 10.1002/mrm.1910060205; ZEKI S, 1988, NATURE, V335, P311, DOI 10.1038/335311a0	42	1301	1361	11	126	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1991	254	5032					716	719		10.1126/science.1948051	http://dx.doi.org/10.1126/science.1948051			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN474	1948051				2022-12-01	WOS:A1991GN47400043
J	BEZANILLA, F; PEROZO, E; PAPAZIAN, DM; STEFANI, E				BEZANILLA, F; PEROZO, E; PAPAZIAN, DM; STEFANI, E			MOLECULAR-BASIS OF GATING CHARGE IMMOBILIZATION IN SHAKER POTASSIUM CHANNELS	SCIENCE			English	Article							SODIUM-CHANNEL; XENOPUS OOCYTES; SQUID AXON; DROSOPHILA; INACTIVATION; ACTIVATION; CURRENTS; LOCUS; GENE; CDNA	Voltage-dependent ion channels respond to changes in the membrane potential by means of charged voltage sensors intrinsic to the channel protein. Changes in transmembrane potential cause movement of these charged residues, which results in conformational changes in the channel. Movements of the charged sensors can be detected as currents known as gating currents. Measurement of the gating currents of the Drosophila Shaker potassium channel indicates that the charge on the voltage sensor of the channels is progressively immobilized by prolonged depolarizations. The charge is not immobilized in a mutant of the channel that lacks inactivation. These results show that the region of the molecule responsible for inactivation interacts, directly or indirectly, with the voltage sensor to prevent the return of the charge to its original position. The gating transitions between closed states of the channel appear not to be independent, suggesting that the channel subunits interact during activation.	BAYLOR COLL MED,DEPT PHYSIOL & MOLEC BIOPHYS,HOUSTON,TX 77030	Baylor College of Medicine	BEZANILLA, F (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT PHYSIOL,LOS ANGELES,CA 90024, USA.				NHLBI NIH HHS [HL37044] Funding Source: Medline; NIGMS NIH HHS [R01 GM043459-12, R01 GM043459-16, R01 GM043459-15S1, R01 GM043459-09, R01 GM043459-11, GM43459, R01 GM043459-15, GM30376, R01 GM043459-17, R01 GM043459-13, R01 GM043459, R01 GM043459-10, R01 GM043459-14] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL037044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030376, R01GM030376, R01GM043459] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almers W, 1978, Rev Physiol Biochem Pharmacol, V82, P96, DOI 10.1007/BFb0030498; ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; BAUMANN A, 1987, EMBO J, V6, P3419, DOI 10.1002/j.1460-2075.1987.tb02665.x; BEZANILLA F, 1982, J GEN PHYSIOL, V79, P21, DOI 10.1085/jgp.79.1.21; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P549, DOI 10.1085/jgp.70.5.549; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; COLE KS, 1960, BIOPHYS J, V1, P161; GILLY WF, 1982, J GEN PHYSIOL, V79, P935, DOI 10.1085/jgp.79.6.935; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; KAMB A, 1987, CELL, V50, P405, DOI 10.1016/0092-8674(87)90494-6; KAMB A, 1988, NEURON, V1, P421, DOI 10.1016/0896-6273(88)90192-4; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MACKINNON R, 1991, Biophysical Journal, V59, p404A; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; STIMERS JR, 1987, J GEN PHYSIOL, V89, P521, DOI 10.1085/jgp.89.4.521; STIMERS JR, 1985, J GEN PHYSIOL, V85, P65, DOI 10.1085/jgp.85.1.65; STUHMER W, 1991, PFLUG ARCH EUR J PHY, V418, P423, DOI 10.1007/BF00550881; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TAGLIALATELA M, IN PRESS BIOPHYS J; TAGLIALATELA M, UNPUB; TAYLOR RE, 1983, J GEN PHYSIOL, V81, P773, DOI 10.1085/jgp.81.6.773; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; TIMPE LC, 1988, NATURE, V331, P143, DOI 10.1038/331143a0; TIMPE LC, 1988, NEURON, V1, P659, DOI 10.1016/0896-6273(88)90165-1; TORO L, IN PRESS NEUR SOC AB; WHITE MM, 1985, J GEN PHYSIOL, V85, P539, DOI 10.1085/jgp.85.4.539; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; ZAGOTTA WN, 1990, J GEN PHYSIOL, V95, P29, DOI 10.1085/jgp.95.1.29; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	33	186	189	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1991	254	5032					679	683		10.1126/science.1948047	http://dx.doi.org/10.1126/science.1948047			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN474	1948047				2022-12-01	WOS:A1991GN47400031
J	BRUNDAGE, RA; FOGARTY, KE; TUFT, RA; FAY, FS				BRUNDAGE, RA; FOGARTY, KE; TUFT, RA; FAY, FS			CALCIUM GRADIENTS UNDERLYING POLARIZATION AND CHEMOTAXIS OF EOSINOPHILS	SCIENCE			English	Article							CYTOLYTIC T-CELLS; AEQUORIN LUMINESCENCE; CONTRACTILE BASIS; AMEBOID MOVEMENT; POLYMORPHONUCLEAR LEUKOCYTES; SEQUENTIAL ACTIVATION; LIVING FIBROBLASTS; ACTIN-FILAMENTS; MYOSIN-I; ENDOCYTOSIS	The concentration of intracellular free calcium ([Ca2+]i) in polarized eosinophils was imaged during chemotaxis by monitoring fluorescence of the calcium-sensitive dye Fura-2 with a modified digital imaging microscope. Chemotactic stimuli caused [Ca2+]i to increase in a nonuniform manner that was related to cell activity. In cells moving persistently in one direction, [Ca2+]i was highest at the rear and lowest at the front of the cell. Before cells turned, [Ca2+]i transiently increased. The region of the cell that became the new leading edge had the lowest [Ca2+]i. These changes in [Ca2+]i provide a basis for understanding the organization and local activity of cytoskeletal proteins thought to underlie the directed migration of many cells.			BRUNDAGE, RA (corresponding author), UNIV MASSACHUSETTS,SCH MED,DEPT PHYSIOL,BIOMED IMAGING GRP,PROGRAM MOLEC MED,WORCESTER,MA 01605, USA.				NHLBI NIH HHS [HL14523] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL014523, R37HL014523] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRAY D, 1988, SCIENCE, V239, P883, DOI 10.1126/science.3277283; BRUNDAGE RT, UNPUB; CASSIMERIS L, 1990, J CELL BIOL, V110, P1067, DOI 10.1083/jcb.110.4.1067; COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; GRAY LS, 1988, J IMMUNOL, V141, P2424; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KOONCE MP, 1984, J CELL BIOL, V98, P1999, DOI 10.1083/jcb.98.6.1999; KURODA K, 1988, PROTOPLASMA, V144, P64, DOI 10.1007/BF01320282; MARKS PW, 1990, J CELL BIOL, V110, P43, DOI 10.1083/jcb.110.1.43; MARKS PW, 1991, J CELL BIOL, V112, P149, DOI 10.1083/jcb.112.1.149; MCKENNA NM, 1989, J CELL BIOL, V109, P1163, DOI 10.1083/jcb.109.3.1163; MOORE EDW, 1990, CELL CALCIUM, V11, P157, DOI 10.1016/0143-4160(90)90068-6; POENIE M, 1987, EMBO J, V6, P2223, DOI 10.1002/j.1460-2075.1987.tb02494.x; POENIE M, 1990, CELL CALCIUM, V11, P85, DOI 10.1016/0143-4160(90)90062-Y; POZZAN T, 1983, SCIENCE, V221, P1413, DOI 10.1126/science.6310757; SAWYER DW, 1985, SCIENCE, V230, P663, DOI 10.1126/science.4048951; SCANLON M, 1987, J BIOL CHEM, V262, P6308; SMITH SJ, 1988, SCIENCE, V242, P708, DOI 10.1126/science.3055292; SNYDERMAN R, 1981, SCIENCE, V213, P830, DOI 10.1126/science.6266014; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; TAYLOR DL, 1982, PHILOS T ROY SOC B, V299, P185, DOI 10.1098/rstb.1982.0125; TAYLOR DL, 1980, J CELL BIOL, V86, P599, DOI 10.1083/jcb.86.2.599; Trinkaus J.P., 1984, CELLS ORGANS; WANG Y, 1982, P NATL ACAD SCI-BIOL, V79, P4660, DOI 10.1073/pnas.79.15.4660; WANG YL, 1985, J CELL BIOL, V101, P597, DOI 10.1083/jcb.101.2.597; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; ZIGMOND SH, 1978, J CELL BIOL, V77, P269, DOI 10.1083/jcb.77.2.269	29	238	242	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1991	254	5032					703	706		10.1126/science.1948048	http://dx.doi.org/10.1126/science.1948048			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN474	1948048				2022-12-01	WOS:A1991GN47400039
J	CROOK, T; TIDY, JA; VOUSDEN, KH				CROOK, T; TIDY, JA; VOUSDEN, KH			DEGRADATION OF P53 CAN BE TARGETED BY HPV E6 SEQUENCES DISTINCT FROM THOSE REQUIRED FOR P53 BINDING AND TRANSACTIVATION	CELL			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; HUMAN FORESKIN KERATINOCYTES; RETINOBLASTOMA GENE-PRODUCT; LARGE TUMOR-ANTIGEN; OPEN READING FRAME; CERVICAL-CARCINOMA; TRANSCRIPTIONAL ACTIVATION; MONOCLONAL-ANTIBODIES; TRANSFORMING GENE; E7 ONCOPROTEIN	Human papillomavirus (HPV) types 16 and 18 appear to play a role in the development of ano-genital malignancies, whereas HPV 6 and 11 are usually associated with benign lesions. One HPV16 oncoprotein, E6, complexes with and promotes degradation of the cellular tumor suppressor p53. Here we show that E6 proteins of both oncogenic and benign HPV types associate in vitro with p53, but binding by E6 proteins of benign HPV types cannot target p53 for degradation. A C-terminal region of E6 conserved among all HPV types is important for p53 binding. However, N-terminal sequences of E6 conserved only between oncogenic HPV types are necessary to direct p53 degradation. p53 binding by E6 appears necessary but not sufficient for this activity. All E6 proteins tested showed comparable transcriptional trans-activating activity, a property that does not require the ability to bind or direct degradation of p53.	SAMARITAN HOSP WOMEN, DEPT GYNECOL ONCOL, LONDON NW1 5YE, ENGLAND		CROOK, T (corresponding author), ST MARYS HOSP, SCH MED, LUDWIG INST CANC RES, NORFOLK PL, LONDON W2 1PG, ENGLAND.							BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BARBOSA MS, 1991, J VIROL, V65, P292, DOI 10.1128/JVI.65.1.292-298.1991; BARBOSA MS, 1989, J VIROL, V63, P1404, DOI 10.1128/JVI.63.3.1404-1407.1989; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CROOK T, 1991, ONCOGENE, V6, P873; CROOK T, 1991, IN PRESS ONCOGENE; DANOS O, 1987, CANCER CELL, V5, P145; DARMANN K, 1986, VIROLOGY, V151, P124, DOI 10.1016/0042-6822(86)90110-8; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GIUS D, 1988, J VIROL, V62, P665, DOI 10.1128/JVI.62.3.665-672.1988; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALL CV, 1983, J BIOL CHEM, V258, P14120; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KANDA T, 1988, J VIROL, V62, P610, DOI 10.1128/JVI.62.2.610-613.1988; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAMBERTI C, 1990, EMBO J, V9, P1907, DOI 10.1002/j.1460-2075.1990.tb08317.x; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; RAWLS JA, 1990, J VIROL, V64, P6121, DOI 10.1128/JVI.64.12.6121-6129.1990; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, IN PRESS P NATL ACAD; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHWARZ E, 1983, EMBO J, V2, P2341, DOI 10.1002/j.1460-2075.1983.tb01744.x; SEDMAN SA, 1991, IN PRESS J VIROL; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; Vousden K H, 1990, Semin Cancer Biol, V1, P415; VOUSDEN KH, 1989, J VIROL, V63, P2340, DOI 10.1128/JVI.63.5.2340-2342.1989; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167; VOUSDEN KH, 1989, CANCER CELL-MON REV, V1, P43; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILKINSON D, 1988, J EXP MED, V167, P1442, DOI 10.1084/jem.167.4.1442; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	53	485	520	1	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 1	1991	67	3					547	556		10.1016/0092-8674(91)90529-8	http://dx.doi.org/10.1016/0092-8674(91)90529-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GN664	1657399				2022-12-01	WOS:A1991GN66400011
J	DESCOMBES, P; SCHIBLER, U				DESCOMBES, P; SCHIBLER, U			A LIVER-ENRICHED TRANSCRIPTIONAL ACTIVATOR PROTEIN, LAP, AND A TRANSCRIPTIONAL INHIBITORY PROTEIN, LIP, ARE TRANSLATED FROM THE SAME MESSENGER-RNA	CELL			English	Article							DNA-BINDING PROTEINS; LEUCINE ZIPPER PROTEINS; AUG INITIATOR CODON; EUKARYOTIC RIBOSOMES; MAMMALIAN-CELLS; C/EBP FAMILY; ALBUMIN GENE; SEQUENCE; EXPRESSION; DOMAIN	LAP, a transcriptional activator, and LIP, a transcriptional repressor, are translated from a single mRNA species by using two AUGs within the same reading frame. These two proteins share the 145 C-terminal amino acids that contain the basic DNA-binding domain and the leucine zipper dimerization helix. Probably owing to its higher affinity for its DNA cognate sequences, LIP can attenuate the transcriptional stimulation by LAP in substoichiometric amounts. As revealed by transient transfection experiments, a moderate increase in the LAP/LIP ratio results in a significantly higher transcriptional activation of an appropriate target gene. The LAP/LIP ratio increases about 5-fold during terminal rat liver differentiation and is thus likely to modulate the activity of LAP in the intact animal.			DESCOMBES, P (corresponding author), DEPT BIOL MOLEC SCI 2,30 QUAI ERNEST ANSERMET,CH-1211 GENEVA 4,SWITZERLAND.							ACKLAND P, 1990, NATURE, V343, P662; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHOE J, 1989, J VIROL, V63, P1743, DOI 10.1128/JVI.63.4.1743-1755.1989; CLEMENS MJ, 1984, TRANSCRIPTION TRANSL, P211; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; FALVEY E, 1991, FASEB J, V5, P309, DOI 10.1096/fasebj.5.3.2001790; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HINNEBUSCH AG, 1990, TRENDS BIOCHEM SCI, V15, P148, DOI 10.1016/0968-0004(90)90215-W; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P3873, DOI 10.1093/nar/12.9.3873; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; KOZAK M, 1986, CELL, V47, P481, DOI 10.1016/0092-8674(86)90609-4; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT PF, 1990, J VIROL, V64, P950, DOI 10.1128/JVI.64.2.950-956.1990; LAMBERT PF, 1987, CELL, V50, P69, DOI 10.1016/0092-8674(87)90663-5; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; PEABODY DS, 1989, J BIOL CHEM, V264, P5031; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Ptashne M., 1986, A GENETIC SWITCH; RUSCONI S, 1990, GENE, V89, P211, DOI 10.1016/0378-1119(90)90008-F; Sambrook J., 1989, MOL CLONING LAB MANU; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WUARIN J, 1990, CELL, V63, P1257, DOI 10.1016/0092-8674(90)90421-A	44	925	938	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1991	67	3					569	579		10.1016/0092-8674(91)90531-3	http://dx.doi.org/10.1016/0092-8674(91)90531-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GN664	1934061				2022-12-01	WOS:A1991GN66400013
J	GOLUMBEK, PT; LAZENBY, AJ; LEVITSKY, HI; JAFFEE, LM; KARASUYAMA, H; BAKER, M; PARDOLL, DM				GOLUMBEK, PT; LAZENBY, AJ; LEVITSKY, HI; JAFFEE, LM; KARASUYAMA, H; BAKER, M; PARDOLL, DM			TREATMENT OF ESTABLISHED RENAL-CANCER BY TUMOR-CELLS ENGINEERED TO SECRETE INTERLEUKIN-4	SCIENCE			English	Article							STIMULATORY FACTOR-I; CYTOLYTIC T-CELLS; LYMPHOCYTES-T; MONOCLONAL-ANTIBODY; GENERATION; EXPRESSION; PEPTIDE; GENE; DNA	The generation of antigen-specific antitumor immunity is the ultimate goal in cancer immunotherapy. When cells from a spontaneously arising murine renal cell tumor were engineered to secrete large doses of interleukin-4 (IL-4) locally, they were rejected in a predominantly T cell-independent manner. However, animals that rejected the IL-4-transfected tumors developed T cell-dependent systemic immunity to the parental tumor. This systemic immunity was tumor-specific and primarily mediated by CD8+ T cells. Established parental tumors could be cured by the systemic immune response generated by injection of the genetically engineered tumors. These results provide a rationale for the use of lymphokine gene-transfected tumor cells as a modality for cancer therapy.	JOHNS HOPKINS UNIV, DEPT MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, DEPT PATHOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, DEPT IMMUNOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Karasuyama, Hajime/A-7966-2011	Karasuyama, Hajime/0000-0003-0689-0836				DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; FERNANDEZBOTRAN R, 1986, P NATL ACAD SCI USA, V83, P9689, DOI 10.1073/pnas.83.24.9689; GOLUMBEK P, UNPUB; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRUSBY MJ, 1990, CELL, V60, P451, DOI 10.1016/0092-8674(90)90596-7; HAVRAN WL, 1987, NATURE, V330, P170, DOI 10.1038/330170a0; HEWITT HB, 1976, BRIT J CANCER, V33, P241, DOI 10.1038/bjc.1976.37; HULI J, 1987, J EXP MED, V165, P157, DOI 10.1084/jem.165.1.157; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; LURQUIN C, 1989, CELL, V58, P293, DOI 10.1016/0092-8674(89)90844-1; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARX JL, 1989, SCIENCE, V245, P813, DOI 10.1126/science.2672332; MARYANSKI JL, 1986, NATURE, V324, P578, DOI 10.1038/324578a0; Mathe G, 1971, Adv Cancer Res, V14, P1, DOI 10.1016/S0065-230X(08)60517-5; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MULLIGAN RC, 1991, NOBEL SYMP, V80, P143; MURPHY GP, 1973, JNCI-J NATL CANCER I, V50, P1013, DOI 10.1093/jnci/50.4.1013; OHARA J, 1985, NATURE, V315, P333, DOI 10.1038/315333a0; PAUL WE, 1987, ANNU REV IMMUNOL, V5, P429, DOI 10.1146/annurev.iy.05.040187.002241; SALUP RR, 1985, J UROLOGY, V134, P1236, DOI 10.1016/S0022-5347(17)47702-0; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TRENN G, 1988, J IMMUNOL, V140, P1101; WIDMER MB, 1987, NATURE, V326, P795, DOI 10.1038/326795a0; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	29	776	836	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 1	1991	254	5032					713	716		10.1126/science.1948050	http://dx.doi.org/10.1126/science.1948050			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN474	1948050				2022-12-01	WOS:A1991GN47400042
J	HUNZIKER, W; WHITNEY, JA; MELLMAN, I				HUNZIKER, W; WHITNEY, JA; MELLMAN, I			SELECTIVE-INHIBITION OF TRANSCYTOSIS BY BREFELDIN-A IN MDCK CELLS	CELL			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; CANINE KIDNEY-CELLS; ENDOPLASMIC-RETICULUM; INTRACELLULAR-TRANSPORT; SECRETORY PROTEINS; RAT HEPATOCYTES; GOLGI PROTEINS; EXPRESSION; ENDOSOMES; PATHWAYS	Treatment of most cells with brefeldin A (BFA) leads to the retrieval of the Golgi complex to the endoplasmic reticulum, presumably reflecting an inhibition of cytoplasmic coat protein binding to Golgi membranes. Although BFA has been thought to act only on biosynthetic organelles, we now show that this drug also reversibly blocks polymeric immunoglobulin receptor-mediated transcytosis in MDCK cells. The action of BFA on transcytosis was selective, since internalization, recycling, and intracellular degradation were unaffected. The block occurred early on the transcytotic pathway, probably before the translocation of IgA-containing vesicles from the basal to the apical cytoplasm. Although BFA caused MDCK cell endosomes to become more tubular, the organization of the Golgi and binding of the 110 kd Golgi coat protein beta-COP was surprisingly unaffected. These results suggest that in MDCK cells, endocytic organelles contain a BFA-sensitive coat that regulates their organization and function even though the Golgi coat is BFA resistant.			HUNZIKER, W (corresponding author), YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA.		Mellman, Ira/ABG-5896-2020; Hunziker, Walter/GSM-8190-2022; Hunziker, Walter/B-3140-2010	Hunziker, Walter/0000-0002-5265-4933				ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BRANDLI AW, 1990, J CELL BIOL, V111, P2909, DOI 10.1083/jcb.111.6.2909; BREITFELD PP, 1990, J CELL BIOL, V111, P2365, DOI 10.1083/jcb.111.6.2365; BREITFELD PP, 1989, J CELL BIOL, V109, P475, DOI 10.1083/jcb.109.2.475; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; COOPER MS, 1990, CELL, V61, P135, DOI 10.1016/0092-8674(90)90221-Y; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GEUZE HJ, 1984, CELL, V37, P195, DOI 10.1016/0092-8674(84)90315-5; HOPPE CA, 1985, J CELL BIOL, V101, P2113, DOI 10.1083/jcb.101.6.2113; HUNZIKER W, 1989, J CELL BIOL, V109, P3291, DOI 10.1083/jcb.109.6.3291; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; HUNZIKER W, 1990, EMBO J, V9, P3515, DOI 10.1002/j.1460-2075.1990.tb07560.x; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MOSTOV KE, 1985, CELL, V43, P389, DOI 10.1016/0092-8674(85)90166-7; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1991, CELL, V64, P1183; PARTON RG, 1989, J CELL BIOL, V109, P3259, DOI 10.1083/jcb.109.6.3259; SANDVIG K, 1991, IN PRESS J CELL BIOL; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SZTUL E, 1991, CELL, V64, P81, DOI 10.1016/0092-8674(91)90210-P	35	255	257	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 1	1991	67	3					617	627		10.1016/0092-8674(91)90535-7	http://dx.doi.org/10.1016/0092-8674(91)90535-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GN664	1934063				2022-12-01	WOS:A1991GN66400017
J	KOSLOWSKY, DJ; BHAT, GJ; READ, LK; STUART, K				KOSLOWSKY, DJ; BHAT, GJ; READ, LK; STUART, K			CYCLES OF PROGRESSIVE REALIGNMENT OF GRNA WITH MESSENGER-RNA IN RNA EDITING	CELL			English	Article							TRYPANOSOMA-BRUCEI; GUIDE RNAS; KINETOPLASTID MITOCHONDRIA; CYTOCHROME-OXIDASE; SUBUNIT-III; ORGANIZATION; MINICIRCLES; TRANSCRIPT; DOMAINS; REGION	We characterized numerous partially edited NADH dehydrogenase 7 and ATPase 6 cDNAs. Most of these have a stretch of incompletely edited sequence at the junction of mature and unedited sequences. The characteristics of the junctions suggest editing of sites multiple times and that editing within each junction does not proceed precisely 3' to 5'. Analyses of gRNAs and corresponding junction sequences predict a series of progressively more stable, but incompletely base-paired, interactions in the junction region. The predicted interactions suggest that the gRNA is progressively realigned with the mRNA being edited. We suggest that gRNA interactions with the mRNA result in regions of lower thermodynamic stability that are selected for editing, thus driving toward the most stable structure, the complete gRNA/mRNA duplex.			KOSLOWSKY, DJ (corresponding author), SEATTLE BIOMED RES INST,SEATTLE,WA 98109, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014102, R37AI014102] Funding Source: NIH RePORTER; NIAID NIH HHS [AI14102] Funding Source: Medline; NIGMS NIH HHS [GM42188] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM JM, 1988, CELL, V55, P267, DOI 10.1016/0092-8674(88)90049-9; BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; BENNE R, 1990, TRENDS GENET, V6, P177, DOI 10.1016/0168-9525(90)90173-4; BHAT GJ, 1990, CELL, V61, P885, DOI 10.1016/0092-8674(90)90199-O; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BLUM B, 1990, CELL, V62, P391, DOI 10.1016/0092-8674(90)90375-O; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; DECKER CJ, 1990, CELL, V61, P1001, DOI 10.1016/0092-8674(90)90065-M; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEAGIN JE, 1985, NUCLEIC ACIDS RES, V13, P4577, DOI 10.1093/nar/13.12.4577; FEAGIN JE, 1988, CELL, V53, P413, DOI 10.1016/0092-8674(88)90161-4; FEAGIN JE, 1989, MOL BIOL RNA, P187; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; JASMER DP, 1986, MOL BIOCHEM PARASIT, V18, P257, DOI 10.1016/0166-6851(86)90084-8; JASMER DP, 1986, MOL BIOCHEM PARASIT, V18, P321, DOI 10.1016/0166-6851(86)90089-7; KOSLOWSKY DJ, 1990, CELL, V62, P901, DOI 10.1016/0092-8674(90)90265-G; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; POLLARD VW, 1990, CELL, V63, P783, DOI 10.1016/0092-8674(90)90144-4; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; SIMPSON L, 1990, SCIENCE, V250, P512, DOI 10.1126/science.1700474; STUART K, 1984, J PARASITOL, V70, P747, DOI 10.2307/3281757; STUART KS, 1990, TRENDS BIOL SCI, V16, P68; STURM NR, 1990, CELL, V61, P879, DOI 10.1016/0092-8674(90)90198-N; STURM NR, 1990, CELL, V61, P871, DOI 10.1016/0092-8674(90)90197-M; VANDERSPEK H, 1991, EMBO J, V10, P1217, DOI 10.1002/j.1460-2075.1991.tb08063.x	27	80	83	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1991	67	3					537	546		10.1016/0092-8674(91)90528-7	http://dx.doi.org/10.1016/0092-8674(91)90528-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GN664	1718605				2022-12-01	WOS:A1991GN66400010
J	KUHN, R; RAJEWSKY, K; MULLER, W				KUHN, R; RAJEWSKY, K; MULLER, W			GENERATION AND ANALYSIS OF INTERLEUKIN-4 DEFICIENT MICE	SCIENCE			English	Article							STIMULATORY FACTOR-I; MURINE B-CELLS; MONOCLONAL-ANTIBODIES; T-CELL; MAST-CELLS; STEM-CELLS; SWITCH; IGE; RECOMBINATION; INDUCTION	Interleukin-4 (IL-4) promotes the growth and differentiation of many hematopoietic cells in vitro; in particular, it directs the immunoglobulin (Ig) class switch to IgG1 and IgE. Mice homozygous for a mutation that inactivates the IL-4 gene were generated to test the requirement for IL-4 in vivo. In the mutant mice T and B cell development was normal, but the serum levels of IgGl and IgE were strongly reduced. The IgG1 dominance in a T cell-dependent immune response was lost, and IgE was not detectable upon nematode infection. Thus, some but not all of the in vitro properties of IL-4 are critical for the physiology of the immune system in vivo.			KUHN, R (corresponding author), UNIV COLOGNE, INST GENET, W-5000 COLOGNE 41, GERMANY.		Muller, Werner/B-9044-2008; Kühn, Ralf/U-1278-2017	Muller, Werner/0000-0002-1297-9725; Kühn, Ralf/0000-0003-1694-9803				BANIYASH M, 1984, EUR J IMMUNOL, V14, P799, DOI 10.1002/eji.1830140907; BHATTACHARYA A, 1981, J IMMUNOL, V127, P2488; BROWN MA, 1987, CELL, V50, P809, DOI 10.1016/0092-8674(87)90339-4; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CARDING SR, 1991, IMMUNOL TODAY, V12, P239, DOI 10.1016/0167-5699(91)90037-T; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; ESSER C, 1989, EMBO J, V8, P483, DOI 10.1002/j.1460-2075.1989.tb03401.x; FINKELMAN FD, 1986, P NATL ACAD SCI USA, V83, P9675, DOI 10.1073/pnas.83.24.9675; FINKELMAN FD, 1991, INT IMMUNOL, V3, P599, DOI 10.1093/intimm/3.6.599; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; GRUTZMANN R, 1981, THESIS U COLOGNE; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; ILLGES H, 1990, MOL BIOL B CELL DEV, V3, P109; ISAKSON PC, 1982, J EXP MED, V155, P734, DOI 10.1084/jem.155.3.734; KENDALL C, 1984, J IMMUNOL METHODS, V56, P319; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KUHN R, UNPUB; LEBRUN P, 1987, J IMMUNOL, V139, P1459; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MOSMANN T, 1991, IMMUNOL TODAY, V12, P257, DOI 10.1016/0167-5699(91)90121-9; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.iy.07.040189.001045; MULLER W, 1989, EUR J IMMUNOL, V19, P923, DOI 10.1002/eji.1830190520; OHARA J, 1985, NATURE, V315, P333, DOI 10.1038/315333a0; OI VT, 1979, MOL IMMUNOL, V16, P1005, DOI 10.1016/0161-5890(79)90034-8; OTSUKA T, 1987, NUCLEIC ACIDS RES, V15, P333, DOI 10.1093/nar/15.1.333; PAUL WE, 1987, ANNU REV IMMUNOL, V5, P429, DOI 10.1146/annurev.iy.05.040187.002241; RADBRUCH A, 1986, P NATL ACAD SCI USA, V83, P3954, DOI 10.1073/pnas.83.11.3954; RENNICK D, 1987, P NATL ACAD SCI USA, V84, P6889, DOI 10.1073/pnas.84.19.6889; RETH M, 1981, THESIS U COLOGNE; ROTHMAN P, 1988, J EXP MED, V168, P2385, DOI 10.1084/jem.168.6.2385; SAVELKOUL HFJ, 1991, J IMMUNOL, V146, P1801; SEEMANN G, 1981, THESIS U COLOGNE; SIDERAS P, 1985, EUR J IMMUNOL, V15, P593, DOI 10.1002/eji.1830150612; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; YENOFSKY RL, 1990, P NATL ACAD SCI USA, V87, P3435, DOI 10.1073/pnas.87.9.3435; ZLOTNIK A, 1987, J IMMUNOL, V138, P4275	39	1146	1184	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 1	1991	254	5032					707	710		10.1126/science.1948049	http://dx.doi.org/10.1126/science.1948049			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN474	1948049				2022-12-01	WOS:A1991GN47400040
J	LIPPINCOTTSCHWARTZ, J; YUAN, L; TIPPER, C; AMHERDT, M; ORCI, L; KLAUSNER, RD				LIPPINCOTTSCHWARTZ, J; YUAN, L; TIPPER, C; AMHERDT, M; ORCI, L; KLAUSNER, RD			BREFELDIN-AS EFFECTS ON ENDOSOMES, LYSOSOMES, AND THE TGN SUGGEST A GENERAL MECHANISM FOR REGULATING ORGANELLE STRUCTURE AND MEMBRANE TRAFFIC	CELL			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; TRANS-GOLGI NETWORK; ENDOPLASMIC-RETICULUM; IMMUNOELECTRON MICROSCOPY; INTRACELLULAR-TRANSPORT; CARCINOMA A431-CELLS; SECRETORY PROTEINS; PLASMA-MEMBRANE; RAT PANCREAS; TRANSFERRIN	Addition of brefeldin A (BFA) to most cells results in both the formation of extensive, uncoated membrane tubules through which Golgi components redistribute into the ER and the failure to transport molecules out of this mixed ER/Golgi system. In this study we provide evidence that suggests BFA's effects are not limited to the Golgi apparatus but are reiterated throughout the central vacuolar system. Addition of BFA to cells resulted in the tubulation of the endosomal system, the trans-Golgi network (TGN), and lysosomes. Tubule formation of these organelles was specific to BFA, shared near identical pharmacologic characteristics as Golgi tubules and resulted in targeted membrane fusion. Analogous to the mixing of the Golgi with the ER during BFA treatment, the TGN mixed with the recycling endosomal system. This mixed system remained functional with normal cycling between plasma membrane and endosomes, but traffic between endosomes and lysosomes was impaired.	UNIV GENEVA, INST HISTOL & EMBRYOL, DEPT MORPHOL, CH-1211 GENEVA 4, SWITZERLAND	University of Geneva	LIPPINCOTTSCHWARTZ, J (corresponding author), NICHHD, CELL BIOL & METAB BRANCH, BETHESDA, MD 20892 USA.							ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; BURKE B, 1984, CELL, V36, P847, DOI 10.1016/0092-8674(84)90034-5; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; COOPER MS, 1990, CELL, V61, P135, DOI 10.1016/0092-8674(90)90221-Y; DABORA SL, 1988, CELL, V54, P27, DOI 10.1016/0092-8674(88)90176-6; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; DIMENT S, 1988, J BIOL CHEM, V263, P6901; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GRAHAM RC, 1966, J HISTOCHEM CYTOCHEM, V14, P291, DOI 10.1177/14.4.291; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HEUSER J, 1989, J CELL BIOL, V108, P855, DOI 10.1083/jcb.108.3.855; HEUSER J, 1989, J CELL BIOL, V109, P1457, DOI 10.1083/jcb.109.4.1457; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; KLAUSNER RD, 1989, CELL, V57, P703, DOI 10.1016/0092-8674(89)90783-6; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; LEWIS V, 1985, J CELL BIOL, V100, P1839, DOI 10.1083/jcb.100.6.1839; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; LIPPINCOTTSCHWARTZ J, 1991, J CELL BIOL, V112, P567, DOI 10.1083/jcb.112.4.567; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MOREMEN KW, 1985, J BIOL CHEM, V260, P6654; ORCI L, 1973, J ULTRA MOL STRUCT R, V43, P270, DOI 10.1016/S0022-5320(73)80039-5; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; ORCI L, 1991, CELL, V64, P1183; SARASTE J, 1987, J CELL BIOL, V105, P2021, DOI 10.1083/jcb.105.5.2021; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SWANSON J, 1987, P NATL ACAD SCI USA, V84, P1921, DOI 10.1073/pnas.84.7.1921; SWANSON J, 1987, J CELL BIOL, V104, P1217, DOI 10.1083/jcb.104.5.1217; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WEIBEL ER, 1979, STEREOLOGICAL METHOD, V1, P101; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; YUAN L, 1987, J CELL BIOL, V105, P215, DOI 10.1083/jcb.105.1.215	48	746	751	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 1	1991	67	3					601	616		10.1016/0092-8674(91)90534-6	http://dx.doi.org/10.1016/0092-8674(91)90534-6			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GN664	1682055				2022-12-01	WOS:A1991GN66400016
J	MANIOTIS, A; SCHLIWA, M				MANIOTIS, A; SCHLIWA, M			MICROSURGICAL REMOVAL OF CENTROSOMES BLOCKS CELL REPRODUCTION AND CENTRIOLE GENERATION IN BSC-1 CELLS	CELL			English	Article							SEA-URCHIN EGGS; MICROTUBULE ORGANIZING CENTERS; HAMSTER OVARY CELLS; SPINDLE POLES; PROTEIN-SYNTHESIS; GOLGI-APPARATUS; MOUSE OOCYTES; BASAL BODIES; M-PHASE; CYCLE	We have removed the centrosome from cultured BSC-1 cells by microsurgery, leaving enough cytoplasm with the nucleated cell fragment (karyoplast) to ensure survival and growth. In each experiment, we followed the fate of the karyoplast as well as the anucleate cell fragment (cytoplast) containing the original pair of centrioles. Experimental karyoplasts reestablish a juxtanuclear microtubule-organizing center, an astral array of microtubules, and a compact Golgi apparatus. They enter and presumably complete S phase, and they grow beyond the size of an average BSC-1 cell. However, they do not regenerate centrioles in time periods equivalent to more than 10 cell cycles and do not undergo cell division. Control-operated cells with centrosomes left in the karyoplast progress through the cell cycle, duplicate the centrosome, and form clonal cell colonies. We conclude that the removal of centrioles uncouples cell growth from cell reproduction and impedes centriole biogenesis and centrosome duplication.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley								BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; Bornens M., 1984, MEMBRANE STRUCTURE F, P99; BOVERI T, 1988, Z NATURWISS, V22, P865; BRE MH, 1987, J CELL BIOL, V105, P1283, DOI 10.1083/jcb.105.3.1283; BRENNER S, 1977, J CELL BIOL, V72, P368, DOI 10.1083/jcb.72.2.368; CALARCOGILLAM PD, 1983, CELL, V35, P621, DOI 10.1016/0092-8674(83)90094-6; COOPER MS, 1990, CELL, V61, P135, DOI 10.1016/0092-8674(90)90221-Y; DEBEC A, 1982, BIOL CELL, V44, P133; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DESSEV G, 1991, J CELL BIOL, V112, P523, DOI 10.1083/jcb.112.4.523; DIETZ R, 1966, CHROMOSOMES TODAY, V1, P161; DIPPELL RV, 1968, P NATL ACAD SCI USA, V61, P461, DOI 10.1073/pnas.61.2.461; DIRKSEN ER, 1961, J BIOPHYS BIOCHEM CY, V11, P244, DOI 10.1083/jcb.11.1.244; FULTON C, 1971, J CELL BIOL, V51, P826, DOI 10.1083/jcb.51.3.826; FULTON C, 1971, ORIGIN CONTINUITY CE, V1, P170; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; HALL JL, 1989, CELL, V59, P121, DOI 10.1016/0092-8674(89)90875-1; HEPLER PK, 1974, ANNU REV PLANT PHYS, V25, P309, DOI 10.1146/annurev.pp.25.060174.001521; JOHNSON DE, 1991, J CELL BIOL, V113, P339, DOI 10.1083/jcb.113.2.339; JOHNSON KA, 1990, CELL, V62, P615, DOI 10.1016/0092-8674(90)90105-N; KALLENBACH RJ, 1982, CELL BIOL INT REP, V6, P1025, DOI 10.1016/0309-1651(82)90018-2; KARSENTI E, 1984, J CELL BIOL, V98, P1763, DOI 10.1083/jcb.98.5.1763; KOCHANSKI RS, 1990, J CELL BIOL, V110, P1599, DOI 10.1083/jcb.110.5.1599; KREIS TE, 1990, CELL MOTIL CYTOSKEL, V15, P67, DOI 10.1002/cm.970150202; KURIYAMA R, 1981, J CELL BIOL, V91, P814, DOI 10.1083/jcb.91.3.814; KURIYAMA R, 1989, CELL MOTIL CYTOSKEL, V12, P90, DOI 10.1002/cm.970120204; KURIYAMA R, 1984, J CELL SCI, V66, P277; LAMB NJC, 1990, CELL, V60, P151, DOI 10.1016/0092-8674(90)90725-T; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; LUSCHER B, 1991, EMBO J, V10, P865, DOI 10.1002/j.1460-2075.1991.tb08019.x; LWOFF A, 1950, KINETOSOMES DEV REPR; MARO B, 1985, J CELL BIOL, V101, P1665, DOI 10.1083/jcb.101.5.1665; MAZIA D, 1960, J BIOPHYS BIOCHEM CY, V7, P1, DOI 10.1083/jcb.7.1.1; MAZIA D, 1987, INT REV CYTOL, V100, P49; MAZIA D, 1984, EXP CELL RES, V153, P1, DOI 10.1016/0014-4827(84)90442-7; MAZIA D, 1978, UCLA S MOL CELL BIOL, V12, P1; MCNIVEN MA, 1988, J CELL BIOL, V106, P1593, DOI 10.1083/jcb.106.5.1593; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PHILLIPS SG, 1976, J CELL BIOL, V70, P9, DOI 10.1083/jcb.70.1.9; PICARD A, 1987, NATURE, V327, P170, DOI 10.1038/327170a0; Pickett-Heaps J.D., 1969, CYTOBIOS, V3, P257; PRESCOTT DM, 1956, EXP CELL RES, V11, P86, DOI 10.1016/0014-4827(56)90192-6; RAFF EC, 1979, INT REV CYTOL, V39, P2; RAFF JW, 1988, J CELL BIOL, V107, P2009, DOI 10.1083/jcb.107.6.2009; SCHATTEN H, 1986, P NATL ACAD SCI USA, V83, P105, DOI 10.1073/pnas.83.1.105; SCHLIWA M, 1981, J CELL BIOL, V90, P222, DOI 10.1083/jcb.90.1.222; SLUDER G, 1990, J CELL BIOL, V110, P2025, DOI 10.1083/jcb.110.6.2025; SLUDER G, 1989, CELL MOTIL CYTOSKEL, V13, P264, DOI 10.1002/cm.970130405; SLUDER G, 1985, J CELL SCI, V76, P35; SLUDER G, 1985, J CELL BIOL, V100, P887, DOI 10.1083/jcb.100.3.887; SLUDER G, 1990, ADV CELL BIOL, V3, P221; SONNEBORN TM, 1970, S INT SOC CELL BIOL, V9; van Beneden E., 1876, B ACAD R BELG, V41, P1160; VANDRE DD, 1984, P NATL ACAD SCI-BIOL, V81, P4439, DOI 10.1073/pnas.81.14.4439; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177; VOROBJEV IA, 1987, INT REV CYTOL, V106, P227, DOI 10.1016/S0074-7696(08)61714-3; WEISENBERG RC, 1984, J CELL BIOL, V99, P1527, DOI 10.1083/jcb.99.4.1527; WHEATLEY DN, 1982, CENTRIOLE CENTRAL EN; Wilson E. B., 1925, CELL DEV HEREDITY; YATSU N, 1905, J EXP ZOOL, V2, P289; ZORN GA, 1979, CELL, V18, P659, DOI 10.1016/0092-8674(79)90121-1	63	181	186	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1991	67	3					495	504		10.1016/0092-8674(91)90524-3	http://dx.doi.org/10.1016/0092-8674(91)90524-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GN664	1934057				2022-12-01	WOS:A1991GN66400006
J	MARU, Y; WITTE, ON				MARU, Y; WITTE, ON			THE BCR GENE ENCODES A NOVEL SERINE THREONINE KINASE-ACTIVITY WITHIN A SINGLE EXON	CELL			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; MUSCLE PYRUVATE-KINASE; ACUTE LYMPHOCYTIC-LEUKEMIA; C-ABL PROTEIN; PHILADELPHIA-CHROMOSOME; FUSED TRANSCRIPT; TYROSINE; PRODUCT; REGION	Sequences encoded by the first exon of BCR that bind to the ABL SH2 domain are essential for the activation of the ABL tyrosine kinase and transforming potential of the chimeric BCR-ABL oncogene. The normal cellular BCR gene encodes a 160,000 dalton phosphoprotein associated with a serine/threonine kinase activity, but it shows only weak dispersed homologies to protein kinases. p160c-BCR Was purified to apparent homogeneity as an oligomer of > 600,000 daltons that contains autophosphorylation activity and transphosphorylation activity for several protein substrates. A region containing paired cysteine residues within the 426 amino acids encoded by the first exon of BCR is essential for its novel phosphotransferase activity, which overlaps with the strong SH2-binding regions. The recent demonstration of a GTPase-activating function within the C-terminal portion of BCR suggests that the protein kinase and SH2-binding domains may work in concert with other regions of the molecule in intracellular signaling processes.	UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	MARU, Y (corresponding author), UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90024, USA.				NATIONAL CANCER INSTITUTE [R35CA053867, R01CA027507] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA27507, R35 CA53867] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMSON RB, 1989, ONCOGENE, V4, P243; ANNAMALAI AE, 1981, J BIOL CHEM, V256, P276; BASU M, 1984, NATURE, V311, P477, DOI 10.1038/311477a0; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; COLLINS S, 1987, MOL CELL BIOL, V7, P2870, DOI 10.1128/MCB.7.8.2870; CROCE CM, 1987, P NATL ACAD SCI USA, V84, P7174, DOI 10.1073/pnas.84.20.7174; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; ESCH FS, 1978, J BIOL CHEM, V253, P6100; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P2674, DOI 10.1073/pnas.81.9.2674; GRIBSKOV M, 1990, METHOD ENZYMOL, V183, P146; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HARTWELL LH, 1973, GENETICS, V74, P267; HEISTERKAMP N, 1989, NUCLEIC ACIDS RES, V17, P8821, DOI 10.1093/nar/17.21.8821; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KONOPKA JB, 1984, J VIROL, V51, P223, DOI 10.1128/JVI.51.1.223-232.1984; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; LI WJ, 1989, ONCOGENE, V4, P127; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; MOLLER W, 1985, FEBS LETT, V186, P1, DOI 10.1016/0014-5793(85)81326-0; MUIRHEAD H, 1986, EMBO J, V5, P475, DOI 10.1002/j.1460-2075.1986.tb04236.x; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; OHYA Y, 1986, J BACTERIOL, V165, P28, DOI 10.1128/jb.165.1.28-33.1986; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PENDERGAST AM, 1989, ONCOGENE, V4, P759; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PENDERGAST AM, 1991, IN PRESS P NATL ACAD; QUILLIAM LA, 1990, MOL CELL BIOL, V11, P1804; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; REISLER E, 1974, BIOCHEMISTRY-US, V13, P3837, DOI 10.1021/bi00716a001; RON D, 1991, NEW BIOL, V3, P372; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SHAH NP, 1991, MOL CELL BIOL, V11, P1854, DOI 10.1128/MCB.11.4.1854; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; Summers MD, 1987, TEXAS AGR EXPT STATI; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TIMMONS MS, 1989, ONCOGENE, V4, P559; TOGASHI CT, 1982, J BIOL CHEM, V257, P112; TOMICH JM, 1981, BIOCHEMISTRY-US, V20, P6711, DOI 10.1021/bi00526a029; WALKER LC, 1987, NATURE, V329, P851, DOI 10.1038/329851a0; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2	59	227	237	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1991	67	3					459	468		10.1016/0092-8674(91)90521-Y	http://dx.doi.org/10.1016/0092-8674(91)90521-Y			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GN664	1657398				2022-12-01	WOS:A1991GN66400003
J	MEISTERERNST, M; ROEDER, RG				MEISTERERNST, M; ROEDER, RG			FAMILY OF PROTEINS THAT INTERACT WITH TFIID AND REGULATE PROMOTER ACTIVITY	CELL			English	Article							RNA POLYMERASE-II; GENERAL TRANSCRIPTION FACTOR; IMMEDIATE EARLY PROTEIN; MAJOR LATE PROMOTER; PREINITIATION COMPLEX; FUNCTIONAL DOMAINS; BINDING-PROTEIN; TATA FACTOR; INITIATION; ACTIVATION	A family of proteins was shown to bind cooperatively with TFIID to core promoters, as previously demonstrated for the general initiation factor TFIIA. These factors form distinct complexes with TFIID, fall to bind DNA in the absence of TFIID, differ chromatographically from TFIIA, and compete with TFIIA for binding to TFIID. Our results suggest the formation of heterogeneous preinitiation complexes at the step involving TFIIA interactions. This establishes a molecular switch that regulates basal level transcription in vitro and has consequences for transcriptional activation by gene-specific activators.			MEISTERERNST, M (corresponding author), ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021, USA.				NATIONAL CANCER INSTITUTE [R35CA042567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027397] Funding Source: NIH RePORTER; NCI NIH HHS [CA42567] Funding Source: Medline; NIAID NIH HHS [AI27397] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABMAYR SM, 1988, GENE DEV, V2, P542, DOI 10.1101/gad.2.5.542; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; HAHN S, 1989, EMBO J, V8, P3379, DOI 10.1002/j.1460-2075.1989.tb08501.x; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1990, GENE DEV, V4, P1141, DOI 10.1101/gad.4.7.1141; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; INOSTROZA J, 1991, J BIOL CHEM, V266, P9304; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MALIK S, 1991, IN PRESS P NATL ACAD; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MEISTERERNST M, 1990, P NATL ACAD SCI USA, V87, P9153, DOI 10.1073/pnas.87.23.9153; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; POON D, 1991, IN PRESS MOL CELL BI; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; REINBERG D, 1987, J BIOL CHEM, V262, P3322; SAMUELS M, 1986, J BIOL CHEM, V261, P2003; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x	39	281	284	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1991	67	3					557	567		10.1016/0092-8674(91)90530-C	http://dx.doi.org/10.1016/0092-8674(91)90530-C			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GN664	1934060				2022-12-01	WOS:A1991GN66400012
J	MOREL, P; GOETZ, FC; MOUDRYMUNNS, K; FREIER, E; SUTHERLAND, DER				MOREL, P; GOETZ, FC; MOUDRYMUNNS, K; FREIER, E; SUTHERLAND, DER			LONG-TERM GLUCOSE CONTROL IN PATIENTS WITH PANCREATIC TRANSPLANTS	ANNALS OF INTERNAL MEDICINE			English	Article							DEPENDENT DIABETES-MELLITUS; MYOCARDIAL-INFARCTION; RETINOPATHY; RECIPIENTS; PREVALENCE; DIAGNOSIS; NEUROPATHY; ALLOGRAFTS; GLYCEMIA; RISK	Objective: To evaluate the long-term effect on blood glucose levels of successful transplantation of part or all of an intact human pancreas in patients with insulin-dependent diabetes mellitus (IDDM). Design: Cohort study. Setting: Referral medical center. Patients: Thirty-seven patients with adequate data, representative of a group of 62 patients with functioning grafts (that is, insulin-independent) at 2 years after transplantation. The 62 patients came from a total of 178 patients in the University of Minnesota series as of July 1987, for a 2-year success rate of 35% (95% CI, 27.8% to 41.8%). These patients were compared to two diabetic control groups (18 patients with IDDM under standard insulin treatment in a university diabetes clinic and 11 patients with IDDM whose pancreas grafts had failed) and to two nondiabetic groups (14 nondiabetic patients who received immunosuppressive drugs after kidney transplantation and 196 healthy control subjects). Measurements: Glycosylated hemoglobin was measured by the high-pressure liquid chromatography method, as total A1 (Hb A1) and the A1C subfraction (Hb A1C); results were expressed as a percentage of total hemoglobin. Main Results: Before pancreas transplantation, the 37 patients in the study group had a mean Hb A1 of 10.8%, consistent with moderate to marked hyperglycemia and not statistically different from the levels in the diabetic control groups. All 37 patients had values above the therapeutic target range of 5.4% to 7.4%. However, at 1 and 2 years after transplantation, the mean Hb A1 value had fallen sharply to 6.7% and 6.5%, respectively, well within target range (CI of the difference, 3.4% to 4.8%; P < 0.001). These levels did not differ from the mean Hb A1 in the nondiabetic kidney transplant recipients but were slightly above the 6.2% value for the 196 healthy controls (CI of the difference at 1 year, 0.2% to 0.8%). Serial values were available on 6 subjects for 5 years; these values were all well within target range. As expected, Hb A1C values were parallel to those of Hb A1. Conclusions: Pancreas transplantation, in our successful cases, lowered glycosylated hemoglobin to normal or near-normal levels that were sustained for as long as 5 years. These results compare favorably with those in our patients on standard treatment, and also with those in similar patients on intensive control reported by others. Further effort to improve transplant methods appears to be warranted.	UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities					NCRR NIH HHS [RR/400] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BILOUS RW, 1989, NEW ENGL J MED, V321, P80, DOI 10.1056/NEJM198907133210204; BILOUS RW, 1987, DIABETES S1, V36, pA43; BOUDREAUX JP, 1987, TRANSPLANTATION, V44, P376, DOI 10.1097/00007890-198709000-00010; BOULTON AJM, 1984, DIABETOLOGIA, V26, P15; CORRY RJ, 1986, SURG GYNECOL OBSTET, V162, P547; COSIMI AB, 1988, ARCH SURG-CHICAGO, V123, P621; DCCT Res Grp, 1990, DIABETES CARE, V13, P427; HANSSEN KF, 1986, DIABETOLOGIA, V29, P677, DOI 10.1007/BF00870275; KENNEDY WR, 1990, NEW ENGL J MED, V322, P1031, DOI 10.1056/NEJM199004123221503; KLEIN BEK, 1987, DIABETES CARE, V10, P273, DOI 10.2337/diacare.10.3.273; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; LIPSETT L, 1990, DIABETES S1, V39, pA126; LITTLE RR, 1986, CLIN CHEM, V32, P1146; MOREL P, 1990, TRANSPLANTATION, V49, P294, DOI 10.1097/00007890-199002000-00014; NAVARRO X, 1990, DIABETES, V39, P802, DOI 10.2337/diabetes.39.7.802; OSWALD GA, 1984, LANCET, V1, P1264; PETERSON CM, 1986, DIABETES ANN, P137; POZZA G, 1983, DIABETOLOGIA, V24, P244; RAMSAY RC, 1988, NEW ENGL J MED, V318, P208, DOI 10.1056/NEJM198801283180403; SELAM JL, 1989, INT HDB PANCREAS TRA, P479; SINGER DE, 1989, ANN INTERN MED, V110, P125, DOI 10.7326/0003-4819-110-2-125; SMITH JL, 1989, TRANSPLANTATION, V47, P304, DOI 10.1097/00007890-198902000-00023; SUTHERLAND DER, 1989, ANN SURG, V210, P274, DOI 10.1097/00000658-198909000-00003; SUTHERLAND DER, 1981, ANN INTERN MED, V95, P537, DOI 10.7326/0003-4819-95-5-537; SUTHERLAND DER, 1988, SURGERY, V104, P453; TYDEN G, 1989, DIABETES, V38, P94, DOI 10.2337/diab.38.1.S94; VANDERVLIET JA, 1988, TRANSPLANTATION, V45, P368, DOI 10.1097/00007890-198802000-00024; WHITE LJ, 1984, ANN INTERN MED, V101, P710, DOI 10.7326/0003-4819-101-5-710; WISEMAN M, 1984, DIABETOLOGIA, V26, P401; YUDKIN JS, 1988, DIABETOLOGIA, V31, P201, DOI 10.1007/BF00290585	31	67	68	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1991	115	9					694	699		10.7326/0003-4819-115-9-694	http://dx.doi.org/10.7326/0003-4819-115-9-694			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL697	1929037				2022-12-01	WOS:A1991GL69700005
J	SEEMAN, H; TRAUBE, M				SEEMAN, H; TRAUBE, M			HICCUPS AND ACHALASIA	ANNALS OF INTERNAL MEDICINE			English	Note							GASTROESOPHAGEAL REFLUX		YALE UNIV, SCH MED, GASTROENTEROL UNIT, POB 3333, NEW HAVEN, CT 06510 USA	Yale University				traube, morris/0000-0002-7028-6695				FELDMAN M, 1988, AM J MED SCI, V295, P60, DOI 10.1097/00000441-198801000-00013; FISHER MJ, 1989, DIGEST DIS SCI, V34, P1277, DOI 10.1007/BF01537278; GLUCK M, 1986, ANN INTERN MED, V105, P219, DOI 10.7326/0003-4819-105-2-219; GOLDENBERG SP, 1991, GASTROENTEROLOGY, V101, P743, DOI 10.1016/0016-5085(91)90534-R; KAUFMANN HJ, 1982, GASTROENTEROLOGY, V82, P1443; LEWIS JH, 1985, J CLIN GASTROENTEROL, V7, P539, DOI 10.1097/00004836-198512000-00021; MARSHALL JB, 1990, AM J GASTROENTEROL, V85, P1172; SHAY SS, 1984, GASTROENTEROLOGY, V87, P204	8	14	14	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1991	115	9					711	712		10.7326/0003-4819-115-9-711	http://dx.doi.org/10.7326/0003-4819-115-9-711			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL697	1929039				2022-12-01	WOS:A1991GL69700008
J	SHARP, PA				SHARP, PA			5 EASY PIECES	SCIENCE			English	Editorial Material							RIBOSOMAL PROTEIN-S12		MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	SHARP, PA (corresponding author), MIT,CTR CANC RES,CAMBRIDGE,MA 02139, USA.							CHAPDELAINE Y, 1991, CELL, V65, P465, DOI 10.1016/0092-8674(91)90464-A; FUKUZAWA H, 1986, FEBS LETT, V198, P11, DOI 10.1016/0014-5793(86)81174-7; GOLDSCHMIDTCLERMONT M, 1991, CELL, V65, P135, DOI 10.1016/0092-8674(91)90415-U; GUTHRIE C, 1991, SCIENCE, V253, P147; JARRELL KA, 1988, MOL CELL BIOL, V8, P2361, DOI 10.1128/MCB.8.6.2361; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; WISSINGER B, 1991, CELL, V65, P473, DOI 10.1016/0092-8674(91)90465-B; ZAITA N, 1987, FEBS LETT, V210, P153, DOI 10.1016/0014-5793(87)81326-1	8	177	182	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1991	254	5032					663	663		10.1126/science.1948046	http://dx.doi.org/10.1126/science.1948046			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN474	1948046				2022-12-01	WOS:A1991GN47400028
J	SMEYNE, RJ; OBERDICK, J; SCHILLING, K; BERREBI, AS; MUGNAINI, E; MORGAN, JI				SMEYNE, RJ; OBERDICK, J; SCHILLING, K; BERREBI, AS; MUGNAINI, E; MORGAN, JI			DYNAMIC ORGANIZATION OF DEVELOPING PURKINJE-CELLS REVEALED BY TRANSGENE EXPRESSION	SCIENCE			English	Article							CENTRAL-NERVOUS-SYSTEM; RAT CEREBELLAR CORTEX; MUTANT MICE; MOUSE; NEURONS; MUTATIONS; MABQ113; BANDS; GENE	The cerebellum has many properties that make it a useful model for investigating neural development. Purkinje cells, the major output neurons of the cerebellar cortex, have drawn special attention because of the availability of biochemical markers and mutants that affect their development. The spatial expression of L7, a protein specific for Purkinje cells, and L7-beta-Gal, a gene expressed in transgenic mice that was constructed from the L7 promoter and the marker beta-galactosidase, delineated bands of Purkinje cells that increased in number during early postnatal development. Expression of the transgene in adult reeler mutant mice, which show inverted cortical lamination, and in primary culture showed that the initial expression of L7 is intrinsic to Purkinje cells and does not depend on extracellular signals. This may reflect an underlying developmental map in cerebellum.	ROCHE INST MOLEC BIOL, ROCHE RES CTR, DEPT NEUROSCI, NUTLEY, NJ 07110 USA; UNIV CONNECTICUT, NEUROMORPHOL LAB, GRAD DEGREE PROGRAM BIOBEHAV SCI, STORRS, CT 06269 USA; UNIV MED & DENT NEW JERSEY, NEWARK, NJ 07103 USA	Roche Holding; University of Connecticut; Rutgers State University New Brunswick; Rutgers State University Medical Center			Morgan, James/GRO-2905-2022; Morgan, James/N-8104-2018	Morgan, James/0000-0002-8920-1065; Smeyne, Richard/0000-0002-8459-5472	NINDS NIH HHS [NS-09904] Funding Source: Medline; NINR NIH HHS [NRSA 08-08601] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		AWGULEWITSCH A, 1986, NATURE, V320, P328, DOI 10.1038/320328a0; BERREBI AS, UNPUB; BERREBI AS, 1991, J COMP NEUROL, V309, P2; BROCHU G, 1990, J COMP NEUROL, V291, P538, DOI 10.1002/cne.902910405; CAVINESS VS, 1978, ANNU REV NEUROSCI, V1, P297, DOI 10.1146/annurev.ne.01.030178.001501; CHRISTAKOS S, 1989, ENDOCR REV, V10, P3, DOI 10.1210/edrv-10-1-3; FISCHER G, 1982, NEUROSCI LETT, V28, P325, DOI 10.1016/0304-3940(82)90079-9; GHETTI B, 1990, PROG BRAIN RES, V82, P197; GOFFINET AM, 1984, BRAIN RES REV, V7, P261, DOI 10.1016/0165-0173(84)90013-4; GOFFINET AM, 1983, ANAT EMBRYOL, V168, P73, DOI 10.1007/BF00305400; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; HAWKES R, 1987, J COMP NEUROL, V256, P29, DOI 10.1002/cne.902560104; HERRUP K, 1979, BRAIN RES, V178, P443, DOI 10.1016/0006-8993(79)90705-4; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; KAWAMURA K, 1979, NEUROSCIENCE, V4, P1615, DOI 10.1016/0306-4522(79)90024-1; LECLERC N, 1988, J COMP NEUROL, V273, P399, DOI 10.1002/cne.902730310; MIALE IL, 1961, EXP NEUROL, V4, P277, DOI 10.1016/0014-4886(61)90055-3; OBERDICK J, 1990, SCIENCE, V248, P223, DOI 10.1126/science.2109351; SCHILLING K, UNPUB; SCHILLING KL, 1988, J NEUROSCI RES, V19, P27, DOI 10.1002/jnr.490190105; SMEYNE RJ, 1990, DEV BRAIN RES, V52, P211, DOI 10.1016/0165-3806(90)90237-S; SOTELO C, 1987, NEUROSCIENCE, V20, P1, DOI 10.1016/0306-4522(87)90002-9; WASSEF M, 1985, DEV BIOL, V111, P129, DOI 10.1016/0012-1606(85)90441-5; WASSEF M, 1987, DEV BIOL, V124, P379, DOI 10.1016/0012-1606(87)90490-8; WASSEF M, 1984, NEUROSCIENCE, V13, P1217, DOI 10.1016/0306-4522(84)90295-1; WETTS R, 1982, J EMBRYOL EXP MORPH, V68, P87; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0	28	99	100	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 1	1991	254	5032					719	721		10.1126/science.1948052	http://dx.doi.org/10.1126/science.1948052			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN474	1948052				2022-12-01	WOS:A1991GN47400044
J	SMITH, JC; ELLENBERGER, HH; BALLANYI, K; RICHTER, DW; FELDMAN, JL				SMITH, JC; ELLENBERGER, HH; BALLANYI, K; RICHTER, DW; FELDMAN, JL			PRE-BOTZINGER COMPLEX - A BRAIN-STEM REGION THAT MAY GENERATE RESPIRATORY RHYTHM IN MAMMALS	SCIENCE			English	Article							SPINAL-CORD PREPARATION; INSPIRATORY DRIVE; NUCLEUS AMBIGUUS; NEWBORN RAT; INVITRO; NEURONS; MEDULLA; PATTERN; MOTONEURONS; MODULATION	The location of neurons generating the rhythm of breathing in mammals is unknown. By microsection of the neonatal rat brainstem in vitro, a limited region of the ventral medulla (the pre-Botzinger Complex) that contains neurons essential for rhythmogenesis was identified. Rhythm generation was eliminated by removal of only this region. Medullary slices containing the pre-Botzinger Complex generated respiratory-related oscillations similar to those generated by the whole brainstem in vitro, and neurons with voltage-dependent pacemaker-like properties were identified in this region. Thus, the respiratory rhythm in the mammalian neonatal nervous system may result from a population of conditional bursting pacemaker neurons in the pre-Botzinger Complex.	UNIV GOTTINGEN,INST PHYSIOL,W-3400 GOTTINGEN,GERMANY	University of Gottingen	SMITH, JC (corresponding author), UNIV CALIF LOS ANGELES,DEPT KINESIOL,SYST NEUROBIOL LAB,LOS ANGELES,CA 90024, USA.		feldman, jack/AAO-7505-2021	feldman, jack/0000-0003-3692-9412	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070029, R01HL040959, K30HL004095] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024742] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL070029, R01 HL070029-01A1, HL4095, R01 HL040959, K30 HL004095, HL02204] Funding Source: Medline; NINDS NIH HHS [R01 NS024742, NS24742] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIEGER D, 1987, J COMP NEUROL, V262, P546, DOI 10.1002/cne.902620408; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; COHEN MI, 1979, PHYSIOL REV, V59, P1105, DOI 10.1152/physrev.1979.59.4.1105; ELLENBERGER HH, 1990, J COMP NEUROL, V294, P202, DOI 10.1002/cne.902940205; EZURE K, 1990, PROG NEUROBIOL, V35, P429, DOI 10.1016/0301-0082(90)90030-K; Feldman J, 1990, EUR J NEUROSCI, V3, P171; FELDMAN JL, 1990, AM J PHYSIOL, V259, pR879, DOI 10.1152/ajpregu.1990.259.5.R879; FELDMAN JL, 1989, ANN NY ACAD SCI, V563, P114, DOI 10.1111/j.1749-6632.1989.tb42194.x; FELDMAN JL, 1986, HDB PHYSL 1, V4, P463; FLUORENS P, 1851, CR HEBD ACAD SCI, V33, P437; GREER JJ, 1991, J PHYSIOL-LONDON, V437, P727, DOI 10.1113/jphysiol.1991.sp018622; HARADA Y, 1985, J PHYSIOL-LONDON, V368, P679, DOI 10.1113/jphysiol.1985.sp015883; HILAIRE G, 1989, BRAIN RES, V485, P325, DOI 10.1016/0006-8993(89)90577-5; LIU GS, 1990, J NEUROPHYSIOL, V64, P423, DOI 10.1152/jn.1990.64.2.423; MCCRIMMON DR, 1989, J NEUROSCI, V9, P1910; ONIMARU H, 1988, BRAIN RES, V445, P314, DOI 10.1016/0006-8993(88)91194-8; ONIMARU H, 1987, NEUROSCI LETT, V78, P151, DOI 10.1016/0304-3940(87)90624-0; OTAKE K, 1990, J COMP NEUROL, V302, P485, DOI 10.1002/cne.903020306; Richter DW, 1986, NEWS PHYSIOL SCI, V1, P109; SCHWARZACHER S W, 1991, Pfluegers Archiv European Journal of Physiology, V418, pR17; SMITH J C, 1989, Society for Neuroscience Abstracts, V15, P505; SMITH J C, 1990, Society for Neuroscience Abstracts, V16, P1130; Smith J. C., 1987, RESPIRATORY MUSCLES, P27; SMITH JC, 1986, FASEB J, V45, P518; SMITH JC, 1987, J NEUROSCI METH, V21, P321, DOI 10.1016/0165-0270(87)90126-9; SMITH JC, 1990, J NEUROPHYSIOL, V64, P1149, DOI 10.1152/jn.1990.64.4.1149; SUZUE T, 1984, J PHYSIOL-LONDON, V354, P173, DOI 10.1113/jphysiol.1984.sp015370	27	1587	1632	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1991	254	5032					726	729		10.1126/science.1683005	http://dx.doi.org/10.1126/science.1683005			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN474	1683005	Green Accepted			2022-12-01	WOS:A1991GN47400047
J	SPITZER, MW; SEMPLE, MN				SPITZER, MW; SEMPLE, MN			INTERAURAL PHASE CODING IN AUDITORY MIDBRAIN - INFLUENCE OF DYNAMIC STIMULUS FEATURES	SCIENCE			English	Article							INFERIOR COLLICULUS; SOUND LOCALIZATION; MOVEMENT ANGLE; NEURONS; CAT; MECHANISMS; FREQUENCY; MOTION	A laterally located sound source stimulates the two ears at slightly different times, generating interaural phase disparities (IPDs) that are used for sound localization. Under natural conditions, such interaural cues are likely to be constantly changing, or dynamic. In the inferior colliculus of gerbils and cats, the nonlinearities in the coding of dynamic interaural phase cues are demonstrated. Responses to ecologically realistic phase cues are more reflective of the change of IPD than of the absolute IPDs over which that change occurs. This observation is inconsistent with the established view that directional information is coded in terms of absolute IPD.			SPITZER, MW (corresponding author), UNIV CALIF IRVINE,DEPT ANAT & NEUROBIOL,IRVINE,CA 92717, USA.				NIDCD NIH HHS [DC00364] Funding Source: Medline	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ALTMAN JA, 1968, EXP NEUROL, V22, P13, DOI 10.1016/0014-4886(68)90016-2; GOLDBERG JM, 1969, J NEUROPHYSIOL, V32, P613, DOI 10.1152/jn.1969.32.4.613; GRANTHAM DW, 1986, J ACOUST SOC AM, V79, P1939, DOI 10.1121/1.393201; JEFFRESS LA, 1948, J COMP PHYSIOL PSYCH, V41, P35, DOI 10.1037/h0061495; KUWADA S, 1979, SCIENCE, V206, P586, DOI 10.1126/science.493964; Perrott D R, 1979, J Aud Res, V19, P277; PERROTT DR, 1977, J ACOUST SOC AM, V62, P1463, DOI 10.1121/1.381675; PERROTT DR, 1988, J ACOUST SOC AM, V83, P1522, DOI 10.1121/1.395908; REALE RA, 1990, J NEUROPHYSIOL, V64, P1247, DOI 10.1152/jn.1990.64.4.1247; ROSE JE, 1966, J NEUROPHYSIOL, V29, P288, DOI 10.1152/jn.1966.29.2.288; ROTH GL, 1980, J ACOUST SOC AM, V68, P1643, DOI 10.1121/1.385196; STRYBEL TZ, 1989, PERCEPT PSYCHOPHYS, V45, P371, DOI 10.3758/BF03204951; SULLIVAN WE, 1986, BRAIN BEHAV EVOLUT, V28, P109, DOI 10.1159/000118696; YIN TCT, 1990, J NEUROPHYSIOL, V64, P465, DOI 10.1152/jn.1990.64.2.465; YIN TCT, 1983, J NEUROPHYSIOL, V50, P1000, DOI 10.1152/jn.1983.50.4.1000	15	77	80	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1991	254	5032					721	724		10.1126/science.1948053	http://dx.doi.org/10.1126/science.1948053			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN474	1948053				2022-12-01	WOS:A1991GN47400045
J	STREMMEL, W; MEYERROSE, KW; NIEDERAU, C; HEFTER, H; KREUZPAINTNER, G; STROHMEYER, G				STREMMEL, W; MEYERROSE, KW; NIEDERAU, C; HEFTER, H; KREUZPAINTNER, G; STROHMEYER, G			WILSON DISEASE - CLINICAL PRESENTATION, TREATMENT, AND SURVIVAL	ANNALS OF INTERNAL MEDICINE			English	Review							TRIETHYLENE TETRAMINE DIHYDROCHLORIDE; COPPER; PENICILLAMINE; DIAGNOSIS; THERAPY; ZINC; DEFICIENCY; TRIENTINE	Objective: To evaluate the diagnostic features, clinical course, and overall long-term survival of patients with Wilson disease. Design: Retrospective cohort study with a mean follow-up period of 14.2 years. Setting: A university medical center and a community hospital. Patients: Fifty-one consecutive patients with Wilson disease were evaluated between 1957 and 1989. Interventions: Patients were treated with D-penicillamine (600 to 1800 mg/d). Two patients with end-stage liver disease had liver transplantation. Main Results: Initial symptoms occurred at a mean age of 15.5 years. At diagnosis, the most common neurologic signs were dysarthria, tremor, writing difficulties, and ataxia followed by hypersalivation and headache. Somatic symptoms included abdominal pain, hepatomegaly, splenomegaly, cirrhosis of the liver, and thrombocytopenia. The mean serum concentrations of ceruloplasmin and copper were 44 mg/L and 4.7-mu-mol/L, respectively. The mean basal urinary copper excretion was 5.5-mu-mol/d, and the mean hepatic copper concentration was 19.6-mu-mol/g dry weight. Free serum copper concentration (mean, 2.7-mu-mol/L) was a reliable indicator of disease and was useful in assessing the effectiveness of therapy (values < 1.6-mu-mol/L). Treatment with D-penicillamine improved most of the hematologic and neurologic abnormalities but had little effect on hepatomegaly and splenomegaly and did not reverse cirrhosis. Two patients died of fulminant hepatic failure during the observation period, whereas two others with end-stage liver disease had successful liver transplantation and remain asymptomatic. Long-term survival of patients with Wilson disease was similar to that of age- and sex-matched controls. Conclusion: Our results suggest that long-term treatment of patients with Wilson disease with D-penicillamine can relieve symptoms and improve prognosis.	UNIV HOSP DUSSELDORF, DUSSELDORF, GERMANY	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital				Stremmel, Wolfgang/0000-0002-8545-1753				Bachmann H, 1979, Psychiatr Neurol Med Psychol (Leipz), V31, P393; BONNETAMIR B, 1990, ANN HUM GENET, V54, P155, DOI 10.1111/j.1469-1809.1990.tb00372.x; BREWER GJ, 1987, P SOC EXP BIOL MED, V184, P446; BREWER GJ, 1983, ANN INTERN MED, V99, P314, DOI 10.7326/0003-4819-99-3-314; CZAJA MJ, 1987, J CLIN INVEST, V80, P1200, DOI 10.1172/JCI113180; EDWARDS CQ, 1979, CLIN GENET, V15, P311; FRYDMAN M, 1985, P NATL ACAD SCI USA, V82, P1819, DOI 10.1073/pnas.82.6.1819; GIBBS K, 1980, LANCET, V2, P538; HALVERSON PB, 1978, JAMA-J AM MED ASSOC, V240, P1870, DOI 10.1001/jama.240.17.1870; HOOGENRAAD TU, 1987, J NEUROL SCI, V77, P137, DOI 10.1016/0022-510X(87)90116-X; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KREUZPAINTER G, 1990, KLIN WOCHENSCHR, V68, P60; NIEDERAU C, 1985, NEW ENGL J MED, V313, P1256, DOI 10.1056/NEJM198511143132004; POPPER H, 1979, LANCET, V1, P1205; SCHEINBERG IH, 1987, NEW ENGL J MED, V317, P209, DOI 10.1056/NEJM198707233170405; SCHEINBERG IH, 1975, NEW ENGL J MED, V293, P1300, DOI 10.1056/NEJM197512182932507; STERNLIEB I, 1979, GASTROENTEROLOGY, V77, P138; STROHMEYER G, 1984, METABOLISM NUTRITION, P211; VANDENHAMER CJA, 1989, LANCET, V2, P442; WALSHE JM, 1956, AM J MED, V21, P487, DOI 10.1016/0002-9343(56)90066-3; WALSHE JM, 1977, Q J MED, V46, P73; WALSHE JM, 1982, LANCET, V1, P643; WALSHE JM, 1984, SEMIN LIVER DIS, V4, P252, DOI 10.1055/s-2008-1041775; WALSHE JM, 1988, LANCET, V2, P435; WALSHE JM, 1973, Q J MED, V42, P441; Walshe JM, 1986, ORPHAN DIS ORPHAN DR, P76; WESCH H, 1980, DEUT MED WOCHENSCHR, V105, P483, DOI 10.1055/s-2008-1070692	27	210	216	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1991	115	9					720	726		10.7326/0003-4819-115-9-720	http://dx.doi.org/10.7326/0003-4819-115-9-720			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL697	1929042				2022-12-01	WOS:A1991GL69700011
J	WONG, ND; WILSON, PWF; KANNEL, WB				WONG, ND; WILSON, PWF; KANNEL, WB			SERUM-CHOLESTEROL AS A PROGNOSTIC FACTOR AFTER MYOCARDIAL-INFARCTION - THE FRAMINGHAM-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY HEART-DISEASE; MIDDLE-AGED MEN; FOLLOW-UP; LIPOPROTEIN CHOLESTEROL; COLESTIPOL-NIACIN; DRUG PROJECT; RISK-FACTORS; MORTALITY; ATHEROSCLEROSIS; PREVENTION	Objective: To determine the relation between serum cholesterol levels and the long-term risk for reinfarction, death from coronary heart disease, and all-cause mortality in persons who recover from myocardial infarction. Design: Prospective, longitudinal study. Setting: A geographically defined population-based cohort of adults participating in the Framingham Heart Study. Patients: Men (n = 260) and women (n = 114), 33 to 88 years of age (mean age, 62 years), who had a history of myocardial infarction. Measurements: A complete physical examination, including electrocardiographic evaluation, blood pressure measurement, height and weight measurements, determination of smoking habits, and casual determinations of blood glucose and serum cholesterol, was done approximately 1 year after recovery from initial myocardial infarction. Patients were followed after infarction for the occurrence of reinfarction or death (mean follow-up, 10.5 years; range, 0.8 to 31.6 years). Main Results: The mean cholesterol level after infarction was 5.21 mmol/L (242.8 mg/dL); 20% of patients had levels below 5.17 mmol/L (200 mg/dL), and 22% had levels of 7.11 mmol/L (275 mg/dL) or more. Compared with patients who had cholesterol levels below 5.17 mmol/L, patients with levels of 7.11 mmol/L or more were at increased risk for reinfarction (relative risk, 3.8; 95% CI, 1.6 to 8.7), death from coronary heart disease (relative risk, 2.6; CI, 1.4 to 4.8), and all-cause mortality (relative risk, 1.9; CI, 1.2 to 2.9) based on multivariate Cox regression analyses adjusted for other coronary risk factors. Intermediate cholesterol levels (5.17 mmol/L to 7.11 mmol/L) were generally not associated with increased risk. The association between elevated serum cholesterol and increased risk was strongest in men; however, elevated cholesterol levels were found to be most strongly related to death from coronary disease and to all-cause mortality in persons who were 65 years of age or more. Conclusions: Patients who have recovered from a myocardial infarction and who have high cholesterol levels are at an increased long-term risk for reinfarction, death from coronary heart disease, and all-cause mortality. Our results confirm the prognostic value of cholesterol levels measured after myocardial infarction and support the role of lipid management in this population.	FRAMINGHAM HEART DIS EPIDEMIOL STUDY, FRAMINGHAM, MA USA	Framingham Heart Study	WONG, ND (corresponding author), UNIV CALIF IRVINE, COLL MED, PREVENT CARDIOL PROGRAM, C240 MED SCI 1, IRVINE, CA 92717 USA.		Wilson, Peter W.F./J-2455-2016					ABELL LL, 1952, J BIOL CHEM, V195, P357; ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; ARONOW WS, 1989, J AM GERIATR SOC, V37, P501, DOI 10.1111/j.1532-5415.1989.tb05679.x; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; CARLSON LA, 1988, ACTA MED SCAND, V223, P405; CASHINHEMPHILL L, 1990, JAMA-J AM MED ASSOC, V264, P3013, DOI 10.1001/jama.264.23.3013; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; COX DR, 1972, J R STAT SOC B, V34, P187; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DIXON WJ, 1985, BMDP STATISTICAL SOF; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FROST PH, 1987, AM HEART J, V113, P1356, DOI 10.1016/0002-8703(87)90648-X; GOLDBOURT U, 1985, BMJ-BRIT MED J, V290, P1239, DOI 10.1136/bmj.290.6477.1239; GORDON T, 1973, DHEW NIH74478 PUBL; HELIOVAARA M, 1982, AM J CARDIOL, V55, P325; JENKINS CD, 1976, CIRCULATION, V53, P342, DOI 10.1161/01.CIR.53.2.342; JOHANSSON S, 1984, AM J EPIDEMIOL, V119, P610, DOI 10.1093/oxfordjournals.aje.a113778; KHAW KT, 1986, J CARDIOPULM REHABIL, V6, P474; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SCHLANT RC, 1982, CIRCULATION, V66, P401, DOI 10.1161/01.CIR.66.2.401; ULVENSTAM G, 1984, PREV MED, V13, P355, DOI 10.1016/0091-7435(84)90027-6; WEDEL H, 1989, 29TH ANN M AHA COUNC; WEINBLATT E, 1973, AM J PUBLIC HEALTH, V63, P577, DOI 10.2105/AJPH.63.7.577; WONG ND, 1989, AM J EPIDEMIOL, V130, P469, DOI 10.1093/oxfordjournals.aje.a115360	28	147	154	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1991	115	9					687	693		10.7326/0003-4819-115-9-687	http://dx.doi.org/10.7326/0003-4819-115-9-687			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL697	1929036				2022-12-01	WOS:A1991GL69700004
J	WOOD, SA; PARK, JE; BROWN, WJ				WOOD, SA; PARK, JE; BROWN, WJ			BREFELDIN-A CAUSES A MICROTUBULE-MEDIATED FUSION OF THE TRANS-GOLGI NETWORK AND EARLY ENDOSOMES	CELL			English	Article							MANNOSE 6-PHOSPHATE RECEPTORS; I-CELL DISEASE; MHC CLASS-II; INTRACELLULAR-TRANSPORT; ENDOPLASMIC-RETICULUM; LYSOSOMAL-ENZYMES; COATED VESICLES; BETA-GLUCURONIDASE; SECRETORY PROTEINS; HUMAN-FIBROBLASTS	Brefeldin A (BFA) is a fungal metabolite that causes a redistribution of the stacked cisternae of the Golgi complex into the endoplasmic reticulum by inhibiting anterograde transport. We report that BFA also causes membrane tubules derived from the trans-Golgi network (TGN) to fuse with early endosomes. In the presence of BFA, a mannose-6-phosphate receptor (M6PR)-enriched tubular network rapidly forms from the TGN, not from the prelysosomal compartment, and can be labeled with endocytic tracers after only 5 min of uptake at either 20-degrees-C or 37-degrees-C, indicating that it is also functionally an early endosome. Formation of the TGN-early endosome network is microtubule dependent and may involve modification of membrane processes affected by microtubule-associated motor activity. Concomitant with the formation of the fused TGN-early endosome network, there is a > 5-fold increase in cell surface M6PRs. The data suggest that BFA has revealed a membrane transport cycle between the TGN and early endosomes, perhaps used for the secretion or delivery of molecules to the cell surface.			WOOD, SA (corresponding author), CORNELL UNIV, BIOCHEM MOLEC & CELL BIOL SECT, ITHACA, NY 14853 USA.		Brown, William/GXN-2777-2022		NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R23AM037249] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM 37249] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BERGER EG, 1987, EXP CELL RES, V173, P267, DOI 10.1016/0014-4827(87)90352-1; BRAULKE T, 1987, J CELL BIOL, V104, P1735, DOI 10.1083/jcb.104.6.1735; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN WJ, 1989, METHOD CELL BIOL, V31, P553; BROWN WJ, 1990, EUR J CELL BIOL, V51, P201; BROWN WJ, 1986, J CELL BIOL, V103, P1235, DOI 10.1083/jcb.103.4.1235; BROWN WJ, 1987, P NATL ACAD SCI USA, V84, P9001, DOI 10.1073/pnas.84.24.9001; CAMPBELL CH, 1983, J BIOL CHEM, V258, P3347; CAMPBELL CH, 1983, J BIOL CHEM, V258, P2628; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; CRESSWELL P, 1985, P NATL ACAD SCI USA, V82, P8188, DOI 10.1073/pnas.82.23.8188; DEBRABANDER MJ, 1976, CANCER RES, V36, P905; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DUNCAN JR, 1988, J CELL BIOL, V106, P617, DOI 10.1083/jcb.106.3.617; FISCHER HD, 1980, J BIOL CHEM, V255, P5069; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GEUZE HJ, 1988, J CELL BIOL, V107, P2491, DOI 10.1083/jcb.107.6.2491; GONATAS NK, 1983, MOL CELL BIOL, V3, P91, DOI 10.1128/MCB.3.1.91; GREEN SA, 1990, J BIOL CHEM, V265, P21269; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; GRIFFITHS G, 1990, J CELL SCI, V95, P441; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; Handley D. A., 1989, COLLOIDAL GOLD PRINC, V1, P13; HASILIK A, 1981, BIOCHEM BIOPH RES CO, V98, P761, DOI 10.1016/0006-291X(81)91177-3; HO WC, 1989, EUR J CELL BIOL, V48, P250; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; JIN M, 1989, J BIOL CHEM, V264, P7675; JOHNSTON PA, 1989, EMBO J, V8, P2863, DOI 10.1002/j.1460-2075.1989.tb08434.x; KELLY RB, 1990, CELL, V61, P5, DOI 10.1016/0092-8674(90)90206-T; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LEMANSKY P, 1987, J CELL BIOL, V104, P1743, DOI 10.1083/jcb.104.6.1743; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; NATOWICZ MR, 1979, P NATL ACAD SCI USA, V76, P4322, DOI 10.1073/pnas.76.9.4322; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NEEFJES JJ, 1990, J CELL BIOL, V111, P1383, DOI 10.1083/jcb.111.4.1383; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; ORCI L, 1991, CELL, V64, P1183; PARK JE, 1991, J CELL BIOL, V112, P245, DOI 10.1083/jcb.112.2.245; PFEFFER SR, 1987, J CELL BIOL, V105, P229, DOI 10.1083/jcb.105.1.229; REITMAN ML, 1981, J CLIN INVEST, V67, P1574, DOI 10.1172/JCI110189; ROGALSKI AA, 1984, J CELL BIOL, V99, P1101, DOI 10.1083/jcb.99.3.1101; ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; SANDVIG K, 1989, J CELL BIOL, V108, P1331, DOI 10.1083/jcb.108.4.1331; SCHULZELOHOFF E, 1985, J CELL BIOL, V101, P824, DOI 10.1083/jcb.101.3.824; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; STOORVOGEL W, 1989, J CELL BIOL, V108, P2137, DOI 10.1083/jcb.108.6.2137; STOORVOGEL W, 1988, J CELL BIOL, V106, P1821, DOI 10.1083/jcb.106.6.1821; SWANSON J, 1987, J CELL BIOL, V104, P1217, DOI 10.1083/jcb.104.5.1217; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; TURNER JR, 1989, J CELL BIOL, V109, P2081, DOI 10.1083/jcb.109.5.2081; VALE RD, 1987, ANNU REV CELL BIOL, V3, P347, DOI 10.1146/annurev.cb.03.110187.002023; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALLEE RB, 1983, P NATL ACAD SCI-BIOL, V80, P6259, DOI 10.1073/pnas.80.20.6259; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WOODS JW, 1986, J CELL BIOL, V103, P277, DOI 10.1083/jcb.103.1.277; ZIJDERHANDBLEEKEMOLEN JE, 1987, J CELL BIOL, V104, P1647, DOI 10.1083/jcb.104.6.1647	68	379	380	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 1	1991	67	3					591	600		10.1016/0092-8674(91)90533-5	http://dx.doi.org/10.1016/0092-8674(91)90533-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GN664	1657400				2022-12-01	WOS:A1991GN66400015
J	YASUDA, LF; YAO, MC				YASUDA, LF; YAO, MC			SHORT INVERTED REPEATS AT A FREE END SIGNAL LARGE PALINDROMIC DNA FORMATION IN TETRAHYMENA	CELL			English	Article							RIBOSOMAL-RNA GENES; NUCLEOTIDE-SEQUENCE; EXTRACHROMOSOMAL RDNA; CHROMOSOME BREAKAGE; DEVELOPING NUCLEI; AMPLIFICATION; THERMOPHILA; DUPLICATION; PYRIFORMIS; CONSERVATION	Large palindromic DNAs are formed in many cell types, but their molecular mechanism is unknown. During nuclear differentiation in Tetrahymena, the ribosomal RNA genes (rDNA) are converted from a single integrated copy to an extrachromosomal head-to-head palindrome. Using in vitro mutagenesis and Tetrahymena transformation, we show that two properties of the rDNA are necessary and sufficient for palindrome formation. The first is a pair of 42 bp inverted repeats found at the rDNA's 5' end. Its inverted symmetry, but not specific sequence, is important. The second is a free end next to the repeats. It is normally created by chromosome breakage in vivo, but can also be provided by restriction endonuclease cutting before transformation. We also demonstrate that the ability to form palindromes is not restricted to developing nuclei, but is present in vegetative cells as well. This process may represent a general mechanism for palindrome formation in eukaryotes.			YASUDA, LF (corresponding author), FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,SEATTLE,WA 98104, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026210, F32GM013293] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26210, 5 F32 GM13293-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSTERBERRY CF, 1984, P NATL ACAD SCI-BIOL, V81, P7383, DOI 10.1073/pnas.81.23.7383; AUSTERBERRY CF, 1987, MOL CELL BIOL, V7, P435, DOI 10.1128/MCB.7.1.435; BEVERLEY SM, 1984, CELL, V38, P431, DOI 10.1016/0092-8674(84)90498-7; BLACKBURN EH, 1978, J MOL BIOL, V120, P33, DOI 10.1016/0022-2836(78)90294-2; BRUNS PJ, 1985, P NATL ACAD SCI USA, V82, P2844, DOI 10.1073/pnas.82.9.2844; CHALLONER PB, 1986, NUCLEIC ACIDS RES, V14, P6299, DOI 10.1093/nar/14.15.6299; COCKBURN AF, 1978, CHROMOSOMA, V70, P19, DOI 10.1007/BF00292212; DIN N, 1979, J MOL BIOL, V134, P555, DOI 10.1016/0022-2836(79)90367-X; ENGBERG J, 1983, NUCLEIC ACIDS RES, V11, P4939, DOI 10.1093/nar/11.14.4939; ENGBERG J, 1976, J MOL BIOL, V104, P455, DOI 10.1016/0022-2836(76)90281-3; FORD M, 1986, CELL, V45, P425, DOI 10.1016/0092-8674(86)90328-4; FORD M, 1985, P NATL ACAD SCI USA, V82, P3370, DOI 10.1073/pnas.82.10.3370; GALL JG, 1974, P NATL ACAD SCI USA, V71, P3078, DOI 10.1073/pnas.71.8.3078; GODISKA R, 1990, CELL, V61, P1237, DOI 10.1016/0092-8674(90)90688-B; Gorovsky M A, 1975, Methods Cell Biol, V9, P311, DOI 10.1016/S0091-679X(08)60080-1; HYRIEN O, 1988, EMBO J, V7, P407, DOI 10.1002/j.1460-2075.1988.tb02828.x; KAN NC, 1981, J MOL BIOL, V153, P1151, DOI 10.1016/0022-2836(81)90472-1; KARRER KM, 1976, J MOL BIOL, V104, P421, DOI 10.1016/0022-2836(76)90280-1; KING BO, 1982, CELL, V31, P177, DOI 10.1016/0092-8674(82)90417-2; KISS GB, 1981, GENE, V13, P281, DOI 10.1016/0378-1119(81)90032-9; LARSON DD, 1986, CELL, V47, P229, DOI 10.1016/0092-8674(86)90445-9; LILLEY DMJ, 1984, CELL, V36, P413, DOI 10.1016/0092-8674(84)90234-4; ORIAS E, 1988, GENE, V70, P295, DOI 10.1016/0378-1119(88)90201-6; PAN WC, 1981, CELL, V23, P459, DOI 10.1016/0092-8674(81)90141-0; PASSANANTI C, 1987, EMBO J, V6, P1697, DOI 10.1002/j.1460-2075.1987.tb02420.x; RUIZ JC, 1988, MOL CELL BIOL, V8, P4302, DOI 10.1128/MCB.8.10.4302; Sambrook J., 1989, MOL CLONING LAB MANU; SPANGLER EA, 1985, J BIOL CHEM, V260, P6334; STARK GR, 1989, CELL, V57, P901, DOI 10.1016/0092-8674(89)90328-0; SWEENEY R, 1989, EMBO J, V8, P933, DOI 10.1002/j.1460-2075.1989.tb03454.x; TONDRAVI MM, 1986, P NATL ACAD SCI USA, V83, P4369, DOI 10.1073/pnas.83.12.4369; VOGT VM, 1976, J MOL BIOL, V106, P567, DOI 10.1016/0022-2836(76)90252-7; WALTON JD, 1986, CELL, V46, P857, DOI 10.1016/0092-8674(86)90067-X; WEST SC, 1985, P NATL ACAD SCI USA, V82, P6445, DOI 10.1073/pnas.82.19.6445; YAO MC, 1985, MOL CELL BIOL, V5, P1260, DOI 10.1128/MCB.5.6.1260; YAO MC, 1987, CELL, V48, P779, DOI 10.1016/0092-8674(87)90075-4; YAO MC, 1974, P NATL ACAD SCI USA, V71, P3082, DOI 10.1073/pnas.71.8.3082; YAO MC, 1990, CELL, V63, P763, DOI 10.1016/0092-8674(90)90142-2; YAO MC, 1989, MOL CELL BIOL, V9, P1092, DOI 10.1128/MCB.9.3.1092; YAO MC, 1977, CELL, V12, P121, DOI 10.1016/0092-8674(77)90190-8; YAO MC, 1981, CELL, V24, P765, DOI 10.1016/0092-8674(81)90102-1; YU GL, 1988, P NATL ACAD SCI USA, V85, P5151, DOI 10.1073/pnas.85.14.5151	42	53	53	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1991	67	3					505	516		10.1016/0092-8674(91)90525-4	http://dx.doi.org/10.1016/0092-8674(91)90525-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GN664	1934058				2022-12-01	WOS:A1991GN66400007
J	AMMALA, C; LARSSON, O; BERGGREN, PO; BOKVIST, K; JUNTTIBERGGREN, L; KINDMARK, H; RORSMAN, P				AMMALA, C; LARSSON, O; BERGGREN, PO; BOKVIST, K; JUNTTIBERGGREN, L; KINDMARK, H; RORSMAN, P			INOSITOL TRISPHOSPHATE-DEPENDENT PERIODIC ACTIVATION OF A CA2+ - ACTIVATED K+ CONDUCTANCE IN GLUCOSE-STIMULATED PANCREATIC BETA-CELLS	NATURE			English	Article							B-CELLS; ELECTRICAL-ACTIVITY; SKELETAL-MUSCLE; CHANNELS; SECRETION; CURRENTS; TOLBUTAMIDE; CALCIUM; APAMIN; SMOOTH	GLUCOSE-STIMULATED insulin secretion is associated with the appearance of electrical activity in the pancreatic beta-cell. At intermediate glucose concentrations, beta-cell electrical activity follows a characteristic pattern of slow oscillations in membrane potential on which bursts of action potentials are superimposed 1. The electrophysiological background of the bursting pattern remains unestablished. Activation of Ca2+-activated large-conductance K+ channels (K(Ca) channel 12) has been implicated in this process 3 but seems unlikely in view of recent evidence demonstrating that the beta-cell electrical activity is unaffected by the specific K(Ca) channel blocker charybdotoxin 4. Another hypothesis postulates that the bursting arises as a consequence of two components of Ca2+-current inactivation 5. Here we show that activation of a novel Ca2+-dependent K+ current in glucose-stimulated-beta-cells produces a transient membrane repolarization. This interrupts action potential firing so that action potentials appear in bursts. Spontaneous activity of this current was seen only rarely but could be induced by addition of compounds functionally related to hormones and neurotransmitters present in the intact pancreatic islet. K+ currents of the same type could be evoked by intracellular application of GTP, the effect of which was mediated by mobilization of Ca2+ from inositol 1,4,5-trisphosphate (InsP3)-sensitive intracellular Ca2+ stores. These observations suggest that oscillatory glucose-stimulated electrical activity, which is correlated with pulsatile release of insulin 6, results from the interaction between the beta-cell and intraislet hormones and neurotransmitters. Our data also provide evidence for a close interplay between ion channels in the plasma membrane and InsP3-induced mobilization of intracellular Ca2+ in an excitable cell.	GOTHENBURG UNIV,DEPT MED PHYS,BOX 33031,S-40033 GOTHENBURG,SWEDEN; KAROLINSKA INST,DEPT ENDOCRINOL,S-10401 STOCKHOLM 60,SWEDEN	University of Gothenburg; Karolinska Institutet			Rorsman, Patrik/A-4331-2016	Rorsman, Patrik/0000-0001-7578-0767; Berggren, Per-Olof/0000-0001-8991-413X				AMMALA C, 1991, BIOCHIM BIOPHYS ACTA, V1092, P347; ARKHAMMAR P, 1987, J BIOL CHEM, V262, P5448; ATWATER I, 1983, CELL CALCIUM, V4, P451, DOI 10.1016/0143-4160(83)90021-0; BENHAM CD, 1986, J PHYSIOL-LONDON, V381, P385, DOI 10.1113/jphysiol.1986.sp016333; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BLATZ AL, 1986, NATURE, V323, P718, DOI 10.1038/323718a0; BOKVIST K, 1990, J PHYSIOL-LONDON, V423, P327, DOI 10.1113/jphysiol.1990.sp018025; CAPIOD T, 1991, BIOCHEM J, V275, P277, DOI 10.1042/bj2750277; COOK DL, 1989, DIABETES, V38, P416, DOI 10.2337/diabetes.38.4.416; COOK DL, 1991, TRENDS NEUROSCI, V14, P411, DOI 10.1016/0166-2236(91)90033-Q; COOK DL, 1984, NATURE, V311, P269, DOI 10.1038/311269a0; FATHERAZI S, 1991, J MEMBRANE BIOL, V120, P105, DOI 10.1007/BF01872393; GRAPENGIESSER E, 1991, J BIOL CHEM, V266, P12207; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; HENQUIN JC, 1988, BIOCHEM BIOPH RES CO, V156, P769, DOI 10.1016/S0006-291X(88)80910-0; HENQUIN JC, 1984, EXPERIENTIA, V40, P1043, DOI 10.1007/BF01971450; HILL TD, 1988, SCIENCE, V242, P1176, DOI 10.1126/science.2847317; KUKULJAN M, 1991, J MEMBRANE BIOL, V119, P187, DOI 10.1007/BF01871418; LEBRUN P, 1983, FEBS LETT, V161, P41, DOI 10.1016/0014-5793(83)80726-1; LUND PE, 1991, BIOCHEM BIOPH RES CO, V177, P777, DOI 10.1016/0006-291X(91)91856-8; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; NUSSINOVITCH I, 1988, J PHYSIOL-LONDON, V395, P303, DOI 10.1113/jphysiol.1988.sp016920; PENNER R, 1988, J EXP BIOL, V139, P329; RASMUSSEN H, 1990, DIABETES CARE, V13, P655, DOI 10.2337/diacare.13.6.655; RORSMAN P, 1991, NATURE, V349, P77, DOI 10.1038/349077a0; ROSARIO LM, 1987, ADV EXP MED BIOL, V211, P413; SMITH PA, 1990, FEBS LETT, V261, P187, DOI 10.1016/0014-5793(90)80667-8; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WALKER JW, 1987, NATURE, V327, P249, DOI 10.1038/327249a0	31	125	126	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 31	1991	353	6347					849	852		10.1038/353849a0	http://dx.doi.org/10.1038/353849a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM732	1719424				2022-12-01	WOS:A1991GM73200061
J	GAHRTON, G; TURA, S; LJUNGMAN, P; BELANGER, C; BRANDT, L; CAVO, M; FACON, T; GRANENA, A; GORE, M; GRATWOHL, A; LOWENBERG, B; NIKOSKELAINEN, J; REIFFERS, JJ; SAMSON, D; VERDONCK, L; VOLIN, L				GAHRTON, G; TURA, S; LJUNGMAN, P; BELANGER, C; BRANDT, L; CAVO, M; FACON, T; GRANENA, A; GORE, M; GRATWOHL, A; LOWENBERG, B; NIKOSKELAINEN, J; REIFFERS, JJ; SAMSON, D; VERDONCK, L; VOLIN, L			ALLOGENEIC BONE-MARROW TRANSPLANTATION IN MULTIPLE-MYELOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; STEM-CELL TRANSPLANTATION; HIGH-DOSE CHEMOTHERAPY; TOTAL-BODY IRRADIATION; 1ST REMISSION; GRAFT; MELPHALAN; SURVIVAL	Background and Methods. In contrast to autologous bone marrow transplants for hematologic cancers, allogeneic transplants contain no tumor cells that might cause a relapse. We report the results of such allogeneic bone marrow transplantation using HLA-compatible sibling donors in 90 patients with multiple myeloma performed in 26 European centers between 1983 and 1989. Results. At the time of the most recent follow-up, 79 months after the start of the study, 47 patients were alive and 43 were dead. The rate of complete remission after bone marrow transplantation was 43 percent for all patients and 58 percent for the patients who had engraftment. The actuarial survival at 76 months was 40 percent. The median duration of relapse-free survival among patients who were in complete remission after bone marrow transplantation was 48 months. The stage of the disease at diagnosis and the number of treatment regimens tried before bone marrow transplantation were predictive of the likelihood of complete remission after engraftment. There were trends toward longer survival among patients who were responsive to treatment before bone marrow transplantation, patients with Stage I disease at diagnosis, and patients who had received only first-line treatment before transplantation, as compared with those who were not responsive, those with Stage II or III disease at diagnosis, and those who had received three or more lines of treatment, but the differences in these factors were not statistically significant. Two post-transplantation factors predicted better long-term survival: complete remission after engraftment and grade I graft-versus-host disease, rather than grade II, III, or IV. Conclusions. Allogeneic bone marrow transplantation with the use of HLA-matched sibling donors appears to be a promising method of treatment for some patients with multiple myeloma.	KAROLINSKA INST, S-14186 HUDDINGE, SWEDEN; HOSP SAN ORSOLA, DEPT HEMATOL, BOLOGNA, ITALY; HOP COCHIN, DEPT HEMATOL, F-75674 PARIS 14, FRANCE; HOSP CLAUDE HURIEZ, SERV MALAD SANG, LILLE, FRANCE; CLIN HOSP BARCELONA, SCH HEMATOL, BARCELONA, SPAIN; ROYAL MARSDEN HOSP, INST CANC RES, LONDON, ENGLAND; UNIV HOSP BASEL, DEPT INTERNAL MED, DIV HEMATOL, CH-4031 BASEL, SWITZERLAND; DR DANIEL DENHOED CANC CTR, ROTTERDAM, NETHERLANDS; UNIV TURKU, DEPT MED, SF-20500 TURKU 50, FINLAND; CTR FRANCOIS MAGENDIE, SERV MALAD SANG, PESSAC, FRANCE; CHARING CROSS HOSP, DEPT HAEMATOL, LONDON W6 8RP, ENGLAND; STATE UNIV UTRECHT HOSP, DEPT HEMATOL, 3511 GV UTRECHT, NETHERLANDS; UNIV HELSINKI, DEPT MED 3, SF-00100 HELSINKI 10, FINLAND	Karolinska Institutet; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite de Lille - ISITE; CHU Lille; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Basel; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; University of Turku; CHU Bordeaux; Imperial College London; Utrecht University; Utrecht University Medical Center; University of Helsinki	GAHRTON, G (corresponding author), HUDDINGE HOSP, DEPT MED, S-14186 HUDDINGE, SWEDEN.		CAVO, MICHELE/AAK-8274-2020	CAVO, MICHELE/0000-0003-4514-3227				ALEXANIAN R, 1969, J AMER MED ASSOC, V208, P1680, DOI 10.1001/jama.208.9.1680; ALEXANIAN R, 1991, AM J CLIN ONCOL-CANC, V14, P188, DOI 10.1097/00000421-199106000-00003; ANDERSON K, 1989, BLOOD S, V474, pA202; ANDERSON KC, 1991, BLOOD, V77, P712; APPERLEY JF, 1988, BRIT J HAEMATOL, V69, P239, DOI 10.1111/j.1365-2141.1988.tb07628.x; BARLOGIE B, 1987, BLOOD, V70, P869; BARLOGIE B, 1986, BLOOD, V67, P1298; BARLOGIE B, 1991, BONE MARROW TRANSPL, V7, P71; BUCKNER CD, 1989, EUR J HAEMATOL, V43, P186; DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U; FERMAND JP, 1989, BLOOD, V73, P20; FRIEDENBERG WR, 1991, AM J HEMATOL, V36, P171, DOI 10.1002/ajh.2830360303; GAHRTON G, 1989, BONE MARROW TRANSPL, V4, P4; GAHRTON G, 1989, EUR J HAEMATOL, V43, P182; GAHRTON G, 1988, HEMATOL ONCOL, V6, P181, DOI 10.1002/hon.2900060219; GAHRTON G, 1986, ACTA MED SCAND, V219, P523; GAHRTON G, 1990, Bone Marrow Transplantation, V5, P2; GOBBI M, 1989, EUR J HAEMATOL, V43, P176; GOLDMAN JM, 1986, NEW ENGL J MED, V314, P202, DOI 10.1056/NEJM198601233140403; GOLDSTONE AH, 1986, BRIT J HAEMATOL, V64, P529, DOI 10.1111/j.1365-2141.1986.tb02209.x; GORIN NC, 1990, BLOOD, V75, P1606; HOROWITZ MM, 1990, BLOOD, V75, P555; JAGANNATH S, 1990, BLOOD, V76, P1860; KOEFFLER HP, 1981, NEW ENGL J MED, V304, P1201, DOI 10.1056/NEJM198105143042004; LOWENBERG B, 1984, CANCER, V54, P2840, DOI 10.1002/1097-0142(19841215)54:12<2840::AID-CNCR2820541204>3.0.CO;2-4; MANDELLI F, 1990, NEW ENGL J MED, V322, P1430, DOI 10.1056/NEJM199005173222005; MCELWAIN TJ, 1983, LANCET, V2, P822; MELLSTEDT H, 1989, EUR J HAEMATOL, V43, P124; OSTERBORG A, 1989, EUR J HAEMATOL, V43, P54; PALVA IP, 1990, EUR J HAEMATOL, V44, P120; REECE DE, 1989, BLOOD S, V74, pA202; REIFFERS J, 1989, LANCET, V2, P1336; REIFFERS J, 1989, BRIT J HAEMATOL, V72, P296, DOI 10.1111/j.1365-2141.1989.tb07705.x; SELBY PJ, 1987, BRIT J HAEMATOL, V66, P55, DOI 10.1111/j.1365-2141.1987.tb06890.x; SPORN JR, 1986, SEMIN ONCOL, V13, P318; THOMAS ED, 1977, BLOOD, V49, P511; THOMAS ED, 1986, ANN INTERN MED, V104, P155, DOI 10.7326/0003-4819-104-2-155; TURA S, 1986, SCAND J HAEMATOL, V36, P176; VENTURA GJ, 1990, BONE MARROW TRANSPL, V5, P265; WEIDEN PL, 1981, NEW ENGL J MED, V304, P1529, DOI 10.1056/NEJM198106183042507; YEAGER AM, 1986, NEW ENGL J MED, V315, P141, DOI 10.1056/NEJM198607173150301	41	344	355	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 31	1991	325	18					1267	1273		10.1056/NEJM199110313251802	http://dx.doi.org/10.1056/NEJM199110313251802			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM041	1922221	Green Published			2022-12-01	WOS:A1991GM04100002
J	HUNT, P; GULISANO, M; COOK, M; SHAM, MH; FAIELLA, A; WILKINSON, D; BONCINELLI, E; KRUMLAUF, R				HUNT, P; GULISANO, M; COOK, M; SHAM, MH; FAIELLA, A; WILKINSON, D; BONCINELLI, E; KRUMLAUF, R			A DISTINCT HOX CODE FOR THE BRANCHIAL REGION OF THE VERTEBRATE HEAD	NATURE			English	Article							HOMEOBOX-CONTAINING GENE; MOUSE HINDBRAIN; EXPRESSION; MURINE; SEGMENTATION; ORGANIZATION; HOX-5.1; HOX-2.6; DOMAINS; HOX-1.5	THE branchial region of the vertebrate head forms through complex interactions involving rhombomeric segments, neural crest and branchial arches 1. It is thought that aspects of their patterning mechanisms are linked 2 and involve Hox-2 genes, whose overlapping and spatially restricted expression domains represent a combinatorial code for generating regional diversity 3-5. Vertebrates possess four Hox clusters of Antennapedia class homeobox genes, related to each other by duplication and divergence from a common ancestral complex 3,6-8. In consequence, at equivalent positions in different clusters there are highly related genes known as subfamilies or paralogous groups. As Hox-2 genes cannot fully account for patterning individual rhombomeres, we investigated whether offsets in expression limits of paralogous genes could account for the generation of regional diversity. We report here that, with the exception of the labial subfamily, paralogues show identical expression limits in rhombomeres, cranial ganglia and branchial arches, providing a combinatorial Hox code for the branchial region that seems to be different in organization to that of the trunk.	NATL INST MED RES, MRC, EUKARYOT MOLEC GENET LAB, RIDGEWAY, LONDON NW7 1AA, ENGLAND; CNR, INT INST GENET & BIOPHYS, NAPLES, ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)			Gulisano, Massimo/F-6609-2012; Sham, Mai Har/AAX-3781-2020; Krumlauf, Robb/AAH-5012-2019	Gulisano, Massimo/0000-0001-8654-1745; Sham, Mai Har/0000-0003-1179-7839; Krumlauf, Robb/0000-0001-9102-7927				BONCINELLI E, 1991, TRENDS GENET, V7, P329, DOI 10.1016/0168-9525(91)90423-N; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; COHEN SM, 1990, NATURE, V346, P482, DOI 10.1038/346482a0; DOLLE P, 1990, DEVELOPMENT, V110, P1133; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DUBOULE D, 1986, EMBO J, V5, P1973, DOI 10.1002/j.1460-2075.1986.tb04452.x; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; FEATHERSTONE MS, 1988, P NATL ACAD SCI USA, V85, P4760, DOI 10.1073/pnas.85.13.4760; FINKELSTEIN R, 1990, NATURE, V346, P485, DOI 10.1038/346485a0; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; FROHMAN MA, 1989, TECHNIQUE, V1, P165; GAUNT SJ, 1987, DEVELOPMENT, V101, P51; GAUNT SJ, 1988, DEVELOPMENT, V103, P135; GAUNT SJ, 1989, DEVELOPMENT, V107, P131; GRAHAM A, 1991, DEVELOPMENT, V112, P255; GRAHAM A, 1988, GENE DEV, V2, P1424, DOI 10.1101/gad.2.11.1424; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; HOLLAND P, 1990, EVOLUTION SEGMENTAL, V1, P135; HUNT P, 1991, DEVELOPMENT, V112, P43; HUNT P, 1991, DEVELOPMENT, P187; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUMSDEN A, 1990, TRENDS NEUROSCI, V13, P329, DOI 10.1016/0166-2236(90)90144-Y; LUMSDEN A, IN PRESS DEVELOPMENT; Lumsden A.G.S., 1990, Seminars in Developmental Biology, V1, P117; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; MURPHY P, 1991, DEVELOPMENT, V111, P61; NODEN DM, 1988, DEVELOPMENT, V103, P121; NOHNO T, 1991, CELL, V64, P1197, DOI 10.1016/0092-8674(91)90274-3; PRICE M, 1991, NATURE, V351, P748, DOI 10.1038/351748a0; SIMEONE A, 1991, MECH DEVELOP, V33, P215, DOI 10.1016/0925-4773(91)90029-6; SUNDIN OH, 1990, GENE DEV, V4, P1267, DOI 10.1101/gad.4.8.1267; THOROGOOD P, 1988, DEVELOPMENT, V103, P141; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0	39	456	463	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 31	1991	353	6347					861	864		10.1038/353861a0	http://dx.doi.org/10.1038/353861a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM732	1682814				2022-12-01	WOS:A1991GM73200065
J	KATZ, H; HOMAN, M; VELOSA, J; ROBERTSON, P; RIZZA, R				KATZ, H; HOMAN, M; VELOSA, J; ROBERTSON, P; RIZZA, R			EFFECTS OF PANCREAS TRANSPLANTATION ON POSTPRANDIAL GLUCOSE-METABOLISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEPENDENT DIABETES-MELLITUS; INSULIN RESISTANCE; C-PEPTIDE; HYPERINSULINEMIA; GLUCONEOGENESIS; STIMULATION; RECIPIENTS; EXTRACTION; SECRETION; TRANSPORT	Background. Because a pancreas allograft is placed in the pelvis, pancreas transplantation abolishes the normal gradient between portal-vein and peripheralvein insulin concentrations and causes systemic hyperinsulinemia. Whether pancreas transplantation restores carbohydrate metabolism to normal is not known. Methods. We studied seven patients with insulin-dependent diabetes mellitus after pancreas-kidney transplantation, seven nondiabetic patients after kidney transplantation (to control for immunosuppression), and eight normal subjects. Measurements were made after an overnight fast and after ingestion of a mixed meal. Results. Although plasma glucose concentrations did not differ in the two transplant groups, plasma insulin concentrations were significantly higher in the diabetic pancreas-kidney recipients than in the nondiabetic kidney recipients, both before the meal (mean +/- SE, 102 +/- 15 vs. 53 +/- 6 pmol per liter; P < 0.05) and afterward (123 +/- 22 vs. 61 +/- 6 nmol per liter per six hours; P < 0.05). Plasma C-peptide concentrations were the same in both groups, indicating that hyperinsulinemia was due to decreased insulin clearance rather than increased insulin secretion. Despite drainage of the venous effluent from the transplanted pancreas into the systemic circulation, the values for splanchnic clearance of ingested glucose, suppression of hepatic glucose release, incorporation of carbon dioxide into glucose, stimulation of glucose oxidation, glucose uptake, and forearm glucose clearance were all similar in the transplant groups and differed minimally from the values in the normal group. The similar rates of glucose uptake in the presence of higher systemic insulin concentrations indicated that the extrahepatic tissues of the diabetic pancreas-kidney recipients were insulin-resistant. Conclusions. Despite systemic delivery of insulin, pancreas-kidney transplantation in patients with diabetes results in carbohydrate metabolism similar to that in nondiabetic subjects receiving the same immunosuppressive agents after kidney transplantation.	MAYO CLIN & MAYO FDN,DEPT MED,ROCHESTER,MN 55905; UNIV MINNESOTA,DEPT MED,MINNEAPOLIS,MN 55455	Mayo Clinic; University of Minnesota System; University of Minnesota Twin Cities					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000585] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039994, R01DK029953, R37DK029953] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00585] Funding Source: Medline; NIDDK NIH HHS [DK-39994, DK-29953] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELL PM, 1986, J CLIN INVEST, V78, P1479, DOI 10.1172/JCI112739; BERGMAN RN, 1974, AM J PHYSIOL, V227, P1314, DOI 10.1152/ajplegacy.1974.227.6.1314; BLACKARD WG, 1970, DIABETES, V19, P302, DOI 10.2337/diab.19.5.302; BROSNAN JT, 1982, FED PROC, V41, P91; BUTLER PC, 1990, DIABETES, V39, P1373, DOI 10.2337/diabetes.39.11.1373; Consolazio CF., 1963, HDB PHYSL, P313; DEBODO RC, 1963, RECENT PROG HORM RES, V19, P445; DIEM P, 1990, DIABETES, V39, P534, DOI 10.2337/diabetes.39.5.534; FALHOLT K, 1991, METABOLISM, V40, P122, DOI 10.1016/0026-0495(91)90161-O; FALOONA GR, 1974, METHOD HORM RADIOIMM, P317; FIRTH RG, 1986, J CLIN INVEST, V77, P1525, DOI 10.1172/JCI112467; FRAYN KN, 1983, J APPL PHYSIOL, V55, P628, DOI 10.1152/jappl.1983.55.2.628; GAVIN JR, 1974, P NATL ACAD SCI USA, V71, P84, DOI 10.1073/pnas.71.1.84; HEDING LG, 1975, DIABETOLOGIA, V11, P201, DOI 10.1007/BF00422322; HERBERT V, 1965, J CLIN ENDOCR METAB, V25, P1375, DOI 10.1210/jcem-25-10-1375; HORWITZ DL, 1975, J CLIN INVEST, V55, P1278, DOI 10.1172/JCI108047; ISSEKUTZ B, 1977, METABOLISM, V26, P157, DOI 10.1016/0026-0495(77)90051-8; KAIHARA S, 1968, J LAB CLIN MED, V71, P400; KATZ J, 1985, AM J PHYSIOL, V248, pR391, DOI 10.1152/ajpregu.1985.248.4.R391; KRUSZYNSKA YT, 1987, METABOLISM, V36, P281, DOI 10.1016/0026-0495(87)90189-2; KRYSHAK EJ, 1990, DIABETES, V39, P142, DOI 10.2337/diabetes.39.2.142; LUZI L, 1990, DIABETOLOGIA, V33, P549, DOI 10.1007/BF00404143; MARCO J, 1973, NEW ENGL J MED, V288, P128, DOI 10.1056/NEJM197301182880305; MARSHALL S, 1980, J CLIN INVEST, V66, P763, DOI 10.1172/JCI109914; MCMAHON M, 1989, DIABETES, V38, P291, DOI 10.2337/diabetes.38.3.291; MCMAHON MM, 1989, DIABETES, V38, P97, DOI 10.2337/diabetes.38.1.97; MYERS SR, 1991, J CLIN INVEST, V87, P930, DOI 10.1172/JCI115100; OSEI K, 1990, DIABETES, V39, P1235, DOI 10.2337/diabetes.39.10.1235; OSTMAN J, 1989, DIABETES, V38, P88, DOI 10.2337/diab.38.1.S88; POLONSKY K, 1990, DIABETES S1, V39, pA15; POLONSKY KS, 1984, DIABETES, V33, P486, DOI 10.2337/diabetes.33.5.486; RADZIUK J, 1978, METABOLISM, V27, P657, DOI 10.1016/0026-0495(78)90003-3; RIZZA RA, 1985, DIABETOLOGIA, V28, P70; RIZZA RA, 1982, J CLIN ENDOCR METAB, V54, P131, DOI 10.1210/jcem-54-1-131; RIZZA RA, 1981, AM J PHYSIOL, V240, pE630, DOI 10.1152/ajpendo.1981.240.6.E630; RUDERMAN NB, 1968, AM J PHYSIOL, V214, P1346, DOI 10.1152/ajplegacy.1968.214.6.1346; STALMANS W, 1974, EUR J BIOCHEM, V41, P117; STEELE R, 1956, AM J PHYSIOL, V187, P15, DOI 10.1152/ajplegacy.1956.187.1.15; SUTHERLAND DE, 1986, CLIN CHEM S10, V10, pB83; WARDZALA LJ, 1985, J CLIN INVEST, V76, P460, DOI 10.1172/JCI111994; WOLFE RR, 1986, AM J PHYSIOL, V250, pE306, DOI 10.1152/ajpendo.1986.250.3.E306	41	129	129	1	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 31	1991	325	18					1278	1283		10.1056/NEJM199110313251804	http://dx.doi.org/10.1056/NEJM199110313251804			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM041	1922222	Bronze			2022-12-01	WOS:A1991GM04100004
J	LENARDO, MJ				LENARDO, MJ			INTERLEUKIN-2 PROGRAMS MOUSE ALPHA-BETA-LYMPHOCYTES-T FOR APOPTOSIS	NATURE			English	Article							STAPHYLOCOCCAL ENTEROTOXIN-B; CELL ANTIGEN RECEPTOR; STIMULATORY FACTOR-I; MONOCLONAL-ANTIBODY; PROLIFERATION; INVIVO; ACTIVATION; CLONES; UNRESPONSIVENESS; THYMOCYTES	ANTIGEN receptor stimulation of mature alpha-beta-T lymphocytes can lead either to proliferation or death 1-4. Programmed cell death, termed apoptosis, leads to the clonal deletion of both thymocytes and mature T cells that establishes tolerance 5-9. How a mature T cell selects between proliferation and death is not understood. Here I show that interleukin-2 (IL-2) is a critical determinant of the choice between these two fates. Both CD4+ and CD8+ T cells previously exposed to IL-2 undergo apoptosis after antigen-receptor stimulation. Antibody blockade of IL-2 but not IL-4 reverses the marked reduction of lymph node V-beta-38+ T cells caused in mice by the bacterial superantigen Staphylococcus aureus enterotoxin B. IL-2 may thus participate in a feedback regulatory mechanism by predisposing mature T lymphocytes to apoptosis.			LENARDO, MJ (corresponding author), NIAID,IMMUNOL LAB,BLDG 10,RM 11N311,BETHESDA,MD 20892, USA.							ASHWELL JD, 1986, J IMMUNOL, V137, P2572; CRISPE IN, 1985, NATURE, V317, P627, DOI 10.1038/317627a0; FINKELMAN FD, 1986, P NATL ACAD SCI USA, V83, P9675, DOI 10.1073/pnas.83.24.9675; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; HECHT TT, 1983, J IMMUNOL, V131, P1049; JANSSEN O, 1991, J IMMUNOL, V146, P35; JONES LA, 1990, SCIENCE, V250, P1726, DOI 10.1126/science.2125368; KANAGAWA O, 1989, J EXP MED, V170, P1513, DOI 10.1084/jem.170.5.1513; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LIU Y, 1990, Journal of Experimental Medicine, V172, P1735, DOI 10.1084/jem.172.6.1735; MACDONALD HR, 1990, NATURE, V343, P642, DOI 10.1038/343642a0; MALEK TR, 1984, J IMMUNOL, V133, P1976; MARRACK P, 1990, J EXP MED, V171, P455, DOI 10.1084/jem.171.2.455; MONOD J, 1961, COLD SPRING HARB SYM, V26, P389, DOI 10.1101/SQB.1961.026.01.048; MUELLER DL, 1989, J IMMUNOL, V142, P2617; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NAU GJ, 1987, J IMMUNOL, V139, P114; OHARA J, 1985, NATURE, V315, P333, DOI 10.1038/315333a0; PENIT C, 1988, J IMMUNOL, V140, P3315; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; RUSSELL JH, 1991, P NATL ACAD SCI USA, V88, P2151, DOI 10.1073/pnas.88.6.2151; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; STAERZ UD, 1985, J IMMUNOL, V134, P3994; TENTORI L, 1988, J EXP MED, V168, P1741, DOI 10.1084/jem.168.5.1741; WEAVER CT, 1988, P NATL ACAD SCI USA, V85, P8181, DOI 10.1073/pnas.85.21.8181; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; WILLIAMS ME, 1990, J IMMUNOL, V144, P1208	29	970	1004	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 31	1991	353	6347					858	861		10.1038/353858a0	http://dx.doi.org/10.1038/353858a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM732	1944559				2022-12-01	WOS:A1991GM73200064
J	LI, JD; CARROLL, J; ELLAR, DJ				LI, JD; CARROLL, J; ELLAR, DJ			CRYSTAL-STRUCTURE OF INSECTICIDAL DELTA-ENDOTOXIN FROM BACILLUS-THURINGIENSIS AT 2.5-A RESOLUTION	NATURE			English	Article							BRUSH-BORDER MEMBRANE; VAR TENEBRIONIS; MACROMOLECULAR CRYSTALLOGRAPHY; PROTEIN-STRUCTURE; SPECIFICITY; GENE; BINDING; PURIFICATION; COLEOPTERA; MECHANISM	The structure of the delta-endotoxin from Bacillus thuringiensis subsp. tenebrionis that is specifically toxic to Coleoptera insects (beetle toxin) has been determined at 2.5 angstrom resolution. It comprises three domains which are, from the N- to C-termini, a seven-helix bundle, a three-sheet domain, and a beta-sandwich. The core of the molecule encompassing all the domain interfaces is built from conserved sequence segments of the active delta-endotoxins. Therefore the structure represents the general fold of this family of insecticidal proteins. The bundle of long, hydrophobic and amphipathic helices is equipped for pore formation in the insect membrane, and regions of the three-sheet domain are probably responsible for receptor binding.	UNIV CAMBRIDGE, DEPT BIOCHEM, CAMBRIDGE CB2 1QW, ENGLAND	University of Cambridge	LI, JD (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.							ADANG MJ, 1985, GENE, V36, P289, DOI 10.1016/0378-1119(85)90184-2; AHMAD W, 1990, FEMS MICROBIOL LETT, V68, P97, DOI 10.1111/j.1574-6968.1990.tb04130.x; ARNDT UW, 1985, METHOD ENZYMOL, V114, P472; BARTON KA, 1987, PLANT PHYSIOL, V85, P1103, DOI 10.1104/pp.85.4.1103; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; CARROLL J, 1989, BIOCHEM J, V261, P99, DOI 10.1042/bj2610099; CHOMA CT, 1990, BIOCHEMISTRY-US, V29, P10971, DOI 10.1021/bi00501a015; CHOTHIA C, 1990, ANNU REV BIOCHEM, V59, P1007, DOI 10.1146/annurev.bi.59.070190.005043; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; CHUNGJATUPORNCHAI W, 1988, EUR J BIOCHEM, V173, P9, DOI 10.1111/j.1432-1033.1988.tb13960.x; ELLAR DJ, 1985, MOL BIOL MICROBIAL D, P230; ENDO Y, 1980, J INVERTEBR PATHOL, V36, P90, DOI 10.1016/0022-2011(80)90140-8; GE AZ, 1989, P NATL ACAD SCI USA, V86, P4037, DOI 10.1073/pnas.86.11.4037; HAIDER MZ, 1987, BIOCHEM J, V248, P197, DOI 10.1042/bj2480197; Hodgman T. C, 1990, J DNA SEQU MAPPING, V1, P97; HOFMANN C, 1988, P NATL ACAD SCI USA, V85, P7844, DOI 10.1073/pnas.85.21.7844; HOFMANN C, 1988, EUR J BIOCHEM, V173, P85, DOI 10.1111/j.1432-1033.1988.tb13970.x; HOFTE H, 1986, EUR J BIOCHEM, V161, P273, DOI 10.1111/j.1432-1033.1986.tb10443.x; HOFTE H, 1989, MICROBIOL REV, V53, P242; HOFTE H, 1987, NUCLEIC ACIDS RES, V15, P7183, DOI 10.1093/nar/15.17.7183; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KNOWLES BH, 1987, BIOCHIM BIOPHYS ACTA, V924, P509, DOI 10.1016/0304-4165(87)90167-X; KNOWLES BH, 1986, J CELL SCI, V83, P89; KNOWLES BH, 1984, FEBS LETT, V168, P197, DOI 10.1016/0014-5793(84)80245-8; KRAULIS P, IN PRESS J APPL CRYS; KRIEG A, 1983, Z ANGEW ENTOMOL, V96, P500; LAKEY JH, 1991, J MOL BIOL, V218, P639, DOI 10.1016/0022-2836(91)90707-D; LESLIE AGW, 1987, ACTA CRYSTALLOGR A, V43, P134, DOI 10.1107/S0108767387099720; LI J, 1988, J MOL BIOL, V199, P543, DOI 10.1016/0022-2836(88)90625-0; MACINTOSH SC, 1990, BIOCHEM BIOPH RES CO, V170, P665, DOI 10.1016/0006-291X(90)92143-N; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; NICHOLLS CN, 1989, J BACTERIOL, V171, P5141, DOI 10.1128/jb.171.9.5141-5147.1989; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; PERLAK FJ, 1991, P NATL ACAD SCI USA, V88, P3324, DOI 10.1073/pnas.88.8.3324; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SCHNEPF HE, 1985, J BIOL CHEM, V260, P6273; SCHNEPF HE, 1990, J BIOL CHEM, V265, P20923; SEKAR V, 1987, P NATL ACAD SCI USA, V84, P7036, DOI 10.1073/pnas.84.20.7036; SONG HY, 1991, J BACTERIOL, V173, P2927, DOI 10.1128/JB.173.9.2927-2934.1991; VAECK M, 1987, NATURE, V328, P33, DOI 10.1038/328033a0; VANRIE J, 1990, APPL ENVIRON MICROB, V56, P1378, DOI 10.1128/AEM.56.5.1378-1385.1990; VISSER B, 1990, J BACTERIOL, V172, P6783, DOI 10.1128/jb.172.12.6783-6788.1990; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WIDNER WR, 1990, J BACTERIOL, V172, P2826, DOI 10.1128/jb.172.6.2826-2832.1990; Wilcox D. R., 1986, PROTEIN ENG APPLICAT, P395	47	614	690	1	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 31	1991	353	6347					815	821		10.1038/353815a0	http://dx.doi.org/10.1038/353815a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM732	1658659				2022-12-01	WOS:A1991GM73200050
J	MISBIN, RI				MISBIN, RI			PHYSICIANS AID IN DYING	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ASSISTED SUICIDE; EUTHANASIA				MISBIN, RI (corresponding author), UNIV FLORIDA, GAINESVILLE, FL 32610 USA.							ALTMAN LK, 1991, NY TIMES        0724, pA10; ANGELL M, 1988, NEW ENGL J MED, V319, P1348, DOI 10.1056/NEJM198811173192010; ANNAS GJ, 1990, NEW ENGL J MED, V323, P686, DOI 10.1056/NEJM199009063231020; BEAUCHAMP TL, 1989, PRINCIPLES BIOMEDICA, P151; BEAUCHAMP TL, PRINCIPLES BIOMEDICA, V127, P89; CALLAHAN D, 1990, WHAT KIND LIFE LIMIT, P233; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; DEWACHTER MAM, 1989, JAMA-J AM MED ASSOC, V262, P3316, DOI 10.1001/jama.262.23.3316; Doerflinger R, 1989, Hastings Cent Rep, V19, P16, DOI 10.2307/3561965; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; GIANELLI DM, 1991, WASHINGTON STATE PHY, P1; GIANELLI DM, 1991, AM MED NEWS     0107, P9; HECHINGER FM, 1991, NY TIMES        0124, pA22; HORAN DJ, 1980, DEATH DYING EUTHANAS, P127; JAKOBOVITS I, 1961, Harofe Haivri Heb Med J, V2, P242; ORENTLICHER D, 1989, JAMA-J AM MED ASSOC, V262, P1844, DOI 10.1001/jama.262.13.1844; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; ROSNER F, 1986, MODERN MED JEWISH ET, P189; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; THOMASMA DC, 1990, EUTHANASIA ETHICAL S; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; WEIR RF, 1989, ABATING TREATMENT CR; WERTHAM F, 1980, DEATH DYING EUTHANAS, P610; Wolf S M, 1989, Hastings Cent Rep, V19, P13, DOI 10.2307/3561964; 1988, JAMA-J AM MED ASSOC, V259, P272	25	37	37	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 31	1991	325	18					1307	1311		10.1056/NEJM199110313251811	http://dx.doi.org/10.1056/NEJM199110313251811			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM041	1922229				2022-12-01	WOS:A1991GM04100011
J	PAMER, EG; HARTY, JT; BEVAN, MJ				PAMER, EG; HARTY, JT; BEVAN, MJ			PRECISE PREDICTION OF A DOMINANT CLASS-I MHC-RESTRICTED EPITOPE OF LISTERIA-MONOCYTOGENES	NATURE			English	Article							LYMPHOCYTES-T; CELLS; HEMOLYSIN; EXPRESSION; IMMUNITY; GROWTH; DETERMINANT; INFECTION; VIRULENCE; PEPTIDE	Listeria monocytogenes is a Gram-positive bacterium which grows in the cytoplasm of eukaryotic cells and can cause severe disease in immunocompromised individuals 1,2. In murine systems CD8+ T lymphocytes have been shown to be important effectors of acquired protective immunity against L. monocytogenes 3-5. Class I MHC restricted CD8+ cytotoxic T lymphocytes (CTL), which lyse J774 macrophage-like targets infected with L. monocytogenes, are induced following in vivo injection of live organisms. Natural peptide epitopes derived from L. monocytogenes can be acid-extracted from heavily infected BALB/c spleens and detected by CTL. A CTL clone, B9, derived from a (BALB/c x C57BL/6)F1 (H-2dxb) mouse, recognizes one of these natural epitopes in an H-2K(d)-restricted fashion. B9 also recognizes P815 (H-2d) mastocytoma cells transfected with the listeriolysin gene. To identify the region of the listeriolysin recognized by CTL we used the H-2K(d) peptide-binding motif described by Rammensee and colleagues 6 to synthesize 11 nonamer peptides. One of these peptides, listeriolysin 91-99, was recognized very efficiently by B9. This represents the first identified class I MHC-restricted epitope of bacteria and demonstrates the utility of the allele-specific motif for predicting CTL epitopes.	UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	PAMER, EG (corresponding author), UNIV WASHINGTON, HOWARD HUGHES MED INST, DEPT IMMUNOL, SEATTLE, WA 98195 USA.			Harty, John/0000-0001-7266-2802	Howard Hughes Medical Institute Funding Source: Medline; NIAID NIH HHS [R01 AI046653, R01 AI039031-11, R01 AI080619, R01 AI046653-05, R01 AI039031, R01 AI019335-19, R01 AI019335] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039031, R01AI046653, R01AI019335, R01AI080619] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AICHELE P, 1990, J EXP MED, V171, P1815, DOI 10.1084/jem.171.5.1815; BERCHE P, 1987, J IMMUNOL, V139, P3813; BISHOP DK, 1987, J IMMUNOL, V139, P2005; BRUNT LM, 1990, J IMMUNOL, V145, P3540; DELIBERO G, 1986, J IMMUNOL, V137, P2688; DERES K, 1989, NATURE, V342, P561, DOI 10.1038/342561a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GAILLARD JL, 1986, INFECT IMMUN, V52, P50, DOI 10.1128/IAI.52.1.50-55.1986; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; KAST WM, 1991, P NATL ACAD SCI USA, V88, P2283, DOI 10.1073/pnas.88.6.2283; KATHARIOU S, 1987, J BACTERIOL, V169, P1291, DOI 10.1128/jb.169.3.1291-1297.1987; KAUFMANN SHE, 1986, J EXP MED, V164, P363, DOI 10.1084/jem.164.1.363; LUKACS K, 1989, J IMMUNOL, V143, P3731; MACKANESS GB, 1962, J EXP MED, V116, P381, DOI 10.1084/jem.116.3.381; MARGET W, 1988, INFECTION, V16, pS175, DOI 10.1007/BF01639744; MENGAUD J, 1988, INFECT IMMUN, V56, P766, DOI 10.1128/IAI.56.4.766-772.1988; MIELKE MEA, 1988, INFECT IMMUN, V56, P1920, DOI 10.1128/IAI.56.8.1920-1925.1988; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; PINE L, 1987, J CLIN MICROBIOL, V25, P2247, DOI 10.1128/JCM.25.11.2247-2251.1987; PORTNOY DA, 1988, J EXP MED, V167, P1459, DOI 10.1084/jem.167.4.1459; ROTZSCHKE O, 1990, SCIENCE, V249, P283, DOI 10.1126/science.1695760; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SAFLEY SA, 1991, J IMMUNOL, V146, P3604; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; VANBLEEK GM, 1990, NATURE, V348, P213	26	398	430	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 31	1991	353	6347					852	855		10.1038/353852a0	http://dx.doi.org/10.1038/353852a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM732	1719425	Green Accepted			2022-12-01	WOS:A1991GM73200062
J	PAOLINI, R; JOUVIN, MH; KINET, JP				PAOLINI, R; JOUVIN, MH; KINET, JP			PHOSPHORYLATION AND DEPHOSPHORYLATION OF THE HIGH-AFFINITY RECEPTOR FOR IMMUNOGLOBULIN-E IMMEDIATELY AFTER RECEPTOR ENGAGEMENT AND DISENGAGEMENT	NATURE			English	Article							CELL ANTIGEN RECEPTOR; NATURAL-KILLER-CELLS; FC-GAMMA RECEPTOR; IGE RECEPTOR; ZETA-CHAIN; MOLECULAR-CLONING; CD16; EXPRESSION; SUBUNIT; RIII	TRIGGERING of mast cells and basophils by immunoglobulin E (IgE) and antigen induces various biochemical signals, including tyrosine kinase activation 1,2, which lead to cell degranulation and the release of mediators of the allergic reaction. The high-affinity receptor for IgE (Fc-epsilon-RI) responsible for initiating these events is a complex structure composed of an IgE-binding alpha-chain, a beta-chain and a homodimer of gamma-chains 3. It has been assumed that beta and gamma, which have extensive cytoplasmic domains, play an important but undefined role in coupling Fc-epsilon-RI to signal transduction mechanisms. Here we show that Fc-epsilon-RI engagement induces immediate in vivo phosphorylation on beta (tyrosine and serine) and gamma (tyrosine and threonine) by at least two different non-receptor kinases. We take advantage of unique features of this receptor system to demonstrate that the phosphorylation signal is restricted to activated receptors and is immediately reversible upon receptor disengagement by undefined phosphatases. Rapid phosphorylation and dephosphorylation may be a general mechanism to couple and uncouple activated receptors to other effector molecules. This could be particularly relevant to other multimeric receptors containing Fc-epsilon-RI gamma-chains or the related-zeta and eta-chains such as the T-cell antigen receptor (TCR) 4-6 and the low-affinity receptor for immunoglobulin G (Fc-gamma-RIII, CD16) (refs 7-11).			PAOLINI, R (corresponding author), NIAID,MOLEC ALLERGY & IMMUNOL SECT,TWINBROOK II BLDG,12441 PARKLAWN DR,ROCKVILLE,MD 20852, USA.			PAOLINI, Rossella/0000-0001-7605-1531				ANDERSON P, 1990, P NATL ACAD SCI USA, V87, P2274, DOI 10.1073/pnas.87.6.2274; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BASCIANO LK, 1986, J BIOL CHEM, V261, P1823; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; CONNELLY PA, 1991, BIOCHEM BIOPH RES CO, V177, P192, DOI 10.1016/0006-291X(91)91967-H; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CUNHAMELO JR, 1987, J BIOL CHEM, V262, P11455; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; HIBBS ML, 1989, SCIENCE, V246, P1608, DOI 10.1126/science.2531918; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JIN YJ, 1990, P NATL ACAD SCI USA, V87, P3319, DOI 10.1073/pnas.87.9.3319; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KUROSAKI T, 1989, NATURE, V342, P805, DOI 10.1038/342805a0; LANE PJL, 1991, J IMMUNOL, V146, P715; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; LIU FT, 1980, J IMMUNOL, V124, P2728; MILLARD PJ, 1988, P NATL ACAD SCI USA, V85, P1854, DOI 10.1073/pnas.85.6.1854; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; OSHEA JJ, 1991, P NATL ACAD SCI USA, V88, P350, DOI 10.1073/pnas.88.2.350; PEREZMONTFORT R, 1983, BIOCHEMISTRY-US, V22, P5733, DOI 10.1021/bi00294a009; QUARTO R, 1986, MOL IMMUNOL, V23, P1215, DOI 10.1016/0161-5890(86)90154-9; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; RIVERA J, 1988, MOL IMMUNOL, V25, P647, DOI 10.1016/0161-5890(88)90100-9; STEPHAN V, 1991, FASEB J, V5; VIVIER E, 1991, J IMMUNOL, V146, P206; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377	28	284	287	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 31	1991	353	6347					855	858		10.1038/353855a0	http://dx.doi.org/10.1038/353855a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM732	1834946				2022-12-01	WOS:A1991GM73200063
J	RALSTON, R				RALSTON, R			COMPLEMENTATION OF TRANSFORMING DOMAINS IN E1A/MYC CHIMERAS	NATURE			English	Article							ADENOVIRUS E1A PROTEINS; C-MYC; LARGE-T; ONCOGENES; PRODUCTS; REGIONS; GENE; CELLS; E7	THE myc oncogene is functionally similar to adenovirus E1a in its ability to collaborate with activated ras oncogenes to transform primary fibroblasts 1,2. The transforming functions of E1a and myc have been mapped to two distinct regions in each protein 3,4. I investigated the functional similarities between E1a and myc by constructing E1a/myc chimaeras to discover whether the individual transforming domains of E1a could complement individual myc-transforming domains. Transformation assays in rat embryo fibroblasts demonstrated that the N-terminal transforming domain of E1a (CR1; ref. 5) could complement the C-terminal transforming domain of myc in cis, and that the reciprocal chimaera (N-terminal myc/C-terminal E1a) was also active. Chimaeras constructed using domains from transformation-defective mutants of either E1a or myc were inactive, indicating that both E1a and myc domains contribute to function. These experiments suggest that transformation by myc and E1a may involve interactions with common substrates.			RALSTON, R (corresponding author), CHIRON CORP, 4560 HORTON ST, EMERYVILLE, CA 94608 USA.		Ralston, Robert O/A-6924-2009					ALITALO K, 1983, NATURE, V306, P274, DOI 10.1038/306274a0; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRANTON PE, 1984, BIOCHIM BIOPHYS ACTA, V780, P67, DOI 10.1016/0304-419X(84)90007-6; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; JONES NC, 1983, MOL CELL BIOL, V3, P2131, DOI 10.1128/MCB.3.12.2131; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MORAN B, 1988, MOL CELL BIOL, V8, P1756, DOI 10.1128/MCB.8.4.1756; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; RALSTON R, 1983, NATURE, V306, P803, DOI 10.1038/306803a0; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; SYMONDS G, 1989, ONCOGENE, V4, P285; VOUSDEN KH, 1989, ONCOGENE, V4, P153; WAGNER S, 1991, NATURE, V352, P189, DOI 10.1038/352189a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988	24	23	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 31	1991	353	6347					866	868		10.1038/353866a0	http://dx.doi.org/10.1038/353866a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM732	1834947				2022-12-01	WOS:A1991GM73200067
J	REVAH, F; BERTRAND, D; GALZI, JL; DEVILLERSTHIERY, A; MULLE, C; HUSSY, N; BERTRAND, S; BALLIVET, M; CHANGEUX, JP				REVAH, F; BERTRAND, D; GALZI, JL; DEVILLERSTHIERY, A; MULLE, C; HUSSY, N; BERTRAND, S; BALLIVET, M; CHANGEUX, JP			MUTATIONS IN THE CHANNEL DOMAIN ALTER DESENSITIZATION OF A NEURONAL NICOTINIC RECEPTOR	NATURE			English	Article							AFFINITY BINDING-SITE; ACETYLCHOLINE-RECEPTOR; H-3 CHLORPROMAZINE; ION CHANNEL; DELTA-SUBUNIT; NONCOMPETITIVE BLOCKERS; ACTIVATED CHANNELS; AMINO-ACIDS; SUPERFAMILY; TRANSPORT	A VARIETY of ligand-gated ion channels undergo a fast activation process after the rapid application of agonist and also a slower transition towards desensitized or inactivated closed channel states when exposure to agonist is prolonged 1-5. Desensitization involves at least two distinct closed states in the acetylcholine receptor, each with an affinity for agonists higher than those of the resting or active conformations 1-5. Here we investigate how structural elements could be involved in the desensitization of the acetylcholine-gated ion channel from the chick brain alpha-bungarotoxin sensitive homo-oligomeric alpha-7 receptor 6,7, using site-directed mutagenesis and expression in Xenopus oocytes. Mutations of the highly conserved leucine 247 residue 8,9 from the uncharged MII segment of alpha-7 suppress inhibition by the open-channel blocker QX-222 (ref. 10), indicating that this residue, like others from MII (refs 11-22), faces the lumen of the channel. But, unexpectedly, the same mutations decrease the rate of desensitization of the response, increase the apparent affinity for acetylcholine and abolish current rectification. Moreover, unlike wild-type alpha-7, which has channels with a single conductance level, the leucine-to-threonine mutant has an additional conducting state active at low acetylcholine concentrations. It is possible that mutation of Leu 247 renders conductive one of the high-affinity desensitized states of the receptor.	UNIV GENEVA,DEPT BIOCHIM,CH-1211 GENEVA 4,SWITZERLAND; UNIV GENEVA,MED CTR,FAC MED,DEPT PHYSIOL,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva; University of Geneva	REVAH, F (corresponding author), INST PASTEUR,CNRS,UNITE RECH ASSOCIEE D1284,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.			Mulle, Christophe/0000-0003-2709-6615				Bertrand D, 1991, METHODS NEUROSCIENCE, V4, P174; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; CHARNET P, 1990, NEURON, V4, P87, DOI 10.1016/0896-6273(90)90445-L; COOPER E, 1991, NATURE, V350, P235, DOI 10.1038/350235a0; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; GIRAUDAT J, 1986, P NATL ACAD SCI USA, V83, P2719, DOI 10.1073/pnas.83.8.2719; GIRAUDAT J, 1987, BIOCHEMISTRY-US, V26, P2410, DOI 10.1021/bi00383a003; GIRAUDAT J, 1989, FEBS LETT, V253, P190, DOI 10.1016/0014-5793(89)80957-3; HEIDMANN T, 1983, BIOCHEMISTRY-US, V22, P5452, DOI 10.1021/bi00292a029; HEIDMANN T, 1979, EUR J BIOCHEM, V94, P281, DOI 10.1111/j.1432-1033.1979.tb12894.x; HUCHO F, 1986, FEBS LETT, V205, P137, DOI 10.1016/0014-5793(86)80881-X; IMOTO K, 1986, NATURE, V324, P670, DOI 10.1038/324670a0; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; JOHNSON JW, 1990, BIOPHYS J, V57, P1085, DOI 10.1016/S0006-3495(90)82626-6; KATZ B, 1957, J PHYSIOL-LONDON, V138, P63, DOI 10.1113/jphysiol.1957.sp005838; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; NEHER E, 1978, J PHYSIOL-LONDON, V277, P153, DOI 10.1113/jphysiol.1978.sp012267; NEUBIG RR, 1982, BIOCHEMISTRY-US, V21, P3460, DOI 10.1021/bi00257a032; OBERTHUR W, 1986, EMBO J, V5, P1815, DOI 10.1002/j.1460-2075.1986.tb04431.x; REVAH F, 1990, P NATL ACAD SCI USA, V87, P4675, DOI 10.1073/pnas.87.12.4675; SAKMANN B, 1980, NATURE, V286, P71, DOI 10.1038/286071a0; SCHOEPFER R, 1990, NEURON, V5, P35, DOI 10.1016/0896-6273(90)90031-A; VILLARROEL A, 1991, P ROY SOC B-BIOL SCI, V243, P69, DOI 10.1098/rspb.1991.0012; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687; [No title captured]	25	461	474	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 31	1991	353	6347					846	849		10.1038/353846a0	http://dx.doi.org/10.1038/353846a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM732	1719423				2022-12-01	WOS:A1991GM73200060
J	WESTWOOD, JT; CLOS, J; WU, C				WESTWOOD, JT; CLOS, J; WU, C			STRESS-INDUCED OLIGOMERIZATION AND CHROMOSOMAL RELOCALIZATION OF HEAT-SHOCK FACTOR	NATURE			English	Article							DNA-BINDING PROPERTIES; DROSOPHILA-MELANOGASTER; TRANSCRIPTION FACTOR; RNA-POLYMERASE; PROTEINS; INVITRO; GENE; ACTIVATION; LOCALIZATION; UPSTREAM	The induction of heat-shock transcription factor (HSF) binding to DNA is accomplished by a heat-induced oligomerization. The transition to the induced state is accompanied by a chromosomal redistribution of HSF to the heat-shock puff sites. Over 150 additional chromosomal sites also accumulate HSF, including developmental loci that are repressed during heat shock. These findings suggest an unforeseen role for HSF as a repressor of normal gene activity during heat stress.			WESTWOOD, JT (corresponding author), NCI, BIOCHEM LAB, BG 37, RM 4C-09, BETHESDA, MD 20892 USA.							AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; ANDERSSON LO, 1972, FEBS LETT, V20, P199, DOI 10.1016/0014-5793(72)80793-2; Ashburner M, 1972, Results Probl Cell Differ, V4, P101; ASHBURNER M, 1970, CHROMOSOMA, V31, P356, DOI 10.1007/BF00321231; BECKER J, 1990, EUR J BIOCHEM, V189, P553, DOI 10.1111/j.1432-1033.1990.tb15522.x; BONNER JJ, 1982, CHROMOSOMA, V85, P93, DOI 10.1007/BF00344596; BONNER JJ, 1976, CELL, V8, P43, DOI 10.1016/0092-8674(76)90183-5; Bridges CB, 1935, J HERED, V26, P60, DOI 10.1093/oxfordjournals.jhered.a104022; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; DIGNAM AD, 1983, METHOD ENZYMOL, V191, P582; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.biochem.60.1.321; HOVEMANN B, 1986, MOL GEN GENET, V204, P334, DOI 10.1007/BF00425519; JAKOBSEN BK, 1991, EMBO J, V10, P369, DOI 10.1002/j.1460-2075.1991.tb07958.x; JAMRICH M, 1977, P NATL ACAD SCI USA, V74, P2079, DOI 10.1073/pnas.74.5.2079; KING WJ, 1984, NATURE, V307, P745, DOI 10.1038/307745a0; LAKHOTIA SC, 1987, J GENET, V66, P139, DOI 10.1007/BF02931660; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; Lefevre G., 1976, GENET BIOL DROSOPHIL, P31; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LIS JT, 1981, GENE, V15, P67, DOI 10.1016/0378-1119(81)90105-0; LIS JT, 1981, NUCLEIC ACIDS RES, V9, P5297, DOI 10.1093/nar/9.20.5297; MASON PJ, 1982, J MOL BIOL, V156, P21, DOI 10.1016/0022-2836(82)90456-9; Morimoto RI, 1990, STRESS PROTEINS BIOL; MOSSER DD, 1990, P NATL ACAD SCI USA, V87, P3748, DOI 10.1073/pnas.87.10.3748; PALTER KB, 1986, MOL CELL BIOL, V6, P1187, DOI 10.1128/MCB.6.4.1187; PARDUE ML, 1977, CHROMOSOMA, V63, P135, DOI 10.1007/BF00292726; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PELHAM HRB, 1982, CELL, V30, P517, DOI 10.1016/0092-8674(82)90249-5; PELHAM HRB, 1990, STRESS PROTEINS BIOL, P287; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; PERKINS LA, 1990, MOL CELL BIOL, V10, P3232, DOI 10.1128/MCB.10.6.3232; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RITOSSA F, 1962, EXPERIENTIA, V18, P571, DOI 10.1007/BF02172188; SARGE KD, IN PRESS GENES DEV; SCHARF KD, 1990, EMBO J, V9, P4495, DOI 10.1002/j.1460-2075.1990.tb07900.x; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SILVER LM, 1976, P NATL ACAD SCI USA, V73, P423, DOI 10.1073/pnas.73.2.423; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; SPRADLING A, 1977, J MOL BIOL, V109, P559, DOI 10.1016/S0022-2836(77)80091-0; THUMMEL CS, 1990, BIOESSAYS, V12, P561, DOI 10.1002/bies.950121202; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WELSHONS WV, 1984, NATURE, V307, P747, DOI 10.1038/307747a0; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X; WIEDERRECHT G, 1987, CELL, V48, P507, DOI 10.1016/0092-8674(87)90201-7; WU C, 1984, NATURE, V311, P81, DOI 10.1038/311081a0; WU C, 1984, NATURE, V309, P229, DOI 10.1038/309229a0; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975; WU C, 1985, NATURE, V317, P84, DOI 10.1038/317084a0; WU C, 1990, STRESS PROTEINS BIOL, P429; XIAO H, 1988, SCIENCE, V239, P1139, DOI 10.1126/science.3125608; ZIMARINO V, 1990, SCIENCE, V249, P546, DOI 10.1126/science.2200124; ZINK B, 1989, NATURE, V337, P468, DOI 10.1038/337468a0	56	320	328	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 31	1991	353	6347					822	823		10.1038/353822a0	http://dx.doi.org/10.1038/353822a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM732	1944557				2022-12-01	WOS:A1991GM73200051
J	WINGARD, JR; MERZ, WG; RINALDI, MG; JOHNSON, TR; KARP, JE; SARAL, R				WINGARD, JR; MERZ, WG; RINALDI, MG; JOHNSON, TR; KARP, JE; SARAL, R			INCREASE IN CANDIDA-KRUSEI INFECTION AMONG PATIENTS WITH BONE-MARROW TRANSPLANTATION AND NEUTROPENIA TREATED PROPHYLACTICALLY WITH FLUCONAZOLE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TORULOPSIS-GLABRATA; FUNGEMIA; FREQUENCY; CANCER; FEVER; COLONIZATION; THERAPY	Background. In early 1990 fluconazole was introduced as a prophylactic antifungal agent after bone marrow transplantation. During the same year Candida krusei emerged as the chief candida pathogen among patients with bone marrow transplants. Methods. To determine whether there was a correlation between the introduction of fluconazole and the increased incidence of C. krusei, we conducted a retrospective study based on the medical, mycologic, and autopsy records of all adult inpatients who had undergone bone marrow transplantation (n = 296) or who had leukemia (n = 167) at the study center during 1989 and 1990. Results. The 84 patients who received antifungal prophylaxis with fluconazole had a sevenfold greater frequency of C. krusei infection than the 335 patients who did not receive fluconazole (8.3 percent vs. 1.2 percent, P = 0.002), despite having a lower frequency of disseminated C. albicans and C. tropicalis infections (0 vs. 6.0 percent, P = 0.02). Ten of the 11 C. krusei infections were controlled by a combination of amphotericin B and flucytosine. Colonization by C. krusei was found in 40.5 percent of the patients who received fluconazole but in only 16.7 percent of those who did not receive it (P < 0.0001). Colonization was independently associated with the prophylactic use of both fluconazole (odds ratio, 3.50; P < 0.001) and norfloxacin (odds ratio, 2.53; P = 0.04). C. krusei was not susceptible to fluconazole in vitro. Conclusions. In patients at high risk for disseminated candida infections, suppression of bacterial flora and the more common candida pathogens may permit some less pathogenic, but natively resistant candida species, such as C. krusei, to emerge as systemic pathogens.	JOHNS HOPKINS MED INST,DEPT LAB MED,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,CTR ONCOL,BALTIMORE,MD 21205; UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL,SAN ANTONIO,TX 78284; NCI,OFF DIRECTOR,BETHESDA,MD 20892	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; University of Texas System; University of Texas Health San Antonio; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	WINGARD, JR (corresponding author), EMORY UNIV,SCH MED,DEPT MED,DIV HEMATOL ONCOL,BONE MARROW TRANSPLANT PROGRAM,ATLANTA,GA 30322, USA.			Wingard, John/0000-0001-7478-5398	NCI NIH HHS [CA15396, CA06973] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006973, P01CA015396] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AISNER J, 1976, AM J MED, V61, P23, DOI 10.1016/0002-9343(76)90026-7; CALDERONE RA, 1987, REV INFECT DIS, V9, pS400; DICK JD, 1980, ANTIMICROB AGENTS CH, V18, P158, DOI 10.1128/AAC.18.1.158; GALGIANI JN, 1990, ANN INTERN MED, V113, P177, DOI 10.7326/0003-4819-113-3-177; HARVEY RL, 1987, ARCH INTERN MED, V147, P2117, DOI 10.1001/archinte.147.12.2117; HORN R, 1985, REV INFECT DIS, V7, P646; HUGHES WT, 1990, J INFECT DIS, V161, P381, DOI 10.1093/infdis/161.3.381; KARP JE, 1991, REV INFECT DIS, V13, P592; KING RD, 1980, INFECT IMMUN, V27, P667, DOI 10.1128/IAI.27.2.667-674.1980; KOMSHIAN SV, 1989, REV INFECT DIS, V11, P379; MCILROY MA, 1991, J INFECT DIS, V163, P420, DOI 10.1093/infdis/163.2.420; MERZ WG, 1984, J CLIN MICROBIOL, V20, P1194, DOI 10.1128/JCM.20.6.1194-1195.1984; MERZ WG, 1986, J CLIN MICROBIOL, V24, P581, DOI 10.1128/JCM.24.4.581-584.1986; PERSONS DA, 1991, NEW ENGL J MED, V325, P1315; PIZZO PA, 1982, AM J MED, V72, P101, DOI 10.1016/0002-9343(82)90594-0; Rinaldi M. G., 1988, DIAGNOSTIC PROCEDURE, P325; SANDFORD GR, 1980, J INFECT DIS, V142, P503, DOI 10.1093/infdis/142.4.503; WILEY JM, 1990, J CLIN ONCOL, V8, P280, DOI 10.1200/JCO.1990.8.2.280; WINGARD JR, 1987, AM J MED, V83, P1103, DOI 10.1016/0002-9343(87)90949-1; WINGARD JR, 1979, ANN INTERN MED, V91, P539, DOI 10.7326/0003-4819-91-4-539; 1989, AM J MED, V86, P668	21	813	830	1	18	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 31	1991	325	18					1274	1277		10.1056/NEJM199110313251803	http://dx.doi.org/10.1056/NEJM199110313251803			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM041	1669837				2022-12-01	WOS:A1991GM04100003
J	BARR, GS; COATESWORTH, AP				BARR, GS; COATESWORTH, AP			PASSIVE SMOKING AND OTITIS-MEDIA WITH EFFUSION	BRITISH MEDICAL JOURNAL			English	Article							CHILDREN		QUEEN ELIZABETH HOSP,DEPT OTOLARYNGOL,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University of Birmingham								HINTON AE, 1989, J LARYNGOL OTOL, V103, P559, DOI 10.1017/S0022215100109326; MAW AR, 1987, SCOTT BROWNS OTOLARY, V6, P159; RICHARDSON K, 1976, BRIT J AUDIOL, V10, P117; ROBINSON GC, 1967, CAN MED ASSOC J, V97, P1199; STRACHAN DP, 1989, BRIT MED J, V298, P1549, DOI 10.1136/bmj.298.6687.1549	5	17	18	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 26	1991	303	6809					1032	1033		10.1136/bmj.303.6809.1032	http://dx.doi.org/10.1136/bmj.303.6809.1032			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM478	1954455	Green Published, Bronze			2022-12-01	WOS:A1991GM47800021
J	HALES, CN; BARKER, DJP; CLARK, PMS; COX, LJ; FALL, C; OSMOND, C; WINTER, PD				HALES, CN; BARKER, DJP; CLARK, PMS; COX, LJ; FALL, C; OSMOND, C; WINTER, PD			FETAL AND INFANT GROWTH AND IMPAIRED GLUCOSE-TOLERANCE AT AGE 64	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DIABETES-MELLITUS; HEART-DISEASE; INSULIN; HYPERTENSION; PREVALENCE; RISK; LIFE	Objective - To discover whether reduced fetal and infant growth is associated with non-insulin dependent diabetes and impaired glucose tolerance in adult life. Design - Follow up study of men born during 1920-30 whose birth weights and weights at 1 year were known. Setting - Hertfordshire, England. Subjects - 468 men born in east Hertfordshire and still living there. Main outcome measures-Fasting plasma glucose, insulin, proinsulin, and 32-33 split proinsulin concentrations and plasma glucose and insulin concentrations 30 and 120 minutes after a 75 g glucose drink. Results - 93 men had impaired glucose tolerance or hitherto undiagnosed diabetes. They had had a lower mean birth weight and a lower weight at 1 year. The proportion of men with impaired glucose tolerance fell progressively from 26% (6/23) among those who had weighed 18 lb (8-16 kg) or less at 1 year to 13% (3/24) among those who had weighed 27 lb (12.25 kg) or more. Corresponding figures for diabetes were 17% (4/23) and nil (0/24). Plasma glucose concentrations at 30 and 120 minutes fell with increasing birth weight and weight at 1 year. Plasma 32-33 split proinsulin concentration fell with increasing weight at 1 year. All these trends were significant and independent of current body mass. Blood pressure was inversely related to birth weight and strongly related to plasma glucose and 32-33 split proinsulin concentrations. Conclusions - Reduced growth in early life is strongly linked with impaired glucose tolerance and non-insulin dependent diabetes. Reduced early growth is also related to a raised plasma concentration of 32-33 split proinsulin, which is interpreted as a sign of beta-cell dysfunction. Reduced intrauterine growth is linked with high blood pressure, which may explain the association between hypertension and impaired glucose tolerance.	SOUTHAMPTON GEN HOSP, MRC, ENVIRONM EPIDEMIOL UNIT, SOUTHAMPTON SO9 4XY, HANTS, ENGLAND	University of Southampton	HALES, CN (corresponding author), UNIV CAMBRIDGE, ADDENBROOKES HOSP, DEPT CLIN BIOCHEM, CAMBRIDGE CB2 2QR, ENGLAND.			Osmond, Clive/0000-0002-9054-4655				[Anonymous], 1989, LANCET, V2, P839; [Anonymous], 1980, CLASSIFICATION OCCUP; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1991, J ROY COLL PHYS LOND, V25, P129; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; COHEN MP, 1988, DIABETES, V37, P824, DOI 10.2337/diabetes.37.6.824; FREINKEL N, 1980, DIABETES, V29, P1023, DOI 10.2337/diabetes.29.12.1023; FULLER JH, 1980, LANCET, V1, P1373; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; Hellerstrom C, 1988, PATHOLOGY ENDOCRINE, P141; JOHANNSSON A, 1985, CLIN CHIM ACTA, V148, P119, DOI 10.1016/0009-8981(85)90221-9; KLOPPEL G, 1985, SURV SYN PATHOL RES, V4, P110; Kunst A., 1984, METHOD ENZYMAT AN, VVI, P163; MODAN M, 1985, J CLIN INVEST, V75, P809, DOI 10.1172/JCI111776; NEWMAN B, 1987, DIABETOLOGIA, V30, P763; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SOBEY WJ, 1989, BIOCHEM J, V260, P535, DOI 10.1042/bj2600535; STAMLER J, 1975, J CHRON DIS, V28, P527, DOI 10.1016/0021-9681(75)90060-0; SWENNE I, 1987, DIABETES, V36, P454, DOI 10.2337/diabetes.36.4.454; TEMPLE RC, 1989, LANCET, V1, P293, DOI 10.1016/S0140-6736(89)91306-8; van Assche F A, 1979, Contrib Gynecol Obstet, V5, P44	21	2013	2071	1	72	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 26	1991	303	6809					1019	1022		10.1136/bmj.303.6809.1019	http://dx.doi.org/10.1136/bmj.303.6809.1019			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM478	1954451	Green Published, Bronze			2022-12-01	WOS:A1991GM47800017
J	MAYOU, R; SEAGROATT, V; GOLDACRE, M				MAYOU, R; SEAGROATT, V; GOLDACRE, M			USE OF PSYCHIATRIC-SERVICES BY PATIENTS IN A GENERAL-HOSPITAL	BRITISH MEDICAL JOURNAL			English	Article							SUBSTANCE USE; DISORDERS; CONSULTATIONS; ANXIETY; PAIN	Objective - To identify physical disorders associated with increased rate of use of psychiatric services. Design - Retrospective analysis of routine s of general hospital inpatient records linked with those of psychiatric care, for inpatients with physical disorders with possible psychiatric associations and for controls. Setting - Oxfordshire health district. Subjects - Inpatients aged 15-64 years discharged from general hospitals during 1975-85 with a diagnosis among 14 selected diagnostic groups (including potentially life threatening conditions, chronic disabling diseases, and non-specific symptomatic conditions) and control inpatients with acute conditions. Main outcome measures - Observed and expected numbers of patients receiving psychiatric care. Results - Observed use of psychiatric services before and after index admission was close to that expected for controls. For most other diagnoses the observed use was significantly increased in the year preceding and that subsequent to the admission. For four diagnostic groups it was significantly greater in the year after admission than in that before (acute myocardial infarction (ratio before to after 2.17, 95% confidence interval 1.5 to 3.3), cancer (2.05, 1.7 to 2.5), diabetes mellitus (1.89, 1.4 to 2.9), and chest pain (1.78, 1.3 to 2.4)). During four years after the admission the use of psychiatric services was significantly higher than in the general population for nonsPecific symptomatic conditions (observed/expected: abdominal pain 1.7, chest pain 2.0, and headache 4.2), cirrhosis of the liver (10.4), and fractures in road accidents and other fractures (1.3, 1.6). Conclusions - More patients with certain physical conditions used psychiatric services. Alternative methods of service delivery may be needed, especially for disabling chronic physical illness, alcohol related disorders, and non-specific symptomatic conditions.	UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,CLIN EPIDEMIOL UNIT,OXFORD OX3 7LF,ENGLAND	University of Oxford	MAYOU, R (corresponding author), UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD OX3 7JX,ENGLAND.							ACHESON ED, 1967, MEDICAL RECORD LINKA; BARSKY AJ, 1986, MED CARE, V24, P548, DOI 10.1097/00005650-198606000-00009; BERKSON J, 1946, BIOMETRICS BULL, V2, P47, DOI 10.2307/3002000; BRESLOW NE, 1987, STAT METHODS CANC RE, V2, P68; COLMAN M, 1986, INT J EPIDEMIOL, V15, P134; Devis T, 1984, POPULATION TRENDS, V36, P18; EASTWOOD MR, 1972, PSYCHOL MED, V2, P363, DOI 10.1017/S0033291700045177; FITZPATRICK RM, 1987, J NEUROL NEUROSUR PS, V44, P1061; FULOP G, 1989, HOSP COMMUNITY PSYCH, V40, P80; GILL LE, 1987, TXB MED RECORD LINKA, V3, P39; Goldberg D, 1980, MENTAL ILLNESS COMMU; HANKIN JR, 1982, ARCH GEN PSYCHIAT, V39, P225; HENGEVELD MW, 1984, GEN HOSP PSYCHIAT, V6, P271, DOI 10.1016/0163-8343(84)90021-5; KESSLER LG, 1987, AM J PUBLIC HEALTH, V77, P18, DOI 10.2105/AJPH.77.1.18; MAYOU R, 1988, J PSYCHOSOM RES, V32, P541, DOI 10.1016/0022-3999(88)90038-4; MAYOU R, 1986, BRIT J PSYCHIAT, V149, P172, DOI 10.1192/bjp.149.2.172; MAYOU R, 1989, J PSYCHOSOM RES, V33, P393, DOI 10.1016/0022-3999(89)90001-9; RANG EH, 1970, BRIT J PREV SOC MED, V24, P47; REGIER DA, 1978, ARCH GEN PSYCHIAT, V35, P685; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; WALLEN J, 1987, ARCH GEN PSYCHIAT, V44, P163; WELLS KB, 1989, AM J PSYCHIAT, V146, P1440; WELLS KB, 1989, GEN HOSP PSYCHIAT, V11, P320, DOI 10.1016/0163-8343(89)90119-9	23	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 26	1991	303	6809					1029	1032		10.1136/bmj.303.6809.1029	http://dx.doi.org/10.1136/bmj.303.6809.1029			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GM478	1954454	Green Published, Bronze			2022-12-01	WOS:A1991GM47800020
J	MELZER, D; HALE, AS; MALIK, SJ; HOGMAN, GA; WOOD, S				MELZER, D; HALE, AS; MALIK, SJ; HOGMAN, GA; WOOD, S			COMMUNITY CARE FOR PATIENTS WITH SCHIZOPHRENIA ONE YEAR AFTER HOSPITAL DISCHARGE	BRITISH MEDICAL JOURNAL			English	Article							FOLLOW-UP	Objectives - To document the circumstances and care of patients with schizophrenia who had recently been discharged from local psychiatric inpatient services, and to establish the extent to which misgivings about community care might be justified. Design - Cross sectional surveys with review of case notes. Follow up interviews with questionnaires administered one year after discharge. Setting - Two inner London districts (West Lambeth and Lewisham) with high levels of social deprivation and at different stages of developing community services. Patients - 90 and 50 patients in the two services respectively, aged 18 to 65, who satisfied the Research Diagnostic Criteria for schizophrenia and who were discharged from inpatient services. Main outcome measures - Diagnosis elicited by present state examination, global social disability rating, use of services during the three months before interview. Results - 89 of the 140 patients (64%) had been ill for five or more years, yet few were former long stay inpatients. 55% (50/91; 95% confidence interval 45% to 65%) of those interviewed had current psychotic mental states and 22% (27/124; 16% to 31%) were functioning socially at very poor or severely maladjusted levels. 86% (107/124) were unemployed. The majority of patients had seen a mental health or social service professional, yet only 16% (20/124) were in specialised accommodation (excluding hospitals) and only 23% (17/73) of those eligible had used day care. Small numbers of people had experienced homelessness (two) or imprisonment (four over six months). Conclusions - Many schizophrenic patients leaving local psychiatric inpatient care have active symptomatology and profound social disabilities. Community care was characterised by high rates of contact with service professionals but little supported accommodation or day activity. This group of clients may require dedicated provision, which would actively encourage them to use services protected from the demands of those with less severe illness.	ST THOMAS HOSP,W LAMBETH HLTH AUTHOR,DIRECTORATE PUBL HLTH,LONDON SE1 7EH,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,ST THOMAS HOSP,LONDON SE1 7EH,ENGLAND; GUYS HOSP,PSYCHIAT,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust				Melzer, David/0000-0002-0170-3838				BACHRACH LL, 1984, HOMELESS MENTALLY IL; BEECHAM J, IN PRESS SCHIZOPH B; CHEADLE AJ, 1978, BRIT J PSYCHIAT, V132, P221, DOI 10.1192/S0007125000283268; COID JW, 1988, BRIT MED J, V296, P1779, DOI 10.1136/bmj.296.6639.1779; CRAMER P, 1989, BRIT J PSYCHIAT, V155, P225, DOI 10.1192/bjp.155.2.225; Davis A., 1974, SCHIZOPHRENICS NEW C; DEAN AG, 1990, EPIINFO VERSION 5; ELLIS RH, 1984, COMMUNITY MENT HLT J, V20, P72; FRY AH, 1989, HLTH TRENDS, V21, P70; GROVES T, 1990, BRIT MED J, V300, P923, DOI 10.1136/bmj.300.6729.923; HOGG LI, 1990, ACTA PSYCHIAT SCAND, V81, P271, DOI 10.1111/j.1600-0447.1990.tb06495.x; JOHNSTONE EC, 1984, BRIT J PSYCHIAT, V145, P586, DOI 10.1192/bjp.145.6.586; JONES K, 1986, BRIT J PSYCHIAT, V149, P537, DOI 10.1192/bjp.149.5.537; KHOOSAL D, 1991, HLTH TRENDS, V22, P137; KNAPP M, 1990, CARE COMMUNITY LESSO; KNAPP M, IN PRESS PSYCHOL MED; KUIPERS L, 1988, PSYCHOL MED, V18, P893, DOI 10.1017/S0033291700009831; MCCREADIE RG, 1982, BRIT J PSYCHIAT, V140, P582, DOI 10.1192/bjp.140.6.582; MILNER G, 1991, HLTH TRENDS, V4, P141; NORUSIS MJ, 1986, STATISTICAL PACKAGE; OLFSON M, 1990, HOSP COMMUNITY PSYCH, V41, P634; RICE P, 1984, INFORMATION DISTRICT; SAYCE L, 1991, SOC PSYCH PSYCH EPID, V26, P14, DOI 10.1007/BF00783575; Spitzer R.L., 1975, RES DIAGNOSTIC CRITE, V2; TANTAM D, 1985, BRIT J PSYCHIAT, V146, P1, DOI 10.1192/bjp.146.1.1; THORNICROFT G, 1989, BRIT J PSYCHIAT, V155, P739, DOI 10.1192/bjp.155.6.739; WATT DC, 1983, PSYCHOL MED, V13, P663, DOI 10.1017/S0033291700048091; WELLER M, 1989, LANCET, V2, P1509; Wing J. K. C., 1974, MEASUREMENT CLASSIFI; WOOD S, 1990, CLOSURE MENTAL HOSPI; 1989, SLIPPING NET; 1990, CARE PROGRAMME APPRO; 1989, INFORMED ACTION HLTH; 1989, 4TH ANN C TEAM ASS P; 1988, WHO PSYCHIATRIC DISA	35	58	59	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 26	1991	303	6809					1023	1026		10.1136/bmj.303.6809.1023	http://dx.doi.org/10.1136/bmj.303.6809.1023			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GM478	1954452	Green Published, Bronze			2022-12-01	WOS:A1991GM47800018
J	NEEQUAYE, JE; BYRNE, J; LEVINE, PH				NEEQUAYE, JE; BYRNE, J; LEVINE, PH			MENARCHE AND REPRODUCTION AFTER TREATMENT FOR AFRICAN BURKITTS-LYMPHOMA	BRITISH MEDICAL JOURNAL			English	Article							GONADAL DAMAGE		NCI,EPIDEMIOL & BIOSTAT PROGRAM,EPN 400,BETHESDA,MD 20892; UNIV GHANA,SCH MED,DEPT CHILD HLTH,BURKITTS TUMOR PROJECT,ACCRA,GHANA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Ghana					DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP051009] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CP-51009] Funding Source: Medline	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BURKITT D, 1967, CANCER, V20, P756, DOI 10.1002/1097-0142(1967)20:5<756::AID-CNCR2820200530>3.0.CO;2-P; KOYAMA H, 1977, CANCER, V36, P1401; QUIGLEY C, 1989, NEW ENGL J MED, V321, P143, DOI 10.1056/NEJM198907203210303; RIVKEES SA, 1988, JAMA-J AM MED ASSOC, V259, P2123; WATSON AR, 1986, FERTIL STERIL, V46, P331	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 26	1991	303	6809					1033	1033		10.1136/bmj.303.6809.1033	http://dx.doi.org/10.1136/bmj.303.6809.1033			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM478	1954456	Green Published, Bronze			2022-12-01	WOS:A1991GM47800022
J	NUDESHIMA, J				NUDESHIMA, J			OBSTACLES TO BRAIN-DEATH AND ORGAN-TRANSPLANTATION IN JAPAN	LANCET			English	Editorial Material											NUDESHIMA, J (corresponding author), MITSUBISHI KASEI INST LIFE SCI,LIFE SCI & SOC PROGRAMME,11 MINAMIOOYA,MACHIDA,TOKYO 194,JAPAN.							LOCK M, 1990, SOCIAL SCI PERSPECTI, P99; MANNINEN DL, 1985, JAMA-J AM MED ASSOC, V253, P3111, DOI 10.1001/jama.253.21.3111; PETERS TG, 1991, JAMA-J AM MED ASSOC, V265, P1302, DOI 10.1001/jama.265.10.1302; Yanagita Kunio, 1970, OUR ANCESTORS JAPANE; 1981, DEFINING DEATH	5	29	29	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 26	1991	338	8774					1063	1064		10.1016/0140-6736(91)91912-E	http://dx.doi.org/10.1016/0140-6736(91)91912-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM253	1681367				2022-12-01	WOS:A1991GM25300015
J	STRANG, J				STRANG, J			THE HEALTH OF THE NATION - RESPONSES - INJECTING DRUG MISUSE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							USERS; NOTIFICATION; ENGLAND; SYSTEM; AIDS				STRANG, J (corresponding author), BETHLEM ROYAL & MAUDSLEY HOSP, DRUG DEPENDENCE CLIN RES & TREATMENT UNIT, BECKENHAM BR3 3BX, ENGLAND.		Strang, John/H-5460-2011	Strang, John/0000-0002-5413-2725				BALL JC, 1988, J HEALTH SOC BEHAV, V29, P214, DOI 10.2307/2137033; BLACK D, 1988, J ROY SOC HEALTH, V108, P83, DOI 10.1177/146642408810800304; BRETTLE RP, 1987, BRIT MED J, V295, P421, DOI 10.1136/bmj.295.6595.421; Buning E., 1990, AIDS DRUG MISUSE CHA, P153; CARBALLO M, 1990, AIDS DRUG MISUSE, P16; DAWE S, 1991, BRIT J ADDICT, V86, P977; De Alarcon R, 1972, Psychol Med, V2, P293; DONMALL M, 1990, DRUGLINK, V5, P10; EDWARDS G, 1981, B WORLD HEALTH ORGAN, V59, P225; EDWARDS G, 1981, DRUG PROBLEMS BRITAI, P25; FARRELL M, 1990, BRIT J ADDICT, V85, P1657; GHODSE AH, 1977, BRIT MED J, V1, P1381, DOI 10.1136/bmj.1.6073.1381; GLANZ A, 1986, BRIT MED J, V293, P427, DOI 10.1136/bmj.293.6544.427; GLANZ A, 1989, BRIT MED J, V299, P1076, DOI 10.1136/bmj.299.6707.1076; GOSSOP M, 1988, BRIT J ADDICT, V83, P1159; JAMESON A, 1984, DEALING DRUG MISUSE; JOHNSON AM, 1991, BRIT MED J, V303, P573, DOI 10.1136/bmj.303.6802.573; LOVE J, 1985, BRIT J ADDICT, V80, P435; MacGregor S., 1990, DRUG SERVICES ENGLAN; MADEN A, 1991, BRIT MED J, V302, P880, DOI 10.1136/bmj.302.6781.880; MCGLOTHLIN WH, 1981, ARCH GEN PSYCHIAT, V38, P1055; OPPENHEIMER E, 1988, BRIT J ADDICT, V83, P635; PARKER H, 1987, BRIT J ADDICT, V82, P147; ROBERTSON R, 1990, AIDS DRUG MISUSE CHA; SMART RG, 1974, BRIT J ADDICT, V69, P225; STIMSON GV, 1988, BRIT MED J, V296, P1717, DOI 10.1136/bmj.296.6638.1717; Strang J., 1987, Health Trends, V19, P16; STRANG J, 1985, BRIT J PSYCHIAT, V147, P195, DOI 10.1192/bjp.147.2.195; STRANG J, 1990, LANCET, V335, P740, DOI 10.1016/0140-6736(90)90865-3; STRANG J, 1990, AIDS DRUG MISUSE CHA; STRANG J, 1989, DRUGS BRIT SOC RESPO; 1988, HLTH ALL AUSTR, P45; 1985, 5TH HOUS COMM INT RE; 1989, REPORT AIDS DRUG M 2; 1984, REPORT PREVENTION; 1984, GUIDELINES GOOD CLIN; 1990, WHO20 Q REP; 1986, MCCLELLAND REPORT; 1991, STATISTICS MISUSE DR; 1982, REPORT TREATMENT REH; 1988, REPORT AIDS DRUG M 1; 1985, DRUG MISUSE PREVALEN; 1991, CM1523; 1988, WATKINS REPORT; 1990, HLTH PEOPLE 2000; 1988, IMMUNISATION INFECTI; 1986, TACKLING DRUG MISUSE	47	5	5	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 26	1991	303	6809					1043	1046		10.1136/bmj.303.6809.1043	http://dx.doi.org/10.1136/bmj.303.6809.1043			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM478	1954460	Bronze, Green Published			2022-12-01	WOS:A1991GM47800027
J	HOFFMAN, BJ; MEZEY, E; BROWNSTEIN, MJ				HOFFMAN, BJ; MEZEY, E; BROWNSTEIN, MJ			CLONING OF A SEROTONIN TRANSPORTER AFFECTED BY ANTIDEPRESSANTS	SCIENCE			English	Article							BRAIN GABA TRANSPORTER; BLOOD-PLATELETS; MEMBRANE-VESICLES; UPTAKE INHIBITOR; 5-HYDROXYTRYPTAMINE; EXPRESSION; SYSTEM; CDNA; <H-3>IMIPRAMINE; DISORDERS	A complementary DNA clone for a serotonin (5HT) transporter has been isolated from rat basophilic leukemia cells. The complementary DNA sequence predicts a 653-amino acid protein with 12 to 13 putative transmembrane domains. The 5HT transporter has significant homology to the gamma-aminobutyric acid, dopamine, and norepinephrine transporters. Uptake by CV-1 cells expressing the transporter complementary DNA resembles 5HT uptake by platelets and brain synaptosomes; it is sensitive to antidepressants, amphetamine derivatives, and cocaine.	SEMMELWEIS UNIV MED,SCH MED,DEPT ANAT 1,H-1085 BUDAPEST 8,HUNGARY	Semmelweis University	HOFFMAN, BJ (corresponding author), NIMH,CELL BIOL LAB,BETHESDA,MD 20892, USA.		Brownstein, Michael/B-8609-2009; Mezey, Eva/A-8105-2008	Mezey, Eva/0000-0002-5907-4691				AGHAJANIAN GK, 1967, J PHARMACOL EXP THER, V156, P23; ANDERSEN PH, 1989, EUR J PHARMACOL, V166, P493, DOI 10.1016/0014-2999(89)90363-4; AXELROD J, 1963, J PHARMACOL EXP THER, V141, P161; BLACKBURN K. J., 1967, LIFE SCI, V6, P1653, DOI 10.1016/0024-3205(67)90176-2; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COOPER SJ, 1989, TRENDS PHARMACOL SCI, V10, P56, DOI 10.1016/0165-6147(89)90076-X; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; FULLER RW, 1990, NEUROPHARMACOLOGY SE, V600, P68; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HOFFMAN BM, UNPUB; HYTTEL J, 1982, PROG NEURO-PSYCHOPH, V6, P277, DOI 10.1016/S0278-5846(82)80179-6; KANNER BI, 1985, BIOCHIM BIOPHYS ACTA, V816, P403, DOI 10.1016/0005-2736(85)90508-5; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUHAR MJ, 1978, J NEUROCHEM, V31, P251, DOI 10.1111/j.1471-4159.1978.tb12456.x; KUHAR MJ, 1972, J PHARMACOL-PARIS, V181, P36; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANGER SZ, 1983, NEUROPHARMACOLOGY, V22, P407, DOI 10.1016/0028-3908(83)90190-9; LINGJAERDE O, 1971, ACTA PHYSIOL SCAND, V81, P75, DOI 10.1111/j.1748-1716.1971.tb04878.x; NELSON H, 1990, FEBS LETT, V269, P181, DOI 10.1016/0014-5793(90)81149-I; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PLETSCHER A, 1987, INT J CARDIOL, V14, P177, DOI 10.1016/0167-5273(87)90007-6; RICUARTE G, 1985, SCIENCE, V229, P986; RITZ MC, 1989, J PHARMACOL EXP THER, V248, P1010; RUDNICK G, 1977, J BIOL CHEM, V252, P2170; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; Sneddon J M, 1973, Prog Neurobiol, V1, P151, DOI 10.1016/0301-0082(73)90019-1; STACEY RS, 1961, BRIT J PHARM CHEMOTH, V16, P284, DOI 10.1111/j.1476-5381.1961.tb01087.x; STAHL SM, 1977, ARCH GEN PSYCHIAT, V34, P509; USDIN T, IN PRESS P NATL ACAD; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WHITE MK, 1989, NATURE, V340, P103, DOI 10.1038/340103b0; WOOD MD, 1986, NEUROPHARMACOLOGY, V25, P519, DOI 10.1016/0028-3908(86)90178-4	34	524	536	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1991	254	5031					579	580		10.1126/science.1948036	http://dx.doi.org/10.1126/science.1948036			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GL799	1948036				2022-12-01	WOS:A1991GL79900053
J	MARGOLIS, P; DRIKS, A; LOSICK, R				MARGOLIS, P; DRIKS, A; LOSICK, R			ESTABLISHMENT OF CELL TYPE BY COMPARTMENTALIZED ACTIVATION OF A TRANSCRIPTION FACTOR	SCIENCE			English	Article							DUPLICATED SPORULATION GENES; BACILLUS-SUBTILIS; RNA-POLYMERASE; SIGMA-FACTOR; ENDOSPORE FORMATION; EXPRESSION; SPOIIA; PROMOTER; MUTATIONS; PROTEINS	Early in the process of spore formation in Bacillus subtilis a septum is formed that partitions the sporangium into daughter cells called the forespore and the mother cell. The daughter cells each have their own chromosome but follow dissimilar programs of gene expression. Differential gene expression in the forespore is now shown to be established by the compartmentalized activity of the transcription factor sigma-F. The sigma-F factor is produced prior to septation, but is active only in the forespore compartment of the post-septation sporangium. The sigma-F factor is controlled by the products of sporulation operons spoIIA and spoIIE, which may be responsible for confining its activity to one of the daughter cells.	HARVARD UNIV,BIOL LABS,DEPT CELLULAR & DEV BIOL,CAMBRIDGE,MA 02138	Harvard University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018568, R37GM018568] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18568] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CUTTING S, 1991, GENE DEV, V5, P456, DOI 10.1101/gad.5.3.456; DRIKS A, IN PRESS P NAT ACAD; DRIKS A, UNPUB; ERRINGTON J, 1985, FEBS LETT, V188, P184, DOI 10.1016/0014-5793(85)80368-9; ERRINGTON J, 1986, J GEN MICROBIOL, V132, P2967; ERRINGTON J, 1990, GENETICS BIOTECHNOLO, V3, P257; FORT P, 1984, J GEN MICROBIOL, V130, P2147; FOULGER D, 1989, MOL MICROBIOL, V3, P1247, DOI 10.1111/j.1365-2958.1989.tb00275.x; FRANCESCONI SC, 1988, J BACTERIOL, V170, P5963, DOI 10.1128/jb.170.12.5963-5967.1988; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GHOLAMHOSEINIAN A, 1989, J BACTERIOL, V171, P5747, DOI 10.1128/jb.171.10.5747-5749.1989; GUZMAN PL, COMMUNICATION; IGO M, 1987, J BACTERIOL, V169, P3464, DOI 10.1128/jb.169.8.3464-3469.1987; IGO MM, 1986, J MOL BIOL, V191, P615, DOI 10.1016/0022-2836(86)90449-3; ILLING N, 1991, J BACTERIOL, V173, P3159, DOI 10.1128/JB.173.10.3159-3169.1991; JONAS RM, 1989, J BACTERIOL, V171, P5226, DOI 10.1128/jb.171.9.5226-5228.1989; JONAS RM, 1988, J BACTERIOL, V170, P507, DOI 10.1128/jb.170.2.507-511.1988; KARMAZYNCAMPELLI C, 1989, GENE DEV, V3, P150, DOI 10.1101/gad.3.2.150; LABELL TL, 1987, P NATL ACAD SCI USA, V84, P1784, DOI 10.1073/pnas.84.7.1784; LOSICK R, 1986, ANNU REV GENET, V20, P625, DOI 10.1146/annurev.ge.20.120186.003205; MARGOLIS PS, UNPUB; MASON JM, 1988, J BACTERIOL, V170, P239, DOI 10.1128/jb.170.1.239-244.1988; PARTRIDGE SR, 1991, MOL MICROBIOL, V5, P757, DOI 10.1111/j.1365-2958.1991.tb00746.x; PIGGOT PJ, 1976, BACTERIOL REV, V40, P908, DOI 10.1128/MMBR.40.4.908-962.1976; PIGGOT PJ, 1984, J GEN MICROBIOL, V130, P2123; RATHER PN, 1990, J BACTERIOL, V172, P709, DOI 10.1128/jb.172.2.709-715.1990; RAY C, 1988, J BACTERIOL, V170, P900, DOI 10.1128/jb.170.2.900-907.1988; SAVVA D, 1986, J GEN MICROBIOL, V132, P3005; SCHMIDT R, 1990, P NATL ACAD SCI USA, V87, P9221, DOI 10.1073/pnas.87.23.9221; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; STRAGIER P, 1990, MOL MICROBIOL, V4, P1801, DOI 10.1111/j.1365-2958.1990.tb02028.x; STRAGIER P, 1986, FEBS LETT, V195, P9, DOI 10.1016/0014-5793(86)80119-3; STRAGIER P, 1988, CELL, V52, P697, DOI 10.1016/0092-8674(88)90407-2; STRAGIER P, 1991, IN PRESS PROCARYOTIC, V47; SUN DX, 1991, J BACTERIOL, V173, P2977, DOI 10.1128/JB.173.9.2977-2984.1991; SUN DX, 1989, GENE DEV, V3, P141, DOI 10.1101/gad.3.2.141; SUSSMAN MD, 1991, J BACTERIOL, V173, P291, DOI 10.1128/jb.173.1.291-300.1991; TREMPY JE, 1985, J BACTERIOL, V161, P340, DOI 10.1128/JB.161.1.340-346.1985; WU JJ, 1989, J BACTERIOL, V171, P692, DOI 10.1128/jb.171.2.692-698.1989; YUDKIN MD, 1987, J GEN MICROBIOL, V133, P475; ZHENG LB, 1990, J MOL BIOL, V212, P645, DOI 10.1016/0022-2836(90)90227-D	41	153	156	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1991	254	5031					562	565		10.1126/science.1948031	http://dx.doi.org/10.1126/science.1948031			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL799	1948031				2022-12-01	WOS:A1991GL79900046
J	ROTHMAN, DL; MAGNUSSON, I; KATZ, LD; SHULMAN, RG; SHULMAN, GI				ROTHMAN, DL; MAGNUSSON, I; KATZ, LD; SHULMAN, RG; SHULMAN, GI			QUANTITATION OF HEPATIC GLYCOGENOLYSIS AND GLUCONEOGENESIS IN FASTING HUMANS WITH C-13 NMR	SCIENCE			English	Article							CONSCIOUS DOG; FASTED HUMANS; GLUCOSE-LOAD; INVIVO; SPECTROSCOPY; METABOLISM; PATHWAYS; LIVER	The rate of net hepatic glycogenolysis was assessed in humans by serially measuring hepatic glycogen concentration at 3- to 12-hour intervals during a 68-hour fast with C-13 nuclear magnetic resonance spectroscopy. The net rate of gluconeogenesis was calculated by subtracting the rate of net hepatic glycogenolysis from the rate of glucose production in the whole body measured with tritiated glucose. Gluconeogenesis accounted for 64 +/- 5% (mean +/- standard error of the mean) of total glucose production during the first 22 hours of fasting. In the subsequent 14-hour and 18-hour periods of the fast, gluconeogenesis accounted for 82 +/- 5% and 96 +/- 1% of total glucose production, respectively. These data show that gluconeogenesis accounts for a substantial fraction of total glucose production even during the first 22 hours of a fast in humans.	YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT DIAGNOST RADIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510	Yale University; Yale University; Yale University			Shulman, Gerald I./P-7176-2019	Shulman, Gerald I./0000-0003-1529-5668	NCRR NIH HHS [MO1-RR-00125-26] Funding Source: Medline; NIDDK NIH HHS [DK-40936, R01 DK040936, DK-34576] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK034576, R01DK040936] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUMRAD NN, 1982, AM J PHYSIOL, V242, pE398, DOI 10.1152/ajpendo.1982.242.6.E398; ADKINS BA, 1987, J CLIN INVEST, V79, P557, DOI 10.1172/JCI112847; BJOKMAN O, 1990, DIABETES, V39, P747; BJORKMAN O, 1982, DIABETES, V31, P516, DOI 10.2337/diabetes.31.6.516; BOTTOMLEY PA, 1989, MAGNET RESON MED, V12, P348, DOI 10.1002/mrm.1910120307; CHERRINGTON AD, 1986, HORMONAL CONTROL GLU, P15; CONSOLI A, 1987, J CLIN INVEST, V80, P1301; GRUETTER R, 1991, MAGNET RESON MED, V20, P327, DOI 10.1002/mrm.1910200216; HAASE A, 1986, J MAGN RESON, V67, P258, DOI 10.1016/0022-2364(86)90433-6; HETENYI G, 1983, BIOCHEM MED METAB B, V29, P372, DOI 10.1016/0006-2944(83)90073-X; HETENYI G, 1986, HORMONAL CONTROL GLU, P79; HULL WE, 1987, 6TH ANN M SOC MAGN R, P488; JACKSON CL, 1989, BIOCHEMISTRY-US, V28, P5024, DOI 10.1021/bi00438a018; JUE T, 1989, P NATL ACAD SCI USA, V86, P4489, DOI 10.1073/pnas.86.12.4489; KATZ J, 1985, AM J PHYSIOL, V248, pR391, DOI 10.1152/ajpregu.1985.248.4.R391; KREBS HA, 1963, ADV ENZYME REGUL, V1, P385; KREBS HA, 1966, BIOCHEM J, V101, P242, DOI 10.1042/bj1010242; KREISBERG RA, 1972, J CLIN ENDOCR METAB, V34, P876, DOI 10.1210/jcem-34-5-876; MAGNUSSON I, 1987, J CLIN INVEST, V80, P1748, DOI 10.1172/JCI113267; MCGARRY JD, 1984, J CLIN INVEST, V74, P1901; NILSSON LH, 1973, SCAND J CLIN LAB INV, V32, P325, DOI 10.3109/00365517309084355; ORDIDGE RJ, 1986, J MAGN RESON, V66, P283, DOI 10.1016/0022-2364(86)90031-4; OWEN OE, 1969, J CLIN INVEST, V48, P574, DOI 10.1172/JCI106016; SCHUMANN WC, 1991, J BIOL CHEM, V266, P6985; SHALWITZ RA, 1987, MAGNET RESON MED, V5, P462, DOI 10.1002/mrm.1910050508; SHULMAN GI, 1990, AM J PHYSIOL, V259, pE335, DOI 10.1152/ajpendo.1990.259.3.E335; SHULMAN GI, 1988, J BIOL CHEM, V263, P5027; SILLERUD LO, 1983, BIOCHEMISTRY-US, V22, P1987; SILVER MS, 1984, NATURE, V310, P681, DOI 10.1038/310681a0; STRISOWER EH, 1952, J BIOL CHEM, V198, P115; TAYLOR R, UNPUB; WAHREN J, 1972, J CLIN INVEST, V51, P1870, DOI 10.1172/JCI106989; WEINMAN E, 1952, PHYSIOL REV, V37, P252; ZANG LH, 1990, BIOCHEMISTRY-US, V29, P6815, DOI 10.1021/bi00481a009	34	423	431	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1991	254	5031					573	576		10.1126/science.1948033	http://dx.doi.org/10.1126/science.1948033			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL799	1948033				2022-12-01	WOS:A1991GL79900050
J	SARIOLA, H; SAARMA, M; SAINIO, K; ARUMAE, U; PALGI, J; VAAHTOKARI, A; THESLEFF, I; KARAVANOV, A				SARIOLA, H; SAARMA, M; SAINIO, K; ARUMAE, U; PALGI, J; VAAHTOKARI, A; THESLEFF, I; KARAVANOV, A			DEPENDENCE OF KIDNEY MORPHOGENESIS ON THE EXPRESSION OF NERVE GROWTH-FACTOR RECEPTOR	SCIENCE			English	Article							NEUROTROPHIC FACTOR; MOLECULAR-CLONING; FACTOR BINDING; MESSENGER-RNA; HIGH-AFFINITY; BRAIN; CELLS; PROTEIN; DIFFERENTIATION; TISSUES	Nerve growth factor receptor (NGFR) serves as the binding site for the neurotrophic growth factors. Although NGFR has been found in several embryonic tissues outside the nervous system, the function of NGFR in embryogenesis of non-neuronal organs remains unknown. NGFR is transiently synthesized by embryonic rat kidney and disappears from nephrons upon their terminal differentiation. Anti-sense oligonucleotide inhibition of NGFR expression inhibits kidney morphogenesis. Therefore, NGFR is required not only for development of the nervous system, but also for differentiation of the kidney tubules.	ACAD SCI ESSSR, INST CHEM PHYS & BIOPHYS, 200103 TALLINN, ESTONIA, USSR; UNIV HELSINKI, INST PEDODONT & ORTHODONT, SF-00100 HELSINKI 10, FINLAND; UNIV HELSINKI, DEPT PATHOL, SF-00100 HELSINKI 10, FINLAND; UNIV HELSINKI, INST BIOTECHNOL, SF-00100 HELSINKI 10, FINLAND	National Institute of Chemical Physics & Biophysics (NICPB); University of Helsinki; University of Helsinki; University of Helsinki	SARIOLA, H (corresponding author), UNIV HELSINKI, CHILDRENS HOSP, DEPT PAEDIAT PATHOL, STENBACKINKATU 11, SF-00290 HELSINKI 29, FINLAND.		Arumäe, Urmas/E-8290-2016	Arumäe, Urmas/0000-0003-3658-6464				BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BENGTSTROM M, IN PRESS NUCLEIC ACI; BOWEN B, 1980, NUCLEIC ACIDS RES, V8, P1, DOI 10.1093/nar/8.1.1; CHESA PG, 1988, J HISTOCHEM CYTOCHEM, V36, P383, DOI 10.1177/36.4.2831267; COSTRINI NV, 1979, P NATL ACAD SCI USA, V76, P3242, DOI 10.1073/pnas.76.7.3242; ENFORS P, 1990, NEURON, V5, P511; ERNFORS P, 1988, NEURON, V1, P983, DOI 10.1016/0896-6273(88)90155-9; ERNFORS P, 1991, INT J DEV NEUROSCI, V9, P57, DOI 10.1016/0736-5748(91)90073-U; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; FROEHLER BC, 1986, NUCLEIC ACIDS RES, V14, P5399, DOI 10.1093/nar/14.13.5399; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GROB PM, 1985, J BIOL CHEM, V260, P8044; GROBSTEIN C, 1955, J EXP ZOOL, V130, P319, DOI 10.1002/jez.1401300207; HEMSTEAD BL, 1991, NATURE, V350, P678; HEUER JG, 1990, DEV BIOL, V137, P287, DOI 10.1016/0012-1606(90)90255-H; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOSANG M, 1985, J BIOL CHEM, V260, P655; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KARAVANOV AA, 1983, EXPERIENTIA, V39, P1015, DOI 10.1007/BF01989779; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; Maniatis T., 1982, MOL CLONING; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; PARTANEN AM, 1987, DEV BIOL, V120, P186, DOI 10.1016/0012-1606(87)90117-5; PERSSON H, 1990, SCIENCE, V247, P704, DOI 10.1126/science.2154035; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SARIOLA H, 1989, DEV BIOL, V132, P271, DOI 10.1016/0012-1606(89)90224-8; SARIOLA H, UNPUB; Saxen L., 1987, ORGANOGENESIS KIDNEY; SUTTER A, 1979, J BIOL CHEM, V254, P5972; TANIUCHI M, 1986, P NATL ACAD SCI USA, V83, P4094, DOI 10.1073/pnas.83.11.4094; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; WILKINSON M, 1988, NUCLEIC ACIDS RES, V16, P10933, DOI 10.1093/nar/16.22.10933; WOODRUFF NR, 1986, BIOCHEMISTRY-US, V25, P7956, DOI 10.1021/bi00372a026; YAN Q, 1988, J NEUROSCI, V8, P3481	41	195	197	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1991	254	5031					571	573		10.1126/science.1658930	http://dx.doi.org/10.1126/science.1658930			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL799	1658930				2022-12-01	WOS:A1991GL79900049
J	SHIMADA, S; KITAYAMA, S; LIN, CL; PATEL, A; NANTHAKUMAR, E; GREGOR, P; KUHAR, M; UHL, G				SHIMADA, S; KITAYAMA, S; LIN, CL; PATEL, A; NANTHAKUMAR, E; GREGOR, P; KUHAR, M; UHL, G			CLONING AND EXPRESSION OF A COCAINE-SENSITIVE DOPAMINE TRANSPORTER COMPLEMENTARY-DNA	SCIENCE			English	Article							XENOPUS-LAEVIS OOCYTES; RAT STRIATUM; UPTAKE SITES; BINDING; NOREPINEPHRINE; INHIBITION; RECEPTORS; LIGAND; GABA	A rat dopamine (DA) transporter complementary DNA has been isolated with combined complementary DNA homology and expression approaches. The DA transporter is a 619-amino acid protein with 12 hydrophobic putative membrane-spanning domains and homology to the norepinephrine and gamma-aminobutyric acid transporters. The expressed complementary DNA confers transport of [H-3]DA in Xenopus oocytes and in COS cells. Binding of the cocaine analog [H-3]CFT {[H-3]2-beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane} to transfected COS cell membranes yields a pharmacological profile similar to that in striatal membranes.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21224; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21224	Johns Hopkins University; Johns Hopkins University			Lin, Chien-liang G/E-3513-2011					BANNON MJ, 1990, J NEUROCHEM, V54, P706, DOI 10.1111/j.1471-4159.1990.tb01929.x; BERGER P, 1985, EUR J PHARMACOL, V107, P289, DOI 10.1016/0014-2999(85)90075-5; BERGMAN J, 1989, J PHARMACOL EXP THER, V251, P150; BLAKELY RD, 1988, P NATL ACAD SCI USA, V85, P9846, DOI 10.1073/pnas.85.24.9846; BOJA JW, 1989, EUR J PHARMACOL, V173, P215, DOI 10.1016/0014-2999(89)90524-4; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HORN AS, 1990, PROG NEUROBIOL, V34, P387, DOI 10.1016/0301-0082(90)90033-D; HYTTEL J, 1982, PROG NEURO-PSYCHOPH, V6, P277, DOI 10.1016/S0278-5846(82)80179-6; IVERSEN LL, 1976, HDB PSYCHOPHARMACOLO, P381; JAVITCH JA, 1984, MOL PHARMACOL, V26, P35; JAVORYAGID F, 1985, N-S ARCH PHARMACOL, V329, P227; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUHAR MJ, 1978, J NEUROCHEM, V31, P251, DOI 10.1111/j.1471-4159.1978.tb12456.x; KUHAR MJ, 1990, EUR NEUROL, V30, P15; MADRAS BK, 1989, MOL PHARMACOL, V36, P518; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; RITZ MC, 1990, LIFE SCI, V46, P635, DOI 10.1016/0024-3205(90)90132-B; SCHAEFFERJC, 1991, MOL BRAIN RES, V9, P271; SCHOEMAKER H, 1985, N-S ARCH PHARMACOL, V329, P227, DOI 10.1007/BF00501873; UHL GR, 1991, MOL BRAIN RES, V9, P23, DOI 10.1016/0169-328X(91)90126-I	21	548	564	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1991	254	5031					576	578		10.1126/science.1948034	http://dx.doi.org/10.1126/science.1948034			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GL799	1948034				2022-12-01	WOS:A1991GL79900051
J	THOMAS, JE; SORIANO, P; BRUGGE, JS				THOMAS, JE; SORIANO, P; BRUGGE, JS			PHOSPHORYLATION OF C-SRC ON TYROSINE-527 BY ANOTHER PROTEIN TYROSINE KINASE	SCIENCE			English	Article							MIDDLE TUMOR-ANTIGEN; ATP-BINDING SITE; MONOCLONAL-ANTIBODIES; TRANSFORMING PROTEIN; CARBOXY TERMINUS; PP60C-SRC; ACTIVATION; DEPHOSPHORYLATION; FIBROBLASTS; P60C-SRC	The protein tyrosine kinase activity of the cellular Src protein is negatively regulated by phosphorylation at tyrosine residue 527 (Tyr527). It has not been established whether this regulatory modification of Src is mediated by autophosphorylation or by another cellular protein kinase. The phosphorylation of a modified form of c-Src that lacks kinase activity was examined in mouse cells that do not express endogenous Src (because of the targeted disruption of both src alleles). Phosphorylation of the inactive form of Src on Tyr527 occurred to a similar extent in cells lacking endogenous Src as it did in cells expressing Src. Therefore, Tyr527 phosphorylation, and thus negative control of Src kinase activity, is mediated by another cellular protein tyrosine kinase.	UNIV PENN, SCH MED, HOWARD HUGHES MED INST, DEPT MICROBIOL, PHILADELPHIA, PA 19104 USA; BAYLOR COLL MED, HOWARD HUGHES MED INST, INST MOLEC GENET, HOUSTON, TX 77030 USA	Howard Hughes Medical Institute; University of Pennsylvania; Baylor College of Medicine; Howard Hughes Medical Institute			Soriano, Philippe M/E-5797-2015	Soriano, Philippe M/0000-0002-0427-926X				BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BOLEN J, COMMUNICATION; BROWN M, 1986, J VIROL, V60, P290, DOI 10.1128/JVI.60.1.290-293.1986; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; COLLETT MS, 1979, J VIROL, V29, P770, DOI 10.1128/JVI.29.2.770-781.1979; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1987, ONCOGENE RES, V1, P297; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KORNBLUTH S, 1987, P NATL ACAD SCI USA, V84, P4455, DOI 10.1073/pnas.84.13.4455; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOO D, 1988, CELL GROWTH DIVISION; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; OKADA M, 1989, J BIOL CHEM, V264, P20886; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; SCHMIDT J, UNPUB; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O	32	94	96	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 25	1991	254	5031					568	571		10.1126/science.1719633	http://dx.doi.org/10.1126/science.1719633			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL799	1719633				2022-12-01	WOS:A1991GL79900048
J	ULLMAN, KS; FLANAGAN, WM; EDWARDS, CA; CRABTREE, GR				ULLMAN, KS; FLANAGAN, WM; EDWARDS, CA; CRABTREE, GR			ACTIVATION OF EARLY GENE-EXPRESSION IN LYMPHOCYTES-T BY OCT-1 AND AN INDUCIBLE PROTEIN, OAP40	SCIENCE			English	Article							RNA POLYMERASE-II; HISTONE H2B GENE; TRANSCRIPTION FACTOR; BINDING-PROTEIN; POU DOMAIN; CONTAINS; PURIFICATION; INTERACTS; COMPLEX; PROMOTERS	After antigenic stimulation of T lymphocytes, genes essential for proliferation and immune function, such as the interleukin-2 (IL-2) gene, are transcriptionally activated. In both transient transfections and T lymphocyte-specific in vitro transcription, the homeodomain-containing protein Oct-1 participated in the inducible regulation of transcription of the IL-2 gene. Oct-1 functioned in this context with a 40-kilodalton protein called Oct-1-associated protein (OAP40). In addition to interacting specifically with DNA, OAP40 reduced the rate of dissociation of Oct-I from its cognate DNA-binding site, suggesting that a direct interaction exists between Oct-1 and OAP40.	STANFORD UNIV,BECKMAN CTR,HOWARD HUGHES MED INST,STANFORD,CA 94305; GENELABS INC,REDWOOD CITY,CA 94063; STANFORD UNIV,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University; Stanford University				Ullman, Katharine/0000-0003-3693-2830	NCI NIH HHS [CA39612] Funding Source: Medline; NHLBI NIH HHS [HL33942] Funding Source: Medline; NIAID NIH HHS [AI07290] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA039612, R01CA039612] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033942] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; CARBON P, 1987, CELL, V51, P71, DOI 10.1016/0092-8674(87)90011-0; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EDWARDS CM, UNPUB; FLANAGAN WM, IN PRESS J BIOL CHEM; FLANAGAN WP, UNPUB; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAMPS MP, 1990, MOL CELL BIOL, V10, P5464, DOI 10.1128/MCB.10.10.5464; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KEMP LM, 1988, EMBO J, V7, P4239, DOI 10.1002/j.1460-2075.1988.tb03321.x; KO HS, 1988, CELL, V55, P135, DOI 10.1016/0092-8674(88)90016-5; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; OHARE P, 1988, EMBO J, V7, P4231, DOI 10.1002/j.1460-2075.1988.tb03320.x; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; SMITH KA, 1985, P NATL ACAD SCI USA, V82, P864, DOI 10.1073/pnas.82.3.864; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Ullman K.S., UNPUB; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113	37	153	155	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1991	254	5031					558	562		10.1126/science.1683003	http://dx.doi.org/10.1126/science.1683003			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL799	1683003				2022-12-01	WOS:A1991GL79900045
J	CHAVRIER, P; GORVEL, JP; STELZER, E; SIMONS, K; GRUENBERG, J; ZERIAL, M				CHAVRIER, P; GORVEL, JP; STELZER, E; SIMONS, K; GRUENBERG, J; ZERIAL, M			HYPERVARIABLE C-TERMINAL DOMAIN OF RAB PROTEINS ACTS AS A TARGETING SIGNAL	NATURE			English	Article							GTP-BINDING-PROTEINS; MOLECULAR-CLONING; CELL-LINE; SECRETION; TRANSFERRIN; FAMILY; CDNAS; BRAIN; GENES; VIRUS	MAMMALIAN cells express many ras-like low molecular mass GTP-binding proteins (rab proteins) 1-6 that are highly homologous to the Ypt1 and Sec4 proteins involved in controlling secretion in yeast 7-9. Owing to their structural similarity and to their variety, rab proteins have been postulated to act as specific regulators of membrane traffic in exocytosis and endocytosis 10, and rab5 has been shown to be involved in early endosome fusion in vitro 11. In agreement with their postulated functions, all rab proteins studied so far have been found in distinct subcompartments along the exocytic or endocytic pathways 5,11-13. To define the region mediating their specific localization, we transiently expressed rab2, rab5 and rab7 hybrid proteins in BHK cells, and determined their intracellular localization by immunofluorescence confocal microscopy and subcellular fractionation. Here we present evidence that the highly variable C-terminal domain contains structural elements necessary for the association of rab proteins with their specific target membranes in the endocytic pathway.	EUROPEAN MOLEC BIOL LAB, POSTFACH 102209, W-6900 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)			CHAVRIER, Philippe/AAG-2645-2020; Stelzer, Ernst H K/A-7648-2011; Gorvel, Jean-Pierre/O-1332-2018; CHAVRIER, Philippe/B-4707-2010	CHAVRIER, Philippe/0000-0002-7351-733X; Stelzer, Ernst H K/0000-0003-1545-0736; Gorvel, Jean-Pierre/0000-0002-2829-9804; CHAVRIER, Philippe/0000-0002-7351-733X; Simons, Kai/0000-0002-9231-9996				BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUCCI C, 1988, NUCLEIC ACIDS RES, V16, P9979, DOI 10.1093/nar/16.21.9979; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; DESCHENES RJ, 1987, MOL CELL BIOL, V7, P2344, DOI 10.1128/MCB.7.7.2344; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GALLWITZ D, 1983, NATURE, V306, P704, DOI 10.1038/306704a0; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GROVEL JP, 1991, CELL, V64, P915; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MOLENAAR CMT, 1988, EMBO J, V7, P971, DOI 10.1002/j.1460-2075.1988.tb02903.x; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394; ZERIAL M, 1986, EMBO J, V5, P1543, DOI 10.1002/j.1460-2075.1986.tb04395.x	25	340	347	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 24	1991	353	6346					769	772		10.1038/353769a0	http://dx.doi.org/10.1038/353769a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL696	1944536	Bronze			2022-12-01	WOS:A1991GL69600073
J	DRISCOLL, PC; CYSTER, JG; CAMPBELL, ID; WILLIAMS, AF				DRISCOLL, PC; CYSTER, JG; CAMPBELL, ID; WILLIAMS, AF			STRUCTURE OF DOMAIN-1 OF RAT LYMPHOCYTE-T CD2 ANTIGEN	NATURE			English	Article							IMMUNOGLOBULIN SUPERFAMILY; 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; PROTEIN; FRAGMENT; SPECTROSCOPY; ACTIVATION; RESOLUTION; RECEPTORS; SEQUENCES	THE CD2 antigen is largely restricted to cells of the T-lymphocyte lineage and has been established as an important adhesion molecule in interactions between human T lymphocytes and accessory cells 1. In the adhesion reaction, CD2 on T cells binds to LFA-3 on other cells, with binding through domain 1 of CD2 (ref. 2). CD2 can also be a target for the delivery of mitogenic signals to T lymphocytes cultured with combinations of anti-CD2 antibodies 3,4. Two predictions that are contradictory have been made for the structure of CD2 domain 1. One suggests an immunoglobulin (Ig) fold, on the basis of sequence patterns conserved in the Ig-superfamily (IgSF) 5, whilst the other proposes a pattern of alternating alpha-helices and beta-strands, on the basis of secondary structure predictions 6. Thus CD2 domain 1 is an important test case for the validity of IgSF assignments based on sequence patterns. We report here the expression of domain 1 of rat CD2 in an Escherichia coli expression system and have determined a low-resolution solution structure by NMR spectroscopy.	UNIV OXFORD, SIR WILLIAM DUNN SCH PATHOL, MRC, CELLULAR IMMUNOL RES UNIT, OXFORD OX1 3RE, ENGLAND	University of Oxford	DRISCOLL, PC (corresponding author), UNIV OXFORD, DEPT BIOCHEM, OXFORD OX1 3QU, ENGLAND.		Driscoll, Paul C/B-8007-2010	Driscoll, Paul C/0000-0002-4124-6950				AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; BECKER JW, 1985, P NATL ACAD SCI USA, V82, P4225, DOI 10.1073/pnas.82.12.4225; BEYERS AD, 1989, IMMUNOL REV, V111, P59, DOI 10.1111/j.1600-065X.1989.tb00542.x; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1990, X PLOR MANUAL VERSIO; CLAYTON LK, 1987, EUR J IMMUNOL, V17, P1367, DOI 10.1002/eji.1830170922; CLORE GM, 1989, CRIT REV BIOCHEM MOL, V24, P479, DOI 10.3109/10409238909086962; DRISCOLL PC, 1990, BIOCHEMISTRY-US, V29, P3542, DOI 10.1021/bi00466a018; EPP O, 1975, BIOCHEMISTRY-US, V14, P4943, DOI 10.1021/bi00693a025; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KILLEEN N, 1988, EMBO J, V7, P3087, DOI 10.1002/j.1460-2075.1988.tb03174.x; KRAULIS P, IN PRESS J APPL CRYS; LABEIT S, 1990, NATURE, V345, P273, DOI 10.1038/345273a0; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; PETERSON A, 1987, NATURE, V329, P842, DOI 10.1038/329842a0; RECNY MA, 1990, J BIOL CHEM, V265, P8542; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SAUL FA, 1978, J BIOL CHEM, V253, P585; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WILLIAMS AF, 1989, COLD SPRING HARB SYM, V54, P637; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS AF, 1987, J EXP MED, V165, P368, DOI 10.1084/jem.165.2.368	29	150	161	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 24	1991	353	6346					762	765		10.1038/353762a0	http://dx.doi.org/10.1038/353762a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL696	1682812				2022-12-01	WOS:A1991GL69600071
J	DRYER, SE; HENDERSON, D				DRYER, SE; HENDERSON, D			A CYCLIC GMP-ACTIVATED CHANNEL IN DISSOCIATED CELLS OF THE CHICK PINEAL-GLAND	NATURE			English	Article							SINGLE ION CHANNELS; ROD INNER SEGMENTS; PHOTOENDOCRINE TRANSDUCTION; CONCENTRATION-DEPENDENCE; MELATONIN RHYTHM; LIGHT	PHOTOTRANSDUCTION in the vertebrate retina is dependent in part on a cyclic GMP-activated ionic channel in the plasma membrane of rods and cones 1,2. But other vertebrate cells are also photosensitive. Cells of the chick pineal gland have a photosensitive circadian rhythm in melatonin secretion that persists in dissociated cell culture 3,4. Exposure to light causes inhibition of melatonin secretion, and entrainment of the intrinsic circadian oscillator 5,6. Chick pinealocytes express several 'retinal' proteins, including arrestin 7, transducin 8 and a protein similar to the visual pigment rhodopsin 9. Pinealocytes of lower vertebrates display hyperpolarizing responses to brief pulses of light 10,11. Thus it is possible that some of the mechanisms of phototransduction are similar in retinal and pineal photoreceptors. We report here the first recordings of cyclic GMP-activated channels in an extraretinal photoreceptor. Application of GMP, but not cyclic AMP, to excised inside-out patches caused activation of a 15-25 pS cationic channel. These channels may be essential for phototransduction in the chick pineal gland.			DRYER, SE (corresponding author), FLORIDA STATE UNIV, DEPT BIOL SCI B157, PROGRAM PSYCHOBIOL & NEUROSCI, TALLAHASSEE, FL 32306 USA.							COLLIN JP, 1986, NEUROSCIENCE, V19, P657, DOI 10.1016/0306-4522(86)90288-5; DEGUCHI T, 1981, NATURE, V290, P706, DOI 10.1038/290706a0; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; HARRISON NL, 1989, J NEUROSCI, V9, P2462; HAYNES LW, 1990, J PHYSIOL-LONDON, V429, P451, DOI 10.1113/jphysiol.1990.sp018267; KAUPP UB, 1988, COLD SPRING HARB SYM, V53, P407, DOI 10.1101/SQB.1988.053.01.048; MATTHEWS G, 1988, J PHYSIOL-LONDON, V403, P389, DOI 10.1113/jphysiol.1988.sp017255; MENINI A, 1990, J PHYSIOL-LONDON, V424, P167, DOI 10.1113/jphysiol.1990.sp018061; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; PU GA, 1981, J NEUROPHYSIOL, V46, P1018, DOI 10.1152/jn.1981.46.5.1018; ROBERTSON LM, 1988, J NEUROSCI, V8, P12; ROBERTSON LM, 1988, J NEUROSCI, V8, P22; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; TAMOTSU S, 1986, J COMP PHYSIOL A, V159, P1, DOI 10.1007/BF00612489; VANVEEN T, 1986, P NATL ACAD SCI USA, V83, P912; WAINWRIGHT SD, 1988, J NEUROCHEM, V413, P358; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.neuro.12.1.289; ZATZ M, 1988, BRAIN RES, V453, P63, DOI 10.1016/0006-8993(88)90143-6; ZATZ M, 1988, BRAIN RES, V438, P199, DOI 10.1016/0006-8993(88)91339-X	19	97	98	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 24	1991	353	6346					756	758		10.1038/353756a0	http://dx.doi.org/10.1038/353756a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL696	1719422				2022-12-01	WOS:A1991GL69600069
J	FLYNN, GC; POHL, J; FLOCCO, MT; ROTHMAN, JE				FLYNN, GC; POHL, J; FLOCCO, MT; ROTHMAN, JE			PEPTIDE-BINDING SPECIFICITY OF THE MOLECULAR CHAPERONE BIP	NATURE			English	Article							NEWLY SYNTHESIZED PROTEINS; HEAT-SHOCK; CELLS; HYDROPHOBICITY; TRANSLOCATION; DEGRADATION; CATALYSTS; CORE; ATP	Members of the heat-shock protein family (hsp70s) can distinguish folded from unfolded proteins. This property is crucial to the role of hsp70s as molecular chaperones and is attributable to the amino-acid specificity of the peptide-binding site. The specificity for peptide ligands is investigated using a set of peptides of random sequence but defined chain length. The peptide-binding site selects for aliphatic residues and accommodates them in an environment energetically equivalent to the interior of a folded protein.	EMORY UNIV, SCH MED, MICROCHEM FACIL, ATLANTA, GA 30322 USA; PRINCETON UNIV, DEPT MOLEC BIOL, MICROCHEM CORE FACIL, PRINCETON, NJ 08544 USA	Emory University; Princeton University	FLYNN, GC (corresponding author), SLOAN KETTERING MEM CANC CTR, ROCKEFELLER RES LAB, PROGRAM CELLULAR BIOCHEM & BIOPHYS, NEW YORK, NY 10021 USA.							BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; CHANG CD, 1978, INT J PEPT PROT RES, V11, P246; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P618; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FLAJNIK MF, 1991, P NATL ACAD SCI USA, V88, P537, DOI 10.1073/pnas.88.2.537; FLAJNIK MF, IN PRESS IMMUNOGENET; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GOLDBERG AL, 1976, ANNU REV BIOCHEM, V45, P747, DOI 10.1146/annurev.bi.45.070176.003531; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KAPPER MH, 1977, BIOCHEM BIOPH RES CO, V78, P1018; LEWIS MJ, 1985, EMBO J, V4, P3137, DOI 10.1002/j.1460-2075.1985.tb04056.x; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; NOZAKI Y, 1971, J BIOL CHEM, V246, P2211; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; POHL J, 1990, FEBS LETT, V272, P200, DOI 10.1016/0014-5793(90)80484-Z; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; TACK BF, 1980, J BIOL CHEM, V255, P8842; TANFORD C, 1962, J AM CHEM SOC, V84, P4240, DOI 10.1021/ja00881a009	35	680	705	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 24	1991	353	6346					726	730		10.1038/353726a0	http://dx.doi.org/10.1038/353726a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL696	1834945				2022-12-01	WOS:A1991GL69600057
J	HARTLEY, SB; CROSBIE, J; BRINK, R; KANTOR, AB; BASTEN, A; GOODNOW, CC				HARTLEY, SB; CROSBIE, J; BRINK, R; KANTOR, AB; BASTEN, A; GOODNOW, CC			ELIMINATION FROM PERIPHERAL LYMPHOID-TISSUES OF SELF-REACTIVE LYMPHOCYTES-B RECOGNIZING MEMBRANE-BOUND ANTIGENS	NATURE			English	Article							PROTEIN TYROSINE PHOSPHORYLATION; TRANSGENIC MICE; CLONAL DELETION; CELL TOLERANCE; T-CELLS; RECEPTOR; EXPRESSION; MATURE; STIMULATION; MECHANISMS	THE long-standing hypothesis 1,2 that tolerance to self antigens is mediated by either elimination 3-8 or functional inactivation (anergy; refs 9-11) of self-reactive lymphocytes is now accepted, but little is known about the factors responsible for initiating one process rather than the other. In the B-cell lineage, tolerant self-reactive cells persist in the peripheral lymphoid organs of transgenic mice expressing lysozyme and anti-lysozyme immunoglobulin genes 9, but are eliminated in similar transgenic mice expressing anti-major histocompatibility complex immunoglobulin genes 8. By modifying the structure of the lysozyme transgene and the isotype of the anti-lysozyme immunoglobulin genes, we demonstrate here that induction of anergy or deletion is not due to differences in antibody affinity or isotype, but to recognition of monomeric or oligomeric soluble antigen versus highly multivalent membrane-bound antigen. Our findings indicate that the degree of receptor crosslinking can have qualitatively distinct signalling consequences for lymphocyte development.	STANFORD UNIV, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA; STANFORD UNIV, BECKMAN CTR MOLEC & GENET MED, DEPT GENET, STANFORD, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University; Stanford University	HARTLEY, SB (corresponding author), UNIV SYDNEY, CENTENARY INST CANC MED & CELL BIOL, SYDNEY, NSW 2006, AUSTRALIA.		Brink, Robert/B-7910-2010; Goodnow, Christopher C/V-8108-2018	Brink, Robert/0000-0002-9586-3655; Goodnow, Christopher C/0000-0001-5296-6155				BRUNSWICK M, 1991, P NATL ACAD SCI USA, V88, P1311, DOI 10.1073/pnas.88.4.1311; Burnet FM, 1959, CLONAL SELECTION THE, DOI DOI 10.5962/BHL.TITLE.8281; CAMBIER JC, 1987, ANNU REV IMMUNOL, V5, P175, DOI 10.1146/annurev.immunol.5.1.175; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; COFFMAN RL, 1983, IMMUNOL REV, V69, P5, DOI 10.1111/j.1600-065X.1983.tb00446.x; DEFRANCO AL, 1987, ANNU REV CELL BIOL, V3, P143; DINTZIS RZ, 1983, J IMMUNOL, V131, P2196; Forster I, 1989, Int Immunol, V1, P321, DOI 10.1093/intimm/1.4.321; GASCOIGNE NRJ, 1987, P NATL ACAD SCI USA, V84, P2936, DOI 10.1073/pnas.84.9.2936; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GOODNOW CC, 1989, IMMUNE RESPONSE TO STRUCTURALLY DEFINED PROTEINS : THE LYSOZYME MODEL, P389; GOODNOW CC, 1989, NATURE, V342, P385, DOI 10.1038/342385a0; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HARNETT MM, 1988, IMMUNOL TODAY, V9, P315, DOI 10.1016/0167-5699(88)91325-4; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KLAUS GGB, 1976, BRIT MED BULL, V32, P141, DOI 10.1093/oxfordjournals.bmb.a071346; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MORELLO D, 1986, EMBO J, V5, P1877, DOI 10.1002/j.1460-2075.1986.tb04439.x; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NEMAZEE D, 1989, P NATL ACAD SCI USA, V86, P8039, DOI 10.1073/pnas.86.20.8039; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NOSSAL GJV, 1983, ANNU REV IMMUNOL, V1, P33, DOI 10.1146/annurev.iy.01.040183.000341; PARKS DR, 1986, HDB EXPT IMMUNOLOGY, V1, P291; RAFF MC, 1975, J EXP MED, V142, P1052, DOI 10.1084/jem.142.5.1052; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; RETH M, 1991, IMMUNOL TODAY, V12, P196, DOI 10.1016/0167-5699(91)90053-V; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SIDMAN CL, 1975, NATURE, V257, P149, DOI 10.1038/257149a0; SMITHGILL SJ, 1984, J IMMUNOL, V132, P963; STALL AM, 1988, P NATL ACAD SCI USA, V85, P3546, DOI 10.1073/pnas.85.10.3546; WEISS E, 1983, EMBO J, V2, P453, DOI 10.1002/j.1460-2075.1983.tb01444.x; Wyllie A H, 1980, Int Rev Cytol, V68, P251	37	589	592	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 24	1991	353	6346					765	769		10.1038/353765a0	http://dx.doi.org/10.1038/353765a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL696	1944535				2022-12-01	WOS:A1991GL69600072
J	HENNECKE, F; KOLMAR, H; BRUNDL, K; FRITZ, HJ				HENNECKE, F; KOLMAR, H; BRUNDL, K; FRITZ, HJ			THE VSR GENE-PRODUCT OF ESCHERICHIA-COLI K-12 IS A STRAND-SPECIFIC AND SEQUENCE-SPECIFIC DNA MISMATCH ENDONUCLEASE	NATURE			English	Article							SHORT PATCH REPAIR; ESCHERICHIA-COLI; POLYMERASE-I; LAMBDA; 5-METHYL-CYTOSINE; RECOMBINATION; METHYLATION; GLYCOSYLASE; REPRESSOR; MECHANISM	IN Escherichia coli K-12, the Dcm methyltransferase catalyses methylation of the inner cytosine residue in the sequence CC(A)/(T)GG 1,2. Hydrolytic deamination of 5-methylcytosine bases in DNA leads to thymine residues, and hence to T/G mismatches, pre-mutagenic DNA lesions consisting of two natural DNA constituents and thus devoid of an obvious marker of the damaged DNA strand. These mismatches are corrected by the VSP repair pathway, which is characterized by very short patches of DNA repair synthesis 3,4. It depends on genes vsr 5 and polA 6 and is strongly stimulated by mutL and mutS 7-9. The vsr gene product (Vsr; M(r) 18,000) was purified and characterized as a DNA mismatch endonuclease, a unique and hitherto unknown type of enzyme. Vsr endonuclease nicks double-stranded DNA within the sequence CT(A)/(T)GN or NT(A)/(T)GG next to the underlined thymidine residue, which is mismatched to 2'-deoxyguanosine. The incision is mismatch-dependent and strand-specific. These results illustrate how Vsr endonuclease initiates VSP mismatch repair.			HENNECKE, F (corresponding author), UNIV GOTTINGEN,INST MOLEK GENET,GRISEBACHSTR 8,W-3400 GOTTINGEN,GERMANY.		Kolmar, Harald/AAK-8316-2021	Kolmar, Harald/0000-0002-8210-1993				AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; BAMBARA RA, 1978, J BIOL CHEM, V253, P413; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; CARTWRIGHT SJ, 1984, BIOCHEM J, V221, P505, DOI 10.1042/bj2210505; COULONDRE C, 1978, NATURE, V274, P775, DOI 10.1038/274775a0; DZIDIC S, 1989, MOL GEN GENET, V217, P254, DOI 10.1007/BF02464889; HANCK T, 1989, NUCLEIC ACIDS RES, V17, P5844, DOI 10.1093/nar/17.14.5844; JONES M, 1987, J MOL BIOL, V194, P155, DOI 10.1016/0022-2836(87)90724-8; KRAMER B, 1984, CELL, V38, P879, DOI 10.1016/0092-8674(84)90283-6; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIEB M, 1987, J BACTERIOL, V169, P5241, DOI 10.1128/jb.169.11.5241-5246.1987; LIEB M, 1985, MOL GEN GENET, V199, P465; LIEB M, 1986, GENETICS, V114, P1041; LIEB M, 1983, MOL GEN GENET, V191, P118, DOI 10.1007/BF00330898; Maniatis T., 1982, MOL CLONING; MARINUS MG, 1973, MOL GEN GENET, V127, P47, DOI 10.1007/BF00267782; Maxam A M, 1980, Methods Enzymol, V65, P499; POHLNER J, 1987, NATURE, V325, P458, DOI 10.1038/325458a0; REYNAUD CA, 1987, CELL, V48, P379, DOI 10.1016/0092-8674(87)90189-9; SCHLAGMAN S, 1976, J BACTERIOL, V126, P990, DOI 10.1128/JB.126.2.990-996.1976; SOHAIL A, 1990, J BACTERIOL, V172, P4214, DOI 10.1128/jb.172.8.4214-4221.1990; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; VONWILCKENBERGMANN B, 1982, P NATL ACAD SCI-BIOL, V79, P2427; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; WYSOCKI LJ, 1989, ANNU REV BIOCHEM, V58, P509; ZELL R, 1987, EMBO J, V6, P1809, DOI 10.1002/j.1460-2075.1987.tb02435.x	26	125	128	1	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 24	1991	353	6346					776	778		10.1038/353776a0	http://dx.doi.org/10.1038/353776a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL696	1944537				2022-12-01	WOS:A1991GL69600075
J	LIMAN, ER; HESS, P; WEAVER, F; KOREN, G				LIMAN, ER; HESS, P; WEAVER, F; KOREN, G			VOLTAGE-SENSING RESIDUES IN THE S4 REGION OF A MAMMALIAN K+ CHANNEL	NATURE			English	Article							POTASSIUM CHANNEL; SODIUM-CHANNEL; DROSOPHILA; OOCYTES	THE ability of ion-channel proteins to respond to a change of the transmembrane voltage is one of the basic mechanisms underlying electrical excitability of nerve and muscle membranes. The voltage sensor has been postulated to be the fourth putative transmembrane segment 1 (S4) of voltage-activated Na+, Ca2+ and K+ channels 1-5. Mutations of positively charged residues within S4 alter gating of Na 4 and Shaker-type K+ channels 5, but quantitative correlations between the charge or a residue in S4 and the gating valence of the channel have not yet been established. Here, with improved resolution of the voltage dependence of steady-state activation, we present estimates of the equivalent gating valence with sufficient precision to allow quantitative examination of the contribution of individual charged residues to the gating valence of a mammalian non-inactivating K+ channel. We conclude that at least part of the gating charge associated with channel activation is indeed contributed by charged residues within the S4 segment.	HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,25 SHATTUCK ST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT CARDIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital			Liman, Emily/AAC-7383-2021	liman, emily/0000-0003-4765-5496				Almers W, 1978, Rev Physiol Biochem Pharmacol, V82, P96, DOI 10.1007/BFb0030498; AULD VJ, 1990, P NATL ACAD SCI USA, V87, P323, DOI 10.1073/pnas.87.1.323; BAUMANN A, 1988, EMBO J, V7, P2457, DOI 10.1002/j.1460-2075.1988.tb03092.x; BENNDORF K, 1989, EUR BIOPHYS J BIOPHY, V17, P257, DOI 10.1007/BF00254283; BEZANILLA F, 1982, NATURE, V296, P657, DOI 10.1038/296657a0; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHRISTIE MJ, 1989, SCIENCE, V244, P221, DOI 10.1126/science.2539643; CONTI F, 1989, EUR BIOPHYS J BIOPHY, V17, P53, DOI 10.1007/BF00257102; GILLY WMF, 1982, J GEN PHYSIOL, V70, P965; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HILLE B, 1984, IONIC CHANNELS EXCIT, P1; KOREN G, 1990, NEURON, V4, P39, DOI 10.1016/0896-6273(90)90442-I; LOGOTHETIS D E, 1991, Biophysical Journal, V59, p196A; LOPEZ GA, 1991, NEURON, V7, P327, DOI 10.1016/0896-6273(91)90271-Z; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MCCORMACK K, 1991, P NATL ACAD SCI USA, V88, P2931, DOI 10.1073/pnas.88.7.2931; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; STUEHMER W, 1989, Nature (London), V339, P597; SWENSON RP, 1981, NATURE, V291, P427, DOI 10.1038/291427a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZAGOTTA WN, 1990, J GEN PHYSIOL, V95, P29, DOI 10.1085/jgp.95.1.29	24	249	252	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 24	1991	353	6346					752	756		10.1038/353752a0	http://dx.doi.org/10.1038/353752a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL696	1944534				2022-12-01	WOS:A1991GL69600068
J	MATSUI, Y; TOKSOZ, D; NISHIKAWA, S; NISHIKAWA, SI; WILLIAMS, D; ZSEBO, K; HOGAN, BLM				MATSUI, Y; TOKSOZ, D; NISHIKAWA, S; NISHIKAWA, SI; WILLIAMS, D; ZSEBO, K; HOGAN, BLM			EFFECT OF STEEL FACTOR AND LEUKEMIA INHIBITORY FACTOR ON MURINE PRIMORDIAL GERM-CELLS IN CULTURE	NATURE			English	Article							TYROSINE KINASE RECEPTOR; C-KIT; GROWTH-FACTOR; W-LOCUS; SI-LOCUS; PROTO-ONCOGENE; MOUSE; LIGAND; EXPRESSION; IDENTIFICATION	DESPITE the importance of germ cells to the survival of species, surprisingly little is known about their embryological origin, proliferation, migration and entry into mitotic arrest or meiosis 1-5. Mutations in the murine Dominant White Spotting (W) and Steel genes, which respectively encode the c-kit tyrosine kinase receptor and the c-kit ligand (or Steel factor), impair the development of primordial germ cells (PGCs) in vivo, as well as haematopoietic stem cells and neural crest-derived melanoblast 3,6-16. Here we use a monoclonal antibody against c-kit tyrosine kinase receptor and recombinant Steel factor to study the c-kit receptor-ligand system in cultured PGCs. In addition, we show that leukaemia inhibitory factor (also known as differentiation inhibitory activity) 17,18, a factor secreted by STO fibroblasts, can stimulate proliferation of primordial germ cells in vitro.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,HOWARD HUGHES MED INST,BOSTON,MA 02115; KUMAMOTO UNIV,INST MED IMMUNOL,DEPT PATHOL,KUMAMOTO 860,JAPAN; AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320	Vanderbilt University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Kumamoto University; Amgen				Matsui, Yasuhisa/0000-0001-7026-6355				ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; DONOVAN PJ, 1986, CELL, V44, P831, DOI 10.1016/0092-8674(86)90005-X; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GINSBURG M, 1990, DEVELOPMENT, V110, P521; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; GODIN I, 1990, DEVELOPMENT, V108, P357; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; MANOVA K, 1991, DEV BIOL, V146, P312, DOI 10.1016/0012-1606(91)90233-S; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; MINTZ B, 1957, J EXP ZOOL, V134, P207, DOI 10.1002/jez.1401340202; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; TAM PPL, 1981, J EMBRYOL EXP MORPH, V64, P133; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WILLIAMS L, 1988, NATURE, V336, P688; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	28	393	416	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 24	1991	353	6346					750	752		10.1038/353750a0	http://dx.doi.org/10.1038/353750a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL696	1719421				2022-12-01	WOS:A1991GL69600067
J	VANTWUYVER, E; MOOIJAART, RJD; TENBERGE, IJM; VANDERHORST, AR; WILMINK, JM; KAST, WM; MELIEF, CJM; DEWAAL, LP				VANTWUYVER, E; MOOIJAART, RJD; TENBERGE, IJM; VANDERHORST, AR; WILMINK, JM; KAST, WM; MELIEF, CJM; DEWAAL, LP			PRETRANSPLANTATION BLOOD-TRANSFUSION REVISITED	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LYMPHOCYTE-T PRECURSORS; CLASS-II DISPARITY; H-2 CLASS-I; TRANSPLANTATION TOLERANCE; ADULT MICE; ALLOGRAFT ENHANCEMENT; CELL REPERTOIRE; INDUCTION; CYCLOSPORINE; RECIPIENTS	Background. Blood transfusion before organ transplantation has a beneficial effect on allograft survival; the mechanism of this effect has remained a mystery. In murine models, the presence of common histocompatibility antigens in the blood donor and the recipient favors the induction of allograft tolerance. Methods. To investigate the effect of HLA compatibility between blood donor and recipient on the induction of allograft tolerance, we determined the relative frequency of cytotoxic T-lymphocyte precursors specific for donor cells before and at several times after blood transfusion in 23 patients awaiting a first renal transplant. We correlated the results with the presence of shared HLA antigens. Results. T-cell nonresponsiveness against donor cells developed after blood transfusion in 10 of the 23 patients. Tolerance developed only if the blood donor and the recipient had one HLA haplotype or at least one HLA-B and one HLA-DR antigen in common (as was observed in 9 of these 10 patients). Tolerance developed relatively late after blood transfusion (one to two months) and was long-lasting. No decline in the T-cell response against donor alloantigens was observed in any of the 13 patients who received transfusions without having HLA-antigen compatibility with the donor. Conclusions. Blood transfusion in which there is a common HLA haplotype or shared HLA-B and HLA-DR antigens induces tolerance to donor antigens. This finding may lead to the development of new strategies with which to induce tolerance for transplantation after blood transfusion. Perhaps transplant donors will be selected not only by HLA-antigen matching, but also on the basis of acceptable HLA-antigen mismatches associated with T-cell non-responsiveness induced by selected blood transfusion.	NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,PUBLICAT SECRETARIAT,POB 9406,1006 AK AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,EXPTL & CLIN IMMUNOL LAB,AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT INTERNAL MED,RENAL TRANSPLANT UNIT,1105 AZ AMSTERDAM,NETHERLANDS; LEIDEN UNIV HOSP,DEPT IMMUNOHEMATOL,2333 AA LEIDEN,NETHERLANDS; LEIDEN UNIV HOSP,DEPT BLOOD BANK,2333 AA LEIDEN,NETHERLANDS	University of Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC)				Kast, W Martin/0000-0003-2321-3159				BREURVRIESENDORP BS, 1990, HUM IMMUNOL, V27, P1, DOI 10.1016/0198-8859(90)90091-3; DEWAAL LP, 1991, CRIT REV IMMUNOL, V10, P417; HEEG K, 1990, J EXP MED, V172, P719, DOI 10.1084/jem.172.3.719; HENON P, 1991, LANCET, P961; HERZOG WR, 1987, TRANSPLANTATION, V43, P384, DOI 10.1097/00007890-198703000-00013; IRSCHICK E, 1989, TRANSPLANTATION, V48, P986, DOI 10.1097/00007890-198912000-00018; KAMINSKI E, 1989, TRANSPLANTATION, V48, P608; KAST WM, 1988, EUR J IMMUNOL, V18, P2105; LAGAAIJ EL, 1989, NEW ENGL J MED, V321, P701, DOI 10.1056/NEJM198909143211101; LAZDA VA, 1990, TRANSPLANTATION, V49, P1084, DOI 10.1097/00007890-199006000-00011; LEIVESTAD T, 1984, TRANSPLANTATION, V37, P175, DOI 10.1097/00007890-198402000-00012; MAYUMI H, 1989, J EXP MED, V169, P213, DOI 10.1084/jem.169.1.213; MCCARTHY DM, 1984, CRC CR REV CL LAB SC, V20, P1; OPELZ G, 1987, TRANSPLANT P, V19, P149; QIN SX, 1989, J EXP MED, V169, P779, DOI 10.1084/jem.169.3.779; SALVATIERRA O, 1987, TRANSPL P, V19, P160; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SHARABI Y, 1989, J EXP MED, V169, P493, DOI 10.1084/jem.169.2.493; SHARROCK CEM, 1990, IMMUNOL TODAY, V11, P281, DOI 10.1016/0167-5699(90)90113-N; VANDEKERCKHOVE BAE, 1989, TRANSPLANTATION, V48, P672; VANROOD JJ, 1990, SCIENCE, V248, P1388, DOI 10.1126/science.1972596; VANTWUYVER E, 1989, TRANSPLANTATION, V48, P844; VANTWUYVER E, 1990, EUR J IMMUNOL, V20, P441, DOI 10.1002/eji.1830200232; 1988, LANCET, V1, P567	24	176	180	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 24	1991	325	17					1210	1213		10.1056/NEJM199110243251704	http://dx.doi.org/10.1056/NEJM199110243251704			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL282	1922208				2022-12-01	WOS:A1991GL28200004
J	ZOMERDIJK, JCBM; KIEFT, R; BORST, P				ZOMERDIJK, JCBM; KIEFT, R; BORST, P			EFFICIENT PRODUCTION OF FUNCTIONAL MESSENGER-RNA MEDIATED BY RNA POLYMERASE-I IN TRYPANOSOMA-BRUCEI	NATURE			English	Article							TRANSCRIPTION UNIT; GENE; EXPRESSION; PROMOTER; TRANS; IDENTIFICATION; PROVIDES; TUBULIN; CELLS; RDNA	THE unicellular eukaryote Trypanosoma brucei evades the immune defence of its mammalian host by antigenic variation 1. The genes for variant-specific surface glycoproteins (VSGs) are expressed within large multicistronic transcription units 2. Mature messenger RNAs are produced by trans-splicing and polyadenylation 3-5. A remarkable feature of the transcription of VSG genes is its insensitivity to the RNA polymerase II inhibitor alpha-amanitin 6. This has led to the speculation that RNA polymerase I, normally only involved in the transcription of ribosomal RNA genes, also mediates expression of these surface antigen genes. In higher eukaryotes, however, transcripts produced by RNA polymerase I were found to be poor substrates for processing into mature mRNAs 7-9. In contrast, we show here that the RNA polymerase I of T. brucei can mediate the efficient production of functional mRNA for neomycin phosphotransferase. The exceptional ability may be related to the unusual way in which pre-mRNAs are capped in trypanosomes. In most eukaryotes, mRNAs are modified at their 5' end by a capping activity associated with RNA polymerase II10; in trypanosomes, mRNAs acquire their 5'-cap from capped mini-exon donor RNA by trans-splicing 3-5, a process that could be independent of the RNA polymerase producing the pre-mRNA.			ZOMERDIJK, JCBM (corresponding author), NETHERLANDS CANC INST,DIV MOLEC BIOL,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS.		Zomerdijk, Joost/A-5142-2008	Zomerdijk, Joost/0000-0003-1865-729X				CLAYTON CE, 1990, MOL CELL BIOL, V10, P3036, DOI 10.1128/MCB.10.6.3036; CROSS GAM, 1990, ANNU REV IMMUNOL, V8, P83, DOI 10.1146/annurev.iy.08.040190.000503; GRIMALDI G, 1986, NUCLEIC ACIDS RES, V14, P6417, DOI 10.1093/nar/14.16.6417; GRUMMT I, 1985, P NATL ACAD SCI USA, V82, P722, DOI 10.1073/pnas.82.3.722; IMBODEN M, 1986, J MOL BIOL, V166, P393; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; JOVE R, 1982, P NATL ACAD SCI-BIOL, V79, P5842, DOI 10.1073/pnas.79.19.5842; KOOTER JM, 1984, NUCLEIC ACIDS RES, V12, P9457, DOI 10.1093/nar/12.24.9457; LAIRD PW, 1987, EMBO J, V6, P1055, DOI 10.1002/j.1460-2075.1987.tb04858.x; LOPATA MA, 1986, P NATL ACAD SCI USA, V83, P6677, DOI 10.1073/pnas.83.18.6677; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; MUSCARELLA DE, 1989, CELL, V56, P443, DOI 10.1016/0092-8674(89)90247-X; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALDITTGEORGIEFF M, 1980, CELL, V19, P69, DOI 10.1016/0092-8674(80)90389-X; SATHER S, 1985, P NATL ACAD SCI USA, V82, P5695, DOI 10.1073/pnas.82.17.5695; SMALE ST, 1985, MOL CELL BIOL, V5, P352, DOI 10.1128/MCB.5.2.352; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; TENASBROEK ALMA, 1990, NATURE, V348, P174, DOI 10.1038/348174a0; WHITE TC, 1986, NUCLEIC ACIDS RES, V14, P9471, DOI 10.1093/nar/14.23.9471; XIONG Y, 1988, CELL, V55, P235, DOI 10.1016/0092-8674(88)90046-3; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5; ZOMERDIJK JCBM, 1991, NUCLEIC ACIDS RES, V19, P5153, DOI 10.1093/nar/19.19.5153; ZOMERDIJK JCBM, 1990, EMBO J, V9, P2791, DOI 10.1002/j.1460-2075.1990.tb07467.x; ZOMERDIJK JCBM, 1991, NUCLEIC ACIDS RES, V19, P1359, DOI 10.1093/nar/19.7.1359	24	83	84	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 24	1991	353	6346					772	775		10.1038/353772a0	http://dx.doi.org/10.1038/353772a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL696	1658658				2022-12-01	WOS:A1991GL69600074
J	CELIN, SE; BLUESTONE, CD; STEPHENSON, J; YILMAZ, HM; COLLINS, JJ				CELIN, SE; BLUESTONE, CD; STEPHENSON, J; YILMAZ, HM; COLLINS, JJ			BACTERIOLOGY OF ACUTE OTITIS-MEDIA IN ADULTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEMOPHILUS-INFLUENZAE; MIDDLE-EAR; CHEMOTHERAPY; CHILDREN	Objective. - The objective of this study was to determine the bacteriology of acute otitis media in adults. Although this has frequently been studied in children, no data have recently been reported from adults in the United States. Additionally, information on the prevalence of Haemophilus influenzae as a causative organism in acute otitis media in adults has not been available. Design. - Middle-ear aspirates for cultures were obtained by myringotomy from adults meeting entry criteria. Setting. - Emergency department, Eye and Ear Hospital of Pittsburgh, Pa. Patients. - Thirty-four patients (volunteer sample) met the eligibility requirements. Exclusion criteria included history of chronic otitis media, recent antibiotic therapy, immunosuppressive illnesses, or prior otologic surgery. Intervention. - Ten days of oral cefuroxime axetil (250 mg) was prescribed. Main Outcome Measures.-Patients were followed closely for at least 6 weeks. Aerobic and anaerobic cultures were incubated and evaluated per the scheduled protocol. Results. - Haemophilus influenzae and Streptococcus pneumoniae were grown on culture of specimens f rom nine and seven patients (26% and 21 %), respectively Twenty-two percent (2/9) of the H influenzae isolates and the single isolate of Moraxella catarrhalis produced beta-lactamase (9% overall). Conclusions. - The present results suggest that, as in children, amoxicillin would be an appropriate first-line agent for empiric therapy of acute otitis media in adults. Antimicrobials inactive against H influenzae (eg, penicillin V, cephalexin, erythromycin, or tetracyclines) are not appropriate for initial therapy. Antimicrobials with efficacy against organisms producing beta-lactamase, such as cefuroxime axetil, which was used to treat the study patients, do not appear to be required for routine initial therapy in adults. However, they would be appropriate when an organism producing beta-lactamase is isolated from the middle ear or when a patient fails to improve rapidly on amoxicillin therapy.	UNIV PITTSBURGH,SCH MED,DEPT OTOLARYNGOL,DIV PEDIAT OTOLARYNGOL,PITTSBURGH,PA 15261; CHILDRENS HOSP PITTSBURGH,DEPT PEDIAT OTOLARYNGOL,MICROBIOL LAB,PITTSBURGH,PA; GLAXO INC,RES INST,DEPT CLIN RES,RES TRIANGLE PK,NC	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; GlaxoSmithKline								Bluestone, 1990, PEDIATRIC OTOLARYNGO, P320; BRANEFORSHELANDER P, 1975, SCAND J INFECT DIS, V7, P103, DOI 10.3109/inf.1975.7.issue-2.05; CHONMAITREE T, 1986, PEDIATRICS, V77, P698; DADSWELL JV, 1967, LANCET, V1, P243; DUDLEY JP, 1980, JAMA-J AM MED ASSOC, V243, P2328; HAUGSTEN P, 1980, J LARYNGOL OTOL, V94, P169, DOI 10.1017/S0022215100088630; HERBERTS G, 1971, PRACT-OTO-RHINO-LARY, V33, P191; HOWIE VM, 1970, PEDIATRICS, V45, P29; HOWIE VM, 1972, CLIN PEDIATR, V11, P205, DOI 10.1177/000992287201100407; KLEIN JO, 1980, ANN OTOL RHINOL LA S, V89, pS98; SCHWARTZ R, 1977, JAMA-J AM MED ASSOC, V238, P1032, DOI 10.1001/jama.238.10.1032; Schwartz R H, 1981, Am J Otolaryngol, V2, P19, DOI 10.1016/S0196-0709(81)80004-X; SHAMBAUGH GE, 1980, OTOLARYNGOLOGY, V2, P1448; STIERNBERG CM, 1986, OTOLARYNG HEAD NECK, V94, P648; SUGITA R, 1983, INT J PEDIATR OTORHI, V6, P135; SUGITA R, 1985, J LARYNGOL OTOL, V99, P629, DOI 10.1017/S0022215100097395; WALLACE RJ, 1978, AM J MED, V64, P87, DOI 10.1016/0002-9343(78)90182-1; [No title captured]	18	32	33	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1991	266	16					2249	2252		10.1001/jama.266.16.2249	http://dx.doi.org/10.1001/jama.266.16.2249			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK661	1920724				2022-12-01	WOS:A1991GK66100033
J	KLEIN, ML				KLEIN, ML			MACULAR DEGENERATION - IS ASPIRIN A RISK FOR PROGRESSIVE DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											KLEIN, ML (corresponding author), OREGON HLTH SCI UNIV,PORTLAND,OR 97201, USA.							KINGHAM JD, 1988, NEW ENGL J MED, V318, P1126; 1990, ARCH OPHTHALMOL-CHIC, V108, P825; 1986, ARCH OPHTHALMOL-CHIC, V104, P503	3	13	13	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1991	266	16					2279	2279						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK661	1920731				2022-12-01	WOS:A1991GK66100041
J	NELSON, KE; VLAHOV, D; COHN, S; LINDSAY, A; SOLOMON, L; ANTHONY, JC				NELSON, KE; VLAHOV, D; COHN, S; LINDSAY, A; SOLOMON, L; ANTHONY, JC			HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION IN DIABETIC INTRAVENOUS-DRUG-USERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; ABUSERS; EXCHANGE; AIDS	Objective. - To evaluate the association between diabetes and human immunodeficiency virus (HIV) seroprevalence in a population of intravenous (IV) drug users. Design. - Cross-sectional survey in a cohort of IV drug users. Setting. - Community-based study clinic. Subjects. - The study included 2921 individuals with a history of IV drug use in the past 10 years; over 90% had injected drugs in the past year and 77% in the past month; only 15% were receiving drug treatment. Outcome Measures. - The HIV seroprevalence among IV drug users with and without a history of diabetes. Results. - Those IV drug users with a history of diabetes had significantly lower HIV seroprevalence (9.8%) than nondiabetic IV drug users (24.3%; P =.03). Despite similar duration and intensity of drug use and sexual practices, diabetic IV drug users tended not to share injection paraphernalia and were less likely to attend shooting galleries than nondiabetic IV drug users. Conclusion. - Our data suggest that the apparent protective effect of diabetes against HIV infection in IV drug users is most likely due to their safer injection practices afforded by their ready access to sterile injection equipment.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT MENTAL HYG,BALTIMORE,MD 21218	Johns Hopkins University; Maryland Department of Health & Mental Hygiene	NELSON, KE (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,624 N BROADWAY ST,ROOM 763,BALTIMORE,MD 21218, USA.		Anthony, Jim/H-3637-2011	Anthony, Jim/0000-0001-7176-0929	NIDA NIH HHS [DA04334, DA0S664] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004334, R37DA004334] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Allen J, 1981, INFECTION COMPROMISE, P229; BUNING EC, 1986, LANCET, V1, P1435; CHAISSON RE, 1987, AM J PUBLIC HEALTH, V77, P169, DOI 10.2105/AJPH.77.2.169; ELIASHIV A, 1978, ARCH SURG-CHICAGO, V113, P1180; HART GJ, 1989, AIDS, V3, P261, DOI 10.1097/00002030-198905000-00002; HAVERKOS HW, 1990, J INFECT DIS, V161, P894, DOI 10.1093/infdis/161.5.894; MARMOR M, 1987, AIDS, V1, P39; NELSON KE, 1991, J INFECT DIS, V164, P457, DOI 10.1093/infdis/164.3.457; ROBERTSON JR, 1986, BRIT MED J, V292, P527, DOI 10.1136/bmj.292.6519.527; ROBERTSON JR, 1990, AIDS DRUG MISUSE; ROSEMAN JM, NIH851468 US DEP HLT, P1; SCHOENBAUM EE, 1989, NEW ENGL J MED, V321, P874, DOI 10.1056/NEJM198909283211306; STIMSON GV, 1989, AIDS, V3, P253, DOI 10.1097/00002030-198905000-00001; TAN JS, 1975, J LAB CLIN MED, V85, P26; TIRELLI U, 1986, JAMA-J AM MED ASSOC, V255, P2289, DOI 10.1001/jama.1986.03370170053010; VLAHOV D, 1990, AM J EPIDEMIOL, V132, P847, DOI 10.1093/oxfordjournals.aje.a115727; Vlahov D, 1991, NIDA Res Monogr, V109, P75	17	35	35	1	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1991	266	16					2259	2261		10.1001/jama.266.16.2259	http://dx.doi.org/10.1001/jama.266.16.2259			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GK661	1920726				2022-12-01	WOS:A1991GK66100035
J	SEGRAVES, RT				SEGRAVES, RT			REVERSING ANORGASMIA ASSOCIATED WITH SEROTONIN UPTAKE INHIBITORS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							FLUOXETINE				SEGRAVES, RT (corresponding author), CASE WESTERN RESERVE UNIV,CLEVELAND,OH 44106, USA.							HERMAN JB, 1990, J CLIN PSYCHIAT, V51, P25; KLINE MD, 1989, AM J PSYCHIAT, V146, P804; MCCORMICK S, 1990, J CLIN PSYCHIAT, V51, P383; MOINTIERO WO, 1985, BRIT J PSYCHIAT, V151, P107; MOSHER JS, 1990, AM J PSYCHIAT, V147, P949; PRICE J, 1990, J CLIN PSYCHIAT, V51, P32; SEGRAVES RT, 1989, ARCH GEN PSYCHIAT, V46, P275; ZAJECKA J, 1991, J CLIN PSYCHIAT, V52, P66	8	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1991	266	16					2279	2279						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GK661	1920732				2022-12-01	WOS:A1991GK66100042
J	BENZER, A; MITTERSCHIFFTHALER, G; MAROSI, M; LUEF, G; PUHRINGER, F; DELARENOTIERE, K; LEHNER, H; SCHMUTZHARD, E				BENZER, A; MITTERSCHIFFTHALER, G; MAROSI, M; LUEF, G; PUHRINGER, F; DELARENOTIERE, K; LEHNER, H; SCHMUTZHARD, E			PREDICTION OF NON-SURVIVAL AFTER TRAUMA - INNSBRUCK COMA SCALE	LANCET			English	Note							SCORES	421 severely injured patients admitted to a major trauma centre in Innsbruck during the ten years, 1981 to 1990, were investigated retrospectively for early prediction of survival by means of the Innsbruck Coma Scale (ICS). All 79 patients scoring 0 or 1 died within 21 days. The findings of this study indicate that the ICS allows a highly accurate prediction of non-survival in patients with scores of 0 or 1 even at the time of first examination after trauma.	UNIV HOSP INNSBRUCK,DEPT NEUROL,A-6020 INNSBRUCK,AUSTRIA	Medical University of Innsbruck	BENZER, A (corresponding author), UNIV HOSP INNSBRUCK,DEPT ANAESTHESIA,ANICHSTR 35,A-6020 INNSBRUCK,AUSTRIA.							[Anonymous], 1988, Crit Care Med, V16, P807; CHANG RWS, 1988, INTENS CARE MED, V14, P558, DOI 10.1007/BF00263530; JACOBS P, 1990, CRIT CARE MED, V11, P1282; ROCCA B, 1989, J TRAUMA, V29, P299, DOI 10.1097/00005373-198903000-00004; TEASDALE G, 1974, LANCET, V2, P81	5	65	67	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 19	1991	338	8773					977	978		10.1016/0140-6736(91)91840-Q	http://dx.doi.org/10.1016/0140-6736(91)91840-Q			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK974	1681344				2022-12-01	WOS:A1991GK97400006
J	BLACK, ME; SCHEUER, MA; VICTOR, C; BENZEVAL, M; GILL, M; JUDGE, K				BLACK, ME; SCHEUER, MA; VICTOR, C; BENZEVAL, M; GILL, M; JUDGE, K			UTILIZATION BY HOMELESS PEOPLE OF ACUTE HOSPITAL SERVICES IN LONDON	BRITISH MEDICAL JOURNAL			English	Article								Objectives - To estimate the numbers and distribution of homeless people in London; to quantify the utilisation of acute inpatient services by homeless people in two health authorities; and to predict the total numbers of admissions in homeless people in district health authorities across London. Design - Data were collected from various sources on the distribution of homeless people across London boroughs. All unplanned acute inpatient admissions during November 1990 to relevant hospitals were identified. Setting - Bloomsbury and Paddington and North Kensington, two former inner London district health authorities. Subjects - Homeless people in London residing in bed and breakfast and private sector leased accommodation, residing in hostels, and of no fixed abode. Main outcome measures - Number and cost of acute unplanned admissions in homeless people in two health authorities in November 1990; predicted number of such admissions each year in district health authorities in London. Results - There were at least 60000 homeless people in London in March 1990. The majority were housed in temporary accommodation (55 412). There were at least 3295 hostel dwellers and 651 people sleeping rough. Homeless people accounted for 105 (8%) of the 1256 acute unbooked admissions in residents of Bloomsbury and Paddington and North Kensington health authorities in November 1990. Considerable variations in the pattern of acute unplanned admissions in homeless people were observed in the two districts with respect to housing status and specialty of admission. The total number of acute unplanned admissions in homeless people across London each year was estimated at 7598, ranging from 38 in Bexley to 1515 in Parkside. Conclusions - The results have fundamental implications for resource allocation across London. Allocation must take better account of the heterogeneity, uneven distribution, and extra health needs of homeless people.	KINGS FUND INST,LONDON NW1 7NF,ENGLAND; BLOOMSBURY & ISLINGTON HLTH AUTHOR,DEPT PUBL HLTH MED,LONDON WC1E 6DB,ENGLAND; PARKSIDE HLTH AUTHOR,DEPT PUBL HLTH MED,LONDON W2 1PF,ENGLAND				Benzeval, Michaela/J-3163-2015	Benzeval, Michaela/0000-0002-0372-2098; Victor, Christina/0000-0002-4213-3974				BARRY A, 1991, 84 U YORK CTR HLTH E; BRAMLEY G, 1987, HOMELESSNESS LONDON; CANTER D, 1990, FACES HOMELESSNESS L; CONNELLY J, 1990, PUBLIC HEALTH, V104, P109, DOI 10.1016/S0033-3506(05)80361-0; CONWAY J, 1988, PRESCRIPTION POOR HL; EVANS A, 1989, RESPONDING HOMELESSN; NEWMAN R, 1989, LONDON HOSTELS DIREC; PRIEST RG, 1976, J PSYCHIATRY, V128, P130; SCHEUER MA, 1991, 4 KINGS FUND I OCC P; SHANKS NJ, 1988, J EPIDEMIOL COMMUN H, V42, P183, DOI 10.1136/jech.42.2.183; STERN R, 1988, MARGINS MAINSTREAM C; THOMAS A, 1989, LIVING TEMPORARY ACC; VICTOR CR, 1989, BRIT MED J, V229, P725; 1991, 1991 CENSUS PRELIMIN; 1991, HOUSING HOMELESSNESS; 1989, WORKING PATIENTS; 1990, EL90MB22 DEP HLTH; 1989, HOMELESS FAMILIES TH; 1990, ACTIONS LOCAL AUTHOR; 1990, LOCATION HOMELESS HO; 1988, HOMELESSNESS USE TEM	21	13	13	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 19	1991	303	6808					958	961		10.1136/bmj.303.6808.958	http://dx.doi.org/10.1136/bmj.303.6808.958			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL127	1954419	Bronze, Green Published			2022-12-01	WOS:A1991GL12700021
J	CLARKE, A				CLARKE, A			IS NONDIRECTIVE GENETIC-COUNSELING POSSIBLE	LANCET			English	Editorial Material											CLARKE, A (corresponding author), UNIV WALES COLL MED,INST MED GENET,CARDIFF CF4 4XN,S GLAM,WALES.							CLARKE A, 1990, LANCET, V335, P1145, DOI 10.1016/0140-6736(90)91139-2; GAVRILOV DK, 1991, STUDY FREQUENCIES AL; LIPPMAN A, 1991, AM J LAW MED, V17, P15; 1989, REPORT PRENATAL DIAG; 1991, NATURE, V351, P591	5	151	153	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 19	1991	338	8773					998	1001		10.1016/0140-6736(91)91849-P	http://dx.doi.org/10.1016/0140-6736(91)91849-P			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GK974	1681352				2022-12-01	WOS:A1991GK97400014
J	HANSEN, MA; OVERGAARD, K; RIIS, BJ; CHRISTIANSEN, C				HANSEN, MA; OVERGAARD, K; RIIS, BJ; CHRISTIANSEN, C			ROLE OF PEAK BONE MASS AND BONE LOSS IN POSTMENOPAUSAL OSTEOPOROSIS - 12 YEAR STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PHOTON-ABSORPTIOMETRY; VERTEBRAL FRACTURES; SINGLE-PHOTON; WOMEN	Objective - To examine the role of peak bone mass and subsequent postmenopausal bone loss in the development of osteoporosis and the reliability of identifying women at risk from one bone mass measurement and one biochemical assessment of the future bone loss. Design - Population based study. Setting - Outpatient clinic for research into osteoporosis. Subjects - 178 healthy early postmenopausal women who had participated in a two year study in 1977. 154 of the women underwent follow up examination in 1989, of whom 33 were excluded because of diseases or taking drugs known to affect calcium metabolism. Main outcome measures - Bone mineral content of the forearm and values of biochemical markers of bone turnover. Results - The average reduction in bone mineral content during 1977-89 was 20%, but the fast losers had lost 10.0% more than had the slow loser group (mean loss 26.6% in fast losers and 16.6% in slow losers; p < 0.001). Prediction of future bone mineral content using baseline bone mineral content and estimated rate of loss gave results almost identical with the actual bone mineral content measured in 1989. Seven women had had a Colles; fracture and 20 a spinal compression fracture. The group with Colles' fracture had low baseline bone mineral content (34.7 (95% confidence interval 31.3 to 38.1) units-upsilon 39.4 (38.1 to 40.8) units in women with no fracture) whereas the group with spinal fracture had a normal baseline bone mineral content (38.1 (35.0 to 41.1) units) but an increased rate of loss (-2.4 (-3.5 to -1.3)%/year v -1.8 (-2.1 to -1.5)%/year in women with no fracture). Conclusions - One baseline measurement of bone mass combined with a single estimation of the rate of bone loss can reliably identify the women at menopause who are at highest risk of developing osteoporosis later in life. The rate of loss may have an independent role in likelihood of vertebral fracture.			HANSEN, MA (corresponding author), UNIV COPENHAGEN, GLOSTRUP HOSP, DEPT CLIN CHEM, DK-2600 GLOSTRUP, DENMARK.							BROWN JP, 1984, LANCET, V1, P1091; Christiansen C, 1990, Osteoporos Int, V1, P35, DOI 10.1007/BF01880414; CHRISTIANSEN C, 1987, LANCET, V1, P1106; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; GEUSENS P, 1986, J NUCL MED, V27, P1540; Hansen M A, 1991, Osteoporos Int, V1, P95; HASSAGER C, 1991, OSTEOPOROSIS INT, V1, P226; HUI SL, 1989, ANN INTERN MED, V111, P355, DOI 10.7326/0003-4819-111-5-355; MELTON LJ, 1989, AM J EPIDEMIOL, V129, P1000, DOI 10.1093/oxfordjournals.aje.a115204; MELTON LJ, 1988, OSTEOPOROSIS ETIOLOG, P111; NILAS L, 1987, J NUCL MED, V28, P960; NILAS L, 1985, J NUCL MED, V26, P1257; OTT SM, 1987, J BONE MINER RES, V2, P201; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; RIIS BJ, 1989, THESIS HANDELSTRYKKE, P16; ROSS PD, 1988, J BONE MINER RES, V3, P1; 1989, FRACTURED NECK FEMUR	17	438	450	0	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 19	1991	303	6808					961	964		10.1136/bmj.303.6808.961	http://dx.doi.org/10.1136/bmj.303.6808.961			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL127	1954420	Green Published			2022-12-01	WOS:A1991GL12700022
J	HARRIS, R				HARRIS, R			MEDICAL GENETICS	BRITISH MEDICAL JOURNAL			English	Article											HARRIS, R (corresponding author), ST MARYS HOSP,DEPT MED GENET,MANCHESTER M13 0JH,LANCS,ENGLAND.							BULOW S, 1987, DAN MED BULL, V34, P1; MCKUSICK VA, 1991, NATURE, V352, P279, DOI 10.1038/352279a0; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; OWEN DJ, 1991, ANTENATAL DIAGNOSIS, P353; PECKHAM M, 1991, LANCET, V338, P367, DOI 10.1016/0140-6736(91)90494-A; RONA RJ, 1989, J MED GENET, V26, P226, DOI 10.1136/jmg.26.4.226; WALD N, 1991, ANTENATAL DIAGNOSIS, P45; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179; 1991, PURCHASERS GUIDELINE; 1991, CMMD1523; 1990, TEACHING GENETICS ME; 1991, CLIN GENETICS 1990; 1989, PRENATAL DIAGNOSIS G	13	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 19	1991	303	6808					977	979		10.1136/bmj.303.6808.977	http://dx.doi.org/10.1136/bmj.303.6808.977			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL127	1954427	Green Published, Bronze			2022-12-01	WOS:A1991GL12700031
J	LEON, DA				LEON, DA			INFLUENCE OF BIRTH-WEIGHT ON DIFFERENCES IN INFANT-MORTALITY BY SOCIAL-CLASS AND LEGITIMACY	BRITISH MEDICAL JOURNAL			English	Article								Objective - To investigate the influence of birth weight on the pronounced social class differences in infant mortality in Britain. Design - Analysis of routine data on births and infant deaths. Setting - England and Wales. Subjects - All live births and infant deaths, 1983-5. Main outcome measure - Mortality in infants by social class, birth weight, and legitimacy according to birth and death certificates. Results - Neonatal and postneonatal mortality (deaths/1000 births) increased with social class. Neonatal and postneonatal mortality was 4.2/1000 and 2.3/1000 respectively for social class I and 6.8/1000 and 5.6/1000 respectively for social class V. Mortality was lower among births registered within marriage (postneonatal 3.5/1000; neonatal 5.2/1000) than among those jointly registered outside marriage (5.1/1000; 6.4/1000); mortality was highest in those solely registered outside marriage (7-2/1000; 7.0/1000). For neonatal mortality the effect of social class varied with birth weight. Social class had little effect on neonatal mortality in low birthweight babies and increasing effect in heavier babies. For postneonatal mortality the effect of social class was similar for all birth weights and was almost as steep as for all birth weights combined. Conclusion - Birth weight mediates little of the effect of social class on postneonatal mortality.			LEON, DA (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1E 7HT,ENGLAND.		Leon, David A/G-2195-2010	Leon, David A/0000-0001-9747-1762				ACHESON ED, 1990, LANCET, V336, P1482; ADELSTEIN AM, 1980, 41 STUD MED POP SUBJ; AITKIN M, 1989, STATISTICAL MODELLIN; [Anonymous], 1980, INEQUALITIES HLTH RE; [Anonymous], 1980, CLASSIFICATION OCCUP; BAKER RJ, 1978, GLIM SYSTEM; BROOKE OG, 1989, BRIT MED J, V298, P795, DOI 10.1136/bmj.298.6676.795; MACFARLANE A, 1988, BRIT MED J, V296, P230, DOI 10.1136/bmj.296.6617.230; MALLOY MH, 1988, AM J EPIDEMIOL, V128, P46, DOI 10.1093/oxfordjournals.aje.a114957; McCullagh P., 1983, GEN LINEAR MODELS, DOI [10.1007/978-1-4899-3244-0, DOI 10.1007/978-1-4899-3244-0]; MORRIS JN, 1955, LANCET, V1, P554; Pharoah P O, 1979, Epidemiol Rev, V1, P170; RODRIGUES L, 1989, OPCS POPULATION TREN, V55, P7; WILCOX AJ, 1986, INT J EPIDEMIOL, V15, P188, DOI 10.1093/ije/15.2.188; 1978, OFFICE POPULATION DS, V1; 1990, DH321 OFF POP CENS S; 1988, OFFICE POPULATION DS, V8	17	24	25	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 19	1991	303	6808					964	967		10.1136/bmj.303.6808.964	http://dx.doi.org/10.1136/bmj.303.6808.964			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL127	1954421	Green Published, Bronze			2022-12-01	WOS:A1991GL12700023
J	MACMAHON, EME; GLASS, JD; HAYWARD, SD; MANN, RB; BECKER, PS; CHARACHE, P; MCARTHUR, JC; AMBINDER, RF				MACMAHON, EME; GLASS, JD; HAYWARD, SD; MANN, RB; BECKER, PS; CHARACHE, P; MCARTHUR, JC; AMBINDER, RF			EPSTEIN-BARR-VIRUS IN AIDS-RELATED PRIMARY CENTRAL-NERVOUS-SYSTEM LYMPHOMA	LANCET			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; INSITU HYBRIDIZATION; MEMBRANE-PROTEIN; GENE-EXPRESSION; INFECTED-CELLS; EBV; DISORDERS; THERAPY; DISEASE; GENOME	Primary central nervous system lymphoma occurs more often in patients with AIDS. Epstein-Barr virus (EBV) has been detected in these tumours, but the degree of association has not been defined because of both the highly restricted expression of EBV in malignant tissue and the lack of a technique that is reliable in formalin-fixed paraffin-embedded specimens. EBV-transformed lymphocytes contain short non-protein coding EBV transcripts (EBERs), which are expressed in much higher quantity than other EBV-latency transcripts. We describe a new strategy for detection of latent EBV with these transcripts as targets for in-situ hybridisation. 18 cases of AIDS-related primary CNS lymphoma from a consecutive necropsy series together with specimens from 3 further cases were studied. In each case, a strong positive signal over tumour cells indicated abundant expression of the EBV-EBER1 transcript. This 100% association suggests that the pathogenesis of these AIDS-associated lymphomas may differ from the systemic disease in which only 30-50% of tumours are associated with EBV. A pathogenetic role for EBV was further supported by showing expression of a viral protein (the latent membrane protein) that is implicated as an effector for EBV-associated lymphomagenesis. EBV might have a role as a tumour marker in the diagnosis and management of AIDS-related primary CNS lymphoma.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NATIONAL CANCER INSTITUTE [R01CA042245, R01CA055529] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007179] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA42245, R01 CA55529] Funding Source: Medline; NINDS NIH HHS [NS 07179] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BASHIR RM, 1989, NEUROLOGY, V39, P813, DOI 10.1212/WNL.39.6.813; BASHIR RM, 1990, MODERN PATHOL, V3, P429; BAUMGARTNER JE, 1990, J NEUROSURG, V73, P206, DOI 10.3171/jns.1990.73.2.0206; BIRX DL, 1986, NEW ENGL J MED, V314, P874, DOI 10.1056/NEJM198604033141403; CARTUN RW, 1989, J HISTOTECHNOL, V12, P273; GILLIGAN K, 1990, P NATL ACAD SCI USA, V87, P8790, DOI 10.1073/pnas.87.22.8790; GLICKMAN JN, 1988, J VIROL, V62, P902, DOI 10.1128/JVI.62.3.902-911.1988; HAMILTONDUTOIT SJ, 1991, AM J PATHOL, V138, P149; HANTO DW, 1981, CANCER RES, V41, P4253; HOCHBERG FH, 1988, J NEUROSURG, V68, P835, DOI 10.3171/jns.1988.68.6.0835; HOWE JG, 1986, P NATL ACAD SCI USA, V83, P9006, DOI 10.1073/pnas.83.23.9006; LAWRENCE JB, 1988, CELL, V52, P51; LERNER MR, 1981, P NATL ACAD SCI USA, V78, P505; NAKHLEH RE, 1991, CANCER, V67, P444, DOI 10.1002/1097-0142(19910115)67:2<444::AID-CNCR2820670221>3.0.CO;2-W; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; PLUDA JM, 1990, ANN INTERN MED, V113, P276, DOI 10.7326/0003-4819-113-4-276; ROSENBERG NL, 1986, ANN NEUROL, V20, P98, DOI 10.1002/ana.410200118; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; SHERMAN ME, 1991, AM J CLIN PATHOL, V95, P878, DOI 10.1093/ajcp/95.6.878; SUBAR M, 1988, BLOOD, V72, P667; TOCZYSKI DPW, 1991, EMBO J, V10, P459, DOI 10.1002/j.1460-2075.1991.tb07968.x; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WU TC, 1991, AM J PATHOL, V138, P1461; WU TC, 1990, INT J CANCER, V46, P801, DOI 10.1002/ijc.2910460509; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051	26	441	455	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 19	1991	338	8773					969	973		10.1016/0140-6736(91)91837-K	http://dx.doi.org/10.1016/0140-6736(91)91837-K			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK974	1681341				2022-12-01	WOS:A1991GK97400003
J	PANDEY, MR; DAULAIRE, NMP; STARBUCK, ES; HOUSTON, RM; MCPHERSON, K				PANDEY, MR; DAULAIRE, NMP; STARBUCK, ES; HOUSTON, RM; MCPHERSON, K			REDUCTION IN TOTAL UNDER-5 MORTALITY IN WESTERN NEPAL THROUGH COMMUNITY-BASED ANTIMICROBIAL TREATMENT OF PNEUMONIA	LANCET			English	Article							CHILDREN; INFECTION; IMPACT; GROWTH	Pneumonia is a leading cause of death among children world wide but those at highest risk in developing countries have limited access to clinical services; effective and low-cost alternatives are a global public health priority. We have done a controlled intervention trial among 13404 children under five in Jumla, Nepal, which relied exclusively on indigenous community health workers to detect and treat pneumonia according to the World Health Organisation decision strategy, with a five-day home-treatment course of oral co-trimoxazole. No other health services were provided, and referral of children to hospital was not practicable. During the three-year study, 2101 deaths were recorded. The programme led to a 28% reduction in the risk of death from all causes by the third year of services (relative risk 0.72, 95% confidence interval 0.63-0.82), with a significant trend (p < 0.02) of lower mortality with greater duration of the programme. The greatest benefit was among infants. In addition to reduction in deaths due to pneumonia, there was a significant reduction in deaths due to diarrhoea and measles, indicating that reduction in pneumonia morbidity had considerable carry-over effect. Our findings show that indigenous community workers can effectively detect and treat pneumonia, and reduce overall child mortality, even without other primary care activities.	INT CTR PREVENT & TREATMENT MAJOR CHILDHOOD DIS, POB 168, HANOVER, NH 03755 USA; MRIGENDRA MED TRUST, Kathmandu, NEPAL; UNIV LONDON LONDON SCH HYG & TROP MED, DEPT PUBL HLTH & POLICY, LONDON WC1E 7HT, ENGLAND; JOHN SNOW INC, BOSTON, MA USA	University of London; London School of Hygiene & Tropical Medicine								BANG AT, 1990, LANCET, V336, P201, DOI 10.1016/0140-6736(90)91733-Q; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; DAULAIRE NMP, 1990, ALRI CHILD SURVIVAL; FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P42, DOI 10.1097/00006454-199101000-00009; Gadomski A., 1990, Health Policy and Planning, V5, P235, DOI 10.1093/heapol/5.3.235; KHAN AJ, 1990, B WORLD HEALTH ORGAN, V68, P577; LAUNER LJ, 1990, AM J EPIDEMIOL, V131, P322, DOI 10.1093/oxfordjournals.aje.a115501; Leowski J, 1986, World Health Stat Q, V39, P138; MANTEL N, 1968, BIOMETRICS, V24, P997, DOI 10.2307/2528886; MARTORELL R, 1975, AM J DIS CHILD, V129, P1296, DOI 10.1001/archpedi.1975.02120480022007; Martorell R, 1984, POPUL DEV REV, V10, P49, DOI 10.2307/2807955; MCCORD C, 1978, TROP DOCT, V8, P220, DOI 10.1177/004947557800800420; MOSLEY WH, 1988, CHILD SURVIVAL PROGR; MTANGO FDE, 1986, T ROY SOC TROP MED H, V80, P851, DOI 10.1016/0035-9203(86)90241-5; PANDEY MR, 1989, ANN TROP PAEDIATR, V9, P212, DOI 10.1080/02724936.1989.11748635; ROWLAND MGM, 1988, AM J CLIN NUTR, V47, P134, DOI 10.1093/ajcn/47.1.134; SELWYN BJ, 1990, REV INFECT DIS, V12, pS870; SHANN F, 1984, B WORLD HEALTH ORGAN, V62, P749; SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017; SHRESTHA MP, 1982, JUMLA COMMUNITY HLTH; ZUMRAWI FY, 1987, HUM NUTR-CLIN NUTR, V41C, P453; 1985, WHORSD85151985 DOC; 1990, WHOARI9051990 DOC; 1986, WHORSD8515REV21686 D; 1990, RATIONAL USE DRUGS M	25	90	90	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 19	1991	338	8773					993	997		10.1016/0140-6736(91)91847-N	http://dx.doi.org/10.1016/0140-6736(91)91847-N			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK974	1681351				2022-12-01	WOS:A1991GK97400013
J	BUKRINSKY, MI; STANWICK, TL; DEMPSEY, MP; STEVENSON, M				BUKRINSKY, MI; STANWICK, TL; DEMPSEY, MP; STEVENSON, M			QUIESCENT LYMPHOCYTES-T AS AN INDUCIBLE VIRUS RESERVOIR IN HIV-1 INFECTION	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE-DEFICIENCY SYNDROME; HTLV-III/LAV ENVELOPE; PERIPHERAL-BLOOD; REVERSE TRANSCRIPTION; CELL ACTIVATION; AIDS VIRUS; TYPE-1; DNA; EXPRESSION	To better understand the basis for human immunodeficiency virus type 1 (HIV-1) persistence and latency, the form in which viral DNA exists in the peripheral T lymphocyte reservoir of infected individuals was investigated. In asymptomatic individuals, HIV-1 was harbored predominantly as full-length, unintegrated complementary DNA. These extrachromosomal DNA forms retained the ability to integrate upon T cell activation in vitro. In patients with acquired immunodeficiency syndrome (AIDS), there was an increase in integrated relative to extrachromosomal DNA forms. By analysis of DNA from patient lymphocyte subpopulations depleted of human lymphocyte antigen-Dr receptor-positive cells, quiescent T cells were identified as the source of extrachromosomal HIV-1 DNA. Thus quiescent T lymphocytes may be a major and inducible HIV-11 reservoir in infected individuals.	UNIV NEBRASKA,MED CTR,DEPT PATHOL & MICROBIOL,OMAHA,NE 68198; NATL INST MED RES,DIV VIROL,LONDON NW7 1AA,ENGLAND	University of Nebraska System; University of Nebraska Medical Center; MRC National Institute for Medical Research					NIAID NIH HHS [R01 AI049152, R01 AI032890] Funding Source: Medline; NIMH NIH HHS [R01 MH064411] Funding Source: Medline; PHS HHS [A124481, A130386] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BUKRINSKY MI, UNPUB; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; DORNER AJ, 1986, CELL, V45, P365, DOI 10.1016/0092-8674(86)90322-3; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FOLKS TM, 1986, J EXP MED, V164, P280, DOI 10.1084/jem.164.1.280; GOEDERT JJ, 1987, JAMA-J AM MED ASSOC, V257, P331, DOI 10.1001/jama.257.3.331; GRANDGENETT DP, 1990, CELL, V60, P3, DOI 10.1016/0092-8674(90)90707-L; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HO DD, 1987, NEW ENGL J MED, V317, P278; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; KESHET E, 1979, J VIROL, V31, P376, DOI 10.1128/JVI.31.2.376-388.1979; LANG W, 1987, JAMA-J AM MED ASSOC, V257, P326, DOI 10.1001/jama.257.3.326; LIFSON JD, 1986, NATURE, V323, P725, DOI 10.1038/323725a0; MCDOUGAL JS, 1985, J IMMUNOL, V135, P3151; MCELRATH MJ, 1989, P NATL ACAD SCI USA, V86, P675, DOI 10.1073/pnas.86.2.675; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MULLINS JI, 1986, NATURE, V319, P333, DOI 10.1038/319333a0; PADMANABHAN R, 1988, ANAL BIOCHEM, V170, P341, DOI 10.1016/0003-2697(88)90640-9; PANG S, 1990, NATURE, V343, P85, DOI 10.1038/343085a0; PANGANIBAN AT, 1988, SCIENCE, V241, P1064, DOI 10.1126/science.2457948; PAUZA CD, 1990, J EXP MED, V172, P1035, DOI 10.1084/jem.172.4.1035; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; PSALLIDOPOULOS MC, 1989, J VIROL, V63, P4626, DOI 10.1128/JVI.63.11.4626-4631.1989; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; REINHERZ EL, 1979, J EXP MED, V150, P1472, DOI 10.1084/jem.150.6.1472; ROBINSON HL, 1990, J VIROL, V64, P4836, DOI 10.1128/JVI.64.10.4836-4841.1990; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SHANK PR, 1978, CELL, V15, P1383, DOI 10.1016/0092-8674(78)90063-6; SHAW GM, 1984, SCIENCE, V226, P1165, DOI 10.1126/science.6095449; SODROSKI J, 1986, NATURE, V322, P470, DOI 10.1038/322470a0; SOMASUNDARAN M, 1987, J VIROL, V61, P3114, DOI 10.1128/JVI.61.10.3114-3119.1987; SOMMERFELT MA, 1990, VIROLOGY, V176, P58, DOI 10.1016/0042-6822(90)90230-O; STECK FT, 1966, VIROLOGY, V29, P642, DOI 10.1016/0042-6822(66)90288-1; STEVENSON M, 1988, CELL, V53, P483, DOI 10.1016/0092-8674(88)90168-7; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; STEVENSON M, 1990, J VIROL, V64, P2421, DOI 10.1128/JVI.64.5.2421-2425.1990; WEISS R, 1984, RNA TUMOR VIRUSES, V1, P209; WELLER SK, 1980, J VIROL, V33, P494, DOI 10.1128/JVI.33.1.494-506.1980; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; ZAGURY D, 1986, SCIENCE, V231, P850, DOI 10.1126/science.2418502	43	529	542	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1991	254	5030					423	427		10.1126/science.1925601	http://dx.doi.org/10.1126/science.1925601			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK729	1925601	Green Accepted			2022-12-01	WOS:A1991GK72900047
J	COLLEY, NJ; BAKER, EK; STAMNES, MA; ZUKER, CS				COLLEY, NJ; BAKER, EK; STAMNES, MA; ZUKER, CS			THE CYCLOPHILIN HOMOLOG NINAA IS REQUIRED IN THE SECRETORY PATHWAY	CELL			English	Article							CIS-TRANS-ISOMERASE; A-BINDING-PROTEIN; CRYSTALLOID ENDOPLASMIC-RETICULUM; CYCLOSPORIN-A; DROSOPHILA-MELANOGASTER; MESSENGER-RNA; NEUROSPORA-CRASSA; PERIPHERAL PHOTORECEPTORS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI	In Drosophila, the major rhodopsin Rh1 is synthesized in endoplasmic reticulum (ER)-bound ribosomes of the R1-R6 photoreceptor cells and is then transported to the rhabdomeres where it functions in phototransduction. Mutations in the cyclophilin homolog ninaA lead to a 90% reduction in Rh1 opsin. Cyclophilins have been shown to be peptidyl-prolyl cis-trans isomerases and have been implicated in catalyzing protein folding. We now show that mutations in the ninaA gene severely inhibit opsin transport from the ER, leading to dramatic accumulations of ER cisternae in the photoreceptor cells. These results demonstrate that ninaA functions in the ER. Interestingly, ninaA and Rh1 also colocalize to secretory vesicles, suggesting that Rh1 may require ninaA as it travels through the distal compartments of the secretory pathway. These results are discussed in relation to the possible role of cyclophilins in protein folding and intracellular protein trafficking.	UNIV CALIF SAN DIEGO,DEPT BIOL,SAN DIEGO,CA 92103; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,SAN DIEGO,CA 92103	University of California System; University of California San Diego; University of California System; University of California San Diego	COLLEY, NJ (corresponding author), UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,SAN DIEGO,CA 92103, USA.			Stamnes, Mark/0000-0002-5869-7985	NATIONAL EYE INSTITUTE [R01EY008768] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY008768] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSON RGW, 1983, J CELL SCI, V63, P1; BACHINGER HP, 1987, J BIOL CHEM, V262, P17144; BAUMANN O, 1989, CELL TISSUE RES, V255, P511, DOI 10.1007/BF00218786; BICKEL M, 1987, P NATL ACAD SCI USA, V84, P3274, DOI 10.1073/pnas.84.10.3274; BLEST AD, 1988, ADV INSECT PHYSIOL, V20, P1, DOI 10.1016/S0065-2806(08)60021-1; BOREL JF, 1976, AGENTS ACTIONS, V6, P468, DOI 10.1007/BF01973261; BOREL JF, 1976, IMMUNOLOGY, V31, P631; CARONI P, 1991, J BIOL CHEM, V266, P10739; CHIN DJ, 1982, P NATL ACAD SCI-BIOL, V79, P1185, DOI 10.1073/pnas.79.4.1185; DAVIS JM, 1989, J BIOL CHEM, V264, P8956; DECOUET HG, 1987, EUR J CELL BIOL, V44, P50; DOI T, 1990, P NATL ACAD SCI USA, V87, P4991, DOI 10.1073/pnas.87.13.4991; DRUGGE RJ, 1988, TRANSPL P, V20, P301; ELDRED WD, 1983, J HISTOCHEM CYTOCHEM, V31, P285, DOI 10.1177/31.2.6339606; ELLIOTT JF, 1984, SCIENCE, V226, P1439, DOI 10.1126/science.6334364; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FEILER R, 1988, NATURE, V333, P737, DOI 10.1038/333737a0; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GRANELLIPIPERNO A, 1988, J EXP MED, V168, P1649, DOI 10.1084/jem.168.5.1649; HEROLD KC, 1986, J IMMUNOL, V136, P1315; HILLMAN P, 1983, PHYSIOL REV, V63, P668, DOI 10.1152/physrev.1983.63.2.668; HOHMAN R J, 1990, New Biologist, V2, P663; HUBER A, 1990, J BIOL CHEM, V265, P17906; HULTSCH T, 1990, J IMMUNOL, V144, P2659; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; IWAI N, 1990, KIDNEY INT, V37, P1460, DOI 10.1038/ki.1990.136; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KAWAMUKAI M, 1989, J BACTERIOL, V171, P4525, DOI 10.1128/JB.171.8.4525-4529.1989; KIEFHABER T, 1990, BIOCHEMISTRY-US, V29, P3053, DOI 10.1021/bi00464a023; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.bi.54.070185.003215; KOSER PL, 1990, NUCLEIC ACIDS RES, V18, P1643, DOI 10.1093/nar/18.6.1643; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LARRIVEE DC, 1981, J GEN PHYSIOL, V78, P521, DOI 10.1085/jgp.78.5.521; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; LIU J, 1990, P NATL ACAD SCI USA, V87, P4028, DOI 10.1073/pnas.87.11.4028; LODISH HF, 1988, J BIOL CHEM, V263, P2107; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MINKE B, 1975, J COMP PHYSIOL, V98, P345, DOI 10.1007/BF00709805; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; PACIFICI M, 1988, J BIOL CHEM, V263, P2483; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; QUESNIAUX VFJ, 1987, EUR J IMMUNOL, V17, P1359, DOI 10.1002/eji.1830170921; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTHMAN JE, 1987, CELL, V50, P521, DOI 10.1016/0092-8674(87)90024-9; SCHNEUWLY S, 1989, P NATL ACAD SCI USA, V86, P5390, DOI 10.1073/pnas.86.14.5390; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SHEVACH EM, 1985, ANNU REV IMMUNOL, V3, P397; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; SIGAL NH, 1990, BIOCHEM PHARMACOL, V40, P2201, DOI 10.1016/0006-2952(90)90712-T; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; SPIK G, 1991, J BIOL CHEM, V266, P10735; Stamnes MA, 1990, CURR OPIN CELL BIOL, V2, P1104, DOI 10.1016/0955-0674(90)90163-9; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STARK WS, 1988, J NEUROCYTOL, V17, P499, DOI 10.1007/BF01189805; STEPHENSON RS, 1983, BIOL PHOTORECEPTION, P477; STJULES RS, 1989, EXP EYE RES, V48, P653, DOI 10.1016/0014-4835(89)90007-9; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRENN G, 1989, J IMMUNOL, V142, P3796; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0; TROPSCHUG M, 1990, NUCLEIC ACIDS RES, V18, P190, DOI 10.1093/nar/18.1.190; TROPSCHUG M, 1988, J BIOL CHEM, V263, P14433; VANVACTOR D, 1988, CELL, V52, P281, DOI 10.1016/0092-8674(88)90517-X; WRIGHT R, 1988, J CELL BIOL, V107, P101, DOI 10.1083/jcb.107.1.101; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7; ZUKER CS, 1988, CELL, V55, P475	79	303	305	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					255	263		10.1016/0092-8674(91)90177-Z	http://dx.doi.org/10.1016/0092-8674(91)90177-Z			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1913822				2022-12-01	WOS:A1991GL47000005
J	CORBIN, V; MICHELSON, AM; ABMAYR, SM; NEEL, V; ALCAMO, E; MANIATIS, T; YOUNG, MW				CORBIN, V; MICHELSON, AM; ABMAYR, SM; NEEL, V; ALCAMO, E; MANIATIS, T; YOUNG, MW			A ROLE FOR THE DROSOPHILA NEUROGENIC GENES IN MESODERM DIFFERENTIATION	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; NEURONAL PRECURSOR CELLS; ACHAETE-SCUTE COMPLEX; EGF-LIKE REPEATS; NOTCH LOCUS; C-ELEGANS; MONONUCLEATED MYOBLASTS; TRANSLATIONAL CONTROL; NEURAL DEVELOPMENT; DIFFERENT PROTEINS	The neurogenic genes of Drosophila have long been known to regulate cell fate decisions in the developing ectoderm. In this paper we show that these genes also control mesoderm development. Embryonic cells that express the muscle-specific gene nautilus are overproduced in each of seven neurogenic mutants (Notch, Delta, Enhancer of split, big brain, mastermind, neuralized, and almondex), at the apparent expense of neighboring, nonexpressing mesodermal cells. The mesodermal defect does not appear to be a simple consequence of associated neural hypertrophy, suggesting that the neurogenic genes may function similarly and independently in establishing cell fates in both ectoderm and mesoderm. Altered patterns of beta-3-tubulin and myosin heavy chain gene expression in the mutants indicate a role for the neurogenic genes in development of most visceral and somatic muscles. We propose that the signal produced by the neurogenic genes is a general one, effective in both ectoderm and mesoderm.	ROCKEFELLER UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA	Howard Hughes Medical Institute; Rockefeller University; Harvard University	CORBIN, V (corresponding author), ROCKEFELLER UNIV, GENET LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA.		, 机智的马小跳和机智的羊不愁/ABC-5169-2020		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM029301] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM5-25103, 5P01GM29301] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPELLA E, 1987, J BIOL CHEM, V262, P4437; ARTAVANISTSAKONAS S, 1988, TRENDS GENET, V4, P95, DOI 10.1016/0168-9525(88)90096-0; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; BALL EE, 1985, J NEUROSCI, V5, P1808; BARAD M, 1988, EMBO J, V7, P2151, DOI 10.1002/j.1460-2075.1988.tb03054.x; BATE M, 1990, DEVELOPMENT, V110, P791; BETTLER D, 1991, DEV BIOL, V144, P436, DOI 10.1016/0012-1606(91)90436-7; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BRAND M, 1988, ROUX ARCH DEV BIOL, V197, P457, DOI 10.1007/BF00385679; CABRERA CV, 1987, CELL, V50, P425, DOI 10.1016/0092-8674(87)90496-X; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; CAMPOS AR, 1985, J NEUROGENET, V2, P197, DOI 10.3109/01677068509100150; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CAMPOSORTEGA JA, 1988, TRENDS NEUROSCI, V11, P400, DOI 10.1016/0166-2236(88)90077-X; CAMPUZANO S, 1986, CELL, V44, P303, DOI 10.1016/0092-8674(86)90764-6; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; COLMENARES C, 1991, MOL CELL BIOL, V11, P1167, DOI 10.1128/MCB.11.2.1167; Cramer L., 1980, DROS INFORM SERV, V55, P197; CROSS DP, 1978, J EMBRYOL EXP MORPH, V45, P173; CROSS DP, 1978, J EMBRYOL EXP MORPH, V45, P161; Dietrich U, 1984, J Neurogenet, V1, P315, DOI 10.3109/01677068409107094; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; EMERSON CP, 1975, J MOL BIOL, V93, P431, DOI 10.1016/0022-2836(75)90238-7; ENDO T, 1987, CELL, V49, P515, DOI 10.1016/0092-8674(87)90454-5; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; GARCIAALONSO L, 1986, ROUX ARCH DEV BIOL, V195, P259; GARCIABELLIDO A, 1978, GENETICS, V88, P469; GARCIABELLIDO A, 1979, GENETICS, V91, P491; GASCH A, 1988, MOL GEN GENET, V211, P8, DOI 10.1007/BF00338387; GREENSPAN R J, 1990, New Biologist, V2, P595; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HARTENSTEIN V, 1984, ROUX ARCH DEV BIOL, V193, P308, DOI 10.1007/BF00848159; HARTLEY DA, 1987, EMBO J, V6, P3407, DOI 10.1002/j.1460-2075.1987.tb02664.x; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HOPPE PE, 1986, CELL, V46, P773, DOI 10.1016/0092-8674(86)90353-3; HOPPE PE, 1990, DEVELOPMENT, V109, P875; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; JIMENEZ F, 1990, NEURON, V5, P81, DOI 10.1016/0896-6273(90)90036-F; JIMENEZ F, 1979, NATURE, V282, P310, DOI 10.1038/282310a0; JIMENEZ F, 1987, J NEUROGENET, V4, P179, DOI 10.3109/01677068709102340; JOHANSEN KM, 1989, J CELL BIOL, V109, P2427, DOI 10.1083/jcb.109.5.2427; JONES FS, 1988, P NATL ACAD SCI USA, V85, P2186, DOI 10.1073/pnas.85.7.2186; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIDD S, 1989, GENE DEV, V3, P1113, DOI 10.1101/gad.3.8.1113; KLAMBT C, 1989, EMBO J, V8, P203, DOI 10.1002/j.1460-2075.1989.tb03365.x; KNUST E, 1987, EMBO J, V6, P4113, DOI 10.1002/j.1460-2075.1987.tb02757.x; KOPCZYNSKI CC, 1989, DEVELOPMENT, V107, P623; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; LAMBIE EJ, 1991, DEVELOPMENT, V112, P231; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEISS D, 1988, DEVELOPMENT, V104, P525; LINDSLEY D, 1985, DROS INFO SERV, V62; LINDSLEY D, 1990, DROS INFO SERV, V68; Lindsley D.L., 1968, GENETIC VARIATIONS D; MANN K, 1989, EMBO J, V8, P65, DOI 10.1002/j.1460-2075.1989.tb03349.x; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; MONTELL DJ, 1988, CELL, V53, P463, DOI 10.1016/0092-8674(88)90166-3; MORRIS GE, 1976, EXP CELL RES, V99, P106, DOI 10.1016/0014-4827(76)90685-6; MOSS PS, 1976, DEV BIOL, V48, P431, DOI 10.1016/0012-1606(76)90104-4; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NGUYEN HT, 1983, CELL, V34, P281, DOI 10.1016/0092-8674(83)90159-9; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PATERSON BM, 1991, P NATL ACAD SCI USA, V88, P3782, DOI 10.1073/pnas.88.9.3782; Poulson D. F., 1950, BIOL DROSOPHILA, P168; Poulson DF, 1940, J EXP ZOOL, V83, P271, DOI 10.1002/jez.1400830207; POULSON DF, 1945, AM NAT, V79, P340, DOI 10.1086/281269; PREISS A, 1988, EMBO J, V7, P3917, DOI 10.1002/j.1460-2075.1988.tb03278.x; PREISS JR, 1987, CELL, V51, P241; RAO Y, 1990, NATURE, V345, P163, DOI 10.1038/345163a0; ROMANI S, 1987, EMBO J, V6, P2085, DOI 10.1002/j.1460-2075.1987.tb02474.x; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SHANNON MP, 1973, J EXP ZOOL, V183, P383, DOI 10.1002/jez.1401830312; SHELLENBARGER DL, 1978, DEV BIOL, V62, P432, DOI 10.1016/0012-1606(78)90226-9; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SIMPSON P, 1990, TRENDS GENET, V6, P343, DOI 10.1016/0168-9525(90)90260-D; SKOOG DA, 1982, FUNDAMENTALS ANAL CH, P55; SMOLLER D, 1990, GENE DEV, V4, P1688, DOI 10.1101/gad.4.10.1688; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; SUZUKI K, 1987, EMBO J, V6, P1891, DOI 10.1002/j.1460-2075.1987.tb02448.x; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TECHNAU GM, 1986, ROUX ARCH DEV BIOL, V195, P445, DOI 10.1007/BF00375748; TROTTER JA, 1976, DEV BIOL, V49, P548, DOI 10.1016/0012-1606(76)90197-4; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; VERTEL BM, 1976, DEV BIOL, V48, P438, DOI 10.1016/0012-1606(76)90105-6; WASSENBERG DR, 1987, J BIOL CHEM, V262, P10741; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WELSHONS WJ, 1965, SCIENCE, V150, P1122, DOI 10.1126/science.150.3700.1122; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WRIGHT TRF, 1970, ADV GENET, V15, P261, DOI 10.1016/S0065-2660(08)60075-9; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4	101	240	243	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 18	1991	67	2					311	323		10.1016/0092-8674(91)90183-Y	http://dx.doi.org/10.1016/0092-8674(91)90183-Y			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1913825				2022-12-01	WOS:A1991GL47000011
J	DERR, LK; STRATHERN, JN; GARFINKEL, DJ				DERR, LK; STRATHERN, JN; GARFINKEL, DJ			RNA-MEDIATED RECOMBINATION IN SACCHAROMYCES-CEREVISIAE	CELL			English	Article							YEAST RETROTRANSPOSON TY; LONG TERMINAL REPEATS; VIRUS-LIKE PARTICLES; SACCHAROMYCES-CEREVISIAE; REVERSE TRANSCRIPTION; ELEMENT TRANSPOSITION; EUKARYOTIC GENOME; GENE-EXPRESSION; CDNA GENES; SPT3 GENE	The existence of pseudogenes and the observation of intron loss suggest that RNA can serve as an intermediate in recombination. We used a HIS3 reporter gene to show that RNA-mediated recombination occurs in yeast. His3+ prototroph formation required transcription and expression of the retrotransposon Ty. Two RNA-mediated recombination events were detected: homologous recombination between the cDNA and plasmid his3 sequences, resulting in intron loss, and insertion of the cDNA into the chromosome in the absence of HIS3 homology. The chromosomal His3+ prototrophs showed many hallmarks of naturally occurring pseudogenes. They integrated at novel sites in the chromosome, lacked introns, and possessed poly(A) tracts. Additionally, their 5' ends corresponded with the site of initiation of the GAL1 transcript.			DERR, LK (corresponding author), NCI, FREDERICK CANC RES FACIL, EUKARYOT GENE EXPRESS LAB, FREDERICK, MD 21701 USA.				PHS HHS [N01-C0-74101] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BALTIMORE D, 1985, CELL, V40, P481, DOI 10.1016/0092-8674(85)90190-4; BILOFSKY HS, 1988, NUCLEIC ACIDS RES, V16, P1861, DOI 10.1093/nar/16.5.1861; BOEKE JD, 1986, MOL CELL BIOL, V6, P3575, DOI 10.1128/MCB.6.11.3575; BOEKE JD, 1985, CELL, V40, P491, DOI 10.1016/0092-8674(85)90197-7; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOEKE JD, 1988, MOL CELL BIOL, V8, P1431; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; COLICELLI J, 1988, J VIROL, V62, P633, DOI 10.1128/JVI.62.2.633-636.1988; CURCIO MJ, 1990, MOL GEN GENET, V220, P213; CURCIO MJ, 1991, P NATL ACAD SCI USA, V88, P936, DOI 10.1073/pnas.88.3.936; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DORNBURG R, 1990, J VIROL, V64, P886, DOI 10.1128/JVI.64.2.886-889.1990; DORNBURG R, 1988, MOL CELL BIOL, V8, P2328, DOI 10.1128/MCB.8.6.2328; DORNBURG R, 1990, MOL CELL BIOL, V10, P68, DOI 10.1128/MCB.10.1.68; EICHINGER DJ, 1988, CELL, V54, P955, DOI 10.1016/0092-8674(88)90110-9; FINK GR, 1987, CELL, V49, P5, DOI 10.1016/0092-8674(87)90746-X; GARFINKEL DJ, 1985, CELL, V42, P507, DOI 10.1016/0092-8674(85)90108-4; HEIDMANN O, 1991, CELL, V64, P159, DOI 10.1016/0092-8674(91)90217-M; HINNEBUSCH AG, 1983, J BIOL CHEM, V258, P5238; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; LEVINE KL, 1990, MOL CELL BIOL, V10, P1891, DOI 10.1128/MCB.10.5.1891; LEVRAJUILLET E, 1989, MOL GEN GENET, V217, P168, DOI 10.1007/BF00330957; LINIAL M, 1987, CELL, V49, P93, DOI 10.1016/0092-8674(87)90759-8; MELLOR J, 1985, NATURE, V318, P583, DOI 10.1038/318583a0; Ochman H., 1990, PCR PROTOCOLS GUIDE, P219; PAQUIN CE, 1984, SCIENCE, V226, P53, DOI 10.1126/science.226.4670.53; SHERMAN F, 1986, LABORATORY COURSE MA; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; TEMIN HM, 1985, MOL BIOL EVOL, V2, P455; WEINSTOCK KG, 1990, MOL CELL BIOL, V10, P2882, DOI 10.1128/MCB.10.6.2882; WILKE CM, 1989, GENETICS, V123, P655; WINSTON F, 1984, CELL, V39, P675, DOI 10.1016/0092-8674(84)90474-4; XU H, 1990, MOL CELL BIOL, V10, P2695, DOI 10.1128/MCB.10.6.2695; YOSHIMATSU T, 1989, SCIENCE, V244, P1346, DOI 10.1126/science.2544026	36	115	119	2	15	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 18	1991	67	2					355	364		10.1016/0092-8674(91)90187-4	http://dx.doi.org/10.1016/0092-8674(91)90187-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1655280				2022-12-01	WOS:A1991GL47000015
J	FRANKS, NP; LIEB, WR				FRANKS, NP; LIEB, WR			STEREOSPECIFIC EFFECTS OF INHALATIONAL GENERAL ANESTHETIC OPTICAL ISOMERS ON NERVE ION CHANNELS	SCIENCE			English	Article							APLYSIA NEURONS; RECEPTORS; STEREOISOMERS; PHARMACOLOGY; INHIBITION; RESPONSES; HALOTHANE; BINDING; SYSTEM; SITES	Although it is generally agreed that general anesthetics ultimately act on neuronal ion channels, there is considerable controversy over whether this occurs by direct binding to protein or secondarily by nonspecific perturbation of lipids. Very pure optical isomers of the inhalational general anesthetic isoflurane exhibited clear stereoselectivity in their effects on particularly sensitive ion channels in identified molluscan central nervous system neurons. At the human median effect dose (ED50) for general anesthesia, the (+)-isomer was about twofold more effective than the (-)-isomer both in eliciting the anesthetic-activated potassium current I(K)(An) and in inhibiting a current mediated by neuronal nicotinic acetylcholine receptors. For inhibiting the much less sensitive transient potassium current I(A), the (-)-isomer was marginally more potent than the (+)-isomer. Both isomers were equally effective at disrupting lipid bilayers.			FRANKS, NP (corresponding author), IMPERIAL COLL SCI TECHNOL & MED,BLACKETT LAB,PRINCE CONSORT RD,LONDON SW7 2BZ,ENGLAND.			Franks, Nicholas/0000-0003-4874-4212	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041609] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 41609] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALIFIMOFF JK, 1987, ANESTHESIOLOGY, V66, P55, DOI 10.1097/00000542-198701000-00010; ANDREWS PR, 1982, ANESTHESIOLOGY, V57, P314, DOI 10.1097/00000542-198210000-00014; ARIMURA H, 1986, BRIT J PHARMACOL, V89, P573, DOI 10.1111/j.1476-5381.1986.tb11158.x; CHEMERIS NK, 1982, J PHYSIOL-LONDON, V323, P1; COTE IL, 1980, J PHARMACOL EXP THER, V214, P161; DLUZEWSKI AR, 1983, MOL ASPECTS MED, V6, P459, DOI 10.1016/0098-2997(83)90001-8; EDAMURA FY, 1970, 159TH NAT M AM CHEM; FRANKS NP, 1987, TRENDS PHARMACOL SCI, V8, P169, DOI 10.1016/0165-6147(87)90160-X; FRANKS NP, 1982, NATURE, V300, P487, DOI 10.1038/300487a0; FRANKS NP, 1988, NATURE, V333, P662, DOI 10.1038/333662a0; FRANKS NP, 1984, NATURE, V310, P599, DOI 10.1038/310599a0; HILL MW, 1974, BIOCHIM BIOPHYS ACTA, V356, P117, DOI 10.1016/0005-2736(74)90299-5; HUANG LYM, 1980, SCIENCE, V207, P195, DOI 10.1126/science.7350656; JUDGE SE, 1982, BRIT J PHARMACOL, V75, P353, DOI 10.1111/j.1476-5381.1982.tb08793.x; KEHOE J, 1972, J PHYSIOL-LONDON, V225, P115, DOI 10.1113/jphysiol.1972.sp009931; KENDIG JJ, 1973, ANESTHESIOLOGY, V39, P518, DOI 10.1097/00000542-197311000-00011; LAASBERG LH, 1971, J BIOL CHEM, V246, P4886; MARIETTA MP, 1977, J PHARMACOL EXP THER, V202, P157; MEINWALD J, 1991, SCIENCE, V251, P560, DOI 10.1126/science.1846702; MILLER KW, 1973, MOL PHARMACOL, V9, P131; MILLER KW, 1985, INT REV NEUROBIOL, V27, P1, DOI 10.1016/S0074-7742(08)60555-3; PFEIFFER CC, 1956, SCIENCE, V124, P29, DOI 10.1126/science.124.3210.29; RICHARDS CD, 1980, TOPICAL REV ANAESTHE, V1, P1; SKOLNICK P, 1982, BRAIN RES, V233, P143, DOI 10.1016/0006-8993(82)90936-2; STEWARD A, 1973, BRIT J ANAESTH, V45, P282, DOI 10.1093/bja/45.3.282; TICKU MK, 1981, BRAIN RES, V211, P127, DOI 10.1016/0006-8993(81)90071-8; WAHLSTROM G, 1984, BRAIN RES, V310, P261, DOI 10.1016/0006-8993(84)90149-5; WEISKOPF RB, 1989, ANESTHESIOLOGY, V70, P793, DOI 10.1097/00000542-198905000-00015; WHITE PF, 1980, ANESTHESIOLOGY, V52, P231, DOI 10.1097/00000542-198003000-00008; WOLFSON B, 1978, ANESTHESIOLOGY, V48, P187	30	250	257	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1991	254	5030					427	430		10.1126/science.1925602	http://dx.doi.org/10.1126/science.1925602			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK729	1925602				2022-12-01	WOS:A1991GK72900048
J	GOODRICH, DW; WANG, NP; QIAN, YW; LEE, EYHP; LEE, WH				GOODRICH, DW; WANG, NP; QIAN, YW; LEE, EYHP; LEE, WH			THE RETINOBLASTOMA GENE-PRODUCT REGULATES PROGRESSION THROUGH THE G1 PHASE OF THE CELL-CYCLE	CELL			English	Article							LARGE-T-ANTIGEN; SV40 LARGE-T; ADENOVIRUS E1A PROTEINS; DNA-BINDING ACTIVITY; SUSCEPTIBILITY GENE; RB GENE; TERMINAL REGION; EXPRESSION; TUMORIGENICITY; IDENTIFICATION	The RB gene product is a nuclear phosphoprotein that undergoes cell cycle-dependent changes in its phosphorylation status. To test whether RB regulates cell cycle progression, purified RB proteins, either full-length or a truncated form containing the T antigen-binding region, were injected into cells. Injection of either protein early in G1 inhibits progression into S phase. Co-injection of anti-RB antibodies antagonizes this effect. Injection of RB into cells arrested at G1/S or late in G1 has no effect on BrdU incorporation, suggesting that RB does not inhibit DNA synthesis in S phase. These results indicate that RB regulates cell proliferation by restricting cell cycle progression at a specific point in G1 and establish a biological assay for RB activity. Neither co-injection of RB with a T antigen peptide nor injection into cells expressing T antigen prevents cells from progressing into S phase, which supports the hypothesis that T antigen binding has functional consequences for RB.			GOODRICH, DW (corresponding author), UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,CTR MOLEC MED,SAN ANTONIO,TX 78284, USA.							ABRAMSON DH, 1984, OPHTHALMOLOGY, V91, P1351; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHENG J, 1990, BLOOD, V75, P730; CHERINGTON V, 1988, MOL CELL BIOL, V8, P1380, DOI 10.1128/MCB.8.3.1380; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HAMEL P, 1990, MOL CELL BIOL, V12, P6585; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HEINTZ NH, 1982, P NATL ACAD SCI-BIOL, V79, P4083, DOI 10.1073/pnas.79.13.4083; HENSEL CH, 1990, CANCER RES, V50, P3067; HONG F, 1991, IN PRESS BIOSCI REP; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Knudson AG, 1973, ADV CANCER RES, V17, P317; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEE WH, 1990, TUMOR SUPPRESSOR GEN, V20, P159; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; Maniatis T., 1982, MOL CLONING; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Shew J.-Y., 1989, ONCOGENE RES, V1, P205; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; SOMPAYRAC L, 1988, VIROLOGY, V163, P391, DOI 10.1016/0042-6822(88)90279-6; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; WANG NP, 1990, CELL GROWTH DIFFER, V1, P233; WANG NP, 1990, CELL GROWTH DIFFER, V1, P429; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	62	725	736	0	28	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					293	302		10.1016/0092-8674(91)90181-W	http://dx.doi.org/10.1016/0092-8674(91)90181-W			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1655277				2022-12-01	WOS:A1991GL47000009
J	JACKSON, CL; KONOPKA, JB; HARTWELL, LH				JACKSON, CL; KONOPKA, JB; HARTWELL, LH			SACCHAROMYCES-CEREVISIAE ALPHA-PHEROMONE RECEPTORS ACTIVATE A NOVEL SIGNAL TRANSDUCTION PATHWAY FOR MATING PARTNER DISCRIMINATION	CELL			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; A-FACTOR; ADENYLATE-CYCLASE; NUCLEAR-FUSION; CELL-FUSION; G-PROTEIN; PHOSPHOINOSITIDE TURNOVER; STRUCTURAL GENE; PLASMA-MEMBRANE; GAMMA-SUBUNITS	Wild-type S. cerevisiae cells of both mating types prefer partners producing high levels of pheromone and mate very infrequently to cells producing no pheromone. However, some mutants that are supersensitive to pheromone lack this ability to discriminate. In this study, we provide evidence for a novel role of alpha-pheromone receptors in mating partner discrimination that is independent of the known G protein-mediated signal transduction pathway. Furthermore, in response to pheromone, receptors become localized to the emerging region of morphogenesis that is positioned adjacent to the nucleus, suggesting that receptor localization may be involved in mating partner discrimination. Actin, myosin 2, and clathrin heavy chain are involved in mating partner discrimination, since strains carrying mutations in the genes encoding these proteins result in a small but significant defect in mating partner discrimination.			JACKSON, CL (corresponding author), UNIV WASHINGTON,DEPT GENET,SK-50,SEATTLE,WA 98195, USA.		Jackson, Catherine/A-3421-2013; Jackson, Catherine/T-5688-2019	Jackson, Catherine/0000-0002-0843-145X; Konopka, James/0000-0001-5989-4086	NIGMS NIH HHS [GM17709] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017709, R37GM017709] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BABA M, 1989, J CELL SCI, V94, P207; BARBER DL, 1989, J BIOL CHEM, V264, P21038; BENDER A, 1986, CELL, V47, P929, DOI 10.1016/0092-8674(86)90808-1; BENDER A, 1989, GENETICS, V121, P463; BERLIN V, 1990, J CELL BIOL, V111, P2573, DOI 10.1083/jcb.111.6.2573; BLINDER D, 1989, CELL, V56, P479, DOI 10.1016/0092-8674(89)90250-X; BLUMER KJ, 1990, P NATL ACAD SCI USA, V87, P4363, DOI 10.1073/pnas.87.11.4363; BLUMER KJ, 1988, J BIOL CHEM, V263, P10836; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; BURKHOLDER AC, 1985, NUCLEIC ACIDS RES, V13, P8463, DOI 10.1093/nar/13.23.8463; BYERS B, 1975, J BACTERIOL, V124, P511, DOI 10.1128/JB.124.1.511-523.1975; Byers B, 1981, MOL BIOL YEAST SACCH, P59; CHAKRABORTY M, 1991, SCIENCE, V251, P1078, DOI 10.1126/science.1847755; CHAN RK, 1982, MOL CELL BIOL, V2, P21, DOI 10.1128/MCB.2.1.21; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; CLACK JW, 1988, P NATL ACAD SCI USA, V85, P9806, DOI 10.1073/pnas.85.24.9806; CROSS F, 1988, ANNU REV CELL BIOL, V4, P429, DOI 10.1146/annurev.cb.04.110188.002241; CROSS FR, 1990, GENETICS, V126, P301; DELGADO MA, 1984, MOL GEN GENET, V193, P188, DOI 10.1007/BF00327435; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; DIETZEL C, 1987, MOL CELL BIOL, V7, P4169, DOI 10.1128/MCB.7.12.4169; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; DOLAN JW, 1989, P NATL ACAD SCI USA, V86, P5703, DOI 10.1073/pnas.86.15.5703; FIELD C, 1980, J CELL BIOL, V86, P123, DOI 10.1083/jcb.86.1.123; FIELDS S, 1990, TRENDS BIOCHEM SCI, V15, P270, DOI 10.1016/0968-0004(90)90052-D; GANZ MB, 1990, J BIOL CHEM, V265, P8989; GEHRUNG S, 1990, J CELL BIOL, V111, P1451, DOI 10.1083/jcb.111.4.1451; HAGEN DC, 1986, P NATL ACAD SCI USA, V83, P1418, DOI 10.1073/pnas.83.5.1418; HARTIG A, 1986, MOL CELL BIOL, V6, P2106, DOI 10.1128/MCB.6.6.2106; HASEK J, 1987, J GEN MICROBIOL, V133, P3355; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HUFFAKER TC, 1988, J CELL BIOL, V106, P1997, DOI 10.1083/jcb.106.6.1997; HYMAN AA, 1989, J CELL BIOL, V109, P1185, DOI 10.1083/jcb.109.3.1185; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACKSON CL, 1990, MOL CELL BIOL, V10, P2202, DOI 10.1128/MCB.10.5.2202; JACKSON CL, 1990, CELL, V63, P1039, DOI 10.1016/0092-8674(90)90507-B; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; JAHNG KY, 1988, MOL CELL BIOL, V8, P2484, DOI 10.1128/MCB.8.6.2484; JENNESS DD, 1983, CELL, V35, P521, DOI 10.1016/0092-8674(83)90186-1; JENNESS DD, 1986, MOL CELL BIOL, V6, P318, DOI 10.1128/MCB.6.1.318; JENNESS DD, 1986, CELL, V46, P345, DOI 10.1016/0092-8674(86)90655-0; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; KONOPKA JB, 1988, CELL, V54, P609, DOI 10.1016/S0092-8674(88)80005-9; KURJAN J, 1985, MOL CELL BIOL, V5, P787, DOI 10.1128/MCB.5.4.787; LEMMON SK, 1987, SCIENCE, V238, P504, DOI 10.1126/science.3116672; LIMBIRD LE, 1988, FASEB J, V2, P2686, DOI 10.1096/fasebj.2.11.2840317; LIPKE PN, 1989, MOL CELL BIOL, V9, P3155, DOI 10.1128/MCB.9.8.3155; MCCAFFREY G, 1987, MOL CELL BIOL, V7, P2680, DOI 10.1128/MCB.7.8.2680; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; MIYAJIMA I, 1988, GENETICS, V119, P797; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; MIYAJIMA I, 1989, MOL CELL BIOL, V9, P2289, DOI 10.1128/MCB.9.6.2289; NAKAFUKU M, 1988, P NATL ACAD SCI USA, V85, P1374, DOI 10.1073/pnas.85.5.1374; NAKAYAMA N, 1987, EMBO J, V6, P249, DOI 10.1002/j.1460-2075.1987.tb04746.x; NAKAYAMA N, 1988, MOL CELL BIOL, V8, P3777, DOI 10.1128/MCB.8.9.3777; NAKAYAMA N, 1985, EMBO J, V4, P2643, DOI 10.1002/j.1460-2075.1985.tb03982.x; NASMYTH K, 1987, SCIENCE, V237, P1162, DOI 10.1126/science.3306917; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; NOVICK P, 1989, GENETICS, V121, P659; OBRIEN DF, 1977, P NATL ACAD SCI USA, V74, P5222, DOI 10.1073/pnas.74.12.5222; OVCHINNIKOV YA, 1982, FEBS LETT, V148, P179, DOI 10.1016/0014-5793(82)80805-3; PAYNE GS, 1988, J CELL BIOL, V106, P1453, DOI 10.1083/jcb.106.5.1453; PAYNE GS, 1989, SCIENCE, V245, P1358, DOI 10.1126/science.2675311; PAYNE GS, 1985, SCIENCE, V230, P1009, DOI 10.1126/science.2865811; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PRAKASH L, 1973, J MOL BIOL, V79, P65, DOI 10.1016/0022-2836(73)90270-2; PRENDERGAST JA, 1990, GENETICS, V124, P81; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; ROSE MD, 1987, CELL, V48, P1047, DOI 10.1016/0092-8674(87)90712-4; ROSE MD, 1986, MOL CELL BIOL, V6, P3490, DOI 10.1128/MCB.6.10.3490; SCHOBERT B, 1982, J BIOL CHEM, V257, P306; SINGER B, 1990, J CELL BIOL, V110, P1911, DOI 10.1083/jcb.110.6.1911; SNYDER M, 1989, J CELL BIOL, V108, P1419, DOI 10.1083/jcb.108.4.1419; SONG OK, 1991, GENE DEV, V5, P741, DOI 10.1101/gad.5.5.741; STEIN R, 1988, EMBO J, V7, P3031, DOI 10.1002/j.1460-2075.1988.tb03167.x; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; TKACZ JS, 1979, J CELL BIOL, V80, P326, DOI 10.1083/jcb.80.2.326; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; TRUEHEART J, 1989, P NATL ACAD SCI USA, V86, P9916, DOI 10.1073/pnas.86.24.9916; WATZELE M, 1988, EMBO J, V7, P1483, DOI 10.1002/j.1460-2075.1988.tb02966.x; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3	84	107	110	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					389	402		10.1016/0092-8674(91)90190-A	http://dx.doi.org/10.1016/0092-8674(91)90190-A			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1655282				2022-12-01	WOS:A1991GL47000018
J	KARALIS, K; SANO, H; REDWINE, J; LISTWAK, S; WILDER, RL; CHROUSOS, GP				KARALIS, K; SANO, H; REDWINE, J; LISTWAK, S; WILDER, RL; CHROUSOS, GP			AUTOCRINE OR PARACRINE INFLAMMATORY ACTIONS OF CORTICOTROPIN-RELEASING HORMONE INVIVO	SCIENCE			English	Article							CENTRAL NERVOUS-SYSTEM; FACTOR-LIKE IMMUNOREACTIVITY; WALL-INDUCED ARTHRITIS; RAT LEYDIG-CELLS; FACTOR RECEPTORS; BETA-ENDORPHIN; LEWIS RATS; BIOCHEMICAL MANIFESTATIONS; INDUCED SECRETION; MOUSE SPLEEN	Corticotropin-releasing hormone (CRH) functions as a regulator of the hypothalamic-pituitary-adrenal axis and coordinator of the stress response. CRH receptors exist in peripheral sites of the immune system, and CRH promotes several immune functions in vitro. The effect of systemic immunoneutralization of CRH was tested in an experimental model of chemically induced aseptic inflammation in rats. Intraperitoneal administration of rabbit antiserum to CRH caused suppression of both inflammatory exudate volume and cell concentration by approximately 50 to 60 percent. CRH was detected in the inflamed area but not in the systemic circulation. Immunoreactive CRH is therefore produced in peripheral inflammatory sites where, in contrast to its systemic indirect immunosuppressive effects, it acts as an autocrine or paracrine inflammatory cytokine.	NIAMSD,ARTHRIT & RHEUMATISM BRANCH,BETHESDA,MD 20892; NIMH,ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,CLIN NEUROENDOCRINOL BRANCH,BETHESDA,MD 20892; NICHHD,DEV ENDOCRINOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; CALOGERO AE, 1989, PEPTIDES, V10, P189, DOI 10.1016/0196-9781(89)90096-X; CARR DJJ, 1990, J NEUROIMMUNOL, V28, P53, DOI 10.1016/0165-5728(90)90040-T; CASE JP, 1989, J CLIN INVEST, V84, P1731, DOI 10.1172/JCI114356; CHROUSOS GP, 1988, MECHANISMS PHYSICAL; CROFFORD LJ, UNPUB; CUMMINGS S, 1983, J NEUROSCI, V3, P1355; DAVE JR, 1985, ENDOCRINOLOGY, V116, P2152, DOI 10.1210/endo-116-6-2152; DESOUZA EB, 1985, J NEUROSCI, V5, P3189; DUNN AJ, 1990, BRAIN RES REV, V15, P71, DOI 10.1016/0165-0173(90)90012-D; FABBRI A, 1990, ENDOCRINOLOGY, V127, P1541, DOI 10.1210/endo-127-3-1541; FELTEN DL, 1987, IMMUNOL REV, V100, P225, DOI 10.1111/j.1600-065X.1987.tb00534.x; FUKUHARA M, 1969, BIOCHEM PHARMACOL, V18, P475; GOLD PW, 1988, NEW ENGL J MED, V319, P348, DOI 10.1056/NEJM198808113190606; GOLD PW, 1988, NEW ENGL J MED, V319, P413, DOI 10.1056/NEJM198808183190706; GRINO M, 1987, BIOCHEM BIOPH RES CO, V148, P1208, DOI 10.1016/S0006-291X(87)80261-9; GUILLEMIN R, 1955, ENDOCRINOLOGY, V57, P599, DOI 10.1210/endo-57-5-599; Guillemin R, 1985, NEURAL MODULATION IM; HARGREAVES KM, 1989, NEUROENDOCRINOLOGY, V49, P476, DOI 10.1159/000125155; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IRWIN M, 1988, AM J PHYSIOL, V255, pR744, DOI 10.1152/ajpregu.1988.255.5.R744; IRWIN M, 1990, ENDOCRINOLOGY, V126, P2837, DOI 10.1210/endo-126-6-2837; IRWIN M R, 1987, Brain Behavior and Immunity, V1, P81, DOI 10.1016/0889-1591(87)90009-2; KARALIS K, 1991, PEDIATR RES, V29, pA80; KAVELAARS A, 1989, J IMMUNOL, V142, P2338; KAVELAARS A, 1990, ENDOCRINOLOGY, V126, P759, DOI 10.1210/endo-126-2-759; KELLER SE, 1988, P NATL ACAD SCI USA, V85, P9297, DOI 10.1073/pnas.85.23.9297; KELLER SE, 1983, SCIENCE, V221, P1301, DOI 10.1126/science.6612346; LAUE L, 1988, J STEROID BIOCHEM, V29, P591, DOI 10.1016/0022-4731(88)90156-2; LEE NM, 1980, PP NATL ACAD SCI US, V77, P3525; MARGIORIS AN, 1988, J CLIN ENDOCR METAB, V66, P922, DOI 10.1210/jcem-66-5-922; MCGILLIS JP, 1989, J NEUROSCI RES, V23, P346, DOI 10.1002/jnr.490230316; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; OLSCHOWKA JA, 1982, PEPTIDES, V3, P995, DOI 10.1016/0196-9781(82)90071-7; PLOTSKY PM, 1987, ENDOCRINOLOGY, V120, P1361, DOI 10.1210/endo-120-4-1361; PLOTSKY PM, 1984, ENDOCRINOLOGY, V114, P164, DOI 10.1210/endo-114-1-164; POTTER E, 1991, NATURE, V349, P423, DOI 10.1038/349423a0; SAFFRAN M, 1955, ENDOCRINOLOGY, V57, P439, DOI 10.1210/endo-57-4-439; SANO H, 1990, J CELL BIOL, V110, P1417, DOI 10.1083/jcb.110.4.1417; SCHURMEYER TH, 1984, J CLIN ENDOCR METAB, V59, P1103, DOI 10.1210/jcem-59-6-1103; SINGH VK, 1989, J NEUROIMMUNOL, V23, P257, DOI 10.1016/0165-5728(89)90058-1; SINGH VK, 1988, IMMUNOL LETT, V18, P5, DOI 10.1016/0165-2478(88)90061-2; SINGH VK, 1990, NEUROSCI LETT, V120, P151, DOI 10.1016/0304-3940(90)90025-5; SMITH EM, 1986, NATURE, V321, P881, DOI 10.1038/321881a0; STEPHANOU A, 1990, BRAIN BEHAV IMMUN, V4, P67, DOI 10.1016/0889-1591(90)90007-D; STERNBERG EM, 1989, P NATL ACAD SCI USA, V86, P2374, DOI 10.1073/pnas.86.7.2374; STERNBERG EM, 1989, P NATL ACAD SCI USA, V86, P4771, DOI 10.1073/pnas.86.12.4771; TECOMA ES, 1985, LIFE SCI, V36, P1799, DOI 10.1016/0024-3205(85)90152-3; TSURUFUJI S, 1978, J PHARMACOBIO-DYNAM, V1, P8; UDELSMAN R, 1986, NATURE, V319, P147, DOI 10.1038/319147a0; ULISSE S, 1989, J BIOL CHEM, V264, P2156; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VALE W, 1983, RECENT PROG HORM RES, V39, P245; WEBSTER EL, 1990, ENDOCRINOLOGY, V127, P440, DOI 10.1210/endo-127-1-440; WEBSTER EL, 1988, ENDOCRINOLOGY, V122, P609, DOI 10.1210/endo-122-2-609; WILDER RL, 1987, J CLIN INVEST, V79, P1160, DOI 10.1172/JCI112933	57	429	438	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1991	254	5030					421	423		10.1126/science.1925600	http://dx.doi.org/10.1126/science.1925600			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK729	1925600				2022-12-01	WOS:A1991GK72900046
J	LEE, WS; KAO, CC; BRYANT, GO; LIU, X; BERK, AJ				LEE, WS; KAO, CC; BRYANT, GO; LIU, X; BERK, AJ			ADENOVIRUS E1A ACTIVATION DOMAIN BINDS THE BASIC REPEAT IN THE TATA BOX TRANSCRIPTION FACTOR	CELL			English	Article							FUNCTIONAL DOMAINS; CELLULAR TARGETS; ESCHERICHIA-COLI; EARLY REGION-1A; INFECTED CELLS; DNA-SYNTHESIS; PROTEIN; GENE; TRANSACTIVATION; CLONING	The adenovirus large E1A protein is a potent activator of transcription. We use several different experimental approaches to demonstrate that the large E1A protein binds specifically and stably to the TATA box-binding factor (TFIID), the general polymerase II transcription factor that initiates assembly of transcription complexes. Sedimentation velocity centrifugation revealed that TFIID and E1A form a heterodimer in vitro. We demonstrate that the activation domain of E1A (conserved region 3) binds to TFIID. E1A interacts with a 51 residue region from the conserved C-terminal domain of TFIID that includes a repeat of basic residues between the homologous direct repeats of TFIID. Analysis of TFIID binding by various E1A mutants indicates that TFIID binding is necessary, although not sufficient, for E1A transactivation.			LEE, WS (corresponding author), UNIV CALIF LOS ANGELES, INST MOLEC BIOL, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90024 USA.		BERK, ARNOLD/AAF-7052-2020		NCI NIH HHS [CA25235] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA025235, R37CA025235] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; CHATTERJEE PK, 1988, EMBO J, V7, P835, DOI 10.1002/j.1460-2075.1988.tb02882.x; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DASMAHAPATRA B, 1987, NUCLEIC ACIDS RES, V15, P3933, DOI 10.1093/nar/15.9.3933; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HOEFFLER WK, 1988, CELL, V53, P907, DOI 10.1016/S0092-8674(88)90409-6; HOEIJMAKERS JHJ, 1990, NATURE, V343, P417, DOI 10.1038/343417b0; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; LEONG K, 1988, MOL CELL BIOL, V8, P1765, DOI 10.1128/MCB.8.4.1765; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIEBERMAN PM, 1990, J VIROL, V64, P2560, DOI 10.1128/JVI.64.6.2560-2568.1990; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LILY W, 1987, NATURE, V326, P512, DOI 10.1038/326512a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MULLER U, 1989, GENE DEV, V3, P1991, DOI 10.1101/gad.3.12a.1991; NAGAI K, 1990, NATURE, V343, P418, DOI 10.1038/343418a0; PEI R, 1989, J VIROL, V63, P3499, DOI 10.1128/JVI.63.8.3499-3506.1989; PENNINGTON TH, 1974, J GEN VIROL, V25, P433, DOI 10.1099/0022-1317-25-3-433; PERRICAUDET M, 1979, NATURE, V281, P694, DOI 10.1038/281694a0; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RAYCHAUDHURI P, 1989, GENE DEV, V3, P620, DOI 10.1101/gad.3.5.620; ROCHETTEEGLY C, 1990, GENE DEV, V4, P137, DOI 10.1101/gad.4.1.137; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPINDLER KR, 1984, J VIROL, V52, P706, DOI 10.1128/JVI.52.2.706-710.1984; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STUCKA R, 1990, FEBS LETT, V261, P223, DOI 10.1016/0014-5793(90)80558-Z; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	54	376	378	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 18	1991	67	2					365	376		10.1016/0092-8674(91)90188-5	http://dx.doi.org/10.1016/0092-8674(91)90188-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1833071				2022-12-01	WOS:A1991GL47000016
J	LEGOUIS, R; HARDELIN, JP; LEVILLIERS, J; CLAVERIE, JM; COMPAIN, S; WUNDERLE, V; MILLASSEAU, P; LEPASLIER, D; COHEN, D; CATERINA, D; BOUGUELERET, L; DELEMARREVANDEWAAL, H; LUTFALLA, G; WEISSENBACH, J; PETIT, C				LEGOUIS, R; HARDELIN, JP; LEVILLIERS, J; CLAVERIE, JM; COMPAIN, S; WUNDERLE, V; MILLASSEAU, P; LEPASLIER, D; COHEN, D; CATERINA, D; BOUGUELERET, L; DELEMARREVANDEWAAL, H; LUTFALLA, G; WEISSENBACH, J; PETIT, C			THE CANDIDATE GENE FOR THE X-LINKED KALLMANN SYNDROME ENCODES A PROTEIN RELATED TO ADHESION MOLECULES	CELL			English	Article							STEROID SULFATASE GENE; AMINO-ACID-SEQUENCE; DISTAL SHORT ARM; IMMUNOGLOBULIN SUPERFAMILY; HYPOGONADOTROPIC HYPOGONADISM; Y-CHROMOSOME; FIBRONECTIN; MEMBER; DELETIONS; BINDING	Kallmann syndrome associates hypogonadotropic hypogonadism and anosmia and is probably due to a defect in the embryonic migration of olfactory and GnRH-synthesizing neurons. The Kallmann gene had been localized to Xp22.3. In this study 67 kb of genomic DNA, corresponding to a deletion interval containing at least part of the Kallmann gene, were sequenced. Two candidate exons, identified by multiparameter computer programs, were found in a cDNA encoding a protein of 679 amino acids. This candidate gene (ADMLX) is interrupted in its 3' coding region in the Kallmann patient, in which the proximal end of the KAL deletion interval was previously defined. A 5' end deletion was detected in another Kallmann patient. The predicted protein sequence shows homologies with the fibronectin type III repeat. ADMLX thus encodes a putative adhesion molecule, consistent with the defect of embryonic neuronal migration.	NIH, NATL LIB MED, NATL CTR BIOTECHNOL INFORMAT, BETHESDA, MD 20892 USA; GENETHON, F-91002 EVRY, FRANCE; CEPH, F-75010 PARIS, FRANCE; FREE UNIV AMSTERDAM HOSP, DEPT PAEDIAT, 1007 MB AMSTERDAM, NETHERLANDS; CNRS, UNITE ONCOL VIRALE, F-94801 VILLEJUIF, FRANCE	National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Centre National de la Recherche Scientifique (CNRS)	LEGOUIS, R (corresponding author), INST PASTEUR, CNRS, URA 1445, UNITE GENET MOLEC HUMAINE, F-75724 PARIS 15, FRANCE.		Legouis, Renaud/G-9088-2014; Claverie, Jean Michel/Z-2183-2019; Claverie, Jean-Michel/AAG-4889-2019; Lutfalla, Georges/AAW-9386-2021; Legouis, Renaud/S-1250-2017	Claverie, Jean-Michel/0000-0003-1424-0315; Legouis, Renaud/0000-0002-2699-2584; Le Paslier, Denis/0000-0003-4335-9956				ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ALTSCHUL SF, 1991, J MOL BIOL, V219, P555, DOI 10.1016/0022-2836(91)90193-A; ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ARAKI K, 1989, BIOCHEM BIOPH RES CO, V164, P496, DOI 10.1016/0006-291X(89)91747-6; AURIVILLIUS M, 1990, FEBS LETT, V264, P267, DOI 10.1016/0014-5793(90)80264-J; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BALLABIO A, 1990, GENOMICS, V8, P263, DOI 10.1016/0888-7543(90)90281-X; BALLABIO A, 1989, P NATL ACAD SCI USA, V86, P10001, DOI 10.1073/pnas.86.24.10001; BALLABIO A, 1987, HUM GENET, V77, P338, DOI 10.1007/BF00291422; BELLANNECHANTELOT C, 1991, NUCLEIC ACIDS RES, V19, P505, DOI 10.1093/nar/19.3.505; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; BOGUSKI M, 1991, IN PRESS PROTEIN ENG; BOULOUX PM, 1991, IN PRESS NUCL ACIDS; BRUMMENDORF T, 1989, NEURON, V2, P1351, DOI 10.1016/0896-6273(89)90073-1; CHANG S, 1987, J CELL BIOL, V104, P355, DOI 10.1083/jcb.104.2.355; CHAUSSAIN JL, 1988, HORM RES, V29, P202, DOI 10.1159/000181003; CLAVERIE JM, 1990, METHOD ENZYMOL, V183, P237; COULSON A, 1988, GENOME ANAL PRACTICA, P25; COX EC, 1990, NEURON, V4, P31, DOI 10.1016/0896-6273(90)90441-H; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DAVIES JA, 1990, NEURON, V4, P11, DOI 10.1016/0896-6273(90)90439-M; De Morster G, 1954, SCHWEIZ ARCH NEUROL, V74, P309; DEAR TN, 1991, BIOCHEM BIOPH RES CO, V176, P247, DOI 10.1016/0006-291X(91)90916-U; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; ERICKSON HP, 1984, NATURE, V311, P267, DOI 10.1038/311267a0; FISCHER G, 1986, J NEUROSCI, V6, P605; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GENNARINI G, 1991, NEURON, V6, P595, DOI 10.1016/0896-6273(91)90062-5; GOWER HJ, 1988, CELL, V55, P955, DOI 10.1016/0092-8674(88)90241-3; GRUMET M, 1991, J CELL BIOL, V113, P399; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HOWLEY PM, 1979, J BIOL CHEM, V254, P4876; JONES FS, 1989, P NATL ACAD SCI USA, V86, P1905, DOI 10.1073/pnas.86.6.1905; Jones J R, 1976, Obstet Gynecol Annu, V5, P443; JONES PCT, 1966, NATURE, V212, P365, DOI 10.1038/212365a0; JUAN AMD, 1856, SIGLO MED, V211; Kallmann FJ, 1944, AM J MENT DEF, V48, P203; KLEIN P, 1986, BIOPOLYMERS, V25, P1659, DOI 10.1002/bip.360250909; KLINGMULLER D, 1987, J CLIN ENDOCR METAB, V65, P581, DOI 10.1210/jcem-65-3-581; KNOWLTON RG, 1989, NUCLEIC ACIDS RES, V17, P423, DOI 10.1093/nar/17.1.423; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MALES JL, 1973, ARCH INTERN MED, V131, P501, DOI 10.1001/archinte.131.4.501; MANFIOLETTI G, 1988, NUCLEIC ACIDS RES, V16, P2873, DOI 10.1093/nar/16.7.2873; MARCUS M, 1976, NATURE, V262, P63, DOI 10.1038/262063a0; McKusick VA, 1990, MENDELIAN INHERITANC; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; NELSON DL, 1989, P NATL ACAD SCI USA, V86, P6686, DOI 10.1073/pnas.86.17.6686; NELSON DL, 1991, P NATL ACAD SCI USA, V88, P6157, DOI 10.1073/pnas.88.14.6157; ODERMATT E, 1985, P NATL ACAD SCI USA, V82, P6571, DOI 10.1073/pnas.82.19.6571; Pearson AA, 1941, J COMP NEUROL, V75, P39, DOI 10.1002/cne.900750104; PETIT C, 1990, GENOMICS, V6, P651, DOI 10.1016/0888-7543(90)90500-T; PETIT C, 1988, EMBO J, V7, P2369, DOI 10.1002/j.1460-2075.1988.tb03081.x; PETIT C, 1990, P NATL ACAD SCI USA, V87, P3680, DOI 10.1073/pnas.87.10.3680; RANSCHT B, 1988, J CELL BIOL, V107, P1561, DOI 10.1083/jcb.107.4.1561; RAPER JA, 1990, NEURON, V4, P21, DOI 10.1016/0896-6273(90)90440-Q; RATHJEN FG, 1987, J CELL BIOL, V104, P343, DOI 10.1083/jcb.104.2.343; RONNEKLEIV OK, 1990, ENDOCRINOLOGY, V126, P498, DOI 10.1210/endo-126-1-498; RUEGG MA, 1989, EMBO J, V8, P55, DOI 10.1002/j.1460-2075.1989.tb03348.x; RUTISHAUSER U, 1988, PHYSIOL REV, V68, P819, DOI 10.1152/physrev.1988.68.3.819; Sambrook J., 1989, MOL CLONING LAB MANU; SANTEN RJ, 1973, J CLIN ENDOCR METAB, V36, P47, DOI 10.1210/jcem-36-1-47; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SCHWANKHAUS JD, 1989, NEUROLOGY, V39, P223, DOI 10.1212/WNL.39.2.223; SCHWANZELFUKUDA M, 1989, MOL BRAIN RES, V6, P311, DOI 10.1016/0169-328X(89)90076-4; SCHWANZELFUKUDA M, 1989, NATURE, V338, P161, DOI 10.1038/338161a0; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SHAPIRO LJ, 1985, ADV HUM GENET, V14, P331; SPARKES RS, 1968, ARCH INTERN MED, V121, P534, DOI 10.1001/archinte.121.6.534; STADEN R, 1982, NUCLEIC ACIDS RES, V10, P141, DOI 10.1093/nar/10.1.141; STADEN R, 1987, NUCLEIC ACID PROTEIN, P173; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TIEPOLO L, 1980, HUM GENET, V54, P205, DOI 10.1007/BF00278973; Ulrich A., 1985, NATURE, V313, P756; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEGENKE JD, 1975, CLIN GENET, V7, P368; WEISSENBACH J, 1989, CYTOGENET CELL GENET, V51, P438, DOI 10.1159/000132802; WHITE BJ, 1983, AM J MED GENET, V15, P417, DOI 10.1002/ajmg.1320150307; WIEDOW O, 1990, J BIOL CHEM, V265, P14791; WRAY S, 1989, P NATL ACAD SCI USA, V86, P8132, DOI 10.1073/pnas.86.20.8132; YEN PH, 1988, CELL, V55, P1123, DOI 10.1016/0092-8674(88)90257-7; YEN PH, 1990, CELL, V61, P603, DOI 10.1016/0092-8674(90)90472-Q	86	562	576	0	33	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 18	1991	67	2					423	435		10.1016/0092-8674(91)90193-3	http://dx.doi.org/10.1016/0092-8674(91)90193-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1913827				2022-12-01	WOS:A1991GL47000021
J	LEVY, F; GABATHULER, R; LARSSON, R; KVIST, S				LEVY, F; GABATHULER, R; LARSSON, R; KVIST, S			ATP IS REQUIRED FOR INVITRO ASSEMBLY OF MHC CLASS-I ANTIGENS BUT NOT FOR TRANSFER OF PEPTIDES ACROSS THE ER MEMBRANE	CELL			English	Article							TOXIC LYMPHOCYTES-T; MAJOR HISTOCOMPATIBILITY COMPLEX; CHAIN BINDING-PROTEIN; HLA-B ANTIGENS; H-2-DEFICIENT LYMPHOMA VARIANTS; ENDOPLASMIC-RETICULUM; INFLUENZA NUCLEOPROTEIN; LYMPHOBLASTOID CELLS; MULTIDRUG RESISTANCE; SYNTHETIC PEPTIDES	We have translated the HLA-B27 heavy chain in vitro and studied its assembly with beta-2-microglobulin and peptide in microsomes from human cells. The assembly process requires ATP. However, the translocation of peptide across the endoplasmic reticulum (ER) membrane does not require ATP, and binding of biotinylated peptide to BiP, an ER luminal protein, occurs after ATP depletion. Proteinase K treatment of the microsomes does not block peptide translocation. Thus, ATP is required in the lumen of the ER for efficient assembly to occur. Microsomes prepared from Raji and T1 cells show similar levels of assembly, whereas assembly in T2 microsomes is 10-fold lower. This difference remains after peptide stimulation of assembly. The inefficient assembly in T2 microsomes is not due to impaired peptide translocation across the ER membrane, as no difference was found compared with microsomes from T1 cells. Instead, the defect seems to reside in the lumen of the ER.			LEVY, F (corresponding author), LUDWIG INST CANC RES,BOX 60202,S-10401 STOCKHOLM,SWEDEN.							ARCEGOMEZ B, 1978, TISSUE ANTIGENS, V11, P96, DOI 10.1111/j.1399-0039.1978.tb01233.x; BARINAGA M, 1990, SCIENCE, V250, P1657, DOI 10.1126/science.2270477; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BLIGHT MA, 1990, MOL MICROBIOL, V4, P873, DOI 10.1111/j.1365-2958.1990.tb00660.x; BODMER HC, 1989, NATURE, V337, P653, DOI 10.1038/337653a0; BRACIALE TJ, 1987, J EXP MED, V166, P678, DOI 10.1084/jem.166.3.678; BURGERT HG, 1985, CELL, V41, P987, DOI 10.1016/S0092-8674(85)80079-9; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CLAYBERGER C, 1987, NATURE, V330, P763, DOI 10.1038/330763a0; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; DEMARS R, 1984, HUM IMMUNOL, V11, P77, DOI 10.1016/0198-8859(84)90047-8; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; ELLIOTT TJ, 1990, P NATL ACAD SCI USA, V87, P5213, DOI 10.1073/pnas.87.13.5213; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GAROFF H, 1978, J MOL BIOL, V124, P587, DOI 10.1016/0022-2836(78)90173-0; GOTCH F, 1987, NATURE, V326, P881, DOI 10.1038/326881a0; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HUET S, 1990, INT IMMUNOL, V2, P311, DOI 10.1093/intimm/2.4.311; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KASSENBROCK CK, 1988, NATURE, V333, P90, DOI 10.1038/333090a0; KETTLUN AM, 1982, PHYTOCHEMISTRY, V21, P551, DOI 10.1016/0031-9422(82)83139-7; KLAR D, 1989, EMBO J, V8, P475, DOI 10.1002/j.1460-2075.1989.tb03400.x; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; KVIST S, 1982, CELL, V29, P61, DOI 10.1016/0092-8674(82)90090-3; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LURQUIN C, 1989, CELL, V58, P293, DOI 10.1016/0092-8674(89)90844-1; MARYANSKI JL, 1986, NATURE, V324, P578, DOI 10.1038/324578a0; MCMICHAEL AJ, 1988, P NATL ACAD SCI USA, V85, P9194, DOI 10.1073/pnas.85.23.9194; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; OLDSTONE MBA, 1988, J EXP MED, V168, P559, DOI 10.1084/jem.168.2.559; PARHAM P, 1990, NATURE, V346, P793, DOI 10.1038/346793a0; PARHAM P, 1990, NATURE, V348, P674, DOI 10.1038/348674a0; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PELHAM HRB, 1989, EMBO J, V8, P3171, DOI 10.1002/j.1460-2075.1989.tb08475.x; PLOEGH HL, 1979, P NATL ACAD SCI USA, V76, P2273, DOI 10.1073/pnas.76.5.2273; REDDEHASE MJ, 1989, NATURE, V337, P651, DOI 10.1038/337651a0; ROTHBARD JB, 1988, EMBO J, V7, P93, DOI 10.1002/j.1460-2075.1988.tb02787.x; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SHIMIZU Y, 1986, MOL CELL BIOL, V6, P1074, DOI 10.1128/MCB.6.4.1074; SIMON SM, 1991, CELL, V65, P671; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TAYLOR PM, 1987, IMMUNOGENETICS, V26, P267, DOI 10.1007/BF00346521; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; TRAVERSOCORI A, 1970, ARCH BIOCHEM BIOPHYS, V137, P133, DOI 10.1016/0003-9861(70)90420-0; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANBLEEK GM, 1990, NATURE, V348, P213; VANBUSKIRK A, 1989, J EXP MED, V170, P1799, DOI 10.1084/jem.170.6.1799; WALLNY HJ, 1990, NATURE, V343, P275, DOI 10.1038/343275a0; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266	70	94	108	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					265	274		10.1016/0092-8674(91)90178-2	http://dx.doi.org/10.1016/0092-8674(91)90178-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1913823				2022-12-01	WOS:A1991GL47000006
J	LI, H; BINGHAM, PM				LI, H; BINGHAM, PM			ARGININE SERINE-RICH DOMAINS OF THE SU(WA) AND TRA RNA PROCESSING REGULATORS TARGET PROTEINS TO A SUBNUCLEAR COMPARTMENT IMPLICATED IN SPLICING	CELL			English	Article							DROSOPHILA-MELANOGASTER; NUCLEOLAR LOCALIZATION; BINDING PROTEINS; MESSENGER-RNA; GENE; SEX; SEQUENCES; SIMILARITY; EXPRESSION; ENCODES	Two unrelated pre-mRNA splicing regulators-suppressor-of-white-apricot (su(w(a))) and transformer (tra)-contain distinctive, approximately 120 amino acid arginine/serine (RS)-rich domains. Deletion of the su(w(a)) RS domain eliminates function. Replacement with the tra RS domain restores su(w(a)) function to nearly wild-type levels. Replacement with a 10 amino acid simple nuclear entry signal allows partial, inefficient function. Thus, the su(w(a)) RS domain apparently serves a generic function(s) subsuming nuclear entry. Moreover, immunocytochemical studies demonstrate that both RS domains specifically direct localization of a fused reporter protein to a punctate subnuclear compartment shown previously to be enriched in several constitutive splicing components. We propose that RS domains are a new class of targeting signals directing concentration of proteins in a subnuclear compartment implicated in splicing metabolism.			LI, H (corresponding author), SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794, USA.				PHS HHS [32003] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; CARMOFONSECA M, 1991, EMBO J, V10, P195, DOI 10.1002/j.1460-2075.1991.tb07936.x; CERVERA M, 1981, CELL, V23, P113, DOI 10.1016/0092-8674(81)90276-2; CHOU TB, 1987, EMBO J, V6, P4095, DOI 10.1002/j.1460-2075.1987.tb02755.x; COCHRANE AW, 1990, J VIROL, V64, P881, DOI 10.1128/JVI.64.2.881-885.1990; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; FAKAN S, 1984, J CELL BIOL, V98, P358, DOI 10.1083/jcb.98.1.358; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; GE H, 1991, IN PRESS CELL; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; KAUFMAN RJ, 1985, MOL CELL BIOL, V5, P1750, DOI 10.1128/MCB.5.7.1750; KRAINER AR, 1991, IN PRESS CELL; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; REED R, 1985, CELL, V41, P95, DOI 10.1016/0092-8674(85)90064-9; RIO DC, 1988, P NATL ACAD SCI USA, V85, P2904, DOI 10.1073/pnas.85.9.2904; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SMITH HC, 1985, J CELL BIOL, V101, P560, DOI 10.1083/jcb.101.2.560; SPECTOR DL, 1983, BIOL CELL, V49, P1; SPECTOR DL, 1990, P NATL ACAD SCI USA, V87, P147, DOI 10.1073/pnas.87.1.147; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; ZACHAR Z, 1987, MOL CELL BIOL, V7, P2498, DOI 10.1128/MCB.7.7.2498; ZACHAR ZZ, 1987, EMBO J, V6, P4105, DOI 10.1002/j.1460-2075.1987.tb02756.x	29	201	204	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					335	342		10.1016/0092-8674(91)90185-2	http://dx.doi.org/10.1016/0092-8674(91)90185-2			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1655279				2022-12-01	WOS:A1991GL47000013
J	MARICQ, AV; PETERSON, AS; BRAKE, AJ; MYERS, RM; JULIUS, D				MARICQ, AV; PETERSON, AS; BRAKE, AJ; MYERS, RM; JULIUS, D			PRIMARY STRUCTURE AND FUNCTIONAL EXPRESSION OF THE 5HT3 RECEPTOR, A SEROTONIN-GATED ION CHANNEL	SCIENCE			English	Article							5-HT3 RECOGNITION SITES; NEURO-BLASTOMA CELLS; NICOTINIC ACETYLCHOLINE-RECEPTOR; CAPSAICIN-SENSITIVE FIBERS; NEUROBLASTOMA-GLIOMA CELLS; H-3 QUIPAZINE BINDING; RAT-BRAIN MEMBRANES; RADIOLIGAND BINDING; GLYCINE RECEPTOR; GABAA RECEPTOR	The neurotransmitter serotonin (5HT) activates a variety of second messenger signaling systems and through them indirectly regulates the function of ion channels. Serotonin also activates ion channels directly, suggesting that it may also mediate rapid, excitatory responses. A complementary DNA clone containing the coding sequence of one of these rapidly responding channels, a 5HT3 subtype of the serotonin receptor, has been isolated by screening a neuroblastoma expression library for functional expression of serotonin-gated currents in Xenopus oocytes. The predicted protein product has many of the features shared by other members of the ligand-gated ion channel family. The pharmacological and electrophysiological characteristics of the cloned receptor are largely consistent with the properties of native 5HT3 receptors. Messenger RNA encoding this receptor is found in the brain, spinal cord, and heart. This receptor defines a new class of excitatory ligand-gated channels.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIGMS NIH HHS [GM44298] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044298] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BARNARD EA, 1987, TRENDS NEUROSCI, V10, P502, DOI 10.1016/0166-2236(87)90130-5; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BLAIR LAC, 1988, SCIENCE, V242, P577, DOI 10.1126/science.2845583; BRADLEY PB, 1986, NEUROPHARMACOLOGY, V25, P563, DOI 10.1016/0028-3908(86)90207-8; BRANCHEK T, 1984, BRAIN RES, V324, P107, DOI 10.1016/0006-8993(84)90627-9; BUNCE K, 1991, TRENDS PHARMACOL SCI, V12, P46, DOI 10.1016/0165-6147(91)90493-C; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHANGEUX JP, 1990, TRENDS PHARM SCI; CHARNET P, 1990, NEURON, V4, P87, DOI 10.1016/0896-6273(90)90445-L; COSTALL B, 1988, REV NEUROSCI, V2, P41; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; DANI JA, 1989, TRENDS NEUROSCI, V12, P125, DOI 10.1016/0166-2236(89)90049-0; DERKACH V, 1989, NATURE, V339, P706, DOI 10.1038/339706a0; FRAZER A, 1990, ANNU REV PHARMACOL, V30, P307; GADDUM JH, 1957, BRIT J PHARM CHEMOTH, V12, P323, DOI 10.1111/j.1476-5381.1957.tb00142.x; GORDON JC, 1989, J PHARMACOL EXP THER, V251, P962; GRENNINGLOH G, 1990, NEURON, V4, P963, DOI 10.1016/0896-6273(90)90149-A; GRENNINGLOH G, 1987, NATURE, V330, P25, DOI 10.1038/330025b0; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; HAMON M, 1989, EUR J PHARMACOL, V164, P315, DOI 10.1016/0014-2999(89)90472-X; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOYER D, 1987, EUR J PHARMACOL, V143, P291, DOI 10.1016/0014-2999(87)90547-4; HOYER D, 1988, MOL PHARMACOL, V33, P303; HOYER D, 1989, N-S ARCH PHARMACOL, V340, P396, DOI 10.1007/BF00167040; IMOTO K, 1986, NATURE, V324, P670, DOI 10.1038/324670a0; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; JULIUS D, 1991, ANNU REV NEUROSCI, V14, P335, DOI 10.1146/annurev.neuro.14.1.335; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KATZ B, 1957, J PHYSIOL-LONDON, V138, P63, DOI 10.1113/jphysiol.1957.sp005838; KILPATRICK GJ, 1990, EUR J PHARMACOL, V182, P193, DOI 10.1016/0014-2999(90)90513-6; KILPATRICK GJ, 1987, NATURE, V330, P746, DOI 10.1038/330746a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAMBERT JJ, 1989, BRIT J PHARMACOL, V97, P27, DOI 10.1111/j.1476-5381.1989.tb11920.x; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; MCKERNAN RM, 1990, J NEUROCHEM, V54, P924, DOI 10.1111/j.1471-4159.1990.tb02339.x; MCKERNAN RM, 1990, J BIOL CHEM, V265, P13572; MILBURN CM, 1989, J NEUROCHEM, V52, P1787, DOI 10.1111/j.1471-4159.1989.tb07258.x; MINNA JD, 1975, GENETICS, V79, P372; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; MONTAL M, 1990, FASEB J, V4, P2623, DOI 10.1096/fasebj.4.9.1693348; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; NEIJT HC, 1988, NEUROPHARMACOLOGY, V27, P301, DOI 10.1016/0028-3908(88)90048-2; NEIJT HC, 1989, J PHYSIOL-LONDON, V411, P257, DOI 10.1113/jphysiol.1989.sp017572; NEVINS JR, 1983, ANNU REV BIOCHEM, V52, P441, DOI 10.1146/annurev.bi.52.070183.002301; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; NUMA S, 1989, HARVEY LECT, V83, P121; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; PEROUTKA SJ, 1988, ANNU REV NEUROSCI, V11, P45, DOI 10.1146/annurev.ne.11.030188.000401; PETERS JA, 1988, EUR J PHARMACOL, V151, P491, DOI 10.1016/0014-2999(88)90550-X; RAPPORT MM, 1948, J BIOL CHEM, V176, P1243; RICHARDSON BP, 1986, TRENDS NEUROSCI, V9, P424, DOI 10.1016/0166-2236(86)90137-2; RICHARDSON BP, 1985, NATURE, V316, P126, DOI 10.1038/316126a0; Richardson BP, 1988, NEURONAL SEROTONIN, P465; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIEDEN V, 1989, EMBO J, V8, P695, DOI 10.1002/j.1460-2075.1989.tb03428.x; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SHAO XM, 1991, J NEUROPHYSIOL, V65, P630, DOI 10.1152/jn.1991.65.3.630; TUTTON PJM, 1987, ANTICANCER RES, V7, P1; YAKEL JL, 1988, NEURON, V1, P615, DOI 10.1016/0896-6273(88)90111-0; YANG J, 1990, J GEN PHYSIOL, V96, P1177, DOI 10.1085/jgp.96.6.1177	62	891	917	1	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 18	1991	254	5030					432	437		10.1126/science.1718042	http://dx.doi.org/10.1126/science.1718042			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK729	1718042				2022-12-01	WOS:A1991GK72900050
J	OELLER, PW; WONG, LM; TAYLOR, LP; PIKE, DA; THEOLOGIS, A				OELLER, PW; WONG, LM; TAYLOR, LP; PIKE, DA; THEOLOGIS, A			REVERSIBLE INHIBITION OF TOMATO FRUIT SENESCENCE BY ANTISENSE RNA	SCIENCE			English	Article							ETHYLENE BIOSYNTHESIS; GENE-EXPRESSION; 1-AMINOCYCLOPROPANE-1-CARBOXYLATE SYNTHASE; POLYGALACTURONASE; PLANTS	Ethylene controls fruit ripening. Expression of antisense RNA to the rate-limiting enzyme in the biosynthetic pathway of ethylene, 1-aminocyclopropane-1-carboxylate synthase, inhibits fruit ripening in tomato plants. Administration of exogenous ethylene or propylene reverses the inhibitory effect. This result demonstrates that ethylene is the trigger and not the by-product of ripening and raises the prospect that the life-span of plant tissues can be extended, thereby preventing spoilage.	UNIV CALIF BERKELEY,USDA,CTR PLANT GENE EXPRESS,ALBANY,CA 94710	United States Department of Agriculture (USDA); University of California System; University of California Berkeley					NIGMS NIH HHS [GM-35447] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035447] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT AB, 1989, BIOTECHNOLOGY FOOD Q, P167; BERG JM, 1989, CELL, V57, P1065, DOI 10.1016/0092-8674(89)90042-1; BIALE JACOB B., 1960, ADVANCES IN FOOD RES, V10, P293; BIALE JB, 1964, SCIENCE, V146, P880, DOI 10.1126/science.146.3646.880; BIALE JB, 1981, RECENT ADV BIOCH FRU, P1, DOI DOI 10.1111/J.1365-313X.2007.03170.X; BURG SP, 1965, SCIENCE, V148, P1190, DOI 10.1126/science.148.3674.1190; BURG SP, 1962, PLANT PHYSIOL, V37, P179, DOI 10.1104/pp.37.2.179; BURG SP, 1967, PLANT PHYSIOL, V42, P144, DOI 10.1104/pp.42.1.144; CHRISTOFFERSEN RE, 1982, PLANTA, V155, P52, DOI 10.1007/BF00402931; DELLAPENNA D, 1986, P NATL ACAD SCI USA, V83, P6420, DOI 10.1073/pnas.83.17.6420; HAMILTON AJ, 1990, NATURE, V346, P284, DOI 10.1038/346284a0; HOLLIDAY R, 1988, PERSPECT BIOL MED, V32, P109; KENDE H, 1981, PLANTA, V151, P476, DOI 10.1007/BF00386542; KENDE H, 1989, PLANT PHYSIOL, V91, P1, DOI 10.1104/pp.91.1.1; KIDD F, 1945, PLANT PHYSIOL, V20, P467, DOI 10.1104/pp.20.4.467; LATIES GG, 1987, MOL BIOL PLANT GROWT, V44, P107; LINCOLN JE, 1987, P NATL ACAD SCI USA, V84, P2793, DOI 10.1073/pnas.84.9.2793; LYONS JM, 1964, AM SOC HORTIC SCI J, V84, P491; MCMURCHIE EJ, 1972, NATURE, V237, P235, DOI 10.1038/237235a0; OW DW, 1987, P NATL ACAD SCI USA, V84, P4870, DOI 10.1073/pnas.84.14.4870; ROTTMAN WH, IN PRESS J MOL BIOL; Sambrook J., 1989, MOL CLONING; SMITH CJS, 1988, NATURE, V334, P724, DOI 10.1038/334724a0; VARNER JE, 1961, ANNU REV PLANT PHYS, V12, P245, DOI 10.1146/annurev.pp.12.060161.001333; YANG SF, 1984, ANNU REV PLANT PHYS, V35, P155, DOI 10.1146/annurev.pp.35.060184.001103; YOSHII H, 1982, PLANT CELL PHYSIOL, V23, P639	26	573	694	3	115	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1991	254	5030					437	439		10.1126/science.1925603	http://dx.doi.org/10.1126/science.1925603			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK729	1925603				2022-12-01	WOS:A1991GK72900051
J	OHTA, Y; STOSSEL, TP; HARTWIG, JH				OHTA, Y; STOSSEL, TP; HARTWIG, JH			LIGAND-SENSITIVE BINDING OF ACTIN-BINDING PROTEIN TO IMMUNOGLOBULIN-G FC RECEPTOR-I (FC-GAMMA-RI)	CELL			English	Article							HUMAN MONONUCLEAR PHAGOCYTES; PERIPHERAL-BLOOD MONOCYTES; IMMUNE INTERFERON; MONOCLONAL-ANTIBODIES; TRANSIENT ACTIVATION; HUMAN-PLATELETS; CYTO-TOXICITY; CROSS-LINKING; NADPH OXIDASE; CELL-LINE	The high affinity receptor that binds the Fc domain of immunoglobulin G (IgG) subclasses 1 and 3 (Fc-gamma-RI) mediates important immune defense functions by inducing cell surface changes on human leukocytes. In this article, we document direct high affinity binding of Fc-gamma-RI to the actin filament cross-linking protein, actin-binding protein (ABP). In the absence of IgG, all Fc-gamma-RI molecules in undifferentiated cells of myeloid line U937 bound to ABP over a 9-fold range of Fc-gamma-RI expression induced by human IFN-gamma. Binding of IgG to U937 cells constitutively expressing Fc-gamma-RI or to COS cells genetically transfected to express Fc-gamma-RI rapidly decreased the avidity of Fc-gamma-RI for ABP. This finding suggests the existence of a pathway communicating a signal between a functional IgG receptor and intracellular components involved in the effector responses to Fc-gamma-RI-ligand interaction.	HARVARD UNIV,SCH MED,DEPT ANAT & CELLULAR BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	OHTA, Y (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV EXPTL MED,BOSTON,MA 02115, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019429, R37HL019429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI028465] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-19429, HL-45154] Funding Source: Medline; NIAID NIH HHS [AI-28465] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKERLEY WL, 1991, BLOOD, V77, P607; AKIYAMA Y, 1984, CANCER RES, V44, P5127; ALLEN JM, 1989, SCIENCE, V243, P378, DOI 10.1126/science.2911749; ANDERSON CL, 1986, J BIOL CHEM, V261, P2856; ANDERSON CL, 1982, J EXP MED, V156, P1794, DOI 10.1084/jem.156.6.1794; ANDREWS RK, 1991, J BIOL CHEM, V266, P7144; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPONNIER C, 1986, J CELL BIOL, V103, P1473, DOI 10.1083/jcb.103.4.1473; DEBETS JMH, 1990, J IMMUNOL, V144, P1304; EZZELL RM, 1988, J BIOL CHEM, V263, P13303; FOX JEB, 1985, J BIOL CHEM, V260, P1970; GOMEZ F, 1989, BLOOD, V74, P1058; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; GRAZIANO RF, 1987, J IMMUNOL, V138, P945; GUYRE PM, 1989, J IMMUNOL, V143, P1650; GUYRE PM, 1990, J CLIN INVEST, V86, P1892, DOI 10.1172/JCI114921; GUYRE PM, 1983, J CLIN INVEST, V72, P393, DOI 10.1172/JCI110980; HARTWIG JH, 1986, J CELL BIOL, V103, P1007, DOI 10.1083/jcb.103.3.1007; HARTWIG JH, 1981, J MOL BIOL, V145, P563, DOI 10.1016/0022-2836(81)90545-3; HARTWIG JH, 1991, J CELL BIOL, V112, P407, DOI 10.1083/jcb.112.3.407; JONES DH, 1985, J CELL BIOL, V100, P558, DOI 10.1083/jcb.100.2.558; KINET JP, 1989, CELL, V57, P351, DOI 10.1016/0092-8674(89)90910-0; KURLANDER RJ, 1982, J CLIN INVEST, V69, P1, DOI 10.1172/JCI110419; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P13857; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUBECK MD, 1985, J IMMUNOL, V135, P1299; ODIN JA, 1990, CELLULAR MOL MECHANI; OKITA JR, 1985, J CELL BIOL, V100, P317, DOI 10.1083/jcb.100.1.317; PERUSSIA B, 1983, J EXP MED, V158, P1092, DOI 10.1084/jem.158.4.1092; PFEFFERKORN LC, 1989, J BIOL CHEM, V264, P14112; PFEFFERKORN LC, 1989, J IMMUNOL, V143, P2640; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; STOSSEL TP, 1976, J CELL BIOL, V68, P602, DOI 10.1083/jcb.68.3.602; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; WEITZ JI, 1987, J EXP MED, V166, P1836, DOI 10.1084/jem.166.6.1836; WRIGHT SD, 1984, NATURE, V309, P359, DOI 10.1038/309359a0	38	92	93	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					275	282		10.1016/0092-8674(91)90179-3	http://dx.doi.org/10.1016/0092-8674(91)90179-3			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1833070				2022-12-01	WOS:A1991GL47000007
J	ORTEGABARRIA, E; PEREIRA, MEA				ORTEGABARRIA, E; PEREIRA, MEA			A NOVEL TRYPANOSOMA-CRUZI HEPARIN-BINDING PROTEIN PROMOTES FIBROBLAST ADHESION AND PENETRATION OF ENGINEERED BACTERIA AND TRYPANOSOMES INTO MAMMALIAN-CELLS	CELL			English	Article							ENHANCE INFECTION; HIGH-DENSITY; BIOLOGY; INVITRO; NEURAMINIDASE; INHIBITION; INVASION; PEPTIDES	T. cruzi invades mammalian cells in various organs after migrating through the ECM. These activities appear to be mediated by a unique 60 kd protein exposed on the T. cruzi surface, which promotes selective adhesion of trypomastigotes to three ECM components: heparin, heparan sulfate, and collagen. The affinity-purified protein binds to host fibroblasts in a saturable and glycosaminoglycan- and collagen-inhibitable manner. When adsorbed to plastic, it promotes adhesion and spreading of fibroblasts, as does the recombinant protein expressed in E. coli. The endogenous protein, and reactive ECM proteins, are very effective in preventing T. cruzi invasion of culture cells. The recombinant protein localizes on the E. coli surface and induces the bacteria that express it to adhere to and penetrate nonphagocytic Vero cells in a proteoglycan-and collagen-inhibitable manner. Therefore, the protein, named penetrin, could play a critical role in T. cruzi binding to the ECM and to cells, and in host cell invasion.			ORTEGABARRIA, E (corresponding author), TUFTS UNIV,DEPT MED,DIV GEOG MED & INFECT DIS,750 WASHINGTON ST,BOSTON,MA 02111, USA.				NIAID NIH HHS [AI 18102] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018102] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alberts B, 1989, MOL BIOL CELL, P802; ANDREWS NW, 1990, CELL, V61, P1277, DOI 10.1016/0092-8674(90)90692-8; BRENER Z, 1973, ANNU REV MICROBIOL, V27, P347, DOI 10.1146/annurev.mi.27.100173.002023; COUGHLIN SR, 1988, J BIOL CHEM, V263, P928; DESOUZA W, 1984, INT REV CYTOL, V86, P197, DOI 10.1016/S0074-7696(08)60180-1; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; GEHLSEN KR, 1988, J CELL BIOL, V106, P925, DOI 10.1083/jcb.106.3.925; HOWARD RJ, 1982, J PROTOZOOL, V29, P114, DOI 10.1111/j.1550-7408.1982.tb02891.x; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; ISBERG RR, 1985, NATURE, V317, P262, DOI 10.1038/317262a0; LEWIN B, 1990, GENES, V4, P451; LOBB RR, 1986, ANAL BIOCHEM, V154, P1, DOI 10.1016/0003-2697(86)90487-2; LU GY, 1991, MOL BIOCHEM PARASIT, V44, P109; MARCH SC, 1974, ANAL BIOCHEM, V60, P149, DOI 10.1016/0003-2697(74)90139-0; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MOULDER JW, 1985, MICROBIOL REV, V49, P298, DOI 10.1128/MMBR.49.3.298-337.1985; NADER HB, 1987, P NATL ACAD SCI USA, V84, P3565, DOI 10.1073/pnas.84.11.3565; OUAISSI MA, 1986, SCIENCE, V234, P603, DOI 10.1126/science.3094145; Pereira M. E. A., 1990, Modern parasite biology: cellular, immunological, and molecular aspects., P64; PEREIRA MEA, 1991, J EXP MED, V174, P179, DOI 10.1084/jem.174.1.179; PRIOLI RP, 1987, P NATL ACAD SCI USA, V84, P3097, DOI 10.1073/pnas.84.10.3097; PRIOLI RP, 1990, MOL BIOCHEM PARASIT, V38, P191, DOI 10.1016/0166-6851(90)90022-E; PRIOLI RP, 1988, MOL BIOCHEM PARASIT, V28, P257, DOI 10.1016/0166-6851(88)90010-2; PRIOLI RP, 1990, J IMMUNOL, V144, P4384; PUGSLEY AP, 1987, PROTEIN TRANSFER ORG, P607; ROBERTS DD, 1989, J BIOL CHEM, V264, P9289; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCHENKMAN S, 1991, CELL, V65, P1117, DOI 10.1016/0092-8674(91)90008-M; SCHENKMAN S, 1988, CELL, V55, P157, DOI 10.1016/0092-8674(88)90018-9; SCHENKMAN S, 1991, EXP PARASITOL, V72, P76, DOI 10.1016/0014-4894(91)90123-E; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; STAATZ WD, 1991, J BIOL CHEM, V266, P7366; VELGE P, 1988, PARASITOLOGY, V97, P255, DOI 10.1017/S0031182000058467; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; 1990, WEEKLY EPIDEMIOL RES, V65, P257	35	191	196	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					411	421		10.1016/0092-8674(91)90192-2	http://dx.doi.org/10.1016/0092-8674(91)90192-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1655283				2022-12-01	WOS:A1991GL47000020
J	OSMANI, AH; MCGUIRE, SL; OSMANI, SA				OSMANI, AH; MCGUIRE, SL; OSMANI, SA			PARALLEL ACTIVATION OF THE NIMA AND P34CDC2 CELL CYCLE-REGULATED PROTEIN-KINASES IS REQUIRED TO INITIATE MITOSIS IN ASPERGILLUS-NIDULANS	CELL			English	Article							MATURATION-PROMOTING FACTOR; GERMINAL VESICLE BREAKDOWN; XENOPUS CDC2 PROTEIN; HISTONE H-1 KINASE; CONTROL GENE CDC2+; FISSION YEAST; ASPERGILLUS-NIDULANS; M-PHASE; TYROSINE PHOSPHORYLATION; MEIOTIC MATURATION	We show that in Aspergillus nidulans, p34cdc2 tyrosine dephosphorylation accompanies activation of p34cdc2 as an H1 kinase at mitosis. However, the nimA5 mutation arrests cells in G2 with p34cdc2 tyrosine dephosphorylated and fully active as an H1 kinase. Activation of NIMA is therefore not required for p34Cdc2 activation. Furthermore, mutation of nimT, which encodes a protein with 50% similarity to fission yeast cdc25, causes a G2 arrest and prevents tyrosine dephosphorylation of p34cdc2 but does not prevent full activation of the NIMA protein kinase. Mitotic activation of p34cdc2 by tyrosine dephosphorylation is therefore not required for activation of NIMA. These data suggest that activation of either the p34cdc2 protein kinase or the NIMA protein kinase alone is not sufficient to initiate mitosis. Parallel activation of both cell cycle-regulated protein kinases is required to trigger mitosis.			OSMANI, AH (corresponding author), BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA.		Osmani, Stephen A./AAS-3904-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042564] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42564] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFA CE, 1990, NATURE, V347, P680, DOI 10.1038/347680a0; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BERGEN LG, 1984, J BACTERIOL, V159, P114, DOI 10.1128/JB.159.1.114-119.1984; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; ENGLE DB, 1988, CELL MOTIL CYTOSKEL, V10, P432, DOI 10.1002/cm.970100310; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; KISHIMOTO T, 1976, NATURE, V260, P321, DOI 10.1038/260321a0; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MORRIS NR, 1975, GENET RES, V26, P237, DOI 10.1017/S0016672300016049; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OAKLEY BR, 1983, J CELL BIOL, V96, P1155, DOI 10.1083/jcb.96.4.1155; OSMANI AH, 1990, J CELL BIOL, V111, P543, DOI 10.1083/jcb.111.2.543; OSMANI AH, 1991, EMBO J, V10, P2669, DOI 10.1002/j.1460-2075.1991.tb07810.x; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; OSMANI SA, 1987, J CELL BIOL, V104, P1495, DOI 10.1083/jcb.104.6.1495; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SUNKARA PS, 1979, P NATL ACAD SCI USA, V76, P2799, DOI 10.1073/pnas.76.6.2799; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TACHIBANA K, 1987, J CELL SCI, V88, P273; VANDRE DD, 1984, P NATL ACAD SCI-BIOL, V81, P4439, DOI 10.1073/pnas.81.14.4439	44	209	225	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					283	291		10.1016/0092-8674(91)90180-7	http://dx.doi.org/10.1016/0092-8674(91)90180-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1913824				2022-12-01	WOS:A1991GL47000008
J	PELLETIER, J; BRUENING, W; KASHTAN, CE; MAUER, SM; MANIVEL, JC; STRIEGEL, JE; HOUGHTON, DC; JUNIEN, C; HABIB, R; FOUSER, L; FINE, RN; SILVERMAN, BL; HABER, DA; HOUSMAN, D				PELLETIER, J; BRUENING, W; KASHTAN, CE; MAUER, SM; MANIVEL, JC; STRIEGEL, JE; HOUGHTON, DC; JUNIEN, C; HABIB, R; FOUSER, L; FINE, RN; SILVERMAN, BL; HABER, DA; HOUSMAN, D			GERMLINE MUTATIONS IN THE WILMS-TUMOR SUPPRESSOR GENE ARE ASSOCIATED WITH ABNORMAL UROGENITAL DEVELOPMENT IN DENYS-DRASH SYNDROME	CELL			English	Article							ZINC FINGER PROTEIN; P53 GENE; CHROMOSOME-11; DELETION; CANCER; LOCUS; DNA; PSEUDOHERMAPHRODITISM; BINDING; SRY	Denys-Drash syndrome is a rare human condition in which severe urogenital aberrations result in renal failure, pseudohermaphroditism, and Wilms' tumor (nephroblastoma). To investigate its possible role, we have analyzed the coding exons of the Wilms' tumor suppressor gene (WT1) for germline mutations. In ten independent cases of Denys-Drash syndrome, point mutations in the zinc finger domains of one WT1 gene copy were found. Nine of these mutations are found within exon 9 (zinc finger III); the remaining mutation is in exon 8 (zinc finger II). These mutations directly affect DNA sequence recognition. In two families analyzed, the mutations were shown to arise de novo. Wilms' tumors from three individuals and one juvenile granulosa cell tumor demonstrate reduction to homozygosity for the mutated WT1 allele. Our results provide evidence of a direct role for WT1 in Denys-Drash syndrome and thus urogenital system development.	MCGILL UNIV,MCGILL CANC CTR,MONTREAL H3G 1Y6,QUEBEC,CANADA; UNIV MINNESOTA,SCH MED,DEPT PEDIAT NEPHROL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455; OREGON HLTH SCI UNIV,DEPT PEDIAT,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT PATHOL,PORTLAND,OR 97201; HOP NECKER ENFANTS MALAD,INSERM,U73,F-75730 PARIS 15,FRANCE; HOP NECKER ENFANTS MALAD,INSERM,U192,F-75730 PARIS 15,FRANCE; UNIV WASHINGTON,SCH MED,DEPT PEDIAT,SEATTLE,WA 98195; SUNY STONY BROOK,DEPT PEDIAT,STONY BROOK,NY 11794; CHILDRENS MEM HOSP,DIV PEDIAT ENDOCRINOL,CHICAGO,IL 60614; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CTR CANC,BOSTON,MA 02114	McGill University; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Oregon Health & Science University; Oregon Health & Science University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Washington; University of Washington Seattle; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; Ann & Robert H. Lurie Children's Hospital of Chicago; Harvard University; Harvard Medical School; Massachusetts General Hospital	PELLETIER, J (corresponding author), MIT,CTR CANC RES,CAMBRIDGE,MA 02139, USA.				NATIONAL CANCER INSTITUTE [K08CA001356] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000299] Funding Source: NIH RePORTER; NCI NIH HHS [1K08CA 01356] Funding Source: Medline; NHGRI NIH HHS [HG00299] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BECKWITH JB, 1989, PEDIATR PATHOL, V10, P1; BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; BOND JV, 1975, LANCET, V2, P482; BRESLOW N, 1988, CANCER RES, V48, P1653; BRESLOW NE, 1982, JNCI-J NATL CANCER I, V68, P429; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; DAO DD, 1987, AM J HUM GENET, V41, P202; DAVIS LM, 1991, GENOMICS, V10, P588, DOI 10.1016/0888-7543(91)90440-P; DENYS P, 1967, ARCH FR PEDIATR, V24, P729; DRASH A, 1970, J PEDIATR-US, V76, P585, DOI 10.1016/S0022-3476(70)80409-7; FRASIER SD, 1964, J PEDIATR-US, V64, P740, DOI 10.1016/S0022-3476(64)80622-3; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GLADE PR, 1976, PROG MED GENET, V1, P1; GREEN MR, 1983, CELL, V32, P681, DOI 10.1016/0092-8674(83)90054-5; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, IN PRESS P NATL ACAD; HABIB R, 1985, CLIN NEPHROL, V24, P269; HUFF V, 1991, AM J HUM GENET, V48, P997; JADRESIC L, 1991, HUM GENET, V86, P497; JAGER RJ, 1990, NATURE, V348, P452, DOI 10.1038/348452a0; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; LANGRIDGE J, 1980, ANAL BIOCHEM, V103, P264, DOI 10.1016/0003-2697(80)90266-3; LEWIS W H, 1988, Genomics, V3, P25, DOI 10.1016/0888-7543(88)90154-1; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MATSUNAGA E, 1981, HUM GENET, V57, P231; MILLER RW, 1964, NEW ENGL J MED, V270, P922, DOI 10.1056/NEJM196404302701802; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, IN PRESS MOL BASIS H; PELLETIER J, 1991, IN PRESS NATURE; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; RICCARDI VM, 1978, PEDIATRICS, V61, P604; ROYERPOKORA B, 1991, GENE CHROMOSOME CANC, V3, P89, DOI 10.1002/gcc.2870030203; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHROEDER WT, 1987, AM J HUM GENET, V40, P413; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TON CCT, 1991, GENOMICS, V10, P293, DOI 10.1016/0888-7543(91)90516-H; VORTKAMP A, 1991, NATURE, V352, P539, DOI 10.1038/352539a0; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; YOUNG JL, 1975, J PEDIATR-US, V86, P254, DOI 10.1016/S0022-3476(75)80484-7; ZUNIN C, 1964, ANN PAEDIATR-BASEL, V203, P29	50	783	803	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					437	447		10.1016/0092-8674(91)90194-4	http://dx.doi.org/10.1016/0092-8674(91)90194-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1655284				2022-12-01	WOS:A1991GL47000022
J	PORAT, R; CLARK, BD; WOLFF, SM; DINARELLO, CA				PORAT, R; CLARK, BD; WOLFF, SM; DINARELLO, CA			ENHANCEMENT OF GROWTH OF VIRULENT-STRAINS OF ESCHERICHIA-COLI BY INTERLEUKIN-1	SCIENCE			English	Article							RECEPTOR ANTAGONIST; EXPRESSION; UROMODULIN; INHIBITOR; CLONING; PROTEIN; SHOCK; SERUM; BINDS; IL-1	Interleukin-1 (IL-1) is a polypeptide cytokine that mediates many physiological responses to infection and inflammation and is a growth factor for certain mammalian cells. Virulent and avirulent clinical isolates of Escherichia coli were grown in culture media in the presence of human IL-1. IL-1-beta, but not tumor necrosis factor or IL-4, enhanced the growth of virulent, but not avirulent, E. coli. This enhancement was blocked by the IL-1 receptor antagonist (IL-lra). Radiolabeled IL-1 bound to virulent but not avirulent E. coli in a specific and saturable fashion; IL-lra inhibited this binding. Thus, human IL-1 may recognize a functional IL-1-like receptor structure on virulent E. coli and may be a virulence factor for bacterial pathogenicity.	TUFTS UNIV,NEW ENGLAND MED CTR HOSP,DEPT MED,DIV GEOG MED & INFECT DIS,BOSTON,MA 02111	Tufts Medical Center; Tufts University					NIAID NIH HHS [AI 15614] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015614, R56AI015614, R37AI015614] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AREND WP, 1985, J IMMUNOL, V134, P3868; BJORNSON BH, 1988, INFECT IMMUN, V56, P1602, DOI 10.1128/IAI.56.6.1602-1607.1988; BRODY DT, 1989, J IMMUNOL, V143, P1183; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; DINARELLO CA, 1991, BLOOD, V77, P1627; DOWER SK, COMMUNICATION; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; FANSLOW WC, 1990, SCIENCE, V248, P739, DOI 10.1126/science.2139736; MANCILLA J, 1989, CYTOKINE, V1, P95; MCCABE WR, 1978, J INFECT DIS, V138, P33, DOI 10.1093/infdis/138.1.33; MUCHMORE AV, 1987, J IMMUNOL, V138, P2541; MUCHMORE AV, 1986, J BIOL CHEM, V261, P3404; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; OKUSAWA S, 1988, J CLIN INVEST, V81, P1162, DOI 10.1172/JCI113431; PENNICA D, 1987, SCIENCE, V236, P83, DOI 10.1126/science.3453112; PORAT R, 1987, INFECT IMMUN, V55, P320, DOI 10.1128/IAI.55.2.320-328.1987; PORAT R, UNPUB; ROANTREE RJ, 1960, J CLIN INVEST, V39, P72, DOI 10.1172/JCI104029; Savage N, 1989, Cytokine, V1, P23, DOI 10.1016/1043-4666(89)91045-4; SECKINGER P, 1987, J IMMUNOL, V139, P1546; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; Sipe J D, 1988, Adv Exp Med Biol, V243, P193; STROM TB, 1988, INFECT IMMUN, V56, P1593; WAKABAYASHI GO, 1991, FASEB J, V5, P338, DOI 10.1096/fasebj.5.3.1825816	24	159	163	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1991	254	5030					430	432		10.1126/science.1833820	http://dx.doi.org/10.1126/science.1833820			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK729	1833820				2022-12-01	WOS:A1991GK72900049
J	ROMERO, DP; BLACKBURN, EH				ROMERO, DP; BLACKBURN, EH			A CONSERVED SECONDARY STRUCTURE FOR TELOMERASE RNA	CELL			English	Article							TERMINAL TRANSFERASE-ACTIVITY; POLYMERASE-III PROMOTER; RIBONUCLEASE-P RNA; RIBOSOMAL-RNA; U6 SNRNA; RIBONUCLEOPROTEIN ENZYME; TETRAHYMENA; DNA; GENE; TRANSCRIPTION	The RNA moiety of the ribonucleoprotein enzyme telomerase contains the template for telomeric DNA synthesis. We present a secondary structure model for telomerase RNA, derived by a phylogenetic comparative analysis of telomerase RNAs from seven tetrahymenine ciliates. The telomerase RNA genes from Tetrahymena malaccensis, T. pyriformis, T. hyperangularis, T. pigmentosa, T. hegewishii, and Glaucoma chattoni were cloned, sequenced, and compared with the previously cloned RNA gene from T. thermophila and with each other. To define secondary structures of these RNAs, homologous complementary sequences were identified by the occurrence of covariation among putative base pairs. Although their primary sequences have diverged rapidly overall, a strikingly conserved secondary structure was identified for all these telomerase RNAs. Short regions of nucleotide conservation include a block of 22 totally conserved nucleotides that contains the telomeric templating region.			ROMERO, DP (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026259, R37GM026259] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 26259] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON DS, 1985, EMBO J, V4, P2657, DOI 10.1002/j.1460-2075.1985.tb03984.x; ANDREAZZOLI M, 1991, EMBO J, V10, P767, DOI 10.1002/j.1460-2075.1991.tb08008.x; BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; CARBON P, 1987, CELL, V51, P71, DOI 10.1016/0092-8674(87)90011-0; CECH TR, 1986, ANNU REV BIOCHEM, V55, P599, DOI 10.1146/annurev.biochem.55.1.599; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CHALLONER PB, 1986, NUCLEIC ACIDS RES, V14, P6299, DOI 10.1093/nar/14.15.6299; CHASTAIN M, 1991, PROG NUCL ACIDS RES, V41, P131; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; DAGGETT PM, 1989, AM TYPE CULTURE CO S; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; DRAPER DE, 1990, RIBOSOME, P160; FOX GE, 1975, NATURE, V256, P505, DOI 10.1038/256505a0; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GREENWOOD SJ, 1991, J PROTOZOOL, V38, P1, DOI 10.1111/j.1550-7408.1991.tb04783.x; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1991, MOL CELL BIOL, V11, P4572, DOI 10.1128/MCB.11.9.4572; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GUERRIERTAKADA C, 1984, BIOCHEMISTRY-US, V23, P6327, DOI 10.1021/bi00321a006; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; JAMES BD, 1988, CELL, V52, P19, DOI 10.1016/0092-8674(88)90527-2; KATZEN AL, 1981, CELL, V24, P313, DOI 10.1016/0092-8674(81)90321-4; LAMOND AI, 1988, P NATL ACAD SCI USA, V85, P411, DOI 10.1073/pnas.85.2.411; LARSEN N, 1991, NUCLEIC ACIDS RES, V19, P209, DOI 10.1093/nar/19.2.209; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; LONGFELLOW CE, 1990, BIOCHEMISTRY-US, V29, P278, DOI 10.1021/bi00453a038; MADHANI HD, 1990, GENE DEV, V4, P2264, DOI 10.1101/gad.4.12b.2264; MATTAJ IW, 1988, CELL, V55, P435, DOI 10.1016/0092-8674(88)90029-3; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1983, EMBO J, V2, P33, DOI 10.1002/j.1460-2075.1983.tb01376.x; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; NOLLER HF, 1984, ANNU REV BIOCHEM, V53, P119, DOI 10.1146/annurev.bi.53.070184.001003; NOLLER HF, 1990, RIBOSOME, P73; NOLLER HF, 1981, SCIENCE, V212, P403, DOI 10.1126/science.6163215; PACE NR, 1989, GENE, V82, P65, DOI 10.1016/0378-1119(89)90031-0; PREPARATA RM, 1989, J MOL EVOL, V28, P427, DOI 10.1007/BF02603078; ROIHA H, 1989, GENE, V82, P137, DOI 10.1016/0378-1119(89)90038-3; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU; SAMPSON JR, 1990, BIOCHEMISTRY-US, V29, P2523, DOI 10.1021/bi00462a014; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SHIPPENLENTZ D, 1989, MOL CELL BIOL, V9, P2761, DOI 10.1128/MCB.9.6.2761; SILICIANO PG, 1987, CELL, V50, P585, DOI 10.1016/0092-8674(87)90031-6; SOGIN ML, 1986, EMBO J, V5, P3625, DOI 10.1002/j.1460-2075.1986.tb04691.x; STROHMAN RC, 1977, CELL, V10, P265, DOI 10.1016/0092-8674(77)90220-3; TANI T, 1991, NUCLEIC ACIDS RES, V19, P2495, DOI 10.1093/nar/19.9.2495; Tinoco I. Jr., 1990, Nucleic Acids and Molecular Biology, V4, P205; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WAIBEL F, 1990, NUCLEIC ACIDS RES, V18, P3451, DOI 10.1093/nar/18.12.3451; WHITE SA, 1989, BIOCHEMISTRY-US, V28, P1892, DOI 10.1021/bi00430a069; YU GL, 1990, MOL CELL BIOL, V10, P2070, DOI 10.1128/MCB.10.5.2070; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAHLER AM, 1988, NUCLEIC ACIDS RES, V16, P6953, DOI 10.1093/nar/16.14.6953; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	65	216	240	0	14	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 18	1991	67	2					343	353		10.1016/0092-8674(91)90186-3	http://dx.doi.org/10.1016/0092-8674(91)90186-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1840508				2022-12-01	WOS:A1991GL47000014
J	SCHIRO, JA; CHAN, BMC; ROSWIT, WT; KASSNER, PD; PENTLAND, AP; HEMLER, ME; EISEN, AZ; KUPPER, TS				SCHIRO, JA; CHAN, BMC; ROSWIT, WT; KASSNER, PD; PENTLAND, AP; HEMLER, ME; EISEN, AZ; KUPPER, TS			INTEGRIN-ALPHA-2-BETA-1 (VLA-2) MEDIATES REORGANIZATION AND CONTRACTION OF COLLAGEN MATRICES BY HUMAN-CELLS	CELL			English	Article							FIBRONECTIN RECEPTOR EXPRESSION; FIBROBLAST TRACTION; SURFACE RECEPTORS; INTEGRIN; ADHESION; BINDING; MORPHOGENESIS; GLYCOPROTEIN; LATTICES; HOMOLOGY	The capacity of cells to organize and contract collagen fibrils is fundamental to processes as diverse as embryogenesis and wound healing. We analyzed different beta-1 integrins on diploid fibroblasts for their role in modifying the tertiary structure of collagen matrices. Using monoclonal antibodies that block the interaction of integrins with their ligands, evidence was obtained that alpha-2-beta-1 integrin is required for the contraction of a type I collagen matrix. Further supporting the role of alpha-2-beta-1, cell lines expressing minimal levels of this integrin uniformly failed to contract collagen matrices. In addition, transfection of a full-length alpha-2 cDNA into one such cell line led to enhanced cell surface expression of alpha-2-beta-1 and conferred the de novo capacity to contract collagen matrices.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115	Washington University (WUSTL); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	SCHIRO, JA (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MED,DIV DERMATOL,ST LOUIS,MO 63110, USA.		Kupper, Thomas/O-4962-2019	Kassner, Paul/0000-0002-1471-1191	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025082, R29AI025082, R37AI025082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040124, R01AR012129, R37AR012129] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 25082] Funding Source: Medline; NIAMS NIH HHS [AR 12129, AR 40124] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAUVOIS B, 1987, CELL BIOCHEM FUNCT, V5, P281, DOI 10.1002/cbf.290050407; BELL E, 1979, P NATL ACAD SCI USA, V76, P1274, DOI 10.1073/pnas.76.3.1274; BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143; BURN P, 1988, P NATL ACAD SCI USA, V85, P497, DOI 10.1073/pnas.85.2.497; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CLARK RAF, 1990, J INVEST DERMATOL, V94, pS128, DOI 10.1111/1523-1747.ep12876104; DEJANA E, 1988, J CELL BIOL, V107, P1215, DOI 10.1083/jcb.107.3.1215; EISEN AZ, 1987, J INVEST DERMATOL, V88, P741, DOI 10.1111/1523-1747.ep12470412; GRINNELL F, 1984, J CELL SCI, V66, P51; GULLBERG D, 1989, J BIOL CHEM, V264, P12686; GULLBERG D, 1990, EXP CELL RES, V186, P264, DOI 10.1016/0014-4827(90)90305-T; GULLBERG D, 1990, EXP CELL RES, V190, P254, DOI 10.1016/0014-4827(90)90194-F; Harlow E, 1988, ANTIBODIES LABORATOR, P359; HARRIS AK, 1981, NATURE, V290, P249, DOI 10.1038/290249a0; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; MOLLENHAUER J, 1983, EMBO J, V2, P45, DOI 10.1002/j.1460-2075.1983.tb01378.x; MUELLER SC, 1989, J CELL BIOL, V109, P3455, DOI 10.1083/jcb.109.6.3455; NAIDET C, 1987, NATURE, V325, P348, DOI 10.1038/325348a0; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; STEINBERG BM, 1980, J CELL BIOL, V87, P304, DOI 10.1083/jcb.87.1.304; STOPAK D, 1982, DEV BIOL, V90, P383, DOI 10.1016/0012-1606(82)90388-8; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; WELCH MP, 1990, J CELL BIOL, V110, P133, DOI 10.1083/jcb.110.1.133; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877	30	356	362	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					403	410		10.1016/0092-8674(91)90191-Z	http://dx.doi.org/10.1016/0092-8674(91)90191-Z			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1913826				2022-12-01	WOS:A1991GL47000019
J	SCHOENLEIN, RW; PETEANU, LA; MATHIES, RA; SHANK, CV				SCHOENLEIN, RW; PETEANU, LA; MATHIES, RA; SHANK, CV			THE 1ST STEP IN VISION - FEMTOSECOND ISOMERIZATION OF RHODOPSIN	SCIENCE			English	Article							PICOSECOND LASER PHOTOLYSIS; CIS-TRANS ISOMERIZATION; ABSORPTION-SPECTRA; ROOM-TEMPERATURE; BATHORHODOPSIN; DYNAMICS; PHOTORHODOPSIN	The kinetics of the primary event in vision have been resolved with the use of femtosecond optical measurement techniques. The 11-cis retinal prosthetic group of rhodopsin is excited with a 35-femtosecond pump pulse at 500 nanometers, and the transient changes in absorption are measured between 450 and 580 nanometers with a 10-femtosecond probe pulse. Within 200 femtoseconds, an increased absorption is observed between 540 and 580 nanometers, indicating the formation of photoproduct on this time scale. These measurements demonstrate that the first step in vision, the 11-cis --> 11-trans torsional isomerization of the rhodopsin chromophore, is essentially complete in only 200 femtoseconds.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720	University of California System; University of California Berkeley	SCHOENLEIN, RW (corresponding author), UNIV CALIF BERKELEY LAWRENCE BERKELEY LAB,BERKELEY,CA 94720, USA.		Schoenlein, Robert W/D-1301-2014; Peteanu, Linda/O-5581-2017	Schoenlein, Robert W/0000-0002-6066-7566; Peteanu, Linda/0000-0003-0075-6521	NEI NIH HHS [T32EY07043, EY 02051] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY002051, T32EY007043, R37EY002051] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BIRGE RR, 1980, J AM CHEM SOC, V102, P2195, DOI 10.1021/ja00527a008; BIRGE RR, 1990, ANNU REV PHYS CHEM, V41, P683, DOI 10.1146/annurev.pc.41.100190.003343; BIRGE RW, COMMUNICATION; BUSCH GE, 1972, P NATL ACAD SCI USA, V69, P2802, DOI 10.1073/pnas.69.10.2802; DOIG SJ, 1991, J PHYS CHEM-US, V95, P6372, DOI 10.1021/j100169a054; DOUKAS AG, 1984, P NATL ACAD SCI-BIOL, V81, P4790, DOI 10.1073/pnas.81.15.4790; EYRING G, 1980, BIOCHEMISTRY-US, V19, P2410, DOI 10.1021/bi00552a020; FHAYWARD G, 1981, SCIENCE, V211, P942; FORK RL, 1987, OPT LETT, V12, P483, DOI 10.1364/OL.12.000483; FRAGNITO HL, 1989, CHEM PHYS LETT, V160, P101, DOI 10.1016/0009-2614(89)87564-5; HURLEY J, 1977, PURE APPL CHEM, V49, P341; KANDORI H, 1989, BIOPHYS J, V56, P453, DOI 10.1016/S0006-3495(89)82692-X; LOPPNOW GR, 1988, BIOPHYS J, V54, P35, DOI 10.1016/S0006-3495(88)82928-X; MATHIES RA, 1988, SCIENCE, V240, P777, DOI 10.1126/science.3363359; MONGER TG, 1979, BIOPHYS J, V27, P105, DOI 10.1016/S0006-3495(79)85205-4; PALINGS I, 1987, BIOCHEMISTRY-US, V26, P254; POLLARD WT, 1990, CHEM PHYS LETT, V168, P239, DOI 10.1016/0009-2614(90)85603-A; POLLARD WT, 1990, J CHEM PHYS, V92, P4012, DOI 10.1063/1.457815; SCHOENLEIN RW, 1991, APPL PHYS LETT, V58, P801, DOI 10.1063/1.104494; SHANK CV, 1986, SCIENCE, V233, P1276, DOI 10.1126/science.233.4770.1276; SHICHIDA Y, 1984, PHOTOBIOCH PHOTOBIOP, V7, P221; SPALINK JD, 1983, P NATL ACAD SCI-BIOL, V80, P1887, DOI 10.1073/pnas.80.7.1887; WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230; WEISS RM, 1979, J AM CHEM SOC, V101, P6131, DOI 10.1021/ja00514a051; YOSHIZAWA T, 1963, NATURE, V197, P1279, DOI 10.1038/1971279a0	25	708	720	2	170	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1991	254	5030					412	415		10.1126/science.1925597	http://dx.doi.org/10.1126/science.1925597			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK729	1925597				2022-12-01	WOS:A1991GK72900043
J	SERAFINI, T; ORCI, L; AMHERDT, M; BRUNNER, M; KAHN, RA; ROTHMAN, JE				SERAFINI, T; ORCI, L; AMHERDT, M; BRUNNER, M; KAHN, RA; ROTHMAN, JE			ADP-RIBOSYLATION FACTOR IS A SUBUNIT OF THE COAT OF GOLGI-DERIVED COP-COATED VESICLES - A NOVEL ROLE FOR A GTP-BINDING PROTEIN	CELL			English	Article							YPT1 GENE-PRODUCT; ADENYLATE-CYCLASE; ENDOPLASMIC-RETICULUM; CHOLERA-TOXIN; REGULATORY COMPONENT; SUCCESSIVE COMPARTMENTS; VESICULAR TRANSPORT; NUCLEOTIDE-BINDING; SECRETORY VESICLES; MOLECULAR-CLONING	ADP-ribosylation factor (ARF) is an abundant and highly conserved low molecular weight GTP-binding protein that was originally identified as a key element required for the action of cholera toxin in mammalian cells, but whose physiological role is unknown. We report that ARF family proteins are highly concentrated in non-clathrin-coated transport vesicles and are coat proteins. About three copies of ARF are present on the outside of coated vesicles per alpha-COP (and thus per coatomer). ARF is highly enriched in coated vesicles as compared with parental Golgi cisternae, as shown both by biochemical and morphological methods, and ARF is removed from transport vesicles through uncoating during transport. Furthermore, ARF binds to Golgi cisternae in a GTP-dependent manner independently of coated vesicle budding. These observations strongly suggest a new role for GTP-binding proteins: ARF proteins may modulate vesicle budding and uncoating through controlled GTP hydrolysis.	PRINCETON UNIV, DEPT MOLEC BIOL, LEWIS THOMAS LABS, PRINCETON, NJ 08544 USA; UNIV GENEVA, INST HISTOL & EMBRYOL, DEPT MORPHOL, CH-1211 GENEVA 4, SWITZERLAND; NCI, DIV CANC TREATMENT, BIOL CHEM LAB, BETHESDA, MD 20892 USA	Princeton University; University of Geneva; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	SERAFINI, T (corresponding author), STANFORD UNIV, BECKMAN CTR, DEPT BIOCHEM, STANFORD, CA 94305 USA.		Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601; Brunner, Michael/0000-0001-9798-3047	NATIONAL CANCER INSTITUTE [R01CA047767] Funding Source: NIH RePORTER; NCI NIH HHS [CA47767-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMBRUSTER BL, 1982, J MICROSC-OXFORD, V126, P77, DOI 10.1111/j.1365-2818.1982.tb00358.x; BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BUCCI C, 1988, NUCLEIC ACIDS RES, V16, P9979, DOI 10.1093/nar/16.21.9979; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P2669, DOI 10.1073/pnas.75.6.2669; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; GALLWITZ D, 1983, NATURE, V306, P704, DOI 10.1038/306704a0; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GODA Y, 1991, J CELL BIOL, V112, P823, DOI 10.1083/jcb.112.5.823; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; HARLOW E, 1988, ANTIBODIES LABORATOR; HAUBRUCK H, 1989, EMBO J, V8, P1427, DOI 10.1002/j.1460-2075.1989.tb03524.x; HAUBRUCK H, 1987, EMBO J, V6, P4049, DOI 10.1002/j.1460-2075.1987.tb02750.x; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P3396; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; LAPETINA EG, 1987, P NATL ACAD SCI USA, V84, P2261, DOI 10.1073/pnas.84.8.2261; LITTLE SP, 1977, VIROLOGY, V81, P37, DOI 10.1016/0042-6822(77)90056-3; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MILLER SG, 1991, J CELL BIOL, V112, P39, DOI 10.1083/jcb.112.1.39; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; ORCI L, 1985, P NATL ACAD SCI USA, V82, P5385, DOI 10.1073/pnas.82.16.5385; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1991, CELL, V64, P1183; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; ROTHMAN JE, 1990, FASEB J, V4, P1460, DOI 10.1096/fasebj.4.5.2407590; RUOHOLA H, 1988, J CELL BIOL, V107, P1465, DOI 10.1083/jcb.107.4.1465; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHLEIFER LS, 1982, J BIOL CHEM, V257, P20; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; TOOZE SA, 1990, NATURE, V347, P207, DOI 10.1038/347207a0; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSAI SC, 1988, J BIOL CHEM, V263, P1768; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WEISS O, 1989, J BIOL CHEM, V264, P21066; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	69	519	529	2	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 18	1991	67	2					239	253		10.1016/0092-8674(91)90176-Y	http://dx.doi.org/10.1016/0092-8674(91)90176-Y			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1680566				2022-12-01	WOS:A1991GL47000004
J	SHERMOEN, AW; OFARRELL, PH				SHERMOEN, AW; OFARRELL, PH			PROGRESSION OF THE CELL-CYCLE THROUGH MITOSIS LEADS TO ABORTION OF NASCENT TRANSCRIPTS	CELL			English	Article							EARLY DROSOPHILA DEVELOPMENT; INSITU HYBRIDIZATION; RNA-POLYMERASE; MELANOGASTER; DIVISION; EMBRYOS; PHOSPHORYLATION; EMBRYOGENESIS; SEGMENTATION; PATTERNS	Nascent transcripts of the Drosophila Ubx gene were detected by in situ hybridization. Following onset of expression, the progress of RNA polymerase (1.4 kb/min) across the gene was visualized as the successive appearance of hybridization signals from different positions within the transcription unit. Nascent transcripts disappeared at mitosis. Hybridization signals reappeared in the next cell cycle first with a 5' probe, and later, following a delay consistent with the transcription rate, with a 3' probe. Nascent transcripts were observed continuously in expressing cells of a mutant embryo in which cells are blocked in interphase. We conclude that progression through mitosis causes abortion of nascent transcripts and suggest that periodic abortion of transcription contributes to regulation of expression of large genes.	UNIV CALIF SAN FRANCISCO,INST CARDIOVASC,PROGRAM EXCELLENCE MOLEC BIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	SHERMOEN, AW (corresponding author), UNIV CALIF SAN FRANCISCO,INST CARDIOVASC,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.			O'Farrell, Patrick/0000-0003-0011-2734	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL043821] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037193] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL43821] Funding Source: Medline; NIGMS NIH HHS [R01 GM037193-10, R01 GM37193, R01 GM037193] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKAM M, 1985, EMBO J, V4, P1687; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; EDGAR BA, 1986, CELL, V44, P871, DOI 10.1016/0092-8674(86)90009-7; EDGAR BA, 1986, CELL, V44, P365, DOI 10.1016/0092-8674(86)90771-3; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; FOE VE, 1983, J CELL SCI, V61, P31; FOE VE, 1989, DEVELOPMENT, V107, P1; HARTENSTEIN V, 1990, DEV BIOL, V138, P147, DOI 10.1016/0012-1606(90)90184-K; HIRAOKA Y, 1990, J CELL BIOL, V111, P2815, DOI 10.1083/jcb.111.6.2815; IRVINE KD, 1991, DEVELOPMENT, V111, P407; JACK JW, 1979, P NATL ACAD SCI USA, V76, P1368, DOI 10.1073/pnas.76.3.1368; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; LEE M, 1987, NATURE, V327, P287; LEHNER CF, 1990, EMBO J, V9, P3573, DOI 10.1002/j.1460-2075.1990.tb07568.x; LEMAIRE MF, 1990, MOL CELL BIOL, V10, P6059, DOI 10.1128/MCB.10.11.6059; LEWIS EB, 1954, AM NAT, V88, P225, DOI 10.1086/281833; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MCKNIGHT SL, 1977, CELL, V12, P795, DOI 10.1016/0092-8674(77)90278-1; MERRILL PT, 1988, DEVELOPMENT, V104, P495; MINDEN JS, 1989, J CELL BIOL, V109, P505, DOI 10.1083/jcb.109.2.505; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; OCONNOR MB, 1988, EMBO J, V7, P435, DOI 10.1002/j.1460-2075.1988.tb02831.x; OFARRELL PH, 1989, SCIENCE, V246, P635, DOI 10.1126/science.2683080; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PRESCOTT DM, 1962, EXP CELL RES, V26, P260, DOI 10.1016/0014-4827(62)90176-3; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TAYLOR JH, 1960, ANN NY ACAD SCI, V90, P409, DOI 10.1111/j.1749-6632.1960.tb23259.x; THUMMEL CS, 1990, CELL, V61, P101, DOI 10.1016/0092-8674(90)90218-4	30	311	313	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					303	310		10.1016/0092-8674(91)90182-X	http://dx.doi.org/10.1016/0092-8674(91)90182-X			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1680567	Green Accepted			2022-12-01	WOS:A1991GL47000010
J	SHI, Y; SETO, E; CHANG, LS; SHENK, T				SHI, Y; SETO, E; CHANG, LS; SHENK, T			TRANSCRIPTIONAL REPRESSION BY YY1, A HUMAN GLI-KRUPPEL-RELATED PROTEIN, AND RELIEF OF REPRESSION BY ADENOVIRUS E1A PROTEIN	CELL			English	Article							MAMMALIAN-CELLS; RNA-POLYMERASE; DNA; EXPRESSION; GENE; ACTIVATION; PROMOTER; ELEMENT; PURIFICATION; DROSOPHILA	A sequence within the transcription control region of the adeno-associated virus P5 promoter has been shown to mediate transcriptional activation by the adenovirus E1A protein. We report here that this same element mediates transcriptional repression in the absence of E1A. Two cellular proteins have been found to bind to overlapping regions within this sequence element. One of these proteins, YY1, is responsible for the repression. E1A relieves repression exerted by YY1 and further activates transcription through its binding site. A YY1-specific cDNA has been isolated. Its sequence reveals YY1 to be a zinc finger protein that belongs to the GLI-Kruppel gene family. The product of the cDNA binds to YY1 sites. When fused to the GAL4 DNA-binding domain, it is capable of repressing transcription directed by a promoter that contains GAL4-binding sites, and E1A proteins can relieve the repression and activate transcription through the fusion protein.	PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544; PRINCETON UNIV,HOWARD HUGHES MED INST,PRINCETON,NJ 08544	Princeton University; Howard Hughes Medical Institute; Princeton University			Chang, Long-sheng/E-2871-2011		NCI NIH HHS [CA 38965] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038965, R37CA038965] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ABERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; CHANG LS, 1989, J VIROL, V63, P3479, DOI 10.1128/JVI.63.8.3479-3488.1989; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRASCH M, 1987, GENE DEV, V1, P981, DOI 10.1101/gad.1.9.981; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HE X, 1991, MOL CELL BIOL, V11, P1739, DOI 10.1128/MCB.11.3.1739; HEARING P, 1983, CELL, V33, P695, DOI 10.1016/0092-8674(83)90012-0; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HOSLER BA, 1989, MOL CELL BIOL, V9, P5623, DOI 10.1128/MCB.9.12.5623; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; LEONG K, 1988, MOL CELL BIOL, V8, P1765, DOI 10.1128/MCB.8.4.1765; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; Maniatis T., 1982, MOL CLONING; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONTALVO EA, 1991, J VIROL, V65, P3647, DOI 10.1128/JVI.65.7.3647-3655.1991; MONUKI ES, 1990, SCIENCE, V249, P1300, DOI 10.1126/science.1975954; MULLER U, 1989, GENE DEV, V3, P1991, DOI 10.1101/gad.3.12a.1991; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; ROONEY C, 1988, P NATL ACAD SCI USA, V85, P9801, DOI 10.1073/pnas.85.24.9801; ROTH SY, 1990, MOL CELL BIOL, V10, P2247, DOI 10.1128/MCB.10.5.2247; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHENK T, 1979, COLD SPRING HARB SYM, V44, P367, DOI 10.1101/SQB.1980.044.01.041; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; TAN S, 1988, EMBO J, V6, P2711; WANG J, 1987, NUCLEIC ACIDS RES, V15, P10105, DOI 10.1093/nar/15.24.10105; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; ZUO P, 1991, GENE DEV, V5, P254, DOI 10.1101/gad.5.2.254	47	889	915	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					377	388		10.1016/0092-8674(91)90189-6	http://dx.doi.org/10.1016/0092-8674(91)90189-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1655281				2022-12-01	WOS:A1991GL47000017
J	STEINGRIMSSON, E; PIGNONI, F; LIAW, GJ; LENGYEL, JA				STEINGRIMSSON, E; PIGNONI, F; LIAW, GJ; LENGYEL, JA			DUAL ROLE OF THE DROSOPHILA PATTERN GENE TAILLESS IN EMBRYONIC TERMINI	SCIENCE			English	Article							CROSS-REGULATORY INTERACTIONS; RECEPTOR TYROSINE KINASE; GAP GENES; TORSO; SEGMENTATION; REQUIREMENT; MUTATIONS; HUNCHBACK; ANTERIOR; PROTEIN	One of the first zygotically active genes required for formation of the terminal domains of the Drosophila embryo is tailless (tll). Expression of the tll gene is activated ectopically in gain-of-function mutants of the maternal terminal gene torso (tor); this suggests that tor normally activates the tll gene in the termini. Ectopic expression of tll under the control of an inducible promoter results in differentiation of ectopic terminal-specific structures, the Filzkorper, and leads to the activation of at least one gene, hunchback, that is required to form these structures. Ectopic expression of the tll gene also represses segmentation by repressing the gap genes Kruppel and knirps and probably also pair rule genes.	UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles				Steingrimsson, Eirikur/0000-0001-5826-7486	PHS HHS [09948] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; ANDERSON KV, 1989, GENES EMBRYOS, P1; CAPMOSORTEGA JA, 1985, EMBRYONIC DEV DROSOP; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; CASANOVA J, 1990, DEVELOPMENT, V110, P621; COULTER DE, 1988, GENE DEV, V2, P1812, DOI 10.1101/gad.2.12b.1812; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; FOE VE, 1983, J CELL SCI, V61, P31; HARDING K, 1986, SCIENCE, V233, P953, DOI 10.1126/science.3755551; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; JACKLE H, 1986, NATURE, V324, P668, DOI 10.1038/324668a0; KLINGER M, 1989, THESIS U TUBINGEN TU; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; LEHMANN R, 1987, DEV BIOL, V119, P402, DOI 10.1016/0012-1606(87)90045-5; MAHONEY PA, 1987, DEV BIOL, V122, P464, DOI 10.1016/0012-1606(87)90310-1; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; NUSSLEINVOLHARD C, 1985, COLD SPRING HARB SYM, V50, P145, DOI 10.1101/SQB.1985.050.01.020; PANKRATZ MJ, 1989, NATURE, V341, P337, DOI 10.1038/341337a0; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; PIGNONI F, UNPUB; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STRECKER TR, 1989, SCIENCE, V243, P1062, DOI 10.1126/science.2922596; STRECKER TR, 1986, DEV BIOL, V113, P64, DOI 10.1016/0012-1606(86)90108-9; STRECKER TR, 1988, DEVELOPMENT, V102, P721; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WEIGEL D, 1990, SCIENCE, V248, P495, DOI 10.1126/science.2158673; Wieschaus E., 1986, P199	37	100	100	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1991	254	5030					418	421		10.1126/science.1925599	http://dx.doi.org/10.1126/science.1925599			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK729	1925599				2022-12-01	WOS:A1991GK72900045
J	SUTTER, TR; GUZMAN, K; DOLD, KM; GREENLEE, WF				SUTTER, TR; GUZMAN, K; DOLD, KM; GREENLEE, WF			TARGETS FOR DIOXIN - GENES FOR PLASMINOGEN-ACTIVATOR INHIBITOR-2 AND INTERLEUKIN-1-BETA	SCIENCE			English	Article							MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATION; GROWTH-FACTORS; CDNA CLONING; CELL-LINE; C-FOS; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN; EXPRESSION; MOUSE; DIFFERENTIATION	Dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin, TCDD), a widespread environmental contaminant, may elicit its effects by altering gene expression in susceptible cells. Five TCDD-responsive complementary DNA clones were isolated from a human keratinocyte cell line. One of these clones encodes plasminogen activator inhibitor-2, a factor that influences growth and differentiation by regulating proteolysis of the extracellular matrix. Another encodes the cytokine interleukin-1-beta. Thus, TCDD alters the expression of growth regulatory genes and has effects similar to those of other tumor-promoting agents that affect both inflammation and differentiation.	CHEM IND INST TOXICOL,RES TRIANGLE PK,NC 27709									ABBOTT BD, 1989, TOXICOL APPL PHARM, V100, P119, DOI 10.1016/0041-008X(89)90096-3; AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANDREASEN PA, 1990, MOL CELL ENDOCRINOL, V68, P1, DOI 10.1016/0303-7207(90)90164-4; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; Bailar J C 3rd, 1991, N Engl J Med, V324, P260, DOI 10.1056/NEJM199101243240409; BERGHARD A, 1990, J BIOL CHEM, V265, P21086; Bravo R, 1990, Semin Cancer Biol, V1, P37; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COOK JC, 1987, ENVIRON HEALTH PERSP, V76, P71, DOI 10.2307/3430467; DINARELLO CA, 1989, B NEW YORK ACAD MED, V65, P80; DOLD KM, 1990, ANAL BIOCHEM, V184, P67, DOI 10.1016/0003-2697(90)90013-Y; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; DUNIGAN DD, 1987, BIOTECHNIQUES, V5, P32; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FINGERHUT MA, 1991, NEW ENGL J MED, V324, P212, DOI 10.1056/NEJM199101243240402; GOUGH M, 1988, RISK ANAL, V8, P337, DOI 10.1111/j.1539-6924.1988.tb00496.x; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANAHAN D, 1980, GENE, V10, P63, DOI 10.1016/0378-1119(80)90144-4; HART DA, 1988, COMP BIOCHEM PHYS B, V90, P691, DOI 10.1016/0305-0491(88)90323-9; HUDSON LG, 1986, TOXICOL APPL PHARM, V82, P481, DOI 10.1016/0041-008X(86)90283-8; ISRAEL DI, 1985, J BIOL CHEM, V260, P5648; KIMURA S, 1986, MOL CELL BIOL, V6, P1471, DOI 10.1128/MCB.6.5.1471; KOCIBA RJ, 1978, TOXICOL APPL PHARM, V46, P279, DOI 10.1016/0041-008X(78)90075-3; KRUITHOF EKO, 1988, BIOCHEM BIOPH RES CO, V156, P383, DOI 10.1016/S0006-291X(88)80852-0; LAIHO M, 1989, CANCER RES, V49, P2533; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; Maniatis T., 1982, MOL CLONING LAB MANU, P191; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; NEBERT DW, 1989, INT J BIOCHEM, V21, P243, DOI 10.1016/0020-711X(89)90182-1; NISHIDA T, 1987, BIOCHEM BIOPH RES CO, V143, P345, DOI 10.1016/0006-291X(87)90671-1; PASCO DS, 1988, J BIOL CHEM, V263, P8671; PHILLIPS CL, 1988, MOL ENDOCRINOL, V2, P641, DOI 10.1210/mend-2-7-641; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; PRATT RM, 1984, TERATOGEN CARCIN MUT, V4, P427, DOI 10.1002/tcm.1770040505; QUATTROCHI LC, 1986, P NATL ACAD SCI USA, V83, P6731, DOI 10.1073/pnas.83.18.6731; REINERS JJ, 1990, P NATL ACAD SCI USA, V87, P1825, DOI 10.1073/pnas.87.5.1825; SAATCIOGLU F, 1990, MOL CELL BIOL, V10, P6408, DOI 10.1128/MCB.10.12.6408; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLEUNING WD, 1987, MOL CELL BIOL, V7, P4564, DOI 10.1128/MCB.7.12.4564; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SKENE SA, 1989, HUM TOXICOL, V8, P173, DOI 10.1177/096032718900800301; SUSKIND RR, 1985, SCAND J WORK ENV HEA, V11, P165, DOI 10.5271/sjweh.2240; SUTTER TR, 1990, J BIOL CHEM, V265, P16428; SUTTER TR, 1989, BIOCHEM BIOPH RES CO, V160, P1257, DOI 10.1016/S0006-291X(89)80139-1; SUTTER TR, UNPUB; Taylor J S, 1979, Ann N Y Acad Sci, V320, P295, DOI 10.1111/j.1749-6632.1979.tb13155.x; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VLASSARA H, 1988, SCIENCE, V240, P1546, DOI 10.1126/science.3259727; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; YE RD, 1987, J BIOL CHEM, V262, P3718	55	305	312	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1991	254	5030					415	418		10.1126/science.1925598	http://dx.doi.org/10.1126/science.1925598			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK729	1925598				2022-12-01	WOS:A1991GK72900044
J	SZABO, A; DALMAU, J; MANLEY, G; ROSENFELD, M; WONG, E; HENSON, J; POSNER, JB; FURNEAUX, HM				SZABO, A; DALMAU, J; MANLEY, G; ROSENFELD, M; WONG, E; HENSON, J; POSNER, JB; FURNEAUX, HM			HUD, A PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGEN, CONTAINS RNA-BINDING DOMAINS AND IS HOMOLOGOUS TO ELAV AND SEX-LETHAL	CELL			English	Article							GENE-PRODUCT; LUNG-CANCER; DROSOPHILA; PROTEINS; ANTIBODY; NEURONS	A neuronal antigen (HuD) recognized by the sera of patients with antibody-associated paraneoplastic encephalomyelitis has been isolated by screening a lambda cerebellar expression library. The recombinant antigen provides an unambiguous assay for this rare condition associated with small cell lung cancer. The recombinant antigen has been used to identify specific infiltrating lymphocytes in tumors and affected brain tissues of patients with antibody-associated paraneoplastic encephalomyelitis and sensory neuronopathy. HuD mRNA is uniquely expressed in brain tissue. The HuD protein shows a remarkable homology to the Drosophila proteins Elav and Sex-lethal and is likely to play a role in neuron-specific RNA processing.	MEM SLOAN KETTERING CANC CTR,DEPT NEUROL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center	SZABO, A (corresponding author), MEM SLOAN KETTERING CANC CTR,MOLEC NEUROONCOL LAB,1275 YORK AVE,NEW YORK,NY 10021, USA.			Dalmau, Josep/0000-0001-5856-2813; Rosenfeld, Myrna/0000-0001-5095-2534; furneaux, henry/0000-0003-2212-1017	NCI NIH HHS [CA 095-12-06, CA 09512] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009512] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BRAIN WR, 1965, BRAIN, V88, P465; CUNNINGHAM JM, 1985, J NEUROCHEM, V45, P159, DOI 10.1111/j.1471-4159.1985.tb05488.x; DALMAU J, 1990, ANN NEUROL, V27, P544, DOI 10.1002/ana.410270515; DALMAU J, 1991, IN PRESS NEUROLOGY; DENNYBROWN D, 1948, J NEUROL NEUROSUR PS, V11, P73, DOI 10.1136/jnnp.11.2.73; FURNEAUX H, 1990, RES PUBL ASSOC RES N, V68, P187; FURNEAUX HF, 1990, NEUROLOGY, V40, P1085, DOI 10.1212/WNL.40.7.1085; FURNEAUX HM, 1990, NEW ENGL J MED, V322, P1844, DOI 10.1056/NEJM199006283222604; GRAUS F, 1985, NEUROLOGY, V35, P538, DOI 10.1212/WNL.35.4.538; HEWITT HB, 1976, BRIT J CANCER, V33, P241, DOI 10.1038/bjc.1976.37; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; LURQUIN C, 1989, CELL, V58, P293, DOI 10.1016/0092-8674(89)90844-1; MEDAWAR PB, 1948, BRIT J EXP PATHOL, V29, P58; ONEILL JH, 1988, BRAIN, V111, P577, DOI 10.1093/brain/111.3.577; QUERY CC, 1989, MOL CELL BIOL, V9, P4872, DOI 10.1128/MCB.9.11.4872; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; ROBERTS A, 1985, NATURE, V317, P737, DOI 10.1038/317737a0; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; ROBINOW S, 1988, SCIENCE, V242, P1570, DOI 10.1126/science.3144044; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X	22	526	541	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					325	333		10.1016/0092-8674(91)90184-Z	http://dx.doi.org/10.1016/0092-8674(91)90184-Z			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1655278				2022-12-01	WOS:A1991GL47000012
J	TELFER, JC; RUDD, CE				TELFER, JC; RUDD, CE			A 32-KD GTP-BINDING PROTEIN ASSOCIATED WITH THE CD4-P56LCK AND CD8-P56LCK T-CELL RECEPTOR COMPLEXES	SCIENCE			English	Article							TYROSINE KINASE P56LCK; HUMAN LYMPHOCYTES-T; PHOSPHOLIPASE-C; CROSS-LINKING; ACTIVATION; CD4; RAS; POLYPEPTIDES; PRODUCT	The guanosine triphosphate (GTP)-binding proteins include signal-transducing heterotrimeric G proteins (for example, G(s), G(i)), smaller GTP-binding proteins that function in protein sorting, and the oncogenic protein p21(ras). The T cell receptor complexes CD4-p56lck and CD8-p56lck were found to include a 32- to 33-kilodalton phosphoprotein (p32) that was recognized by an antiserum to a consensus GTP-binding region in G proteins. Immununoprecipitated CD4 and CD8 complexes bound GTP and hydrolyzed it to guanosine diphosphate (GDP). The p32 protein was covalently linked to [alpha-P-32]GTP by ultraviolet photoaffinity labeling. These results demonstrate an interaction between T cell receptor complexes and an intracellular GTP-binding protein.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV TUMOR IMMUNOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School			Rudd, Christopher E/GOH-2021-2022; Rudd, Christopher E/ABF-7259-2021	Rudd, Christopher E/0000-0001-5295-9019; 				ANDERSON P, 1987, J IMMUNOL, V139, P678; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BURGESS KE, 1991, EUR J IMMUNOL, V21, P1663, DOI 10.1002/eji.1830210712; CARNEY WP, 1989, HUMAN TUMOR ANTIGENS, P53; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CHURCH JG, 1988, J BIOL CHEM, V263, P4242; COCKCROFT S, 1985, NATURE, V314, P534, DOI 10.1038/314534a0; DISANTO JP, 1987, LEUCOCYTE TYPING 3 W, P210; EICHMANN K, 1987, EUR J IMMUNOL, V17, P643, DOI 10.1002/eji.1830170510; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HARNETT MM, 1988, IMMUNOL TODAY, V9, P315, DOI 10.1016/0167-5699(88)91325-4; LETOURNEUR F, 1990, P NATL ACAD SCI USA, V87, P2339, DOI 10.1073/pnas.87.6.2339; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MEUER SC, 1982, P NATL ACAD SCI-BIOL, V79, P4395, DOI 10.1073/pnas.79.14.4395; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PESSAMORIKAWA T, 1990, J IMMUNOL, V144, P2690; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RUDD CE, 1985, J BIOL CHEM, V260, P1927; SCHMIDT RE, 1985, NATURE, V318, P289, DOI 10.1038/318289a0; SMITH CD, 1986, SCIENCE, V232, P97, DOI 10.1126/science.3006254; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TELFER J, UNPUB; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; VIELLETTE A, 1988, CELL, V55, P301; WANG P, 1989, J BIOCHEM-TOKYO, V105, P461, DOI 10.1093/oxfordjournals.jbchem.a122687; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0	30	70	71	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 18	1991	254	5030					439	441		10.1126/science.1925604	http://dx.doi.org/10.1126/science.1925604			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK729	1925604				2022-12-01	WOS:A1991GK72900052
J	BANCHEREAU, J; ROUSSET, F				BANCHEREAU, J; ROUSSET, F			GROWING HUMAN LYMPHOCYTES-B IN THE CD40 SYSTEM	NATURE			English	Article							CELLS				BANCHEREAU, J (corresponding author), SCHERING PLOUGH CORP, IMMUNOL RES LAB, 27 CHEMIN PEUPLIERS, BP 11, F-69571 DARDILLY, FRANCE.							BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; MACLENNAN ICM, 1990, CURR TOP MICROBIOL, V159, P37; MALLETT S, 1991, IMMUNOL TODAY, V12, P220, DOI 10.1016/0167-5699(91)90033-P; ROUSSET F, 1991, J EXP MED, V173, P705, DOI 10.1084/jem.173.3.705; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0	9	182	192	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 17	1991	353	6345					678	679		10.1038/353678a0	http://dx.doi.org/10.1038/353678a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK672	1717852				2022-12-01	WOS:A1991GK67200077
J	GOLDBERG, RJ; GORE, JM; ALPERT, JS; OSGANIAN, V; DEGROOT, J; BADE, J; CHEN, Z; FRID, D; DALEN, JE				GOLDBERG, RJ; GORE, JM; ALPERT, JS; OSGANIAN, V; DEGROOT, J; BADE, J; CHEN, Z; FRID, D; DALEN, JE			CARDIOGENIC-SHOCK AFTER ACUTE MYOCARDIAL-INFARCTION - INCIDENCE AND MORTALITY FROM A COMMUNITY-WIDE PERSPECTIVE, 1975 TO 1988	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AORTIC BALLOON COUNTERPULSATION; TISSUE PLASMINOGEN-ACTIVATOR; LUMINAL CORONARY ANGIOPLASTY; WORCESTER-HEART-ATTACK; CARE UNIT; TRIAL; STREPTOKINASE; PROGNOSIS; EMERGENCY; THERAPY	Background. Cardiogenic shock resulting from acute myocardial infarction is a serious complication with a high mortality rate, but little is known about whether its incidence or outcome has changed over time. As part of an ongoing population-based study of acute myocardial infarction, we examined trends over time in the incidence and mortality rate of cardiogenic shock after acute myocardial infarction. Methods. We studied 4762 patients with acute myocardial infarction who were admitted to 16 hospitals in the Worcester, Massachusetts, metropolitan area between 1975 and 1988. We determined the incidence of and short-term and long-term mortality due to cardiogenic shock in each of six years during this study period. Results. The incidence of cardiogenic shock complicating acute myocardial infarction remained relatively constant, averaging 7.5 percent. Multivariate regression analysis that controlled for variables affecting incidence revealed significant though inconsistent temporal trends in the incidence of cardiogenic shock. As compared with the risk in 1975, the adjusted relative risk (with 95 percent confidence interval) was 0.83 (0.54 to 1.28) in 1978, 0.96 (0.63 to 1.48) in 1981, 0.68 (0.42 to 1.12) in 1984, 1.16 (0.70 to 1.92) in 1986, and 1.65 (0.99 to 2.77) in 1988. The overall in-hospital mortality rate among patients with cardiogenic shock was significantly higher than that among patients without this complication (77.7 percent vs. 13.5 percent, P < 0.001). The in-hospital mortality among the patients with shock did not improve between 1975 (73.7 percent) and 1988 (81.7 percent). Long-term survival during the 14-year follow-up period was significantly worse among patients who survived cardiogenic shock during hospitalization than among patients who did not have shock (P < 0.001). Conclusions. The results of this observational, community-wide study suggest that neither the incidence nor the prognosis of cardiogenic shock resulting from acute myocardial infarction has improved over time. Both in-hospital and long-term survival remain poor for patients with this complication.			GOLDBERG, RJ (corresponding author), UNIV MASSACHUSETTS, SCH MED, DEPT MED, 55 LAKE AVE N, WORCESTER, MA 01655 USA.				NHLBI NIH HHS [R01-HL-35434] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035434] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AFIFI AA, 1974, AM J CARDIOL, V33, P826, DOI 10.1016/0002-9149(74)90628-6; ALONSO DR, 1973, CIRCULATION, V48, P588, DOI 10.1161/01.CIR.48.3.588; ALTHOUSE R, 1990, AM J CARDIOL, V66, P1298, DOI 10.1016/0002-9149(90)91157-2; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1986, LANCET, V2, P57; BINDER MJ, 1955, AM J MED, V18, P622, DOI 10.1016/0002-9343(55)90463-0; BOLOOKI H, 1990, JAMA-J AM MED ASSOC, V263, P1237, DOI 10.1001/jama.263.9.1237; BRAUNWALD E, 1985, CIRCULATION, V71, P1087, DOI 10.1161/01.CIR.71.6.1087; CAULFIELD JB, 1972, ARCH PATHOL, V93, P532; CHATTERJEE K, 1976, CIRCULATION, V53, P797, DOI 10.1161/01.CIR.53.5.797; CHEITLIN MD, 1988, JAMA-J AM MED ASSOC, V260, P2894, DOI 10.1001/jama.260.19.2894; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; COBB LA, 1975, CIRCULATION, V52, P223; DALEN JE, 1984, CHEST, V86, P257, DOI 10.1378/chest.86.2.257; DEWOOD MA, 1980, CIRCULATION, V61, P1105, DOI 10.1161/01.CIR.61.6.1105; GHEORGHIADE M, 1988, AM HEART J, V116, P1212; GOLDBERG R, 1979, JOHNS HOPKINS MED J, V144, P73; GOLDBERG RJ, 1987, AM HEART J, V113, P273, DOI 10.1016/0002-8703(87)90265-1; GOLDBERG RJ, 1988, AM HEART J, V115, P761, DOI 10.1016/0002-8703(88)90876-9; GOLDBERG RJ, 1986, JAMA-J AM MED ASSOC, V255, P2774, DOI 10.1001/jama.255.20.2774; GOLDBERG RJ, 1987, CLIN CARDIOL, V10, P3, DOI 10.1002/clc.4960100103; GORE JM, 1987, ARCH INTERN MED, V147, P1729, DOI 10.1001/archinte.147.10.1729; GORE JM, 1989, JAMA-J AM MED ASSOC, V261, P2829; GUNNAR RM, 1974, SHOCK MYOCARDIAL INF, P113; GUTOVITZ AL, 1978, AM J CARDIOL, V41, P469, DOI 10.1016/0002-9149(78)90001-2; GUYTON RA, 1987, CIRCULATION, V76, P22; HARTZLER GO, 1988, AM J CARDIOL, V61, pG33, DOI 10.1016/S0002-9149(88)80030-4; JUGDUTT BI, 1988, CIRCULATION, V78, P906, DOI 10.1161/01.CIR.78.4.906; KENNEDY JW, 1985, AM J CARDIOL, V55, P871, DOI 10.1016/0002-9149(85)90709-X; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; KOBAYASHI M, 1984, JPN CIRC J, V48, P650, DOI 10.1253/jcj.48.650; KUHN LA, 1967, AM HEART J, V74, P578, DOI 10.1016/0002-8703(67)90019-1; LEE L, 1988, CIRCULATION, V78, P1345, DOI 10.1161/01.CIR.78.6.1345; LEINBACH RC, 1972, CIRCULATION, V45, P845, DOI 10.1161/01.CIR.45.4.845; MALACH M, 1960, AM J CARDIOL, V5, P487, DOI 10.1016/0002-9149(60)90106-5; MAROKO PR, 1972, CIRCULATION, V45, P1150, DOI 10.1161/01.CIR.45.6.1150; MEINERTZ T, 1988, AM J CARDIOL, V62, P347, DOI 10.1016/0002-9149(88)90956-3; MERRELL M, 1955, J Chronic Dis, V1, P12, DOI 10.1016/0021-9681(55)90018-7; MUELLER H, 1971, J CLIN INVEST, V50, P1885, DOI 10.1172/JCI106681; MUELLER HS, 1990, CLIN CARDIOL, V13, P239, DOI 10.1002/clc.4960130403; MUNDTH ED, 1970, NEW ENGL J MED, V283, P1382, DOI 10.1056/NEJM197012172832506; OROURKE MF, 1981, AM J CARDIOL, V47, P815, DOI 10.1016/0002-9149(81)90179-X; PAGE DL, 1971, NEW ENGL J MED, V285, P133, DOI 10.1056/NEJM197107152850301; REICHENBACH DD, 1975, CIRCULATION, V52, P60; ROTHBAUM DA, 1987, J AM COLL CARDIOL, V10, P264, DOI 10.1016/S0735-1097(87)80006-2; SCHEIDT S, 1970, AM J CARDIOL, V26, P556, DOI 10.1016/0002-9149(70)90407-8; SCHEIDT S, 1973, NEW ENGL J MED, V288, P979, DOI 10.1056/NEJM197305102881901; SIMOONS ML, 1988, LANCET, V1, P199; TAKANO T, 1984, JPN CIRC J, V48, P678, DOI 10.1253/jcj.48.678; TOPOL EJ, 1987, NEW ENGL J MED, V317, P581, DOI 10.1056/NEJM198709033171001; WALKER SH, 1967, BIOMETRIKA, V54, P167, DOI 10.1093/biomet/54.1-2.167; WILLERSON JT, 1975, AM J MED, V58, P183, DOI 10.1016/0002-9343(75)90568-9; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088	53	334	352	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 17	1991	325	16					1117	1122		10.1056/NEJM199110173251601	http://dx.doi.org/10.1056/NEJM199110173251601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK538	1891019	Bronze			2022-12-01	WOS:A1991GK53800001
J	JACOBS, GH; NEITZ, J; DEEGAN, JF				JACOBS, GH; NEITZ, J; DEEGAN, JF			RETINAL RECEPTORS IN RODENTS MAXIMALLY SENSITIVE TO ULTRAVIOLET-LIGHT	NATURE			English	Article							SPECTRAL SENSITIVITY; PHOTOSENSITIVITY; SCIUREUS; MONKEYS; SAIMIRI; SYSTEM; RAT	HIGH sensitivity to near-ultraviolet light is a fundamental feature of vision in many invertebrates 1,2. Among vertebrates there are some amphibians, birds and fishes that are also sensitive to near-ultraviolet wavelengths 3-6. This sensitivity can be achieved through a class of cone photoreceptor containing an ultraviolet-sensitive pigment 7-9. Although these receptors were thought not to exist in the eyes of mammals, we now report that some rodents have a retinal mechanism that is maximally sensitive to ultraviolet light.			JACOBS, GH (corresponding author), UNIV CALIF SANTA BARBARA,DEPT PSYCHOL,SANTA BARBARA,CA 93106, USA.							BAYLOR DA, 1987, J PHYSIOL-LONDON, V390, P145, DOI 10.1113/jphysiol.1987.sp016691; BENSHOFF HM, 1987, BRAIN RES, V420, P397, DOI 10.1016/0006-8993(87)91264-9; DOUGLAS RH, 1986, J COMP PHYSIOL A, V159, P415, DOI 10.1007/BF00603986; EBREY TG, 1977, VISION RES, V17, P147, DOI 10.1016/0042-6989(77)90213-9; EMMERTON J, 1980, J COMP PHYSIOL, V141, P47, DOI 10.1007/BF00611877; GOLDSMITH TH, 1980, SCIENCE, V207, P786, DOI 10.1126/science.7352290; HAROSI FI, 1983, SCIENCE, V222, P1021, DOI 10.1126/science.6648514; HAWRYSHYN CW, 1985, VISION RES, V25, P11, DOI 10.1016/0042-6989(85)90075-6; JACOBS GH, 1989, EXPERIENTIA, V45, P317, DOI 10.1007/BF01957461; JACOBS GH, 1983, VISION RES, V23, P239, DOI 10.1016/0042-6989(83)90112-8; JACOBS GH, 1987, P NATL ACAD SCI USA, V84, P2545, DOI 10.1073/pnas.84.8.2545; Jacobs GH, 1981, COMP COLOR VISION; Menzel R, 1979, HDB SENSORY PHYSL, VVII/6A, P503; NEITZ J, 1986, J COMP PSYCHOL, V100, P21, DOI 10.1037/0735-7036.100.1.21; NEITZ J, 1984, J OPT SOC AM A, V1, P1175, DOI 10.1364/JOSAA.1.001175; PERRY RJ, 1991, J PHYSIOL-LONDON, V443, P561; RAPP LM, 1990, INVEST OPHTHAL VVIS, V31, P1187; STARK WS, 1982, PHOTOCHEM PHOTOBIOL, V36, P371, DOI 10.1111/j.1751-1097.1982.tb04389.x; VANNORREN D, 1990, VISION RES, V30, P1517, DOI 10.1016/0042-6989(90)90032-G; [No title captured]	20	318	323	4	31	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1991	353	6345					655	656		10.1038/353655a0	http://dx.doi.org/10.1038/353655a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK672	1922382				2022-12-01	WOS:A1991GK67200068
J	KELLY, A; POWIS, SH; GLYNNE, R; RADLEY, E; BECK, S; TROWSDALE, J				KELLY, A; POWIS, SH; GLYNNE, R; RADLEY, E; BECK, S; TROWSDALE, J			2ND PROTEASOME-RELATED GENE IN THE HUMAN MHC CLASS-II REGION	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MULTICATALYTIC PROTEINASE; ANTIGEN PRESENTATION; LYMPHOCYTE-T; TRANSPORTERS; CELLS; SEQUENCES; PATHWAY; CLONING; CDNA	ANTIGEN processing involves the generation of peptides from cytosolic proteins and their transport into the endoplasmic reticulum where they associate with major histocompatibility complex (MHC) class I molecules 1-6. Two genes have been identified in the MHC class II region, RING4 and RING11 in humans, which are believed to encode the peptide transport proteins 7-12. Attention is now focused on how the transporters are provided with peptides. The proteasome, a large complex of subunits with multiple proteolytic activities, is a candidate for this function 13-16. Recently we reported a proteasome-related sequence, RING1O, mapping between the transporter genes 17. Here we describe a second human proteasome-like gene, RING12, immediately centromeric of the RING4 locus. Therefore RING12, 4, 10 and 11 form a tightly linked cluster of interferon-inducible genes within the MHC with an essential role in antigen processing.			KELLY, A (corresponding author), IMPERIAL CANC RES FUND,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.							ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BAIROCH A, 1990, PROSITE DICT PROTEIN; BANKIER AT, 1987, METHOD ENZYMOL, V155, P51; BLANCK G, 1988, J IMMUNOL, V141, P1734; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; Dupont B, 1989, IMMUNOBIOLOGY HLA, V1st; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAWLOR DA, 1990, ANNU REV IMMUNOL, V8, P23, DOI 10.1146/annurev.iy.08.040190.000323; LEE LW, 1990, BIOCHIM BIOPHYS ACTA, V1037, P178, DOI 10.1016/0167-4838(90)90165-C; LILLEY KS, 1990, FEBS LETT, V262, P327, DOI 10.1016/0014-5793(90)80220-D; Maniatis T., 1982, MOL CLONING; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MONACO JJ, 1982, P NATL ACAD SCI-BIOL, V79, P3001, DOI 10.1073/pnas.79.9.3001; MONACO JJ, 1986, HUM IMMUNOL, V15, P416, DOI 10.1016/0198-8859(86)90019-4; MONACO JJ, 1984, NATURE, V309, P797, DOI 10.1038/309797a0; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; PARHAM P, 1990, NATURE, V348, P674, DOI 10.1038/348674a0; POWIS SH, UNPUB P NATN ACAD SC; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; STADEN R, 1990, COMPUT APPL BIOSCI, V6, P387; TAMURA T, 1991, BIOCHIM BIOPHYS ACTA, V1089, P95, DOI 10.1016/0167-4781(91)90090-9; TIWARI JL, 1985, HLA DISEASE ASS; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J	33	344	353	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1991	353	6345					667	668		10.1038/353667a0	http://dx.doi.org/10.1038/353667a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK672	1922385				2022-12-01	WOS:A1991GK67200073
J	NOMURA, A; STEMMERMANN, GN; CHYOU, PH; KATO, I; PEREZPEREZ, GI; BLASER, MJ				NOMURA, A; STEMMERMANN, GN; CHYOU, PH; KATO, I; PEREZPEREZ, GI; BLASER, MJ			HELICOBACTER-PYLORI INFECTION AND GASTRIC-CARCINOMA AMONG JAPANESE-AMERICANS IN HAWAII	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CAMPYLOBACTER-PYLORI; ANTIBODY PREVALENCE; ATROPHIC GASTRITIS; PEPTIC-ULCER; CANCER; POPULATIONS; DISEASE; ASSOCIATION; RISKS; MEN	Background. Helicobacter pylori are gram-negative spiral bacteria that are associated with chronic gastritis, a known precursor of gastric carcinoma. Persons at high risk for gastric carcinoma have been shown to have a high prevalence of H. pylori infection. Methods. We studied the relation of H. pylori infection and gastric carcinoma in a cohort of Japanese American men living in Hawaii. The 5908 men were enrolled and examined from 1967 to 1970. By 1989, 109 cases of pathologically confirmed gastric carcinoma had been identified. The stored serum of each patient with gastric carcinoma and of each matched control subject was tested for the presence of serum IgG antibody to H. pylori. Results. Ninety-four percent of the men with gastric carcinoma and 76 percent of the matched control subjects had a positive test for H. pylori antibodies, for an odds ratio of 6.0 (95 percent confidence interval, 2.1 to 17.3). As the level of antibody to H. pylori increased, there was a progressive increase in the risk of gastric carcinoma (P for trend = 0.0009). The association was strong even for men in whom the diagnosis was made 10 or more years after the serum sample was obtained (odds ratio, 10.5; 95 percent confidence interval, 2.5 to 44.8). Conclusions. Infection with H. pylori is strongly associated with an increased risk of gastric carcinoma. However, most persons infected with H. pylori will never have gastric carcinoma. Therefore, other factors that increase the risk of gastric carcinoma among persons infected with H. pylori need to be identified.	VANDERBILT UNIV,MED CTR,SCH MED,DIV INFECT DIS,NASHVILLE,TN 37232; VET AFFAIRS MED CTR,NASHVILLE,TN	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	NOMURA, A (corresponding author), KUAKINI MED CTR,JAPAN HAWAII CANC STUDY,347 N KUAKINI ST,HONOLULU,HI 96817, USA.		Perez, Guillermo Perez/AAJ-3761-2020	Perez Perez, Guillermo/0000-0002-0131-5798	NCI NIH HHS [R01-CA-33644] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033644] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMES BN, 1990, SCIENCE, V249, P970, DOI 10.1126/science.2136249; [Anonymous], 1983, LANCET, V1, P1273; BEAHRS OH, 1978, MANUAL STAGING CANCE, P71; BLASER MJ, 1991, REV INFECT DIS, V13, pS704; BLASER MJ, 1990, J INFECT DIS, V161, P626, DOI 10.1093/infdis/161.4.626; BLASER MJ, 1990, NEW ANTIBACTERIAL ST, P143; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; BRESLOW NE, 1980, IARC SCI PUBL, V32, P164; BUCK GE, 1986, J INFECT DIS, V153, P664, DOI 10.1093/infdis/153.4.664; CORREA P, 1983, CANCER SURV, V2, P437; CORREA P, 1990, CANCER-AM CANCER SOC, V66, P2569, DOI 10.1002/1097-0142(19901215)66:12<2569::AID-CNCR2820661220>3.0.CO;2-I; CORREA P, 1973, JNCI-J NATL CANCER I, V51, P1449, DOI 10.1093/jnci/51.5.1449; DOLL R, 1970, CANCER INCIDENCE 5 C, V2; DOOLEY CP, 1988, ANN INTERN MED, V108, P70, DOI 10.7326/0003-4819-108-1-70; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1562, DOI 10.1056/NEJM198912073212302; DRUMM B, 1990, NEW ENGL J MED, V322, P359, DOI 10.1056/NEJM199002083220603; EKBOM A, 1990, NEW ENGL J MED, V323, P1228, DOI 10.1056/NEJM199011013231802; EVANS DJ, 1989, GASTROENTEROLOGY, V96, P1004, DOI 10.1016/0016-5085(89)91616-8; FORMAN D, 1990, INT J CANCER, V46, P608, DOI 10.1002/ijc.2910460410; GLASSMAN MS, 1990, DIGEST DIS SCI, V35, P993, DOI 10.1007/BF01537248; GRAHAM DY, 1989, GASTROENTEROLOGY, V96, P615, DOI 10.1016/S0016-5085(89)80057-5; Harrell F., 1983, SUGI SUPPLEMENTAL LI, P267; HOWSON CP, 1986, EPIDEMIOL REV, V8, P1; IMAI K, 1991, HELICOBACTER PYLORI, V3, P26; KAGAN A, 1974, J CHRON DIS, V27, P345, DOI 10.1016/0021-9681(74)90014-9; KRAKOWKA S, 1987, INFECT IMMUN, V55, P2789, DOI 10.1128/IAI.55.11.2789-2796.1987; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; LOFFELD RJLF, 1990, HISTOPATHOLOGY, V17, P537, DOI 10.1111/j.1365-2559.1990.tb00793.x; MAI EUH, 1991, J CLIN INVEST, V87, P894; MARSHALL BJ, 1984, LANCET, V1, P1311; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; MEGRAUD F, 1989, J CLIN MICROBIOL, V27, P1870; MORRIS AJ, 1991, ANN INTERN MED, V114, P662, DOI 10.7326/0003-4819-114-8-662; MUIR C, 1987, IARC SCI PUBLICATION, V88; Nomura A, 1982, CANCER EPIDEMIOL, P624; PARSONNET J, 1991, JNCI-J NATL CANCER I, V83, P640, DOI 10.1093/jnci/83.9.640; PARSONNET J, IN PRESS GASTROENTER; PEREZPEREZ GI, 1988, ANN INTERN MED, V109, P11, DOI 10.7326/0003-4819-109-1-11; PEREZPEREZ GI, 1990, J INFECT DIS, V161, P1237, DOI 10.1093/infdis/161.6.1237; SITAS F, 1991, GUT, V32, P25, DOI 10.1136/gut.32.1.25; SIURALA M, 1985, SCAND J GASTROENTERO, V20, P69, DOI 10.3109/00365528509103939; STRAUSS RM, 1990, AM J MED, V89, P464, DOI 10.1016/0002-9343(90)90377-P; STRICKLAND RG, 1973, AM J DIG DIS, V18, P426, DOI 10.1007/BF01071995; TALLEY NJ, IN PRESS J NATL CANC; TALLEY NJ, 1990, REV ESP ENFERM DIG S, V78, pS7; TAYLOR DN, IN PRESS EPIDEMIOL R; WALKER IR, 1971, GUT, V12, P906, DOI 10.1136/gut.12.11.906; WALTER SD, 1978, INT J EPIDEMIOL, V7, P175, DOI 10.1093/ije/7.2.175; WORTH RM, 1970, J CHRON DIS, V23, P389, DOI 10.1016/0021-9681(70)90022-6; YOUNG JL, 1981, NCI MONOGRAPH, V57; 1991, CANCER FACTS FIGURES, P3	51	1638	1682	1	49	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 17	1991	325	16					1132	1136		10.1056/NEJM199110173251604	http://dx.doi.org/10.1056/NEJM199110173251604			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK538	1891021	Bronze			2022-12-01	WOS:A1991GK53800004
J	ORTIZNAVARRETE, V; SEELIG, A; GERNOLD, M; FRENTZEL, S; KLOETZEL, PM; HAMMERLING, GJ				ORTIZNAVARRETE, V; SEELIG, A; GERNOLD, M; FRENTZEL, S; KLOETZEL, PM; HAMMERLING, GJ			SUBUNIT OF THE 20S PROTEASOME (MULTICATALYTIC PROTEINASE) ENCODED BY THE MAJOR HISTOCOMPATIBILITY COMPLEX	NATURE			English	Article							CLASS-II REGION; ANTIGEN PRESENTATION; CELLS; IDENTIFICATION; TRANSPORTERS; INTERFERON; GENE; EXPRESSION; PARTICLES; PATHWAY	CYTOTOXiC T lymphocytes recognize fragments (peptides) of protein antigens presented by major histocompatibility complex (MHC) class I molecules. In general, the peptides are derived from cytosolic proteins and are then transported to the endoplasmic reticulum where they assemble with the MHC class I heavy chains and beta-2-microglobulin to form stable and functional class I molecules 1-4. The proteases involved in the generation of these peptides are unknown. One candidate is the proteasome, a nonlysosomal proteinase complex abundantly present in the cytosol. Proteasomes have several proteolytically active sites and are complexes of high relative molecular mass (M(r) about 600K), consisting of about 20-30 subunits with M(r)s between 15 and 30K (refs 5-10). Here we show that at least one of these subunits is encoded by the mouse MHC in the region between the K locus and the MHC class II region, and inducible by interferon-gamma. This raises the intriguing possibility that the MHC encodes not only the MHC class I molecules themselves but also proteases involved in the formation of MHC-binding peptides.	GERMAN CANC RES CTR,INST IMMUNOL & GENET,NEUENHEIMER FELD 280,W-6900 HEIDELBERG,GERMANY; UNIV HEIDELBERG,ZMBH,W-6900 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg			Ortiz-Navarrete, Vianney/H-1932-2016	Ortiz-Navarrete, Vianney/0000-0001-6546-9713				ARRIGO AP, 1987, J MOL EVOL, V25, P141, DOI 10.1007/BF02101756; CERUNDOLO V, 1990, NATURE, V345, P349; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; FALKENBURG PE, 1989, J BIOL CHEM, V264, P6660; FUJIWARA T, 1990, J BIOL CHEM, V265, P16604; HAASS C, 1990, GENE, V90, P235, DOI 10.1016/0378-1119(90)90185-T; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; KLAR D, 1989, EMBO J, V8, P475, DOI 10.1002/j.1460-2075.1989.tb03400.x; KLOETZEL PM, 1987, MOL BIOL REP, V12, P223, DOI 10.1007/BF00356912; KLOETZEL PM, 1991, BIOMED BIOCHIM ACTA, V50, P451; KOCH N, 1982, J IMMUNOL, V128, P1155; KOPP F, 1986, BIOCHIM BIOPHYS ACTA, V872, P253, DOI 10.1016/0167-4838(86)90278-5; LINDAHL P, 1973, P NATL ACAD SCI USA, V70, P2785, DOI 10.1073/pnas.70.10.2785; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MONACO JJ, 1982, P NATL ACAD SCI-BIOL, V79, P3001, DOI 10.1073/pnas.79.9.3001; MONACO JJ, 1986, HUM IMMUNOL, V15, P416, DOI 10.1016/0198-8859(86)90019-4; MONACO JJ, 1984, NATURE, V309, P797, DOI 10.1038/309797a0; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; PARHAM P, 1990, NATURE, V348, P674, DOI 10.1038/348674a0; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; SEELIG A, IN PRESS BIOCH J; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TANAKA K, 1988, J BIOL CHEM, V263, P16209; TANAKA K, 1986, J BIOL CHEM, V261, P5197; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; UEMATSU Y, 1988, IMMUNOGENETICS, V27, P96, DOI 10.1007/BF00351082; WALLACH D, 1982, NATURE, V299, P833, DOI 10.1038/299833a0	33	244	248	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1991	353	6345					662	664		10.1038/353662a0	http://dx.doi.org/10.1038/353662a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK672	1922384				2022-12-01	WOS:A1991GK67200071
J	PARSONNET, J; FRIEDMAN, GD; VANDERSTEEN, DP; CHANG, Y; VOGELMAN, JH; ORENTREICH, N; SIBLEY, RK				PARSONNET, J; FRIEDMAN, GD; VANDERSTEEN, DP; CHANG, Y; VOGELMAN, JH; ORENTREICH, N; SIBLEY, RK			HELICOBACTER-PYLORI INFECTION AND THE RISK OF GASTRIC-CARCINOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CAMPYLOBACTER-PYLORI; IMMUNE-RESPONSE; CANCER; ASSOCIATION; EPIDEMIOLOGY; POPULATION; STOMACH; DIET	Background. Infection with Helicobacter pylori has been linked with chronic atrophic gastritis, an inflammatory precursor of gastric adenocarcinoma. In a nested case-control study, we explored whether H. pylori infection increases the risk of gastric carcinoma. Methods. From a cohort of 128,992 persons followed since the mid-1960s at a health maintenance organization, 186 patients with gastric carcinoma were selected as case patients and were matched according to age, sex, and race with 186 control subjects without gastric carcinoma. Stored serum samples collected during the 1960s were tested for IgG antibodies to H. pylori by enzyme-linked immunosorbent assay. Data on cigarette use, blood group, ulcer disease, and gastric surgery were obtained from questionnaires administered at enrollment. Tissue sections and pathology reports were reviewed to confirm the histologic results. Results. The mean time between serum collection and the diagnosis of gastric carcinoma was 14.2 years. Of the 109 patients with confirmed gastric adenocarcinoma (excluding tumors of the gastroesophageal junction), 84 percent had been infected previously with H. pylori, as compared with 61 percent of the matched control subjects (odds ratio, 3.6; 95 percent confidence interval, 1.8 to 7.3). Tumors of the gastroesophageal junction were not linked to H. pylori infection, nor were tumors in the gastric cardia. H. pylori was a particularly strong risk factor for stomach cancer in women (odds ratio, 18) and blacks (odds ratio, 9). A history of gastric surgery was independently associated with the development of cancer (odds ratio, 17; P = 0.03), but a history of peptic ulcer disease was negatively associated with subsequent gastric carcinoma (odds ratio, 0.2; P = 0.02). Neither blood group nor smoking history affected risk. Conclusions. Infection with H. pylori is associated with an increased risk of gastric adenocarcinoma and may be a cofactor in the pathogenesis of this malignant condition.	ORENTREICH FDN ADVANCEMENT SCI INC, NEW YORK, NY 10021 USA; STANFORD UNIV, MED CTR, SCH MED, DEPT PATHOL, STANFORD, CA 94305 USA; KAISER PERMANENTE MED CARE PROGRAM, DIV RES, OAKLAND, CA USA	Stanford University; Kaiser Permanente	PARSONNET, J (corresponding author), STANFORD UNIV, MED CTR,SCH MED,DEPT MED,HRP BLDG, RM 109A, STANFORD, CA 94305 USA.		Chang, Yuan/F-4146-2011	Chang, Yuan/0000-0003-1125-4041; Parsonnet, Julie/0000-0001-7342-5366	NCI NIH HHS [R35CA49761] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA049761] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMES BN, 1990, SCIENCE, V249, P970, DOI 10.1126/science.2136249; ARMIJO R, 1981, INT J EPIDEMIOL, V10, P53, DOI 10.1093/ije/10.1.53; BUIATTI E, 1990, INT J CANCER, V45, P896, DOI 10.1002/ijc.2910450520; COLLEN MF, 1969, JOM-J OCCUP MED, V11, P355; CORREA P, 1970, J NATL CANCER I, V44, P297; CORREA P, 1983, JNCI-J NATL CANCER I, V70, P673; CORREA P, 1985, SEMIN ONCOL, V12, P2; CORREA P, 1976, JNCI-J NATL CANCER I, V57, P1027, DOI 10.1093/jnci/57.5.1027; CORREA P, 1990, CANCER RES, V50, P4737; CORREA P, 1982, EPIDEMIOLOGY CANCER, P58; EVANS DJ, 1989, GASTROENTEROLOGY, V96, P1004, DOI 10.1016/0016-5085(89)91616-8; FAULDE M, 1991, J CLIN MICROBIOL, V29, P323, DOI 10.1128/JCM.29.2.323-327.1991; FORMAN D, 1990, INT J CANCER, V46, P608, DOI 10.1002/ijc.2910460410; FOX JG, 1989, AM J GASTROENTEROL, V84, P775; FRIEDMAN GD, 1986, AM J EPIDEMIOL, V123, P781, DOI 10.1093/oxfordjournals.aje.a114307; FRIEDMAN GD, 1974, NEW ENGL J MED, V290, P469, DOI 10.1056/NEJM197402282900901; GAREWAL HS, 1989, PREV MED, V18, P749, DOI 10.1016/0091-7435(89)90046-7; GOODWIN CS, 1987, J INFECT DIS, V155, P488, DOI 10.1093/infdis/155.3.488; GOODWIN CS, 1989, INT J SYST BACTERIOL, V39, P397, DOI 10.1099/00207713-39-4-397; HAENSZEL W, 1972, JNCI-J NATL CANCER I, V49, P969; HIRSCHL AM, 1988, EUR J CLIN MICROBIOL, V7, P570, DOI 10.1007/BF01962618; HOWSON CP, 1986, EPIDEMIOL REV, V8, P1; JASKIEWICZ K, 1989, S AFR MED J, V75, P417; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; LOFFELD RJLF, 1990, HISTOPATHOLOGY, V17, P537, DOI 10.1111/j.1365-2559.1990.tb00793.x; MORRIS A, 1989, J CLIN PATHOL, V42, P727, DOI 10.1136/jcp.42.7.727; MUIR C, 1987, IARC SCI PUBLICATION, V88; MUNOZ N, 1971, INT J CANCER, V8, P158, DOI 10.1002/ijc.2910080119; MUNOZ N, 1968, INT J CANCER, V3, P809, DOI 10.1002/ijc.2910030614; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; PARKIN DM, 1986, IARC SCI PUBLICATION, V75; PARSONNET J, 1991, JNCI-J NATL CANCER I, V83, P640, DOI 10.1093/jnci/83.9.640; PARSONNET J, 1989, CAMPYLOBACTER PYLORI, P51; PEREZPEREZ GI, 1988, ANN INTERN MED, V109, P11, DOI 10.7326/0003-4819-109-1-11; PEREZPEREZ GI, 1990, J INFECT DIS, V161, P1237, DOI 10.1093/infdis/161.6.1237; RAUWS EAJ, 1989, CAMPYLOBACTER PYLORI, P187; ROBINS J, 1986, AM J EPIDEMIOL, V124, P719, DOI 10.1093/oxfordjournals.aje.a114447; SCOTT N, 1990, LANCET, V335, P728, DOI 10.1016/0140-6736(90)90845-V; SIPPONEN P, 1987, SCAND J GASTROENTERO, V22, P865, DOI 10.3109/00365528708991927; STRAUSS RM, 1990, AM J MED, V89, P464, DOI 10.1016/0002-9343(90)90377-P; TALLEY NJ, IN PRESS J NATL CANC	41	3407	3521	9	364	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 17	1991	325	16					1127	1131		10.1056/NEJM199110173251603	http://dx.doi.org/10.1056/NEJM199110173251603			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK538	1891020				2022-12-01	WOS:A1991GK53800003
J	PULVERER, BJ; KYRIAKIS, JM; AVRUCH, J; NIKOLAKAKI, E; WOODGETT, JR				PULVERER, BJ; KYRIAKIS, JM; AVRUCH, J; NIKOLAKAKI, E; WOODGETT, JR			PHOSPHORYLATION OF C-JUN MEDIATED BY MAP KINASES	NATURE			English	Article							V-JUN; PROTEIN; AP-1; TRANSCRIPTION; ACTIVATION; ENCODES	THE proto-oncogene c-jun is a component of the AP-1 transcription factor family involved in the mediation of nuclear events elicited by extracellular stimuli 1-3. The c-jun protein is negatively regulated by phosphorylation of residues near the carboxy terminus which are dephosphorylated in response to phorbol esters 4. Here we identify two serine residues in the amino terminal A1 transactivation domain which are phosphorylated in response to a variety of mitogens, phorbol esters and activated ras (ref. 5). We present evidence that mitogen-activated protein-serine (MAP) kinases (pp54 and pp42/44) specifically phosphorylate these sites and that their phosphorylation positively regulates the transacting activity of c-jun. The MAP kinase enzymes pp54 and pp42/44 are regulated by tyrosine as well as serine/threonine phosphorylation 6,7. MAP kinase activation of c-jun may underlie the common stimulation of this transcription factor by mitogens, growth factors and oncogenes.	LUDWIG INST CANC RES,91 RIDING HOUSE ST,LONDON W1P 8BT,ENGLAND; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DIABET UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,MED SERV,BOSTON,MA 02114	Ludwig Institute for Cancer Research; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital			Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797				ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DARROW AL, 1990, METHOD ENZYMOL, V190, P110; KYRAIKIS JM, 1991, FASEB J, V5, pA797; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; SCHANENKING C, 1991, NEURON, V6, P915, DOI 10.1016/0896-6273(91)90232-O; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; VICENDO P, 1991, BIOCHEM J, V278, P435, DOI 10.1042/bj2780435; WOODGETT JR, 1990, SEMIN CANCER BIOL, V4, P389	20	1404	1436	0	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1991	353	6345					670	674		10.1038/353670a0	http://dx.doi.org/10.1038/353670a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK672	1922387				2022-12-01	WOS:A1991GK67200075
J	RUDENSKY, AY; PRESTONHURLBURT, P; HONG, SC; BARLOW, A; JANEWAY, CA				RUDENSKY, AY; PRESTONHURLBURT, P; HONG, SC; BARLOW, A; JANEWAY, CA			SEQUENCE-ANALYSIS OF PEPTIDES BOUND TO MHC CLASS-II MOLECULES	NATURE			English	Article							ANTIGEN-BINDING SITE; T-CELL RECOGNITION; HISTOCOMPATIBILITY MOLECULES; MONOCLONAL-ANTIBODIES; IA; SPECIFICITY; COMPLEX; CLONES; CHAIN; RESTRICTION	CD4 T cells recognize peptide fragments of foreign proteins bound to self class II molecules of the major histocompatibility complex (MHC). Naturally processed peptide fragments bound to MHC class II molecules are peptides of 13-17 amino acids which appear to be precessively truncated from the carboxy terminus, perhaps after binding to the MHC class II molecule. The finding of predominant self peptides has interesting implications for antigen processing and self-non-self discrimination.	YALE UNIV,SCH MED,PSYCHOL SECT,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	Yale University; Howard Hughes Medical Institute; Yale University								ACHAORBEA H, 1987, P NATL ACAD SCI USA, V84, P2435, DOI 10.1073/pnas.84.8.2435; AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BENOIST C, 1991, Current Biology, V1, P143, DOI 10.1016/0960-9822(91)90213-G; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; Briner T. J., 1987, T CELL RECEPTORS, P309; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BUUS S, 1988, SCIENCE, V242, P1045, DOI 10.1126/science.3194755; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CEASE KB, 1986, J EXP MED, V164, P1779, DOI 10.1084/jem.164.5.1779; CRESSWELL P, 1989, COLD SH Q B, V54, P309; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DEMOTZ S, 1989, NATURE, V342, P682, DOI 10.1038/342682a0; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FINNEGAN A, 1986, J EXP MED, V164, P897, DOI 10.1084/jem.164.3.897; FOX BS, 1988, NATURE, V331, P538, DOI 10.1038/331538a0; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GERMAIN RN, 1986, NATURE, V322, P687, DOI 10.1038/322687a0; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; HEATH WR, 1989, NATURE, V341, P749, DOI 10.1038/341749a0; JANEWAY CA, 1984, J IMMUNOL, V132, P662; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; LERNER EA, 1980, J EXP MED, V152, P1085, DOI 10.1084/jem.152.4.1085; M/ller G., 1988, IMMUNOL REV, V98, P1; MATZINGER P, 1977, CELL IMMUNOL, V29, P1, DOI 10.1016/0008-8749(77)90269-6; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; MURPHY DB, 1989, NATURE, V338, P765, DOI 10.1038/338765a0; PANINABORDIGNON P, 1991, SCIENCE, V252, P1548, DOI 10.1126/science.1710827; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; R/tzschke O., 1990, NATURE, V348, P253; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROTZSCHKE O, 1990, SCIENCE, V249, P283, DOI 10.1126/science.1695760; RUDENSKY AY, 1991, NATURE, V353, P660, DOI 10.1038/353660a0; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SRINIVASAN M, 1990, P NATL ACAD SCI USA, V87, P919, DOI 10.1073/pnas.87.3.919; Stone K. L., 1988, MACROMOLECULAR SEQUE, P7; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; TAKAHASHI H, 1989, J IMMUNOL, V142, P2221; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; VANBLEEK GM, 1990, NATURE, V348, P213; vonBoehmer H., 1989, IMMUNOL TODAY, V10, P61; WATTS TH, 1984, P NATL ACAD SCI-BIOL, V81, P7564, DOI 10.1073/pnas.81.23.7564; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X	49	1016	1062	0	28	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1991	353	6345					622	627		10.1038/353622a0	http://dx.doi.org/10.1038/353622a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK672	1656276				2022-12-01	WOS:A1991GK67200057
J	RUDENSKY, AY; RATH, S; PRESTONHURLBURT, P; MURPHY, DB; JANEWAY, CA				RUDENSKY, AY; RATH, S; PRESTONHURLBURT, P; MURPHY, DB; JANEWAY, CA			ON THE COMPLEXITY OF SELF	NATURE			English	Article							ANTIGEN	SELF peptides bound to self major histocompatibility complex (MHC) molecules have been implicated both in positive 1,2 and in negative 3,4 selection of T cells during intrathymic development. We report here that the novel MHC-restricted monoclonal antibody Y-Ae (ref. 5) detects the MHC class II bound form of a major self peptide 6. Y-Ae binds approximately 12% of the relevant MHC class II molecules on self antigen presenting cells. The peptide detected by Y-Ae is one of several major peptides eluted from the MHC molecule 6. These data suggest that self peptides presented by self MHC class II molecules at densities sufficient to signal a CD4 T cell are of very limited complexity. Furthermore, as Y-Ae stains antigen presenting cells that mediate negative selection but not thymic cortical epithelial cells 5 that drive positive selection 3, differential expression of self peptide:self MHC class II complexes may be a key feature of intrathymic selection.	YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510; HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	Yale University; Howard Hughes Medical Institute								BERG LJ, 1990, CELL, V60, P1043, DOI 10.1016/0092-8674(90)90352-F; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; JANEWAY CA, 1984, J IMMUNOL, V132, P662; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; LERNER EA, 1980, J EXP MED, V152, P1085, DOI 10.1084/jem.152.4.1085; MURPHY DB, 1989, NATURE, V338, P765, DOI 10.1038/338765a0; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; RUDENSKY AY, NATURE, V353, P622; vonBoehmer H., 1989, IMMUNOL TODAY, V10, P61	11	252	255	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1991	353	6345					660	662		10.1038/353660a0	http://dx.doi.org/10.1038/353660a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK672	1656278				2022-12-01	WOS:A1991GK67200070
J	RUPPERSBERG, JP; FRANK, R; PONGS, O; STOCKER, M				RUPPERSBERG, JP; FRANK, R; PONGS, O; STOCKER, M			CLONED NEURONAL IK(A) CHANNELS REOPEN DURING RECOVERY FROM INACTIVATION	NATURE			English	Article							POTASSIUM CHANNELS; DIVERSITY	THE kinetic behaviour and functional role of potassium ion (K+) channels mediating a fast-inactivating K+ current (I(K)(A)) has been widely discussed 1. Activating in the subthreshold range of excitation, I(K)(A) channels are assumed to reduce the excitatory effect of depolarizing membrane currents in a time-dependent manner. Here we report that I(K)(A) channels not only open in response to a depolarization but open again after repolarization of the membrane. Although the current in response to the depolarization is rapidly inactivating, the current elicited by repolarization declines slowly and produces long-lasting after hyperpolarizations under current-clamp conditions. This implies an additional physiological role for I(K)(A) channels, particularly those that activate positive to the threshold of excitation. The underlying biophysical mechanism was studied by fast-application of peptides corresponding to the N-terminal end of the I(K)(A) channel proteins. It was found to be a voltage-dependent release of the inactivation gate.	ZENTRUM MOLEK BIOL,W-6900 HEIDELBERG,GERMANY; RUHR UNIV BOCHUM,LEHRSTUHL BIOCHEM,W-4300 BOCHUM,GERMANY	Ruprecht Karls University Heidelberg; Ruhr University Bochum	RUPPERSBERG, JP (corresponding author), MAX PLANCK INST MED RES,ZELLPHYSIOL ABT,JAHNSTR 29,W-6900 HEIDELBERG 1,GERMANY.		Stocker, Martin/C-1844-2008					CASTRO B, 1977, J CHEM RES, V182, P2118; FRANK R, 1988, MODERN METHODS PROTE, V3, P42; FRANKE C, 1987, NEUROSCI LETT, V77, P199, DOI 10.1016/0304-3940(87)90586-6; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; LANCASTER B, 1986, J NEUROPHYSIOL, V55, P1268, DOI 10.1152/jn.1986.55.6.1268; LANCASTER B, 1984, NEUROSCIENCE, V127, P267; LANCASTER B, 1986, J PHYSIOL-LONDON, V389, P187; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; PAK MD, 1991, P NATL ACAD SCI USA, V88, P4386, DOI 10.1073/pnas.88.10.4386; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; SCHROTER KH, 1991, FEBS LETT, V278, P211, DOI 10.1016/0014-5793(91)80119-N; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	14	133	135	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1991	353	6345					657	660		10.1038/353657a0	http://dx.doi.org/10.1038/353657a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK672	1922383				2022-12-01	WOS:A1991GK67200069
J	YANG, L; LI, R; MOHR, IJ; CLARK, R; BOTCHAN, MR				YANG, L; LI, R; MOHR, IJ; CLARK, R; BOTCHAN, MR			ACTIVATION OF BPV-1 REPLICATION INVITRO BY THE TRANSCRIPTION FACTOR E2	NATURE			English	Article							SV40 DNA-REPLICATION; SIMIAN VIRUS-40 DNA; T-ANTIGEN; HUMAN-CELLS; PROTEIN; ORIGIN; PHOSPHORYLATION; BINDING; COMPLEX	Soluble extracts from uninfected murine cells supplemented with purified viral E1 and E2 proteins support the replication of exogenously added papilloma virus DNA. The E2 transactivator stimulates the binding of the E1 replication protein to the minimal origin of replication and activates DNA replication. These results support the concept that transcription factors have a direct role in the initiation of DNA replication in eukaryotes by participating in the assembly of a complex at the origin of replication.			YANG, L (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV BIOCHEM & MOLEC BIOL, BERKELEY, CA 94720 USA.							BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DODSON M, 1989, J BIOL CHEM, V264, P10719; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HATTON KS, 1988, CANCER CELL, V6, P335; HAUSEN HZ, 1988, PAPILLOMAVIRUSES, P245; HOWLEY PM, 1990, VIROLOGY, P1625; Hurst EW, 1933, J EXP MED, V58, P607, DOI 10.1084/jem.58.5.607; KNIGHT JD, 1991, P NATL ACAD SCI USA, V88, P3204, DOI 10.1073/pnas.88.8.3204; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LIN SY, 1974, P NATL ACAD SCI USA, V71, P947, DOI 10.1073/pnas.71.3.947; LIU Y, 1990, J VIROL, V64, P5903, DOI 10.1128/JVI.64.12.5903-5911.1990; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MOHR IJ, 1987, EMBO J, V6, P153, DOI 10.1002/j.1460-2075.1987.tb04733.x; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; NAKANO N, 1966, TOHOKU J EXP MED, V88, P69, DOI 10.1620/tjem.88.69; PARSONS RE, 1991, J VIROL, V65, P2798, DOI 10.1128/JVI.65.6.2798-2806.1991; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SHARP PA, 1991, NATURE, V351, P16, DOI 10.1038/351016d0; SHAW K, 1990, VIROLOGY, P1652; SPALHOLZ BA, 1985, CELL, V42, P183, DOI 10.1016/S0092-8674(85)80114-8; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; SUN S, 1990, J VIROL, V64, P5093, DOI 10.1128/JVI.64.10.5093-5105.1990; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; VIRSHUP DM, 1989, EMBO J, V8, P3891, DOI 10.1002/j.1460-2075.1989.tb08568.x; WOBBE CR, 1986, P NATL ACAD SCI USA, V83, P4612, DOI 10.1073/pnas.83.13.4612	33	280	286	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 17	1991	353	6345					628	632		10.1038/353628a0	http://dx.doi.org/10.1038/353628a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK672	1656277				2022-12-01	WOS:A1991GK67200058
J	HEALY, B				HEALY, B			MONONUCLEAR CELL SECRETORY PRODUCTS CONTRIBUTE TO BONE TURNOVER FOLLOWING OOPHORECTOMY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							1991, P NATL ACAD SCI USA, V88, P5134	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1991	266	15					2054	2054						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ474	1920686				2022-12-01	WOS:A1991GJ47400008
J	HEALY, B				HEALY, B			BONE-MARROW TRANSPLANTATION FOR ADULTS WITH ACUTE LYMPHOBLASTIC-LEUKEMIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							1991, ANN INTERN MED, V115, P13	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1991	266	15					2054	2054						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ474	1920686				2022-12-01	WOS:A1991GJ47400006
J	HEALY, B				HEALY, B			CHEMOTHERAPY DURING CHILDHOOD DOES NOT ADVERSELY AFFECT OFFSPRING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							1991, JAMA-J AM MED ASSOC, V325, P141	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1991	266	15					2054	2054						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ474	1920686				2022-12-01	WOS:A1991GJ47400007
J	LEVINE, WC; SMART, JF; ARCHER, DL; BEAN, NH; TAUXE, RV				LEVINE, WC; SMART, JF; ARCHER, DL; BEAN, NH; TAUXE, RV			FOODBORNE DISEASE OUTBREAKS IN NURSING-HOMES, 1975 THROUGH 1987	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ESCHERICHIA-COLI O157-H7; ROTAVIRUS INFECTION; SALMONELLA; GASTROENTERITIS; TRANSMISSION; SURVEILLANCE; FACILITIES; HOSPITALS; GUIDELINE	Objective. - To describe the epidemiology of foodborne disease outbreaks in nursing homes and to identify where preventive efforts might be focused. Data Sources. - Reports by state and local health departments of foodborne disease outbreaks occurring from January 1, 1975, through December 31, 1987. Study Selection. - Foodborne disease outbreaks reported to the Centers for Disease Control, Atlanta, Ga, on standard investigation forms. Data Extraction. - Each foodborne disease outbreak report was examined by an epidemiologist or statistician. Outbreaks were considered to have a known pathogen if confirmed by laboratory tests, and a known vehicle when an epidemiologic investigation implicated a specific food item. Data Synthesis. - From 1975 through 1987, 26 states reported 115 outbreaks of foodborne disease in nursing homes, causing illness in 4944 persons and death in 51. These outbreaks represented 2% of all reported foodborne disease outbreaks and 19% of outbreak-associated deaths in this period. Of 52 outbreaks with a known cause, Salmonella was the most frequently reported pathogen, accounting for 52% of outbreaks and 81% of deaths. Salmonella enteritidis outbreaks accounted for 56% of the Salmonella-associated deaths since 1981. The implicated food vehicles in S enteritidis outbreaks were made with eggs or prepared with equipment contaminated with eggs. Staphylococcal foodborne disease was the next most commonly identified cause, accounting for 23% of outbreaks. Conclusions. - Since the elderly are at high risk for serious morbidity from foodborne disease, nursing homes should practice careful food handling, preparation, and storage procedures; provide education for food handlers; and have active infection control programs to rapidly detect and control outbreaks of foodborne disease.	US FDA, CTR FOOD SAFETY & APPL NUTR, DIV MICROBIOL, WASHINGTON, DC 20204 USA	US Food & Drug Administration (FDA)	LEVINE, WC (corresponding author), CTR DIS CONTROL, NATL CTR INFECT DIS, DIV BACTERIAL & MYCOT DIS, ENTER DIS BRANCH, ATLANTA, GA 30333 USA.							ASERKOFF B, 1969, NEW ENGL J MED, V281, P636, DOI 10.1056/NEJM196909182811202; AVORN J, 1981, NEW ENGL J MED, V305, P759, DOI 10.1056/NEJM198109243051309; BAINE WB, 1973, J INFECT DIS, V128, P357, DOI 10.1093/infdis/128.3.357; BARTLETT PC, 1982, PUBLIC HEALTH REP, V97, P258; Bean N H, 1990, MMWR CDC Surveill Summ, V39, P15; BLACK PH, 1960, NEW ENGL J MED, V262, P921, DOI 10.1056/NEJM196005052621806; BLACK PH, 1960, NEW ENGL J MED, V262, P864, DOI 10.1056/NEJM196004282621706; BLACK PH, 1960, NEW ENGL J MED, V262, P811, DOI 10.1056/NEJM196004212621606; BLASER MJ, 1981, J INFECT DIS, V143, P743, DOI 10.1093/infdis/143.5.743; BRYAN FL, 1968, J MILK FOOD TECHNOL, V31, P110, DOI 10.4315/0022-2747-31.4.110; CARTER AO, 1987, NEW ENGL J MED, V317, P1496, DOI 10.1056/NEJM198712103172403; CELUM CL, 1987, J INFECT DIS, V156, P998, DOI 10.1093/infdis/156.6.998; CROSSLEY KB, 1985, JAMA-J AM MED ASSOC, V254, P2918, DOI 10.1001/jama.254.20.2918; CUBITT WD, 1981, J CLIN PATHOL, V34, P924, DOI 10.1136/jcp.34.8.924; CUBITT WD, 1980, J CLIN PATHOL, V33, P306, DOI 10.1136/jcp.33.3.306; GARIBALDI RA, 1981, NEW ENGL J MED, V305, P731, DOI 10.1056/NEJM198109243051304; GARNER JS, 1983, INFECT CONT HOSP EP, V4, P245; GIANNELLA RA, 1971, AM J DIG DIS, V16, P1000, DOI 10.1007/BF02235012; GORDON SM, 1990, AM J EPIDEMIOL, V131, P702, DOI 10.1093/oxfordjournals.aje.a115554; GRIFFIN PM, 1988, ANN INTERN MED, V109, P705, DOI 10.7326/0003-4819-109-9-705; HOLMBERG SD, 1984, JAMA-J AM MED ASSOC, V251, P487, DOI 10.1001/jama.251.4.487; HOLMBERG SD, 1984, NEW ENGL J MED, V311, P617, DOI 10.1056/NEJM198409063111001; HONISH A, 1986, ALBERTA SOC SERV COM, V10, P363; JOSEPH CA, 1989, BRIT MED J, V298, P1161, DOI 10.1136/bmj.298.6681.1161; KAPLAN JE, 1982, AM J EPIDEMIOL, V116, P940, DOI 10.1093/oxfordjournals.aje.a113496; KAPLAN JE, 1982, AM J PUBLIC HEALTH, V72, P1329, DOI 10.2105/AJPH.72.12.1329; LEVINE WC, 1991, J INFECT DIS, V164, P81, DOI 10.1093/infdis/164.1.81; MARRIE TJ, 1982, ARCH INTERN MED, V142, P313, DOI 10.1001/archinte.142.2.313; NEILL MA, 1991, ANN INTERN MED, V114, P195, DOI 10.7326/0003-4819-114-3-195; NICOLLE LE, 1984, J AM GERIATR SOC, V32, P513, DOI 10.1111/j.1532-5415.1984.tb02236.x; PAVIA AT, 1990, J INFECT DIS, V161, P255, DOI 10.1093/infdis/161.2.255; REID JA, 1988, LANCET, V2, P321; RILEY LW, 1984, J INFECT DIS, V149, P878, DOI 10.1093/infdis/149.6.878; RYAN CA, 1986, J INFECT DIS, V154, P631, DOI 10.1093/infdis/154.4.631; SCHROEDER SA, 1968, NEW ENGL J MED, V279, P674, DOI 10.1056/NEJM196809262791303; SMITH PW, 1987, AM J INFECT CONTROL, V15, P97, DOI 10.1016/0196-6553(87)90162-3; STLOUIS ME, 1988, JAMA-J AM MED ASSOC, V259, P2103, DOI 10.1001/jama.259.14.2103; TAUXE RV, 1988, J INFECT DIS, V157, P370, DOI 10.1093/infdis/157.2.370; VLAHOV D, 1987, AM J INFECT CONTROL, V15, P47, DOI 10.1016/0196-6553(87)90001-0; WHITE KE, 1986, AM J EPIDEMIOL, V124, P120, DOI 10.1093/oxfordjournals.aje.a114356; WHITE KE, 1989, J INFECT DIS, V160, P298, DOI 10.1093/infdis/160.2.298; WILLIAMS WW, 1983, INFECT CONT HOSP EP, V4, P326; 1989, VITAL HLTH STAT 14, V33; 1990, MMWR, V38, P877; 1983, CAN DISEASE WEEKLY R, V9, P29	45	95	98	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1991	266	15					2105	2109		10.1001/jama.266.15.2105	http://dx.doi.org/10.1001/jama.266.15.2105			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ474	1656108				2022-12-01	WOS:A1991GJ47400031
J	SAMUELS, B; GLANTZ, SA				SAMUELS, B; GLANTZ, SA			THE POLITICS OF LOCAL TOBACCO CONTROL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Until the nonsmokers' rights movement, tobacco control activity was at the federal or state levels, which is where the tobacco industry dominates. Since the appearance of the nonsmokers' rights movement, progress in tobacco control has occurred primarily at the local level. In response to the success of this movement, the tobacco industry has developed "smokers' rights" groups and other tactics to fight local legislation. Several recent local campaigns in California illustrate these tactics. Tobacco control forces follow many paths, from sitting on the sidelines to making a serious commitment to smoking control legislation. Despite the tobacco industry's superior financial resources, the outcome of proposed local tobacco control legislation appears to depend on how seriously the health advocates mobilize in support of the local legislation. When the health community makes a serious commitment of time and resources, it wins. When it fails to make such a commitment, the tobacco industry prevails, more by default than by its superior financial resources.	UNIV CALIF SAN FRANCISCO,DEPT MED,DIV CARDIOL,BOX 0124,ROOM 1186M,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco								ARNOLD R, 1987, LOS ANGELES TIM 0403; BEGAY ME, 1991, U CALIFORNIA I HLTH, P55; BLOOM S, 1991, SACRAMENTO BEE  0419, pB1; CHAVEZ K, 1990, SACRAMENTO BEE  1201, pB1; DEMPSTER D, 1990, SACRAMENTO BEE  0912, pA1; FERREL D, 1990, LOS ANGELES TIM 1017, pA1; FERRIS J, 1991, CONTRA COSTA TI 0623; FITCH A, 1990, MUNICIPAL LEGISLATIV; FREEDMAN A, 1988, WALL ST J       0411; GALLUP G, 1989, GALLUP POLL     0416; GLANTZ SA, 1987, CIRCULATION, V76, P746, DOI 10.1161/01.CIR.76.4.746; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; HAGER P, 1987, LOS ANGELES TIM 0521; HANAUER P, 1985, NEW YORK STATE J MED, V85, P369; HANAUER P, 1986, LEGISLATIVE APPROACH, P1; IFERGAN SJ, 1987, BEVERLY HILLS CO MAY; JACOBS C, 1991, LOS ANGELES BUS 1022; JOSON J, 1991, DAILY REV       0317, P1; KING J, 1991, CONTRA COSTA TI 0511, pA5; KONRAD W, 1990, BUSINESS WEEK   0806, P48; MATHEWS J, 1991, SACRAMENTO BEE  0422; MAXWELL JC, 1989, ADVERTISING AGE 1204; MORRIS P, 1990, INDEPENDENT MAJOR DO; PERTSCHUK M, 1989, MAJOR LOCAL SMOKING; Pritchard R., 1986, US TOBACCO CAND 0717, P86; REYNOLDS RJ, 1989, INDEPENDENT EXPENDIT; SAMUELS BE, 1991, U CALIFORNIA I HLTH; STILLMAN FA, 1990, JAMA-J AM MED ASSOC, V264, P1565, DOI 10.1001/jama.264.12.1565; STUMBO B, 1986, LOS ANGELES TIM 0824, P11; STUMBO B, 1986, LOS ANGELES TIM 0824, P24; SYLVESTER K, 1989, GOVERNING        MAY, P34; TAYLOR P, 1984, SMOKE RING, P189; WARNER KE, 1989, AM J PUBLIC HEALTH, V79, P144, DOI 10.2105/AJPH.79.2.144; 1991, P MORRIS MAGAZINE, V6, P22; 1990, PRELIMINARY ANAL IMP; 1982, KERN COUNTY SMOKING; 1991, 1991 92 DIRECTORY LO, P195; 1986, HLTH CONSEQUENCES IN; 1991, SLO RESTAURANTS JOIN; 1978, PUBLIC ATTITUDES CIG; 1990, GENERAL PURPOSE RECI; 1990, US EPA600690006A PUB; 1987, CHOICE, V1, P4	43	106	107	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1991	266	15					2110	2117		10.1001/jama.266.15.2110	http://dx.doi.org/10.1001/jama.266.15.2110			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GJ474	1920699				2022-12-01	WOS:A1991GJ47400032
J	ANDERSON, FA; WHEELER, HB; GOLDBERG, RJ; HOSMER, DW; FORCIER, A; PATWARDHAN, NA				ANDERSON, FA; WHEELER, HB; GOLDBERG, RJ; HOSMER, DW; FORCIER, A; PATWARDHAN, NA			PHYSICIAN PRACTICES IN THE PREVENTION OF VENOUS THROMBOEMBOLISM	ANNALS OF INTERNAL MEDICINE			English	Article						HEPARIN; INTERMITTENT CALF COMPRESSION; THROMBOEMBOLISM; VENA CAVA FILTER; WARFARIN	PULMONARY-EMBOLISM; SURGICAL PATIENTS; UNITED-STATES; MORTALITY; DIAGNOSIS	Objective: To determine the rate of use of prophylaxis for venous thromboembolism in high-risk hospital patients. Design: A retrospective medical record review. Setting: A community-wide study in 16 short-stay hospitals in central Massachusetts. Patients: A total of 2017 patients with multiple risk factors for venous thromboembolism. Measurements and Main Results: On the basis of age, length of hospitalization, and the presence of at least one additional major risk factor, 17% of 151 349 discharges (25 410 patients) were identified as being at high risk for venous thromboembolism. Eight percent of these discharges were randomly selected for medical record review. Prophylaxis for venous thromboembolism was received by 32% of these high-risk patients. Prophylaxis use among the 16 study hospitals varied widely, ranging from 9% to 56%, and was higher in teaching hospitals than in nonteaching hospitals (44% compared with 19%; P < 0.001). One or more of the following methods of prophylaxis was used: low-dose heparin (78%), intermittent calf compression (13%), warfarin (12%), and inferior vena caval filter (3%). Use of prophylaxis increased with the number of risk factors identified (P < 0.001). Conclusion: Prophylaxis for venous thromboembolism is underused, particularly in nonteaching hospitals.			ANDERSON, FA (corresponding author), UNIV MASSACHUSETTS, MED CTR, SCH MED, 55 LAKE AVE N, WORCESTER, MA 01655 USA.				NHLBI NIH HHS [HL RO1-35862] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035862] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; [Anonymous], 1975, LANCET, V2, P45; BERGQVIST D, 1985, BRIT J SURG, V72, P105, DOI 10.1002/bjs.1800720211; BERGQVIST D, 1983, POSTOPERATIVE THROMB, P156; BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; Carter C, 1982, HEMOSTASIS THROMBOSI, P805; CHAMBLESS LE, 1985, COMMUN STAT-THEOR M, V14, P1377, DOI 10.1080/03610928508828982; CLAGETT GP, 1988, ANN SURG, V208, P227, DOI 10.1097/00000658-198808000-00016; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; CONTI S, 1982, ARCH SURG-CHICAGO, V117, P1036; CONTI S, 1980, VASCULAR SURG, V14, P382, DOI 10.1177/153857448001400604; DALEN JE, 1975, PROG CARDIOVASC DIS, V17, P259, DOI 10.1016/S0033-0620(75)80017-X; DISMUKE SE, 1986, JAMA-J AM MED ASSOC, V255, P2039, DOI 10.1001/jama.255.15.2039; GILLUM RF, 1987, AM HEART J, V114, P1262, DOI 10.1016/0002-8703(87)90212-2; GOLDHABER SZ, 1982, AM J MED, V73, P822, DOI 10.1016/0002-9343(82)90764-1; GOLDHABER SZ, 1982, AM HEART J, V104, P305, DOI 10.1016/0002-8703(82)90207-1; HIRSH J, 1981, VENOUS THROMBOEMBOLI, P1; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; NICOLAIDES AN, 1975, THROMBOEMBOLISM AETI, P193; SEVITT S, 1959, LANCET, V2, P981; SIMON TL, 1974, CLIN ORTHOP RELAT R, V102, P181; 1985, SAS USERS GUIDE STAT; 1977, CIRCULATION, V55, P423; 1975, AMA HEIGHT WEIGHT TA	24	176	180	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1991	115	8					591	595		10.7326/0003-4819-591	http://dx.doi.org/10.7326/0003-4819-591			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ902	1892330				2022-12-01	WOS:A1991GJ90200002
J	BARRERA, JM; BRUGUERA, M; ERCILLA, G; SANCHEZTAPIAS, JM; GIL, MP; GIL, C; COSTA, J; GELABERT, A; RODES, J; CASTILLO, R				BARRERA, JM; BRUGUERA, M; ERCILLA, G; SANCHEZTAPIAS, JM; GIL, MP; GIL, C; COSTA, J; GELABERT, A; RODES, J; CASTILLO, R			INCIDENCE OF NON-A, NON-B HEPATITIS AFTER SCREENING BLOOD-DONORS FOR ANTIBODIES TO HEPATITIS-C VIRUS AND SURROGATE MARKERS	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS, VIRAL, NON-A, NON-B; HEPATITIS-C VIRUS; HEPATITIS ANTIBODIES; BLOOD DONORS; BLOOD TRANSFUSION	TRANSFUSION-TRANSMITTED VIRUSES; CORE ANTIGEN; RECIPIENTS; EPIDEMIOLOGY; INFECTIVITY; AGENTS; ASSAY	Objective: To compare the effect of screening blood donors for antibodies to hepatitis C virus (anti-HCV) on the incidence of non-A, non-B hepatitis in recipients with that of screening blood donors for antibodies to hepatitis B core antigen (anti-HBc) and elevated alanine aminotransferase levels. Design: Cohort analysis of serum samples from donors and recipients. Recipients were followed for 12 months to determine the occurrence of non-A, non-B hepatitis. Setting: The blood-transmitted viruses unit and the liver unit of a university teaching hospital. Subjects: A total of 250 patients who had open heart surgery and their 3142 blood donors. Measurements: Donor sera were tested for anti-HCV by enzyme-linked immunosorbent assay (ELISA) and, in the event of a positive result, by recombinant immunoblot assay (RIBA). Antibodies to anti-HBc and serum alanine aminotransferase (ALT) levels were also measured. Measurements of anti-HCV and ALT activity in recipients were done before transfusion and at regular intervals during follow-up. Main Results: Of the 250 transfusion recipients, 40 developed non-A, non-B hepatitis. Of the 3142 donors, 70 were positive for anti-HCV by ELISA, 440 were positive for anti-HBc, and 177 had alanine aminotransferase levels between 0.67 and 1.33-mu-kat/L. The sensitivity (87%), specificity (89%), positive predictive value (59%), and negative predictive value (97%) of blood-donor screening were higher for anti-HCV than for anti-HBc (82%, 36%, 21%, and 91%, respectively) and for elevated alanine aminotransferase levels (65%, 70%, 29%, and 91%, respectively). The expected number of donors excluded because of the presence of anti-HCV was considerably smaller than that of donors with positive results for surrogate markers of hepatitis. Conclusions: Screening blood donors for the presence of anti-HCV is more accurate than screening for surrogate markers (anti-HBc and ALT) and protects more effectively against post-transfusion non-A, non-B hepatitis.	UNIV BARCELONA, HOSP CLIN & PROVINCIAL, VILLARROEL 170, E-08036 BARCELONA, SPAIN	University of Barcelona				Gil, M. Pilar/0000-0002-6281-0282; Gil, Cristina/0000-0002-2692-8814				AACH RD, 1981, NEW ENGL J MED, V304, P989, DOI 10.1056/NEJM198104233041701; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1981, JAMA-J AM MED ASSOC, V246, P630, DOI 10.1001/jama.246.6.630; ALTER HJ, 1972, ANN INTERN MED, V77, P691, DOI 10.7326/0003-4819-77-5-691; BARRERA JM, 1987, MED CLIN-BARCELONA, V89, P759; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P439; EBELING F, 1990, LANCET, V335, P982, DOI 10.1016/0140-6736(90)91055-F; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; GRINER PF, 1981, ANN INTERN MED, V94, P553, DOI 10.7326/0003-4819-94-4-571; HOLLINGER FB, 1980, J INFECT DIS, V142, P400, DOI 10.1093/infdis/142.3.400; HOYOS M, 1989, HEPATOLOGY, V9, P449, DOI 10.1002/hep.1840090318; KOZIOL DE, 1986, ANN INTERN MED, V104, P488, DOI 10.7326/0003-4819-104-4-488; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MOSLEY JW, 1990, JAMA-J AM MED ASSOC, V263, P77, DOI 10.1001/jama.263.1.77; SANCHEZTAPIAS JM, 1990, ANN INTERN MED, V112, P921, DOI 10.7326/0003-4819-112-12-921; STEVENS CE, 1990, JAMA-J AM MED ASSOC, V263, P49, DOI 10.1001/jama.263.1.49; STEVENS CE, 1984, ANN INTERN MED, V101, P733, DOI 10.7326/0003-4819-101-6-733; TREMOLADA F, 1991, ANN INTERN MED, V114, P277, DOI 10.7326/0003-4819-114-4-277; VANDERPOEL CL, 1990, LANCET, V335, P558, DOI 10.1016/0140-6736(90)90347-8; VANDERPOEL CL, 1989, LANCET, V2, P297	21	53	53	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1991	115	8					596	600		10.7326/0003-4819-115-8-596	http://dx.doi.org/10.7326/0003-4819-115-8-596			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ902	1909848				2022-12-01	WOS:A1991GJ90200003
J	CHOW, JW; FINE, MJ; SHLAES, DM; QUINN, JP; HOOPER, DC; JOHNSON, MP; RAMPHAL, R; WAGENER, MM; MIYASHIRO, DK; YU, VL				CHOW, JW; FINE, MJ; SHLAES, DM; QUINN, JP; HOOPER, DC; JOHNSON, MP; RAMPHAL, R; WAGENER, MM; MIYASHIRO, DK; YU, VL			ENTEROBACTER BACTEREMIA - CLINICAL-FEATURES AND EMERGENCE OF ANTIBIOTIC-RESISTANCE DURING THERAPY	ANNALS OF INTERNAL MEDICINE			English	Article						CEPHALOSPORINS; DRUG RESISTANCE, MICROBIAL; ENTEROBACTER; SEPTICEMIA; AMINOGLYCOSIDES	SERIOUS BACTERIAL-INFECTIONS; GRAM-NEGATIVE BACTERIA; INDUCIBLE BETA-LACTAMASES; CEFTRIAXONE THERAPY; CEPHALOSPORINS; CEFTAZIDIME; CLOACAE; CEFAMANDOLE; PSEUDOMONAS; GENTAMICIN	Objectives: To study the effect of previously administered antibiotics on the antibiotic susceptibility profile of Enterobacter, the factors affecting mortality, and the emergence of antibiotic resistance during therapy for Enterobacter bacteremia. Design: Prospective, observational study of consecutive patients with Enterobacter bacteremia. Setting: Three university tertiary care centers, one major university-affiliated hospital, and two university-affiliated Veterans Affairs medical centers. Patients: A total of 129 adult patients were studied. Measurements: The two main end points were emergence of resistance during antibiotic therapy and death. Main Results: Previous administration of third-generation cephalosporins was more likely to be associated with multiresistant Enterobacter isolates in an initial, positive blood culture (22 of 32, 69%) than was administration of antibiotics that did not include a third-generation cephalosporin (14 of 71, 20%; P < 0.001). Isolation of multiresistant Enterobacter sp. in the initial blood culture was associated with a higher mortality rate (12 of 37, 32%) than was isolation of a more sensitive Enterobacter sp. (14 of 92, 15%; P = 0.03). Emergence of resistance to third-generation cephalosporin therapy (6 of 31, 19%) occurred more often than did emergence of resistance to aminoglycoside (1 of 89, 0.01%; P = 0.001) or other beta-lactam (0 of 50; P = 0.002) therapy. Conclusions: More judicious use of third-generation cephalosporins may decrease the incidence of nosocomial multiresistant Enterobacter spp., which in turn may result in a lower mortality for Enterobacter bacteremia. When Enterobacter organisms are isolated from blood, it may be prudent to avoid third-generation cephalosporin therapy regardless of in-vitro susceptibility.	UNIV PITTSBURGH, SCH MED, 968 SCAIFE, PITTSBURGH, PA 15261 USA; PITTSBURGH DEPT VET AFFAIRS MED CTR, PITTSBURGH, PA USA; MASSACHUSETTS GEN HOSP, BOSTON, MA 02114 USA; CLEVELAND DEPT VET AFFAIRS MED CTR, CLEVELAND, OH USA; MICHAEL REESE HOSP & MED CTR, CHICAGO, IL 60616 USA; UNIV FLORIDA, GAINESVILLE, FL 32611 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Massachusetts General Hospital; Michael Reese Hospital & Medical Center; State University System of Florida; University of Florida			Chow, Joseph W/W-4164-2017	Chow, Joseph W/0000-0002-5934-5877	PHS HHS [5T32A107333] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ausubel F, 1990, CURRENT PROTOCOLS MO, V1; BECKWITH DG, 1980, J CLIN MICROBIOL, V12, P517, DOI 10.1128/JCM.12.4.517-520.1980; BITTNER MJ, 1983, ANTIMICROB AGENTS CH, V23, P261, DOI 10.1128/AAC.23.2.261; BOUZA E, 1985, ARCH INTERN MED, V145, P1024, DOI 10.1001/archinte.145.6.1024; BRYAN CS, 1985, AM J DIS CHILD, V139, P1086, DOI 10.1001/archpedi.1985.02140130024022; BURCHARD KW, 1986, SURGERY, V100, P857; BUSH K, 1982, ANTIMICROB AGENTS CH, V22, P414, DOI 10.1128/AAC.22.3.414; DWORZACK DL, 1987, EUR J CLIN MICROBIOL, V6, P456, DOI 10.1007/BF02013110; ERON LJ, 1983, J ANTIMICROB CHEMOTH, V12, P65, DOI 10.1093/jac/12.1.65; FOLLATH F, 1987, EUR J CLIN MICROBIOL, V6, P446, DOI 10.1007/BF02013108; FUNG CP, 1988, CHUNG HUA I HSUEH TS, V42, P297; GALLAGHER PG, 1990, REV INFECT DIS, V12, P808; GASTON MA, 1988, J HOSP INFECT, V11, P197, DOI 10.1016/0195-6701(88)90098-9; GRIBBLE MJ, 1983, ANTIMICROB AGENTS CH, V24, P388, DOI 10.1128/AAC.24.3.388; HILF M, 1989, AM J MED, V87, P540, DOI 10.1016/S0002-9343(89)80611-4; JARLIER V, 1984, PATHOL BIOL, V32, P399; KORVICK J, 1988, ANN M AM SOC MICROBI; KORVICK JA, 1991, SURGERY, V109, P62; LANDESMAN SH, 1981, AM J MED, V71, P693, DOI 10.1016/0002-9343(81)90240-0; LEVINE LR, 1978, J INFECT DIS, V137, pS125, DOI 10.1093/infdis/137.Supplement.S125; Maniatis T, 1982, MOL CLONING LABORATO, P89; MARIER RL, 1982, J ANTIMICROB CHEMOTH, V9, P85, DOI 10.1093/jac/9.suppl_B.85; MATTHEW M, 1975, J GEN MICROBIOL, V88, P169, DOI 10.1099/00221287-88-1-169; MILATOVIC D, 1987, EUR J CLIN MICROBIOL, V6, P234, DOI 10.1007/BF02017607; Miller G., 1980, DEV IND MICROBIOL, V21, P91; MURPHY TF, 1982, ANTIMICROB AGENTS CH, V21, P568, DOI 10.1128/AAC.21.4.568; MURRAY PR, 1983, J INFECT DIS, V147, P590, DOI 10.1093/infdis/147.3.590; NEU HC, 1990, AM J MED, V88, pS3, DOI 10.1016/0002-9343(90)90321-4; OLSON B, 1983, J ANTIMICROB CHEMOTH, V11, P299, DOI 10.1093/jac/11.4.299; PECHERE JC, 1983, J ANTIMICROB CHEMOTH, V12, P181, DOI 10.1093/jac/12.suppl_A.181; PERKINS RL, 1978, J INFECT DIS, V137, pS110, DOI 10.1093/infdis/137.Supplement.S110; QUINN JP, 1989, ANTIMICROB AGENTS CH, V33, P1451, DOI 10.1128/AAC.33.9.1451; QUINN JP, 1987, J INFECT DIS, V155, P942, DOI 10.1093/infdis/155.5.942; SANDERS CC, 1982, J INFECT DIS, V145, P118, DOI 10.1093/infdis/145.1.118; SANDERS CC, 1985, J INFECT DIS, V151, P399, DOI 10.1093/infdis/151.3.399; SANDERS CC, 1983, REV INFECT DIS, V5, P639; SANDERS WE, 1988, REV INFECT DIS, V10, P830; SCULLY BE, 1984, ARCH INTERN MED, V144, P57, DOI 10.1001/archinte.144.1.57; SPRATT BG, 1977, EUR J BIOCHEM, V72, P341, DOI 10.1111/j.1432-1033.1977.tb11258.x; WATANAKUNAKORN C, 1989, SCAND J INFECT DIS, V21, P1, DOI 10.3109/00365548909035673; WEINSTEIN RA, 1986, INFECT CONT HOSP EP, V7, P120, DOI 10.1017/S0195941700065632; Young LS, 1990, PRINCIPLES PRACTICE, P611; 1983, MMWR, V22, P155; 1988, PROPHET STATISTICS U, P115	44	709	725	1	45	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1991	115	8					585	590		10.7326/0003-4819-115-8-585	http://dx.doi.org/10.7326/0003-4819-115-8-585			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ902	1892329				2022-12-01	WOS:A1991GJ90200001
J	MILNER, MR; HAWLEY, RJ; JACHIM, M; LINDSAY, J; FLETCHER, RD				MILNER, MR; HAWLEY, RJ; JACHIM, M; LINDSAY, J; FLETCHER, RD			VENTRICULAR LATE POTENTIALS IN MYOTONIC-DYSTROPHY	ANNALS OF INTERNAL MEDICINE			English	Article						MYOTONIA DYSTROPHY; ELECTROCARDIOGRAPHY; VENTRICULAR LATE POTENTIALS; HEART CONDUCTION SYSTEM; ARRHYTHMIA	SIGNAL-AVERAGED ELECTROCARDIOGRAM; CARDIAC INVOLVEMENT; MUSCULAR-DYSTROPHY; CONDUCTION SYSTEM; NATURAL-HISTORY; SUDDEN-DEATH; TACHYCARDIA; DISEASE; ELECTROGRAMS; SURFACE	Objective: To determine the prevalence of ventricular late potentials, as determined by signal-averaged electrocardiography, in patients with myotonic dystrophy. Design: Cross sectional, with blinded analysis of all electrocardiographic data. Setting: Outpatient departments of a Veterans Affairs medical center and a tertiary care private hospital. Participants: Twenty-four patients with myotonic dystrophy. Patients were excluded from the study if they had either a history suggestive of significant ventricular arrhythmias or electrocardiographic evidence of a bundle-branch block. Two comparison groups were also formed; one group included 44 healthy employees at the tertiary hospital and the other, 30 cardiac patients with inducible ventricular tachycardia. Main Results: A time-domain analysis of the signal-averaged electrocardiograms showed that 75% of patients with myotonic dystrophy met one criterion for the presence of late potentials, 67% met two criteria, and 29% met all three criteria. Spectrotemporal mapping in these patients showed markedly abnormal spectral peaks with a mean factor of normality that was significantly lower than that of the normal volunteers; the frequency of electrocardiographic abnormalities approached that seen in patients with known ventricular tachycardia. The presence of late potentials correlated directly with the length of the PR interval and inversely with left ventricular fractional shortening. Conclusions: In our study, the prevalence of late potentials on signal-averaged electrocardiography in patients with myotonic dystrophy approached that seen in cardiac patients with inducible ventricular tachycardia. It is possible that ventricular arrhythmias play a role in the occurrence of sudden death in some patients with myotonic dystrophy.	GEORGETOWN UNIV, WASHINGTON HOSP CTR, VET AFFAIRS MED CTR, WASHINGTON, DC USA; GEORGE WASHINGTON UNIV, SCH MED, WASHINGTON, DC 20052 USA	Georgetown University; MedStar Washington Hospital Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); George Washington University								BACIARELLO G, 1986, AM HEART J, V111, P413, DOI 10.1016/0002-8703(86)90162-6; CANNOM DS, 1984, J AM COLL CARDIOL, V4, P625, DOI 10.1016/S0735-1097(84)80112-6; DENNISS AR, 1987, AM J CARDIOL, V59, P586, DOI 10.1016/0002-9149(87)91174-X; GARDNER PI, 1985, CIRCULATION, V72, P596, DOI 10.1161/01.CIR.72.3.596; GOMES JA, 1987, J AM COLL CARDIOL, V10, P349; GRIGG LE, 1985, J AM COLL CARDIOL, V6, P254, DOI 10.1016/S0735-1097(85)80286-2; HABERL R, 1989, EUR HEART J, V10, P316, DOI 10.1093/oxfordjournals.eurheartj.a059488; HAWLEY RJ, 1991, NEUROLOGY, V41, P259, DOI 10.1212/WNL.41.2_Part_1.259; HIROMASA S, 1988, AM HEART J, V115, P914, DOI 10.1016/0002-8703(88)90901-5; KUCHAR DL, 1987, J AM COLL CARDIOL, V9, P531, DOI 10.1016/S0735-1097(87)80045-1; MELACINI P, 1988, CLIN CARDIOL, V11, P231, DOI 10.1002/clc.4960110407; MIELKE U, 1985, J NEUROL, V232, P271, DOI 10.1007/BF00313863; MILNER MR, 1989, CLIN RES, V37, pA280; MOTTA J, 1979, AM J MED, V67, P467, DOI 10.1016/0002-9343(79)90795-2; MUNSAT TL, 1967, NEUROLOGY, V17, P359, DOI 10.1212/WNL.17.4.359; NGUYEN HH, 1988, J AM COLL CARDIOL, V11, P662, DOI 10.1016/0735-1097(88)91547-1; OLOFSSON BO, 1988, BRIT HEART J, V59, P47; PERLOFF JK, 1984, AM J CARDIOL, V54, P1074, DOI 10.1016/S0002-9149(84)80147-2; PRYSTOWSKY EN, 1979, CIRCULATION, V60, P1360, DOI 10.1161/01.CIR.60.6.1360; RENAUD JF, 1987, BIOCHIMIE, V69, P407, DOI 10.1016/0300-9084(87)90032-0; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SIMSON MB, 1983, AM J CARDIOL, V51, P105, DOI 10.1016/S0002-9149(83)80020-4; STREIB EW, 1985, MUSCLE NERVE, V8, P650, DOI 10.1002/mus.880080804; WALTON JN, 1981, DISORDERS VOLUNTARY, P510	24	24	24	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1991	115	8					607	613		10.7326/0003-4819-115-8-607	http://dx.doi.org/10.7326/0003-4819-115-8-607			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ902	1892332				2022-12-01	WOS:A1991GJ90200005
J	POWARS, DR; ELLIOTTMILLS, DD; CHAN, L; NILAND, J; HITI, AL; OPAS, LM; JOHNSON, C				POWARS, DR; ELLIOTTMILLS, DD; CHAN, L; NILAND, J; HITI, AL; OPAS, LM; JOHNSON, C			CHRONIC-RENAL-FAILURE IN SICKLE-CELL DISEASE - RISK-FACTORS, CLINICAL COURSE, AND MORTALITY	ANNALS OF INTERNAL MEDICINE			English	Article						KIDNEY FAILURE, CHRONIC; ANEMIA, SICKLE CELL; HEMOGLOBIN-SC DISEASE; HYPERTENSION; NEPHROTIC SYNDROME	NATURAL-HISTORY; CONFIDENCE-INTERVAL; ENDOTHELIAL-CELLS; FETAL HEMOGLOBIN; BLOOD-PRESSURE; GLOBIN GENE; ANEMIA; NEPHROPATHY; TRANSPLANTATION; ERYTHROCYTES	Objective: To determine the incidence, clinical course, and risk factors associated with the onset of chronic renal failure in sickle cell anemia and sickle C disease. Design: A prospective, 25-year longitudinal demographic and clinical cohort study. A matched case-control study was conducted to determine risk factors. Patients: A total of 725 patients with sickle cell anemia and 209 patients with sickle C disease who received medical care from the hematology service in a large municipal hospital. Most were observed from birth or early childhood. Measurements: Thirty-six patients developed sickle renal failure: 4.2% of patients with sickle cell anemia and 2.4% of patients with sickle C disease. The median age of disease onset for these patients was 23.1 and 49.9 years, respectively. Survival time for patients with sickle cell anemia after the diagnosis of sickle renal failure, despite dialysis, was 4 years, and the median age at the time of death was 27 years. Relative risk for mortality was 1.42 (95% CI, 1.12 to 1.81; P = 0.02) compared with patients who did not develop renal insufficiency. Main Results: Histopathologic studies showed characteristic lesions of glomerular "drop out" and glomerulosclerosis. Case-control analysis showed that ineffective erythropoiesis with increasingly severe anemia, hypertension, proteinuria, the nephrotic syndrome, and microscopic hematuria were significant pre-azotemic predictors of chronic renal failure. The risk for sickle renal failure was increased in patients who had inherited the Central African Republic beta-S-gene cluster haplotype. Conclusions: The pre-azotemic manifestations of hypertension, proteinuria, and increasingly severe anemia predict end-stage renal failure in patients with sickle cell disease. The rate of progression of renal insufficiency is genetically determined. Treatment of the uremic phase has been dismal, underscoring the need for the development of useful pre-azotemic therapeutic modalities.			POWARS, DR (corresponding author), UNIV SO CALIF, SCH MED, PEDIAT PAVILION, 1129 N STATE ST, ROOM 2E19, LOS ANGELES, CA 90033 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL015162] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 15162] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1987, PEDIATRICS, V79, P1; ANTONARAKIS SE, 1984, P NATL ACAD SCI-BIOL, V81, P853, DOI 10.1073/pnas.81.3.853; BARANOWSKI T, 1988, PEDIATR RES, V23, P270, DOI 10.1203/00006450-198803000-00008; BRENNER BM, 1982, NEW ENGL J MED, V307, P652, DOI 10.1056/NEJM198209093071104; BRESLOW NE, 1984, INT J EPIDEMIOL, V13, P112, DOI 10.1093/ije/13.1.112; BUCKALEW VM, 1974, ARCH INTERN MED, V133, P660, DOI 10.1001/archinte.133.4.660; CHAN LS, 1982, J CHRON DIS, V35, P401, DOI 10.1016/0021-9681(82)90010-8; CHATTERJEE SN, 1987, TRANSPLANT P, V19, P33; COE FL, 1976, KIDNEY, V2, P767; CRUZ IA, 1982, J NATL MED ASSOC, V74, P1103; Dean A. G., 1990, EPI INFO VERSION 5 W; DEJONG PE, 1985, KIDNEY INT, V27, P711, DOI 10.1038/ki.1985.70; Diggs LW, 1934, SOUTH MED J, V27, P839; EATON WA, 1987, BLOOD, V70, P1245; ESCHBACH JW, 1987, NEW ENGL J MED, V316, P73, DOI 10.1056/NEJM198701083160203; FLEISS JL, 1973, STATISTICAL METHODS; FREEDMAN BI, 1990, AM J KIDNEY DIS, V15, P361, DOI 10.1016/S0272-6386(12)80082-5; FRIEDMAN EA, 1974, NEW ENGL J MED, V291, P431, DOI 10.1056/NEJM197408292910902; GONZALEZCARRILLO M, 1982, CLIN NEPHROL, V18, P209; GREEN MA, 1988, J CLIN INVEST, V81, P1669, DOI 10.1172/JCI113504; HADDY TB, 1982, AM J PEDIAT HEMATOL, V4, P191; HENDERSON AB, 1950, AM J MED, V9, P757, DOI 10.1016/0002-9343(50)90291-9; HOWE GR, 1983, BIOMETRICS, V39, P325, DOI 10.2307/2531005; HOWE GR, 1986, INT J EPIDEMIOL, V15, P257, DOI 10.1093/ije/15.2.257; JOHNSON CS, 1981, ARCH INTERN MED, V141, P891, DOI 10.1001/archinte.141.7.891; KAPLOW LS, 1968, J AMER MED ASSOC, V203, P1135; KAUL DK, 1989, P NATL ACAD SCI USA, V86, P3356, DOI 10.1073/pnas.86.9.3356; KEIDAN AJ, 1989, BRIT J HAEMATOL, V71, P551, DOI 10.1111/j.1365-2141.1989.tb06316.x; KLAHR S, 1988, NEW ENGL J MED, V318, P1657; KOSHY M, 1989, BLOOD, V74, P1403; LINDEMAN RD, 1990, AM J KIDNEY DIS, V16, P275, DOI 10.1016/S0272-6386(12)80002-3; MANTEL N, 1959, J NATL CANCER I, V22, P719; MCCOY RC, 1969, LAB INVEST, V21, P85; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; MINER DJ, 1987, AM J KIDNEY DIS, V10, P306, DOI 10.1016/S0272-6386(87)80027-6; MOHANDAS N, 1984, BLOOD, V64, P282; MORGAN AG, 1981, BMJ-BRIT MED J, V282, P1181, DOI 10.1136/bmj.282.6271.1181; NAGEL RL, 1990, SEMIN HEMATOL, V27, P342; NAGPAL KC, 1977, SURV OPHTHALMOL, V21, P391, DOI 10.1016/0039-6257(77)90042-X; Nduke N, 1987, Folia Haematol Int Mag Klin Morphol Blutforsch, V114, P508; NISSENSON AR, 1989, Q J MED, V73, P1055; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; POWARS D, 1978, AM J MED, V65, P461, DOI 10.1016/0002-9343(78)90772-6; POWARS D, 1990, SEMIN HEMATOL, V27, P360; POWARS D, 1988, MEDICINE, V67, P66, DOI 10.1097/00005792-198801000-00005; POWARS DR, 1989, ANN NY ACAD SCI, V565, P262, DOI 10.1111/j.1749-6632.1989.tb24174.x; POWARS DR, 1975, SEMIN HEMATOL, V12, P267; POWARS DR, 1984, BLOOD, V63, P921, DOI 10.1182/blood.V63.4.921.921; QUADRACCI LJ, 1976, KIDNEY INT, V10, P179, DOI 10.1038/ki.1976.93; REID CDL, 1988, BRIT J HAEMATOL, V70, P375, DOI 10.1111/j.1365-2141.1988.tb02497.x; SANDLER DP, 1989, NEW ENGL J MED, V320, P1238, DOI 10.1056/NEJM198905113201903; SCHROEDER WA, 1989, HEMOGLOBIN, V13, P325, DOI 10.3109/03630268909003397; SCHROEDER WA, 1980, CHROMATOGRAPHY HEMOG; SHERWOOD JB, 1986, BLOOD, V67, P46; SPECTOR D, 1978, AM J MED, V64, P835, DOI 10.1016/0002-9343(78)90524-7; Statius van Eps LW, 1970, LANCET, V1, P450; STRAUSS J, 1986, NEPHRON, V43, P241, DOI 10.1159/000183848; STRAUSS J, 1975, AM J MED, V58, P382, DOI 10.1016/0002-9343(75)90604-X; SZWED JJ, 1980, AM J MED SCI, V279, P169, DOI 10.1097/00000441-198005000-00006; TEJANI A, 1985, NEPHRON, V39, P352, DOI 10.1159/000183404; WALKER BR, 1971, J AMER MED ASSOC, V215, P437, DOI 10.1001/jama.215.3.437; WEINSTEIN R, 1990, BLOOD, V76, P2146; WESTNEY LS, 1984, OBSTET GYNECOL, V63, P752; WICK TM, 1987, J CLIN INVEST, V80, P905, DOI 10.1172/JCI113151	64	242	249	1	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1991	115	8					614	620		10.7326/0003-4819-115-8-614	http://dx.doi.org/10.7326/0003-4819-115-8-614			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ902	1892333				2022-12-01	WOS:A1991GJ90200006
J	BRAHAMS, D				BRAHAMS, D			TRIAZOLAM SUSPENDED	LANCET			English	Editorial Material																		BRAHAMS D, 1991, LANCET, V338, P502, DOI 10.1016/0140-6736(91)90565-7; BRAHAMS D, 1991, LANCET, V338, P243, DOI 10.1016/0140-6736(91)90367-X; OSWALD I, 1991, LANCET, V338, P516, DOI 10.1016/0140-6736(91)90592-D	3	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1991	338	8772					938	938		10.1016/0140-6736(91)91792-S	http://dx.doi.org/10.1016/0140-6736(91)91792-S			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ899	1681280				2022-12-01	WOS:A1991GJ89900018
J	DARGIE, HJ; GRANT, S				DARGIE, HJ; GRANT, S			EXERCISE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; PHYSICAL-ACTIVITY; LEISURE-TIME; RISK-FACTORS; ATTACK; HEALTH; DEATH		UNIV GLASGOW, DEPT PHYS EDUC & SPORTS SCI, GLASGOW G12 8QQ, SCOTLAND	University of Glasgow	DARGIE, HJ (corresponding author), WESTERN INFIRM & ASSOCIATED HOSP, GLASGOW G11 6NT, SCOTLAND.							[Anonymous], 1990, Med Sci Sports Exerc, V22, P265; BOUCHARD C, 1988, EXERCISE FITNESS HLT, P3; BRAY GA, 1988, EXERCISE FITNESS HLT, P497; COOPER KH, 1976, JAMA-J AM MED ASSOC, V236, P166, DOI 10.1001/jama.236.2.166; DISHMAN RK, 1990, 24 P WORLD C SPORTS, P11; DUNCAN JJ, 1985, JAMA-J AM MED ASSOC, V254, P2609, DOI 10.1001/jama.254.18.2609; DURNIN JVG, 1984, UNPUB COMA COMMITTEE; FENTEM P, 1987, EXERCISE HEART HLTH, P110; Fentem P.H., 1988, NEW CASE EXERCISE; FIATARONE MA, 1990, JAMA-J AM MED ASSOC, V263, P3029, DOI 10.1001/jama.263.22.3029; FOLKINS CH, 1981, AM PSYCHOL, V36, P373, DOI 10.1037/0003-066X.36.4.373; GARFINKEL PE, 1988, EXERCISE FITNESS HLT, P455; GOLDBERG AP, 1986, NEPHRON, V42, P311, DOI 10.1159/000183694; GOLDBERG L, 1987, SPORTS MED, V4, P307, DOI 10.2165/00007256-198704050-00001; LAW MR, 1991, BMJ-BRIT MED J, V303, P453, DOI 10.1136/bmj.303.6800.453; Leon A S, 1977, Ann N Y Acad Sci, V301, P561, DOI 10.1111/j.1749-6632.1977.tb38230.x; MARCUS BH, 1991, AM J CARDIOL, V68, P406, DOI 10.1016/0002-9149(91)90843-A; MORRIS JN, 1953, LANCET, V265, P1053; MORRIS JN, 1990, BRIT HEART J, V63, P325; MORRIS JN, 1973, LANCET, V1, P333; NORTHCOTE RJ, 1984, SPORTS MED, V1, P181, DOI 10.2165/00007256-198401030-00002; OCONNOR GT, 1989, CIRCULATION, V80, P234, DOI 10.1161/01.CIR.80.2.234; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; POOLE GW, 1984, SPORTS MED, V1, P341, DOI 10.2165/00007256-198401050-00002; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; SHEPHARD RJ, 1986, SPORTS MED, V3, P26, DOI 10.2165/00007256-198603010-00004; SMITH EL, 1987, PHYSICIAN SPORTSMED, V15, P91; SULLIVAN MJ, 1988, CIRCULATION, V78, P506, DOI 10.1161/01.CIR.78.3.506; TODD IC, 1990, BRIT HEART J, V64, P14; TUNSTALLPEDOE H, 1989, SCOT MED J, V34, P556, DOI 10.1177/003693308903400604; TUNSTALLPEDOE H, 1975, LANCET, V2, P833; WORK JA, 1989, PHYSICIAN SPORTSMED, V17, P226, DOI 10.1080/00913847.1989.11709746; 1991, HLTH ED SCOTLAND NAT; 1987, BRIT HEART J, V57, P188; 1990, PREVENTION CORONARY; 1991, J R COLL PHYSICIANS, V25, P193; 1991, CM1523; [No title captured]	38	9	9	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 12	1991	303	6807					910	912		10.1136/bmj.303.6807.910	http://dx.doi.org/10.1136/bmj.303.6807.910			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK221	1933009	Green Published, Bronze			2022-12-01	WOS:A1991GK22100029
J	HARARI, M; SHANN, F; SPOONER, V; MEISNER, S; CARNEY, M; DECAMPO, J				HARARI, M; SHANN, F; SPOONER, V; MEISNER, S; CARNEY, M; DECAMPO, J			CLINICAL SIGNS OF PNEUMONIA IN CHILDREN	LANCET			English	Article							RESPIRATORY-TRACT INFECTIONS; DIAGNOSIS; CRITERIA	Clinical and chest radiographic findings were recorded prospectively in 185 children with cough who attended an outpatient clinic in Papua New Guinea. Children were studied if they were between 8 weeks and 6 years of age; patients with wheeze, stridor, measles, or pertussis were excluded. 56 children (30%) had radiological evidence of pneumonia. The presence of either a respiratory rate greater-than-or-equal-to 50/min or chest indrawing, or of both signs, was a good indication of pneumonia, with a predictive power of 46% for a positive test and 83% for a negative test. A more complex definition of tachypnoea, as a respiratory rate greater-than-or-equal-to 40/min in children over 12 months old and greater-than-or-equal-to 50/min in infants, showed little additional diagnostic benefit.	ROYAL CHILDRENS HOSP, INTENS CARE UNIT, FLEMINGTON RD, PARKVILLE, VIC 3052, AUSTRALIA; GOROKA BASE HOSP, GOROKA, PAPUA N GUINEA	Royal Children's Hospital Melbourne			Campbell, Harry/E-2959-2010; Shann, Frank/C-9510-2011	Campbell, Harry/0000-0002-6169-6262; 				CAMPBELL H, 1989, LANCET, V1, P297, DOI 10.1016/S0140-6736(89)91308-1; CAMPBELL H, 1988, LANCET, V2, P742; CHERIAN T, 1988, LANCET, V2, P125; GRISKA L, 1984, PNEUMONIAS CLIN APPR, P23; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Leowski J, 1986, World Health Stat Q, V39, P138; LEVENTHAL JM, 1982, CLIN PEDIATR, V21, P730, DOI 10.1177/000992288202101205; MANSKI CF, 1977, ECONOMETRICA, V45, P1977, DOI 10.2307/1914121; SHANN F, 1989, PEDIATR INFECT DIS J, V8, P852, DOI 10.1097/00006454-198912000-00005; SHANN F, 1984, B WORLD HEALTH ORGAN, V62, P749; SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017; ZUKIN DD, 1986, ANN EMERG MED, V15, P792	12	78	82	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 12	1991	338	8772					928	930		10.1016/0140-6736(91)91785-S	http://dx.doi.org/10.1016/0140-6736(91)91785-S			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ899	1681277				2022-12-01	WOS:A1991GJ89900015
J	HARRINGTON, JM				HARRINGTON, JM			WORK RELATED DISEASE AND INJURIES	BRITISH MEDICAL JOURNAL			English	Article							HEALTH				HARRINGTON, JM (corresponding author), UNIV BIRMINGHAM,INST OCCUPAT HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.							AW TC, 1989, BMJ, V303, P68; BAKER EL, 1989, AM J PUBLIC HLTH S1, V79, P64; CARTER JT, 1991, BRIT J IND MED, V48, P289; Doll R, 1981, THE CAUSES OF CANCER; FOX AJ, 1978, J EPIDEMIOL COMMUN H, V32, P73, DOI 10.1136/jech.32.2.73; HARRINGTON JM, 1990, J ROY COLL PHYS LOND, V24, P189; HARRINGTON JM, IN PRESS HUNTERS DIS; LEGGE T, 1934, IND MALADIES; MERIDITH SK, 1991, BR J IND MED, V48, P292; MULLAN RJ, 1991, AM J IND MED, V19, P775, DOI 10.1002/ajim.4700190610; OLSEN O, 1991, J EPIDEMIOL COMMUN H, V45, P4, DOI 10.1136/jech.45.1.4; PLESS IB, 1991, BRIT MED J, V303, P462, DOI 10.1136/bmj.303.6800.462; SCHILLING RSF, 1989, BRIT J IND MED, V46, P683; WILLIAMS CJ, 1991, BMJ, V303, P576; 1990, HLTH SAFETY STATISTI; 1991, CM1523	16	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 12	1991	303	6807					908	910		10.1136/bmj.303.6807.908	http://dx.doi.org/10.1136/bmj.303.6807.908			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK221	1933008	Green Published, Bronze			2022-12-01	WOS:A1991GK22100028
J	HIGGINS, GD; DAVY, M; RODER, D; UZELIN, DM; PHILLIPS, GE; BURRELL, CJ				HIGGINS, GD; DAVY, M; RODER, D; UZELIN, DM; PHILLIPS, GE; BURRELL, CJ			INCREASED AGE AND MORTALITY ASSOCIATED WITH CERVICAL CARCINOMAS NEGATIVE FOR HUMAN PAPILLOMAVIRUS RNA	LANCET			English	Article							PROGNOSTIC-SIGNIFICANCE; INVASIVE-CARCINOMA; DNA; MAINTENANCE; NEOPLASIA; CANCER	Attempts to relate presence and type of human papillomavirus in cervical carcinoma with prognosis have yielded conflicting results. To further investigate this relation, the association between survival of cervical cancer patients after diagnosis and the presence of human papillomavirus (HPV) RNA within the tumour was assessed retrospectively. Formalin-fixed biopsy specimens from 212 patients with cervical carcinoma who had been followed for up to 6 years were tested by in-situ hybridisation with I-125-labelled riboprobes. HPV-RNA-positive women were 11.9 years younger than HPV-negative women at diagnosis (p < 0.001). Case-fatality rates from cervical cancer rose with absence of HPV RNA, age at diagnosis, or FIGO stage. Multivariate analysis confirmed that absence of detectable HPV RNA and advanced FIGO stage were independent risk factors. No differences in survival between HPV types 16, 18, 31, or 33 were seen. These observations suggest that cervical carcinoma patients fall into two groups-a younger, HPV-RNA-positive group, with a better prognosis, and an older, HPV-RNA-negative group with poorer prognosis. Treatment regimens for the two groups may need to differ.	ROYAL ADELAIDE HOSP,INST MED & VET SCI,DIV TISSUE PATHOL,ADELAIDE,SA 5000,AUSTRALIA; ROYAL ADELAIDE HOSP,INST MED & VET SCI,DEPT GYNAECOL ONCOL,ADELAIDE,SA 5000,AUSTRALIA; UNIV ADELAIDE,S AUSTRALIAN HLTH COMM,EPIDEMIOL BRANCH,ADELAIDE,SA 5001,AUSTRALIA; UNIV ADELAIDE,DEPT MICROBIOL & IMMUNOL,ADELAIDE,SA 5001,AUSTRALIA	Institute Medical & Veterinary Science Australia; Royal Adelaide Hospital; Institute Medical & Veterinary Science Australia; Royal Adelaide Hospital; University of Adelaide; University of Adelaide	HIGGINS, GD (corresponding author), ROYAL ADELAIDE HOSP,INST MED & VET SCI,DIV MED VIROL,FROME RD,ADELAIDE,SA 5000,AUSTRALIA.		Roder, David/B-7038-2013; Phillips, Gael E/H-6321-2012	Roder, David/0000-0001-6442-4409; 				BARNES W, 1988, GYNECOL ONCOL, V29, P267, DOI 10.1016/0090-8258(88)90225-9; BONETT A, 1989, AUST NZ J OBSTET GYN, V29, P193, DOI 10.1111/j.1479-828X.1989.tb01717.x; BONETT P, 1988, MED J AUSTRALIA, V148, P556; CAMPO MS, 1985, EMBO J, V4, P1819, DOI 10.1002/j.1460-2075.1985.tb03856.x; COLLINS JE, 1988, J CLIN PATHOL, V41, P289, DOI 10.1136/jcp.41.3.289; CROOK T, 1991, ONCOGENE, V6, P873; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; HIGGINS GD, 1991, J GEN VIROL, V72, P885, DOI 10.1099/0022-1317-72-4-885; HIGGINS GD, 1991, CANCER-AM CANCER SOC, V68, P561, DOI 10.1002/1097-0142(19910801)68:3<561::AID-CNCR2820680320>3.0.CO;2-R; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KING LA, 1989, CANCER, V63, P897, DOI 10.1002/1097-0142(19890301)63:5<897::AID-CNCR2820630517>3.0.CO;2-W; LORINCZ AT, 1987, J NATL CANCER I, V79, P671; MORGAN D, 1990, J VIROL, V64, P969, DOI 10.1128/JVI.64.3.969-976.1990; RIOU G, 1990, LANCET, V335, P1171; ROSE BR, 1991, LANCET, V337, P489, DOI 10.1016/0140-6736(91)93422-6; WALKER J, 1989, OBSTET GYNECOL, V74, P781; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; [No title captured]	19	152	154	2	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1991	338	8772					910	913		10.1016/0140-6736(91)91773-N	http://dx.doi.org/10.1016/0140-6736(91)91773-N			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ899	1681267				2022-12-01	WOS:A1991GJ89900004
J	HOLLOWELL, JG; HILL, PD; DUFFY, PG; RANSLEY, PG				HOLLOWELL, JG; HILL, PD; DUFFY, PG; RANSLEY, PG			BLADDER FUNCTION AND DYSFUNCTION IN EXSTROPHY AND EPISPADIAS	LANCET			English	Article								Bladder exstrophy and epispadias are congenital abnormalities of the urinary bladder. Evaluation of bladder function before and after bladder-neck reconstruction has not been done in patients with these conditions. We report the preliminary results of a prospective study of lower-urinary-tract function in 36 children (10 girls, 26 boys; age range 1.5-16 years) with bladder exstrophy and epispadias. Children's bladder function was measured by cystometry and cystography, and their upper urinary tracts were examined by ultrasound imaging. Normal bladder function was seen in children with primary epispadias but this was severely impaired in children who had had conventional bladder-neck surgery for continence, implying that this may not be the optimal treatment. Contrary to current assumption, children with closed exstrophy bladders are not capable of normal function, and the abnormalities we identified may be a major cause of upper-urinary-tract damage and may impair development of bladder capacity. Although unrecognised in the past, involuntary bladder contractions are a primary cause of urine leakage persisting in children with exstrophy and epispadias after continence surgery. Detailed functional testing should become a routine part of the evaluation of children with exstrophy and epispadias.	HOSP SICK CHILDREN,DEPT UROL,LONDON WC1N 3JL,ENGLAND; ST PETERS HOSP,DEPT PAEDIAT UROL,LONDON WC2A 2EX,ENGLAND; ST PETERS HOSP,DEPT MED PHYS,LONDON WC2A 2EX,ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; University of London; University College London								ANSELL JS, 1979, J UROLOGY, V121, P650, DOI 10.1016/S0022-5347(17)56924-4; BLOOM DA, 1991, DIAL PED UROL, V14, P2; DECTER RM, 1988, J UROLOGY, V140, P1202, DOI 10.1016/S0022-5347(17)42002-7; GEARHART JP, 1988, J UROLOGY, V139, P790, DOI 10.1016/S0022-5347(17)42639-5; HOLLOWELL JG, IN PRESS BR J UROL; JEFFS RD, 1986, CAMPELLS UROLOGY, V2, P1882; OSTERLING JE, 1987, J UROLOGY, V137, P258; RANSLEY PG, 1988, PAEDIAT SURG, P620	8	36	36	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1991	338	8772					926	928		10.1016/0140-6736(91)91784-R	http://dx.doi.org/10.1016/0140-6736(91)91784-R			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ899	1681276				2022-12-01	WOS:A1991GJ89900014
J	LUNN, PG; NORTHROPCLEWES, CA; DOWNES, RM				LUNN, PG; NORTHROPCLEWES, CA; DOWNES, RM			INTESTINAL PERMEABILITY, MUCOSAL INJURY, AND GROWTH FALTERING IN GAMBIAN INFANTS	LANCET			English	Article							AUTOMATED ENZYMATIC ASSAYS; CATCH-UP GROWTH; DIARRHEA; LACTULOSE; MANNITOL; PROBES; URINE	There is controversy over whether children in developing countries can catch up on their growth rates after bouts of diarrhoea. A factor influencing catch-up growth is the extent and duration of mucosal injury. To explore the relation between intestinal disease and growth performance, a non-invasive test of intestinal integrity, the lactulose:mannitol permeability test, was done regularly on children aged 2-15 months, whose growth was monitored over a mean of 7.5 months. The study revealed persistent abnormalities in the small bowel mucosa of 2-15 month old Gambian infants and a negative correlation between these abnormalities and growth. Up to 43% of observed growth faltering can be explained on the basis of these long-term intestinal lesions.	MRC,DUNN NUTR CTR,KENEBA,SENEGAMBIA		LUNN, PG (corresponding author), MRC,DUNN NUTR CTR,CAMBRIDGE CB4 1XJ,ENGLAND.							BEHRENS RH, 1987, AM J CLIN NUTR, V45, P1433, DOI 10.1093/ajcn/45.6.1433; BRIEND A, 1990, LANCET, V335, P1157, DOI 10.1016/0140-6736(90)91159-8; BRIEND A, 1989, LANCET, V2, P319; BRUNSER O, 1990, NESTLE NUTR WORKS SE, V19, P261; ELIA M, 1987, CLIN SCI, V73, P197, DOI 10.1042/cs0730197; FORD RP, 1985, J PAEDIATRIC GASTROE, V4, P468; HAMMILL PVV, 1979, AM J CLIN NUTR, V32, P607; KEUSCH GT, 1990, NESTLE NUTR WORKS SE, V19, P37; LEBENTHAL E, 1986, NESTLE NUTRITION WOR, V6, P5; LIFSCHITZ C, 1985, J PEDIATR GASTR NUTR, V4, P520, DOI 10.1097/00005176-198508000-00003; LUNN PG, 1989, CLIN CHIM ACTA, V183, P163, DOI 10.1016/0009-8981(89)90332-X; LUNN PG, 1991, T ROY SOC TROP MED H, V85, P8, DOI 10.1016/0035-9203(91)90137-N; MOY RJD, 1990, LANCET, V335, P600; NORTHROP CA, 1990, CLIN CHIM ACTA, V187, P79, DOI 10.1016/0009-8981(90)90333-N; Prentice A., 1990, BREASTFEEDING NUTR I, P87; ROWLAND S G J G, 1985, Journal of Diarrhoeal Diseases Research, V3, P7; ROY SK, IN PRESS J PEDIATR G; SCHORLING JB, 1990, LANCET, V335, P599, DOI 10.1016/0140-6736(90)90378-I; SULLIVAN PB, IN PRESS J PEDIATR G; 1985, LANCET, V1, P256	20	267	272	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1991	338	8772					907	910		10.1016/0140-6736(91)91772-M	http://dx.doi.org/10.1016/0140-6736(91)91772-M			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ899	1681266				2022-12-01	WOS:A1991GJ89900003
J	NIMMANNIT, S; MALASIT, P; CHAOVAKUL, V; SUSAENGRAT, W; VASUVATTAKUL, S; NILWARANGKUR, S				NIMMANNIT, S; MALASIT, P; CHAOVAKUL, V; SUSAENGRAT, W; VASUVATTAKUL, S; NILWARANGKUR, S			PATHOGENESIS OF SUDDEN UNEXPLAINED NOCTURNAL DEATH (LAI TAI) AND ENDEMIC DISTAL RENAL TUBULAR-ACIDOSIS	LANCET			English	Editorial Material							ASIAN REFUGEES; SLEEP; THAILAND	Sudden unexplained nocturnal death (SUND), a disorder of unknown cause that occurs in otherwise healthy young adults, mostly male, during their sleep, is prevalent in the north-east region of Thailand, where it has been known for generations as lai tai. It occurs in the same population and area where hypokalaemic periodic paralysis (HPP), endemic distal renal tubular acidosis (EdRTA), and renal stones are also endemic. SUND has occurred in families of patients with EdRTA, and HPP can present as sudden onset of muscle paralysis with potentially lethal cardiac arrhythmias and respiratory failure from severe hypokalaemia occurring in the middle of the night. Surveys in which serum and urinary potassium have been measured indicate a deficiency of the electrolyte in the population. Potassium deficiency is probably the prime factor responsible for SUND and HPP. Low urinary citrate concentrations and the high prevalence of acidification defects in the population indicate that potassium deficiency is also responsible for the prevalence of EdRTA and for renal stones.	UBOLRAJATHANI HOSP,BANGKOK,THAILAND; KHONKAEN HOSP,BANGKOK,THAILAND		NIMMANNIT, S (corresponding author), MAHIDOL UNIV,SIRIRAJ HOSP,DEPT MED,RENAL UNIT,BANGKOK 10700,THAILAND.							ANDRES R, 1957, J CLIN INVEST, V36, P723, DOI 10.1172/JCI103475; APONTE GE, 1960, ANN INTERN MED, V52, P1258, DOI 10.7326/0003-4819-52-6-1258; CHAMBUMRUNG S, 1985, AM J CLIN NUTR, V41, P770; DEFONZO R, 1981, KIDNEY INT, V20, P83; GOH KT, 1990, LANCET, V335, P1154, DOI 10.1016/0140-6736(90)91153-2; HALPERIN M, 1991, CLIN DISORDER FLUID; HALPERIN ML, 1989, KIDNEY INT, V35, P1277, DOI 10.1038/ki.1989.122; HELFANT RH, 1986, AM J MED, V80, P13, DOI 10.1016/0002-9343(86)90336-0; KNEPPER MA, 1989, PHYSIOL REV, V69, P179, DOI 10.1152/physrev.1989.69.1.179; KNOCHEL JP, 1972, J CLIN INVEST, V51, P1750, DOI 10.1172/JCI106976; MOORE FJ, 1974, THAILAND ITS PEOPLE; MUNGER RG, 1986, LANCET, V2, P1093; MUNGER RG, 1987, AM J PUBLIC HEALTH, V77, P1187, DOI 10.2105/AJPH.77.9.1187; MUNGER RG, 1990, LANCET, V335, P1154, DOI 10.1016/0140-6736(90)91154-3; NATH KA, 1985, J CLIN INVEST, V76, P667, DOI 10.1172/JCI112020; NATH KA, 1989, KIDNEY INT, V36, pS52; NILWARANGKUR S, 1990, Q J MED, V74, P289; NILWARANGKUR S, 1990, Southeast Asian Journal of Tropical Medicine and Public Health, V21, P437; NIMMANNIT S, 1990, LANCET, V336, P116, DOI 10.1016/0140-6736(90)91631-J; NIMMANNIT S, 1989, 6TH P INT S UR NEW Y, P681; OTTO CM, 1984, ANN INTERN MED, V100, P45; TATSANAVIVAT A, 1991, 7TH ANN M ROYAL COLL, P101; WILLIAMS ME, 1985, NEW ENGL J MED, V312, P923; ZIERLER KL, 1957, J CLIN INVEST, V36, P730, DOI 10.1172/JCI103476; 1981, MMWR, V30, P581; 1948, J PHILIPP MED ASSOC, V24, P627	26	50	52	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1991	338	8772					930	932		10.1016/0140-6736(91)91786-T	http://dx.doi.org/10.1016/0140-6736(91)91786-T			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ899	1681278				2022-12-01	WOS:A1991GJ89900016
J	SATOW, YI; HASHIDO, M; ISHIKAWA, KI; HONDA, H; MIZUNO, M; KAWANA, T; HAYAMI, M				SATOW, YI; HASHIDO, M; ISHIKAWA, KI; HONDA, H; MIZUNO, M; KAWANA, T; HAYAMI, M			DETECTION OF HTLV-I ANTIGEN IN PERIPHERAL AND CORD BLOOD-LYMPHOCYTES FROM CARRIER MOTHERS	LANCET			English	Note							T-CELL LEUKEMIA; TRANSMISSION; ANTIBODY; VIRUS	Vertical transmission of human T-cell lymphotropic virus type-I (HTLV-I) from an antibody-positive carrier mother to her infant has been reported, but it is not clear when and by what route such transmission occurs. Peripheral blood and cord blood lymphocytes from 40 antibody-positive carrier mothers were cultured for 2 months and HTLV-I antigen was sought by indirect immunofluorescence. Viral antigen was detected in 28 (70%) samples of peripheral blood lymphocytes and in 2 of cord blood lymphocytes, both from mothers positive for antigen in peripheral blood. From these data it is estimated that transplacental infection occurs at a rate of about 7%.	UNIV TOKYO,DEPT OBSTET & GYNAECOL,MEJIRODAI,JAPAN; MITSUI MEM HOSP,DEPT OBSTET & GYNAECOL,TOKYO 101,JAPAN; UNIV TOKYO,DEPT OBSTET & GYNAECOL,TOKYO 113,JAPAN; UNIV TOKYO,INST MED SCI,DEPT ANIM PATHOL,SHIROGANEDAI,JAPAN; KYOTO UNIV,INST VIRUS RES,IMMUNODEFICIENCY VIRUS RES CTR,KYOTO 606,JAPAN	University of Tokyo; Mitsui Memorial Hospital; University of Tokyo; University of Tokyo; Kyoto University								HINO S, 1987, LANCET, V2, P158; HINO S, 1985, JPN J CANCER RES, V76, P474; HINUMA Y, 1982, GANN, V73, P341; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; ICHIJO M, 1988, OBSTET GYNECOL PRACT, V37, P45; KOMURO A, 1983, LANCET, V1, P240; MAEDA Y, 1989, JPN J CANCER RES, V80, P915, DOI 10.1111/j.1349-7006.1989.tb01625.x; SAITO S, 1990, JPN J CANCER RES, V81, P890, DOI 10.1111/j.1349-7006.1990.tb02663.x	8	28	29	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 12	1991	338	8772					915	916		10.1016/0140-6736(91)91775-P	http://dx.doi.org/10.1016/0140-6736(91)91775-P			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ899	1681269				2022-12-01	WOS:A1991GJ89900006
J	BELLACOSA, A; TESTA, JR; STAAL, SP; TSICHLIS, PN				BELLACOSA, A; TESTA, JR; STAAL, SP; TSICHLIS, PN			A RETROVIRAL ONCOGENE, AKT, ENCODING A SERINE-THREONINE KINASE CONTAINING AN SH2-LIKE REGION	SCIENCE			English	Article							PHOSPHOTYROSINE-CONTAINING PROTEINS; TYROSINE KINASES; CATALYTIC DOMAINS; PHOSPHOLIPASE-C; SRC; GENE; MUTAGENESIS; EXPRESSION; SIMILARITY; ACTIVATION	The v-akt oncogene codes for a 105-kilodalton fusion phosphoprotein containing Gag sequences at its amino terminus. Sequence analysis of v-akt and biochemical characterization of its product revealed that it codes for a protein kinase C-related serine-threonine kinase whose cellular homolog is expressed in most tissues, with the highest amount found in thymus. Although Akt is a serine-threonine kinase, part of its regulatory region is similar to the Src homology-2 domain, a structural motif characteristic of cytoplasmic tyrosine kinases that functions in protein-protein interactions. This suggests that Akt may form a functional link between tyrosine and serine-threonine phosphorylation pathways.	FOX CHASE CANC INST,DEPT MED ONCOL,PHILADELPHIA,PA 19111	Fox Chase Cancer Center					NCI NIH HHS [CA-38047, CA-06927] Funding Source: Medline; NCRR NIH HHS [RR-05539] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038047, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLACOSA A, UNPUB; BERTNESS VL, 1990, CANCER GENET CYTOGEN, V44, P47, DOI 10.1016/0165-4608(90)90196-H; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; ONO Y, 1988, J BIOL CHEM, V263, P6927; PAWSON T, 1988, ONCOGENE, V3, P491; REDDY EP, 1983, P NATL ACAD SCI USA, V80, P2623; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; STAAL SP, 1988, J EXP MED, V167, P1259, DOI 10.1084/jem.167.3.1259; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065; Staal SP, 1988, GENOMICS, V2, P96, DOI 10.1016/0888-7543(88)90114-0; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TSICHLIS PN, IN PRESS CURR TOP MI; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WEISS R, 1985, RNA TUMOR VIRUSES, V2, P139	32	777	820	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1991	254	5029					274	277		10.1126/science.1833819	http://dx.doi.org/10.1126/science.1833819			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ642	1833819				2022-12-01	WOS:A1991GJ64200035
J	CLARKE, ND; BEAMER, LJ; GOLDBERG, HR; BERKOWER, C; PABO, CO				CLARKE, ND; BEAMER, LJ; GOLDBERG, HR; BERKOWER, C; PABO, CO			THE DNA-BINDING ARM OF LAMBDA-REPRESSOR - CRITICAL CONTACTS FROM A FLEXIBLE REGION	SCIENCE			English	Article							OPERATOR; DOMAIN; OR1; CRO	Segments of protein that do not adopt a well-ordered conformation in the absence of DNA can still contribute to site-specific recognition of DNA. The first six residues (NH2-Ser1-Thr2-Lys3-Lys4-Lys5-Pro6-) of phage-lambda repressor are flexible but are important for site-specific binding. Low-temperature x-ray crystallography and codon-directed saturation mutagenesis were used to study the role of this segment. All of the functional sequences have the form [X]1-[X]2-[Lys or Arg]3-[Lys]4-[Lys or Arg]5-[X]6. A high-resolution (1.8 angstrom) crystal structure shows that Lys3 and Lys4 each make multiple hydrogen bonds with guanines and that Lys5 interacts with the phosphate backbone. The symmetry of the complex breaks down near the center of the site, and these results suggest a revision in the traditional alignment of the six lambda-operator sites.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS & BIOPHYS CHEM,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Clarke, Neil/D-9613-2014		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031471] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31471] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAMER L, UNPUB; BEAMER LJ, 1991, THESIS J HOPKINS U B; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; ELIASON JL, 1985, P NATL ACAD SCI USA, V82, P2339, DOI 10.1073/pnas.82.8.2339; HOCHSCHILD A, 1986, CELL, V47, P807, DOI 10.1016/0092-8674(86)90523-4; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; MEYER BJ, 1980, J MOL BIOL, V139, P163, DOI 10.1016/0022-2836(80)90303-4; PABO CO, 1982, NATURE, V298, P443, DOI 10.1038/298443a0; PABO CO, 1982, NATURE, V298, P441, DOI 10.1038/298441a0; Ptashne M., 1986, A GENETIC SWITCH; SARAI A, 1989, P NATL ACAD SCI USA, V86, P6513, DOI 10.1073/pnas.86.17.6513; SAUER RT, 1979, NATURE, V279, P396, DOI 10.1038/279396a0; WEISS MA, 1984, P NATL ACAD SCI-BIOL, V81, P6019, DOI 10.1073/pnas.81.19.6019	13	100	101	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1991	254	5029					267	270		10.1126/science.1833818	http://dx.doi.org/10.1126/science.1833818			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ642	1833818				2022-12-01	WOS:A1991GJ64200033
J	DOWDY, SF; FASCHING, CL; ARAUJO, D; LAI, KM; LIVANOS, E; WEISSMAN, BE; STANBRIDGE, EJ				DOWDY, SF; FASCHING, CL; ARAUJO, D; LAI, KM; LIVANOS, E; WEISSMAN, BE; STANBRIDGE, EJ			SUPPRESSION OF TUMORIGENICITY IN WILMS-TUMOR BY THE P15.5-P14 REGION OF CHROMOSOME-11	SCIENCE			English	Article							SHORT ARM; DELETION; ALLELES; CELLS; 11P13; GENES; LOCUS; DNA; HETEROZYGOSITY; CANCER	Wilms tumor has been associated with genomic alterations at both the 11p13 and 11p15 regions. To differentiate between the involvement of these two loci, a chromosome 11 was constructed that had one or the other region deleted, and this chromosome was introduced into the tumorigenic Wilms tumor cell line G401. When assayed for tumor-forming activity in nude mice, the 11p13-deleted, but not the 11p15.5-p14.1-deleted chromosome, retained its ability to suppress tumor formation. These results provide in vivo functional evidence for the existence of a second genetic locus (WT2) involved in suppressing the tumorigenic phenotype of Wilms tumor.	UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717; UNIV N CAROLINA,LINEBERGER CANC RES CTR,CHAPEL HILL,NC 27599	University of California System; University of California Irvine; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL CANCER INSTITUTE [R01CA044470] Funding Source: NIH RePORTER; NCI NIH HHS [CA19104, CA44470] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; BECKWITH JB, 1983, HUM PATHOL, V14, P481, DOI 10.1016/S0046-8177(83)80003-3; BEST LG, 1981, AM J MED GENET, V9, P291, DOI 10.1002/ajmg.1320090405; BROWN KW, 1989, BRIT J CANCER, V60, P25, DOI 10.1038/bjc.1989.213; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COMPTON DA, 1990, GENOMICS, V6, P309, DOI 10.1016/0888-7543(90)90571-B; DAVIS LM, 1988, GENOMICS, V3, P264, DOI 10.1016/0888-7543(88)90087-0; DOWDY SF, 1990, GENE CHROMOSOME CANC, V2, P318, DOI 10.1002/gcc.2870020410; DOWDY SF, UNPUB; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; FOURNIER REK, 1977, P NATL ACAD SCI USA, V74, P319, DOI 10.1073/pnas.74.1.319; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GRUNDY P, 1988, NATURE, V336, P374, DOI 10.1038/336374a0; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; HUFF V, 1988, NATURE, V336, P377, DOI 10.1038/336377a0; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KOUFOS A, 1985, NATURE, V316, P330, DOI 10.1038/316330a0; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; LITTLE MH, 1988, HUM GENET, V79, P186, DOI 10.1007/BF00280564; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MATSUNAGA E, 1981, HUM GENET, V57, P231; MCKUSICK VA, 1990, MENDELIAN INHERITANC, P984; ORKIN SH, 1984, NATURE, V309, P172, DOI 10.1038/309172a0; PEEBLES PT, 1978, PEDIATR RES, V12, P485, DOI 10.1203/00006450-197804001-00732; PLRITCHARDJONES K, 1990, NATURE, V364, P194; REEVE AE, 1984, NATURE, V309, P174, DOI 10.1038/309174a0; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; RICCARDI VM, 1978, PEDIATRICS, V61, P604; ROONEY CW, 1986, HUMAN CYTOGENETICS P; RUSSELL WC, 1975, NATURE, V253, P461, DOI 10.1038/253461a0; SAXON PJ, 1985, MOL CELL BIOL, V5, P140, DOI 10.1128/MCB.5.1.140; SCOTT AF, 1979, P NATL ACAD SCI USA, V76, P4563, DOI 10.1073/pnas.76.9.4563; SCRABLE HJ, 1987, NATURE, V329, P645, DOI 10.1038/329645a0; STANBRIDGE EJ, 1981, ISRAEL J MED SCI, V17, P563; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099	41	136	136	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1991	254	5029					293	295		10.1126/science.1656527	http://dx.doi.org/10.1126/science.1656527			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ642	1656527				2022-12-01	WOS:A1991GJ64200042
J	LAYBOURN, PJ; KADONAGA, JT				LAYBOURN, PJ; KADONAGA, JT			ROLE OF NUCLEOSOMAL CORES AND HISTONE-H1 IN REGULATION OF TRANSCRIPTION BY RNA POLYMERASE-II	SCIENCE			English	Article							MINICHROMOSOMES ASSEMBLED INVITRO; INDUCIBLE MMTV PROMOTER; XENOPUS-LAEVIS OOCYTES; HIGH-SPEED SUPERNATANT; DNA-BINDING PROTEINS; CHROMATIN STRUCTURE; PREINITIATION COMPLEXES; IONIC-STRENGTH; MAJOR LATE; GENES	The relation between chromatin structure and transcriptional activity was examined by in vitro transcription analysis of chromatin reconstituted in the absence or presence of histone H1. To maintain well-defined template DNA, purified components were used in the reconstitution of chromatin. Reconstitution of nucleosomal cores to an average density of 1 nucleosome per 200 base pairs of DNA resulted in a mild reduction of basal RNA polymerase II transcription to 25 to 50 percent of that obtained with naked DNA templates. This nucleosome-mediated repression was due to nucleosomal cores located at the RNA start site and could not be counteracted by the sequence-specific transcription activators Sp1 and GAL4-VP16. When H1 was incorporated into the chromatin at 0.5 to 1.0 molecule per nucleosome (200 base pairs of DNA), RNA synthesis was reduced to 1 to 4 percent of that observed with chromatin containing only nucleosomal cores, and this H1-mediated repression could be counteracted by the addition of Sp1 or GAL4-VP16 (antirepression). With naked DNA templates, transcription was increased by a factor of 3 and 8 by Sp1 and GAL4-VP-16, respectively (true activation). With H1-repressed chromatin templates, however, the magnitude of transcriptional activation mediated by Sp1 and GAL4-VP16 was 90 and more than 200 times higher, respectively, because of the combined effects of true activation and antirepression. The data provide direct biochemical evidence that support and clarify previously proposed models in which there is depletion or reconfiguration of nucleosomal cores and histone H1 at the promoter regions of active genes.	UNIV CALIF SAN DIEGO, DEPT BIOL, 0322, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego								ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; BATES DL, 1981, NUCLEIC ACIDS RES, V9, P5883, DOI 10.1093/nar/9.22.5883; BEARD P, 1978, CELL, V15, P955, DOI 10.1016/0092-8674(78)90279-9; BECKER PB, 1991, P NATL ACAD SCI USA, V88, P4109, DOI 10.1073/pnas.88.10.4109; BENEZRA R, 1986, CELL, V44, P697, DOI 10.1016/0092-8674(86)90835-4; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BUTLER PJG, 1980, J MOL BIOL, V140, P505, DOI 10.1016/0022-2836(80)90268-5; CAMERINIOTERO RD, 1977, NUCLEIC ACIDS RES, V4, P1159, DOI 10.1093/nar/4.5.1159-a; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CARTWRIGHT IL, 1987, EMBO J, V6, P3097, DOI 10.1002/j.1460-2075.1987.tb02618.x; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CLARKADAMS CD, 1988, GENE DEV, V2, P150, DOI 10.1101/gad.2.2.150; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; CROSTON GE, IN PRESS PROTIEN EXP, V2; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Elgin SCR, 1990, CURR OPIN CELL BIOL, V2, P437, DOI 10.1016/0955-0674(90)90125-X; FEDOR MJ, 1989, MOL CELL BIOL, V9, P1721, DOI 10.1128/MCB.9.4.1721; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HAN M, 1988, EMBO J, V7, P2221, DOI 10.1002/j.1460-2075.1988.tb03061.x; JAVAHERIAN K, 1982, NUCLEIC ACIDS RES, V10, P6945, DOI 10.1093/nar/10.21.6945; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KADONAGA JT, 1990, J BIOL CHEM, V265, P2624; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; KAMAKAKA RT, 1991, P NATL ACAD SCI USA, V88, P1024, DOI 10.1073/pnas.88.3.1024; KERRIGAN LA, 1991, J BIOL CHEM, V266, P574; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KNEZETIC JA, 1988, MOL CELL BIOL, V8, P3114, DOI 10.1128/MCB.8.8.3114; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; MATSUI T, 1987, MOL CELL BIOL, V7, P1401, DOI 10.1128/MCB.7.4.1401; MEISTERERNST M, 1990, P NATL ACAD SCI USA, V87, P9153, DOI 10.1073/pnas.87.23.9153; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORSE RH, 1989, EMBO J, V8, P2343, DOI 10.1002/j.1460-2075.1989.tb08362.x; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; NELSON PP, 1979, J BIOL CHEM, V254, P1751; NOLL M, 1977, J MOL BIOL, V109, P393, DOI 10.1016/S0022-2836(77)80019-3; PECK LJ, 1983, P NATL ACAD SCI-BIOL, V80, P6206, DOI 10.1073/pnas.80.20.6206; PEDERSON DS, 1986, ANNU REV CELL BIOL, V2, P117, DOI 10.1146/annurev.cellbio.2.1.117; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SALZMAN AG, 1989, FASEB J, V3, P1723; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCHLISSEL MS, 1984, CELL, V37, P903, DOI 10.1016/0092-8674(84)90425-2; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; SHIMAMURA A, 1989, MOL CELL BIOL, V9, P5573, DOI 10.1128/MCB.9.12.5573; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SPADAFORA C, 1979, EUR J BIOCHEM, V100, P225, DOI 10.1111/j.1432-1033.1979.tb02053.x; STEIN A, 1989, METHOD ENZYMOL, V170, P585; STEIN A, 1984, J MOL BIOL, V178, P341, DOI 10.1016/0022-2836(84)90148-7; STEIN A, 1983, NATURE, V302, P548, DOI 10.1038/302548a0; STEIN A, 1979, P NATL ACAD SCI USA, V76, P5000, DOI 10.1073/pnas.76.10.5000; STEIN A, 1988, J MOL BIOL, V203, P1029, DOI 10.1016/0022-2836(88)90127-1; THOMAS GH, 1988, EMBO J, V7, P2191, DOI 10.1002/j.1460-2075.1988.tb03058.x; van Holde K E, 1988, CHROMATIN; VARSHAVSKY AJ, 1976, NUCLEIC ACIDS RES, V3, P477, DOI 10.1093/nar/3.2.477; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223; WEINTRAUB H, 1976, SCIENCE, V193, P848, DOI 10.1126/science.948749; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WOLFFE A P, 1990, New Biologist, V2, P211; WOLFFE AP, 1989, P NATL ACAD SCI USA, V86, P9817, DOI 10.1073/pnas.86.24.9817; WOLFFE AP, 1989, EMBO J, V8, P527, DOI 10.1002/j.1460-2075.1989.tb03407.x; WOLFFE AP, 1988, SCIENCE, V241, P1626, DOI 10.1126/science.3420414; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x	73	348	357	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 11	1991	254	5029					238	245		10.1126/science.1718039	http://dx.doi.org/10.1126/science.1718039			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ642	1718039				2022-12-01	WOS:A1991GJ64200031
J	MACAYA, RF; GILBERT, DE; MALEK, S; SINSHEIMER, JS; FEIGON, J				MACAYA, RF; GILBERT, DE; MALEK, S; SINSHEIMER, JS; FEIGON, J			STRUCTURE AND STABILITY OF X.G.C MISMATCHES IN THE 3RD STRAND OF INTRAMOLECULAR TRIPLEXES	SCIENCE			English	Article							DIMENSIONAL NMR-SPECTRA; C-MYC GENE; HELIX FORMATION; H-DNA; BASE-PAIRS; SEQUENCE; CLEAVAGE; INHIBITION; COMPLEXES; BINDING	Intramolecular DNA triplexes that contain eight base triplets formed from the folding of a single DNA strand tolerate a single X.G.C mismatch in the third strand at acidic pH. The structure and relative stability of all four triplets that are possible involving a G.C Watson-Crick base pair were determined with one- and two-dimensional proton nuclear magnetic resonance techniques. Triplexes containing A.G.C, G.G.C, or T.G.C triplets were less stable than the corresponding parent molecule containing a C.G.C triplet. However, all mismatched bases formed specific hydrogen bonds in the major groove of the double helix. The relative effect of these mismatches on the stability of the triplex differs from the effect assayed (under different conditions) by two-dimensional gel electrophoresis and DNA cleavage with oligonucleotide EDTA.Fe(II).	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	MACAYA, RF (corresponding author), UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024, USA.			Macaya, Roman/0000-0001-8335-3984; Malek, Shiva/0000-0002-9526-7968	NIGMS NIH HHS [GM-08185, R01 GM 37254-01, GM-08375] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008185, T32GM008375, R01GM037254] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOTT S, 1974, J MOL BIOL, V88, P509, DOI 10.1016/0022-2836(74)90498-7; BELOTSERKOVSKII BP, 1990, NUCLEIC ACIDS RES, V18, P6621, DOI 10.1093/nar/18.22.6621; BERNUES J, 1990, NUCLEIC ACIDS RES, V18, P4067, DOI 10.1093/nar/18.14.4067; BROWN T, 1989, J MOL BIOL, V207, P455, DOI 10.1016/0022-2836(89)90268-4; Cantor C. R., 1980, BIOPHYSICAL CHEM 3; COLLIER DA, 1988, J BIOL CHEM, V263, P7397; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DELOSSANTOS C, 1989, BIOCHEMISTRY-US, V28, P7282, DOI 10.1021/bi00444a021; DOAN TL, 1987, NUCLEIC ACIDS RES, V15, P7749; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; FRANCOIS JC, 1989, BIOCHEMISTRY-US, V28, P9617, DOI 10.1021/bi00451a011; FRANCOIS JC, 1989, J BIOL CHEM, V264, P5891; GAO XL, 1988, J AM CHEM SOC, V110, P5178, DOI 10.1021/ja00223a045; GRIFFIN LC, 1989, SCIENCE, V245, P967, DOI 10.1126/science.2549639; HANER R, 1990, BIOCHEMISTRY-US, V29, P9761, DOI 10.1021/bi00494a001; HANVEY JC, 1990, NUCLEIC ACIDS RES, V18, P157, DOI 10.1093/nar/18.1.157; HANVEY JC, 1989, J BIOL CHEM, V264, P5950; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; KATO M, 1990, BIOCHEM J, V268, P175, DOI 10.1042/bj2680175; KINNIBURGH AJ, 1989, NUCLEIC ACIDS RES, V17, P7771, DOI 10.1093/nar/17.19.7771; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LEE JS, 1979, NUCLEIC ACIDS RES, V6, P3073, DOI 10.1093/nar/6.9.3073; LEE JS, 1989, GENE, V82, P191, DOI 10.1016/0378-1119(89)90044-9; LEE JS, 1987, NUCLEIC ACIDS RES, V15, P1047, DOI 10.1093/nar/15.3.1047; LETAI AG, 1988, BIOCHEMISTRY-US, V27, P9108, DOI 10.1021/bi00426a007; MACAYA RF, UNPUB; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MANZINI G, 1990, J MOL BIOL, V213, P833, DOI 10.1016/S0022-2836(05)80267-0; MARCK C, 1978, NUCLEIC ACIDS RES, V5, P1017, DOI 10.1093/nar/5.3.1017; MARION D, 1989, J MAGN RESON, V84, P425, DOI 10.1016/0022-2364(89)90391-0; MCCARTHY JG, 1987, NUCLEIC ACIDS RES, V15, P8069, DOI 10.1093/nar/15.19.8069; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; MOOREN MMW, 1990, NUCLEIC ACIDS RES, V18, P6523, DOI 10.1093/nar/18.22.6523; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; PILCH DS, 1990, P NATL ACAD SCI USA, V87, P1942, DOI 10.1073/pnas.87.5.1942; PLUM GE, 1990, P NATL ACAD SCI USA, V87, P9436, DOI 10.1073/pnas.87.23.9436; PRASEUTH D, 1988, P NATL ACAD SCI USA, V85, P1349, DOI 10.1073/pnas.85.5.1349; RAJAGOPAL P, 1989, BIOCHEMISTRY-US, V28, P7859, DOI 10.1021/bi00445a048; RAJAGOPAL P, 1989, NATURE, V339, P637, DOI 10.1038/339637a0; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SKLENAR V, 1990, NATURE, V345, P836, DOI 10.1038/345836a0; SKLENAR V, 1987, J MAGN RESON, V74, P469, DOI 10.1016/0022-2364(87)90269-1; STROBEL SA, 1988, J AM CHEM SOC, V110, P7927, DOI 10.1021/ja00231a082; WANG EG, UNPUB; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307	46	63	63	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1991	254	5029					270	274		10.1126/science.1925581	http://dx.doi.org/10.1126/science.1925581			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ642	1925581				2022-12-01	WOS:A1991GJ64200034
J	MCCONNELL, SK; KAZNOWSKI, CE				MCCONNELL, SK; KAZNOWSKI, CE			CELL-CYCLE DEPENDENCE OF LAMINAR DETERMINATION IN DEVELOPING NEOCORTEX	SCIENCE			English	Article							VISUAL CORTICAL-NEURONS; CEREBRAL-CORTEX; MIGRATION PATTERNS; REELER MOUSE; LINEAGE; DIFFERENTIATION; TRANSPLANTATION; INVITRO; FERRET; RETINA	The neocortex is patterned in layers of neurons that are generated in an orderly sequence during development. This correlation between cell birthday and laminar fate prompted an examination of how neuronal phenotypes are determined in the developing cortex. At various times after labeling with [H-3]thymidine, embryonic progenitor cells were transplanted into older host brains. The laminar fate of transplanted neurons correlates with the position of their progenitors in the cell cycle at the time of transplantation. Daughters of cells transplanted in S-phase migrate to layer 2/3, as do host neurons. Progenitors transplanted later in the cell cycle, however, produce daughters that are committed to their normal, deep-layer fates. Thus, environmental factors are important determinants of laminar fate, but embryonic progenitors undergo cyclical changes in their ability to respond to such cues.			MCCONNELL, SK (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.				NEI NIH HHS [EY08411] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008411] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSON DJ, 1989, NEURON, V3, P1, DOI 10.1016/0896-6273(89)90110-4; ANGEVINE JB, 1961, NATURE, V192, P766, DOI 10.1038/192766b0; AUSTIN CP, 1990, DEVELOPMENT, V110, P713; DRAGER UC, 1981, J COMP NEUROL, V201, P555, DOI 10.1002/cne.902010407; HOY CA, 1987, J BIOL CHEM, V262, P11927; HUETTNER JE, 1986, J NEUROSCI, V6, P3044; JACKSON CA, 1989, J NEUROSCI, V9, P1242; KIM GY, IN PRESS J NEUROBIOL; LEMMON V, 1981, J NEUROSCI, V1, P83, DOI 10.1523/JNEUROSCI.01-01-00083.1981; LUSKIN MB, 1985, J COMP NEUROL, V242, P611, DOI 10.1002/cne.902420409; LUSKIN MB, 1988, NEURON, V1, P635, DOI 10.1016/0896-6273(88)90163-8; MCCONNELL SK, 1991, ANNU REV NEUROSCI, V14, P269, DOI 10.1146/annurev.ne.14.030191.001413; MCCONNELL SK, 1988, J NEUROSCI, V8, P945; MCCONNELL SK, 1985, SCIENCE, V229, P1268, DOI 10.1126/science.4035355; MCCONNELL SK, 1989, TRENDS NEUROSCI, V12, P342, DOI 10.1016/0166-2236(89)90041-6; NOWAKOWSKI RS, 1989, J NEUROCYTOL, V18, P311, DOI 10.1007/BF01190834; PINTOLORD MC, 1982, DEV BRAIN RES, V4, P379, DOI 10.1016/0165-3806(82)90181-X; PRICE J, 1988, DEVELOPMENT, V104, P473; RAKIC P, 1974, SCIENCE, V183, P425, DOI 10.1126/science.183.4123.425; REH TA, 1989, J NEUROSCI, V9, P4179; REH TA, 1986, DEV BIOL, V114, P463, DOI 10.1016/0012-1606(86)90210-1; SHATZ CJ, 1990, COLD SPRING HARB SYM, V55, P469; von Waechter R, 1972, Brain Res, V46, P235; WALSH C, 1990, EXPERIENTIA, V46, P940, DOI 10.1007/BF01939387; WALSH C, 1988, SCIENCE, V241, P1342, DOI 10.1126/science.3137660; WATANABE T, 1990, NEURON, V4, P461, DOI 10.1016/0896-6273(90)90058-N	26	635	638	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1991	254	5029					282	285		10.1126/science.1925583	http://dx.doi.org/10.1126/science.1925583			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ642	1925583				2022-12-01	WOS:A1991GJ64200038
J	MONTELL, DJ; KESHISHIAN, H; SPRADLING, AC				MONTELL, DJ; KESHISHIAN, H; SPRADLING, AC			LASER ABLATION STUDIES OF THE ROLE OF THE DROSOPHILA OOCYTE NUCLEUS IN PATTERN-FORMATION	SCIENCE			English	Article							MELANOGASTER; GENE; VASA; ANTEROPOSTERIOR; LOCALIZATION; OOGENESIS; EMBRYO; LOCI	Somatic and germline cells interact during oogenesis to establish the pattern axes of the Drosophila eggshell and embryo. The role of the oocyte nucleus in pattern formation was tested with the use of laser ablation. Ablation in stage 6 to 9 egg chambers caused partial or complete ventralization of the eggshell, phenotypes similar to those of eggs produced by gurken or torpedo females. Accumulation of vasa protein at the posterior pole of treated oocytes was also disrupted. Thus the oocyte nucleus is required as late as stage 9 for dorsoventral patterning within the follicle cells and for polar plasm assembly in the oocyte.	HOWARD HUGHES MED INST,BALTIMORE,MD 21210; YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University	MONTELL, DJ (corresponding author), CARNEGIE INST WASHINGTON,BALTIMORE,MD 21210, USA.				Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		ASHBURNER M, 1990, GENETICS, V126, P679; GUTZEIT HO, 1982, J EMBRYOL EXP MORPH, V67, P101; HAY B, 1988, DEVELOPMENT, V103, P625; HAY B, 1990, DEVELOPMENT, V109, P425; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; Mahowald A.P., 1980, Genetics and Biology of Drosophila, V2d, P141; MAHOWALD AP, 1970, ROUX ARCH DEV BIOL, V165, P8; MANSEAU LJ, 1989, TRENDS GENET, V5, P400, DOI 10.1016/0168-9525(89)90198-4; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; STEVENS L, 1990, NATURE, V335, P275; WIESCHAUS E, 1978, ROUX ARCH DEV BIOL, V184, P75, DOI 10.1007/BF00848670	16	42	42	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1991	254	5029					290	293		10.1126/science.1925585	http://dx.doi.org/10.1126/science.1925585			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ642	1925585				2022-12-01	WOS:A1991GJ64200041
J	SALGAME, P; ABRAMS, JS; CLAYBERGER, C; GOLDSTEIN, H; CONVIT, J; MODLIN, RL; BLOOM, BR				SALGAME, P; ABRAMS, JS; CLAYBERGER, C; GOLDSTEIN, H; CONVIT, J; MODLIN, RL; BLOOM, BR			DIFFERING LYMPHOKINE PROFILES OF FUNCTIONAL SUBSETS OF HUMAN CD4 AND CD8 T-CELL CLONES	SCIENCE			English	Article							COLONY-STIMULATING FACTOR; SUSCEPTIBLE BALB/C MICE; CHIMERA PRODUCE IL-5; HOST-REACTIVE CD4+; LYMPHOCYTE-T; IFN-GAMMA; INTERFERON-GAMMA; CUTANEOUS LEISHMANIASIS; MURINE LEISHMANIASIS; MONOCLONAL-ANTIBODY	Functional subsets of human T cells were delineated by analyzing patterns of lymphokines produced by clones from individuals with leprosy and by T cell clones of known function. CD4 clones from individuals with strong cell-mediated immunity produced predominantly interferon-gamma, whereas those clones that enhanced antibody formation produced interleukin-4. CD8 cytotoxic T cells secreted interferon-gamma. Interleukin-4 was produced by CD8 T suppressor clones from immunologically unresponsive individuals with leprosy and was found to be necessary for suppression in vitro. Both the classic reciprocal relation between antibody formation and cell-mediated immunity and resistance or susceptibility to certain infections may be explained by T cell subsets differing in patterns of lymphokine production.	DNAX RES INST MOLEC & CELLULAR BIOL INC, DEPT IMMUNOL, PALO ALTO, CA 94304 USA; INST BIOMED, CARACAS, VENEZUELA; STANFORD UNIV, MED CTR, DEPT CARDIOVASC SURG, PALO ALTO, CA 94304 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MICROBIOL & IMMUNOL, BRONX, NY 10461 USA; UNIV CALIF LOS ANGELES, SCH MED, DIV DERMATOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MICROBIOL & IMMUNOL, LOS ANGELES, CA 90024 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Stanford University; Yeshiva University; Albert Einstein College of Medicine; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	SALGAME, P (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, HOWARD HUGHES MED INST, BRONX, NY 10461 USA.		Modlin, Robert L/M-7941-2014	Modlin, Robert L/0000-0003-4720-031X	NIAID NIH HHS [AI-20111, AI-26491, AI-07118] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020111, P01AI026491] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABE M, 1980, INT J LEPROSY, V51, P387; ABRAMS JM, UNPUB; ASHERSON GL, 1966, IMMUNOLOGY, V10, P179; AWWAD M, 1988, J EXP MED, V168, P2193, DOI 10.1084/jem.168.6.2193; BACCHETTA R, 1990, J IMMUNOL, V144, P902; BATTISTO JR, 1962, P SOC EXP BIOL MED, V111, P111; BLOOM BR, 1983, REV INFECT DIS, V5, P765; BOREL Y, 1966, J EXP MED, V123, P585, DOI 10.1084/jem.123.4.585; CHERWINSKI HM, 1987, J EXP MED, V166, P1229, DOI 10.1084/jem.166.5.1229; CLAYBERGER C, 1985, J EXP MED, V162, P1709, DOI 10.1084/jem.162.5.1709; Crowle A J, 1966, Clin Exp Immunol, V1, P323; DAMLE NK, 1984, J IMMUNOL, V132, P644; FERNANDEZBOTRAN R, 1988, J EXP MED, V168, P543, DOI 10.1084/jem.168.2.543; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; GOLDSTEIN H, 1990, J IMMUNOL, V145, P952; HART PH, 1989, P NATL ACAD SCI USA, V86, P3803, DOI 10.1073/pnas.86.10.3803; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HILL JO, 1989, J EXP MED, V169, P1819, DOI 10.1084/jem.169.5.1819; HOWARD JG, 1981, J EXP MED, V153, P557, DOI 10.1084/jem.153.3.557; KARPUS WJ, 1991, J IMMUNOL, V146, P1163; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; KING CL, 1990, J CLIN INVEST, V85, P1810, DOI 10.1172/JCI114639; LAMB JR, 1982, J IMMUNOL, V128, P233; LEHN M, 1989, J IMMUNOL, V143, P3020; LI SG, 1990, EUR J IMMUNOL, V20, P1281, DOI 10.1002/eji.1830200613; MAGGI E, 1988, EUR J IMMUNOL, V18, P1045, DOI 10.1002/eji.1830180712; MAGGI E, 1991, J IMMUNOL, V146, P1169; MARTINEZ OM, 1990, J IMMUNOL, V144, P2211; MEHRA V, 1989, J IMMUNOL, V142, P2873; MODLIN RL, 1983, J AM ACAD DERMATOL, V8, P182, DOI 10.1016/S0190-9622(83)70021-6; MODLIN RL, 1988, P NATL ACAD SCI USA, V85, P1213, DOI 10.1073/pnas.85.4.1213; MODLIN RL, 1986, NATURE, V322, P459, DOI 10.1038/322459a0; MODLIN RL, 1986, J IMMUNOL, V137, P2831; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; MOSMANN TR, 1991, IMMUNOPARASITOL TOD, pA49; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSSMANN TR, 1989, ANNU REV IMMUNOL, V145, P73; OTTENHOFF THM, 1986, NATURE, V322, P462, DOI 10.1038/322462a0; PALIARD X, 1988, J IMMUNOL, V141, P849; PARISH CR, 1972, TRANSPLANT REV-DENMA, V13, P35; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PEARCE EJ, 1991, J EXP MED, V173, P159, DOI 10.1084/jem.173.1.159; PELEMAN R, 1989, J EXP MED, V170, P1751, DOI 10.1084/jem.170.5.1751; POND L, 1989, J IMMUNOL, V143, P4232; Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255; SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115; SALGAME P, 1991, P NATL ACAD SCI USA, V88, P2598, DOI 10.1073/pnas.88.6.2598; Salgame P, 1989, Int Immunol, V1, P121, DOI 10.1093/intimm/1.2.121; TITUS RG, 1985, J IMMUNOL, V135, P2108; UMETSU DT, 1988, J IMMUNOL, V140, P4211; VANVOORHIS WC, 1982, NEW ENGL J MED, V307, P1593, DOI 10.1056/NEJM198212233072601; YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582	53	1052	1076	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 11	1991	254	5029					279	282		10.1126/science.1681588	http://dx.doi.org/10.1126/science.1681588			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ642	1681588				2022-12-01	WOS:A1991GJ64200037
J	TANG, CM; SHI, QY; KATCHMAN, A; LYNCH, G				TANG, CM; SHI, QY; KATCHMAN, A; LYNCH, G			MODULATION OF THE TIME COURSE OF FAST EPSCS AND GLUTAMATE CHANNEL KINETICS BY ANIRACETAM	SCIENCE			English	Article							MOUSE CENTRAL NEURONS; QUISQUALATE RECEPTORS; DESENSITIZATION; CURRENTS; POTENTIATION	It is generally accepted that glutamate serves as the neurotransmitter at most excitatory synapses in the mammalian central nervous system (CNS). Synaptic release of glutamate may trigger a fast and a slow excitatory postsynaptic current (EPSC). The slow EPSC is mediated by N-methyl-D-aspartate (NMDA) receptor channels, whereas the fast EPSC is mediated by non-NMDA receptor channels. The nootropic agent aniracetam selectively and reversibly slows the desensitization kinetics of non-NMDA channels and lengthens their single-channel open times. Aniracetam also modulates the kinetics of the fast EPSC in a manner that mirrors its action on the kinetics of the non-NMDA channels. These results support the hypothesis that the properties of the non-NMDA glutamate channels rather than the rate of neurotransmitter clearance are the primary determinants of the kinetics of the fast EPSC in the mammalian CNS.	UNIV CALIF IRVINE,BONNEY CTR LEARNING & MEMORY,IRVINE,CA 92717; GRAD HOSP PHILADELPHIA,PHILADELPHIA,PA 19146	University of California System; University of California Irvine; University of Pennsylvania; Pennsylvania Medicine	TANG, CM (corresponding author), UNIV PENN,DEPT NEUROL,PHILADELPHIA,PA 19104, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS028158] Funding Source: NIH RePORTER; NINDS NIH HHS [NS28158] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASCHER P, 1988, J PHYSIOL-LONDON, V399, P227; FORSYTHE ID, 1988, J PHYSIOL-LONDON, V396, P515, DOI 10.1113/jphysiol.1988.sp016975; FROSTL W, 1989, PHARMACOPSYCHIATRY, V22, P54, DOI 10.1055/s-2007-1014626; HESTRIN S, 1990, J PHYSIOL-LONDON, V422, P203, DOI 10.1113/jphysiol.1990.sp017980; ITO I, 1990, J PHYSIOL-LONDON, V424, P533, DOI 10.1113/jphysiol.1990.sp018081; LARSON J, 1986, SCIENCE, V232, P985, DOI 10.1126/science.3704635; LESTER RAJ, 1990, NATURE, V346, P565, DOI 10.1038/346565a0; MAGLEBY KL, 1972, J PHYSIOL-LONDON, V223, P173, DOI 10.1113/jphysiol.1972.sp009840; MAYER ML, 1989, P NATL ACAD SCI USA, V86, P1411, DOI 10.1073/pnas.86.4.1411; STAUBLI U, IN PRESS HIPPOCAMPUS; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; WESTBROOK GL, 1989, SEMINARS NEUROSCIENC, V1, P103; XIAO P, IN PRESS HIPPOCAMPUS; ZORUMSKI CF, 1989, CELL MOL NEUROBIOL, V9, P95, DOI 10.1007/BF00711446; ZORUMSKI CF, 1990, SOC NEUR ABSTR, V16, P547	16	183	185	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1991	254	5029					288	290		10.1126/science.1681589	http://dx.doi.org/10.1126/science.1681589			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ642	1681589				2022-12-01	WOS:A1991GJ64200040
J	WANG, CY; LOONEY, DJ; LI, ML; WALFIELD, AM; YE, J; HOSEIN, B; TAM, JP; WONGSTAAL, F				WANG, CY; LOONEY, DJ; LI, ML; WALFIELD, AM; YE, J; HOSEIN, B; TAM, JP; WONGSTAAL, F			LONG-TERM HIGH-TITER NEUTRALIZING ACTIVITY INDUCED BY OCTAMERIC SYNTHETIC HIV-1 ANTIGEN	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MATERNAL ANTIBODIES; GLYCOPROTEIN GP120; ENVELOPE PROTEIN; TYPE-1 ENVELOPE; AIDS VACCINES; T-CELL; PEPTIDE; CHIMPANZEES; DETERMINANT	A titer for homologous viral neutralization activity (> 1:19,683) was observed after a 3.5-year immunization period with an octameric, branching peptide representing the principal neutralizing determinant (PND) of the human immunodeficiency virus-1IIIB envelope protein. Booster immunizations elicited persistent and potent antibodies in guinea pigs, exceeding responses produced by a conventional bovine serum albumin conjugate by 100-fold. Peptide length, central presentation of a conserved sequence, and inclusion of an upstream sequence contributed to immunogenicity. Titers (> 1:1,000) of heterotypic neutralizing antibodies also developed. Octameric PND peptides are a promising approach for an acquired immunodeficiency syndrome (AIDS) vaccine.	VET ADM MED CTR,SAN DIEGO,CA 92161; VET ADM MED CTR,SAN DIEGO,CA 92161; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; ROCKEFELLER UNIV,NEW YORK,NY 10021	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego; University of California System; University of California San Diego; Rockefeller University	WANG, CY (corresponding author), UNITED BIOMED INC,LAKE SUCCESS,NY 11042, USA.		Tam, James P/A-2176-2011	Tam, James P/0000-0003-4433-198X	NIAID NIH HHS [IU01-AI-30238] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI030238] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; CHESEBRO B, 1988, J VIROL, V62, P3779, DOI 10.1128/JVI.62.10.3779-3788.1988; DEVASH Y, 1990, P NATL ACAD SCI USA, V87, P3445, DOI 10.1073/pnas.87.9.3445; EMINI EA, 1990, J VIROL, V64, P3674, DOI 10.1128/JVI.64.8.3674-3678.1990; FREED EO, 1991, J VIROL, V65, P190, DOI 10.1128/JVI.65.1.190-194.1991; GIRARD M, 1991, P NATL ACAD SCI USA, V88, P542, DOI 10.1073/pnas.88.2.542; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; JAVAHERIAN K, 1990, SCIENCE, V250, P1590, DOI 10.1126/science.1703322; KOFF WC, 1988, SCIENCE, V241, P426, DOI 10.1126/science.3293212; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; LOONEY DJ, 1988, SCIENCE, V241, P357, DOI 10.1126/science.3388046; MATTHEWS TJ, 1988, SCI AM, V259, P120, DOI 10.1038/scientificamerican1088-120; MELOEN RH, 1989, J GEN VIROL, V70, P1505, DOI 10.1099/0022-1317-70-6-1505; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; POSNETT DN, 1988, J BIOL CHEM, V263, P1719; ROSSI P, 1989, P NATL ACAD SCI USA, V86, P8055, DOI 10.1073/pnas.86.20.8055; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SCOTT CF, 1990, P NATL ACAD SCI USA, V87, P8597, DOI 10.1073/pnas.87.21.8597; TAM JP, 1990, J EXP MED, V171, P299, DOI 10.1084/jem.171.1.299; TAM JP, 1989, P NATL ACAD SCI USA, V86, P9084, DOI 10.1073/pnas.86.23.9084; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; TSCHACHLER E, 1990, J VIROL, V64, P2250, DOI 10.1128/JVI.64.5.2250-2259.1990; Wang C.-W., UNPUB; WANG CY, 1989, Patent No. 328403; WANG JJG, 1986, P NATL ACAD SCI USA, V83, P6159, DOI 10.1073/pnas.83.16.6159	26	124	140	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1991	254	5029					285	288		10.1126/science.1925584	http://dx.doi.org/10.1126/science.1925584			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ642	1925584				2022-12-01	WOS:A1991GJ64200039
J	YAMAMURA, M; UYEMURA, K; DEANS, RJ; WEINBERG, K; REA, TH; BLOOM, BR; MODLIN, RL				YAMAMURA, M; UYEMURA, K; DEANS, RJ; WEINBERG, K; REA, TH; BLOOM, BR; MODLIN, RL			DEFINING PROTECTIVE RESPONSES TO PATHOGENS - CYTOKINE PROFILES IN LEPROSY LESIONS	SCIENCE			English	Article							T-CELL SUBSETS; MURINE LEISHMANIASIS; INTERFERON-GAMMA; RECIPROCAL EXPRESSION; SKIN-LESIONS; INTERLEUKIN-4; PROGRESSION; RESOLUTION; EXPANSION	The immunological mechanisms required to engender resistance have been defined in few infectious diseases of man, and the role of specific cytokines is unclear. Leprosy presents clinically as a spectrum in which resistance correlates with cell-mediated immunity to the pathogen. To assess in situ cytokine patterns, messenger RNA extracted from leprosy skin biopsy specimens was amplified by the polymerase chain reaction with 14 cytokine-specific primers. In lesions of the resistant form of the disease, messenger RNAs coding for interleukin-2 and interferon-gamma were most evident. In contrast, messenger RNAs for interleukin-4, interleukin-5, and interleukin-10 predominated in the multibacillary form. Thus, resistance and susceptibility were correlated with distinct patterns of cytokine production.	UNIV CALIF LOS ANGELES,SCH MED,DIV DERMATOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024; UNIV SO CALIF,SCH MED,DEPT NEUROL,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DERMATOL SECT,LOS ANGELES,CA 90033; CHILDRENS HOSP LOS ANGELES,LOS ANGELES,CA 90054; YESHIVA UNIV ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED INST,BRONX,NY 10461	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Southern California; University of Southern California; University of Southern California; Children's Hospital Los Angeles; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine			Modlin, Robert L/M-7941-2014	Modlin, Robert L/0000-0003-4720-031X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022553, R22AI022553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040312] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 07118, AI 22553] Funding Source: Medline; NIAMS NIH HHS [AR 40312] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARNOLDI J, 1990, AM J PATHOL, V137, P749; BLOOM BR, 1989, NATURE, V342, P115, DOI 10.1038/342115a0; COOPER CL, 1989, J EXP MED, V169, P1565, DOI 10.1084/jem.169.5.1565; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; MODLIN RL, 1984, J IMMUNOL, V132, P3085; MODLIN RL, 1983, CLIN EXP IMMUNOL, V53, P17; MODLIN RL, 1983, J AM ACAD DERMATOL, V8, P182, DOI 10.1016/S0190-9622(83)70021-6; MODLIN RL, 1988, P NATL ACAD SCI USA, V85, P1213, DOI 10.1073/pnas.85.4.1213; MODLIN RL, 1986, NATURE, V322, P459, DOI 10.1038/322459a0; MODLIN RL, 1986, J IMMUNOL, V137, P2831; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; PEARCE EJ, 1991, J EXP MED, V173, P159, DOI 10.1084/jem.173.1.159; POND L, 1989, J IMMUNOL, V143, P4232; Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255; SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; VANVOORHIS WC, 1982, NEW ENGL J MED, V307, P1593, DOI 10.1056/NEJM198212233072601	17	1174	1224	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1991	254	5029					277	279		10.1126/science.1925582	http://dx.doi.org/10.1126/science.1925582			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ642	1925582				2022-12-01	WOS:A1991GJ64200036
J	CARRELL, RW; EVANS, DL; STEIN, PE				CARRELL, RW; EVANS, DL; STEIN, PE			MOBILE REACTIVE CENTER OF SERPINS AND THE CONTROL OF THROMBOSIS	NATURE			English	Article							CRYSTAL-STRUCTURE; ALPHA-1-PROTEINASE INHIBITOR; CONFORMATIONAL CHANGE; OVALBUMIN; ALPHA-1-ANTITRYPSIN; ABSENCE; MODEL	TWO protease inhibitors in human plasma play a key part in the control of thrombosis: antithrombin inhibits coagulation and the plasminogen activator inhibitor PAI-1 inhibits fibrinolysis, the dissolving of clots. Both inhibitors are members of the serpin family and both exist in the plasma in latent or inactive forms. We show here that the reactive centre of the serpins can adopt varying conformations and that mobility of the reactive centre is necessary for the function of antithrombin and its binding and activation by heparin; the identification of a new locked conformation explains the latent inactive state of PAI-1. This ability to vary conformation not only allows the modulation of inhibitory activity but also protects the circulating inhibitor against proteolytic attack. Together these findings explain the retention by the serpins of a large and unconstrained reactive centre as compared to the small fixed peptide loop of other families of serine protease inhibitors.			CARRELL, RW (corresponding author), UNIV CAMBRIDGE,CTR MRC,DEPT HAEMATOL,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AUSTIN RC, 1991, FEBS LETT, V280, P254, DOI 10.1016/0014-5793(91)80305-M; BODE W, 1987, EUR J BIOCHEM, V166, P673, DOI 10.1111/j.1432-1033.1987.tb13566.x; CARRELL RW, 1986, NATURE, V322, P730; DEURAJKIZUK R, 1988, BLOOD, V72, P1518; ENGH RA, 1990, PROTEIN ENG, V3, P469, DOI 10.1093/protein/3.6.469; GETTINS P, 1989, J BIOL CHEM, V264, P3781; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KATAGIRI K, 1988, EUR J BIOCHEM, V176, P81, DOI 10.1111/j.1432-1033.1988.tb14253.x; KRESS LF, 1981, BIOCHEMISTRY-US, V20, P7432, DOI 10.1021/bi00529a017; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; PERRY DJ, 1989, FEBS LETT, V254, P174, DOI 10.1016/0014-5793(89)81033-6; PERRY DJ, 1991, FEBS LETT, V286, P2; POWELL LM, 1990, THESIS U NEWCASTLE U; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SKRIVER K, 1991, J BIOL CHEM, V14, P9216; STEIN P, 1991, J MOL BIOL, V221, P615, DOI 10.1016/0022-2836(91)80076-7; STEIN PE, 1989, BIOCHEM J, V262, P103, DOI 10.1042/bj2620103; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; VILLANUEVA GB, 1983, J BIOL CHEM, V258, P1010; WRIGHT HT, 1990, J MOL BIOL, V213, P518	21	291	298	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1991	353	6344					576	578		10.1038/353576a0	http://dx.doi.org/10.1038/353576a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1922367				2022-12-01	WOS:A1991GJ64300074
J	CHO, SG; ATTAYA, M; MONACO, JJ				CHO, SG; ATTAYA, M; MONACO, JJ			NEW CLASS-II-LIKE GENES IN THE MURINE MHC	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CHAIN GENE; NUCLEOTIDE-SEQUENCE; BETA-CHAIN; MOUSE; ALPHA; CDNA; HAPLOTYPE; SUBREGION; DISTINCT	MAJOR histocompatibility complex (MHC) class I molecules present endogenous antigens to CD8+ (cytotoxic) T cells. MHC class II molecules present primarily exogenously derived antigens to CD4+ T cells. Three new genes (Ma, Mb1 and Mb2) located between the Pb and Ob genes of the murine MHC have properties indicating that they are members of the MHC class II gene family, but they are the most divergent class II members so far identified and are almost as closely related in sequence to class I genes as they are to the known class II genes.			CHO, SG (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MICROBIOL & IMMUNOL,RICHMOND,VA 23298, USA.							BEALE D, 1976, Q REV BIOPHYS, V9, P135, DOI 10.1017/S0033583500002390; BRAUNSTEIN NS, 1986, EMBO J, V5, P2469, DOI 10.1002/j.1460-2075.1986.tb04523.x; CHO SG, 1991, P NATL ACAD SCI USA, V88, P5197, DOI 10.1073/pnas.88.12.5197; Compagnone-Post P, 1988, GENOMICS, V2, P8, DOI 10.1016/0888-7543(88)90103-6; COSGROVE D, IN PRESS CELL; DAS HK, 1983, P NATL ACAD SCI-BIOL, V80, P3543, DOI 10.1073/pnas.80.12.3543; HOOD L, 1983, ANNU REV IMMUNOL, V1, P529, DOI 10.1146/annurev.iy.01.040183.002525; JONSSON AK, 1987, J BIOL CHEM, V262, P8767; KELLY AP, 1991, NATURE, V353, P571, DOI 10.1038/353571a0; LARHAMMAR D, 1985, J BIOL CHEM, V260, P4111; LAWRANCE SK, 1985, NUCLEIC ACIDS RES, V13, P7515, DOI 10.1093/nar/13.20.7515; LIU CP, 1988, J IMMUNOL, V140, P3631; MALISSEN M, 1983, SCIENCE, V221, P750, DOI 10.1126/science.6410508; MALOY WL, 1981, J BIOL CHEM, V256, P2863; MATHIS DJ, 1983, CELL, V32, P745, DOI 10.1016/0092-8674(83)90060-0; PARNES JR, 1982, CELL, V29, P661, DOI 10.1016/0092-8674(82)90182-9; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P5520, DOI 10.1073/pnas.80.18.5520; SCHREIER PH, 1986, NUCLEIC ACIDS RES, V14, P2381, DOI 10.1093/nar/14.5.2381; SHARMA S, 1987, IMMUNOL INVEST, V16, P425, DOI 10.3109/08820138709087096; TIEBER VL, 1986, J BIOL CHEM, V261, P2738; TONNELLE C, 1985, EMBO J, V4, P2839, DOI 10.1002/j.1460-2075.1985.tb04012.x; TROWSDALE J, 1985, EMBO J, V4, P2231, DOI 10.1002/j.1460-2075.1985.tb03919.x; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4	23	120	127	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1991	353	6344					573	576		10.1038/353573a0	http://dx.doi.org/10.1038/353573a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1922366				2022-12-01	WOS:A1991GJ64300073
J	FRANCO, B; GUIOLI, S; PRAGLIOLA, A; INCERTI, B; BARDONI, B; TONLORENZI, R; CARROZZO, R; MAESTRINI, E; PIERETTI, M; TAILLONMILLER, P; BROWN, CJ; WILLARD, HF; LAWRENCE, C; PERSICO, MG; CAMERINO, G; BALLABIO, A				FRANCO, B; GUIOLI, S; PRAGLIOLA, A; INCERTI, B; BARDONI, B; TONLORENZI, R; CARROZZO, R; MAESTRINI, E; PIERETTI, M; TAILLONMILLER, P; BROWN, CJ; WILLARD, HF; LAWRENCE, C; PERSICO, MG; CAMERINO, G; BALLABIO, A			A GENE DELETED IN KALLMANNS SYNDROME SHARES HOMOLOGY WITH NEURAL CELL-ADHESION AND AXONAL PATH-FINDING MOLECULES	NATURE			English	Article							AMINO-ACID-SEQUENCE; SYNDROME HYPOGONADOTROPIC HYPOGONADISM; HUMAN X-CHROMOSOME; DISTAL SHORT ARM; IMMUNOGLOBULIN SUPERFAMILY; STEROID SULFATASE; TYROSINE KINASE; MESSENGER-RNA; Y-CHROMOSOME; CDNA CLONE	Kallmann's syndrome (clinically characterized by hypogonadotropic hypogonadism and inability to smell) is caused by a defect in the migration of olfactory neurons, and neurons producing hypothalamic gonadotropin-releasing hormone. A gene has now been isolated from the critical region on Xp22.3 to which the syndrome locus has been assigned: this gene escapes X inactivation, has a homologue on the Y chromosome, and shows an unusual pattern of conservation across species. The predicted protein has significant similarities with proteins involved in neural cell adhesion and axonal pathfinding, as well as with protein kinases and phosphatases, which suggests that this gene could have a specific role in neuronal migration.	BAYLOR COLL MED,INST MOLEC GENET,1 BAYLOR PLAZA,HOUSTON,TX 77030; INST G GASLINI,GENOA,ITALY; NAPLES UNIV,DEPT PEDIAT,I-80138 NAPLES,ITALY; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; INT INST GENET & BIOPHYS,I-80125 NAPLES,ITALY; WASHINGTON UNIV,SCH MED,CTR GENET MED,ST LOUIS,MO 63110; STANFORD UNIV,MED CTR,SCH MED,DEPT GENET,STANFORD,CA 94305; IST BIOCHIM GENET EVOLUZION ST,PAVIA,ITALY	Baylor College of Medicine; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Naples Federico II; Baylor College of Medicine; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Washington University (WUSTL); Stanford University			Bardoni, Barbara/F-9918-2013; Brown, Carolyn J/A-5159-2014; Tonlorenzi, Rossana/AAN-2241-2020; BALLABIO, Andrea/AAL-2672-2020; Maestrini, Elena/K-7508-2012; FRANCO, Brunella/S-2882-2018	Brown, Carolyn J/0000-0002-8959-0101; BALLABIO, Andrea/0000-0003-1381-4604; Maestrini, Elena/0000-0001-5924-3179; FRANCO, Brunella/0000-0001-5588-4569; Guioli, Silvana/0000-0002-4920-7745; Bardoni, Barbara/0000-0001-6411-1517; Tonlorenzi, Rossana/0000-0002-6060-8208				BALLABIO A, 1989, ANN HUM GENET, V53, P9, DOI 10.1111/j.1469-1809.1989.tb01117.x; BALLABIO A, 1986, HUM GENET, V72, P237, DOI 10.1007/BF00291885; BALLABIO A, 1990, GENOMICS, V8, P263, DOI 10.1016/0888-7543(90)90281-X; BARDONI B, 1991, GENOMICS, V11, P443, DOI 10.1016/0888-7543(91)90153-6; BARDONI B, 1988, Genomics, V3, P32, DOI 10.1016/0888-7543(88)90155-3; BASLER K, 1988, CELL, V54, P299; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; BIRCHMEIER C, 1990, P NATL ACAD SCI USA, V87, P4799, DOI 10.1073/pnas.87.12.4799; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BRESLOW EA, 1979, REV BIOCH, V48, P251; BROWN CJ, 1991, NATURE, V349, P882; CARLE GF, 1984, NUCLEIC ACIDS RES, V12, P5647, DOI 10.1093/nar/12.14.5647; DEAR TN, 1988, CANCER RES, V48, P5203; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; DRENTH J, 1980, J BIOL CHEM, V255, P2652; EINHEBER S, 1990, P NATL ACAD SCI USA, V87, P2157, DOI 10.1073/pnas.87.6.2157; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FISHER EH, 1991, SCIENCE, V253, P401; FRASER N, 1987, DEVELOPMENT, V101, P127; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GENNARINI G, 1989, J CELL BIOL, V109, P775, DOI 10.1083/jcb.109.2.775; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; GUERRIERO V, 1986, BIOCHEMISTRY-US, V25, P8372, DOI 10.1021/bi00374a007; HENNINGHAUSEN LG, 1982, NUCLEIC ACIDS RES, V10, P3733, DOI 10.1093/nar/10.12.3733; HERMANUSSEN M, 1985, CLIN GENET, V28, P106; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; Kallmann FJ, 1944, AM J MENT DEF, V48, P203; KATO I, 1979, FED PROC, V38, P832; KEITGES E, 1985, NATURE, V315, P226, DOI 10.1038/315226a0; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDER AD, 1989, TRENDS NEUROSCI, V12, P189, DOI 10.1016/0166-2236(89)90070-2; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LIPKIN VM, 1989, FEBS LETT, V254, P69, DOI 10.1016/0014-5793(89)81011-7; MEITINGER T, 1990, AM J HUM GENET, V47, P664; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; NELSON DL, 1991, P NATL ACAD SCI USA, V88, P6157, DOI 10.1073/pnas.88.14.6157; PETIT C, 1990, P NATL ACAD SCI USA, V87, P3680, DOI 10.1073/pnas.87.10.3680; PIERETTI M, 1991, NUCLEIC ACIDS RES, V19, P2795, DOI 10.1093/nar/19.10.2795; RANSCHT B, 1988, J CELL BIOL, V107, P1561, DOI 10.1083/jcb.107.4.1561; ROSS MT, 1990, GENOMICS, V6, P528, DOI 10.1016/0888-7543(90)90482-A; Sambrook J., 1989, MOL CLONING LAB MANU; SCHWANKHAUS JD, 1989, NEUROLOGY, V39, P223, DOI 10.1212/WNL.39.2.223; SCHWANZELFUKUDA M, 1989, MOL BRAIN RES, V6, P311, DOI 10.1016/0169-328X(89)90076-4; SHAPIRO LJ, 1979, SCIENCE, V204, P1224, DOI 10.1126/science.156396; SMALL SJ, 1987, J CELL BIOL, V105, P2335, DOI 10.1083/jcb.105.5.2335; STETLER G, 1986, NUCLEIC ACIDS RES, V14, P7883, DOI 10.1093/nar/14.20.7883; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; STREULI M, 1988, J EXP MED, V168, P1553; SUNOHARA N, 1986, ANN NEUROL, V19, P174, DOI 10.1002/ana.410190211; SUZUKI S, 1990, EMBO J, V9, P757, DOI 10.1002/j.1460-2075.1990.tb08170.x; WEGENKE JD, 1975, CLIN GENET, V7, P368; WHITE BJ, 1983, AM J MED GENET, V15, P417, DOI 10.1002/ajmg.1320150307; WIEDOW O, 1990, J BIOL CHEM, V265, P14791; WRAY S, 1989, P NATL ACAD SCI USA, V86, P8132, DOI 10.1073/pnas.86.20.8132; YEN PH, 1988, CELL, V55, P1123, DOI 10.1016/0092-8674(88)90257-7; YEN PH, 1990, CELL, V61, P603, DOI 10.1016/0092-8674(90)90472-Q	60	680	692	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1991	353	6344					529	536		10.1038/353529a0	http://dx.doi.org/10.1038/353529a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1922361				2022-12-01	WOS:A1991GJ64300057
J	HILBERT, P; LINDPAINTNER, K; BECKMANN, JS; SERIKAWA, T; SOUBRIER, F; DUBAY, C; CARTWRIGHT, P; DEGOUYON, B; JULIER, C; TAKAHASI, S; VINCENT, M; GANTEN, D; GEORGES, M; LATHROP, GM				HILBERT, P; LINDPAINTNER, K; BECKMANN, JS; SERIKAWA, T; SOUBRIER, F; DUBAY, C; CARTWRIGHT, P; DEGOUYON, B; JULIER, C; TAKAHASI, S; VINCENT, M; GANTEN, D; GEORGES, M; LATHROP, GM			CHROMOSOMAL MAPPING OF 2 GENETIC-LOCI ASSOCIATED WITH BLOOD-PRESSURE REGULATION IN HEREDITARY HYPERTENSIVE RATS	NATURE			English	Article							RECOMBINANT INBRED STRAINS; INVITRO AMPLIFICATION; ANGIOTENSIN-I; RENIN GENE; DNA; HYBRIDIZATION; PROBES	The spontaneously hypertensive rat and the stroke-prone spontaneously hypertensive rat are useful models for human hypertension. In these strains hypertension is a polygenic trait, in which both autosomal and sex-linked genes can influence blood pressure 1-7. Linkage studies in crosses between the stroke-prone spontaneously hypertensive rat and the normotensive control strain Wistar-Kyoto have led to the localization of two genes, BP/SP-1 and BP/SP-2, that contribute significantly to blood pressure variation in the F2 population. BP/SP-1 and BP/SP-2 were assigned to rat chromosomes 10 and X, respectively. Comparison of the human and rat genetic maps indicates that BP/SP-1 could reside on human chromosome 17q in a region that also contains the angiotensin I-converting enzyme gene (ACE) 8. This encodes a key enzyme of the renin-angiotensin system 9, and is therefore a candidate gene in primary hypertension. A rat microsatellite marker of ACE was mapped to rat chromosome 10 within the region containing BP/SP-1.	CTR ETUD POLYMORPHISME HUMAIN,27 RUE JULIETTE DODU,F-75010 PARIS,FRANCE; CTR MOLEC MED,W-1115 BERLIN,GERMANY; INST RECH INTERDISCIPLINAIRE BIOL HUMAINE & NUCL,B-1070 BRUSSELS,BELGIUM; HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115; UNIV HEIDELBERG,GERMAN INST HIGH BLOOD PRESSURE,W-6900 HEIDELBERG,GERMANY; COLL FRANCE,MED EXPTL LAB,INSERM,U36,F-75231 PARIS 05,FRANCE; UNIV CLAUDE BERNARD,PHYSIOL LAB,F-69373 LYONS,FRANCE; UNIV UTAH,DEPT HUMAN GENET,SALT LAKE CITY,UT 84132; GENMARK INC,SALT LAKE CITY,UT 84108; UNIV HEIDELBERG,DEPT PHARMACOL,W-6900 HEIDELBERG,GERMANY; KYOTO UNIV,FAC MED,INST LAB ANIM,KYOTO 606,JAPAN	Harvard University; Harvard Medical School; Ruprecht Karls University Heidelberg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Utah System of Higher Education; University of Utah; Ruprecht Karls University Heidelberg; Kyoto University			Beckmann, Jacques Simon/A-9772-2008; JULIER, Cécile/M-9824-2017	Beckmann, Jacques Simon/0000-0002-9741-1900; JULIER, Cécile/0000-0002-1538-0240				AOKI K, 1972, JPN CIRCULATION J, V36, P539, DOI 10.1253/jcj.36.539; BIOLLAZ J, 1986, HYPERTENSION, V8, P117, DOI 10.1161/01.HYP.8.2.117; COOKE NE, 1986, ENDOCRINOLOGY, V119, P2451, DOI 10.1210/endo-119-6-2451; DANNERBERG AL, 1987, HYPERTENSION, V10, P266; DIETZ R, 1984, J CARDIOVASC PHARM, V6, pS230, DOI 10.1097/00005344-198400061-00036; DIETZ R, 1982, HYPERTENSION, V4, P773, DOI 10.1161/01.HYP.4.6.773; DIXON WJ, 1988, BMDP STATISTICAL SOF; ELY DL, 1990, HYPERTENSION, V16, P277, DOI 10.1161/01.HYP.16.3.277; GEORGES M, 1988, CYTOGENET CELL GENET, V47, P127, DOI 10.1159/000132529; GRADIN K, 1987, ACTA PHYSIOL SCAND, V131, P273, DOI 10.1111/j.1748-1716.1987.tb08237.x; Guyton A.C., 1980, ARTERIAL PRESSURE HY; HALL JE, 1986, AM J PHYSIOL, V250, pR960, DOI 10.1152/ajpregu.1986.250.6.R960; HARRAP SB, 1986, HYPERTENSION, V8, P572, DOI 10.1161/01.HYP.8.7.572; HILLYARD AL, 1991, LOCUS MAP MOUSE COMP; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; JULIER C, 1990, P NATL ACAD SCI USA, V87, P4585, DOI 10.1073/pnas.87.12.4585; KURTZ TW, 1990, J CLIN INVEST, V85, P1328, DOI 10.1172/JCI114572; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LATHROP GM, 1988, GENOMICS, V2, P157; LEVAN G, IN PRESS GENOMCIS; LINDPAINTNER K, 1990, J HYPERTENS, V8, P763, DOI 10.1097/00004872-199008000-00011; LITT M, 1989, AM J HUM GENET, V44, P397; LOUIS WJ, 1969, LANCET, V1, P1035; LUFT FC, 1988, J CLI SCI, V74, P577; MATTEI MG, 1989, CYTOGENET CELL GENET, V51, P1041; PICKERING G, 1972, AM J MED, V52, P570, DOI 10.1016/0002-9343(72)90049-6; PRAVENEC M, 1991, HYPERTENSION, V17, P242, DOI 10.1161/01.HYP.17.2.242; PRAVENEC M, 1989, J HYPERTENS, V7, P217; PRAVENEC M, 1991, GENOMICS, V9, P466, DOI 10.1016/0888-7543(91)90412-8; RAPP JP, 1989, SCIENCE, V243, P542, DOI 10.1126/science.2563177; RAPP JP, 1982, HYPERTENSION, V4, P459, DOI 10.1161/01.HYP.4.4.459; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; SOLOMON E, 1989, CYTOGENET CELL GENET, V51, P319, DOI 10.1159/000132797; TANASE H, 1970, JPN CIRCULATION J, V34, P1197; TANASE H, 1987, JAP CIRC J, V51, P1184; TODD JA, 1991, NATURE, V351, P542, DOI 10.1038/351542a0; VANDEVEN CJM, 1983, PFLUG ARCH EUR J PHY, V399, P74, DOI 10.1007/BF00652525; WARD R, 1990, PATHOPHYSIOLOGY DIAG, P81; WEBER JL, 1989, AM J HUM GENET, V44, P388; YAMORI Y, 1970, LAB INVEST, V22, P206; YANG HYT, 1970, BIOCHIM BIOPHYS ACTA, V214, P374, DOI 10.1016/0005-2795(70)90017-6; YASUE Y, IN PRESS CYTOGENET C; YEN TT, 1974, HEREDITY, V33, P309, DOI 10.1038/hdy.1974.97	43	591	608	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1991	353	6344					521	529		10.1038/353521a0	http://dx.doi.org/10.1038/353521a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1656270				2022-12-01	WOS:A1991GJ64300056
J	HOLBROOK, SR; CHEONG, CJ; TINOCO, I; KIM, SH				HOLBROOK, SR; CHEONG, CJ; TINOCO, I; KIM, SH			CRYSTAL-STRUCTURE OF AN RNA DOUBLE HELIX INCORPORATING A TRACK OF NON-WATSON-CRICK BASE-PAIRS	NATURE			English	Article							DNA; MISMATCHES	THE crystal structure of the RNA dodecamer duplex (r-GGACUUCGGUCC)2 has been determined. The dodecamers stack end-to-end in the crystal, simulating infinite A-form helices with only a break in the phosphodiester chain. These infinite helices are held together in the crystal by hydrogen bonding between ribose hydroxyl groups and a variety of donors and acceptors. The four noncomplementary nucleotides in the middle of the sequence did not form an internal loop, but rather a highly regular double-helix incorporating the non-Watson-Crick base pairs, G . U and U . C. This is the first direct observation of a U . C (or T . C) base pair in a crystal structure. The U . C pairs each form only a single base-base hydrogen bond, but are stabilized by a water molecule which bridges between the ring nitrogens and by four waters in the major groove which link the bases and phosphates. The lack of distortion introduced in the double helix by the U . C mismatch may explain its low efficiency of repair in DNA. The G . U wobble pair is also stabilized by a minor-groove water which bridges between the unpaired guanine amino and the ribose hydroxyl of the uracil. This structure emphasizes the importance of specific hydrogen bonding between not only the nucleotide bases, but also the ribose hydroxyls, phosphate oxygens and tightly bound waters in stabilization of the intramolecular and intermolecular structures of double helical RNA.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720	University of California System; University of California Berkeley	HOLBROOK, SR (corresponding author), UNIV CALIF BERKELEY LAWRENCE BERKELEY LAB,BERKELEY,CA 94720, USA.		Cheong, Chaejoon/GWC-3135-2022					ARNOTT S, 1972, BIOCHEM BIOPH RES CO, V48, P1392, DOI 10.1016/0006-291X(72)90867-4; BARFOD ET, 1989, MOL CELL BIOL, V9, P3657, DOI 10.1128/MCB.9.9.3657; BHATTACHARYYA A, 1989, J MOL BIOL, V209, P583, DOI 10.1016/0022-2836(89)90596-2; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; CHEONG CJ, 1990, NATURE, V346, P680, DOI 10.1038/346680a0; COMARMOND MB, 1986, ACTA CRYSTALLOGR B, V42, P272, DOI 10.1107/S0108768186098233; DOCKBREGEON AC, 1989, J MOL BIOL, V209, P459, DOI 10.1016/0022-2836(89)90010-7; EISENSTEIN M, 1990, NUCLEIC ACIDS RES, V18, P3185, DOI 10.1093/nar/18.11.3185; HINGERTY B, 1978, J MOL BIOL, V124, P523, DOI 10.1016/0022-2836(78)90185-7; HOLBROOK SR, 1978, J MOL BIOL, V123, P631, DOI 10.1016/0022-2836(78)90210-3; HUNTER WN, 1987, J BIOL CHEM, V262, P9962; KNEALE G, 1985, J MOL BIOL, V186, P805, DOI 10.1016/0022-2836(85)90398-5; MODRICH P, 1987, ANNU REV BIOCHEM, V56, P435, DOI 10.1146/annurev.biochem.56.1.435; PATEL DJ, 1984, FED PROC, V43, P2663; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; SUGIMOTO N, 1989, NUCLEIC ACIDS RES, V17, P355, DOI 10.1093/nar/17.1.355; VARANI G, 1991, BIOCHEMISTRY-US, V30, P3280, DOI 10.1021/bi00227a016	18	318	319	0	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1991	353	6344					579	581		10.1038/353579a0	http://dx.doi.org/10.1038/353579a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1922368				2022-12-01	WOS:A1991GJ64300075
J	INFANTERIVARD, C; DAVID, M; GAUTHIER, R; RIVARD, GE				INFANTERIVARD, C; DAVID, M; GAUTHIER, R; RIVARD, GE			LUPUS ANTICOAGULANTS, ANTICARDIOLIPIN ANTIBODIES, AND FETAL LOSS - A CASE CONTROL STUDY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VIPER VENOM TIME; ANTIPHOSPHOLIPID ANTIBODIES; SPONTANEOUS-ABORTION; HABITUAL ABORTION; WOMEN; MISCARRIAGE; DIAGNOSIS; ABORTERS; DEATH	Background. Lupus anticoagulants and anticardiolipin antibodies are antiphospholipid antibodies that have been associated with fetal loss, but they have not been shown unequivocally to be a risk factor for this event. Methods. To estimate the risk of fetal loss in association with these antibodies, we conducted a hospital-based case-control study of 331 women with spontaneous abortion or fetal death (case patients) and 993 controls. The subjects were included in the study only if they reported that they had had no previous spontaneous fetal loss. Each control was a pregnant woman who, in the same period of pregnancy as a case patient, had not had a fetal loss. Lupus anticoagulants were identified in blood samples through a series of coagulation tests, and IgG anticardiolipins by an enzyme-linked immunosorbent assay. Each subject was interviewed in person to obtain information on potential confounding variables, such as sociodemographic characteristics and medical conditions. Results. Lupus anticoagulants were found in blood from 17 case patients (5.1 percent) and 38 controls (3.8 percent). The crude odds ratio for the association between lupus anticoagulants and fetal loss was 1.36 (95 percent confidence interval, 0.75 to 2.43); the odds ratio adjusted for confounders was 1.42 (95 percent confidence interval, 0.72 to 2.80). An IgG anticardiolipin level of 5 units or more was found in 4 case patients (1.2 percent) and 15 controls (1.5 percent). The crude and adjusted odds ratios for fetal loss were 0.80 (95 percent confidence interval, 0.26 to 2.41) and 1.28 (95 percent confidence interval, 0.38 to 4.21), respectively. Conclusions. There is no apparent justification for considering lupus anticoagulants or IgG anticardiolipins to be risk factors for fetal loss among women who present with spontaneous abortion or fetal death and have had no previous spontaneous fetal loss.	UNIV MONTREAL,HOP ST JUSTINE,DEPT OBSTET & GYNECOL,MONTREAL H3T 1C5,QUEBEC,CANADA; UNIV MONTREAL,HOP ST JUSTINE,DEPT COMMUNITY HLTH,MONTREAL H3T 1C5,QUEBEC,CANADA; UNIV MONTREAL,HOP ST JUSTINE,DEPT HEMATOL,MONTREAL H3T 1C5,QUEBEC,CANADA	Universite de Montreal; Universite de Montreal; Universite de Montreal	INFANTERIVARD, C (corresponding author), MCGILL UNIV,SCH OCCUPAT HLTH,1130 PINE AVE W,MONTREAL H3A 1A3,QUEBEC,CANADA.							Bakketeig L. S., 1984, PERINATAL EPIDEMIOLO, P99; BARBUI T, 1988, FERTIL STERIL, V50, P589; BRANDT JT, 1989, ARCH PATHOL LAB MED, V113, P1376; BRESLOW N. E., 1980, STATISTICAL METHODS; EDELMAN P, 1986, PRESSE MED, V15, P961; ELIAS M, 1984, ARCH INTERN MED, V144, P510, DOI 10.1001/archinte.144.3.510; FIRKIN BG, 1978, AM J HEMATOL, V5, P81, DOI 10.1002/ajh.2830050202; FRANCOIS A, 1988, ANN INTERN MED, V109, P993, DOI 10.7326/0003-4819-109-12-993; GLADEN BC, 1986, STAT MED, V5, P557, DOI 10.1002/sim.4780050602; GREENLAND S, 1989, AM J PUBLIC HEALTH, V79, P340, DOI 10.2105/AJPH.79.3.340; HARRIS EN, 1990, BRIT J HAEMATOL, V74, P1, DOI 10.1111/j.1365-2141.1990.tb02530.x; HARRIS EN, 1990, AM J CLIN PATHOL, V94, P476, DOI 10.1093/ajcp/94.4.476; HOWARD MA, 1987, AM J HEMATOL, V26, P175, DOI 10.1002/ajh.2830260208; KACZOR DA, 1991, AM J CLIN PATHOL, V95, P408, DOI 10.1093/ajcp/95.3.408; Kline J., 1984, PERINATAL EPIDEMIOLO, P23; LESPERANCE B, 1988, THROMB HAEMOSTASIS, V60, P217; LOCKSHIN MD, 1985, NEW ENGL J MED, V313, P152, DOI 10.1056/NEJM198507183130304; LOCKSHIN MD, 1989, AM J OBSTET GYNECOL, V160, P439, DOI 10.1016/0002-9378(89)90468-7; LOCKWOOD CJ, 1989, AM J OBSTET GYNECOL, V161, P369, DOI 10.1016/0002-9378(89)90522-X; MAIER DB, 1989, FERTIL STERIL, V51, P280; MODVIG J, 1990, AM J EPIDEMIOL, V132, P1021, DOI 10.1093/oxfordjournals.aje.a115744; PETRI M, 1987, ARTHRITIS RHEUM, V30, P601, DOI 10.1002/art.1780300601; RODRIGUES L, 1990, INT J EPIDEMIOL, V19, P205, DOI 10.1093/ije/19.1.205; ROSOVE MH, 1990, OBSTET GYNECOL, V75, P630; STIRRAT GM, 1990, LANCET, V336, P673, DOI 10.1016/0140-6736(90)92159-F; THIAGARAJAN P, 1986, BLOOD, V68, P869; TRIPLETT DA, 1983, AM J CLIN PATHOL, V79, P678, DOI 10.1093/ajcp/79.6.678; TRIPLETT DA, 1989, AM J REPROD IMMUNOL, V20, P52, DOI 10.1111/j.1600-0897.1989.tb00639.x; WALLENBURG HCS, 1987, AM J OBSTET GYNECOL, V157, P1230, DOI 10.1016/S0002-9378(87)80300-9	29	164	169	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 10	1991	325	15					1063	1066		10.1056/NEJM199110103251503	http://dx.doi.org/10.1056/NEJM199110103251503			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ108	1909770				2022-12-01	WOS:A1991GJ10800003
J	KELLY, AP; MONACO, JJ; CHO, SG; TROWSDALE, J				KELLY, AP; MONACO, JJ; CHO, SG; TROWSDALE, J			A NEW HUMAN HLA CLASS-II-RELATED LOCUS, DM	NATURE			English	Article							DQ-SUBREGION; CHAIN GENE; MHC; MOLECULES; SEQUENCE; DISTINCT; REGION; BETA	HLA CLASS II molecules have a crucial role in the immune response to antigens. We have isolated two new class II-like complementary DNA sequences, RING6 and RING7, which map between the HLA-DNA and -DOB loci. They are novel members of the immunoglobulin gene family which may have diverged before the duplications that gave rise to the main class II loci. The RING6 and RING7 genes seem to encode alpha- and beta-chains of a previously undiscovered class II-related protein.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MICROBIOL & IMMUNOL,RICHMOND,VA 23298	Virginia Commonwealth University	KELLY, AP (corresponding author), IMPERIAL CANC RES FUND,HUMAN IMMUNOGENET LAB,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.							BANKIER AT, 1987, METHOD ENZYMOL, V155, P51; BLANCK G, 1988, J IMMUNOL, V141, P1734; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; CHO SG, 1991, NATURE, V353, P573, DOI 10.1038/353573a0; GUESSOW D, 1987, J IMMUNOL, V139, P3122; HANSON IM, 1991, IMMUNOGENETICS, V34, P5, DOI 10.1007/BF00212306; HOOD L, 1985, CELL, V40, P225, DOI 10.1016/0092-8674(85)90133-3; KELLY A, 1985, NUCLEIC ACIDS RES, V13, P1607, DOI 10.1093/nar/13.5.1607; Klein J., 1986, NATURAL HIST MAJOR H; LINDAHL KF, 1989, COLD SH Q B, V54, P563; OSULLIVAN DM, 1986, P NATL ACAD SCI USA, V83, P4484, DOI 10.1073/pnas.83.12.4484; RAGOUSSIS J, 1991, P NATL ACAD SCI USA, V88, P3753, DOI 10.1073/pnas.88.9.3753; Sambrook J., 1989, MOL CLONING LAB MANU; SHAWAR SM, 1990, J EXP MED, V171, P897, DOI 10.1084/jem.171.3.897; STADEN R, 1990, COMPUT APPL BIOSCI, V6, P387; TONNELLE C, 1985, EMBO J, V4, P2839, DOI 10.1002/j.1460-2075.1985.tb04012.x; TROWSDALE J, 1985, EMBO J, V4, P2231, DOI 10.1002/j.1460-2075.1985.tb03919.x; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0	18	254	265	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1991	353	6344					571	573		10.1038/353571a0	http://dx.doi.org/10.1038/353571a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1922365				2022-12-01	WOS:A1991GJ64300072
J	LIN, YS; HA, I; MALDONADO, E; REINBERG, D; GREEN, MR				LIN, YS; HA, I; MALDONADO, E; REINBERG, D; GREEN, MR			BINDING OF GENERAL TRANSCRIPTION FACTOR TFIIB TO AN ACIDIC ACTIVATING REGION	NATURE			English	Article							RNA POLYMERASE-II; GAL4 DERIVATIVES; TATA-BOX; INITIATION; MECHANISM; CLONING; DOMAIN	A CENTRAL issue in eukaryotic transcriptional regulation is the mechanism by which promoter-specific transcription factors (activators) stimulate transcription. Two lines of evidence indicate that the general transcription factor TFIIB is a pivotal component in the mechanism by which an acidic activator functions. First, during assembly of the preinitiation complex TFIIB binding is a rate-limiting step enhanced by an acidic activator 1. Second, the TFIIB activity in a HeLa cell nuclear extract is specifically retained on a column containing an acidic activating region 1. But because our previous study monitored only TFIIB activity, it remains possible that the interaction between TFIIB and the acidic activating region is mediated through additional proteins, for example, those designated as adaptors 2, coactivators 3 or mediators 4,5. A complementary clone encoding TFIIB has recently been isolated and shown to encode a polypeptide of relative molecular mass 35,000 (ref. 6). Here we report that TFIIB expressed in and purified from Escherichia coli (recombinant TFIIB) binds directly to the potent acidic activating region of the herpes simplex virus-1 VP16 protein.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center	LIN, YS (corresponding author), UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,373 PLANTAT ST,WORCESTER,MA 01605, USA.			Reinberg, Danny/0000-0003-4288-2016				BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764	19	340	349	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1991	353	6344					569	571		10.1038/353569a0	http://dx.doi.org/10.1038/353569a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1922364				2022-12-01	WOS:A1991GJ64300071
J	NOVICK, AC; GEPHARDT, G; GUZ, B; STEINMULLER, D; TUBBS, RR				NOVICK, AC; GEPHARDT, G; GUZ, B; STEINMULLER, D; TUBBS, RR			LONG-TERM FOLLOW-UP AFTER PARTIAL REMOVAL OF A SOLITARY KIDNEY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROGRESSIVE RENAL-FAILURE; CELL-CARCINOMA; UNILATERAL NEPHRECTOMY; CONSERVATIVE SURGERY; GLOMERULAR INJURY; VERAPAMIL; PROTEIN; DONORS; MASS; RATS	Background. The removal of more than one kidney in animals leads to proteinuria and progressive renal failure due to focal segmental glomerulosclerosis. This injury may be the result of chronic glomerular hyperfiltration. The purpose of this study was to determine the effect of a reduction in renal mass of more than 50 percent on residual renal function and morphology in humans. Methods. We evaluated long-term renal function in 14 patients with a solitary kidney who had undergone partial nephrectomy for renal-cell or transitional-cell carcinoma. In 12, the first kidney had been removed 2 months to 21 years previously for the same type of cancer; in 2, the other kidney was congenitally atrophic. Before surgery, no patient had clinical or histopathological evidence of primary renal disease. All 14 patients underwent partial nephrectomy to remove a localized tumor, with 25 to 75 percent of the solitary kidney being excised. They were evaluated 5 to 17 years after surgery (mean, 7.7). Results. Twelve patients had stable postoperative renal function, and end-stage renal failure developed in two. There were no changes in blood pressure in any patient during follow-up. Nine patients had proteinuria, which was mild (0.15 to 0.8 g of urinary protein per day) in four and moderate to severe (0.9 to 6.7 g per day) in five. The extent of proteinuria was inversely correlated with the amount of remaining renal tissue (P = 0.0065) and directly correlated with the duration of follow-up (P = 0.0005). Four patients with moderate-to-severe proteinuria had renal biopsies, which revealed focal segmental glomerulosclerosis in three patients and global glomerulosclerosis in one. Conclusions. Long-term renal function remains stable in most patients with a reduction in renal mass of more than 50 percent. These patients are, however, at increased risk for proteinuria, glomerulopathy, and progressive renal failure.	CLEVELAND CLIN EDUC FDN,DEPT NEPHROL,CLEVELAND,OH 44106; CLEVELAND CLIN EDUC FDN,DEPT PATHOL & HYPERTENS,CLEVELAND,OH 44106	Cleveland Clinic Foundation; Cleveland Clinic Foundation	NOVICK, AC (corresponding author), CLEVELAND CLIN FDN,DEPT UROL,1 CLIN CTR DR,CLEVELAND,OH 44195, USA.							ANDERSON CF, 1985, MAYO CLIN PROC, V60, P367, DOI 10.1016/S0025-6196(12)60845-3; BOVEE KC, 1979, INVEST UROL, V16, P378; BRAS G, 1969, J INFECT DIS, V120, P131, DOI 10.1093/infdis/120.1.131; BRENNER BM, 1985, AM J PHYSIOL, V249, pF324, DOI 10.1152/ajprenal.1985.249.3.F324; BRUNNER FP, 1989, KIDNEY INT, V36, P969, DOI 10.1038/ki.1989.289; FOSTER MH, 1991, AM J KIDNEY DIS, V17, P261, DOI 10.1016/S0272-6386(12)80471-9; GEPHARDT GN, 1986, ARCH PATHOL LAB MED, V110, P902; GOLDSTEIN AE, 1988, TRANSPLANTATION, V45, P59; HAKIM RM, 1984, KIDNEY INT, V25, P930, DOI 10.1038/ki.1984.112; HARRIS DCH, 1987, KIDNEY INT, V31, P41, DOI 10.1038/ki.1987.6; HOSTETTER TH, 1981, AM J PHYSIOL, V241, pF85, DOI 10.1681/ASN.V1261315; HOSTETTER TH, 1986, KIDNEY INT, V30, P509, DOI 10.1038/ki.1986.215; ICHIKAWA I, 1988, KIDNEY INT, V34, P638, DOI 10.1038/ki.1988.228; KAPPEL B, 1980, VIRCHOWS ARCH A, V387, P271, DOI 10.1007/BF00454830; KASISKE BL, 1988, CIRC RES, V62, P367, DOI 10.1161/01.RES.62.2.367; Kretschmer HL, 1943, J AMER MED ASSOC, V121, P473, DOI 10.1001/jama.1943.02840070001001; LHOTTA K, 1991, AM J KIDNEY DIS, V17, P266, DOI 10.1016/S0272-6386(12)80472-0; MEYER TW, 1985, AM J MED, V79, P31, DOI 10.1016/0002-9343(85)90077-4; NOVICK AC, 1987, UROL CLIN N AM, V14, P419; NOVICK AC, 1989, J UROLOGY, V141, P835, DOI 10.1016/S0022-5347(17)41026-3; ROBITAILLE P, 1985, LANCET, V1, P1297; SCHIMAMURA T, 1975, AM J PATHOL, V79, P95; SOLOMON LR, 1985, BRIT MED J, V291, P1610, DOI 10.1136/bmj.291.6509.1610; STAHL RAK, 1988, KLIN WOCHENSCHR, V66, P508, DOI 10.1007/BF01876174; VINCENTI F, 1983, TRANSPLANTATION, V36, P626, DOI 10.1097/00007890-198336060-00006; ZIEGELBAUM M, 1987, J UROLOGY, V138, P1146, DOI 10.1016/S0022-5347(17)43529-4	26	250	257	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 10	1991	325	15					1058	1062		10.1056/NEJM199110103251502	http://dx.doi.org/10.1056/NEJM199110103251502			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ108	1891007	Bronze			2022-12-01	WOS:A1991GJ10800002
J	ODELL, TJ; KANDEL, ER; GRANT, SGN				ODELL, TJ; KANDEL, ER; GRANT, SGN			LONG-TERM POTENTIATION IN THE HIPPOCAMPUS IS BLOCKED BY TYROSINE KINASE INHIBITORS	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; EPIDERMAL GROWTH-FACTOR; SRC GENE-PRODUCT; RAT-BRAIN; PHORBOL ESTERS; PHOSPHORYLATION; RECEPTOR; SLICES; CELLS	LONG-TERM potentiation (LTP) in the hippocampus is thought to contribute to memory formation. In the Ca1 region, LTP requires the NMDA (N-methyl-D-aspartate) receptor-dependent influx of Ca2+ and activation of serine and threonine protein kinases. Because of the high amount of protein tyrosine kinases in hippocampus and cerebellum 1,2, two regions implicated in learning and memory, we examined the possible additional requirement of tyrosine kinase activity in LTP. We first examined the specificity in brain of five inhibitors of tyrosine kinase 3-5 (Table 1) and found that two of them, lavendustin A and genistein, showed substantially greater specificity for tyrosine kinase from hippocampus 6 than for three serine-threonine kinases: protein kinase A, protein kinase C, and Ca2+/calmodulin kinase II. Lavendustin A and genistein selectively blocked the induction of LTP when applied in the bath or injected into the postsynaptic cell. By contrast, the inhibitors had no effect on the established LTP, on normal synaptic transmission, or on the neurotransmitter actions attributable to the actions of protein kinase A or protein kinase C. These data suggest that tyrosine kinase activity could be required postsynaptically for long-term synaptic plasticity in the hippocampus. As Ca2+ calmodulin kinase II or protein kinase C seem also to be required 7,8, the tyrosine kinases could participate postsynaptically in a kinase network together with serine and threonine kinases.	COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute	ODELL, TJ (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,722 W 168TH ST,NEW YORK,NY 10032, USA.			Grant, Seth/0000-0001-8732-8735				AKIYAMA T, 1986, J BIOL CHEM, V261, P4797; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; AURICCHIO F, 1987, METHOD ENZYMOL, V139, P731; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1986, J PHYSIOL-LONDON, V377, P391, DOI 10.1113/jphysiol.1986.sp016193; BRAUN S, 1984, J BIOL CHEM, V259, P2051; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; HIRANO AA, 1988, J NEUROCHEM, V50, P1447, DOI 10.1111/j.1471-4159.1988.tb03029.x; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; LYALL RM, 1989, J BIOL CHEM, V264, P14503; MADISON DV, 1982, NATURE, V299, P636, DOI 10.1038/299636a0; MALENKA RC, 1986, J NEUROSCI, V6, P475; MALENKA RC, 1986, NATURE, V321, P175, DOI 10.1038/321175a0; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MIGLIACCIO A, 1984, P NATL ACAD SCI-BIOL, V81, P5921, DOI 10.1073/pnas.81.19.5921; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; NICOLL RA, 1988, NEURON, V1, P7; ODELL TJ, IN PRESS P NATN ACAD; ONODA T, 1989, J NAT PROD, V52, P1252, DOI 10.1021/np50066a009; PANG DT, 1988, P NATL ACAD SCI USA, V85, P762, DOI 10.1073/pnas.85.3.762; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; STRATTON KR, 1989, P NATL ACAD SCI USA, V86, P2498, DOI 10.1073/pnas.86.7.2498; SUGRUE MM, 1990, J NEUROSCI, V10, P2513; TERLAU H, 1990, EUR J NEUROSCI, V2, P973, DOI 10.1111/j.1460-9568.1990.tb00009.x; TERLAU H, 1989, BRAIN RES, V484, P352, DOI 10.1016/0006-8993(89)90380-6; WALAAS SI, 1988, MOL BRAIN RES, V3, P215, DOI 10.1016/0169-328X(88)90044-7	29	510	523	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1991	353	6344					558	560		10.1038/353558a0	http://dx.doi.org/10.1038/353558a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1656271				2022-12-01	WOS:A1991GJ64300067
J	REPRESA, J; LEON, Y; MINER, C; GIRALDEZ, F				REPRESA, J; LEON, Y; MINER, C; GIRALDEZ, F			THE INT-2 PROTOONCOGENE IS RESPONSIBLE FOR INDUCTION OF THE INNER-EAR	NATURE			English	Article							CHICK-EMBRYO; SEQUENCE	THE int-2 proto-oncogene encodes several products related to the fibroblast growth factor (FGF) family 1,2. FGFs have been associated with mesoderm induction in the amphibian embryo 2,3 and int-2 has a distinct pattern of expression throughout development in vertebrates 4,5. But evidence for a function of int-2 in embryo-genesis has been lacking. In the mouse embryo, int-2 transcripts have been detected in the rhombencephalon at a developmental stage where classical experiments showed that the induction of the inner ear occurs 6,7. This raises the possibility that int-2 may constitute a signal for the induction of the otic vesicle, the primordium of the inner ear. We provide direct evidence for this view by showing that (1) the formation of the otic vesicle is inhibited by antisense oligonucleotides targeted to the secreted form of int-2, and by antibodies against int-2 oncoproteins, and (2) basic FGF (bFGF) can mimic the inductive signal in the absence of the rhombencephalon.	FAC MED VALLADOLID,DEPT BIOQUIM & BIOL MOLEC & FISIOL,E-47005 VALLADOLID,SPAIN; FAC MED VALLADOLID,DEPT CIENCIAS MORFOL,E-47005 VALLADOLID,SPAIN				Leon, Yolanda/ABG-6797-2020; Giraldez, Fernando/C-9821-2014	Leon Alvarez, Yolanda/0000-0002-4536-8373				ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; ALVAREZ IS, 1990, ANAT RECORD, V228, P315, DOI 10.1002/ar.1092280311; DODGSON JB, 1983, J BIOL CHEM, V258, P2685; GIRALDEZ F, 1987, DEVELOPMENT, V100, P271; Gospodarowicz D, 1990, Curr Top Dev Biol, V24, P57, DOI 10.1016/S0070-2153(08)60084-8; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; LUMSDEN AGS, 1983, NATURE, V306, P786, DOI 10.1038/306786a0; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; REPRESA J, 1990, DEVELOPMENT, V110, P1081; SCHOENWOLF GC, 1990, DEVELOPMENT, V109, P243; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; Waddington CH, 1937, J EXP BIOL, V14, P232; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x	14	163	164	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1991	353	6344					561	563		10.1038/353561a0	http://dx.doi.org/10.1038/353561a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1922362				2022-12-01	WOS:A1991GJ64300068
J	SAUER, F; JACKLE, H				SAUER, F; JACKLE, H			CONCENTRATION-DEPENDENT TRANSCRIPTIONAL ACTIVATION OR REPRESSION BY KRUPPEL FROM A SINGLE BINDING-SITE	NATURE			English	Article							ALCOHOL-DEHYDROGENASE GENE; EARLY DROSOPHILA EMBRYO; ARAC PROTEIN; HUNCHBACK; PRODUCTS; KNIRPS; EXPRESSION; PROMOTERS; PATTERN; REGION	ONE of the gap class of segmentation genes 1, Kruppel (Kr), is required for normal thorax and abdominal development of the Drosophila embryo. Its gene product, a zinc-finger type protein 2, forms a bell-shape concentration gradient in a central position of the blastoderm 3-6. Genetic and molecular studies suggested that the Kr protein (KR) may act both as a positive and as a negative regulator of transcription on several other genes 3-9 of the zygotic segmentation hierarchy 1. We have examined the regulatory potential of Kr by a series of cotransfection experiments in the Drosophila Schneider cell line system. Different doses of Kr expression plasmid were tested for their ability to drive reporter gene expression mediated by a single 11-base pair KR in vitro binding site common to several putative Kr target genes 4-6,8-10. Our results show that low amounts of Kr expression plasmid lead to transcriptional activation, whereas high amounts result in repression. Distinct portions of KR other than the DNA-binding domain are required for gene activation and repression, suggesting that KR itself can act as a concentration-dependent positive and negative regulator of transcription.			SAUER, F (corresponding author), MAX PLANCK INST BIOPHYS CHEM,MOLEK ENTWICKLUNGSBIOL ABT,FASSBERG,W-3400 GOTTINGEN,GERMANY.							BIGGIN MD, 1989, CELL, V58, P433, DOI 10.1016/0092-8674(89)90424-8; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; GAUL U, 1987, CELL, V51, P549, DOI 10.1016/0092-8674(87)90124-3; GAUL U, 1989, DEVELOPMENT, V107, P651; GAUL U, 1988, THESUS U TUBINGEN; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HEBERLEIN U, 1985, CELL, V41, P965, DOI 10.1016/S0092-8674(85)80077-5; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; HOCH MM, IN PRESS EMBO J; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; LEE N, 1987, P NATL ACAD SCI USA, V84, P8814, DOI 10.1073/pnas.84.24.8814; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; MANIATIS T, 1990, MOL CLONING; MARTIN K, 1986, P NATL ACAD SCI USA, V83, P3654, DOI 10.1073/pnas.83.11.3654; MEYER BJ, 1980, J MOL BIOL, V139, P163, DOI 10.1016/0022-2836(80)90303-4; PANKRATZ MJ, 1989, NATURE, V341, P337, DOI 10.1038/341337a0; PANKRATZ MJ, 1990, CELL, V61, P309, DOI 10.1016/0092-8674(90)90811-R; PING Z, 1991, GENE DEV, V5, P254; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; ROTHE M, 1989, EMBO J, V8, P3087, DOI 10.1002/j.1460-2075.1989.tb08460.x; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; TREISMAN J, 1989, NATURE, V341, P335, DOI 10.1038/341335a0	32	142	145	1	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1991	353	6344					563	566		10.1038/353563a0	http://dx.doi.org/10.1038/353563a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1922363				2022-12-01	WOS:A1991GJ64300069
J	SEARS, MR; BURROWS, B; FLANNERY, EM; HERBISON, GP; HEWITT, CJ; HOLDAWAY, MD				SEARS, MR; BURROWS, B; FLANNERY, EM; HERBISON, GP; HEWITT, CJ; HOLDAWAY, MD			RELATION BETWEEN AIRWAY RESPONSIVENESS AND SERUM IGE IN CHILDREN WITH ASTHMA AND IN APPARENTLY NORMAL-CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BRONCHIAL REACTIVITY; POPULATION-SAMPLE; CHILDHOOD ASTHMA; NEW-ZEALAND; HISTAMINE; METHACHOLINE; ATOPY; HYPERRESPONSIVENESS; PREVALENCE; ALLERGY	Background. Although asthma diagnosed by a physician is known to be related to serum IgE levels, it is not known whether there is a relation between the level of IgE and airway hyperresponsiveness to a methacholine challenge. The characteristics of asymptomatic persons that predispose them to airway hyperresponsiveness are also unknown. Methods. We studied the relation between the serum total IgE level and airway hyperresponsiveness in the presence or absence of asthma and other atopic diseases in a birth cohort of children. Data from a questionnaire regarding respiratory symptoms, plus measurements of the serum total IgE level and airway responsiveness to inhaled methacholine, were obtained for 562 11-year-olds in New Zealand. Results. The boys had a higher prevalence than the girls of current diagnosed asthma (13 percent vs. 6 percent), current symptoms of wheezing (22 percent vs. 15 percent), and airflow obstruction at base line (6 percent vs. 1 percent) and had a wider distribution of IgE levels, although mean IgE levels (120.8 IU per milliliter in the boys and 98.1 IU per milliliter in the girls) did not differ significantly between the sexes. The prevalence of diagnosed asthma was strongly related to the serum IgE level (P for trend < 0.0001). No asthma was reported in children with IgE levels < 32 IU per milliliter, whereas 36 percent of those with IgE levels greater-than-or-equal-to 1000 IU per milliliter were reported to have asthma. This relation with the serum IgE level was not explained by a concomitant diagnosis of allergic rhinitis or eczema. Airway hyperresponsiveness to a methacholine challenge also correlated very highly (P < 0.0001) with the serum IgE level. This relation remained significant even after the exclusion of children with diagnosed asthma (P < 0.0001) and of all children with a history of wheezing, allergic rhinitis, or eczema (P < 0.0001). Conclusions. Even in children who have been asymptomatic throughout their lives and have no history of atopic disease, airway hyperresponsiveness appears to be closely linked to an allergic diathesis, as reflected by the serum total IgE level.	UNIV ARIZONA,COLL MED,DIV RESP SCI,TUCSON,AZ 85721; UNIV OTAGO,SCH MED,DEPT MED,DUNEDIN,NEW ZEALAND; UNIV OTAGO,SCH MED,DEPT PREVENT & SOCIAL MED,DUNEDIN,NEW ZEALAND; UNIV OTAGO,SCH MED,DEPT PAEDIAT & CHILD HLTH,DUNEDIN,NEW ZEALAND	University of Arizona; University of Otago; University of Otago; University of Otago				Herbison, Graham Peter/0000-0002-5684-024X	NHLBI NIH HHS [HL-14136] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P1013, DOI 10.1016/0091-6749(89)90441-7; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BRYANT DH, 1976, CLIN ALLERGY, V6, P373, DOI 10.1111/j.1365-2222.1976.tb01919.x; BURROWS B, 1983, CHEST, V84, P657, DOI 10.1378/chest.84.6.657; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CLINE MG, 1989, THORAX, V44, P425, DOI 10.1136/thx.44.5.425; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1984, ANN ALLERGY, V53, P26; DAVIES RJ, 1976, THORAX, V31, P419, DOI 10.1136/thx.31.4.419; GRAINGER DN, 1990, CLIN EXP ALLERGY, V20, P181, DOI 10.1111/j.1365-2222.1990.tb02665.x; JOHANSSON SGO, 1976, CLIN ALLERGY, V6, P91, DOI 10.1111/j.1365-2222.1976.tb01417.x; JONES DT, 1987, BRIT J DIS CHEST, V81, P332, DOI 10.1016/0007-0971(87)90181-1; LAM S, 1983, J ALLERGY CLIN IMMUN, V72, P134, DOI 10.1016/0091-6749(83)90520-1; LEE DA, 1983, BRIT MED J, V286, P1256, DOI 10.1136/bmj.286.6373.1256; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; MURANAKA M, 1974, J ALLERGY CLIN IMMUN, V54, P32, DOI 10.1016/S0091-6749(74)80006-0; OCONNOR GT, 1989, AM REV RESPIR DIS, V140, P1520, DOI 10.1164/ajrccm/140.6.1520; RIJCKEN B, 1988, AM REV RESPIR DIS, V137, P826, DOI 10.1164/ajrccm/137.4.826; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; SALOME CM, 1987, CLIN ALLERGY, V17, P271, DOI 10.1111/j.1365-2222.1987.tb02015.x; SEARS MR, 1986, THORAX, V41, P283, DOI 10.1136/thx.41.4.283; Silva P A, 1990, Paediatr Perinat Epidemiol, V4, P76, DOI 10.1111/j.1365-3016.1990.tb00621.x; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P429; WOOLCOCK AJ, 1978, CLIN ALLERGY, V8, P155, DOI 10.1111/j.1365-2222.1978.tb00460.x; ZIMMERMAN B, 1988, J ALLERGY CLIN IMMUN, V81, P63, DOI 10.1016/0091-6749(88)90221-7	26	655	670	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 10	1991	325	15					1067	1071		10.1056/NEJM199110103251504	http://dx.doi.org/10.1056/NEJM199110103251504			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ108	1891008				2022-12-01	WOS:A1991GJ10800004
J	TURNLEY, AM; MORAHAN, G; OKANO, H; BERNARD, O; MIKOSHIBA, K; ALLISON, J; BARTLETT, PF; MILLER, JFAP				TURNLEY, AM; MORAHAN, G; OKANO, H; BERNARD, O; MIKOSHIBA, K; ALLISON, J; BARTLETT, PF; MILLER, JFAP			DYSMYELINATION IN TRANSGENIC MICE RESULTING FROM EXPRESSION OF CLASS-I HISTOCOMPATIBILITY MOLECULES IN OLIGODENDROCYTES	NATURE			English	Article							PANCREATIC BETA-CELLS; MYELIN BASIC-PROTEIN; MULTIPLE-SCLEROSIS; MHC MOLECULES; SCHWANN-CELLS; ANTIGENS; TOLERANCE; GENE; TRANSCRIPTION; INTERFERON	MAJOR histocompatibility complex (MHC) molecules are not normally expressed in the central nervous system (CNS) 1-3. However, aberrant expression has been observed in multiple sclerosis lesions and could contribute to the destruction of myelin or the myelinating cells known as oligodendrocytes 4,5. The mechanism of cell damage associated with aberrant MHC molecule expression is unclear: for example, overexpression of class I (ref. 6) and class II (refs 7, 8) MHC molecules in pancreatic beta-cells in transgenic mice leads to nonimmune destruction of the cells and insulin-dependent diabetes mellitus. We have generated transgenic mice that express class I H-2K(b) MHC molecules, under the control of the myelin basic protein promoter, specifically in oligodendrocytes. Homozygous transgenic mice have a shivering phenotype, develop tonic seizures and die at 15-22 days. This phenotype, which we term 'wonky', is due to hypomyelination in the CNS, and not to involvement of the immune system. The primary defect appears to be a shortage of myelinating oligodendrocytes resulting from overexpression of the class I MHC molecules.	OSAKA UNIV,INST PROT RES,OSAKA 565,JAPAN	Osaka University	TURNLEY, AM (corresponding author), ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PO ROYAL MELBOURNE HOSP,PARKVILLE,VIC 3050,AUSTRALIA.		Bartlett, Perry/F-3813-2012; Okano, Hideyuki/I-7584-2019; Turnley, Ann/A-8125-2010; Morahan, Grant/T-7501-2019; Mikoshiba, Katsuhiko/N-7943-2015	Turnley, Ann/0000-0002-8442-127X				ALLISON J, 1988, NATURE, V333, P529, DOI 10.1038/333529a0; BARTLETT PF, 1983, J CLIN LAB IMMUNOL, V11, P1; BARTLETT PF, 1989, TRANSPLANT P, V21, P3166; DEROSBO NK, 1984, NEUROCHEM RES, V9, P1359, DOI 10.1007/BF00964663; GILFILLAN S, 1990, P NATL ACAD SCI USA, V87, P7319, DOI 10.1073/pnas.87.18.7319; GOULD RM, 1977, J CELL BIOL, V75, P326, DOI 10.1083/jcb.75.2.326; JONESYOUNGBLOOD SL, 1990, J IMMUNOL, V144, P1187; KIDD GJ, 1990, J NEUROSCI RES, V26, P409, DOI 10.1002/jnr.490260403; LO D, 1988, CELL, V53, P159, DOI 10.1016/0092-8674(88)90497-7; MCFARLIN DE, 1982, NEW ENGL J MED, V307, P1183, DOI 10.1056/NEJM198211043071905; MILLER J, 1990, J IMMUNOL, V144, P334; MITCHELL LS, 1990, J NEUROSCI RES, V27, P125, DOI 10.1002/jnr.490270202; MORAHAN G, 1989, P NATL ACAD SCI USA, V86, P3782, DOI 10.1073/pnas.86.10.3782; MORAHAN G, 1989, NATURE, V339, P622, DOI 10.1038/339622a0; MURPHY KM, 1989, P NATL ACAD SCI USA, V86, P10034, DOI 10.1073/pnas.86.24.10034; OKANO H, 1988, EMBO J, V7, P77, DOI 10.1002/j.1460-2075.1988.tb02785.x; PANITCH HS, 1987, LANCET, V1, P893; PERIER O, 1965, BRAIN, V88, P937, DOI 10.1093/brain/88.5.937; RANSCHT B, 1982, P NATL ACAD SCI-BIOL, V79, P2709, DOI 10.1073/pnas.79.8.2709; SARVETNICK N, 1988, CELL, V52, P773, DOI 10.1016/0092-8674(88)90414-X; SCHEN HZ, 1989, J NEUROSCI RES, V23, P425; SMITH MH, 1986, MOL IMMUNOL, V23, P1077, DOI 10.1016/0161-5890(86)90006-4; Sternberger L. A., 1979, IMMUNOCYTOCHEMISTRY; TAMURA T, 1988, NUCLEIC ACIDS RES, V16, P11441, DOI 10.1093/nar/16.24.11441; TRAUGOTT U, 1987, J NEUROIMMUNOL, V16, P283, DOI 10.1016/0165-5728(87)90082-8; WONG GHW, 1984, NATURE, V310, P688, DOI 10.1038/310688a0	26	107	107	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1991	353	6344					566	569		10.1038/353566a0	http://dx.doi.org/10.1038/353566a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1717849				2022-12-01	WOS:A1991GJ64300070
J	FLANCE, IJ				FLANCE, IJ			SCAR CANCER OF THE LUNG	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											FLANCE, IJ (corresponding author), WASHINGTON UNIV,SCH MED,ST LOUIS,MO 63110, USA.							CHAUDHURI MR, 1973, INDIAN J MED RES, V61, P858; KUNG ITM, 1985, AM J SURG PATHOL, V9, P391; MADRI JA, 1984, HUM PATHOL, V15, P625, DOI 10.1016/S0046-8177(84)80286-5; MEYER EC, 1965, CANCER-AM CANCER SOC, V18, P322, DOI 10.1002/1097-0142(196503)18:3<322::AID-CNCR2820180310>3.0.CO;2-J; MONTGOMERY GL, 1947, BRIT J SURG, V31, P292; ROSAI J, 1989, ACKERMANS SURGICAL P, V1, P297	6	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					2003	2004		10.1001/jama.266.14.2003	http://dx.doi.org/10.1001/jama.266.14.2003			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH406	1895484				2022-12-01	WOS:A1991GH40600033
J	HOLMES, SJ; LUCAS, AH; OSTERHOLM, MT; FROESCHLE, JE; GRANOFF, DM				HOLMES, SJ; LUCAS, AH; OSTERHOLM, MT; FROESCHLE, JE; GRANOFF, DM			IMMUNOGLOBULIN DEFICIENCY AND IDIOTYPE EXPRESSION IN CHILDREN DEVELOPING HAEMOPHILUS-INFLUENZAE TYPE-B DISEASE AFTER VACCINATION WITH CONJUGATE VACCINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CAPSULAR POLYSACCHARIDE VACCINE; HEMOPHILUS DISEASE; ANTIBODIES; EFFICACY; SUBCLASS; AGE; IMMUNOGENICITY; IMMUNIZATION; MINNESOTA; INFANTS	Objective. Haemophilus influenzae type b (Hib) conjugate vaccines are effective in preventing Haemophilus disease in most children. The reasons why the vaccination fails in some children are unknown. This study investigated host factors in children who developed the disease despite conjugate vaccination. Design, Patients, Outcome Measures. A convenience sample of 23 patients in whom Hib disease developed 14 days or more after conjugate vaccination was investigated for the presence of subnormal serum immunoglobulin concentrations and anticapsular antibody responses to Hib disease. We also investigated expression of the Hib idiotype 1 (Hibld-1), a serological marker of a V(K)II chain that comprises a major portion of the normal variable region repertoire of the antibody response to Hib polysaccharide. The results were compared with those of 149 patients in whom the unconjugated Hib polysaccharide vaccine failed and of 90 unvaccinated patients who developed the disease. Results. Compared with children in whom the unconjugated polysaccharide vaccination failed, the relative risk of a subnormal serum concentration of IgM, IgA, IgG, and/or IgG2 in the children in whom the conjugate vaccination failed was 4.9 (95% confidence interval [Cl], 1.8 to 14; P < .003) and of IgG2 was 22 (95% Cl, 3.5 to 146; P < .001). With the exception of the children with subnormal serum immunoglobulin concentrations, most of the children with conjugate vaccination failure showed normal or high anticapsular antibody responses to the disease, whereas the children with polysaccharide vaccination failure showed impaired responses. The Hibld-1 was expressed by the majority of the children in both vaccination failure groups and of the unvaccinated patients. Conclusions. In most patients, vaccination failure is not attributable to lack of expression of the variable region gene encoding Hibld-1. However, children in whom conjugate vaccination has failed frequently have subnormal serum immunoglobulin concentrations and should be evaluated for immunodeficiency.	WASHINGTON UNIV,SCH MED,ST LOUIS CHILDRENS HOSP,EDWARD MALLINCKRODT DEPT PEDIAT,ST LOUIS,MO 63110; MINNESOTA DEPT HLTH,ACUTE DIS EPIDEMIOL SECT,MINNEAPOLIS,MN; CONNAUGHT LABS INC,SWIFTWATER,PA; CHILDRENS HOSP OAKLAND RES INST,OAKLAND,CA	St. Louis Children's Hospital; Washington University (WUSTL); Minnesota Department of Health (MHD); Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021842, R37AI025008, R01AI025008, R01AI017962] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 25008, AI 21842, AI 17962] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADDERSON EE, 1991, J IMMUNOL, V147, P1667; BLACK SB, 1988, PEDIATR INFECT DIS J, V7, P149, DOI 10.1097/00006454-198803000-00003; ESKOLA J, 1990, NEW ENGL J MED, V323, P1381, DOI 10.1056/NEJM199011153232004; GRANOFF DM, 1989, J PEDIATR-US, V114, P925, DOI 10.1016/S0022-3476(89)80432-9; GRANOFF DM, 1986, NEW ENGL J MED, V315, P1584, DOI 10.1056/NEJM198612183152505; GRANOFF DM, 1988, MONOGR ALLERGY, V23, P256; GRANOFF DM, 1986, J INFECT DIS, V154, P257, DOI 10.1093/infdis/154.2.257; GRANOFF DM, 1989, J INFECT DIS, V159, P908, DOI 10.1093/infdis/159.5.908; GRANOFF DM, 1988, PEDIATR RES, V24, P180, DOI 10.1203/00006450-198808000-00008; GREENBERG DP, 1991, JAMA-J AM MED ASSOC, V265, P987, DOI 10.1001/jama.265.8.987; HALDANE JBS, 1956, ANN HUM GENET, V20, P309; HARRISON LH, 1988, JAMA-J AM MED ASSOC, V260, P1413, DOI 10.1001/jama.260.10.1413; KAYHTY H, 1983, J INFECT DIS, V147, P1100; KAYHTY H, 1988, J INFECT DIS, V158, P973, DOI 10.1093/infdis/158.5.973; LUCAS AH, 1990, J CLIN INVEST, V85, P1158, DOI 10.1172/JCI114548; LUCAS AH, IN PRESS J CLIN INVE; MADASSERY JV, 1988, CLIN CHEM, V34, P1407; MADORE DV, 1990, PEDIATRICS, V86, P527; MURPHY TV, 1990, FEB W SOC PED RES CA; OSTERHOLM MT, 1988, JAMA-J AM MED ASSOC, V260, P1423, DOI 10.1001/jama.260.10.1423; OSTERHOLM MT, 1989, 29TH INT C ANT AG CH; PELTOLA H, 1977, PEDIATRICS, V60, P730; SCOTT MG, 1989, J IMMUNOL, V143, P293; SHACKELFORD PG, 1990, J PEDIATR-US, V116, P529, DOI 10.1016/S0022-3476(05)81598-7; SHAPIRO ED, 1988, JAMA-J AM MED ASSOC, V260, P1419, DOI 10.1001/jama.260.10.1419; SHAPIRO ED, 1990, 30TH INT C ANT AG CH; WEINBERG GA, 1990, PEDIATRICS, V86, P617	27	25	25	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					1960	1965		10.1001/jama.266.14.1960	http://dx.doi.org/10.1001/jama.266.14.1960			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH406	1895474				2022-12-01	WOS:A1991GH40600022
J	KHOURI, RK; KOUDSI, B; REDDI, H				KHOURI, RK; KOUDSI, B; REDDI, H			TISSUE TRANSFORMATION INTO BONE INVIVO - A POTENTIAL PRACTICAL APPLICATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BIOLOGICAL PRINCIPLE; INDUCED OSTEOGENESIS; INDUCTIVE PROTEIN; RECONSTRUCTION; DIFFERENTIATION; DEFECTS; GRAFTS; REPAIR; RATS	The transformation of mesenchymal tissue, such as muscle, into cartilage and bone can be induced by the recently purified osteoinductive factor, osteogenin, and by its parent substratum, demineralized bone matrix. We investigated the possibility of transforming readily available muscle flaps into vascularized bone grafts of various shapes that could be used as skeletal replacement parts. In a rat experimental model, thigh adductor muscle island flaps were placed inside bivalved silicone rubber molds. Prior to closure of the mold, 18 flaps were injected with osteogenin and coated with demineralized bone matrix. Five flaps served as controls and were injected with the vehicle only, and not coated with demineralized bone matrix. The molds were implanted subcutaneously in the rats' flanks and reopened 10 days later. The control flaps consisted of intact muscle without any evidence of tissue transformation, whereas the flaps treated with osteogenin and demineralized bone matrix were entirely transformed into cancellous bone that matched the exact shape of the mold. Using tissue transformation, we were able to generate in vivo, autogenous, well-perfused bones in the shapes of femoral heads and mandibles.	NIDR,BONE CELL BIOL SECT,BETHESDA,MD 20892; WASHINGTON UNIV,SCH MED,PLAST SURG RES LAB,ST LOUIS,MO 63110	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Washington University (WUSTL)	KHOURI, RK (corresponding author), WASHINGTON UNIV,SCH MED,DEPT SURG,DIV PLAST SURG,ONE BARNES HOSP PLAZA,SUITE 17424,ST LOUIS,MO 63110, USA.				PHS HHS [22-3335 44901A] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BANIS JC, 1984, ARCH SURG-CHICAGO, V119, P673; BLEIBERG I, 1987, EXP HEMATOL, V15, P309; CHALMERS J, 1975, J BONE JOINT SURG BR, VB 57, P36, DOI 10.1302/0301-620X.57B1.36; FISHER J, 1988, PLAST RECONSTR SURG, V82, P857, DOI 10.1097/00006534-198811000-00021; GLOWACKI J, 1981, LANCET, V1, P959; HABAL MB, 1987, ADV PLASTIC RECONSTR; HIDALGO DA, 1990, PLAST RECONSTR SURG, V86, P492, DOI 10.1097/00006534-199009000-00019; HOLLINGER J, 1989, J ORAL MAXIL SURG, V47, P1182, DOI 10.1016/0278-2391(89)90009-8; KABAN LB, 1989, J ORAL MAXIL SURG, V47, P1187, DOI 10.1016/0278-2391(89)90010-4; KABAN LB, 1984, J DENT RES, V63, P998, DOI 10.1177/00220345840630071801; KHOURI RK, 1989, J TRAUMA, V29, P1086, DOI 10.1097/00005373-198908000-00005; KHOURI RK, 1991, PLAST RECONSTR SURG, V87, P108, DOI 10.1097/00006534-199101000-00017; KHOURI RK, 1988, SURG FORUM, V439, P597; KHOURI RK, 1991, J TRAUMA, P1029; KHOURI RK, 1991, PLASTIC SURGERY, P1029; LACROIX P, 1945, NATURE, V156, P576, DOI 10.1038/156576a0; LUYTEN FP, 1989, J BIOL CHEM, V264, P13377; MARK DE, 1990, PLAST RECONSTR SURG, V86, P623, DOI 10.1097/00006534-199010000-00001; MULLIKEN JB, 1984, J SURG RES, V37, P487, DOI 10.1016/0022-4804(84)90218-X; MUTHUKUMARAN N, 1988, COLLAGEN REL RES, V8, P433; NILSSON OS, 1986, J BONE JOINT SURG BR, V68, P635, DOI 10.1302/0301-620X.68B4.3733844; REDDI AH, 1987, ORTHOP CLIN N AM, V18, P207; REDDI AH, 1972, P NATL ACAD SCI USA, V69, P1601, DOI 10.1073/pnas.69.6.1601; SAMPATH TK, 1987, P NATL ACAD SCI USA, V84, P7109, DOI 10.1073/pnas.84.20.7109; SPORN MB, 1990, HDB EXPT PHARM; TAYLOR GI, 1983, CLIN PLAST SURG, V10, P185; URIST MR, 1983, SCIENCE, V220, P680, DOI 10.1126/science.6403986; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; URIST MR, 1981, CLIN ORTHOP RELAT R, V154, P97; WEILAND AJ, 1984, PLAST RECONSTR SURG, V74, P368, DOI 10.1097/00006534-198409000-00006; WEINTROUB S, 1990, CALCIFIED TISSUE INT, V46, P38; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	32	139	146	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					1953	1955		10.1001/jama.266.14.1953	http://dx.doi.org/10.1001/jama.266.14.1953			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH406	1895472				2022-12-01	WOS:A1991GH40600020
J	LEFRAK, S				LEFRAK, S			TUBERCULOSIS SCREENING IN A NURSING-HOME - INDICATIONS FOR PREVENTIVE THERAPY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											LEFRAK, S (corresponding author), WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,ST LOUIS,MO 63110, USA.							1990, MMWR, V39, P7; [No title captured]; 1990, MMWR, V39, P1	3	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					2000	&						0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH406	1895483				2022-12-01	WOS:A1991GH40600032
J	LITTLE, JR				LITTLE, JR			STAPHYLOCOCCUS-AUREUS CARRIAGE IN THE NURSING-HOME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											LITTLE, JR (corresponding author), WASHINGTON UNIV, MED CTR, ST LOUIS, MO 63130 USA.							CEDERNA JE, 1990, INFECT CONT HOSP EP, V11, P13, DOI 10.1086/646072; MUDER RR, 1991, ANN INTERN MED, V114, P107, DOI 10.7326/0003-4819-114-2-1-107; REAGAN DR, 1991, ANN INTERN MED, V114, P101, DOI 10.7326/0003-4819-114-2-101; STORCH GA, 1987, INFECT CONT HOSP EP, V8, P24, DOI 10.1017/S0195941700066947; STRAUSBAUGH LJ, 1991, INFECT CONT HOSP EP, V12, P36, DOI 10.2307/30147087	5	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					1999	2000		10.1001/jama.266.14.1999	http://dx.doi.org/10.1001/jama.266.14.1999			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH406	1823539				2022-12-01	WOS:A1991GH40600030
J	SIEGEL, MJ; CAREL, C; SURRATT, S				SIEGEL, MJ; CAREL, C; SURRATT, S			ULTRASONOGRAPHY OF ACUTE ABDOMINAL-PAIN IN CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							ACUTE APPENDICITIS; ACUTE ABDOMEN; SONOGRAPHY; US	Objective. To determine the ability of ultrasonography to detect appendicitis and to identify other conditions responsible for symptoms in children with acute abdominal pain. Design. Cohort study. The accuracy of ultrasonographic results was assessed in relation to final diagnoses established by surgery or by composite clinical data and follow-up. Setting. Metropolitan, pediatric hospital; ambulatory and hospitalized patients. Patients. Consecutive sample of 178 pediatric patients who were referred for ultrasonography because of suspected acute appendicitis, but in whom the diagnosis could not be definitely established by clinical criteria. Results. Appendicitis was proven at surgery in 38 patients. Ultrasonography demonstrated the findings of appendicitis (noncompressible appendix with or without concomitant periappendiceal fluid collection or appendicolith) in 31 (82%) of these patients. Among the 140 children without appendicitis, other specific diagnoses were established by clinical, laboratory, and radiologic findings in 58 patients (including gynecologic diseases in 25, gastrointestinal tract abnormalities in 17, renal diseases in six, and extra-abdominal disease in 10). Ultrasonography aided in the diagnosis of other conditions in 34 (59%) of these 58 patients. No definitive clinical diagnosis was established in the remaining 82 patients. There were no false-positive results of ultrasonography. Conclusion. Approximately half of children referred for suspected appendicitis will have a final diagnosis of abdominal pain of unknown origin. In the remainder, ultrasonography is useful, both to establish the diagnosis of appendicitis and to aid in diagnosing other causes of acute abdominal pain.			SIEGEL, MJ (corresponding author), WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT INST RADIOL,510 S KINGSHIGHWAY BLVD,ST LOUIS,MO 63110, USA.							ABUYOUSEF MM, 1987, AM J ROENTGENOL, V149, P53, DOI 10.2214/ajr.149.1.53; CAMPBELL JPM, 1988, BRIT J SURG, V75, P554, DOI 10.1002/bjs.1800750616; FEEDYSHIN P, 1984, AJR AM J ROENTGENOL, V143, P99; FRANKEN EA, 1989, AM J ROENTGENOL, V153, P921, DOI 10.2214/ajr.153.5.921; GAENSLER EHL, 1989, AM J ROENTGENOL, V152, P49, DOI 10.2214/ajr.152.1.49; JEFFREY RB, 1987, RADIOLOGY, V163, P11, DOI 10.1148/radiology.163.1.3547490; JEFFREY RB, 1988, RADIOLOGY, V167, P327, DOI 10.1148/radiology.167.2.3282253; JOFFE N, 1975, Critical Reviews in Clinical Radiology and Nuclear Medicine, V7, P97; JONES PF, 1976, BRIT MED J, V2, P551, DOI 10.1136/bmj.2.6035.551; MENDELSON RM, 1987, BRIT J RADIOL, V60, P414, DOI 10.1259/0007-1285-60-712-414; PARELUKAR SG, 1983, J ULTRASOUNDMED, V2, P59; PUYLAERT JBCM, 1987, NEW ENGL J MED, V317, P666, DOI 10.1056/NEJM198709103171103; PUYLAERT JBCM, 1986, RADIOLOGY, V158, P355, DOI 10.1148/radiology.158.2.2934762; RUBIN SZ, 1990, J PEDIATR SURG, V25, P737, DOI 10.1016/S0022-3468(05)80008-9; VIGNAULT F, 1990, RADIOLOGY, V176, P501, DOI 10.1148/radiology.176.2.2195594; WINSEY HS, 1967, BMJ-BRIT MED J, V1, P653, DOI 10.1136/bmj.1.5541.653	16	68	70	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					1987	1989		10.1001/jama.266.14.1987	http://dx.doi.org/10.1001/jama.266.14.1987			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH406	1895479				2022-12-01	WOS:A1991GH40600027
J	STANLEY, SL; JACKSON, TFHG; REED, SL; CALDERON, J; KUNZJENKINS, C; GATHIRAM, V; LI, E				STANLEY, SL; JACKSON, TFHG; REED, SL; CALDERON, J; KUNZJENKINS, C; GATHIRAM, V; LI, E			SERODIAGNOSIS OF INVASIVE AMEBIASIS USING A RECOMBINANT ENTAMOEBA-HISTOLYTICA PROTEIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							ANTIBODY RESPONSE; ZYMODEMES; ANTIGEN	One hundred eight serum samples from 106 patients were examined by Western blot analysis for the presence of antibodies to a recombinant fusion protein containing the sequence of the newly described serine-rich Entamoeba histolytica protein (SREHP). Among patients with invasive amebiasis from Durban, Republic of South Africa; San Diego, Calif; Mexico City, Mexico; and St Louis, Mo, 53 (82%) of 65 had antibodies to SREHP. In contrast, only one patient (2%) of 43 without acute invasive amebiasis had antibodies to SREHP. The predictive value of a positive test for anti-SREHP antibodies in the detection of acute invasive amebiasis was most marked when analyzed in the patients from Durban, where 11 (92%) of 12 patients who were seropositive for SREHP had acute invasive amebiasis vs 17 (65%) of 26 patients who had a positive serologic diagnosis as determined by agar gel diffusion. The use of a serologic test based on the recombinant SREHP fusion protein may be a useful adjunct to the diagnosis of acute invasive amebiasis in endemic regions.	S AFRICAN MRC,DIS TROP ENVIRONM RES INST,DURBAN,SOUTH AFRICA; NATL POLYTECH INST,CTR INVEST & ESTUDIOS AVANZADOS,MEXICO CITY 14,DF,MEXICO; WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOCHEM & BIOPHYS,ST LOUIS,MO 63110; UNIV CALIF SAN DIEGO,DEPT MED,SAN DIEGO,CA 92103; UNIV CALIF SAN DIEGO,DEPT PATHOL,SAN DIEGO,CA 92103	South African Medical Research Council; CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico; Washington University (WUSTL); Washington University (WUSTL); University of California System; University of California San Diego; University of California System; University of California San Diego	STANLEY, SL (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MED,BOX 8051,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.							GATHIRAM V, 1985, LANCET, V1, P719; JACKSON TFHG, 1985, LANCET, V1, P716; JACKSON TFHG, 1984, T ROY SOC TROP MED H, V78, P342, DOI 10.1016/0035-9203(84)90115-9; JUNIPER K, 1972, AM J TROP MED HYG, V21, P157, DOI 10.4269/ajtmh.1972.21.157; KRUPP IM, 1970, AM J TROP MED HYG, V19, P57, DOI 10.4269/ajtmh.1970.19.57; KRUPP IM, 1971, AM J TROP MED HYG, V20, P421, DOI 10.4269/ajtmh.1971.20.421; LOBEL HO, 1978, ANNU REV MICROBIOL, V32, P329, DOI 10.1146/annurev.mi.32.100178.001553; STANLEY SL, 1990, P NATL ACAD SCI USA, V87, P4976, DOI 10.1073/pnas.87.13.4976; TORIAN BE, 1989, J INFECT DIS, V159, P794, DOI 10.1093/infdis/159.4.794; Walsh J.A., 1988, P93	10	39	43	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					1984	1986		10.1001/jama.266.14.1984	http://dx.doi.org/10.1001/jama.266.14.1984			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH406	1895478				2022-12-01	WOS:A1991GH40600026
J	TRULOCK, EP; COOPER, JD; KAISER, LR; PASQUE, MK; ETTINGER, NA; DRESLER, CM				TRULOCK, EP; COOPER, JD; KAISER, LR; PASQUE, MK; ETTINGER, NA; DRESLER, CM			THE WASHINGTON-UNIVERSITY BARNES-HOSPITAL EXPERIENCE WITH LUNG TRANSPLANTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SINGLE; EMPHYSEMA; DISEASE	Objective. - To review our experience with lung transplantation, emphasizing recipient selection, choice of procedure, functional results, and outcome. Design. - Retrospective review of patients who received lung transplants at Barnes Hospital, St Louis, Mo, between July 1, 1988, and January 31, 1991. Setting. - Washington University School of Medicine, St Louis, Mo, and Barnes Hospital, a medical school and its affiliated referral hospital, respectively. Patients. - Sixty-nine lung transplant procedures were performed in 66 recipients. Patients with clinically and physiologically severe lung disease were selected according to predetermined guidelines. Underlying diseases in the recipients included chronic obstructive pulmonary disease, alpha-1-antitrypsin deficiency emphysema, cystic fibrosis, pulmonary fibrosis, primary pulmonary hypertension, Eisenmenger's syndrome associated with an atrial septal defect, bronchiectasis, eosinophilic granuloma, and lymphangiomyomatosis. Intervention. - Double-lung, bilateral sequential, and single-lung transplantations were performed. Eight patients underwenten bloc double-lung transplantations or a modification of this procedure with separate bronchial anastomoses. Thereafter, the bilateral sequential approach to replacement of both lungs was performed in 26 patients. Thirty-two patients underwent single-lung transplantations. Main Outcome Measures. - Pulmonary function tests, arterial blood gas levels, pulmonary artery pressure, pulmonary vascular resistance, and actuarial survival. Results. - Actuarial survival at 1 year for the 66 lung transplant recipients was 79%. Actuarial survival at 1 year was 82% for the bilateral lung transplant recipients and was 90% for the single-lung transplant recipients. In patients with either restrictive or obstructive lung disease, pulmonary function tests and arterial blood gas levels improved markedly after lung transplantation. In patients with primary pulmonary hypertension or Eisenmenger's syndrome, the pulmonary artery pressure decreased and the cardiac index increased into the normal range after single-lung transplantation. Conclusions. - In carefully selected patients with end-stage lung disease, single-lung and bilateral lung transplantations can significantly improve functional capacity, with promising early actuarial survival statistics after 1 year.	WASHINGTON UNIV, SCH MED, DIV CARDIOTHORAC SURG, ST LOUIS, MO 63110 USA	Washington University (WUSTL)	TRULOCK, EP (corresponding author), WASHINGTON UNIV, SCH MED, DIV RESP & CRIT CARE, GEN THORAC SURG SECT, BOX 8052, ST LOUIS, MO 63110 USA.		Kaiser, Larry/L-7940-2019					[Anonymous], 1988, JAMA, V259, P2258; BATES DV, 1970, NEW ENGL J MED, V282, P277, DOI 10.1056/NEJM197001292820511; COOPER JD, 1986, NEW ENGL J MED, V314, P1140; COOPER JD, 1989, AM REV RESPIR DIS, V139, P303, DOI 10.1164/ajrccm/139.2.303; COOPER JD, 1987, J THORAC CARDIOV SUR, V93, P173; EGAN TM, 1991, CHEST, V99, P867, DOI 10.1378/chest.99.4.867; ETTINGER NA, 1991, AM REV RESPIR DIS, V143, P1386, DOI 10.1164/ajrccm/143.6.1386; GROSSMAN RF, 1990, NEW ENGL J MED, V322, P727, DOI 10.1056/NEJM199003153221104; HENES G, 1991, Journal of the American College of Cardiology, V17, p372A; LEVINE SM, 1990, CHEST, V98, P1107, DOI 10.1378/chest.98.5.1107; LIMA O, 1981, J THORAC CARDIOV SUR, V82, P211; LIMA O, 1982, J THORAC CARDIOV SUR, V83, P418; MAL H, 1989, AM REV RESPIR DIS, V140, P797, DOI 10.1164/ajrccm/140.3.797; MIYOSHI S, 1990, CHEST, V97, P1130, DOI 10.1378/chest.97.5.1130; MORGAN E, 1982, J THORAC CARDIOV SUR, V84, P204; PASQUE MK, 1990, ANN THORAC SURG, V49, P785, DOI 10.1016/0003-4975(90)90023-Y; PATTERSON GA, 1988, ANN THORAC SURG, V45, P626, DOI 10.1016/S0003-4975(10)64763-7; STEVENS PM, 1970, NEW ENGL J MED, V282, P245, DOI 10.1056/NEJM197001292820504; THEODORE J, 1990, NEW ENGL J MED, V322, P772, DOI 10.1056/NEJM199003153221110; TRULOCK EP, 1989, CHEST, V96, P738, DOI 10.1378/chest.96.4.738; Veith F J, 1974, Vasc Surg, V8, P273; VEITH FJ, 1973, ANN SURG, V178, P463, DOI 10.1097/00000658-197310000-00009; Wildevuur C R, 1970, Ann Thorac Surg, V9, P489	23	67	70	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					1943	1946		10.1001/jama.266.14.1943	http://dx.doi.org/10.1001/jama.266.14.1943			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH406	1895470				2022-12-01	WOS:A1991GH40600018
J	TUTEUR, PG				TUTEUR, PG			THE RISK OF SIDESTREAM SMOKE TO PIPE SMOKERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							PASSIVE SMOKING; TOBACCO-SMOKE; LUNG-CANCER; COTININE; EXPOSURE; CHILDREN				TUTEUR, PG (corresponding author), WASHINGTON UNIV,SCH MED,ST LOUIS,MO 63110, USA.							DALAGER NA, 1986, CANCER RES, V46, P4808; DOLL R, 1978, J EPIDEMIOL COMMUN H, V32, P303, DOI 10.1136/jech.32.4.303; EVANS D, 1987, AM REV RESPIR DIS, V135, P567; GREENBERG RA, 1984, NEW ENGL J MED, V310, P1075, DOI 10.1056/NEJM198404263101703; MASI MA, 1988, AM REV RESPIR DIS, V138, P296, DOI 10.1164/ajrccm/138.2.296; MATSUKURA S, 1984, NEW ENGL J MED, V311, P828, DOI 10.1056/NEJM198409273111305; TAGER IB, 1983, NEW ENGL J MED, V309, P699, DOI 10.1056/NEJM198309223091204; TAGER IB, 1988, NEW ENGL J MED, V138, P296; WEISS ST, 1986, AM REV RESPIR DIS, V133, P1; 1982, DHHS PHS8250179 PUBL	10	2	2	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					2000	2000						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH406	1895482				2022-12-01	WOS:A1991GH40600031
J	YAZIGI, RA; ODEM, RR; POLAKOSKI, KL				YAZIGI, RA; ODEM, RR; POLAKOSKI, KL			DEMONSTRATION OF SPECIFIC BINDING OF COCAINE TO HUMAN SPERMATOZOA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							H-3 COCAINE; ASSOCIATION; RECEPTORS	Exposure of males to cocaine has been linked to abnormal development of their offspring. To investigate the possible role of sperm, this study examined the interaction of cocaine with human spermatozoa. Washed sperm were incubated with tritiated cocaine (6.7 nmol/L) with or without unlabeled cocaine (670-mu-mol/L), and the samples were filtered and the remaining radioactivity quantitated. The specific binding was optimal at 20 minutes and 23-degrees-C. Competition studies with tritiated cocaine (3.4 to 66.6 nmol/L) indicated the presence of approximately 3.6 x 10(3) binding sites per cell, with a high affinity receptor dissociation constant (K(d) = 12.6 nmol/L). Cocaine concentrations as high as 670-mu-mol/L had no detectable effect on either the motility or viability of the cells. These results support the hypothesis that the sperm may act as a vector to transport cocaine into an ovum. This novel mechanism could be involved in the abnormal development of offspring of cocaine-exposed males.	WASHINGTON UNIV,SCH MED,DEPT OBSTET & GYNECOL,ST LOUIS,MO 63110	Washington University (WUSTL)	YAZIGI, RA (corresponding author), TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT OBSTET & GYNECOL,3401 N BROAD ST,PHILADELPHIA,PA 19140, USA.							ABEL EL, 1987, ALCOHOL CLIN EXP RES, V11, P533, DOI 10.1111/j.1530-0277.1987.tb00168.x; ABEL EL, 1989, J ANDROL, V10, P17; AHMED MS, 1990, LIFE SCI, V46, P553, DOI 10.1016/0024-3205(90)90122-8; BOJA JW, 1989, EUR J PHARMACOL, V173, P215, DOI 10.1016/0014-2999(89)90524-4; BRACKEN MB, 1990, FERTIL STERIL, V53, P315; BRACKETT BG, 1971, P NATL ACAD SCI USA, V68, P353, DOI 10.1073/pnas.68.2.353; BRIGGS M, 1974, ACTA ENDOCRINOL-COP, V75, P785, DOI 10.1530/acta.0.0750785; CALLIGARO DO, 1987, J PHARMACOL EXP THER, V243, P61; CICERO TJ, 1985, ANAL BIOCHEM, V150, P67, DOI 10.1016/0003-2697(85)90441-5; ELMAGHRABI EA, 1988, LIFE SCI, V42, P1675, DOI 10.1016/0024-3205(88)90447-X; ERICSSON RJ, 1967, NATURE, V214, P403, DOI 10.1038/214403a0; FRIEDLER G, 1987, RES COMMUN SUBSTANCE, V8, P109; GERBER N, 1976, LIFE SCI, V19, P782; JATLOW P, 1988, YALE J BIOL MED, V61, P105; LITTLE RE, 1986, NEW ENGL J MED, V314, P1644, DOI 10.1056/NEJM198606193142516; MADRAS BK, 1989, J PHARMACOL EXP THER, V251, P131; MULE SJ, 1977, COCAINE OTHER STIMUL, P215; PAULSON JD, 1977, FERTIL STERIL, V28, P178; REITH MEA, 1980, LIFE SCI, V27, P1055, DOI 10.1016/0024-3205(80)90029-6; REITH MEA, 1980, J NEUROCHEM, V46, P309; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SWEET F, 1987, ENDOCR REV, V8, P154, DOI 10.1210/edrv-8-2-154; WOZNIAK DF, 1991, PSYCHOPHARMACOLOGY, V43, P74; Zaneweld LJD, 1977, TECHNIQUES HUMAN AND, P147	24	65	66	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					1956	1959		10.1001/jama.266.14.1956	http://dx.doi.org/10.1001/jama.266.14.1956			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GH406	1895473				2022-12-01	WOS:A1991GH40600021
J	BLACKWELL, CC; JAMES, VS; DAVIDSON, S; WYLD, R; BRETTLE, RP; ROBERTSON, RJ; WEIR, DM				BLACKWELL, CC; JAMES, VS; DAVIDSON, S; WYLD, R; BRETTLE, RP; ROBERTSON, RJ; WEIR, DM			SECRETOR STATUS AND HETEROSEXUAL TRANSMISSION OF HIV	BRITISH MEDICAL JOURNAL			English	Article									CITY HOSP EDINBURGH,INFECT DIS UNIT,EDINBURGH EH10 5SB,MIDLOTHIAN,SCOTLAND; MUIRHOUSE MED GRP,EDINBURGH,SCOTLAND		BLACKWELL, CC (corresponding author), UNIV EDINBURGH,SCH MED,DEPT MED MICROBIOL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLACKWELL C C, 1989, FEMS (Federation of European Microbiological Societies) Microbiology Immunology, V47, P341, DOI 10.1016/0378-1097(89)90256-5; BLACKWELL CC, 1989, P ROYAL COLLEGE PHYS, V19, P129; RAZA MW, 1991, BMJ-BRIT MED J, V303, P815, DOI 10.1136/bmj.303.6806.815; 1989, BMJ, V298, P411	4	16	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 5	1991	303	6806					825	826		10.1136/bmj.303.6806.825-a	http://dx.doi.org/10.1136/bmj.303.6806.825-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GH946	1932975	Green Published, Bronze			2022-12-01	WOS:A1991GH94600026
J	CRUICKSHANK, JK; COOPER, J; BURNETT, M; MACDUFF, J; DRUBRA, U				CRUICKSHANK, JK; COOPER, J; BURNETT, M; MACDUFF, J; DRUBRA, U			ETHNIC-DIFFERENCES IN FASTING PLASMA C-PEPTIDE AND INSULIN IN RELATION TO GLUCOSE-TOLERANCE AND BLOOD-PRESSURE	LANCET			English	Article							DEPENDENT DIABETES-MELLITUS; BETA-CELL; POPULATION; DISEASE; HYPERINSULINEMIA; BIMODALITY; PREVALENCE; RESISTANCE; DEFICIENCY; SECRETION	The frequency of non-insulin-dependent diabetes mellitus (NIDDM) and of high blood pressure (or hypertension) is higher in some ethnic groups than in others for reasons that remain unclear. To investigate the mechanisms leading to these ethnic differences, plasma C-peptide and insulin concentrations were measured after overnight fast and during an oral glucose tolerance test in subjects aged 45-74 years sampled from the practice lists of two north west London health centres. Ethnic group was defined by grandparental origin as Afro-Caribbean in 106, Gujerati Indian in 107, and white European in 101. The total age-adjusted prevalence of NIDDM was 29% in the Afro-Caribbean, 30% in the Gujerati, and 3% in the white groups, respectively. Fasting C-peptide and insulin concentrations increased from the subgroup with normal glucose tolerance, through impaired glucose tolerance, to new NIDDM, and were lower again in subjects with known NIDDM. The odds ratio for new NIDDM was 1.87 (95% confidence interval 1.26-2.77) per 1 SD increase in fasting C-peptide, which was the most powerful independent indicator of new NIDDM (p = 0.0005) and accounted for the effect of ethnic group. Fasting insulin had a similarly strong effect. There was no relation between any index of insulin secretion and blood pressure or hypertension. There were differences among the ethnic groups in the C-peptide response relative to the insulin response. These results suggest that factors determining insulin secretion and its hepatic clearance, possibly including dietary fat, are the main causes of ethnic variation in rates of new NIDDM.	NORTHWICK PK HOSP & CLIN RES CTR,DEPT MED,HARROW HA1 3UJ,MIDDX,ENGLAND; NORTHWICK PK HOSP & CLIN RES CTR,MRC,EPIDEMIOL & MED CARE UNIT,HARROW HA1 3UJ,MIDDX,ENGLAND; RADCLIFFE INFIRM,DIABET RES LABS,OXFORD OX2 6HE,ENGLAND	Imperial College London; Imperial College London; Radcliffe Infirmary; University of Oxford					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBANO JDM, 1972, ACTA ENDOCRINOL-COP, V70, P487, DOI 10.1530/acta.0.0700487; Alleyne S I, 1989, Bull Pan Am Health Organ, V23, P306; BECKLES GLA, 1986, LANCET, V1, P1298; Bennett P H, 1976, Recent Prog Horm Res, V32, P333; CAHILL GF, 1988, NEW ENGL J MED, V318, P1268, DOI 10.1056/NEJM198805123181909; CLARK A, 1988, DIABETES RES, V9, P155; CRUICKSHANK JK, 1990, DIABETIC MED S2, V7, P52; CRUICKSHANK JK, 1989, ETHNIC FACTORS HLTH, P33; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; Ferrannini E, 1989, J NEPHROL, V1, P3; HAFFNER SM, 1986, NEW ENGL J MED, V315, P220, DOI 10.1056/NEJM198607243150403; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; HUGHES LO, 1989, BRIT MED J, V299, P537, DOI 10.1136/bmj.299.6698.537; LILLIOJA S, 1988, NEW ENGL J MED, V318, P1217, DOI 10.1056/NEJM198805123181901; MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P; MILLER GJ, 1988, ATHEROSCLEROSIS, V70, P63, DOI 10.1016/0021-9150(88)90100-1; MODAN M, 1985, J CLIN INVEST, V75, P809, DOI 10.1172/JCI111776; ORAHILLY SP, 1986, LANCET, V2, P360; POLONSKY KS, 1984, DIABETES, V33, P486, DOI 10.2337/diabetes.33.5.486; POLONSKY KS, 1988, NEW ENGL J MED, V318, P1231, DOI 10.1056/NEJM198805123181903; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; ROSENTHAL M, 1985, J CHRON DIS, V38, P5, DOI 10.1016/0021-9681(85)90003-7; SAAD MF, 1989, LANCET, V1, P1356; STOUT RW, 1990, DIABETES CARE, V13, P631, DOI 10.2337/diacare.13.6.631; TEMPLE RC, 1989, LANCET, V1, P293, DOI 10.1016/S0140-6736(89)91306-8; THOMPSON R, 1990, CLIN SCI S22, V78, P29; VERMA NPS, 1986, BRIT MED J, V293, P423, DOI 10.1136/bmj.293.6544.423; WARD WK, 1984, J CLIN INVEST, V74, P1318, DOI 10.1172/JCI111542; WELBORN TA, 1969, DIABETOLOGIA, V5, P263, DOI 10.1007/BF01212096; ZIMMET P, 1978, DIABETES, V27, P793, DOI 10.2337/diabetes.27.8.793	30	130	130	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 5	1991	338	8771					842	847		10.1016/0140-6736(91)91501-K	http://dx.doi.org/10.1016/0140-6736(91)91501-K			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GH945	1681214				2022-12-01	WOS:A1991GH94500003
J	DEKEYSER, J; DEKLIPPEL, N; EBINGER, G				DEKEYSER, J; DEKLIPPEL, N; EBINGER, G			THROMBOCYTOSIS AND ISCHEMIC COMPLICATIONS IN GIANT-CELL ARTERITIS	BRITISH MEDICAL JOURNAL			English	Article							TEMPORAL ARTERITIS; MANIFESTATIONS				DEKEYSER, J (corresponding author), VRIJE UNIV BRUSSELS,ACAD ZIEKENHUIS,DEPT NEUROL,B-1090 BRUSSELS,BELGIUM.		De Keyser, Jacques/D-3725-2013	De Keyser, Jacques/0000-0002-3394-7757				BENGTSSON BA, 1982, ACTA MED SCAND S, V658, P1; CALAMIA KT, 1980, CLIN RHEUM DIS, V6, P389; GOODMAN BW, 1979, AM J MED, V67, P839, DOI 10.1016/0002-9343(79)90744-7; REICH KA, 1990, AM J MED, V89, P67, DOI 10.1016/0002-9343(90)90100-R; SELROOS O, 1973, ACTA MED SCAND, V193, P431	5	34	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 5	1991	303	6806					825	825		10.1136/bmj.303.6806.825	http://dx.doi.org/10.1136/bmj.303.6806.825			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH946	1932974	Green Published, Bronze			2022-12-01	WOS:A1991GH94600025
J	GANGAR, KF; VYAS, S; WHITEHEAD, M; CROOK, D; MEIRE, H; CAMPBELL, S				GANGAR, KF; VYAS, S; WHITEHEAD, M; CROOK, D; MEIRE, H; CAMPBELL, S			PULSATILITY INDEX IN INTERNAL CAROTID-ARTERY IN RELATION TO TRANSDERMAL ESTRADIOL AND TIME SINCE MENOPAUSE	LANCET			English	Article							CORONARY HEART-DISEASE; BLOOD-FLOW; ESTROGEN; WOMEN; MORTALITY; THERAPY; DOPPLER; FETAL; RISK	The protection afforded by postmenopausal oestrogen replacement against cardiovascular disease is not fully explained by changes in plasma lipoproteins. To investigate the effect of oestrogen on arterial tone, doppler ultrasound was used to assess blood flow characteristics in the internal carotid arteries of 12 postmenopausal women. Patients were studied pretreatment and at weeks 4, 6, 9, and 22 of therapy with transdermal oestradiol 50-mu-g/day. The pulsatility index (PI), which is thought to represent impedance to blood flow distal to the point of sampling, was measured from the flow velocity waveform. 11 of the 12 patients were within 5 years of menopause; 1 was 8 years postmenopausal but had experienced bleeding 4 years after menopause. In the 11 women there was a highly significant correlation (r = 0.77) between time since menopause and baseline PI. A similar correlation (r = 0.74) was observed when the episode of postmenopausal bleeding was redefined as time of menopause in the twelfth patient. For all 12 patients, there was a significant negative correlation (r = -0.70) between change in PI during transdermal oestradiol therapy and mean of baseline plus week 22 PI value. For all correlations between changes in PI and time since menopause, the longer the time the greater the fall in PI. These results, and previous observations of a reduction in uterine artery PI with oestradiol treatment, suggest that oestrogen has a generalised effect on the arterial system.	UNIV LONDON KINGS COLL, SCH MED & DENT, MENOPAUSE CLIN, ACAD DEPT OBSTET & GYNAECOL, LONDON WC2R 2LS, ENGLAND; WYNN INST METAB RES, LONDON, ENGLAND; UNIV LONDON KINGS COLL HOSP, DEPT RADIOL, LONDON SE5 8RX, ENGLAND	University of London; King's College London; Imperial College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London				Crook, David/0000-0002-9587-3730				ANDERSON SG, 1977, AM J OBSTET GYNECOL, V127, P138, DOI 10.1016/S0002-9378(16)33239-2; BOURNE T, 1990, LANCET, V335, P1470, DOI 10.1016/0140-6736(90)91505-5; BUSH TL, 1983, JAMA-J AM MED ASSOC, V249, P903, DOI 10.1001/jama.249.7.903; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; CLARKSON TB, 1990, OBSTET GYNECOL, V75, P217; COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; DOWSETT M, 1987, CANCER RES, V47, P1957; FARISH E, 1990, BRIT J OBSTET GYNAEC, V97, P78, DOI 10.1111/j.1471-0528.1990.tb01721.x; GILL JS, 1985, LANCET, V1, P567; GINSBURG J, 1989, BRIT MED J, V298, P1488, DOI 10.1136/bmj.298.6686.1488; GORDON T, 1978, ANN INTERN MED, V89, P157, DOI 10.7326/0003-4819-89-2-157; Gosling RG., 1975, ARTERIES VEINS, P61; GRIFFIN D, 1983, CLIN OBSTET GYNAECOL, V10, P565; HENDERSON BE, 1988, AM J OBSTET GYNECOL, V159, P312, DOI 10.1016/S0002-9378(88)80074-7; MATTA WHM, 1988, FERTIL STERIL, V49, P1083; MATTHEWS KA, 1989, NEW ENGL J MED, V321, P641, DOI 10.1056/NEJM198909073211004; MEIRE HB, 1990, CLIN RADIOL, V41, P223, DOI 10.1016/S0009-9260(05)81651-4; MEIRE HB, 1983, RECENT ADV RADIOLOGY, P63; OLDHAM PD, 1968, MEASUREMENT MED INTE, P148; PADWICK ML, 1988, MENOPAUSE, P227; PAGANINIHILL A, 1988, BMJ-BRIT MED J, V297, P519, DOI 10.1136/bmj.297.6647.519; SARREL P, 1989, CIRCULATION FEMALE C, P117; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; VYAS S, 1990, BRIT J OBSTET GYNAEC, V97, P797, DOI 10.1111/j.1471-0528.1990.tb02573.x; VYAS S, 1989, AM J OBSTET GYNECOL, V161, P168, DOI 10.1016/0002-9378(89)90257-3; WAHL P, 1983, NEW ENGL J MED, V308, P862, DOI 10.1056/NEJM198304143081502; WOLINSKY H, 1972, CIRC RES, V30, P341, DOI 10.1161/01.RES.30.3.341; 1979, DHEW PHS7955071 PUBL	28	374	375	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 5	1991	338	8771					839	842						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH945	1681213				2022-12-01	WOS:A1991GH94500002
J	HALPIN, SFS; YEOMAN, L; DUNDAS, DD				HALPIN, SFS; YEOMAN, L; DUNDAS, DD			RADIOGRAPHIC EXAMINATION OF THE LUMBAR SPINE IN A COMMUNITY-HOSPITAL - AN AUDIT OF CURRENT PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							DIAGNOSTIC-RADIOLOGY; ROYAL-COLLEGE; GUIDELINES	Objective - To assess general practitioners' decisions to request lumbar spine radiographs according to the guidelines of the Royal College of Radiologists. Design - Prospective questionnaire survey of outpatients attending for lumbar spine radiography. Setting - London community hospital. Subjects - 100 consecutive adult outpatients attending for lumbar spine radiography at their general practitioner's request. Main outcome measures - Patient's history and clinical signs; radiological diagnosis; change in management of patients with significant radiological abnormality in response to the radiologist's report. Results - 60 patients were aged between 18 and 45, 27 (45%) of whom were women. Five patients were fully examined by their doctor before radiographs were requested, 76 were partially examined, and 19 were not examined. In 37 patients the examinations showed radiologically normal findings; 30 had radiologically significant disc or degenerative disease. Pain score and radiological diagnosis was not correlated (6.43 (range 1-10) for patients with significant disease v 6.14 (range 1-10) for those without, p > 0.05). There were no cases of malignancy or infection. One patient with radiologically significant disease was referred to a hospital specialist, and the management of only two such patients was altered by the report. 52 of the examinations should not have been requested if the guidelines had been strictly applied. Conclusions - There is a need to inform doctors of the efficacy of radiological examinations. An awareness of the college's guidelines among general practitioners should be actively promoted by radiologists.	BOLINGBROKE HOSP,DEPT RADIOL,LONDON SW11,ENGLAND									BUTT WP, 1989, CLIN RADIOL, V40, P6, DOI 10.1016/S0009-9260(89)80004-2; Edelstyn G A, 1967, Clin Radiol, V18, P158, DOI 10.1016/S0009-9260(67)80010-2; FOWKES FGR, 1987, CLIN RADIOL, V38, P45, DOI 10.1016/S0009-9260(87)80399-9; FOWKES FGR, 1984, LANCET, V2, P795; Her Majesty's Stationery Office, 1985, IONISING RAD REGULAT; KELEN GD, 1986, ANN EMERG MED, V15, P245, DOI 10.1016/S0196-0644(86)80556-X; NACHEMSON A, 1976, LUMBAR SPINE BACK PA, P355; PEARSON R, 1989, BRIT MED J, V299, P1175, DOI 10.1136/bmj.299.6709.1175; QUINET RJ, 1979, SEMIN ARTHRITIS RHEU, V8, P261, DOI 10.1016/0049-0172(79)90005-2; ROBERTS CJ, 1984, J ROY COLL PHYS LOND, V18, P62; ROBERTS CJ, 1981, LANCET, V2, P791; ROBERTS CJ, 1988, CLIN RADIOL, V39, P3, DOI 10.1016/S0009-9260(88)80325-8; RYAN M, 1991, RES MED PRACTICE VAR; WADDELL G, 1982, BRIT J HOSP MED, V28, P187; 1989, NRPBR227; 1990, PATIENT DOSE REDUCTI; 1987, NATIONAL RADIOLOGI S, V86; 1986, NRPBR200; 1990, MAKING BEST IMAGING; 1989, LIVING RAD; 1989, MAKING BEST USE DEP	21	40	40	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 5	1991	303	6806					813	815		10.1136/bmj.303.6806.813	http://dx.doi.org/10.1136/bmj.303.6806.813			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH946	1932970	Green Published, Bronze			2022-12-01	WOS:A1991GH94600020
J	MACINTYRE, S; SOOMAN, A				MACINTYRE, S; SOOMAN, A			NON-PATERNITY AND PRENATAL GENETIC SCREENING	LANCET			English	Editorial Material							CYSTIC-FIBROSIS GENE				MACINTYRE, S (corresponding author), MRC,MED SOCIOL UNIT,6 LILYBANK GARDENS,GLASGOW G12 8QQ,SCOTLAND.		Ellaway, Anne/A-3065-2009; Macintyre, Sally/P-6246-2014					ASHTON GC, 1980, AM J HUM GENET, V32, P601; BELLIS MA, 1990, ANIM BEHAV, V40, P997, DOI 10.1016/S0003-3472(05)81008-5; EDWARDS J H, 1957, Br J Prev Soc Med, V11, P79; EMERY AEH, 1983, ELEMENTS MED GENETIC; GOODFELLOW PN, 1989, NATURE, V341, P102, DOI 10.1038/341102a0; Johnstone JM, 1954, BRIT J PREV SOC MED, V8, P117; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; SALMON D, 1980, AM J HUM GENET, V32, P432; SCHACHT LE, 1963, 2ND P INT C HUM GEN, P894; STEWART AD, 1989, NATURE, V341, P696, DOI 10.1038/341696b0; WILFOND BS, 1990, JAMA-J AM MED ASSOC, V263, P2777, DOI 10.1001/jama.263.20.2777; WOLSTENHOLME GEW, 1973, CIBA FDN S LOND DEC, P66	12	85	87	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 5	1991	338	8771					869	871		10.1016/0140-6736(91)91513-T	http://dx.doi.org/10.1016/0140-6736(91)91513-T			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH945	1681226				2022-12-01	WOS:A1991GH94500015
J	MEADE, TW; COOPER, J; MILLER, GJ; HOWARTH, DJ; STIRLING, Y				MEADE, TW; COOPER, J; MILLER, GJ; HOWARTH, DJ; STIRLING, Y			ANTITHROMBIN-III AND ARTERIAL-DISEASE	LANCET			English	Note							HEMOSTATIC VARIABLES	Cross-sectional studies suggest that both low and high antithrombin III levels are associated with the risk of arterial disease, principally ischaemic heart disease (IHD). The prospective relation between antithrombin III and subsequent death from arterial disease has been investigated in 893 men in the Northwick Park Heart Study. Antithrombin III levels were directly correlated with high rather than low levels of factor VII activity and of plasma fibrinogen. There were more deaths from arterial disease in the low and high thirds of the antithrombin III distribution than in the middle third.			MEADE, TW (corresponding author), NORTHWICK PK HOSP & CLIN RES CTR,MRC,EPIDEMIOL & MED CARE UNIT,WATFORD RD,HARROW HA1 3UJ,MIDDX,ENGLAND.							BANERJEE RN, 1974, THROMB DIATH HAEMOST, V31, P339, DOI 10.1055/s-0038-1649168; BROZE GJ, 1980, J BIOL CHEM, V255, P1242; FULLER JH, 1979, BMJ-BRIT MED J, V2, P964, DOI 10.1136/bmj.2.6196.964; HAINES AP, 1980, THROMB RES, V19, P139, DOI 10.1016/0049-3848(80)90413-2; INNERFIELD I, 1976, AM J CLIN PATHOL, V65, P64; JORDAN RE, 1982, J BIOL CHEM, V257, P400; MEADE TW, 1990, BRIT J HAEMATOL, V74, P77, DOI 10.1111/j.1365-2141.1990.tb02541.x; MEADE TW, 1977, BRIT MED BULL, V33, P283, DOI 10.1093/oxfordjournals.bmb.a071448; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MEADE TW, 1987, THROMB DIATH HAEMO, P37; MEADE TW, 1987, HAEMOSTASIS THROMBOS, P697; MEILAHN E, 1988, AM J EPIDEMIOL, V128, P908; OBRIEN JR, 1975, THROMB DIATH HAEMOST, V34, P483, DOI 10.1055/s-0038-1651407; ROSENBERG RD, 1984, REV HAEMATOLOGY; YUE RH, 1976, THROMB HAEMOSTASIS, V35, P598, DOI 10.1055/s-0038-1647958	15	57	57	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 5	1991	338	8771					850	851		10.1016/0140-6736(91)91503-M	http://dx.doi.org/10.1016/0140-6736(91)91503-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH945	1681216				2022-12-01	WOS:A1991GH94500005
J	PATERSON, CM; SAUNDERS, NJS				PATERSON, CM; SAUNDERS, NJS			MODE OF DELIVERY AFTER ONE CESAREAN-SECTION - AUDIT OF CURRENT PRACTICE IN A HEALTH REGION	BRITISH MEDICAL JOURNAL			English	Article							CESAREAN-SECTION; VAGINAL DELIVERY; BIRTH	Objective - To audit the subsequent obstetric management of women who had had one previous baby delivered by caesarean section. Design - Retrospective analysis of a regional obstetric database. Setting - Data derived from the 17 obstetric units in North West Thames region. Subjects - 1059 women who delivered a singleton fetus of at least 37 weeks' gestation with a cephalic presentation in 1988 who had a history of one previous caesarean section and no other deliveries. Main outcome measures - Mode of delivery, postnatal morbidity, and duration of hospital stay. Results - 395 (37%) women were delivered by elective repeat caesarean section and 664 (63%) were allowed a trial of labour. Maternal height and birth weight of the previous infant differed significantly between those who were and those who were not allowed to labour. 471 (71%) of those allowed to labour achieved a vaginal delivery. In individual units there was no significant correlation between the proportion of patients allowed to labour and the rate of the successful trial of labour. There was a trend towards greater success rates in units that allowed a longer duration of labour (p < 0.05) and units with greater use of oxytocin for augmentation of labour (not significant). Both elective and intrapartum caesarean section was associated with a significantly higher rate of postnatal infection than vaginal delivery (14.7% and 16.0% v 3.4%). Conclusions - In patients with a history of caesarean section there is no evidence that the likelihood of successful vaginal delivery after trial of labour is modified by the proportion of such patients allowed the option of attempted vaginal delivery. Until selection criteria of adequate prognostic value can be identified a more liberal approach to allowing women a trial of labour seems justified.			PATERSON, CM (corresponding author), ST MARYS HOSP,IMPERIAL COLL SCI TECHNOL & MED,SCH MED,LONDON W2 1PG,ENGLAND.							DUFF P, 1988, OBSTET GYNECOL, V71, P380; EVRARD JR, 1977, OBSTET GYNECOL, V50, P594; FLAMM BL, 1989, OBSTET GYNECOL, V74, P694; GARDNER MJ, 1989, CONFIDENCE INTERVAL; LAVIN JP, 1982, OBSTET GYNECOL, V59, P135; MEEHAN FP, 1988, EUR J OBSTET GYN R B, V31, P109; MOLLOY BG, 1987, BRIT MED J, V294, P1645, DOI 10.1136/bmj.294.6588.1645; PHELAN JP, 1987, AM J OBSTET GYNECOL, V157, P1510, DOI 10.1016/S0002-9378(87)80252-1; WHITESIDE DC, 1983, J REPROD MED, V28, P785; [No title captured]	10	26	26	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 5	1991	303	6806					818	821		10.1136/bmj.303.6806.818	http://dx.doi.org/10.1136/bmj.303.6806.818			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH946	1932972	Bronze, Green Published			2022-12-01	WOS:A1991GH94600022
J	PIACQUADIO, K; HOLLINGSWORTH, DR; MURPHY, H				PIACQUADIO, K; HOLLINGSWORTH, DR; MURPHY, H			EFFECTS OF INUTERO EXPOSURE TO ORAL HYPOGLYCEMIC DRUGS	LANCET			English	Article							DIABETIC MOTHERS; MALFORMATIONS; INFANTS; PREGNANCY	The observation that several Mexican-American women were taking oral hypoglycaemic agents while pregnant led to a study to confirm reports of associations between these agents and congenital abnormalities. 20 non-insulin-dependent (NIDDM) pregnant diabetic women with exposure to oral hypoglycaemic drugs during embryogenesis and 40 pregnant NIDDM women matched for age, race, parity, weight, and glycaemic control but not exposed to oral hypoglycaemic drugs were followed up. 10 infants (50%) in the exposed group had congenital malformations, compared with only 6 (15%) in the control group (p < 0.002). 5 (25%) infants in the exposed group had ear malformations, anomalies not commonly described in diabetic embryopathy. Hyperbilirubinemia (p < 0.04), polycythaemia, and hyperviscosity requiring partial exchange transfusions (p < 0.03) were commoner among babies in the exposed than in the control group. 3 babies in the exposed group but none in the comparison group had severe prolonged neonatal hypoglycaemia lasting 2, 4, and 7 days; 2 of the 3 had been exposed for 22 and 28 weeks during gestation, whereas the third had been exposed throughout the first trimester. Although exposure to oral hypoglycaemic drugs during fetal life seems to be associated with congenital malformations and neonatal hypoglycaemia, a large, prospective study is needed to exclude the confounding effect of maternal metabolic derangement secondary to diabetes.	UNIV CALIF SAN DIEGO,DEPT REPROD MED & MED 0802,LA JOLLA,CA 92093; USN HOSP,DEPT OBSTET & GYNECOL,SAN DIEGO,CA 92134	University of California System; University of California San Diego; United States Department of Defense; United States Navy			Brugnara, Carlo/A-8041-2010	Brugnara, Carlo/0000-0001-8192-8713				ADAM PAJ, 1968, PEDIATRICS, V42, P819; CALDERA R, 1970, Annales de Pediatrie (Paris), V17, P432; CAMPBELL GD, 1961, LANCET, V1, P891; Chung C S, 1975, Birth Defects Orig Artic Ser, V11, P1; COETZEE EJ, 1988, CONTROVERSIES DIABET, P56; DEMEYER R, 1958, SOC BELGE ENDOCRINOL, V19, P167; DEROT M, 1962, B MEM SOC MED HOP P, V113, P426; DOLGER H, 1962, DIABETES, V11, P97; FERNER RE, 1989, Q J MED, V73, P987; GHANEM MH, 1960, ALEXANDRIA MED J, V6, P14; GREENE MF, 1989, TERATOLOGY, V39, P225, DOI 10.1002/tera.1420390303; GRIX A, 1982, BIRTH DEFECTS-ORIG, V18, P55; JACKSON WPU, 1962, DIABETES, V11, P98; JOHNSON JP, 1982, AM J MED GENET, V13, P125, DOI 10.1002/ajmg.1320130204; KEMBALL ML, 1970, ARCH DIS CHILD, V45, P696, DOI 10.1136/adc.45.243.696; LARSSON Y, 1960, LANCET, V2, P1424; LAZAROW A, 1962, DIABETES, V11, P103; MALINS JM, 1964, BRIT MED J, V2, P187, DOI 10.1136/bmj.2.5402.187; MILLER DI, 1962, DIABETES, V11, P93; MILLS JL, 1979, DIABETES, V28, P292, DOI 10.2337/diabetes.28.4.292; MILLS JL, 1982, TERATOLOGY, V25, P385, DOI 10.1002/tera.1420250316; MOORE KL, 1973, DEV HUMAN CLIN ORIEN, P346; MOSS J M, 1965, Med Ann Dist Columbia, V34, P253; SCHIFF D, 1970, J PEDIATR-US, V77, P457, DOI 10.1016/S0022-3476(70)80015-4; STOWERS JM, 1975, CARBOHYD METABOL, P205; SUTHERLAND HW, 1973, BMJ-BRIT MED J, V3, P9, DOI 10.1136/bmj.3.5870.9; TUCHMANNDUPLESS.H, 1975, DRUG EFFECTS FETUS S, P198; Wilson JG, 1973, ENV BIRTH DEFECTS; ZUCKER P, 1968, PEDIATRICS, V42, P824	29	85	87	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 5	1991	338	8771					866	869		10.1016/0140-6736(91)91512-S	http://dx.doi.org/10.1016/0140-6736(91)91512-S			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH945	1681225				2022-12-01	WOS:A1991GH94500014
J	RAZA, MW; BLACKWELL, CC; MOLYNEAUX, P; JAMES, VS; OGILVIE, MM; INGLIS, JM; WEIR, DM				RAZA, MW; BLACKWELL, CC; MOLYNEAUX, P; JAMES, VS; OGILVIE, MM; INGLIS, JM; WEIR, DM			ASSOCIATION BETWEEN SECRETOR STATUS AND RESPIRATORY VIRAL ILLNESS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ABO BLOOD-GROUP; NEISSERIA-MENINGITIDIS; DIABETES-MELLITUS; GROUP ANTIGENS; ORAL CARRIAGE; INFECTION; SUSCEPTIBILITY; ETIOLOGY; WOMEN	Objective - To determine whether non-secretion of blood group antigens is associated with respiratory virus diseases. Design - Study of secretor status in patients with respiratory virus diseases determined by an enzyme linked immunosorbent assay (ELISA) developed to identify Lewis (Le) blood group antigen phenotypes (Le(a) non-secretor; Le(b) secretor). Subjects - Patients aged 1 month to 90 years in hospital with respiratory virus diseases (584 nasal specimens). Main outcome measures - Criteria for validation of ELISA (congruence between results on ELISA testing of 1155 saliva samples from a previous study and previously established results on haemagglutination inhibition (HAI) testing, proportions of Le(a), Le(b), and Le- phenotypes in 872 samples of nasal washings from a previous study compared with the normal population). Secretor status of patients determined by ELISA and viruses isolated. Results - Agreement between HAI and ELISA for 1155 saliva samples was 97%. Lewis antigens were detected by ELISA in 854 (97.9%) of nasal washings (Le(a) 233 (26.7%), Le(b) 621 (71.2%), and Le- 18 (2.1%)) in proportions predicted for a northern European population. Secretors were significantly overrepresented among patients from whom influenza viruses A and B (55/64, 86%; p < 0.025), rhinoviruses (63/72, 88%; p < 0.01), respiratory syncytial virus (97/109, 89%; p < 0.0005), and echo-viruses (44/44, p < 0.0005) had been isolated compared with the distribution of secretors in the local population. Conclusion - Secretion of blood group antigens is associated with respiratory virus diseases.	UNIV EDINBURGH, SCH MED, DEPT MED MICROBIOL, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND; CITY HOSP EDINBURGH, EDINBURGH EH10 5SB, MIDLOTHIAN, SCOTLAND	University of Edinburgh								ANDERSEN J, 1960, DIABETES, V9, P20, DOI 10.2337/diab.9.1.20; BLACKWELL CC, 1990, EPIDEMIOL INFECT, V104, P203, DOI 10.1017/S0950268800059367; BLACKWELL CC, 1987, BRIT MED J, V295, P1024, DOI 10.1136/bmj.295.6605.1024; BLACKWELL CC, 1989, EPIDEMIOL INFECT, V102, P1, DOI 10.1017/S0950268800029629; BLACKWELL CC, 1986, LANCET, V2, P284; BLACKWELL CC, 1987, J CLIN LAB IMMUNOL, V22, P133; BLACKWELL CC, 1986, LANCET, V2, P687; BLACKWELL CC, 1989, DIABETES RES CLIN EX, V12, P101; BLACKWELL CC, 1989, P ROYAL COLLEGE PHYS, V19, P129; BURFORDMASON AP, 1988, J MED VET MYCOL, V26, P49; CHAUDHURI A, 1978, T ROY SOC TROP MED H, V72, P664, DOI 10.1016/0035-9203(78)90031-7; COLLIER A, 1988, BRIT MED J, V296, P1162, DOI 10.1136/bmj.296.6630.1162; HAVERKORN MJ, 1969, AM J HUM GENET, V21, P360; KINANE DF, 1982, BRIT MED J, V285, P7, DOI 10.1136/bmj.285.6334.7; MACKENZIE JS, 1978, J HYG-CAMBRIDGE, V80, P21, DOI 10.1017/S0022172400053365; MAY S J, 1989, FEMS (Federation of European Microbiological Societies) Microbiology Immunology, V47, P407, DOI 10.1016/0378-1097(89)90266-8; MCDONALD JC, 1962, BRIT MED J, P89, DOI 10.1136/bmj.2.5297.89; MOLLISON PL, 1979, BLOOD TRANSFUSION CL, P414; Mourant AE., 1976, DISTRIBUTION HUMAN B; POTTER CW, 1969, J HYG-CAMB, V67, P67, DOI 10.1017/S0022172400041437; RAHAT A, 1990, VOX SANG, V59, P101, DOI 10.1111/j.1423-0410.1990.tb05019.x; SHINEBAUM R, 1987, BRIT MED J, V294, P208, DOI 10.1136/bmj.294.6566.208; THOM SM, 1989, FEMS MICROBIOL IMMUN, V7, P401	23	63	65	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 5	1991	303	6806					815	818		10.1136/bmj.303.6806.815	http://dx.doi.org/10.1136/bmj.303.6806.815			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH946	1932971	Green Published, Bronze			2022-12-01	WOS:A1991GH94600021
J	VANDERMAST, RC; FEKKES, D; MOLEMAN, P; PEPPLINKHUIZEN, L				VANDERMAST, RC; FEKKES, D; MOLEMAN, P; PEPPLINKHUIZEN, L			IS POSTOPERATIVE DELIRIUM RELATED TO REDUCED PLASMA TRYPTOPHAN	LANCET			English	Note								The cause of postoperative delirium is unknown. In 7 patients with postcardiotomy delirium (6 men, 1 woman; mean age 67 years), we observed a plasma concentration of tryptophan and a plasma tryptophan ratio significantly lower than in 8 non-delirious postoperative control patients. We suggest that the mental symptoms of postcardiotomy delirium are the consequence of a reduced cerebral tryptophan availability due to a catabolic state.			VANDERMAST, RC (corresponding author), DIJKZIGT ACAD HOSP, DEPT PSYCHIAT, DR MOLEWATERPLEIN 40, 3015 GD ROTTERDAM, NETHERLANDS.							BRUINVELS J, 1984, J PSYCHIAT RES, V18, P307, DOI 10.1016/0022-3956(84)90021-9; FERNSTROM JD, 1972, SCIENCE, V178, P414, DOI 10.1126/science.178.4059.414; FRANCIS J, 1990, JAMA-J AM MED ASSOC, V263, P1097, DOI 10.1001/jama.263.8.1097; LEHMANN J, 1982, ACTA PSYCHIAT SCAND, V65, P1; Lipowski, 1990, DELIRIUM ACUTE CONFU; ROGERS MP, 1989, INT J PSYCHIAT MED, V19, P109; SKAUG OE, 1989, TIDSSKRIFT NORSKE LA, V104, P97; SMITH LW, 1989, AM J PSYCHIAT, V146, P452	8	47	49	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 5	1991	338	8771					851	852		10.1016/0140-6736(91)91504-N	http://dx.doi.org/10.1016/0140-6736(91)91504-N			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH945	1681217				2022-12-01	WOS:A1991GH94500006
J	ARUFFO, A; KOLANUS, W; WALZ, G; FREDMAN, P; SEED, B				ARUFFO, A; KOLANUS, W; WALZ, G; FREDMAN, P; SEED, B			CD62/P-SELECTIN RECOGNITION OF MYELOID AND TUMOR-CELL SULFATIDES	CELL			English	Article							GRANULE MEMBRANE-PROTEIN; ENDOTHELIAL VONWILLEBRAND-FACTOR; WEIBEL-PALADE BODIES; ACTIVATED PLATELETS; ADHESIVE INTERACTION; MONOCLONAL-ANTIBODY; NEUTROPHIL ADHESION; SEQUENCE HOMOLOGY; HOMING RECEPTOR; SIALYL-LEX	CD62, also called PADGEM protein, GMP-140, or P-selectin, is a granule membrane protein of endothelial cells and platelets that is mobilized to the plasma membrane following exposure to mediators such as thrombin, histamine, complement components, or peroxides. Data presented to date suggest that one ligand of CD62 includes CD15 (Lewis x determinant) and sialic acid. We show here that sulfatides, heterogeneous 3-sulfated galactosyl ceramides, are an apparently unrelated ligand of CD62. Sulfatides are expressed on the plasma membrane of, and are excreted by, granulocytes, and constitute the principal ligand for CD62 on the plasma membrane of some tumor cells. CD62 binds to sulfatides adsorbed to plastic as avidly as it binds to myeloid or tumor cells. We find that granulocytes excrete sulfatides at a rate predicted to allow them to be rapidly released from CD62 once they have exited the bloodstream.	MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; GOTHENBURG UNIV,DEPT MED BIOCHEM,S-40033 GOTHENBURG,SWEDEN; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121	Harvard University; Massachusetts General Hospital; University of Gothenburg; Bristol-Myers Squibb	ARUFFO, A (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115, USA.				NIAID NIH HHS [AI27849] Funding Source: Medline; NIDDK NIH HHS [DK43031] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027849, R37AI027849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043031] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BONFANTI R, 1989, BLOOD, V73, P1109; CORRAL L, 1990, BIOCHEM BIOPH RES CO, V172, P1349, DOI 10.1016/0006-291X(90)91598-M; DIETRICH CP, 1988, FASEB J, V2, P56, DOI 10.1096/fasebj.2.1.2961646; FREDMAN P, 1988, BIOCHEM J, V251, P17, DOI 10.1042/bj2510017; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GAMBLE JR, 1990, SCIENCE, V249, P414; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; Hakomori S I, 1974, Methods Enzymol, V32, P345; HAMBURGER SA, 1990, BLOOD, V75, P550; HATTORI R, 1989, J BIOL CHEM, V264, P9053; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HIRAIWA N, 1990, CANCER RES, V50, P2917; HOLT GD, 1989, J BIOL CHEM, V264, P12138; HOLT GD, 1990, J BIOL CHEM, V265, P2852; HSULIN SC, 1984, J BIOL CHEM, V259, P9121; IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225; ISHIZUKA I, 1978, J BIOL CHEM, V253, P898; KRIVAN HC, 1989, J BIOL CHEM, V264, P9283; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MAGNANI JL, 1982, METHOD ENZYMOL, V83, P235; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; PATEL KD, 1991, J CELL BIOL, V112, P749, DOI 10.1083/jcb.112.4.749; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; PRENCE EM, 1986, BIOCHEM J, V237, P655, DOI 10.1042/bj2370655; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; ROBERTS DD, 1985, J BIOL CHEM, V260, P9405; ROBERTS DD, 1985, P NATL ACAD SCI USA, V82, P1306, DOI 10.1073/pnas.82.5.1306; ROBERTS DD, 1986, J BIOL CHEM, V261, P3306; SARLIEVE LL, 1984, BIOCHIM BIOPHYS ACTA, V795, P166, DOI 10.1016/0005-2760(84)90118-8; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SKINNER MP, 1991, J BIOL CHEM, V266, P5371; SKINNER MP, 1989, BIOCHEM BIOPH RES CO, V164, P1373, DOI 10.1016/0006-291X(89)91821-4; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; STOOLMAN LM, 1983, J CELL BIOL, V96, P722, DOI 10.1083/jcb.96.3.722; STOOLMAN LM, 1984, J CELL BIOL, V99, P1535, DOI 10.1083/jcb.99.4.1535; TUSZYNSKI GP, 1987, J BIOL CHEM, V262, P9718; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WATSON SR, 1990, J CELL BIOL, V110, P2221, DOI 10.1083/jcb.110.6.2221	44	295	320	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1991	67	1					35	44		10.1016/0092-8674(91)90570-O	http://dx.doi.org/10.1016/0092-8674(91)90570-O			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1717159				2022-12-01	WOS:A1991GJ32000005
J	BUERSTEDDE, JM; TAKEDA, S				BUERSTEDDE, JM; TAKEDA, S			INCREASED RATIO OF TARGETED TO RANDOM INTEGRATION AFTER TRANSFECTION OF CHICKEN B-CELL LINES	CELL			English	Article							LIGHT-CHAIN GENE; BETA-ACTIN GENE; HOMOLOGOUS RECOMBINATION; MAMMALIAN-CELLS; OVALBUMIN GENE; NUCLEOTIDE-SEQUENCE; DNA-SEQUENCES; STEM-CELLS; EXPRESSION; REGION	Constructs of four different genetic loci were transfected into the avian leukosis virus-induced chicken B cell line DT40, which continues diversification of its rearranged light chain immunoglobulin gene by gene conversion. Analysis of stable transfectants revealed an unexpectedly high frequency of targeted integration into the homologous gene loci of DT40. Transcriptional activity of the target gene locus is not required, since a construct of the untranscribed ovalbumin gene also integrated predominantly by homologous recombination. A construct derived from the beta-actin locus was transfected into other chicken cell lines to determine the cell type specificity of the phenomenon. Targeted integration still occurred at high frequency in two other B cell lines that do not have the gene conversion activity. However, the ratios of targeted to random integration were reduced by at least one order of magnitude in three non-B cell lines.			BUERSTEDDE, JM (corresponding author), BASEL INST IMMUNOL, GRENZACHERSTR 487, CH-4005 BASEL, SWITZERLAND.			Takeda, Shunichi/0000-0002-7924-7991				ADAIR GM, 1989, P NATL ACAD SCI USA, V86, P4574, DOI 10.1073/pnas.86.12.4574; BARTH CF, 1988, MOL CELL BIOL, V8, P5358, DOI 10.1128/MCB.8.12.5358; BEUG H, 1982, J CELL PHYSIOL, P195; BOLLAG RJ, 1989, ANNU REV GENET, V23, P199, DOI 10.1146/annurev.ge.23.120189.001215; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; CALNEK BW, 1981, INFECT IMMUN, V34, P483, DOI 10.1128/IAI.34.2.483-491.1981; CARLSON LM, 1991, CELL, V64, P201, DOI 10.1016/0092-8674(91)90221-J; CHANG XB, 1987, P NATL ACAD SCI USA, V84, P4959, DOI 10.1073/pnas.84.14.4959; CRUZ A, 1990, NATURE, V348, P171, DOI 10.1038/348171a0; FREGIEN N, 1986, GENE, V48, P1, DOI 10.1016/0378-1119(86)90346-X; HEILIG R, 1982, J MOL BIOL, V156, P1, DOI 10.1016/0022-2836(82)90455-7; JASIN M, 1988, GENE DEV, V2, P1353, DOI 10.1101/gad.2.11.1353; KIM S, 1990, MOL CELL BIOL, V10, P3224, DOI 10.1128/MCB.10.6.3224; KOST TA, 1983, NUCLEIC ACIDS RES, V11, P8287, DOI 10.1093/nar/11.23.8287; LAI EC, 1980, P NATL ACAD SCI-BIOL, V77, P244, DOI 10.1073/pnas.77.1.244; MANSIKKA A, 1990, P NATL ACAD SCI USA, V87, P9416, DOI 10.1073/pnas.87.23.9416; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MIYAZAKI J, 1989, GENE, V79, P269; MOSCOVICI C, 1982, EXPRESSION DIFFERENT; OMALLEY BW, 1974, SCIENCE, V183, P610, DOI 10.1126/science.183.4125.610; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; REYNAUD CA, 1989, CELL, V59, P171, DOI 10.1016/0092-8674(89)90879-9; REYNAUD CA, 1985, CELL, V40, P283, DOI 10.1016/0092-8674(85)90142-4; REYNAUD CA, 1987, CELL, V48, P379, DOI 10.1016/0092-8674(87)90189-9; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; SMITHIES O, 1985, NATURE, V317, P230, DOI 10.1038/317230a0; TENASBROEK ALMA, 1990, NATURE, V348, P174, DOI 10.1038/348174a0; THOMAS KR, 1986, CELL, V44, P419, DOI 10.1016/0092-8674(86)90463-0; THOMPSON CB, 1987, CELL, V48, P369, DOI 10.1016/0092-8674(87)90188-7; THOMPSON CB, 1987, CELL, V51, P371, DOI 10.1016/0092-8674(87)90633-7; WONG EA, 1987, MOL CELL BIOL, V7, P2294, DOI 10.1128/MCB.7.6.2294; WOO SLC, 1981, BIOCHEMISTRY-US, V20, P6437, DOI 10.1021/bi00525a024; ZHENG H, 1990, NATURE, V344, P170, DOI 10.1038/344170a0	34	467	482	1	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 4	1991	67	1					179	188		10.1016/0092-8674(91)90581-I	http://dx.doi.org/10.1016/0092-8674(91)90581-I			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1913816				2022-12-01	WOS:A1991GJ32000016
J	DAVIDSON, HW; REID, PA; LANZAVECCHIA, A; WATTS, C				DAVIDSON, HW; REID, PA; LANZAVECCHIA, A; WATTS, C			PROCESSED ANTIGEN BINDS TO NEWLY SYNTHESIZED MHC CLASS II MOLECULES IN ANTIGEN-SPECIFIC LYMPHOCYTES-B	CELL			English	Article							RESTRICTED T-CELLS; INVARIANT CHAIN; PRESENTING CELLS; HLA-DR; TRANSFERRIN RECEPTOR; PEPTIDE COMPLEXES; PROTEIN ANTIGENS; VIRAL PEPTIDES; BREFELDIN-A; ALPHA-CHAIN	We describe the direct detection of radiolabeled antigen fragments bound to class II MHC molecules following immunoglobulin-mediated endocytosis and processing of native antigen in B lymphoblastoid cells. Tris-Tricine SDS gels revealed six distinct iodinated processing products that could be detected on class II MHC 1 hr after antigen endocytosis and persisted for at least 20 hr. These physiological processed antigen-class II complexes were remarkably stable, as judged by the fact that class II-alpha-beta dimers, which remain associated in SDS, became labeled with the same set of processed peptides. Using a lectin-binding assay, we show that these physiological processing products bind to the newly maturing population of MHC molecules rather than binding to the preexisting cell surface population; in contrast, an exogenous peptide binds predominantly to the latter population. A direct T cell-independent assay for processed peptide-MHC complex formation should facilitate additional studies on the exogenous antigen processing pathway.	BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND		DAVIDSON, HW (corresponding author), UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND.			Watts, Colin/0000-0001-6183-2087	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADORINI L, 1990, NATURE, V346, P63, DOI 10.1038/346063a0; ADORINI L, 1989, NATURE, V342, P800, DOI 10.1038/342800a0; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; BRACIALE TJ, 1991, IMMUNOL TODAY, V12, P124, DOI 10.1016/0167-5699(91)90096-C; BRODSKY FM, 1991, ANNU REV IMMUNOL, V9, P707; BUSCH R, 1990, INT IMMUNOL, V2, P443, DOI 10.1093/intimm/2.5.443; BUUS S, 1988, SCIENCE, V242, P1045, DOI 10.1126/science.3194755; CEPPELLINI R, 1989, NATURE, V339, P392, DOI 10.1038/339392a0; CRESSWELL P, 1977, EUR J IMMUNOL, V7, P636, DOI 10.1002/eji.1830070911; CRESSWELL P, 1985, P NATL ACAD SCI USA, V82, P8188, DOI 10.1073/pnas.82.23.8188; Cresswell P, 1990, Semin Immunol, V2, P273; DAVIDSON HW, 1989, J CELL BIOL, V109, P85, DOI 10.1083/jcb.109.1.85; DAVIDSON HW, 1990, J IMMUNOL, V144, P4101; DAVIS JE, 1990, J IMMUNOL, V144, P990; DEMOTZ S, 1989, NATURE, V342, P682, DOI 10.1038/342682a0; DEMOTZ S, 1989, J IMMUNOL, V142, P394; DORNMAIR K, 1989, COLD SH Q B, V54, P409; DUNN WA, 1980, J BIOL CHEM, V255, P5971; EISENLOHR LC, 1988, J IMMUNOL, V141, P1870; ELLIOTT WL, 1987, J IMMUNOL, V138, P2949; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; GUY K, 1982, EUR J IMMUNOL, V12, P942, DOI 10.1002/eji.1830121109; HARDING CV, 1989, P NATL ACAD SCI USA, V86, P4230, DOI 10.1073/pnas.86.11.4230; HARDING CV, 1991, CELL, V64, P393, DOI 10.1016/0092-8674(91)90647-H; HARDING CV, 1990, EUR J IMMUNOL, V20, P323, DOI 10.1002/eji.1830200214; HARDING CV, 1989, J IMMUNOL, V142, P12; JARAQUEMADA D, 1990, J EXP MED, V172, P947, DOI 10.1084/jem.172.3.947; JENSEN PE, 1990, J EXP MED, V171, P1779, DOI 10.1084/jem.171.5.1779; KOCH N, 1989, TRENDS BIOCHEM SCI, V14, P383, DOI 10.1016/0968-0004(89)90013-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; LEE JM, 1990, J IMMUNOL, V144, P1829; LEE P, 1988, J IMMUNOL, V140, P1063; LONG EO, 1989, IMMUNOL TODAY, V10, P232, DOI 10.1016/0167-5699(89)90259-4; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MACHY P, 1990, J IMMUNOL, V145, P1350; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; NADIMI F, 1991, EUR J IMMUNOL, V21, P1255, DOI 10.1002/eji.1830210524; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NUCHTERN JG, 1990, NATURE, V343, P74, DOI 10.1038/343074a0; OSULLIVAN D, 1990, J IMMUNOL, V145, P1799; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PETERSON M, 1990, NATURE, V345, P172, DOI 10.1038/345172a0; REID PA, 1990, NATURE, V346, P655, DOI 10.1038/346655a0; ROCHE PA, 1990, J IMMUNOL, V144, P1849; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROOSNEK E, 1988, J IMMUNOL, V140, P4079; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SALAMERO J, 1990, EMBO J, V9, P3489, DOI 10.1002/j.1460-2075.1990.tb07557.x; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SETTE A, 1989, J IMMUNOL, V143, P1265; SHAGGER H, 1987, ANAL BIOCHEM, V166, P368; SHIMONKEVITZ R, 1983, J EXP MED, V158, P303, DOI 10.1084/jem.158.2.303; SNIDER MD, 1985, J CELL BIOL, V100, P826, DOI 10.1083/jcb.100.3.826; SPRINGER TA, 1977, J BIOL CHEM, V252, P6201; STPIERRE Y, 1990, J IMMUNOL, V145, P812; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; THOMPSON JA, 1987, BIOCHEMISTRY-US, V26, P743, DOI 10.1021/bi00377a014; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; UNANUE ER, 1984, ANNU REV IMMUNOL, V2, P95; VANBLEEK GM, 1990, NATURE, V348, P213; WATTS C, 1988, EMBO J, V7, P1937, DOI 10.1002/j.1460-2075.1988.tb03031.x; Watts C, 1990, Semin Immunol, V2, P247; WATTS C, 1989, COLD SPRING HARB SYM, V54, P345; WATTS C, 1985, J CELL BIOL, V100, P633, DOI 10.1083/jcb.100.2.633; WEBER DA, 1990, J MOL CELL IMMUNOL, V4, P255; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J; ZIEGLER HK, 1982, P NATL ACAD SCI-BIOL, V79, P175, DOI 10.1073/pnas.79.1.175	75	180	180	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1991	67	1					105	116		10.1016/0092-8674(91)90575-J	http://dx.doi.org/10.1016/0092-8674(91)90575-J			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1913812				2022-12-01	WOS:A1991GJ32000010
J	DOHERTY, P; ASHTON, SV; MOORE, SE; WALSH, FS				DOHERTY, P; ASHTON, SV; MOORE, SE; WALSH, FS			MORPHOREGULATORY ACTIVITIES OF NCAM AND N-CADHERIN CAN BE ACCOUNTED FOR BY G PROTEIN-DEPENDENT ACTIVATION OF L-TYPE AND N-TYPE NEURONAL CA2+ CHANNELS	CELL			English	Article							NERVE GROWTH-FACTOR; CELL-ADHESION MOLECULES; NEURITE OUTGROWTH; PC12 CELLS; KINASE-C; EXTRACELLULAR-MATRIX; EXPRESSION; CALCIUM; CAM; MUSCLE	We present evidence that the morphoregulatory activities of neural cell adhesion molecule (NCAM) and N-cadherin involve activation of intracellular second messenger pathways. PC12 cells were cultured on monolayers of control 3T3 cells or 3T3 cells expressing transfected N-cadherin or NCAM. NCAM and N-cadherin directly induced a transcription-independent change in the morphology of PC12 cells from an adrenal to neuronal phenotype and also specifically increased Thy-1, but not L1/NILE or low affinity NGF receptor, immunoreactivity. The morphological response was more rapid and, in the case of N-cadherin, more substantial than that induced by NGF. It could be fully inhibited by pertussis toxin and a combination of L- and N-type Ca2+ channel antagonists, but not by broad-specificity kinase inhibitors. It was blocked, however, by the kinase inhibitor K-252b. These studies suggest that cell adhesion molecules directly alter cell phenotype and provide direct evidence for transmembrane signaling mediating both the morphological and biochemical responses induced by NCAM and N-cadherin.			DOHERTY, P (corresponding author), UNIV MED & DENT SCH GUYS & ST THOMAS HOSP,DEPT EXPTL PATHOL,LONDON BRIDGE,LONDON SE1 9RT,ENGLAND.		Doherty, Patrick/A-8752-2008		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BIRREN SJ, 1990, NEURON, V4, P189, DOI 10.1016/0896-6273(90)90094-V; BIXBY JL, 1990, J CELL BIOL, V111, P2725, DOI 10.1083/jcb.111.6.2725; BIXBY JL, 1987, P NATL ACAD SCI USA, V84, P2555, DOI 10.1073/pnas.84.8.2555; BOTELHO LHP, 1988, METHOD ENZYMOL, V159, P159; CAMPENOT RB, 1989, NEURON, V3, P733, DOI 10.1016/0896-6273(89)90242-0; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DAVIES AM, 1987, NATURE, V326, P353, DOI 10.1038/326353a0; DETRICK RJ, 1990, NEURON, V4, P493, DOI 10.1016/0896-6273(90)90108-R; DICKSON G, 1990, NATURE, V344, P348, DOI 10.1038/344348a0; DOHERTY P, 1987, DEVELOPMENT, V101, P605; DOHERTY P, 1990, NATURE, V343, P464, DOI 10.1038/343464a0; DOHERTY P, 1987, J NEUROCHEM, V49, P610, DOI 10.1111/j.1471-4159.1987.tb02907.x; DOHERTY P, 1988, EXP CELL RES, V179, P233, DOI 10.1016/0014-4827(88)90362-X; DOHERTY P, 1990, NEURON, V5, P209, DOI 10.1016/0896-6273(90)90310-C; DOHERTY P, 1989, J CELL BIOL, V109, P789, DOI 10.1083/jcb.109.2.789; DOHERTY P, 1991, NEURON, V6, P247, DOI 10.1016/0896-6273(91)90360-C; DOHERTY P, 1988, J CELL BIOL, V107, P333, DOI 10.1083/jcb.107.1.333; DOHERTY P, 1988, NEUROSCI LETT, V92, P222, DOI 10.1016/0304-3940(88)90065-1; Doherty P, 1989, CURR OPIN CELL BIOL, V1, P1102, DOI 10.1016/S0955-0674(89)80057-2; DOLPHIN AC, 1990, ANNU REV PHYSIOL, V52, P243; EDELMAN GM, 1987, P NATL ACAD SCI USA, V84, P8502, DOI 10.1073/pnas.84.23.8502; ERNSBERGER U, 1989, DEV BIOL, V135, P250, DOI 10.1016/0012-1606(89)90177-2; FUJIMOTO M, 1991, NEUROSCI LETT, V122, P9, DOI 10.1016/0304-3940(91)90180-2; GREENE LA, 1984, TRENDS NEUROSCI, V7, P91, DOI 10.1016/S0166-2236(84)80164-2; GREENE LA, 1982, DEV BIOL, V91, P305, DOI 10.1016/0012-1606(82)90037-9; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P424; GUNDERSEN RW, 1987, DEV BIOL, V121, P423, DOI 10.1016/0012-1606(87)90179-5; GUNNING PW, 1981, J NEUROSCI, V1, P1085; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; INOUE K, 1988, J BIOL CHEM, V263, P8157; KATER SB, 1991, J NEUROSCI, V11, P891; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; KOIZUMI S, 1988, J NEUROSCI, V8, P715; LENDAHL U, 1990, TRENDS NEUROSCI, V13, P132, DOI 10.1016/0166-2236(90)90004-T; MANN DA, 1989, J NEUROCHEM, V53, P1581, DOI 10.1111/j.1471-4159.1989.tb08555.x; MATSUNAGA M, 1988, NATURE, V334, P62, DOI 10.1038/334062a0; MATTHIES HJG, 1987, J NEUROSCI, V7, P1198; MOORE SE, 1987, J CELL BIOL, V105, P1377, DOI 10.1083/jcb.105.3.1377; NEUGEBAUER KM, 1988, J CELL BIOL, V107, P1177, DOI 10.1083/jcb.107.3.1177; PIZZEY JA, 1989, J CELL BIOL, V109, P3465, DOI 10.1083/jcb.109.6.3465; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; PRENTICE HM, 1987, EMBO J, V6, P1859, DOI 10.1002/j.1460-2075.1987.tb02444.x; REBER BFX, 1991, J PHYSIOL-LONDON, V435, P145, DOI 10.1113/jphysiol.1991.sp018502; SCHUCH U, 1989, NEURON, V3, P13, DOI 10.1016/0896-6273(89)90111-6; SCHULTZ G, 1990, ANNU REV PHYSIOL, V52, P275, DOI 10.1146/annurev.ph.52.030190.001423; SCOTT RH, 1990, MOL PHARMACOL, V38, P711; SEILHEIMER B, 1988, J CELL BIOL, V107, P341, DOI 10.1083/jcb.107.1.341; SILVER RA, 1990, NATURE, V343, P751, DOI 10.1038/343751a0; STRITTMATTER SM, 1991, BIOESSAYS, V13, P127, DOI 10.1002/bies.950130306; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1991, DEVELOPMENT, V251, P1451; TOGARI A, 1985, J NEUROSCI, V5, P307; WALSH FS, 1990, J NEUROCHEM, V55, P805, DOI 10.1111/j.1471-4159.1990.tb04563.x; WALSH FS, 1991, IN PRESS SEMIN NEURO, V3	57	388	395	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1991	67	1					21	33		10.1016/0092-8674(91)90569-K	http://dx.doi.org/10.1016/0092-8674(91)90569-K			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1680564				2022-12-01	WOS:A1991GJ32000004
J	DUNPHY, WG; KUMAGAI, A				DUNPHY, WG; KUMAGAI, A			THE CDC25 PROTEIN CONTAINS AN INTRINSIC PHOSPHATASE-ACTIVITY	CELL			English	Article							FISSION YEAST CDC25; CELL-CYCLE; TYROSINE-PHOSPHATASES; M-PHASE; MITOTIC INDUCER; HUMAN-PLACENTA; KINASE; ACTIVATION; MITOSIS; DIVISION	Genetic and biochemical studies have indicated that the cdc25 protein controls the entry into mitosis by triggering tyrosine dephosphorylation of the cdc2 protein kinase. We show that the isolated cdc25 protein can catalyze dephosphorylation of several model phosphatase substrates, including p-nitrophenyl phosphate and two distinct tyrosine-phosphorylated peptides. The cdc25-dependent cleavage reaction closely resembles dephosphorylation by known tyrosine phosphatases: the reaction requires a reducing agent, shows high sensitivity to sodium vanadate, and proceeds efficiently in the presence of metal chelators. Moreover, the phosphatase activity of the cdc25 protein is eliminated by treatment with N-ethylmaleimide or by alteration of a single conserved cysteine residue by site-directed mutagenesis. These observations indicate that the cdc25 protein can function as a tyrosine phosphatase in the absence of any other protein.			DUNPHY, WG (corresponding author), CALTECH, DIV BIOL, PASADENA, CA 91125 USA.							BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; Doree M, 1990, CURR OPIN CELL BIOL, V2, P269, DOI 10.1016/0955-0674(90)90018-A; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DUCOMMUN B, 1990, BIOCHEM BIOPH RES CO, V167, P301, DOI 10.1016/0006-291X(90)91765-K; DUNPHY WG, 1988, CELL, V55, P925, DOI 10.1016/0092-8674(88)90234-6; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1990, SCIENCE, V250, P1573, DOI 10.1126/science.1703321; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; JESSUS C, 1990, FEBS LETT, V266, P4, DOI 10.1016/0014-5793(90)90002-C; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; MEIJER L, 1991, EMBO J, V10, P1545, DOI 10.1002/j.1460-2075.1991.tb07674.x; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1991, NATURE, V351, P194, DOI 10.1038/351194b0; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORGAN DO, 1991, METHOD ENZYMOL, V200, P645; MORIA AO, 1989, CELL, V58, P193; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OFARRELL PH, 1989, SCIENCE, V246, P635, DOI 10.1126/science.2683080; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; PINES J, 1990, New Biologist, V2, P389; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722	43	539	553	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 4	1991	67	1					189	196		10.1016/0092-8674(91)90582-J	http://dx.doi.org/10.1016/0092-8674(91)90582-J			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1655274				2022-12-01	WOS:A1991GJ32000017
J	HANN, BC; WALTER, P				HANN, BC; WALTER, P			THE SIGNAL RECOGNITION PARTICLE IN SACCHAROMYCES-CEREVISIAE	CELL			English	Article							YEAST ENDOPLASMIC-RETICULUM; PREPRO-ALPHA-FACTOR; SECRETORY PROTEIN TRANSLOCATION; COLI 4.5S RNA; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; HEAT-SHOCK; MICROSOMAL MEMBRANE; PLASMA-MEMBRANE	We have identified the Saccharomyces cerevisiae homolog of the signal recognition particle (SRP) and characterized its function in vivo. S. cerevisiae SRP is a 16S particle that includes a homolog of the signal sequence-binding protein subunit of SRP (SRP54p) and a small cytoplasmic RNA (scR1). Surprisingly, the genes encoding scR1 and SRP54p are not essential for growth, though SRP-deficient cells grow poorly, suggesting that SRP function can be partially bypassed in vivo. Protein translocation across the ER membrane is impaired in SRP-deficient cells, indicating that yeast SRP, like its mammalian counterpart, functions in this process. Unexpectedly, the degree of the translocation defect varies for different proteins. The ability of some proteins to be efficiently targeted in SRP-deficient cells may explain why previous genetic and biochemical analyses in yeast and bacteria did not reveal components of the SRP-dependent protein targeting pathway.			HANN, BC (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.							AMAYA Y, 1990, J BIOCHEM-TOKYO, V107, P457, DOI 10.1093/oxfordjournals.jbchem.a123067; AMAYA Y, 1991, FEBS LETT, V283, P325, DOI 10.1016/0014-5793(91)80619-E; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BERNSTEIN M, 1985, J CELL BIOL, V101, P2374, DOI 10.1083/jcb.101.6.2374; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BIEKER KL, 1990, CELL, V61, P833, DOI 10.1016/0092-8674(90)90193-I; BIRD P, 1987, J CELL BIOL, V105, P2905, DOI 10.1083/jcb.105.6.2905; BRENNWALD P, 1988, MOL CELL BIOL, V8, P1580, DOI 10.1128/MCB.8.4.1580; BROWN S, 1984, J MOL BIOL, V178, P533, DOI 10.1016/0022-2836(84)90237-7; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; Davis R W, 1980, Methods Enzymol, V65, P404; DESHAIES RJ, 1990, MOL CELL BIOL, V10, P6024, DOI 10.1128/MCB.10.11.6024; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DIDOMENICO BJ, 1982, P NATL ACAD SCI-BIOL, V79, P6181, DOI 10.1073/pnas.79.20.6181; FELICI F, 1989, MOL CELL BIOL, V9, P3260, DOI 10.1128/MCB.9.8.3260; GARCIA PD, 1988, J CELL BIOL, V106, P1043, DOI 10.1083/jcb.106.4.1043; GARDEL C, 1990, EMBO J, V9, P3209, DOI 10.1002/j.1460-2075.1990.tb07519.x; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; HANN BC, 1989, J CELL BIOL, V109, P3223, DOI 10.1083/jcb.109.6.3223; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HANSEN W, 1988, J CELL BIOL, V106, P1075, DOI 10.1083/jcb.106.4.1075; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HE F, 1989, CURR GENET, V16, P347, DOI 10.1007/BF00340713; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KOSHLAND D, 1982, CELL, V30, P893, DOI 10.1016/0092-8674(82)90294-X; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; Maniatis T., 1982, MOL CLONING; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7421, DOI 10.1073/pnas.81.23.7421; NGSEE JK, 1989, MOL CELL BIOL, V9, P3400, DOI 10.1128/MCB.9.8.3400; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; PARKER R, 1988, MOL CELL BIOL, V8, P3150, DOI 10.1128/MCB.8.8.3150; PHILLIPS GJ, 1990, NATURE, V344, P882, DOI 10.1038/344882a0; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; RHOADS DB, 1984, J BACTERIOL, V159, P63, DOI 10.1128/JB.159.1.63-70.1984; RIBES V, 1988, EMBO J, V7, P231, DOI 10.1002/j.1460-2075.1988.tb02804.x; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; ROTHBLATT JA, 1986, EMBO J, V5, P1031; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHLOSS P, 1988, EMBO J, V7, P2889, DOI 10.1002/j.1460-2075.1988.tb03146.x; Sherman F., 1986, METHODS YEAST GENETI; SHUSTER EO, 1988, CELL, V55, P41, DOI 10.1016/0092-8674(88)90007-4; SIEGEL V, 1988, P NATL ACAD SCI USA, V85, P1801, DOI 10.1073/pnas.85.6.1801; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRUB K, 1991, IN PRESS MOL CELL BI; STRUCK JCR, 1988, NUCLEIC ACIDS RES, V16, P7740, DOI 10.1093/nar/16.15.7740; WALTER P, 1983, J CELL BIOL, V97, P1693, DOI 10.1083/jcb.97.6.1693; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; WITTE C, 1988, EMBO J, V7, P1439, DOI 10.1002/j.1460-2075.1988.tb02961.x	60	264	265	1	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 4	1991	67	1					131	144		10.1016/0092-8674(91)90577-L	http://dx.doi.org/10.1016/0092-8674(91)90577-L			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1655273				2022-12-01	WOS:A1991GJ32000012
J	HEBELL, T; AHEARN, JM; FEARON, DT				HEBELL, T; AHEARN, JM; FEARON, DT			SUPPRESSION OF THE IMMUNE-RESPONSE BY A SOLUBLE COMPLEMENT RECEPTOR OF LYMPHOCYTES-B	SCIENCE			English	Article							EPSTEIN-BARR-VIRUS; MONOCLONAL-ANTIBODY; CR-2 CD21; PROLIFERATION; BINDING; C3D; DEFICIENCIES; ACTIVATION; INVIVO; CELLS	The CD19-CR2 complex of B lymphocytes contains proteins that participate in two host-defense systems, the immune and complement systems. The ligand for the subunit of the immune system, CD19, is not known, but the complement receptor subunit, CR2 (CD21), binds activation fragments of the C3 component of the complement system and may mediate immunopotentiating effects of complement. A recombinant, soluble CR2 was prepared by fusing the C3-binding region of the receptor to immunoglobulin G1 (IgG1). The (CR2)2-IgG1 chimera competed with cellular CR2 for C3 binding and suppressed the antibody response to a T cell-dependent antigen when administered to mice at the time of immunization. This inhibitory effect of (CR2)2-IgG1 demonstrates the B cell-activating function of the CD19-CR2 complex and suggests a new method for humoral immunosuppression.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV MOLEC & CLIN RHEUMATOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, GRAD PROGRAM IMMUNOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University					NIAID NIH HHS [AI-22833, AI-28191] Funding Source: Medline; NIGMS NIH HHS [GM-43803] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028191, R01AI022833] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHEARN JM, 1989, ADV IMMUNOL, V46, P183, DOI 10.1016/S0065-2776(08)60654-9; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BALLARD DW, 1986, P NATL ACAD SCI USA, V83, P9626, DOI 10.1073/pnas.83.24.9626; BIRD P, 1988, EUR J IMMUNOL, V18, P1217, DOI 10.1002/eji.1830180811; BOTTGER EC, 1985, J IMMUNOL, V135, P4100; BRUGGEMANN M, 1987, J EXP MED, V166, P1351, DOI 10.1084/jem.166.5.1351; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CAREL JC, 1990, J BIOL CHEM, V265, P12293; CARTER R, UNPUB; CARTER RH, 1989, J IMMUNOL, V143, P1755; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; COOPER NR, 1988, ANNU REV IMMUNOL, V6, P85; COULIE PG, 1985, EUR J IMMUNOL, V15, P793, DOI 10.1002/eji.1830150810; FINGEROTH JD, 1989, IMMUNOL LETT, V21, P291, DOI 10.1016/0165-2478(89)90022-9; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HEYMAN B, 1990, J EXP MED, V172, P665, DOI 10.1084/jem.172.2.665; HEYMAN B, 1984, J IMMUNOL METHODS, V68, P193, DOI 10.1016/0022-1759(84)90150-9; JACKSON CG, 1979, NEW ENGL J MED, V300, P1124, DOI 10.1056/NEJM197905173002002; KALLI KR, 1991, J IMMUNOL, V147, P590; LOWELL CA, 1989, J EXP MED, V170, P1931, DOI 10.1084/jem.170.6.1931; MARTINELLI GP, 1978, J IMMUNOL, V121, P2043; MATSUMOTO AK, 1991, J EXP MED, V173, P55, DOI 10.1084/jem.173.1.55; MOORE MD, 1989, J BIOL CHEM, V264, P20576; NEMEROW GR, 1985, J VIROL, V55, P347, DOI 10.1128/JVI.55.2.347-351.1985; OI VT, 1983, P NATL ACAD SCI-BIOL, V80, P825, DOI 10.1073/pnas.80.3.825; PEPYS MB, 1974, J EXP MED, V140, P126, DOI 10.1084/jem.140.1.126; PEZZUTTO A, 1987, J IMMUNOL, V138, P2793; SCHIFFERLI JA, 1986, NEW ENGL J MED, V315, P488; TUVESON DA, 1991, J EXP MED, V173, P1083, DOI 10.1084/jem.173.5.1083; WEIS JJ, 1988, J EXP MED, V167, P1047, DOI 10.1084/jem.167.3.1047	30	232	248	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 4	1991	254	5028					102	105		10.1126/science.1718035	http://dx.doi.org/10.1126/science.1718035			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH605	1718035				2022-12-01	WOS:A1991GH60500038
J	HUBER, AR; KUNKEL, SL; TODD, RF; WEISS, SJ				HUBER, AR; KUNKEL, SL; TODD, RF; WEISS, SJ			REGULATION OF TRANSENDOTHELIAL NEUTROPHIL MIGRATION BY ENDOGENOUS INTERLEUKIN-8	SCIENCE			English	Article							HUMAN-ENDOTHELIAL-CELLS; TUMOR-NECROSIS-FACTOR; ACTIVATING PEPTIDE NAP/IL-8; MGSA-GRO PROTEIN; MONOCLONAL-ANTIBODIES; POLYMORPHONUCLEAR LEUKOCYTES; BIOCHEMICAL-CHARACTERIZATION; RECOMBINANT EXPRESSION; BIOLOGICAL-ACTIVITIES; GENE-EXPRESSION	Movement of neutrophils from the bloodstream to inflamed tissue depends on the activation of both the neutrophil and the endothelial cell. Endothelial cells lining the postcapillary venule respond to proinflammatory mediators by expressing adhesion molecules and synthesizing a variety of neutrophil-activating factors. Endothelial cell production of a 77-amino acid variant of interleukin-8 (IL-8) was found to be a requirement for the invasion of neutrophils through a vessel wall model. IL-8 secreted by cytokine- or lipopolysaccharide-stimulated endothelial cells induced the rapid shedding of neutrophil lectin adhesion molecule-1, the up-regulation of leukocyte beta-2 integrins, and the attachment and transmigration of the neutrophils. Thus, endogenous endothelial IL-8 regulates transvenular traffic during acute inflammatory responses.	UNIV MICHIGAN,DEPT INTERNAL MED,DIV HEMATOL & ONCOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT PATHOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Todd, Robert/GWM-4486-2022		NATIONAL CANCER INSTITUTE [R01CA039064] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028024] Funding Source: NIH RePORTER; NCI NIH HHS [CA 39064] Funding Source: Medline; NHLBI NIH HHS [HL 28024] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BORISH L, 1989, CELL IMMUNOL, V121, P280, DOI 10.1016/0008-8749(89)90026-9; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; BREVIARIO F, 1988, J IMMUNOL, V141, P3391; BUSSOLINO F, 1988, J BIOL CHEM, V263, P11586; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; DERYNCK R, 1990, BIOCHEMISTRY-US, V29, P10225, DOI 10.1021/bi00496a011; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; FEINMARK SJ, 1986, J BIOL CHEM, V261, P6466; FURIE MB, 1989, J IMMUNOL, V143, P3309; GIMBRONE MA, 1989, SCIENCE, V246, P1601, DOI 10.1126/science.2688092; HECHTMAN DH, 1991, J IMMUNOL, V147, P883; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HUBER AM, UNPUB; HUBER AR, 1989, J CLIN INVEST, V83, P1122, DOI 10.1172/JCI113992; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KYANAUNG U, 1991, J IMMUNOL, V146, P521; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEONARD EJ, 1990, AM J RESP CELL MOL, V2, P479, DOI 10.1165/ajrcmb/2.6.479; LEONARD EJ, 1990, IMMUNOL TODAY, V11, P97, DOI 10.1016/0167-5699(90)90035-8; Matsushima K, 1989, Cytokine, V1, P2, DOI 10.1016/1043-4666(89)91043-0; MOVAT HZ, 1987, J LAB CLIN MED, V110, P668; OPPENHEIMERMARKS N, 1990, J IMMUNOL, V145, P140; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; SCHRODER JM, 1990, J EXP MED, V171, P1091, DOI 10.1084/jem.171.4.1091; SICA A, 1990, J IMMUNOL, V144, P3034; SIEGBAHN A, 1990, J CLIN INVEST, V85, P916, DOI 10.1172/JCI114519; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STANDIFORD TJ, 1990, J CLIN INVEST, V86, P1945, DOI 10.1172/JCI114928; STICHERLING M, 1989, J IMMUNOL, V143, P1628; STRIETER RM, 1989, J BIOL CHEM, V264, P10621; TEDDER TF, 1990, J IMMUNOL, V144, P532; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WANG JM, 1987, IMMUNOLOGY, V60, P439; WEN DZ, 1989, EMBO J, V8, P1761, DOI 10.1002/j.1460-2075.1989.tb03569.x; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZIMMERMAN GA, 1990, J CELL BIOL, V110, P529, DOI 10.1083/jcb.110.2.529	40	742	770	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1991	254	5028					99	102		10.1126/science.1718038	http://dx.doi.org/10.1126/science.1718038			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH605	1718038				2022-12-01	WOS:A1991GH60500037
J	JACOB, HJ; LINDPAINTNER, K; LINCOLN, SE; KUSUMI, K; BUNKER, RK; MAO, YP; GANTEN, D; DZAU, VJ; LANDER, ES				JACOB, HJ; LINDPAINTNER, K; LINCOLN, SE; KUSUMI, K; BUNKER, RK; MAO, YP; GANTEN, D; DZAU, VJ; LANDER, ES			GENETIC-MAPPING OF A GENE CAUSING HYPERTENSION IN THE STROKE-PRONE SPONTANEOUSLY HYPERTENSIVE RAT	CELL			English	Article							ANGIOTENSIN-CONVERTING ENZYME; FRAGMENT LENGTH POLYMORPHISMS; QUANTITATIVE-TRAIT LOCI; BLOOD-PRESSURE; GROWTH-HORMONE; MENDELIAN FACTORS; LINKAGE MAP; DNA; IDENTIFICATION; CHROMOSOME-17	The stroke-prone spontaneously hypertensive rat (SHRSP) is a well-characterized model for primary hypertension in humans. High blood pressure in SHRSP shows polygenic inheritance, but none of the loci responsible have previously been identified. To locate genes controlling this quantitative trait, we mapped a large collection of DNA polymorphisms in a cross between SHRSP and the normotensive WKY strain. Here we report strong genetic evidence that a gene, Bp1, having a major effect on blood pressure maps to rat chromosome 10 with a LOD score of 5.10 and is closely linked to the rat gene encoding angiotensin-converting enzyme (ACE), an enzyme that plays a major role in blood pressure homeostasis and is an important target of anti-hypertensive drugs. We also find significant, albeit weaker, linkage to a locus, Bp2, on chromosome 18. We discuss the implications of genetic dissection of quantitative disease-related phenotypes in mammals.	UNIV HEIDELBERG, GERMAN INST HIGH BLOOD PRESSURE RES, W-6900 HEIDELBERG, GERMANY; CTR MOLEC MED, BERLIN, GERMANY; STANFORD UNIV, MED CTR, DIV CARDIOL, STANFORD, CA 94305 USA; UNIV HEIDELBERG, DEPT PHARMACOL, W-6900 HEIDELBERG, GERMANY; HARVARD UNIV, CHILDRENS HOSP, DEPT CARDIOL, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, DIV CARDIOL, BOSTON, MA 02115 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Ruprecht Karls University Heidelberg; Stanford University; Ruprecht Karls University Heidelberg; Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Massachusetts Institute of Technology (MIT)	JACOB, HJ (corresponding author), WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA.		Kusumi, Kenro/J-2626-2012	Kusumi, Kenro/0000-0002-1458-4540	NHGRI NIH HHS [HG00198] Funding Source: Medline; NHLBI NIH HHS [HL35610, HL42663] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042663, R01HL035610, R37HL035610] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000198, R37HG000198] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BERNSTEIN KE, 1989, J BIOL CHEM, V264, P11945; BIANCH G, 1990, HYPERTENSION PATHOPH, pCH78; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COOKE NE, 1986, ENDOCRINOLOGY, V119, P2451, DOI 10.1210/endo-119-6-2451; Dollery CT., 1985, CECIL TXB MED, V17th, P266; DZAU VJ, 1988, CIRCULATION, V77, P4; East EM, 1916, GENETICS, V1, P164; EDWARDS MD, 1987, GENETICS, V116, P113; ELY DL, 1990, HYPERTENSION, V16, P277, DOI 10.1161/01.HYP.16.3.277; HABER E, 1986, SCI AM MED CARDIOLOG; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; HARPER ME, 1982, AM J HUM GENET, V34, P227; HAVLIK RJ, 1979, AM J EPIDEMIOL, V110, P304, DOI 10.1093/oxfordjournals.aje.a112815; HIGGINS M, 1980, AM J EPIDEMIOL, V111, P142, DOI 10.1093/oxfordjournals.aje.a112882; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; KURTZ TW, 1990, J CLIN INVEST, V85, P1328, DOI 10.1172/JCI114572; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LANDER ES, 1989, GENETICS, V121, P185; LANDER ES, 1986, COLD SPRING HARB SYM, V51, P49, DOI 10.1101/SQB.1986.051.01.007; LEVAN G, 1991, GENOMICS, V10, P699, DOI 10.1016/0888-7543(91)90455-N; LEVAN G, 1990, GENETIC MAPS LOCUS M; LEVINE RS, 1982, AM J EPIDEMIOL, V116, P759, DOI 10.1093/oxfordjournals.aje.a113465; LINDPAINTNER K, 1990, J HYPERTENS, V8, P763, DOI 10.1097/00004872-199008000-00011; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; MATTEI MG, 1989, CYTOGENET CELL GENET, V51, P1041; MUELLER SM, 1985, ARTERY, V12, P337; NAKATA K, 1987, J CARDIOVASC PHARM, V9, P305, DOI 10.1097/00005344-198703000-00007; NEUMANN PE, 1991, P NATL ACAD SCI USA, V88, P5408, DOI 10.1073/pnas.88.12.5408; Nilsson-Ehle H, 1909, LUNDS U AARSKR, V5, P1; OKAMOTO KOZO, 1963, JAPAN CIRCULATION JOUR, V27, P282; PAGE RCL, 1995, DIABETIC MED, V12, P209, DOI 10.1111/j.1464-5491.1995.tb00460.x; PATERSON AH, 1991, GENETICS, V127, P181; PATERSON AH, 1988, NATURE, V335, P721, DOI 10.1038/335721a0; PATERSON AH, 1990, GENETICS, V124, P735; PRATT RE, 1989, AM J PHYSIOL, V256, pF469, DOI 10.1152/ajprenal.1989.256.3.F469; PRAVENEC M, 1991, HYPERTENSION, V17, P242, DOI 10.1161/01.HYP.17.2.242; RAPP JP, 1982, HYPERTENSION, P582; RIORDAN JR, 1989, SCIENCE, V245, P1066; RISE ML, 1991, SCIENCE, V253, P669, DOI 10.1126/science.1871601; ROBINSON R, 1972, GENE MAPPING LABOR B; ROBINSON R, 1979, LABORATORY RAT, V1, P38; Sambrook J., 1989, MOL CLONING LAB MANU; SCHLAGER G, 1967, GENETICS, V55, P497; STALLINGS RL, 1991, GENOMICS, V10, P807, DOI 10.1016/0888-7543(91)90467-S; TANASE H, 1970, JPN CIRCULATION J, V34, P1197; THODAY JM, 1961, NATURE, V191, P368, DOI 10.1038/191368a0; THOMAS MJ, 1990, MOL CELL BIOL, V10, P5378, DOI 10.1128/MCB.10.10.5378; TODD JA, 1991, NATURE, V351, P542, DOI 10.1038/351542a0; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WEBER JL, 1989, AM J HUM GENET, V44, P388; Wright S., 1968, EVOLUTION GENETICS P, V1; YAMORI Y, 1982, HYPERTENSION, P556	54	685	699	0	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 4	1991	67	1					213	224		10.1016/0092-8674(91)90584-L	http://dx.doi.org/10.1016/0092-8674(91)90584-L			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1655275				2022-12-01	WOS:A1991GJ32000019
J	KESSEL, M; GRUSS, P				KESSEL, M; GRUSS, P			HOMEOTIC TRANSFORMATIONS OF MURINE VERTEBRAE AND CONCOMITANT ALTERATION OF HOX CODES INDUCED BY RETINOIC ACID	CELL			English	Article							EMBRYONAL CARCINOMA-CELLS; CHICK LIMB BUD; HOMEOBOX-CONTAINING GENES; MOUSE EMBRYOS; EXPRESSION PATTERN; BOX GENE; SPATIAL-DISTRIBUTION; TRANSGENIC MICE; CODING SEQUENCE; DROSOPHILA	Exposure of murine embryos to teratogenic doses of retinoic acid (RA) induced homeotic transformations of vertebrae. Posterior transformations occurred along the complete body axis after RA administration on day 7 of gestation and were accompanied by anterior shifts of Hox gene expression domains in embryos. Anterior transformations of vertebrae in the caudal half of the vertebral column were induced on day 8.5. We suggest that the identity of a vertebral segment is specified by a combination of functionally active Hox genes, a "Hox code." In this concept the sequential activation of Hox genes defines sequentially more posterior axial levels, while mesodermal cells leave the primitive streak. Exogenous RA interferes with the normal estabishment of Hox codes and thus with axial specification.			KESSEL, M (corresponding author), MAX PLANCK INST BIOPHYS CHEM, MOLEK ZELLBIOL ABT, POB 2841, W-3400 GOTTINGEN, GERMANY.							AKAM M, 1988, DEVELOPMENT, V104, P123; ALTABA ARI, 1991, GENE DEV, V5, P175, DOI 10.1101/gad.5.2.175; BALLING R, 1989, CELL, V58, P337, DOI 10.1016/0092-8674(89)90848-9; Bateson W., 1894, MAT STUDY VARIATION, DOI [10.5962/bhl.title.1348, DOI 10.5962/BHL.TITLE.1348]; BELLAIRS R, 1986, ANAT EMBRYOL, V174, P1, DOI 10.1007/BF00318331; BOGARAD LD, 1989, DEV BIOL, V133, P537, DOI 10.1016/0012-1606(89)90056-0; BONCINELLI E, 1988, HUM REPROD, V3, P880, DOI 10.1093/oxfordjournals.humrep.a136802; BREIER G, 1986, EMBO J, V5, P2209, DOI 10.1002/j.1460-2075.1986.tb04486.x; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; CHEVALIER A, 1977, VERTEBRATE LIMB SOMI, P420; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHO KWY, 1990, GENE DEV, V4, P1910, DOI 10.1101/gad.4.11.1910; CHO KWY, 1991, CELL, V65, P55, DOI 10.1016/0092-8674(91)90407-P; COLBERGPOLEY AM, 1985, NATURE, V314, P713, DOI 10.1038/314713a0; CREECHKRAFT J, 1987, TOXICOL APPL PHARM, V87, P474; DESCHAMPS J, 1987, P NATL ACAD SCI USA, V84, P1304, DOI 10.1073/pnas.84.5.1304; DOLLE P, 1990, DEVELOPMENT, V110, P1133; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DOLLE P, 1991, IN PRESS MECH DEV; DRESSLER GR, 1989, DIFFERENTIATION, V41, P193, DOI 10.1111/j.1432-0436.1989.tb00747.x; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; ERSELIUS JR, 1990, DEVELOPMENT, V110, P629; FAINSOD A, 1987, DEV BIOL, V124, P125, DOI 10.1016/0012-1606(87)90465-9; FIBI M, 1988, DEVELOPMENT, V102, P349; FRISCHER LE, 1986, CELL, V47, P1017, DOI 10.1016/0092-8674(86)90816-0; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; FUJINAGA M, 1989, TERATOLOGY, V40, P439, DOI 10.1002/tera.1420400505; GAUNT SJ, 1987, DEVELOPMENT, V101, P51; GAUNT SJ, 1988, DEVELOPMENT, V103, P135; GAUNT SJ, 1990, DEVELOPMENT, V109, P329; GAUNT SJ, 1988, DEVELOPMENT, V104, P169; GAUNT SJ, 1989, DEVELOPMENT, V107, P131; GEHRING WJ, 1986, ANNU REV GENET, V20, P147, DOI 10.1146/annurev.ge.20.120186.001051; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; GREEN EL, 1953, SCIENCE, V117, P81, DOI 10.1126/science.117.3030.81; GREGG BC, 1983, J EMBRYOL EXP MORPH, V731, P135; GRUNEBERG H, 1952, GENETICS MOUSE; GRUNEBERG H, 1950, J GENET, V50, P111; HORNBRUCH A, 1986, J EMBRYOL EXP MORPH, V94, P257; IZPISUABELMONTE JC, 1990, DEVELOPMENT, V110, P733; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KESSEL M, 1987, P NATL ACAD SCI USA, V84, P5306, DOI 10.1073/pnas.84.15.5306; KEYNES R, 1990, NEURON, V2, P1; KIENY M, 1972, DEV BIOL, V28, P142, DOI 10.1016/0012-1606(72)90133-9; KOCHHAR DM, 1973, TERATOLOGY, V7, P289, DOI 10.1002/tera.1420070310; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MADEN M, 1988, NATURE, V335, P733, DOI 10.1038/335733a0; MAHON KA, 1988, DEVELOPMENT, V104, P187; MAVILIO F, 1988, DIFFERENTIATION, V37, P73, DOI 10.1111/j.1432-0436.1988.tb00798.x; MCGINNIS W, 1984, CELL, V37, P403, DOI 10.1016/0092-8674(84)90370-2; MENKES B, 1977, VERTEBRATE LIMB SOMI, P405; NOHNO T, 1991, CELL, V64, P1197, DOI 10.1016/0092-8674(91)90274-3; NOJI S, 1991, NATURE, V350, P83, DOI 10.1038/350083a0; PEIFER M, 1987, GENE DEV, V1, P891, DOI 10.1101/gad.1.9.891; PUSCHEL AW, 1990, DEVELOPMENT, V108, P435; PUSCHEL AW, 1991, DEVELOPMENT, V112, P279; RUBIN MR, 1987, MOL CELL BIOL, V7, P3836, DOI 10.1128/MCB.7.10.3836; RUSSELL LB, 1956, J EXP ZOOL, V131, P329, DOI 10.1002/jez.1401310308; SATRE MA, 1989, DEV BIOL, V133, P529, DOI 10.1016/0012-1606(89)90055-9; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SEARLE AG, 1954, J GENET, V52, P68, DOI 10.1007/BF02981491; SHARPE PT, 1988, DEVELOPMENT, V102, P397; SHENEFELT RE, 1972, TERATOLOGY, V5, P103, DOI 10.1002/tera.1420050115; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SIMEONE A, 1991, MECH DEVELOP, V33, P169; SIVE HL, 1990, GENE DEV, V4, P932, DOI 10.1101/gad.4.6.932; SNOW MHL, 1987, SOMITES DEV EMBRYOS, P301; SUMMERBELL D, 1990, TRENDS NEUROSCI, V13, P142, DOI 10.1016/0166-2236(90)90006-V; SUNDIN OH, 1990, DEVELOPMENT, V108, P47; TAM PPL, 1987, DEVELOPMENT, V99, P109; TAMARIN A, 1984, J EMBRYOL EXP MORPH, V84, P105; TASSIN MT, 1981, J CRAN GENET DEV BIO, V1, P299; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; THEILER K, 1988, ADV ANAT EMBRYOL CEL, V90, P1; TIBBLES L, 1988, TERATOLOGY, V37, P113, DOI 10.1002/tera.1420370204; VOGELS R, 1990, IN PRESS DEVELOPMENT, V110; WAGNER M, 1990, NATURE, V345, P819, DOI 10.1038/345819a0; WANEK N, 1991, NATURE, V350, P81, DOI 10.1038/350081a0; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; WRIGHT CVE, 1989, CELL, V59, P81, DOI 10.1016/0092-8674(89)90871-4; YASUDA Y, 1986, TERATOLOGY, V34, P37, DOI 10.1002/tera.1420340106	88	892	909	1	27	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1991	67	1					89	104		10.1016/0092-8674(91)90574-I	http://dx.doi.org/10.1016/0092-8674(91)90574-I			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1680565	hybrid			2022-12-01	WOS:A1991GJ32000009
J	KJEMS, J; FRANKEL, AD; SHARP, PA				KJEMS, J; FRANKEL, AD; SHARP, PA			SPECIFIC REGULATION OF MESSENGER-RNA SPLICING INVITRO BY A PEPTIDE FROM HIV-1 REV	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRANS-ACTIVATOR; GENE-PRODUCT; SEXUAL-DIFFERENTIATION; MUTATIONAL ANALYSIS; STRUCTURED REGION; TARGET SEQUENCE; TYPE-1 AFFECTS; PROTEIN; EXPRESSION	The Rev protein of HIV-1 regulates the synthesis of partially spliced forms of cytoplasmic viral mRNA by binding to a cis-acting RNA sequence, the Rev response element (RRE). We have investigated the regulation of splicing in vitro and have shown that Rev specifically inhibits splicing of pre-mRNAs containing an RRE by 3- to 4-fold. A synthetic peptide of 17 amino acids containing the RNA-binding domain of Rev is highly functional and specifically inhibits splicing by up to 30-fold. Other peptides that bind to the RRE with high affinity, but with low specificity, do not specifically inhibit splicing. Six repeated monomeric binding sites for the peptide can substitute for the RRE, indicating that regulation by Rev requires interactions with multiple sites. The peptide acts at a step in the assembly of splicing complexes, suggesting that one of the functions of the basic region of Rev is to prevent formation of a functional spliceosome.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute	KJEMS, J (corresponding author), MIT,CTR CANC RES,CAMBRIDGE,MA 02139, USA.		Kjems, Jorgen/I-3490-2016	Kjems, Jorgen/0000-0003-4128-9317	NCI NIH HHS [CA 14051] Funding Source: Medline; NIAID NIH HHS [AI29135] Funding Source: Medline; NIGMS NIH HHS [GM34277] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029135] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034277, R37GM034277] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRIS CH, 1989, MOL CELL BIOL, V9, P259, DOI 10.1128/MCB.9.1.259; ANDREADIS A, 1987, ANNU REV CELL BIOL, V3, P207, DOI 10.1146/annurev.cb.03.110187.001231; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CHANG DD, 1990, SCIENCE, V249, P614, DOI 10.1126/science.2143313; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; COCHRANE AW, 1990, P NATL ACAD SCI USA, V87, P1198, DOI 10.1073/pnas.87.3.1198; COOK KS, 1991, NUCLEIC ACIDS RES, V19, P1577, DOI 10.1093/nar/19.7.1577; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; DALY TJ, 1990, BIOCHEMISTRY-US, V29, P9791, DOI 10.1021/bi00494a005; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FU XD, 1991, GENE DEV, V5, P211, DOI 10.1101/gad.5.2.211; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GRABOWSKI PJ, 1985, CELL, V42, P345, DOI 10.1016/S0092-8674(85)80130-6; HADZOPOULOUCLADARAS M, 1989, J VIROL, V63, P1265, DOI 10.1128/JVI.63.3.1265-1274.1989; HAMMARSKJOLD ML, 1989, J VIROL, V63, P1959; HEAPHY S, 1990, CELL, V60, P685, DOI 10.1016/0092-8674(90)90671-Z; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HOPE TJ, 1990, J VIROL, V64, P5360, DOI 10.1128/JVI.64.11.5360-5366.1990; HUANG XJ, 1991, J VIROL, V65, P2131, DOI 10.1128/JVI.65.4.2131-2134.1991; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; KATZ RA, 1990, MOL CELL BIOL, V10, P696, DOI 10.1128/MCB.10.2.696; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; LAMOND AI, 1987, GENE DEV, V1, P532, DOI 10.1101/gad.1.6.532; LU XB, 1990, P NATL ACAD SCI USA, V87, P7598, DOI 10.1073/pnas.87.19.7598; MALIM MH, 1988, NATURE, V335, P181, DOI 10.1038/335181a0; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MALIM MH, 1991, CELL, V65, P251; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; OLSEN HS, 1990, GENE DEV, V4, P1357, DOI 10.1101/gad.4.8.1357; OLSEN HS, 1990, SCIENCE, V247, P845, DOI 10.1126/science.2406903; PADGETT RA, 1985, P NATL ACAD SCI USA, V82, P8349, DOI 10.1073/pnas.82.24.8349; ROSEN CA, 1988, P NATL ACAD SCI USA, V85, P2071, DOI 10.1073/pnas.85.7.2071; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; VARMUS H, 1988, SCIENCE, V240, P1427, DOI 10.1126/science.3287617; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	52	111	113	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1991	67	1					169	178		10.1016/0092-8674(91)90580-R	http://dx.doi.org/10.1016/0092-8674(91)90580-R			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1913815				2022-12-01	WOS:A1991GJ32000015
J	KOSMAN, D; IP, YT; LEVINE, M; ARORA, K				KOSMAN, D; IP, YT; LEVINE, M; ARORA, K			ESTABLISHMENT OF THE MESODERM-NEUROECTODERM BOUNDARY IN THE DROSOPHILA EMBRYO	SCIENCE			English	Article							SCUTE GENE-COMPLEX; SINGLE-MINDED GENE; NUCLEAR-LOCALIZATION; DORSOVENTRAL PATTERN; NERVOUS-SYSTEM; EXPRESSION; PROTEIN; MELANOGASTER; CELLS; NEUROGENESIS	A gradient of the maternal morphogen dorsal establishes asymmetric patterns of gene expression along the dorsal-ventral axis of early embryos and activates the regulatory genes twist and snail, which are responsible for the differentiation of the ventral mesoderm. Expression of snail is restricted to the presumptive mesoderm, and the sharp lateral limits of this expression help to define the mesoderm-neuroectoderm boundary by repressing the expression of regulatory genes that are responsible for the differentiation of the neuroectoderm. The snail gene encodes a zinc finger protein, and neuroectodermal genes that are normally restricted to ventral-lateral regions of early embryos are expressed throughout ventral regions of snail- mutants. The formation of the sharp snail border involves dosage-sensitive interactions between dorsal and twist, which encode regulatory proteins that are related to the mammalian transcription factors NF-kB and MyoD, respectively.			KOSMAN, D (corresponding author), UNIV CALIF SAN DIEGO,CTR MOLEC GENET,DEPT BIOL,LA JOLLA,CA 92093, USA.			Levine, Michael/0000-0001-7629-0081	NIGMS NIH HHS [GM 46638] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046638, R01GM046638] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERGA A, 1991, DEVELOPMENT, V111, P983; ALONSON MC, 1988, EMBO J, V7, P2588; BIER E, 1990, GENE DEV, V4, P190, DOI 10.1101/gad.4.2.190; BOULAY JL, 1987, NATURE, V330, P395, DOI 10.1038/330395a0; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CABRERA CV, 1987, CELL, V50, P425, DOI 10.1016/0092-8674(87)90496-X; CAMPOSORTEGA JA, 1990, EUR J BIOCHEM, V190, P1, DOI 10.1111/j.1432-1033.1990.tb15538.x; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; HAENLIN M, 1990, DEVELOPMENT, V110, P905; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; IP YT, 1991, CELL, V64, P439; KOSMAN D, UNPUB; LEPTIN M, 1991, GENE DEV, V5, P1568, DOI 10.1101/gad.5.9.1568; LEPTIN M, 1990, DEVELOPMENT, V110, P73; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; MAYER U, 1988, GENE DEV, V2, P1496, DOI 10.1101/gad.2.11.1496; MCCLAY DR, 1987, ANNU REV CELL BIOL, V3, P319, DOI 10.1146/annurev.cellbio.3.1.319; MITCHISON TJ, 1983, DEV BIOL, V99, P261, DOI 10.1016/0012-1606(83)90275-0; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAMBU JR, 1990, CELL, V63, P63, DOI 10.1016/0092-8674(90)90288-P; ROMANI S, 1987, EMBO J, V6, P2085, DOI 10.1002/j.1460-2075.1987.tb02474.x; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; Rushlow C, 1990, Semin Cell Biol, V1, P137; SIMPSON P, 1983, GENETICS, V105, P615; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THISSE B, 1987, GENE DEV, V1, P709, DOI 10.1101/gad.1.7.709; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; THOMAS JB, 1988, CELL, V52, P133, DOI 10.1016/0092-8674(88)90537-5; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8	30	205	206	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1991	254	5028					118	122		10.1126/science.1925551	http://dx.doi.org/10.1126/science.1925551			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH605	1925551				2022-12-01	WOS:A1991GH60500043
J	MARTIN, K; HELENIUS, A				MARTIN, K; HELENIUS, A			NUCLEAR TRANSPORT OF INFLUENZA-VIRUS RIBONUCLEOPROTEINS - THE VIRAL MATRIX PROTEIN (M1) PROMOTES EXPORT AND INHIBITS IMPORT	CELL			English	Article							MESSENGER-RNA; A VIRUS; MONOCLONAL-ANTIBODIES; INFECTED-CELLS; MEDIATED TRANSLOCATION; XENOPUS OOCYTES; KINASE-C; NUCLEOPROTEIN; SEQUENCE; BINDING	Because influenza virus replicates in the nucleus and buds from the plasma membrane, its ribonucleoproteins (RNPs) must undergo bidirectional transport across the nuclear membrane. Export from the nucleus to the cytoplasm was found to depend on the viral matrix protein (M1). M1 associated with newly assembled viral RNPs (vRNPs) in the nucleus and escorted them to the cytoplasm through the nuclear pores. In contrast, during entry of the virus into a new host cell, M1 protein dissociated from the RNPs, allowing them to enter the nucleus. Amantadine, an antiviral agent that induces an early block in influenza A infection, was found to block the dissociation event and thereby to prevent import of incoming RNPs into the nucleus. Together, these results showed that M1 modulates the directionality of vRNP transport into and out of the nucleus.	YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA	Yale University	MARTIN, K (corresponding author), YALE UNIV, SCH MED, DEPT MOLEC BIOPHYS & BIOCHEM, NEW HAVEN, CT 06510 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018599, R37AI018599] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18599] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BATAILLE N, 1990, J CELL BIOL, V111, P1571, DOI 10.1083/jcb.111.4.1571; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BRADSHAW GL, 1989, J VIROL, V63, P1704, DOI 10.1128/JVI.63.4.1704-1714.1989; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; BUKRINSKAYA AG, 1982, J GEN VIROL, V60, P49, DOI 10.1099/0022-1317-60-1-49; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHOPPIN PW, 1975, INFLUENZA VIRUSES IN, P15; COMPANS PM, 1975, COMPREHENSIVE VIROLO, P179; COMPANS RW, 1972, J VIROL, V10, P795, DOI 10.1128/JVI.10.4.795-800.1972; DAVEY J, 1985, CELL, V40, P667, DOI 10.1016/0092-8674(85)90215-6; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; DWORETZKY SI, 1988, J CELL BIOL, V106, P575, DOI 10.1083/jcb.106.3.575; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; FLAWITH JWF, 1979, J GEN VIROL, V45, P527, DOI 10.1099/0022-1317-45-2-527; FRANKLIN RM, 1959, VIROLOGY, V8, P293, DOI 10.1016/0042-6822(59)90031-5; Goldfarb DS, 1989, CURR OPIN CELL BIOL, V1, P441, DOI 10.1016/0955-0674(89)90003-3; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HAY AJ, 1985, EMBO J, V4, P3021, DOI 10.1002/j.1460-2075.1985.tb04038.x; HAY AJ, 1975, NEGATIVE STRAND VIRU, P635; HEGGENESS MH, 1982, VIROLOGY, V118, P466, DOI 10.1016/0042-6822(82)90367-1; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HSU MT, 1987, P NATL ACAD SCI USA, V84, P8140, DOI 10.1073/pnas.84.22.8140; INGLIS SC, 1984, J GEN VIROL, V65, P153, DOI 10.1099/0022-1317-65-1-153; JONES IM, 1986, EMBO J, V5, P2371, DOI 10.1002/j.1460-2075.1986.tb04506.x; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KAWAKAMI K, 1983, J BIOCHEM-TOKYO, V93, P989, DOI 10.1093/oxfordjournals.jbchem.a134254; KEMP BE, 1988, METHOD ENZYMOL, V159, P173; KISTNER O, 1989, J GEN VIROL, V70, P2421, DOI 10.1099/0022-1317-70-9-2421; KRUG RM, 1989, INFLUENZA VIRUSES, P89; KUROKAWA M, 1990, J GEN VIROL, V71, P2149, DOI 10.1099/0022-1317-71-9-2149; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamb R.A., 1989, INFLUENZA VIRUSES, P1; LAMB RA, 1985, CELL, V40, P627, DOI 10.1016/0092-8674(85)90211-9; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUBECK MD, 1978, J VIROL, V28, P710, DOI 10.1128/JVI.28.3.710-716.1978; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MANDELL RB, 1990, J CELL BIOL, V111, P1775, DOI 10.1083/jcb.111.5.1775; MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7; MARTIN K, 1991, J VIROL, V65, P232, DOI 10.1128/JVI.65.1.232-244.1991; MATLIN KS, 1981, J CELL BIOL, V91, P601, DOI 10.1083/jcb.91.3.601; MATTAJ IW, 1985, CELL, V40, P111, DOI 10.1016/0092-8674(85)90314-9; MURTI KG, 1988, VIROLOGY, V164, P562, DOI 10.1016/0042-6822(88)90574-0; NATH ST, 1990, MOL CELL BIOL, V10, P4139, DOI 10.1128/MCB.10.8.4139; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; PALESE P, 1977, CELL, V10, P1, DOI 10.1016/0092-8674(77)90133-7; PATTERSON S, 1988, J GEN VIROL, V69, P1859, DOI 10.1099/0022-1317-69-8-1859; REES PJ, 1981, J GEN VIROL, V53, P125, DOI 10.1099/0022-1317-53-1-125; REES PJ, 1982, J GEN VIROL, V59, P403, DOI 10.1099/0022-1317-59-2-403; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIGG RJ, 1989, J GEN VIROL, V70, P2097, DOI 10.1099/0022-1317-70-8-2097; RITCHEY MB, 1977, J VIROL, V21, P1196, DOI 10.1128/JVI.21.3.1196-1204.1977; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; RODRIGUEZBOULAN E, 1983, METHOD ENZYMOL, V98, P486; RUIGROK RWH, 1989, VIROLOGY, V173, P311, DOI 10.1016/0042-6822(89)90248-1; SCHNABEL E, 1989, EUR J CELL BIOL, V48, P313; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SKEHEL JJ, 1971, VIROLOGY, V44, P396, DOI 10.1016/0042-6822(71)90270-4; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SUGRUE RJ, 1990, EMBO J, V9, P3469, DOI 10.1002/j.1460-2075.1990.tb07555.x; SUGRUE RJ, 1991, VIROLOGY, V180, P617, DOI 10.1016/0042-6822(91)90075-M; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; VANWYKE KL, 1980, J VIROL, V35, P24, DOI 10.1128/JVI.35.1.24-30.1980; VANWYKE KL, 1981, J VIROL, V39, P313, DOI 10.1128/JVI.39.1.313-317.1981; WINTER G, 1980, NUCLEIC ACIDS RES, V8, P1965, DOI 10.1093/nar/8.9.1965; WINTER G, 1981, VIROLOGY, V114, P423, DOI 10.1016/0042-6822(81)90223-3; YE ZP, 1989, J VIROL, V63, P3586, DOI 10.1128/JVI.63.9.3586-3594.1989; ZASLOFF M, 1983, P NATL ACAD SCI-BIOL, V80, P6436, DOI 10.1073/pnas.80.21.6436; ZHIRNOV OP, 1990, VIROLOGY, V176, P274, DOI 10.1016/0042-6822(90)90253-N	78	489	509	4	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 4	1991	67	1					117	130		10.1016/0092-8674(91)90576-K	http://dx.doi.org/10.1016/0092-8674(91)90576-K			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1913813				2022-12-01	WOS:A1991GJ32000011
J	MATSUOKA, M; NAGAWA, F; OKAZAKI, K; KINGSBURY, L; YOSHIDA, K; MULLER, U; LARUE, DT; WINER, JA; SAKANO, H				MATSUOKA, M; NAGAWA, F; OKAZAKI, K; KINGSBURY, L; YOSHIDA, K; MULLER, U; LARUE, DT; WINER, JA; SAKANO, H			DETECTION OF SOMATIC DNA RECOMBINATION IN THE TRANSGENIC MOUSE-BRAIN	SCIENCE			English	Article							HEAVY-CHAIN GENES; BETA-ACTIN GENE; NUCLEOTIDE-SEQUENCE; IMMUNE-SYSTEM; IMMUNOGLOBULIN; TRANSCRIPTION; SEGMENTS; ELEMENTS; NUCLEUS; REGION	A DNA construct containing the bacterial beta-galactosidase gene (lacZ) was used to study somatic DNA recombination in the transgenic mouse brain. Recombination-positive areas of the adult brain were stained blue with X-gal, a substrate of beta-galactosidase. Blue-colored cells appeared soon after birth, and continued to emerge in postnatal tissue. Staining was prominent in sensory as opposed to motor regions of the brain, and was present in more than 70 discrete areas of the nervous system. The possibility of DNA rearrangement is discussed with respect to the development of the central nervous system.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV NEUROBIOL,BERKELEY,CA 94720; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,IBARAKI 305,JAPAN; BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND	University of California System; University of California Berkeley; RIKEN	MATSUOKA, M (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV IMMUNOL,BERKELEY,CA 94720, USA.		Okazaki, Kenji/H-4393-2012	Matsuoka, Masao/0000-0002-0473-754X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018790, R01AI018790] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016832] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18790] Funding Source: Medline; NINDS NIH HHS [NS16832] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKIRA S, 1987, SCIENCE, V238, P1134, DOI 10.1126/science.3120312; ALT FW, 1982, P NATL ACAD SCI-BIOL, V79, P4118, DOI 10.1073/pnas.79.13.4118; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; CHUN JJM, 1989, CELL, V59, P189; DREYER WJ, 1965, P NATL ACAD SCI USA, V54, P864, DOI 10.1073/pnas.54.3.864; EARLY P, 1980, CELL, V19, P981, DOI 10.1016/0092-8674(80)90089-6; FREGIEN N, 1986, GENE, V48, P1, DOI 10.1016/0378-1119(86)90346-X; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; HU H, 1986, BRAIN RES, V368, P201, DOI 10.1016/0006-8993(86)91064-4; Jerne N., 1967, NEUROSCIENCES STUDY, P200; KOST TA, 1983, NUCLEIC ACIDS RES, V11, P8287, DOI 10.1093/nar/11.23.8287; LEDOUX JE, 1990, J NEUROSCI, V10, P1062; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Neff WD, 1975, HDB SENSORY PHYSIOLO, P307; PARNES JR, 1987, IMMUNOL REV, V100, P109, DOI 10.1111/j.1600-065X.1987.tb00529.x; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; SAKANO H, 1979, NATURE, V280, P288, DOI 10.1038/280288a0; SAKANO H, 1980, NATURE, V286, P676, DOI 10.1038/286676a0; SAKANO H, 1981, NATURE, V290, P562, DOI 10.1038/290562a0; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; Sarnat H. B., 1981, EVOLUTION NERVOUS SY, V2nd; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854; WHITLOCK CA, 1982, P NATL ACAD SCI-BIOL, V79, P3608, DOI 10.1073/pnas.79.11.3608; WINER JA, 1988, J COMP NEUROL, V274, P422, DOI 10.1002/cne.902740310; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641	26	104	111	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1991	254	5028					81	86		10.1126/science.1925563	http://dx.doi.org/10.1126/science.1925563			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH605	1925563				2022-12-01	WOS:A1991GH60500031
J	MURRELL, J; FARLOW, M; GHETTI, B; BENSON, MD				MURRELL, J; FARLOW, M; GHETTI, B; BENSON, MD			A MUTATION IN THE AMYLOID PRECURSOR PROTEIN ASSOCIATED WITH HEREDITARY ALZHEIMERS-DISEASE	SCIENCE			English	Article							GERSTMANN-STRAUSSLER SYNDROME; PRION PROTEIN; CYSTATIN-C; GENE; INHIBITOR; CDNA; LINKAGE; VARIANT; LOCUS	Alzheimer's disease is a form of localized amyloidosis characterized by cerebral cortical amyloid plaques, neurofibrillary tangles, and amyloid deposits within the walls of leptomeningeal vessels. Although most cases of Alzheimer's disease are sporadic, kindreds with autosomal-dominant inheritance of the syndrome suggest that a single mutation may be important in pathogenesis. Direct sequencing of DNA from a family with autopsy-proven Alzheimer's disease revealed a single amino acid substitution (Phe for Val) in the transmembrane domain of the amyloid precursor protein. This mutation correlates with the presence of Alzheimer's disease in all patients in this study, and may be the inherited factor causing both amyloid fibril formation and dementia.	INDIANA UNIV,SCH MED,DEPT MED,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MED & MOLEC GENET,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT NEUROL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT PATHOL,INDIANAPOLIS,IN 46202; VET AFFAIRS RICHARD L ROUDEBUSH MED CTR,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center					NCRR NIH HHS [RR-00750] Funding Source: Medline; NIA NIH HHS [U24 AG021886] Funding Source: Medline; PHS HHS [34881, 42111] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [U24AG021886] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Benson MD, 1989, METABOLIC BASIS INHE, P2439; CHRISTMANSON L, 1990, AMYLOID AMYLOIDOSIS, P635; DOHURA K, 1989, BIOCHEM BIOPH RES CO, V163, P974, DOI 10.1016/0006-291X(89)92317-6; GHISO J, 1986, P NATL ACAD SCI USA, V83, P2974, DOI 10.1073/pnas.83.9.2974; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1990, BIOCHIM BIOPHYS ACTA, V1038, P105, DOI 10.1016/0167-4838(90)90017-A; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; LEMAIRE HG, 1989, NUCLEIC ACIDS RES, V17, P517, DOI 10.1093/nar/17.2.517; LEVY E, 1989, J EXP MED, V169, P1771, DOI 10.1084/jem.169.5.1771; MURRELL JN, UNPUB; NARUSE S, 1991, LANCET, V337, P978, DOI 10.1016/0140-6736(91)91612-X; NICHOLS WC, 1990, GENOMICS, V8, P318, DOI 10.1016/0888-7543(90)90288-6; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; SCHELLENBERG GD, 1991, AM J HUM GENET, V48, P563; TAGLIAVINI F, 1991, EMBO J, V10, P513, DOI 10.1002/j.1460-2075.1991.tb07977.x; TANZI RE, 1987, NATURE, V329, P156, DOI 10.1038/329156a0; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VAN BROECKHOVEN C, 1987, NATURE, V329, P153; VITEK MP, 1988, MOL BRAIN RES, V4, P121, DOI 10.1016/0169-328X(88)90004-6; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N	28	988	1089	0	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1991	254	5028					97	99		10.1126/science.1925564	http://dx.doi.org/10.1126/science.1925564			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH605	1925564				2022-12-01	WOS:A1991GH60500036
J	NUMANN, R; CATTERALL, WA; SCHEUER, T				NUMANN, R; CATTERALL, WA; SCHEUER, T			FUNCTIONAL MODULATION OF BRAIN SODIUM-CHANNELS BY PROTEIN-KINASE-C PHOSPHORYLATION	SCIENCE			English	Article							RAT-BRAIN; ALPHA-SUBUNIT; GATING PROPERTIES; CLONED CDNA; EXPRESSION; NA+; ACTIVATION; INHIBITION; CELLS	Voltage-gated sodium channels, which are responsible for the generation of action potentials in the brain, are phosphorylated by protein kinase C (PKC) in purified form. Activation of PKC decreases peak sodium current up to 80 percent and slows its inactivation for sodium channels in rat brain neurons and for rat brain type IIA sodium channel alpha-subunits heterologously expressed in Chinese hamster ovary cells. These effects are specific for PKC because they can be blocked by specific peptide inhibitors of PKC and can be reproduced by direct application of PKC to the cytoplasmic surface of sodium channels in excised inside-out membrane patches. Modulation of brain sodium channels by PKC is likely to have important effects on signal transduction and synaptic transmission in the central nervous system.	UNIV WASHINGTON,DEPT PHARMACOL,SJ-30,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025704, R01NS015751] Funding Source: NIH RePORTER; NINDS NIH HHS [NS25704, NS15751] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AULD VJ, 1990, P NATL ACAD SCI USA, V87, P323, DOI 10.1073/pnas.87.1.323; AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG HC, 1985, BIOCHEM J, V231, P655, DOI 10.1042/bj2310655; CHENG HC, 1986, J BIOL CHEM, V261, P989; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; COSTA MRC, 1984, CELL MOL NEUROBIOL, V4, P291, DOI 10.1007/BF00733592; DASCAL N, 1991, NEURON, V6, P165, DOI 10.1016/0896-6273(91)90131-I; GOLDIN AL, 1986, P NATL ACAD SCI USA, V83, P7503, DOI 10.1073/pnas.83.19.7503; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOCKBERGER P, 1989, NATURE, V338, P340, DOI 10.1038/338340a0; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; KACZMAREK LK, 1987, TRENDS NEUROSCI, V10, P30, DOI 10.1016/0166-2236(87)90122-6; KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; RANE SG, 1989, NEURON, V3, P239, DOI 10.1016/0896-6273(89)90037-8; SCHEUER T, 1990, SCIENCE, V247, P854, DOI 10.1126/science.2154850; SCHEUER T, 1991, Biophysical Journal, V59, p262A; SCHMIDT JW, 1987, J BIOL CHEM, V262, P13713; SHEARMAN MS, 1989, PHARMACOL REV, V41, P211; SIGEL E, 1988, P NATL ACAD SCI USA, V85, P6192, DOI 10.1073/pnas.85.16.6192; SUZUKI H, 1988, FEBS LETT, V228, P195, DOI 10.1016/0014-5793(88)80615-X; VASSILEV P, 1989, P NATL ACAD SCI USA, V86, P8147, DOI 10.1073/pnas.86.20.8147; WESTENBROEK RE, 1989, NEURON, V3, P695, DOI 10.1016/0896-6273(89)90238-9; WESTENBROEK RE, UNPUB; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836	28	284	287	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1991	254	5028					115	118		10.1126/science.1656525	http://dx.doi.org/10.1126/science.1656525			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH605	1656525				2022-12-01	WOS:A1991GH60500042
J	ROMAN, C; COHN, L; CALAME, K				ROMAN, C; COHN, L; CALAME, K			A DOMINANT NEGATIVE FORM OF TRANSCRIPTION ACTIVATOR MTFE3 CREATED BY DIFFERENTIAL SPLICING	SCIENCE			English	Article							LOOP-HELIX PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING; DNA-BINDING; THYROID-HORMONE; MESSENGER-RNA; DOMAIN; CELLS; EXTRAMACROCHAETAE; DIMERIZATION; DROSOPHILA	Transcription factor E3 (mTFE3) is a murine transcription activator that binds to the intronic enhancer of the immunoglobulin heavy chain gene. A naturally occurring splice product of mTFE3 messenger RNA (mRNA) lacked 105 nucleotides that encode an activation domain; both absolute and relative amounts of long and truncated mRNAs varied in different tissues. Cells were cotransfected with complementary DNAs that encoded the two mRNA forms in amounts that corresponded to the amounts of each mRNA found in different cells. Small changes in substoichiometric amounts of the truncated form of mRNA effected trans-dominant negative modulation of mTFE3 activity. These findings identify a function for differential splicing in the regulation of transcription factor activity.	UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90024; COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MOLEC BIOPHYS,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	University of California System; University of California Los Angeles; Columbia University; Columbia University; Columbia University; Columbia University					NCI NIH HHS [R01CA38571] Funding Source: Medline; NIGMS NIH HHS [R01GM28361] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038571] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CHO KWY, 1988, EMBO J, V7, P2139, DOI 10.1002/j.1460-2075.1988.tb03053.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HUBBERT NL, 1988, P NATL ACAD SCI USA, V85, P5864, DOI 10.1073/pnas.85.16.5864; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KILEDJIAN M, 1990, NUCLEIC ACIDS RES, V18, P957, DOI 10.1093/nar/18.4.957; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LAMBERT PF, 1987, CELL, V50, P69, DOI 10.1016/0092-8674(87)90663-5; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MERCOLA M, 1985, SCIENCE, V227, P266, DOI 10.1126/science.3917575; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; PETERSON CL, 1989, MOL CELL BIOL, V9, P776, DOI 10.1128/MCB.9.2.776; RAMAKRISHNAN L, 1988, MOL CELL BIOL, V8, P5216, DOI 10.1128/MCB.8.12.5216; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; Roman C., UNPUB; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WRIGHT CVE, 1989, CELL, V59, P81, DOI 10.1016/0092-8674(89)90871-4; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077	33	115	117	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1991	254	5028					94	97		10.1126/science.1840705	http://dx.doi.org/10.1126/science.1840705			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH605	1840705				2022-12-01	WOS:A1991GH60500035
J	SOMMER, B; KOHLER, M; SPRENGEL, R; SEEBURG, PH				SOMMER, B; KOHLER, M; SPRENGEL, R; SEEBURG, PH			RNA EDITING IN BRAIN CONTROLS A DETERMINANT OF ION FLOW IN GLUTAMATE-GATED CHANNELS	CELL			English	Article							B MESSENGER-RNA; ACID RECEPTOR CHANNELS; FUNCTIONAL EXPRESSION; NERVOUS-SYSTEM; DNA; CLONING; RAT; MITOCHONDRIA; SUBUNIT; NEURONS	L-glutamate, the principal excitatory transmitter in the brain, gates ion channels mediating fast neurotrans-mission. Subunit components of two related classes of glutamate receptor channels have been characterized by cDNA cloning and shown to carry either an arginine or a glutamine residue in a defined position of their putative channel-forming segment. The arginine residue in this segment profoundly alters, and dominates, the properties of ion flow, as demonstrated for one channel class. We now show that the genomic DNA sequences encoding the particular channel segment of all subunits harbor a glutamine codon (CAG), even though an arginine codon (CGG) is found in mRNAs of three subunits. Multiple genes and alternative exons were excluded as sources for the arginine codon; hence, we propose that transcripts for three subunits are altered by RNA editing. This process apparently edits subunit transcripts of the two glutamate receptor classes with different efficiency and selectivity.			SOMMER, B (corresponding author), UNIV HEIDELBERG, CTR MOLEC BIOL, MOLEC NEUROENDOCRINOL LAB, NEUENHEIMER FELD 282, W-6900 HEIDELBERG, GERMANY.							BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; CATTANEO R, 1991, ANNU REV GENET, V25, P71, DOI 10.1146/annurev.ge.25.120191.000443; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; COVELLO PS, 1989, NATURE, V341, P662, DOI 10.1038/341662a0; DRISCOLL DM, 1989, CELL, V58, P519, DOI 10.1016/0092-8674(89)90432-7; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; GREEVE J, 1991, NUCLEIC ACIDS RES, V19, P3569, DOI 10.1093/nar/19.13.3569; HERRMANN BG, 1987, METHOD ENZYMOL, V152, P180; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; JONAS P, 1991, IN PRESS J PHYSL; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KENNEDY MB, 1989, CELL, V59, P777, DOI 10.1016/0092-8674(89)90601-6; KLEINSCHMIDT A, 1987, SCIENCE, V238, P355, DOI 10.1126/science.2443978; LUO GX, 1990, J VIROL, V64, P1021, DOI 10.1128/JVI.64.3.1021-1027.1990; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MAYER ML, 1990, TRENDS PHARMACOL SCI, V11, P254, DOI 10.1016/0165-6147(90)90254-6; MONAGHAN DT, 1982, BRAIN RES, V252, P91, DOI 10.1016/0006-8993(82)90981-7; MONYER H, 1991, NEURON, V6, P799, DOI 10.1016/0896-6273(91)90176-Z; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; NAVARATNAM N, 1991, NUCLEIC ACIDS RES, V19, P1741, DOI 10.1093/nar/19.8.1741; Olney J W, 1986, Adv Exp Med Biol, V203, P631; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; SAKIMURA K, 1990, FEBS LETT, V272, P73, DOI 10.1016/0014-5793(90)80452-O; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOMMER B, 1990, DNA CELL BIOL, V9, P561, DOI 10.1089/dna.1990.9.561; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; SPENCER PS, 1987, SCIENCE, V237, P517, DOI 10.1126/science.3603037; TENG BB, 1990, J BIOL CHEM, V265, P20616; VEWRYVERDOORN TA, 1991, SCIENCE, V252, P1715; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; WU JH, 1990, J BIOL CHEM, V265, P12312; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	46	1185	1222	0	51	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 4	1991	67	1					11	19		10.1016/0092-8674(91)90568-J	http://dx.doi.org/10.1016/0092-8674(91)90568-J			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1717158				2022-12-01	WOS:A1991GJ32000003
J	STEIMER, KS; SCANDELLA, CJ; SKILES, PV; HAIGWOOD, NL				STEIMER, KS; SCANDELLA, CJ; SKILES, PV; HAIGWOOD, NL			NEUTRALIZATION OF DIVERGENT HIV-1 ISOLATES BY CONFORMATION-DEPENDENT HUMAN-ANTIBODIES TO GP120	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ENVELOPE GLYCOPROTEIN; HTLV-III/LAV; CD4 RECEPTOR; CHIMPANZEES; INFECTION; IDENTIFICATION; DETERMINANT; RETROVIRUS; SEQUENCE	The spectrum of human immunodeficiency virus type 1 (HIV-1) isolates neutralized by antibodies from HIV-1-infected humans is broader than the spectrum of isolates neutralized by sera from animals immunized with purified gp120 subunits. This broader neutralization was due, in part, to the presence of antibodies to conserved gp120 conformational epitopes. Purified conformation-dependent gp120-specific human antibodies neutralized a wider range of virus isolates than human antibodies directed to linear determinants in gp120 and were also responsible for the majority of the gp120-specific CD4-blocking activity of HIV-1-infected human sera. A gp120 subunit vaccine that effectively presents these conformation-dependent neutralization epitopes should protect against a broader range of HIV-1 variants than a vaccine that presents exclusively linear determinants.			STEIMER, KS (corresponding author), CHIRON CORP,EMERYVILLE,CA 94608, USA.		Haigwood, Nancy Logan/AAV-7484-2020	Haigwood, Nancy/0000-0002-1477-9575				ARTHUR LO, 1987, P NATL ACAD SCI USA, V84, P8583, DOI 10.1073/pnas.84.23.8583; BARR PJ, 1987, VACCINE, V5, P90, DOI 10.1016/0264-410X(87)90053-3; BARR PJ, 1987, S MOL CELLULAR BIOL, V43, P205; BERKOWER I, 1989, J EXP MED, V170, P1681, DOI 10.1084/jem.170.5.1681; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; CHAPMAN BS, 1991, NUCLEIC ACIDS RES, V19, P3979, DOI 10.1093/nar/19.14.3979; CHENGMAYER C, 1988, P NATL ACAD SCI USA, V85, P2815, DOI 10.1073/pnas.85.8.2815; GARVEY JS, 1977, METHOD IMMUNOL, P218; GOUDSMIT J, 1989, AIDS, V3, pS119, DOI 10.1097/00002030-198901001-00017; HAIGWOOD NL, 1991, VACCINES, V91, P51; HAIGWOOD NL, 1990, VACCINES, V90, P31; HO DD, 1987, J VIROL, V61, P2024, DOI 10.1128/JVI.61.6.2024-2028.1987; HO DD, 1991, J VIROL, V65, P489, DOI 10.1128/JVI.65.1.489-493.1991; JAVAHERIAN K, 1990, SCIENCE, V250, P1590, DOI 10.1126/science.1703322; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; LASKY LA, 1986, SCIENCE, V233, P209, DOI 10.1126/science.3014647; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563; MCDOUGAL JS, 1986, J IMMUNOL, V137, P2937; Means G.E., 1971, CHEM MODIFICATION PR; MYERS G, 1990, HUMAN RETROVIRUSES A; NARA PL, 1988, J VIROL, V62, P2622, DOI 10.1128/JVI.62.8.2622-2628.1988; NARA PL, 1990, J VIROL, V64, P3779, DOI 10.1128/JVI.64.8.3779-3791.1990; OLSHEVSKY U, 1990, J VIROL, V64, P5701, DOI 10.1128/JVI.64.12.5701-5707.1990; PRINCE AM, 1987, J INFECT DIS, V156, P268, DOI 10.1093/infdis/156.2.268; PROFY AT, 1990, J IMMUNOL, V144, P4641; PUTNEY SD, 1986, SCIENCE, V234, P1392, DOI 10.1126/science.2431482; PYLE SW, 1989, VACCINE, V7, P465, DOI 10.1016/0264-410X(89)90164-3; ROBEY WG, 1986, P NATL ACAD SCI USA, V83, P7023, DOI 10.1073/pnas.83.18.7023; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SARIN PS, 1986, SCIENCE, V232, P1135, DOI 10.1126/science.3010464; SCANDELLA CJ, UNPUB; STEIMER KS, 1988, VACCINES, V88, P347; STEIMER KS, 1987, VACCINES, V87, P236; STEIMER KS, IN PRESS AIDS RES RE, V2; WEISS RA, 1986, NATURE, V324, P572, DOI 10.1038/324572a0	36	253	259	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1991	254	5028					105	108		10.1126/science.1718036	http://dx.doi.org/10.1126/science.1718036			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH605	1718036				2022-12-01	WOS:A1991GH60500039
J	STEWART, PL; BURNETT, RM; CYRKLAFF, M; FULLER, SD				STEWART, PL; BURNETT, RM; CYRKLAFF, M; FULLER, SD			IMAGE-RECONSTRUCTION REVEALS THE COMPLEX MOLECULAR-ORGANIZATION OF ADENOVIRUS	CELL			English	Article							CRYO-ELECTRON MICROSCOPY; 3-DIMENSIONAL STRUCTURE; SPHERICAL VIRUSES; POLYPEPTIDE-IX; HEXON; MICROGRAPHS; CHROMATIN; TYPE-2; CORE; VISUALIZATION	The three-dimensional structure of adenovirus has been determined by image reconstruction from cryoelectron micrographs. Comparison with the high resolution X-ray crystal structure of hexon, the major capsid protein, enabled an unusually detailed interpretation of the density map and confirmed the validity of the reconstruction. The hexon packing in the capsid shows more extensive intermolecular interfaces between facets than previously proposed. The reconstruction provides the first three-dimensional visualization of the vertex proteins, including the penton base and its associated protruding fiber. Three minor capsid proteins that stabilize and modulate capsomer interactions are revealed. One of these components stabilizes the group-of-nine hexons in the center of each facet and the other two bridge hexons in adjacent facets. The strategic positions of these proteins highlight the importance of cementing proteins in stabilizing a complex assembly.	EUROPEAN MOLEC BIOL LAB,BIOL STRUCT & BIOCOMP PROGRAMME,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)	STEWART, PL (corresponding author), WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104, USA.				NCI NIH HHS [CA 10815, 2T32 CA 09171-13] Funding Source: Medline; NIAID NIH HHS [AI 17270] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA010815, T32CA009171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017270] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADRIAN M, 1984, NATURE, V308, P32, DOI 10.1038/308032a0; ANDERSON CW, 1990, VIROLOGY, V177, P259, DOI 10.1016/0042-6822(90)90479-B; BAKER TS, 1988, P NATL ACAD SCI USA, V85, P422, DOI 10.1073/pnas.85.2.422; BROWN DT, 1975, J VIROL, V16, P366, DOI 10.1128/JVI.16.2.366-387.1975; BURNETT RM, 1990, USE OF X-RAY CRYSTALLOGRAPHY IN THE DESIGN OF ANTIVIRAL AGENTS, P35; BURNETT RM, 1985, J MOL BIOL, V185, P125, DOI 10.1016/0022-2836(85)90187-1; COLBY WW, 1981, J VIROL, V39, P977, DOI 10.1128/JVI.39.3.977-980.1981; CORDEN J, 1976, P NATL ACAD SCI USA, V73, P401, DOI 10.1073/pnas.73.2.401; CROWTHER RA, 1971, PHILOS T R SOC B, V261, P221, DOI 10.1098/rstb.1971.0054; EVERITT E, 1975, VIROLOGY, V67, P197, DOI 10.1016/0042-6822(75)90417-1; FULLER SD, 1987, CELL, V48, P923, DOI 10.1016/0092-8674(87)90701-X; FURCINITTI PS, 1989, EMBO J, V8, P3563, DOI 10.1002/j.1460-2075.1989.tb08528.x; GREEN NM, 1983, EMBO J, V2, P1357, DOI 10.1002/j.1460-2075.1983.tb01592.x; HOMO JC, 1984, J MICROSC-OXFORD, V136, P337, DOI 10.1111/j.1365-2818.1984.tb00543.x; JENG TW, 1989, J MOL BIOL, V205, P251, DOI 10.1016/0022-2836(89)90379-3; LAVER WG, 1969, VIROLOGY, V39, P599, DOI 10.1016/0042-6822(69)90111-1; MIRZA MA, 1982, BIOCHIM BIOPHYS ACTA, V696, P76, DOI 10.1016/0167-4781(82)90012-4; NERMUT MV, 1984, ADENOVIRUSES, P5; NEWCOMB WW, 1984, J VIROL, V51, P52, DOI 10.1128/JVI.51.1.52-56.1984; PEREIRA HG, 1974, J MOL BIOL, V85, P617, DOI 10.1016/0022-2836(74)90319-2; PHILIPSON L, 1983, CURR TOP MICROBIOL, V109, P1; PHILIPSON L, 1968, J VIROL, V2, P1064, DOI 10.1128/JVI.2.10.1064-1075.1968; PRASAD BVV, 1988, J MOL BIOL, V199, P269, DOI 10.1016/0022-2836(88)90313-0; ROBERTS MM, 1986, SCIENCE, V232, P1148, DOI 10.1126/science.3704642; ROBERTS RJ, 1984, J BIOL CHEM, V259, P3968; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; ROWE WP, 1953, P SOC EXP BIOL MED, V84, P570, DOI 10.3181/00379727-84-20714; RUIGROK RWH, 1990, J MOL BIOL, V215, P589, DOI 10.1016/S0022-2836(05)80170-6; RUSSELL WC, 1982, J GEN VIROL, V63, P69, DOI 10.1099/0022-1317-63-1-69; SCHRAG JD, 1989, CELL, V56, P651, DOI 10.1016/0092-8674(89)90587-4; STEWART PL, 1990, SEMIN VIROL, V1, P477; TATE VE, 1979, NUCLEIC ACIDS RES, V6, P2769, DOI 10.1093/nar/6.8.2769; TORBET J, 1983, EMBO J, V2, P63, DOI 10.1002/j.1460-2075.1983.tb01381.x; VANOOSTRUM J, 1987, J MOL BIOL, V198, P73, DOI 10.1016/0022-2836(87)90459-1; VANOOSTRUM J, 1985, J VIROL, V56, P439, DOI 10.1128/JVI.56.2.439-448.1985; VOGEL RH, 1986, NATURE, V320, P533, DOI 10.1038/320533a0	36	238	245	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1991	67	1					145	154		10.1016/0092-8674(91)90578-M	http://dx.doi.org/10.1016/0092-8674(91)90578-M			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1913814				2022-12-01	WOS:A1991GJ32000013
J	TAMPE, R; CLARK, BR; MCCONNELL, HM				TAMPE, R; CLARK, BR; MCCONNELL, HM			ENERGY-TRANSFER BETWEEN 2 PEPTIDES BOUND TO ONE MHC CLASS-II MOLECULE	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; ANTIGEN; RECOGNITION	The 17-amino acid peptide from chicken ovalbumin, Ova(323-339), was labeled at the amino terminus with fluorescein [FOva(323-339)] and near the carboxyl terminus with Texas Red [AcOva(323-338)KTR]. Fluorescence spectroscopy was carried out on resolved electrophoretic bands on nonreducing polyacrylamide gels derived from incubation mixtures containing major histocompatibility complex (MHC) class II molecules IA(d) and the FOva(323-339)- and AcOva(323-338)KTR-labeled peptides. Energy transfer between fluorescein and Texas Red was observed in the "floppy" alpha-beta heterodimer band, but not in the "compact" alpha-beta heterodimer band. Energy transfer was detected between the truncated peptides FOva(323-328)CONH2 and AcOva(331-338)KTR in both the compact alpha-beta and floppy alpha-beta gel bands. The energy-transfer data suggest that the two binding sites of floppy alpha-beta arise from splitting apart a putative large, single binding site region in compact alpha-beta.	ANERGEN INC,REDWOOD CITY,CA 94063		TAMPE, R (corresponding author), STANFORD UNIV,STAUFFER LAB PHYS CHEM,STANFORD,CA 94305, USA.		Tampé, Robert/H-2953-2015	Tampé, Robert/0000-0002-0403-2160	NIAID NIH HHS [2R37 AI 13587-16] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI013587] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BHAYANI H, 1989, J EXP MED, V170, P1609, DOI 10.1084/jem.170.5.1609; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; DORMAIR K, 1990, P NATL ACAD SCI USA, V87, P4143; DORNMAIR K, UNPUB; DORNMAIR K, 1990, COLD SPRING HARB SYM, V54, P409; FOSTER T, 1946, NATURWISSENSCHAFTEN, V6, P166; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OHNO S, 1991, P NATL ACAD SCI USA, V88, P3065, DOI 10.1073/pnas.88.8.3065; PEDRAZZINI T, 1991, J IMMUNOL, V146, P3496; PERUTZ MF, 1972, NATURE, V237, P495, DOI 10.1038/237495a0; ROTHBARD JB, 1991, ANNU REV IMMUNOL, V9, P527, DOI 10.1146/annurev.iy.09.040191.002523; ROTHENHAUSLER B, 1990, P NATL ACAD SCI USA, V87, P352, DOI 10.1073/pnas.87.1.352; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SETTE A, 1987, NATURE, V328, P395, DOI 10.1038/328395a0; TAMPE R, 1991, P NATL ACAD SCI USA, V88, P4661, DOI 10.1073/pnas.88.11.4661; TAMPE R, UNPUB	17	40	42	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1991	254	5028					87	89		10.1126/science.1656526	http://dx.doi.org/10.1126/science.1656526			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH605	1656526				2022-12-01	WOS:A1991GH60500032
J	THRON, CD				THRON, CD			MATHEMATICAL-ANALYSIS OF A MODEL OF THE MITOTIC CLOCK	SCIENCE			English	Article											THRON, CD (corresponding author), DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT PHARMACOL & TOXICOL,HANOVER,NH 03756, USA.							HIGGINS J, 1967, IND ENG CHEM, V59, P18, DOI 10.1021/ie50689a006; NOREL R, 1991, SCIENCE, V251, P1076, DOI 10.1126/science.1825521	2	20	20	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1991	254	5028					122	123		10.1126/science.1833817	http://dx.doi.org/10.1126/science.1833817			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH605	1833817				2022-12-01	WOS:A1991GH60500044
J	WEISS, DS; BATUT, J; KLOSE, KE; KEENER, J; KUSTU, S				WEISS, DS; BATUT, J; KLOSE, KE; KEENER, J; KUSTU, S			THE PHOSPHORYLATED FORM OF THE ENHANCER-BINDING PROTEIN NTRC HAS AN ATPASE ACTIVITY THAT IS ESSENTIAL FOR ACTIVATION OF TRANSCRIPTION	CELL			English	Article							RNA POLYMERASE-II; NITROGEN REGULATOR-I; ESCHERICHIA-COLI; KLEBSIELLA-PNEUMONIAE; INVITRO TRANSCRIPTION; GENE-TRANSCRIPTION; GLNA TRANSCRIPTION; ENTERIC BACTERIA; PLASMID VECTORS; LATE PROMOTER	The NTRC protein of enteric bacteria is an enhancer-binding protein that activates transcription in response to limitation of combined nitrogen. NTRC activates transcription by catalyzing formation of open complexes by RNA polymerase (sigma-54 holoenzyme form) in an ATP-dependent reaction. To catalyze open complex formation, NTRC must be phosphorylated. We show that phosphorylated NTRC has an ATPase activity, and we present biochemical and genetic evidence that NTRC must hydrolyze ATP to catalyze open complex formation. It is likely that all activators of sigma-54 holo-enzyme have an ATPase activity.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	WEISS, DS (corresponding author), UNIV CALIF BERKELEY,DEPT PLANT PATHOL,BERKELEY,CA 94720, USA.		BATUT, Jacques/B-6506-2008		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038361, R37GM038361] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38361] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBRIGHT LM, 1989, ANNU REV GENET, V23, P311, DOI 10.1146/annurev.ge.23.120189.001523; BIEKER JJ, 1986, J BIOL CHEM, V261, P9732; BIEKER JJ, 1985, CELL, V40, P119, DOI 10.1016/0092-8674(85)90315-0; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; BROYLES SS, 1988, J BIOL CHEM, V263, P10761; BUIKEMA WJ, 1985, NUCLEIC ACIDS RES, V13, P4539, DOI 10.1093/nar/13.12.4539; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; Corbin J D, 1974, Methods Enzymol, V38, P287; DEAKIN H, 1963, BIOCHEM J, V89, P296, DOI 10.1042/bj0890296; DRUMMOND M, 1986, EMBO J, V5, P441, DOI 10.1002/j.1460-2075.1986.tb04230.x; DRUMMOND MH, 1990, MOL MICROBIOL, V4, P29, DOI 10.1111/j.1365-2958.1990.tb02012.x; EBERZ G, 1991, J BACTERIOL, V173, P1845, DOI 10.1128/jb.173.6.1845-1854.1991; ELLIOTT T, 1984, CELL, V36, P211, DOI 10.1016/0092-8674(84)90091-6; GRIMM C, 1989, J BACTERIOL, V171, P5031, DOI 10.1128/jb.171.9.5031-5038.1989; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; HERENDEEN DR, 1990, SCIENCE, V248, P573, DOI 10.1126/science.2185541; HIRSCHMAN J, 1985, P NATL ACAD SCI USA, V82, P7525, DOI 10.1073/pnas.82.22.7525; INOUYE S, 1988, GENE, V66, P301; KASSAVETIS GA, 1983, CELL, V33, P887, DOI 10.1016/0092-8674(83)90031-4; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; KOFOID EC, 1988, P NATL ACAD SCI USA, V85, P4981, DOI 10.1073/pnas.85.14.4981; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; LUSE DS, 1987, J BIOL CHEM, V262, P14990; MAUPIN JA, 1990, J BACTERIOL, V172, P4798, DOI 10.1128/jb.172.9.4798-4806.1990; MINCHIN SD, 1988, MOL MICROBIOL, V2, P433, DOI 10.1111/j.1365-2958.1988.tb00049.x; MINTON AP, 1983, MOL CELL BIOCHEM, V55, P119, DOI 10.1007/BF00673707; MOTT JE, 1985, P NATL ACAD SCI USA, V82, P88, DOI 10.1073/pnas.82.1.88; NARASIMHAN N, 1987, P NATL ACAD SCI USA, V84, P4078, DOI 10.1073/pnas.84.12.4078; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; NIXON BT, 1986, P NATL ACAD SCI USA, V83, P7850, DOI 10.1073/pnas.83.20.7850; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; RAMAKRISHNAN G, 1990, P NATL ACAD SCI USA, V87, P2369, DOI 10.1073/pnas.87.6.2369; REITZER LJ, 1985, P NATL ACAD SCI USA, V82, P1979, DOI 10.1073/pnas.82.7.1979; REITZER LJ, 1989, J BACTERIOL, V171, P5512, DOI 10.1128/jb.171.10.5512-5522.1989; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; REMAUT E, 1981, GENE, V15, P81, DOI 10.1016/0378-1119(81)90106-2; RICHET E, 1989, EMBO J, V8, P981, DOI 10.1002/j.1460-2075.1989.tb03461.x; RONSON CW, 1987, NUCLEIC ACIDS RES, V15, P7921, DOI 10.1093/nar/15.19.7921; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCHLENSOG V, 1990, MOL MICROBIOL, V4, P1319, DOI 10.1111/j.1365-2958.1990.tb00711.x; SHUMAN S, 1980, J BIOL CHEM, V255, P5396; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; TABOR S, 1990, CURRENT PROTOCOLS MO; THONY B, 1989, FEMS MICROBIOL LETT, V63, P341; VOS JC, 1991, CELL, V65, P105, DOI 10.1016/0092-8674(91)90412-R; WEDEL A, 1990, SCIENCE, V248, P486, DOI 10.1126/science.1970441; WEGLENSKI P, 1989, J BACTERIOL, V171, P4479, DOI 10.1128/JB.171.8.4479-4485.1989; WEI GR, 1981, MOL GEN GENET, V183, P392, DOI 10.1007/BF00270646; WEISS DS, 1991, P NATL ACAD SCI USA, V85, P8923; WONG PK, 1987, J BACTERIOL, V169, P2876, DOI 10.1128/jb.169.6.2876-2880.1987; WOZNIAK DJ, 1991, J BACTERIOL, V173, P1406, DOI 10.1128/jb.173.4.1406-1413.1991	56	296	298	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1991	67	1					155	167		10.1016/0092-8674(91)90579-N	http://dx.doi.org/10.1016/0092-8674(91)90579-N			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1833069				2022-12-01	WOS:A1991GJ32000014
J	BONHOEFFER, T; GRINVALD, A				BONHOEFFER, T; GRINVALD, A			ISO-ORIENTATION DOMAINS IN CAT VISUAL-CORTEX ARE ARRANGED IN PINWHEEL-LIKE PATTERNS	NATURE			English	Article							MONKEY STRIATE CORTEX; FUNCTIONAL ARCHITECTURE; INTRINSIC SIGNALS; ORGANIZATION; COLUMNS; GEOMETRY	THE mammalian cortex is organized in a columnar fashion: neurons lying below each other from the pia to the white matter usually share many functional properties. Across the cortical surface, cells with similar response properties are also clustered together, forming elongated bands or patches. Some response properties, such as orientation preference in the visual cortex, change gradually across the cortical surface forming 'orientation maps'. To determine the precise layout of iso-orientation domains, knowledge of responses not only to one but to many stimulus orientations is essential. Therefore, the exact depiction of orientation maps has been hampered by technical difficulties and remained controversial for almost thirty years. Here we use in vivo optical imaging based on intrinsic signals to gather information on the responses of a piece of cortex to gratings in many different orientations. This complete set of responses then provides detailed information on the structure of the orientation map in a large patch of cortex from area 18 of the cat. We find that cortical regions that respond best to one orientation form highly ordered patches rather than elongated bands. These iso-orientation patches are organized around 'orientation centres', producing pinwheel-like patterns in which the orientation preference of cells is changing continuously across the cortex. We have also analysed our data for fast changes in orientation preference and find that these 'fractures' are limited to the orientation centres. The pinwheels and orientation centres are such a prominent organizational feature that it should be important to understand their development as well as their function in the processing of visual information.	ROCKEFELLER UNIV,NEUROBIOL LAB,NEW YORK,NY 10021; IBM CORP,DIV RES,YORKTOWN HTS,NY 10598; WEIZMANN INST SCI,IL-76100 REHOVOT,ISRAEL	Rockefeller University; International Business Machines (IBM); Weizmann Institute of Science			Bonhoeffer, Tobias/B-9481-2009	Bonhoeffer, Tobias/0000-0001-7897-6634				Batschelet E, 1981, CIRCULAR STAT BIOL; BLASDEL GG, 1986, NATURE, V321, P579, DOI 10.1038/321579a0; BRAITENBERG V, 1979, BIOL CYBERN, V33, P179, DOI 10.1007/BF00337296; DURBIN R, 1990, NATURE, V343, P644, DOI 10.1038/343644a0; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; GOTZ KG, 1987, BIOL CYBERN, V56, P107, DOI 10.1007/BF00317985; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; HUBEL DH, 1978, J COMP NEUROL, V177, P361, DOI 10.1002/cne.901770302; HUBEL DH, 1974, J COMP NEUROL, V158, P267, DOI 10.1002/cne.901580304; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; LINSKER R, 1986, P NATL ACAD SCI USA, V83, P8779, DOI 10.1073/pnas.83.22.8779; LOWEL S, 1987, J COMP NEUROL, V255, P401, DOI 10.1002/cne.902550307; OBERMAYER K, 1990, P NATL ACAD SCI USA, V90, P8245; RATZLAFF EH, 1991, J NEUROSCI METH, V36, P127, DOI 10.1016/0165-0270(91)90038-2; SWINDALE NV, 1982, PROC R SOC SER B-BIO, V215, P211, DOI 10.1098/rspb.1982.0038; SWINDALE NV, 1987, J NEUROSCI, V7, P1414; TSO DY, 1990, SCIENCE, V249, P417, DOI 10.1126/science.2165630; von Seelen W, 1970, Kybernetik, V7, P89	18	630	638	1	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1991	353	6343					429	431		10.1038/353429a0	http://dx.doi.org/10.1038/353429a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH606	1896085				2022-12-01	WOS:A1991GH60600056
J	GYOEVA, FK; GELFAND, VI				GYOEVA, FK; GELFAND, VI			COALIGNMENT OF VIMENTIN INTERMEDIATE FILAMENTS WITH MICROTUBULES DEPENDS ON KINESIN	NATURE			English	Article							MONOCLONAL-ANTIBODY; MICRO-INJECTION; COLLAPSE; CELLS; MOVEMENT; TUBULIN	INTERMEDIATE filaments in most types of cultured cells coalign with microtubules. Depolymerization of microtubules results in collapse of vimentin and desmin intermediate filaments to the nucleus where they form a perinuclear cap (reviewed in ref. 1). Collapse can also be induced by microinjection of antibodies against intermediate filament or microtubule proteins 2-7. Thus, two filament systems interact with each other. But the molecules mediating this interaction are unknown. One of the candidates for this role is a microtubule motor kinesin 8. Recent data showed that kinesin is involved in the plus end-directed movement of the membranous organelles along microtubules such as radial extension of lysosomes in macrophages 9 and centrifugal movement of pigment in melanophores 10. Here we report that injection of the anti-kinesin antibody into human fibroblasts results in the redistribution of intermediate filaments to a tight perinuclear aggregate but had no effect on the distribution of microtubules. Thus, kinesin is involved not only in organelle movement but also in interaction of the two major cytoskeletal systems, intermediate filaments and microtubules.	ACAD SCI USSR,INST PROT RES,PUSHCHINO 142292,USSR	Russian Academy of Sciences			Gelfand, Vladimir/M-1974-2019; Gelfand, Vladimir I/D-2545-2013	Gelfand, Vladimir/0000-0002-6361-2798; Gelfand, Vladimir I/0000-0002-6361-2798				BLOSE SH, 1984, J CELL BIOL, V98, P847, DOI 10.1083/jcb.98.3.847; DABORA SL, 1988, CELL, V54, P27, DOI 10.1016/0092-8674(88)90176-6; FRANKE WW, 1987, CELL, V49, P131, DOI 10.1016/0092-8674(87)90763-X; GAWLITTA W, 1981, EUR J CELL BIOL, V26, P83; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; HOLLENBECK PJ, 1989, J CELL SCI, V92, P621; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; KATSUMOTO T, 1990, BIOL CELL, V68, P139, DOI 10.1016/0248-4900(90)90299-I; KLYMKOWSKY MW, 1989, CELL MOTIL CYTOSKEL, V14, P309, DOI 10.1002/cm.970140302; KLYMKOWSKY MW, 1981, NATURE, V291, P249, DOI 10.1038/291249a0; LIN JJC, 1981, CELL, V24, P185, DOI 10.1016/0092-8674(81)90514-6; PERIDES G, 1987, J BIOL CHEM, V262, P13742; RODONOV VI, 1991, P NATL ACAD SCI USA, V88, P4956; STACEY DW, 1977, P NATL ACAD SCI USA, V74, P1514; TOLLE HG, 1986, EXP CELL RES, V162, P462, DOI 10.1016/0014-4827(86)90350-2; TRAUB P, 1987, EUR J CELL BIOL, V43, P55; TROYANOVSKII SN, 1985, IMMUNOLOGIYA, V6, P70; VALE RD, 1987, ANNU REV CELL BIOL, V3, P347, DOI 10.1146/annurev.cb.03.110187.002023; VALE RD, 1988, J CELL BIOL, V107, P2233, DOI 10.1083/jcb.107.6.2233; WEHLAND J, 1983, J CELL BIOL, V97, P1476, DOI 10.1083/jcb.97.5.1476	20	198	201	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1991	353	6343					445	448		10.1038/353445a0	http://dx.doi.org/10.1038/353445a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH606	1832745				2022-12-01	WOS:A1991GH60600062
J	HARRINGTON, LA; GREIDER, CW				HARRINGTON, LA; GREIDER, CW			TELOMERASE PRIMER SPECIFICITY AND CHROMOSOME HEALING	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; TERMINAL TRANSFERASE; DNA; TETRAHYMENA; IDENTIFICATION	CHROMOSOME healing by de novo telomere addition at non-telomeric sites has been well characterized in several organisms 1-9. The Tetrahymena telomerase ribonucleoprotein uses an internal RNA template to catalyse d(TTGGGG)n telomere addition to the 3' end of telomeric sequence in vitro and in vivo 10,11. Studies of telomerase RNA indicated that hybridization of the RNA template region, 5'-CAACCCCAA-3', to the 3' end of single-stranded telomeric oligonucleotides might be important for primer recognition and utilization 10. The apparent requirement of telomerase for pre-existing telomeric sequence has raised questions regarding its role in chromosome healing 12,13. We report here that Tetrahymena telomerase can specifically elongate single-stranded DNA oligonucleotides whose termini are not complementary to the RNA template sequence 5'-CAACCCCAA-3'. These data suggest that telomerase may be able to heal chromosomes directly in vivo.	COLD SPRING HARBOR LAB,POB 100,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory								BAROIN A, 1987, NUCLEIC ACIDS RES, V15, P1717, DOI 10.1093/nar/15.4.1717; FORNEY JD, 1988, MOL CELL BIOL, V8, P251, DOI 10.1128/MCB.8.1.251; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HABER JE, 1984, GENETICS, V106, P207; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; HENDERSON ER, 1990, BIOCHEMISTRY-US, V29, P732, DOI 10.1021/bi00455a020; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; MATSUMOTO T, 1987, MOL CELL BIOL, V7, P4424, DOI 10.1128/MCB.7.12.4424; Maxam A M, 1980, Methods Enzymol, V65, P499; McClintock B, 1941, GENETICS, V26, P234; MCCLINTOCK B, 1942, GENETICS, V28, P458; MURRAY A, 1990, NATURE, V346, P797, DOI 10.1038/346797a0; MURRAY AW, 1988, MOL CELL BIOL, V8, P4642, DOI 10.1128/MCB.8.11.4642; POLOGE LG, 1988, CELL, V55, P869, DOI 10.1016/0092-8674(88)90142-0; RICHARDS EJ, 1988, CELL, V53, P127, DOI 10.1016/0092-8674(88)90494-1; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SPANGLER EA, 1988, NUCLEIC ACIDS RES, V16, P5569, DOI 10.1093/nar/16.12.5569; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; WILKIE AOM, 1990, NATURE, V346, P868, DOI 10.1038/346868a0; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; Yao MC, 1989, MOBILE DNA, P715; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0; ZAKIAN VA, 1990, TRENDS GENET, V6	28	158	169	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1991	353	6343					451	454		10.1038/353451a0	http://dx.doi.org/10.1038/353451a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH606	1896088				2022-12-01	WOS:A1991GH60600064
J	LERMAN, A; EDWARDS, BS; HALLETT, JW; HEUBLEIN, DM; SANDBERG, SM; BURNETT, JC				LERMAN, A; EDWARDS, BS; HALLETT, JW; HEUBLEIN, DM; SANDBERG, SM; BURNETT, JC			CIRCULATING AND TISSUE ENDOTHELIN IMMUNOREACTIVITY IN ADVANCED ATHEROSCLEROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SMOOTH-MUSCLE CELLS; INCREASED PLASMA ENDOTHELIN; ARTERIES; PROLIFERATION; PATHOGENESIS; RESPONSES; PRIMATES; DISEASE; ANGINA	Background. Atherosclerosis is characterized by endothelial injury and the proliferation of arterial smooth-muscle cells. The latter may be a result of the release of growth factors from the vessel wall; such growth factors may include an endothelium-derived vasoconstrictor peptide with mitogenic properties. We tested the hypothesis that plasma endothelin concentrations are elevated in persons with symptomatic atherosclerosis, independently of age. Methods. We measured plasma endothelin levels in 100 normal subjects and in 40 patients with atherosclerosis predominantly of the following types: aortic and peripheral vascular disease (14 patients), renovascular disease (9 patients), coronary artery disease (9 patients), and carotid disease (8 patients). We also performed immunohistochemical staining for endothelin in the walls of atherosclerotic vessels. Results. In the normal subjects, the mean (+/- SD) plasma endothelin concentration was 1.4 +/- 0.2 pmol per liter, with no correlation between age and plasma endothelin concentration (r = 0.13, P = 0.2). In the patients with symptomatic atherosclerosis, the mean plasma endothelin concentration was 3.2 +/- 1.2 pmol per liter (P < 0.001), and there was a significant correlation between plasma endothelin and the number of sites of disease involvement (r = 0.89, P < 0.001). In the immunohistochemical studies, endothelin-1-like immunoreactivity was observed in vascular smooth muscle as well as in endothelial cells. Conclusions. Endothelin may be a marker for arterial vascular disease. Whether it participates in the atherogenic process or is merely released from damaged endothelial cells is unclear.	MAYO CLIN & MAYO FDN,DIV CARDIOVASC SURG,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT SURG,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic	LERMAN, A (corresponding author), MAYO CLIN & MAYO FDN,DEPT INTERNAL MED,CARDIORENAL RES LAB,200 1ST ST SW,ROCHESTER,MN 55905, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036634] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07111, HL36634] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDO K, 1989, FEBS LETT, V245, P164, DOI 10.1016/0014-5793(89)80213-3; ARENDT RM, 1990, CIRCULATION, V82, P248; BOULANGER C, 1990, J CLIN INVEST, V85, P587, DOI 10.1172/JCI114477; CAVERO PG, 1990, AM J PHYSIOL, V259, pF312, DOI 10.1152/ajprenal.1990.259.2.F312; DREXLER H, 1990, Journal of the American College of Cardiology, V15, p158A; Dubin D, 1989, J VASC MED BIOL, V1, P150; EDWARDS BS, 1990, AM J HYPERTENS, V3, pA64; FINGERLE J, 1987, INT ANGIOL, V6, P65; GOETZ KL, 1988, AM J PHYSIOL, V255, pR1064, DOI 10.1152/ajpregu.1988.255.6.R1064; GUYTON JR, 1979, AM J PATHOL, V94, P585; HEUBLEIN DM, 1989, AM J HYPERTENS, V2, pA37; HIRATA Y, 1989, ATHEROSCLEROSIS, V78, P225, DOI 10.1016/0021-9150(89)90227-X; HIROE M, 1989, PEPTIDES, V10, P1281, DOI 10.1016/0196-9781(89)90021-1; KON V, 1989, CIRCULATION S2, V80, P483; LERMAN A, 1991, TRANSPLANTATION, V51, P646, DOI 10.1097/00007890-199103000-00020; LERMAN A, 1991, CIRCULATION, V83, P1808, DOI 10.1161/01.CIR.83.5.1808; LOPEZ JAG, 1989, CLIN RES, V37, pA883; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; LUSCHER TF, 1989, EUR HEART J, V10, P847; LUSCHER TF, 1989, J CARDIOVASC PHARM, V14, pS63; MILLER WL, 1989, J CLIN INVEST, V83, P317, DOI 10.1172/JCI113876; MIYAUCHI T, 1989, LANCET, V2, P53, DOI 10.1016/S0140-6736(89)90303-6; MIYAUCHI T, 1990, CIRCULATION, V81, P1874, DOI 10.1161/01.CIR.81.6.1874; OBRIEN RF, 1987, J CELL PHYSIOL, V132, P263, DOI 10.1002/jcp.1041320210; RESINK TJ, 1990, MOL PHARMACOL, V38, P244; RESINK TJ, 1990, BIOCHEM BIOPH RES CO, V168, P1303, DOI 10.1016/0006-291X(90)91171-N; ROBERTS WC, 1982, AM J CARDIOL, V50, P203, DOI 10.1016/0002-9149(82)90030-3; ROSS R, 1981, ARTERIOSCLEROSIS, V1, P293, DOI 10.1161/01.ATV.1.5.293; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1976, NEW ENGL J MED, V295, P369, DOI 10.1056/NEJM197608122950707; SAITO T, 1989, Japanese Journal of Pharmacology, V49, p215P; SAITO Y, 1990, NEW ENGL J MED, V322, P205; SCHICHIRI M, 1989, CIRUCLATION S2, V80, P125; SCHWARTZ SM, 1990, PHYSIOL REV, V70, P1177, DOI 10.1152/physrev.1990.70.4.1177; STEMERMAN MB, 1972, J EXP MED, V136, P769, DOI 10.1084/jem.136.4.769; TAKAGI Y, 1990, BIOCHEM BIOPH RES CO, V168, P537, DOI 10.1016/0006-291X(90)92354-3; VITA J A, 1990, Journal of the American College of Cardiology, V15, p158A; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YANG ZH, 1990, CIRCULATION, V82, P188, DOI 10.1161/01.CIR.82.1.188; YASUDA M, 1990, AM HEART J, V119, P801, DOI 10.1016/S0002-8703(05)80315-1	40	940	994	1	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 3	1991	325	14					997	1001		10.1056/NEJM199110033251404	http://dx.doi.org/10.1056/NEJM199110033251404			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH447	1886637	Green Submitted			2022-12-01	WOS:A1991GH44700004
J	MENNELLA, JA; BEAUCHAMP, GK				MENNELLA, JA; BEAUCHAMP, GK			THE TRANSFER OF ALCOHOL TO HUMAN-MILK - EFFECTS ON FLAVOR AND THE INFANTS BEHAVIOR	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EARLY EXPERIENCE; LACTATING WOMEN; BREAST-MILK; MOTHERS	Background. The amount of alcohol ingested by a breast-fed infant is only a small fraction of that consumed by its mother, but even this small amount may have an effect on the infant. We investigated whether the ingestion of alcohol by a lactating woman altered the odor of her milk and whether exposure to a small amount of alcohol in the mother's milk had immediate effects on the behavior of the infant. Methods. Twelve lactating women and their infants were tested on two days separated by an interval of one week. On each testing day, the mother expressed a small quantity of breast milk and then drank either orange juice or orange juice containing a small quantity of ethanol (0.3 g per kilogram of body weight). Additional milk samples were obtained at fixed intervals after the ingestion of the beverage and analyzed to determine their ethanol content. The samples were also evaluated by a panel of adults of determine whether any difference in the odor of the milk was detectable after alcohol ingestion. The infants were weighed before and after nursing to assess the amount of milk they ingested, and their behavior during breast-feeding was monitored by videotape. Results. Short-term alcohol consumption by lactating women significantly and uniformly increased the perceived intensity of the odor of their milk as assessed by the panel; this increase in the intensity of the odor peaked 30 minutes to 1 hour after the alcohol was consumed and decreased thereafter. The alteration in the odor of the milk closely paralleled the changes in the concentration of ethanol in the milk (mean range, 0 to 6.9 mmol per liter [0 to 32 mg per deciliter]). The infants sucked more frequently during the first minute of feedings after their mothers had consumed alcohol (67.0 +/- 6.5 sucks, as compared with 58.4 +/- 5.9 sucks for feedings after the consumption of the nonalcoholic beverage; P < 0.05), but they consumed significantly less milk (120.4 +/- 9.5 ml vs. 156.4 +/- 8.2 ml, P < 0.001) during the testing sessions in which their mothers drank the alcoholic beverage. Conclusions. Although the mechanisms underlying this reduction in milk intake remain to be elucidated, this study shows that short-term alcohol consumption by nursing mothers has an immediate effect on the sensory characteristics (odor) or their milk and the feeding behavior of their infants.			MENNELLA, JA (corresponding author), MONELL CHEM SENSES CTR,3500 MARKET ST,PHILADELPHIA,PA 19104, USA.			Mennella, Julie/0000-0002-8855-0204	NICHD NIH HHS [HD07375] Funding Source: Medline; NIDCD NIH HHS [DC00882] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000882] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Bernt E, 1974, METHOD ENZYMAT AN, V3, P1499; BLUME S, 1987, JAMA-J AM MED ASSOC, V258, P2126; BUTTE NF, 1988, AM J CLIN NUTR, V47, P815, DOI 10.1093/ajcn/47.5.815; CAMPBELL RG, 1976, ANIM PROD, V23, P417, DOI 10.1017/S0003356100031536; CAPRETTA PJ, 1975, NATURE, V254, P689, DOI 10.1038/254689a0; COBO E, 1969, AM J OBSTET GYNECOL, V105, P877, DOI 10.1016/0002-9378(69)90094-5; COBO E, 1973, AM J OBSTET GYNECOL, V115, P817, DOI 10.1016/0002-9378(73)90526-7; Fazzalari F.A., 1978, COMPILATION ODOR TAS; Fildes VA, 1986, BREASTS BOTTLES BABI; FOMON SJ, 1987, AM J CLIN NUTR, V46, P171, DOI 10.1093/ajcn/46.1.171; GALEF BG, 1973, J COMP PHYSIOL PSYCH, V83, P374, DOI 10.1037/h0034665; GALEF BG, 1972, J COMP PHYSIOL PSYCH, V78, P213, DOI 10.1037/h0032186; JONES KL, 1973, LANCET, V1, P1267; JONES KL, 1973, LANCET, V2, P999; KESANIEMI YA, 1974, J OBSTET GYN BR COMM, V81, P84; LAWRENCE RA, 1989, BREASTFEEDING GUIDE; LAWTON ME, 1985, AUST NZ J OBSTET GYN, V25, P71, DOI 10.1111/j.1479-828X.1985.tb00609.x; LEGUENNEC JC, 1987, PEDIATRICS, V79, P264; LITTLE RE, 1989, NEW ENGL J MED, V321, P425, DOI 10.1056/NEJM198908173210703; LITTLE RE, 1984, AM J EPIDEMIOL, V120, P794, DOI 10.1093/oxfordjournals.aje.a113949; MAINARDI M, 1989, BIOL BEHAV, V14, P185; MENNELLA JA, 1991, PEDIATRICS, V88, P737; NEVILLE MC, 1988, AM J CLIN NUTR, V48, P1375, DOI 10.1093/ajcn/48.6.1375; NICLOUX M, 1899, C R SOC BIOL, V51, P982; PHILLIPS DS, 1976, PHYSIOL PSYCHOL, V4, P473; PIKKARAINEN PH, 1967, PEDIATR RES, V1, P165, DOI 10.1203/00006450-196705000-00001; Siegel S., 1956, NONPARAMETRIC STAT B; SUBRAMANIAN MG, 1988, ALCOHOL, V5, P95, DOI 10.1016/0741-8329(88)90002-X; THIRY L, 1985, LANCET, V2, P891; WALTER M, 1975, B NEW YORK ACAD MED, V51, P870	30	205	206	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 3	1991	325	14					981	985		10.1056/NEJM199110033251401	http://dx.doi.org/10.1056/NEJM199110033251401			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH447	1886634				2022-12-01	WOS:A1991GH44700001
J	MORIN, GB				MORIN, GB			RECOGNITION OF A CHROMOSOME TRUNCATION SITE ASSOCIATED WITH ALPHA-THALASSEMIA BY HUMAN TELOMERASE	NATURE			English	Article							TERMINAL TRANSFERASE-ACTIVITY; PROTOZOAN OXYTRICHA-NOVA; MACRONUCLEAR DNA; TETRAHYMENA; SEQUENCES; BREAKAGE; RIBONUCLEOPROTEIN; IDENTIFICATION; DELETIONS; REPEATS	TELOMERES define the ends of chromosomes; they consist of short tandemly repeated DNA sequences loosely conserved in eukaryotes (G1-8(T/A)1-4) 1. Telomerase is a ribonucleoprotein which, in vitro, recognizes a single-stranded G-rich telomere primer and adds multiple telomeric repeats to its 3' end by using a template in the RNA moiety 2-6. In conjunction with other components, telomerase may balance the loss of telomeric repeats due to DNA replication 7. Another role of telomerase may be the de novo formation of telomeres. In eukaryotes like Tetrahymena, this process is an integral part of the formation of macronuclear chromosomes 8. In other eukaryotes this process stabilizes broken chromosomes. A case of human alpha-thalassaemia is caused by a truncation of chromosome 16 that has been healed by the addition of telomeric repeats (TTAGGG)n (ref. 9). Using an in vitro assay 4, I show here that human telomerase correctly recognizes the chromosome 16 breakpoint sequence and adds (TTAGGG)n repeats. The DNA sequence requirements are minimal and seem to define two modes of DNA recognition by telomerase.	YALE UNIV,HOWARD HUGHES MED INST,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University			Morin, Gregg B/E-9123-2012	Morin, Gregg B/0000-0001-8949-4374				ADAM RD, 1991, MOL CELL BIOL, V11, P3326, DOI 10.1128/MCB.11.6.3326; BAROIN A, 1987, NUCLEIC ACIDS RES, V15, P1717, DOI 10.1093/nar/15.4.1717; BLACKBURN EH, 1986, ANNU REV GENET, V20, P501; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BLACKBURN EH, 1984, CELL, V37, P7, DOI 10.1016/0092-8674(84)90295-2; FORNEY JD, 1988, MOL CELL BIOL, V8, P251, DOI 10.1128/MCB.8.1.251; GILLEY D, 1988, MOL CELL BIOL, V8, P4765, DOI 10.1128/MCB.8.11.4765; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GUSELLA JF, 1985, NATURE, V318, P75, DOI 10.1038/318075a0; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; HERRICK G, 1987, GENE DEV, V1, P1047, DOI 10.1101/gad.1.10.1047; KAMPER J, 1989, MOL CELL BIOL, V9, P3931; KLOBUTCHER LA, 1986, MOL CELL BIOL, V6, P3606, DOI 10.1128/MCB.6.11.3606; KLOBUTCHER LA, 1984, CELL, V36, P1045, DOI 10.1016/0092-8674(84)90054-0; KLOBUTCHER LA, 1988, NUCLEIC ACIDS RES, V16, P251, DOI 10.1093/nar/16.1.251; LEDBETTER DH, 1989, P NATL ACAD SCI USA, V86, P5136, DOI 10.1073/pnas.86.13.5136; MATSUMOTO T, 1987, MOL CELL BIOL, V7, P4424, DOI 10.1128/MCB.7.12.4424; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MURRAY AW, 1988, MOL CELL BIOL, V8, P4642, DOI 10.1128/MCB.8.11.4642; POLOGE LG, 1988, CELL, V55, P869, DOI 10.1016/0092-8674(88)90142-0; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SHIPPENLENTZ D, 1989, MOL CELL BIOL, V9, P2761, DOI 10.1128/MCB.9.6.2761; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; WILKIE AOM, 1990, NATURE, V346, P868, DOI 10.1038/346868a0; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; YAO MC, 1987, CELL, V48, P779, DOI 10.1016/0092-8674(87)90075-4; YAO MC, 1990, CELL, V63, P763, DOI 10.1016/0092-8674(90)90142-2; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0	31	191	199	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1991	353	6343					454	456		10.1038/353454a0	http://dx.doi.org/10.1038/353454a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH606	1896089				2022-12-01	WOS:A1991GH60600065
J	PANZA, JA; EPSTEIN, SE; QUYYUMI, AA				PANZA, JA; EPSTEIN, SE; QUYYUMI, AA			CIRCADIAN VARIATION IN VASCULAR TONE AND ITS RELATION TO ALPHA-SYMPATHETIC VASOCONSTRICTOR ACTIVITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUDDEN CARDIAC DEATH; ATHEROSCLEROTIC CORONARY-ARTERIES; ACUTE MYOCARDIAL-INFARCTION; ESSENTIAL-HYPERTENSION; MORNING INCREASE; ANGINA-PECTORIS; ADRENERGIC VASOCONSTRICTION; MEDIATED VASOCONSTRICTION; PLATELET AGGREGABILITY; DIURNAL-VARIATION	Background. The frequency of several cardiovascular events, such as myocardial infarction, sudden death, and stroke, is increased during the early morning hours. There is also a similar circadian pattern in several physiologic variables, including blood pressure, suggesting that certain dynamic processes may contribute to the circadian distribution and onset of acute events. Methods. To determine whether there are circadian variations in vascular tone and to investigate their underlying mechanisms, we measured blood flow and vascular resistance in the forearm and their responses to phentolamine (an alpha-adrenergic-antagonist drug) and sodium nitroprusside (a direct vasodilator) in 12 normal subjects 7 men and 5 women; mean age [+/- SD], 44 +/- 9 years) at three different times of day (7 a.m., 2 p.m., and 9 p.m.). The drugs were infused into the brachial artery, and the responses were measured by strain-gauge plethysmography. Results. The basal forearm vacular resistance was significantly higher, and the blood flow significantly lower, in the morning than in the afternoon and evening (mean vascular resistance, 31 +/- 8, 25 +/- 6, and 22 +/- 7 mm Hg per milliliter per minute per 100 ml of forearm volume, respectively; P < 0.01). The vasodilator effect of phentolamine was also significantly greater in the morning (mean decrease in vascular resistance, 38 +/- 6 percent) than in the afternoon (26 +/- 6 percent) and evening (21 +/- 7 percent) (P < 0.05). Consequently, there was no circadian variation in vascular resistance or blood flow after the infusion of this drug. In contrast, the vasodilation in response to sodium nitroprusside was similar at all three times of day. Conclusions. There is a circadian rhythm in basal vascular tone, due either partly or entirely to increased alpha-sympathetic vasoconstrictor activity during the morning. This variation may contribute to higher blood pressure and the increased incidence of cardiovascular events at this time of day.			PANZA, JA (corresponding author), NHLBI,BLDG 10,RM 7B-15,BETHESDA,MD 20892, USA.							AMANN FW, 1981, HYPERTENSION, V3, P119; ANDREOTTI F, 1988, AM J CARDIOL, V62, P635, DOI 10.1016/0002-9149(88)90669-8; BERKENBOOM GM, 1986, AM J CARDIOL, V57, P195, DOI 10.1016/0002-9149(86)90889-1; Bohme E, 1978, Adv Cyclic Nucleotide Res, V9, P131; BREZINSKI DA, 1988, CIRCULATION, V78, P35, DOI 10.1161/01.CIR.78.1.35; BROWN BG, 1984, CIRCULATION, V70, P18, DOI 10.1161/01.CIR.70.1.18; COCKS TM, 1983, NATURE, V305, P627, DOI 10.1038/305627a0; COHEN RA, 1988, AM J PHYSIOL, V254, pH871, DOI 10.1152/ajpheart.1988.254.5.H871; COLLINS P, 1985, BRIT HEART J, V53, P488; EGAN B, 1987, J CLIN INVEST, V80, P812, DOI 10.1172/JCI113138; EPSTEIN SE, 1981, AM J CARDIOL, V48, P797, DOI 10.1016/0002-9149(81)90160-0; FUJITA M, 1987, CIRCULATION, V76, P488, DOI 10.1161/01.CIR.76.2.488; GORDON RD, 1966, J CLIN INVEST, V45, P1587, DOI 10.1172/JCI105464; GREENFIELD ADM, 1963, BRIT MED BULL, V19, P101, DOI 10.1093/oxfordjournals.bmb.a070026; HOKANSON DE, 1975, IEEE T BIO-MED ENG, VBM22, P25, DOI 10.1109/TBME.1975.324535; KANEKO M, 1968, J APPL PHYSIOL, V25, P109, DOI 10.1152/jappl.1968.25.2.109; KERSLAKE DM, 1949, J PHYSIOL-LONDON, V108, P451, DOI 10.1113/jphysiol.1949.sp004348; KIOWSKI W, 1981, CLIN SCI, V60, P483, DOI 10.1042/cs0600483; KUKOVETZ WR, 1979, N-S ARCH PHARMACOL, V310, P129, DOI 10.1007/BF00500277; LINSELL CR, 1985, J CLIN ENDOCR METAB, V60, P1210, DOI 10.1210/jcem-60-6-1210; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; MARLER JR, 1989, STROKE, V20, P473, DOI 10.1161/01.STR.20.4.473; MILLARCRAIG MW, 1978, LANCET, V1, P795; MUDGE GH, 1976, NEW ENGL J MED, V295, P1333, DOI 10.1056/NEJM197612092952401; MULCAHY D, 1988, LANCET, V2, P755; MULLER JE, 1987, CIRCULATION, V75, P131, DOI 10.1161/01.CIR.75.1.131; MULLER JE, 1985, NEW ENGL J MED, V313, P1315, DOI 10.1056/NEJM198511213132103; MULLER JE, 1989, CIRCULATION, V79, P733, DOI 10.1161/01.CIR.79.4.733; NABEL EG, 1988, CIRCULATION, V77, P43, DOI 10.1161/01.CIR.77.1.43; PANZA JA, 1990, NEW ENGL J MED, V323, P22, DOI 10.1056/NEJM199007053230105; ROCCO MB, 1987, CIRCULATION, V75, P395, DOI 10.1161/01.CIR.75.2.395; ROSENDORFF C, 1981, CIRC RES, V48, P320, DOI 10.1161/01.RES.48.3.320; ROSING DR, 1970, CIRC RES, V27, P171, DOI 10.1161/01.RES.27.2.171; SCHULTZ KD, 1977, NATURE, V265, P750, DOI 10.1038/265750a0; TESFAMARIAM B, 1988, CIRC RES, V63, P720, DOI 10.1161/01.RES.63.4.720; THOMPSON DR, 1985, INT J CARDIOL, V7, P139, DOI 10.1016/0167-5273(85)90354-7; TOFLER GH, 1987, NEW ENGL J MED, V316, P1514, DOI 10.1056/NEJM198706113162405; TSEMENTZIS SA, 1985, NEUROSURGERY, V17, P901, DOI 10.1227/00006123-198512000-00005; VERDECCHIA P, 1990, CIRCULATION, V81, P528, DOI 10.1161/01.CIR.81.2.528; WEITZMAN ED, 1971, J CLIN ENDOCR METAB, V33, P14, DOI 10.1210/jcem-33-1-14; WHITNEY RJ, 1953, J PHYSIOL-LONDON, V121, P1; WILLICH SN, 1987, AM J CARDIOL, V60, P801, DOI 10.1016/0002-9149(87)91027-7; YASUE H, 1979, CIRCULATION, V59, P938, DOI 10.1161/01.CIR.59.5.938	43	469	477	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 3	1991	325	14					986	990		10.1056/NEJM199110033251402	http://dx.doi.org/10.1056/NEJM199110033251402			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH447	1886635				2022-12-01	WOS:A1991GH44700002
J	PEASE, RJ; HARRISON, GB; SCOTT, J				PEASE, RJ; HARRISON, GB; SCOTT, J			COTRANSLOCATIONAL INSERTION OF APOLIPOPROTEIN-B INTO THE INNER LEAFLET OF THE ENDOPLASMIC-RETICULUM	NATURE			English	Article							PROTEIN TRANSLOCATION; MICROSOMAL-MEMBRANES; TRANSLATION SYSTEM; STOP-TRANSFER; SEQUENCE; CORONAVIRUS; FRACTIONS; INVITRO	APOLIPOPROTEIN (apo) B100 is required for the distribution of hepatic triglyceride to peripheral tissues as very-low-density lipoproteins. The translocation of apo B100 into the endoplasmic reticulum (ER) and its subsequent assembly into lipoprotein particles is of particular interest as the protein is both very large (relative molecular mass 512,000) and insoluble in water. It has been proposed that apo B translocation occurs in discrete stages and is completed post-translationally 1. Several sites of arrest of translocation were reported to be present in apo B15 (the N-terminal 15% of the protein). We have re-examined this question by in vitro translation coupled with translocation into microsomes, and find no evidence for transmembrane segments in truncated apo B proteins. Translocated apo B17 is strongly associated with the membrane of the ER, being only partially releasable with alkaline carbonate, and remaining bound to the microsomes following disruption with saponin. The efficient binding of short segments of apo B, despite the absence of transmembrane domains, suggests that apo B is cotranslationally inserted into the inner leaflet of the ER. This will obviate problems caused by the size and insolubility of apo B100, because the growing hydrophobic protein chains will never exist in a lipid-free form during translocation. From the inner leaflet, apo B in association with membrane-derived lipid can bud into the lumen of the ER to form nascent lipoprotein particles.			PEASE, RJ (corresponding author), MRC,CLIN RES CTR,DIV MOLEC MED,WATFORD RD,HARROW HA1 3UJ,MIDDX,ENGLAND.							ARMSTRONG J, 1984, NATURE, V308, P751, DOI 10.1038/308751a0; BOSTROM K, 1988, J BIOL CHEM, V263, P4432; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; KAMINSKI A, 1990, EMBO J, V9, P3753, DOI 10.1002/j.1460-2075.1990.tb07588.x; KASSENBROCK CK, 1988, NATURE, V333, P90, DOI 10.1038/333090a0; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KNOTT TJ, 1986, NUCLEIC ACIDS RES, V14, P7501, DOI 10.1093/nar/14.18.7501; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWN RM, 1980, CELL, V21, P647, DOI 10.1016/0092-8674(80)90428-6; ROGERS G, 1982, J BIOL CHEM, V257, P4179; ROTTIER P, 1984, P NATL ACAD SCI-BIOL, V81, P1421, DOI 10.1073/pnas.81.5.1421; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEELE G, 1983, METHOD ENZYMOL, V96, P94; SPIESS M, 1989, J BIOL CHEM, V264, P19117; WALTER P, 1983, METHOD ENZYMOL, V96, P84; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0	20	76	76	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1991	353	6343					448	450		10.1038/353448a0	http://dx.doi.org/10.1038/353448a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH606	1896087	Green Published, Bronze			2022-12-01	WOS:A1991GH60600063
J	TENG, DHF; ENGELE, CM; VENKATESH, TR				TENG, DHF; ENGELE, CM; VENKATESH, TR			A PRODUCT OF THE PRUNE LOCUS OF DROSOPHILA IS SIMILAR TO MAMMALIAN GTPASE-ACTIVATING PROTEIN	NATURE			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; TUMOR-METASTASIS; AWD PROTEINS; RAS P21; GAP; GENE; DNA; MELANOGASTER; ELEMENTS; CLONING	THE X-linked prune (pn) eye-colour mutation of Drosophila melanogaster has a highly specific, complementary lethal interaction with the conditional dominant Killer of prune (awd(K-pn)) mutation 1,2. Although awd(K-pn) flies have no apparent phenotype on their own, pn awd(K-pn) double mutants die as second or third larval instars. The awd locus encodes a nucleoside diphosphate kinase 3, an enzyme that catalyses the transfer of high-energy phosphate bonds between nucleoside diphosphates and nucleoside triphosphates 4, which is essential for the normal development of Drosophila. Analysis of the pn locus has suggested that the complementary DNA, TcD37, encodes a putative pn+ product 5. Here we report the nucleotide sequence of TcD37 and the similarity of its deduced protein product to the catalytic domain of mammalian GTPase-activating proteins (GAPs); GAPs stimulate the GTPase activity of Ras (ref. 6), which are plasma membrane-bound proteins involved in the regulation of cell proliferation and differentiation 7. These results suggest that the Drosophila TcD37 protein participates in a biochemical pathway similar to that of Ras and GAPs in mammals and yeast. We propose that the interaction between pn and awd is due to a neomorphic mutation that enhances the ability of Awd(K-pn) nucleoside diphosphate kinase to induce a regulatory GTPase into a GTP-bound 'on' state, whereas Pn modulates the activity of this GTPase either by switching it to a GDP-bound 'off' state or by interfering with its effector function.	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403; UNIV OREGON,INST NEUROSCI,EUGENE,OR 97403; UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon; University of Oregon; University of Oregon								BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROWN GM, 1985, CHEM BIOCH PTERINS, P115; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; COLICELLI J, 1991, P NATL ACAD SCI USA, V88, P2913, DOI 10.1073/pnas.88.7.2913; DEAROLF CR, 1988, DEV BIOL, V129, P159, DOI 10.1016/0012-1606(88)90170-4; EMKEY R, 1991, J BIOL CHEM, V266, P9703; EVANS BA, 1978, BIOCHEM GENET, V16, P13, DOI 10.1007/BF00484381; GARRETT MD, 1989, J BIOL CHEM, V264, P10; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1990, J NATL CANCER I, V82, P1170, DOI 10.1093/jnci/82.14.1170; MACKAY WJ, 1983, GENETICS, V105, P35; MACLEAN JR, 1990, GENETICS, V126, P1007; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; OHARE K, 1983, CELL, V34, P25, DOI 10.1016/0092-8674(83)90133-2; PARKS RW, 1973, ENZYMES, P307; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STURTEVANT AH, 1956, GENETICS, V41, P118; TANAKA K, 1991, P NATL ACAD SCI USA, V88, P468, DOI 10.1073/pnas.88.2.468; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TENG DHF, 1991, GENETICS, V128, P373; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALLET V, 1990, J NATL CANCER I, V82, P1199, DOI 10.1093/jnci/82.14.1199; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	35	69	69	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1991	353	6343					437	440		10.1038/353437a0	http://dx.doi.org/10.1038/353437a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH606	1654526				2022-12-01	WOS:A1991GH60600059
J	TREZISE, AEO; BUCHWALD, M				TREZISE, AEO; BUCHWALD, M			INVIVO CELL-SPECIFIC EXPRESSION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR	NATURE			English	Article							IDENTIFICATION; GENE	CYSTIC fibrosis (CF) is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) 1-3. The principal manifestations of CF include increased concentration of Cl- in exocrine gland secretions 4,5, pancreatic insufficiency, chronic lung disease, intestinal blockage and malabsorption of fat 5,6, and male and female infertility 7. Insight into the function of CFTR can be gained by correlating its cell-specific expression with the physiology of those cells and with CF pathology. Determination of CFTR messenger RNA in rat tissues by in situ hybridization shows that it is specifically expressed in the ductal cells of the pancreas and the salivary glands. In the intestine, decreasing gradients of expression of the CFTR gene are observed on both the crypt-villus and the proximal-distal axes. This expression is consistent with CFTR being responsible for bidirectional Cl- transport, secretion in the intestinal crypts 8 and reabsorption in the salivary gland ducts 4, and suggests that in these tissues CFTR functions as a regulated Cl- channel. In the lung, a broad band of hybridization includes the mucosa and submucosa of the bronchi and bronchioles. In the testis, CFTR expression is regulated during the cycle of the seminiferous epithelium. Post-meiotic expression is maximal in the round spermatids of stages VII and VIII, suggesting that CFTR plays a critical role in spermatogenesis and that deficiency of this function contributes to CF male infertility.	HOSP SICK CHILDREN,RES INST,DEPT GENET,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto								BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; BERSCHNEIDER HM, 1988, FASEB J, V2, P2625, DOI 10.1096/fasebj.2.10.2838365; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BURGMAN SM, 1984, CYSTIC FIBROSIS, P323; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; QUINTON PM, 1990, FASEB J, V4, P1709; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; Taussig LM, 1984, CYSTIC FIBROSIS, P338; TRABER PG, 1990, BIOCHEM BIOPH RES CO, V173, P765, DOI 10.1016/S0006-291X(05)80853-8; TRAPNELL BC, 1991, P NATL ACAD SCI USA, V88, P6565, DOI 10.1073/pnas.88.15.6565; WELSH MJ, 1982, SCIENCE, V218, P1219, DOI 10.1126/science.6293054	13	322	329	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1991	353	6343					434	437		10.1038/353434a0	http://dx.doi.org/10.1038/353434a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH606	1716739				2022-12-01	WOS:A1991GH60600058
J	TURELLI, M; HOFFMANN, AA				TURELLI, M; HOFFMANN, AA			RAPID SPREAD OF AN INHERITED INCOMPATIBILITY FACTOR IN CALIFORNIA DROSOPHILA	NATURE			English	Article							LONG-DISTANCE MIGRATION; CYTOPLASMIC INCOMPATIBILITY; UNIDIRECTIONAL INCOMPATIBILITY; REPRODUCTIVE INCOMPATIBILITY; NATURAL-POPULATIONS; MITOCHONDRIAL-DNA; GENE FLOW; SIMULANS; MELANOGASTER; POLYMORPHISM	IN Drosophila simulans in California, an inherited cytoplasmic incompatibility factor reduces egg hatch when infected males mate with uninfected females 1-7. The infection is spreading at a rate of more than 100 km per year; populations in which the infection was rare have become almost completely infected within three years. Analyses of the spread using estimates of selection in the field suggest dispersal distances far higher than those found by direct observation of flies. Hence, occasional long-distance dispersal, possibly coupled with local extinction and recolonization, may be important to the dynamics. Incompatibility factors that can readily spread through natural populations may be useful for population manipulation and important as a post-mating isolating mechanism.	UNIV CALIF DAVIS, CTR POPULAT BIOL, DAVIS, CA 95616 USA; LA TROBE UNIV, DEPT GENET & HUMAN VARIAT, BUNDOORA, VIC 1083, AUSTRALIA	University of California System; University of California Davis; La Trobe University	TURELLI, M (corresponding author), UNIV CALIF DAVIS, DEPT GENET, DAVIS, CA 95616 USA.		Hoffmann, Ary/R-2972-2019; Hoffmann, Ary/C-2961-2011	Hoffmann, Ary/0000-0001-9497-7645; 				BARTON NH, 1979, HEREDITY, V43, P341, DOI 10.1038/hdy.1979.87; BINNINGTON KC, 1989, J INVERTEBR PATHOL, V54, P344, DOI 10.1016/0022-2011(89)90118-3; BREEUWER JAJ, 1990, NATURE, V346, P558, DOI 10.1038/346558a0; CASPARI E, 1959, EVOLUTION, V13, P568, DOI 10.1111/j.1558-5646.1959.tb03045.x; COYNE JA, 1987, AM NAT, V130, P70, DOI 10.1086/284698; COYNE JA, 1982, AM NAT, V119, P589, DOI 10.1086/283936; FINE PEM, 1978, J INVERTEBR PATHOL, V31, P10, DOI 10.1016/0022-2011(78)90102-7; Fisher RA, 1937, ANN EUGENIC, V7, P355, DOI 10.1111/j.1469-1809.1937.tb02153.x; FLEURIET A, 1988, EVOL BIOL, V23, P1; HALE LR, 1990, EVOLUTION, V44, P1383, DOI 10.1111/j.1558-5646.1990.tb05241.x; HOFFMANN AA, 1988, GENETICS, V119, P435; HOFFMANN AA, 1986, EVOLUTION, V40, P692, DOI 10.1111/j.1558-5646.1986.tb00531.x; HOFFMANN AA, 1990, GENETICS, V126, P933; HOFFMANN AA, 1988, ENTOMOL EXP APPL, V48, P61, DOI 10.1007/BF00343386; JONES JS, 1981, GENETICS, V98, P157; JONES JS, 1987, AM NAT, V130, P83, DOI 10.1086/284699; KELLEN WR, 1981, J INVERTEBR PATHOL, V37, P273, DOI 10.1016/0022-2011(81)90087-2; LEU SJC, 1989, J INVERTEBR PATHOL, V54, P248, DOI 10.1016/0022-2011(89)90035-9; LOUIS C, 1989, J INVERTEBR PATHOL, V54, P39, DOI 10.1016/0022-2011(89)90137-7; Model Gressel J., 1986, PESTICIDE RESISTANCE, P54; Murray J., 1993, MATH BIOL, V2nd, DOI DOI 10.1007/978-3-662-08539-4; NIGRO L, 1990, GENETICS, V125, P551; NODA H, 1984, ENTOMOL EXP APPL, V35, P263, DOI 10.1007/BF00369142; ONEILL SL, 1990, NATURE, V348, P178, DOI 10.1038/348178a0; SKINNER SW, 1985, GENETICS, V109, P745; SLATKIN M, 1985, ANNU REV ECOL SYST, V16, P393, DOI 10.1146/annurev.ecolsys.16.1.393; STEVENS L, 1989, J INVERTEBR PATHOL, V53, P78, DOI 10.1016/0022-2011(89)90076-1; Subbarao S.K., 1982, P313; TURELLI M, 1986, DROS INFORM SERV, V63, P131	29	483	495	0	47	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 3	1991	353	6343					440	442		10.1038/353440a0	http://dx.doi.org/10.1038/353440a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH606	1896086				2022-12-01	WOS:A1991GH60600060
J	WARE, RE; HALL, SE; ROSSE, WF				WARE, RE; HALL, SE; ROSSE, WF			PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA WITH ONSET IN CHILDHOOD AND ADOLESCENCE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ERYTHROCYTE-MEMBRANE-PROTEIN; GLYCOSYL-PHOSPHATIDYLINOSITOL; APLASTIC-ANEMIA; REACTIVE LYSIS; RED-CELLS; COMPLEMENT; CD14; DEFICIENCY; INHIBITOR; RECEPTOR	Background. Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal hematologic disorder characterized by hemoglobinuria, thrombosis, infection, and a tendency toward bone marrow aplasia. Onset usually occurs in adulthood. Few children and adolescents with PNH have been described, and data on diagnosis, clinical course, and survival in young patients are unavailable. Methods. We retrospectively reviewed clinical and laboratory data on all patients 21 years old or younger in whom PNH had been diagnosed at Duke University Medical Center from 1966 to 1991. Results. Medical records and clinical follow-up data were available for 26 young patients. Although 50 percent of adult patients present with hemoglobinuria, only four of our patients (15 percent) presented with this feature. In contrast, 15 of our patients (58 percent) had moderate or severe bone marrow failure at presentation, as compared with about 25 percent of adults in cases from the literature; all 26 patients eventually had evidence of bone marrow dysfunction. Eight patients (31 percent) have died, with a median survival of 13.5 years since their initial symptoms. Conclusions. Children and adolescents with PNH have a greater prevalence of bone marrow failure than do adults with this disorder, and their morbidity and mortality are high. Bone marrow transplantation should be considered for selected young patients with PNH.	DUKE UNIV,MED CTR,DEPT PEDIAT,DIV HEMATOL ONCOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DIV HEMATOL ONCOL,DURHAM,NC 27710	Duke University; Duke University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031379] Funding Source: NIH RePORTER; NIDDK NIH HHS [5-R37-DK-31379] Funding Source: Medline; PHS HHS [K11-H02015] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AUDITORE JV, 1960, ARCH PATHOL, V69, P534; DACIE JV, 1961, BRIT J HAEMATOL, V7, P442, DOI 10.1111/j.1365-2141.1961.tb00354.x; DACIE JV, 1963, P ROY SOC MED, V56, P587, DOI 10.1177/003591576305600723; DEVINE DV, 1987, J CLIN INVEST, V79, P131, DOI 10.1172/JCI112773; DEVINE DV, 1987, J CLIN INVEST, V79, P314, DOI 10.1172/JCI112802; DOERING TL, 1990, J BIOL CHEM, V265, P611; GOYERT SM, 1988, SCIENCE, V239, P497, DOI 10.1126/science.2448876; Gull WW, 1866, GUYS HOSP REP, V12, P381; HARTMANN RC, 1977, ANNU REV MED, V28, P187, DOI 10.1146/annurev.me.28.020177.001155; HIRSCH VJ, 1981, ARCH INTERN MED, V141, P525, DOI 10.1001/archinte.141.4.525; HOLGUIN MH, 1989, J CLIN INVEST, V84, P1387, DOI 10.1172/JCI114311; HOLGUIN MH, 1989, J CLIN INVEST, V84, P7, DOI 10.1172/JCI114172; KUNSTLING TR, 1969, BLOOD-J HEMATOL, V33, P607, DOI 10.1182/blood.V33.4.607.607; LEWIS SM, 1965, BRIT J HAEMATOL, V11, P549, DOI 10.1111/j.1365-2141.1965.tb00099.x; LEWIS SM, 1967, BRIT J HAEMATOL, V13, P236, DOI 10.1111/j.1365-2141.1967.tb08736.x; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MOORE JG, 1986, EXP HEMATOL, V14, P222; NICHOLSONWELLER A, 1982, J IMMUNOL, V129, P184; NICHOLSONWELLER A, 1983, P NATL ACAD SCI-BIOL, V80, P5066, DOI 10.1073/pnas.80.16.5066; ONI SB, 1970, BLOOD-J HEMATOL, V36, P145, DOI 10.1182/blood.V36.2.145.145; PANGBURN MK, 1983, P NATL ACAD SCI-BIOL, V80, P5430, DOI 10.1073/pnas.80.17.5430; POLLI E, 1973, EMOGLOBINURIA PAROSS; ROSSE WF, 1985, CLIN HAEMATOL, V14, P105; ROSSE WF, 1966, J CLIN INVEST, V45, P736, DOI 10.1172/JCI105388; ROSSE WF, 1974, BRIT J HAEMATOL, V28, P181; ROSSE WF, 1978, CLIN HAEMATOL, V7, P541; ROSSE WF, 1973, BRIT J HAEMATOL, V24, P327, DOI 10.1111/j.1365-2141.1973.tb01657.x; ROSSE WF, 1990, BLOOD, V75, P1595; ROTOLI B, 1982, BLOOD, V60, P157; SCHONERMARK S, 1986, J IMMUNOL, V136, P1772; SELVARAJ P, 1988, NATURE, V333, P565, DOI 10.1038/333565a0; SELVARAJ P, 1987, J EXP MED, V166, P1011, DOI 10.1084/jem.166.4.1011; SIMMONS DL, 1989, BLOOD, V73, P284; SIRCHIA G, 1975, CLIN HAEMATOL, V4, P199; Strubing P., 1882, DTSCH MED WOCHENSCHR, V8, P1, DOI DOI 10.1055/S-0029-1196307; TICHELLI A, 1988, BRIT J HAEMATOL, V69, P413, DOI 10.1111/j.1365-2141.1988.tb02382.x; VANDERSCHOOT CE, 1989, LEUCOCYTE TYPING, V4, P887; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; ZALMAN LS, 1986, P NATL ACAD SCI USA, V83, P6975, DOI 10.1073/pnas.83.18.6975	39	118	121	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 3	1991	325	14					991	996		10.1056/NEJM199110033251403	http://dx.doi.org/10.1056/NEJM199110033251403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH447	1886636				2022-12-01	WOS:A1991GH44700003
J	YOKOUCHI, Y; SASAKI, H; KUROIWA, A				YOKOUCHI, Y; SASAKI, H; KUROIWA, A			HOMEOBOX GENE-EXPRESSION CORRELATED WITH THE BIFURCATION PROCESS OF LIMB CARTILAGE DEVELOPMENT	NATURE			English	Article							RETINOIC ACID; MORPHOGENESIS; CELLS	THE complex architecture of the limb cartilage pattern probably develops by the sequential segmentation and branching process of precartilaginous cell condensation under the control of positional signalling 1,2 provided by the zone of polarizing activity (anteroposterior) 3,4 and the apical ectodermal ridge (proximodistal) 5. This signalling is monitored and interpreted in the mesenchymal cells and induces the position-specific response of subsets of genes. Homeobox genes may be responsible for the interpretation of signalling 6-11. A correlation between limb pattern and expression domains of the homeobox genes in the upstream region of Hox/Chox-4 has been proposed 10-12. We have analysed the spatial expression pattern of the Chox-1 genes during development of chick limb buds. In contrast to genes in Hox/Chox-4 expressed coordinately along the anteroposterior axis 10,11, homeobox genes in Chox-1 have unique and mutually exclusive expression domains along the proximodistal axis. We report here that the expression domains of the Chox-1 genes are closely related to the segmental structure of cartilage along the proximodistal axis, whereas the expression domains of the Chox-4 genes are related to the cartilage branching pattern.	TOHOKU UNIV,TB & CANC RES INST,DEPT CELL BIOL,4-1 SEIRYOMACHI,AOBA KU,SENDAI,MIYAGI 980,JAPAN; TOHOKU UNIV,FAC SCI,INST BIOL,AOBA KU,SENDAI,MIYAGI 980,JAPAN	Tohoku University; Tohoku University				Sasaki, Hiroshi/0000-0001-8752-6846; Kuroiwa, Atsushi/0000-0001-7710-4041				ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385; AULTHOUSE AL, 1987, DEV BIOL, V120, P377, DOI 10.1016/0012-1606(87)90240-5; CRAWFORD K, 1988, DEVELOPMENT, V104, P703; DOLLE P, 1989, EMBO J, V8, P1507, DOI 10.1002/j.1460-2075.1989.tb03535.x; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; NARDI JB, 1983, DIFFERENTIATION, V25, P27; NOHNO T, 1991, CELL, V64, P1197, DOI 10.1016/0092-8674(91)90274-3; OLIVER G, 1989, GENE DEV, V3, P641, DOI 10.1101/gad.3.5.641; OLIVER G, 1990, EMBO J, V9, P3093, DOI 10.1002/j.1460-2075.1990.tb07506.x; OSTER GF, 1988, EVOLUTION, V42, P862, DOI 10.1111/j.1558-5646.1988.tb02508.x; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; SHUBIN NH, 1986, EVOL BIOL, V20, P319; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; YOKOUCHI Y, IN PRESS DEVELOPMENT, V113	20	294	297	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1991	353	6343					443	445		10.1038/353443a0	http://dx.doi.org/10.1038/353443a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH606	1680221				2022-12-01	WOS:A1991GH60600061
J	CORRALDEBRINSKI, M; STEPIEN, G; SHOFFNER, JM; LOTT, MT; KANTER, K; WALLACE, DC				CORRALDEBRINSKI, M; STEPIEN, G; SHOFFNER, JM; LOTT, MT; KANTER, K; WALLACE, DC			HYPOXEMIA IS ASSOCIATED WITH MITOCHONDRIAL-DNA DAMAGE AND GENE INDUCTION - IMPLICATIONS FOR CARDIAC DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OXIDATIVE-PHOSPHORYLATION; MYOCARDIAL ISCHEMIA; PARKINSONS-DISEASE; FREE-RADICALS; REPERFUSION; MUTATIONS; DELETION; INCREASE; SEQUENCE; NUCLEAR	Objective. - Oxidative phosphorylation (OXPHOS) deficiency due to hypoxemia or other causes was hypothesized to increase oxygen radical generation, damage mitochondrial DNA (mtDNA), and reduce adenosine triphosphate synthesis, resulting in compensatory OXPHOS gene induction. Therefore, we investigated the levels of mtDNA damage and OXPHOS transcripts in normal and ischemic hearts, and then in other forms of heart disease. Design. - DNA was extracted from the heart and the levels of the common 4977 base pair mtDNA deletion were quantitated as an index for mtDNA damage. Total RNA was extracted from hearts and analyzed for OXPHOS transcript levels. Results. - In control hearts, the 4977 base pair mtDNA deletion appeared at age 40 years and reached a maximum deletion of 0.0035%. Much higher levels were found in ischemic hearts (0.02% to 0.85%), as well as in three of 10 cases with other types of heart disease (0.017% to 0.16%). The OXPHOS transcripts were increased in all diseased hearts. Conclusion. - Ischemic hearts have increased mtDNA damage and OXPHOS gene expression, suggesting that mtDNA damage is associated with OXPHOS deficiency. Oxidative phosphorylation defects may also play a role in some other forms of cardiac disease.	EMORY UNIV, SCH MED,DEPT GENET & MOLEC MED, 3031 ROLLINS RES CTR,1510 CLIFTON RD, ATLANTA, GA 30322 USA; EMORY UNIV, SCH MED, DEPT NEUROL, ATLANTA, GA 30322 USA; EMORY UNIV, SCH MED, DEPT BIOCHEM, ATLANTA, GA 30322 USA; EMORY UNIV, SCH MED, DEPT PEDIAT, ATLANTA, GA 30322 USA; EMORY UNIV, SCH MED, DEPT SURG, ATLANTA, GA 30322 USA; CTR COCHIN GENET MOLEC, PARIS, FRANCE; UNIV PARIS 11, CNRS, F-91405 ORSAY, FRANCE	Emory University; Emory University; Emory University; Emory University; Emory University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay				Lott, Marie/0000-0003-2035-479X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001336, R01NS021328] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45572] Funding Source: Medline; NINDS NIH HHS [NS01336, NS21328] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARROYO CM, 1987, FREE RADICAL BIO MED, V3, P313, DOI 10.1016/S0891-5849(87)80037-0; BANDY B, 1990, FREE RADICAL BIO MED, V8, P523, DOI 10.1016/0891-5849(90)90152-9; CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HATTORI K, 1991, AM HEART J, V121, P1735, DOI 10.1016/0002-8703(91)90020-I; IKEBE S, 1990, BIOCHEM BIOPH RES CO, V170, P1044, DOI 10.1016/0006-291X(90)90497-B; KOTAKA K, 1982, J MOL CELL CARDIOL, V14, P223, DOI 10.1016/0022-2828(82)90191-2; LOCHNER A, 1981, J MOL CELL CARDIOL, V13, P991, DOI 10.1016/0022-2828(81)90474-0; MCCORD JM, 1988, FREE RADICAL BIO MED, V4, P9, DOI 10.1016/0891-5849(88)90005-6; NECKELMANN N, 1987, P NATL ACAD SCI USA, V84, P7580, DOI 10.1073/pnas.84.21.7580; OTANI H, 1984, CIRC RES, V55, P168, DOI 10.1161/01.RES.55.2.168; OZAWA T, 1990, BIOCHEM BIOPH RES CO, V170, P830, DOI 10.1016/0006-291X(90)92166-W; PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606; PARKER WD, 1990, NEUROLOGY, V40, P1302, DOI 10.1212/WNL.40.8.1302; PIPER HM, 1985, J MOL CELL CARDIOL, V17, P885, DOI 10.1016/S0022-2828(85)80102-4; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; ROUSLIN W, 1983, AM J PHYSIOL, V244, pH743, DOI 10.1152/ajpheart.1983.244.6.H743; Sambrook J., 1989, MOL CLONING LAB MANU; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184; SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952; SHOFFNER JM, 1990, ADV HUM GENET, V19, P267; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; SHOFFNER JM, IN PRESS ANN NEUROL; TORRONI A, 1990, J BIOL CHEM, V265, P20589; TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0; WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8; WALLACE DC, 1987, CURR GENET, V12, P81, DOI 10.1007/BF00434661; WILKINSON L, 1989, SYSTAT SYSTEM STATIS; YEN TC, 1989, BIOCHEM BIOPH RES CO, V165, P994, DOI 10.1016/0006-291X(89)92701-0	30	301	307	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1991	266	13					1812	1816		10.1001/jama.266.13.1812	http://dx.doi.org/10.1001/jama.266.13.1812			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG551	1890710				2022-12-01	WOS:A1991GG55100034
J	GELERNTER, J; OMALLEY, S; RISCH, N; KRANZLER, HR; KRYSTAL, J; MERIKANGAS, K; KENNEDY, JL; KIDD, KK				GELERNTER, J; OMALLEY, S; RISCH, N; KRANZLER, HR; KRYSTAL, J; MERIKANGAS, K; KENNEDY, JL; KIDD, KK			NO ASSOCIATION BETWEEN AN ALLELE AT THE D2-DOPAMINE RECEPTOR GENE (DRD2) AND ALCOHOLISM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEHYDROGENASE; DEFICIENCY; JAPANESE; DISEASE; LIVER	Objective. - We attempted to replicate a positive allelic association between the A1 allele of DRD2 (the D2 dopamine receptor locus) and alcoholism that has been reported. Design. - We compared allele frequencies at the previously described Taq I restriction fragment length polymorphism system of DRD2 in alcoholics and random population controls. Subjects. - The alcoholic subjects were 44 unrelated white individuals, diagnosed by direct structured interview to have alcohol dependence (by the Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition, criteria). The subjects in our random population control group (N = 68) were also white. Results. - For the control group, allele frequencies at DRD2 were 0.20 (A1) and 0.80 (A2). For the alcoholic group overall, allele frequencies were 0.23 (A1) and 0.77 (A2). There were no significant differences in allele frequencies at the DRD2 locus between alcoholics and controls. The allele frequencies in both groups agreed closely with those observed in most previously described control populations. Subtyping the alcoholic group according to presence or absence of family history of alcoholism, presence or absence of antisocial personality disorder, age of onset, presence or absence of physical withdrawal symptoms, or recent alcohol consumption (as a measure of severity) did not in any case reveal significant differences in allele frequencies. Conclusion. - We were not able to replicate the results previously reported. We conclude that our data do not support an allelic association between the A1 allele at DRD2 and alcoholism.	YALE UNIV,SCH MED,DEPT PSYCHIAT,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,NEW HAVEN,CT 06510; UNIV CONNECTICUT,SCH MED,FARMINGTON,CT 06032; YALE UNIV,SCH MED,DEPT HUMAN GENET,NEW HAVEN,CT 06510	Yale University; Yale University; University of Connecticut; Yale University	GELERNTER, J (corresponding author), DEPT VET AFFAIRS MED CTR,950 CAMPBELL AVE,W HAVEN,CT 06516, USA.		kranzler, henry/AAS-1113-2020	kranzler, henry/0000-0002-1018-0450; Gelernter, Joel/0000-0002-4067-1859	NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH030929, P50MH030929] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA003510, R01AA008033] Funding Source: NIH RePORTER; NIAAA NIH HHS [5RO1AA08033, P50AA03510] Funding Source: Medline; NIMH NIH HHS [MH30929] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BLUM K, 1990, JAMA-J AM MED ASSOC, V263, P2055, DOI 10.1001/jama.263.15.2055; BOLOS AM, 1990, JAMA-J AM MED ASSOC, V264, P3156; Bowcock A M, 1987, Gene Geogr, V1, P47; BOWCOCK AM, 1991, P NATL ACAD SCI USA, V88, P839, DOI 10.1073/pnas.88.3.839; BREG WR, 1980, TRISOMY 21 DOWN SYND, P205; CLONINGER CR, 1987, SCIENCE, V236, P410, DOI 10.1126/science.2882604; COMINGS DE, 1990, AM J HUM GENET S, V47, P52; CONNEALLY PM, 1991, ARCH GEN PSYCHIAT, V48, P664; FINEMAN RM, 1976, NATURE, V260, P320, DOI 10.1038/260320a0; GELERNTER J, 1990, ARCH GEN PSYCHIAT, V47, P1073; GELERNTER J, 1990, AM J HUM GENET S, V447, P179; GOEDDE HW, 1979, HUM GENET, V51, P331; GOEDERS NE, 1983, SCIENCE, V221, P773, DOI 10.1126/science.6879176; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; GRANDY DK, 1989, AM J HUM GENET, V45, P778; HARADA S, 1982, LANCET, V2, P827, DOI 10.1016/s0140-6736(82)92722-2; HARADA S, 1981, LANCET, V2, P982; HAUGE XY, 1991, GENOMICS, V10, P527, DOI 10.1016/0888-7543(91)90431-D; LI TK, 1977, P NATL ACAD SCI USA, V74, P4378, DOI 10.1073/pnas.74.10.4378; MERIKANGAS KR, 1990, PSYCHIAT CLIN N AM, V13, P613; MERIKANGAS KR, 1990, PSYCHOL MED, V20, P11, DOI 10.1017/S0033291700013192; Modell J G, 1990, J Neuropsychiatry Clin Neurosci, V2, P123; MOISES HW, 1991, ARCH GEN PSYCHIAT, V48, P643; NOBLE EP, 1991, JAMA-J AM MED ASSOC, V265, P2667, DOI 10.1001/jama.1991.03460200047016; NOBLE EP, 1991, ARCH GEN PSYCHIAT, V48, P648; PARSIAN A, 1991, ARCH GEN PSYCHIAT, V48, P655; RISCH N, 1987, AM J HUM GENET, V40, P1; Robins LN, 1985, EPIDEMIOLOGIC FIELD, P143; Sambrook J., 1989, MOL CLONING LAB MANU; SHIBUYA A, 1988, AM J HUM GENET, V43, P744; SMITH SS, 1991, JAMA-J AM MED ASSOC, V265, P2667, DOI 10.1001/jama.1991.03460200047017; Sobell M. B., 1980, EVALUATING ALCOHOL D, P129, DOI DOI 10.1016/B978-0-08-022997-3.50013-2; Spitzer R., 1985, STRUCTURED CLIN INTE; Spitzer R.L., 1975, SCHEDULE AFFECTIVE D; THOMASSON HR, 1991, AM J HUM GENET, V48, P677; WEISSMAN MM, 1986, ARCH GEN PSYCHIAT, V43, P1104; WISE RA, 1988, J ABNORM PSYCHOL, V97, P118, DOI 10.1037/0021-843X.97.2.118; WISE RA, 1982, PHARMACOL BIOCHEM BE, V17, P239, DOI 10.1016/0091-3057(82)90076-4; WU JS, 1990, AM J HUM GENET, V46, P624; YOSHIDA A, 1984, P NATL ACAD SCI-BIOL, V81, P258, DOI 10.1073/pnas.81.1.258; 1980, DIAGNOSTIC STATISTIC; 1987, DIAGNOSTIC STATISTIC	42	223	228	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1991	266	13					1801	1807		10.1001/jama.266.13.1801	http://dx.doi.org/10.1001/jama.266.13.1801			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GG551	1832467				2022-12-01	WOS:A1991GG55100032
J	NIGHTINGALE, SL				NIGHTINGALE, SL			CONCENTRATED MORPHINE APPROVED FOR USE IN CONTINUOUS MICROINFUSION DEVICES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1991	266	13					1751	1751						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG551	1890706				2022-12-01	WOS:A1991GG55100004
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA-800 MEDICAL ADVERTISING INFORMATION LINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1991	266	13					1751	1751						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG551	1890706				2022-12-01	WOS:A1991GG55100005
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PUBLIC HEARING ON ORGAN AND TISSUE-TRANSPLANTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1991, FED REG         0830	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1991	266	13					1751	1751						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG551	1890706				2022-12-01	WOS:A1991GG55100003
J	NUSSLEINVOLHARD, C				NUSSLEINVOLHARD, C			FROM EGG TO ORGANISM - STUDIES ON EMBRYONIC PATTERN-FORMATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							BICOID PROTEIN; DROSOPHILA; POLARITY				NUSSLEINVOLHARD, C (corresponding author), MAX PLANCK INST ENTWICKLUNGSBIOL,GENET ABT 3,SPEMANNSTR 35-111,W-7400 TUBINGEN,GERMANY.							DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156	5	1	1	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1991	266	13					1848	1849		10.1001/jama.266.13.1848	http://dx.doi.org/10.1001/jama.266.13.1848			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG551	1890716				2022-12-01	WOS:A1991GG55100043
J	SCHAPIRA, DV; KUMAR, NB; LYMAN, GH; CAVANAGH, D; ROBERTS, WS; LAPOLLA, J				SCHAPIRA, DV; KUMAR, NB; LYMAN, GH; CAVANAGH, D; ROBERTS, WS; LAPOLLA, J			UPPER-BODY FAT DISTRIBUTION AND ENDOMETRIAL CANCER RISK	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREMENOPAUSAL WOMEN; ADIPOSE-TISSUE; BREAST-CANCER; OBESITY; ASSOCIATION; METABOLISM; WEIGHT; TOPOGRAPHY; CARCINOMA; ESTROGEN	Study Objective. - To determine if body fat distribution affected endometrial cancer risk. Design. - Case-control study. Setting. - This study was carried out at the H. Lee Moffitt Cancer Center at the University of South Florida, Tampa, where all patients in the case group received their diagnoses and histological confirmations. Patients. - Forty consecutive women newly diagnosed with endometrial cancer and 40 controls matched for age and Quetelet index. Main Outcome Measures. - Anthropometric measurements were taken for the abdomen, thigh, suprailiac, subscapular, biceps, and triceps skin fold thicknesses; waist and hip circumferences, weight, and height. Relative risks for endometrial cancer were calculated according to these anthropometric measurements. Results. - Case patients with endometrial cancer had significantly greater waist-to-hip circumference ratios (P < .001), abdomen-to-thigh skin fold ratios (P < .01), and suprailiac-to-thigh skin fold ratios (P = .02) compared with control subjects matched for age and Quetelet index. The relative risk for endometrial cancer increased with an increasing waist-to-hip circumference ratio (less-than-or-equal-to 1.14 = 1.0; > 1.14 = 15.0), with an increasing abdomen-to-thigh skin fold ratio (less-than-or-equal-to 0.82 = 1.0; > 0.82 = 5.0), and with an increasing suprailiac to-thigh skin fold thickness ratio (less-than-or-equal-to 0.67 = 1.0; > 0.67 = 3.50). Conclusion. - Upper-body fat localization is a significant risk factor for endometrial cancer in women matched for age and Quetelet index.			SCHAPIRA, DV (corresponding author), UNIV S FLORIDA,COLL MED,H LEE MOFFITT CANC CTR & RES INST,CANC PREVENT SECT,TAMPA,FL 33612, USA.		Lyman, Gary H/K-5227-2019; Kumar, Nagi/AGI-6573-2022	Lyman, Gary H/0000-0002-0823-8086; 				AUSTIN H, 1991, CANCER RES, V51, P568; BALLARDBARBASH R, 1990, J NATL CANCER I, V82, P286, DOI 10.1093/jnci/82.4.286; Behnke AR, 1974, EVALUATION REGULATIO; Cornfield J, 1961, B INT STAT I, V38, P97; ELLIOTT EA, 1990, GYNECOL ONCOL, V39, P253, DOI 10.1016/0090-8258(90)90247-I; ELWOOD JM, 1977, J NATL CANCER I, V59, P1055, DOI 10.1093/jnci/59.4.1055; ENRIORI CL, 1984, GYNECOL ONCOL, V17, P1, DOI 10.1016/0090-8258(84)90055-6; EVANS DJ, 1983, J CLIN ENDOCR METAB, V57, P304, DOI 10.1210/jcem-57-2-304; EVANS DJ, 1984, METABOLISM, V33, P68, DOI 10.1016/0026-0495(84)90164-1; FOLSOM AR, 1989, CANCER RES, V49, P6828; HARTZ AJ, 1983, PREV MED, V12, P351, DOI 10.1016/0091-7435(83)90244-X; HARTZ AJ, 1984, AM J EPIDEMIOL, V119, P71, DOI 10.1093/oxfordjournals.aje.a113727; HULKA BS, 1980, AM J OBSTET GYNECOL, V137, P92, DOI 10.1016/0002-9378(80)90391-9; KALKHOFF RK, 1983, J LAB CLIN MED, V102, P621; KATCH FI, 1980, RES Q EXERCISE SPORT, V51, P249, DOI 10.1080/02701367.1980.10609286; KELSEY JL, 1982, AM J EPIDEMIOL, V116, P333, DOI 10.1093/oxfordjournals.aje.a113417; KELSEY JL, 1983, BREAST GYNECOLOGIC C, P71; KEYS A, 1956, HUM BIOL, V28, P111; KIRSCHNER MA, 1990, J CLIN ENDOCR METAB, V70, P473, DOI 10.1210/jcem-70-2-473; KISSEBAH AH, 1982, J CLIN ENDOCR METAB, V54, P254, DOI 10.1210/jcem-54-2-254; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P430; LAPIDUS L, 1988, INT J OBESITY, V12, P361; MIETTINEN OS, 1970, BIOMETRICS, V26, P75, DOI 10.2307/2529046; NISKER JA, 1980, AM J OBSTET GYNECOL, V138, P637, DOI 10.1016/0002-9378(80)90080-0; PAGEL J, 1984, DAN MED BULL, V31, P333; PEIRIS AN, 1986, J CLIN INVEST, V78, P1648, DOI 10.1172/JCI112758; PETTERSSON B, 1985, ACTA U UPPSAL, V6, P1; SCHAPIRA DV, 1991, CANCER, V67, P2215, DOI 10.1002/1097-0142(19910415)67:8<2215::AID-CNCR2820670836>3.0.CO;2-Q; SCHAPIRA DV, 1990, ANN INTERN MED, V112, P182, DOI 10.7326/0003-4819-112-3-182; SCHAPIRA DV, 1991, CANCER, V67, P523, DOI 10.1002/1097-0142(19910115)67:2<523::AID-CNCR2820670234>3.0.CO;2-O; SCHAPIRA DV, 1991, CANCER, V67, P2622, DOI 10.1002/1097-0142(19910515)67:10<2622::AID-CNCR2820671037>3.0.CO;2-J; SEGAL KR, 1987, J CLIN INVEST, V80, P1050, DOI 10.1172/JCI113159; SIITERI PK, 1978, CANCER RES, V38, P4360; SJOSTROM L, 1972, METABOLISM, V21, P1143, DOI 10.1016/0026-0495(72)90109-6; SMITH U, 1979, EUR J CLIN INVEST, V9, P327, DOI 10.1111/j.1365-2362.1979.tb00892.x; SPENGLER RF, 1981, AM J EPIDEMIOL, V114, P497, DOI 10.1093/oxfordjournals.aje.a113215; WYNDER EL, 1966, CANCER, V19, P489, DOI 10.1002/1097-0142(196604)19:4<489::AID-CNCR2820190406>3.0.CO;2-W	37	85	86	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1991	266	13					1808	1811		10.1001/jama.266.13.1808	http://dx.doi.org/10.1001/jama.266.13.1808			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG551	1890709				2022-12-01	WOS:A1991GG55100033
J	CLEAVELAND, CR				CLEAVELAND, CR			CPR	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						PHYSICIAN-PATIENT RELATIONS; RESUSCITATION; MORTALITY; BURNOUT, PROFESSIONAL; STRESS, PSYCHOLOGICAL		A doctor, after a discouraging week at work, seeks respite in the new film version of Hamlet. However, real tragedy intervenes. In an adjoining theater, an old man collapses, the victim of an apparent cardiac arrest. The doctor responds to the appeal for medical help and does all he can to save the man. The intensity and cathartic nature of this experience lead to revelations and insights of interest to all doctors.											0	4	4	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1991	115	7					570	571		10.7326/0003-4819-115-7-570	http://dx.doi.org/10.7326/0003-4819-115-7-570			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG283	1810284				2022-12-01	WOS:A1991GG28300011
J	DRESSLER, F; YOSHINARI, NH; STEERE, AC				DRESSLER, F; YOSHINARI, NH; STEERE, AC			THE T-CELL PROLIFERATIVE ASSAY IN THE DIAGNOSIS OF LYME-DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						LYME DISEASE; LYMPHOCYTES-T; BORRELIA-BURGDORFERI; T-CELL PROLIFERATIVE ASSAY; ARTHRITIS	LINKED IMMUNOSORBENT-ASSAY; POLYMERASE CHAIN-REACTION; BORRELIA-BURGDORFERI; IMMUNE-COMPLEXES; NEUROLOGIC MANIFESTATIONS; ARTHRITIS; ANTIBODY; RESPONSES; LYMPHOCYTES; EVOLUTION	Objective: To determine the sensitivity and specificity of the T-cell proliferative assay as a diagnostic test in Lyme disease. Design: Cross-sectional study of patients with Lyme arthritis or chronic neuroborreliosis who had a history of erythema migrans, positive antibody responses to Borrelia burgdorferi by enzyme-linked immunosorbent assay (ELISA), or both; patients with other diseases; and healthy subjects. Setting: Diagnostic Lyme disease clinic in a university hospital. Patients: Forty-two of the 67 patients with active Lyme arthritis or chronic neuroborreliosis who were seen during the study period; 16 patients with inactive late Lyme disease; 77 patients with other rheumatologic or neurologic diseases; 9 workers from the Borrelia laboratory; and 9 healthy subjects. Measurements and Main Results: Nineteen of 42 patients with Lyme arthritis or chronic neuroborreliosis and 4 of 77 patients with other diseases had positive T-cell proliferative responses to B. burgdorferi antigens. The sensitivity of the proliferative assay was 45% (95% Cl, 30% to 60%) and the specificity was 95% (95% Cl, 87% to 99%). Twelve of 27 patients with active Lyme arthritis, 7 of 15 patients with chronic neuroborreliosis, 4 of 16 patients with inactive Lyme disease, 4 of 9 healthy Borrelia laboratory workers, and 0 of 9 healthy subjects had positive responses. Three of five patients with Lyme disease who had negative or indeterminant antibody responses by ELISA had positive T-cell proliferative responses. Conclusion: The T-cell proliferative assay may be a helpful diagnostic test in the small subset of patients with late Lyme disease who have negative or indeterminant antibody responses by ELISA.	TUFTS UNIV, NEW ENGLAND MED CTR, SCH MED, BOSTON, MA 02111 USA	Tufts Medical Center; Tufts University			Yoshinari, Natalino Hajime/E-8853-2012	Steere, Allen/0000-0002-5268-9853	NIAMS NIH HHS [AR-20358, AR-40576] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040576, R01AR020358] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BERARDI VP, 1988, J INFECT DIS, V158, P754, DOI 10.1093/infdis/158.4.754; CRAFT JE, 1984, J INFECT DIS, V149, P789, DOI 10.1093/infdis/149.5.789; DATTWYLER RJ, 1988, ANN NY ACAD SCI, V539, P93, DOI 10.1111/j.1749-6632.1988.tb31842.x; DATTWYLER RJ, 1988, NEW ENGL J MED, V319, P1441, DOI 10.1056/NEJM198812013192203; GRODZICKI RL, 1988, J INFECT DIS, V157, P790, DOI 10.1093/infdis/157.4.790; HALPERIN JJ, 1987, NEUROLOGY, V37, P1700, DOI 10.1212/WNL.37.11.1700; HARDIN JA, 1979, J CLIN INVEST, V63, P468, DOI 10.1172/JCI109324; HARDIN JA, 1979, NEW ENGL J MED, V301, P1358, DOI 10.1056/NEJM197912203012502; KRAUSE A, 1991, ARTHRITIS RHEUM-US, V34, P393, DOI 10.1002/art.1780340404; LASTAVICA CC, 1989, NEW ENGL J MED, V320, P133, DOI 10.1056/NEJM198901193200301; LOGIGIAN EL, 1990, NEW ENGL J MED, V323, P1438, DOI 10.1056/NEJM199011223232102; MAGNARELLI LA, 1984, J CLIN MICROBIOL, V20, P181, DOI 10.1128/JCM.20.2.181-184.1984; MASSAROTTI E, 1990, Arthritis and Rheumatism, V33, pS37; NEUMANN A, 1989, RHEUMATOL INT, V9, P237; PACHNER AR, 1985, NEUROLOGY, V35, P47, DOI 10.1212/WNL.35.1.47; PACHNER AR, 1985, NEUROLOGY, V35, P1642, DOI 10.1212/WNL.35.11.1642; PERSING DH, 1990, J CLIN MICROBIOL, V28, P566, DOI 10.1128/JCM.28.3.566-572.1990; PREACMURSIC V, 1989, INFECTION, V17, P355, DOI 10.1007/BF01645543; ROSA PA, 1989, J INFECT DIS, V160, P1018, DOI 10.1093/infdis/160.6.1018; RUSSELL H, 1984, J INFECT DIS, V149, P465, DOI 10.1093/infdis/149.3.465; SCHUTZER SE, 1990, LANCET, V335, P312, DOI 10.1016/0140-6736(90)90606-6; SHRESTHA M, 1985, AM J MED, V78, P235, DOI 10.1016/0002-9343(85)90432-2; SIGAL LH, 1986, ARTHRITIS RHEUM, V29, P761, DOI 10.1002/art.1780290609; STEERE AC, 1983, ANN INTERN MED, V99, P76, DOI 10.7326/0003-4819-99-1-76; STEERE AC, 1980, ANN INTERN MED, V93, P8, DOI 10.7326/0003-4819-93-1-8; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1983, ANN INTERN MED, V99, P22, DOI 10.7326/0003-4819-99-1-22; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725; YOSHINARI NH, 1991, ARTHRITIS RHEUM-US, V34, P707, DOI 10.1002/art.1780340611; ZOSCHKE DC, 1991, ANN INTERN MED, V114, P285, DOI 10.7326/0003-4819-114-4-285	30	72	72	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1991	115	7					533	539		10.7326/0003-4819-115-7-533	http://dx.doi.org/10.7326/0003-4819-115-7-533			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG283	1883122				2022-12-01	WOS:A1991GG28300005
J	GRUNSTEIN, RR; HO, KY; SULLIVAN, CE				GRUNSTEIN, RR; HO, KY; SULLIVAN, CE			SLEEP-APNEA IN ACROMEGALY	ANNALS OF INTERNAL MEDICINE			English	Article						ACROMEGALY; SLEEP APNEA SYNDROMES; SOMATOTROPIN; INSULIN-LIKE GROWTH FACTOR-I; HYPERTENSION	EPIDEMIOLOGY; MORTALITY	Objective: To provide information on the nature, prevalence, and severity of sleep apnea in patients with acromegaly. Design: Consecutive case series. Setting: Tertiary referral hospital. Patients: Fifty-three patients with acromegaly were consecutively referred: 33 patients were referred because of clinical suspicion of sleep apnea and 20 patients were referred without suspected apnea. Measurements: Sleep studies as well as growth hormone and insulin-like growth factor 1 (IGF-1) measurements were done. Main Results: Thirty-one patients (93%; 95% Cl, 85% to 100%) referred because of suspicion of sleep apnea had sleep apnea compared with 12 patients (60%; Cl, 37% to 83%) referred without suspected sleep apnea. Patients with sleep apnea did not have biochemical evidence of increased disease activity (random growth hormone, 12.7 +/- 4.4-mu-g/L; mean growth hormone at 24-hour sampling, 10.8 +/- 8.4-mu-g/L; IGF-1, 90.0 +/- 7.5 nmol/L) compared with patients without sleep apnea (random growth hormone, 14.2 +/- 4.9-mu-g/L, P > 0.2; mean growth hormone, 12.4 +/- 3.5-mu-g/L, P > 0.2; IGF-1, 90.0 +/- 10.0 nmol/L, P > 0.2). Central sleep apnea was the predominant type of apnea in 33% (Cl, 18% to 47%) of patients and was associated with higher random growth hormone and IGF-1 levels than was obstructive apnea (random growth hormone, 23.4 +/- 3.9 compared with 8.8 +/- 3.1-mu-g/L, P < 0.001; IGF-1, 126 +/- 17.5 compared with 72.5 +/- 7.5 nmol/L, P < 0.01). Conclusions: Sleep apnea is common in acromegaly. The rate of central sleep apnea was unexpectedly high in patients with acromegaly, and biochemical evidence of increased disease activity was associated with the presence of central apnea rather than with the degree of sleep apnea. Altered respiratory control is a possible mechanism producing sleep apnea in acromegaly.	ST VINCENTS HOSP, GARVAN INST MED RES, DARLINGHURST, NSW 2010, AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney	GRUNSTEIN, RR (corresponding author), ROYAL PRINCE ALFRED HOSP, SLEEP DISORDERS CTR, MISSENDEN RD, SYDNEY, NSW 2050, AUSTRALIA.							ALEXANDER L, 1980, CLIN ENDOCRINOL, V12, P71, DOI 10.1111/j.1365-2265.1980.tb03135.x; BAXTER RC, 1982, CLIN CHEM, V28, P488; BENGTSSON BA, 1988, ACTA MED SCAND, V223, P327; BENGTSSON BA, 1989, CLIN ENDOCRINOL, V30, P121, DOI 10.1111/j.1365-2265.1989.tb03733.x; BRADLEY TD, 1986, AM REV RESPIR DIS, V134, P217; CHAPPEL W, 1896, J LARYNGOL OTOL, V10, P142; DAUGHADAY WH, 1987, ACROMEGALY CENTURY S, P129; Guilleminault C., 1978, SLEEP APNEAS SYNDROM, V1, P1; HART TB, 1985, ARCH INTERN MED, V145, P865, DOI 10.1001/archinte.145.5.865; HE J, 1988, CHEST, V94, P9, DOI 10.1378/chest.94.1.9; HEDNER J, 1988, J HYPERTENS, V6, pS529, DOI 10.1097/00004872-198812040-00166; HO KY, 1990, ANN INTERN MED, V112, P173, DOI 10.7326/0003-4819-112-3-173; ISSA FG, 1986, CHEST, V90, P165, DOI 10.1378/chest.90.2.165; KALIA M, 1984, BRAIN RES, V296, P339, DOI 10.1016/0006-8993(84)90070-2; KARLBERG BE, 1982, ACTA ENDOCRINOL-COP, V100, P581, DOI 10.1530/acta.0.1000581; LAROCHE C, 1976, ANN MED INTERNE, V127, P381; LUGARESI E, 1980, SLEEP, V3, P221, DOI 10.1093/sleep/3.3-4.221; Marie P, 1886, REV MED-PARIS, V6, P297; MEZON BJ, 1980, AM J MED, V69, P615, DOI 10.1016/0002-9343(80)90477-5; PEKKARINEN T, 1987, CLIN ENDOCRINOL, V27, P649, DOI 10.1111/j.1365-2265.1987.tb02947.x; PERKS WH, 1980, BRIT MED J, V280, P894, DOI 10.1136/bmj.280.6218.894; Phillipson E.A., 1989, AM REV RESPIR DIS, V139, P559, DOI 10.1164/ajrccm/139.2.559; ROXBURGH F, 1896, BRIT MED J, V2, P63; SHEPARD JW, 1989, PRINCIPLES PRACTICE, P537; Sullivan C, 1984, LUNG BIOL HLTH DIS S, V21, P299; SULLIVAN CE, 1985, CLIN CHEST MED, V6, P633; VELDHUIS JD, 1986, AM J PHYSIOL, V250, pE486, DOI 10.1152/ajpendo.1986.250.4.E486; WHITE DP, 1989, PRINCIPLES PRACTICE, P513; WRIGHT AD, 1970, Q J MED, V39, P1	29	162	166	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1991	115	7					527	532		10.7326/0003-4819-115-7-527	http://dx.doi.org/10.7326/0003-4819-115-7-527			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG283	1883121				2022-12-01	WOS:A1991GG28300004
J	STRICKBERGER, SA; CANTILLON, CO; FRIEDMAN, PL				STRICKBERGER, SA; CANTILLON, CO; FRIEDMAN, PL			WHEN SHOULD PATIENTS WITH LETHAL VENTRICULAR ARRHYTHMIA RESUME DRIVING - AN ANALYSIS OF STATE REGULATIONS AND PHYSICIAN PRACTICES	ANNALS OF INTERNAL MEDICINE			English	Article						ARRHYTHMIA; ELECTRIC COUNTERSHOCK; DEATH, SUDDEN; AUTOMOBILE DRIVING; LEGISLATION, MEDICAL	IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; HOSPITAL CARDIAC-ARREST; FOLLOW-UP; SURVIVORS; FIBRILLATION; THERAPY	Most states have specific laws governing whether patients with seizure disorders can drive. To learn whether similar laws exist for patients with lethal ventricular arrhythmias, we surveyed the Departments of Motor Vehicles in all 50 states. In addition, either an arrhythmia specialist (n = 25) or a general cardiologist (n = 25) was chosen randomly from each state and interviewed to study physician awareness of such laws and physician attitudes toward driving by patients with arrhythmias. Forty-two states (84%) have laws restricting driving by patients who have seizures; only 8 states (16%) have specific laws for patients with arrhythmias. No state makes a distinction between driving by patients with arrhythmias who are managed with an implantable cardioverter-defibrillator (ICD) compared with patients who are managed medically. Seventy-four percent of physicians did not know their own state's laws about driving by patients who have ventricular arrhythmias. Cardiologists were more likely to advise no driving restriction for medically treated patients than for ICD-treated patients. Cardiologists were also more likely to advise permanent restriction for patients with ICDs than for patients treated medically. We conclude that greater legal and medical consensus is needed to guide physicians in advising patients with lethal ventricular arrhythmias about driving restrictions.	BRIGHAM & WOMENS HOSP, DIV CARDIOVASC, 75 FRANCIS ST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School								AXTELL KA, 1990, CIRCULATION, V82, P211; BAUM RS, 1974, CIRCULATION, V50, P1231, DOI 10.1161/01.CIR.50.6.1231; ECHT DS, 1985, CIRCULATION, V71, P289, DOI 10.1161/01.CIR.71.2.289; FOGOROS RN, 1989, PACE, V12, P1465, DOI 10.1111/j.1540-8159.1989.tb06151.x; LARSEN GC, 1990, CIRCULATION, V82, P83; LEHMANN MH, 1988, AM J CARDIOL, V62, P803, DOI 10.1016/0002-9149(88)91226-X; LIBERTHSON RR, 1974, NEW ENGL J MED, V291, P317, DOI 10.1056/NEJM197408152910701; MYERBURG RJ, 1982, JAMA-J AM MED ASSOC, V247, P1485, DOI 10.1001/jama.247.10.1485; MYERBURG RJ, 1987, CARDIAC ARRHYTHMIAS, P505; ROY D, 1983, AM J CARDIOL, V52, P969, DOI 10.1016/0002-9149(83)90514-3; RUSKIN JN, 1980, NEW ENGL J MED, V303, P607, DOI 10.1056/NEJM198009113031103; SKALE BT, 1986, AM J CARDIOL, V57, P113, DOI 10.1016/0002-9149(86)90962-8; TCHOU PJ, 1988, ANN INTERN MED, V109, P529, DOI 10.7326/0003-4819-109-7-529; WILBER DJ, 1988, NEW ENGL J MED, V318, P19, DOI 10.1056/NEJM198801073180105; WINKLE RA, 1989, J AM COLL CARDIOL, V13, P1353, DOI 10.1016/0735-1097(89)90310-0	15	39	39	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1991	115	7					560	563		10.7326/0003-4819-115-7-560	http://dx.doi.org/10.7326/0003-4819-115-7-560			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG283	1883126				2022-12-01	WOS:A1991GG28300009
J	ALBERTI, KGMM				ALBERTI, KGMM			THE HEALTH OF THE NATION - RESPONSES - ROLE OF DIABETES	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE				ALBERTI, KGMM (corresponding author), UNIV NEWCASTLE UPON TYNE, DEPT MED, NEWCASTLE UPON TYNE NE2 4HH, ENGLAND.							ANDERSEN AR, 1983, DIABETOLOGIA, V25, P496; [Anonymous], 1988, DIABETES, V37, P1574, DOI 10.2337/diabetes.37.11.15742903105; CAMPBELL I, 1991, DIABETIC MED, V8, P3, DOI 10.1111/j.1464-5491.1991.tb01507.x; CULLINAN TR, 1982, DIABETOLOGIA, V23, P504; DCCT Res Grp, 1987, DIABETES CARE, V10, P1; DOWSE GK, 1991, DIABETES CARE, V14, P271, DOI 10.2337/diacare.14.4.271; GALE EAM, 1981, DIABETOLOGIA, V21, P25, DOI 10.1007/BF03216218; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; HOME PD, IN PRESS DIABETES AN; MARSHALL SM, 1989, Q J MED, V70, P61; MATHER HM, 1985, BRIT MED J, V291, P1081, DOI 10.1136/bmj.291.6502.1081; MILLER LV, 1972, NEW ENGL J MED, V286, P1388, DOI 10.1056/NEJM197206292862605; MOGENSEN CE, 1988, DIABETES ANN 4, P411; NEIL HAW, 1987, DIABETIC MED, V4, P539, DOI 10.1111/j.1464-5491.1987.tb00926.x; POTTER J, 1982, BRIT MED J, V285, P1180, DOI 10.1136/bmj.285.6349.1180; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SCULPHER MJ, 1991, DIABETIC MED, V8, P644, DOI 10.1111/j.1464-5491.1991.tb01671.x; TUNBRIDGE WMG, 1981, LANCET, V2, P569; Williams D R, 1985, Diabet Med, V2, P27; 1989, VINCENT DECLARATION; 1983, DIABETOLOGIA, V24, P404; [No title captured]; 1985, PROVISION MED CARE A; 1991, CM1523; 1988, DIABETIC MED, V5, P79	25	6	6	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 28	1991	303	6805					769	772		10.1136/bmj.303.6805.769	http://dx.doi.org/10.1136/bmj.303.6805.769			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG981	1932942	Bronze, Green Published			2022-12-01	WOS:A1991GG98100027
J	GALLAGHER, G; MACKAY, I				GALLAGHER, G; MACKAY, I			DOCTORS AND DROPS	BRITISH MEDICAL JOURNAL			English	Article									CHARING CROSS HOSP,LONDON W6 8RP,ENGLAND	Imperial College London								CHALTON R, 1985, BRIT MED J, V291, P788, DOI 10.1136/bmj.291.6498.788; STAMMBERGER H, 1986, OTOLARYNG HEAD NECK, V94, P143, DOI 10.1177/019459988609400202	2	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1991	303	6805					761	761		10.1136/bmj.303.6805.761	http://dx.doi.org/10.1136/bmj.303.6805.761			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG981	1932938	Green Published, Bronze			2022-12-01	WOS:A1991GG98100023
J	LARSEN, JP				LARSEN, JP			PARKINSONS-DISEASE AS COMMUNITY-HEALTH PROBLEM - STUDY IN NORWEGIAN NURSING-HOMES	BRITISH MEDICAL JOURNAL			English	Article							EPIDEMIOLOGY	Objective - To examine the extent of underdiagnosis and overdiagnosis of Parkinson's disease and to determine quality of treatment in a defined population. Design - Clinical evaluation of an elderly population. Setting - 40 Norwegian nursing homes. Subjects - 3322 residents of nursing homes, of whom 500 were selected by nursing staff for evaluation on the basis of a structured information programme on Parkinson's disease and 269 were examined in detail by neurologists. Main outcome measures - Patients' scores on clinical rating scales, diagnosis of parkinsonism, and effect of changing drug treatment. Results - 169 (5.1%) patients were found to have clinical idiopathic Parkinson's disease, 31 of whom had not had the disease diagnosed previously. In addition, 31 patients without the disease were taking antiparkinsonian drugs unnecessarily. Eighty patients were judged to be receiving "optimal" treatment. In the remaining 58, the treatment was changed, and 36 patients showed a definite functional improvement after a 12 week observation period. Conclusions - The quality of life of many elderly patients with Parkinson's disease could be improved by increasing medical and neurological services.			LARSEN, JP (corresponding author), CENT HOSP ROGALAND,DEPT NEUROL,N-4011 STAVANGER,NORWAY.							BARBEAU A, 1984, CLIN NEUROL NEUROSUR, V86, P164, DOI 10.1016/0303-8467(84)90193-8; CROXSON S, 1989, GENERAL PRACTIT 1027, P4; DEPEDRO J, 1987, ACTA NEUROL SCA S112, V75, P40; Gottfries C G, 1982, Arch Gerontol Geriatr, V1, P311, DOI 10.1016/0167-4943(82)90031-0; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; LARSEN J P, 1988, Tidsskrift for den Norske Laegeforening, V108, P1377; LARSEN J P, 1988, Tidsskrift for den Norske Laegeforening, V108, P1380; MARSDEN CD, 1990, LANCET, V335, P948, DOI 10.1016/0140-6736(90)91006-V; MARSDEN CD, 1987, MOVEMENT DISORD, V2, P65; MARTILA RJ, 1987, HDB PARKINSONS DISEA, P38; MARTTILA RJ, 1976, ACTA NEUROL SCAND, V53, P81; MUTCH WJ, 1986, BRIT MED J, V292, P534, DOI 10.1136/bmj.292.6519.534; PLAYFER J, 1989, GERIATRIC MED, V19, P77; QUINN NP, 1986, BRIT MED J, V293, P379, DOI 10.1136/bmj.293.6543.379; RAJPUT AH, 1984, ANN NEUROL, V16, P278, DOI 10.1002/ana.410160303; SCHOENBERG BS, 1985, NEUROLOGY, V35, P841, DOI 10.1212/WNL.35.6.841; SCHOENBERG BS, 1987, MOVEMENT DISORD, V2, P17; WEBSTER DD, 1968, MOD TREAT, V5, P257	18	44	44	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1991	303	6805					741	743		10.1136/bmj.303.6805.741	http://dx.doi.org/10.1136/bmj.303.6805.741			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG981	1932932	Green Published, Bronze			2022-12-01	WOS:A1991GG98100017
J	MCLAUCHLIN, J; HALL, SM; VELANI, SK; GILBERT, RJ				MCLAUCHLIN, J; HALL, SM; VELANI, SK; GILBERT, RJ			HUMAN LISTERIOSIS AND PATE - A POSSIBLE ASSOCIATION	BRITISH MEDICAL JOURNAL			English	Article							MONOCYTOGENES; EPIDEMIOLOGY; BRITAIN	Objectives - To study trends in human listeriosis and determine possible sources of infection. Design - Descriptive analysis of laboratory reports of human listeriosis together with a survey of subtypes of Listeria monocytogenes isolated from patients and foodstuffs and an interview survey of patients to obtain food histories. Setting - United Kingdom and Republic of Ireland 1985 to 1990. Results - There was a near doubling in the incidence of human listeriosis in England, Wales, and Northern Ireland between 1985 and mid-1989 followed by a sharp decline. The upsurge in cases was caused largely by two strains of L monocytogenes, which accounted for 30-54% of the annual totals. These strains were less common before 1987 and after July 1989. A survey of pate in England and Wales in July 1989 showed that it frequently contained L monocytogenes. A similar survey in July 1990 showed a reduction in the proportions of samples contaminated. In 1989 pates from a single plant (manufacturer Y) were more likely to be contaminated by L monocytogenes and at higher levels than those from other producers. Most strains of L monocytogenes recovered from manufacturer Y's pate in 1989 were indistinguishable from those responsible for the 1987-9 upsurge in human listeriosis and were uncommon among isolates from pates from other manufacturers and from a wide range of other foodstuffs. Patients infected with the types of L monocytogenes found in pate were significantly more likely to have recently eaten pate than those affected by other strains. The start of the decline in numbers of cases of listeriosis coincided with government health warnings on pate consumption and the suspension of supplies from manufacturer Y. Conclusions - Contamination of pate was a likely contributory cause of the increase in the incidence of listeriosis between 1987 and 1989.	CENT PUBL HLTH LAB,PUBL HLTH LAB SERV,FOOD HYG LAB,LONDON NW9 5HT,ENGLAND; COMMUNICABLE DIS SURVEILLANCE CTR,PUBL HLTH LAB SERV,LONDON NW9 5EQ,ENGLAND	Public Health England; Public Health England	MCLAUCHLIN, J (corresponding author), CENT PUBL HLTH LAB,PUBL HLTH LAB SERV,DIV MICROBIOL REAGENTS & QUAL CONTROL,LONDON NW9 5HT,ENGLAND.							CAMPBELL DM, 1990, J INFECTION, V20, P241, DOI 10.1016/0163-4453(90)91219-4; Gilbert R. J., 1989, PHLS (Public Health Laboratory Service) Microbiology Digest, V6, P33; JOHNSON JL, 1990, J FOOD PROTECT, V53, P81, DOI 10.4315/0362-028X-53.1.81; JONES D, 1990, LANCET, V336, P1171, DOI 10.1016/0140-6736(90)92778-G; MCLAUCHLIN J, 1987, J APPL BACTERIOL, V63, P1, DOI 10.1111/j.1365-2672.1987.tb02411.x; MCLAUCHLIN J, 1989, J INFECTION, V18, P179, DOI 10.1016/S0163-4453(89)91290-5; MCLAUCHLIN J, 1986, J MED MICROBIOL, V22, P367, DOI 10.1099/00222615-22-4-367; MCLAUCHLIN J, 1990, EPIDEMIOL INFECT, V104, P191, DOI 10.1017/S0950268800059355; MORRIS IJ, 1989, LANCET, V2, P1285; SAUNDERS NA, 1989, ACTA MICROBIOL HUNG, V36, P205; 1989, LISTERIA FOUND PATE; 1989, ADVICE VULNERABLE GR; 1989, DHSS PLCMO893 DEP HL	13	188	194	1	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1991	303	6805					773	775		10.1136/bmj.303.6805.773	http://dx.doi.org/10.1136/bmj.303.6805.773			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG981	1932944	Green Published, Bronze			2022-12-01	WOS:A1991GG98100029
J	RAY, R; AGGARWAL, R; SALUNKE, PN; MEHROTRA, NN; TALWAR, GP; NAIK, SR				RAY, R; AGGARWAL, R; SALUNKE, PN; MEHROTRA, NN; TALWAR, GP; NAIK, SR			HEPATITIS-E VIRUS GENOME IN STOOLS OF HEPATITIS PATIENTS DURING LARGE EPIDEMIC IN NORTH-INDIA	LANCET			English	Note							NON-B HEPATITIS; TRANSMITTED NON-A	Stool samples from patients affected during a large epidemic of hepatitis in north India were examined for the presence of hepatitis E virus (HEV) genome by means of reverse transcription-polymerase chain reaction. 6 to 10 samples studied were positive for the HEV genome, which suggests that HEV caused this large epidemic.	SANJAY GANDHI POSTGRAD INST MED SCI,DEPT GASTROENTEROL,PB 375,RAEBARELI RD,LUCKNOW 226001,INDIA; NATL INST IMMUNOL,NEW DELHI,INDIA; CENT DRUG RES INST,LUCKNOW 226001,UTTAR PRADESH,INDIA	Sanjay Gandhi Postgraduate Institute of Medical Sciences; Department of Biotechnology (DBT) India; National Institute of Immunology (NII); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI)			Aggarwal, Rakesh/D-1583-2009	Aggarwal, Rakesh/0000-0001-9689-494X				ARANKALLE VA, 1988, LANCET, V2, P550; BRADLEY DW, 1990, BRIT MED BULL, V46, P442, DOI 10.1093/oxfordjournals.bmb.a072409; BRADLEY DW, 1987, P NATL ACAD SCI USA, V84, P6277, DOI 10.1073/pnas.84.17.6277; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Khuroo M S, 1991, Indian J Gastroenterol, V10, P96; KHUROO MS, 1980, AM J MED, V68, P818, DOI 10.1016/0002-9343(80)90200-4; RAMALINGASWAMI V, 1988, LANCET, V1, P571; REYES GR, 1990, SCIENCE, V247, P1335, DOI 10.1126/science.2107574; Viswanathan R., 1957, INDIAN J MED RES S, V45, P1; ZUCKERMAN AJ, 1990, BRIT MED J, V300, P1475, DOI 10.1136/bmj.300.6738.1475	10	70	71	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 28	1991	338	8770					783	784		10.1016/0140-6736(91)90667-E	http://dx.doi.org/10.1016/0140-6736(91)90667-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG979	1681163				2022-12-01	WOS:A1991GG97900006
J	RUTGEERTS, P; GOBOES, K; PEETERS, M; HIELE, M; PENNINCKX, F; AERTS, R; KERREMANS, R; VANTRAPPEN, G				RUTGEERTS, P; GOBOES, K; PEETERS, M; HIELE, M; PENNINCKX, F; AERTS, R; KERREMANS, R; VANTRAPPEN, G			EFFECT OF FECAL STREAM DIVERSION ON RECURRENCE OF CROHNS-DISEASE IN THE NEOTERMINAL ILEUM	LANCET			English	Article							FECAL STREAM; COLITIS; ILEOSTOMY; COLON; MANAGEMENT; RESECTION; SURGERY	Aphthous lesions recur in the neoterminal ileum within the first few months after curative resection of the distal ileum in patients with Crohn's disease. These lesions do not originate from microscopic disease that is already present at the time of surgery. To investigate the importance of faecal stream in the pathogenesis of recurrent Crohn's lesions, we have studied 5 patients with Crohn's disease who had ileal resection. After curative resection and ileocolonic anastomosis, a diverting terminal ileostomy was constructed 25-35 cm proximal to the anastomosis thereby excluding the neoterminal ileum, the anastomosis, and the colon from intestinal transit. After six months of exclusion, endoscopy of the ileocolon was undertaken and biopsy specimens were taken. Transit was then restored. Six months after reanastomosis further biopsy specimens were taken. These patients were compared with a control group of 75 patients with Crohn's disease who underwent a one-step ileal resection and ileocolonic anastomosis. None of the 5 patients had endoscopic lesions in the neoterminal ileum after six months of exclusion and biopsies did not show inflammatory changes characteristic of Crohn's disease. By contrast, 53 of 75 patients with one-step surgery had endoscopic recurrence in the neoterminal ileum within six months of surgery. All 5 patients had an important recurrence of disease, both endoscopically and histologically, at ileocolonoscopy six months after reanastomosis. Our findings strongly support the view that recurrence of Crohn's disease in the neoterminal ileum after curative ileal resection is dependent on faecal stream.	UNIV HOSP LEUVEN,DEPT MED,LOUVAIN,BELGIUM; UNIV HOSP LEUVEN,DEPT SURG,LOUVAIN,BELGIUM; UNIV HOSP LEUVEN,DEPT PATHOL,LOUVAIN,BELGIUM	KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven			Peeters, Marc/C-5525-2013	Peeters, Marc/0000-0003-4969-2303				AUFSES AH, 1971, ANN SURG, V73, P91; BURMAN JH, 1971, GUT, V12, P11, DOI 10.1136/gut.12.1.11; GLOTZER DJ, 1981, GASTROENTEROLOGY, V80, P438; GREENSTEIN AJ, 1988, GUT, V29, P588, DOI 10.1136/gut.29.5.588; HARPER PH, 1985, GUT, V26, P279, DOI 10.1136/gut.26.3.279; HARPER PH, 1983, GUT, V24, P106, DOI 10.1136/gut.24.2.106; JONES JH, 1966, GUT, V7, P448, DOI 10.1136/gut.7.5.448; LESCUT D, 1990, GASTROENTEROL CLIN B, V4, pA20; MALCHOW H, 1987, GASTROINTEST ENDOSC, V33, P163; MCILRATH DC, 1971, ARCH SURG-CHICAGO, V103, P308; NUGENT FW, 1973, GASTROENTEROLOGY, V65, P398; OLAISON G, IN PRESS GUT; RUTGEERTS P, 1984, GUT, V25, P665, DOI 10.1136/gut.25.6.665; RUTGEERTS P, 1990, GASTROENTEROLOGY, V99, P950; TYTGAT GNJ, 1988, ENDOSCOPY, V20, P260, DOI 10.1055/s-2007-1018188; WILLIAMS JG, 1991, BRIT J SURG, V78, P10, DOI 10.1002/bjs.1800780106; WINSLET MC, 1988, GUT, V29, pA1475; ZELAS P, 1980, ANN SURG, V191, P164, DOI 10.1097/00000658-198002000-00006	18	584	590	0	26	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 28	1991	338	8770					771	774		10.1016/0140-6736(91)90663-A	http://dx.doi.org/10.1016/0140-6736(91)90663-A			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG979	1681159				2022-12-01	WOS:A1991GG97900002
J	SKARFORS, ET; SELINUS, KI; LITHELL, HO				SKARFORS, ET; SELINUS, KI; LITHELL, HO			RISK-FACTORS FOR DEVELOPING NON-INSULIN-DEPENDENT DIABETES - A 10 YEAR FOLLOW-UP OF MEN IN UPPSALA	BRITISH MEDICAL JOURNAL			English	Article							IMPAIRED GLUCOSE-TOLERANCE; PIMA-INDIANS; ESSENTIAL-HYPERTENSION; RESISTANCE; OBESITY; METABOLISM; MELLITUS; HISTORY; SODIUM	Objective - To analyse anthropometric and metabolic characteristics as risk factors for development of non-insulin dependent diabetes mellitus in middle aged normoglycaemic men. Design - Prospective population study based on data collected in a health survey and follow up 10 years later. Setting - Uppsala, a middle sized city in Sweden. Subjects - 2322 men aged 47-53, of whom 1860 attended the follow up 7-14 years later, at which time they were aged 56-64. Main outcome measures - Incidence of non-insulin dependent diabetes. Results - In a multivariate logistic regression analysis, variations of 1 SD from the mean of the group that remained euglycaemic were used to calculate odds ratios and 95% confidence intervals. Blood glucose concentration 60 minutes after the start of an intravenous glucose tolerance test (odds ratio = 5.93, 95% confidence interval 3.05 to 11.5), fasting serum insulin concentration (2.12, 1.54 to 2.93), acute insulin increment at an intravenous glucose tolerance test (1.71, 1.21 to 2.43), body mass index (1.41, 1.01 to 1.97), and systolic blood pressure (1.23, 0.97 to 1.56) were independent predictors of diabetes. In addition, the use of antihypertensive drugs at follow up (selective or unselective beta-blocking agents, thiazides, or hydralazine) was an independent risk factor (1.70, 1.11 to 2.60). Conclusions - Metabolic and anthropometric characteristics associated with or reflecting insulin resistance as well as a poor acute insulin response to glucose challenge were important predictors of future diabetes in middle aged men. Antihypertensive drugs were found to constitute a further, iatrogenic risk factor.			SKARFORS, ET (corresponding author), UNIV UPPSALA,DEPT GERIATR,S-75012 UPPSALA,SWEDEN.							BARNETT AH, 1982, SERONO S, V47, P225; BENGTSSON C, 1984, BMJ-BRIT MED J, V289, P1495, DOI 10.1136/bmj.289.6457.1495; BOBERG J, 1976, SCAND J CLIN LAB INV, V36, P145, DOI 10.3109/00365517609055241; BURSTEIN M, 1960, CLIN CHIM ACTA, V5, P609, DOI 10.1016/0009-8981(60)90075-9; CERASI E, 1967, DIABETES, V16, P615, DOI 10.2337/diab.16.9.615; CERASI E, 1967, ACTA ENDOCRINOL-COP, V55, P278, DOI 10.1530/acta.0.0550278; COLLEN MF, 1969, ARCH INTERN MED, V123, P664, DOI 10.1001/archinte.123.6.664; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DEFRONZO RA, 1975, J CLIN INVEST, V55, P845, DOI 10.1172/JCI107996; DIXON WJ, 1981, BMDP STATISTICAL SOF, P330; EDWARDS DAW, 1955, BRIT J NUTR, V9, P133, DOI 10.1079/BJN19550021; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; HAFFNER SM, 1988, NEW ENGL J MED, V319, P1297, DOI 10.1056/NEJM198811173192001; HAFFNER SM, 1989, DIABETES S2, V38, pA92; HARVALD B, 1963, ACTA MED SCAND, V173, P459; HEDSTRAND H, 1975, SCAND J CLIN LAB INV, V35, P331, DOI 10.3109/00365517509095749; HESTRAND H, 1975, UPSALA J MED SCI S, V19, P28; HILTON PJ, 1986, NEW ENGL J MED, V314, P222, DOI 10.1056/NEJM198601233140407; IKKOS D, 1957, ACTA ENDOCRINOL-COP, V25, P312, DOI 10.1530/acta.0.0250312; KADOWAKI T, 1984, DIABETOLOGIA, V26, P44, DOI 10.1007/BF00252262; KEEN H, 1982, DIABETOLOGIA, V22, P73, DOI 10.1007/BF00254832; KNOWLER WC, 1981, AM J EPIDEMIOL, V113, P144, DOI 10.1093/oxfordjournals.aje.a113079; KNOWLER WC, 1989, DIABETES S2, V38, pA92; LEE ET, 1985, DIABETES CARE, V8, P107, DOI 10.2337/diacare.8.2.107; LILLIOJA S, 1988, NEW ENGL J MED, V318, P1217, DOI 10.1056/NEJM198805123181901; LITHELL H, 1984, ACTA MED SCAND, V215, P403; LUFT R, 1981, DIABETES CARE, V4, P58, DOI 10.2337/diacare.4.1.58; LUNDGREN H, 1988, BRIT MED J, V297, P1512, DOI 10.1136/bmj.297.6662.1512; LUNDGREN H, 1990, DIABETIC MED, V7, P407, DOI 10.1111/j.1464-5491.1990.tb01415.x; NAGULESPARAN M, 1979, DIABETES, V28, P980, DOI 10.2337/diabetes.28.11.980; OHLSON LO, 1985, DIABETES, V34, P1055, DOI 10.2337/diabetes.34.10.1055; OSULLIVAN JB, 1968, NEW ENGL J MED, V278, P1038, DOI 10.1056/NEJM196805092781904; POLLARE T, 1990, METABOLISM, V39, P167, DOI 10.1016/0026-0495(90)90071-J; POLLARE T, 1989, BRIT MED J, V298, P1152, DOI 10.1136/bmj.298.6681.1152; POLLARE T, 1989, NEW ENGL J MED, V321, P868, DOI 10.1056/NEJM198909283211305; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; ROWE JW, 1981, DIABETES, V30, P219, DOI 10.2337/diab.30.3.219; RUSH RL, 1971, ADV AUTOMAT ANAL, V1, P503; SAAD MF, 1988, NEW ENGL J MED, V319, P1500, DOI 10.1056/NEJM198812083192302; SAYEGH HAI, 1979, LANCET, V1, P431; SKARFORS ET, 1989, BRIT MED J, V298, P1147, DOI 10.1136/bmj.298.6681.1147; WAHLBERG F, 1966, ACTA MED SCAND S453, V180, P22; 1979, DIABETES, V28, P1039; 1985, WHO TECH REP SER, V724, P183	44	172	174	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1991	303	6805					755	760		10.1136/bmj.303.6805.755	http://dx.doi.org/10.1136/bmj.303.6805.755			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG981	1932936	Bronze, Green Published			2022-12-01	WOS:A1991GG98100021
J	TUNSTALLPEDOE, H				TUNSTALLPEDOE, H			THE DUNDEE CORONARY RISK-DISK FOR MANAGEMENT OF CHANGE IN RISK-FACTORS	BRITISH MEDICAL JOURNAL			English	Article							SCOTTISH-HEART-HEALTH; DISEASE-PREVENTION-PROJECT; CHOLESTEROL; MORTALITY	Objective - To devise a simplified system for grading and monitoring modifiable coronary risk in primary care, to be used with an action plan. Methods - The risk equation came from 5203 men aged 40-59 in the United Kingdom heart disease prevention project, who had 331 coronary events over five years; the population rank (reading 1-100) was obtained by scoring 10359 participants in the Scottish heart health study. Calculation of rank was embodied in the Dundee coronary risk-disk; the formula was tested against the Whitehall study; disk and action plan were evaluated in primary care. Results - The system measures modifiable coronary risk from smoking, blood pressure, and blood cholesterol concentration by a sex and age related rank running from 1 (high risk, priority action) to 100 (low risk, general advice). The formula predicted outcome acceptably in the Whitehall study and is built into a circular slide rule. Only eight (11%) of 76 general practitioners and practice nurses surveyed already used risk factor scores. After evaluation most thought they should use one and proposed to incorporate the Dundee coronary risk-disk and the associated action plan into their routines. Conclusion - The Dundee coronary risk-disk readout of Dundee rank, standardised on a scale of 1 to 100 by age and sex, is a simple, valid means of assessing and monitoring modifiable coronary risk. It puts single risk factors (such as cholesterol concentration) in perspective and can aid selective testing. Understood by medical staff and patients, it should improve the efficiency and effectiveness of the high risk approach to coronary prevention.			TUNSTALLPEDOE, H (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,CARDIOVASC EPIDEMIOL UNIT,DUNDEE DD1 9SY,SCOTLAND.							CHAMBLESS LE, 1990, STAT MED, V9, P385, DOI 10.1002/sim.4780090410; HELLER RF, 1984, BRIT MED J, V288, P1409, DOI 10.1136/bmj.288.6428.1409; JARRETT RJ, 1982, BRIT MED J, V285, P535, DOI 10.1136/bmj.285.6341.535; LEE AJ, 1990, J CLIN EPIDEMIOL, V43, P913, DOI 10.1016/0895-4356(90)90075-Z; PETRIE JC, 1986, BRIT MED J, V293, P611, DOI 10.1136/bmj.293.6547.611; ROSE G, 1983, LANCET, V1, P1062; Shaper A G, 1987, Health Trends, V19, P37; SMITH WCS, 1989, SCOT MED J, V34, P550, DOI 10.1177/003693308903400603; SMITH WCS, 1990, J CLIN EPIDEMIOL, V43, P637, DOI 10.1016/0895-4356(90)90033-L; THORSEN RD, 1979, PREV MED, V8, P548, DOI 10.1016/0091-7435(79)90330-X; TUNSTALLPEDOE H, 1989, BMJ-BRIT MED J, V298, P1593, DOI 10.1136/bmj.298.6688.1593; TUNSTALLPEDOE H, 1989, LANCET, V1, P540; 1989, BMJ, V298, P694; 1991, BMJ, V303, P748; 1988, J CLIN EPIDEMIOL, V41, P105; 1991, BMJ, V302, P1057; [No title captured]	17	117	119	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1991	303	6805					744	747		10.1136/bmj.303.6805.744	http://dx.doi.org/10.1136/bmj.303.6805.744			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG981	1932933	Green Published, Bronze			2022-12-01	WOS:A1991GG98100018
J	WILSON, P; LEESE, T; MORGAN, WP; KELLY, JF; BRIGG, JK				WILSON, P; LEESE, T; MORGAN, WP; KELLY, JF; BRIGG, JK			ELECTIVE LAPAROSCOPIC CHOLECYSTECTOMY FOR ALL-COMERS	LANCET			English	Article								Laparoscopic cholecystectomy is a safe and effective procedure in specialist centres, but its wider application will depend on the ability of general surgeons to become skilled in this technique. 180 patients underwent elective laparoscopic cholecystectomy during a nine-month period at a single district general hospital. All patients who would have been eligible for elective open cholecystectomy were offered the laparoscopic alternative. Laparoscopic cholecystectomy was abandoned in favour of an open procedure in 10 (6%) patients. Median operating time was 55 min. 2 patients had serious morbidity (right hepatic duct injury and a duodenal fistula) and there were no deaths. 3 patients required subsequent treatment for retained common duct stones. 90% of patients were discharged within 48 h of the operation and the median time to resume full activity after discharge was 12 days. Laparoscopic cholecystectomy is a safe and cost-effective technique in a district general hospital.	ROYAL LANCASTER INFIRM,DEPT SURG,LANCASTER LA1 4RP,ENGLAND									CUSCHIERI A, 1991, AM J SURG, V161, P385, DOI 10.1016/0002-9610(91)90603-B; DENT TL, 1991, AM J SURG, V161, P399, DOI 10.1016/0002-9610(91)90607-F; GRACE PA, 1991, BRIT J SURG, V78, P160, DOI 10.1002/bjs.1800780209; PATERSONBROWN S, 1991, BRIT J SURG, V78, P131, DOI 10.1002/bjs.1800780203; REDDICK E J, 1989, Surgical Endoscopy, V3, P131, DOI 10.1007/BF00591357; SULLIVAN DM, 1982, AM J SURG, V143, P218, DOI 10.1016/0002-9610(82)90072-1; TODD GJ, 1978, AM J SURG, V135, P622, DOI 10.1016/0002-9610(78)90121-6; 1991, AM J SURG, V161, P324	8	78	79	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 28	1991	338	8770					795	797		10.1016/0140-6736(91)90674-E	http://dx.doi.org/10.1016/0140-6736(91)90674-E			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG979	1681169				2022-12-01	WOS:A1991GG97900013
J	MADDEN, SL; COOK, DM; MORRIS, JF; GASHLER, A; SUKHATME, VP; RAUSCHER, FJ				MADDEN, SL; COOK, DM; MORRIS, JF; GASHLER, A; SUKHATME, VP; RAUSCHER, FJ			TRANSCRIPTIONAL REPRESSION MEDIATED BY THE WT1 WILMS-TUMOR GENE-PRODUCT	SCIENCE			English	Article							FINGER POLYPEPTIDE GENE; MAMMALIAN-CELLS; SEQUENCE; ACTIVATION; BINDING; LOCUS; EXPRESSION; PROTEIN; SITE; FOS	The wt1 gene, a putative tumor suppressor gene located at the Wilms tumor (WT) locus on chromosome 11p13, encodes a zinc finger-containing protein that binds to the same DNA sequence as EGR-1, a mitogen-inducible immediate-early gene product that activates transcription. The transcriptional regulatory potential of WT1 has not been demonstrated. In transient transfection assays, the WT1 protein functioned as a repressor of transcription when bound to the EGR-1 site. The repression function was mapped to the glutamine- and proline-rich NH2-terminus of WT1; fusion of this domain to the zinc finger region of EGR-1 converted EGR-1 into a transcriptional repressor.	WISTAR INST, 3601 SPRUCE ST, PHILADELPHIA, PA 19104 USA; HOWARD HUGHES MED INST, DEPT MED MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA	The Wistar Institute; Howard Hughes Medical Institute			Sukhatme, Vikas/W-2776-2019		NATIONAL CANCER INSTITUTE [P01CA052009, R01CA023413] Funding Source: NIH RePORTER; NCI NIH HHS [CA-52009, CA-23413, CA-0917-15] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COOK DM, UNPUB; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COWELL JK, 1991, ONCOGENE, V6, P595; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUFF V, 1991, AM J HUM GENET, V48, P997; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; MADDEN SL, UNPUB; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORGAN JI, 1989, TRENDS NEUROSCI, V12, P459, DOI 10.1016/0166-2236(89)90096-9; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; MORRIS JDH, IN PRESS ONCOGENE; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; ROYERPOKORA B, 1991, GENE CHROMOSOME CANC, V3, P89, DOI 10.1002/gcc.2870030203; SPAETE RR, 1985, J VIROL, V56, P135, DOI 10.1128/JVI.56.1.135-143.1985; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; TON CCT, 1991, GENOMICS, V10, P293, DOI 10.1016/0888-7543(91)90516-H	31	497	515	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 27	1991	253	5027					1550	1553		10.1126/science.1654597	http://dx.doi.org/10.1126/science.1654597			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG651	1654597				2022-12-01	WOS:A1991GG65100044
J	SINGER, D; BIEL, M; LOTAN, I; FLOCKERZI, V; HOFMANN, F; DASCAL, N				SINGER, D; BIEL, M; LOTAN, I; FLOCKERZI, V; HOFMANN, F; DASCAL, N			THE ROLES OF THE SUBUNITS IN THE FUNCTION OF THE CALCIUM-CHANNEL	SCIENCE			English	Article							SKELETAL-MUSCLE; XENOPUS OOCYTES; DIHYDROPYRIDINE RECEPTOR; GAMMA-SUBUNIT; MESSENGER-RNA; ION CHANNELS; HEART-CELLS; RAT-HEART; EXPRESSION; INACTIVATION	Dihydropyridine-sensitive voltage-dependent L-type calcium channels are critical to excitation-secretion and excitation-contraction coupling. The channel molecule is a complex of the main, pore-forming subunit alpha-1 and four additional subunits: alpha-2, delta, beta, and gamma (alpha-2 and delta are encoded by a single messenger RNA). The alpha-1 subunit messenger RNA alone directs expression of functional calcium channels in Xenopus oocytes, and coexpression of the alpha-2/delta and beta-subunits enhances the amplitude of the current. The alpha-2, delta, and gamma-subunits also have pronounced effects on its macroscopic characteristics, such as kinetics, voltage dependence of activation and inactivation, and enhancement by a dihydropyridine agonist. In some cases, specific modulatory functions can be assigned to individual subunits, whereas in other cases the different subunits appear to act in concert to modulate the properties of the channel.	TEL AVIV UNIV, SACKLER SCH MED, DEPT PHYSIOL & PHARMACOL, IL-69978 TEL AVIV, ISRAEL; TECH UNIV MUNICH, INST PHARMACOL & TOXIKOL, W-8000 MUNICH 40, GERMANY; UNIV SAARLAND, INST MED BIOCHEM, W-6650 HOMBURG, GERMANY	Tel Aviv University; Sackler Faculty of Medicine; Technical University of Munich; Saarland University			Tuluc, Petronel/C-2527-2011; Dascal, Nathan/O-3915-2015; Biel, Martin/G-1175-2014	Dascal, Nathan/0000-0002-5397-4146; Biel, Martin/0000-0002-9974-3052				AARONSON PI, 1988, J PHYSIOL-LONDON, V405, P57, DOI 10.1113/jphysiol.1988.sp017321; ADAMS BA, 1990, NATURE, V346, P569, DOI 10.1038/346569a0; AUDET RG, 1987, DEV BIOL, V121, P58, DOI 10.1016/0012-1606(87)90138-2; BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; BIEL M, UNPUB; BIEL M, IN PRESS EUR J BIOCH; BOSSE E, 1990, FEBS LETT, V267, P153, DOI 10.1016/0014-5793(90)80312-7; BROWN AM, 1986, J PHYSIOL-LONDON, V379, P495, DOI 10.1113/jphysiol.1986.sp016266; CAMPBELL DL, 1988, J PHYSIOL-LONDON, V403, P287, DOI 10.1113/jphysiol.1988.sp017250; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHANG FC, 1988, J BIOL CHEM, V263, P18929; COGNARD C, 1986, P NATL ACAD SCI USA, V83, P1518, DOI 10.1073/pnas.83.5.1518; DASCAL N, 1986, SCIENCE, V231, P1147, DOI 10.1126/science.2418503; DASCAL N, UNPUB; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; DONALDSON PL, 1983, J GEN PHYSIOL, V82, P449, DOI 10.1085/jgp.82.4.449; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; GLOSSMANN H, 1990, REV PHYSL BIOCH PHAR, V114, P1; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HERING S, 1989, PFLUG ARCH EUR J PHY, V414, P690, DOI 10.1007/BF00582137; Hille B, 1984, IONIC CHANNELS EXCIT; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; Hofmann F, 1990, Curr Top Cell Regul, V31, P223; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; KASS RS, 1987, J GEN PHYSIOL, V89, P629, DOI 10.1085/jgp.89.4.629; KASS RS, 1984, J GEN PHYSIOL, V84, P705, DOI 10.1085/jgp.84.5.705; KRAFTE DS, 1990, J GEN PHYSIOL, V96, P689, DOI 10.1085/jgp.96.4.689; LEE KS, 1985, J PHYSIOL-LONDON, V364, P395, DOI 10.1113/jphysiol.1985.sp015752; LORY P, 1990, J PHYSIOL-LONDON, V429, P95, DOI 10.1113/jphysiol.1990.sp018246; LOTAN I, 1989, SCIENCE, V243, P666, DOI 10.1126/science.2464853; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; MORTON ME, 1989, NEURON, V2, P1499, DOI 10.1016/0896-6273(89)90196-7; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SANCHEZ JA, 1983, J PHYSIOL-LONDON, V337, P1; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; UMBACH JA, 1987, P NATL ACAD SCI USA, V84, P5464, DOI 10.1073/pnas.84.15.5464; WALSH KB, 1989, J GEN PHYSIOL, V93, P841, DOI 10.1085/jgp.93.5.841	43	470	482	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 27	1991	253	5027					1553	1557		10.1126/science.1716787	http://dx.doi.org/10.1126/science.1716787			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG651	1716787	Green Submitted			2022-12-01	WOS:A1991GG65100045
J	STCLAIR, MH; MARTIN, JL; TUDORWILLIAMS, G; BACH, MC; VAVRO, CL; KING, DM; KELLAM, P; KEMP, SD; LARDER, BA				STCLAIR, MH; MARTIN, JL; TUDORWILLIAMS, G; BACH, MC; VAVRO, CL; KING, DM; KELLAM, P; KEMP, SD; LARDER, BA			RESISTANCE TO DDI AND SENSITIVITY TO AZT INDUCED BY A MUTATION IN HIV-1 REVERSE-TRANSCRIPTASE	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ZIDOVUDINE AZT; THERAPY; DNA; SUSCEPTIBILITIES; MUTAGENESIS; TYPE-1; AGENTS; AIDS	Serial human immunodeficiency virus type-1 (HIV-1) isolates were obtained from five individuals with acquired immunodeficiency syndrome (AIDS) who changed therapy to 2',3'-dideoxyinosine (ddI) after at least 12 months of treatment with 3'-azido-3'-deoxythymidine (zidovudine, AZT). The in vitro sensitivity to ddI decreased during the 12 months following ddI initiation, whereas AZT sensitivity increased. Analysis of the reverse transcriptase coding region revealed a mutation associated with reduced sensitivity to ddI. When this mutation was present in the same genome as a mutation known to confer AZT resistance, the isolates showed increased sensitivity to AZT. Analysis of HIV-1 variants confirmed that the ddI resistance mutation alone conferred ddI and 2',3'-dideoxycytidine resistance, and suppressed the effect of the AZT resistance mutation. The use of combination therapy for HIV-1 disease may prevent drug-resistant isolates from emerging.	DUKE UNIV,MED CTR,DURHAM,NC 27710; MAINE MED CTR,PORTLAND,ME 04102; WELLCOME RES LABS,DIV MOLEC SCI,BECKENHAM BR3 3BS,KENT,ENGLAND	Duke University; Maine Medical Center; GlaxoSmithKline; Wellcome Research Laboratories	STCLAIR, MH (corresponding author), BURROUGHS WELLCOME CO,DIV VIROL,RES TRIANGLE PK,NC 27709, USA.		Larder, Brendan/AAB-3106-2020	Kellam, Paul/0000-0003-3166-4734				BACH MC, 1990, NEW ENGL J MED, V323, P275; BOUCHER CAB, 1990, LANCET, V336, P585, DOI 10.1016/0140-6736(90)93391-2; CANN AJ, 1988, ONCOGENE, V3, P123; DORNSIFE RE, 1991, ANTIMICROB AGENTS CH, V35, P322, DOI 10.1128/AAC.35.2.322; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; JACKSON JB, 1988, J CLIN MICROBIOL, V26, P1416, DOI 10.1128/JCM.26.7.1416-1418.1988; KELLAM P, UNPUB; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; KWOK S, 1989, NATURE, V339, P490; LAND S, 1990, J INFECT DIS, V161, P326, DOI 10.1093/infdis/161.2.326; LARDER BA, 1989, P NATL ACAD SCI USA, V86, P4803, DOI 10.1073/pnas.86.13.4803; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1991, AIDS, V5, P137, DOI 10.1097/00002030-199102000-00002; LARDER BA, 1990, ANTIMICROB AGENTS CH, V34, P436, DOI 10.1128/AAC.34.3.436; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; ROCOANCOURT D, 1990, J VIROL, V64, P2660; ROOKE R, 1989, AIDS, V3, P411, DOI 10.1097/00002030-198907000-00001; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ O, 1988, AIDS RES HUM RETROV, V4, P441, DOI 10.1089/aid.1988.4.441; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; YARCHOAN R, 1989, SCIENCE, V245, P412, DOI 10.1126/science.2502840; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	25	718	737	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 27	1991	253	5027					1557	1559		10.1126/science.1716788	http://dx.doi.org/10.1126/science.1716788			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG651	1716788				2022-12-01	WOS:A1991GG65100046
J	VIGILANT, L; STONEKING, M; HARPENDING, H; HAWKES, K; WILSON, AC				VIGILANT, L; STONEKING, M; HARPENDING, H; HAWKES, K; WILSON, AC			AFRICAN POPULATIONS AND THE EVOLUTION OF HUMAN MITOCHONDRIAL-DNA	SCIENCE			English	Article							PAPUA-NEW-GUINEA; HUMAN ORIGINS; SEQUENCES; PRIMATES; TIME	The proposal that all mitochondrial DNA (mtDNA) types in contemporary humans stem from a common ancestor present in an African population some 200,000 years ago has attracted much attention. To study this proposal further, two hypervariable segments of mtDNA were sequenced from 189 people of diverse geographic origin, including 121 native Africans. Geographic specificity was observed in that identical mtDNA types are shared within but not between populations. A tree relating these mtDNA sequences to one another and to a chimpanzee sequence has many deep branches leading exclusively to African mtDNAs. An African origin for human mtDNA is supported by two statistical tests. With the use of the chimpanzee and human sequences to calibrate the rate of mtDNA evolution, the age of the common human mtDNA ancestor is placed between 166,000 and 249,000 years. These results thus support and extend the African origin hypothesis of human mtDNA evolution.	UNIV CALIF BERKELEY,DEPT BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720; UNIV UTAH,DEPT ANTHROPOL,SALT LAKE CITY,UT 84112	University of California System; University of California Berkeley; Utah System of Higher Education; University of Utah	VIGILANT, L (corresponding author), PENN STATE UNIV,DEPT ANTHROPOL,UNIVERSITY PK,PA 16802, USA.		Klein, Richard G/B-5910-2009					AQUADRO CF, 1983, GENETICS, V103, P287; Bowcock A M, 1987, Gene Geogr, V1, P47; BOWCOCK AM, 1991, P NATL ACAD SCI USA, V88, P839, DOI 10.1073/pnas.88.3.839; BRAUER G, 1989, HUMAN REVOLUTION, P123; BROWN WM, 1982, J MOL EVOL, V18, P225, DOI 10.1007/BF01734101; BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967; CANN RL, 1987, NATURE, V329, P111, DOI 10.1038/329111c0; CANN RL, 1984, GENETICS, V106, P479; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; CAVALLISFORZA LL, 1988, P NATL ACAD SCI USA, V85, P6002, DOI 10.1073/pnas.85.16.6002; DARLU P, 1987, HUM EVOL, V2, P407; DIRIENZO A, 1991, P NATL ACAD SCI USA, V88, P1597, DOI 10.1073/pnas.88.5.1597; EXCOFFIER L, 1989, AM J HUM GENET, V44, P73; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; FORAN DR, 1988, NUCLEIC ACIDS RES, V16, P5841, DOI 10.1093/nar/16.13.5841; GAUT BS, 1991, P NATL ACAD SCI USA, V88, P2060, DOI 10.1073/pnas.88.6.2060; GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715; HASEGAWA M, 1991, J MOL EVOL, V32, P37, DOI 10.1007/BF02099927; HASEGAWA M, 1990, J MOL EVOL, V31, P113, DOI 10.1007/BF02109480; HASEGAWA M, IN PRESS NEW APSECTS; HORAI S, 1990, AM J HUM GENET, V46, P828; Howells W.W., 1980, YEARB PHYS ANTHROPOL, V23, P1, DOI DOI 10.1002/AJPA.1330230503; Kimura M., 1983, NEUTRAL THEORY MOL E; KOCHER TD, 1991, EVOLUTION OF LIFE, P391; KRUGER J, 1989, HUM GENET, V82, P308; LONG JC, 1990, AM J PHYS ANTHROPOL, V81, P113, DOI 10.1002/ajpa.1330810112; NEI M, 1982, EVOL BIOL, V14, P1; NEI M, 1991, EVOLUTION OF LIFE, P415; PRAGER EM, 1988, J MOL EVOL, V27, P326, DOI 10.1007/BF02101195; SAITOU N, 1987, NATURE, V327, P288, DOI 10.1038/327288a0; SMITH FH, 1989, YEARB PHYS ANTHROPOL, V32, P35; Sokal R., 1981, BIOMETRY; SPUHLER JN, 1988, YEARB PHYS ANTHROPOL, V31, P15; STONEKING M, 1990, GENETICS, V124, P717; STONEKING M, 1986, COLD SPRING HARB SYM, V51, P433, DOI 10.1101/SQB.1986.051.01.052; STONEKING M, 1989, HUMAN REVOLUTION, P17; STRINGER CB, 1989, HUMAN REVOLUTION, P232; STRINGER CB, 1988, SCIENCE, V239, P1263, DOI 10.1126/science.3125610; Swofford David L., 1990, P411; SWOFFORD DL, 1990, PAUP VERSION 3 0; VIGILANT L, 1989, P NATL ACAD SCI USA, V86, P9350, DOI 10.1073/pnas.86.23.9350; VIGILANT L, 1990, THESIS U CALIFORNIA; WAINSCOAT JS, 1986, NATURE, V319, P491, DOI 10.1038/319491a0; Wilson A. C., 1987, HUM GENET, P158; WILSON AC, 1987, TRENDS GENET, V3, P241, DOI 10.1016/0168-9525(87)90257-5; WILSON AC, IN PRESS SYS ZOOL; Wolpoff M. H, 1980, PALEOANTHROPOLOGY; WOLPOFF MH, 1989, HUMAN REVOLUTION, P62; ZUCKERKANDL EMILE, 1965, P97	49	990	1024	1	127	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 27	1991	253	5027					1503	1507		10.1126/science.1840702	http://dx.doi.org/10.1126/science.1840702			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG651	1840702				2022-12-01	WOS:A1991GG65100032
J	BELONGIA, EA; GOODMAN, JL; HOLLAND, EJ; ANDRES, CW; HOMANN, SR; MAHANTI, RL; MIZENER, MW; ERICE, A; OSTERHOLM, MT				BELONGIA, EA; GOODMAN, JL; HOLLAND, EJ; ANDRES, CW; HOMANN, SR; MAHANTI, RL; MIZENER, MW; ERICE, A; OSTERHOLM, MT			AN OUTBREAK OF HERPES-GLADIATORUM AT A HIGH-SCHOOL WRESTLING CAMP	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SIMPLEX VIRUS TYPE-1	Background and Methods. Herpes simplex virus type 1 (HSV-1) has been identified as a cause of cutaneous or ocular infection among athletes involved in contact sports; in this context it is known as herpes gladiatorum. In July 1989, we investigated an outbreak among 175 high-school wrestlers attending a four-week intensive-training camp. Cases of infection were identified by review of medical records, interview and examination of the wrestlers, and culture of skin lesions. Oropharyngeal swabs were obtained for HSV-1 culture, and serum samples for HSV-1 serologic studies. HSV-1 isolates were compared by restriction-endonuclease analysis. Results. HSV-1 infection was diagnosed in 60 wrestlers (34 percent). The lesions were on the head in 73 percent of the wrestlers, the extremities in 42 percent, and the trunk in 28 percent. HSV-1 was isolated from 21 wrestlers (35 percent), and in 39 (65 percent) infection was identified by clinical criteria. Five had conjunctivitis or blepharitis; none had keratitis. Constitutional symptoms were common, including fever (25 percent), chills (27 percent), sore throat (40 percent), and headache (22 percent). The attack rate varied significantly among the three practice groups, ranging from 25 percent for practice group 1 (lightweights) to 67 percent for group 3 (heavyweights). Restriction-endonuclease analysis identified four strains of HSV-1 among the 21 isolates. All 10 isolates from practice group 3 were identical (strain A), and 5 of 7 isolates from practice group 2 (middleweights) were identical (strain B), which suggested concurrent transmission of different strains within different groups. HSV-1 was not isolated from any oropharyngeal swabs. Conclusions. Herpes gladiatorum may cause substantial morbidity among wrestlers, and it is primarily transmitted by direct skin-to-skin contact. Prompt identification and exclusion of wrestlers with skin lesions may reduce transmission.	MINNESOTA DEPT HLTH,ACUTE DIS EPIDEMIOL SECT,717 SE DELAWARE ST,BOX 9441,MINNEAPOLIS,MN 55440; CTR DIS CONTROL,DIV FIELD SERV,ATLANTA,GA 30333; UNIV MINNESOTA HOSP & CLIN,MINNEAPOLIS,MN 55455	Minnesota Department of Health (MHD); Centers for Disease Control & Prevention - USA; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota Hospital				Belongia, Edward/0000-0001-7478-0415				BECKER TM, 1988, AM J SPORT MED, V16, P665, DOI 10.1177/036354658801600620; DYKE LM, 1965, J AMER MED ASSOC, V194, P1001, DOI 10.1001/jama.194.9.1001; GOODMAN JL, 1986, VIRUS RES, V5, P191, DOI 10.1016/0168-1702(86)90017-1; LIESEGANG TJ, 1989, ARCH OPHTHALMOL-CHIC, V107, P1160, DOI 10.1001/archopht.1989.01070020226030; PORTER PS, 1965, J AMER MED ASSOC, V194, P998, DOI 10.1001/jama.194.9.998; SELLING B, 1964, NEW ENGL J MED, V270, P979, DOI 10.1056/NEJM196405072701903; SOSIN DM, 1989, AM J SPORT MED, V17, P828, DOI 10.1177/036354658901700618; WALBOOMERS JMM, 1976, VIROLOGY, V74, P256, DOI 10.1016/0042-6822(76)90151-3; WHEELER CE, 1965, J AMER MED ASSOC, V194, P993; WHITE WB, 1984, JAMA-J AM MED ASSOC, V252, P533	10	90	91	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 26	1991	325	13					906	910		10.1056/NEJM199109263251302	http://dx.doi.org/10.1056/NEJM199109263251302			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF856	1652687				2022-12-01	WOS:A1991GF85600002
J	GLYNNE, R; POWIS, SH; BECK, S; KELLY, A; KERR, LA; TROWSDALE, J				GLYNNE, R; POWIS, SH; BECK, S; KELLY, A; KERR, LA; TROWSDALE, J			A PROTEASOME-RELATED GENE BETWEEN THE 2 ABC TRANSPORTER LOCI IN THE CLASS-II REGION OF THE HUMAN MHC	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR-WEIGHT PROTEINASE; INFLUENZA NUCLEOPROTEIN; ANTIGEN PRESENTATION; T-CELLS; PURIFICATION; SEQUENCES; MACROPAIN; PATHWAY; LIVER	IT is now possible to paint a detailed picture of how cytoplasmic proteins are handled by the immune system 1-7. They are apparently degraded in the cytoplasm into peptides. These are then transported into the endoplasmic reticulum where they encounter class I major histocompatibility complex (MHC) molecules. Once loaded with peptide, the HLA molecules move through the Golgi apparatus to the cell membrane. Until recently, it had not been established how peptides without signal sequences cross the ER membrane. However, a number of papers have now described a pair of membrane transporter genes of the ABC (ATP-binding cassette) super-family which are attractive candidates for this function 8-12. Both transporter genes, which may encode two halves of a heterodimer, are situated in the class II region of the MHC. There is evidence that other putative components of the processing machinery, the LMPs (low molecular mass polypeptides), are also encoded in the MHC 13-15. Similarities between the properties of the LMPs and a large intracellular protease complex, called proteasome, have led to the suggestion that LMPs are involved in processing antigens 16. We have now identified a human gene with sequence homology to proteasome components. Remarkably, this gene maps between the two putative peptide transporter genes.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,LONDON SE1 9RT,ENGLAND	University of London; King's College London	GLYNNE, R (corresponding author), IMPERIAL CANC RES FUND,HUMAN IMMUNOGENET LAB,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.							ARGOS P, 1987, J MOL BIOL, V193, P385, DOI 10.1016/0022-2836(87)90226-9; AUSABEL FM, 1987, CURRENT PROTOCOLS MO; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEE LW, 1990, BIOCHIM BIOPHYS ACTA, V1037, P178, DOI 10.1016/0167-4838(90)90165-C; LILLEY KS, 1990, FEBS LETT, V262, P327, DOI 10.1016/0014-5793(90)80220-D; MCGUIRE MJ, 1986, BIOCHIM BIOPHYS ACTA, V873, P279, DOI 10.1016/0167-4838(86)90055-5; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MONACO JJ, 1982, P NATL ACAD SCI-BIOL, V79, P3001, DOI 10.1073/pnas.79.9.3001; MONACO JJ, 1986, HUM IMMUNOL, V15, P416, DOI 10.1016/0198-8859(86)90019-4; MONACO JJ, 1984, NATURE, V309, P797, DOI 10.1038/309797a0; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; PARHAM P, 1990, NATURE, V348, P674, DOI 10.1038/348674a0; RIVETT AJ, 1985, J BIOL CHEM, V260, P2600; RIVETT AJ, 1988, ARCH BIOCHEM BIOPHYS, V268, P1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; STERNBERG MJE, 1991, COMPUT APPL BIOSCI, V7, P257; TAMURA T, 1991, BIOCHIM BIOPHYS ACTA, V1089, P95, DOI 10.1016/0167-4781(91)90090-9; TANAKA K, 1986, J BIOL CHEM, V261, P5197; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; WEISS S, 1991, CELL, V64, P767, DOI 10.1016/0092-8674(91)90506-T; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J; ZWICKL P, 1991, FEBS LETT, V278, P217, DOI 10.1016/0014-5793(91)80120-R	32	417	427	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1991	353	6342					357	360		10.1038/353357a0	http://dx.doi.org/10.1038/353357a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG654	1922342				2022-12-01	WOS:A1991GG65400063
J	JARDETZKY, TS; LANE, WS; ROBINSON, RA; MADDEN, DR; WILEY, DC				JARDETZKY, TS; LANE, WS; ROBINSON, RA; MADDEN, DR; WILEY, DC			IDENTIFICATION OF SELF PEPTIDES BOUND TO PURIFIED HLA-B27	NATURE			English	Article							TOXIC LYMPHOCYTES-T; CLASS-I MOLECULES; MAJOR HISTOCOMPATIBILITY COMPLEX; AMINO-ACID SEQUENCES; HEAT-SHOCK PROTEIN; DEVELOPMENTAL BIOLOGY; ANTIGEN PRESENTATION; VIRAL PEPTIDES; HLA ANTIGENS; MHC	A pool of endogenous peptides bound to the human class I MHC molecule, HLA-B27, has been isolated. Microsequence analysis of the pool and of 11 HPLC-purified peptides provides information on the binding specificity of the HLA-B27 molecule. The peptides all seem to be nonamers, seven of which match to protein sequences in a database search. These self peptides derive from abundant cytosolic or nuclear proteins, such as histone, ribosomal proteins, and members of the 90K heat-shock protein family.	HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138; HARVARD UNIV,COMM HIGHER DEGREES BIOPHYS,CAMBRIDGE,MA 02138; HARVARD MICROCHEM FACIL,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute; Harvard University; Harvard University	JARDETZKY, TS (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,7 DIVIN AVE,CAMBRIDGE,MA 02138, USA.							ALBERTS B, 1989, MOL BIOL CELL, P496; ATTSCHUL SF, 1990, J MOL BIOL, V215, P403; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; ELLIOTT T, 1991, NATURE, V351, P402, DOI 10.1038/351402a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; HUET S, 1990, INT IMMUNOL, V2, P311, DOI 10.1093/intimm/2.4.311; IGGO RD, 1991, MOL CELL BIOL, V11, P1326, DOI 10.1128/MCB.11.3.1326; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; LAI BT, 1984, MOL CELL BIOL, V4, P2802, DOI 10.1128/MCB.4.12.2802; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MATZINGER P, 1977, CELL IMMUNOL, V29, P1, DOI 10.1016/0008-8749(77)90269-6; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; PARHAM P, 1977, J BIOL CHEM, V252, P7555; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SILVER ML, 1991, NATURE, V350, P619, DOI 10.1038/350619a0; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; STONE KL, 1989, TECHNIQUES PROTEIN C, P377; STROMINGER JL, 1989, SCIENCE, V244, P943, DOI 10.1126/science.2658058; TERHORST C, 1977, P NATL ACAD SCI USA, V74, P4002, DOI 10.1073/pnas.74.9.4002; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1988, J EXP MED, V168, P1211, DOI 10.1084/jem.168.4.1211; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1986, NATURE, V324, P575, DOI 10.1038/324575a0; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; ULLRICH SJ, 1986, P NATL ACAD SCI USA, V83, P3121, DOI 10.1073/pnas.83.10.3121; VANBLEEK GM, 1990, NATURE, V348, P213; VANDENEYNDE B, 1991, J EXP MED, V173, P1373, DOI 10.1084/jem.173.6.1373; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WATSON JD, 1987, MOL BIOL GENE, P466; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	46	856	891	0	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1991	353	6342					326	329		10.1038/353326a0	http://dx.doi.org/10.1038/353326a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG654	1922338				2022-12-01	WOS:A1991GG65400049
J	MADDEN, DR; GORGA, JC; STROMINGER, JL; WILEY, DC				MADDEN, DR; GORGA, JC; STROMINGER, JL; WILEY, DC			THE STRUCTURE OF HLA-B27 REVEALS NONAMER SELF-PEPTIDES BOUND IN AN EXTENDED CONFORMATION	NATURE			English	Article							CLASS-I MOLECULES; DIRECT BINDING; HISTOCOMPATIBILITY ANTIGEN; VIRAL PEPTIDES; INTACT-CELLS; T-CELLS; INVITRO; RECOGNITION; PROTEIN; CHAINS	X-ray crystallography reveals electron density in the antigen-binding site of HLA-B27 that is an interpretable image of nonameric peptides in a largely extended conformation. Clear density exists for the main chain and several side chains and is consistent with the sequence of 11 nonameric self-peptides eluted from HLA-B27 (see accompanying article 1). Pockets in the antigen-binding cleft bind four side chains and the amino and carboxyl termini of the peptide.	HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute; Harvard University	MADDEN, DR (corresponding author), HARVARD UNIV,COMM HIGHER DEGREES BIOPHYS,7 DIVIN AVE,CAMBRIDGE,MA 02138, USA.							BENJAMIN RJ, 1991, NATURE, V351, P74, DOI 10.1038/351074a0; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1988, X PLOR MANUAL VERSIO; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; CHEN BP, 1989, NATURE, V337, P743, DOI 10.1038/337743a0; CROWTHER RA, 1967, ACTA CRYSTALLOGR, V23, P544, DOI 10.1107/S0365110X67003172; CROWTHER RA, 1972, MOL REPLACEMENT METH; DORNMAIR K, 1991, P NATL ACAD SCI USA, V88, P1335, DOI 10.1073/pnas.88.4.1335; DURBIN RM, 1986, SCIENCE, V232, P1127, DOI 10.1126/science.3704639; ELLIOTT TJ, 1990, P NATL ACAD SCI USA, V87, P5213, DOI 10.1073/pnas.87.13.5213; ELVIN J, 1991, EUR J IMMUNOL, V21, P2025, DOI 10.1002/eji.1830210909; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GORGA JC, IN PRESS PROTEINS; HUET S, 1990, INT IMMUNOL, V2, P311, DOI 10.1093/intimm/2.4.311; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; KHAN MA, 1987, ANKYLOSING SPONDYLIT, V1, P23; KRIEGER JI, 1991, J IMMUNOL, V146, P2331; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; LATTMAN EE, 1970, ACTA CRYSTALL B-STRU, VB 26, P1854, DOI 10.1107/S0567740870004995; MARYANSKI JL, 1990, CELL, V60, P63, DOI 10.1016/0092-8674(90)90716-R; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; PARHAM P, 1988, P NATL ACAD SCI USA, V85, P4005, DOI 10.1073/pnas.85.11.4005; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SAPER MA, 1991, J MOL BIOL, V219, P227; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SETTE A, 1989, P NATL ACAD SCI USA, V86, P3296, DOI 10.1073/pnas.86.9.3296; SETTE A, 1989, J IMMUNOL, V143, P3289; SETTE A, 1987, NATURE, V328, P395, DOI 10.1038/328395a0; SILVER ML, 1991, NATURE, V350, P619, DOI 10.1038/350619a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; VANBLEEK GM, 1990, NATURE, V348, P213	41	698	722	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1991	353	6342					321	325		10.1038/353321a0	http://dx.doi.org/10.1038/353321a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG654	1922337				2022-12-01	WOS:A1991GG65400048
J	RASHBASS, P; COOKE, LA; HERRMANN, BG; BEDDINGTON, RSP				RASHBASS, P; COOKE, LA; HERRMANN, BG; BEDDINGTON, RSP			A CELL AUTONOMOUS FUNCTION OF BRACHYURY IN T/T EMBRYONIC STEM-CELL CHIMERAS	NATURE			English	Article							MESODERM FORMATION; MOUSE EMBRYO; T-GENE; INVERSION; MUTATION; COMPLEX; LOCUS	DEVELOPMENTAL genetics has shown that the Brachyury (T) gene has a key role in mesoderm formation during gastrulation in the mouse 1,2. Homozygous embryos (Fig. 1) have a defective allantois, degenerate or absent notochord and disrupted primitive streak and node. The neural tube is kinked and somite formation interrupted 3-6. The T gene has been cloned 7 and is expressed during the early stages of gastrulation, being restricted to the primitive streak region, nascent mesoderm and notochord 8. Neither the sequence of the gene nor its expression pattern define its developmental function 7,9. To study the cell autonomy of the T mutation we have isolated and genetically characterized embryonic stem cell lines and studied their behaviour in chimaeras. T/+ embryonic stem cells form normal chimaeras, whereas T/T <-> +/+ chimaeras mimic the T/T mutant phenotype. The results indicate that the T gene acts cell autonomously in the primitive streak and notochord but may activate a signalling pathway involved in the specification of other mesodermal tissues.	MAX PLANCK INST ENTWICKLUNGSBIOL,W-7400 TUBINGEN,GERMANY	Max Planck Society	RASHBASS, P (corresponding author), AFRC,CTR GENOME RES,KINGS BLDG,EDINBURGH EH9 3JQ,MIDLOTHIAN,SCOTLAND.		Pillay, Nischalan/F-9536-2012					BENNETT D, 1978, NATURE, V272, P539, DOI 10.1038/272539a0; Chesley P, 1935, J EXP ZOOL, V70, P429, DOI 10.1002/jez.1400700306; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Dobrovolskaia-Zavadskaia N, 1927, CR SOC BIOL, V97, P114; EICHER EM, 1978, P NATL ACAD SCI USA, V75, P949; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJIMOTO H, 1983, DIFFERENTIATION, V25, P44; Gluecksohn-Schoenheimer S, 1944, P NATL ACAD SCI USA, V30, P134, DOI 10.1073/pnas.30.6.134; GRUNEBERG H, 1958, J EMBRYOL EXP MORPH, V6, P424; HERRMANN B, 1986, CELL, V44, P469, DOI 10.1016/0092-8674(86)90468-X; HERRMANN BG, 1987, CELL, V48, P813, DOI 10.1016/0092-8674(87)90078-X; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; LYON M. F., 1959, JOUR HEREDITY, V50, P140; MACMURRAY A, 1988, GENETICS, V120, P545; MCLAREN A, 1981, GENET RES CAMB, V37, P305; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SEARLE AG, 1966, GENET RES, V7, P86, DOI 10.1017/S0016672300009496; TAM PPL, 1987, DEVELOPMENT, V99, P109; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; WILLISON K, 1990, TRENDS GENET, V6, P104, DOI 10.1016/0168-9525(90)90106-G; YANAGISAWA KO, 1990, JPN J GENET, V65, P287, DOI 10.1266/jjg.65.287; YANAGISAWA KO, 1981, DEV BIOL, V87, P242, DOI 10.1016/0012-1606(81)90147-0	22	87	88	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1991	353	6342					348	351		10.1038/353348a0	http://dx.doi.org/10.1038/353348a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG654	1922339				2022-12-01	WOS:A1991GG65400059
J	RIZZO, T; METZGER, BE; BURNS, WJ; BURNS, K				RIZZO, T; METZGER, BE; BURNS, WJ; BURNS, K			CORRELATIONS BETWEEN ANTEPARTUM MATERNAL METABOLISM AND INTELLIGENCE OF OFFSPRING	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREGNANCY; INFANT	Background. It is not clear to what extent maternal metabolism during pregnancy affects the cognitive and behavioral function of the offspring by altering brain development in utero. To investigate this question, we correlated measures of metabolism in pregnant diabetic and nondiabetic women with the intellectual development of their offspring. Methods. The study included 223 pregnant women and their singleton offspring: 89 women had diabetes before pregnancy (pregestational diabetes mellitus), 99 had the onset of diabetes during pregnancy (gestational diabetes mellitus), and 35 had normal carbohydrate metabolism during their pregnancy. We correlated measures of maternal glucose and lipid metabolism (fasting plasma glucose levels, hemoglobin A1c levels, episodes of hypoglycemia, episodes of acetonuria, and plasma beta-hydroxybutyrate and free fatty acid levels) with two measures of intellectual development in the offspring - the mental-development index of the Bayley Scales of Infant Development, given at the age of two years, and the Stanford-Binet Intelligence Scale, given at the ages of three, four, and five years and expressed as an average of the three scores. Results. After correction for socioeconomic status, race or ethnic origin, and patient group, the children's mental-development-index scores at the age of two years correlated inversely with the mothers' third-trimester plasma beta-hydroxybutyrate levels (r = -0.21, P < 0.01); the average Stanford-Binet scores correlated inversely with third-trimester plasma beta-hydroxybutyrate (r = -0.20, P < 0.02) and free fatty acid (r = -0.27, P < 0.002) levels. No other correlations were significant. Including various perinatal events (e.g., prematurity and acidemia) in the analyses did not alter the results. Conclusions. Maternal diabetes during pregnancy may affect behavioral and intellectual development in the offspring. The associations between gestational ketonemia in the mother and a lower IQ in the child warrant continued efforts to avoid ketoacidosis and accelerated starvation in all pregnant women.	NORTHWESTERN UNIV,SCH MED,DEPT MED,CHICAGO,IL 60611; NORTHWESTERN UNIV,CTR ENDOCRINOL METAB & NUTR,SCH MED,CHICAGO,IL 60611; NW MEM HOSP,PRENTICE WOMENS HOSP,CHICAGO,IL 60611	Northwestern University; Northwestern University; Northwestern Memorial Hospital	RIZZO, T (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT PSYCHIAT,SEARLE BLDG 10-526,303 E CHICAGO AVE,CHICAGO,IL 60611, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007169, R01DK010699] Funding Source: NIH RePORTER; NICHD NIH HHS [HD11021] Funding Source: Medline; NIDDK NIH HHS [DK07169, DK10699] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bayley N., 1969, BAYLEY SCALES INFANT; BERENDES HW, 1975, EARLY DIABETES EARLY, P135; BIBERGEIL H, 1975, EARLY DIABETES EARLY, P427; Brazelton T. B., 1973, CLIN DEV MED, V50; Castellan N J Jr, 1965, Psychol Bull, V64, P330; CHURCHIL.JA, 1969, AM J OBSTET GYNECOL, V105, P257, DOI 10.1016/0002-9378(69)90067-2; Cornblath M, 1976, DISORDERS CARBOHYDRA, V2nd; Dobbing J., 1981, SCI F PAEDIATRICS, P744; DUBOWITZ LM, 1970, J PEDIATR-US, V77, P1, DOI 10.1016/S0022-3476(70)80038-5; FREINKEL N, 1980, DIABETES, V29, P1023, DOI 10.2337/diabetes.29.12.1023; Freinkel N, 1979, CARBOHYD METABOL, P1; Freinkel N, 1979, CIBA F S, P3; FREINKEL N, 1979, 10TH P C INT DIAB FE, P731; LI PK, 1980, CLIN CHEM, V26, P1713; LUBCHENCO LO, 1963, PEDIATRICS, V32, P793; MCCALL RB, 1972, AM PSYCHOL, V27, P728, DOI 10.1037/h0033148; MCNEMAR Q, 1962, PSYCHOL STATISTICS, P139; MENARD L, 1980, CLIN CHEM, V26, P1598; METZGER BE, 1980, DIABETES CARE, V3, P402, DOI 10.2337/diacare.3.3.402; MORRIS MA, 1988, DIABETES S1, V37, pA112; NAEYE RL, 1979, CIBA F S, V63, P227; OSULLIVAN JB, 1964, DIABETES, V13, P278; PEDERSEN J, 1977, PREGNANT DIABETIC HE; PEDERSEN JF, 1984, OBSTET GYNECOL, V64, P351; PETERSEN MB, 1988, BRIT MED J, V296, P598, DOI 10.1136/bmj.296.6622.598; RIZZO T, 1990, AM J OBSTET GYNECOL, V163, P1458, DOI 10.1016/0002-9378(90)90606-8; SCARR S, 1981, RACE SOCIAL CLASS IN; STEHBENS JA, 1977, AM J OBSTET GYNECOL, V127, P408; TERMAN LM, 1973, STANFORDBINET INTELL; TRIVELLI LA, 1971, NEW ENGL J MED, V284, P353, DOI 10.1056/NEJM197102182840703; Wechsler D, 1981, ADULT INTELLIGENCE S; Yssing M, 1975, EARLY DIABETES EARLY, P575; 1988, SPSS PCPLUS V2 0 BAS, pB153; 1985, DIABETES S2, V34, P123; 1988, SPSS PCPLUS ADV STAT, P103	35	313	317	0	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 26	1991	325	13					911	916		10.1056/NEJM199109263251303	http://dx.doi.org/10.1056/NEJM199109263251303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF856	1881416				2022-12-01	WOS:A1991GF85600003
J	ROUSSEL, MF; CLEVELAND, JL; SHURTLEFF, SA; SHERR, CJ				ROUSSEL, MF; CLEVELAND, JL; SHURTLEFF, SA; SHERR, CJ			MYC RESCUE OF A MUTANT CSF-1 RECEPTOR IMPAIRED IN MITOGENIC SIGNALING	NATURE			English	Article							RECOMBINANT MURINE RETROVIRUS; FACTOR-I RECEPTOR; NIH 3T3 CELLS; C-MYC; GROWTH-FACTOR; BONE-MARROW; TRANSCRIPTION; KINASE; FOS; MACROPHAGES	THE colony-stimulating factor-1 receptor (CSF-1R) mediates its pleiotropic effects through the coupling of its ligand-activated tyrosine kinase to multiple intracellular effector proteins, whose combined actions determine the magnitude and specificity of the biological response. The interaction of cytoplasmic signalling molecules with CSF-1R is mediated in part by sequence motifs flanking sites of receptor tyrosine phosphorylation 1. Mutation of an autophosphorylation site at tyrosine 809 in the cytoplasmic domain of human CSF-1R does not significantly reduce its ligand-stimulated tyrosine kinase activity, binding to phosphatidylinositol 3-kinase, or induction of the immediate early response genes, c-fos and junB (ref. 2). Unlike cells bearing wild-type receptors, mouse NIH3T3 cells expressing mutant CSF-1R(Phe 809) were unable to grow in serum-free medium containing human recombinant CSF-1 and did not form colonies in semi-solid medium in its presence. CSF-1 induction of c-myc messenger RNA in these cells was impaired, but enforced expression of an exogenous c-myc gene restored their ability to proliferate in response to the growth factor. These studies demonstrate a receptor-mediated bifurcation of intracellular signal transduction pathways during the immediate early response and assign a central role for c-myc in CSF-1-induced mitogenesis.	ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, 332 N LAUDERDALE, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, HOWARD HUGHES MED INST, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; Howard Hughes Medical Institute; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center			Sherr, Charles J/N-8074-2018; Roussel, Martine F/F-1469-2016	Sherr, Charles J/0000-0002-5516-6206; Roussel, Martine F/0000-0002-1740-8139				ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; DEAN M, 1987, ONCOGENE RES, V1, P279; DEAN M, 1986, J BIOL CHEM, V261, P9161; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; PRINCIPATO M, 1990, MOL CELL BIOL, V10, P3562, DOI 10.1128/MCB.10.7.3562; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; ROUSSEL MF, 1989, P NATL ACAD SCI USA, V86, P7924, DOI 10.1073/pnas.86.20.7924; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; SIEGFRIED Z, 1990, MOL CELL BIOL, V10, P6073, DOI 10.1128/MCB.10.11.6073	24	170	171	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 26	1991	353	6342					361	363		10.1038/353361a0	http://dx.doi.org/10.1038/353361a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG654	1833648				2022-12-01	WOS:A1991GG65400064
J	SIMILOWSKI, T; YAN, S; GAUTHIER, AP; MACKLEM, PT; BELLEMARE, F				SIMILOWSKI, T; YAN, S; GAUTHIER, AP; MACKLEM, PT; BELLEMARE, F			CONTRACTILE PROPERTIES OF THE HUMAN DIAPHRAGM DURING CHRONIC HYPERINFLATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; PHRENIC-NERVE STIMULATION; LUNG-VOLUME; EMPHYSEMATOUS HAMSTERS; RESPIRATORY MUSCLES; BODY-WEIGHT; ADAPTABILITY; ACTIVATION; PRESSURE; STRENGTH	Background. In patients with chronic obstructive pulmonary disease (COPD) and hyperinflation of the lungs, dysfunction of the diaphragm may contribute to respiratory decompensation. We evaluated the contractile function of the diaphragm in well-nourished patients with stable COPD, using supramaximal, bilateral phrenic-nerve stimulation, which provides information about the strength and inspiratory action of the diaphragm. Methods. In eight patients with COPD and five control subjects of similar age, the transdiaphragmatic pressure generated by the twitch response to phrenic-nerve stimulation was recorded at various base-line lung volumes, from functional residual capacity to total lung capacity, and during relaxation and graded voluntary efforts at functional residual capacity (twitch occlusion). Results. At functional residual capacity, the twitch transdiaphragmatic pressure ranged from 10.9 to 26.6 cm of water (1.07 to 2.60 kPa) in the patients and from 19.8 to 37.1 cm of water (1.94 to 3.64 kPa) in the controls, indicating considerable overlap between the two groups. The ratio of esophageal pressure to twitch transdiaphragmatic pressure, an index of the inspiratory action of the diaphragm, was -0.50 +/- 0.05 in the patients, as compared with -0.43 +/- 0.02 in the controls (indicating more efficient inspiratory action in the patients than in the controls). At comparable volumes, the twitch transdiaphragmatic pressure and esophageal-to-transdiaphragmatic pressure ratio were higher in the patients than in normal subjects, indicating that the strength and inspiratory action of the diaphragm in the patients were actually better than in the controls. Twitch occlusion (a measure of the maximal activation of the diaphragm) indicated near-maximal activation in the patients with COPD, and the maximal transdiaphragmatic pressure was 106.9 +/- 13.8 cm of water (10.48 +/- 1.35 kPa). Conclusions. The functioning of the diaphragms of the patients with stable COPD is as good as in normal subjects at the same lung volume. Compensatory phenomena appear to counterbalance the deleterious effects of hyperinflation on the contractility and inspiratory action of the diaphragm in patients with COPD. Our findings cast doubt on the existence of chronic fatigue of the diaphragm in such patients and therefore on the need for therapeutic interventions aimed at improving diaphragm function.	MCGILL UNIV, ROYAL VICTORIA HOSP, MEAKINS CHRISTIE LABS, 3626 ST URBAIN ST, MONTREAL H2X 2P2, QUEBEC, CANADA; MCGILL UNIV, CTR HOSP THORAC MONTREAL, MONTREAL H3A 2T5, QUEBEC, CANADA	McGill University; Royal Victoria Hospital; McGill University								AGOSTONI E, 1960, J APPL PHYSIOL, V15, P1087, DOI 10.1152/jappl.1960.15.6.1087; AGOSTONI E, 1985, THORAX A, V29, P259; ARORA NS, 1982, J APPL PHYSIOL, V52, P64, DOI 10.1152/jappl.1982.52.1.64; AUBIER M, 1985, J APPL PHYSIOL, V58, P58, DOI 10.1152/jappl.1985.58.1.58; BELLEMARE F, 1984, RESP PHYSIOL, V58, P263, DOI 10.1016/0034-5687(84)90003-3; BELLEMARE F, 1987, J APPL PHYSIOL, V62, P1307, DOI 10.1152/jappl.1987.62.3.1307; BELLEMARE F, 1983, J APPL PHYSIOL, V55, P8, DOI 10.1152/jappl.1983.55.1.8; BELLEMARE F, 1986, J APPL PHYSIOL, V61, P1153, DOI 10.1152/jappl.1986.61.3.1153; BRAUN NMT, 1982, J APPL PHYSIOL, V53, P405, DOI 10.1152/jappl.1982.53.2.405; BUTLER C, 1976, AM REV RESPIR DIS, V114, P155; DAVIS JN, 1967, J NEUROL NEUROSUR PS, V30, P420, DOI 10.1136/jnnp.30.5.420; DELHEZ L, 1965, ARCH INT PHYS BIOCH, V73, P832, DOI 10.3109/13813456509084906; FARKAS GA, 1983, J APPL PHYSIOL, V54, P1635, DOI 10.1152/jappl.1983.54.6.1635; FARKAS GA, 1982, J APPL PHYSIOL, V53, P1263, DOI 10.1152/jappl.1982.53.5.1263; GANDEVIA SC, 1990, J PHYSIOL-LONDON, V428, P387, DOI 10.1113/jphysiol.1990.sp018218; GIBSON GJ, 1981, AM REV RESPIR DIS, V124, P685; HUBMAYR RD, 1989, AM REV RESPIR DIS, V139, P647, DOI 10.1164/ajrccm/139.3.647; ISHIKAWA S, 1973, AM REV RESPIR DIS, V108, P135; LAPORTA D, 1985, J APPL PHYSIOL, V58, P1469, DOI 10.1152/jappl.1985.58.5.1469; LORING SH, 1985, J APPL PHYSIOL, V59, P1961, DOI 10.1152/jappl.1985.59.6.1961; LORING SH, 1982, J APPL PHYSIOL, V53, P756, DOI 10.1152/jappl.1982.53.3.756; MACKLEM PT, 1983, J APPL PHYSIOL, V55, P547, DOI 10.1152/jappl.1983.55.2.547; MERTON PA, 1954, J PHYSIOL-LONDON, V123, P553, DOI 10.1113/jphysiol.1954.sp005070; MILICEMILI J, 1964, J APPL PHYSIOL, V19, P207, DOI 10.1152/jappl.1964.19.2.207; MURCIANO D, 1989, NEW ENGL J MED, V320, P1521, DOI 10.1056/NEJM198906083202304; OLIVEN A, 1986, J APPL PHYSIOL, V60, P225, DOI 10.1152/jappl.1986.60.1.225; ROCHESTER DF, 1979, AM REV RESPIR DIS, V119, P151; SANCHEZ J, 1982, B EUR PHYSIOPATH RES, V18, P901; SARNOFF SJ, 1951, SURG GYNECOL OBSTET, V93, P190; SIMILOWSKI T, 1989, J APPL PHYSIOL, V67, P1311, DOI 10.1152/jappl.1989.67.4.1311; SMITH J, 1987, J APPL PHYSIOL, V62, P1893, DOI 10.1152/jappl.1987.62.5.1893; SUPINSKI GS, 1982, J CLIN INVEST, V70, P978, DOI 10.1172/JCI110709; TABARY JC, 1972, J PHYSIOL-LONDON, V224, P231, DOI 10.1113/jphysiol.1972.sp009891; THURLBECK WM, 1978, THORAX, V33, P483, DOI 10.1136/thx.33.4.483	34	299	309	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 26	1991	325	13					917	923		10.1056/NEJM199109263251304	http://dx.doi.org/10.1056/NEJM199109263251304			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF856	1881417	Bronze			2022-12-01	WOS:A1991GF85600004
J	VANLOHUIZEN, M; FRASCH, M; WIENTJENS, E; BERNS, A				VANLOHUIZEN, M; FRASCH, M; WIENTJENS, E; BERNS, A			SEQUENCE SIMILARITY BETWEEN THE MAMMALIAN BMI-1 PROTOONCOGENE AND THE DROSOPHILA REGULATORY GENES PSC AND SU(Z)2	NATURE			English	Article							ZESTE; EXPRESSION; MELANOGASTER; TRANSVECTION; COMPLEX	THE bmi-1 proto-oncogene can be activated by Moloney murine leukaemia proviral insertions in E-mu-myc transgenic mice 1,2. It encodes a highly conserved nuclear protein of 324 amino acids which belongs to a family of proteins containing a putative new zinc-finger. Another closely related member of this family is the mouse protein Mel-18 (ref. 3). Here we report on the cloning and characterization of a homologous gene (D-bmi) from Drosophila melanogaster. Our analysis indicates that distinct domains of the mouse Bmi-1 protein, including the putative zinc-finger motif, are highly conserved within the much larger D-Bmi protein. Chromosomal localization and sequence comparison reveal that D-bmi is identical to Posterior Sex Combs (Psc) 4-6 and indicate that the conserved domains between mouse bmi and Psc are also conserved within Suppressor-2 of Zeste (Su(z)2) 6-8.	UNIV AMSTERDAM,DEPT BIOCHEM,AMSTERDAM,NETHERLANDS; MAX PLANCK INST ENTWICKLUNGSBIOL,GENET ABT,W-7400 TUBINGEN,GERMANY	University of Amsterdam; Max Planck Society	VANLOHUIZEN, M (corresponding author), NETHERLANDS CANC INST,DIV MOLEC GENET,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS.		Frasch, Manfred/H-7002-2013	Frasch, Manfred/0000-0003-1373-9798				ADLER P, IN PRESS DEV GENET; ADLER PN, 1989, DEV GENET, V10, P249, DOI 10.1002/dvg.1020100314; BICKEL S, 1990, EMBO J, V9, P2959, DOI 10.1002/j.1460-2075.1990.tb07488.x; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BRUNK BP, 1990, GENETICS, V124, P145; BRUNK BP, 1991, GENETICS, V128, P119; BRUNK BP, 1991, NATURE, V353, P351, DOI 10.1038/353351a0; GAUNT SJ, 1990, TRENDS GENET, V6, P208; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; JURGENS G, 1985, NATURE, V316, P153, DOI 10.1038/316153a0; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LOCKE J, 1988, GENETICS, V120, P181; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; TAGAWA M, 1990, J BIOL CHEM, V265, P20021; TARTOF KD, 1991, CELL, V65, P201, DOI 10.1016/0092-8674(91)90153-P; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; WU CT, 1989, MOL GEN GENET, V218, P559, DOI 10.1007/BF00332424; WU CT, 1989, TRENDS GENET, V5, P189, DOI 10.1016/0168-9525(89)90074-7; ZINK B, 1989, NATURE, V337, P468, DOI 10.1038/337468a0; ZINK B, 1991, EMBO J, V10, P153, DOI 10.1002/j.1460-2075.1991.tb07931.x	22	199	212	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1991	353	6342					353	355		10.1038/353353a0	http://dx.doi.org/10.1038/353353a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG654	1922340				2022-12-01	WOS:A1991GG65400061
J	VONAHSEN, U; DAVIES, J; SCHROEDER, R				VONAHSEN, U; DAVIES, J; SCHROEDER, R			ANTIBIOTIC INHIBITION OF GROUP-I RIBOZYME FUNCTION	NATURE			English	Article							CATALYTIC CORE; RIBOSOMAL-RNA; BINDING-SITE; INTRONS; BACTERIOPHAGE-T4; SEQUENCE; PROTEIN	THE discovery of catalytically active RNA has provided the basis for the evolutionary concept of an RNA world. It has been proposed that during evolution the functions of ancient catalytic RNA were modulated by low molecular weight effectors, related to antibiotics, present in the primordial soup. Antibiotics and RNA may have coevolved in the formation of the modern ribosome 1. Here we report that a set of aminoglycoside antibiotics, which are known to interact with the decoding region of the 16S ribosomal RNA of Escherichia coli 2-4, inhibit the second step of splicing of the T4 phage-derived td intron. Thus catalytic RNA seems to interact not only with a mononucleotide 5 and an amino acid 6, but also with another class of biomolecules, the sugars. Splicing of other group I introns but not group II introns was inhibited. The similarity in affinity and specificity of these antibiotics for group I introns and rRNAs may result from recognition of evolutionarily conserved structures.	INST PASTEUR,UNITE GENIE MICROBIOL,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	VONAHSEN, U (corresponding author), UNIV VIENNA,INST MIKROBIOL & GENET,ALTHANSTR 14,A-1090 VIENNA,AUSTRIA.							AKINS RA, 1987, CELL, V50, P331, DOI 10.1016/0092-8674(87)90488-0; BASS BL, 1986, BIOCHEMISTRY-US, V25, P4473, DOI 10.1021/bi00364a001; BENVENISTE R, 1973, ANTIMICROB AGENTS CH, V4, P2402; BURKE JM, 1990, NATURE, V344, P80, DOI 10.1038/344080a0; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CUNDLIFFE E, 1990, RIBOSOME, P479; DAVIES J, 1990, MOL MICROBIOL, V4, P1227, DOI 10.1111/j.1365-2958.1990.tb00701.x; DAVIES JE, 1983, BIOCH GENETIC REGULA, P329; EHRENMAN K, 1986, P NATL ACAD SCI USA, V83, P5875, DOI 10.1073/pnas.83.16.5875; GALE EF, 1966, BIOCH STUDIES ANTIMI, P1; HERBERT CJ, 1988, EMBO J, V7, P473, DOI 10.1002/j.1460-2075.1988.tb02835.x; MICHEL F, 1990, GENE DEV, V4, P777, DOI 10.1101/gad.4.5.777; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; NOLLER HF, 1984, ANNU REV BIOCHEM, V53, P119, DOI 10.1146/annurev.bi.53.070184.001003; SALVO JLG, 1990, J MOL BIOL, V211, P537, DOI 10.1016/0022-2836(90)90264-M; SCHROEDER R, 1991, BIOCHEMISTRY-US, V30, P3295, DOI 10.1021/bi00227a018; SERAPHIN B, 1989, NATURE, V337, P84, DOI 10.1038/337084a0; VONAHSEN U, 1990, NATURE, V346, P801; VONAHSEN U, 1991, NUCLEIC ACIDS RES, V19, P2261, DOI 10.1093/nar/19.9.2261; YARUS M, 1988, SCIENCE, V240, P1751, DOI 10.1126/science.3381099; YARUS M, 1990, NATURE, V342, P349	23	233	244	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1991	353	6342					368	370		10.1038/353368a0	http://dx.doi.org/10.1038/353368a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG654	1922343				2022-12-01	WOS:A1991GG65400066
J	ALLEN, S; LINDAN, C; SERUFILIRA, A; VANDEPERRE, P; RUNDLE, AC; NSENGUMUREMYI, F; CARAEL, M; SCHWALBE, J; HULLEY, S				ALLEN, S; LINDAN, C; SERUFILIRA, A; VANDEPERRE, P; RUNDLE, AC; NSENGUMUREMYI, F; CARAEL, M; SCHWALBE, J; HULLEY, S			HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION IN URBAN RWANDA - DEMOGRAPHIC AND BEHAVIORAL-CORRELATES IN A REPRESENTATIVE SAMPLE OF CHILDBEARING WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEXUALLY-TRANSMITTED DISEASES; HIV-INFECTION; RISK-FACTORS; HETEROSEXUAL TRANSMISSION; FEMALE PROSTITUTES; GENITAL ULCERS; CENTRAL-AFRICA; AIDS; SEROPOSITIVITY; UGANDA	Objective. - To determine behavioral and demographic risk factors for human immunodeficiency virus (HIV) infection in central Africa. Design. - Cross-sectional survey. Setting. - Kigali, Rwanda. Participants. - A representative sample of 1458 childbearing women aged 19 to 37 years who were recruited from outpatient prenatal and pediatric clinics at the only community hospital in the city. Main Outcome Measure. - Antibodies to HIV assessed by enzyme immuno-assay and confirmed by Western blot or indirect immunofluorescence. Results. - The HIV seroprevalence was 32% overall. Infection rates were higher in women who were single, in those in steady relationships that began after 1981, and in the 33% of women reporting more than one lifetime sexual partner. Women in legal marriages or monogamous partnerships had lower rates of infection, but even low-riskrisk women had prevalences on the order of 20%. History of venereal diseases in the past 5 years, although the strongest risk factor in a multiple logistic analysis (odds ratio, 2.7; 95% confidence interval, 2.0 to 3.7), was reported by only 30% of those infected. Having a male sexual partner who drank alcohol or who had higher income were significant risk factors for HIV infection in the multivariate analysis, but use of oral contraceptives and having an uncircumcised partner were not. Conclusions. - The epidemic of the acquired immunodeficiency syndrome in Rwanda has spread beyond high-risk groups to the general population of women without known risk factors. For most of these women, a steady male partner is the source of their HIV risk and therefore a vital target for intervention efforts.	UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,DIV CLIN EPIDEMIOL,SAN FRANCISCO,CA 94143; MINIST HLTH,NATL AIDS PROGRAM,KIGALI,RWANDA; GLOBAL PROGRAMME AIDS,GENEVA,SWITZERLAND; MINIST HLTH,PROJET SAN FRANCISCO,KIGALI,RWANDA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	ALLEN, S (corresponding author), UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,UCSF BOX 0886,SAN FRANCISCO,CA 94143, USA.		Van de Perre, Philippe/B-9692-2008	Van de Perre, Philippe/0000-0002-3912-0427	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-23980] Funding Source: Medline; NIMH NIH HHS [MH-42459] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALLEN S, 1991, J INFECT DIS, V164, P67, DOI 10.1093/infdis/164.1.67; BERKLEY SF, 1989, J INFECT DIS, V160, P22, DOI 10.1093/infdis/160.1.22; BONGAARTS J, 1989, AIDS, V3, P373, DOI 10.1097/00002030-198906000-00006; BUGINGO G, 1988, REV MED RWANDAISE, V20, P37; CARAEL M, 1988, AIDS, V2, P201; CARSWELL JW, 1987, AIDS, V1, P223; CHIN J, 1989, B WORLD HEALTH ORGAN, V87, P1; CLUMECK N, 1985, NEW ENGL J MED, V313, P182; CLUMECK N, 1985, JAMA-J AM MED ASSOC, V254, P2599, DOI 10.1001/jama.254.18.2599; Clumeck N, 1987, Antibiot Chemother (1971), V38, P41; COLEBUNDERS RL, 1989, EUR J CLIN MICROBIOL, V8, P505, DOI 10.1007/BF01967468; DELALLA F, 1988, AIDS, V2, P317, DOI 10.1097/00002030-198808000-00013; FLEMING AF, 1988, BIOMED PHARMACOTHER, V42, P309; GREENBERG AE, 1988, JAMA-J AM MED ASSOC, V259, P545, DOI 10.1001/jama.259.4.545; GREENBLATT RM, 1988, AIDS, V2, P47, DOI 10.1097/00002030-198802000-00008; HUDSON CP, 1988, AIDS, V2, P255, DOI 10.1097/00002030-198808000-00003; LATIF AS, 1989, AIDS, V3, P519, DOI 10.1097/00002030-198908000-00006; MANN JM, 1988, AIDS, V2, P249, DOI 10.1097/00002030-198808000-00002; MELBYE M, 1986, LANCET, V2, P1113; MERTENS TE, 1990, AIDS, V4, P57, DOI 10.1097/00002030-199001000-00008; NGALY B, 1988, J ACQ IMMUN DEF SYND, V1, P551; NZILAMBI N, 1988, NEW ENGL J MED, V318, P276, DOI 10.1056/NEJM198802043180503; PIOT P, 1989, BRIT MED J, V298, P623, DOI 10.1136/bmj.298.6674.623; PIOT P, 1987, AIDS, V1, P199; PIOT P, 1988, SCIENCE, V239, P573, DOI 10.1126/science.3277271; PIOT P, 1988, BRIT MED BULL, V44, P68, DOI 10.1093/oxfordjournals.bmb.a072247; PIOT P, 1987, J INFECT DIS, V155, P1108, DOI 10.1093/infdis/155.6.1108; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; QUINN TC, 1986, SCIENCE, V234, P955, DOI 10.1126/science.3022379; RWANDAN HIV, 1989, LANCET, V1, P941; SCHMUTZHARD E, 1989, AM J EPIDEMIOL, V130, P309, DOI 10.1093/oxfordjournals.aje.a115337; SIMONSEN JN, 1988, NEW ENGL J MED, V319, P274, DOI 10.1056/NEJM198808043190504; STALL R, 1986, HEALTH EDUC QUART, V13, P359, DOI 10.1177/109019818601300407; VANDEPERRE P, 1987, AIDS, V1, P213; VANDEPERRE P, 1984, LANCET, V2, P62; VANDEPERRE P, 1985, LANCET, V2, P524; VANDEPERRE P, 1987, AIDS, V1, P207; VANDEPERRE P, 1988, GENITOURIN MED, V64, P30; WINKELSTEIN W, 1987, AM J PUBLIC HEALTH, V77, P685, DOI 10.2105/AJPH.77.6.685; ZUNZUNEGUI MV, 1986, AM J EPIDEMIOL, V123, P302, DOI 10.1093/oxfordjournals.aje.a114238; 1988, MMWR, V37, P565; 1990, AIDS, V4, P1305	42	181	181	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1991	266	12					1657	1663		10.1001/jama.266.12.1657	http://dx.doi.org/10.1001/jama.266.12.1657			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GF419	1886188				2022-12-01	WOS:A1991GF41900031
J	GOODWIN, FK				GOODWIN, FK			TELLTALE NEUROTOXIN AND DEMENTIAS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,WASHINGTON,DC, USA.							1991, ANN NEUROL, V29, P202	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1991	266	12					1619	1619						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF419	1832194				2022-12-01	WOS:A1991GF41900005
J	GOODWIN, FK				GOODWIN, FK			ANABOLIC-STEROIDS AND DEPENDENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,WASHINGTON,DC, USA.							BROWER KJ, 1991, BRIT J ADDICT, V86, P759	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1991	266	12					1619	1619						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GF419	1832194				2022-12-01	WOS:A1991GF41900007
J	GOODWIN, FK				GOODWIN, FK			STRESS OF CARING FOR THE DEMENTED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,WASHINGTON,DC, USA.							KIECOLTGLASER JK, 1991, PSYCHOSOM MED, V53, P345, DOI 10.1097/00006842-199107000-00001; DIAGNOSTIC STATISTIC	2	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1991	266	12					1619	1619						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GF419	1832194				2022-12-01	WOS:A1991GF41900006
J	IRWIG, L; GLASZIOU, P; WILSON, A; MACASKILL, P				IRWIG, L; GLASZIOU, P; WILSON, A; MACASKILL, P			ESTIMATING AN INDIVIDUALS TRUE CHOLESTEROL LEVEL AND RESPONSE TO INTERVENTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DENSITY LIPOPROTEIN CHOLESTEROL; CORONARY HEART-DISEASE; SERUM-CHOLESTEROL; APOLIPOPROTEIN MEASUREMENTS; SCREENING PROGRAMS; PLASMA-CHOLESTEROL; RELIABILITY; TRIGLYCERIDE; VARIABILITY; PREVALENCE	An individual's blood cholesterol measurement may differ from the true level because of short-term biological and technical measurement variability. Using data on the within-individual and population variance of serum cholesterol, we addressed the following clinical concerns: Given a cholesterol measurement, what is the individual's likely true level? The confidence interval for the true level is wide and asymmetrical around extreme measurements because of regression to the mean. Of particular concern is the misclassification of people with a screening measurement below 5.2 mmol/L who may be advised that their cholesterol level is "desirable" when their true level warrants further action. To what extent does blood cholesterol change in response to an intervention? In general, confidence intervals are too wide to allow decision making and patient feedback about an individual's cholesterol response to a dietary intervention, even with multiple measurements. If no change is observed in an individual's cholesterol value based on three measurements before and three after dietary intervention, the 80% confidence interval ranges from a true increase of 4% to a true decrease of 9%.	WESTMEAD HOSP, DEPT COMMUNITY MED, SYDNEY, AUSTRALIA	University of Sydney	IRWIG, L (corresponding author), UNIV SYDNEY, DEPT PUBL HLTH, SYDNEY, NSW 2006, AUSTRALIA.		Glasziou, Paul/A-7832-2008	Glasziou, Paul/0000-0001-7564-073X; Wilson, Andrew/0000-0002-1809-7846; Macaskill, Petra/0000-0001-5879-6193				[Anonymous], 1988, CLIN CHEM, V34, P193; BELSEY R, 1990, JAMA-J AM MED ASSOC, V263, P1250, DOI 10.1001/jama.263.9.1250; Berger J. O., 1985, STAT DECISION THEORY, V2nd; BYERS T, 1989, AM J EPIDEMIOL, V130, P853; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; COOPER GR, 1988, CLIN CHEM, V34, pB95; DEGROOT MH, 1986, PROBABILITY STATISTI; DEMACKER PNM, 1982, ATHEROSCLEROSIS, V45, P259, DOI 10.1016/0021-9150(82)90227-1; EHNHOLM C, 1982, NEW ENGL J MED, V307, P850, DOI 10.1056/NEJM198209303071403; FULWOOD R, PHS861686 US DEP HLT; GARDNER MJ, 1973, J CHRON DIS, V26, P781, DOI 10.1016/0021-9681(73)90013-1; HJERMANN I, 1981, LANCET, V2, P1303; Hjermann I, 1980, J Oslo City Hosp, V30, P3; JACOBS DR, 1982, AM J EPIDEMIOL, V116, P878, DOI 10.1093/oxfordjournals.aje.a113490; KAUFMAN HW, 1990, JAMA-J AM MED ASSOC, V263, P1245, DOI 10.1001/jama.263.9.1245; KEIL U, 1989, INT J EPIDEMIOL, V18, pS46; KINLAY S, 1990, BRIT MED J, V300, P1545, DOI 10.1136/bmj.300.6739.1545; MANN JI, 1988, BRIT MED J, V296, P1702, DOI 10.1136/bmj.296.6638.1702; MANNINEN V, 1988, JAMA-J AM MED ASSOC, V260, P641, DOI 10.1001/jama.260.5.641; MORRISON JA, 1979, PEDIATRICS, V64, P197; NAITO HK, 1988, CLIN CHEM, V34, pB84; NAUGHTON MJ, 1990, JAMA-J AM MED ASSOC, V263, P1213, DOI 10.1001/jama.263.9.1213; Nunnally J.C., 1994, PSYCHOMETRIC THEORY; OBRIEN RC, 1990, MED J AUSTRALIA, V152, P480, DOI 10.5694/j.1326-5377.1990.tb125308.x; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; ROBERTS L, 1987, SCIENCE, V238, P482, DOI 10.1126/science.3659924; ROBERTS WC, 1989, AM J CARDIOL, V64, P693, DOI 10.1016/0002-9149(89)90511-0; ROTTERDAM EP, 1987, CLIN CHEM, V33, P1913; SHEPARD DS, 1981, J CHRON DIS, V34, P191, DOI 10.1016/0021-9681(81)90064-3; THOMPSON SG, 1990, J CLIN EPIDEMIOL, V43, P783, DOI 10.1016/0895-4356(90)90238-K; TUNSTALLPEDOE H, 1989, LANCET, V1, P540; TYROLER HA, 1987, CIRCULATION, V76, P515, DOI 10.1161/01.CIR.76.3.515; WEISSFELD JL, 1990, MED DECIS MAKING, V10, P135, DOI 10.1177/0272989X9001000208	33	45	47	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1991	266	12					1678	1685		10.1001/jama.266.12.1678	http://dx.doi.org/10.1001/jama.266.12.1678			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF419	1886192				2022-12-01	WOS:A1991GF41900035
J	PADIAN, NS; SHIBOSKI, SC; JEWELL, NP				PADIAN, NS; SHIBOSKI, SC; JEWELL, NP			FEMALE-TO-MALE TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HETEROSEXUAL PARTNERS; HIV; ADULTS; WOMEN; AIDS; RISK	Objective. - To examine rates of heterosexual transmission of human immunodeficiency virus (HIV) and associated risk factors and to determine the relative efficiency of female-to-female and male-to-female transmission. Design. - Survey of infected individuals and their heterosexual partners recruited since 1985. Setting. - Participants were recruited from various HIV counseling and testing sites throughout California but were generally interviewed and tested in their homes. Participants. - Data from 379 couples at entry to the study are reported: 72 male partners of infected women and 307 female partners of infected men. The infected index case had a well-established source of risk; couples were eliminated if the direction of transmission could not be established. The majority of couples were monogamous since 1978, white, and in their 30s. Most partners did not know their serostatus at entry into the study. Main Outcome Measure. - HIV serostatus in the exposed sexual partner. Results. - We observed one probable instance (1%) of female-to-male transmission compared with 20% transmission rates in the female partners of infected men. All couples were sampled in the same way. Male index cases were more likely to be symptomatic than female index cases. Conclusions. - The odds of male-to-female transmission were signifiicantly greater than female-to-male transmission. The one case of female-to-male transmission was unique in that the couple reported numerous unprotected sexual contacts and noted several instances of vaginal and penile bleeding during intercourse.	UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; UNIV CALIF BERKELEY,DEPT BIOSTAT,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT STAT,BERKELEY,CA 94720	University of California System; University of California San Francisco; University of California System; University of California Berkeley; University of California System; University of California Berkeley								ALNOZHA M, 1990, J ACQ IMMUN DEF SYND, V3, P193; BENETUCCI J, 1990, 6TH INT C AIDS SAN F; CHIODO F, 1990, 6TH INT C AIDS SAN F; COSTIGIOLA P, 1989, 5TH INT C AIDS MONTR; DAVIDSON S, 1989, 5TH INT C AIDS MONTR; DEVINCENZI I, 1989, 5TH INT C AIDS MONTR; DEVINCENZI I, 1990, 6TH INT C AIDS SAN F; FISCHL MA, 1987, JAMA-J AM MED ASSOC, V257, P640, DOI 10.1001/jama.257.5.640; GUINAN ME, 1987, JAMA-J AM MED ASSOC, V257, P2039; HIRA S, 1988, 4TH INT C AIDS STOCK; JOHNSON AM, 1989, AIDS, V3, P367, DOI 10.1097/00002030-198906000-00005; LAGA M, 1988, 4TH INT C AIDS STOCK; LEKATSAS AM, 1987, 3 INT C AIDS WASH; NICOLOSI A, 1990, 6TH INT C AIDS SAN F; PADIAN N, 1987, JAMA-J AM MED ASSOC, V258, P788, DOI 10.1001/jama.258.6.788; PADIAN N, 1989, 5TH INT C AIDS MONTR; PADIAN NS, 1987, REV INFECT DIS, V9, P947; PADIAN NS, 1990, J INFECT DIS, V161, P883, DOI 10.1093/infdis/161.5.883; PADIAN NS, 1990, AM J PUBLIC HEALTH, V80, P990, DOI 10.2105/AJPH.80.8.990; PAPE JW, 1987, CLIN RES, V35, P486; PETERMAN TA, 1988, JAMA-J AM MED ASSOC, V259, P55, DOI 10.1001/jama.259.1.55; PIOT P, 1989, BRIT MED J, V298, P623, DOI 10.1136/bmj.298.6674.623; POTTERAT JJ, 1987, JAMA-J AM MED ASSOC, V258, P1727; REHNET S, 1990, 6TH INT C AIDS SAN F; SION FS, 1990, 6TH INT C AIDS SAN F; STASZEWSKI S, 1989, 5 INT C AIDS MONTR; STEIGBIGEL NH, 1988, 4TH INT C AIDS STOCK; STEWART GJ, 1985, LANCET, V2, P581; VIGEVANI GM, 1988, 4TH INT C AIDS STOCK; WYKOFF RF, 1986, JAMA-J AM MED ASSOC, V255, P1704, DOI 10.1001/jama.1986.03370130059011; 1991, HIV AIDS SURVEILLANC	31	221	224	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1991	266	12					1664	1667						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF419	1886189				2022-12-01	WOS:A1991GF41900032
J	STEINHERZ, LJ; STEINHERZ, PG; TAN, CTC; HELLER, G; MURPHY, ML				STEINHERZ, LJ; STEINHERZ, PG; TAN, CTC; HELLER, G; MURPHY, ML			CARDIAC TOXICITY 4 TO 20 YEARS AFTER COMPLETING ANTHRACYCLINE THERAPY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONGESTIVE HEART-FAILURE; DOXORUBICIN CARDIOTOXICITY; ADRIAMYCIN CARDIOTOXICITY; WEEKLY SCHEDULE; DAUNOMYCIN; EXPERIENCE; CHILDREN	Objective. - To assess the cardiac status of long-term survivors of pediatric malignancies who received chemotherapy, including anthracyclines. Design and Method. - Patients were evaluated by echocardiogram from 4 to 20 years (median, 7 years) after completion of anthracyclines, with prospective and retrospective analysis. Patients. - The consecutive sample of 201 patients had received a total anthracycline dose of 200 to 1275 mg/m2 (median, 450 mg/m2), and 51 patients had mediastinal radiotherapy. Main Outcome Measures. - The overall incidence and severity of abnormal systolic cardiac function were determined for the entire cohort. Risk factors of total anthracycline dose, mediastinal radiotherapy, age during treatment, and length of follow-up were examined. Results. - Twenty-three percent (47/201) of the cohort had abnormal cardiac function on noninvasive testing at long-term follow-up. Correlation between total cumulative dose, length of follow-up, and mediastinal irradiation with incidence of abnormalities was significant. Fifty-six patients were followed up for 10 years or more (median, 12 years), with a median anthracycline dose of 495 mg/m2. Thirty-eight percent (21/56) of these patients, compared with 18% (26/145) of patients evaluated after less than 10 years, had abnormal findings. Sixty-three percent of patients followed up for 10 years or more after receiving 500 mg/m2 or more of anthracyclines had abnormal findings. Nine of 201 patients had late symptoms, including cardiac failure and dysrhythmia, and three patients died suddenly. Microscopic examination of the myocardium on biopsy and autopsy revealed fibrosis. Conclusion. - The 23% incidence of late cardiac abnormalities warrants continued evaluation of patients after anthracyclines to guide patient care and the design of future chemotherapeutic protocols.	MEM SLOAN KETTERING CANC CTR,DEPT EPIDEMIOL & BIOSTAT,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center	STEINHERZ, LJ (corresponding author), MEM SLOAN KETTERING CANC CTR,DEPT PEDIAT,1275 YORK AVE,NEW YORK,NY 10021, USA.							BLOOM KR, 1978, CANCER, V41, P1265, DOI 10.1002/1097-0142(197804)41:4<1265::AID-CNCR2820410408>3.0.CO;2-R; BRISTOW MR, 1978, CANCER TREAT REP, V62, P873; BROSTOW MR, 1980, ANTHRACYCLINES CURRE, P255; DRESDALE A, 1983, CANCER, V52, P51, DOI 10.1002/1097-0142(19830701)52:1<51::AID-CNCR2820520111>3.0.CO;2-#; GILLADOGA AC, 1976, CANCER, V37, P1070, DOI 10.1002/1097-0142(197602)37:2+<1070::AID-CNCR2820370814>3.0.CO;2-6; LEFRAK EA, 1973, CANCER-AM CANCER SOC, V32, P302, DOI 10.1002/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2; LEGHA SS, 1982, ANN INTERN MED, V96, P133, DOI 10.7326/0003-4819-96-2-133; LIPSHULTZ S E, 1988, Journal of the American College of Cardiology, V11, p135A; LIPSHULTZ SE, 1989, PEDIATR RES, V25, pA153; LIPSHULTZ SE, 1987, BLOOD, V70, pA234; PALMERI ST, 1986, AM J CARDIOL, V58, P607, DOI 10.1016/0002-9149(86)90284-5; SCHWARTZ RG, 1987, AM J MED, V82, P1109, DOI 10.1016/0002-9343(87)90212-9; SINGER J W, 1978, Cancer Treatment Reports, V62, P945; STEINHERZ L, 1985, WORLD C PEDIATR CARD, V2, P58; STEINHERZ L, 1986, PEDIATRIC CARDIOL, P1056; STEINHERZ L, 1989, P AN M AM SOC CLIN, V8, P296; STEINHERZ L, 1984, P AM SOC CLIN ONCOL, V3, P198; STEINHERZ LJ, 1987, MED PEDIATR ONCOL, V15, P326; TAN C, 1967, CANCER-AM CANCER SOC, V20, P333, DOI 10.1002/1097-0142(1967)20:3<333::AID-CNCR2820200302>3.0.CO;2-K; TORTI FM, 1983, ANN INTERN MED, V99, P745, DOI 10.7326/0003-4819-99-6-745; VONHOFF DD, 1977, AM J MED, V62, P200, DOI 10.1016/0002-9343(77)90315-1; VONHOFF DD, 1979, ANN INTERN MED, V91, P710, DOI 10.7326/0003-4819-91-5-710; WEISS AJ, 1977, CANCER, V40, P2046, DOI 10.1002/1097-0142(197711)40:5<2046::AID-CNCR2820400508>3.0.CO;2-5	23	765	781	2	28	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1991	266	12					1672	1677		10.1001/jama.266.12.1672	http://dx.doi.org/10.1001/jama.266.12.1672			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF419	1886191				2022-12-01	WOS:A1991GF41900034
J	WRIGHT, JG; MCGEER, AJ; CHYATTE, D; RANSOHOFF, DF				WRIGHT, JG; MCGEER, AJ; CHYATTE, D; RANSOHOFF, DF			MECHANISMS OF GLOVE TEARS AND SHARP INJURIES AMONG SURGICAL PERSONNEL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; NEEDLESTICK INJURIES; HIV-INFECTION; RISK; SURGERY; OPERATIONS; BLOOD; CONTAMINATION; EXPOSURE	Objective. - The development of strategies to prevent exposure to blood for operating room personnel has been hampered by a lack of knowledge about the specific mechanisms of exposure. The purpose of this study was to classify the mechanisms of glove tears and sharp injuries in the operating room. Design. - During a 3-month period, a nurse interviewed operating room personnel immediately after a glove tear or sharp injury had occurred. Setting. - Yale-New Haven (Conn) Hospital is a tertiary care teaching hospital. Results. - There were 249 glove tears and 70 sharp injuries. Visible skin contact with the patient's blood occurred in 156 glove tears (63%). The mechanisms causing the tear could be identified in only 81 (33%). For 230 glove tears (92%), personnel were wearing single gloves. Of 70 sharp injuries, 47 (67%) were caused by needles and usually occurred during suturing. The following three mechanisms accounted for 40 sharp injuries (57%): (1) hands injured while stationary and holding an instrument, 11 (16%) - a position of risk not previously identified; (2) hands injured while retracting tissue, 12 (17%); and (3) injuries caused by sharp instruments not being used, 17 (24%). Instrument passage caused only four sharp injuries (6%). Conclusions. - The majority of glove tears have an unknown mechanism, and alteration in the manufacture or number of gloves worn may be helpful in reducing cutaneous blood exposures. The identification of specific mechanisms of sharp injuries should lead to effective strategies to prevent exposure to the human immunodeficiency virus and other blood-borne pathogens in the operating room.	YALE UNIV,SCH MED,DEPT SURG,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT EPIDEMIOL & INFECT CONTROL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT MED,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT EPIDEMIOL,NEW HAVEN,CT 06510	Yale University; Yale University; Yale University; Yale University			mcgeer, allison/H-7747-2014; McGeer, Allison/AAB-6885-2020	mcgeer, allison/0000-0001-5647-6137; McGeer, Allison/0000-0001-5647-6137				ADLER MW, 1987, BRIT MED J, V295, P1297, DOI 10.1136/bmj.295.6609.1297; BECKER CE, 1989, ANN INTERN MED, V110, P653, DOI 10.7326/0003-4819-110-8-653; BESSINGER CD, 1988, SURG GYNECOL OBSTET, V167, P287; COHN GM, 1990, AM J OBSTET GYNECOL, V162, P715, DOI 10.1016/0002-9378(90)90992-G; GERBERDING JL, 1991, JAMA-J AM MED ASSOC, V265, P1572, DOI 10.1001/jama.265.12.1572; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; HEALD AE, 1990, J GEN INTERN MED, V5, P389, DOI 10.1007/BF02599422; HUSSAIN SA, 1988, BRIT J SURG, V75, P314, DOI 10.1002/bjs.1800750407; LAFFERTY K, 1987, BRIT MED J, V295, P392, DOI 10.1136/bmj.295.6594.392-a; LOWENFELS AB, 1989, ARCH SURG-CHICAGO, V124, P1284; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; MATTA H, 1988, BRIT MED J, V297, P597, DOI 10.1136/bmj.297.6648.597; MCGEER A, 1990, J INFECT DIS, V162, P961, DOI 10.1093/infdis/162.4.961; MCKINNEY WP, 1990, INFECT CONT HOSP EP, V11, P243; MCLEOD GG, 1989, J BONE JOINT SURG BR, V71, P489, DOI 10.1302/0301-620X.71B3.2722946; MCNICHOLAS TA, 1989, BRIT J UROL, V63, P565, DOI 10.1111/j.1464-410X.1989.tb05246.x; PANLILIO AL, 1991, JAMA-J AM MED ASSOC, V265, P1533, DOI 10.1001/jama.265.12.1533; ROSENBERG J, 1989, STATE ART REV OCCU S, V4, P3; STOCK SR, 1990, CAN MED ASSS J, V143, P256; 1991, UNIVERSAL PRECAUTION, P237; 1989, RECOMMENDATIONS PREV; 1986, MMWR, V35, P221; 1991, HLTH POLICY BIOMED R, V34, P5	23	54	57	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1991	266	12					1668	1671		10.1001/jama.266.12.1668	http://dx.doi.org/10.1001/jama.266.12.1668			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF419	1886190				2022-12-01	WOS:A1991GF41900033
J	BARKER, DJP; GODFREY, KM; FALL, C; OSMOND, C; WINTER, PD; SHAHEEN, SO				BARKER, DJP; GODFREY, KM; FALL, C; OSMOND, C; WINTER, PD; SHAHEEN, SO			RELATION OF BIRTH-WEIGHT AND CHILDHOOD RESPIRATORY-INFECTION TO ADULT LUNG-FUNCTION AND DEATH FROM CHRONIC OBSTRUCTIVE AIRWAYS DISEASE	BRITISH MEDICAL JOURNAL			English	Article							AIR-FLOW OBSTRUCTION; POCKET SPIROMETER; WHOOPING-COUGH; CHILDREN; BRONCHIOLITIS; BRONCHITIS; INFANCY	Objective - To examine whether birth weight, infant weight, and childhood respiratory infection are associated with adult lung function and death from chronic obstructive airways disease. Design - Follow up study of men born during 1911-30 whose birth weights, weights at 1 year, and childhood illnesses were recorded at the time by health visitors. Setting - Hertfordshire, England. Subjects - 5718 men born in the county during 1911-30 and a subgroup of 825 men born in the county during 1920-30 and still living there. Main outcome measures - Death from chronic obstructive airways disease, mean forced expiratory volume in one second (FEV1) and forced vital capacity (FVC), and respiratory symptoms. Results - 55 men died of chronic obstructive airways disease. Death rates fell with increasing birth weight and weight at 1 year. Mean FEV1 at age 59 to 70 years, adjusted for height and age, rose by 0.06 litre (95% confidence interval 0.02 to 0.09) with each pound (450 g) increase in birth weight, independently of smoking habit and social class. Bronchitis or pneumonia in infancy was associated with a 0.17 litre (0.02 to 0.32) reduction in adult FEV1 and with an increased odds ratio of wheezing and persistent sputum production in adult life independently of birth weight, smoking habit, and social class. Whooping cough in infancy was associated with a 0.22 litre (0.02 to 0.42) reduction in adult FEV1.			BARKER, DJP (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON S09 4XY,ENGLAND.			Osmond, Clive/0000-0002-9054-4655; Godfrey, Keith/0000-0002-4643-0618	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARKER DJP, 1986, BRIT MED J, V293, P1271, DOI 10.1136/bmj.293.6557.1271; BOCK GR, 1991, CIBA F S, V156; BRESLOW N. E., 1980, STATISTICAL METHODS; BRITTEN N, 1987, BRIT MED J, V294, P1317, DOI 10.1136/bmj.294.6583.1317; BRITTEN N, 1986, BRIT MED J, V292, P441, DOI 10.1136/bmj.292.6518.441; BUCHER U., 1961, THORAX, V16, P207, DOI 10.1136/thx.16.3.207; CHAN KN, 1989, ARCH DIS CHILD, V64, P1284, DOI 10.1136/adc.64.9.1284; CHEN Y, 1989, LANCET, V2, P54; DAVIS DL, 1991, LANCET, V337, P123; FLETCHER C, 1977, BMJ-BRIT MED J, V1, P1645, DOI 10.1136/bmj.1.6077.1645; GUNAWARDENA KA, 1987, THORAX, V42, P689, DOI 10.1136/thx.42.9.689; HALLIDAY JL, 1928, MRC SPECIAL REPORT S, V120; HOSIE HE, 1988, ANAESTHESIA, V43, P233; JOHNSTON IDA, 1983, LANCET, V2, P1104; KATTAN M, 1977, PEDIATRICS, V59, P683; MCCALL MG, 1968, J CHRON DIS, V21, P349, DOI 10.1016/0021-9681(68)90043-X; MOK JYQ, 1984, ARCH DIS CHILD, V59, P306, DOI 10.1136/adc.59.4.306; OSMOND C, 1990, SERIES DS, V9; PETO R, 1983, AM REV RESPIR DIS, V128, P491, DOI 10.1164/arrd.1983.128.3.491; PULLAN CR, 1982, BRIT MED J, V284, P1665, DOI 10.1136/bmj.284.6330.1665; REID DD, 1969, P ROY SOC MED, V62, P311, DOI 10.1177/003591576906200401; REID DD, 1971, BRIT MED BULL, V27, P59, DOI 10.1093/oxfordjournals.bmb.a070816; ROWLAND MGM, 1988, AM J CLIN NUTR, V47, P134, DOI 10.1093/ajcn/47.1.134; THJURLBECK WM, 1982, THORAX, V37, P564; WINICK M, 1966, J NUTR, V89, P300, DOI 10.1093/jn/89.3.300; 1985, BMJ, V290, P1937; 1986, QUESTIONNAIRE RESPIR	27	601	615	1	20	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1991	303	6804					671	675		10.1136/bmj.303.6804.671	http://dx.doi.org/10.1136/bmj.303.6804.671			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG980	1912913	Green Published, Bronze			2022-12-01	WOS:A1991GG98000017
J	COHN, KH; WANG, FS; DESOTOLAPAIX, F; SOLOMON, WB; PATTERSON, LG; ARNOLD, MR; WEIMAR, J; FELDMAN, JG; LEVY, AT; LEONE, A; STEEG, PS				COHN, KH; WANG, FS; DESOTOLAPAIX, F; SOLOMON, WB; PATTERSON, LG; ARNOLD, MR; WEIMAR, J; FELDMAN, JG; LEVY, AT; LEONE, A; STEEG, PS			ASSOCIATION OF NM23-H1 ALLELIC DELETIONS WITH DISTANT METASTASES IN COLORECTAL-CARCINOMA	LANCET			English	Note							INDICATORS	A prospective study analysed the prognostic value of nm23-H1 allelic deletions in colorectal cancer. Of 21 patients with no evidence of distant metastases at initial operation, 11 showed nm23-H1 allelic deletions (including 1 homozygous deletion); 10 had no nm23-H1 deletions. After median follow-up of 25 months, distant metastases had developed in 8 of 11 (73%) patients with nm23-H1 deletions but in only 2 of 10 (20%) without nm23-H1 deletions (p < 0.03). Tests with probe YNZ 22.1, near p53, showed no significant association with distant metastases. nm23-H1 may be, or may be located near, a late-acting suppressor gene in colorectal carcinoma, in which deletions may have prognostic value.	SUNY HLTH SCI CTR,DEPT MED,BROOKLYN,NY; SUNY HLTH SCI CTR,DEPT SURG,BROOKLYN,NY; SUNY HLTH SCI CTR,DEPT PREVENT MED & COMMUNITY HLTH,BROOKLYN,NY; NCI,PATHOL LAB,BETHESDA,MD 20892; VET ADM MED CTR,DEPT PATHOL,BROOKLYN,NY 11209	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Department of Veterans Affairs; Veterans Health Administration (VHA)	COHN, KH (corresponding author), VET ADM MED CTR,DEPT SURG 112,800 POLY PL,BROOKLYN,NY 11209, USA.		leone, alvaro/AAQ-7051-2020; Leone, Alvaro/K-6410-2016	Leone, Alvaro/0000-0003-3815-9052				BEVILACQUA G, 1989, CANCER RES, V49, P5185; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; HAMMSDAHL E, 1988, J SURG ONCOL, V37, P109; HAUT M, 1991, J NATL CANCER I, V83, P712, DOI 10.1093/jnci/83.10.712; HENNESSY C, 1991, J NATL CANCER I, V83, P281, DOI 10.1093/jnci/83.4.281; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1991, CANCER RES, V51, P2490; MEHTA CR, 1988, J AM STAT ASSOC, V83, P999; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; WIGGERS T, 1988, CANCER, V61, P386, DOI 10.1002/1097-0142(19880115)61:2<386::AID-CNCR2820610231>3.0.CO;2-J	10	154	164	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 21	1991	338	8769					722	724		10.1016/0140-6736(91)91444-Y	http://dx.doi.org/10.1016/0140-6736(91)91444-Y			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG104	1679868				2022-12-01	WOS:A1991GG10400005
J	DOCKRELL, HM; EASTCOTT, H; YOUNG, S; MACFARLANE, A; HUSSAIN, R; WATERS, MFR				DOCKRELL, HM; EASTCOTT, H; YOUNG, S; MACFARLANE, A; HUSSAIN, R; WATERS, MFR			POSSIBLE TRANSMISSION OF MYCOBACTERIUM-LEPRAE IN A GROUP OF UK LEPROSY CONTACTS	LANCET			English	Article							HOUSEHOLD CONTACTS; ANTIGEN; ANTIBODIES; SERODIAGNOSIS; TUBERCULOSIS; AGE	A case of infectious leprosy in residential accommodation in the UK prompted a study of the cellular and humoral response to Mycobacterium leprae in two groups of individuals who were in contact with the index case for almost a year. In the younger staff group (mean age 44 years) 23 of 30 individuals had positive Mitsuda skin tests, 25 showed lymphocyte transformation to a soluble sonicate of M leprae and 2 had slightly raised IgM antibody concentrations to the terminal disaccharide of M leprae phenolic glycolipid-1. In the older group of residents (mean age 83 years) 7 of 36 individuals were skin-test-positive, 25 of 33 were positive by lymphocyte transformation, but none had raised antibody levels. When retested on two further occasions, the same 2 individuals in the younger group still had raised antibody concentrations, 1 of whom had a persistent lepromin skin-test response for over 8 months and showed a pronounced increase in lymphocyte transformation to mycobacterial antigens. The findings suggest that transmission of M leprae may have occurred in these 2 contacts, who were therefore given 6 months' chemoprophylaxis with rifampicin.	MID DOWNS HLTH AUTHOR, HAYWARDS HEATH, W SUSSEX, ENGLAND; AGA KHAN UNIV, FAC HLTH SCI, DEPT MICROBIOL, KARACHI, PAKISTAN; HOSP TROP DIS, LONDON NW1 0PE, ENGLAND	Aga Khan University; University College London Hospitals NHS Foundation Trust; University of London; London School of Hygiene & Tropical Medicine	DOCKRELL, HM (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED, DEPT CLIN SCI, KEPPEL ST, LONDON WC1E 7HT, ENGLAND.		Hussain, Rabia/E-9982-2015	Dockrell, Hazel/0000-0003-1869-9107				ADLER WH, 1990, PRINCIPLES GERIATRIC, P60; BAGSHAWE AF, 1990, INT J LEPROSY, V58, P25; BUCHANAN TM, 1983, INT J LEPROSY, V51, P638; CHANTEAU S, 1987, INT J LEPROSY, V55, P626; CHO SN, 1984, J INFECT DIS, V150, P311, DOI 10.1093/infdis/150.3.311; DESFORGES S, 1989, INT J LEPROSY, V57, P794; DOCKRELL HM, 1989, INFECT IMMUN, V57, P1979, DOI 10.1128/IAI.57.7.1979-1983.1989; DOUGLAS JT, 1987, INT J LEPROSY, V55, P718; GODAL T, 1973, BRIT MED J, V3, P557, DOI 10.1136/bmj.3.5880.557; GONZALEZABREU E, 1990, LEPROSY REV, V61, P145; HASAN R, 1989, INT J LEPROSY, V57, P766; HUNTER SW, 1982, J BIOL CHEM, V257, P5072; HUSSAIN R, 1990, INT J LEPROSY, V58, P491; JOPLING WH, 1991, LEPROSY REV, V62, P1; MacLeod JMH, 1925, BMJ-BRIT MED J, V1925, P107, DOI 10.1136/bmj.1.3342.107; Makinodan T, 1980, Adv Immunol, V29, P287, DOI 10.1016/S0065-2776(08)60047-4; STEAD WW, 1981, ANN INTERN MED, V94, P606, DOI 10.7326/0003-4819-94-5-606; STEAD WW, 1983, J INFECT DIS, V147, P951, DOI 10.1093/infdis/147.5.951; WATERS MFR, 1973, INT J LEPROSY, V41, P563; WILLIAMS DL, 1990, J INFECT DIS, V162, P193, DOI 10.1093/infdis/162.1.193; YOUNG DB, 1983, SCIENCE, V221, P1057, DOI 10.1126/science.6348948; 1980, BRIT MED J, V281, P895	22	14	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 21	1991	338	8769					739	743		10.1016/0140-6736(91)91454-3	http://dx.doi.org/10.1016/0140-6736(91)91454-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG104	1679878				2022-12-01	WOS:A1991GG10400015
J	FARISH, E; ROLTON, HA; BARNES, JF; HART, DM				FARISH, E; ROLTON, HA; BARNES, JF; HART, DM			LIPOPROTEIN (A) CONCENTRATIONS IN POSTMENOPAUSAL WOMEN TAKING NORETHISTERONE	BRITISH MEDICAL JOURNAL			English	Article							LP(A) LIPOPROTEIN		STOBHILL GEN HOSP,DEPT OBSTET & GYNAECOL,GLASGOW G21 3UW,SCOTLAND		FARISH, E (corresponding author), STOBHILL GEN HOSP,DEPT BIOCHEM,GLASGOW G21 3UW,SCOTLAND.							ABDALLA HI, 1985, OBSTET GYNECOL, V66, P789; ALBERS JJ, 1984, BIOCHIM BIOPHYS ACTA, V795, P293, DOI 10.1016/0005-2760(84)90078-X; ALBERS JJ, 1975, METABOLISM, V24, P1047, DOI 10.1016/0026-0495(75)90098-0; FARISH E, 1986, CLIN CHIM ACTA, V159, P147; MBEWU AD, 1990, ATHEROSCLEROSIS, V85, P1, DOI 10.1016/0021-9150(90)90177-K	5	125	125	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1991	303	6804					694	694		10.1136/bmj.303.6804.694	http://dx.doi.org/10.1136/bmj.303.6804.694			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG980	1833013	Green Published, Bronze			2022-12-01	WOS:A1991GG98000023
J	GARROW, J				GARROW, J			THE HEALTH OF THE NATION - RESPONSES - IMPORTANCE OF OBESITY	BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR-DISEASE; BODY-WEIGHT; RISK FACTOR; OVERWEIGHT; TIME				GARROW, J (corresponding author), ST BARTHOLOMEWS HOSP,HUMAN NUTR,LONDON EC1A 7BE,ENGLAND.							BINGHAM S, 1991, BRIT MED J, V303, P353, DOI 10.1136/bmj.303.6798.353; BORKAN GA, 1986, AM J EPIDEMIOL, V124, P410, DOI 10.1093/oxfordjournals.aje.a114411; BORTZ WM, 1969, AM J MED, V47, P325, DOI 10.1016/0002-9343(69)90159-4; Bush A., 1988, Journal of Human Nutrition and Dietetics, V1, P429, DOI 10.1111/j.1365-277X.1988.tb00216.x; DIXON AS, 1973, PRESCRIBERS J, V13, P41; DUBLIN LI, 1953, NEW ENGL J MED, V248, P971, DOI 10.1056/NEJM195306042482304; FORDE OH, 1986, ACTA MED SCAND, V219, P167; FRIEDMAN CI, 1985, CLIN OBSTET GYNECOL, V28, P645, DOI 10.1097/00003081-198528030-00019; GARFINKEL L, 1985, ANN INTERN MED, V103, P1034, DOI 10.7326/0003-4819-103-6-1034; Garrow J.S., 1988, OBESITY RELATED DISE; GARROW JS, 1991, BRIT MED J, V302, P803, DOI 10.1136/bmj.302.6780.803; GARROW JS, IN PRESS OVERWEIGHT; Gregory F., 1990, DIETARY NUTR SURVEY; HALL A, 1989, NEW ZEAL MED J, V102, P134; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; HUBERT HB, 1986, ANNU REV PUBL HEALTH, V7, P493, DOI 10.1146/annurev.pu.07.050186.002425; JEANRENAUD B, 1991, PROG OBES R, P409; KEYS A, 1972, ANN INTERN MED, V77, P15, DOI 10.7326/0003-4819-77-1-15; MODAN M, 1985, J CLIN INVEST, V75, P809, DOI 10.1172/JCI111776; NOMURA F, 1986, INT J OBESITY, V10, P349; PENTECOST BL, 1991, MED ASPECTS EXERCISE; REUBEN A, 1985, CLIN SCI, V69, P71, DOI 10.1042/cs0690071; RISSANEN A, 1990, BRIT MED J, V301, P835, DOI 10.1136/bmj.301.6756.835; SHAPER AG, 1988, CORONARY HEART DISEA; Sims E A, 1973, Recent Prog Horm Res, V29, P457; SONNEHOLM S, 1986, BRIT MED J, V292, P586, DOI 10.1136/bmj.292.6520.586; 1991, CM1523	27	59	60	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1991	303	6804					704	706		10.1136/bmj.303.6804.704	http://dx.doi.org/10.1136/bmj.303.6804.704			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GG980	1912920	Bronze, Green Published			2022-12-01	WOS:A1991GG98000028
J	GRIGG, JM; SAVILL, JS; SARRAF, C; HASLETT, C; SILVERMAN, M				GRIGG, JM; SAVILL, JS; SARRAF, C; HASLETT, C; SILVERMAN, M			NEUTROPHIL APOPTOSIS AND CLEARANCE FROM NEONATAL LUNGS	LANCET			English	Article							CELL-DEATH; INFLAMMATION; MACROPHAGES; PHAGOCYTOSIS; ELASTASE	8 newborn babies with airways inflammation, who were mechanically ventilated, underwent bronchoalveolar lavage to examine the fate of neutrophils in the inflamed airways. Light microscopy and electronmicroscopy showed evidence of neutrophil apoptosis and ingestion of intact neutrophils by macrophages in specimens from all 8 infants. Neutrophil apoptosis, without the local release of intracellular contents that promote inflammation, might represent a mechanism by which tissue injury is reduced during the resolution of neonatal pulmonary inflammation.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED,LONDON W12 0HS,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT HISTOPATHOL,LONDON W12 0HS,ENGLAND; CITY HOSP EDINBURGH,DEPT RESP MED,EDINBURGH EH10 5SB,MIDLOTHIAN,SCOTLAND	Imperial College London; Imperial College London	GRIGG, JM (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT PAEDIAT,DU CANE RD,LONDON W12 0NN,ENGLAND.			Grigg, Jonathan/0000-0003-3109-6028				HASLETT C, 1989, CURR OPIN IMMUNOL, V2, P10, DOI 10.1016/0952-7915(89)90091-5; HENSON PM, 1978, J IMMUNOL, V121, P851; MEAGHER L, 1989, BIOCHEM SOC T, V17, P608, DOI 10.1042/bst0170608; MERRITT TA, 1983, J CLIN INVEST, V72, P656, DOI 10.1172/JCI111015; NEWMAN SL, 1982, J EXP MED, V156, P430, DOI 10.1084/jem.156.2.430; OGDEN BE, 1984, AM REV RESPIR DIS, V130, P817; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SHELLITO J, 1987, AM J PATHOL, V129, P567; VARTIO T, 1981, J BIOL CHEM, V256, P471; Wyllie A H, 1980, Int Rev Cytol, V68, P251	10	189	190	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 21	1991	338	8769					720	722		10.1016/0140-6736(91)91443-X	http://dx.doi.org/10.1016/0140-6736(91)91443-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG104	1679867				2022-12-01	WOS:A1991GG10400004
J	HARGREAVES, AD; LOGAN, RL; THOMSON, M; ELTON, RA; OLIVER, MF; RIEMERSMA, RA				HARGREAVES, AD; LOGAN, RL; THOMSON, M; ELTON, RA; OLIVER, MF; RIEMERSMA, RA			TOTAL CHOLESTEROL, LOW-DENSITY-LIPOPROTEIN CHOLESTEROL, AND HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL AND CORONARY HEART-DISEASE IN SCOTLAND	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MAJOR RISK FACTOR; MIDDLE-AGED MEN; SERUM-CHOLESTEROL; FRAMINGHAM	Objective - To investigate long term changes in total cholesterol, high density lipoprotein cholesterol, and low density lipoprotein cholesterol concentrations and in measures of other risk factors for coronary heart disease and to assess their importance for the development of coronary heart disease in Scottish men. Design - Longitudinal study entailing follow up in 1988-9 of men investigated during a study in 1976. Setting - Edinburgh, Scotland. Subjects - 107 men from Edinburgh who had taken part in a comparative study of risk factors for heart disease with Swedish men in 1976 when aged 40. Intervention - The men were invited to attend a follow up clinic in 1988-9 for measurement of cholesterol concentrations and other risk factor measurements. Eighty three attended and 24 refused to or could not attend. Main outcome measures - Changes in total cholesterol, high density lipoprotein cholesterol, and low density lipoprotein cholesterol concentrations, body weight, weight to height index, prevalence of smoking, and alcohol intake; number of coronary artery disease events. Results - Mean serum total cholesterol concentration increased over the 12 years mainly due to an increase in the low density lipoprotein cholesterol fraction (from 3.53 (SD 0.09) to 4.56 (0.11) mmol/l) despite a reduction in high density lipoprotein cholesterol concentration. Body weight and weight to height index increased. Fewer men smoked more than 15 cigarettes/day in 1988-9 than in 1976. Blood pressure remained stable and fasting triglyceride concentrations did not change. The frequency of corneal arcus doubled. Alcohol consumption decreased significantly. Eleven men developed clinical coronary heart disease. High low density lipoprotein and low high density lipoprotein cholesterol concentrations in 1976, but not total cholesterol concentration, significantly predicted coronary heart disease (p = 0.05). Almost all of the men who developed coronary heart disease were smokers (91% v 53%, p < 0.05). Conclusion - Over 12 years the lipid profile deteriorated significantly in this healthy cohort of young men. Smoking, a low high density lipoprotein concentration and a raised low density lipoprotein concentration were all associated with coronary heart disease in middle aged Scottish men, whereas there was no association for total cholesterol concentration. The findings have implications for screening programmes.	UNIV EDINBURGH, DEPT MED, EDINBURGH EH8 9XF, SCOTLAND; UNIV EDINBURGH, DEPT COMMUNITY MED, MED STAT UNIT, EDINBURGH EH8 9YL, MIDLOTHIAN, SCOTLAND	University of Edinburgh; University of Edinburgh	HARGREAVES, AD (corresponding author), UNIV EDINBURGH, DEPT CARDIOL, CARDIOVASC RES UNIT, EDINBURGH EH8 9XF, SCOTLAND.							CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; CLARK DA, 1967, AM J CLIN NUTR, V20, P743, DOI 10.1093/ajcn/20.7.743; CRIQUI MH, 1983, AM J EPIDEMIOL, V118, P52, DOI 10.1093/oxfordjournals.aje.a113616; ELFORD J, 1989, LANCET, V1, P343; GIDEZ LI, 1984, CLIN METABOLIC ASPEC, P415; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; KANNEL WB, 1979, ANN INTERN MED, V90, P85, DOI 10.7326/0003-4819-90-1-85; KEYS A, 1984, INT J EPIDEMIOL, V13, P428, DOI 10.1093/ije/13.4.428; KROMHOUT D, 1983, AM J CLIN NUTR, V38, P591, DOI 10.1093/ajcn/38.4.591; LOGAN RL, 1978, LANCET, V1, P949; MILLER NE, 1977, LANCET, V1, P965, DOI 10.1016/S0140-6736(77)92274-7; OLIVER MF, 1975, EUR J CLIN INVEST, V5, P507, DOI 10.1111/j.1365-2362.1975.tb00483.x; POCOCK SJ, 1986, BMJ-BRIT MED J, V292, P515, DOI 10.1136/bmj.292.6519.515; POCOCK SJ, 1989, BMJ-BRIT MED J, V298, P998, DOI 10.1136/bmj.298.6679.998; ROSE G, 1977, BRIT J PREV SOC MED, V31, P42; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SMITH WCS, 1989, SCOT MED J, V34, P550, DOI 10.1177/003693308903400603; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; THOMAS DG, 1971, APPLIED STATISTICS, V20, P105, DOI DOI 10.2307/2346643; THOMSON M, 1982, HUM NUTR-APPL NUTR, V36, P272; TUNSTALLPEDOE H, 1989, SCOT MED J, V34, P556, DOI 10.1177/003693308903400604; WOOD DA, 1987, LANCET, V1, P177; 1987, WORLD HLTH STAT Q, V40, P171	23	13	13	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 21	1991	303	6804					678	681		10.1136/bmj.303.6804.678	http://dx.doi.org/10.1136/bmj.303.6804.678			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG980	1912914	Bronze, Green Published			2022-12-01	WOS:A1991GG98000019
J	KAPELRUD, H; BANGSTAD, HJ; DAHLJORGENSEN, K; BERG, K; HANSSEN, KF				KAPELRUD, H; BANGSTAD, HJ; DAHLJORGENSEN, K; BERG, K; HANSSEN, KF			SERUM LP(A) LIPOPROTEIN CONCENTRATIONS IN INSULIN-DEPENDENT DIABETIC-PATIENTS WITH MICROALBUMINURIA	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; URINARY ALBUMIN EXCRETION; APOLIPOPROTEIN-B; RISK-FACTORS; NEPHROPATHY; TYPE-1; PLASMA; PROTEINURIA; CHOLESTEROL; MELLITUS	Objective - To compare the serum concentrations of lipoproteins and apolipoproteins in insulin dependent diabetic patients with and without microalbuminuria. Design - Cross sectional study. Setting - Paediatric and medical outpatient clinic at a university hospital. Patients - 76 insulin dependent diabetic patients: 41 with microalbuminuria (20 males, 21 females) and 35 controls without microalbuminuria (18 males, 17 females). The two groups were similar with respect to age, duration of disease, and haemoglobin A1c concentrations before the study. Main outcome measures - Serum concentrations of Lp(a) lipoprotein, total cholesterol, high density lipoprotein cholesterol, very low density lipoprotein cholesterol, low density lipoprotein cholesterol, triglycerides, and apolipoproteins A-I, A-II, and B. Results - Median serum Lp(a) lipoprotein concentration was 10.0 mg/100 ml in the microalbuminuric group and 4.9 mg/100 ml in the control group (p = 0.007). 17 (41%) of the microalbuminuric patients and five (14%) of the control patients had Lp(a) lipoprotein values above the upper quartile of a normal population. Median serum triglycerides concentrations in the microalbuminuric and control groups were 1.15 mmol/l and 0.88 mmol/l respectively (p = 0.03). Median very low density lipoprotein cholesterol concentration was 0.52 mmol/l in the microalbuminuric group and 0.40 mmol/l in the control group (p = 0.03). No significant differences in serum concentrations of total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, or apolipoproteins A-I, A-II, and B were found between the groups. Conclusions - Serum concentrations of Lp(a) lipoprotein are twice as high in insulin dependent diabetic patients with microalbuminuria as in those without microalbuminuria. Increased concentrations of Lp(a) lipoprotein might partly explain the increased morbidity and mortality from cardiovascular disease observed among patients with diabetic nephropathy.	AKER UNIV HOSP,N-0514 OSLO 5,NORWAY; UNIV OSLO,INST MED GENET,N-0315 OSLO 3,NORWAY	University of Oslo; University of Oslo								ANDERSEN AR, 1983, DIABETOLOGIA, V25, P496; ARAUZ C, 1990, DIABETES S1, V39, pA64; BERG K, 1963, ACTA PATHOL MIC SC, V59, P369; BERG K, 1974, CLIN GENET, V6, P230; BERG K, 1990, FROM PHENOTYPE TO GENE IN COMMON DISORDERS, P138; Berg K., 1990, LIPOPROTEIN A, P1; BERG K, 1983, PROGR MED GENETICS, P35; BORCHJOHNSEN K, 1985, DIABETOLOGIA, V28, P590, DOI 10.1007/BF00281993; BORCHJOHNSEN K, 1987, BMJ-BRIT MED J, V294, P1651, DOI 10.1136/bmj.294.6588.1651; BROWN MS, 1987, NATURE, V330, P113, DOI 10.1038/330113a0; COOPER ME, 1988, DIABETIC MED, V5, P361, DOI 10.1111/j.1464-5491.1988.tb01006.x; CUSHING GL, 1989, ARTERIOSCLEROSIS, V9, P593, DOI 10.1161/01.ATV.9.5.593; DAHLJORGENSEN K, 1988, ACTA ENDOCRINOL-COP, V117, P19, DOI 10.1530/acta.0.1170019; DAHLJORGENSEN K, 1990, DIABETES S1, V39, pA16; DAVIDHOFF E, 1989, DIABETES S2, V38, pA70; DECKERT T, 1989, DIABETOLOGIA, V32, P219, DOI 10.1007/BF00285287; FELDTRASMUSSEN B, 1986, LANCET, V2, P1300; FRICK MH, 1978, CHEST, V73, P62, DOI 10.1378/chest.73.1.62; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GUYTON JR, 1985, ARTERIOSCLEROSIS, V5, P265, DOI 10.1161/01.ATV.5.3.265; JENSEN T, 1988, DIABETOLOGIA, V31, P142, DOI 10.1007/BF00276846; JENSEN T, 1987, DIABETOLOGIA, V30, P144, DOI 10.1007/BF00274218; JENSEN T, 1989, LANCET, V1, P461; JONES SL, 1989, BRIT MED J, V298, P487, DOI 10.1136/bmj.298.6672.487; MASAREI JRL, 1984, AM J CLIN NUTR, V40, P468, DOI 10.1093/ajcn/40.3.468; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; MOGENSEN CE, 1984, NEW ENGL J MED, V311, P89, DOI 10.1056/NEJM198407123110204; MORTON N E, 1985, Genetic Epidemiology, V2, P113, DOI 10.1002/gepi.1370020202; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; RHOADS GG, 1986, JAMA-J AM MED ASSOC, V256, P2540, DOI 10.1001/jama.256.18.2540; ROSCHLAU P, 1974, Z KLIN CHEM KLIN BIO, V12, P403; ROSENGREN A, 1990, BRIT MED J, V301, P1248, DOI 10.1136/bmj.301.6763.1248; SCHRIEWER H, 1984, J CLIN CHEM CLIN BIO, V22, P591; SEAQUIST ER, 1989, NEW ENGL J MED, V320, P1161, DOI 10.1056/NEJM198905043201801; SIMON DI, 1990, CIRCULATION, V82, P599; VANNINI P, 1984, DIABETES CARE, V7, P151, DOI 10.2337/diacare.7.2.151; WAHLEFELD AW, 1974, METHOD ENZYMAT AN, P1831	38	123	127	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1991	303	6804					675	678		10.1136/bmj.303.6804.675	http://dx.doi.org/10.1136/bmj.303.6804.675			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG980	1833011	Green Published, Bronze			2022-12-01	WOS:A1991GG98000018
J	LANDAY, AL; JESSOP, C; LENNETTE, ET; LEVY, JA				LANDAY, AL; JESSOP, C; LENNETTE, ET; LEVY, JA			CHRONIC FATIGUE SYNDROME - CLINICAL CONDITION ASSOCIATED WITH IMMUNE ACTIVATION	LANCET			English	Article							BARR VIRUS-INFECTION; LYMPHOCYTE-T SUBSETS; IMMUNOLOGICAL ABNORMALITIES; EARLY ANTIGEN; MONONUCLEOSIS; PERSISTENT; DYSFUNCTION; ANTIBODIES	There is much conflicting immunological and viral data about the causes of chronic fatigue syndrome (CFS); some findings support the notion that CFS may be due to one or more immune disorders that have resulted from exposure to an infectious agent. In the present study, flow cytometry and several different monoclonal antibodies recognising T, B, and natural killer (NK) cell populations as well as activation and cell adhesion antigens were used to study 147 individuals with CFS. Compared with healthy controls, a reduced CD8 suppressor cell population and increased activation markers (CD38, HLA-DR) on CD8 cells were found. The differences were significant (p = 0.01) in patients with major symptoms of the disease. These immunological indices were not observed in 80 healthy individuals, in 22 contacts of CFS patients, or in 43 patients with other diseases. No correlation of these findings in CFS patients with any known human viruses could be detected by serology. The findings suggest that immune activation is associated with many cases of CFS.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,ROOM S1280,3RD & PARNASSUS,SAN FRANCISCO,CA 94143; VIROLAB,BERKELEY,CA; UNIV CALIF SAN FRANCISCO,SCH MED,CANC RES INST,SAN FRANCISCO,CA 94143; RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT IMMUNOL MICROBIOL,CHICAGO,IL 60612	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Rush University								ALTAY HT, 1990, INT J PSYCHIAT MED, V20, P141, DOI 10.2190/T6GX-JJ2L-VCVV-T81B; AOKI T, 1987, NAT IMMUN CELL GROW, V6, P116; ARCHARD LC, 1988, J ROY SOC MED, V81, P326, DOI 10.1177/014107688808100608; BEHAN PO, 1985, J INFECTION, V10, P211, DOI 10.1016/S0163-4453(85)92488-0; BORYSIEWICZ LK, 1986, Q J MED, V58, P111; BUCHWALD D, 1991, REV INFECT DIS, V13, P512; CALIGIURI M, 1987, J IMMUNOL, V139, P3306; CARNEY WP, 1981, J IMMUNOL, V126, P2114; CASALI P, 1987, SCIENCE, V236, P77, DOI 10.1126/science.3105056; COON J, 1987, LAB INVEST, V15, P453; DEFREITAS E, 1991, P NATL ACAD SCI USA, V88, P2922, DOI 10.1073/pnas.88.7.2922; GRATAMA JW, 1987, BLOOD, V70, P516; HELLINGER WC, 1988, JAMA-J AM MED ASSOC, V260, P971; HENLE W, 1981, CANCER RES, V41, P4222; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; JONES JF, 1985, ANN INTERN MED, V102, P1, DOI 10.7326/0003-4819-102-1; KIBLER R, 1985, J CLIN IMMUNOL, V5, P46, DOI 10.1007/BF00915168; KLIMAS NG, 1990, J CLIN MICROBIOL, V28, P1403, DOI 10.1128/JCM.28.6.1403-1410.1990; KOMAROFF AL, 1991, REV INFECT DIS, V13, pS8; LANDAY AL, 1990, 6TH INT C AIDS SAN F, P141; LENNETTE ET, 1982, J CLIN MICROBIOL, V15, P69, DOI 10.1128/JCM.15.1.69-73.1982; LEVY JA, 1990, LANCET, V335, P1047, DOI 10.1016/0140-6736(90)92628-U; LLOYD AR, 1989, MED J AUSTRALIA, V151, P122, DOI 10.5694/j.1326-5377.1989.tb139594.x; MILLER NA, 1991, BMJ-BRIT MED J, V302, P140, DOI 10.1136/bmj.302.6769.140; NOTKINS AL, 1970, ANNU REV MICROBIOL, V24, P525, DOI 10.1146/annurev.mi.24.100170.002521; PRIETO J, 1989, SCAND J IMMUNOL, V30, P13, DOI 10.1111/j.1365-3083.1989.tb01183.x; ROUSE BT, 1986, REV INFECT DIS, V8, P850; Siegel S., 1956, NONPARAMETRIC STAT B; STRAUS SE, 1989, J INFECT DIS, V160, P1085, DOI 10.1093/infdis/160.6.1085; STRAUS SE, 1991, REV INFECT DIS, V13, pS2; TOBI M, 1982, LANCET, V1, P61; TOMKINSON BE, 1987, J IMMUNOL, V139, P3802; TOSATO G, 1985, J IMMUNOL, V134, P3082	33	263	271	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 21	1991	338	8769					707	712		10.1016/0140-6736(91)91440-6	http://dx.doi.org/10.1016/0140-6736(91)91440-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG104	1679864				2022-12-01	WOS:A1991GG10400001
J	MAKI, M; HALLSTROM, O; MARTTINEN, A				MAKI, M; HALLSTROM, O; MARTTINEN, A			REACTION OF HUMAN NONCOLLAGENOUS POLYPEPTIDES WITH CELIAC-DISEASE AUTOANTIBODIES	LANCET			English	Note							IGA-CLASS RETICULIN; CELIAC-DISEASE; DERMATITIS-HERPETIFORMIS; ANTIBODY; RECOGNITION	We identified and purified six human noncollagenous protein molecules that specifically bind to serum IgA from patients with coeliac disease, and which as a combination can act as true antigen to reticulin antibodies. In affinity chromatography, the purified human protein molecules removed antibodies against reticulin and endomysium from serum samples of coeliac disease patients. We postulate that an autoimmune mechanism operates in generating the jejunal damage in gluten-sensitive enteropathy and that the human protein molecules described here act as self-antigens in the disease.			MAKI, M (corresponding author), UNIV TAMPERE,DEPT CLIN SCI,TEISKONTIE 35,POB 607,SF-33101 TAMPERE,FINLAND.							BORN W, 1990, SCIENCE, V249, P67, DOI 10.1126/science.1695022; CHORZELSKI TP, 1984, BRIT J DERMATOL, V111, P395, DOI 10.1111/j.1365-2133.1984.tb06601.x; HALLSTROM O, 1989, GUT, V30, P1225, DOI 10.1136/gut.30.9.1225; KARPATI S, 1990, LANCET, V336, P1335, DOI 10.1016/0140-6736(90)92893-M; KARPATI S, 1991, J INVEST DERMATOL, V96, P228, DOI 10.1111/1523-1747.ep12462097; LAMB JR, 1990, MOL BIOL MED, V7, P311; MAKI M, 1984, J PEDIATR-US, V105, P901, DOI 10.1016/S0022-3476(84)80074-8; MAKI M, IN PRESS GUT; SEAH PP, 1971, LANCET, V1, P834	9	72	72	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 21	1991	338	8769					724	725		10.1016/0140-6736(91)91445-Z	http://dx.doi.org/10.1016/0140-6736(91)91445-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG104	1679869				2022-12-01	WOS:A1991GG10400006
J	OLUBODUN, JOB; JAIYESIMI, AEA; FAKOYA, EA; OLASODE, OA				OLUBODUN, JOB; JAIYESIMI, AEA; FAKOYA, EA; OLASODE, OA			MALNUTRITION IN PRISONERS ADMITTED TO A MEDICAL WARD IN A DEVELOPING COMMUNITY	BRITISH MEDICAL JOURNAL			English	Article									OGUN STATE UNIV,TEACHING HOSP,DEPT MED,PMB,SHAGAMU 2001,NIGERIA				Olasode, Olayinka/AAL-6831-2020					BAKER JP, 1982, NEW ENGL J MED, V306, P969, DOI 10.1056/NEJM198204223061606; BURGESS RC, 1956, LANCET, V2, P411; OLUBODUN JOB, IN PRESS TROP GEOGR; SMITH R, 1984, BRIT MED J, V288, P995, DOI 10.1136/bmj.288.6422.995; WATERLOW JC, 1972, BRIT MED J, V3, P566, DOI 10.1136/bmj.3.5826.566	5	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1991	303	6804					693	694		10.1136/bmj.303.6804.693	http://dx.doi.org/10.1136/bmj.303.6804.693			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GG980	1912916	Bronze, Green Published			2022-12-01	WOS:A1991GG98000022
J	RADANOV, BP; DISTEFANO, G; SCHNIDRIG, A; BALLINARI, P				RADANOV, BP; DISTEFANO, G; SCHNIDRIG, A; BALLINARI, P			ROLE OF PSYCHOSOCIAL STRESS IN RECOVERY FROM COMMON WHIPLASH	LANCET			English	Article							SOMATIZATION; INJURIES; NECK	It is widely accepted that psychosocial factors are related to illness behaviour and there is some evidence that they may influence the rate of recovery from post-traumatic disorders. The abilities of psychosocial stress, somatic symptoms, and subjectively assessed cognitive impairment to predict delayed recovery from common whiplash were investigated in a follow-up study. 78 consecutive patients referred 7.2 (SD 4.5) days after they had sustained common whiplash in car accidents were assessed for psychosocial stress, negative affectivity, personality traits, somatic complaints, and cognitive impairment by semistructured interview and by several standardised tests. On examination 6 months later 57 patients were fully recovered and 21 had persisting symptoms. The groups' scores for the independent variables assessed at the baseline examination were compared. Stepwise regression analysis showed that psychosocial factors, negative affectivity, and personality traits were not significant in predicting the outcome. However, initial neck pain intensity, injury-related cognitive impairment, and age were significant factors predicting illness behaviour. This study, which was based on a random sample and which considered many other possible predictive factors as well as psychosocial status, does not support previous findings that psychosocial factors predict illness behaviour in post-trauma patients.	UNIV BERN,DEPT PSYCHOL,CH-3010 BERN,SWITZERLAND	University of Bern	RADANOV, BP (corresponding author), UNIV BERN,DEPT PSYCHIAT,MURTENSTR 21,CH-3010 BERN,SWITZERLAND.							BALLA JI, 1982, CULT MED PSYCHIAT, V6, P191, DOI 10.1007/BF00051428; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; COSTA PJ, 1988, J PERS, V55, P299; Fahrenberg J, 1984, FREIBURGER PERSONLIC; GAY JR, 1953, JAMA-J AM MED ASSOC, V152, P1698, DOI 10.1001/jama.1953.03690180020006; GOLDBERG DP, 1988, J PSYCHOSOM RES, V32, P137, DOI 10.1016/0022-3999(88)90048-7; HIRSCH SA, 1988, ORTHOP CLIN N AM, V19, P791; HODGE JR, 1971, PSYCHOSOMATICS, V12, P245; LEAVITT F, 1990, J PSYCHOSOM RES, V34, P447, DOI 10.1016/0022-3999(90)90068-F; LIPOWSKI ZJ, 1988, AM J PSYCHIAT, V145, P1358; MAIMARIS C, 1988, INJURY, V19, P393, DOI 10.1016/0020-1383(88)90131-3; MERSKEY H, 1984, CAN MED ASSOC J, V130, P1119; MILLER H, 1961, BRIT MED J, V1, P992, DOI 10.1136/bmj.1.5231.992; MILLS H, 1986, NEW ZEAL MED J, V99, P373; MURPHY M, 1989, BRIT MED J, V298, P1331, DOI 10.1136/bmj.298.6684.1331; NORRIS SH, 1983, J BONE JOINT SURG BR, V65, P608, DOI 10.1302/0301-620X.65B5.6643566; PEARCE JMS, 1989, J NEUROL NEUROSUR PS, V52, P1329, DOI 10.1136/jnnp.52.12.1329; REINHERZ HZ, 1989, J AM ACAD CHILD PSY, V28, P942, DOI 10.1097/00004583-198911000-00021; RODGERS B, 1990, J CHILD PSYCHOL PSYC, V31, P393, DOI 10.1111/j.1469-7610.1990.tb01577.x; Von Zerssen D., 1976, BEFINDLICHKEITSSKALA; VONZERSSEN D, 1983, METHODOLOGY EVALUATI, P183; WATSON D, 1989, PSYCHOL REV, V96, P234, DOI 10.1037/0033-295X.96.2.234; 1986, SPSS X	23	161	164	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 21	1991	338	8769					712	715		10.1016/0140-6736(91)91441-V	http://dx.doi.org/10.1016/0140-6736(91)91441-V			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GG104	1679865				2022-12-01	WOS:A1991GG10400002
J	SUTTER, RW; PATRIARCA, PA; BROGAN, S; MALANKAR, PG; PALLANSCH, MA; KEW, OM; BASS, AG; COCHI, SL; ALEXANDER, JP; HALL, DB; SULEIMAN, AJM; ALGHASSANY, AAK; ELBUALY, MS				SUTTER, RW; PATRIARCA, PA; BROGAN, S; MALANKAR, PG; PALLANSCH, MA; KEW, OM; BASS, AG; COCHI, SL; ALEXANDER, JP; HALL, DB; SULEIMAN, AJM; ALGHASSANY, AAK; ELBUALY, MS			OUTBREAK OF PARALYTIC POLIOMYELITIS IN OMAN - EVIDENCE FOR WIDESPREAD TRANSMISSION AMONG FULLY VACCINATED CHILDREN	LANCET			English	Article								From January, 1988, to March, 1989, a widespread outbreak (118 cases) of poliomyelitis type 1 occurred in Oman. Incidence of paralytic disease was highest in children younger than 2 years (87/100 000) despite an immunisation programme that recently had raised coverage with 3 doses of oral poliovirus vaccine (OPV) among 12-month-old children from 67% to 87%. We did a case-control study (70 case-patients, 692 age-matched controls) to estimate the clinical efficacy of OPV, assessed the immunogenicity of OPV and extent of poliovirus spread by serology, retrospectively evaluated the cold chain and vaccine potency, and sought the origin of the outbreak strain by genomic sequencing. 3 doses of OPV reduced the risk of paralysis by 91%; vaccine failures could not be explained by failures in the cold chain nor on suboptimum vaccine potency. Cases and controls had virtually identical type 1 neutralising antibody profiles, suggesting that poliovirus type 1 circulation was widespread. Genomic sequencing indicated that the outbreak strain had been recently imported from South Asia and was distinguishable from isolates indigenous to the Middle East. Accumulation of enough children to sustain the outbreak seems to have been due to previous success of the immunisation programme in reducing spread of endemic strains, suboptimum efficacy of OPV, and delay in completing the primary immunisation series until 7 months of age. Additionally, the estimated attack rate of infection among children aged 9-23 months exceeded 25% in some regions, suggesting that a substantial proportion of fully vaccinated children had been involved in the chain of transmission.	CTR DIS CONTROL, DIV VIRAL & RICKETTSIAL DIS, ATLANTA, GA 30333 USA; UNICEF, Muscat, OMAN; WHO, EXPANDED PROGRAMME IMMUNISAT, CH-1211 GENEVA 27, SWITZERLAND; MINIST HLTH, Muscat, OMAN	Centers for Disease Control & Prevention - USA; World Health Organization	SUTTER, RW (corresponding author), CTR DIS CONTROL, DIV IMMUNISAT E05, ATLANTA, GA 30333 USA.							BASS AG, 1989, REVIEW VACCINE OLD C; BERNIER RH, 1984, REV INFECT DIS, V6, pS371; De-Xiang D, 1986, B WORLD HEALTH ORGAN, V64, P853; DEMING MS, IN PRESS AM J EPIDEM; GAIL MH, 1981, BIOMETRIKA, V68, P703, DOI 10.1093/biomet/68.3.703; HANLON P, 1987, LANCET, V1, P800; JOHN TJ, 1984, REV INFECT DIS, V6, pS438; KIMFARLEY RJ, 1984, LANCET, V2, P1322; Melnick JL, 1979, DIAGNOSTIC PROCEDURE, V5th, P471; OTTEN MW, IN PRESS AM J EPIDEM; PATRIARCA PA, 1988, LANCET, V1, P429; PATRIARCA PA, IN PRESS REV INFECT; RICOHESSE R, 1987, VIROLOGY, V160, P311, DOI 10.1016/0042-6822(87)90001-8; SABIN AB, 1960, JAMA-J AM MED ASSOC, V173, P1521, DOI 10.1001/jama.1960.03020320001001; SABIN AB, 1982, YALE J BIOL MED, V55, P383; SLATER PE, 1990, LANCET, V335, P1192, DOI 10.1016/0140-6736(90)92705-M; SUTTER RW, 1989, AM J PUBLIC HEALTH, V79, P495, DOI 10.2105/AJPH.79.4.495; SUTTER RW, 1989, 38TH ANN M AM SOC TR; TULCHINSKY T, 1989, AM J PUBLIC HEALTH, V79, P1648, DOI 10.2105/AJPH.79.12.1648; 1988, WHO TECH REP SER, V771; 1989, WEEKLY EPIDEMIOL REC, V64, P273; 1990, MMWR, V39, P557; 1985, TRAINING COURSE MID; 1988, WEEKLY EPIDEMIOL REC, V63, P161	24	81	81	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 21	1991	338	8769					715	720		10.1016/0140-6736(91)91442-W	http://dx.doi.org/10.1016/0140-6736(91)91442-W			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG104	1679866				2022-12-01	WOS:A1991GG10400003
J	TUNSTALLPEDOE, H				TUNSTALLPEDOE, H			THE HEALTH OF THE NATION - RESPONSES - CORONARY HEART-DISEASE	BMJ-BRITISH MEDICAL JOURNAL			English	Article											TUNSTALLPEDOE, H (corresponding author), UNIV DUNDEE, NINEWELLS HOSP & MED SCH, CARDIOVASC EPIDEMIOL UNIT, DUNDEE DD1 9SY, SCOTLAND.							Gregory F., 1990, DIETARY NUTR SURVEY; ROSE G, 1983, EUR HEART J, V4, P141; THELLE DS, 1983, BRIT HEART J, V49, P205, DOI 10.1136/hrt.49.3.205; TUNSTALLPEDOE H, 1989, LANCET, V1, P540; 1990, HLTH UPDATE, V1; 1985, PROMOTING HLTH PREVE; 1990, WHO TECH REP SER, P797; 1989, 208 NAT AUD OFF HOUS; 1988, J CLIN EPIDEMIOL, V41, P105, DOI [10.1016/0895-4356(88)90084-4, DOI 10.1016/0895-4356(88)90084-4]; 1984, CORONARY HEART DISEA; 1989, WORLDWIDE MONITORING; 1990, WORLD HLTH STATISTIC; 1989, 26TH HOUS COMM COMM; 1988, ACTION UK 1984 1987; 1991, CM1523; 1991, DEP HLTH REPORT HLTH, V4	16	19	19	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 21	1991	303	6804					701	704		10.1136/bmj.303.6804.701	http://dx.doi.org/10.1136/bmj.303.6804.701			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG980	1912919	Green Published, Bronze			2022-12-01	WOS:A1991GG98000027
J	APARICIO, OM; BILLINGTON, BL; GOTTSCHLING, DE				APARICIO, OM; BILLINGTON, BL; GOTTSCHLING, DE			MODIFIERS OF POSITION EFFECT ARE SHARED BETWEEN TELOMERIC AND SILENT MATING-TYPE LOCI IN SACCHAROMYCES-CEREVISIAE	CELL			English	Article							AUTONOMOUSLY REPLICATING SEQUENCES; SACCHAROMYCES-CEREVISIAE; CHROMOSOME-III; DNA-SEQUENCES; SIR GENES; EFFECT VARIEGATION; YEAST; IDENTIFICATION; EXPRESSION; TRANSCRIPTION	Genes placed near telomeres in S. cerevisiae succumb to position-effect variegation. SIR2, SIR3, SIR4, NAT1, ARD1, and HHF2 (histone H4) were identified as modifiers of the position effect at telomeres, since transcriptional repression near telomeres was no longer observed when any of the modifier genes were mutated. These genes, in addition to SIR1, have previously been shown to repress transcription at the silent mating loci, HML and HMR. However, there were differences between transcriptional silencing at telomeres and the HM loci, as demonstrated by suppressor analysis and the lack of involvement of SIR1 in telomeric silencing. These findings provide insights into telomeric structure and function that are likely to apply to many eukaryotes. In addition, the distinctions between telomeres and the HM loci suggest a hierarchy of chromosomal silencing in S. cerevisiae.			APARICIO, OM (corresponding author), UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA.			Aparicio, Oscar/0000-0002-5591-0277	NATIONAL CANCER INSTITUTE [P30CA014599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043893] Funding Source: NIH RePORTER; NCI NIH HHS [CA14599-16] Funding Source: Medline; NIGMS NIH HHS [GM43893] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM J, 1984, J MOL BIOL, V176, P307, DOI 10.1016/0022-2836(84)90492-3; ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALBERTS B, 1989, MOL BIOL CELL, P1219; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BLOBEL G, 1985, P NATL ACAD SCI USA, V82, P8527, DOI 10.1073/pnas.82.24.8527; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; BUTTON LL, 1986, MOL CELL BIOL, V6, P1352, DOI 10.1128/MCB.6.4.1352; CHAN CSM, 1983, J MOL BIOL, V168, P505, DOI 10.1016/S0022-2836(83)80299-X; CHAN CSM, 1983, CELL, V33, P563, DOI 10.1016/0092-8674(83)90437-3; CHUNG HMM, 1990, EMBO J, V9, P2611, DOI 10.1002/j.1460-2075.1990.tb07443.x; DIFFLEY JFX, 1989, NATURE, V342, P24, DOI 10.1038/342024a0; EISSENBERG JC, 1989, BIOESSAYS, V11, P14, DOI 10.1002/bies.950110105; FELDMAN JB, 1984, J MOL BIOL, V178, P815, DOI 10.1016/0022-2836(84)90313-9; FUSSELL CP, 1975, CHROMOSOMA, V50, P201, DOI 10.1007/BF00283240; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HABER JE, 1979, GENETICS, V93, P13; HENIKOFF S, 1990, TRENDS GENET, V6, P422, DOI 10.1016/0168-9525(90)90304-O; HOCHSTRASSER M, 1986, J CELL BIOL, V102, P112, DOI 10.1083/jcb.102.1.112; HOPPER AK, 1975, GENETICS, V80, P77; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; IVY JM, 1986, MOL CELL BIOL, V6, P688, DOI 10.1128/MCB.6.2.688; IVY JM, 1985, GENETICS, V111, P735; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KIM UJ, 1988, EMBO J, V7, P2211, DOI 10.1002/j.1460-2075.1988.tb03060.x; KIMMERLY WJ, 1987, MOL CELL BIOL, V7, P4225, DOI 10.1128/MCB.7.12.4225; KLAR AJS, 1979, GENETICS, V93, P37; KLAR AJS, 1981, NATURE, V289, P239, DOI 10.1038/289239a0; KOSTRIKEN R, 1983, CELL, V35, P167, DOI 10.1016/0092-8674(83)90219-2; KURTZ S, 1991, GENE DEV, V5, P616, DOI 10.1101/gad.5.4.616; LEVIS R, 1985, SCIENCE, V229, P558, DOI 10.1126/science.2992080; LIMADEFARIA A, 1983, MOL EVOLUTION ORG CH, P701; LOISON G, 1980, CURR GENET, V2, P39, DOI 10.1007/BF00445692; LONGTINE MS, 1989, CURR GENET, V16, P225, DOI 10.1007/BF00422108; MAHONEY DJ, 1991, GENE DEV, V5, P605, DOI 10.1101/gad.5.4.605; MAHONEY DJ, 1989, MOL CELL BIOL, V9, P4621, DOI 10.1128/MCB.9.11.4621; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; NASMYTH KA, 1982, CELL, V30, P567, DOI 10.1016/0092-8674(82)90253-7; NASMYTH KA, 1981, NATURE, V289, P244, DOI 10.1038/289244a0; PARK EC, 1990, MOL CELL BIOL, V10, P4932, DOI 10.1128/MCB.10.9.4932; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; RAWLINS DJ, 1990, J MICROSC-OXFORD, V157, P83, DOI 10.1111/j.1365-2818.1990.tb02949.x; RINE J, 1979, GENETICS, V93, P877; RINE J, 1987, GENETICS, V116, P9; ROMAN H, 1956, COLD SPRING HARB SYM, V21, P175, DOI 10.1101/SQB.1956.021.01.015; ROSE M, 1984, MOL GEN GENET, V193, P557, DOI 10.1007/BF00382100; SCHNELL R, 1986, MOL CELL BIOL, V6, P494, DOI 10.1128/MCB.6.2.494; SHOEMAN RL, 1990, J BIOL CHEM, V265, P9055; SHORE D, 1987, EMBO J, V6, P461, DOI 10.1002/j.1460-2075.1987.tb04776.x; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SHORE D, 1984, EMBO J, V3, P2817, DOI 10.1002/j.1460-2075.1984.tb02214.x; SPOFFORD JB, 1976, GENETICS BIOL DROS C, V1, P955; SPRADLING AC, 1990, GENETICS, V126, P779; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STONE EM, 1991, MOL CELL BIOL, V11, P2253, DOI 10.1128/MCB.11.4.2253; STOTZ A, 1990, GENE, V95, P91, DOI 10.1016/0378-1119(90)90418-Q; STRATHERN JN, 1982, CELL, V31, P183, DOI 10.1016/0092-8674(82)90418-4; STRATHERN JN, 1979, CELL, V18, P309, DOI 10.1016/0092-8674(79)90050-3; TRAVERSE KL, 1989, CHROMOSOMA, V97, P261, DOI 10.1007/BF00371965; VANHOLDE KE, 1989, SPRINGER SERIES MOL, P497; White M.J.D., 1973, ANIMAL CYTOLOGY EVOL, P1; WHITEWAY M, 1987, MOL CELL BIOL, V7, P3713, DOI 10.1128/MCB.7.10.3713; WILSON C, 1990, ANNU REV CELL BIOL, V6, P679, DOI 10.1146/annurev.cb.06.110190.003335; YOSHIKAWA A, 1990, YEAST, V6, P383, DOI 10.1002/yea.320060504; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	71	620	647	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	1991	66	6					1279	1287		10.1016/0092-8674(91)90049-5	http://dx.doi.org/10.1016/0092-8674(91)90049-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1913809				2022-12-01	WOS:A1991GG55200021
J	BALK, SP; EBERT, EC; BLUMENTHAL, RL; MCDERMOTT, FV; WUCHERPFENNIG, KW; LANDAU, SB; BLUMBERG, RS				BALK, SP; EBERT, EC; BLUMENTHAL, RL; MCDERMOTT, FV; WUCHERPFENNIG, KW; LANDAU, SB; BLUMBERG, RS			OLIGOCLONAL EXPANSION AND CD1 RECOGNITION BY HUMAN INTESTINAL INTRAEPITHELIAL LYMPHOCYTES	SCIENCE			English	Article							T-CELL RECEPTOR; INTRA-THYMIC DIFFERENTIATION; VARIABLE REGION GENES; GAMMA-DELTA-CELLS; ANTIGEN RECEPTOR; MONOCLONAL-ANTIBODIES; ALPHA-CHAIN; LEUKEMIC LYMPHOBLASTS; NORMAL THYMOCYTES; DISCRETE STAGES	A human intestinal intraepithelial lymphocyte (IEL) T cell line was established from jejunum to characterize the structure and function of the alpha-beta T cell antigen receptors (TCRs) expressed by this population. Single-sided polymerase chain reaction (PCR) amplification cloning and quantitative PCR amplification of the TCR chains from the cell line and from fresh IELs demonstrated that IELs were oligoclonal. The IEL T cell line exhibited CD1-specific cytotoxicity and a dominant IEL T cell clone was CD1c-specific. Thus, human jejunal intraepithelial lymphocytes are oligoclonal and recognize members of the CD1 gene family.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV GASTROENTEROL,MED RES BLDG,ROOM 013B,BOSTON,MA 02115; UNIV MED & DENT NEW JERSEY,DIV EBERT GASTROENTEROL,NEW BRUNSWICK,NJ 08903; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DIV HEMATOL ONCOL,BOSTON,MA 02215; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CTR NEUROL DIS,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Rutgers State University New Brunswick; Rutgers State University Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School					NATIONAL CANCER INSTITUTE [K11CA001310] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042166, K08DK001886] Funding Source: NIH RePORTER; NCI NIH HHS [CA-01310] Funding Source: Medline; NIDDK NIH HHS [DK42166, 5 KO8 DK01886] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER J, 1989, IMMUNOGENETICS, V29, P380, DOI 10.1007/BF00375866; AMIOT M, 1986, J IMMUNOL, V136, P1752; ARUFFO A, 1989, J IMMUNOL, V143, P1723; ASARNOW DM, 1988, CELL, V55, P837, DOI 10.1016/0092-8674(88)90139-0; ASARNOW DM, 1989, NATURE, V341, P60, DOI 10.1038/341060a0; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BALK SP, 1989, P NATL ACAD SCI USA, V86, P252, DOI 10.1073/pnas.86.1.252; BALK SP, UNPUB; BAND H, 1987, SCIENCE, V238, P682, DOI 10.1126/science.3672118; BENEDITA R, 1991, J EXP MED, V173, P483; BLEICHER PA, 1990, SCIENCE, V250, P679, DOI 10.1126/science.1700477; BLUESTONE JA, 1988, J EXP MED, V168, P1899, DOI 10.1084/jem.168.5.1899; BLUMBERG RS, 1990, J BIOL CHEM, V265, P14036; BLUMBERG RS, IN PRESS J IMMUNOL; BONNEVILLE M, 1989, P NATL ACAD SCI USA, V86, P5928, DOI 10.1073/pnas.86.15.5928; BONNEVILLE M, 1988, NATURE, V336, P479, DOI 10.1038/336479a0; BRANDTZAEG P, 1989, SCAND J IMMUNOL, V30, P123, DOI 10.1111/j.1365-3083.1989.tb01196.x; BROD SA, 1990, CELL IMMUNOL, V125, P426, DOI 10.1016/0008-8749(90)90096-A; BUCY RP, 1989, J IMMUNOL, V142, P3045; CERFBENSUSSAN N, 1983, J IMMUNOL, V130, P2615; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; DEUSCH K, 1991, EUR J IMMUNOL, V21, P1053, DOI 10.1002/eji.1830210429; DRENO B, 1987, ACTA DERM-VENEREOL, V76, P406; DRIJKONINGEN M, 1986, BRIT J DERMATOL, V115, P511, DOI 10.1111/j.1365-2133.1986.tb06248.x; EBERT EC, 1989, GASTROENTEROLOGY, V97, P1372, DOI 10.1016/0016-5085(89)90379-X; ERNST PB, 1985, IMMUNOL TODAY, V6, P50, DOI 10.1016/0167-5699(85)90047-7; FAURE F, 1990, EUR J IMMUNOL, V20, P703, DOI 10.1002/eji.1830200336; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOODMAN T, 1988, NATURE, V333, P855, DOI 10.1038/333855a0; GROH V, 1989, P NATL ACAD SCI USA, V86, P5059, DOI 10.1073/pnas.86.13.5059; GROH V, 1989, J EXP MED, V169, P1277, DOI 10.1084/jem.169.4.1277; HERSHBERG R, 1990, P NATL ACAD SCI USA, V87, P9727, DOI 10.1073/pnas.87.24.9727; ITO K, 1990, CELL, V62, P549, DOI 10.1016/0092-8674(90)90019-B; ITOHARA S, 1990, NATURE, V343, P754, DOI 10.1038/343754a0; JANEWAY CA, 1988, IMMUNOL TODAY, V9, P73, DOI 10.1016/0167-5699(88)91267-4; KAHNPERLES B, 1985, J IMMUNOL, V134, P1759; KIMURA N, 1986, J EXP MED, V164, P739, DOI 10.1084/jem.164.3.739; KLEIN MH, 1987, P NATL ACAD SCI USA, V84, P6884, DOI 10.1073/pnas.84.19.6884; KYES S, 1989, P NATL ACAD SCI USA, V86, P5527, DOI 10.1073/pnas.86.14.5527; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MARTIN LH, 1987, P NATL ACAD SCI USA, V84, P9189, DOI 10.1073/pnas.84.24.9189; MCMICHAEL AJ, 1979, EUR J IMMUNOL, V9, P205, DOI 10.1002/eji.1830090307; PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; SPITS H, 1983, HYBRIDOMA, V2, P423, DOI 10.1089/hyb.1983.2.423; TAKAGAKI Y, 1989, NATURE, V339, P712, DOI 10.1038/339712a0; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAX WJM, 1983, NATURE, V304, P445, DOI 10.1038/304445a0; TOYONAGA B, 1987, ANNU REV IMMUNOL, V5, P585, DOI 10.1146/annurev.iy.05.040187.003101; TREJDOSIEWICZ LK, 1989, IMMUNOLOGY, V68, P7; VINEY JL, 1989, IMMUNOLOGY, V66, P583; WALSH LJ, 1988, J INVEST DERMATOL, V90, P13, DOI 10.1111/1523-1747.ep12462413; WILSON RK, 1988, IMMUNOL REV, V101, P149, DOI 10.1111/j.1600-065X.1988.tb00736.x; WUCHERPFENNIG KW, 1990, SCIENCE, V248, P1016, DOI 10.1126/science.1693015	54	236	237	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1991	253	5026					1411	1415		10.1126/science.1716785	http://dx.doi.org/10.1126/science.1716785			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF851	1716785				2022-12-01	WOS:A1991GF85100039
J	BERNAT, RL; DELANNOY, MR; ROTHFIELD, NF; EARNSHAW, WC				BERNAT, RL; DELANNOY, MR; ROTHFIELD, NF; EARNSHAW, WC			DISRUPTION OF CENTROMERE ASSEMBLY DURING INTERPHASE INHIBITS KINETOCHORE MORPHOGENESIS AND FUNCTION IN MITOSIS	CELL			English	Article							MAMMALIAN KINETOCHORE; CHROMOSOME CONDENSATION; CENP-B; CYTOPLASMIC DYNEIN; AUTOIMMUNE SERA; MOVEMENT; SCLERODERMA; ANTIBODIES; PROTEINS; ANAPHASE	The relationship between the kinetochore and the centromeric heterochromatin that surrounds it is unknown. Anti-centromere autoantibodies (ACAs) that recognize antigens found in the heterochromatin beneath the kinetochore disrupt mitotic events when microinjected into human cells. We show here that ACAs interfere with two different stages of centromere assembly during interphase, resulting in abnormal kinetochore structures during mitosis. Antibody injection prior to late G2 results in the subsequent failure to assemble a trilaminar kinetochore. Such chromosomes bind microtubules but are incapable of movement. Antibody disruption of events during G2 produces unstable kinetochores that prevent the normal transition into anaphase. These experiments present a novel way to examine events in the pathway of kinetochore assembly that occur during interphase, at a time when this structure cannot be visualized directly.	UNIV CONNECTICUT,CTR HLTH,DEPT MED,DIV RHEUMAT DIS,FARMINGTON,CT 06032	University of Connecticut	BERNAT, RL (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21205, USA.		Earnshaw, William/AAY-7438-2020	Earnshaw, William/0000-0002-7191-0621	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035212] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35212] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALCZON RD, 1987, J CELL BIOL, V105, P855, DOI 10.1083/jcb.105.2.855; BERNAT RL, 1990, J CELL BIOL, V111, P1519, DOI 10.1083/jcb.111.4.1519; BISCHOFF FR, 1990, P NATL ACAD SCI USA, V87, P8617, DOI 10.1073/pnas.87.21.8617; BRENNER S, 1981, J CELL BIOL, V91, P95, DOI 10.1083/jcb.91.1.95; BRINKLEY BR, 1966, CHROMOSOMA, V19, P28, DOI 10.1007/BF00332792; BRINKLEY BR, 1988, NATURE, V336, P251, DOI 10.1038/336251a0; COMPTON DA, 1991, J CELL BIOL, V112, P1083, DOI 10.1083/jcb.112.6.1083; COOKE CA, 1990, J CELL BIOL, V110, P1475, DOI 10.1083/jcb.110.5.1475; EARNSHAW W, 1986, J CLIN INVEST, V77, P426, DOI 10.1172/JCI112320; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; EARNSHAW WC, 1989, CHROMOSOMA, V98, P1, DOI 10.1007/BF00293329; GORBSKY GJ, 1987, J CELL BIOL, V104, P9, DOI 10.1083/jcb.104.1.9; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; JOKELAINEN PT, 1967, J ULTRA MOL STRUCT R, V19, P19, DOI 10.1016/S0022-5320(67)80058-3; KINGWELL B, 1987, CHROMOSOMA, V95, P403, DOI 10.1007/BF00333991; LUYKX P, 1965, EXP CELL RES, V39, P643, DOI 10.1016/0014-4827(65)90068-6; MASUMOTO H, 1989, J CELL BIOL, V109, P1963, DOI 10.1083/jcb.109.5.1963; MOROI Y, 1980, P NATL ACAD SCI-BIOL, V77, P1627, DOI 10.1073/pnas.77.3.1627; NICKLAS RB, 1989, J CELL BIOL, V109, P2245, DOI 10.1083/jcb.109.5.2245; NICKLAS RB, 1969, J CELL BIOL, V43, P40, DOI 10.1083/jcb.43.1.40; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; OHTSUBO M, 1987, GENE DEV, V1, P585, DOI 10.1101/gad.1.6.585; PALMER DK, 1991, IN PRESS P NATL ACAD, V88; PANKOV R, 1990, CHROMOSOMA, V99, P95, DOI 10.1007/BF01735324; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; RATTNER JB, 1986, CHROMOSOMA, V93, P515, DOI 10.1007/BF00386793; RIEDER CL, 1982, INT REV CYTOL, V79, P1, DOI 10.1016/S0074-7696(08)61672-1; RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81; RIEDER CL, 1990, ELECTRON MICROSC REV, V3, P269, DOI 10.1016/0892-0354(90)90005-D; RIEDER CL, 1989, MECHANISMS CHROMOSOM, P185; RIS H, 1981, CHROMOSOMA, V82, P153, DOI 10.1007/BF00286101; ROOS UP, 1973, CHROMOSOMA, V41, P195, DOI 10.1007/BF00319696; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; SCHLIWA M, 1981, J CELL BIOL, V90, P222, DOI 10.1083/jcb.90.1.222; SIMERLY C, 1990, J CELL BIOL, V111, P1491, DOI 10.1083/jcb.111.4.1491; SLUDER G, 1979, J CELL BIOL, V80, P674, DOI 10.1083/jcb.80.3.674; SNYDER J A, 1985, European Journal of Cell Biology, V39, P373; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; TAYLOR EW, 1959, J BIOPHYS BIOCHEM CY, V6, P193, DOI 10.1083/jcb.6.2.193; TENHAGEN KG, 1990, MOL CELL BIOL, V10, P6348, DOI 10.1128/MCB.10.12.6348; WORDEMAN L, 1991, IN PRESS J CELL BIOL; YEN TJ, 1991, IN PRESS EMBO J, V10; ZIRKLE RE, 1970, RADIAT RES, V41, P516, DOI 10.2307/3572841	43	81	84	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1991	66	6					1229	1238		10.1016/0092-8674(91)90045-Z	http://dx.doi.org/10.1016/0092-8674(91)90045-Z			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1913807				2022-12-01	WOS:A1991GG55200017
J	COULOMBE, PA; HUTTON, ME; LETAI, A; HEBERT, A; PALLER, AS; FUCHS, E				COULOMBE, PA; HUTTON, ME; LETAI, A; HEBERT, A; PALLER, AS; FUCHS, E			POINT MUTATIONS IN HUMAN KERATIN-14 GENES OF EPIDERMOLYSIS-BULLOSA SIMPLEX PATIENTS - GENETIC AND FUNCTIONAL ANALYSES	CELL			English	Article							INTERMEDIATE FILAMENT PROTEINS; TERMINAL DIFFERENTIATION; CULTURED FIBROBLASTS; EPIDERMAL KERATIN; WEBER-COCKAYNE; LAMIN-A; EXPRESSION; CELLS; DOMINANT; SEQUENCE	Previously we demonstrated that transgenic mice expressing mutant basal epidermal keratin genes exhibited a phenotype resembling a group of autosomal dominant human skin disorders known as epidermolysis bullosa simplex (EBS). EBS diseases affect approximately 1: 50,000 and are of unknown etiology, although all subtypes exhibit blistering arising from basal cell cytolysis. We now demonstrate that two patients with spontaneous cases of Dowling-Meara EBS have point mutations in a critical region in one (K14) of two basal keratin genes. To demonstrate function, we engineered one of these point mutations in a cloned human K14 cDNA, and showed that a K14 with an Arg-125 --> Cys mutation disrupted keratin network formation in transfected keratinocytes and perturbed filament assembly in vitro. Since we had previously shown that keratin network perturbation is an essential component of EBS diseases, these data suggest that the basis for the phenotype in this patients resides in this point mutation.	UNIV TEXAS,DEPT DERMATOL,HOUSTON,TX 77030; NORTHWESTERN UNIV,CHILDRENS MEM HOSP,SCH MED,DEPT DERMATOL,CHICAGO,IL 60614	University of Texas System; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University	COULOMBE, PA (corresponding author), UNIV CHICAGO,HOWARD HUGHES MED INST,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637, USA.		Fuchs, Elaine/G-1565-2016	Paller, Amy/0000-0001-6187-6549	NIAMS NIH HHS [AR27883] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027883, R37AR027883] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AEBI U, 1988, PROTOPLASMA, V145, P73, DOI 10.1007/BF01349341; ALBERS K, 1987, J CELL BIOL, V105, P791, DOI 10.1083/jcb.105.2.791; ALBERS K, 1989, J CELL BIOL, V108, P1477, DOI 10.1083/jcb.108.4.1477; ANTONLAMPRECHT I, 1983, J INVEST DERMATOL, V81, pS149, DOI 10.1111/1523-1747.ep12540961; BONIFAS JM, 1991, J INVEST DERMATOL, V96, pA550; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COULOMBE PA, 1989, J CELL BIOL, V109, P2295, DOI 10.1083/jcb.109.5.2295; COULOMBE PA, 1990, J CELL BIOL, V111, P3049, DOI 10.1083/jcb.111.6.3049; COULOMBE PA, 1990, J CELL BIOL, V111, P153, DOI 10.1083/jcb.111.1.153; COULOMBE PA, 1991, IN PRESS J CELL BIOL; DODEMONT H, 1990, EMBO J, V9, P4083, DOI 10.1002/j.1460-2075.1990.tb07630.x; FINE JD, 1985, ARCH DERMATOL, V121, P1292, DOI 10.1001/archderm.121.10.1292; FINE JD, 1989, PEDIATR DERMATOL, V6, P1, DOI 10.1111/j.1525-1470.1989.tb00256.x; FINE JD, 1991, J AM ACAD DERMATOL, V24, P119, DOI 10.1016/0190-9622(91)70021-S; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; FRANKE WW, 1983, P NATL ACAD SCI-BIOL, V80, P7113, DOI 10.1073/pnas.80.23.7113; FUCHS E, 1983, P NATL ACAD SCI-BIOL, V80, P5857, DOI 10.1073/pnas.80.19.5857; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; GILL SR, 1990, J CELL BIOL, V111, P2005, DOI 10.1083/jcb.111.5.2005; HANEKE E, 1982, J INVEST DERMATOL, V78, P219, DOI 10.1111/1523-1747.ep12506502; HANUKOGLU I, 1982, CELL, V31, P243, DOI 10.1016/0092-8674(82)90424-X; HATZFELD M, 1990, J CELL SCI, V97, P317; HATZFELD M, 1991, J CELL SCI, V99, P351; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; ITO M, 1991, ARCH DERMATOL, V127, P367, DOI 10.1001/archderm.127.3.367; JOHNSON LD, 1985, P NATL ACAD SCI USA, V82, P1896, DOI 10.1073/pnas.82.7.1896; KITAJIMA Y, 1989, ARCH DERMATOL RES, V281, P5, DOI 10.1007/BF00424265; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LU X, 1990, CELL, V62, P681, DOI 10.1016/0092-8674(90)90114-T; MARCHUK D, 1984, CELL, V39, P491, DOI 10.1016/0092-8674(84)90456-2; NELSON WG, 1983, J CELL BIOL, V97, P244, DOI 10.1083/jcb.97.1.244; PEARSON RW, 1971, DERMATOLOGY GENERAL, P621; QUAXJEUKEN YEFM, 1983, P NATL ACAD SCI-BIOL, V80, P3548, DOI 10.1073/pnas.80.12.3548; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; ROSENBERG M, 1988, MOL CELL BIOL, V8, P722, DOI 10.1128/MCB.8.2.722; ROSENBERG M, 1991, CYTOGENET CELL GENET, V57, P33, DOI 10.1159/000133109; SANCHEZ G, 1983, J INVEST DERMATOL, V81, P576, DOI 10.1111/1523-1747.ep12523269; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SAVOLAINEN ER, 1981, NEW ENGL J MED, V304, P197, DOI 10.1056/NEJM198101223040403; SAVTCHENKO ES, 1988, MOL BIOL EVOL, V5, P97; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; SUN TT, 1978, J BIOL CHEM, V253, P2053; TOWBIN H, 1979, P NATL ACAD SCI USA, V81, P4683; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F; WONG PC, 1990, J CELL BIOL, V111, P1987, DOI 10.1083/jcb.111.5.1987; WU YJ, 1981, CELL, V25, P627, DOI 10.1016/0092-8674(81)90170-7; WU YJ, 1982, CELL, V31, P693, DOI 10.1016/0092-8674(82)90324-5; [No title captured]	50	548	555	1	31	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1991	66	6					1301	1311		10.1016/0092-8674(91)90051-Y	http://dx.doi.org/10.1016/0092-8674(91)90051-Y			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1717157				2022-12-01	WOS:A1991GG55200023
J	DELVAL, M; SCHLICHT, HJ; RUPPERT, T; REDDEHASE, MJ; KOSZINOWSKI, UH				DELVAL, M; SCHLICHT, HJ; RUPPERT, T; REDDEHASE, MJ; KOSZINOWSKI, UH			EFFICIENT PROCESSING OF AN ANTIGENIC SEQUENCE FOR PRESENTATION BY MHC CLASS-I MOLECULES DEPENDS ON ITS NEIGHBORING RESIDUES IN THE PROTEIN	CELL			English	Article							HEPATITIS-B VIRUS; CYTOLYTIC LYMPHOCYTE-T; IMMEDIATE-EARLY PROTEIN-PP89; RECOMBINANT VACCINIA VIRUS; INFLUENZA HEMAGGLUTININ; VIRAL PEPTIDES; CORE PROTEIN; CELL-SURFACE; RECOGNITION; GENE	Processing of endogenously synthesized proteins generates short peptides that are presented by MHC class I molecules to CD8 T lymphocytes. Here it is documented that not only the sequence of the presented peptide but also the residues by which it is flanked in the protein determine the efficiency of processing and presentation. This became evident when a viral sequence of proven antigenicity was inserted at different positions into an unrelated carrier protein. Not different peptides, but different amounts of the antigenic insert itself were retrieved by isolation of naturally processed peptides from cells expressing the different chimeric proteins. Low yield of antigenic peptide from an unfavorable integration site could be overcome by flanking the insert with oligo-alanine to space it from disruptive neighboring sequences. Notably, the degree of protection against lethal virus disease related directly to the amount of naturally processed antigenic peptide.			DELVAL, M (corresponding author), UNIV ULM, DEPT VIROL, ALBERT EINSTEIN ALLEE 11, W-7900 ULM, GERMANY.		Ruppert, Thomas/AAC-2467-2021; Del Val, Margarita/E-4769-2010	Ruppert, Thomas/0000-0001-9152-2266; Del Val, Margarita/0000-0001-6769-4279; Reddehase, Matthias/0000-0002-3509-7573				BRACIALE TJ, 1987, J EXP MED, V166, P678, DOI 10.1084/jem.166.3.678; CHIMINI G, 1989, J EXP MED, V169, P297, DOI 10.1084/jem.169.1.297; COLBEREGARAPIN F, 1981, J MOL BIOL, V150, P1, DOI 10.1016/0022-2836(81)90321-1; DELISI C, 1985, P NATL ACAD SCI USA, V82, P7048, DOI 10.1073/pnas.82.20.7048; DELVAL M, 1988, J VIROL, V62, P3965, DOI 10.1128/JVI.62.11.3965-3972.1988; DELVAL M, 1989, CELL, V58, P305, DOI 10.1016/0092-8674(89)90845-3; DELVAL M, 1991, J VIROL, V65, P3641, DOI 10.1128/JVI.65.7.3641-3646.1991; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; JONJIC S, 1988, J VIROL, V62, P1653; JUNKER M, 1987, NUCLEIC ACIDS RES, V15, P10117, DOI 10.1093/nar/15.24.10117; KEIL GM, 1987, J VIROL, V61, P1901, DOI 10.1128/JVI.61.6.1901-1908.1987; NASSAL M, 1988, GENE, V66, P279, DOI 10.1016/0378-1119(88)90364-2; OU JH, 1986, P NATL ACAD SCI USA, V83, P1578, DOI 10.1073/pnas.83.6.1578; PARHAM P, 1990, NATURE, V348, P674, DOI 10.1038/348674a0; PONTA H, 1985, EMBO J, V4, P3447, DOI 10.1002/j.1460-2075.1985.tb04103.x; REDDEHASE MJ, 1989, NATURE, V337, P651, DOI 10.1038/337651a0; REDDEHASE MJ, 1991, EUR J IMMUNOL, V21, P1697, DOI 10.1002/eji.1830210717; ROTHBARD JB, 1988, EMBO J, V7, P93, DOI 10.1002/j.1460-2075.1988.tb02787.x; ROTZSCHKE O, 1990, SCIENCE, V249, P283, DOI 10.1126/science.1695760; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SCHLICHT HJ, 1989, J VIROL, V63, P5399, DOI 10.1128/JVI.63.12.5399-5404.1989; SCHLICHT HJ, 1991, J VIROL, V65, P3489, DOI 10.1128/JVI.65.7.3489-3495.1991; TOWNSEND A, 1988, J EXP MED, V168, P1211, DOI 10.1084/jem.168.4.1211; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TOWNSEND ARM, 1986, NATURE, V324, P575, DOI 10.1038/324575a0; VANBLEEK GM, 1990, NATURE, V348, P213; VOLKMER H, 1987, J EXP MED, V166, P668, DOI 10.1084/jem.166.3.668; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J	32	236	241	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	1991	66	6					1145	1153		10.1016/0092-8674(91)90037-Y	http://dx.doi.org/10.1016/0092-8674(91)90037-Y			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1913805	Green Published			2022-12-01	WOS:A1991GG55200009
J	ENGEBRECHT, J; VOELKELMEIMAN, K; ROEDER, GS				ENGEBRECHT, J; VOELKELMEIMAN, K; ROEDER, GS			MEIOSIS-SPECIFIC RNA SPLICING IN YEAST	CELL			English	Article							MEIOTIC GENE CONVERSION; SACCHAROMYCES-CEREVISIAE; SEXUAL-DIFFERENTIATION; DROSOPHILA-MELANOGASTER; CHROMOSOME SEGREGATION; BETA-GALACTOSIDASE; TRANSFORMER GENE; ESCHERICHIA-COLI; DNA-SEQUENCE; RECOMBINATION	Previous studies have suggested that the differentiated state of meiosis in yeast is regulated primarily at the transcriptional level. This study reports a case of posttranscriptional regulation of a gene whose product is essential for meiosis. The MER2 gene is transcribed in mitosis as well as meiosis; however, the transcript is spliced efficiently to generate a functional gene product only in meiosis. Meiotic levels of splicing depend on the MER1 gene product, which is also essential for meiosis and which is produced only in meiotic cells. Therefore, at least one of the functions of the MER1 protein is to mediate splicing of the MER2 transcript. Genetic data suggest that the MER1 gene may also be responsible for splicing the transcript of at least one other gene.	YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06511	Yale University			Engebrecht, JoAnne/K-3355-2019	Engebrecht, JoAnne/0000-0002-2733-7506	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028904] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28904] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMMERER G, 1983, METHOD ENZYMOL, V101, P192; AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; ATCHESON CL, 1987, P NATL ACAD SCI USA, V84, P8035, DOI 10.1073/pnas.84.22.8035; BAKER BS, 1976, ANNU REV GENET, V10, P53, DOI 10.1146/annurev.ge.10.120176.000413; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; COLE GM, 1989, MOL CELL BIOL, V9, P3101, DOI 10.1128/MCB.9.7.3101; CONEY LR, 1988, MOL CELL BIOL, V8, P4009, DOI 10.1128/MCB.8.10.4009; DABEVA MD, 1987, J BIOL CHEM, V262, P16055; DABEVA MD, 1986, P NATL ACAD SCI USA, V83, P5854, DOI 10.1073/pnas.83.16.5854; DOMDEY H, 1984, CELL, V39, P611, DOI 10.1016/0092-8674(84)90468-9; ELDER RT, 1983, P NATL ACAD SCI-BIOL, V80, P2432, DOI 10.1073/pnas.80.9.2432; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; ENGEBRECHT J, 1990, CELL, V62, P927, DOI 10.1016/0092-8674(90)90267-I; ENGEBRECHT J, 1990, MOL CELL BIOL, V10, P2379, DOI 10.1128/MCB.10.5.2379; ENGEBRECHT JA, 1989, GENETICS, V121, P237; FARNET C, 1988, MECHANISMS CONSEQUEN, P201; GALLWITZ D, 1980, P NATL ACAD SCI-BIOL, V77, P2546, DOI 10.1073/pnas.77.5.2546; Game J.C., 1983, YEAST GENETICS FUNDA, P109; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOLLINGSWORTH NM, 1989, GENETICS, V121, P445; HOLLINGSWORTH NM, 1990, CELL, V61, P73, DOI 10.1016/0092-8674(90)90216-2; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KASSIR Y, 1988, CELL, V52, P853, DOI 10.1016/0092-8674(88)90427-8; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; KLAPHOLZ S, 1980, GENETICS, V96, P589; KLAPHOLZ S, 1985, GENETICS, V110, P187; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LAMBIE EJ, 1988, CELL, V52, P863, DOI 10.1016/0092-8674(88)90428-X; LANGFORD CJ, 1983, CELL, V33, P519, DOI 10.1016/0092-8674(83)90433-6; LASKI FA, 1986, CELL, V44, P7, DOI 10.1016/0092-8674(86)90480-0; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; Maniatis T., 1982, MOL CLONING; MENEES TM, 1989, GENETICS, V123, P675; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; PERCIVALSMITH A, 1984, MOL CELL BIOL, V4, P142, DOI 10.1128/MCB.4.1.142; PERKINS DD, 1949, GENETICS, V34, P607; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; ROCKMILL B, 1988, P NATL ACAD SCI USA, V85, P6057, DOI 10.1073/pnas.85.16.6057; ROCKMILL B, 1990, GENETICS, V126, P563; RODRIGUEZ JR, 1984, CELL, V39, P603, DOI 10.1016/0092-8674(84)90467-7; ROSE M, 1983, METHOD ENZYMOL, V101, P167; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Sherman F., 1986, METHODS YEAST GENETI; SIEBEL CW, 1990, SCIENCE, V248, P1200, DOI 10.1126/science.2161558; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SMITH HE, 1989, MOL CELL BIOL, V9, P2142, DOI 10.1128/MCB.9.5.2142; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; STEWART SE, 1989, MOL CELL BIOL, V9, P3464, DOI 10.1128/MCB.9.8.3464; THOMPSON EA, 1989, MOL GEN GENET, V218, P293, DOI 10.1007/BF00331281; VONWETTSTEIN D, 1984, ANNU REV GENET, V18, P331, DOI 10.1146/annurev.ge.18.120184.001555; WANG HT, 1987, MOL CELL BIOL, V7, P1425, DOI 10.1128/MCB.7.4.1425; WOOLFORD JL, 1989, YEAST, V5, P439, DOI 10.1002/yea.320050604	64	166	171	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1991	66	6					1257	1268		10.1016/0092-8674(91)90047-3	http://dx.doi.org/10.1016/0092-8674(91)90047-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1840507				2022-12-01	WOS:A1991GG55200019
J	ERVASTI, JM; CAMPBELL, KP				ERVASTI, JM; CAMPBELL, KP			MEMBRANE ORGANIZATION OF THE DYSTROPHIN-GLYCOPROTEIN COMPLEX	CELL			English	Article							RABBIT SKELETAL-MUSCLE; DUCHENNE MUSCULAR-DYSTROPHY; MOLECULE N-CAM; SARCOPLASMIC-RETICULUM; CELL-ADHESION; ULTRASTRUCTURAL-LOCALIZATION; 1,4-DIHYDROPYRIDINE RECEPTOR; RYANODINE RECEPTOR; PROTEINS; IDENTIFICATION	The stoichiometry, cellular location, glycosylation, and hydrophobic properties of the components in the dystrophin-glycoprotein complex were examined. The 156, 59, 50, 43, and 35 kd dystrophin-associated proteins each possess unique antigenic determinants, enrich quantitatively with dystrophin, and were localized to the skeletal muscle sarcolemma. The 156, 50, 43, and 35 kd dystrophin-associated proteins contained Asn-linked oligosaccharides. The 156 kd dystrophin-associated glycoprotein contained terminally sialylated Ser/Thr-linked oligosaccharides. Dystrophin, the 156 kd, and the 59 kd dystrophin-associated proteins were found to be peripheral membrane proteins, while the 50 kd, 43 kd, and 35 kd dystrophin-associated glycoproteins and the 25 kd dystrophin-associated protein were confirmed as integral membrane proteins. These results demonstrate that dystrophin and its 59 kd associated protein are cytoskeletal elements that are tightly linked to a 156 kd extracellular glycoprotein by way of a complex of transmembrane proteins.	UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	University of Iowa	ERVASTI, JM (corresponding author), UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, IOWA CITY, IA 52242 USA.		Pillay, Nischalan/F-9536-2012; Ervasti, James/AAZ-4786-2020	Campbell, Kevin/0000-0003-2066-5889				ARAHATA K, 1988, NATURE, V333, P861, DOI 10.1038/333861a0; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BONILLA E, 1988, CELL, V54, P447, DOI 10.1016/0092-8674(88)90065-7; BRUNNER J, 1981, BIOCHEMISTRY-US, V20, P7174, DOI 10.1021/bi00528a019; CAMPBELL KP, 1987, J BIOL CHEM, V262, P6460; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; CAMPBELL KP, 1991, INT CONGR SER, P321; Carney S.L., 1986, CARBOHYDRATE ANAL, P97; CARRAWAY KL, 1989, BIOCHIM BIOPHYS ACTA, V988, P147, DOI 10.1016/0304-4157(89)90017-8; CHANG HW, 1989, J BIOL CHEM, V264, P20831; CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847; CULLEN MJ, 1990, PROC R SOC SER B-BIO, V240, P197, DOI 10.1098/rspb.1990.0034; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FONG P, 1990, SCIENCE, V250, P673, DOI 10.1126/science.2173137; FRANCO A, 1990, NATURE, V344, P670, DOI 10.1038/344670a0; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOLDEN KG, 1971, BIOCHEMISTRY-US, V10, P3105, DOI 10.1021/bi00792a019; JAY SD, 1991, J BIOL CHEM, V266, P3287; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; JORGENSEN AO, 1990, J CELL BIOL, V110, P1173, DOI 10.1083/jcb.110.4.1173; KOENIG M, 1990, J BIOL CHEM, V265, P4560; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBERER E, 1989, J BIOL CHEM, V264, P3484; LEBERER E, 1990, J BIOL CHEM, V265, P10118; LEUNG AT, 1987, J BIOL CHEM, V262, P7943; MENKE A, 1991, NATURE, V349, P69, DOI 10.1038/349069a0; MOORE SE, 1987, J CELL BIOL, V105, P1377, DOI 10.1083/jcb.105.3.1377; MURAYAMA T, 1990, P JPN ACAD B-PHYS, V66, P96, DOI 10.2183/pjab.66.96; OHLENDIECK K, 1991, FEBS LETT, V283, P230, DOI 10.1016/0014-5793(91)80595-T; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; RUTISHAUSER U, 1988, PHYSIOL REV, V68, P829; SHARP AH, 1987, J BIOL CHEM, V262, P12309; SHARP AH, 1989, J BIOL CHEM, V264, P2816; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALSH FS, 1989, DEVELOPMENT, V105, P803; WATKINS SC, 1988, NATURE, V333, P863, DOI 10.1038/333863a0; WELLER B, 1990, J NEUROL SCI, V100, P9, DOI 10.1016/0022-510X(90)90005-8; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276; ZARAINHERZBERG A, 1988, J BIOL CHEM, V263, P4807; ZUBRZYCKAGAARN EF, 1988, NATURE, V333, P466, DOI 10.1038/333466a0	49	1125	1143	2	62	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	SEP 20	1991	66	6					1121	1131		10.1016/0092-8674(91)90035-W	http://dx.doi.org/10.1016/0092-8674(91)90035-W			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1913804				2022-12-01	WOS:A1991GG55200007
J	GERSHON, PD; AHN, BY; GARFIELD, M; MOSS, B				GERSHON, PD; AHN, BY; GARFIELD, M; MOSS, B			POLY(A) POLYMERASE AND A DISSOCIABLE POLYADENYLATION STIMULATORY FACTOR ENCODED BY VACCINIA VIRUS	CELL			English	Article							THYMIDINE KINASE GENE; EARLY TRANSCRIPTION FACTOR; RNA-CAPPING ENZYME; MESSENGER-RNA; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; BINDING-PROTEIN; FOWLPOX VIRUS; ACID; DNA	mRNA made in eukaryotic cells typically has a 3' poly(A) tail that is added posttranscriptionally. To investigate mechanisms by which 3' poly(A) is formed, we identified the genes for the two vaccinia virus-encoded polypeptides, VP55 and VP39. Primer-dependent polyadenylation activity was associated exclusively with purified VP55-VP39 heterodimer, which, although stable to column chromatography and glycerol gradient sedimentation, was readily dissociated by antibody to an N-terminal peptide of VP55. Poly(A) polymerase activity was associated with immunopurified VP55, but not with immunopurified or chromatographically purified VP39. VP39 was, however, required for the formation of long poly(A) molecules, in conjunction with either purified VP55 or low concentrations of the heterodimer, and was shown to bind free poly(A). Thus, a catalytic polypeptide and a dissociable poly(A)-binding stimulatory factor each contribute to poly(A) tail formation. No prokaryotic or eukaryotic homologs of either polypeptide were detected in sequence data bases, consistent with the absence of previously reported poly(A) polymerase genes from any source.	NIAID,BIOL RESOURCES BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	GERSHON, PD (corresponding author), NIAID,VIRAL DIS LAB,BETHESDA,MD 20892, USA.			Moss, Bernard/0000-0002-2154-8564				AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AHN BY, 1990, MOL CELL BIOL, V10, P5433, DOI 10.1128/MCB.10.10.5433; BINNS MM, 1988, J GEN VIROL, V69, P1275, DOI 10.1099/0022-1317-69-6-1275; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROYLES SS, 1990, J VIROL, V64, P1523, DOI 10.1128/JVI.64.4.1523-1529.1990; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; CHRISTOFORI G, 1989, MOL CELL BIOL, V9, P193, DOI 10.1128/MCB.9.1.193; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRILLIEN R, 1987, VIROLOGY, V160, P203, DOI 10.1016/0042-6822(87)90061-4; EDMONDS M, 1990, METHOD ENZYMOL, V181, P161; GERSHON PD, 1989, J GEN VIROL, V70, P525, DOI 10.1099/0022-1317-70-3-525; GERSHON PD, 1990, P NATL ACAD SCI USA, V87, P4401, DOI 10.1073/pnas.87.11.4401; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; GRANGE T, 1987, NUCLEIC ACIDS RES, V15, P4771, DOI 10.1093/nar/15.12.4771; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; JACOB ST, 1983, ENZYMES NUCLEIC ACID, P135; JONES EV, 1987, J VIROL, V61, P1765, DOI 10.1128/JVI.61.6.1765-1771.1987; KATES J, 1970, J MOL BIOL, V50, P19, DOI 10.1016/0022-2836(70)90101-4; KOIWAI O, 1986, NUCLEIC ACIDS RES, V14, P5777, DOI 10.1093/nar/14.14.5777; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; MOORE CL, 1985, CELL, V41, P845, DOI 10.1016/S0092-8674(85)80065-9; MORGAN JR, 1984, J VIROL, V52, P206, DOI 10.1128/JVI.52.1.206-214.1984; MOSS B, 1975, J BIOL CHEM, V250, P4722; MOSS B, 1990, ANNU REV BIOCHEM, V59, P661, DOI 10.1146/annurev.biochem.59.1.661; NEVINS JR, 1975, VIROLOGY, V63, P1, DOI 10.1016/0042-6822(75)90365-7; NEVINS JR, 1977, J BIOL CHEM, V252, P6939; NILES EG, 1989, VIROLOGY, V172, P513, DOI 10.1016/0042-6822(89)90194-3; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PLUCIENNICZAK A, 1985, NUCLEIC ACIDS RES, V13, P985, DOI 10.1093/nar/13.3.985; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; REGNIER P, 1987, J BIOL CHEM, V262, P63; ROHRMANN G, 1986, CELL, V46, P1029, DOI 10.1016/0092-8674(86)90702-6; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROSENBERG AH, 1987, GENE, V59, P191, DOI 10.1016/0378-1119(87)90327-1; RYNER LC, 1989, MOL CELL BIOL, V9, P4229, DOI 10.1128/MCB.9.10.4229; Sambrook J., 1989, MOL CLONING LAB MANU; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SHEETS MD, 1989, GENE DEV, V3, P1401, DOI 10.1101/gad.3.9.1401; SHUMAN S, 1988, J BIOL CHEM, V263, P8405; SHUMAN S, 1988, J BIOL CHEM, V263, P6220; STADEN R, 1984, NUCLEIC ACIDS RES, V12, P521, DOI 10.1093/nar/12.1Part2.521; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; WAHLE E, 1991, J BIOL CHEM, V266, P3131; WEI CM, 1975, P NATL ACAD SCI USA, V72, P318, DOI 10.1073/pnas.72.1.318; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; YUEN L, 1987, P NATL ACAD SCI USA, V84, P6417, DOI 10.1073/pnas.84.18.6417	50	111	116	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1991	66	6					1269	1278		10.1016/0092-8674(91)90048-4	http://dx.doi.org/10.1016/0092-8674(91)90048-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1670500				2022-12-01	WOS:A1991GG55200020
J	GRUSBY, MJ; JOHNSON, RS; PAPAIOANNOU, VE; GLIMCHER, LH				GRUSBY, MJ; JOHNSON, RS; PAPAIOANNOU, VE; GLIMCHER, LH			DEPLETION OF CD4+ T-CELLS IN MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II DEFICIENT MICE	SCIENCE			English	Article							EMBRYONIC STEM-CELLS; GERM-LINE TRANSMISSION; HOMOLOGOUS RECOMBINATION; POSITIVE SELECTION; GENE-EXPRESSION; PHENOTYPE; ANTIGENS; RECEPTOR	The maturation of T cells in the thymus is dependent on the expression of major histocompatibility complex (MHC) molecules. By disruption of the MHC class II A-beta-b gene in embryonic stem cells, mice were generated that lack cell surface expression of class II molecules. These MHC class II-deficient mice were depleted of mature CD4+ T cells and were deficient in cell-mediated immune responses. These results provide genetic evidence that class II molecules are required for the maturation and function of mature CD4+ T cells.	HARVARD UNIV, SCH PUBL HLTH, DEPT CANC BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; TUFTS UNIV, SCH MED & VET MED, DEPT PATHOL, BOSTON, MA 02111 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Tufts University; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School			Johnson, Randall/AAM-1189-2021	Johnson, Randall/0000-0002-4084-6639; Papaioannou, Virginia/0000-0001-7558-8601	NIAID NIH HHS [AI21569] Funding Source: Medline; NICHD NIH HHS [HD27295] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027295] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI021569, R01AI021569] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUCHINCLOSS H, UNPUB; BENOIST C, 1989, CELL, V58, P1027, DOI 10.1016/0092-8674(89)90501-1; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BILL J, 1989, NATURE, V341, P649, DOI 10.1038/341649a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GERMAIN R, COMMUNICATION; GRUSBY M, UNPUB; JOHNSON RS, 1989, SCIENCE, V245, P1234, DOI 10.1126/science.2506639; KARLSSON L, 1991, NATURE, V351, P485, DOI 10.1038/351485a0; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KRUISBEEK AM, 1985, J EXP MED, V161, P1029, DOI 10.1084/jem.161.5.1029; LARHAMMAR D, 1983, CELL, V34, P179, DOI 10.1016/0092-8674(83)90148-4; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATHIS DJ, 1983, P NATL ACAD SCI-BIOL, V80, P273, DOI 10.1073/pnas.80.1.273; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; VANEWIJK W, 1988, CELL, V53, P357, DOI 10.1016/0092-8674(88)90156-0; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	27	635	646	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 20	1991	253	5026					1417	1420		10.1126/science.1910207	http://dx.doi.org/10.1126/science.1910207			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF851	1910207				2022-12-01	WOS:A1991GF85100041
J	KANDEL, J; BOSSYWETZEL, E; RADVANYI, F; KLAGSBRUN, M; FOLKMAN, J; HANAHAN, D				KANDEL, J; BOSSYWETZEL, E; RADVANYI, F; KLAGSBRUN, M; FOLKMAN, J; HANAHAN, D			NEOVASCULARIZATION IS ASSOCIATED WITH A SWITCH TO THE EXPORT OF BFGF IN THE MULTISTEP DEVELOPMENT OF FIBROSARCOMA	CELL			English	Article							FIBROBLAST GROWTH-FACTOR; CELL-GROWTH; TRANSGENIC MICE; ENDOTHELIAL-CELLS; HEPARIN AFFINITY; TRANSFORMING GENE; PURIFICATION; ANGIOGENESIS; SEQUENCE; PROTEIN	In a transgenic mouse model, dermal fibrosarcomas develop in a pathway comprised of at least three stages: mild fibromatosis, aggressive fibromatosis, and fibrosarcoma. The latter two stages are highly vascularized when compared with both the normal dermis and the initial mild lesion. Analysis of cell cultures derived from biopsies of these lesions has revealed that basic fibroblast growth factor (bFGF) is synthesized in all three stages and in normal dermal fibroblasts derived from the same mice. Unexpectedly, there is a change in the localization of bFGF from its normal cell-associated state to extracellular release in the latter two stages, which is concomitant both with the neovascularization seen in vivo and with the tumorigenicity of these cell lines. Thus, in this multistep tumorigenesis pathway there appears to be a discrete switch to the angiogenic phenotype that correlates with the export of bFGF, a known angiogenic factor.	HARVARD UNIV, SCH MED, DEPT SURG, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT ANAT & CELLULAR BIOL, BOSTON, MA 02115 USA; UNIV CALIF SAN FRANCISCO, HORMONE RES INST, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of California System; University of California San Francisco	KANDEL, J (corresponding author), HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT SURG, BOSTON, MA 02115 USA.			Radvanyi, Francois/0000-0002-5696-6424	NATIONAL CANCER INSTITUTE [R37CA037392, R01CA037392] Funding Source: NIH RePORTER; NCI NIH HHS [CA 37392, CA 70118] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAIRD A, 1986, J CELL BIOCHEM, V30, P79, DOI 10.1002/jcb.240300109; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; DELAPEYRIERE O, 1990, ONCOGENE, V5, P823; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; IBERG N, 1989, J BIOL CHEM, V264, P19951; KLAGSBRUN M, 1985, P NATL ACAD SCI USA, V82, P805, DOI 10.1073/pnas.82.3.805; KLAGSBRUN M, 1986, P NATL ACAD SCI USA, V83, P2448, DOI 10.1073/pnas.83.8.2448; KLAGSBRUN M, 1977, EXP CELL RES, V105, P99, DOI 10.1016/0014-4827(77)90155-0; LACEY M, 1986, NATURE, V322, P609, DOI 10.1038/322609a0; LINDGREN V, 1989, P NATL ACAD SCI USA, V86, P5025, DOI 10.1073/pnas.86.13.5025; LOBB R, 1986, J BIOL CHEM, V261, P1924; LOBB RR, 1984, BIOCHEMISTRY-US, V23, P6295, DOI 10.1021/bi00321a001; MACKMAN N, 1987, EMBO J, V6, P2835, DOI 10.1002/j.1460-2075.1987.tb02580.x; MARICS I, 1989, ONCOGENE, V4, P335; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MCNEIL PL, 1989, J CELL BIOL, V109, P811, DOI 10.1083/jcb.109.2.811; MERGIA A, 1986, BIOCHEM BIOPH RES CO, V138, P644, DOI 10.1016/S0006-291X(86)80545-9; PARNES JR, 1981, P NATL ACAD SCI-BIOL, V78, P2253, DOI 10.1073/pnas.78.4.2253; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SARVER N, 1984, J VIROL, V52, P377, DOI 10.1128/JVI.52.2.377-388.1984; SCHWEIGERER L, 1987, P NATL ACAD SCI USA, V84, P842, DOI 10.1073/pnas.84.3.842; SCOTT G, 1991, J INVEST DERMATOL, V96, P318, DOI 10.1111/1523-1747.ep12465203; SENGER DR, 1990, CANCER RES, V50, P1774; SHING Y, 1985, J CELL BIOCHEM, V29, P275, DOI 10.1002/jcb.240290402; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SIPPOLATHIELE M, 1989, MOL CELL BIOL, V9, P925, DOI 10.1128/MCB.9.3.925; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; USUKI K, 1989, P NATL ACAD SCI USA, V86, P7427, DOI 10.1073/pnas.86.19.7427; VLODAVSKY I, 1987, J CELL PHYSIOL, V131, P402, DOI 10.1002/jcp.1041310312; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	48	501	527	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	1991	66	6					1095	1104		10.1016/0092-8674(91)90033-U	http://dx.doi.org/10.1016/0092-8674(91)90033-U			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1717155				2022-12-01	WOS:A1991GG55200005
J	KLEVIT, RE				KLEVIT, RE			RECOGNITION OF DNA BY CYS2, HIS2 ZINC FINGERS	SCIENCE			English	Editorial Material							TRANSCRIPTION FACTOR-IIIA; YEAST ADR1; BINDING; DOMAIN; PROTEIN				KLEVIT, RE (corresponding author), UNIV WASHINGTON,DEPT BIOCHEM SJ-70,SEATTLE,WA 98195, USA.		Klevit, Rachel/AAI-7038-2021	Klevit, Rachel/0000-0002-3476-969X				BROWN RS, 1985, FEBS LETT, V186, P271, DOI 10.1016/0014-5793(85)80723-7; FAIRALL L, 1986, J MOL BIOL, V192, P577, DOI 10.1016/0022-2836(86)90278-0; KLEVIT RE, 1990, PROTEINS, V7, P215, DOI 10.1002/prot.340070303; KOCHOYAN M, 1991, BIOCHEMISTRY-US, V30, P3371, DOI 10.1021/bi00228a004; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NAGAI K, 1988, NATURE, V332, P284, DOI 10.1038/332284a0; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; OMICHINSKI JG, 1990, BIOCHEMISTRY-US, V29, P9324, DOI 10.1021/bi00492a004; PARRAGA G, 1988, SCIENCE, V241, P1489, DOI 10.1126/science.3047872; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; THUKRAL SK, 1991, MOL CELL BIOL, V11, P1566, DOI 10.1128/MCB.11.3.1566; XU RX, 1991, BIOCHEMISTRY-US, V30, P3365, DOI 10.1021/bi00228a003	14	121	123	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1991	253	5026					1367	&		10.1126/science.1896847	http://dx.doi.org/10.1126/science.1896847			0	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF851	1896847				2022-12-01	WOS:A1991GF85100028
J	KOFF, A; CROSS, F; FISHER, A; SCHUMACHER, J; LEGUELLEC, K; PHILIPPE, M; ROBERTS, JM				KOFF, A; CROSS, F; FISHER, A; SCHUMACHER, J; LEGUELLEC, K; PHILIPPE, M; ROBERTS, JM			HUMAN CYCLIN-E, A NEW CYCLIN THAT INTERACTS WITH 2 MEMBERS OF THE CDC2 GENE FAMILY	CELL			English	Article							MATURATION-PROMOTING FACTOR; P34CDC2 PROTEIN-KINASE; MAMMALIAN-CELL-CYCLE; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; M-PHASE; DNA-REPLICATION; MESSENGER-RNA; SCHIZOSACCHAROMYCES-POMBE; MATING-PHEROMONE	A new human cyclin, named cyclin E, was isolated by complementation of a triple cln deletion in S. cerevisiae. Cyclin E showed genetic interactions with the CDC28 gene, suggesting that it functioned at START by interacting with the CDC28 protein. Two human genes were identified that could interact with cyclin E to perform START in yeast containing a cdc28 mutation. One was CDC2-HS, and the second was the human homolog of Xenopus CDK2. Cyclin E produced in E. coli bound and activated the CDC2 protein in extracts from human G1 cells, and antibodies against cyclin E immunoprecipitated a histone H1 kinase from HeLa cells. The interactions between cyclin E and CDC2, or CDK2, may be important at the G1 to S transition in human cells.	ROCKEFELLER UNIV, NEW YORK, NY 10021 USA; UNIV RENNES 1, BIOL & GENET DEV LAB, CNRS, UNITE 256, F-35042 RENNES, FRANCE	Rockefeller University; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes 1	KOFF, A (corresponding author), FRED HUTCHINSON CANC RES CTR, DEPT BASIC SCI, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.		Schumacher, Jill/B-2932-2012; Fisher, Alfred/H-3031-2012	Fisher, Alfred/0000-0001-6451-2644				ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DURKACZ B, 1986, EMBO J, V5, P369, DOI 10.1002/j.1460-2075.1986.tb04221.x; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HAGAN I, 1988, J CELL SCI, V91, P587; HARTWELL LH, 1973, GENETICS, V74, P267; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; MARSHAK DR, 1991, J CELL BIOCHEM, V45, P391, DOI 10.1002/jcb.240450413; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MENDENHALL MD, 1987, CELL, V50, P927, DOI 10.1016/0092-8674(87)90519-8; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROBERTS JM, 1988, SCIENCE, V241, P1486, DOI 10.1126/science.2843984; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROSENTHAL ET, 1980, CELL, V20, P487, DOI 10.1016/0092-8674(80)90635-2; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SOLOMON M, 1988, CELL, V54, P738, DOI 10.1016/S0092-8674(88)90933-6; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; SUDBERY PE, 1980, NATURE, V288, P401, DOI 10.1038/288401a0; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; WITTENBERG C, 1989, MOL CELL BIOL, V9, P4064, DOI 10.1128/MCB.9.9.4064; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zetterberg A, 1990, CURR OPIN CELL BIOL, V2, P296, DOI 10.1016/0955-0674(90)90022-7; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365	77	627	683	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	1991	66	6					1217	1228		10.1016/0092-8674(91)90044-Y	http://dx.doi.org/10.1016/0092-8674(91)90044-Y			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1833068				2022-12-01	WOS:A1991GG55200016
J	LUFKIN, T; DIERICH, A; LEMEUR, M; MARK, M; CHAMBON, P				LUFKIN, T; DIERICH, A; LEMEUR, M; MARK, M; CHAMBON, P			DISRUPTION OF THE HOX-1.6 HOMEOBOX GENE RESULTS IN DEFECTS IN A REGION CORRESPONDING TO ITS ROSTRAL DOMAIN OF EXPRESSION	CELL			English	Article							SEGMENT-SPECIFIC EXPRESSION; CENTRAL-NERVOUS-SYSTEM; MOUSE EMBRYOS; NEURAL CREST; FUNCTIONAL-ORGANIZATION; ANTENNAPEDIA-COMPLEX; INT-1 PROTOONCOGENE; HOMEOTIC GENES; RETINOIC ACID; MURINE	The Hox-1.6 gene disrupted in embryonic stem cells by homologous recombination was introduced into the mouse germline. Heterozygous mice were normal, but homozygous mice died at birth from anoxia and had numerous defects that were centered at the level of rhombomeres 4 to 7 and included delayed hindbrain neural tube closure, absence of certain cranial nerves and ganglia, and malformed inner ears and bones of the skull. Thus, Hox-1.6 is involved in regional specification along the rostrocaudal axis, but only in its most rostral domain of expression. Hox-1.6 appears to specify neurogenic neural crest cells prior to specification of mesenchymal neural crest cells by Hox-1.5. Thus, within the same region of the presumptive hindbrain, two HOX-1 genes are involved in the patterning of two different populations of neural crest cells. The implication of these results for the function of the Hox network during mouse embryogenesis is discussed.			LUFKIN, T (corresponding author), FAC MED STRASBOURG, INST CHIM BIOL,INSERM,U184,CNRS, GENET MOLEC LAB, 11 RUE HUMANN, F-67085 STRASBOURG, FRANCE.		Lufkin, Thomas/AAG-7476-2019; Lufkin, Thomas/B-5352-2011	Lufkin, Thomas/0000-0002-7902-4771; Lufkin, Thomas/0000-0002-7902-4771				AKAM M, 1987, DEVELOPMENT, V101, P1; AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; AUERBACH R, 1954, J EXP ZOOL, V127, P305, DOI 10.1002/jez.1401270206; AWGULEWITSCH A, 1986, NATURE, V320, P328, DOI 10.1038/320328a0; BARON A, 1987, EMBO J, V6, P2977, DOI 10.1002/j.1460-2075.1987.tb02603.x; BRADLEY A, 1987, TERATOCARCINOMAS EMB; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHO KWY, 1991, CELL, V65, P55, DOI 10.1016/0092-8674(91)90407-P; COPP AJ, 1990, PROG NEUROBIOL, V35, P363, DOI 10.1016/0301-0082(90)90037-H; COULY G, 1990, DEVELOPMENT, V108, P543; DAVSON H, 1962, PRINCIPLES HUMAN PHY, P380; DEOL MS, 1966, NATURE, V209, P219, DOI 10.1038/209219a0; DIEDERICH RJ, 1989, GENE DEV, V3, P399, DOI 10.1101/gad.3.3.399; DO MS, 1988, GENOMICS, V3, P195, DOI 10.1016/0888-7543(88)90079-1; DRESSLER GR, 1989, DIFFERENTIATION, V41, P193, DOI 10.1111/j.1432-0436.1989.tb00747.x; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; Duboule D, 1991, CURR OPIN GENET DEV, V1, P211, DOI 10.1016/S0959-437X(05)80072-3; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; FROMENTAL C, 1988, CELL, V54, P943, DOI 10.1016/0092-8674(88)90109-2; GAUNT SJ, 1987, DEVELOPMENT, V101, P51; GAUNT SJ, 1988, DEVELOPMENT, V103, P135; GAUNT SJ, 1986, NATURE, V324, P662, DOI 10.1038/324662a0; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GONZALEZREYES A, 1990, NATURE, V344, P78, DOI 10.1038/344078a0; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; Goulding MD, 1989, CURR OPIN CELL BIOL, V1, P1088, DOI 10.1016/S0955-0674(89)80055-9; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; HAMILTON WJ, 1946, HUMAN EMBRYOLOGY; HART C P, 1987, Genomics, V1, P182, DOI 10.1016/0888-7543(87)90011-5; HOLLAND PWH, 1988, DEVELOPMENT, V103, P17; HOLLAND PWH, 1988, GENE DEV, V2, P773, DOI 10.1101/gad.2.7.773; HOLTFRETER J, 1968, EPITHELIAL MESENCHYM, P1; HUNT P, 1991, DEVELOPMENT, V112, P43; HUNT P, 1991, DEVELOPMENT, P187; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KEYNES R, 1990, NEURON, V4, P1, DOI 10.1016/0896-6273(90)90438-L; KOCHHAR DM, 1973, TERATOLOGY, V7, P289, DOI 10.1002/tera.1420070310; LAROSA GJ, 1988, MOL CELL BIOL, V8, P3906, DOI 10.1128/MCB.8.9.3906; LATHE R, 1987, GENE, V57, P193, DOI 10.1016/0378-1119(87)90122-3; LEDOUARIN NM, 1986, TRENDS NEUROSCI, V9, P175, DOI 10.1016/0166-2236(86)90055-X; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; MCKNIGHT SL, 1980, NUCLEIC ACIDS RES, V8, P5949, DOI 10.1093/nar/8.24.5949; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MLODZIK M, 1988, EMBO J, V7, P2569, DOI 10.1002/j.1460-2075.1988.tb03106.x; MOODY SA, 1983, J COMP NEUROL, V213, P344, DOI 10.1002/cne.902130309; MORRISSKAY G, 1987, TRENDS GENET, V3, P257, DOI 10.1016/0168-9525(87)90260-5; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; MURPHY P, 1991, DEVELOPMENT, V111, P61; NICHOLS DH, 1981, J EMBRYOL EXP MORPH, V64, P105; NODEN DM, 1983, DEV BIOL, V96, P144, DOI 10.1016/0012-1606(83)90318-4; NODEN DM, 1988, DEVELOPMENT, V103, P121; REID L, 1990, CELL, V63, P875, DOI 10.1016/0092-8674(90)90491-V; SCHUGHART K, 1989, GENOMICS, V5, P76, DOI 10.1016/0888-7543(89)90089-X; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; STUBBS L, 1990, GENOMICS, V7, P422, DOI 10.1016/0888-7543(90)90177-V; SUNDIN OH, 1990, DEVELOPMENT, V108, P47; Theiler K., 1972, HOUSE MOUSE; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TWIGG AJ, 1980, NATURE, V283, P216, DOI 10.1038/283216a0; VANDEWATER TR, 1988, DEVELOPMENT, V103, P185; VERWOERD CDA, 1979, ADV ANATOMY EMBRYOLO, V58; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; WRIGHT C, 1991, NATURE, V350, P458, DOI 10.1038/350458a0	67	632	641	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	1991	66	6					1105	1119		10.1016/0092-8674(91)90034-V	http://dx.doi.org/10.1016/0092-8674(91)90034-V			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1680563				2022-12-01	WOS:A1991GG55200006
J	MICHELSON, HB; WONG, RKS				MICHELSON, HB; WONG, RKS			EXCITATORY SYNAPTIC RESPONSES MEDIATED BY GABA(A) RECEPTORS IN THE HIPPOCAMPUS	SCIENCE			English	Article							SOMATOSTATIN-LIKE IMMUNOREACTIVITY; CENTRAL-NERVOUS-SYSTEM; PYRAMIDAL CELLS; GABAERGIC NEURONS; RAT; INTERNEURONS; ANTAGONISTS; SUBTYPES; SLICES; ACID	Gamma-aminobutyric acid (GABA) is a major inhibitory neurotransmitter in the cortex. Activation of postsynaptic GABA(A) receptors hyperpolarizes cells and inhibits neuronal activity. Synaptic responses mediated by GABA(A) receptors also strongly excited hippocampal neurons. This excitatory response was recorded in morphologically identified interneurons in the presence of 4-aminopyridine or after elevation of extracellular potassium concentrations. The synaptic excitation sustained by GABA(A) receptors synchronized the activity of inhibitory interneurons. This synchronized discharge of interneurons in turn elicited large-amplitude inhibitory postsynaptic potentials in pyramidal and granule cells. Excitatory synaptic responses mediated by GABA(A) receptors may thus provide a mechanism for the recruitment of GABAergic interneurons through their recurrent connections.			MICHELSON, HB (corresponding author), SUNY HLTH SCI CTR,DEPT PHARMACOL,BROOKLYN,NY 11203, USA.							ALGER BE, 1982, J PHYSIOL-LONDON, V328, P105, DOI 10.1113/jphysiol.1982.sp014255; ALGER BE, 1982, J PHYSIOL-LONDON, V328, P125, DOI 10.1113/jphysiol.1982.sp014256; ANDERSEN P, 1980, J PHYSIOL-LONDON, V305, P279, DOI 10.1113/jphysiol.1980.sp013363; ANDERSEN P, 1964, J NEUROPHYSIOL, V27, P608, DOI 10.1152/jn.1964.27.4.608; ARAM J, 1989, BRIT J PHARMACOL, V96, P82; ARAM JA, 1991, J NEUROPHYSIOL, V65, P1034, DOI 10.1152/jn.1991.65.5.1034; CHAGNACAMITAI Y, 1989, J NEUROPHYSIOL, V62, P1149, DOI 10.1152/jn.1989.62.5.1149; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; KNOWLES WD, 1981, J NEUROSCI, V1, P318; KOSAKA T, 1988, EXP BRAIN RES, V71, P388; LACAILLE JC, 1988, J NEUROSCI, V8, P1411; LACAILLE JC, 1987, J NEUROSCI, V7, P1979; Lux H D, 1986, Adv Neurol, V44, P619; MILES R, 1987, J PHYSIOL-LONDON, V388, P611, DOI 10.1113/jphysiol.1987.sp016634; MILES R, 1990, J PHYSIOL-LONDON, V423, P95; MULLER W, 1990, J NEUROPHYSIOL, V64, P46, DOI 10.1152/jn.1990.64.1.46; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; PERREAULT P, 1989, Society for Neuroscience Abstracts, V15, P1213; SLOVITER RS, 1987, J COMP NEUROL, V256, P42, DOI 10.1002/cne.902560105; SOMOGYI P, 1984, J NEUROSCI, V4, P2590; STEWART WW, 1981, NATURE, V292, P17, DOI 10.1038/292017a0; TRAUB RD, 1989, SCIENCE, V243, P1319, DOI 10.1126/science.2646715; WATKINS JC, 1987, TRENDS NEUROSCI, V10, P265, DOI 10.1016/0166-2236(87)90171-8; WONG RKS, 1982, J NEUROPHYSIOL, V48, P938, DOI 10.1152/jn.1982.48.4.938; WONG RKS, 1982, SCIENCE, V216, P745	25	271	271	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1991	253	5026					1420	1423		10.1126/science.1654594	http://dx.doi.org/10.1126/science.1654594			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF851	1654594				2022-12-01	WOS:A1991GF85100042
J	OSTERGAARD, HL; TROWBRIDGE, IS				OSTERGAARD, HL; TROWBRIDGE, IS			NEGATIVE REGULATION OF CD45 PROTEIN TYROSINE PHOSPHATASE-ACTIVITY BY IONOMYCIN IN T-CELLS	SCIENCE			English	Article							LEUKOCYTE-COMMON ANTIGEN; ACTIVATION; PHOSPHORYLATION; CALCIUM; KINASE; EXPRESSION; FLUORESCENCE; RESPONSES; MEMBRANE; ALTERS	CD45 is a leukocyte-specific, transmembrane protein tyrosine phosphatase (PTPase) required for T cell responsiveness. How the activity of PTPases is regulated in vivo is unclear. Treatment of murine thymocytes and a variety of murine T cell lines with the calcium ionophore ionomycin decreased CD45 PTPase activity. Ionomycin treatment also led to a decreased phosphorylation of serine residues in CD45. These results indicate that increased intracellular calcium modulates CD45 PTPase activity, demonstrating regulation of CD45 PTPase activity in vivo, and also implicate serine dephosphorylation as a possible mechanism.	SALK INST,DEPT CANC BIOL,SAN DIEGO,CA 92186	Salk Institute					NCI NIH HHS [CA-17733] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA017733, R37CA017733] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERT PR, 1985, J BIOL CHEM, V260, P8746; ALEXANDER DR, 1988, BIOCHEM J, V256, P885, DOI 10.1042/bj2560885; AUTERO M, 1987, EUR J IMMUNOL, V17, P1503, DOI 10.1002/eji.1830171018; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1988, PROC R SOC SER B-BIO, V234, P115, DOI 10.1098/rspb.1988.0040; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; DEBER CM, 1986, BIOCHEM BIOPH RES CO, V134, P731, DOI 10.1016/S0006-291X(86)80481-8; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; KAPPLER JW, 1981, J EXP MED, V153, P1198, DOI 10.1084/jem.153.5.1198; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; OMARY MB, 1980, J BIOL CHEM, V255, P1662; OSTERGAARD H, 1987, J IMMUNOL, V139, P3573; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; OSTERGAARD HL, UNPUB; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.iy.07.040189.002011; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TROWBRIDGE IS, 1978, J EXP MED, V148, P313, DOI 10.1084/jem.148.1.313; TROWBRIDGE IS, 1991, ADV PROT PHOSPHATASE, V6, P227; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; YAMADA A, 1990, EUR J IMMUNOL, V20, P1655, DOI 10.1002/eji.1830200806	30	108	109	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1991	253	5026					1423	1425		10.1126/science.1654595	http://dx.doi.org/10.1126/science.1654595			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF851	1654595				2022-12-01	WOS:A1991GF85100043
J	PADMORE, R; CAO, L; KLECKNER, N				PADMORE, R; CAO, L; KLECKNER, N			TEMPORAL COMPARISON OF RECOMBINATION AND SYNAPTONEMAL COMPLEX-FORMATION DURING MEIOSIS IN SACCHAROMYCES-CEREVISIAE	CELL			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER FEMALES; MEIOTIC GENE CONVERSION; DOUBLE-STRAND BREAKS; CHROMOSOME SYNAPSIS; WILD-TYPE; INITIATION SITE; CROSSING-OVER; CELL-CYCLE; SEGREGATION	In synchronous cultures of S. cerevisiae undergoing meiosis, an early event in the meiotic recombination pathway, site-specific double strand breaks (DSBs), occurs early in prophase, in some instances well before tripartite synaptonemal complex (SC) begins to form. This observation, together with previous results, supports the view that events involving DSBs are required for SC formation. We discuss the possibility that the mitotic pathway for recombinational repair of DSBs served as the primordial mechanism for connecting homologous chromosomes during the evolution of meiosis. DSBs disappear during the period when tripartite SC structure is forming and elongating (zygotene); presumably, they are converted to another type of recombination intermediate. Neither DSBs nor mature recombinant molecules are present when SCs are full length (pachytene). Mature reciprocally recombinant molecules arise at the end of or just after pachytene. We suggest that the SC might coordinate recombinant maturation with other events of meiosis.			PADMORE, R (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA.		Cao, Liang/K-7806-2017	Cao, Liang/0000-0001-7293-8338	NIGMS NIH HHS [GM44794] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; ALBINI SM, 1987, CHROMOSOMA, V95, P324, DOI 10.1007/BF00293179; BAILEY NTJ, 1981, STATISTICAL METHODS, P24; BAKER BS, 1976, ANNU REV GENET, V10, P53, DOI 10.1146/annurev.ge.10.120176.000413; BELL LR, 1982, COLD SPRING HARB SYM, V47, P829, DOI 10.1101/SQB.1983.047.01.095; BORTS RH, 1984, COLD SPRING HARB SYM, V49, P67, DOI 10.1101/SQB.1984.049.01.010; Bridges CB, 1925, GENETICS, V10, P418; BYERS B, 1975, P NATL ACAD SCI USA, V72, P5056, DOI 10.1073/pnas.72.12.5056; BYERS B, 1973, COLD SPRING HARB SYM, V38, P123, DOI 10.1101/SQB.1974.038.01.016; Byers B, 1981, MOL BIOL YEAST SACCH, P59; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CARPENTER ATC, 1987, BIOESSAYS, V6, P232, DOI 10.1002/bies.950060510; CARPENTER ATC, 1981, CHROMOSOMA, V83, P59, DOI 10.1007/BF00286016; CARPENTER ATC, 1979, GENETICS, V92, P511; CARPENTER ATC, 1975, P NATL ACAD SCI USA, V72, P3186, DOI 10.1073/pnas.72.8.3186; COMINGS DE, 1970, NATURE, V227, P451, DOI 10.1038/227451a0; COMINGS DE, 1971, NATURE, V233, P48, DOI 10.1038/233048a0; DAVIDOW LS, 1984, GENETICS, V106, P165; DONAHUE TF, 1982, GENE, V18, P47, DOI 10.1016/0378-1119(82)90055-5; DRESSER ME, 1988, J CELL BIOL, V106, P567, DOI 10.1083/jcb.106.3.567; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; EGEL R, 1978, HEREDITY, V41, P233, DOI 10.1038/hdy.1978.92; ENGEBRECHT J, 1990, CELL, V62, P927, DOI 10.1016/0092-8674(90)90267-I; ENGEBRECHT J, 1990, MOL CELL BIOL, V10, P2379, DOI 10.1128/MCB.10.5.2379; Esposito R. E., 1981, MOL BIOL YEAST SACCH, V11, P211; FARNET C, 1988, UCLA S MOL CELL BIOL, V83, P201; FINK GR, 1984, NATURE, V310, P728, DOI 10.1038/310728a0; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GIROUX CN, 1989, GENOME, V31, P88, DOI 10.1139/g89-017; GIROUX CN, 1988, GENETIC RECOMBINATIO, P465; Hawley R.S., 1988, GENETIC RECOMBINATIO, P497; HENDERSON SA, 1970, ANNU REV GENET, V4, P295, DOI 10.1146/annurev.ge.04.120170.001455; HOLLIDAY R, 1977, PHILOS T R SOC B, V277, P359, DOI 10.1098/rstb.1977.0024; HOLLINGSWORTH NM, 1990, CELL, V61, P73, DOI 10.1016/0092-8674(90)90216-2; HORESH O, 1979, CHROMOSOMA, V75, P101, DOI 10.1007/BF00330628; Howard-Flanders P, 1968, Adv Biol Med Phys, V12, P299; HOWARDFL.P, 1968, ANNU REV BIOCHEM, V37, P175, DOI 10.1146/annurev.bi.37.070168.001135; HUTTER KJ, 1979, J GEN MICROBIOL, V113, P369, DOI 10.1099/00221287-113-2-369; JACKSON JA, 1985, GENETICS, V109, P303; JONES G H, 1987, P213; JONES GH, 1984, CONTROLLING EVENTS M, P293; KANE SM, 1974, J BACTERIOL, V118, P8, DOI 10.1128/JB.118.1.8-14.1974; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; KING JS, 1990, GENETICS, V126, P1127; King R. C., 1970, Int. Rev. Cytol., V28, P125, DOI 10.1016/S0074-7696(08)62542-5; KLECKNER N, 1991, IN PRESS COLD SPRING, V56; KOLODKIN AL, 1986, CELL, V46, P733, DOI 10.1016/0092-8674(86)90349-1; KUROIWA T, 1984, EXP CELL RES, V153, P259, DOI 10.1016/0014-4827(84)90469-5; MAGUIRE MP, 1978, EXP CELL RES, V112, P297, DOI 10.1016/0014-4827(78)90213-6; MAGUIRE MP, 1977, PHILOS T R SOC B, V277, P245, DOI 10.1098/rstb.1977.0015; MOENS PB, 1971, J CELL BIOL, V50, P344, DOI 10.1083/jcb.50.2.344; MOENS PB, 1969, CHROMOSOMA, V28, P1, DOI 10.1007/BF00325986; Moses M. J., 1968, Annual Review of Genetics, V2, P363, DOI 10.1146/annurev.ge.02.120168.002051; MOSES MJ, 1969, GENETICS, V61, P41; MOSES MJ, 1984, CONTROLLING EVENTS M, P245; MURRAY AW, 1985, ANNU REV CELL BIOL, V1, P289, DOI 10.1146/annurev.cb.01.110185.001445; NICOLAS A, 1989, NATURE, V338, P35, DOI 10.1038/338035a0; OLSON LW, 1978, MOL GEN GENET, V166, P151, DOI 10.1007/BF00285917; PERKINS DD, 1949, GENETICS, V34, P607; PETERSON JB, 1976, J CELL SCI, V22, P219; PETES TD, 1991, IN PRESS MOL BIOL YE; RASMUSSEN SW, 1986, CARLSBERG RES COMMUN, V51, P401, DOI 10.1007/BF02907315; RASMUSSEN SW, 1984, CONTROLLING EVENTS M, P271; RESNICK M A, 1987, P157; Rhoades MM., 1968, REPLICATION RECOMBIN, P229; ROCKMILL B, 1990, GENETICS, V126, P563; ROEDER GS, 1990, TRENDS GENET, V6, P385, DOI 10.1016/0168-9525(90)90297-J; ROMAN H, 1990, GENETICS, V124, P7; ROSE M, 1984, GENE, V29, P113, DOI 10.1016/0378-1119(84)90172-0; Sherman F., 1983, METHODS YEAST GENETI; SHUSTER EO, 1989, GENETICS, V123, P29; SMITHIES O, 1986, PHILOS T ROY SOC B, V312, P291, DOI 10.1098/rstb.1986.0008; SOLARI AJ, 1970, CHROMOSOMA, V31, P217, DOI 10.1007/BF00326080; SOLARI AJ, 1981, INT CELL BIOL 1980 1, P178; STERN H, 1987, P303; STERN H, 1975, P NATL ACAD SCI USA, V72, P961, DOI 10.1073/pnas.72.3.961; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; UEKI K, 1981, J GEN APPL MICROBIOL, V27, P1, DOI 10.2323/jgam.27.1; VONWETTSTEIN D, 1984, ANNU REV GENET, V18, P331, DOI 10.1146/annurev.ge.18.120184.001555; WANG HT, 1987, MOL CELL BIOL, V7, P1425, DOI 10.1128/MCB.7.4.1425; WILDENBERG J, 1970, GENETICS, V66, P291; WILLIAMSON DH, 1983, EXP CELL RES, V145, P209, DOI 10.1016/S0014-4827(83)80022-6; ZICKLER D, 1975, CHROMOSOMA, V50, P1; ZICKLER D, 1977, CHROMOSOMA, V61, P289, DOI 10.1007/BF00288615; ZOLAN ME, 1988, GENETICS, V120, P379	88	389	392	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	1991	66	6					1239	1256		10.1016/0092-8674(91)90046-2	http://dx.doi.org/10.1016/0092-8674(91)90046-2			18	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1913808				2022-12-01	WOS:A1991GG55200018
J	PEI, D; ULRICH, HD; SCHULTZ, PG				PEI, D; ULRICH, HD; SCHULTZ, PG			A COMBINATORIAL APPROACH TOWARD DNA RECOGNITION	SCIENCE			English	Article							TRIPLE-HELIX FORMATION; SEQUENCE-SPECIFIC CLEAVAGE; SITE-SPECIFIC CLEAVAGE; DUPLEX DNA; PLASMID DNA; LIGANDS; NUCLEASE; POLYMERASE; MOLECULES; INVITRO	A combinatorial approach has been used to identify individual RNA molecules from a large population of sequences that bind a 16-base pair homopurine-homopyrimidine DNA sequence through triple-helix formation. Fourteen of the seventeen clones selected contained stretches of pyrimidines highly homologous to the target DNA sequence (T.AT and C+.GC). In addition, these RNA molecules contained hairpin loops, interior loops, and nonstandard base triplets [C+(or C).AT, U.GC, G.GC, and A.AT] at various positions. Affinity cleavage experiments confirmed the ability of selected sequences to bind specifically to the target DNA. Systematic variation in both the target DNA sequence and buffer components should provide increased insight into the molecular interactions required for triple-helix-mediated recognition of natural DNA.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720	University of California System; University of California Berkeley			Pei, Dehua/P-4594-2016	Pei, Dehua/0000-0002-2057-6934; Ulrich, Helle D./0000-0003-0431-2223	NIGMS NIH HHS [R01GM41679] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041679] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOTT S, 1974, J MOL BIOL, V88, P509, DOI 10.1016/0022-2836(74)90498-7; BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; BROITMAN SL, 1987, P NATL ACAD SCI USA, V84, P5120, DOI 10.1073/pnas.84.15.5120; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; COREY DR, 1989, BIOCHEMISTRY-US, V28, P8277, DOI 10.1021/bi00447a004; COREY DR, 1989, J AM CHEM SOC, V111, P8523, DOI 10.1021/ja00204a038; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DELOSSANTOS C, 1989, BIOCHEMISTRY-US, V28, P7282, DOI 10.1021/bi00444a021; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FELSENFE.G, 1967, ANNU REV BIOCHEM, V36, P407, DOI 10.1146/annurev.bi.36.070167.002203; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; GRIFFIN LC, 1989, SCIENCE, V245, P967, DOI 10.1126/science.2549639; KAISER R, 1991, NATURE, V350, P656, DOI 10.1038/350656d0; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LIPSETT MN, 1964, J BIOL CHEM, V239, P1256; LIPSETT MN, 1963, BIOCHEM BIOPH RES CO, V11, P224, DOI 10.1016/0006-291X(63)90338-3; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; MILLER JH, 1966, P NATL ACAD SCI USA, V55, P1201, DOI 10.1073/pnas.55.5.1201; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MILLS DR, 1967, P NATL ACAD SCI USA, V58, P217, DOI 10.1073/pnas.58.1.217; MORGAN AR, 1968, J MOL BIOL, V37, P63, DOI 10.1016/0022-2836(68)90073-9; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; MUAIYAMA T, 1968, TETRAHEDRON LETT, V56, P5907; PEI D, 1990, J AM CHEM SOC, V112, P4579, DOI 10.1021/ja00167a085; PEI DF, UNPUB; PEI DH, 1990, P NATL ACAD SCI USA, V87, P9858, DOI 10.1073/pnas.87.24.9858; PILCH DS, 1990, NUCLEIC ACIDS RES, V18, P5743, DOI 10.1093/nar/18.19.5743; PLUM GE, 1990, P NATL ACAD SCI USA, V87, P9436, DOI 10.1073/pnas.87.23.9436; RAJAGOPAL P, 1989, BIOCHEMISTRY-US, V28, P7859, DOI 10.1021/bi00445a048; SCHULTZ PG, 1989, ANGEW CHEM INT EDIT, V28, P1283, DOI 10.1002/anie.198912833; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; STROBEL SA, 1991, NATURE, V350, P172, DOI 10.1038/350172a0; TAYLOR JS, 1984, TETRAHEDRON, V40, P457, DOI 10.1016/0040-4020(84)85050-4; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WU TF, 1989, NUCLEIC ACIDS RES, V17, P3501, DOI 10.1093/nar/17.9.3501	40	58	66	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1991	253	5026					1408	1411		10.1126/science.1716784	http://dx.doi.org/10.1126/science.1716784			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF851	1716784				2022-12-01	WOS:A1991GF85100038
J	RICHET, E; VIDALINGIGLIARDI, D; RAIBAUD, O				RICHET, E; VIDALINGIGLIARDI, D; RAIBAUD, O			A NEW MECHANISM FOR COACTIVATION OF TRANSCRIPTION INITIATION - REPOSITIONING OF AN ACTIVATOR TRIGGERED BY THE BINDING OF A 2ND ACTIVATOR	CELL			English	Article							ESCHERICHIA-COLI; SUPERCOILED DNA; MALT PRODUCT; PROMOTERS; PROTEIN; OPERON; MUTATIONS; REGION; CRP; EXPRESSION	The cAMP receptor protein (CRP) and MalT, the maltose regulon activator, synergistically activate transcription from the E. coli malKp promoter. The malKp regulatory region comprises two series of MalT-binding sites separated by three CRP-binding sites. By combining genetic and biochemical studies, we demonstrate that the promoter-proximal region contains two overlapping sets of three MalT-binding sites. Occupation of the higher affinity set of sites, which occurs in the absence of CRP, does not lead to malKp activation. In contrast, in the presence of CRP, MalT binds to the lower affinity set of sites and triggers transcription initiation because, unlike the high affinity set, the low affinity set of sites is properly positioned with respect to the Pribnow box. The CRP effect requires the malKp-distal MalT-binding sites. The synergistic action of MalT and CRP therefore relies on MalT repositioning via the formation of a nucleoprotein structure involving the entire regulatory region.			RICHET, E (corresponding author), INST PASTEUR,UNITE GENET MOLEC,CNRS,URA 1149,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.							AIBA H, 1981, J BIOL CHEM, V256, P1905; BEDOUELLE H, 1983, J MOL BIOL, V170, P861, DOI 10.1016/S0022-2836(83)80192-2; BOLES TC, 1990, J MOL BIOL, V213, P931, DOI 10.1016/S0022-2836(05)80272-4; BUC H, 1987, RNA POLYMERASE REGUL, P115; CHAPON C, 1985, J BACTERIOL, V164, P639, DOI 10.1128/JB.164.2.639-645.1985; CLAVERIEMARTIN F, 1991, P NATL ACAD SCI USA, V88, P1631, DOI 10.1073/pnas.88.5.1631; COHEN RS, 1988, NATURE, V332, P856, DOI 10.1038/332856a0; DEBARBOUILLE M, 1982, MOL GEN GENET, V185, P88, DOI 10.1007/BF00333795; DECROMBRUGGHE B, 1984, SCIENCE, V224, P831, DOI 10.1126/science.6372090; DEVARGAS LM, 1991, P NATL ACAD SCI USA, V88, P588, DOI 10.1073/pnas.88.2.588; EISMANN ER, 1990, J MOL BIOL, V213, P763, DOI 10.1016/S0022-2836(05)80262-1; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; GUTIERREZ C, 1985, BIOCHIMIE, V67, P145, DOI 10.1016/S0300-9084(85)80241-8; GUTIERREZ C, 1984, J MOL BIOL, V177, P69, DOI 10.1016/0022-2836(84)90058-5; HOFNUNG M, 1974, J BACTERIOL, V117, P40, DOI 10.1128/JB.117.1.40-47.1974; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LICHENSTEIN HS, 1987, J BACTERIOL, V169, P811, DOI 10.1128/jb.169.2.811-822.1987; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; LOBELL RB, 1991, J MOL BIOL, V218, P45, DOI 10.1016/0022-2836(91)90872-4; LOBELL RB, 1990, SCIENCE, V250, P528, DOI 10.1126/science.2237403; MENENDEZ M, 1987, EMBO J, V6, P4227, DOI 10.1002/j.1460-2075.1987.tb02771.x; Miller JH., 1972, EXPT MOL GENETICS; RAIBAUD O, 1983, J MOL BIOL, V163, P395, DOI 10.1016/0022-2836(83)90065-7; RAIBAUD O, 1985, J BACTERIOL, V161, P1201, DOI 10.1128/JB.161.3.1201-1208.1985; RAIBAUD O, 1989, J MOL BIOL, V205, P471, DOI 10.1016/0022-2836(89)90218-0; RAIBAUD O, 1987, J BACTERIOL, V169, P3059, DOI 10.1128/jb.169.7.3059-3061.1987; REITZER LJ, 1985, P NATL ACAD SCI USA, V82, P1979, DOI 10.1073/pnas.82.7.1979; RICHET E, 1991, J MOL BIOL, V218, P529; RICHET E, 1986, CELL, V46, P1011, DOI 10.1016/0092-8674(86)90700-2; RICHET E, 1989, EMBO J, V8, P981, DOI 10.1002/j.1460-2075.1989.tb03461.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSEDWIGHT S, 1988, J MOL BIOL, V202, P107, DOI 10.1016/0022-2836(88)90523-2; Schwartz M, 1987, ESCHERICHIA COLI SAL, P1482; SOGAARDANDERSEN L, 1991, MOL MICROBIOL, V5, P969, DOI 10.1111/j.1365-2958.1991.tb00772.x; TAKAHASHI K, 1986, NATURE, V319, P121, DOI 10.1038/319121a0; USHIDA C, 1990, NUCLEIC ACIDS RES, V18, P6325, DOI 10.1093/nar/18.21.6325; VALENTINHANSEN P, 1982, EMBO J, V1, P317, DOI 10.1002/j.1460-2075.1982.tb01167.x; VALENTINHANSEN P, 1991, MOL MICROBIOL, V5, P433, DOI 10.1111/j.1365-2958.1991.tb02126.x; VIDALINGIGLIARDI D, 1991, P NATL ACAD SCI USA, V88, P229, DOI 10.1073/pnas.88.1.229; VIDALINGIGLIARDI D, 1985, NUCLEIC ACIDS RES, V13, P5919, DOI 10.1093/nar/13.16.5919; VIDALINGIGLIARDI D, 1991, J MOL BIOL, V218, P323, DOI 10.1016/0022-2836(91)90715-I; VIDALINGIGLIARDI D, 1985, NUCLEIC ACIDS RES, V13, P1163, DOI 10.1093/nar/13.4.1163	44	80	81	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1991	66	6					1185	1195		10.1016/0092-8674(91)90041-V	http://dx.doi.org/10.1016/0092-8674(91)90041-V			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1913806				2022-12-01	WOS:A1991GG55200013
J	SHAMANSKI, FL; ORRWEAVER, TL				SHAMANSKI, FL; ORRWEAVER, TL			THE DROSOPHILA PLUTONIUM AND PAN GU GENES REGULATE ENTRY INTO S-PHASE AT FERTILIZATION	CELL			English	Article							PROTO-ONCOGENE PRODUCT; CELL-CYCLE; EARLY EMBRYOGENESIS; DNA-REPLICATION; XENOPUS-LAEVIS; MELANOGASTER; EGGS; DIVISION; NUCLEAR; MUTATION	Mutations in the Drosophila maternal genes plutonium (plu) and pan gu (png) have the striking phenotype that DNA replication initiates in unfertilized eggs. Fertilized eggs from plu or png mutant mothers also have a mutant phenotype; DNA replication is uncoupled from nuclear division, resulting in giant, polyploid nuclei. Analysis of multiple alleles of these genes indicates that their wild-type function is required to maintain repression of DNA replication until fertilization. The phenotype of two png alleles suggests that this gene also may play a direct role in coupling S phase and mitosis during the early cleavage divisions. We describe genetic interactions among png, plu, and the previously identified gene gnu that demonstrate these three genes regulate the same process.	WHITEHEAD INST,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT); Whitehead Institute	SHAMANSKI, FL (corresponding author), MIT,DEPT BIOL,CAMBRIDGE,MA 02139, USA.				NCI NIH HHS [CA09541-06] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009541] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLEN HJ, 1988, ROUX ARCH DEV BIOL, V197, P258, DOI 10.1007/BF00380019; BERG CA, 1991, GENETICS, V127, P515; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; Blumenthal AB, 1974, COLD SPRING HARB SYM, V38, P205, DOI 10.1101/sqb.1974.038.01.024; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; COPPOCK DL, 1987, MOL CELL BIOL, V7, P2925, DOI 10.1128/MCB.7.8.2925; DECICCO DV, 1984, CELL, V38, P45, DOI 10.1016/0092-8674(84)90525-7; DIXON WJ, 1951, INTRO STATISTICAL AN; DOANE WW, 1960, SCIENCE, V132, P677, DOI 10.1126/science.132.3428.677; EDGAR BA, 1986, CELL, V44, P365, DOI 10.1016/0092-8674(86)90771-3; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; Ephrussi B, 1936, AM NAT, V70, P218, DOI 10.1086/280658; FREEMAN M, 1986, CELL, V46, P457, DOI 10.1016/0092-8674(86)90666-5; FREEMAN M, 1987, GENE DEV, V1, P924, DOI 10.1101/gad.1.9.924; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GONZALEZ C, 1990, J CELL SCI, V96, P605; HARA K, 1980, P NATL ACAD SCI-BIOL, V77, P462, DOI 10.1073/pnas.77.1.462; HARLAND RM, 1980, CELL, V21, P761, DOI 10.1016/0092-8674(80)90439-0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; KELLOGG DR, 1989, J CELL BIOL, V109, P2977, DOI 10.1083/jcb.109.6.2977; KONGSUWAN K, 1985, NATURE, V317, P555, DOI 10.1038/317555a0; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LIN HF, 1991, CELL, V64, P49, DOI 10.1016/0092-8674(91)90208-G; LINDREN BW, 1978, PROBABILITY STATISTI; LINDSLEY D, 1987, DROS INF SERV, V65; LINDSLEY D, 1990, DROS INF SERV, V68; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; MAHOWALD AP, 1983, DEV BIOL, V98, P437, DOI 10.1016/0012-1606(83)90373-1; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MCKNIGHT SL, 1976, CELL, V8, P305, DOI 10.1016/0092-8674(76)90014-3; Mohler D., 1984, DROSOPHILA INFORMATI, V60, P236; MOHLER JD, 1977, GENETICS, V85, P259; NEWPORT JW, 1984, CELL, V37, P731, DOI 10.1016/0092-8674(84)90409-4; ORRWEAVER TL, 1986, MOL CELL BIOL, V6, P4624, DOI 10.1128/MCB.6.12.4624; PERRIMON N, 1989, GENETICS, V121, P333; PICARD A, 1987, NATURE, V327, P170, DOI 10.1038/327170a0; RAFF JW, 1988, J CELL BIOL, V107, P2009, DOI 10.1083/jcb.107.6.2009; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SANDER K, 1985, BIOL FERTILIZATION, V2, P409; SCHUPBACH T, 1989, GENETICS, V121, P101; SHELLENBARGER DL, 1978, MUTAT RES, V52, P395, DOI 10.1016/0027-5107(78)90178-1; Sokal Robert R., 1969, BIOMETRY; Sonnenblick B., 1950, BIOL DROSOPHILA, P62; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; ZALOKAR M, 1976, J MICROSC BIOL CELL, V25, P97; ZALOKAR M, 1975, DEV BIOL, V47, P419, DOI 10.1016/0012-1606(75)90295-X	51	87	87	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1991	66	6					1289	1300		10.1016/0092-8674(91)90050-9	http://dx.doi.org/10.1016/0092-8674(91)90050-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1913810				2022-12-01	WOS:A1991GG55200022
J	STAMENKOVIC, I; SGROI, D; ARUFFO, A; SY, MS; ANDERSON, T				STAMENKOVIC, I; SGROI, D; ARUFFO, A; SY, MS; ANDERSON, T			THE LYMPHOCYTE-B ADHESION MOLECULE CD22 INTERACTS WITH LEUKOCYTE COMMON ANTIGEN CD45RO ON T-CELLS AND ALPHA-2-6 SIALYLTRANSFERASE, CD75, ON B-CELLS	CELL			English	Article							MONOCLONAL-ANTIBODIES; COGNATE INTERACTIONS; MEMBRANE-PROTEIN; IMMUNE-SYSTEM; SIALYL-LEX; RECEPTOR; ACTIVATION; CDNA; DIFFERENTIATION; EXPRESSION	Functional maturation of B lymphocytes correlates with expression of the B lineage-specific cell surface glycoprotein CD22. Two CD22 polypeptides have been characterized and suggested to play a role in B cell-B cell interaction as well as in B cell adhesion to monocytes. In this work we provide evidence that CD22 is directly involved in the cognate interaction between B and T cells. One of the two CD22 polypeptides, CD22-beta, interacts with a specific ligand on a subpopulation of CD4+ T cells. Our results suggest that the T cell ligand of CD22 is CD45RO, an isoform of the leukocyte common antigen class of phosphotyrosine phosphatases associated with the helper T cell phenotype. We further demonstrate that CD22 recognizes a second ligand, CD75, expressed predominantly on activated B cells and shown to be a cell surface alpha-2-6 sialytransferase.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP E, BOSTON, MA 02129 USA; BRISTOL MYERS SQUIBB, PHARMACEUT RES INST, SEATTLE, WA 98121 USA	Harvard University; Harvard Medical School; Bristol-Myers Squibb	STAMENKOVIC, I (corresponding author), MASSACHUSETTS GEN HOSP, DEPT PATHOL, BOSTON, MA 02114 USA.		Sgroi, Dennis/AAV-2487-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043257] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43257] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], PROG IMMUNOL, DOI DOI 10.1016/B978-0-12-057550-3.50033-8; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BARSOUMIAN EL, 1989, LEUKOCYTE TYPING 4, P75; BARTLETT WC, 1990, J IMMUNOL, V145, P3956; BARTLETT WC, 1989, J IMMUNOL, V143, P1745; BOUE DR, 1988, J IMMUNOL, V140, P192; CAMERINI D, 1989, NATURE, V342, P78, DOI 10.1038/342078a0; CLARK EA, 1989, IMMUNOL TODAY, V10, P225, DOI 10.1016/0167-5699(89)90257-0; COLLEY KJ, 1989, J BIOL CHEM, V264, P17619; DORKEN B, 1986, J IMMUNOL, V136, P4470; ERIKSTEIN BK, 1989, LEUKOCYTE TYPING 4, P110; GOLAY JT, 1985, J IMMUNOL, V135, P3795; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; KAPLAN HA, 1983, J BIOL CHEM, V258, P1505; KISHIMOTO T, 1988, ANNU REV IMMUNOL, V6, P485, DOI 10.1146/annurev.iy.06.040188.002413; KISHIMOTO T, 1985, ANNU REV IMMUNOL, V3, P133, DOI 10.1146/annurev.iy.03.040185.001025; KUPFER A, 1989, ANNU REV IMMUNOL, V7, P309, DOI 10.1146/annurev.immunol.7.1.309; KUPFER A, 1986, P NATL ACAD SCI USA, V83, P6080, DOI 10.1073/pnas.83.16.6080; LAMMERS G, 1988, J BIOCH, V256, P623; LEDBETTER JA, 1988, P NATL ACAD SCI USA, V85, P8628, DOI 10.1073/pnas.85.22.8628; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MITCHISON N A, 1971, European Journal of Immunology, V1, P18, DOI 10.1002/eji.1830010104; MORIMOTO C, 1986, J IMMUNOL, V137, P3247; NOELLE RJ, 1989, J IMMUNOL, V143, P1807; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PEZZUTTO A, 1988, J IMMUNOL, V140, P1791; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PULIDO R, 1989, J IMMUNOL, V143, P1930; PULIDO R, 1990, EUR J IMMUNOL, V20, P2667, DOI 10.1002/eji.1830201221; ROTHSTEIN DM, 1991, J IMMUNOL, V146, P1175; SANDERS VM, 1986, J IMMUNOL, V137, P2395; SCHIMPL A, 1972, NATURE-NEW BIOL, V237, P15, DOI 10.1038/newbio237015a0; SCHWARTZALBIEZ R, 1989, LEUKOCYTE TYPING 4, P65; SCHWINZER R, 1989, LEUKOCYTE TYPING, V4, P628; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHIBUYA N, 1987, ARCH BIOCHEM BIOPHYS, V254, P1, DOI 10.1016/0003-9861(87)90074-9; SMITH SH, 1986, IMMUNOLOGY, V58, P63; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1987, ANNU REV IMMUNOL, V5, P223, DOI 10.1146/annurev.immunol.5.1.223; STAMENKOVIC I, 1990, J EXP MED, V172, P641, DOI 10.1084/jem.172.2.641; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; STAMENKOVIC I, 1988, J EXP MED, V167, P1975, DOI 10.1084/jem.167.6.1975; STENGELIN S, 1988, EMBO J, V7, P1053, DOI 10.1002/j.1460-2075.1988.tb02913.x; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; STREULI M, 1988, J IMMUNOL, V141, P3910; STROSS WP, 1989, LEUKOCYTE TYPING, V4, P615; SWAIN SL, 1987, IMMUNOL REV, V99, P263, DOI 10.1111/j.1600-065X.1987.tb01180.x; TAIARA S, 1986, J IMMUNOL, V137, P2448; TEDDER TF, 1985, J IMMUNOL, V135, P973; TERRY LA, 1988, IMMUNOLOGY, V64, P331; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.iy.07.040189.002011; TONKS NK, 1988, BIOCHEMISTRY-US, V27, P8696; VITETTA ES, 1987, IMMUNOL REV, V99, P193, DOI 10.1111/j.1600-065X.1987.tb01178.x; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; WHALEN BJ, 1988, J IMMUNOL, V141, P2230; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137; WONG JT, 1989, J IMMUNOL, V143, P3404; YEDNOCK TA, 1989, ADV IMMUNOL, V44, P313	60	369	399	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	1991	66	6					1133	1144		10.1016/0092-8674(91)90036-X	http://dx.doi.org/10.1016/0092-8674(91)90036-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1717156				2022-12-01	WOS:A1991GG55200008
J	TAVERNIER, J; DEVOS, R; CORNELIS, S; TUYPENS, T; VANDERHEYDEN, J; FIERS, W; PLAETINCK, G				TAVERNIER, J; DEVOS, R; CORNELIS, S; TUYPENS, T; VANDERHEYDEN, J; FIERS, W; PLAETINCK, G			A HUMAN HIGH-AFFINITY INTERLEUKIN-5 RECEPTOR (IL5R) IS COMPOSED OF AN IL5-SPECIFIC ALPHA-CHAIN AND A BETA-CHAIN SHARED WITH THE RECEPTOR FOR GM-CSF	CELL			English	Article							COLONY-STIMULATING FACTOR; EOSINOPHIL DIFFERENTIATION FACTOR; MOLECULAR-CLONING; HISTAMINE-RELEASE; SOLUBLE FORM; GENE FAMILY; HUMAN-URINE; EXPRESSION; BINDING; CELLS	cDNA clones encoding two receptor proteins involved in the binding of human interleukin 5 (hIL5) have been isolated. A first class codes for an IL5-specific chain (hIL5R-alpha). The major transcript of this receptor gene, as analyzed in both HL-60 eosinophilic cells and eosinophilic myelocytes grown from cord blood, encodes a secreted form of this receptor. This soluble hIL5R-alpha has antagonistic properties. A second component of the hIL5R is found to be identical to the beta-chain of the human granulocyte-macrophage colony-stimulating factor (GM-CSF) high affinity receptor. The finding that IL5 and GM-CSF share a receptor subunit provides a molecular basis for the observation that these cytokines can partially interfere with each other's binding and have highly overlapping biological activities on eosinophils.	STATE UNIV GHENT, MOLEC BIOL LAB, B-9000 GHENT, BELGIUM	Ghent University	TAVERNIER, J (corresponding author), ROCHE RES GENT, PLATEAUST 22, B-9000 GHENT, BELGIUM.							ASHWORTH A, 1990, NUCLEIC ACIDS RES, V18, P7178, DOI 10.1093/nar/18.23.7178; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BISCHOFF SC, 1990, J EXP MED, V172, P1577, DOI 10.1084/jem.172.6.1577; CLUTTERBUCK E, 1987, EUR J IMMUNOL, V17, P1743, DOI 10.1002/eji.1830171210; COFFMAN RL, 1989, SCIENCE, V245, P308, DOI 10.1126/science.2787531; DENT LA, 1990, J EXP MED, V172, P1425, DOI 10.1084/jem.172.5.1425; DEVOS R, 1991, EMBO J, V10, P2133, DOI 10.1002/j.1460-2075.1991.tb07747.x; DEVOS R, 1991, EUR J IMMUNOL, V21, P1315, DOI 10.1002/eji.1830210533; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; ENOKIHARA H, 1989, BLOOD, V73, P1809; FANSLOW WC, 1990, SCIENCE, V248, P739, DOI 10.1126/science.2139736; FISCHKOFF SA, 1988, LEUKEMIA RES, V12, P679, DOI 10.1016/0145-2126(88)90103-8; GAMBLE JR, 1990, SCIENCE, V249, P414; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HIRAI K, 1990, J EXP MED, V172, P1525, DOI 10.1084/jem.172.5.1525; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KANAKURA Y, 1990, BLOOD, V76, P706; KHANDJIAN EW, 1986, MOL BIOL REP, V11, P107, DOI 10.1007/BF00364822; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LIMAYE AP, 1990, J EXP MED, V172, P399, DOI 10.1084/jem.172.1.399; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LOPEZ AF, 1990, J CELL PHYSIOL, V145, P69, DOI 10.1002/jcp.1041450111; LOPEZ AF, 1989, P NATL ACAD SCI USA, V86, P7022, DOI 10.1073/pnas.86.18.7022; MARCON L, 1988, CLIN EXP IMMUNOL, V73, P29; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MITA S, 1989, P NATL ACAD SCI USA, V86, P2311, DOI 10.1073/pnas.86.7.2311; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MURATA Y, 1990, BIOCHEM BIOPH RES CO, V173, P1102, DOI 10.1016/S0006-291X(05)80899-X; NOVICK D, 1989, J EXP MED, V170, P1409, DOI 10.1084/jem.170.4.1409; OWEN WF, 1989, J EXP MED, V170, P343, DOI 10.1084/jem.170.1.343; OWEN WF, 1990, P NATL ACAD SCI USA, V87, P8647, DOI 10.1073/pnas.87.21.8647; PLAETINCK G, 1990, J EXP MED, V172, P683, DOI 10.1084/jem.172.3.683; ROLINK AG, 1989, J EXP MED, V169, P1693, DOI 10.1084/jem.169.5.1693; SAITO H, 1988, P NATL ACAD SCI USA, V85, P2288, DOI 10.1073/pnas.85.7.2288; Sambrook J., 1989, MOL CLONING LAB MANU; SANDERSON CJ, 1986, P NATL ACAD SCI USA, V83, P437, DOI 10.1073/pnas.83.2.437; SANDERSON CJ, 1988, IMMUNOL REV, V102, P29, DOI 10.1111/j.1600-065X.1988.tb00740.x; SANDERSON CJ, 1990, INT J CELL CLONING, V8, P147, DOI 10.1002/stem.5530080713; SECKINGER P, 1989, J BIOL CHEM, V264, P11966; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; TAKATSU K, 1988, IMMUNOL REV, V102, P107, DOI 10.1111/j.1600-065X.1988.tb00743.x; TAVERNIER J, 1989, DNA-J MOLEC CELL BIO, V8, P491, DOI 10.1089/dna.1.1989.8.491; TAVERNIER J, 1983, NATURE, V301, P634, DOI 10.1038/301634a0; TOMINAGA A, 1991, J EXP MED, V173, P429, DOI 10.1084/jem.173.2.429; VANDERHEYDEN J, 1991, IN PRESS J IMMUNOL; VANLEEUWEN BH, 1989, BLOOD, V73, P1142; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YAMAGUCHI Y, 1990, EXP HEMATOL, V18, P1152; YOKOTA T, 1987, P NATL ACAD SCI USA, V84, P7388, DOI 10.1073/pnas.84.21.7388; ZUPAN AA, 1989, J BIOL CHEM, V264, P11714	56	580	592	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	1991	66	6					1175	1184		10.1016/0092-8674(91)90040-6	http://dx.doi.org/10.1016/0092-8674(91)90040-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1833065				2022-12-01	WOS:A1991GG55200012
J	WEISSMAN, JS; KIM, PS				WEISSMAN, JS; KIM, PS			REEXAMINATION OF THE FOLDING OF BPTI - PREDOMINANCE OF NATIVE INTERMEDIATES	SCIENCE			English	Article							PANCREATIC TRYPSIN-INHIBITOR; STRUCTURAL CHARACTERIZATION; DISULFIDE BOND; RIBONUCLEASE-A; CYTOCHROME-C; PROTEIN; NMR; EXCHANGE; PATHWAY; ENERGETICS	Bovine pancreatic trypsin inhibitor (BPTI) continues to be the only protein for which a detailed pathway of folding has been described. Previous studies led to the conclusion that nonnative states are well populated in the oxidative folding of BPTI. This conclusion has broadly influenced efforts to understand protein folding. The population of intermediates present during the folding of BPTI has been reexamined by modern separation techniques. It was found that all well-populated folding intermediates contain only native disulfide bonds. These data emphasize the importance of native protein structure for understanding protein folding.	MIT,DEPT PHYS,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	WEISSMAN, JS (corresponding author), WHITEHEAD INST BIOMED RES,HOWARD HUGHES MED INST,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041307] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 05927] Funding Source: Medline; NIGMS NIH HHS [GM 41307] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; BROWN JR, 1966, BIOCHEM J, V101, P214, DOI 10.1042/bj1010214; BYCROFT M, 1990, NATURE, V346, P488, DOI 10.1038/346488a0; CARR C, 1991, BIOCHEMISTRY-US, V30, P1515, DOI 10.1021/bi00220a011; CREIGHTON TE, 1974, J MOL BIOL, V87, P603, DOI 10.1016/0022-2836(74)90106-5; CREIGHTON TE, 1984, METHOD ENZYMOL, V107, P305; CREIGHTON TE, 1977, J MOL BIOL, V113, P275, DOI 10.1016/0022-2836(77)90142-5; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; CREIGHTON TE, 1975, J MOL BIOL, V95, P167, DOI 10.1016/0022-2836(75)90389-7; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; CREIGHTON TE, 1977, J MOL BIOL, V113, P295, DOI 10.1016/0022-2836(77)90143-7; CREIGHTON TE, 1977, J MOL BIOL, V113, P313, DOI 10.1016/0022-2836(77)90144-9; CREIGHTON TE, 1988, BIOPHYS CHEM, V31, P155, DOI 10.1016/0301-4622(88)80021-8; CREIGHTON TE, 1974, J MOL BIOL, V87, P579, DOI 10.1016/0022-2836(74)90105-3; CREIGHTON TE, 1974, J MOL BIOL, V87, P563, DOI 10.1016/0022-2836(74)90104-1; CREIGHTON TE, 1975, J MOL BIOL, V96, P777, DOI 10.1016/0022-2836(75)90152-7; Creighton TE, 1991, CURR OPIN STRUC BIOL, V1, P3, DOI 10.1016/0959-440X(91)90003-C; DARBY NJ, 1991, FEBS LETT, V279, P61, DOI 10.1016/0014-5793(91)80251-W; Dobson CM, 1991, CURR OPIN STRUC BIOL, V1, P22, DOI 10.1016/0959-440X(91)90006-F; EIGENBROT C, 1990, PROTEIN ENG, V3, P591, DOI 10.1093/protein/3.7.591; GOLDENBERG DP, 1985, BIOPOLYMERS, V24, P167, DOI 10.1002/bip.360240114; GOTO Y, 1981, J MOL BIOL, V146, P321, DOI 10.1016/0022-2836(81)90391-0; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; JENG MF, 1990, BIOCHEMISTRY-US, V29, P10433, DOI 10.1021/bi00498a001; KIEFHABER T, IN PRESS PROTEINS; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.bi.59.070190.003215; LIN TY, 1989, BIOCHEMISTRY-US, V28, P5282, DOI 10.1021/bi00438a054; MCCOY LF, 1980, BIOCHEMISTRY-US, V19, P4738, DOI 10.1021/bi00562a003; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; ROSE GD, 1979, J MOL BIOL, V134, P447, DOI 10.1016/0022-2836(79)90363-2; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; ROTHWARF DM, 1991, J AM CHEM SOC, V113, P6293, DOI 10.1021/ja00016a068; Schmid FX, 1991, CURR OPIN STRUC BIOL, V1, P36, DOI 10.1016/0959-440X(91)90008-H; SCHMID FX, 1979, J MOL BIOL, V135, P199, DOI 10.1016/0022-2836(79)90347-4; SNYDER GH, 1981, BIOCHEMISTRY-US, V20, P6509, DOI 10.1021/bi00526a001; STALEY JP, 1990, NATURE, V344, P685, DOI 10.1038/344685a0; STALEY JP, UNPUB; STASSINOPOULOU CI, 1984, EUR J BIOCHEM, V145, P423, DOI 10.1111/j.1432-1033.1984.tb08571.x; STATES DJ, 1980, NATURE, V286, P630, DOI 10.1038/286630a0; STATES DJ, 1987, J MOL BIOL, V195, P731, DOI 10.1016/0022-2836(87)90192-6; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; WEISSMAN JG, UNPUB; WEISSMAN JS, 1982, J MOL BIOL, V155, P347; YAGISAWA S, 1989, BIOCHEM J, V263, P985, DOI 10.1042/bj2630985	46	512	517	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1991	253	5026					1386	1393		10.1126/science.1716783	http://dx.doi.org/10.1126/science.1716783			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF851	1716783				2022-12-01	WOS:A1991GF85100032
J	ZHOU, XL; STUMPF, MA; HOCH, HC; KUNG, C				ZHOU, XL; STUMPF, MA; HOCH, HC; KUNG, C			A MECHANOSENSITIVE CHANNEL IN WHOLE CELLS AND IN MEMBRANE PATCHES OF THE FUNGUS UROMYCES	SCIENCE			English	Article							ACTIVATED ION CHANNELS; ESCHERICHIA-COLI; RUST FUNGUS; K+ CHANNEL; MUSCLE	Bean leaf stomata provide a topographical signal that induces germlings of the phytopathogen Uromyces appendiculatus to develop specialized infection structures. Protoplasts from germ tubes of this fungus, when examined with patch-clamp electrodes, displayed the Activities of a 600-picosiemen mechanosensitive ion channel. This channel passes a variety of cations, including Ca2+, and is blocked by Gd3+ at 50 micromolar. This channel could transduce the membrane stress induced by the leaf topography into an influx of ions, including Ca2+, that may trigger differentiation.	UNIV WISCONSIN,MOLEC BIOL LAB,MADISON,WI 53706; UNIV WISCONSIN,DEPT GENET,MADISON,WI 53706; CORNELL UNIV,NEW YORK STATE AGR EXPT STN,DEPT PLANT PATHOL,GENEVA,NY 14456	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Cornell University								ALLEN EA, 1991, PHYTOPATHOLOGY, V81, P323, DOI 10.1094/Phyto-81-323; BREHM P, 1984, J PHYSIOL-LONDON, V350, P631, DOI 10.1113/jphysiol.1984.sp015222; COLE GT, 1991, FUNGAL SPORE DISEASE, P25; EMMETT RW, 1975, ANNU REV PHYTOPATHOL, V13, P147, DOI 10.1146/annurev.py.13.090175.001051; GUHARAY F, 1984, J PHYSIOL-LONDON, V352, P685, DOI 10.1113/jphysiol.1984.sp015317; GUSTIN MC, 1988, SCIENCE, V242, P762, DOI 10.1126/science.2460920; HOCH HC, 1987, ANNU REV PHYTOPATHOL, V25, P231, DOI 10.1146/annurev.py.25.090187.001311; HOCH HC, 1987, SCIENCE, V235, P1659, DOI 10.1126/science.235.4796.1659; HUANG D, 1990, PHYTOPATHOLOGY, V80, P81, DOI 10.1094/Phyto-80-81; KWON Y, IN PRESS CAN J BOT; LANSMAN JB, 1987, NATURE, V325, P811, DOI 10.1038/325811a0; MARTINAC B, 1990, NATURE, V348, P261, DOI 10.1038/348261a0; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; MORRIS CE, 1991, SCIENCE, V251, P246; Sachs F., 1986, P181; SACKIN H, 1989, P NATL ACAD SCI USA, V86, P1731, DOI 10.1073/pnas.86.5.1731; SIGURDSON WJ, 1987, J EXP BIOL, V127, P191; Spangler S G, 1972, Ala J Med Sci, V9, P218; STUMPF MPH, UNPUB; WYNN WK, 1976, PHYTOPATHOLOGY, V66, P136, DOI 10.1094/Phyto-66-136; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333	21	151	153	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1991	253	5026					1415	1417		10.1126/science.1716786	http://dx.doi.org/10.1126/science.1716786			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF851	1716786				2022-12-01	WOS:A1991GF85100040
J	BAVINCK, JNB; VERMEER, BJ; VANDERWOUDE, FJ; VANDENBROUCKE, JP; SCHREUDER, GMT; THOROGOOD, J; PERSIJN, GG; CLAAS, FHJ				BAVINCK, JNB; VERMEER, BJ; VANDERWOUDE, FJ; VANDENBROUCKE, JP; SCHREUDER, GMT; THOROGOOD, J; PERSIJN, GG; CLAAS, FHJ			RELATION BETWEEN SKIN-CANCER AND HLA ANTIGENS IN RENAL-TRANSPLANT RECIPIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALLOGRAFT RECIPIENTS; SURVIVAL; INFECTION; WARTS; DNA	Background. Recipients of renal allografts are at an increased risk for skin cancer. It is also known that recipients who are homozygous for HLA antigens are at an increased risk for certain cancers, as are those who are mismatched with their donors for these antigens. In a case-control study we assessed the relation between skin cancer in renal-transplant recipients and HLA homozygosity and mismatching. Methods. Of 764 patients who received renal transplants between 1966 and 1988, 66 had squamous-cell carcinoma or basal-cell carcinoma of the skin after transplantation. HLA homozygosity was assessed in all 66 recipients, and HLA mismatching in 39; the results were compared with those in 124 recipients without skin cancer. We also investigated the relation between skin cancer and the use of immunosuppressive drugs. In separate case-control analyses we investigated the influence of exposure to the sun and keratotic skin lesions on the risk of skin cancer. Results. The risk of squamous-cell carcinoma was increased in recipients mismatched for HLA-B antigens; the relative risks were 2.6 (95 percent confidence interval, 1.1 to 6.5) and 5.0 (95 percent confidence interval, 1.3 to 19.0) with mismatching for one and two antigens, respectively, as compared with no mismatching. Mismatching for HLA-A or HLA-DR antigens had no effect on the risk of squamous-cell carcinoma, and there was no association between mismatches at any of the HLA loci and the occurrence of basal-cell carcinoma. The total doses of azathioprine and prednisone were not associated with the occurrence of skin cancer or with HLA matching. Exposure to sunlight and keratotic ski in lesions were strongly associated with skin cancer but not with HLA mismatching. Homozygosity for HLA-DR was more frequent among the patients with squamous-cell carcinoma (relative risk, 2.5; 95 percent confidence interval, 0.95 to 4.6) and among patients with 100 or more keratotic skin lesions (relative risk, 4.8; 95 percent confidence interval, 1.5 to 15.1). Conclusions. HLA-B mismatching is significantly associated with the risk of squamous-cell carcinoma in renal-transplant recipients, as is HLA-DR homozygosity. An indirect effect on the level of immunosuppression does not appear to explain these findings, nor does exposure to sunlight or the number of keratotic skin lesions account for this observation.	LEIDEN UNIV HOSP, DEPT NEPHROL, 2333 AA LEIDEN, NETHERLANDS; LEIDEN UNIV HOSP, DEPT CLIN EPIDEMIOL, 2333 AA LEIDEN, NETHERLANDS; LEIDEN UNIV HOSP, DEPT IMMUNOHEMATOL, 2333 AA LEIDEN, NETHERLANDS; LEIDEN UNIV HOSP, BLOOD BANK, 2333 AA LEIDEN, NETHERLANDS; EUROTRANSPLANT FDN, LEIDEN, NETHERLANDS; LEIDEN UNIV, DEPT MED STAT, 2300 RA LEIDEN, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University - Excl LUMC	BAVINCK, JNB (corresponding author), LEIDEN UNIV HOSP, DEPT DERMATOL, RIJNSBURGERWEG 10, 2333 AA LEIDEN, NETHERLANDS.		Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				BARR BBB, 1989, LANCET, V1, P124; BAVINCK JNB, 1990, NEW ENGL J MED, V323, P1350; BOYLE J, 1984, LANCET, V1, P702; CARPENTER CB, 1989, CONTEMP ISS NEPHROL, V19, P1; Dausset J., 1982, CANCER SURV, V1, P119; DYER PA, 1989, TRANSPLANTATION, V48, P131, DOI 10.1097/00007890-198907000-00030; FESTENSTEIN H, 1986, NATURE, V322, P502, DOI 10.1038/322502a0; FLIEDNER VEV, 1980, TISSUE ANTIGENS, V16, P399; GASSENMAIER A, 1986, ARCH DERMATOL RES, V278, P219, DOI 10.1007/BF00412927; GERKINS VR, 1974, JNCI-J NATL CANCER I, V52, P1909, DOI 10.1093/jnci/52.6.1909; GUPTA AK, 1986, ARCH DERMATOL, V122, P1288, DOI 10.1001/archderm.122.11.1288; HARDIE IR, 1980, SURGERY, V87, P177; HARTEVELT MM, 1990, TRANSPLANTATION, V49, P506, DOI 10.1097/00007890-199003000-00006; Henny F C, 1986, Nephrol Dial Transplant, V1, P44; KINLEN LJ, 1985, AM J MED, V78, P44, DOI 10.1016/0002-9343(85)90245-1; KOOTTE AMM, 1988, NEPHROL DIAL TRANSPL, V3, P666, DOI 10.1093/oxfordjournals.ndt.a091725; LUTZNER MA, 1983, LANCET, V2, P422; OPELZ G, 1988, LANCET, V2, P61; PENN I, 1988, TRANSPLANT P, V20, P885; PERSIJN GG, 1982, NEW ENGL J MED, V307, P905, DOI 10.1056/NEJM198210073071501; RAY JG, 1979, NIH80545 DHEW PUBL; RUDLINGER R, 1986, BRIT J DERMATOL, V115, P681, DOI 10.1111/j.1365-2133.1986.tb06649.x; RUDLINGER R, 1989, LANCET, V1, P1132; SHEIL AGR, 1989, KIDNEY TRANSPLANTATI, P603; THOROGOOD J, 1990, TRANSPLANTATION, V50, P146, DOI 10.1097/00007890-199007000-00027; TING A, 1989, KIDNEY TRANSPLANTATI, P183; VANDERLEEST RJ, 1987, ARCH DERMATOL, V123, P354, DOI 10.1001/archderm.123.3.354; VANHOOFF PJ, 1980, P EUR DIAL TRANSPLAN, V17, P435; VANROOD JJ, 1985, TRANSPLANT P, V17, P681; VANROOD JJ, 1976, NATURE, V262, P795, DOI 10.1038/262795a0	30	152	155	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 19	1991	325	12					843	848		10.1056/NEJM199109193251203	http://dx.doi.org/10.1056/NEJM199109193251203			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF616	1875968				2022-12-01	WOS:A1991GF61600003
J	CORNALL, RJ; PRINS, JB; TODD, JA; PRESSEY, A; DELARATO, NH; WICKER, LS; PETERSON, LB				CORNALL, RJ; PRINS, JB; TODD, JA; PRESSEY, A; DELARATO, NH; WICKER, LS; PETERSON, LB			TYPE-1 DIABETES IN MICE IS LINKED TO THE INTERLEUKIN-1 RECEPTOR AND LSH/ITY/BCG GENES ON CHROMOSOME-1	NATURE			English	Article							NOD MOUSE; NONOBESE; RESISTANCE; PREVENTION; DISEASE; CYCLOPHOSPHAMIDE; INSULITIS; MELLITUS; ALPHA; MAP	HUMAN type 1 (insulin-dependent) diabetes is a common autoimmune disease of the insulin-producing beta-cells of the pancreas which is caused by both genetic and environmental factors 1,2. Several features or the genetics and immunopathology of diabetes in nonobese diabetic (NOD) mice are shared with the human disease 1,3,4. Of the three diabetes-susceptibility genes, Idd-1 (refs 5-7), -3 and -4 (ref. 4) that have been mapped in mice to date, only in the case of Idd-1 is there any evidence for the identity of the gene product: allelic variation within the murine immune response I-A-beta gene and its human homologue HLA-DQB1 correlates with susceptibility, implying that I-A-beta is a component of Idd-1 (refs 5-11). We report here the mapping of Idd-5 to the proximal region of mouse chromosome 1. This region contains at least two candidate susceptibility genes, the interleukin-1 receptor gene (Il-1r1; ref. 12) and Lsh/Ity/Bcg (refs 13-19), which encodes resistance to bacterial and parasitic infections and affects the function of macrophages.	MERCK SHARP & DOHME LTD, DEPT CELLULAR & MOLEC PHARMACOL, RAHWAY, NJ 07065 USA; MERCK SHARP & DOHME LTD, AUTOIMMUNE DIS RES, RAHWAY, NJ 07065 USA	Merck & Company; Merck & Company	CORNALL, RJ (corresponding author), JOHN RADCLIFFE HOSP, NUFFIELD DEPT SURG, OXFORD OX3 9DU, ENGLAND.		Wicker, Linda S/F-7384-2010; Todd, John A/A-3542-2010	Todd, John A/0000-0003-2740-8148; Prins, Jan-Bas/0000-0002-1831-8522	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLACKWELL JM, IN PRESS IMMUN LETT; CASTANO L, 1990, ANNU REV IMMUNOL, V8, P647, DOI 10.1146/annurev.iy.08.040190.003243; COPELAND NG, 1991, GENOMICS, V9, P44, DOI 10.1016/0888-7543(91)90219-5; CORNALL RJ, 1991, GENOMICS, V10, P874, DOI 10.1016/0888-7543(91)90175-E; HARADA M, 1984, DIABETOLOGIA, V27, P604, DOI 10.1007/BF00276978; HATTORI M, 1986, SCIENCE, V231, P733, DOI 10.1126/science.3003909; HEARNE CM, 1991, MAMM GENOME, V1, P273, DOI 10.1007/BF00352339; HILLYARD AL, 1991, LOCUS MAP MOUSE COMP; HOGARTH PM, 1991, J IMMUNOL, V146, P369; HUTCHINGS P, 1990, NATURE, V348, P639, DOI 10.1038/348639a0; JACOB CO, 1990, P NATL ACAD SCI USA, V87, P968, DOI 10.1073/pnas.87.3.968; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; LUND T, 1990, NATURE, V345, P727, DOI 10.1038/345727a0; MAKINO S, 1980, Experimental Animals (Tokyo), V29, P1; MALO D, 1991, ENOMICS, V10, P356; MANDRUPPOULSEN T, 1990, CURR TOP MICROBIOL, V164, P169; MIYAZAKI T, 1990, NATURE, V345, P722, DOI 10.1038/345722a0; MOCK B, 1990, GENOMICS, V7, P57, DOI 10.1016/0888-7543(90)90518-Y; PROCHAZKA M, 1987, SCIENCE, V237, P286, DOI 10.1126/science.2885918; RISCH N, 1987, AM J HUM GENET, V40, P1; SCHURR E, 1991, IMMUNOL TODAY, V12, P42; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SKAMENE E, 1982, NATURE, V297, P506, DOI 10.1038/297506a0; SLATTERY RM, 1990, NATURE, V345, P724, DOI 10.1038/345724a0; TODD JA, 1991, NATURE, V351, P542, DOI 10.1038/351542a0; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; WICKER LS, 1987, J EXP MED, V165, P1639, DOI 10.1084/jem.165.6.1639; WICKER LS, 1991, FRONTIERS DIABETES R, V2, P67; WICKER LS, IN PRESS P P S BIOME; YASUNAMI R, 1988, EUR J IMMUNOL, V18, P481, DOI 10.1002/eji.1830180325	30	186	187	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 19	1991	353	6341					262	265		10.1038/353262a0	http://dx.doi.org/10.1038/353262a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF674	1832743				2022-12-01	WOS:A1991GF67400061
J	GARCHON, HJ; BEDOSSA, P; ELOY, L; BACH, JF				GARCHON, HJ; BEDOSSA, P; ELOY, L; BACH, JF			IDENTIFICATION AND MAPPING TO CHROMOSOME-1 OF A SUSCEPTIBILITY LOCUS FOR PERIINSULITIS IN NONOBESE DIABETIC MICE	NATURE			English	Article							MELLITUS; MOUSE; PANCREAS; INSULITIS; ISLETS; GENE; HLA	INSULIN-DEPENDENT diabetes mellitus (IDDM) is a polygenic disease caused by autoimmune destruction of insulin-producing beta-cells in the islets of Langerhans 1,2. Its onset is preceded by a long and variable period in which lymphoid cells infiltrate the pancreas but first remain outside the islets (peri-insulitis) before invading them (insulitis) 3-7. Among susceptibility loci, only the major histocompatibility complex (MHC) has been clearly assigned 8-12. Genetic study of the nonobese diabetic (NOD) mouse model for insulin-dependent diabetes mellitus has revealed genetic linkage of insulitis and of early onset diabetes with two non-MHC loci mapping to chromosome 3 and 11 respectively 13. Here we report a close association of periinsulitis with a third non-MHC locus mapping to chromosome 1. Successive stages in the progression of diabetic disease thus appear to be controlled by distinct genes or sets of genes.	HOP ANTOINE BECLERE, SERV ANAT PATHOL, F-92140 CLAMART, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP	GARCHON, HJ (corresponding author), HOP NECKER ENFANTS MALAD, INSERM, U25, 161 RUE SEVRES, F-75743 PARIS 15, FRANCE.			Bedossa, Pierre/0000-0002-8487-7322				AITMAN TJ, IN PRESS MAMMALIAN G; ASAMOTO H, 1984, Journal of the Japan Diabetes Society, V27, P775; BEDOSSA P, 1989, EUR J IMMUNOL, V19, P1947, DOI 10.1002/eji.1830191028; CAHILL GF, 1981, NEW ENGL J MED, V304, P1454, DOI 10.1056/NEJM198106113042403; CORNALL RJ, IN PRESS GENOMICS; FOULIS AK, 1984, DIABETOLOGIA, V26, P456; FOULIS AK, 1986, DIABETOLOGIA, V29, P267, DOI 10.1007/BF00452061; GEPTS W, 1981, AM J MED, V70, P105, DOI 10.1016/0002-9343(81)90417-4; GOILLOT E, 1991, CLIN IMMUNOL IMMUNOP, V59, P462, DOI 10.1016/0090-1229(91)90041-8; GORSUCH AN, 1981, LANCET, V2, P1363; HATTORI M, 1986, SCIENCE, V231, P733, DOI 10.1126/science.3003909; HEARNE CM, IN PRESS MAMMALIAN G; KESSLER HS, 1968, AM J PATHOL, V52, P671; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; LUDWIG H, 1977, GUT, V18, P311, DOI 10.1136/gut.18.4.311; MIYAGAWA J, 1986, VIRCHOWS ARCH B, V51, P215, DOI 10.1007/BF02899031; NADEAU JH, 1990, GENETIC VARIANTS STR, P506; OKAZAKI K, 1989, INT J PANCREATOL, V5, P359; PROCHAZKA M, 1987, SCIENCE, V237, P286, DOI 10.1126/science.2885918; SIGNORE A, 1989, DIABETOLOGIA, V32, P282, DOI 10.1007/BF00265543; SVEJGAARD A, 1983, IMMUNOL REV, V70, P193, DOI 10.1111/j.1600-065X.1983.tb00715.x; TODD JA, 1991, NATURE, V351, P542, DOI 10.1038/351542a0; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; WHALEY K, 1973, Q J MED, V42, P279; WICKER LS, 1987, J EXP MED, V165, P1639, DOI 10.1084/jem.165.6.1639	25	139	140	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 19	1991	353	6341					260	262		10.1038/353260a0	http://dx.doi.org/10.1038/353260a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF674	1896073				2022-12-01	WOS:A1991GF67400060
J	KALLEN, J; SPITZFADEN, C; ZURINI, MGM; WIDER, G; WIDMER, H; WUTHRICH, K; WALKINSHAW, MD				KALLEN, J; SPITZFADEN, C; ZURINI, MGM; WIDER, G; WIDMER, H; WUTHRICH, K; WALKINSHAW, MD			STRUCTURE OF HUMAN CYCLOPHILIN AND ITS BINDING-SITE FOR CYCLOSPORINE-A DETERMINED BY X-RAY CRYSTALLOGRAPHY AND NMR-SPECTROSCOPY	NATURE			English	Article							CIS-TRANS ISOMERASE; PROTEIN; REFINEMENT	THE protein cyclophilin is the major intracellular receptor for the immunosuppressive drug cyclosporin A (ref. 1). Cyclosporin A acts as an inhibitor of T-cell activation and can prevent graft rejection in organ and bone marrow transplantation 2. Cyclophilin may be responsible for mediating this immunosuppressive response. Cyclophilin also catalyses the interconversion of the cis and trans isomers of the peptidyl-prolyl amide bonds of peptide and protein substrates 3,4. Here we report the X-ray crystal structure of human recombinant cyclophilin complexed with a tetrapeptide and the identification, by nuclear magnetic resonance spectroscopy, of the specific binding site for cyclosporin A. Cyclophilin has an eight-stranded antiparallel beta-barrel structure. The prolyl isomerase substrate-binding site is coincident with the cyclosporin-binding site. These results may help to provide a structural basis for rationalizing the immunosuppressive function of the cyclosporin-cyclophilin system and will also be important in the design of improved immunosuppressant drugs.	SANDOZ PHARMA AG,PRECLIN RES,CH-4002 BASEL,SWITZERLAND; SWISS FED INST TECHNOL,INST MOLEK BIOL & BIOPHYS,CH-8093 ZURICH,SWITZERLAND	Novartis; Sandoz; Swiss Federal Institutes of Technology Domain; ETH Zurich			walkinshaw, malcolm/AAB-7497-2019	Wider, Gerhard/0000-0001-9366-7645; walkinshaw, malcolm/0000-0001-5955-9325				BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BLUNDELL TL, 1976, PROTEIN CRYSTALLOGRA, P357; BOREL JF, 1989, PHARMACOL REV, V41, P259; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; FESIK SW, 1991, BIOCHEMISTRY-US, V30, P6574, DOI 10.1021/bi00240a030; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KE H, IN PRESS P NATN ACAD; LIU J, 1991, BIOCHEMISTRY-US, V30, P2306, DOI 10.1021/bi00223a003; LIU J, 1990, P NATL ACAD SCI USA, V87, P2304, DOI 10.1073/pnas.87.6.2304; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MOORE JM, 1991, NATURE, V351, P248, DOI 10.1038/351248a0; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WEBER C, 1991, BIOCHEMISTRY-US, V30, P6563, DOI 10.1021/bi00240a029; WUTHRICH K, IN PRESS FEBS LETT; ZURINI M, 1990, FEBS LETT, V276, P63, DOI 10.1016/0014-5793(90)80507-F; 1986, CCP4 SUITE PROGRAMS	22	254	260	3	42	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 19	1991	353	6341					276	279		10.1038/353276a0	http://dx.doi.org/10.1038/353276a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF674	1896075				2022-12-01	WOS:A1991GF67400066
J	MAKITA, Z; RADOFF, S; RAYFIELD, EJ; YANG, Z; SKOLNIK, E; DELANEY, V; FRIEDMAN, EA; CERAMI, A; VLASSARA, H				MAKITA, Z; RADOFF, S; RAYFIELD, EJ; YANG, Z; SKOLNIK, E; DELANEY, V; FRIEDMAN, EA; CERAMI, A; VLASSARA, H			ADVANCED GLYCOSYLATION END-PRODUCTS IN PATIENTS WITH DIABETIC NEPHROPATHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLUCOSE-MODIFIED PROTEINS; SURFACE BINDING-PROTEIN; CHRONIC-HEMODIALYSIS; HUMAN COLLAGEN; COMPLICATIONS; RECEPTOR; MELLITUS; DISEASE; TISSUE; BETA-2-MICROGLOBULIN	Background. Glucose reacts nonenzymatically with proteins in vivo, chemically forming covalently attached glucose-addition products and cross-links between proteins. The excessive accumulation of rearranged late-glucose-addition products, or advanced glycosylation end products (AGEs), is believed to contribute to the chronic complications of diabetes mellitus. Methods. To elucidate the relation of AGEs to diabetic complications, we used a radioreceptor assay to measure serum and tissue AGEs in diabetic (Types I and II) and nondiabetic patients with different levels of renal function. Serum AGEs were measured as a low-molecular-weight (less-than-or-equal-to 10 kd) peptide fraction and a high-molecular-weight (> 10 kd) protein fraction. Results. The mean (+/- SD) AGE content of samples of arterial-wall collagen from 9 diabetic patients was significantly higher than that of samples from 18 nondiabetic patients (14.5 +/- 5.2 vs. 3.6 +/- 1.5 AGE units per milligram, P < 0.001). Moreover, diabetic patients with end-stage renal disease had almost twice as much AGE in tissue as diabetic patients without renal disease (21.3 +/- 2.8 vs. 11.5 +/- 1.9 AGE units per milligram, P < 0.001). The AGE levels in both serum fractions were elevated in the patients with-diabetes, and the levels of AGE peptides correlated directly with serum creatinine (P < 0.001) and inversely with creatinine clearance (P < 0.005), suggesting that levels of AGE peptides increased with the severity of diabetic nephropathy. In six patients with diabetes who required hemodialysis, the levels of AGE peptides were five times higher than in eight normal subjects (82.8 +/- 9.4 vs. 15.6 +/- 3.4 AGE units per milliliter, P < 0.001). In another group of diabetic patients, the mean serum creatinine level decreased by 75 percent during a session of hemodialysis, whereas the level of AGE peptides decreased by only 24 percent. Serum levels of AGE peptides were normal in two patients with normal serum creatinine levels after renal transplantation. Conclusions. AGEs accumulate at a faster-than-normal rate in arteries and the circulation of patients with diabetes; the increase in circulating AGE peptides parallels the severity of renal functional impairment in diabetic nephropathy.	SUNY DOWNSTATE MED CTR HOSP, DEPT MED, DIV RENAL DISEASES, NEW YORK, NY USA; ROCKEFELLER UNIV, MED BIOCHEM LAB, NEW YORK, NY 10021 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Rockefeller University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG008245, R01AG006943] Funding Source: NIH RePORTER; NIA NIH HHS [AG6943, AG8245] Funding Source: Medline; NIDDK NIH HHS [DK19655] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BABB AL, 1971, T AM SOC ART INT ORG, V17, P81; BERGSTROM J, 1986, REPLACEMENT RENAL FU, P354; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNAN M, 1989, J BIOL CHEM, V264, P20947; BROWNLEE M, 1984, ANN INTERN MED, V101, P527, DOI 10.7326/0003-4819-101-4-527; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; CERAMI A, 1987, SCI AM, V256, P90, DOI 10.1038/scientificamerican0587-90; DAVIS JE, 1978, DIABETES, V27, P102, DOI 10.2337/diabetes.27.2.102; EDWARDS CA, 1980, CLIN CHIM ACTA, V104, P161, DOI 10.1016/0009-8981(80)90192-8; ESPOSITO C, 1989, J EXP MED, V170, P1387, DOI 10.1084/jem.170.4.1387; FARMAR JG, 1988, J ORG CHEM, V53, P2346, DOI 10.1021/jo00245a039; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GEJYO F, 1985, BIOCHEM BIOPH RES CO, V129, P701, DOI 10.1016/0006-291X(85)91948-5; GEJYO F, 1986, KIDNEY INT, V30, P385, DOI 10.1038/ki.1986.196; GOLDSTEIN DE, 1986, CLIN CHEM, V32, pB64; GREENE DA, 1987, NEW ENGL J MED, V316, P599; HAMMER C, 1988, COMP BIOCHEM PHYS B, V90, P7, DOI 10.1016/0305-0491(88)90030-2; JACOBS C, 1981, P EUR DIAL TRANS, V18, P4; JEBSEN RH, 1967, NEW ENGL J MED, V277, P327, DOI 10.1056/NEJM196708172770702; KIRSTEIN M, 1990, P NATL ACAD SCI USA, V87, P9010, DOI 10.1073/pnas.87.22.9010; MAKITA Z, 1990, DIABETES S, V39, pA29; MERIMEE TJ, 1990, NEW ENGL J MED, V322, P978, DOI 10.1056/NEJM199004053221406; MONNIER VM, 1984, P NATL ACAD SCI-BIOL, V81, P583, DOI 10.1073/pnas.81.2.583; MONNIER VM, 1988, DIABETES, V37, P867, DOI 10.2337/diabetes.37.7.867; MONNIER VM, 1986, NEW ENGL J MED, V314, P403, DOI 10.1056/NEJM198602133140702; NAKAYAMA H, 1987, J IMMUNOL METHODS, V99, P95; PONGOR S, 1984, P NATL ACAD SCI-BIOL, V81, P2684, DOI 10.1073/pnas.81.9.2684; RADOFF S, 1990, DIABETES, V39, P1510, DOI 10.2337/diabetes.39.12.1510; RADOFF S, 1988, ARCH BIOCHEM BIOPHYS, V263, P418, DOI 10.1016/0003-9861(88)90654-6; RADOFF S, IN PRESS DIABETES; SELL DR, 1990, J CLIN INVEST, V85, P380, DOI 10.1172/JCI114449; VISHWANATH V, 1986, DIABETES, V35, P916, DOI 10.2337/diabetes.35.8.916; VLASSARA H, 1989, J CLIN INVEST, V84, P1813, DOI 10.1172/JCI114366; VLASSARA H, 1986, J EXP MED, V164, P1301, DOI 10.1084/jem.164.4.1301; VLASSARA H, 1985, P NATL ACAD SCI USA, V82, P5588, DOI 10.1073/pnas.82.17.5588; VLASSARA H, 1988, SCIENCE, V240, P1546, DOI 10.1126/science.3259727; WING AJ, 1986, REPLACEMENT RENAL FU, P850; WOLFF SP, 1989, MAILLARD REACTION AG, P259	38	784	805	1	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 19	1991	325	12					836	842		10.1056/NEJM199109193251202	http://dx.doi.org/10.1056/NEJM199109193251202			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF616	1875967				2022-12-01	WOS:A1991GF61600002
J	RUBIN, EM; KRAUSS, RM; SPANGLER, EA; VERSTUYFT, JG; CLIFT, SM				RUBIN, EM; KRAUSS, RM; SPANGLER, EA; VERSTUYFT, JG; CLIFT, SM			INHIBITION OF EARLY ATHEROGENESIS IN TRANSGENIC MICE BY HUMAN APOLIPOPROTEIN-A-I	NATURE			English	Article							HIGH-DENSITY-LIPOPROTEIN; DETERMINING ATHEROSCLEROSIS SUSCEPTIBILITY; CHOLESTEROL; GENE; PATHOGENESIS; DISEASE; MOUSE	EPIDEMIOLOGICAL surveys have identified a strong inverse relationship between the amount in the plasma of high density lipoproteins (HDL), apolipoprotein AI (ApoA-I), the major protein component of HDL, and the risk for atherosclerosis in humans 1,2. It is not known if this relationship arises from a direct antiatherogenic effect of these plasma components or if it is the result of other factors also associated with increases in ApoA-I and HDL levels. Because some strains of mice are susceptible to diet-induced formation of preatherosclerotic fatty streak lesions, and because of available techniques for the genetic manipulation of this organism, the murine system offers a unique setting in which to investigate the process of early atherogenesis. To test the hypothesis that induction of a high plasma concentration of ApoA-I and HDL would inhibit this process, we studied the effects of atherogenic diets on transgenic mice expressing high amounts of human ApoA-I. We report that transgenic mice with high plasma ApoA-I and HDL levels were significantly protected from the development of fatty streak lesions.	UNIV CALIF BERKELEY LAWRENCE BERKELEY LAB,DIV CELL & MOLEC BIOL,BERKELEY,CA 94720	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	RUBIN, EM (corresponding author), UNIV CALIF BERKELEY LAWRENCE BERKELEY LAB,DIV RES MED & RADIAT BIOPHYS,BERKELEY,CA 94720, USA.							BRINTON EA, 1991, J CLIN INVEST, V87, P536, DOI 10.1172/JCI115028; CHEUNG MC, 1991, J LIPID RES, V32, P383; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; ISHIDA B, 1989, GENETIC FACTORS ATHE, P198; IZZO C, 1981, CLIN CHEM, V27, P371; LEBOEUF RC, 1990, J LIPID RES, V31, P9; MCGILL HC, 1984, ARTERIOSCLEROSIS, V4, P443, DOI 10.1161/01.ATV.4.5.443; MILLER NE, 1978, LIPIDS, V13, P914, DOI 10.1007/BF02533850; MILLER NE, 1987, AM HEART J, V113, P589, DOI 10.1016/0002-8703(87)90638-7; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; NISHINA PM, 1990, J LIPID RES, V31, P859; PAIGEN B, 1989, GENETICS, V122, P163; PAIGEN B, 1987, P NATL ACAD SCI USA, V84, P3763, DOI 10.1073/pnas.84.11.3763; PAIGEN B, 1990, ARTERIOSCLEROSIS, V10, P316, DOI 10.1161/01.ATV.10.2.316; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; PATSCH J, 1983, P NATL ACAD SCI USA, V80, P1435; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; RUDEL LL, 1973, J LIPID RES, V14, P364; SORCITHOMAS M, 1988, J BIOL CHEM, V263, P5183; STEWARTPHILLIPS JL, 1989, CLIN INVEST MED, V12, P121; WALSH A, 1989, J BIOL CHEM, V264, P6488	23	862	922	0	27	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 19	1991	353	6341					265	267		10.1038/353265a0	http://dx.doi.org/10.1038/353265a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF674	1910153				2022-12-01	WOS:A1991GF67400062
J	CHAVKIN, W				CHAVKIN, W			MANDATORY TREATMENT FOR DRUG-USE DURING PREGNANCY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CIVIL COMMITMENT; INTERVENTIONS; RETENTION; ADDICTION		COLUMBIA UNIV,SCH PUBL HLTH,NEW YORK,NY 10027	Columbia University	CHAVKIN, W (corresponding author), BETH ISRAEL MED CTR,INST CHEM DEPENDENCY,1ST AVE & 16TH ST,NEW YORK,NY 10003, USA.							Allen A E, 1990, Womens Health Issues, V1, P37, DOI 10.1016/S1049-3867(05)80014-3; ANGLIN MD, 1988, RES MONOGRAPH SERIES, P8; BARRY E, 1989, HARVARD WOM LAW J, V12, P198; BENARIES O, 1986, INT J LAW PSYCHIAT, V8, P31; BESCHNER G, 1981, RES MONOGRAPH SERIES; BROWN BS, 1988, J DRUG ISSUES, V18, P663, DOI 10.1177/002204268801800410; BROWN SS, 1991, CHILDREN PARENTAL IL; CHASNOFF IJ, 1990, NEW ENGL J MED, V322, P1202, DOI 10.1056/NEJM199004263221706; Chavkin W, 1990, J Am Med Womens Assoc (1972), V45, P55; CHAVKIN W, 1990, AM J PUBLIC HEALTH, V80, P483, DOI 10.2105/AJPH.80.4.483; CHAVKIN W, 1991, J CLIN ETHICS, V1, P140; CHAVKIN W, 1991, EVALUATIVE STUDY EFF; DELEON G, 1988, RES MONOGRAPH SERIES, P160; FAMULARO R, 1989, CHILD ABUSE NEGLECT, V13, P507, DOI 10.1016/0145-2134(89)90054-9; FIZEK LS, 1988, EMPLOYEE ASSISTANCE, V4, P31; FOSTERCOOK L, 1988, RES MONOGRAPH SERIES, P99; FRANK B, 1990, CURRENT DRUG USE TRE; GERNSTEIN DR, 1990, I MED TREATING DRUG, V1; GURNACK AM, 1989, J ALCOHOL DRUG EDUC, V35, P45; HABEL L, 1988, NOV AM PUBL HLTH ASS; HATCH M, 1984, WOMENS HLTH HAZARDS, P161; HOLDEN RT, 1983, J RES CRIME DELINQ, V20, P55, DOI 10.1177/002242788302000105; HUBBARD RL, 1988, RES MONOGRAPH SERIES, P56; INCIARDI JA, 1988, RES MONOGRAPH SERIES, P126; IRUESTEMONTES AM, 1988, CHILD ABUSE NEGLECT, V12, P33, DOI 10.1016/0145-2134(88)90005-1; KOLDER VEB, 1987, NEW ENGL J MED, V316, P1192, DOI 10.1056/NEJM198705073161905; LEUKEFELD CG, 1988, RES MONOGRAPH SERIES, P236; MADDUX JF, 1988, RES MONOGRAPH SERIES, P35; MARINER WK, 1990, CRIM JUST ETHICS WIN, P30; MASI PA, 1987, EMPLOYEE ASSISTANCE, V12, P33; MCCARTY DA, 1986, J STUD ALCOHOL, V49, P1; MCNULTY M, 1987, REV LAW SOC CHANGE, V16, P277; MOISE R, 1981, INT J ADDICT, V16, P1295, DOI 10.3109/10826088109039187; MOORE KG, 1990, SUBSTANCE ABUSE PREG, P9; Moss Kary, 1990, Harv Women's Law J, V13, P278; NEWMAN RG, 1972, CONTEMP DRUG PROBL, V1, P183; NEWMAN RG, 1973, YALE REV LAW SOC ACT, V3, P246; NEWMAN RG, 1977, DRUG FORUM, V5, P1976; PALTROW L, 1989, CASE OVERVIEW ARGUME; PALTROW L, 1990, STATE STATE SUMMARY; PALTROW LM, 1990, CRIM JUST ETHICS WIN, P41; PLATT JJ, 1988, J DRUG ISSUES, V18, P505, DOI 10.1177/002204268801800402; POMPI KF, 1987, AM J DRUG ALCOHOL AB, V13, P309, DOI 10.3109/00952998709001516; PORTER L, 1986, LAW TREATMENT DRUG A; REED B, 1979, FAMILY DYNAMICS SELF, P114; ROOT MPP, 1989, AM J ORTHOPSYCHIAT, V59, P542, DOI 10.1111/j.1939-0025.1989.tb02744.x; ROSENTHAL MP, 1988, J DRUG ISSUES, V18, P641, DOI 10.1177/002204268801800409; RUBENSTEIN LS, 1986, AM J PSYCHIAT, V143, P1264; SCHOTTENFELD RS, 1989, PSYCHIATRY, V52, P164, DOI 10.1080/00332747.1989.11024441; SIMPSON D, 1988, RES MONOGRAPH SERIES, P81; WINICK C, 1988, J DRUG ISSUES, V19, P561; MASS ANNOTATED LAWS, P35; 1990, GAOHRD90138 GEN ACC; 1990, ADM901711; 1990, STATE STATE SURVEY C; 1990, WOM HLTH ISSUES  FAL, V1, P13; 1967, TASK FORCE REPORT NA; 1988, GUIDELINES IMPLEMENT; 1990, JAMA-J AM MED ASSOC, V264, P2663	59	40	40	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1991	266	11					1556	1561		10.1001/jama.266.11.1556	http://dx.doi.org/10.1001/jama.266.11.1556			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GE458	1880889				2022-12-01	WOS:A1991GE45800038
J	DALESSIO, DJ				DALESSIO, DJ			THYROXINE - TREATMENT FOR HEADACHE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											DALESSIO, DJ (corresponding author), SCRIPPS CLIN & RES FDN,LA JOLLA,CA 92037, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1991	266	11					1573	1573						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE458	1880895				2022-12-01	WOS:A1991GE45800043
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA MEDICAL BULLETIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							FDA MED B; FDA DRUG B	2	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1991	266	11					1482	1482						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE458	1880875				2022-12-01	WOS:A1991GE45800006
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PHARMACY-LINKED SYSTEMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1991	266	11					1482	1482						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE458	1880875				2022-12-01	WOS:A1991GE45800005
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW REQUIREMENTS PROPOSED FOR PANCREATIC-ENZYME PRODUCTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							FED REGISTER, V56, P32282	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1991	266	11					1482	1482						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE458	1880875				2022-12-01	WOS:A1991GE45800004
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA ADOPTS COMMON FEDERAL-POLICY FOR PROTECTION OF HUMAN-SUBJECTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							FED REGISTER, V56, P28023	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1991	266	11					1482	1482						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE458	1880875				2022-12-01	WOS:A1991GE45800003
J	PENNINGTON, BF; GILGER, JW; PAULS, D; SMITH, SA; SMITH, SD; DEFRIES, JC				PENNINGTON, BF; GILGER, JW; PAULS, D; SMITH, SA; SMITH, SD; DEFRIES, JC			EVIDENCE FOR MAJOR GENE TRANSMISSION OF DEVELOPMENTAL DYSLEXIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							READING-DISABILITY	Objective. - There is strong evidence that developmental dyslexia is both familial and heritable, but the mode of genetic transmission has remained unclear. In this article, we examine specific genetic hypotheses about the mode of transmission of developmental dyslexia by performing complex segregation analyses. Design. - A family study method was applied, whereby the relatives of dyslexic probands were examined for dyslexia. The families studied represent four independently ascertained samples. Setting. - The four samples of families were primarily from rural and suburban communities of Colorado, Washington State, and Iowa. Participants. - A total of 204 families and 1698 individuals in the four samples combined. Main Outcome Measures. - The complex segregation program, POINTER, was used to test competing genetic hypotheses of how a categorical trait (dyslexia) is transmitted in families. Results. - The results were consistent with major locus transmission in three of four samples and with polygenic transmission in the fourth. In these three samples, the estimates of penetrance for the AA, Aa, and aa genotypes (where A is the abnormal allele) were, respectively, 1.000, 1.000, and 0.001 to 0.039 in males, and 0.560 to 1.000, 0.550 to 0.897, and 0.000 in females. The estimated gene frequency of the major locus was between 3% and 5%. Conclusions. - Sex-influenced, additive, or dominant transmission occurs in a significant proportion of dyslexic families. Other evidence indicates, however, that dyslexia is etiologically heterogeneous and that there is genetic heterogeneity even among families selected for apparent dominant transmission. Thus, while no single major locus may account for all of dyslexia, it is important to pursue potential major loci for dyslexia using linkage techniques.	BOYSTOWN NATL INST COMMUN DISORDERS CHILDREN, OMAHA, NE USA; SEQUIM WASHINGTON SCH DISTRICT, SEQUIM, WA USA; YALE UNIV, SCH MED, DEPT PSYCHIAT, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT HUMAN GENET, NEW HAVEN, CT 06510 USA; UNIV COLORADO, INST BEHAV GENET, DENVER, CO 80202 USA	Yale University; Yale University; University of Colorado System; University of Colorado Denver	PENNINGTON, BF (corresponding author), UNIV DENVER, DEPT PSYCHOL, 2155 S RACE ST, DENVER, CO 80208 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH000419] Funding Source: NIH RePORTER; NIMH NIH HHS [MH00419, MH38870, MH15442] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BISGAARD ML, 1987, CLIN GENET, V32, P118; DEFRIES JC, 1987, NATURE, V329, P537, DOI 10.1038/329537a0; DeFries JC, 1991, READING BRAIN BIOL B; Dunn L. M., 1970, MANUAL PEABODY INDIV; EAVES LJ, 1983, AM J HUM GENET, V35, P1179; FINUCCI JM, 1976, ANN HUM GENET, V40, P1, DOI 10.1111/j.1469-1809.1976.tb00161.x; Fisher J. H., 1905, OPHTHALMIC REV, V24, P315; FULKER DW, 1991, READ WRIT INTERDISCI, V4, P107; GILGER J, 1991, READ WRIT, V4, P13; Gray W. S., 1963, GRAY ORAL READING TE; Hallgren B, 1950, ACTA PSYCH NEUROL SU, P1; HIERONYMOUS AN, 1986, MANUAL SCH ADM ITBS, P111; Hinshelwood J, 1911, BRIT MED J, V1911, P608, DOI 10.1136/bmj.1.2620.608; Hinshelwood J, 1907, BRIT MED J, V1907, P1229; HOLLINGSHEAD AB, 1975, 4 FACTOR INDEX SOCIA, V1; Jastak J.F., 1978, WRAT WIDE RANGE ACHI; KERR J, 1896, J R STAT SOC, V60, P613; LALOUEL JM, 1981, HUM HERED, V31, P312, DOI 10.1159/000153231; LALOUEL JM, 1983, AM J HUM GENET, V35, P816; LEFLY DL, IN PRESS ANN DYSLEXI; LEWITTER FI, 1980, BEHAV GENET, V10, P9, DOI 10.1007/BF01067316; Lindgren SD, 1986, DEV NEUROPSYCHOL, V2, P173, DOI 10.1080/87565648609540340; MCGUFFIN P, 1987, J CHILD PSYCHOL PSYC, V28, P215, DOI 10.1111/j.1469-7610.1987.tb00205.x; MCGUFFIN P, 1990, AM J HUM GENET, V46, P994; Morgan W.P., 1896, BMJ-BRIT MED J, V2, P1543, DOI [10.1136/bmj.2.1871.1378, DOI 10.1136/BMJ.2.1871.1378]; Pennington B.F., 1984, CONTINUITIES DISCONT, P123; PENNINGTON BF, 1990, J CHILD PSYCHOL PSYC, V31, P193, DOI 10.1111/j.1469-7610.1990.tb01561.x; PLOMIN R, 1989, AM PSYCHOL, V44, P105, DOI 10.1037/0003-066X.44.2.105; Raven J. C., 1938, STANDARD PROGRESSIVE; RAVEN JC, 1984, COLOURED PROGR MATRI; REICH T, 1981, GENETIC RES STRATEGI; Reiss AlbertJ JR, 1961, OCCUPATIONS SOCIAL S; Richman L. C., 1983, ADV DEV BEHAVIORAL P, V4, P87; SHAYWITZ SE, 1990, JAMA-J AM MED ASSOC, V264, P998, DOI 10.1001/jama.264.8.998; SLADEN BK, 1970, B ORTON SOC, V20, P30; SMITH SD, 1990, J AM ACAD CHILD PSY, V29, P204, DOI 10.1097/00004583-199003000-00008; SMITH SD, 1983, SCIENCE, V219, P1345, DOI 10.1126/science.6828864; SMITH SD, 1991, READ WRIT, V4, P92; Stephenson S., 1907, OPHTHALMOSCOPE, V5, P482; Thomas C. J., 1905, OPHTHALMOSCOPE, V3, P380; VOGEL SA, 1990, J LEARN DISABIL-US, V23, P44, DOI 10.1177/002221949002300111; 1980, DIAGNOSTIC STATISTIC; MANUAL TEACHERS ADM	43	150	152	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1991	266	11					1527	1534		10.1001/jama.266.11.1527	http://dx.doi.org/10.1001/jama.266.11.1527			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE458	1880884				2022-12-01	WOS:A1991GE45800033
J	SURKS, MI				SURKS, MI			THYROID-STIMULATING HORMONE - REFERENCE RANGE VALIDITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							THYROTROPIN				SURKS, MI (corresponding author), MONTEFIORE MED CTR,ALBERT EINSTEIN COLL MED,BRONX,NY 10467, USA.							CHOPRA IJ, 1990, METABOLISM, V39, P538, DOI 10.1016/0026-0495(90)90014-4; NICOLOFF JT, 1990, J CLIN ENDOCR METAB, V71, P553, DOI 10.1210/jcem-71-3-553	2	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1991	266	11					1573	1573						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE458	1880894				2022-12-01	WOS:A1991GE45800044
J	BARRETTCONNOR, E				BARRETTCONNOR, E			POSTMENOPAUSAL ESTROGEN AND PREVENTION BIAS	ANNALS OF INTERNAL MEDICINE			English	Note						ESTROGEN REPLACEMENT THERAPY; PREVENTIVE HEALTH SERVICES; HEALTH BEHAVIOR; LIPOPROTEINS, HDL CHOLESTEROL; BIAS (EPIDEMIOLOGY)	REPLACEMENT THERAPY; BREAST-CANCER; WOMEN; RISK	A mailed health survey questionnaire was returned by 1008 of 1057 (95%) previously studied older women from Rancho Bernardo, a socioeconomiclaly upper-middle-class California community where replacement estrogen use was known to be common. Women currently using estrogen had significantly healthier behaviors and more preventive services by physicians (recent cholesterol check, rectal examination, papanicolaou smear, and mammogram) than nonusers. These differences may explain some of the benefits and risks currently attributed to hormone replacement therapy.			BARRETTCONNOR, E (corresponding author), UNIV CALIF SAN DIEGO,DEPT COMMUNITY & FAMILY MED,9500 GILMAN DR,LA JOLLA,CA 92093, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL040207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG007181, R01AG007181] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 40207] Funding Source: Medline; NIA NIH HHS [AGO 7181] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; BARRETTCONNOR E, 1989, JAMA-J AM MED ASSOC, V261, P2095, DOI 10.1001/jama.261.14.2095; BARRETTCONNOR E, 1990, MENOPAUSE, P199; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; BERGKVIST L, 1989, AM J EPIDEMIOL, V130, P221, DOI 10.1093/oxfordjournals.aje.a115328; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; ERNSTER VL, 1988, PREV MED, V17, P201, DOI 10.1016/0091-7435(88)90064-3; HORWITZ RI, 1990, LANCET, V336, P542, DOI 10.1016/0140-6736(90)92095-Y; TIKKANEN MJ, 1978, LANCET, V2, P490; 1980, NEW ENGL J MED, V303, P1038	10	347	351	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	SEP 15	1991	115	6					455	456		10.7326/0003-4819-115-6-455	http://dx.doi.org/10.7326/0003-4819-115-6-455			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE810	1872493				2022-12-01	WOS:A1991GE81000007
J	BOWTON, DL; SCUDERI, PE; HARRIS, L; HAPONIK, EF				BOWTON, DL; SCUDERI, PE; HARRIS, L; HAPONIK, EF			PULSE OXIMETRY MONITORING OUTSIDE THE INTENSIVE-CARE UNIT - PROGRESS OF PROBLEM	ANNALS OF INTERNAL MEDICINE			English	Article						OXIMETRY; ANOXEMIA; RESPIRATORY THERAPY; MONITORING, PHYSIOLOGICAL; ARRHYTHMIAS	VENTRICULAR ECTOPY; OXYGEN-SATURATION; DESATURATION	Objective: To evaluate the use of continuous pulse oximetry monitoring in general care units. Design: Hemoglobin oxygen saturation data collected prospectively by use of pulse oximetry with concurrent review of the medical record. Setting: General medical-surgical nursing units in a large, tertiary care university hospital. Patients: Forty patients on two nursing units monitored with continuous, bedside pulse oximetry at the request of their primary physicians. Measurements: All patients had continuous pulse oximetry monitoring. A research associate visited the bedside two or three times daily and recorded saturation compared with time data from the previous 8.75 hours. Patients were studied for 36 hours or until pulse oximetry monitoring was discontinued. Episodes of desaturation were counted. Patient charts were reviewed for documentation of desaturation in either nursing or physician notes. Orders adjusting oxygen therapy or other respiratory therapy within 12 hours of any desaturation episode were also recorded. Main Results: Thirty of the 40 patients (75%) had at least one episode of desaturation to less than 90%; 23 (58%) had at least one episode to less than 85%. Desaturation episodes were documented in nursing notes for only 33% of those patients who desaturated to less than 90% and in physician notes in only 7% of cases. Changes in respiratory therapy were ordered in 20% of patients who desaturated to less than 90% and in only 26% who desaturated to less than 85%. Conclusions: Despite their repeated occurrence, episodes of hypoxemia were rarely documented in either nursing or physician notes. Further, even in patients who had episodic desaturation, pulse oximetry monitoring had little effect on changes in physician-directed respiratory care.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT ANESTHESIA, CRIT CARE SECT, WINSTON SALEM, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center	BOWTON, DL (corresponding author), WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT MED, PULM & CRIT CARE MED SECT, MED CTR BLVD, WINSTON SALEM, NC 27157 USA.		Bowton, David/AAZ-2916-2020					DODSON SR, 1988, CHEST, V94, P28, DOI 10.1378/chest.94.1.28; EICHHORN JH, 1986, JAMA-J AM MED ASSOC, V256, P1017; MCKAY WPS, 1988, CAN J ANAESTH, V35, P265, DOI 10.1007/BF03010621; MIHM FG, 1985, ANESTHESIOLOGY, V62, P85, DOI 10.1097/00000542-198501000-00020; NEFF TA, 1988, CHEST, V94, P227, DOI 10.1378/chest.94.2.227a; PROUGH DS, 1990, CRITICAL CARE STATE, P271; SCHNAPP LM, 1990, CHEST, V98, P1244, DOI 10.1378/chest.98.5.1244; SHEPARD JW, 1985, CHEST, V88, P335, DOI 10.1378/chest.88.3.335; SHEPARD JW, 1985, AM J MED, V78, P28, DOI 10.1016/0002-9343(85)90457-7; TRASK CH, 1962, NEW ENGL J MED, V266, P639, DOI 10.1056/NEJM196203292661303; TREMPER KK, 1989, ANESTHESIOLOGY, V70, P98, DOI 10.1097/00000542-198901000-00019; TYLER IL, 1985, ANESTH ANALG, V64, P1108	12	24	24	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1991	115	6					450	454		10.7326/0003-4819-115-6-450	http://dx.doi.org/10.7326/0003-4819-115-6-450			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE810	1872492				2022-12-01	WOS:A1991GE81000006
J	BRADLEY, SF; TERPENNING, MS; RAMSEY, MA; ZARINS, LT; JORGENSEN, KA; SOTTILE, WS; SCHABERG, DR; KAUFFMAN, CA				BRADLEY, SF; TERPENNING, MS; RAMSEY, MA; ZARINS, LT; JORGENSEN, KA; SOTTILE, WS; SCHABERG, DR; KAUFFMAN, CA			METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS - COLONIZATION AND INFECTION IN A LONG-TERM CARE FACILITY	ANNALS OF INTERNAL MEDICINE			English	Article						METHICILLIN RESISTANCE; STAPHYLOCOCCUS-AUREUS; LONG-TERM CARE; COST BENEFIT ANALYSIS; CROSS INFECTION	NURSING-HOME; NOSOCOMIAL INFECTIONS; UNITED-STATES; OUTBREAK; ERADICATION; EPIDEMIC; CARRIAGE; REHABILITATION; CIPROFLOXACIN; MUPIROCIN	Objective: To assess methicillin-resistant Staphylococcus aureus (MRSA) colonization, transmission, and infection over a 1-year period in a long-term care facility with endemic MRSA. Design: Monthly surveillance for MRSA colonization of nares, perineum, rectum, and wounds. Setting: Long-term care facility attached to an acute care Veterans Affairs medical center. Patients: All 341 patients in the facility had monthly surveillance cultures for 1 year. Outcome Measurements: Colonization and infection with MRSA. Main Results: The monthly MRSA colonization rate was 23% +/- 1.0%; colonization occurred most commonly in the nares and wounds. Poor functional status was associated with MRSA colonization. Most patients (65%) never acquired MRSA; 25% of patients were already colonized at admission to the facility or at the start of the study, and only 10% of newly admitted patients acquired MRSA while in the facility. These latter patients acquired several different strains in a pattern of acquisition similar to that generally seen within the facility. In the course of 1 year, only nine patients who acquired MRSA had a roommate with the same phage type; no clustering was evident, and none of these patients developed infection. Nine other patients (3%) developed MRSA infection; five of these patients required hospitalization, but none died as a result of infection. Conclusions: In the long-term care facility in which our study took place, MRSA was endemic, and the infection rate was low. In such settings, the cost effectiveness of aggressive management of MRSA (wide-spread screening for MRSA and eradication with antimicrobial agents) needs to be assessed.	UNIV MICHIGAN, SCH MED, ANN ARBOR, MI 48104 USA; MICHIGAN DEPT PUBL HLTH, HOUGHTON, MI 49931 USA	University of Michigan System; University of Michigan	BRADLEY, SF (corresponding author), DEPT VET AFFAIRS MED CTR, 2215 FULLER RD, ANN ARBOR, MI 48105 USA.							AEILTS GD, 1982, J CLIN MICROBIOL, V16, P218, DOI 10.1128/JCM.16.2.218-223.1982; BARTZOKAS CA, 1984, NEW ENGL J MED, V311, P1422, DOI 10.1056/NEJM198411293112207; BITAR CM, 1987, INFECT CONT HOSP EP, V8, P15, DOI 10.1017/S0195941700066935; BOYCE JM, 1982, INFECT CONT HOSP EP, V3, P377, DOI 10.1017/S0195941700057337; BOYCE JM, 1981, INFECT CONT HOSP EP, V2, P110, DOI 10.1017/S0195941700053881; BOYCE JM, 1990, INFECT CONT HOSP EP, V11, P639; CEDERNA JE, 1990, INFECT CONT HOSP EP, V11, P13, DOI 10.1086/646072; COOKSON B, 1989, J CLIN MICROBIOL, V27, P1471, DOI 10.1128/JCM.27.7.1471-1476.1989; CROSSLEY K, 1979, J INFECT DIS, V139, P280, DOI 10.1093/infdis/139.3.280; DAUM TE, 1990, ANTIMICROB AGENTS CH, V34, P1862, DOI 10.1128/AAC.34.9.1862; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; HALEY RW, 1982, ANN INTERN MED, V97, P297, DOI 10.7326/0003-4819-97-3-297; HSU CCS, 1988, ARCH INTERN MED, V148, P569, DOI 10.1001/archinte.148.3.569; KAUFFMAN CA, 1990, INFECT CONT HOSP EP, V11, P600; LINNEMANN CC, 1990, 3RD P DEC INT C NOS; MAKI DG, 1990, 3RD P DEC INT C NOS; MUDER RR, 1991, ANN INTERN MED, V114, P107, DOI 10.7326/0003-4819-114-2-1-107; MULLIGAN ME, 1987, AM J MED, V82, P215; MURRAYLEISURE KA, 1990, INFECT CONT HOSP EP, V11, P343; OTOOLE RD, 1970, J AMER MED ASSOC, V213, P257, DOI 10.1001/jama.213.2.257; PEACOCK JE, 1980, ANN INTERN MED, V93, P526, DOI 10.7326/0003-4819-93-4-526; PENINGTON GR, 1982, AUST NZ J SURG, V52, P534, DOI 10.1111/j.1445-2197.1982.tb06047.x; PREHEIM LC, 1987, INFECT CONT HOSP EP, V8, P191, DOI 10.1017/S0195941700065929; RAHMAN M, 1989, EPIDEMIOL INFECT, V102, P261, DOI 10.1017/S0950268800029939; REAGAN DR, 1991, ANN INTERN MED, V114, P101, DOI 10.7326/0003-4819-114-2-101; REBOLI AC, 1990, INFECT CONT HOSP EP, V11, P291, DOI 10.1086/646174; REBOLI AC, 1989, AM J DIS CHILD, V143, P34, DOI 10.1001/archpedi.1989.02150130044013; RUTALA WA, 1983, J CLIN MICROBIOL, V18, P683, DOI 10.1128/JCM.18.3.683-688.1983; SMITH PB, 1972, STAPHYLOCOCCI, P431; STORCH GA, 1987, INFECT CONT HOSP EP, V8, P24, DOI 10.1017/S0195941700066947; STRAUSBAUGH LJ, 1991, INFECT CONT HOSP EP, V12, P36, DOI 10.2307/30147087; THOMAS JC, 1989, INFECT CONT HOSP EP, V10, P106, DOI 10.1086/645976; THOMPSON RL, 1982, ANN INTERN MED, V97, P309, DOI 10.7326/0003-4819-97-3-309; THORNSBERRY C, 1983, J CLIN MICROBIOL, V18, P1084, DOI 10.1128/JCM.18.5.1084-1091.1983; WARD TT, 1981, INFECT CONT HOSP EP, V2, P453, DOI 10.1017/S0195941700055715; YU VL, 1986, NEW ENGL J MED, V315, P91, DOI 10.1056/NEJM198607103150204	36	243	246	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1991	115	6					417	422		10.7326/0003-4819-115-6-417	http://dx.doi.org/10.7326/0003-4819-115-6-417			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE810	1908198				2022-12-01	WOS:A1991GE81000001
J	CULPEPPER, RC; WILLIAMS, RG; MEASE, PJ; KOEPSELL, TD; KOBAYASHI, JM				CULPEPPER, RC; WILLIAMS, RG; MEASE, PJ; KOEPSELL, TD; KOBAYASHI, JM			NATURAL-HISTORY OF THE EOSINOPHILIA-MYALGIA-SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article						EOSINOPHILIA; MUSCULAR DISEASES; TRYPTOPHAN; FATIGUE; PREDNISONE	TOXIC OIL SYNDROME; TRYPTOPHAN; SCLERODERMA; INGESTION; FASCIITIS; FEATURES	Objective: To describe the natural history and disease progression of the eosinophilia-myalgia syndrome and to assess the therapeutic effects of orally administered steroids on the disorder as of October 1990. Design: Case-series analysis. A cohort of 45 patients with the eosinophilia-myalgia syndrome was followed prospectively by periodic telephone interviews and medical examinations for an average of 14 months after onset of illness. Setting: Washington state. Patients: The cases of 47 patients were reported to the Washington State Department of Health from 1 July to 12 December 1989. Two patients were unavailable for follow-up, and the remaining 45 completed the study. Main Results: Patients were predominantly non-Hispanic white women (87%) with an average age of 49 years. Symptoms typically progressed from early onset of myalgia and fatigue to later development of neurologic and scleroderma-like skin changes. Six (13%) patients recovered completely within 2 to 5 months of symptom onset. After 14 months of illness, over half of the patients who initially presented with myalgia, fatigue, or scleroderma-like skin changes remained symptomatic. The average severity of each major symptom was measured using interviews and patient self-reports and has improved subjectively by at least 40%. Statistical analyses showed no significant difference in long-term symptom duration or severity between patients treated and those not treated with prednisone. Conclusions: The eosinophilia-myalgia syndrome is a long-term illness characterized by progressive improvement during the first 25 weeks after symptom onset, followed by a protracted phase of symptom resolution. We could not show a clear-cut benefit of prednisone in reducing the long-term severity or duration of the disease.	UNIV WASHINGTON, SCH PUBL HLTH & COMMUNITY MED, SEATTLE, WA 98195 USA; MADIGAN ARMY MED CTR, TACOMA, WA 98431 USA; MINOR & JAMES MED CLIN, SEATTLE, WA 98104 USA; WASHINGTON STATE DEPT HLTH, SEATTLE, WA 98155 USA	University of Washington; University of Washington Seattle; Madigan Army Medical Center								ALONSORUIZ A, 1986, SEMIN ARTHRITIS RHEU, V15, P200, DOI 10.1016/0049-0172(86)90017-X; BELONGIA EA, 1990, NEW ENGL J MED, V323, P357, DOI 10.1056/NEJM199008093230601; CALLAHAN LF, 1987, ARTHRITIS RHEUM, V30, P630, DOI 10.1002/art.1780300605; CLAUW DJ, 1990, JAMA-J AM MED ASSOC, V263, P1502; FLANNERY MT, 1990, ANN INTERN MED, V112, P300, DOI 10.7326/0003-4819-112-4-300; HERTZMAN PA, 1990, NEW ENGL J MED, V322, P869, DOI 10.1056/NEJM199003293221301; KAUFMAN LD, 1991, LANCET, V337, P1071, DOI 10.1016/0140-6736(91)91717-9; KILBOURNE EM, 1990, ANN INTERN MED, V112, P85, DOI 10.7326/0003-4819-112-2-85; KILBOURNE EM, 1988, AM J EPIDEMIOL, V127, P1210, DOI 10.1093/oxfordjournals.aje.a114914; MARTIN RW, 1990, ANN INTERN MED, V113, P124, DOI 10.7326/0003-4819-113-2-124; MAYENO AN, 1990, SCIENCE, V250, P1707, DOI 10.1126/science.2270484; MEDSGER TA, 1990, NEW ENGL J MED, V322, P926, DOI 10.1056/NEJM199003293221309; MINDEL A, 1982, LANCET, V1, P697; PHILEN RM, 1991, ARCH INTERN MED, V151, P533, DOI 10.1001/archinte.151.3.533; SILVER RM, 1990, NEW ENGL J MED, V322, P874, DOI 10.1056/NEJM199003293221302; SLUTSKER L, 1990, JAMA-J AM MED ASSOC, V264, P213, DOI 10.1001/jama.264.2.213; STERNBERG EM, 1980, NEW ENGL J MED, V303, P782, DOI 10.1056/NEJM198010023031403; SWYGERT LA, 1990, JAMA-J AM MED ASSOC, V264, P1698, DOI 10.1001/jama.264.13.1698; VARGA J, 1990, ANN INTERN MED, V112, P344, DOI 10.7326/0003-4819-112-5-344; 1990, SPSS REFERENCE GUIDE, P687; 1990, MMWR, V39, P89; 1990, MMWR, V39, P14; 1990, MMWR, V38, P327; 1989, MMWR, V38, P785; 1989, MMWR, V38, P765	25	43	43	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1991	115	6					437	442		10.7326/0003-4819-115-6-437	http://dx.doi.org/10.7326/0003-4819-115-6-437			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE810	1651673				2022-12-01	WOS:A1991GE81000004
J	ESTEBAN, JI; LOPEZTALAVERA, JC; GENESCA, J; MADOZ, P; VILADOMIU, L; MUNIZ, E; MARTINVEGA, C; ROSELL, M; ALLENDE, H; VIDAL, X; GONZALEZ, A; HERNANDEZ, JM; ESTEBAN, R; GUARDIA, J				ESTEBAN, JI; LOPEZTALAVERA, JC; GENESCA, J; MADOZ, P; VILADOMIU, L; MUNIZ, E; MARTINVEGA, C; ROSELL, M; ALLENDE, H; VIDAL, X; GONZALEZ, A; HERNANDEZ, JM; ESTEBAN, R; GUARDIA, J			HIGH-RATE OF INFECTIVITY AND LIVER-DISEASE IN BLOOD-DONORS WITH ANTIBODIES TO HEPATITIS-C VIRUS	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS, CHRONIC ACTIVE; HEPATITIS-C VIRUS; LIVER CIRRHOSIS; BLOOD DONORS; HEPATITIS ANTIBODIES	NON-B-HEPATITIS; NON-A-HEPATITIS; HEPATOCELLULAR-CARCINOMA; VIRAL SEQUENCES; FRACTIONATION; PLASMA	Objective: To determine the epidemiologic, clinical, serologic, and histologic importance of antibodies to hepatitis C virus (anti-HCV) in blood donors. Design: Cross-sectional identification and prospective evaluation of seropositive donors; retrospective assessment of infectivity; and nested case-control study for risk factors. Setting: Liver unit of a referral-based university hospital. Subjects: Of 30 231 consecutive donors, 368 (1.2%) were found to be anti-HCV-reactive by enzyme-linked immunosorbent assay (ELISA). Two hundred and fifty-four of these 368 donors were evaluated for risk factors by comparison with 284 age- and sex-matched controls. Eighty-six spouses of seropositive donors were also evaluated. Measurements and Main Results: Twenty-four percent of the seropositive donors had a history of percutaneous exposure to blood. This rate increased to 45% when only those donors confirmed to be anti-HCV positive by a second-generation recombinant immunoblot assay (RIBA-2) were considered. A family history of liver disease (odds ratio, 2.8; 95% Cl, 1.6 to 4.8), previous blood transfusion (odds ratio, 6.1; 95% Cl, 3 to 12.5), and a history of tattooing or intravenous drug abuse (odds ratio, 8.4; 95% Cl, 2.3 to 31) were associated with anti-HCV seropositivity. An elevated alanine aminotransferase (ALT) level was found in 58% of the seropositive donors. Of the 150 donors tested, 104 (69%; Cl, 62% to 77%) were confirmed by RIBA-2 to be anti-HCV positive. Of the 105 donors who had a biopsy, 16% had normal histologic findings, 11% had minimal changes, 21% had chronic persistent hepatitis, 45% had chronic active hepatitis, and 7% had active cirrhosis. All 77 donors with RIBA-2-confirmed seropositivity had histologic abnormalities. Of 43 donors evaluated in an infectivity study, 82% were implicated in previous HCV transmission. Only 2.3% of the spouses were anti-HCV positive. The ELISA, RIBA-2, and ALT results correlated with infectivity and abnormal histologic findings. Conclusions: In our geographic area, almost 70% of donors who are anti-HCV positive by ELISA are confirmed to be positive by RIBA-2; most of these donors appear to be chronic carriers of HCV and have substantial liver disease.	HOSP SANTA CRUZ & SAN PABLO, BLOOD BANK, E-08025 BARCELONA, SPAIN; HOSP GEN UNIV VALL HEBRON, INST CATALA SALUT, BLOOD BANK, E-08035 BARCELONA, SPAIN; HOSP GEN UNIV VALL HEBRON, DEPT PATHOL, E-08035 BARCELONA, SPAIN; HOSP GEN UNIV VALL HEBRON, DEPT CLIN PHARMACOL, E-08035 BARCELONA, SPAIN; HOSP GEN UNIV VALL HEBRON, DEPT MED, HEMATOL HEMOTHERAPY SERV, E-08035 BARCELONA, SPAIN	Fundacio Banc Sang Teixits de les Illes Balears; Fundacio Banc Sang Teixits de les Illes Balears; Hospital Universitari Vall d'Hebron; Hospital Universitari Vall d'Hebron; Hospital Universitari Vall d'Hebron; Hospital Universitari Vall d'Hebron	ESTEBAN, JI (corresponding author), HOSP GEN UNIV VALL HEBRON, DEPT MED, LIVER UNIT, PASSEIG VALL HEBRON S-N, E-08035 BARCELONA, SPAIN.		Vidal, Xavier/I-5958-2019; Genesca, Joan/H-7467-2019	Vidal, Xavier/0000-0001-6705-4298; Genesca, Joan/0000-0002-0831-8422; Viladomiu, Lluis/0000-0002-3434-9847; esteban, rafael/0000-0001-5280-392X				ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; BRUIX J, 1989, LANCET, V2, P1004; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; FINLAYSON JS, 1990, LANCET, V335, P1274, DOI 10.1016/0140-6736(90)91335-8; FORTUNY C, 1991, VIRAL HEPATITIS LIVE; GARSON JA, 1990, LANCET, V335, P1419, DOI 10.1016/0140-6736(90)91446-H; GIOVANNINI M, 1990, LANCET, V335, P1166, DOI 10.1016/0140-6736(90)91174-9; HABIBI B, 1990, LANCET, V335, P855, DOI 10.1016/0140-6736(90)90968-B; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; QUAN S, 1990, 2ND P INT S HCV LOS; VANDERPOEL CL, 1990, LANCET, V335, P558, DOI 10.1016/0140-6736(90)90347-8; VARGAS V, 1990, ANN INTERN MED, V112, P232, DOI 10.7326/0003-4819-112-3-232_2; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q; [No title captured]; 1989, 1ST P INT S HEP C VI, P25; 1989, 1ST P INT S HEP C VI, P9	18	314	316	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1991	115	6					443	449		10.7326/0003-4819-115-6-443	http://dx.doi.org/10.7326/0003-4819-115-6-443			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE810	1651674				2022-12-01	WOS:A1991GE81000005
J	FARR, BM; SLOMAN, AJ; FISCH, MJ				FARR, BM; SLOMAN, AJ; FISCH, MJ			PREDICTING DEATH IN PATIENTS HOSPITALIZED FOR COMMUNITY-ACQUIRED PNEUMONIA	ANNALS OF INTERNAL MEDICINE			English	Article						PNEUMONIA; TRIAGE; PROGNOSTIC FACTORS; HYPOTENSION; TACHYPNEA PNEUMONIA	INTENSIVE-CARE UNIT; PNEUMOCOCCAL BACTEREMIA; LOBAR PNEUMONIA; MORTALITY; DISEASE; FAILURE; INFECTIONS; ETIOLOGY; FEATURES; SURVIVAL	Objective: To validate a previously reported discriminant rule for predicting mortality in adult patients with primary community-acquired pneumonia and to determine which factors available at hospital admission predict a fatal outcome among such patients. Design: Historical cohort study. Setting: University hospital. Patients: Adults admitted to the hospital for community-acquired pneumonia. Measurements: Using stepwise logistic regression, we analyzed prognostic factors (data available at admission and recorded in the medical record) that showed a univariate association with mortality. The predictive values of three discriminant rules were measured to validate the results of a previous study. Main Results: Of 245 patients, 20 (8.2%) died. Of 42 prognostic factors identified in previous studies, 8 were associated with mortality, but only a respiratory rate of 30/min or more, a diastolic blood pressure of 60 mm Hg or less, and a blood urea nitrogen of more than 7 mmol/L remained predictive in the multivariate analysis. A discriminant rule composed of these three variables was 70% sensitive and 84% specific in predicting mortality, yielding an overall accuracy of 82%. Conclusion: Tachypnea, diastolic hypotension, and an elevated blood urea nitrogen were independently associated with death from pneumonia in our study, confirming the value of a previously reported discriminant rule from the British Thoracic Society. This rule may be useful in triage decisions because it identifies high-risk patients who may benefit from special medical attention.			FARR, BM (corresponding author), UNIV VIRGINIA, HLTH SCI CTR, BOX 473, CHARLOTTESVILLE, VA 22908 USA.							ALLEN SC, 1984, THORAX, V39, P612, DOI 10.1136/thx.39.8.612; ANDREWS BE, 1987, Q J MED, V62, P195; ANDREWS J, 1984, GERONTOLOGY, V30, P290, DOI 10.1159/000212648; AUSTRIAN R, 1964, ANN INTERN MED, V60, P759, DOI 10.7326/0003-4819-60-5-759; BANKS RA, 1984, BRIT J DIS CHEST, V78, P352; BENSON H, 1970, J CLIN INVEST, V49, P791, DOI 10.1172/JCI106292; BILLE J, 1980, PNEUMONIA PNEUMONOCO; BISNO AL, 1971, AM J MED SCI, V261, P251, DOI 10.1097/00000441-197105000-00004; BURNS MW, 1976, MED J AUSTRALIA, V2, P787, DOI 10.5694/j.1326-5377.1976.tb115356.x; CALDER MA, 1970, LANCET, V1, P5; CROFTON J, 1981, RESPIRATORY DISEASES, P190; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; DORFF GJ, 1973, AM J MED SCI, V266, P349, DOI 10.1097/00000441-197311000-00002; EBRIGHT JR, 1980, J AM GERIATR SOC, V28, P220, DOI 10.1111/j.1532-5415.1980.tb00523.x; ESPOSITO AL, 1984, ARCH INTERN MED, V144, P945, DOI 10.1001/archinte.144.5.945; FEDULLO AJ, 1985, J GERONTOL, V40, P29, DOI 10.1093/geronj/40.1.29; FEKETY RF, 1971, AM REV RESPIR DIS, V104, P499; FELDMAN C, 1989, S AFR MED J, V76, P593; FINE MJ, 1990, AM J MED, V88, pN1; FLETCHER RH, 1988, CLIN EPIDEMIOLOGY ES, P61; GOLD MI, 1974, CHEST, V65, P388, DOI 10.1378/chest.65.4.388; GRANSDEN WR, 1985, BRIT MED J, V290, P505, DOI 10.1136/bmj.290.6467.505; HOLLAND WW, 1960, BMJ-BRIT MED J, V1, P1917, DOI 10.1136/bmj.1.5190.1917; HOOK EW, 1983, JAMA-J AM MED ASSOC, V249, P1055, DOI 10.1001/jama.249.8.1055; LOURIA DB, 1959, J CLIN INVEST, V38, P213, DOI 10.1172/JCI103789; MACFARLANE JT, 1982, LANCET, V2, P255; MACFARLANE JT, 1983, THORAX, V38, P231; MARRIE TJ, 1985, J AM GERIATR SOC, V33, P671, DOI 10.1111/j.1532-5415.1985.tb01775.x; MARRIE TJ, 1988, CLIN INVEST MED, V11, P10; MCNABB WR, 1984, J ROY SOC MED, V77, P550, DOI 10.1177/014107688407700705; MOORE MA, 1977, JOHNS HOPKINS MED J, V140, P9; MUFSON MA, 1967, AM J EPIDEMIOL, V86, P526, DOI 10.1093/oxfordjournals.aje.a120763; MUFSON MA, 1982, JAMA-J AM MED ASSOC, V248, P1486, DOI 10.1001/jama.248.12.1486; MUFSON MA, 1974, ARCH INTERN MED, V134, P505, DOI 10.1001/archinte.134.3.505; ORTQVIST A, 1985, SCAND J INFECT DIS, V17, P377; POTGIETER PD, 1985, CRIT CARE MED, V13, P798, DOI 10.1097/00003246-198510000-00005; ROBERTSON L, 1958, LANCET, V2, P233; ROGERS RM, 1972, CHEST, V62, P94, DOI 10.1378/chest.62.1.94; SPENCER RC, 1976, J CLIN PATHOL, V29, P187, DOI 10.1136/jcp.29.3.187; STARCZEWSKI AR, 1988, AGE AGEING, V17, P181, DOI 10.1093/ageing/17.3.181; SULLIVAN RJ, 1972, ARCH INTERN MED, V129, P935, DOI 10.1001/archinte.129.6.935; VALENTI WM, 1978, AM REV RESPIR DIS, V117, P233; WHITE RJ, 1981, THORAX, V36, P566, DOI 10.1136/thx.36.8.566; WOODHEAD MA, 1985, J INFECTION, V10, P204, DOI 10.1016/S0163-4453(85)92463-6; [No title captured]; 1989, VITAL HLTH STATIS 13, V99	47	225	227	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1991	115	6					428	436		10.7326/0003-4819-115-6-428	http://dx.doi.org/10.7326/0003-4819-115-6-428			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE810	1872491				2022-12-01	WOS:A1991GE81000003
J	TUNICK, PA; PEREZ, JL; KRONZON, I				TUNICK, PA; PEREZ, JL; KRONZON, I			PROTRUDING ATHEROMAS IN THE THORACIC AORTA AND SYSTEMIC EMBOLIZATION	ANNALS OF INTERNAL MEDICINE			English	Article						ATHEROSCLEROSIS; AORTA, THORACIC; ECHOCARDIOGRAPHY; CEREBROVASCULAR DISORDERS; CEREBRAL ISCHEMIA, TRANSIENT	TRANSESOPHAGEAL ECHOCARDIOGRAPHY; STROKE; ARCH	Objective: To determine whether protruding atheromas in the thoracic aorta are a risk factor for systemic embolization. Design: Case-control study. Setting: A referral hospital. Patients: A total of 122 patients with a history of stroke, transient ischemic attack, or peripheral emboli and an equal number of age- and sex-matched control patients. Measurements: Evaluation using transesophageal echocardiography was done in case patients to detect protruding atheromas in the thoracic aorta and in control patients for cardiac indications other than emboli. Main Results: Matched logistic regression showed that the presence of protruding atheromas was strongly related to the occurrence of embolic symptoms (odds ratio, 3.2; 95% Cl, 1.6 to 6.5; P < 0.001). Furthermore, atheromas with mobile components were present only in case patients. When known risk factors for stroke (hypertension and diabetes) were added to the model, the presence of protruding atheromas remained an independent risk factor for embolic symptoms (odds ratio, 3.8). Hypertension was also independently associated with embolic symptoms (odds ratio, 2.7), but diabetes was not (odds ratio, 1.0). Conclusion: Protruding atheromas in the thoracic aorta can be detected by transesophageal echocardiography and should be considered as a cause of strokes, transient ischemic attacks, and peripheral emboli.			TUNICK, PA (corresponding author), NYU MED CTR, 560 1ST AVE, SUITE 2-E, NEW YORK, NY 10016 USA.							CULLIFORD AT, 1986, ANN THORAC SURG, V41, P27, DOI 10.1016/S0003-4975(10)64492-X; DANIEL W G, 1989, European Heart Journal, V10, P204; DANIEL WG, 1991, CIRCULATION, V83, P817, DOI 10.1161/01.CIR.83.3.817; DIXON WJ, 1985, BMDP STATISTICAL SOF; Fletcher RH, 1988, CLIN EPIDEMIOLOGY ES, V2nd; GOOD DC, 1986, STROKE, V17, P6, DOI 10.1161/01.STR.17.1.6; GUSSENHOVEN WJ, 1988, EUR HEART J SUPPL, V9, P1572; KARALIS DG, 1991, J AM COLL CARDIOL, V17, P73, DOI 10.1016/0735-1097(91)90706-F; LE CT, 1988, COMPUT BIOMED RES, V21, P48, DOI 10.1016/0010-4809(88)90041-9; PEARSON AC, 1991, J AM COLL CARDIOL, V17, P66, DOI 10.1016/0735-1097(91)90705-E; POP G, 1990, STROKE, V21, P560, DOI 10.1161/01.STR.21.4.560; TUNICK PA, 1991, ANN INTERN MED, V114, P391, DOI 10.7326/0003-4819-114-5-391; TUNICK PA, 1990, AM HEART J, V120, P658, DOI 10.1016/0002-8703(90)90024-R; WOLF PA, 1981, JAMA-J AM MED ASSOC, V245, P1442, DOI 10.1001/jama.245.14.1442; YOUNG W, 1960, AM J CARDIOL, V6, P300, DOI 10.1016/0002-9149(60)90319-2; ZENKER G, 1988, STROKE, V19, P345, DOI 10.1161/01.STR.19.3.345	16	266	270	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1991	115	6					423	427		10.7326/0003-4819-115-6-423	http://dx.doi.org/10.7326/0003-4819-115-6-423			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE810	1872490				2022-12-01	WOS:A1991GE81000002
J	BRIGGS, DC; VAUGHAN, RW; WELSH, KI; MYERS, A; DUBOIS, RM; BLACK, CM				BRIGGS, DC; VAUGHAN, RW; WELSH, KI; MYERS, A; DUBOIS, RM; BLACK, CM			IMMUNOGENETIC PREDICTION OF PULMONARY FIBROSIS IN SYSTEMIC-SCLEROSIS	LANCET			English	Note							CLINICAL CORRELATIONS; ANTIGENS	75 systemic sclerosis patients were independently tested for pulmonary fibrosis, autoantibodies, and MHC class II genes. 24 of 42 (57%) patients with pulmonary fibrosis had either HLA DR3/DRw52a or anti-Scl-70 vs 2 of 33 (6%) patients without pulmonary fibrosis. The presence of DR3/DRw52a or anti-Scl-70 gives a relative risk of 16.7 for the development of pulmonary fibrosis in a patient with scleroderma-a risk substantial enough to require careful monitoring of these patients and treatment at an early stage of disease.	TEMPLE UNIV,HLTH SCI CTR,PHILADELPHIA,PA 19140; ROYAL BROMPTON HOSP,DEPT THORAC MED,LONDON,ENGLAND; ROYAL FREE HOSP,DEPT RHEUMATOL,LONDON,ENGLAND	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Royal Brompton Hospital; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	BRIGGS, DC (corresponding author), GUYS HOSP,DEPT IMMUNOGENET,TISSUE TYPING LAB,ST THOMAS ST,LONDON SE1 9RT,ENGLAND.			Briggs, David/0000-0002-6796-7086				BIDWELL J, 1988, IMMUNOL TODAY, V9, P18, DOI 10.1016/0167-5699(88)91351-5; CATOGGIO LJ, 1983, ANN RHEUM DIS, V42, P23, DOI 10.1136/ard.42.1.23; HARRISON NK, 1989, RESPIR MED, V83, P404; LEROY EC, 1988, J RHEUMATOL, V15, P202; LYNCH CJ, 1982, J CLIN IMMUNOL, V2, P314, DOI 10.1007/BF00915073; STEEN VD, 1988, ARTHRITIS RHEUM, V31, P196, DOI 10.1002/art.1780310207; TURNERWARWICK M, 1980, THORAX, V35, P171, DOI 10.1136/thx.35.3.171; WEINER ES, 1990, ARTHRITIS RHEUM, V34, P68	8	112	114	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 14	1991	338	8768					661	662		10.1016/0140-6736(91)91235-M	http://dx.doi.org/10.1016/0140-6736(91)91235-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF105	1679476				2022-12-01	WOS:A1991GF10500006
J	CASH, JD				CASH, JD			HIGH POTENCY FACTOR-VIII CONCENTRATES - VALUE NOT PROVED	BRITISH MEDICAL JOURNAL			English	Article											CASH, JD (corresponding author), SCOTTISH NATL BLOOD TRANSFUS SERV,HEADQUARTERS MED UNIT,EDINBURGH EH1 1JH,SCOTLAND.							BELL BA, 1990, LANCET, V336, P638, DOI 10.1016/0140-6736(90)93444-T; BURNOUF T, 1991, VOX SANG, V60, P8, DOI 10.1111/j.1423-0410.1991.tb00864.x; CASH JD, 1988, LANCET, V1, P1270; CASH JD, 1991, BRIT MED J, V302, P849, DOI 10.1136/bmj.302.6780.849-b; KESSLER GM, 1990, LANCET, V335, P1403; MONTORO JB, 1991, LANCET, V338, P1222	6	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1991	303	6803					633	634		10.1136/bmj.303.6803.633	http://dx.doi.org/10.1136/bmj.303.6803.633			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF675	1932909	Green Published, Bronze			2022-12-01	WOS:A1991GF67500029
J	DENNIS, M; WARLOW, C				DENNIS, M; WARLOW, C			THE HEALTH OF THE NATION - RESPONSES - STRATEGY FOR STROKE	BRITISH MEDICAL JOURNAL			English	Article							DISEASE; MORTALITY; TRENDS				DENNIS, M (corresponding author), WESTERN GEN HOSP,DEPT CLIN NEUROSCI,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							BALARAJAN R, 1991, BMJ-BRIT MED J, V302, P560, DOI 10.1136/bmj.302.6776.560; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BONITA R, 1986, BRIT MED J, V292, P191, DOI 10.1136/bmj.292.6514.191; BONITA R, 1990, STROKE, V21, P989, DOI 10.1161/01.STR.21.7.989; CAMERON HM, 1981, J PATHOL, V133, P273, DOI 10.1002/path.1711330402; CARSTAIRS V R M, 1990, Health Bulletin (Edinburgh), V48, P162; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; ISARD P, IN PRESS DISEASES; LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819; MALMGREN R, 1987, LANCET, V2, P1196; ROSE G, 1981, BMJ-BRIT MED J, V282, P1847, DOI 10.1136/bmj.282.6279.1847; SHINTON R, 1989, BMJ-BRIT MED J, V298, P789, DOI 10.1136/bmj.298.6676.789; 1991, LANCET, V337, P1235; 1988, BMJ, V297, P126; 1988, PREVALENCE DISABILIT; 1988, BMJ, V296, P320; 1991, CM1523; 1991, BMJ, V302, P1057	18	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1991	303	6803					636	638		10.1136/bmj.303.6803.636	http://dx.doi.org/10.1136/bmj.303.6803.636			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GF675	1932911	Green Published			2022-12-01	WOS:A1991GF67500031
J	EGGER, M; SMITH, GD; IMHOOF, H; TEUSCHER, A				EGGER, M; SMITH, GD; IMHOOF, H; TEUSCHER, A			RISK OF SEVERE HYPOGLYCEMIA IN INSULIN TREATED DIABETIC-PATIENTS TRANSFERRED TO HUMAN INSULIN - A CASE CONTROL STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RARE DISEASE ASSUMPTION; PORCINE INSULIN; HYPOGLYCEMIA UNAWARENESS; AWARENESS	Objective - To examine whether transfer from animal insulin to human insulin is associated with an increased risk of severe hypoglycaemia. Design - Matched case-control study of insulin treated diabetic patients admitted to hospital because of hypoglycaemia during 1984-7, the period when human insulin was introduced into treatment. Setting - Case admissions and control admissions were obtained from eight public hospitals within the Swiss canton of Berne and a second control group comprised members of the Bernese section of the Swiss Diabetes Association. Subjects - 94 patients with insulin treated diabetes with a total of 112 admissions for hypoglycaemia during 1984-7 (case admissions), 182 patients with insulin treated diabetes seen in the same hospitals for reasons other than hypoglycaemia with a total of 225 admissions (control admissions), and 86 insulin treated diabetic patients who were members of the Bernese section of the Swiss Diabetes Association. Main outcome measures - Type of insulin used at time of admission, glycaemic control as measured by amount of glycated haemoglobin or glucose concentration; severity of hypoglycaemia. Results - Treatment with human insulin at admission was more common in cases than controls (52/112 (46%) admissions v 77/225 (34%); p = 0.003). 116 out of 129 (90%) of admissions taking human insulin had been transferred from animal insulin, mainly because of non-availability of porcine insulins. The ratio of rate of hypoglycaemia in those taking human insulin to the rate in those taking animal insulin was 2.4 (95% confidence interval 1.3 to 4.4). Other risk factors for hypoglycaemia were a history of hypoglycaemic coma (rate ratio of history to no history 3.8, 2.3 to 6.4) and good glycaemic control (rate ratio of good to poor control 3.9, 1.4 to 7.5). With multivariate analysis the increase in rate ratio associated with use of human insulin rose to 3.0 (1.4 to 6.4). Comparison with the diabetes association controls also showed an increased risk associated with use of human insulin (2.2; 1.1 to 4.8). Conclusions - Transfer of treatment from animal insulin to human insulin was associated with an increased risk of severe hypoglycaemia. Caution should be exercised when transferring diabetic patients to human insulin. Further studies are required to elucidate why this effect occurs,	UNIV BERN, DEPT MED, DIABET SECT, CH-3000 BERN, SWITZERLAND; UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT SCI, LONDON WC1E 7HT, ENGLAND	University of Bern; University of London; London School of Hygiene & Tropical Medicine			Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314; Egger, Matthias/0000-0001-7462-5132				BERGER W, 1989, LANCET, V1, P1041, DOI 10.1016/S0140-6736(89)92444-6; BERGER WG, 1987, DIABETES CARE, V10, P260, DOI 10.2337/diacare.10.2.260; CASPARIE AF, 1985, DIABETES CARE, V8, P141, DOI 10.2337/diacare.8.2.141; CLARK AJL, 1982, LANCET, V2, P354; CRYER PE, 1990, DIABETES CARE, V13, P536, DOI 10.2337/diacare.13.5.536; DCCT Res Grp, 1987, DIABETES CARE, V10, P1; DCCT Res Grp, 1990, DIABETES CARE, V13, P427; EGGER M, 1988, DIABETOLOGIA, V31, P453, DOI 10.1007/BF00271592; EGGER M, 1991, BMJ-BRIT MED J, V303, P622, DOI 10.1136/bmj.303.6803.622; GORDEN P, 1990, NEW ENGL J MED, V322, P1007; GREENLAND S, 1982, AM J EPIDEMIOL, V116, P547, DOI 10.1093/oxfordjournals.aje.a113439; HEINE RJ, 1989, LANCET, V2, P946; HEPBURN DA, 1989, DIABETIC MED, V6, P586, DOI 10.1111/j.1464-5491.1989.tb01233.x; Home P D, 1984, Diabet Med, V1, P93; Hosmer D, 2013, APPL LOGISTIC REGRES; NIULSSON A, 1988, ACTA MED SCAND, V224, P257; PEACOCK I, 1983, LANCET, V1, P149; PHILLIPS AN, IN PRESS J CLIN EPID; POTTER J, 1982, BRIT MED J, V285, P1180, DOI 10.1136/bmj.285.6349.1180; RIFKIN H, 1988, PHYSICIANS GUIDE NON; RODRIGUES L, 1990, INT J EPIDEMIOL, V19, P205, DOI 10.1093/ije/19.1.205; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; SCHLESSELMAN JJ, 1974, AM J EPIDEMIOL, V99, P381, DOI 10.1093/oxfordjournals.aje.a121625; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P257, DOI 10.1136/jech.44.4.257; STEPHENSON J, 1990, LANCET, V335, P661, DOI 10.1016/0140-6736(90)90448-E; TEUSCHER A, 1987, LANCET, V2, P382; 1983, PROJEKTBESCHRIEB DIA; 1986, BMJ, V292, P155	28	48	48	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 14	1991	303	6803					617	621		10.1136/bmj.303.6803.617	http://dx.doi.org/10.1136/bmj.303.6803.617			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF675	1932902	Green Published, Bronze			2022-12-01	WOS:A1991GF67500022
J	GATELEY, CA; MADDOX, PR; MANSEL, RE				GATELEY, CA; MADDOX, PR; MANSEL, RE			PNEUMOTHORAX - A COMPLICATION OF FINE NEEDLE ASPIRATION OF THE BREAST	BRITISH MEDICAL JOURNAL			English	Article									UNIV HOSP S MANCHESTER,DEPT SURG,MANCHESTER M20 8LR,LANCS,ENGLAND; UNIV WALES COLL MED,DEPT SURG,CARDIFF CF4 4XN,S GLAM,WALES	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Cardiff University								BEVELAQUA FA, 1982, CHEST, V81, P693, DOI 10.1378/chest.81.6.693; DIXON JM, 1984, BRIT J SURG, V71, P593, DOI 10.1002/bjs.1800710809; DIXON JM, 1991, BRIT MED J, V302, P428, DOI 10.1136/bmj.302.6774.428; LEAHY BC, 1986, MED INT, V35, P1446; THOMPSON AM, 1988, J HAND SURG-BRIT EUR, V13B, P195, DOI 10.1016/0266-7681(88)90137-4	5	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1991	303	6803					627	628		10.1136/bmj.303.6803.627	http://dx.doi.org/10.1136/bmj.303.6803.627			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF675	1932905	Green Published, Bronze			2022-12-01	WOS:A1991GF67500025
J	HAYWOOD, GA; JOY, MD; CAMM, AJ				HAYWOOD, GA; JOY, MD; CAMM, AJ			INFLUENCE OF POSTURE AND REFERENCE POINT ON CENTRAL VENOUS-PRESSURE MEASUREMENT	BRITISH MEDICAL JOURNAL			English	Article									ST GEORGE HOSP,SCH MED,LONDON SW17 0RE,ENGLAND; ST PETERS HOSP,CHERTSEY KT16 0PZ,SURREY,ENGLAND	St Georges University London								Blomqvist CG., 1983, COMPR PHYSIOL, V3, P1025, DOI DOI 10.1002/CPHY.CP020328; SYKES M K, 1963, Ann R Coll Surg Engl, V33, P185; WILSON JN, 1962, ARCH SURG-CHICAGO, V85, P563	3	7	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1991	303	6803					626	627		10.1136/bmj.303.6803.626	http://dx.doi.org/10.1136/bmj.303.6803.626			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF675	1932904	Green Published, Bronze			2022-12-01	WOS:A1991GF67500024
J	QIZILBASH, N; JONES, L; WARLOW, C; MANN, J				QIZILBASH, N; JONES, L; WARLOW, C; MANN, J			FIBRINOGEN AND LIPID CONCENTRATIONS AS RISK-FACTORS FOR TRANSIENT ISCHEMIC ATTACKS AND MINOR ISCHEMIC STROKES	BRITISH MEDICAL JOURNAL			English	Article							SERUM-CHOLESTEROL; ISCHEMIC ATTACKS; CEREBROVASCULAR-DISEASE; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; CEREBRAL INFARCTION; MEN BORN; COMMUNITY; MORTALITY; COHORT	Objective - To determine whether fibrinogen and lipid concentrations are risk factors for ischaemic stroke. Design-Case - control study with a population based comparison within the overall study. Setting - Oxfordshire community stroke project and a neurology clinic. Subjects - 105 patients who had a transient ischaemic attack or minor ischaemic stroke and 352 randomly chosen controls matched for age and sex from the same general practitioners as the incident cases. 52 controls were ineligible or refused interview. 104 cases and 241 controls gave blood samples for analysis. Main outcome measures - Response to structured questionnaire, height, weight, blood pressure, and serum concentrations of fibrinogen and lipids. Results - Adjusted for other variables, odds ratios of ischaemic stroke were 1.78 (95% confidence interval 0.91 to 3.48; p = 0.009) for fibrinogen concentrations > 3.6 g/l; 1.73 (0.90 to 3.29; p = 0.009) for total cholesterol concentrations > 6.0 mmol/l; 1.34 (0.69 to 2.61; p > 0.4) for low density lipoprotein cholesterol concentrations > 3.5 mmol/l; and 0.32 (0.15 to 0.69; p = 0.002) for high density lipoprotein cholesterol concentration > 1.2 mmol/l. Similar results emerged comparing only community derived cases with transient ischaemic attacks and controls. The effects of fibrinogen, total cholesterol, and high density lipoprotein cholesterol were significant in a test of trend after adjusting for all other variable in the study (chi-2 = 4.14, p < 0.05; chi-2 = 4.31, p < 0.05, and chi-2 = 12.15, p > 0.001, respectively). History of ischaemic heart disease and hypertension were the only other variables that showed significance, though both lost significance after adjustment (2.06, p = 0.08 and 1.53, p = 0.2, respectively). Conclusions - Fibrinogen and lipids are important risk factors for ischaemic stroke. The pattern of changes mirrors that found in ischaemic heart disease.	RADCLIFFE INFIRM,DEPT COMMUNITY MED & GEN PRACTICE,OXFORD OX2 6HE,ENGLAND; UNIV OXFORD,RADCLIFFE INFIRM,DEPT CLIN NEUROL,OXFORD OX2 6HE,ENGLAND	Radcliffe Infirmary; Radcliffe Infirmary; University of Oxford					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BRESLOW N. E., 1980, STATISTICAL METHODS; BURSTEIN M, 1970, J LIPID RES, V11, P583; DENNIS MS, 1989, STROKE, V20, P1494, DOI 10.1161/01.STR.20.11.1494; DIPERRI T, 1985, CEPHALALGIA S2, V51, P71; ELLIS BC, 1961, J LAB CLIN MED, V58, P477; GAMBINA G, 1984, ITAL J NEUROL SCI, V5, P157, DOI 10.1007/BF02043217; GLOMSET JA, 1968, J LIPID RES, V9, P155; Heyman A, 1971, STROKE, V2, P509, DOI 10.1161/01.STR.2.6.509; HOSSMANN V, 1977, BRAIN HEART INFARCT, P81; HUMPHREY PRD, 1981, STROKE, V12, P765, DOI 10.1161/01.STR.12.6.765; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; KHAW KT, 1984, STROKE, V15, P244, DOI 10.1161/01.STR.15.2.244; MARKOWE HLJ, 1982, EUR HEART J SB, V3, P5; MENDEZ I, 1987, NEUROLOGY, V37, P507, DOI 10.1212/WNL.37.3.507; ONONOGBU IC, 1976, CLIN CHIM ACTA, V71, P397, DOI 10.1016/0009-8981(76)90090-5; OSTFELD AM, 1974, AM J PUBLIC HEALTH, V64, P450, DOI 10.2105/AJPH.64.5.450; OTT E, 1983, EUR NEUROL, V22, P35, DOI 10.1159/000115609; OTT E, 1979, CEREBRAL VASCULAR DI, P216; PARTINEN M, 1985, LANCET, V1, P893; PEACOCK PB, 1972, TRENDS EPIDEMIOLOGY, P231; RHOADS GG, 1980, STROKE, V11, P21, DOI 10.1161/01.STR.11.1.21; RHOADS GG, 1983, ARTERIOSCLEROSIS, V3, P316, DOI 10.1161/01.ATV.3.4.316; SADOSHIMA S, 1979, ATHEROSCLEROISIS, V34, P43; SALONEN JT, 1983, INT J EPIDEMIOL, V12, P26, DOI 10.1093/ije/12.1.26; SHINTON R, 1989, BMJ-BRIT MED J, V298, P789, DOI 10.1136/bmj.298.6676.789; SIEDEL J, 1981, J CLIN CHEM CLIN BIO, V19, P838; SIRTORI CR, 1979, ATHEROSCLEROSIS, V32, P205, DOI 10.1016/0021-9150(79)90084-4; SPRIGGS DA, 1990, AGE AGEING, V19, P288; SZATROWSKI TP, 1984, J CHRON DIS, V37, P569, DOI 10.1016/0021-9681(84)90007-9; TANAKA H, 1982, STROKE, V13, P62, DOI 10.1161/01.STR.13.1.62; UEDA K, 1980, J CHRON DIS, V33, P13, DOI 10.1016/0021-9681(80)90081-8; WARLOW CP, 1976, THROMB HAEMOSTASIS, V36, P127, DOI 10.1055/s-0038-1648016; WARLOW CP, 1987, OXFORD TXB MED; WELIN L, 1987, NEW ENGL J MED, V317, P521, DOI 10.1056/NEJM198708273170901; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; Wolf P A, 1983, Neurol Clin, V1, P317; 1985, SAS USERS GUIDE STAT; 1982, JAMA-J AM MED ASSOC, V248, P2853	40	160	162	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1991	303	6803					605	609		10.1136/bmj.303.6803.605	http://dx.doi.org/10.1136/bmj.303.6803.605			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF675	1932900	Green Published, Bronze			2022-12-01	WOS:A1991GF67500019
J	SHAW, J; HOLLOWAY, J				SHAW, J; HOLLOWAY, J			WHO IS YOUR GENERAL-PRACTITIONER	BRITISH MEDICAL JOURNAL			English	Article											SHAW, J (corresponding author), PRESTWICH HOSP,REG SECURE UNIT,SALFORD,ENGLAND.			shaw, jennifer/0000-0003-2569-7687				BLUEGLASS R, 1983, GUIDE MENTAL HLTH AC	1	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1991	303	6803					628	628		10.1136/bmj.303.6803.628	http://dx.doi.org/10.1136/bmj.303.6803.628			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF675	1932906	Bronze, Green Published			2022-12-01	WOS:A1991GF67500026
J	WIECK, A; KUMAR, R; HIRST, AD; MARKS, MN; CAMPBELL, IC; CHECKLEY, SA				WIECK, A; KUMAR, R; HIRST, AD; MARKS, MN; CAMPBELL, IC; CHECKLEY, SA			INCREASED SENSITIVITY OF DOPAMINE-RECEPTORS AND RECURRENCE OF AFFECTIVE PSYCHOSIS AFTER CHILDBIRTH	BRITISH MEDICAL JOURNAL			English	Article							HORMONE; APOMORPHINE; ESTRADIOL; DISORDERS; ESTROGEN; NEURONS	Objective - To test the hypothesis that affective psychosis after childbirth is associated with an altered sensitivity to dopaminergic stimulation. Design - Prospective study of pregnant women at high risk of developing an affective psychosis after childbirth. Clinical assessments in pregnancy and after delivery were made by using a semistructured interview (schedule for affective disorders and schizophrenia) and psychiatric illnesses were categorised according to operational criteria (research diagnostic criteria). Setting - Obstetric and psychiatric departments in and around Greater London. Subjects - 29 pregnant women with a history of bipolar or schizoaffective psychosis and 47 control pregnant women. Of these, 16 from each group participated in a growth hormone challenge test and the results for 15 women in each group were analysed. Interventions - On the fourth day postpartum women participating in the hormone challenge test were given a subcutaneous injection of a small dose (0.005 mg/kg) of the dopamine agonist apomorphine. Main outcome measures - Growth hormone secretion in response to apomorphine as an index of the functional state of hypothalamic dopamine receptors. Results - Eight of the 15 women at risk of psychosis subsequently had a recurrence of illness (five bipolar, one schizomanic, and two major depressive illnesses); these women had significantly greater growth hormone responses to apomorphine than the seven at risk women who remained well and the 15 controls, and there were no significant differences between groups in average baseline growth hormone concentrations. The mean (SD) concentrations for women with recurrence, women at risk who remained well, and control women respectively were: average baseline concentrations 1.06 (1.14), 1.44 (1.39), and 0.90 (1.34) mU/l; peak increase in concentrations 13.68 (12.95), 3.46 (4.68), and 3.40 (3.83) mU/l (between group difference p < 0.05); average increase in concentrations 6.74 (7.01), 1.78 (3.39), and 1.40 (2.05) mU/l (p < 0.05). Conclusions - The onset of affective psychosis after childbirth was associated with increased sensitivity of dopamine receptors in the hypothalamus and possibly elsewhere in the brain. Such changes may be triggered by the sharp fall in circulating oestrogen concentrations after delivery.	INST PSYCHIAT,DEPT PSYCHIAT,LONDON SE5 8AF,ENGLAND; INST PSYCHIAT,DEPT NEUROSCI,LONDON SE5 8AF,ENGLAND	University of London; King's College London; University of London; King's College London								BACKSTROM T, 1976, J STEROID BIOCHEM, V7, P469, DOI 10.1016/0022-4731(76)90114-X; BLUM M, 1987, J BIOL CHEM, V262, P817; CHECKLEY SA, 1980, PSYCHOL MED, V10, P35, DOI 10.1017/S0033291700039593; CHECKLEY SA, 1986, BIOL DEPRESSION, P100; COOKSON JC, 1985, J AFFECT DISORDERS, V8, P233, DOI 10.1016/0165-0327(85)90021-7; CORN TH, 1984, BRIT J PSYCHIAT, V144, P636, DOI 10.1192/bjp.144.6.636; DEAKIN JWF, 1988, MOTHERHOOD MENTAL IL, P113; DEAN C, 1989, PSYCHOL MED, V19, P637, DOI 10.1017/S0033291700024235; DEMAREST KT, 1984, NEUROENDOCRINOLOGY, V39, P193, DOI 10.1159/000123979; ENDICOTT J, 1978, ARCH GEN PSYCHIAT, V35, P837; ETTIGI P, 1975, J CLIN ENDOCR METAB, V40, P1094, DOI 10.1210/jcem-40-6-1094; GELATO MC, 1984, J CLIN ENDOCR METAB, V59, P197, DOI 10.1210/jcem-59-2-197; HAMILTON JA, 1982, MOTHERHOOD MENTAL IL, P1; KENDELL RE, 1987, BRIT J PSYCHIAT, V150, P662, DOI 10.1192/bjp.150.5.662; KUMAR R, 1983, BRIT J PSYCHIAT, V142, P618, DOI 10.1192/bjp.142.6.618; LAL S, 1981, J NEURAL TRANSM, V50, P39, DOI 10.1007/BF01254912; MATUSSEK N, 1988, CURRENT TOPICS NEURO, V8, P141; MELTZER HY, 1980, SCHIZOPHRENIA BULL, V6, P456, DOI 10.1093/schbul/6.3.456; ROSS RJM, 1987, CLIN ENDOCRINOL, V27, P155, DOI 10.1111/j.1365-2265.1987.tb01140.x; SPITZER RL, 1978, ARCH GEN PSYCHIAT, V35, P773, DOI 10.1001/archpsyc.1978.01770300115013; VANHARTESVELDT C, 1986, NEUROSCI BIOBEHAV R, V10, P1, DOI 10.1016/0149-7634(86)90029-1; WIECK A, 1989, BAILLIERE CLIN OB GY, V3, P857, DOI 10.1016/S0950-3552(89)80069-0; WIECK A, 1989, BRIT J CLIN PHARMACO, V27, pP700	23	119	121	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1991	303	6803					613	616		10.1136/bmj.303.6803.613	http://dx.doi.org/10.1136/bmj.303.6803.613			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GF675	1805821	Bronze, Green Published			2022-12-01	WOS:A1991GF67500021
J	DAUNICHT, WJ				DAUNICHT, WJ			AUTOASSOCIATION AND NOVELTY DETECTION BY NEUROMECHANICS	SCIENCE			English	Article							NETWORKS	Many biomechanical systems contain ball joints with several clastic actuators (muscles) obliquely attached to the links. The problem, of calculating the optimum actuator commands to achieve a desired link orientation is a difficult one for any control system; however, the elasticity of the actuators may be part of the solution. Mechanoreceptors such as those found in muscles and tendons are capable of performing operations that can be regarded as autoassociation and novelty detection, respectively, by minimization of potential energy. The information provided by such sensors may then be exploited for optimization of muscle coordination.			DAUNICHT, WJ (corresponding author), UNIV DUSSELDORF,INST PHYS BIOL,BIOKYBERNET ABT,W-4000 DUSSELDORF 1,GERMANY.							ABUMOSTAFA YS, 1987, SCI AM, V256, P88, DOI 10.1038/scientificamerican0387-88; BENISRAEL A, 1974, GENERALIZED INVERSES; COOPER S, 1949, BRAIN, V72, P1, DOI 10.1093/brain/72.1.1; DAUNICHT WJ, 1988, BIOL CYBERN, V58, P225, DOI 10.1007/BF00364128; DAUNICHT WJ, UNPUB; GRAF HP, 1988, COMPUTER, V21, P41, DOI 10.1109/2.30; HOPFIELD JJ, 1982, P NATL ACAD SCI-BIOL, V79, P2554, DOI 10.1073/pnas.79.8.2554; KIRKPATRICK S, 1978, PHYS REV B, V17, P4384, DOI 10.1103/PhysRevB.17.4384; KLEIN CA, 1983, IEEE T SYST MAN CYB, V13, P245, DOI 10.1109/TSMC.1983.6313123; KOHONEN T, 1976, BIOL CYBERN, V21, P85, DOI 10.1007/BF01259390; KOHONEN T, 1989, SELF ORG ASS MEMORY, pCH4; MAEKAWA K, 1980, BRAIN RES, V191, P313, DOI 10.1016/0006-8993(80)91283-4; PELLIONISZ A, 1980, NEUROSCIENCE, V5, P1125, DOI 10.1016/0306-4522(80)90191-8; PELLIONISZ A, 1985, ADAPTIVE MECHANISMS, P281; Reilly D. L., 1990, INTRO NEURAL ELECT N, P227; RICHMOND FJR, 1984, INVEST OPHTH VIS SCI, V25, P471; Volkmann A.W., 1869, BER VERH SACHS GES W, V21, P28	17	10	10	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 13	1991	253	5025					1289	1291		10.1126/science.1891718	http://dx.doi.org/10.1126/science.1891718			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE689	1891718				2022-12-01	WOS:A1991GE68900044
J	GIORDANO, A; LEE, JH; SCHEPPLER, JA; HERRMANN, C; HARLOW, E; DEUSCHLE, U; BEACH, D; FRANZA, BR				GIORDANO, A; LEE, JH; SCHEPPLER, JA; HERRMANN, C; HARLOW, E; DEUSCHLE, U; BEACH, D; FRANZA, BR			CELL-CYCLE REGULATION OF HISTONE-H1 KINASE-ACTIVITY ASSOCIATED WITH THE ADENOVIRAL PROTEIN-E1A	SCIENCE			English	Article							CONTROL GENE CDC2+; FISSION YEAST; E1A PROTEINS; DIVISION CYCLE; DNA-SYNTHESIS; SCHIZOSACCHAROMYCES-POMBE; FUNCTIONAL DOMAINS; TRANSFORMATION; GROWTH; EXPRESSION	Several cellular proteins form stable complexes with the proteins encoded by the adenovirus early region 1A (E1A) gene in extracts derived from adenovirus infected or transformed cells. Two of the cellular proteins that bind to E1A have been identified; one, a 105-kilodalton protein (pRb), is the product of the retinoblastoma gene, and the other, a 60-kilodalton protein, is a human cyclin A. Two other proteins that bind E1A have now been shown to be related to p34cdc2. This E1A complex displayed histone H1-specific kinase activity; the kinase activity was modulated during the cell division cycle, and association of pRb with E1A apparently was not required for this activity.	COLD SPRING HARBOR LAB,FREEMAN LAB CANC CELL BIOL,COLD SPRING HARBOR,NY 11724; COLD SPRING HARBOR LAB,HOWARD HUGHES MED INST,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory; Cold Spring Harbor Laboratory; Howard Hughes Medical Institute			Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAITHWAITE AW, 1983, J VIROL, V45, P192, DOI 10.1128/JVI.45.1.192-199.1983; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GARRELS JI, 1983, METHOD ENZYMOL, V100, P411; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, UNPUB; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HADWIGER JA, 1989, MOL CELL BIOL, V9, P2034, DOI 10.1128/MCB.9.5.2034; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; HINDLEY J, 1987, MOL CELL BIOL, V7, P504, DOI 10.1128/MCB.7.1.504; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; KACZMAREK L, 1986, VIROLOGY, V152, P1, DOI 10.1016/0042-6822(86)90366-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LISCHWE MA, 1977, J BIOL CHEM, V252, P4976; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MORAN B, 1988, MOL CELL BIOL, V8, P1756, DOI 10.1128/MCB.8.4.1756; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; STEPHENS C, 1987, EMBO J, V6, P2027, DOI 10.1002/j.1460-2075.1987.tb02467.x; STEPHENS C, 1986, CANCER CELL, V4, P429; VANDENELSEN P, 1983, VIROLOGY, V128, P377; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	53	93	99	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 13	1991	253	5025					1271	1275		10.1126/science.1653969	http://dx.doi.org/10.1126/science.1653969			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE689	1653969				2022-12-01	WOS:A1991GE68900038
J	JOLY, E; MUCKE, L; OLDSTONE, MBA				JOLY, E; MUCKE, L; OLDSTONE, MBA			VIRAL PERSISTENCE IN NEURONS EXPLAINED BY LACK OF MAJOR HISTOCOMPATIBILITY CLASS-1 EXPRESSION	SCIENCE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; CENTRAL NERVOUS-SYSTEM; CLASS-II REGION; UNIQUE CLEARANCE PATTERN; MESSENGER-RNA LEVELS; MONOCLONAL-ANTIBODIES; INTERFERON-GAMMA; ANTIGEN PRESENTATION; SURFACE EXPRESSION; INFECTION REVEALS	Viruses frequently persist in neurons, suggesting that these cells can evade immune surveillance. In a mouse model, 5 x 10(6) cytotoxic T lymphocytes (CTLs), specific for lymphocytic choriomeningitis virus (LCMV), did not lyse infected neurons or cause immunopathologic injury. In contrast, intracerebral injection of less than 10(3) CTL caused disease and death when viral antigens were expressed on leptomeningial and choroid plexus cells of the nervous system. The neuronal cell tine OBL21 expresses little or no major histocompatibility (MHC) class I surface glycoproteins and when infected with LCMV, resisted lysis by virus-specific CTLs. Expression of MHC heavy chain messenger RNA was limited, but beta-2-microglobulin messenger RNA and protein was made normally. OBL21 cells were made sensitive to CTL lysis by transfection with a fusion gene encoding another MHC class I molecule. Hence, neuronal cells probably evade immune surveillance by failing to express MHC class I molecules.	SCRIPPS RES INST, DEPT NEUROPHARMACOL, DIV VIROL, LA JOLLA, CA 92037 USA	Scripps Research Institute			Joly, Etienne/A-5644-2009	Joly, Etienne/0000-0002-7264-2681; Mucke, Lennart/0000-0001-6256-9559				AHMED R, 1990, FIELDS VIROLOGY, V1, P241; ALLEN H, 1986, P NATL ACAD SCI USA, V83, P7447, DOI 10.1073/pnas.83.19.7447; ARCEGOMEZ B, 1978, TISSUE ANTIGENS, V11, P96, DOI 10.1111/j.1399-0039.1978.tb01233.x; BROWN P, 1968, ARCH GES VIRUSFORSCH, V24, P220, DOI 10.1007/BF01241294; BURKE PA, 1989, J EXP MED, V169, P1309, DOI 10.1084/jem.169.4.1309; BYRNE JA, 1984, J VIROL, V51, P682, DOI 10.1128/JVI.51.3.682-686.1984; COLLINS T, 1986, P NATL ACAD SCI USA, V83, P446, DOI 10.1073/pnas.83.2.446; DANIEL F, 1983, EMBO J, V2, P1061, DOI 10.1002/j.1460-2075.1983.tb01546.x; DELALUNA S, 1988, GENE, V62, P121; DELLABONA P, 1989, J IMMUNOL, V142, P2902; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DOHERTY PC, 1984, CONCEPTS VIRAL PATHO, P53; GILDEN DH, 1972, J EXP MED, V135, P874, DOI 10.1084/jem.135.4.874; ISRAEL A, 1987, P NATL ACAD SCI USA, V84, P2653, DOI 10.1073/pnas.84.9.2653; JOHNSON RT, 1980, BRAIN, V103, P447, DOI 10.1093/brain/103.3.447; JOLY E, 1991, GENE, V97, P213, DOI 10.1016/0378-1119(91)90054-F; KLAR D, 1989, EMBO J, V8, P475, DOI 10.1002/j.1460-2075.1989.tb03400.x; KLAVINSKIS LS, 1989, J IMMUNOL, V143, P2013; LEHMANNGRUBE F, 1988, ANN NY ACAD SCI, V532, P238, DOI 10.1111/j.1749-6632.1988.tb36343.x; LEMKE H, 1979, IMMUNOL REV, V47, P175, DOI 10.1111/j.1600-065X.1979.tb00293.x; LIPKIN WI, 1988, BRAIN RES, V451, P333; Mims C.A., 1984, VIRAL PATHOGENESIS I; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MUCKE L, 1991, NEW BIOL, V3, P465; OLDSTONE MB, 1969, J EXP MED, V129, P483, DOI 10.1084/jem.129.3.483; OLDSTONE MBA, 1988, J EXP MED, V168, P559, DOI 10.1084/jem.168.2.559; OLDSTONE MBA, 1986, NATURE, V321, P239, DOI 10.1038/321239a0; OLDSTONE MBA, 1989, SCI AM, V261, P42, DOI 10.1038/scientificamerican0889-42; OLDSTONE MBA, 1989, CELL, V56, P517, DOI 10.1016/0092-8674(89)90573-4; OZATO K, 1980, J IMMUNOL, V125, P2473; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; PARHAM P, 1990, NATURE, V346, P793, DOI 10.1038/346793a0; RAHMSDORF HJ, 1986, J IMMUNOL, V136, P2293; ROCK KL, 1991, P NATL ACAD SCI USA, V88, P301, DOI 10.1073/pnas.88.1.301; RYDER EF, 1990, J NEUROBIOL, V21, P356, DOI 10.1002/neu.480210209; Sambrook J., 1989, MOL CLONING LAB MANU; SCHILLING G, UNPUB; SEGE K, 1981, BIOCHEMISTRY-US, V20, P4523, DOI 10.1021/bi00519a003; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; WEKERLE H, 1986, TRENDS NEUROSCI, V9, P271, DOI 10.1016/0166-2236(86)90077-9; WHITTON JL, 1989, J VIROL, V63, P4303, DOI 10.1128/JVI.63.10.4303-4310.1989; WHITTON JL, 1988, J VIROL, V62, P687, DOI 10.1128/JVI.62.3.687-695.1988; WONG GHW, 1984, EUR J IMMUNOL, V14, P52, DOI 10.1002/eji.1830140110; WONG GHW, 1984, NATURE, V310, P688, DOI 10.1038/310688a0; YOUNG LHY, 1989, J EXP MED, V169, P2159, DOI 10.1084/jem.169.6.2159; ZINKERNAGEL RM, 1977, J EXP MED, V145, P644, DOI 10.1084/jem.145.3.644	49	261	264	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 13	1991	253	5025					1283	1285		10.1126/science.1891717	http://dx.doi.org/10.1126/science.1891717			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE689	1891717				2022-12-01	WOS:A1991GE68900042
J	MAJOR, F; TURCOTTE, M; GAUTHERET, D; LAPALME, G; FILLION, E; CEDERGREN, R				MAJOR, F; TURCOTTE, M; GAUTHERET, D; LAPALME, G; FILLION, E; CEDERGREN, R			THE COMBINATION OF SYMBOLIC AND NUMERICAL COMPUTATION FOR 3-DIMENSIONAL MODELING OF RNA	SCIENCE			English	Article							PHENYLALANINE TRANSFER-RNA; HAMMERHEAD RNA; PREDICTION; PROTEIN; LOOP; CONFORMATION; SIMULATIONS; PSEUDOKNOTS; RESOLUTION; SEQUENCE	Three-dimensional (3-D) structural models of RNA are essential for understanding of the cellular roles played by RNA. Such models have been obtained by a technique based on a constraint satisfaction algorithm that allows for the facile incorporation of secondary and other structural information. The program generates 3-D structures of RNA with atomic-level resolution that can be refined by numerical techniques such as energy minimization. The precision of this technique was evaluated by comparing predicted transfer RNA loop and RNA pseudoknot structures with known or consensus structures. The root-mean-square deviation (2.0 to 3.0 angstroms before minimization) between predicted and control structures reveal this system to be an effective method in modeling RNA.	UNIV MONTREAL, DEPT BIOCHIM, MONTREAL H3C 3J7, QUEBEC, CANADA; UNIV MONTREAL, DEPT INFORMAT & RECH OPERAT, MONTREAL H3C 3J7, QUEBEC, CANADA	Universite de Montreal; Universite de Montreal			Turcotte, Marcel/AAB-5397-2019	Turcotte, Marcel/0000-0002-4877-1029; Gautheret, Daniel/0000-0002-1508-8469				ABELSON H, 1989, COMMUN ACM, V32, P546, DOI 10.1145/63485.63486; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUCCOLERI RE, 1987, BIOPOLYMERS, V26, P137, DOI 10.1002/bip.360260114; DUMAS P, 1987, J BIOMOL STRUCT DYN, V4, P707, DOI 10.1080/07391102.1987.10507674; FASMAN GD, 1989, TRENDS BIOCHEM SCI, V14, P295, DOI 10.1016/0968-0004(89)90068-6; FULLER W, 1967, NATURE, V215, P817, DOI 10.1038/215817a0; HANEEF I, 1989, J MOL GRAPHICS, V7, P186, DOI 10.1016/0263-7855(89)80001-3; HARALICK RM, 1980, ARTIF INTELL, V14, P263, DOI 10.1016/0004-3702(80)90051-X; HEUS HA, 1990, NUCLEIC ACIDS RES, V18, P1103, DOI 10.1093/nar/18.5.1103; KARPLUS M, 1990, NATURE, V347, P631, DOI 10.1038/347631a0; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; LEVITT M, 1969, NATURE, V224, P759, DOI 10.1038/224759a0; Major F., 1991, Journal of Functional Programming, V1, P213; MALHOTRA A, 1990, P NATL ACAD SCI USA, V87, P1950, DOI 10.1073/pnas.87.5.1950; MEI HY, 1989, P NATL ACAD SCI USA, V86, P9727, DOI 10.1073/pnas.86.24.9727; MORAS D, 1980, NATURE, V288, P669, DOI 10.1038/288669a0; MUTTER M, 1988, TRENDS BIOCHEM SCI, V13, P260, DOI 10.1016/0968-0004(88)90159-4; NILSSON L, 1990, BIOCHEMISTRY-US, V29, P10317, DOI 10.1021/bi00497a005; PLEIJ CWA, 1990, TRENDS BIOCHEM SCI, V15, P143, DOI 10.1016/0968-0004(90)90214-V; PUGLISI JD, 1990, J MOL BIOL, V214, P437, DOI 10.1016/0022-2836(90)90192-O; PUGLISI JD, 1990, BIOCHEMISTRY-US, V29, P4215, DOI 10.1021/bi00469a026; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; Saenger W., 1984, PRINCIPLES NUCLEIC A, VDM79; SCHERAGA HA, 1968, ADV PHYS ORG CHEM, V6, P103; SKOLNICK J, 1990, SCIENCE, V250, P1121, DOI 10.1126/science.250.4984.1121; SUMMERS MF, 1990, BIOCHEMISTRY-US, V29, P329, DOI 10.1021/bi00454a005; TURNER DA, 1985, P FUNCTIONAL PROGRAM; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; WYATT JR, 1990, J MOL BIOL, V214, P455, DOI 10.1016/0022-2836(90)90193-P	31	153	157	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 13	1991	253	5025					1255	1260		10.1126/science.1716375	http://dx.doi.org/10.1126/science.1716375			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE689	1716375				2022-12-01	WOS:A1991GE68900033
J	SUNDELL, CL; SINGER, RH				SUNDELL, CL; SINGER, RH			REQUIREMENT OF MICROFILAMENTS IN SORTING OF ACTIN MESSENGER-RNA	SCIENCE			English	Article							LABEL INSITU HYBRIDIZATION; CYTOSKELETAL FRAMEWORK; ULTRASTRUCTURAL VISUALIZATION; PROTEIN-SYNTHESIS; HELA-CELLS; LOCALIZATION; ASSOCIATION; SEQUENCES; PATTERN; EMBRYOS	Specific messenger RNAs (mRNAs) can be sequestered within distinct cellular locations, but little is known about how this is accomplished. The participation of the Three major cellular filaments in the localization of actin mRNA was studied in chicken embryo fibroblasts. Movement of actin mRNA to the cell periphery and maintenance of that regionalization required intact microfilaments (composed of actin) but not microtubules or intermediate filaments. The results presented here suggest that actin-binding proteins may participate in mRNA sorting.	UNIV MASSACHUSETTS,SCH MED,DEPT CELL BIOL,WORCESTER,MA 01655	University of Massachusetts System; University of Massachusetts Worcester					NICHD NIH HHS [HD18066] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018066] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABERCROM.M, 1971, EXP CELL RES, V67, P359, DOI 10.1016/0014-4827(71)90420-4; ADAMS RJ, 1986, NATURE, V322, P754, DOI 10.1038/322754a0; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BONNEAU AM, 1985, J CELL BIOL, V100, P1209, DOI 10.1083/jcb.100.4.1209; BRODEUR RD, 1987, CELL MOTIL CYTOSKEL, V7, P129, DOI 10.1002/cm.970070205; CERVERA M, 1981, CELL, V23, P113, DOI 10.1016/0092-8674(81)90276-2; CHENG H, 1989, J MOL BIOL, V210, P541, DOI 10.1016/0022-2836(89)90130-7; FONTAINE B, 1988, EMBO J, V7, P603, DOI 10.1002/j.1460-2075.1988.tb02853.x; GARNER CC, 1988, NATURE, V336, P674, DOI 10.1038/336674a0; HOOCK TC, 1991, J CELL BIOL, V112, P653, DOI 10.1083/jcb.112.4.653; ISAACS W, 1987, P NATL ACAD SCI USA, V84, P408; JEFFERY WR, 1983, DEV BIOL, V99, P408, DOI 10.1016/0012-1606(83)90290-7; LAWRENCE JB, 1986, CELL, V45, P407, DOI 10.1016/0092-8674(86)90326-0; LENK R, 1977, CELL, V10, P67, DOI 10.1016/0092-8674(77)90141-6; LENK R, 1979, CELL, V16, P289, DOI 10.1016/0092-8674(79)90006-0; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; MCINTOSH JR, 1989, J BIOL CHEM, V264, P6001; MOON RT, 1983, DEV BIOL, V95, P447, DOI 10.1016/0012-1606(83)90046-5; ORNELLES DA, 1986, MOL CELL BIOL, V6, P1650, DOI 10.1128/MCB.6.5.1650; PAPANDRIKOPOULOU A, 1989, NATURE, V340, P650, DOI 10.1038/340650a0; SHEETZ MP, 1983, NATURE, V303, P31, DOI 10.1038/303031a0; SINGER RH, 1989, J CELL BIOL, V108, P2343, DOI 10.1083/jcb.108.6.2343; SUNDELL CL, 1990, J CELL BIOL, V111, P2397, DOI 10.1083/jcb.111.6.2397; TANEJA KL, UNPUB; TRAPP BD, 1987, P NATL ACAD SCI USA, V84, P7773, DOI 10.1073/pnas.84.21.7773; VANVENROOIJ WJ, 1981, EXP CELL RES, V135, P79, DOI 10.1016/0014-4827(81)90301-3; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0; YISRAELI JK, 1990, DEVELOPMENT, V108, P289	29	233	235	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 13	1991	253	5025					1275	1277		10.1126/science.1891715	http://dx.doi.org/10.1126/science.1891715			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE689	1891715				2022-12-01	WOS:A1991GE68900039
J	CAMERON, DA; PUGH, EN				CAMERON, DA; PUGH, EN			DOUBLE CONES AS A BASIS FOR A NEW TYPE OF POLARIZATION VISION IN VERTEBRATES	NATURE			English	Article							ORIENTATION; LIGHT; PATTERNS; SENSITIVITY; GOLDFISH; RETINA; FISH	MANY invertebrates 1-4 and vertebrates 5-14 are sensitive to the polarization of light. The biophysical basis of invertebrate polarization sensitivity is an intrinsic dichroism, the alignment of chromophores along the photoreceptor microvilli 3. But such dichroism to axially propagating light is not present in vertebrate photoreceptors, whose chromophores are free to rotate in the plane of the outer-segment disc membranes, and a biophysical mechanism responsible for vertebrate polarization sensitivity has not been established. We hypothesize that the roughly elliptical cross-sectioned double-cone inner segment acts as a birefringent, polarization-sensitive dielectric waveguide, and that the double cone mosaic generates a 'polarization contrast' neural image. Here we confirm three predictions derived from these hypotheses: (1) 90-degrees periodicity for polarization sensitivity; (2) polarization sensitivity maxima corresponding to the absolute orientation of the axes of the double-cone inner-segment cross-sections; and (3) action spectrum for polarization sensitivity corresponding to the absorption spectrum of the double cones. We also present evidence for a polarization-opponent neural encoding in vertebrates.	UNIV PENN,SCH ARTS & SCI,DEPT PSYCHOL,PHILADELPHIA,PA 19104	University of Pennsylvania	CAMERON, DA (corresponding author), UNIV PENN,SCH ARTS & SCI,INST NEUROL SCI,3815 WALNUT ST,PHILADELPHIA,PA 19104, USA.							AALTO E, 1985, MED BIOL ENG COMPUT, V23, P111; ABLE KP, 1982, NATURE, V299, P550, DOI 10.1038/299550a0; ADAMS MJ, 1979, ELECTRON LETT, V15, P298, DOI 10.1049/el:19790212; ADLER K, 1985, J COMP PHYSIOL A, V156, P547, DOI 10.1007/BF00613978; Ali M.A., 1976, RETINAS FISHES ATLAS; BOEHLERT GW, 1978, SCIENCE, V202, P309, DOI 10.1126/science.694534; BRINES ML, 1982, J EXP BIOL, V96, P69; CHARMAN WN, 1973, VISION RES, V13, P1, DOI 10.1016/0042-6989(73)90160-0; DEARRY A, 1987, J GEN PHYSIOL, V89, P745, DOI 10.1085/jgp.89.5.745; Easter S.S. Jr., 1975, P609; ENGSTROM KJELL, 1963, ACTA ZOOL, V44, P179; FRISCH K V, 1949, Experientia, V5, P142; HAWRYSHYN CW, 1987, J COMP PHYSIOL A, V160, P459, DOI 10.1007/BF00615079; HELBIG AJ, 1989, NATURWISSENSCHAFTEN, V76, P227, DOI 10.1007/BF00627697; HUBBARD E, 1971, EXPL EYE RES, V12, P175; KUNZ YW, 1980, EXPERIENTIA, V36, P1371, DOI 10.1007/BF01960104; LYALL AH, 1957, Q J MICROSC SCI, V98, P189; LYTHGOE JN, 1967, NATURE, V213, P893, DOI 10.1038/213893a0; MENZEL R, 1975, LIGHT ECOLOGICAL FAC, P289; Northmore D. P. M., 1975, VISION FISHES, P689; POWERS MK, 1978, VISION RES, V18, P1137, DOI 10.1016/0042-6989(78)90097-4; Snyder A.W., 1975, PHOTORECEPTOR OPTICS; TAYLOR DH, 1973, SCIENCE, V181, P285, DOI 10.1126/science.181.4096.285; THORNTON JE, 1983, SCIENCE, V219, P191, DOI 10.1126/science.6849131; WALDVOGEL J, 1980, AM CI, V78, P342; WATERMAN TH, 1970, NATURE, V228, P85, DOI 10.1038/228085a0; Waterman TH, 1981, HDB SENSORY PHYSL, VVII/6B, P283; WATERMAN TH, 1975, LIGHT ECOLOGICAL FAC, P305; WEHNER R, 1976, SCI AM, V235, P106, DOI 10.1038/scientificamerican0776-106; WEHNER R, 1989, TRENDS NEUROSCI, V12, P353, DOI 10.1016/0166-2236(89)90043-X	30	100	102	0	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1991	353	6340					161	164		10.1038/353161a0	http://dx.doi.org/10.1038/353161a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE731	1891046				2022-12-01	WOS:A1991GE73100052
J	GERMAIN, RN; HENDRIX, LR				GERMAIN, RN; HENDRIX, LR			MHC CLASS-II STRUCTURE, OCCUPANCY AND SURFACE EXPRESSION DETERMINED BY POST-ENDOPLASMIC RETICULUM ANTIGEN-BINDING	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; B-CELL ALLOANTIGENS; HLA-DR ANTIGENS; INVARIANT CHAIN; MONOCLONAL-ANTIBODIES; T-CELLS; IMMUNOGENIC PEPTIDES; IA ANTIGENS; MOLECULES; RECOGNITION	Class II major histocompatibility complex molecules undergo a change in structure upon stable binding of peptide antigen. Analysis of the site and extent of this change among class II molecules of splenic antigen-presenting cells reveals the preference of class II for peptide acquisition outside the endoplasmic reticulum and indicates that the class II presentation system is not saturated with self peptides. There are numerous empty class II molecules on the cell surface and peptide antigen is evidently important in regulating surface class II expression.			GERMAIN, RN (corresponding author), NIAID,IMMUNOL LAB,LYMPHOCYTE BIOL SECT,BETHESDA,MD 20892, USA.		Germain, Ronald N./Z-1945-2019; Germain, Ronald/ABE-7090-2020					BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BHATTACHARYA A, 1981, J IMMUNOL, V127, P2488; BIKOFF EK, IN PRESS EUR J IMMUN; BILLING RJ, 1976, J IMMUNOL, V117, P1589; BRAUNSTEIN NS, 1990, J IMMUNOL, V145, P1635; BROOKS A, 1991, P NATL ACAD SCI USA, V88, P3290, DOI 10.1073/pnas.88.8.3290; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CHEN BP, 1990, J EXP MED, V172, P779, DOI 10.1084/jem.172.3.779; CRESSWELL P, 1977, EUR J IMMUNOL, V7, P636, DOI 10.1002/eji.1830070911; CULLEN SE, 1984, METHOD ENZYMOL, V108, P523; DEMOTZ S, 1989, NATURE, V342, P682, DOI 10.1038/342682a0; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; DORNMAIR K, 1989, COLD SH Q B, V54, P409; GERMAIN RN, 1986, NATURE, V322, P687, DOI 10.1038/322687a0; GORGA JC, 1987, J BIOL CHEM, V262, P16087; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HARDING CV, 1990, P NATL ACAD SCI USA, V87, P5553, DOI 10.1073/pnas.87.14.5553; HARDING CV, 1990, CELL REGUL, V1, P499, DOI 10.1091/mbc.1.7.499; HARDING CV, 1991, P NATL ACAD SCI USA, V88, P7170; HOLT GD, 1985, J IMMUNOL, V135, P399; HUBBARD AL, 1972, J CELL BIOL, V55, P390, DOI 10.1083/jcb.55.2.390; JACOBSON S, 1989, J VIROL, V63, P1756, DOI 10.1128/JVI.63.4.1756-1762.1989; JANEWAY CA, 1984, J IMMUNOL, V132, P662; JIN Y, 1988, J EXP MED, V168, P293, DOI 10.1084/jem.168.1.293; JONES PP, 1979, MOL IMMUNOL, V16, P51, DOI 10.1016/0161-5890(79)90027-0; KAPPLER JW, 1981, J EXP MED, V153, P1198, DOI 10.1084/jem.153.5.1198; KOCH N, 1987, EMBO J, V6, P1677, DOI 10.1002/j.1460-2075.1987.tb02417.x; KVIST S, 1982, CELL, V29, P61, DOI 10.1016/0092-8674(82)90090-3; LEE JM, 1990, J IMMUNOL, V144, P1829; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LONG EO, 1989, IMMUNOL TODAY, V10, P232, DOI 10.1016/0167-5699(89)90259-4; LORENZ RG, 1990, J IMMUNOL, V144, P1600; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MACHAMER CE, 1984, P NATL ACAD SCI-BIOL, V81, P1287, DOI 10.1073/pnas.81.5.1287; MACHAMER CE, 1982, J IMMUNOL, V129, P2564; MEHRINGER JH, 1991, J IMMUNOL, V146, P920; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; MURPHY DB, 1989, NATURE, V338, P76; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NOWELL J, 1985, J EXP MED, V162, P1371, DOI 10.1084/jem.162.4.1371; NUCHTERN JG, 1990, NATURE, V343, P74, DOI 10.1038/343074a0; Oi V T, 1978, Curr Top Microbiol Immunol, V81, P115; OZATO K, 1980, J IMMUNOL, V124, P533; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; RESKE K, 1985, EUR J IMMUNOL, V15, P1229, DOI 10.1002/eji.1830151216; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROTHENHAUSLER B, 1990, P NATL ACAD SCI USA, V87, P352, DOI 10.1073/pnas.87.1.352; SADEGHNASSERI S, 1989, NATURE, V337, P274, DOI 10.1038/337274a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SHACKELFORD DA, 1981, J IMMUNOL, V127, P1403; SOBEL RA, 1986, J IMMUNOL, V137, P2132; SPRINGER TA, 1977, J BIOL CHEM, V252, P6201; SRINIVASAN M, 1990, P NATL ACAD SCI USA, V87, P919, DOI 10.1073/pnas.87.3.919; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; WEISS S, 1991, CELL, V64, P767, DOI 10.1016/0092-8674(91)90506-T; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J	63	405	414	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1991	353	6340					134	139		10.1038/353134a0	http://dx.doi.org/10.1038/353134a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE731	1891045				2022-12-01	WOS:A1991GE73100043
J	GOMEZ, N; COHEN, P				GOMEZ, N; COHEN, P			DISSECTION OF THE PROTEIN-KINASE CASCADE BY WHICH NERVE GROWTH-FACTOR ACTIVATES MAP KINASES	NATURE			English	Article							MYELIN BASIC-PROTEIN; OKADAIC ACID; PHOSPHORYLATION; INSULIN; CELLS; IDENTIFICATION; PHOSPHATASE-2A; LINE	MITOGEN activated protein (MAP) kinases (MAPKs) are a family of protein-serine/threonine kinases activated as an early intracellular response to a variety of hormones and growth factors 1-4. They are unique in requiring both serine/threonine and tyrosine phosphorylation to become active 5 and are the only examples of protein-serine/threonine kinases activated by tyrosine phosphorylation. Nerve growth factor (NGF) promotes differentiation of phaeochromocytoma (PC12) cells, which respond by conversion within hours from a chromaffin-like to a sympathetic neuron-like phenotype 6,7. NGF stimulation of PC12 cells increases the activity of two protein kinases by > 20-fold within minutes 8, both strikingly similar to MAPKs. They are inactivated by either protein-tyrosine phosphatases or the protein-serine/threonine phosphatase termed protein phosphatase 2A (ref. 8), they activate protein S6 kinase-II (refs 9, 10), and they phosphorylate identical threonine residues on myelin basic protein (our unpublished results) to those phosphorylated by other MAPKs 11,12. Immunological data 13 indicate that these protein kinases, termed peak-I and peak-II (Fig. 1a) are probably ERK2 and ERK1, respectively, two widely expressed MAPK isoforms 13. Here we identify the 'MAP kinase kinases' (MAPKKs) in PC12 cells which are activated by NGF and report that MAPKKs are dependent on serine/threonine phosphorylation for activity and promote phosphorylation of serine/threonine and tyrosine residues on MAPKs.			GOMEZ, N (corresponding author), UNIV DUNDEE,DEPT BIOCHEM,MRC,PROT PHOSPHORYLAT UNIT,DUNDEE DD1 4HN,SCOTLAND.		Gomez, Nestor/I-2522-2015	Gomez, Nestor/0000-0002-1348-2737				AHN NG, 1990, J BIOL CHEM, V265, P11487; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1988, METHOD ENZYMOL, V159, P390; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; DAILEY D, 1990, MOL CELL BIOL, V10, P6244, DOI 10.1128/MCB.10.12.6244; DICHTER MA, 1977, NATURE, V268, P501, DOI 10.1038/268501a0; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GORIS J, 1988, BIOCHEM J, V256, P1029, DOI 10.1042/bj2561029; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HER JH, 1991, NUCLEIC ACIDS RES, V19, P3743, DOI 10.1093/nar/19.13.3743; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SANGHERA JS, 1990, FEBS LETT, V273, P223, DOI 10.1016/0014-5793(90)81090-B; SCOTT JD, 1986, P NATL ACAD SCI USA, V83, P1613, DOI 10.1073/pnas.83.6.1613; STREULI M, 1988, J EXP MED, V168, P1553; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001	30	564	571	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1991	353	6340					170	173		10.1038/353170a0	http://dx.doi.org/10.1038/353170a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE731	1716348				2022-12-01	WOS:A1991GE73100055
J	HAGAR, JM; RAHIMTOOLA, SH				HAGAR, JM; RAHIMTOOLA, SH			CHAGAS HEART-DISEASE IN THE UNITED-STATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMERICAN IMMIGRANTS	Background and Methods. Chagas' heart disease is believed to be rare in the United States, although many persons from countries where the disease is endemic reside here. We performed a retrospective case review and prospective follow-up of 25 patients with Chagas' heart disease and no obstructive coronary artery disease on angiography. Results. The patients mainly presented with symptomatic atrioventricular block, congestive heart failure, anginal chest pain, sudden death averted by resuscitation, or sustained ventricular tachycardia. Of the 25 patients, 18 had been treated for coronary artery disease or idiopathic dilated cardiomyopathy for up to 108 months before the diagnosis of Chagas' disease was considered. The electrocardiograms frequently suggested coronary artery disease. Six of the seven patients who had exercise thallium-perfusion scans had abnormalities suggesting ischemia or infarction. A left ventricular aneurysm was found in 14 of the 25 patients, segmental akinesia or hypokinesia in 5, and diffuse hypokinesia in 3. Programmed ventricular stimulation performed in 13 patients induced sustained ventricular tachycardia in 9 and nonsustained ventricular tachycardia in 2. Actuarial survival (mean +/- SE) after four years for the entire group was 56 +/- 12 percent; it was 32 +/- 16 percent among those with global left ventricular dysfunction, and 78 +/- 14 percent among those without such dysfunction (P = 0.03). Only patients with left ventricular dysfunction or an aneurysm died (four-year survival, 45 +/- 14 percent, as compared with 100 percent for the remaining patients; P = 0.0002). Heart failu8re and left ventricular aneurysm or dysfunction were the only independent predictors of death. Nine patients required permanent pacemakers. Conclusions. In the United States, Chagas' heart disease commonly mimics coronary artery disease or idiopathic dilated cardiomyopathy. The prognosis is poor for patients with heart failure or left ventricular aneurysm or dysfunction. The disease may be underdiagnosed in the United States.	UNIV SO CALIF, LOS ANGELES CTY MED CTR,DEPT MED,DIV CARDIOL, 2025 ZONAL AVE, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, SCH MED, LOS ANGELES, CA 90033 USA	University of Southern California; University of Southern California				Hagar, Mohamed Esam/0000-0003-0169-7738				ACQUATELLA H, 1987, CIRCULATION, V76, P556, DOI 10.1161/01.CIR.76.3.556; ACQUATELLA H, 1980, CIRCULATION, V62, P787, DOI 10.1161/01.CIR.62.4.787; AMORIM DS, 1979, PROGR CARDIOLOGY, V8, P235; ANSELMI A, 1966, AM HEART J, V72, P469, DOI 10.1016/0002-8703(66)90104-9; ANSELMI A, 1974, CIBA F S, V20, P125; CAMARGO ME, 1988, LABORATORY DIAGNOSIS, V1, P744; COURA JR, 1976, SCI PUBLICATION PAN, V318, P378; DEOLIVEIRA JAM, 1972, ARQ BRAS CARDIOL, V25, P17; DEPAOLA AAV, 1990, AM J CARDIOL, V65, P360, DOI 10.1016/0002-9149(90)90302-H; EARLAM RJ, 1972, AM J DIG DIS, V17, P559, DOI 10.1007/BF02231217; EDMISTON WA, 1978, WESTERN J MED, V128, P248; ESPINOSA R, 1985, INT J CARDIOL, V8, P45, DOI 10.1016/0167-5273(85)90262-1; FEIT A, 1983, ARCH INTERN MED, V143, P144, DOI 10.1001/archinte.143.1.144; KIRCHHOFF LV, 1987, AM J MED, V82, P915, DOI 10.1016/0002-9343(87)90152-5; KIRCHHOFF LV, 1985, JAMA-J AM MED ASSOC, V254, P3058, DOI 10.1001/jama.254.21.3058; LARANJA FS, 1956, CIRCULATION, V14, P1035, DOI 10.1161/01.CIR.14.6.1035; LORENZAN.R, 1967, AM J CLIN PATHOL, V48, P39; MAGUIRE JH, 1987, CIRCULATION, V75, P1140, DOI 10.1161/01.CIR.75.6.1140; MAHMOUD AAF, 1975, J INFECT DIS, V132, P121, DOI 10.1093/infdis/132.1.121; Marsden P D, 1971, Int Rev Trop Med, V4, P97; MARSDEN PD, 1984, REV INFECT DIS, V6, P855; MASSUMI RA, 1965, ARCH INTERN MED, V116, P531, DOI 10.1001/archinte.116.4.531; MORRIS SA, 1990, CIRCULATION, V82, P1900, DOI 10.1161/01.CIR.82.6.1900; OLIVEIRA JSM, 1985, AM HEART J, V110, P1092, DOI 10.1016/0002-8703(85)90222-4; OLIVEIRA JSM, 1981, BRIT HEART J, V46, P432, DOI 10.1136/hrt.46.4.432; PEARLMAN JD, 1983, AM J MED, V75, P1057, DOI 10.1016/0002-9343(83)90888-4; Prata A, 1986, Rev Soc Bras Med Trop, V19, P9, DOI 10.1590/S0037-86821986000100003; PRATA AR, 1976, SCI PUBLICATION PAN, V318, P191; PUIGBO JJ, 1968, B WORLD HEALTH ORGAN, V39, P341; PUIGBO JJ, 1966, B WORLD HEALTH ORGAN, V34, P655; ROSENBAUM MB, 1964, PROG CARDIOVASC DIS, V7, P199, DOI 10.1016/S0033-0620(64)80020-7; ROSENBAUM MB, 1955, AM HEART J, V50, P492, DOI 10.1016/0002-8703(55)90296-9; SHAFII A, 1977, NEW YORK STATE J MED, V77, P418; TAKLE GB, 1989, CURR TOP MICROBIOL, V145, P79; 1990, SCI PUBLICATION 524, V1, P160; 1990, BUREAU CENSUS STATIS, P41	36	124	134	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 12	1991	325	11					763	768		10.1056/NEJM199109123251103	http://dx.doi.org/10.1056/NEJM199109123251103			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE456	1870649				2022-12-01	WOS:A1991GE45600003
J	HAMMOND, KB; ABMAN, SH; SOKOL, RJ; ACCURSO, FJ				HAMMOND, KB; ABMAN, SH; SOKOL, RJ; ACCURSO, FJ			EFFICACY OF STATEWIDE NEONATAL SCREENING FOR CYSTIC-FIBROSIS BY ASSAY OF TRYPSINOGEN CONCENTRATIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INFANTS; PROGRAM; AGE	Background. To evaluate the feasibility and efficacy of measuring immunoreactive trypsinogen in blood to screen for cystic fibrosis, we performed this test in 279,399 newborns in Colorado from 1982 to 1987. Methods. Immunoreactive trypsinogen was measured in dried blood spots when the infants were 1 to 4 days old; if the level was elevated (greater-than-or-equal-to 140-mu-g per liter), the measurement was repeated (mean age, 38 days); if the level was again elevated, sweat testing was performed (mean age, 49 days). For the second test, two cutoff levels (120 and 80-mu-g per liter) were evaluated. Results. We found an incidence of cystic fibrosis of 1 in 3827 (0.26 per 1000), with 3.2 newborns per 1000 requiring repeat measurement. When adjusted for race and compliance with testing, the incidence among the white infants (1 in 2521) was close to the expected incidence. The false positive rate with the initial cutoff level (92.2 percent) was similar to the rate found in neonatal screening programs for other diseases. False negative results occurred because of laboratory error or changes in procedure (three infants) and trypsinogen concentrations lower than the initial cutoff level (three infants) or lower than the remeasurement cutoff level of 120-mu-g per liter (one infant). Sweat tests were negative in 168 infants with an elevated initial trypsinogen level but a level below 80-mu-g per liter on remeasurement, confirming the value of 80-mu-g per liter as an appropriate cutoff for repeat-test results. Overall, 95.2 percent of the infants with cystic fibrosis (95 percent confidence interval, 85 to 99 percent) who did not have meconium ileus could be identified with the use of a trypsinogen cutoff level of 140-mu-g per liter on initial testing and 80-mu-g per liter on repeat testing. Conclusions. Statewide screening for cystic fibrosis based on measurements of immunoreactive trypsinogen in dried blood spots is feasible and can be implemented with acceptable rates of repeat testing and false positive and false negative results.	UNIV COLORADO, SCH MED, DIV PERINATAL MED, DENVER, CO 80262 USA; CHILDRENS HOSP, DENVER, CO 80218 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Children's Hospital Colorado	HAMMOND, KB (corresponding author), UNIV COLORADO, SCH MED, DEPT PEDIAT, BOX C228, 4200 E 9TH AVE, DENVER, CO 80262 USA.				NCRR NIH HHS [RR-00069] Funding Source: Medline; PHS HHS [MCJ-080508-03] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000069] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ADRIAENSSENS K, 1981, LANCET, V1, P833; [Anonymous], 1983, PEDIATRICS; BOLAND C, 1990, ARCH DIS CHILD, V65, P1240, DOI 10.1136/adc.65.11.1240; BURLINA A, 1980, SCAND J GASTROENTERO, V15, P35; CROSSLEY JR, 1981, CLIN CHIM ACTA, V113, P111, DOI 10.1016/0009-8981(81)90145-5; DANKERTROELSE JE, 1989, J PEDIATR-US, V114, P362, DOI 10.1016/S0022-3476(89)80552-9; Diem K., 1970, SCI TABLES, VSeventh; DIXON WJ, 1969, INTRO STATISTICAL AN, P249; DUHAMEL JF, 1984, CYSTIC FIBROSIS HORI, P208; GIBSON LE, 1973, CLIN PEDIATR, V12, P450, DOI 10.1177/000992287301200817; HAMMOND KB, 1984, LANCET, V1, P42; HAMMOND KB, 1986, GENETIC DISEASE SCRE, P81; HEELEY AF, 1982, ARCH DIS CHILD, V57, P18; KING DN, 1979, LANCET, V2, P1217; KRAMM ER, 1962, AM J PUBLIC HEALTH N, V52, P2041, DOI 10.2105/AJPH.52.12.2041; ORENSTEIN DM, 1977, AM J DIS CHILD, V131, P973, DOI 10.1001/archpedi.1977.02120220039005; REARDON MC, 1984, J PEDIATR-US, V105, P271, DOI 10.1016/S0022-3476(84)80128-6; ROCK MJ, 1990, PEDIATRICS, V85, P1001; ROCK MJ, 1989, PEDIATR PULM, V6, P42, DOI 10.1002/ppul.1950060111; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SHEPHERD RW, 1989, J PEDIATR GASTR NUTR, V9, P200, DOI 10.1097/00005176-198908000-00012; SHWACHMAN H., 1967, MOD PROBL PAEDIATR, V10, P158; SOKOL RJ, 1989, AM J CLIN NUTR, V50, P1064, DOI 10.1093/ajcn/50.5.1064; SORENSON JR, 1984, PEDIATRICS, V73, P183; STEINBERG AG, 1960, AM J HUM GENET, V12, P416; WATERS DL, 1990, NEW ENGL J MED, V322, P303, DOI 10.1056/NEJM199002013220505; WILCKEN B, 1985, LANCET, V2, P1319; WILCKEN B, 1983, J PEDIATR-US, V102, P383, DOI 10.1016/S0022-3476(83)80653-2; 1990, NEW ENGL J MED, V323, P70; 1985, SAS USERS GUIDE STAT	30	125	129	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 12	1991	325	11					769	774		10.1056/NEJM199109123251104	http://dx.doi.org/10.1056/NEJM199109123251104			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE456	1870650				2022-12-01	WOS:A1991GE45600004
J	HOCH, B; MAIER, RM; APPEL, K; IGLOI, GL; KOSSEL, H				HOCH, B; MAIER, RM; APPEL, K; IGLOI, GL; KOSSEL, H			EDITING OF A CHLOROPLAST MESSENGER-RNA BY CREATION OF AN INITIATION CODON	NATURE			English	Article							NUCLEOTIDE-SEQUENCE; PLANT-MITOCHONDRIA; GENE ORGANIZATION; DNA-SEQUENCE; GENOME; MAIZE; MAP	PRIMARY mRNA transcripts in several systems are edited by single base substitutions, small deletions or insertions to yield functional messenger RNA species 1,2. Mitochondrial mRNAs in particular, including those from plants 3-5, seem to be the subject of extensive editing, unlike mRNAs encoded by chloroplast DNA, for which the prediction of amino-acid sequence from the corresponding gene sequence is generally unambiguous 6-8. Occasionally, however, an ACG codon appears at the 5' terminus of chloroplast genes, where the initiation codon ATG would be expected. Here we present evidence for a C --> U editing that is responsible for the conversion of the ACG codon to an AUG initiation codon in the mRNA transcript from the rpl2 gene of the maize plastome, showing that mRNA editing can also occur in chloroplasts.			HOCH, B (corresponding author), UNIV FREIBURG,INST BIOL 3,SCHANZLE STR 1,W-7800 FREIBURG,GERMANY.		/ABF-9144-2020					ANSORGE W, 1986, J BIOCHEM BIOPH METH, V13, P315, DOI 10.1016/0165-022X(86)90038-2; BACHMANN B, 1990, NUCLEIC ACIDS RES, V18, P1309, DOI 10.1093/nar/18.5.1309; BENNE R, 1990, TRENDS GENET, V6, P177, DOI 10.1016/0168-9525(90)90173-4; COVELLO PS, 1989, NATURE, V341, P662, DOI 10.1038/341662a0; FOX TD, 1981, CELL, V26, P315, DOI 10.1016/0092-8674(81)90200-2; GUALBERTO JM, 1989, NATURE, V341, P660, DOI 10.1038/341660a0; HIESEL R, 1989, SCIENCE, V246, P1632, DOI 10.1126/science.2480644; HIRATSUKA J, 1989, MOL GEN GENET, V217, P185, DOI 10.1007/BF02464880; KAVOUSI M, 1990, NUCLEIC ACIDS RES, V18, P4244, DOI 10.1093/nar/18.14.4244; LARRINUA IM, 1983, PLANT MOL BIOL, V2, P129, DOI 10.1007/BF01578513; LONSDALE DM, 1983, CELL, V34, P1007, DOI 10.1016/0092-8674(83)90558-5; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; PRUITT KD, 1991, CURR GENET, V19, P191, DOI 10.1007/BF00336486; SCHUSTER W, 1991, PHYSIOL PLANTARUM, V81, P437, DOI [10.1111/j.1399-3054.1991.tb08754.x, 10.1034/j.1399-3054.1991.810321.x]; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; STERN DB, 1982, NATURE, V299, P698, DOI 10.1038/299698a0; STERN DB, 1986, NUCLEIC ACIDS RES, V14, P5651, DOI 10.1093/nar/14.14.5651; [No title captured]	18	263	290	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1991	353	6340					178	180		10.1038/353178a0	http://dx.doi.org/10.1038/353178a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE731	1653905				2022-12-01	WOS:A1991GE73100057
J	INGHAM, PW; TAYLOR, AM; NAKANO, Y				INGHAM, PW; TAYLOR, AM; NAKANO, Y			ROLE OF THE DROSOPHILA PATCHED GENE IN POSITIONAL SIGNALING	NATURE			English	Article							SEGMENT POLARITY GENE; SPATIAL-DISTRIBUTION; EMBRYONIC PATTERN; FUSHI-TARAZU; PROTEIN; EXPRESSION; WINGLESS; BLASTODERM; REGION	AFTER cellularization of the Drosophila embryo, positional differences within each primordial segment are maintained and elaborated by processes that require cell interactions. The best-documented examples 1,2 of such intercellular signalling are the mutual interactions between neighbouring cells expressing the homeodomain protein engrailed 3 and the secreted glycoprotein encoded by wingless 4, the Drosophila homologue of the murine Wnt-1 gene 5. Little is known about the molecular basis of these signalling mechanisms but the activities of several other genes, notably patched and hedgehog, have been implicated in the process 1,2. Here we show that the role of patched in positional signalling is permissive rather than instructive, its activity being required to suppress wingless transcription in cells predisposed to express the latter. According to this view, expression of wingless is normally maintained only in those cells receiving an extrinsic signal, encoded by hedgehog, that antagonizes the repressive activity of patched. We suggest that the patched protein may itself be the receptor for this signal, implying that this is an unusual mechanism of ligand-dependent receptor inactivation.			INGHAM, PW (corresponding author), IMPERIAL CANC RES FUND, DEPT ZOOL, DEV BIOL UNIT, MOLEC EMBRYOL LAB, S PARKS RD, OXFORD OX1 3PS, ENGLAND.		Ingham, Philip William/AAH-5884-2020; Ingham, Philip W/E-6710-2010; Ingham, Philip W/G-9903-2011	Ingham, Philip William/0000-0001-8224-9958; Ingham, Philip W/0000-0001-8224-9958				ARIAS AM, 1988, DEVELOPMENT, V103, P157; ARIAS AM, 1989, TRENDS GENET, V5, P262, DOI 10.1016/0168-9525(89)90099-1; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; DINARDO S, 1987, GENE DEV, V1, P1212, DOI 10.1101/gad.1.10.1212; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; FJOSE A, 1985, NATURE, V313, P284, DOI 10.1038/313284a0; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; HIDALGO A, 1990, DEVELOPMENT, V110, P291; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HOWARD K, 1986, CELL, V44, P949, DOI 10.1016/0092-8674(86)90018-8; INGHAM PW, 1988, NATURE, V331, P73, DOI 10.1038/331073a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MOHLER J, 1988, GENETICS, V120, P1061; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2	22	380	398	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 12	1991	353	6340					184	187		10.1038/353184a0	http://dx.doi.org/10.1038/353184a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE731	1653906				2022-12-01	WOS:A1991GE73100059
J	PIOMELLI, D; PILON, C; GIROS, B; SOKOLOFF, P; MARTRES, MP; SCHWARTZ, JC				PIOMELLI, D; PILON, C; GIROS, B; SOKOLOFF, P; MARTRES, MP; SCHWARTZ, JC			DOPAMINE ACTIVATION OF THE ARACHIDONIC-ACID CASCADE AS A BASIS FOR D1/D2 RECEPTOR SYNERGISM	NATURE			English	Article							SIGNAL TRANSDUCTION; ADENYLATE-CYCLASE; D1; METABOLITES; EXPRESSION; NEURONS; INHIBITION	UNDERSTANDING the actions of the neurotransmitter dopamine in the brain is important in view of its roles in neuropsychiatric illnesses 1. Dopamine D1 receptors, which stimulate both adenylyl cyclase 2 and phospholipase C3, and D2 receptors, which inhibit them 4,5, can nevertheless act synergistically to produce many electrophysiological and behavioural responses 6. Because this functional synergism can occur at the level of single neurons, another, as yet unidentified, signalling pathway activated by dopamine has been hypothesized 7. We report here that in Chinese hamster ovary (CHO) cells transfected with the D2 receptor complementary DNA, D2 agonists potently enhance arachidonic acid release, provided that such release has been initiated by stimulating constitutive purinergic receptors or by increasing intracellular Ca2+. In CHO cells expressing D1 receptors, D1 agonists exert no such effect. When D1 and D2 receptors are coexpressed, however, activation of both subtypes results in a marked synergistic potentiation of arachidonic acid release. The numerous actions of arachidonic acid and its metabolites in neuronal signal transduction 8 suggest that facilitation of its release may be implicated in dopaminergic responses, such as feedback inhibition mediated by D2 autoreceptors, and may constitute a molecular basis for D1/D2 receptor synergism.			PIOMELLI, D (corresponding author), CTR PAUL BROCA,INSERM,U109,UNITE NEUROBIOL & PHARMACOL,2TER RUE ALESIA,F-75014 PARIS,FRANCE.		Giros, Bruno/ABD-5790-2021	Giros, Bruno/0000-0001-5876-9822				BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERTORELLO AM, 1990, NATURE, V347, P386, DOI 10.1038/347386a0; BLEY KR, 1990, NEURON, V2, P379; BURCH RM, 1989, MOL NEUROBIOL, V3, P156; CARLSSON A, 1988, NEUROPSYCHOPHARMACOL, V1, P179, DOI 10.1016/0893-133X(88)90012-7; CLARK D, 1987, SYNAPSE, V1, P347, DOI 10.1002/syn.890010408; DALTOSO R, 1989, EMBO J, V8, P4025, DOI 10.1002/j.1460-2075.1989.tb08585.x; DECAMILLI P, 1979, NATURE, V278, P252, DOI 10.1038/278252a0; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; EXTON JH, 1990, J BIOL CHEM, V265, P1; FITZPATRICK FA, 1989, PHARMACOL REV, V40, P229; FREEMAN EJ, 1991, J NEUROCHEM, V56, P1079, DOI 10.1111/j.1471-4159.1991.tb02032.x; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; GIROS B, 1989, NATURE, V342, P923, DOI 10.1038/342923a0; GIROS B, 1990, CR ACAD SCI III-VIE, V311, P501; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; KANTERMAN RY, 1991, MOL PHARMACOL, V39, P364; KEBABIAN JW, 1972, P NATL ACAD SCI USA, V69, P2145, DOI 10.1073/pnas.69.8.2145; MAHAN LC, 1990, P NATL ACAD SCI USA, V87, P2196, DOI 10.1073/pnas.87.6.2196; PIOMELLI D, 1987, NATURE, V328, P38, DOI 10.1038/328038a0; SALMON JA, 1982, METHOD ENZYMOL, V86, P477; SCHWEITZER P, 1990, NATURE, V346, P464, DOI 10.1038/346464a0; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; SIDHU A, 1986, EUR J PHARMACOL, V128, P213, DOI 10.1016/0014-2999(86)90768-5; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; STARKE K, 1989, PHYSIOL REV, V69, P864, DOI 10.1152/physrev.1989.69.3.864; Stoof JC, 1981, NATURE, V294, P366, DOI 10.1038/294366a0; VALLAR L, 1989, TRENDS PHARMACOL SCI, V10, P74, DOI 10.1016/0165-6147(89)90082-5	28	264	266	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1991	353	6340					164	167		10.1038/353164a0	http://dx.doi.org/10.1038/353164a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE731	1909771	Green Published			2022-12-01	WOS:A1991GE73100053
J	RAHEMTULLA, A; FUNGLEUNG, WP; SCHILHAM, MW; KUNDIG, TM; SAMBHARA, SR; NARENDRAN, A; ARABIAN, A; WAKEHAM, A; PAIGE, CJ; ZINKERNAGEL, RM; MILLER, RG; MAK, TW				RAHEMTULLA, A; FUNGLEUNG, WP; SCHILHAM, MW; KUNDIG, TM; SAMBHARA, SR; NARENDRAN, A; ARABIAN, A; WAKEHAM, A; PAIGE, CJ; ZINKERNAGEL, RM; MILLER, RG; MAK, TW			NORMAL DEVELOPMENT AND FUNCTION OF CD8+ CELLS BUT MARKEDLY DECREASED HELPER-CELL ACTIVITY IN MICE LACKING CD4	NATURE			English	Article							EMBRYONIC STEM-CELLS; TOXIC T-CELL; HOMOLOGOUS RECOMBINATION; ANTIGEN EXPRESSION; PRECURSOR CELLS; VIRUS-INFECTION; SUBSETS; THYMOCYTES; RESPONSES; INVIVO	T CELLs express T-cell antigen receptors (TCR) for the recognition of antigen in conjunction with the products of the major histocompatibility complex 1,2. They also express two key surface coreceptors, CD4 and CD8, which are involved in the interaction with their ligands 3,4. As CD4 is expressed on the early haemopoietic progenitor 5 as well as the early thymic precursor cells 6, a role for CD4 in haemopoiesis and T-cell development is implicated. Thymocytes undergo a series of differentiation 7 and selection steps 8,9 to become mature CD4+8- or CD4-8+ (single positive) T cells 10,11. Studies of the role of CD4+ T cells in vivo have been based on adoptive transfer of selected or depleted lymphocytes, or in vivo treatment of thymectomized mice with monoclonal antibodies causing depletion of CD4+ T cells 12-14. In order to study the role of the CD4 molecule in the development and function of lymphocytes, we have disrupted the CD4 gene in embryonic stem cells 15,16 by homologous recombination 17,18. Germ-like transmission 19,20 of the mutation produces mutant mouse strains that do not express CD4 on the cell surface. In these mice, the development of CD8+ T cells and myeloid components is unaltered, indicating that expression of CD4 on progenitor cells and CD4+ CD8+ (double positive) thymocytes is not obligatory. Here we report that these mice have markedly decreased helper cell activity for antibody responses, although cytotoxic T-cell activity against viruses is in the normal range. This differential requirement for CD4+ helper T cells is important to our understanding of immune disorders, including AIDS, in which CD4+ cells are reduced or absent.	UNIV TORONTO, ONTARIO CANC INST, DEPT MED BIOPHYS & IMMUNOL, 500 SHERBOURNE ST, TORONTO M4X 1K9, ONTARIO, CANADA; UNIV ZURICH, INST PATHOL, CH-8091 ZURICH, SWITZERLAND	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Zurich			Schilham, Marco W./AAL-7223-2021; Sambhara, Suryaprakash/AAC-4428-2021	Schilham, Marco W./0000-0003-4391-6003; Fung-Leung, Wai-Ping/0000-0001-7013-8855				AHMED R, 1988, J VIROL, V62, P2102, DOI 10.1128/JVI.62.6.2102-2106.1988; ASHMAN RB, 1979, J EXP MED, V150, P1277, DOI 10.1084/jem.150.5.1277; BENNINK JR, 1978, NATURE, V276, P829, DOI 10.1038/276829a0; BULLER RML, 1987, NATURE, V328, P77, DOI 10.1038/328077a0; CANTOR H, 1975, J EXP MED, V141, P1376, DOI 10.1084/jem.141.6.1376; COBBOLD S, 1986, TRANSPLANTATION, V41, P634, DOI 10.1097/00007890-198605000-00016; COBBOLD SP, 1984, NATURE, V312, P548, DOI 10.1038/312548a0; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; FREDRICKSON GG, 1989, J EXP MED, V169, P1473, DOI 10.1084/jem.169.4.1473; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GILLIS S, 1978, J IMMUNOL, V120, P2027; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; HUDSON L, 1989, PRACTICAL IMMUNOLOGY; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAST WM, 1986, J EXP MED, V164, P723, DOI 10.1084/jem.164.3.723; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LEIST TP, 1989, SCAND J IMMUNOL, V30, P679, DOI 10.1111/j.1365-3083.1989.tb02476.x; LEIST TP, 1987, J IMMUNOL, V138, P2278; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MATHIESON BJ, 1984, IMMUNOL REV, V82, P141, DOI 10.1111/j.1600-065X.1984.tb01121.x; NASH AA, 1987, J GEN VIROL, V68, P825, DOI 10.1099/0022-1317-68-3-825; PARNES JR, 1989, ADV IMMUNOL, V44, P265; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SCOLLAY R, 1984, IMMUNOL REV, V82, P79, DOI 10.1111/j.1600-065X.1984.tb01118.x; SCOLLAY R, 1988, IMMUNOL REV, V104, P81, DOI 10.1111/j.1600-065X.1988.tb00760.x; SMITHIES O, 1985, NATURE, V317, P230, DOI 10.1038/317230a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; WU L, 1991, NATURE, V349, P71, DOI 10.1038/349071a0; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0; ZINKERNAGEL RM, 1978, J EXP MED, V147, P897, DOI 10.1084/jem.147.3.897	34	643	658	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 12	1991	353	6340					180	184		10.1038/353180a0	http://dx.doi.org/10.1038/353180a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE731	1832488				2022-12-01	WOS:A1991GE73100058
J	SADEGHNASSERI, S; GERMAIN, RN				SADEGHNASSERI, S; GERMAIN, RN			A ROLE FOR PEPTIDE IN DETERMINING MHC CLASS-II STRUCTURE	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; SEPARATE ALPHA-CHAINS; IMMUNOGENIC PEPTIDES; ANTIGENIC PEPTIDES; LYMPHOCYTE-T; BETA-CHAINS; MOLECULES; BINDING; IA; RECOGNITION	T LYMPHOCYTES recognize antigen-derived peptides associated with major histocompatibility complex (MHC) class I or class II proteins 1,2. Peptide is critical in class I heavy folding and/or stable association with beta-2-Microglobulin 3-6. Although data exist suggesting a relationship between class II structure and peptide association 7-9, no equivalent positive contribution of peptide to the folding state or stability of class II dimers has yet been demonstrated. We report here that most purified E-alpha(k)E-beta-k molecules leaving low pH in the absence of specific peptide lack a compact, stable dimeric structure. Brief exposure to the appropriate peptide just before and during neutralization promotes this specific conformation in proportion to stably bound peptide, indicating that peptide is important in determining class II MHC structure. Our results also indicate that efficient generation of long-lived peptide-class II complexes involves two stages: initial peptide binding in an acidic environment, which enhances the ability of class II to enter a conformation, from which stabilization upon neutralization results in high-affinity binding of previously associated peptide.			SADEGHNASSERI, S (corresponding author), NIAID,IMMUNOL LAB,LYMPHOCYTE BIOL SECT,BETHESDA,MD 20892, USA.		Germain, Ronald N./Z-1945-2019; Germain, Ronald/ABE-7090-2020	Sadegh-Nasseri, Scheherazade/0000-0002-8127-1720				BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BEVAN MJ, 1989, NATURE, V342, P478, DOI 10.1038/342478a0; BUSCH R, 1990, INT IMMUNOL, V2, P443, DOI 10.1093/intimm/2.5.443; BUUS S, 1988, SCIENCE, V242, P1045, DOI 10.1126/science.3194755; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; DORNMAIR K, 1989, COLD SH Q B, V54, P409; DORNMAIR K, 1990, P NATL ACAD SCI USA, V87, P4134, DOI 10.1073/pnas.87.11.4134; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; HARDING CV, 1990, CELL REGUL, V1, P499, DOI 10.1091/mbc.1.7.499; HARDING CV, 1991, P NATL ACAD SCI USA, V88, P7170; JENSEN PE, 1990, J EXP MED, V171, P1779, DOI 10.1084/jem.171.5.1779; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; OZATO K, 1980, J IMMUNOL, V124, P533; ROTHENHAUSLER B, 1990, P NATL ACAD SCI USA, V87, P352, DOI 10.1073/pnas.87.1.352; SADEGHNASSERI S, 1989, NATURE, V337, P274, DOI 10.1038/337274a0; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; VIGUIER M, 1990, P NATL ACAD SCI USA, V87, P7170, DOI 10.1073/pnas.87.18.7170; WATTS TH, 1986, P NATL ACAD SCI USA, V83, P9660, DOI 10.1073/pnas.83.24.9660; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	26	290	297	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1991	353	6340					167	170		10.1038/353167a0	http://dx.doi.org/10.1038/353167a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE731	1653903				2022-12-01	WOS:A1991GE73100054
J	SAMPEDRO, J; GUERRERO, I				SAMPEDRO, J; GUERRERO, I			UNRESTRICTED EXPRESSION OF THE DROSOPHILA GENE PATCHED ALLOWS A NORMAL SEGMENT POLARITY	NATURE			English	Article							PATTERN-FORMATION; BODY PATTERN; EMBRYOS; REQUIREMENTS; WINGLESS; PROTEIN; CUTICLE; LARVAL	IN the Drosophila embryo, mutations in the segment polarity gene patched (ptc) cause the replacement of the middle region of each segment by a mirror-image duplication of the remaining structures, including the parasegmental border 1-3. This gene, which encodes a transmembrane protein, is initially expressed in a generalized way at blastoderm, but later stops being transcribed in cells expressing the engrailed gene, and even later in cells in the middle of the parasegment 2-4. The genes engrailed (en) and wingless (wg) are also segment-polarity genes, and they are expressed in adjacent stripes flanking the parasegment borders in the embryo 5; in ptc mutants wg expression extends anteriorly and an ectopic stripe of en expression is induced 6,7. The suggestion has been made that ptc must be transcribed in a specific subset of cells to prevent en expression anterior to the wg-expressing stripe 4. Here we report that unrestricted expression of ptc from a heat-shock promoter has no adverse effect on development of Drosophila embryos. The heat-shock construct can also rescue ptc mutants, restoring wg expression to its normal narrow stripe. The ectopic en stripe fails to appear, but the normal one remains unaffected. The results imply that, despite its localized requirement, the restricted expression of ptc does not itself allocate positional information.	UNIV AUTONOMA MADRID, CSIC, CTR BIOL MOLEC, E-28049 MADRID, SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Guerrero, Isabel/K-2518-2014	Guerrero, Isabel/0000-0001-6761-1218				ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; COHEN SM, 1989, EMBO J, V8, P2045, DOI 10.1002/j.1460-2075.1989.tb03613.x; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DiNardo S, 1990, Semin Cell Biol, V1, P173; HIDALGO A, 1990, DEVELOPMENT, V110, P291; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM P, 1985, NATURE, V317, P634, DOI 10.1038/317634a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MOHLER J, 1988, GENETICS, V120, P1061; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041	19	31	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 12	1991	353	6340					187	190		10.1038/353187a0	http://dx.doi.org/10.1038/353187a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE731	1653907				2022-12-01	WOS:A1991GE73100060
J	STAMPFER, MJ; COLDITZ, GA; WILLETT, WC; MANSON, JE; ROSNER, B; SPEIZER, FE; HENNEKENS, CH				STAMPFER, MJ; COLDITZ, GA; WILLETT, WC; MANSON, JE; ROSNER, B; SPEIZER, FE; HENNEKENS, CH			POSTMENOPAUSAL ESTROGEN THERAPY AND CARDIOVASCULAR-DISEASE - 10-YEAR FOLLOW-UP FROM THE NURSES HEALTH STUDY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; RISK-FACTORS; PROSPECTIVE COHORT; WOMEN; REPRODUCIBILITY; QUESTIONNAIRE; MENOPAUSE; VALIDITY; CANCER; STROKE	Background. The effect of postmenopausal estrogen therapy on the risk of cardiovascular disease remains controversial. Our 1985 report in the Journal, based on four years of follow-up, suggested that estrogen therapy reduced the risk of coronary heart disease, but a report published simultaneously from the Framingham Study suggested that the risk was increased. In addition, studies of the effect of estrogens on stroke have yielded conflicting results. Methods. We followed 48,470 postmenopausal women, 30 to 63 years old, who were participants in the Nurses' Health Study and who did not have a history of cancer or cardiovascular disease at base line. During up to 10 years of follow-up (337,854 person-years), we documented 224 strokes, 405 cases of major coronary disease (nonfatal myocardial infarctions or deaths from coronary causes), and 1263 deaths from all causes. Results. After adjustment for age and other risk factors, the overall relative risk of major coronary disease in women currently taking estrogen was 0.56 (95 percent confidence interval, 0.40 to 0.80); the risk was significantly reduced among women with either natural or surgical menopause. We observed no effect of the duration of estrogen use independent of age. The findings were similar in analyese limited to women who had recently visited their physicians (relative risk, 0.45; 95 percent confidence interval, 0.31 to 0.66) and in a low-risk group that excluded women reporting current cigarette smoking, diabetes, hypertension, hypercholesterolemia, or a Quetelet index above the 90th percentile (relative risk, 0.53; 95 percent confidence interval, 0.31 to 0.91). The relative risk for current and former users of estrogen as compared with those who had never used it was 0.89 (95 percent confidence interval, 0.78 to 1.00) for total mortality and 0.72 (95 percent confidence interval, 0.55 to 0.95) for mortality from cardiovascular disease. The relative risk of stroke when current users were compared with those who had never used estrogen was 0.97 (95 percent confidence interval, 0.65 to 1.45), with no marked differences according to type of stroke. Conclusions. Current estrogen use is associated with a reduction in the incidence of coronary heart disease as well as in mortality from cardiovascular disease, but it is not associated with any change in the risk of stroke.	HARVARD UNIV, SCH MED, CHANNING LAB, DEPT PREVENT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT ENVIRONM HLTH, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	STAMPFER, MJ (corresponding author), HARVARD UNIV, SCH MED, CHANNING LAB, DEPT MED, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL 34594] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAILAR JC, 1985, NEW ENGL J MED, V313, P1080, DOI 10.1056/NEJM198510243131709; BOYSEN G, 1988, STROKE, V19, P1345, DOI 10.1161/01.STR.19.11.1345; BUSH TL, 1986, MENOPAUSE PHYSL PHAR, P187; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P48, DOI 10.1093/oxfordjournals.aje.a114223; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; COLDITZ GA, 1990, JAMA-J AM MED ASSOC, V264, P2648, DOI 10.1001/jama.264.20.2648; COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; Colditz GA, 1990, CURR PROB OBST GYN F, V13, P129; COX DR, 1972, J R STAT SOC B, V34, P187; EAKER ED, 1987, CORONARY HEART DISEA, P122; GRUCHOW HW, 1988, AM HEART J, V115, P954, DOI 10.1016/0002-8703(88)90063-4; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HILLNER BE, 1986, AM J MED, V80, P1115, DOI 10.1016/0002-9343(86)90674-1; JUDD HL, 1980, AM J OBSTET GYNECOL, V136, P859, DOI 10.1016/0002-9378(80)91043-1; LOBO RA, 1990, ANN NY ACAD SCI, V592, P286; MCFARLAND KF, 1989, AM HEART J, V117, P1209, DOI 10.1016/0002-8703(89)90398-0; PAGANINIHILL A, 1988, BMJ-BRIT MED J, V297, P519, DOI 10.1136/bmj.297.6647.519; ROTHMAN KJ, 1979, NIH791649 PHS PUBL; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1990, ANN NY ACAD SCI, V592, P193; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; STAMPFER MJ, 1987, CORONARY HEART DISEA, P112; SULLIVAN JM, 1988, ANN INTERN MED, V108, P358, DOI 10.7326/0003-4819-108-3-358; Walker AE, 1981, STROKE S1, V12, pI13; Weinstein M C, 1983, Obstet Gynecol Surv, V38, P445, DOI 10.1097/00006254-198308000-00001; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WILSON PWF, 1985, NEW ENGL J MED, V313, P1038, DOI 10.1056/NEJM198510243131702; [No title captured]	31	1873	1904	0	66	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 12	1991	325	11					756	762		10.1056/NEJM199109123251102	http://dx.doi.org/10.1056/NEJM199109123251102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE456	1870648				2022-12-01	WOS:A1991GE45600002
J	TSAI, LH; HARLOW, E; MEYERSON, M				TSAI, LH; HARLOW, E; MEYERSON, M			ISOLATION OF THE HUMAN CDK2 GENE THAT ENCODES THE CYCLIN-A-ASSOCIATED AND ADENOVIRUS-E1A-ASSOCIATED P-33 KINASE	NATURE			English	Article							ADENOVIRUS E1A PROTEINS; REGION 1A PROTEINS; CELL-CYCLE; FISSION YEAST; M-PHASE; CDC2; HOMOLOG; MITOSIS; DNA; PHOSPHORYLATION	CYCLINS are regulatory subunits which associate with kinases to form complexes that control many of the important steps in cell-cycle progression. The best characterized of the cyclin-containing complexes is the association of cyclin B with the p34cdc2 kinase. The p34cdc2/cyclin B complex is required for the G2 to M transition (see refs 1-4 for review), but the physiological role of other cyclin complexes is unclear. Human cyclin A binds independently to two kinases, associating with either p34cdc2 or a related protein, p33 (refs 5-7). In adenovirus-transformed cells, the viral E1A oncoprotein seems to associate with p33/cyclin A but not with p34cdc2/cyclin A (B. Faha, M.M., L-H.T. and E.H., manuscript submitted). To isolate the gene for p33, we have cloned several novel human cdc2-related genes. The protein product of one of these genes, cdk2 (cyclin-dependent kinase 2), shares 65% sequence identity with p34cdc2 (ref. 8) and 89% identity with the Xenopus Eg-1 gene product 9. Immunochemical characterization and partial proteolytic mapping show that the cdk2 gene product is the cyclin A-associated p33. Immunoprecipitations of the p33cdk2 protein suggest that it can act as a protein kinase in vitro. As p33cdk2 is bound to cyclin A and is targeted by the viral E1A protein, we suggest that the p33cdk2/cyclin A complex has a unique role in cell-cycle regulation of vertebrate cells.			TSAI, LH (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,BLDG 149,13TH ST,BOSTON,MA 02129, USA.		Meyerson, Matthew L/E-7123-2012					ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BELLETT AJD, 1985, MOL CELL BIOL, V5, P1933, DOI 10.1128/MCB.5.8.1933; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, IN PRESS SCIENCE; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HERMANN CH, IN PRESS J VIROL; KACZMAREK L, 1986, VIROLOGY, V152, P1, DOI 10.1016/0042-6822(86)90366-1; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LANE DP, 1978, VIROLOGY, V87, P182, DOI 10.1016/0042-6822(78)90170-8; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEHNER CF, 1990, EMBO J, V9, P3573, DOI 10.1002/j.1460-2075.1990.tb07568.x; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NINOMIYATSUJI J, IN PRESS P NATN ACAD; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PINES J, 1990, New Biologist, V2, P389; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	35	490	520	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1991	353	6340					174	177		10.1038/353174a0	http://dx.doi.org/10.1038/353174a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE731	1653904				2022-12-01	WOS:A1991GE73100056
J	DUMLER, JS; TAYLOR, JP; WALKER, DH				DUMLER, JS; TAYLOR, JP; WALKER, DH			CLINICAL AND LABORATORY FEATURES OF MURINE TYPHUS IN SOUTH TEXAS, 1980 THROUGH 1987	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MOUNTAIN SPOTTED-FEVER; MICROIMMUNOFLUORESCENCE TEST; EPIDEMIOLOGICAL FEATURES	Objective. - The clinical and laboratory features of patients with murine typhus have not been extensively reviewed since 1946. We have updated these findings in patients from south Texas who were examined by modern clinical and laboratory methods from 1980 through 1987. Design. - Patients were identified by serological methods in this case series, and clinical, epidemiologic, laboratory, and therapeutic data were compiled and analyzed. Setting. - The majority of patients (77 of 80) were identified in a primary care community hospital setting; the remainder (3 of 80) were ambulatory hospital outpatients. Patients. - From 1980 through 1987, a total of 345 patients were diagnosed with murine typhus; 90 of these patients were seen at four hospitals in south Texas; of these, 80 had clinical and laboratory data available for review. Main Outcome Measures. - The frequency of common clinical manifestations (eg, headache, fever, and rash) and laboratory findings (eg, leukocyte and platelet counts and serum chemistry abnormalities) of patients with infectious diseases was tabulated. Clinical severity was semiquantitatively assessed and was correlated with clinical, laboratory, and therapeutic results. Results. - Most cases (69%) occurred from April through August. Rash occurred in 54%; the triad of fever, headache, and rash was observed in only 12.5% of patients when first examined by a physician; respiratory and gastrointestinal symptoms were also frequent. Multiple organ involvement was documented by frequent abnormal laboratory findings of the hematologic, respiratory, hepatic, and renal systems. Disease severity was related to older patient age, the presence of renal dysfunction, leukocytosis, and hypoalbuminemia, and previous therapy with sulfa antibiotics. Conclusions. - Infection by Rickettsia typhi causes a systemic illness with clinical and laboratory abnormalities not previously recognized or described. Early clinical diagnosis and treatment are needed to avoid undue morbidity and mortality.	TEXAS DEPT HLTH, DIV EPIDEMIOL, AUSTIN, TX USA	Texas Department of State Health Services	DUMLER, JS (corresponding author), UNIV TEXAS, MED BRANCH, DEPT PATHOL, 101 KEILLER BLDG, F09, GALVESTON, TX 77550 USA.							ALAWADI AR, 1982, B WORLD HEALTH ORGAN, V60, P283; AZAD AF, 1985, AM J TROP MED HYG, V34, P555, DOI 10.4269/ajtmh.1985.34.555; BELTRAN RR, 1991, RICKETTSIAE RICKETTS, P714; BETZ TG, 1983, TEX MED, V79, P48; BINFORD CH, 1947, AM J CLIN PATHOL, V17, P797; BOTROS BAM, 1989, J TROP MED HYG, V92, P373; BROWN AE, 1989, AM J TROP MED HYG, V92, P373; BURGDORFER W, 1976, TROPICAL MED, P110; BUTTERY CMG, 1984, TEX MED, V80, P53; FAN MY, 1987, REV INFECT DIS, V9, P823; FARHANGAZAD A, 1984, J MED ENTOMOL, V21, P675, DOI 10.1093/jmedent/21.6.675; FARHANGAZAD A, 1988, BIOL RICKETTSIAL DIS, V1, P51; GROSS EM, 1984, B WORLD HEALTH ORGAN, V62, P301; HECHEMY KE, 1979, J CLIN MICROBIOL, V9, P292; HECHEMY KE, 1981, J CLIN MICROBIOL, V13, P214, DOI 10.1128/JCM.13.1.214-216.1981; HELMICK CG, 1984, J INFECT DIS, V150, P480, DOI 10.1093/infdis/150.4.480; Irons J. V., 1944, AMER JOUR TROP MED, V24, P359; KIRK JL, 1990, MEDICINE, V69, P35, DOI 10.1097/00005792-199001000-00003; LOVE GJ, 1960, PUBLIC HEALTH REP, V75, P429, DOI 10.2307/4590821; MAXCY K. F., 1926, Public Health Reports, V41, P2967, DOI 10.2307/4578110; MILLER ES, 1946, MEDICINE, V25, P1; OLDER JJ, 1970, J AMER MED ASSOC, V214, P2011, DOI 10.1001/jama.214.11.2011; PETERSON JC, 1947, J PEDIATR, V30, P495, DOI 10.1016/S0022-3476(47)80046-0; PHILIP RN, 1976, J CLIN MICROBIOL, V3, P51; QUINBY GE, 1953, AM J PUBLIC HEALTH, V43, P160; RAOULT D, 1986, J INFECTION, V12, P111, DOI 10.1016/S0163-4453(86)93508-5; RAOULT D, 1986, AM J TROP MED HYG, V35, P845, DOI 10.4269/ajtmh.1986.35.845; SAMRA Y, 1989, ARCH INTERN MED, V149, P949, DOI 10.1001/archinte.149.4.949; SMADEL JE, 1959, ANN INTERN MED, V51, P421, DOI 10.7326/0003-4819-51-3-421; SNYDER JC, 1946, RICKETTSIAL DISEASES, P169; STASKO T, 1982, J AM ACAD DERMATOL, V7, P377, DOI 10.1016/S0190-9622(82)80318-6; STUART BM, 1945, ANN INTERN MED, V23, P520, DOI 10.7326/0003-4819-23-4-520; TAYLOR JP, 1986, JAMA-J AM MED ASSOC, V255, P2173; Traub R, 1978, Trop Dis Bull, V75, P237; TSELENTIS Y, 1986, J INFECTION, V13, P91, DOI 10.1016/S0163-4453(86)92371-6; WALKER DH, 1989, AM J CLIN PATHOL, V91, P720, DOI 10.1093/ajcp/91.6.720; WALKER DH, 1980, J INFECT DIS, V142, P771, DOI 10.1093/infdis/142.5.771; WOODRUFF PWR, 1988, T ROY SOC TROP MED H, V82, P761, DOI 10.1016/0035-9203(88)90229-5; WOODWARD TE, 1988, BIOL RICKETTSIAL DIS, V1, P79; 1990, MMWR, V38, P47	40	177	184	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 11	1991	266	10					1365	1370		10.1001/jama.266.10.1365	http://dx.doi.org/10.1001/jama.266.10.1365			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD807	1880866				2022-12-01	WOS:A1991GD80700030
J	BRAHAMS, D				BRAHAMS, D			GROUP LITIGATION ON THE HORIZON	LANCET			English	Editorial Material							PORCINE INSULIN; HYPOGLYCEMIA											BERGER W, 1989, LANCET, V1, P1041, DOI 10.1016/S0140-6736(89)92444-6; DENISON S, 1991, INDEPENDENT     0807; GALE EAM, 1989, LANCET, V2, P1264; TEUSCHER A, 1987, LANCET, V2, P382	4	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 7	1991	338	8767					625	626		10.1016/0140-6736(91)90624-X	http://dx.doi.org/10.1016/0140-6736(91)90624-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD809	1679162				2022-12-01	WOS:A1991GD80900015
J	BURNEY, PGJ				BURNEY, PGJ			THE HEALTH OF THE NATION - RESPONSES - STRATEGY FOR ASTHMA	BRITISH MEDICAL JOURNAL			English	Article							ADULT ASTHMA; MANAGEMENT; ENGLAND; WALES; ADMISSIONS; PREVALENCE; MORTALITY; EDUCATION; INCREASE				BURNEY, PGJ (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DEPT PUBL HLTH MED,ST THOMAS CAMPUS,LONDON SE1 7EH,ENGLAND.			Burney, Peter/0000-0001-8635-5678				Alderson M., 1987, POP TRENDS, V49, P18; ALI NJ, 1991, THORAX, V46, P160, DOI 10.1136/thx.46.3.160; [Anonymous], 1990, BMJ, V301, P651; BEASLEY R, 1989, THORAX, V44, P200, DOI 10.1136/thx.44.3.200; BLAINEY D, 1991, HLTH TRENDS, V22, P151; BUCKNALL CE, 1988, LANCET, V1, P748; BUCKNALL CE, 1988, BRIT MED J, V296, P1637, DOI 10.1136/bmj.296.6637.1637; BURNEY P, 1988, J EPIDEMIOL COMMUN H, V42, P316, DOI 10.1136/jech.42.4.316; BURNEY PGJ, 1986, LANCET, V2, P323; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; CHARLTON I, 1990, BRIT MED J, V301, P1355, DOI 10.1136/bmj.301.6765.1355; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; HAY I, 1987, LANCET, V1, P609; HILL AM, 1989, BRIT MED J, V298, P1479, DOI 10.1136/bmj.298.6686.1479; HILL RA, 1989, ARCH DIS CHILD, V64, P246, DOI 10.1136/adc.64.2.246; HILTON S, 1986, LANCET, V1, P26; JOHNSON AJ, 1984, BRIT MED J, V288, P1870, DOI 10.1136/bmj.288.6434.1870; MAIMAN LA, 1979, JAMA-J AM MED ASSOC, V241, P1919; MAYO PH, 1990, ANN INTERN MED, V112, P864, DOI 10.7326/0003-4819-112-11-864; NOCON A, 1991, ARCH DIS CHILD, V66, P458, DOI 10.1136/adc.66.4.458; REES PJ, 1991, BMJ, V302, P1166; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; WARNER JO, 1989, ARCH DIS CHILD, V64, P165; WOLTHERS OD, 1991, BMJ-BRIT MED J, V303, P163, DOI 10.1136/bmj.303.6795.163; 1991, CM1523; 1990, BMJ, V301, P797	27	12	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1991	303	6802					571	573		10.1136/bmj.303.6802.571	http://dx.doi.org/10.1136/bmj.303.6802.571			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GE948	1912890	Bronze, Green Published			2022-12-01	WOS:A1991GE94800029
J	JOHNSON, AM				JOHNSON, AM			HIV AND AIDS	BRITISH MEDICAL JOURNAL			English	Article											JOHNSON, AM (corresponding author), UNIV COLL & MIDDLESEX SCH MED,ACAD DEPT GENITOURINARY MED,LONDON W1N 8AA,ENGLAND.			Johnson, Anne/0000-0003-1330-7100				ADES AE, 1991, LANCET, P1562; BROOKMEYER R, 1991, SCIENCE, V253, P37, DOI 10.1126/science.2063206; DUNNELL K, 1991, POPULATION TRENDS, V64, P38; JOHNSON AM, 1989, AIDS, V3, P135, DOI 10.1097/00002030-198903000-00003; JOHNSON AM, 1989, PHILOS T R SOC LOND, V325, P115; MCGINNIS JM, 1985, OXFORD TXB PUBLIC HL, P385; WELLINGS K, 1990, NATURE, V348, P276, DOI 10.1038/348276a0; WODAK A, 1990, AIDS (London), V4, pS105; 1988, REPORT; 1988, AIDS STRATEGIC MONIT; 1980, PROMOTING HLTH PERVE; 1988, MMWR, V37, P565; 1990, MMWR, V39, P54; 1990, NEW CASES NHS GENITO; 1991, UK LEVELS HLTH; 1991, HLTH NATION; 1990, MMWR, V40, P41; 1990, DHHS PHS9050212 PUBL; 1979, DHEW PHS7955071 PUBL; 1991, 1 PUBL HLTH LAB SERV, pR69	20	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1991	303	6802					573	576		10.1136/bmj.303.6802.573	http://dx.doi.org/10.1136/bmj.303.6802.573			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE948	1912891	Green Published, Bronze			2022-12-01	WOS:A1991GE94800030
J	LAVERICK, MD; CROAL, SA; MOLLAN, RAB				LAVERICK, MD; CROAL, SA; MOLLAN, RAB			ORTHOPEDIC SURGEONS AND THROMBOPROPHYLAXIS	BRITISH MEDICAL JOURNAL			English	Article							DEEP VENOUS THROMBOSIS; TOTAL HIP-REPLACEMENT; VEIN THROMBOSIS; PREVENTION; THROMBOEMBOLISM; COMPRESSION; STOCKINGS; HEPARIN	Objective - To assess attitudes to the use of thromboprophylaxis among orthopaedic surgeons in the United Kingdom. Design and subjects - Single page postal questionnaire to all 926 active orthopaedic surgeons who are members of the British Orthopaedic Association. Results - The response rate was 70% (659 surgeons), of whom 595 (90%) used some form of prophylaxis. Most (548; 83%) used drugs but 47 (7%) used only elasticated stockings. A history of thromboembolic disease, hip surgery, and obesity was seen as the main risk factor. Ineffectiveness was the principal reason for not using prophylaxis. Conclusions - Most orthopaedic surgeons use regimens of thromboprophylaxis, though many of these are of limited value. Improvements in the efficacy and safety of prophylactic agents, combined with ease of administration, would increase the use of such agents and make orthopaedic surgery safer for the patient.			LAVERICK, MD (corresponding author), QUEENS UNIV BELFAST,MUSGRAVE PK HOSP,DEPT ORTHOPAED SURG,BELFAST BT9 7JB,NORTH IRELAND.							BEISAW NE, 1988, J BONE JOINT SURG AM, V70A, P2, DOI 10.2106/00004623-198870010-00002; BRENKEL I, 1989, BRIT J HOSP MED, V42, P282; CHRISMAN OD, 1976, J BONE JOINT SURG AM, V58, P918, DOI 10.2106/00004623-197658070-00003; COTTON LT, 1977, SURGERY, V81, P228; EVARTS CM, 1971, J BONE JOINT SURG AM, VA 53, P1271, DOI 10.2106/00004623-197153070-00002; JOHNSON R, 1986, CLIN ORTHOPAEDICS, V211, P151; Ljungstrom K G, 1988, Acta Chir Scand Suppl, V543, P26; NICOLAIDES AN, 1983, SURGERY, V94, P21; PLANES A, 1986, HAEMOSTASIS, V16, P152; PLANES A, 1990, J BONE JOINT SURG BR, V72, P9, DOI 10.1302/0301-620X.72B1.2298803; SALZMAN EW, 1976, J BONE JOINT SURG AM, V58, P903, DOI 10.2106/00004623-197658070-00001; SCURR JH, 1988, BRIT MED J, V297, P28, DOI 10.1136/bmj.297.6640.28; STRINGER MD, 1989, J BONE JOINT SURG BR, V71, P492, DOI 10.1302/0301-620X.71B3.2785998; STULBERG BN, 1984, J BONE JOINT SURG AM, V66A, P194, DOI 10.2106/00004623-198466020-00005; TORNGREN S, 1980, BRIT J SURG, V67, P482, DOI 10.1002/bjs.1800670710; WHITEHOUSE G, 1987, BRIT MED J, V295, P801, DOI 10.1136/bmj.295.6602.801; WOLFE JHN, 1987, BMJ, V295, P1365; 1986, JAMA-J AM MED ASSOC, V256, P744	18	77	78	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1991	303	6802					549	550		10.1136/bmj.303.6802.549	http://dx.doi.org/10.1136/bmj.303.6802.549			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE948	1912884	Bronze, Green Published			2022-12-01	WOS:A1991GE94800021
J	LAZARUS, NB; KAPLAN, GA; COHEN, RD; LEU, DJ				LAZARUS, NB; KAPLAN, GA; COHEN, RD; LEU, DJ			CHANGE IN ALCOHOL-CONSUMPTION AND RISK OF DEATH FROM ALL CAUSES AND FROM ISCHEMIC-HEART-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							ALAMEDA COUNTY; MORTALITY; LINKAGE; WOMEN; MEN	Objective - To examine the association between alcohol consumption and mortality from all causes and from ischaemic heart disease with a focus on differentiating between long term abstainers and more recent non-drinkers. Design - Cohort study of changes in alcohol consumption from 1965 to 1974 and mortality from all causes and ischaemic heart disease during 1974-84. Setting - Population based study of adult residents of Alameda County, California. Subjects - 2225 women and 1845 men aged 35 and over in 1965. Main outcome measures - Alcohol consumption in 1964 and 1974 and mortality from all causes and from ischaemic heart disease during 1974-84. Results - There was a significantly higher risk of death from all causes and from ischaemic heart disease in women who gave up drinking between 1965 and 1974 than in women who continued to drink (relative risk 1.72, 95% confidence interval 1.11 to 2.66, and 2.75, 1.44 to 5.23, for all causes and ischaemic heart disease respectively). A significant increase in risk was not seen in men who gave up drinking (1.32, 0.87 to 2.01, and 0.95, 0.41 to 2.20, respectively). Among men, long term abstainers compared with drinkers were at increased risk of death from all causes and from ischaemic heart disease, though the associations were not significant (1.40, 0.98 to 2.00, and 1.40, 0.76 to 2.58, for all causes and ischaemic heart disease respectively). Conclusion- Some of the increased risk of death from all causes and from ischaemic heart disease associated with not drinking in women seems to be accounted for by higher risks among those who gave up drinking. Men who are long term abstainers may also be at an increased risk of death. The heterogeneity of the non-drinking group should be considered when comparisons are made with drinkers.	CALIF DEPT HLTH SCI,HUMAN POPULAT LAB,BERKELEY,CA 94704; CALIF PUBL HLTH FDN,HUMAN POPULAT LAB,BERKELEY,CA 94704	California Department of Public Health			Kaplan, George/AAJ-2398-2020					ARELLANO MG, 1984, AM J PUBLIC HEALTH, V74, P1324, DOI 10.2105/AJPH.74.12.1324; BELLOC NB, 1973, HEALTH SERV REP, V88, P344, DOI 10.2307/4594792; Berkman LF, 1983, HLTH WAYS LIVING ALA; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; CAMACHO TC, 1987, J CHRON DIS, V40, P229, DOI 10.1016/0021-9681(87)90158-5; CASTELLI WP, 1977, LANCET, V2, P153; COLSHER PL, 1989, ANNU REV PUBL HEALTH, V10, P203, DOI 10.1146/annurev.pu.10.050189.001223; CRIQUI MH, 1985, BEHAVIORAL EPIDEMIOL, P67; DYER AR, 1980, PREV MED, V9, P78, DOI 10.1016/0091-7435(80)90060-2; DYER AR, 1977, CIRCULATION, V56, P1067, DOI 10.1161/01.CIR.56.6.1067; Ellison R C, 1990, Epidemiology, V1, P337; ERNST N, 1980, CIRCULATION, V62, P41; FREZZA M, 1990, NEW ENGL J MED, V322, P95, DOI 10.1056/NEJM199001113220205; JACKSON R, 1991, BRIT MED J, V303, P211, DOI 10.1136/bmj.303.6796.211; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KLATSKY AL, 1974, ANN INTERN MED, V81, P294, DOI 10.7326/0003-4819-81-3-294; MARMOT MG, 1981, LANCET, V1, P580; MEADE TW, 1979, BMJ-BRIT MED J, V1, P153, DOI 10.1136/bmj.1.6157.153; MOORE RD, 1986, MEDICINE, V65, P242, DOI 10.1097/00005792-198607000-00004; SEEMAN TE, 1987, AM J EPIDEMIOL, V126, P714, DOI 10.1093/oxfordjournals.aje.a114711; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; WANNAMETHEE G, 1988, INT J EPIDEMIOL, V17, P307, DOI 10.1093/ije/17.2.307; YANO K, 1984, AM J EPIDEMIOL, V119, P653, DOI 10.1093/oxfordjournals.aje.a113787; YANO K, 1977, NEW ENGL J MED, V297, P405, DOI 10.1056/NEJM197708252970801; 1974, 2ND US DEP HLTH ED W	25	68	68	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1991	303	6802					553	556		10.1136/bmj.303.6802.553	http://dx.doi.org/10.1136/bmj.303.6802.553			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE948	1912885	Green Submitted, Green Published, Bronze			2022-12-01	WOS:A1991GE94800023
J	LEWIS, M; FAED, MJW; HOWIE, PW				LEWIS, M; FAED, MJW; HOWIE, PW			SCREENING FOR DOWNS-SYNDROME BASED ON INDIVIDUAL RISK	BRITISH MEDICAL JOURNAL			English	Article							SERUM ALPHA-FETOPROTEIN; CHORIONIC-GONADOTROPIN; PREGNANCY; ABNORMALITIES	Objective - To evaluate the effectiveness of biochemical screening of individual pregnancies for Down's syndrome risk. Design - Retrospective determination of risk. Setting - Obstetric and cytogenetic services in Tayside, Scotland. Subjects - 3436 pregnant women who had screening for neural tube defects in the second trimester during November 1988 to March 1990 and whose pregnancies were dated by ultrasonography. Three women with pregnancies associated with Down's syndrome reported later in 1990. Main outcome measures - Individual risk calculated from age at estimated date of delivery; chorionic gonadotrophin and a fetoprotein concentrations in serum samples obtained at precisely determined gestational ages in second trimester. Results of karyotype determination and outcome of pregnancy. Results - During November 1988 to March 1990 karyotypes were determined for 5% of pregnancies for reasons of maternal age and genetic history and one of the eight affected fetuses was detected. Individual risk could not be calculated for 347 pregnancies, but screening on this basis would have detected five of the cases and required screening in 194 out of 3089 (6.3%) pregnancies; all three affected pregnancies reported later in 1990 would also have been detected, giving a success rate of 73% (95% confidence interval 39% to 94%). The age distribution of women according to individual risk suggests that women over 35 would be screened effectively. Conclusion - Screening based on individual risk would use resources more effectively than screening based on maternal age and genetic history without affecting detection rates in older women.			LEWIS, M (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DUNDEE DD1 9SY,SCOTLAND.							BOGART MH, 1987, PRENATAL DIAG, V7, P623, DOI 10.1002/pd.1970070904; CANICK JA, 1988, BRIT J OBSTET GYNAEC, V95, P330, DOI 10.1111/j.1471-0528.1988.tb06601.x; CHRISTIE AD, 1980, THESIS U DUNDEE DUND; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; MACRI JN, 1990, AM J OBSTET GYNECOL, V163, P1248, DOI 10.1016/0002-9378(90)90700-H; MANCINI G, 1991, PRENATAL DIAG, V11, P245, DOI 10.1002/pd.1970110406; MERKATZ IR, 1984, AM J OBSTET GYNECOL, V148, P886, DOI 10.1016/0002-9378(84)90530-1; NORGAARDPEDERSEN B, 1990, CLIN GENET, V37, P35; STEVENSON JD, 1987, ANN CLIN BIOCHEM, V24, P411, DOI 10.1177/000456328702400411; SUCHY SF, 1990, OBSTET GYNECOL, V76, P20; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; WALD NJ, 1989, OBSTETRICS, P269; WALKER EM, 1988, BRIT J OBSTET GYNAEC, V95, P659, DOI 10.1111/j.1471-0528.1988.tb06526.x	13	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1991	303	6802					551	553		10.1136/bmj.303.6802.551	http://dx.doi.org/10.1136/bmj.303.6802.551			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE948	1717087	Green Published, Bronze			2022-12-01	WOS:A1991GE94800022
J	MARMOT, M; BRUNNER, E				MARMOT, M; BRUNNER, E			ALCOHOL AND CARDIOVASCULAR-DISEASE - THE STATUS OF THE U-SHAPED CURVE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; MORTALITY; CONSUMPTION; DEATH; RISK; MEN; DRINKING				MARMOT, M (corresponding author), UCL, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6EA, ENGLAND.		Brunner, Eric/H-2114-2011; Marmot, M G/Y-3920-2019	Brunner, Eric/0000-0002-0595-4474; Marmot, M G/0000-0002-2431-6419	Medical Research Council [G8802774] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		AENDERSON P, 1988, BMJ-BRIT MED J, V297, P824; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; CAMACHO TC, 1987, J CHRON DIS, V40, P229, DOI 10.1016/0021-9681(87)90158-5; CASTELLI WP, 1977, LANCET, V2, P153; CRIQUI MH, 1990, BRIT J ADDICT, V85, P854; CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702; CULLEN K, 1982, INT J EPIDEMIOL, V11, P67, DOI 10.1093/ije/11.1.67; DEAN G, 1977, 14 TOB RES COUNC P 1; DEBUSK RF, 1986, NEW ENGL J MED, V314, P161, DOI 10.1056/NEJM198601163140307; DUFFY JC, 1982, PSYCHOL REP, V50, P125, DOI 10.2466/pr0.1982.50.1.125; DYER AR, 1980, PREV MED, V9, P78, DOI 10.1016/0091-7435(80)90060-2; FRIEDMAN LA, 1986, AM J EPIDEMIOL, V124, P481, DOI 10.1093/oxfordjournals.aje.a114418; GORDON T, 1987, AM J EPIDEMIOL, V125, P263, DOI 10.1093/oxfordjournals.aje.a114525; HEGSTED DM, 1988, J NUTR, V118, P1184, DOI 10.1093/jn/118.10.1184; HENNEKENS CH, 1978, AM J EPIDEMIOL, V107, P196, DOI 10.1093/oxfordjournals.aje.a112525; JACKSON R, 1991, BRIT MED J, V303, P211, DOI 10.1136/bmj.303.6796.211; KITTNER SJ, 1983, AM J EPIDEMIOL, V117, P538, DOI 10.1093/oxfordjournals.aje.a113576; KLATSKY AL, 1986, AM J CARDIOL, V58, P710, DOI 10.1016/0002-9149(86)90342-5; KLATSKY AL, 1990, CIRCULATION, V81, P720; KLATSKY AL, 1979, ALCOHOL CLIN EXP RES, V3, P33, DOI 10.1111/j.1530-0277.1979.tb04764.x; KLATSKY AL, 1989, CIRCULATION, V80, P611; KONO S, 1986, INT J EPIDEMIOL, V15, P527, DOI 10.1093/ije/15.4.527; KOZAREVIC D, 1983, INT J EPIDEMIOL, V12, P145, DOI 10.1093/ije/12.2.145; LAZARUS NB, 1991, BRIT MED J, V303, P553, DOI 10.1136/bmj.303.6802.553; MARMOT MG, 1984, INT J EPIDEMIOL, V13, P160, DOI 10.1093/ije/13.2.160; MARMOT MG, 1981, LANCET, V1, P580; MEADE TW, 1979, BMJ-BRIT MED J, V1, P153, DOI 10.1136/bmj.1.6157.153; MILLER GJ, 1990, INT J EPIDEMIOL, V19, P923, DOI 10.1093/ije/19.4.923; ROSE G, 1990, BRIT MED J, V301, P1031, DOI 10.1136/bmj.301.6759.1031; ROSS RK, 1981, LANCET, V1, P858; SHAPER AG, 1990, BRIT J ADDICT, V85, P837; SHAPER AG, 1988, LANCET, V2, P1267; SISCOVICK DS, 1986, AM J EPIDEMIOL, V123, P490, DOI 10.1093/oxfordjournals.aje.a114265; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; STLEGER AS, 1979, LANCET, V1, P1017, DOI 10.1016/S0140-6736(79)92765-X; YANO K, 1977, NEW ENGL J MED, V297, P405, DOI 10.1056/NEJM197708252970801; 1988, LANCET, V2, P1292	37	316	319	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 7	1991	303	6802					565	568		10.1136/bmj.303.6802.565	http://dx.doi.org/10.1136/bmj.303.6802.565			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE948	1912889	Green Published, Bronze			2022-12-01	WOS:A1991GE94800027
J	MCKHANN, GM; CORNBLATH, DR; HO, T; LI, CY; BAI, AY; WU, HS; YEI, QF; ZHANG, WC; ZHAORI, Z; JIANG, Z; GRIFFIN, JW; ASBURY, AK				MCKHANN, GM; CORNBLATH, DR; HO, T; LI, CY; BAI, AY; WU, HS; YEI, QF; ZHANG, WC; ZHAORI, Z; JIANG, Z; GRIFFIN, JW; ASBURY, AK			CLINICAL AND ELECTROPHYSIOLOGICAL ASPECTS OF ACUTE PARALYTIC DISEASE OF CHILDREN AND YOUNG-ADULTS IN NORTHERN CHINA	LANCET			English	Article								Acute peripheral nervous system diseases leading to paralysis in children are rare in Europe and the USA, whereas epidemics of a Guillain-Barre-like syndrome occur annually among children in rural parts of northern China. To clarify the features of this disorder 36 patients, aged 15 months to 37 years (median 7) with this syndrome were investigated; 91% were from rural areas. In 47%, a prodromal illness was reported in the preceding 4 weeks. Leg weakness and resistance to neck flexion were the earliest symptoms. The weakness ascended rapidly and symmetrically to affect the arms and respiratory muscles, with maximum weakness occurring a mean of 6 days after onset of weakness. Bulbar weakness occurred in 61% of patients, but only 1 had extraocular paresis. Respiratory assistance was needed by 31% of patients. Tendon reflexes were lost as weakness developed. 42% of patients had raised concentrations of protein in the cerebrospinal fluid, and the mean cell count was 3 cells/mu-l (range 0-12/mu-l). Electrodiagnostic studies in 22 patients showed severe reductions in motor evoked amplitudes from distal stimulation. Sensory action potentials were normal. Electromyography revealed denervation potentials in limb muscles. The distinctive epidemiological, clinical, and neurophysiological characteristics of this illness suggest that the disorder is different from both Guillain-Barre syndrome and poliomyelitis. The neurophysiological findings support the hypothesis that the disorder is a reversible distal motor nerve terminal or anterior horn cell lesion.	HEBEI MED COLL,SECOND TEACHING HOSP,DEPT NEUROL,SHIJIAZHUANG,PEOPLES R CHINA; BEIJING CHILDRENS HOSP,DEPT NEUROL,BEIJING,PEOPLES R CHINA; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; UNIV PENN,SCH MED,DEPT NEUROL,PHILADELPHIA,PA 19104	Capital Medical University; Johns Hopkins University; University of Pennsylvania			Ho, Tony W/F-1019-2011		NINDS NIH HHS [NS23936, NS22849] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS022849, R01NS023936] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBERS JW, 1985, MUSCLE NERVE, V8, P528, DOI 10.1002/mus.880080609; ALTER M, 1990, ANN NEUROL, V27, pS7, DOI 10.1002/ana.410270704; ASBURY AK, 1990, ANN NEUROL, V27, pS21, DOI 10.1002/ana.410270707; BROWN WF, 1984, BRAIN, V107, P219, DOI 10.1093/brain/107.1.219; CHIAE CK, 1986, CHINESE J PSYCHIATRY, V19, P149; CORNBLATH D R, 1990, Neurology, V40, P458; CORNBLATH DR, 1990, ANN NEUROL, V27, pS17, DOI 10.1002/ana.410270706; HUSHENG W, 1988, BRAIN DEV, V10, P147; PAULSON GW, 1970, DEV MED CHILD NEUROL, V12, P604; RAMOSALV.M, 1969, J AMER MED ASSOC, V207, P1481; SUN JY, 1991, CHINESE J NEUROL PSY, V15, P75; WADIA NH, 1983, J NEUROL NEUROSUR PS, V46, P599, DOI 10.1136/jnnp.46.7.599; WITTE JJ, 1966, AM J EPIDEMIOL, V83, P189, DOI 10.1093/oxfordjournals.aje.a120574; XUE G, 1980, ZHOGHUA YUFANGYIXUE, V14, P123; YOHANNAN MD, 1991, J INFECTION, V22, P129, DOI 10.1016/0163-4453(91)91503-P; ZHANG ZL, 1979, CHIN J NEUROL PSYCHI, V12, P17; ZHAO BX, 1981, ANN NEUROL, V9, P146, DOI 10.1002/ana.410090720	17	180	188	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 7	1991	338	8767					593	597		10.1016/0140-6736(91)90606-P	http://dx.doi.org/10.1016/0140-6736(91)90606-P			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD809	1679153				2022-12-01	WOS:A1991GD80900003
J	ONG, ELC; BILTON, D; ABBOTT, J; WEBB, AK; MCCARTNEY, RA; CAUL, EO				ONG, ELC; BILTON, D; ABBOTT, J; WEBB, AK; MCCARTNEY, RA; CAUL, EO			INFLUENZA VACCINATION IN ADULTS WITH CYSTIC-FIBROSIS	BRITISH MEDICAL JOURNAL			English	Article									MONSALL HOSP,ADULT CYST FIBROSIS UNIT,MANCHESTER M10 8WR,ENGLAND; MONSALL HOSP,REG DEPT INFECT DIS & TROP MED,MANCHESTER M10 8WR,ENGLAND; REG PUBL HLTH & DIST VIROL LAB,BRISTOL BS2 8EL,ENGLAND					Ong, Edmund/0000-0002-6594-0509; Bilton, Diana/0000-0002-1913-9171				DAVIES JR, 1989, EPIDEMIOL INFECT, V102, P325, DOI 10.1017/S0950268800030004; EICKHOFF TC, 1961, JAMA-J AM MED ASSOC, V176, P776, DOI 10.1001/jama.1961.03040220024005; GRILLI EA, 1983, J HYG-CAMBRIDGE, V91, P147, DOI 10.1017/S0022172400060125; ONG ELC, 1989, THORAX, V4, P739; WANG EEL, 1984, NEW ENGL J MED, V311, P1653, DOI 10.1056/NEJM198412273112602	5	23	25	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1991	303	6802					557	557		10.1136/bmj.303.6802.557	http://dx.doi.org/10.1136/bmj.303.6802.557			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE948	1912886	Green Published, Bronze			2022-12-01	WOS:A1991GE94800024
J	ADAM, SA; GERACE, L				ADAM, SA; GERACE, L			CYTOSOLIC PROTEINS THAT SPECIFICALLY BIND NUCLEAR LOCATION SIGNALS ARE RECEPTORS FOR NUCLEAR IMPORT	CELL			English	Article							LARGE-T-ANTIGEN; RAT-LIVER NUCLEI; ASP-GLU-ASP; PORE COMPLEX; SEQUENCE REQUIREMENTS; TRANSPORT SIGNALS; MAMMALIAN-CELLS; LOCALIZATION; TRANSLOCATION; ENVELOPE	We have purified two major polypeptides of 54 and 56 kd from bovine erythrocytes that specifically bind the nuclear location sequence (NLS) of the SV40 large T antigen. When added to a permeabilized cell system for nuclear import, the purified proteins increase by 2- to 3-fold the nuclear accumulation of a fluorescent protein containing the large T antigen NLS. The import stimulation is saturable and dependent upon the presence of cytosol. Nuclear protein accumulation in vitro is sensitive to inactivation by N-ethylmaleimide (NEM). NEM inactivation can be overcome by addition of the purified NLS-binding proteins to the import system. NEM treatment of the purified proteins abolishes their ability to stimulate import but does not affect NLS binding. Our results indicate that the NLS-binding proteins are NEM-sensitive receptors for nuclear import. At least one other NEM-sensitive cytosolic activity and an NEM-insensitive cytosolic activity are also necessary for protein import in vitro.	Scripps Res Inst, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	ADAM, SA (corresponding author), NORTHWESTERN UNIV, SCH MED, DEPT CELL MOLEC & STRUCT BIOL, CHICAGO, IL 60611 USA.			Adam, Stephen/0000-0003-3444-7655				ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; BATAILLE N, 1990, J CELL BIOL, V111, P1571, DOI 10.1083/jcb.111.4.1571; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; DALES S, 1973, VIROLOGY, V56, P465, DOI 10.1016/0042-6822(73)90050-0; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; DWORETZKY SI, 1988, J CELL BIOL, V106, P575, DOI 10.1083/jcb.106.3.575; FEATHERSTONE C, 1988, J CELL BIOL, V107, P1289, DOI 10.1083/jcb.107.4.1289; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; FELDHERR CM, 1990, J CELL BIOL, V111, P1, DOI 10.1083/jcb.111.1.1; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HUNT T, 1989, CELL, V59, P949, DOI 10.1016/0092-8674(89)90747-2; IMAMOTOSONOBE N, 1990, J BIOL CHEM, V265, P16504; IMAMOTOSONOBE N, 1988, P NATL ACAD SCI USA, V85, P3426, DOI 10.1073/pnas.85.10.3426; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KALINICH JF, 1989, J BIOL CHEM, V264, P17979; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LANFORD RE, 1988, MOL CELL BIOL, V8, P2722, DOI 10.1128/MCB.8.7.2722; LEE WC, 1989, P NATL ACAD SCI USA, V86, P8808, DOI 10.1073/pnas.86.22.8808; LI RH, 1989, J CELL BIOL, V109, P2623, DOI 10.1083/jcb.109.6.2623; MANDELL RB, 1990, J CELL BIOL, V111, P1175; MARKLAND W, 1987, MOL CELL BIOL, V7, P4255, DOI 10.1128/MCB.7.12.4255; MARTIN K, 1991, J VIROL, V65, P232, DOI 10.1128/JVI.65.1.232-244.1991; MEHLIN H, 1988, CELL BIOL INT REP, V12, P729, DOI 10.1016/0309-1651(88)90086-0; MEIER UT, 1990, J CELL BIOL, V111, P2235, DOI 10.1083/jcb.111.6.2235; MICHAUD N, 1991, J CELL BIOL, V112, P215, DOI 10.1083/jcb.112.2.215; NEHRBASS U, 1990, CELL, V61, P979, DOI 10.1016/0092-8674(90)90063-K; NELSON M, 1989, MOL CELL BIOL, V9, P384, DOI 10.1128/MCB.9.2.384; NEWMEYER DD, 1986, J CELL BIOL, V103, P2091, DOI 10.1083/jcb.103.6.2091; NEWMEYER DD, 1990, J CELL BIOL, V110, P547, DOI 10.1083/jcb.110.3.547; NEWMEYER DD, 1986, EMBO J, V5, P501, DOI 10.1002/j.1460-2075.1986.tb04239.x; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; PARNAIK VK, 1990, MOL CELL BIOL, V10, P1287, DOI 10.1128/MCB.10.3.1287; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SILVER P, 1989, J CELL BIOL, V109, P983, DOI 10.1083/jcb.109.3.983; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; STEVENS BJ, 1966, J CELL BIOL, V31, P55, DOI 10.1083/jcb.31.1.55; TOGNON M, 1981, J VIROL, V40, P870, DOI 10.1128/JVI.40.3.870-880.1981; WELCH WJ, 1984, J BIOL CHEM, V259, P4501; WHITE EM, 1989, J CELL BIOL, V109, P1983, DOI 10.1083/jcb.109.5.1983; YAMASAKI L, 1989, MOL CELL BIOL, V9, P3028, DOI 10.1128/MCB.9.7.3028; YONEDA Y, 1988, SCIENCE, V242, P275, DOI 10.1126/science.3051382; YONEDA Y, 1987, EXP CELL RES, V170, P439, DOI 10.1016/0014-4827(87)90319-3	61	370	378	1	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1991	66	5					837	847		10.1016/0092-8674(91)90431-W	http://dx.doi.org/10.1016/0092-8674(91)90431-W			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1653647				2022-12-01	WOS:A1991GE46000004
J	BOSHART, M; WEIH, F; NICHOLS, M; SCHUTZ, G				BOSHART, M; WEIH, F; NICHOLS, M; SCHUTZ, G			THE TISSUE-SPECIFIC EXTINGUISHER LOCUS TSE1 ENCODES A REGULATORY SUBUNIT OF CAMP-DEPENDENT PROTEIN-KINASE	CELL			English	Article							SOMATIC-CELL HYBRIDS; LIVER-SPECIFIC GENES; AMINO-ACID SEQUENCE; NUCLEAR FACTOR CREB; CYCLIC-AMP; MESSENGER-RNA; MOLECULAR-CLONING; CDNA STRUCTURE; HUMAN TESTIS; TRANSCRIPTION FACTOR	The tissue-specific extinguisher locus TSE1, a dominant negative regulator of transcription in somatic cell hybrids, acts via a cAMP response element (CRE) to repress activity of a hepatocyte-specific enhancer. Guided by the antagonism between TSE1 and cAMP-mediated signal transduction, we identified the regulatory subunit RI-alpha of protein kinase A (PKA) as the product of the TSE1 locus. The evidence derives from concordant expression of RI-alpha mRNA and TSE1 genetic activity, high resolution mapping of the RI-alpha gene and TSE1 on human chromosome 17, and the ability of a transfected RI-alpha cDNA to generate a phenocopy of TSE1-mediated extinction. The mechanism of TSE1/RI-alpha-mediated extinction involves repression of basal PKA activity, reduced phosphorylation of CREB at Ser-133, and a corresponding reduction of in vivo protein binding at the target CRE.			BOSHART, M (corresponding author), GERMAN CANC RES CTR, INST CELL & TUMOR BIOL, NEUENHEIMER FELD 280, W-6900 HEIDELBERG, GERMANY.		Boshart, Michael/A-2700-2011	Boshart, Michael/0000-0002-5070-2663				BECKER PB, 1988, GENETIC ENG, V10, P1; BERGMAN Y, 1990, EMBO J, V9, P849, DOI 10.1002/j.1460-2075.1990.tb08182.x; BOLTON ET, 1962, P NATL ACAD SCI USA, V48, P1390, DOI 10.1073/pnas.48.8.1390; BOSHART M, 1990, CELL, V61, P905, DOI 10.1016/0092-8674(90)90201-O; CADD G, 1989, NEURON, V3, P71, DOI 10.1016/0896-6273(89)90116-5; CEREGHINI S, 1990, EMBO J, V9, P2257, DOI 10.1002/j.1460-2075.1990.tb07396.x; CHIN AC, 1987, P NATL ACAD SCI USA, V84, P1614, DOI 10.1073/pnas.84.6.1614; CHIN AC, 1989, MOL CELL BIOL, V9, P3736, DOI 10.1128/MCB.9.9.3736; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; CORRELL LA, 1989, J BIOL CHEM, V264, P16672; DAVIDSON RL, 1974, ANNU REV GENET, V8, P195, DOI 10.1146/annurev.ge.08.120174.001211; DAVIS FM, 1973, BACTERIOL REV, V37, P197, DOI 10.1128/MMBR.37.2.197-214.1973; DAY RN, 1989, J BIOL CHEM, V264, P431; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DRAIN P, 1991, NEURON, V6, P71, DOI 10.1016/0896-6273(91)90123-H; DYNAN WS, 1989, CELL, V58, P1, DOI 10.1016/0092-8674(89)90393-0; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOURDEAU H, 1990, ANNU REV CELL BIOL, V6, P69, DOI 10.1146/annurev.cb.06.110190.000441; GOURDEAU H, 1989, MOL CELL BIOL, V9, P1813, DOI 10.1128/MCB.9.5.1813; GREENGARD O, 1970, BIOCHEMICAL ACTIONS, V1, P53; GROVE JR, 1989, J BIOL CHEM, V264, P19506; GROVE JR, 1987, SCIENCE, V238, P530; JUNKER S, 1988, EMBO J, V7, P3093, DOI 10.1002/j.1460-2075.1988.tb03175.x; JUNKER S, 1990, CELL, V61, P467, DOI 10.1016/0092-8674(90)90528-M; KILLARY AM, 1984, CELL, V38, P523, DOI 10.1016/0092-8674(84)90507-5; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; KUNO T, 1987, BIOCHEM BIOPH RES CO, V146, P878, DOI 10.1016/0006-291X(87)90612-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH RJ, 1989, GENOMICS, V5, P167, DOI 10.1016/0888-7543(89)90043-8; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEM J, 1988, P NATL ACAD SCI USA, V85, P7302, DOI 10.1073/pnas.85.19.7302; MCCORMICK A, 1988, CELL, V55, P379, DOI 10.1016/0092-8674(88)90061-X; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MCKNIGHT GS, 1988, RECENT PROG HORM RES, V44, P307; MCKNIGHT GS, 1988, COLD SPRING HARB SYM, V53, P111, DOI 10.1101/SQB.1988.053.01.017; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; NITSCH D, 1990, MOL CELL BIOL, V10, P3334, DOI 10.1128/MCB.10.7.3334; NOWAK I, 1987, EUR J BIOCHEM, V167, P27, DOI 10.1111/j.1432-1033.1987.tb13300.x; OTTEN AD, 1989, J BIOL CHEM, V264, P20255; OYEN O, 1988, ENDOCRINOLOGY, V122, P2658; OYEN O, 1989, FEBS LETT, V246, P57, DOI 10.1016/0014-5793(89)80253-4; PETERSON TC, 1989, MOL BIOL MED, V6, P109; PETIT C, 1986, P NATL ACAD SCI USA, V83, P2561, DOI 10.1073/pnas.83.8.2561; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; RUIZBRAVO N, 1982, P NATL ACAD SCI-BIOL, V79, P365, DOI 10.1073/pnas.79.2.365; RUPPERT S, 1990, CELL, V61, P895, DOI 10.1016/0092-8674(90)90200-X; Sambrook J., 1989, MOL CLONING LAB MANU; SANDBERG M, 1988, BIOCHEM BIOPH RES CO, V154, P705, DOI 10.1016/0006-291X(88)90197-0; SANDBERG M, 1987, BIOCHEM BIOPH RES CO, V149, P939, DOI 10.1016/0006-291X(87)90499-2; SANDBERG M, 1990, BIOCHEM BIOPH RES CO, V167, P323, DOI 10.1016/0006-291X(90)91768-N; SCAMBLER P, 1987, AM J HUM GENET, V41, P925; SCOTT JD, 1986, P NATL ACAD SCI USA, V83, P1613, DOI 10.1073/pnas.83.6.1613; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; STEINBERG RA, 1981, J BIOL CHEM, V256, P731; SVOBODA J, 1960, NATURE, V186, P980, DOI 10.1038/186980b0; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; THAYER MJ, 1989, MOL CELL BIOL, V9, P2837, DOI 10.1128/MCB.9.7.2837; THAYER MJ, 1990, MOL CELL BIOL, V10, P2660, DOI 10.1128/MCB.10.6.2660; TRIPPUTI P, 1988, SCIENCE, V241, P1205, DOI 10.1126/science.2842865; UHLER MD, 1987, J BIOL CHEM, V262, P15202; WEIH F, 1988, NUCLEIC ACIDS RES, V16, P1628, DOI 10.1093/nar/16.4.1628; WEIH F, 1990, GENE DEV, V4, P1437, DOI 10.1101/gad.4.8.1437; WITTMAACK FM, 1983, EUR J BIOCHEM, V129, P669; WOODFORD TA, 1989, J BIOL CHEM, V264, P13321; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YU H, 1989, CELL, V58, P441, DOI 10.1016/0092-8674(89)90425-X; ZALLER DM, 1988, MOL CELL BIOL, V8, P1932, DOI 10.1128/MCB.8.5.1932	70	183	185	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1991	66	5					849	859		10.1016/0092-8674(91)90432-X	http://dx.doi.org/10.1016/0092-8674(91)90432-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1832337	Green Published			2022-12-01	WOS:A1991GE46000005
J	CHALEPAKIS, G; FRITSCH, R; FICKENSCHER, H; DEUTSCH, U; GOULDING, M; GRUSS, P				CHALEPAKIS, G; FRITSCH, R; FICKENSCHER, H; DEUTSCH, U; GOULDING, M; GRUSS, P			THE MOLECULAR-BASIS OF THE UNDULATED PAX-1 MUTATION	CELL			English	Article							DEVELOPING EXCRETORY SYSTEM; PAIRED-BOX; HORMONE RECEPTORS; MAMMALIAN-CELLS; PROTO-ONCOGENE; AMINO-ACIDS; W-LOCUS; PROTEINS; DNA; GENES	The murine paired box gene Pax-1 has been associated with the mouse developmental mutant undulated (un), which exhibits malformations in the vertebral column. In un mice, a point mutation leading to a Gly-Ser exchange in a conserved part of the paired domain of Pax-1 is present. Here we show that Pax-1 encodes a DNA-binding protein with transcriptional activating properties. The DNA-binding specificity of the Pax-1 protein has been extensively analyzed in gel shift assays, and in conjunction with binding interference experiments, a DNA-binding core motif was defined. Comparison of the DNA-binding properties of wild-type and un Pax-1 proteins demonstrates that the Gly-Ser replacement at position 15 within the paired domain dramatically decreases the DNA-binding affinity of the un Pax-1 protein and alters its DNA-binding specificity. These results decipher the molecular basis of the un mutation.			CHALEPAKIS, G (corresponding author), MAX PLANCK INST BIOPHYS CHEM, DEPT MOLEC CELL BIOL, W-3400 GOTTINGEN, GERMANY.		Fickenscher, Helmut/J-9655-2019; Fickenscher, Helmut/A-3004-2010	Fickenscher, Helmut/0000-0003-0043-1153; Deutsch, Urban/0000-0003-4265-6262				BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BASH PA, 1983, SCIENCE, V222, P1325, DOI 10.1126/science.222.4630.1325; BAUMGARTNER S, 1987, GENE DEV, V1, P1247, DOI 10.1101/gad.1.10.1247; Blandova ZK, 1975, MOUSE NEWS LETT, V52, P43; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BOPP D, 1989, EMBO J, V8, P3447, DOI 10.1002/j.1460-2075.1989.tb08509.x; BURRI M, 1989, EMBO J, V8, P1183, DOI 10.1002/j.1460-2075.1989.tb03490.x; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COTE S, 1987, EMBO J, V6, P2793, DOI 10.1002/j.1460-2075.1987.tb02575.x; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRESSLER GR, 1988, DEVELOPMENT, V104, P181; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; FAHRNER K, 1987, EMBO J, V6, P1265, DOI 10.1002/j.1460-2075.1987.tb02363.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; GRUNEBERG H, 1954, J GENET, V52, P441, DOI 10.1007/BF02981536; GRUNEBERG H, 1950, J GENET, V50, P142, DOI 10.1007/BF02986800; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JOSTES B, 1990, MECH DEVELOP, V33, P27, DOI 10.1016/0925-4773(90)90132-6; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; Maxam A M, 1980, Methods Enzymol, V65, P499; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NORNES HO, 1990, DEVELOPMENT, V109, P797; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; PLACHOV D, 1990, DEVELOPMENT, V110, P643; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SIRACUSA LD, 1990, GENOMICS, V6, P491, DOI 10.1016/0888-7543(90)90479-E; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; TREISMAN J, 1989, CELL, V59, P553; TRUSS M, 1990, P NATL ACAD SCI USA, V87, P7180, DOI 10.1073/pnas.87.18.7180; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; WALLACE ME, 1985, J HERED, V76, P271, DOI 10.1093/oxfordjournals.jhered.a110091; WALTHER C, 1991, IN PRESS GENOMICS; WRIGHT ME, 1947, HEREDITY, V1, P137, DOI 10.1038/hdy.1947.10	55	247	249	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1991	66	5					873	884		10.1016/0092-8674(91)90434-Z	http://dx.doi.org/10.1016/0092-8674(91)90434-Z			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1889089				2022-12-01	WOS:A1991GE46000007
J	CHENG, SH; RICH, DP; MARSHALL, J; GREGORY, RJ; WELSH, MJ; SMITH, AE				CHENG, SH; RICH, DP; MARSHALL, J; GREGORY, RJ; WELSH, MJ; SMITH, AE			PHOSPHORYLATION OF THE R-DOMAIN BY CAMP-DEPENDENT PROTEIN-KINASE REGULATES THE CFTR CHLORIDE CHANNEL	CELL			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS GENE; AIRWAY EPITHELIA; TRANSPORT; EXPRESSION; IDENTIFICATION; INACTIVATION; MECHANISMS; PP60C-SRC; TYROSINE	CFTR, the protein associated with cystic fibrosis, is phosphorylated on serine residues in response to cAMP agonists. Serines 660, 737, 795, and 813 were identified as in vivo targets for phosphorylation by protein kinase A. The SPQ fluorescence assay revealed that mutagenesis of any one of these sites did not affect Cl- channel activity. Indeed, concomitant mutagenesis of three of the four sites still resulted in cAMP-responsive Cl- channel activity. However, mutagenesis of all four sites abolished the response. One interpretation of these results is that the CFTR Cl- channel is blocked by the R domain and that phosphorylation on serines by protein kinase A electrostatically repels the domain, allowing passage of Cl-. The four phosphorylation events appear to be degenerate: no one site is essential for channel activity, and, at least in the case of serine 660, phosphorylation at one site alone is sufficient for regulation of Cl- channel activity.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT INTERNAL MED & PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Howard Hughes Medical Institute; University of Iowa; University of Iowa	CHENG, SH (corresponding author), GENZYME CORP,1 MT RD,FRAMINGHAM,MA 01701, USA.		Cheng, Seng H/AAC-6564-2022	Welsh, Michael/0000-0002-1646-6206; Marshall, John/0000-0003-1361-2869				ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BERGER HA, 1991, IN PRESS J CLIN INVE; BOUCHER RC, 1989, J CLIN INVEST, V84, P1424, DOI 10.1172/JCI114316; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1988, MOL CELL BIOL, V6, P1562; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; ESPINO PC, 1990, ONCOGENE, V5, P283; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; ILLSLEY NP, 1987, BIOCHEMISTRY-US, V26, P1215, DOI 10.1021/bi00379a002; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEMP BE, 1979, J BIOL CHEM, V254, P2638; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1059; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Sambrook J., 1989, MOL CLONING LAB MANU; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; TATA F, 1991, GENOMICS, V10, P301, DOI 10.1016/0888-7543(91)90312-3; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520; ZHANG B, 1991, J BIOL CHEM, V266, P990	34	575	584	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1991	66	5					1027	1036		10.1016/0092-8674(91)90446-6	http://dx.doi.org/10.1016/0092-8674(91)90446-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1716180				2022-12-01	WOS:A1991GE46000019
J	COSGROVE, D; GRAY, D; DIERICH, A; KAUFMAN, J; LEMEUR, M; BENOIST, C; MATHIS, D				COSGROVE, D; GRAY, D; DIERICH, A; KAUFMAN, J; LEMEUR, M; BENOIST, C; MATHIS, D			MICE LACKING MHC CLASS-II MOLECULES	CELL			English	Article							T-CELL-RECEPTOR; HISTOCOMPATIBILITY COMPLEX ANTIGEN; LYMPHOCYTE-B DEVELOPMENT; E-ALPHA-D; TRANSGENIC MICE; MONOCLONAL-ANTIBODIES; SURFACE EXPRESSION; ACCESSORY CELLS; A-BETA; DIFFERENTIATION ANTIGENS	We have produced mice that lack major histocompatibility complex class II antigens, permitting us to evaluate the role of these molecules in diverse aspects of T and B cell differentiation. The mutant mice show near-complete elimination of CD4+ T lymphocytes from the spleen and lymph nodes; the few remaining CD4-positive cells are preferentially localized to B cell follicles. Surprisingly, substantial numbers of CD4 single-positive cells reside in the thymus; however, these are not mature thymocytes as we currently recognize them. B lymphocytes occur in normal numbers and are capable of terminal differentiation to plasma cells. Nevertheless, several aberrations in the B cell compartment are demonstrable: a lack of germinal centers, fewer IgM+IgD+ cells in certain individuals, reduced production of serum IgG1, and complete inability to respond to T-dependent antigens. In short, the class II-negative mice have confirmed some old ideas about lymphocyte differentiation, but have provided some surprises.	BASEL INST IMMUNOL, CH-4058 BASEL, SWITZERLAND		COSGROVE, D (corresponding author), FAC MED STRASBOURG, INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB, INSERM, U184, F-67085 STRASBOURG, FRANCE.		Gray, David/L-8295-2013	Gray, David/0000-0003-3785-4934; Kaufman, Jim/0000-0002-7216-8422				ACHAORBEA H, 1985, EUR J IMMUNOL, V15, P31, DOI 10.1002/eji.1830150107; ANDERSON GD, 1989, J IMMUNOL, V143, P3757; ANDERSON GD, 1989, J EXP MED, V170, P1003, DOI 10.1084/jem.170.3.1003; ASHIDA ER, 1987, P NATL ACAD SCI USA, V84, P3395, DOI 10.1073/pnas.84.10.3395; BECK BN, 1986, J IMMUNOL, V136, P2953; BENOIST C, 1989, CELL, V58, P1027, DOI 10.1016/0092-8674(89)90501-1; BERG LJ, 1989, NATURE, V340, P559, DOI 10.1038/340559a0; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BHATTACHARYA A, 1981, J IMMUNOL, V127, P2488; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; BILL J, 1990, J MOL CELL IMMUNOL, V4, P269; BLUESTONE JA, 1987, NATURE, V326, P82, DOI 10.1038/326082a0; BONIFACINO JS, 1990, NATURE, V344, P247, DOI 10.1038/344247a0; BORGULYA P, 1991, EMBO J, V10, P913, DOI 10.1002/j.1460-2075.1991.tb08024.x; BOSWELL HS, 1980, J IMMUNOL, V125, P1340; BOSWELL HS, 1980, J EXP MED, V152, P1194, DOI 10.1084/jem.152.5.1194; BRAUNSTEIN NS, 1987, P NATL ACAD SCI USA, V84, P2921, DOI 10.1073/pnas.84.9.2921; BRAUNSTEIN NS, 1986, EMBO J, V5, P2469, DOI 10.1002/j.1460-2075.1986.tb04523.x; BRUCE J, 1981, J IMMUNOL, V127, P2496; BUDD RC, 1987, J EXP MED, V166, P577, DOI 10.1084/jem.166.2.577; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Carbone F. R., 1989, Fundamental immunology., P541; CEBRA JJ, 1984, ANNU REV IMMUNOL, V2, P493, DOI 10.1146/annurev.immunol.2.1.493; CEREDIG R, 1987, P NATL ACAD SCI USA, V84, P8578, DOI 10.1073/pnas.84.23.8578; CHUSED TM, 1976, J IMMUNOL, V116, P1579; COFFMAN RL, 1981, NATURE, V289, P681, DOI 10.1038/289681a0; CRISPE IN, 1987, NATURE, V329, P336, DOI 10.1038/329336a0; CRISPE IN, 1987, J IMMUNOL, V139, P3585; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; EGERTON M, 1990, INT IMMUNOL, V2, P157, DOI 10.1093/intimm/2.2.157; ESSER C, 1990, ANNU REV IMMUNOL, V8, P717, DOI 10.1146/annurev.iy.08.040190.003441; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FOWLKES BJ, 1987, NATURE, V329, P251, DOI 10.1038/329251a0; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; FULTZ MJ, 1982, J IMMUNOL, V129, P992; GERMAIN RN, 1986, NATURE, V320, P72, DOI 10.1038/320072a0; GOODMAN T, 1989, J EXP MED, V170, P1569, DOI 10.1084/jem.170.5.1569; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GRAY D, 1991, INT IMMUNOL, V3, P141, DOI 10.1093/intimm/3.2.141; Griscelli C, 1989, Immunodefic Rev, V1, P135; GUTMAN GA, 1972, IMMUNOLOGY, V23, P465; Hardy R R, 1990, Semin Immunol, V2, P197; HASHIMOTO Y, 1987, P NATL ACAD SCI USA, V84, P5883, DOI 10.1073/pnas.84.16.5883; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; HEINEN E, 1988, IMMUNOL TODAY, V9, P240, DOI 10.1016/0167-5699(88)91223-6; HERZENBERG LA, 1989, COLD SH Q B, V54, P219; HODES RJ, 1989, FUNDAMENTAL IMMUNOLO, P587; HOLUB M, 1989, IMMUNOLOGY NUDE MICE; HUGO P, 1991, EUR J IMMUNOL, V21, P835, DOI 10.1002/eji.1830210346; HUGO P, 1990, INT IMMUNOL, V2, P209, DOI 10.1093/intimm/2.3.209; KARLSSON L, 1991, NATURE, V351, P485, DOI 10.1038/351485a0; KAUFMAN J, 1990, J IMMUNOL, V144, P2258; KAUFMAN J, 1990, J IMMUNOL, V144, P2243; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KIMOTO M, 1989, IMMUNOLOGY, V67, P154; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KRUISBEEK AM, 1985, J EXP MED, V161, P1029, DOI 10.1084/jem.161.5.1029; KRUISBEEK AM, 1983, J EXP MED, V157, P1932, DOI 10.1084/jem.157.6.1932; KUBO RT, 1989, J IMMUNOL, V142, P2736; LAMERS MC, 1989, EUR J IMMUNOL, V19, P459, DOI 10.1002/eji.1830190308; LANDAIS D, 1986, J IMMUNOL, V137, P3002; LARHAMMAR D, 1985, J BIOL CHEM, V260, P4111; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEFRANCOIS L, 1990, CELL, V63, P333, DOI 10.1016/0092-8674(90)90166-C; LEMEUR M, 1985, NATURE, V316, P38, DOI 10.1038/316038a0; LESLEY J, 1988, CELL IMMUNOL, V112, P40, DOI 10.1016/0008-8749(88)90274-2; LIAO NS, 1989, J EXP MED, V170, P135, DOI 10.1084/jem.170.1.135; LYNCH F, 1989, EUR J IMMUNOL, V19, P223, DOI 10.1002/eji.1830190202; MACPHAIL S, 1987, J IMMUNOL, V139, P4007; MACPHAIL S, 1988, P NATL ACAD SCI USA, V85, P5205, DOI 10.1073/pnas.85.14.5205; MALISSEN B, 1986, P NATL ACAD SCI USA, V83, P3958, DOI 10.1073/pnas.83.11.3958; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATHIS DJ, 1983, P NATL ACAD SCI-BIOL, V80, P273, DOI 10.1073/pnas.80.1.273; MATIS LA, 1989, SCIENCE, V245, P746, DOI 10.1126/science.2528206; MATSUBAYASHI Y, 1989, IMMUNOBIOLOGY, V180, P33, DOI 10.1016/S0171-2985(89)80028-2; MATSUMOTO K, 1989, EUR J IMMUNOL, V19, P1203, DOI 10.1002/eji.1830190708; MATSUNAGA M, 1990, J EXP MED, V171, P577, DOI 10.1084/jem.171.2.577; MCCARTHY SA, 1988, NATURE, V336, P76, DOI 10.1038/336076a0; MCKNIGHT SL, 1980, NUCLEIC ACIDS RES, V8, P5949, DOI 10.1093/nar/8.24.5949; MIESCHER GC, 1987, J IMMUNOL, V138, P1959; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MOND JJ, 1987, IMMUNOL REV, V99, P105, DOI 10.1111/j.1600-065X.1987.tb01174.x; MORRISSEY PJ, 1981, J IMMUNOL, V127, P1345; NAKAYAMA T, 1990, SCIENCE, V249, P1558, DOI 10.1126/science.2120773; NIKOLICZUGIC J, 1990, INT IMMUNOL, V2, P135, DOI 10.1093/intimm/2.2.135; OZATO K, 1980, J IMMUNOL, V124, P533; PATERSON DJ, 1987, J EXP MED, V166, P1603, DOI 10.1084/jem.166.5.1603; PIERRES A, 1984, J IMMUNOL, V132, P2775; PIERRES M, 1981, IMMUNOGENETICS, V14, P481, DOI 10.1007/BF00350120; QUILL H, 1986, J IMMUNOL, V136, P3351; RELLAHAN BL, 1991, J EXP MED, V173, P503, DOI 10.1084/jem.173.2.503; Robertson E. J., 1987, TERATOCARCINOMAS EMB; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; Robinson M. A., 1989, Fundamental immunology., P489; ROUSE RV, 1982, J IMMUNOL, V128, P2243; SANT AJ, 1987, P NATL ACAD SCI USA, V84, P8065, DOI 10.1073/pnas.84.22.8065; SANT AJ, 1989, CELL, V57, P797, DOI 10.1016/0092-8674(89)90794-0; SCHUURMAN HJ, 1985, HUM IMMUNOL, V13, P69, DOI 10.1016/0198-8859(85)90014-X; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SPENCER JS, 1989, J EXP MED, V169, P625, DOI 10.1084/jem.169.3.625; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; TEW JG, 1990, IMMUNOL REV, V117, P185, DOI 10.1111/j.1600-065X.1990.tb00573.x; TOMONARI K, 1990, IMMUNOGENETICS, V31, P333, DOI 10.1007/BF02115007; TOMONARI K, 1988, IMMUNOGENETICS, V28, P455, DOI 10.1007/BF00355379; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; VANVLIET E, 1984, EUR J IMMUNOL, V14, P524, DOI 10.1002/eji.1830140608; VELARDI A, 1985, BLOOD, V65, P149; VELARDI A, 1986, J CLIN IMMUNOL, V6, P205, DOI 10.1007/BF00918700; VELARDI A, 1986, J IMMUNOL, V137, P2808; VERNACHIO J, 1989, J IMMUNOL, V142, P48; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WAKE CT, 1985, CELL, V42, P623, DOI 10.1016/0092-8674(85)90119-9; WALDMANN H, 1989, ANNU REV IMMUNOL, V7, P407, DOI 10.1146/annurev.iy.07.040189.002203; WU L, 1990, INT IMMUNOL, V2, P51, DOI 10.1093/intimm/2.1.51; ZUNIGAPFLUCKER JC, 1989, J EXP MED, V169, P2085, DOI 10.1084/jem.169.6.2085	118	776	801	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1991	66	5					1051	1066		10.1016/0092-8674(91)90448-8	http://dx.doi.org/10.1016/0092-8674(91)90448-8			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1909605				2022-12-01	WOS:A1991GE46000021
J	FERNS, GAA; RAINES, EW; SPRUGEL, KH; MOTANI, AS; REIDY, MA; ROSS, R				FERNS, GAA; RAINES, EW; SPRUGEL, KH; MOTANI, AS; REIDY, MA; ROSS, R			INHIBITION OF NEOINTIMAL SMOOTH-MUSCLE ACCUMULATION AFTER ANGIOPLASTY BY AN ANTIBODY TO PDGF	SCIENCE			English	Article							GROWTH-FACTOR RECEPTOR; HUMAN ATHEROSCLEROTIC PLAQUES; CORONARY ANGIOPLASTY; CELL-PROLIFERATION; DIFFERENT ISOFORMS; LESION FORMATION; GENE-EXPRESSION; ARTERIAL INJURY; PLATELET; RAT	Approximately 30 to 40 percent of atherosclerotic coronary arteries treated by angioplasty or by bypass surgery occlude as a result of restenosis. This restenosis is due principally to the accumulation of neointimal smooth muscle cells, which is also a prominent feature of the advanced lesions of atherosclerosis. The factors responsible for the accumulation of intimal smooth muscle cells have not been identified. Platelet-derived growth factor (PDGF) is a potent smooth muscle chemoattractant and mitogen. It is present in platelets and can be formed by endothelium, smooth muscle, and monocyte-derived macrophages. The development of an intimal lesion in the carotid artery of athymic nude rats induced by intraarterial balloon catheter deendothelialization was inhibited by a polyclonal antibody to PDGF. These data demonstrate that endogenous PDGF is involved in the accumulation of neointimal smooth muscle cells associated with balloon injury and may be involved in restenosis after angioplasty, and perhaps in atherogenesis as well.	ST BARTHOLOMEWS HOSP,COLL MED,WILLIAM HARVEY RES INST,LONDON EC1M 6BQ,ENGLAND; ZYMOGENET INC,SEATTLE,WA 98105	University of London; Queen Mary University London; Zymogenet Inc.			Ghayour-Mobarhan, Majid/AAY-5963-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-03174, HL-18645] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRETT TB, 1988, P NATL ACAD SCI USA, V85, P2810, DOI 10.1073/pnas.85.8.2810; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BAUMGART.HR, 1966, PATHOL MICROBIOL, V29, P393, DOI 10.1159/000161922; BOWENPOPE DF, 1989, J BIOL CHEM, V264, P2502; BOWENPOPE DF, 1985, METHOD ENZYMOL, V109, P69; CLOWES AW, 1983, LAB INVEST, V49, P327; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; FELLSTROM B, 1989, TRANSPLANT P, V21, P3689; FERNS GAA, UNPUB; Ferns GAA, 1990, GROWTH FACTORS, V3, P315, DOI 10.3109/08977199009003674; FESTING MFW, 1978, NATURE, V274, P365, DOI 10.1038/274365a0; FINGERLE J, 1989, P NATL ACAD SCI USA, V86, P8412, DOI 10.1073/pnas.86.21.8412; FRENS GAA, 1991, AM J PATHOL, V138, P1045; FRIEDMAN RJ, 1977, J CLIN INVEST, V60, P1191, DOI 10.1172/JCI108872; GOLDEN MA, 1991, J CLIN INVEST, V87, P406, DOI 10.1172/JCI115011; HARKER LA, 1976, J CLIN INVEST, V58, P731, DOI 10.1172/JCI108520; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; JAWIEN A, 1991, FASEB J, V55, pA1246; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIMGRUBER PP, 1986, CIRCULATION, V73, P710, DOI 10.1161/01.CIR.73.4.710; LINDNER V, 1991, CIRC RES, V68, P103; MAJESKY MW, 1990, J CELL BIOL, V111, P2149, DOI 10.1083/jcb.111.5.2149; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; RAINES E, UNPUB; RAINES EW, 1982, J BIOL CHEM, V257, P5154; RAINES EW, 1989, SCIENCE, V243, P393, DOI 10.1126/science.2783498; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; REIDY MA, 1985, LAB INVEST, V53, P513; REIDY MA, 1981, LAB INVEST, V44, P301; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROSS R, 1990, SCIENCE, V248, P1009, DOI 10.1126/science.2343305; SASAHARA M, 1991, CELL, V64, P217, DOI 10.1016/0092-8674(91)90223-L; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; STEMERMAN MB, 1972, J EXP MED, V136, P769, DOI 10.1084/jem.136.4.769; VAESSEN LMB, 1986, SCAND J IMMUNOL, V24, P223, DOI 10.1111/j.1365-3083.1986.tb02089.x; WIJNS W, 1985, AM J CARDIOL, V55, P357, DOI 10.1016/0002-9149(85)90375-3; WILCOX JN, 1988, J CLIN INVEST, V82, P1134, DOI 10.1172/JCI113671; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	40	1012	1107	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 6	1991	253	5024					1129	1132		10.1126/science.1653454	http://dx.doi.org/10.1126/science.1653454			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD808	1653454				2022-12-01	WOS:A1991GD80800029
J	FLEURY, S; LAMARRE, D; MELOCHE, S; RYU, SE; CANTIN, C; HENDRICKSON, WA; SEKALY, RP				FLEURY, S; LAMARRE, D; MELOCHE, S; RYU, SE; CANTIN, C; HENDRICKSON, WA; SEKALY, RP			MUTATIONAL ANALYSIS OF THE INTERACTION BETWEEN CD4 AND CLASS-II MHC - CLASS-II ANTIGENS CONTACT CD4 ON A SURFACE OPPOSITE THE GP120-BINDING SITE	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL HYBRIDOMA; ENVELOPE GLYCOPROTEIN; MONOCLONAL-ANTIBODIES; POSSIBLE INVOLVEMENT; STRUCTURAL-ANALYSIS; LYMPHOCYTES-T; BINDING-SITE; HLA ANTIGENS; SB ANTIGENS	Using functional and adhesion assays, we have studied the ability of 30 human CD4 mutants to interact with class II major histocompatibility complex (MHC) molecules and also with gp120 from human immunodeficiency virus. The mutants cover the four domains (D1-D4) of CD4 and include several single-site substitutions. Analysis of the results, in the context of the CD4 crystal structure, shows that mutations that affect the interaction with class II MHC molecules are located on three exposed loops from CD4 domains 1 and 2. The specifically implicated residues, 19, 89, and 165, are separated from one another by 9 angstrom, 24 angstrom, and 24 angstrom on one face of the CD4 molecule. Moreover, the class II binding site does not include residues 43 to 49 of the CD4 molecule, a region on an opposite face known to be involved in the binding of gp120.	UNIV MONTREAL, DEPT MICROBIOL & IMMUNOL, MONTREAL H3C 3J7, QUEBEC, CANADA; COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10027 USA; COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10027 USA	Universite de Montreal; Columbia University; Columbia University; Howard Hughes Medical Institute	FLEURY, S (corresponding author), INST RECH CLIN MONTREAL, IMMUNOL LAB, MONTREAL H2W 1R7, QUEBEC, CANADA.							ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; ASHKENAZI A, 1990, P NATL ACAD SCI USA, V87, P7150, DOI 10.1073/pnas.87.18.7150; BIDDISON WE, 1982, J EXP MED, V156, P1065, DOI 10.1084/jem.156.4.1065; BIDDISON WE, 1983, J IMMUNOL, V131, P152; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BOWMAN MR, 1990, P NATL ACAD SCI USA, V87, P9052, DOI 10.1073/pnas.87.22.9052; BRODSKY MH, 1990, J IMMUNOL, V144, P3078; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; CLAYTON LK, 1988, NATURE, V335, P363, DOI 10.1038/335363a0; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DELEAN A, 1982, MOL PHARMACOL, V21, P5; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; EGLITIS MA, 1988, BIOTECHNIQUES, V6, P608; GAY D, 1987, NATURE, V328, P626, DOI 10.1038/328626a0; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENSTEIN JL, 1984, J EXP MED, V159, P1213, DOI 10.1084/jem.159.4.1213; HEALEY D, 1990, J EXP MED, V172, P1233, DOI 10.1084/jem.172.4.1233; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660; KUPFER A, 1987, P NATL ACAD SCI USA, V84, P5888, DOI 10.1073/pnas.84.16.5888; LAMARRE D, 1989, EMBO J, V8, P3271, DOI 10.1002/j.1460-2075.1989.tb08487.x; LAMARRE D, 1989, SCIENCE, V245, P743, DOI 10.1126/science.2549633; LANDAU NR, 1988, NATURE, V334, P159, DOI 10.1038/334159a0; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; LITTMAN DR, 1987, ANNU REV IMMUNOL, V5, P561, DOI 10.1146/annurev.iy.05.040187.003021; LITTMAN DR, 1987, NATURE, V325, P453, DOI 10.1038/325453a0; MADDON PJ, 1987, P NATL ACAD SCI USA, V84, P9155, DOI 10.1073/pnas.84.24.9155; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P299, DOI 10.1042/bj1130299; MARRACK P, 1983, J EXP MED, V158, P1077, DOI 10.1084/jem.158.4.1077; MAZEROLLES F, 1988, CELL, V55, P497, DOI 10.1016/0092-8674(88)90036-0; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MERKENSCHLAGER M, 1990, J IMMUNOL, V145, P3181; MERKENSCHLAGER M, 1990, J IMMUNOL, V145, P2839; MITTLER RS, 1989, SCIENCE, V245, P1380, DOI 10.1126/science.2571187; MIZUKAMI T, 1988, P NATL ACAD SCI USA, V85, P9273, DOI 10.1073/pnas.85.23.9273; PETERSON A, 1988, CELL, V54, P65, DOI 10.1016/0092-8674(88)90180-8; ROSENSTEIN Y, 1990, J IMMUNOL, V144, P526; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SAIZAWA K, 1987, NATURE, V328, P260, DOI 10.1038/328260a0; SATTENTAU QJ, 1989, J EXP MED, V170, P1319, DOI 10.1084/jem.170.4.1319; SATTENTAU QJ, 1986, SCIENCE, V234, P1120, DOI 10.1126/science.2430333; SLECKMAN BP, 1987, NATURE, V328, P351, DOI 10.1038/328351a0; SLECKMAN BP, 1988, J IMMUNOL, V141, P49; SWAIN SL, 1984, J IMMUNOL, V132, P1118; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; VONHOEGEN P, 1989, J EXP MED, V170, P1879, DOI 10.1084/jem.170.6.1879; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WILDE DB, 1983, J IMMUNOL, V131, P2178; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	53	150	157	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1991	66	5					1037	1049		10.1016/0092-8674(91)90447-7	http://dx.doi.org/10.1016/0092-8674(91)90447-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1889086				2022-12-01	WOS:A1991GE46000020
J	GALIONE, A; LEE, HC; BUSA, WB				GALIONE, A; LEE, HC; BUSA, WB			CA2+-INDUCED CA2+ RELEASE IN SEA-URCHIN EGG HOMOGENATES - MODULATION BY CYCLIC ADP-RIBOSE	SCIENCE			English	Article							MUSCLE RYANODINE RECEPTOR; INOSITOL TRISPHOSPHATE; CALCIUM RELEASE; SARCOPLASMIC-RETICULUM; ENDOPLASMIC-RETICULUM; SYMPATHETIC NEURONS; CHROMAFFIN CELLS; XENOPUS-LAEVIS; CA-2+ RELEASE; FERTILIZATION	Calcium-induced calcium release (CICR) may function widely in calcium-mediated cell signaling, but has been most thoroughly characterized in muscle cells. In a homogenate of sea urchin eggs, which display transients in the intracellular free calcium concentration ([Ca2+]i) during fertilization and anaphase, addition of Ca2+ triggered CICR. Ca2+ release was also induced by the CICR modulators ryanodine and caffeine. Responses to both Ca2+ and CICR modulators (but not Ca2+ release mediated by inositol 1,4,5-trisphosphate) were inhibited by procaine and ruthenium red, inhibitors of CICR. Intact eggs also displayed transients of [Ca2+]i when microinjected with ryanodine. Cyclic ADP-ribose, a metabolite with potent Ca2+-releasing properties, appears to act by way of the CICR mechanism and may thus be an endogenous modulator of CICR. A CICR mechanism is present in these nonmuscle cells as is assumed in various models of intracellular Ca2+ wave propagation.	UNIV MINNESOTA, DEPT PHYSIOL, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	GALIONE, A (corresponding author), JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA.		Lee, Hon Cheung/C-4329-2009; Galione, Antony/E-5884-2011	Galione, Antony/0000-0002-4132-7646	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017484, R01HD022879, R29HD022879] Funding Source: NIH RePORTER; NICHD NIH HHS [HD22879, HD17484] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BURGOYNE RD, 1989, NATURE, V342, P72, DOI 10.1038/342072a0; BUSA WB, 1985, J CELL BIOL, V100, P1325, DOI 10.1083/jcb.100.4.1325; BUSA WB, 1985, J CELL BIOL, V101, P677, DOI 10.1083/jcb.101.2.677; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; DARGE PJ, 1989, CELL REGUL, V1, P279; EISEN A, 1984, J CELL BIOL, V99, P1878, DOI 10.1083/jcb.99.5.1878; EISEN A, 1984, J CELL BIOL, V99, P1647, DOI 10.1083/jcb.99.5.1647; ELLISMAN MH, 1990, NEURON, V5, P135, DOI 10.1016/0896-6273(90)90304-X; ENDO M, 1985, CURR TOP MEMBR TRANS, V25, P181; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FUJIWARA A, 1990, DEV GROWTH DIFFER, V32, P303; GALIONE A, UNPUB; GILKEY JC, 1978, J CELL BIOL, V76, P448, DOI 10.1083/jcb.76.2.448; JAFFE LF, 1990, NATO ADV SCI I H-CEL, V45, P389; LAI FA, 1989, J BIOENERG BIOMEMBR, V21, P227, DOI 10.1007/BF00812070; LEE HC, 1989, J BIOL CHEM, V264, P1608; LIPSCOMBE D, 1988, NEURON, V1, P355, DOI 10.1016/0896-6273(88)90185-7; MALGAROLI A, 1990, J BIOL CHEM, V265, P3005; MARTY A, 1989, J PHYSIOL-LONDON, V419, P665, DOI 10.1113/jphysiol.1989.sp017892; MIYAZAKI S, 1986, DEV BIOL, V118, P259, DOI 10.1016/0012-1606(86)90093-X; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; PALADE P, 1989, J BIOENERG BIOMEMBR, V21, P295, DOI 10.1007/BF00812074; PALADE P, 1983, J BIOL CHEM, V258, P8098; RAKOW TL, 1990, P NATL ACAD SCI USA, V87, P9285, DOI 10.1073/pnas.87.23.9285; RODGERS MT, UNPUB; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; SCHMID A, 1990, NATURE, V346, P374, DOI 10.1038/346374a0; SHOSHANBARMATZ V, 1990, FEBS LETT, V263, P317, DOI 10.1016/0014-5793(90)81403-B; SWANN K, 1986, J CELL BIOL, V103, P2333, DOI 10.1083/jcb.103.6.2333; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; THAYER SA, 1988, MOL PHARMACOL, V34, P664; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; WALSETH TF, J CELL BIOL, V111, pA467; WHITAKER M, 1984, NATURE, V312, P636, DOI 10.1038/312636a0; WHITAKER MJ, 1985, BIOL FERTILIZATION, V3, P167	39	577	585	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 6	1991	253	5024					1143	1146		10.1126/science.1909457	http://dx.doi.org/10.1126/science.1909457			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD808	1909457				2022-12-01	WOS:A1991GD80800034
J	GLOOR, GB; NASSIF, NA; JOHNSONSCHLITZ, DM; PRESTON, CR; ENGELS, WR				GLOOR, GB; NASSIF, NA; JOHNSONSCHLITZ, DM; PRESTON, CR; ENGELS, WR			TARGETED GENE REPLACEMENT IN DROSOPHILA VIA P-ELEMENT-INDUCED GAP REPAIR	SCIENCE			English	Article							HYBRID DYSGENESIS; TRANSPOSABLE ELEMENT; MOLECULAR ANALYSIS; GERM-LINE; RECOMBINATION; MELANOGASTER; DNA; MUTAGENESIS; LOCUS; CHROMOSOMES	Transposable elements of the P family in Drosophila are thought to transpose by a cut-and-paste process that leaves a double-strand gap. The repair of such gaps resulted in the transfer of up to several kilobase pairs of information from a homologous template sequence to the site of P element excision by a process similar to gene conversion. The template was an in vitro-modified sequence that was tested at various genomic positions. Characterization of 123 conversion tracts provided a detailed description of their length and distribution. Most events were continuous conversion tracts that overlapped the P insertion site without concomitant conversion of the template. The average conversion tract was 1379 base pairs, and the distribution of tract lengths fit a simple model of gap enlargement. The conversion events occurred at sufficiently high frequencies to form the basis of an efficient means of directed gene replacement.	UNIV WISCONSIN,DEPT GENET,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	GLOOR, GB (corresponding author), MEM UNIV NEWFOUNDLAND,FAC MED,ST JOHNS A1C 5S7,NEWFOUNDLAND,CANADA.		Gloor, Greg B/D-1671-2013	Gloor, Gregory/0000-0001-5803-3380	NIGMS NIH HHS [GM30948] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030948, R56GM030948] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AJIOKA JW, 1989, MOBILE DNA, P939; BALLINGER DG, 1989, P NATL ACAD SCI USA, V86, P9402, DOI 10.1073/pnas.86.23.9402; BERG DE, 1989, MOBILE DNA, pCH6; BINGHAM PM, 1982, CELL, V29, P995, DOI 10.1016/0092-8674(82)90463-9; BORTS RH, 1989, GENETICS, V123, P69; BORTS RH, 1987, SCIENCE, V237, P1459, DOI 10.1126/science.2820060; COEN ES, 1989, MOBILE DNA, P413; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; CURTIS D, 1991, GENETICS, V127, P739; CURTIS D, 1989, GENETICS, V122, P653; DANIELS SB, 1990, GENETICS, V124, P339; Engels W.R, 1989, MOBILE DNA, P437; ENGELS WR, 1990, CELL, V62, P515, DOI 10.1016/0092-8674(90)90016-8; ENGELS WR, 1984, GENETICS, V107, P657; ENGELS WR, 1986, FOCUS, V8, P6; FELLER W, 1950, INTRO PROBABILITY TH, V1; GEYER PK, 1988, P NATL ACAD SCI USA, V85, P6455, DOI 10.1073/pnas.85.17.6455; GLOOR GB, IN PRESS DROS INFORM; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; HASTINGS PJ, 1988, BIOESSAYS, V9, P61, DOI 10.1002/bies.950090206; HIGUCHI R, 1990, PCR PROTOCOLS GUIDE, P177; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; HOUCK MA, 1991, SCIENCE, V253, P1125, DOI 10.1126/science.1653453; Innis MA, 1990, PCR PROTOCOLS GUIDE; KAISER K, 1990, P NATL ACAD SCI USA, V87, P1686, DOI 10.1073/pnas.87.5.1686; KASSIS JA, COMMUNICATION; KIDWELL MG, 1983, P NATL ACAD SCI-BIOL, V80, P1655, DOI 10.1073/pnas.80.6.1655; KOSTRIKEN R, 1984, COLD SPRING HARB SYM, V49, P89, DOI 10.1101/SQB.1984.049.01.012; LEVERE G, 1976, GENETICS BIOL DROS A, V1, P32; LIM JK, 1988, P NATL ACAD SCI USA, V85, P9153, DOI 10.1073/pnas.85.23.9153; MATHOG D, 1984, NATURE, V308, P414, DOI 10.1038/308414a0; MCGILL C, 1989, CELL, V57, P459, DOI 10.1016/0092-8674(89)90921-5; OHARE K, 1984, J MOL BIOL, V180, P437, DOI 10.1016/0022-2836(84)90021-4; OHARE K, 1983, CELL, V34, P25, DOI 10.1016/0092-8674(83)90133-2; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; ORRWEAVER TL, 1985, MICROBIOL REV, V49, P33, DOI 10.1128/MMBR.49.1.33-58.1985; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; PLASTERK RHA, 1991, EMBO J, V10, P1919, DOI 10.1002/j.1460-2075.1991.tb07718.x; RESNICK MA, 1976, J THEOR BIOL, V59, P97, DOI 10.1016/S0022-5193(76)80025-2; ROBERTSON HM, 1988, GENETICS, V118, P461; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SALZ HK, 1987, GENETICS, V117, P221; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; SVED JA, 1990, GENETICS, V124, P331; SVED JA, 1991, MOL GEN GENET, V225, P443, DOI 10.1007/BF00261685; SYMINGTON LS, 1988, MOL CELL BIOL, V8, P595, DOI 10.1128/MCB.8.2.595; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; WILLIAMS JA, 1988, MOL CELL BIOL, V8, P1489, DOI 10.1128/MCB.8.4.1489; [No title captured]	51	318	334	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 6	1991	253	5024					1110	1117		10.1126/science.1653452	http://dx.doi.org/10.1126/science.1653452			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD808	1653452				2022-12-01	WOS:A1991GD80800024
J	GREENGARD, P; JEN, J; NAIRN, AC; STEVENS, CF				GREENGARD, P; JEN, J; NAIRN, AC; STEVENS, CF			ENHANCEMENT OF THE GLUTAMATE RESPONSE BY CAMP-DEPENDENT PROTEIN-KINASE IN HIPPOCAMPAL-NEURONS	SCIENCE			English	Article							EXCITATORY AMINO-ACIDS; RAT HIPPOCAMPUS; RECEPTOR DESENSITIZATION; CHANNELS; MODULATION; QUISQUALATE; FORSKOLIN; KAINATE; CELLS; CONDUCTANCES	Receptor channels activated by glutamate, an excitatory neurotransmitter in the mammalian brain, are involved in processes such as long-term potentiation and excitotoxicity. Studies of glutamate receptor channels expressed in cultured hippocampal pyramidal neurons reveal that these channels are subject to neuromodulatory regulation through the adenylate cyclase cascade. The whole-cell current response to glutamate and kainate [a non-NMDA (N-methyl-D-aspartate) receptor agonist] was enhanced by forskolin, an activator of adenylate cyclase. Single-channel analysis revealed that an adenosine 3',5'-monophosphate-dependent protein kinase (PKA) increases the opening frequency and the mean open time of the non-NMDA-type glutamate receptor channels. Analysis of synaptic events indicated that forskolin, acting through PKA, increased the amplitude and decay time of spontaneous excitatory postsynaptic currents.	SALK INST BIOL STUDIES, MOLEC NEUROBIOL LAB, LA JOLLA, CA 92037 USA; ROCKEFELLER UNIV, MOLEC & CELLULAR NEUROSCI LAB, NEW YORK, NY 10021 USA; YALE UNIV, NEUROSCI PROGRAM, NEW HAVEN, CT 06510 USA	Salk Institute; Rockefeller University; Yale University				Nairn, Angus/0000-0002-7075-0195				BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BROCKES JP, 1975, BIOCHEMISTRY-US, V14, P2100, DOI 10.1021/bi00681a009; CATTERALL WA, 1990, ADV SEC MESS PHOSPH, V24, P30; CHENG HC, 1986, J BIOL CHEM, V261, P989; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; CULLCANDY SG, 1987, NATURE, V325, P525, DOI 10.1038/325525a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; Kaczmarek L. K., 1987, NEUROMODULATION; KNAPP AG, 1987, NATURE, V325, P437, DOI 10.1038/325437a0; LANDFIELD PW, 1988, LONG TERM POTENTIATI; LEVITAN IB, 1990, ADV SEC MESS PHOSPH, V24, P36; MARKRAM H, 1990, NEUROSCI LETT, V113, P62, DOI 10.1016/0304-3940(90)90495-U; MODY I, 1988, NEUROSCI LETT, V93, P73, DOI 10.1016/0304-3940(88)90015-8; PIN JP, 1989, EUR J PHARM-MOLEC PH, V172, P81, DOI 10.1016/0922-4106(89)90047-3; RASSENDREN FA, 1989, NEUROSCI LETT, V99, P333, DOI 10.1016/0304-3940(89)90469-2; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; SONG Y, 1990, NATURE, V348, P242, DOI 10.1038/348242a0; WAGONER PK, 1988, SCIENCE, V240, P1655, DOI 10.1126/science.2454507; WATANABE K, 1987, NEUROSCI LETT, V78, P211, DOI 10.1016/0304-3940(87)90635-5; WEINBERG CB, 1979, P NATL ACAD SCI USA, V76, P504, DOI 10.1073/pnas.76.1.504; ZORUMSKI CF, 1988, J NEUROSCI, V8, P4277	25	383	392	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 6	1991	253	5024					1135	1138		10.1126/science.1716001	http://dx.doi.org/10.1126/science.1716001			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD808	1716001				2022-12-01	WOS:A1991GD80800031
J	HOUCK, MA; CLARK, JB; PETERSON, KR; KIDWELL, MG				HOUCK, MA; CLARK, JB; PETERSON, KR; KIDWELL, MG			POSSIBLE HORIZONTAL TRANSFER OF DROSOPHILA GENES BY THE MITE PROCTOLAELAPS-REGALIS	SCIENCE			English	Article							SCAPTOMYZA-PALLIDA DROSOPHILIDAE; P-TRANSPOSABLE ELEMENTS; SALTANS SPECIES GROUPS; HYBRID DYSGENESIS; ENZYMATIC AMPLIFICATION; HOMOLOGOUS SEQUENCES; MELANOGASTER GENOME; OBSCURA GROUP; DNA; POPULATIONS	There is strong inferential evidence for recent horizontal gene transfer of the P (mobile) element to Drosophila melanogaster from a species of the Drosophila willistoni group. One potential vector of this transfer is a semiparasitic mite, Proctolaelaps regalis DeLeon, whose morphology, behavior, and co-occurrence with Drosophila are consistent with the properties necessary for such a vector. Southern blot hybridization, polymerase chain reaction (PCR) amplification, and DNA sequencing showed that samples of P. regalis associated with a P strain of D. melanogaster carried P element sequences. Similarly, Drosophila ribosomal DNA sequences were identified in P. regalis samples that had been associated with Drosophila cultures. These result, have potentially important evolutionary implications, not only for understanding the mechanisms by which genes may be transferred between reproductively isolated species, but also for improved detection of some host-parasite and predator-prey relationships.	UNIV ARIZONA,CTR INSECT SCI,TUCSON,AZ 85721; UNIV ARIZONA,DEPT ECOL & EVOLUT BIOL,TUCSON,AZ 85721	University of Arizona; University of Arizona					PHS HHS [36715] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANXOLABEHERE D, 1988, MOL BIOL EVOL, V5, P252; ANXOLABEHERE D, 1985, GENET SEL EVOL, V17, P579, DOI 10.1186/1297-9686-17-4-579; APPENZELLER T, 1990, SCIENCE, V247, P1030, DOI 10.1126/science.2309117; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BINGHAM PM, 1982, CELL, V29, P995, DOI 10.1016/0092-8674(82)90463-9; BROOKFIELD JFY, 1984, NATURE, V310, P330, DOI 10.1038/310330a0; Cantelo WW, 1973, DROSOPHILA INF SERV, V50, P163; CASANOVA JL, 1990, NUCLEIC ACIDS RES, V18, P4028, DOI 10.1093/nar/18.13.4028; DANIELS SB, 1987, GENETICS, V115, P711; DANIELS SB, 1986, J MOL EVOL, V23, P138, DOI 10.1007/BF02099908; DANIELS SB, 1990, GENETICS, V129, P399; DELEON D, FLA ENTOMOL, V196; Ehrman L., 1982, Genetics and Biology of Drosophila, V3b, P193; Engels W.R, 1989, MOBILE DNA, P437; Evans G. O, 1961, TERRESTRIAL ACARI BR, V1; GOOD AG, 1989, GENETICS, V122, P387; HAGEMANN S, 1990, J MOL EVOL, V31, P478, DOI 10.1007/BF02102074; Hammen L, 1964, ZOOLOGISCHE VERHANDE, V71; IWANO M, 1984, JPN J GENET, V59, P403, DOI 10.1266/jjg.59.403; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; KIDWELL MG, 1983, P NATL ACAD SCI-BIOL, V80, P1655, DOI 10.1073/pnas.80.6.1655; KIYASU PK, 1984, GENET RES, V44, P251, DOI 10.1017/S0016672300026495; KONDO S, 1985, P NATL ACAD SCI USA, V82, P6236; Krantz G.W., 1978, MANUAL ACAROLOGY, VSecond; OHARE K, 1983, CELL, V34, P25, DOI 10.1016/0092-8674(83)90133-2; PAABO S, 1989, P NATL ACAD SCI USA, V86, P1939, DOI 10.1073/pnas.86.6.1939; PERSING DH, 1990, SCIENCE, V249, P1420, DOI 10.1126/science.2402635; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; TAUTZ D, 1988, MOL BIOL EVOL, V5, P366; Woolley TA, 1988, ACAROLOGY MITES HUMA	32	202	208	2	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 6	1991	253	5024					1125	1129		10.1126/science.1653453	http://dx.doi.org/10.1126/science.1653453			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD808	1653453				2022-12-01	WOS:A1991GD80800028
J	HUNZIKER, W; HARTER, C; MATTER, K; MELLMAN, I				HUNZIKER, W; HARTER, C; MATTER, K; MELLMAN, I			BASOLATERAL SORTING IN MDCK CELLS REQUIRES A DISTINCT CYTOPLASMIC DOMAIN DETERMINANT	CELL			English	Article							CANINE KIDNEY-CELLS; PLASMA-MEMBRANE PROTEINS; POLYMERIC IMMUNOGLOBULIN RECEPTOR; INFLUENZA-VIRUS HEMAGGLUTININ; COATED PIT LOCALIZATION; EPITHELIAL-CELLS; INTRACELLULAR-TRANSPORT; LYSOSOMAL MEMBRANE; VIRAL GLYCOPROTEINS; BIOGENESIS	In MDCK cells, Golgi to basolateral transport of several membrane proteins has been found to involve a cytoplasmic domain determinant. In some cases (Fc receptor, lysosomal glycoprotein Igp120), the determinant appears similar to that required for endocytosis via clathrin-coated pits; for Igp120, elimination of a single cytoplasmic domain tyrosine both blocks internalization and results in apical transport. In other cases (LDL receptor), the determinant does not involve the cytoplasmic domain tyrosine required for endocytosis. Thus, contrary to current models, basolateral transport in MCDK cells occurs not by default but depends on one or more cytoplasmic domain determinants, the precise nature of which is unknown. For some proteins, it is closely related to coated pit determinants. The fact that many membrane proteins can reach the apical surface in the absence of this determinant suggests that signals for apical transport are widely distributed.			HUNZIKER, W (corresponding author), YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA.		Mellman, Ira/ABG-5896-2020; Matter, Karl/C-4880-2008; Hunziker, Walter/GSM-8190-2022; Hunziker, Walter/B-3140-2010	Matter, Karl/0000-0001-8026-7220; Hunziker, Walter/0000-0002-5265-4933				AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CAPLAN M, 1989, FUNCTIONAL EPITHELIA, P71; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; GREEN SA, 1987, J CELL BIOL, V105, P1227, DOI 10.1083/jcb.105.3.1227; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; HOWE CL, 1988, P NATL ACAD SCI USA, V85, P7577, DOI 10.1073/pnas.85.20.7577; HUBBARD AL, 1989, ANNU REV PHYSIOL, V51, P755, DOI 10.1146/annurev.ph.51.030189.003543; HUNZIKER W, 1989, J CELL BIOL, V109, P3291, DOI 10.1083/jcb.109.6.3291; HUNZIKER W, 1990, NATURE, V345, P628, DOI 10.1038/345628a0; HUNZIKER W, 1990, EMBO J, V9, P3515, DOI 10.1002/j.1460-2075.1990.tb07560.x; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LEBIVIC A, 1990, J CELL BIOL, V110, P1533, DOI 10.1083/jcb.110.5.1533; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; LEWIS V, 1985, J CELL BIOL, V100, P1839, DOI 10.1083/jcb.100.6.1839; LI CX, 1991, J BIOL CHEM, V266, P9263; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; MATLIN KS, 1984, J CELL BIOL, V99, P2131, DOI 10.1083/jcb.99.6.2131; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; MISEK DE, 1984, CELL, V39, P537, DOI 10.1016/0092-8674(84)90460-4; MOSTOV KE, 1985, CELL, V43, P389, DOI 10.1016/0092-8674(85)90166-7; MOSTOV KE, 1987, J CELL BIOL, V105, P2031, DOI 10.1083/jcb.105.5.2031; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; PATHAK RK, 1990, J CELL BIOL, V111, P347, DOI 10.1083/jcb.111.2.347; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cellbio.6.1.151; PFEIFFER S, 1985, J CELL BIOL, V101, P470, DOI 10.1083/jcb.101.2.470; RINDLER MJ, 1984, J CELL BIOL, V98, P1304, DOI 10.1083/jcb.98.4.1304; RINDLER MJ, 1985, J CELL BIOL, V100, P136, DOI 10.1083/jcb.100.1.136; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; RODRIGUEZBOULAN E, 1984, J CELL BIOL, V98, P308, DOI 10.1083/jcb.98.1.308; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; ROMAN LM, 1986, J CELL BIOL, V103, P2607, DOI 10.1083/jcb.103.6.2607; ROTH MG, 1987, J CELL BIOL, V104, P769, DOI 10.1083/jcb.104.3.769; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SZTUL E, 1991, CELL, V64, P81, DOI 10.1016/0092-8674(91)90210-P; VEGASALAS DE, 1987, J CELL BIOL, V104, P905, DOI 10.1083/jcb.104.4.905; VEGASALAS DE, 1987, J CELL BIOL, V104, P1249, DOI 10.1083/jcb.104.5.1249; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; WANDINGERNESS A, 1990, INTRACELLULAR TRAFFI, P575; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955	53	277	279	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1991	66	5					907	920		10.1016/0092-8674(91)90437-4	http://dx.doi.org/10.1016/0092-8674(91)90437-4			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1909606				2022-12-01	WOS:A1991GE46000010
J	KERNAN, MJ; KURODA, MI; KREBER, R; BAKER, BS; GANETZKY, B				KERNAN, MJ; KURODA, MI; KREBER, R; BAKER, BS; GANETZKY, B			NAPTS, A MUTATION AFFECTING SODIUM-CHANNEL ACTIVITY IN DROSOPHILA, IS AN ALLELE OF MLE, A REGULATOR OF X-CHROMOSOME TRANSCRIPTION	CELL			English	Article							SENSITIVE PARALYTIC MUTANTS; DOSAGE COMPENSATION; MEMBRANE EXCITABILITY; NERVOUS-SYSTEM; MELANOGASTER; BINDING; GENE; RNA; DNA; CONDUCTION	nap(ts) is a recessive mutation that affects the level of sodium channel activity and, at high temperature, causes paralysis associated with a loss of action potentials. We show, by genetic complementation tests, germline transformation, and analysis of mutations, that nap(ts) is a gain-of-function mutation of mle, a gene required for X chromosome dosage compensation and male viability. Molecular analyses of nap and mle mutations indicate that mle+, nap+, and nap(ts) activities are encoded by the same open reading frame and suggest that nap(ts) is due to a single amino acid substitution. Although nap(ts) is known to act via para+, an X-linked sodium channel structural gene, its effect is not due to a simple defect in para+ dosage compensation.	UNIV WISCONSIN,GENET LAB,MADISON,WI 53706; STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94306	University of Wisconsin System; University of Wisconsin Madison; Stanford University	KERNAN, MJ (corresponding author), UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093, USA.			Kernan, Maurice/0000-0002-1546-6159	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015390] Funding Source: NIH RePORTER; NINDS NIH HHS [NS15390] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BACHILLER D, 1986, DEV BIOL, V118, P379, DOI 10.1016/0012-1606(86)90007-2; BAKER BS, 1983, ANNU REV GENET, V17, P345, DOI 10.1146/annurev.ge.17.120183.002021; BELOTE JM, 1980, NATURE, V285, P573, DOI 10.1038/285573a0; BELOTE JM, 1980, GENETICS, V96, P165; BURGESS S, 1990, CELL, V60, P705, DOI 10.1016/0092-8674(90)90086-T; COLQUHOUN D, 1972, J PHYSIOL-LONDON, V221, P533, DOI 10.1113/jphysiol.1972.sp009766; COMPANY M, 1991, NATURE, V349, P497; ELKINS T, 1990, J NEUROGENET, V6, P207, DOI 10.3109/01677069009107111; FUKUNAGA A, 1975, GENETICS, V81, P135; GANETZKY B, 1986, ANNU REV GENET, V20, P13; GANETZKY B, 1984, GENETICS, V108, P897; GANETZKY B, 1982, GENETICS, V100, P597; GOLUBOVSKY MD, 1972, DROS INF SERV, V49, P117; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P8413, DOI 10.1093/nar/17.21.8413; HALL JC, 1982, Q REV BIOPHYS, V15, P223, DOI 10.1017/S0033583500004844; HODGKIN AL, 1949, J PHYSIOL-LONDON, V109, P240, DOI 10.1113/jphysiol.1949.sp004388; JACKSON FR, 1984, NATURE, V308, P189, DOI 10.1038/308189a0; JAFFE E, 1986, TRENDS GENET, V2, P316, DOI 10.1016/0168-9525(86)90287-8; KAUVAR LM, 1982, MOL GEN GENET, V187, P172, DOI 10.1007/BF00384402; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; LASKI FA, 1986, CELL, V44, P7, DOI 10.1016/0092-8674(86)90480-0; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; LOUGHNEY K, 1989, CELL, V58, P1143, DOI 10.1016/0092-8674(89)90512-6; LOUGHNEY K, 1989, MOL BIOL NEURORECEPT, P201; LOVERRE A, 1980, DROS INF SERV, V55, P88; LUCCHESI J C, 1982, Genetics, V100, pS42; LUCCHESI JC, 1987, ADV GENET, V24, P371, DOI 10.1016/S0065-2660(08)60013-9; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; ODOWD DK, 1988, J NEUROSCI, V8, P3633; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STERN M, 1990, GENETICS, V124, P133; SUZUKI DT, 1971, P NATL ACAD SCI USA, V68, P890, DOI 10.1073/pnas.68.5.890; UCHIDA S, 1981, JPN J GENET, V56, P523, DOI 10.1266/jjg.56.523; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WU CF, 1980, NATURE, V286, P814, DOI 10.1038/286814a0; WU CF, 1983, J NEUROSCI, V3, P1888; WU CF, 1978, P NATL ACAD SCI USA, V75, P4047, DOI 10.1073/pnas.75.8.4047	40	104	108	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1991	66	5					949	959		10.1016/0092-8674(91)90440-A	http://dx.doi.org/10.1016/0092-8674(91)90440-A			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1653649				2022-12-01	WOS:A1991GE46000013
J	KION, TA; HOFFMANN, GW				KION, TA; HOFFMANN, GW			ANTI-HIV AND ANTI-ANTI-MHC ANTIBODIES IN ALLOIMMUNE AND AUTOIMMUNE MICE	SCIENCE			English	Article							IMMUNODEFICIENCY VIRUS HIV; IMMUNE-SYSTEM; AIDS; CD4; INFECTION; IDENTIFICATION; PATHOGENESIS; DISEASE; BINDING	Alloimmune mice (mice that have been exposed to cells from another murine strain) were shown to make antibodies against gp120 and p24 of human immunodeficiency virus (HIV, and mice of the autoimmune strains MRL-lpr/lpr and MRL-+/+ made antibodies against gp120. This is surprising because the mice were not exposed to HIV. Furthermore, anti-anti-MHC antibodies (molecules that have shapes similar to those of major histocompatibility complex molecules) were detected in both alloimmune sera and MRL mice. These results are discussed in the context of a possible role for allogeneic stimuli in the pathogenesis of acquired immunodeficiency syndrome, as suggested by an idiotypic network model.	UNIV BRITISH COLUMBIA,DEPT MICROBIOL,VANCOUVER V6T 1W5,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT PHYS,VANCOUVER V6T 1W5,BC,CANADA	University of British Columbia; University of British Columbia								ANDRIEU JM, 1986, AIDS RES HUM RETROV, V2, P163, DOI 10.1089/aid.1.1986.2.163; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; DIAMOND DC, 1988, J IMMUNOL, V141, P3715; FORSYTH RB, 1990, J IMMUNOL, V145, P215; GOLDING H, 1989, J CLIN INVEST, V83, P1430, DOI 10.1172/JCI114034; GOLDING H, 1988, J EXP MED, V167, P914, DOI 10.1084/jem.167.3.914; HABESHAW JA, 1989, J ACQ IMMUN DEF SYND, V2, P457; HOFFMANN GW, 1986, J IMMUNOL, V137, P61; HOFFMANN GW, 1991, P NATL ACAD SCI USA, V88, P3060, DOI 10.1073/pnas.88.8.3060; HOFFMANN GW, 1988, SEMIOTICS CELLULAR C, P257; Hsu D H, 1989, Int Immunol, V1, P197, DOI 10.1093/intimm/1.2.197; KAYE BR, 1989, ANN INTERN MED, V111, P158, DOI 10.7326/0003-4819-111-2-158; KION TA, UNPUB; LAMARRE D, 1989, SCIENCE, V245, P743, DOI 10.1126/science.2549633; SATTENTAU QJ, 1986, SCIENCE, V234, P1120, DOI 10.1126/science.2430333; SHEARER GM, 1983, NEW ENGL J MED, V308, P223, DOI 10.1056/NEJM198301273080415; THOMAS Y, 1983, IMMUNOL REV, V74, P113, DOI 10.1111/j.1600-065X.1983.tb01086.x; VEGA MA, 1990, NATURE, V345, P26, DOI 10.1038/345026a0; WEINHOLD KJ, 1989, J IMMUNOL, V142, P3091; YOUNG JAT, 1988, NATURE, V333, P215, DOI 10.1038/333215c0; ZIEGLER JL, 1986, CLIN IMMUNOL IMMUNOP, V41, P305, DOI 10.1016/0090-1229(86)90001-2	21	130	142	1	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 6	1991	253	5024					1138	1140		10.1126/science.1909456	http://dx.doi.org/10.1126/science.1909456			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD808	1909456				2022-12-01	WOS:A1991GD80800032
J	LAROSA, GJ; WEINHOLD, K; PROFY, AT; LANGLOIS, AJ; DREESMAN, GR; BOSWELL, RN; SHADDUCK, P; BOLOGNESI, DP; MATTHEWS, TJ; EMINI, EA; PUTNEY, SD				LAROSA, GJ; WEINHOLD, K; PROFY, AT; LANGLOIS, AJ; DREESMAN, GR; BOSWELL, RN; SHADDUCK, P; BOLOGNESI, DP; MATTHEWS, TJ; EMINI, EA; PUTNEY, SD			CONSERVED SEQUENCE AND STRUCTURAL ELEMENTS IN THE HIV-1 PRINCIPAL NEUTRALIZING DETERMINANT - FURTHER CLARIFICATIONS	SCIENCE			English	Article									BIOTECH RESOURCES INC,SAN ANTONIO,TX 78249; WILFORD HALL USAF MED CTR,DEPT MED,LACKLAND AFB,TX 78236; MERCK SHARP & DOHME LTD,W POINT,PA 19486; DUKE UNIV,SCH MED,DEPT SURG,DURHAM,NC 27710	United States Department of Defense; United States Air Force; Merck & Company; Duke University	LAROSA, GJ (corresponding author), REPLIGEN CORP,CAMBRIDGE,MA 02139, USA.		Shadduck MD DrHC, Phillip/AAZ-9781-2021	Shadduck MD DrHC, Phillip/0000-0002-7519-4319				LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685	1	19	20	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 6	1991	253	5024					1146	1146		10.1126/science.1887238	http://dx.doi.org/10.1126/science.1887238			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD808	1887238				2022-12-01	WOS:A1991GD80800035
J	LOEB, DM; MARAGOS, J; MARTINZANCA, D; CHAO, MV; PARADA, LF; GREENE, LA				LOEB, DM; MARAGOS, J; MARTINZANCA, D; CHAO, MV; PARADA, LF; GREENE, LA			THE TRK PROTOONCOGENE RESCUES NGF RESPONSIVENESS IN MUTANT NGF-NONRESPONSIVE PC12 CELL-LINES	CELL			English	Article							NERVE GROWTH-FACTOR; FACTOR RECEPTOR; GENE-TRANSFER; PHEOCHROMOCYTOMA CELLS; MOLECULAR-CLONING; EXPRESSION; DIFFERENTIATION; SURVIVAL; AFFINITY; RESPOND	The trk tyrosine kinase proto-oncogene product gp140prototrk binds nerve growth factor (NGF) and is rapidly and selectively activated by this neurotrophic factor. To determine whether gp140prototrk is involved in transducing a functional NGF signal, PC12 cell mutants (PC12nnr) deficient in high affinity NGF binding and unresponsive to NGF were used. Northern analysis revealed that these mutant cells have greatly reduced levels of trk expression. PC12nnr cultures were transiently transfected with expression vectors encoding the full-length rat trk cDNA and assessed for responsiveness to NGF. Expression of exogenous trk rescued the capacity for NGF-promoted neurite outgrowth, cellular hypertrophy, and serum-free survival by these cells. These results indicate that gp140prototrk is necessary for functional NGF signal transduction.	COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032	Columbia University	LOEB, DM (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032, USA.		Parada, luis F/B-9400-2014	Chao, Moses/0000-0002-6969-3744	NINDS NIH HHS [NS 27680, NS 21072, NS 16036] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021072, P50NS027680, P01NS027680, R01NS016036] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTIN JG, 1991, J BIOL CHEM, V266, P5401; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; BURSTEIN DE, 1978, P NATL ACAD SCI USA, V75, P6059, DOI 10.1073/pnas.75.12.6059; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GORIN PD, 1979, P NATL ACAD SCI USA, V76, P5382, DOI 10.1073/pnas.76.10.5382; GREEN SH, 1986, J BIOL CHEM, V261, P5316; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GREENE LA, 1991, IN PRESS CULTURING N; HEMPSTEAD B, 1988, COLD SPRING HARB SYM, V53, P477, DOI 10.1101/SQB.1988.053.01.055; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOIZUMI S, 1988, J NEUROSCI, V8, P715; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; LAZAROVICI P, 1989, J NEUROSCI RES, V23, P1, DOI 10.1002/jnr.490230102; LEVI A, 1991, ANNU REV PHARMACOL, V31, P205; LEVIMONTALCINI R, 1960, P NATL ACAD SCI USA, V46, P384, DOI 10.1073/pnas.46.3.384; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; MANIATIS T, 1982, MOL CLONING LABORATO, P383; MARTINEZ HJ, 1985, P NATL ACAD SCI USA, V82, P7777, DOI 10.1073/pnas.82.22.7777; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RAUSCH DM, 1989, J NEUROSCI RES, V24, P49, DOI 10.1002/jnr.490240108; RUIT KG, 1990, J NEUROSCI, V10, P2412; RUKENSTEIN A, 1991, IN PRESS J NEUROSCI; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; VOLONTE C, 1989, J CELL BIOL, V109, P2395, DOI 10.1083/jcb.109.5.2395; Volonte C, 1990, GROWTH FACTORS, V2, P321; YAN Q, 1988, J NEUROSCI, V8, P3481	41	242	243	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1991	66	5					961	966		10.1016/0092-8674(91)90441-Z	http://dx.doi.org/10.1016/0092-8674(91)90441-Z			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1653650				2022-12-01	WOS:A1991GE46000014
J	MCCARTY, DR; HATTORI, T; CARSON, CB; VASIL, V; LAZAR, M; VASIL, IK				MCCARTY, DR; HATTORI, T; CARSON, CB; VASIL, V; LAZAR, M; VASIL, IK			THE VIVIPAROUS-1 DEVELOPMENTAL GENE OF MAIZE ENCODES A NOVEL TRANSCRIPTIONAL ACTIVATOR	CELL			English	Article							AMINO-ACID-SEQUENCE; ZEA-MAYS-L; ABSCISIC-ACID; WILD-TYPE; POLYACRYLAMIDE GELS; SECONDARY-STRUCTURE; WHEAT EMBRYOS; PROTEIN; EXPRESSION; DNA	The Viviparous-1 (Vp1) gene of maize is specifically required for expression of the maturation program in seed development. We show that Vp1 encodes a 73,335 dalton protein with no detectable homology to known proteins. An acidic transcriptional activation sequence was identified by fusion to the GAL4 DNA-binding domain. Expression of VP1 in maize protoplasts resulted in strong activation (> 130-fold) of a reporter gene fused to the promoter of a presumptive target gene. The acidic domain in VP1 was essential for transactivation and could be functionally replaced by the activator sequence of the herpes simplex virus VP16 protein. Our results indicate that VP1 is a novel transcription factor possibly involved in potentiation of a seed-specific hormone response.			MCCARTY, DR (corresponding author), UNIV FLORIDA, DEPT VEGETABLE CROPS, GAINESVILLE, FL 32611 USA.		Vasil, Indra K/F-6192-2011	Vasil, Indra K/0000-0002-8900-4897				ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; CUMING AC, 1984, EUR J BIOCHEM, V145, P351, DOI 10.1111/j.1432-1033.1984.tb08561.x; DOONER HK, 1985, PLANT PHYSIOL, V77, P486, DOI 10.1104/pp.77.2.486; DURE L, 1981, BIOCHEMISTRY-US, V20, P4162, DOI 10.1021/bi00517a033; DURE L, 1989, PLANT MOL BIOL, V12, P475, DOI 10.1007/BF00036962; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GOFF SA, 1991, GENE DEV, V5, P298, DOI 10.1101/gad.5.2.298; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUILTINAN MJ, 1990, SCIENCE, V250, P267, DOI 10.1126/science.2145628; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; Jefferson RA., 1987, PLANT MOL BIOL REP, V5, P387, DOI DOI 10.1007/BF02667740; JONES RJ, 1987, PLANT PHYSIOL, V83, P905, DOI 10.1104/pp.83.4.905; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRIZ AR, 1990, PLANT PHYSIOL, V92, P538, DOI 10.1104/pp.92.2.538; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MA J, 1988, NATURE, V334, P631, DOI 10.1038/334631a0; Maniatis T., 1982, MOL CLONING; MARCOTTE WR, 1988, NATURE, V335, P454, DOI 10.1038/335454a0; MARCOTTE WR, 1989, PLANT CELL, V1, P969, DOI 10.2307/3868997; MCCARTY DR, 1989, DEV GENET, V10, P473, DOI 10.1002/dvg.1020100608; MCCARTY DR, 1989, PLANT CELL, V1, P523, DOI 10.1105/tpc.1.5.523; MCCARTY DR, 1991, PHYSIOL PLANTARUM, V81, P267, DOI 10.1111/j.1399-3054.1991.tb02140.x; McCarty DR, 1986, MAIZE GEN COOP NEWSL, V60, P61; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NEILL SJ, 1986, PLANTA, V169, P87, DOI 10.1007/BF01369779; NEILL SJ, 1987, PLANTA, V171, P358, DOI 10.1007/BF00398681; OLESEN JT, 1990, GENE DEV, V4, P1714, DOI 10.1101/gad.4.10.1714; PAZARES J, 1987, EMBO J, V6, P3553, DOI 10.1002/j.1460-2075.1987.tb02684.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PELLETT PE, 1985, P NATL ACAD SCI USA, V82, P5870, DOI 10.1073/pnas.82.17.5870; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROBERTSON DS, 1955, GENETICS, V40, P744; ROBICHAUD C, 1987, J PLANT PHYSIOL, V130, P181, DOI 10.1016/S0176-1617(87)80222-5; ROBICHAUD C, 1986, J PLANT PHYSIOL, V126, P235, DOI 10.1016/S0176-1617(86)80025-6; ROBICHAUD CS, 1980, DEV GENET, V1, P325, DOI 10.1002/dvg.1020010405; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKRIVER K, 1990, PLANT CELL, V2, P503, DOI 10.1105/tpc.2.6.503; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; VASIL V, 1989, PLANT PHYSIOL, V91, P1575, DOI 10.1104/pp.91.4.1575; WILLIAMSON JD, 1988, PLANT PHYSIOL, V86, P208, DOI 10.1104/pp.86.1.208	56	547	603	1	50	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1991	66	5					895	905		10.1016/0092-8674(91)90436-3	http://dx.doi.org/10.1016/0092-8674(91)90436-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1889090				2022-12-01	WOS:A1991GE46000009
J	MEISTERERNST, M; ROY, AL; LIEU, HM; ROEDER, RG				MEISTERERNST, M; ROY, AL; LIEU, HM; ROEDER, RG			ACTIVATION OF CLASS-II GENE-TRANSCRIPTION BY REGULATORY FACTORS IS POTENTIATED BY A NOVEL ACTIVITY	CELL			English	Article							RNA POLYMERASE-II; MAJOR LATE PROMOTER; IMMEDIATE EARLY PROTEIN; TATA BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL DOMAINS; UPSTREAM ELEMENT; FACTOR USF; INITIATION; INVITRO	A novel activity (USA) stimulated activator-dependent transcription in a reconstituted system in conjunction with natural TFIID, resulting in 10- to 50-fold levels of induction by regulatory factors. USA mediated a modest induction by USF in conjunction with either recombinant human TFIID, intact yeast TFIID, or the evolutionarily conserved C-terminal portion of yeast TFIID. Upon further purification, USA was resolved into two components that had opposite effects on core promoter activity and that in combination potentiated activator function. Gel mobility shift experiments indicated physical interactions between the inhibitory activity and TFIID, suggesting that the additional components (cofactors) associate with the preinitiation complex both to reduce promoter activity in the absence and to increase promoter activity in the presence of transcriptional activators.			MEISTERERNST, M (corresponding author), ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021, USA.				NATIONAL CANCER INSTITUTE [R35CA042567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027397] Funding Source: NIH RePORTER; NCI NIH HHS [CA42567] Funding Source: Medline; NIAID NIH HHS [AI27397] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABMAYR SM, 1988, GENE DEV, V2, P542, DOI 10.1101/gad.2.5.542; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BITTER GA, 1983, ANAL BIOCHEM, V128, P294, DOI 10.1016/0003-2697(83)90378-0; BROWN DD, 1984, CELL, V37, P359, DOI 10.1016/0092-8674(84)90366-0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1990, GENE DEV, V4, P1141, DOI 10.1101/gad.4.7.1141; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; HORIKOSHI M, 1990, CELL, V61, P1172; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KIM WY, 1988, J BIOL CHEM, V263, P18880; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MEISTERERNST M, 1990, P NATL ACAD SCI USA, V87, P9153, DOI 10.1073/pnas.87.23.9153; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; MUHICH ML, 1990, P NATL ACAD SCI USA, V87, P9148, DOI 10.1073/pnas.87.23.9148; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; REINBERG D, 1987, J BIOL CHEM, V262, P3322; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x	58	280	285	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1991	66	5					981	993		10.1016/0092-8674(91)90443-3	http://dx.doi.org/10.1016/0092-8674(91)90443-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1889091				2022-12-01	WOS:A1991GE46000016
J	NASMYTH, K; DIRICK, L				NASMYTH, K; DIRICK, L			THE ROLE OF SWI4 AND SWI6 IN THE ACTIVITY OF G1 CYCLINS IN YEAST	CELL			English	Article							CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; HO GENE; FISSION YEAST; ESCHERICHIA-COLI; MATING-PHEROMONE; DNA; DIVISION; IDENTIFICATION; TRANSCRIPTION	Entry into the mitotic cycle (START) requires a protein kinase encoded by the CDC28 gene and one of three redundant G1-specific cyclins encoded by CLN1, -2, and -3. SWI4 and SWI6 are transcription factors required for the START-dependent activation of the HO endonuclease gene. They also fulfill an overlapping but essential role for cell division since cells deleted for both genes are inviable. We show that the essential role of SWI4 and SWI6 is to ensure the activity of G1-specific cyclin genes. SWI4 and SWI6 appear necessary for the transcription of CLN1 and CLN2, but not for that of CLN3. CLN3 function is, however, also dependent on SWI4 and SWI6.			NASMYTH, K (corresponding author), INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.			Nasmyth, Kim/0000-0001-7030-4403				ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; AMMERER G, 1990, GENE DEV, V4, P299, DOI 10.1101/gad.4.2.299; ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; ANDREWS BJ, 1989, NATURE, V342, P803; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; CARTER BLA, 1980, GENETICS, V96, P561; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; CHAMBERS SP, 1988, GENE, V68, P139, DOI 10.1016/0378-1119(88)90606-3; CROSS F, 1988, ANNU REV CELL BIOL, V4, P429, DOI 10.1146/annurev.cb.04.110188.002241; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HABER JE, 1977, GENETICS, V87, P33; HADWIGER JA, 1990, NUCLEIC ACIDS RES, V18, P4025, DOI 10.1093/nar/18.13.4025; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; MORTIMER RK, 1969, YEASTS, V1, P385; MURRAY AW, 1989, NATURE, V342, P14, DOI 10.1038/342014a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH K, 1985, CELL, V42, P225, DOI 10.1016/S0092-8674(85)80118-5; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NASMYTH K, 1987, EMBO J, V6, P243, DOI 10.1002/j.1460-2075.1987.tb04745.x; NASMYTH K, 1985, CELL, V42, P213, DOI 10.1016/S0092-8674(85)80117-3; NASMYTH K, 1983, NATURE, V302, P670, DOI 10.1038/302670a0; NASMYTH KA, 1990, CELL, V63, P1117, DOI 10.1016/0092-8674(90)90404-3; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PRICE C, 1991, J MOL BIOL, V218, P543, DOI 10.1016/0022-2836(91)90700-G; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SOCKANATHAN S, 1991, THESIS U CAMBRIDGE C; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; STILLMAN DJ, 1988, EMBO J, V7, P485, DOI 10.1002/j.1460-2075.1988.tb02836.x; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	46	291	296	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1991	66	5					995	1013		10.1016/0092-8674(91)90444-4	http://dx.doi.org/10.1016/0092-8674(91)90444-4			19	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1832338				2022-12-01	WOS:A1991GE46000017
J	OGAS, J; ANDREWS, BJ; HERSKOWITZ, I				OGAS, J; ANDREWS, BJ; HERSKOWITZ, I			TRANSCRIPTIONAL ACTIVATION OF CLN1, CLN2, AND A PUTATIVE NEW G1-CYCLIN (HCS26) BY SWI4, A POSITIVE REGULATOR OF G1-SPECIFIC TRANSCRIPTION	CELL			English	Article							YEAST HO GENE; CELL-CYCLE CONTROL; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; EXPRESSION; PROTEIN; INTERCONVERSION; SEQUENCE	SWI4 of budding yeast codes for a component of a transcription factor (cell cycle box factor, or CCBF) necessary for G1-specific expression of HO. We show that SWI4 is essential for haploid cell viability at high temperature and in a/alpha-cells at all temperatures: SWI4-deficient cells arrest as large unbudded cells. Eight high copy number plasmids were identified that allow swi4- strains to grow under nonpermissive conditions. Two carry G1 cyclin genes, CLN1 and CLN2; another carries HCS26, coding for a putative cyclin. a/alpha-swi4- mutants exhibit 3- to 20-fold reductions in the levels of CLN1, CLN2, and HCS26 transcripts. The requirement of SWI4 for transcription appears to be direct: each gene contains sites similar to the CCBF-binding site; CCBF binds to the upstream region of HCS26. We propose that SWI4 participates in a positive feedback loop by which CLN1, CLN2, and possibly HCS26 promote their own transcription in G1.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, PROGRAM GENET, SAN FRANCISCO, CA 94143 USA; UNIV TORONTO, DEPT MED & MOLEC GENET, TORONTO M5S 1A8, ONTARIO, CANADA	University of California System; University of California San Francisco; University of Toronto	OGAS, J (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, PROGRAM CELL BIOL, SAN FRANCISCO, CA 94143 USA.			Ogas, Joe/0000-0002-1332-7729	NIAID NIH HHS [AI18738] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018738, R01AI018738] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; ANDREWS BJ, 1990, J BIOL CHEM, V265, P14057; ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GUARENTE L, 1984, P NATL ACAD SCI-BIOL, V81, P7860, DOI 10.1073/pnas.81.24.7860; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HICKS JB, 1976, GENETICS, V83, P245; HUISMAN O, 1987, GENETICS, V116, P191; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JENSEN R, 1983, P NATL ACAD SCI-BIOL, V80, P3035, DOI 10.1073/pnas.80.10.3035; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; MACKAY VL, 1988, P NATL ACAD SCI USA, V85, P55, DOI 10.1073/pnas.85.1.55; Maniatis T., 1982, MOL CLONING; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH K, 1985, CELL, V42, P225, DOI 10.1016/S0092-8674(85)80118-5; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; Sherman F., 1982, METHODS YEAST GENETI; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; VAI M, 1987, EXP CELL RES, V171, P448, DOI 10.1016/0014-4827(87)90176-5; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	34	282	284	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1991	66	5					1015	1026		10.1016/0092-8674(91)90445-5	http://dx.doi.org/10.1016/0092-8674(91)90445-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1832336				2022-12-01	WOS:A1991GE46000018
J	PICKER, LJ; WARNOCK, RA; BURNS, AR; DOERSCHUK, CM; BERG, EL; BUTCHER, EC				PICKER, LJ; WARNOCK, RA; BURNS, AR; DOERSCHUK, CM; BERG, EL; BUTCHER, EC			THE NEUTROPHIL SELECTIN LECAM-1 PRESENTS CARBOHYDRATE LIGANDS TO THE VASCULAR SELECTINS ELAM-1 AND GMP-140	CELL			English	Article							NODE HOMING RECEPTOR; LEUKOCYTE ADHESION MOLECULE-1; CELL-ADHESION; MONOCLONAL-ANTIBODY; INTERACTION DOMAINS; SIALYL-LEX; ENDOTHELIUM; EXPRESSION; PROTEINS; RECOGNITION	LECAM-1 (leukocyte-endothelial cell adhesion molecule 1), the lymphocyte lectin ("selectin") homing receptor for peripheral lymph nodes (PLNs), participates in the earliest interactions of polymorphonuclear neutrophilic leukocytes (PMNs) with inflamed venules. Here, we present evidence that LECAM-1 mediates this function through a novel mechanism - presentation of oligosaccharide ligands to the inducible vascular selectins endothelial-leukocyte adhesion molecule (ELAM-1) and granule membrane protein 140 (GMP-140). PMN, but not lymphocyte, LECAM-1 is modified with the vascular selectin ligand sialyl Lewis x (sLex) and specifically binds ELAM-1-transfected cells. Although only a small fraction of total cell surface sLex, LECAM-1-associated sLex appears to play a prominent role in PMN interactions with cell-associated ELAM-1 and GMP-140, as anti-LECAM-1 monoclonal antibodies or selective removal of cell surface LECAM-1 inhibits PMN binding to vascular selectin transfectants by up to 70%. The enhanced function of LECAM-1-associated sLex may reflect the striking concentration, shown here, of LECAM-1 on PMN surface microvilli, the site of initial cellular contact.	STANFORD UNIV, MED CTR, SCH MED, DEPT PATHOL, STANFORD, CA 94305 USA; VET ADM MED CTR, CTR MOLEC BIOL & MED, PALO ALTO, CA 94304 USA; UNIV BRITISH COLUMBIA, ST PAULS HOSP, PULM RES LAB, VANCOUVER V6Z 1Y6, BC, CANADA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); St. Paul's Hospital; University of British Columbia; University of Saskatchewan	PICKER, LJ (corresponding author), UNIV TEXAS, DEPT PATHOL, MOLEC PATHOL LAB, SW MED CTR, DALLAS, TX 75235 USA.		Berg, Ellen/T-8827-2019; Berg, Ellen/D-9076-2014	Berg, Ellen/0000-0001-5149-6665	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041965, R37GM037734, R01GM037734] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19957] Funding Source: Medline; NIGMS NIH HHS [GM37734, GM41965] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARFORS KE, 1987, BLOOD, V69, P338; ATHERTON A, 1972, J PHYSIOL-LONDON, V222, P447, DOI 10.1113/jphysiol.1972.sp009808; BEESLEY JE, 1978, J CELL SCI, V33, P85; BEESLEY JE, 1979, J CELL SCI, V38, P237; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BERG EL, 1991, IN PRESS J BIOL CHEM; BERG M, 1990, BLOOD, V76, P2381; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; CARLOS T, 1991, BLOOD, V77, P2266; CARLOS TM, 1990, IMMUNOL REV, V114, P5, DOI 10.1111/j.1600-065X.1990.tb00559.x; CORRAL L, 1990, BIOCHEM BIOPH RES CO, V172, P1349, DOI 10.1016/0006-291X(90)91598-M; DOBRINA A, 1989, IMMUNOLOGY, V67, P502; DUIJVESTIJN AM, 1988, AM J PATHOL, V130, P147; EWIJK WV, 1980, CIBA F S, V71, P21; FUKUDA M, 1984, J BIOL CHEM, V259, P925; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GRIFFIN JD, 1990, J IMMUNOL, V145, P576; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; HALLMANN R, 1991, BIOCHEM BIOPH RES CO, V174, P236, DOI 10.1016/0006-291X(91)90511-5; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; JUTILA MA, 1991, CELL IMMUNOL, V132, P201, DOI 10.1016/0008-8749(91)90019-8; JUTILA MA, 1989, J IMMUNOL, V143, P3318; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; KISHIMOTO TK, 1991, BLOOD, V78, P805; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LAWRENCE MB, 1990, BLOOD, V75, P227; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; MULLIGAN RC, 1981, MOL CELL BIOL, V1, P449, DOI 10.1128/MCB.1.5.449; MUNRO JM, 1989, AM J PATHOL, V135, P121; ORD DC, 1990, J BIOL CHEM, V265, P7760; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PICKER LJ, 1990, J IMMUNOL, V145, P3247; PICKER LJ, 1990, AM J PATHOL, V136, P1053; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; PICKER LJ, 1989, J CELL BIOL, V109, P927, DOI 10.1083/jcb.109.2.927; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; Richardson P D, 1980, Ciba Found Symp, V71, P313, DOI 10.1002/9780470720547.ch17; SHIMIZU Y, 1991, NATURE, V349, P799, DOI 10.1038/349799a0; SIEGELMAN MH, 1989, P NATL ACAD SCI USA, V86, P5562, DOI 10.1073/pnas.86.14.5562; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SPERTINI O, 1991, NATURE, V349, P691, DOI 10.1038/349691a0; Staehelin T, 1981, Methods Enzymol, V79, P589; STEPHENS PE, 1989, NUCLEIC ACIDS RES, V17, P7110, DOI 10.1093/nar/17.17.7110; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; SYMINGTON FW, 1985, J IMMUNOL, V134, P2498; TOKUYASU KT, 1983, J HISTOCHEM CYTOCHEM, V31, P164, DOI 10.1177/31.1A_Suppl.6186722; TOKUYASU KT, 1973, J CELL BIOL, V57, P551, DOI 10.1083/jcb.57.2.551; TOKUYASU KT, 1978, J ULTRA MOL STRUCT R, V63, P287, DOI 10.1016/S0022-5320(78)80053-7; TRUE DD, 1990, J CELL BIOL, V111, P2757, DOI 10.1083/jcb.111.6.2757; VONANDRIAN UH, 1991, IN PRESS P NATL ACAD; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WATSON SR, 1991, NATURE, V349, P164, DOI 10.1038/349164a0; WOOD GS, 1984, AM J CLIN PATHOL, V81, P176, DOI 10.1093/ajcp/81.2.176	65	579	612	1	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1991	66	5					921	933		10.1016/0092-8674(91)90438-5	http://dx.doi.org/10.1016/0092-8674(91)90438-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1716182				2022-12-01	WOS:A1991GE46000011
J	WANG, LY; SALTER, MW; MACDONALD, JF				WANG, LY; SALTER, MW; MACDONALD, JF			REGULATION OF KAINATE RECEPTORS BY CAMP-DEPENDENT PROTEIN-KINASE AND PHOSPHATASES	SCIENCE			English	Article							HIPPOCAMPAL-NEURONS; ACID; CHANNELS; QUISQUALATE; MODULATION; CALCIUM; FAMILY	In the mammalian central nervous system, receptors for excitatory amino acid neurotransmitters such as the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-kainate receptor mediate a large fraction of excitatory transmission. Currents induced by activation of the AMPA-kainate receptor were potentiated by agents that specifically stimulate adenosine 3',5'-monophosphate (cAMP)-dependent protein kinase A (PKA) activity or were supported by intracellular application of the catalytic subunit of PKA by itself or in combination with cAMP. Furthermore, depression of these currents by a competitive inhibitor of PKA indicates that AMPA-kainate receptors are regulated by endogenous PKA. Endogenous protein phosphatases also regulate these receptors because an inhibitor of cellular phosphatases enhanced kainate currents. Modulation of PKA and phosphatases may regulate the function of these receptors and thus contribute to synaptic plasticity in hippocampal neurons.	HOSP SICK CHILDREN, DIV NEUROSCI, TORONTO M5G 1X8, ONTARIO, CANADA; UNIV TORONTO, DEPT PHARMACOL, TORONTO M5S 1A8, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	WANG, LY (corresponding author), UNIV TORONTO, DEPT PHYSIOL, MED SCI BLDG, TORONTO M5S 1A8, ONTARIO, CANADA.							BARNARD EA, 1990, TRENDS PHARMACOL SCI, V11, P500, DOI 10.1016/0165-6147(90)90051-9; BLAKE JF, 1988, NEUROSCI LETT, V89, P182, DOI 10.1016/0304-3940(88)90378-3; BRAUMANN T, 1985, J CHROMATOGR, V350, P105, DOI 10.1016/S0021-9673(01)93510-1; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; FORSCHER P, 1985, J GEN PHYSIOL, V85, P743, DOI 10.1085/jgp.85.5.743; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; ISHIDA AT, 1985, P NATL ACAD SCI USA, V82, P1837, DOI 10.1073/pnas.82.6.1837; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KISKIN NI, 1986, NEUROSCI LETT, V63, P225, DOI 10.1016/0304-3940(86)90360-5; KNAPP AG, 1987, NATURE, V325, P437, DOI 10.1038/325437a0; MACDONALD JF, 1989, J PHYSIOL-LONDON, V414, P17, DOI 10.1113/jphysiol.1989.sp017674; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MALINOW R, 1991, NEURON, V6, P53; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; SONG Y, 1990, NATURE, V348, P242, DOI 10.1038/348242a0; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; YUSTA B, 1988, J NEUROCHEM, V51, P1807, DOI 10.1111/j.1471-4159.1988.tb01162.x	23	387	389	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 6	1991	253	5024					1132	1135		10.1126/science.1653455	http://dx.doi.org/10.1126/science.1653455			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD808	1653455				2022-12-01	WOS:A1991GD80800030
J	ANNAS, GJ				ANNAS, GJ			FETAL PROTECTION AND EMPLOYMENT DISCRIMINATION - THE JOHNSON-CONTROLS CASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				ANNAS GJ, 1988, JUDGING MED, P53; BECKER ME, 1990, JAMA-J AM MED ASSOC, V264, P2113, DOI 10.1001/jama.264.16.2113; FUCHS VR, 1986, SCIENCE, V232, P459, DOI 10.1126/science.232.4749.459; 1987, PATIENT CHOICE MATER	4	16	16	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 5	1991	325	10					740	743		10.1056/NEJM199109053251020	http://dx.doi.org/10.1056/NEJM199109053251020			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GD497	1870647	Green Published			2022-12-01	WOS:A1991GD49700029
J	BENDELAC, A; SCHWARTZ, RH				BENDELAC, A; SCHWARTZ, RH			CD4+ AND CD8+ T-CELLS ACQUIRE SPECIFIC LYMPHOKINE SECRETION POTENTIALS DURING THYMIC MATURATION	NATURE			English	Article							MONOCLONAL-ANTIBODIES; MOUSE THYMOCYTES; STEM-CELLS; EXPRESSION; IL-4; SUBSETS; PRECURSORS; DEFINITION; RECEPTORS; PROFILES	PERIPHERAL CD4+ and CD8+ T lymphocytes carry out different functions during immune reactions, partly as a result of the distinct patterns of lymphokines that they secrete upon stimulation. Using thymic cells from adult and newborn mice as well as from fetal organ cultures, we show here that this functional differentiation occurs inside the thymus and is completed during the single positive stage by the time the T-cell receptor becomes fully coupled to the intracellular activation pathways leading to lymphokine secretion. Surprisingly, CD4+8- thymocytes differ from their immediate progeny, naive peripheral CD4+ cells, in that they secrete a broader range of lymphokines, including interleukins 4, 5 and 10 and gamma-interferon, and more closely resemble immunologically experienced (activated or memory) CD4+ lymphocytes.			BENDELAC, A (corresponding author), NIAID,CELLULAR & MOLEC IMMUNOL LAB,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							AGUS DB, 1991, J EXP MED, V173, P1039, DOI 10.1084/jem.173.5.1039; BENSASSON SZ, 1990, J IMMUNOL, V145, P1127; BEVAN MJ, 1978, IMMUNOL REV, V42, P3, DOI 10.1111/j.1600-065X.1978.tb00256.x; BOTTOMLY K, 1989, EUR J IMMUNOL, V19, P617, DOI 10.1002/eji.1830190407; BUDD RC, 1987, J IMMUNOL, V138, P3583; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; CEREDIG R, 1988, J IMMUNOL, V141, P355; CHERWINSKI HM, 1987, J EXP MED, V166, P1229, DOI 10.1084/jem.166.5.1229; CRISPE IN, 1987, J IMMUNOL, V138, P2013; DAHL H, 1972, ACTA PATH MICRO IM B, VB 80, P863; ERNST DN, 1990, J IMMUNOL, V145, P1295; FINKEL TH, 1987, NATURE, V330, P179, DOI 10.1038/330179a0; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; GROSSMANN J, 1991, J IMMUNOL, V146, P293; HAYAKAWA K, 1988, J EXP MED, V168, P1825, DOI 10.1084/jem.168.5.1825; HULI J, 1989, J IMMUNOL, V142, P800; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEE WT, 1990, J IMMUNOL, V144, P3288; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; MICHIE SA, 1988, J EXP MED, V168, P1929, DOI 10.1084/jem.168.5.1929; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSMANN TR, 1990, J IMMUNOL, V145, P2938; NUSSENZWEIG MC, 1980, J EXP MED, V151, P1196, DOI 10.1084/jem.151.5.1196; OHARA J, 1985, NATURE, V315, P333, DOI 10.1038/315333a0; ORTEGA G, 1984, J IMMUNOL, V133, P1970; PILARSKI LM, 1989, EUR J IMMUNOL, V19, P589, DOI 10.1002/eji.1830190403; SCHUMACHER JH, 1988, J IMMUNOL, V141, P1575; SWAIN SL, 1990, J IMMUNOL, V144, P1788; SWAIN SL, 1988, J IMMUNOL, V141, P3445	30	176	177	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1991	353	6339					68	71		10.1038/353068a0	http://dx.doi.org/10.1038/353068a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1831881				2022-12-01	WOS:A1991GD80500059
J	BORNER, C; FILIPUZZI, I; WEINSTEIN, IB; IMBER, R				BORNER, C; FILIPUZZI, I; WEINSTEIN, IB; IMBER, R			FAILURE OF WILD-TYPE OR A MUTANT FORM OF PROTEIN KINASE-C-ALPHA TO TRANSFORM FIBROBLASTS	NATURE			English	Article							RAS ONCOGENE; CELLS; GROWTH	A MUTANT form of the alpha-isoform of protein kinase C (PKC) was recently isolated from an ultraviolet radiation-induced murine fibrosarcoma cell line and reported to transform mouse BALB/c 3T3 fibroblasts on transfection 1. Four point mutations in the regulatory domain were assumed to be responsible for its oncogenicity and unusual preference for membrane localization. Here, we report that overexpression of the reported mutant PKC-alpha complementary DNA in three fibroblast cell lines, including BALB/c 3T3, does not enable these cells to grow in soft agar or nude mice. In addition, this mutant PKC-alpha form seems to be indistinguishable from the wild-type PKC-alpha with respect to its dependence on cofactors, phorbol ester binding, subcellular distribution and its effects on growth and morphology. These results fail to confirm the previous study 1 and indicate that overexpression of either the wild-type or the reported mutant form of PKC-alpha does not transform rodent fibroblasts.	COLUMBIA UNIV,CTR COMPREHENS CANC,NEW YORK,NY 10032; COLUMBIA UNIV,INST CANC RES,NEW YORK,NY 10032; UNIV BASEL CLIN,SCH MED,MOLEC TUMORBIOL LAB,CH-4031 BASEL,SWITZERLAND	Columbia University; Columbia University; University of Basel								BORNER C, 1987, INT J CANCER, V40, P344, DOI 10.1002/ijc.2910400310; BORNER C, 1990, CELL GROWTH DIFFER, V1, P653; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; COSTA SD, 1985, BIOCHEM BIOPH RES CO, V133, P814, DOI 10.1016/0006-291X(85)90977-5; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; IMBER R, 1991, CANCER RES, V51, P632; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; OBRIAN CA, 1984, BIOCHEM BIOPH RES CO, V124, P296, DOI 10.1016/0006-291X(84)90951-3; REGAZZI R, 1986, INT J CANCER, V37, P731, DOI 10.1002/ijc.2910370514; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	12	82	83	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1991	353	6339					78	80		10.1038/353078a0	http://dx.doi.org/10.1038/353078a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1881450				2022-12-01	WOS:A1991GD80500063
J	COEN, ES; MEYEROWITZ, EM				COEN, ES; MEYEROWITZ, EM			THE WAR OF THE WHORLS - GENETIC INTERACTIONS CONTROLLING FLOWER DEVELOPMENT	NATURE			English	Review							ANTIRRHINUM-MAJUS; TRANSCRIPTION FACTORS; ARABIDOPSIS-THALIANA; FLORAL DEVELOPMENT; MORPHOGENESIS	The analysis of mutations affecting flower structure has led to the identification of some of the genes that direct flower development. Cloning of these genes has allowed the formulation of molecular models of how floral meristem and organ identity may be specified, and has shown that the distantly related flowering plants Arabidopsis thaliana and Antirrhinum majus use homologous mechanisms in floral pattern formation.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA; JOHN INNES INST, DEPT GENET, NORWICH NR4 7UH, NORFOLK, ENGLAND	California Institute of Technology; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center			Meyerowitz, Elliot M/A-7118-2009					BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; BOWMAN JL, 1988, PLANT MOL CELL BIOL, V5, P57; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; CARPENTER R, 1990, GENE DEV, V4, P1483, DOI 10.1101/gad.4.9.1483; COEN ES, 1991, ANNU REV PLANT PHYS, V42, P241, DOI 10.1146/annurev.pp.42.060191.001325; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; HAUGHN GW, 1988, DEV GENET, V9, P73, DOI 10.1002/dvg.1020090202; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; KOMAKI MK, 1988, DEVELOPMENT, V104, P195; KUCKUCK H, 1930, Z IND ABST VER, V56, P51; KUNST L, 1989, PLANT CELL, V1, P1195, DOI 10.1105/tpc.1.12.1195; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MEYEROWITZ EM, 1989, DEVELOPMENT, V106, P209; MEYEROWITZ EM, 1991, DEVELOPMENT S1, V112, P157; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; Pruitt RE, 1987, GENETIC REGULATION D, P327; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; STRUHL K, 1989, TRENDS BIOCHEM SCI, V14, P137, DOI 10.1016/0968-0004(89)90145-X; Stubbe H, 1966, GENETIK ZYTOLOGIE AN; Weberling F., 1989, MORPHOLOGY FLOWERS I; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	27	2122	2494	23	474	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 5	1991	353	6339					31	37		10.1038/353031a0	http://dx.doi.org/10.1038/353031a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1715520				2022-12-01	WOS:A1991GD80500048
J	COLOMBO, M; DEFRANCHIS, R; DELNINNO, E; SANGIOVANNI, A; DEFAZIO, C; TOMMASINI, M; DONATO, MF; PIVA, A; DICARLO, V; DIOGUARDI, N				COLOMBO, M; DEFRANCHIS, R; DELNINNO, E; SANGIOVANNI, A; DEFAZIO, C; TOMMASINI, M; DONATO, MF; PIVA, A; DICARLO, V; DIOGUARDI, N			HEPATOCELLULAR-CARCINOMA IN ITALIAN PATIENTS WITH CIRRHOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background and Methods. Patients with cirhosis of the liver are recognized as being at risk for hepatocellular carcinoma. The magnitude of the risk, the natural history of this disease, and the possibilities for detecting potentially curable tumors in patients in the Western world are unknown. To address these questions, we examined 447 Italian patients with well-compensated cirrhosis (which was of viral origin in 62 percent of them) from 1985 through 1990, performing serum alpha-fetoprotein assays and real-time ultrasonography every 3 to 12 months. Results. Hepatocellular carcinoma was found in 30 patients (7 percent) at base line and in another 29 patients (7 percent of 417 patients free of tumor at base line) during follow-up periods averaging 33 months (range, 1 to 48). The cumulative hazard of the development of hepatocellular carcinoma during follow-up was higher among patients with persistently elevated serum alpha-fetaprotein levels (12 with tumors among 42 with such levels) than among those with fluctuating levels (11 among 82) or those with consistently normal levels (6 among 255). Only 17 patients had potentially operable tumors. The proportion of potentially operable tumors among those detected during follow-up was significantly lower than the proportion at enrollment (4 of 29 vs. 13 of 30, P = 0.027). The survival at one year of the 12 patients who underwent surgery was 67 percent, and the tumor-recurrence rate was 60 percent. Outcome was not appreciably different for the five patients who refused surgery. Conclusions. In the West, as in Asia, patients with cirrhosis of the liver are at substantial risk for hepatocellular carcinoma, with a yearly incidence rate of 3 percent. Our screening program did not appreciably increase the rate of detection of potentially curable tumors.	UNIV MILAN, SAN RAFFAELE HOSP, DEPT SURG, I-20122 MILAN, ITALY	University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	COLOMBO, M (corresponding author), POLICLIN HOSP MILAN, CTR A MIGLIAVACCA, INST INTERNAL MED, VIA PACE 9, I-20122 MILAN, ITALY.		Donato, Maria francesca/AAC-2372-2019; Piemonti, Lorenzo/P-7605-2017	Piemonti, Lorenzo/0000-0002-2172-2198; sangiovanni, angelo/0000-0002-9996-9385				ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; [Anonymous], 1990, ANN SURG, V211, P277; BENEDETTI J, 1983, BMDP STATISTICAL SOF, P557; COLOMBO M, 1985, LIVER, V5, P336; COTTONE M, 1988, HEPATO-GASTROENTEROL, V35, P101; CUTLER SJ, 1958, J CHRON DIS, V8, P699; EBARA M, 1986, GASTROENTEROLOGY, V90, P289, DOI 10.1016/0016-5085(86)90923-6; FROST JK, 1984, AM REV RESPIR DIS, V130, P549; GIBSON JB, 1978, INT HISTOLOGICAL CLA, V20, P12; HSU HC, 1988, CANCER, V61, P2095, DOI 10.1002/1097-0142(19880515)61:10<2095::AID-CNCR2820611027>3.0.CO;2-H; JOHNSON PJ, 1987, J HEPATOL, V4, P140, DOI 10.1016/S0168-8278(87)80021-1; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KEW MC, 1984, SEMIN LIVER DIS, V4, P136, DOI 10.1055/s-2008-1040653; KOBAYASHI K, 1985, HEPATOLOGY, V5, P1100, DOI 10.1002/hep.1840050607; KONDO F, 1990, HEPATOLOGY, V12, P592, DOI 10.1002/hep.1840120324; KUBO Y, 1978, GASTROENTEROLOGY, V74, P578; LIAW YF, 1986, GASTROENTEROLOGY, V90, P263, DOI 10.1016/0016-5085(86)90919-4; MARINGHINI A, 1988, DIGEST DIS SCI, V33, P47, DOI 10.1007/BF01536630; MUNOZ N, 1987, NEOPLASMS LIVER, P3, DOI DOI 10.1007/978-4-431-68349-0_1; NELSON W, 1972, TECHNOMETRICS, V14, P945, DOI 10.2307/1267144; OKA H, 1990, HEPATOLOGY, V12, P680, DOI 10.1002/hep.1840120411; OKAZAKI N, 1989, CANCER, V63, P2207, DOI 10.1002/1097-0142(19890601)63:11<2207::AID-CNCR2820631124>3.0.CO;2-C; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; SHELL JC, 1985, CANCER, V56, P660, DOI 10.1002/1097-0142(19850801)56:3<660::AID-CNCR2820560338>3.0.CO;2-F; TANAKA R, 1987, LIVER, V7, P316; TANG Z-Y, 1986, Seminars in Surgical Oncology, V2, P103, DOI 10.1002/ssu.2980020207; ZAMAN SN, 1985, LANCET, V1, P1357; [No title captured]	28	750	769	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 5	1991	325	10					675	680		10.1056/NEJM199109053251002	http://dx.doi.org/10.1056/NEJM199109053251002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD497	1651452				2022-12-01	WOS:A1991GD49700002
J	IGARASHI, M; NAGATA, A; JINNO, S; SUTO, K; OKAYAMA, H				IGARASHI, M; NAGATA, A; JINNO, S; SUTO, K; OKAYAMA, H			WEE1+-LIKE GENE IN HUMAN-CELLS	NATURE			English	Article							HIGH-EFFICIENCY TRANSFORMATION; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; HUMAN HOMOLOG; INDUCER; DNA	THE wee1+ gene is a mitotic inhibitor controlling the G2 to M transition of the fission yeast Schizosaccharomyces pombe 1 and encodes a protein kinase with both serine- and tyrosine-phosphorylating activities 2. We have cloned a human gene (WEE1Hu) similar to wee1+ by transcomplementation of a yeast mutant 3,4. WEE1Hu encodes a protein homologous to the S. pombe wee1+ and mik1+ (a functionally redundant sibling of wee1+) 5 kinases and effectively rescues a wee1 mutation. We report here that overexpression of WEE1Hu in fission yeast generates very elongated cells as a result of inhibition of the G2-M transition in the cell cycle. In addition, we detected a 3-kilobase-long WEE1Hu messenger RNA in all the human cell lines we examined. We conclude that a wee1+-like gene exists and is expressed in human cells.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT MOLEC GENET,3-1 YAMADAOKA,SUITA,OSAKA 565,JAPAN	Osaka University								CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; Gutz H., 1974, HDB GENETICS, V1, P395; HANKS SK, 1988, SCIENCE, V241, P24; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; OKAZAKI K, 1990, NUCLEIC ACIDS RES, V18, P6485, DOI 10.1093/nar/18.22.6485; Rothstein R., 1985, DNA CLONING, VII, P45; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TOYAMA R, 1990, FEBS LETT, V268, P217, DOI 10.1016/0014-5793(90)81012-D	16	182	191	1	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1991	353	6339					80	83		10.1038/353080a0	http://dx.doi.org/10.1038/353080a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1840647				2022-12-01	WOS:A1991GD80500064
J	ISACOFF, EY; JAN, YN; JAN, LY				ISACOFF, EY; JAN, YN; JAN, LY			PUTATIVE RECEPTOR FOR THE CYTOPLASMIC INACTIVATION GATE IN THE SHAKER K+ CHANNEL	NATURE			English	Article							POTASSIUM CHANNELS; SODIUM-CHANNEL; DROSOPHILA MUSCLE; XENOPUS-OOCYTES; RAT-BRAIN; CLONING	INACTIVATION of ion channels is important in the control of membrane excitability. For example, delayed-rectifier K+ channels, which regulate action potential repolarization, are inactivated only slowly, whereas A-type K+ channels, which affect action potential duration and firing frequency, have both fast and slow inactivation 1. Fast inactivation of Na+ and K+ channels may result from the blocking of the permeation pathway by a positively charged cytoplasmic gate 2 such as the one encoded by the first 20 amino acids of the Shaker B (ShB) K+ channel 3,4. We report here that mutation of five highly conserved residues between the proposed membrane-spanning segments S4 and S5 (also termed H4) 5 of ShB affects the stability of the inactivated state and alters channel conductance. One such mutation stabilizes the inactivated state of ShB as well as the inactivated state induced in the delayed-rectifier type K+ channel drk1 (ref. 6) by the cytoplasmic application of the ShB N-terminal peptide. The S4-S5 loop, therefore, probably forms part of a receptor for the inactivation gate and lies near the channel's permeation pathway.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	ISACOFF, EY (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.		isacoff, ehud/AAP-1459-2020	Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299; Isacoff, Ehud Y./0000-0003-4775-9359				ARMSTRON.CM, 1969, J GEN PHYSIOL, V54, P553, DOI 10.1085/jgp.54.5.553; ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; BAUMANN A, 1988, EMBO J, V7, P2457, DOI 10.1002/j.1460-2075.1988.tb03092.x; CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.bi.55.070186.004513; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GREENBLATT RE, 1985, FEBS LETT, V193, P125, DOI 10.1016/0014-5793(85)80136-8; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; Hille B, 1984, IONIC CHANNELS EXCIT; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISACOFF E, 1990, COLD SPRING HARB SYM, V55, P9; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; JAN LY, 1990, TRENDS NEUROSCI, V13, P415, DOI 10.1016/0166-2236(90)90123-R; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MCCORMACK T, 1990, P NATL ACAD SCI USA, V87, P5227, DOI 10.1073/pnas.87.13.5227; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PFAFFINGER PJ, 1991, J NEUROSCI, V11, P918; RIBERA AB, 1990, NEURON, V5, P691, DOI 10.1016/0896-6273(90)90223-3; ROBERDS SL, 1991, P NATL ACAD SCI USA, V88, P1798, DOI 10.1073/pnas.88.5.1798; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZAGOTTA WN, 1990, J GEN PHYSIOL, V95, P29, DOI 10.1085/jgp.95.1.29; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520; ZAGOTTA WN, 1989, P NATL ACAD SCI USA, V86, P7243, DOI 10.1073/pnas.86.18.7243	30	309	314	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1991	353	6339					86	90		10.1038/353086a0	http://dx.doi.org/10.1038/353086a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1881453				2022-12-01	WOS:A1991GD80500066
J	KLEUSS, C; HESCHELER, J; EWEL, C; ROSENTHAL, W; SCHULTZ, G; WITTIG, B				KLEUSS, C; HESCHELER, J; EWEL, C; ROSENTHAL, W; SCHULTZ, G; WITTIG, B			ASSIGNMENT OF G-PROTEIN SUBTYPES TO SPECIFIC RECEPTORS INDUCING INHIBITION OF CALCIUM CURRENTS	NATURE			English	Article							GTP-BINDING-PROTEIN; PITUITARY CELL-LINE; ANTI-SENSE RNA; MESSENGER-RNA; ALPHA-SUBUNIT; MOLECULAR-CLONING; GENETIC-ANALYSIS; 2 FORMS; ANTISENSE; CHANNELS	The inhibition of voltage-dependent Ca2+ channels in secretory cells by plasma membrane receptors is mediated by pertussis toxin-sensitive G proteins. Multiple forms of G proteins have been described, differing principally in their alpha-subunits, but it has not been possible to establish which G-protein subtype mediates inhibition by a specific receptor. By intranuclear injection of antisense oligonucleotides into rat pituitary GH3 cells, the essential role of the G(o)-type G proteins in Ca2+-channel inhibition is established: the subtypes G(o1) and G(o2) mediate inhibition through the muscarinic and somatostatin receptors, respectively.	FREE UNIV BERLIN, INST PHARMAKOL, W-1000 BERLIN 33, GERMANY	Free University of Berlin	KLEUSS, C (corresponding author), FREE UNIV BERLIN, INST MOLEK BIOL & BIOCHEM, ARNIMALLEE 22, W-1000 BERLIN 33, GERMANY.							ASANO T, 1988, J NEUROCHEM, V50, P1164, DOI 10.1111/j.1471-4159.1988.tb10588.x; BERTRAND P, 1990, J BIOL CHEM, V265, P18576; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BIRNBAUMER LA, 1990, REV PHARM TOX, V30, P675; CAZENAVE C, 1989, NUCLEIC ACIDS RES, V17, P4255, DOI 10.1093/nar/17.11.4255; CHANGEUX JP, 1990, TRENDS PHARMACOL SCI, V11, P485, DOI 10.1016/0165-6147(90)90049-E; COLLU R, 1988, ENDOCRINOLOGY, V122, P1176, DOI 10.1210/endo-122-3-1176; CORNISHBOWDEN A, 1985, EUR J BIOCHEM, V150, P1; DREYER C, 1982, ROUX ARCH DEV BIOL, V191, P228, DOI 10.1007/BF00848409; EWALD DA, 1988, P NATL ACAD SCI USA, V85, P3633, DOI 10.1073/pnas.85.10.3633; FINDLAY J, 1990, TRENDS PHARMACOL SCI, V11, P492, DOI 10.1016/0165-6147(90)90050-I; GRAESSMANN M, 1983, METHOD ENZYMOL, V101, P482; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; GREEN PJ, 1986, ANNU REV BIOCHEM, V55, P569, DOI 10.1146/annurev.bi.55.070186.003033; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARRISWARRICK RM, 1988, NEURON, V1, P27, DOI 10.1016/0896-6273(88)90206-1; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HSU WH, 1990, J BIOL CHEM, V265, P11220; IZANT JG, 1984, CELL, V36, P1007, DOI 10.1016/0092-8674(84)90050-3; JACKSON DA, 1988, J CELL SCI, V90, P365; JONES DT, 1987, J BIOL CHEM, V262, P14241; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; MASTERS SB, 1986, PROTEIN ENG, V1, P47, DOI 10.1093/protein/1.1.47; MATTERA R, 1989, J BIOL CHEM, V264, P465; MCFADZEAN I, 1989, NEURON, V3, P177, DOI 10.1016/0896-6273(89)90030-5; MINSHULL J, 1986, NUCLEIC ACIDS RES, V14, P6433, DOI 10.1093/nar/14.16.6433; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; OFFERMANNS S, 1991, J BIOL CHEM, V266, P3365; OFFERMANNS S, 1989, EUR J BIOCHEM, V180, P283, DOI 10.1111/j.1432-1033.1989.tb14645.x; OFFERMANNS S, 1991, MOL ENDOCRINOL, V5, P995, DOI 10.1210/mend-5-7-995; PAULSSEN EJ, 1991, MOL CELL ENDOCRINOL, V76, P45, DOI 10.1016/0303-7207(91)90258-T; ROSENTHAL W, 1988, EMBO J, V7, P1627, DOI 10.1002/j.1460-2075.1988.tb02989.x; SCHULTZ G, 1990, ANNU REV PHYSIOL, V52, P275, DOI 10.1146/annurev.ph.52.030190.001423; SHUTTLEWORTH J, 1988, EMBO J, V7, P427, DOI 10.1002/j.1460-2075.1988.tb02830.x; SILBERT S, 1990, J BIOL CHEM, V265, P3102; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; TANABE T, 1985, NATURE, V315, P242, DOI 10.1038/315242a0; TOSELLI M, 1989, PFLUG ARCH EUR J PHY, V415, P255, DOI 10.1007/BF00370874; TSUKAMOTO T, 1991, P NATL ACAD SCI USA, V88, P2974, DOI 10.1073/pnas.88.8.2974; WEINTRAUB H, 1985, TRENDS GENET, V1, P22, DOI 10.1016/0168-9525(85)90010-1; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0; ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280	47	562	563	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 5	1991	353	6339					43	48		10.1038/353043a0	http://dx.doi.org/10.1038/353043a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1679199				2022-12-01	WOS:A1991GD80500050
J	MACEJAK, DG; SARNOW, P				MACEJAK, DG; SARNOW, P			INTERNAL INITIATION OF TRANSLATION MEDIATED BY THE 5' LEADER OF A CELLULAR MESSENGER-RNA	NATURE			English	Article							CAP-BINDING-PROTEIN; SECONDARY STRUCTURE; NONCODING REGION; POLIOVIRUS; VIRUS; CELLS; GENE; CONSERVATION; INVOLVEMENT; ADENOVIRUS	A RIBOSOME-SCANNING model has been proposed to explain the initiation of eukaryotic messenger RNAs 1 in which binding of the 43S ternary ribosomal subunit near or at the 5' end of the mRNA is facilitated by an interaction between the methylated cap-structure at the end of the mRNA and the cap-binding protein complex eIF-4F (refs 2, 3). But picornaviral mRNAs do not have a 5' terminal cap structure and are translated by internal ribosome binding 4-7. A cellular mRNA, encoding the immunoglobulin heavy-chain binding protein, can be translated in poliovirus-infected cells at a time when cap-dependent translation of host cell mRNAs is inhibited 8. We report here that the 5' leader of the binding protein mRNA can directly confer internal ribosome binding to an mRNA in mammalian cells, indicating that translation initiation by an internal ribosome-binding mechanism is used by eukaryotic mRNAs.	UNIV COLORADO,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	MACEJAK, DG (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,MOLEC BIOL PROGRAM,DENVER,CO 80262, USA.			Sarnow, Peter/0000-0002-2043-2770				Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BELSHAM GJ, 1990, J VIROL, V64, P5389, DOI 10.1128/JVI.64.11.5389-5395.1990; BENERJEE AK, 1980, MICROBIOL REV, V44, P175; BONNEAU AM, 1987, J BIOL CHEM, V262, P11134; CALZONE FJ, 1982, NUCLEIC ACIDS RES, V10, P2145, DOI 10.1093/nar/10.6.2145; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; KAMINSKI A, 1990, EMBO J, V9, P3753, DOI 10.1002/j.1460-2075.1990.tb07588.x; KATZE MG, 1986, J VIROL, V60, P1027, DOI 10.1128/JVI.60.3.1027-1039.1986; KIRKEGAARD K, 1986, CELL, V47, P433, DOI 10.1016/0092-8674(86)90600-8; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1983, MICROBIOL REV, V47, P1; LAUGHON A, 1986, MOL CELL BIOL, V6, P4676, DOI 10.1128/MCB.6.12.4676; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; SARNOW P, 1989, P NATL ACAD SCI USA, V86, P5795, DOI 10.1073/pnas.86.15.5795; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; SONENBERG N, 1987, ADV VIRUS RES, V33, P175, DOI 10.1016/S0065-3527(08)60318-8; TING J, 1988, DNA-J MOLEC CELL BIO, V7, P275, DOI 10.1089/dna.1988.7.275	24	462	711	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1991	353	6339					90	94		10.1038/353090a0	http://dx.doi.org/10.1038/353090a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1652694				2022-12-01	WOS:A1991GD80500067
J	NUNEZ, G; HOCKENBERY, D; MCDONNELL, TJ; SORENSEN, CM; KORSMEYER, SJ				NUNEZ, G; HOCKENBERY, D; MCDONNELL, TJ; SORENSEN, CM; KORSMEYER, SJ			BCL-2 MAINTAINS B-CELL MEMORY	NATURE			English	Article							ANTIGEN-DRIVEN SELECTION; IMMUNOLOGICAL MEMORY; GERMINAL-CENTERS; BONE-MARROW; SECONDARY; EXPRESSION; SURVIVAL; MICE; POPULATION; RESPONSES	THE number of lymphocytes in an animal is remarkably constant despite antigen-driven proliferation and a high rate of B-cell lymphopoiesis. This reflects the relatively brief lifespan of many newly generated B cells and argues for a well-regulated death mechanism 1-3. Even so, a secondary immune response can be generated years after a primary exposure to antigen 4. Antigen that might restimulate B cells persists for extended periods on follicular dendritic cells in the light zone of germinal centres 5-13. Antigen binding B cells have also been found months after the end of obvious cell division 14. The precise signal that enables certain B cells to emerge as long-term surviving memory cells 14-17 is unknown. Bcl-2, an inner mitochondrial membrane protein 18, blocks programmed cell death in B cells 18-20. We report here that this proto-oncogene maintains immune responsiveness. Transgenic mice overproducing Bcl-2 have a long-term persistence of immunoglobulin-secreting cells and an extended lifetime for memory B cells.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	NUNEZ, G (corresponding author), WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110, USA.		Nuñez, Gabriel/A-7160-2014					BEREK C, 1987, EUR J IMMUNOL, V17, P1121, DOI 10.1002/eji.1830170808; CELADA F, 1967, J EXP MED, V125, P199, DOI 10.1084/jem.125.2.199; COICO RF, 1983, J IMMUNOL, V131, P2254; COLLE JH, 1988, EUR J IMMUNOL, V18, P1307, DOI 10.1002/eji.1830180902; FLIEDNER TM, 1964, ANN NY ACAD SCI, V113, P578, DOI 10.1111/j.1749-6632.1964.tb40692.x; FORSTER I, 1990, P NATL ACAD SCI USA, V87, P4781, DOI 10.1073/pnas.87.12.4781; GOWANS JL, 1966, J EXP MED, V124, P1017, DOI 10.1084/jem.124.5.1017; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; GRAY D, 1988, J EXP MED, V167, P805, DOI 10.1084/jem.167.3.805; GRAY D, 1988, NATURE, V336, P70, DOI 10.1038/336070a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, IN PRESS P NATN ACAD; KLAUS GGB, 1980, IMMUNOL REV, V53, P3, DOI 10.1111/j.1600-065X.1980.tb01038.x; KOSKO MH, 1989, IMMUNOLOGY, V68, P312; KRAAL G, 1982, NATURE, V298, P377, DOI 10.1038/298377a0; KRAAL G, 1988, CELL IMMUNOL, V115, P78, DOI 10.1016/0008-8749(88)90163-3; LINTON PJ, 1989, CELL, V59, P1049, DOI 10.1016/0092-8674(89)90761-7; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; MACLENNAN ICM, 1986, IMMUNOL REV, V91, P61, DOI 10.1111/j.1600-065X.1986.tb01484.x; MCDONNELL TJ, 1990, MOL CELL BIOL, V10, P1901, DOI 10.1128/MCB.10.5.1901; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OPSTELTEN D, 1983, J IMMUNOL, V131, P2635; PEZELLA F, 1990, AM J PATHOL, V137, P225; SCHITTEK B, 1990, NATURE, V346, P749, DOI 10.1038/346749a0; SIEKEVITZ M, 1987, CELL, V48, P757, DOI 10.1016/0092-8674(87)90073-0; TEW TG, 1979, IMMUNOLOGY, V37, P69; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0	28	213	216	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1991	353	6339					71	73		10.1038/353071a0	http://dx.doi.org/10.1038/353071a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1908951				2022-12-01	WOS:A1991GD80500060
J	PETRENKO, AG; PERIN, MS; DAVLETOV, BA; USHKARYOV, YA; GEPPERT, M; SUDHOF, TC				PETRENKO, AG; PERIN, MS; DAVLETOV, BA; USHKARYOV, YA; GEPPERT, M; SUDHOF, TC			BINDING OF SYNAPTOTAGMIN TO THE ALPHA-LATROTOXIN RECEPTOR IMPLICATES BOTH IN SYNAPTIC VESICLE EXOCYTOSIS	NATURE			English	Article							WIDOW SPIDER VENOM; FROG NEUROMUSCULAR-JUNCTION; LONG-TERM POTENTIATION; PROTEIN KINASE-C; NERVE-TERMINALS; PURIFICATION; MEMBRANE	A VERTEBRATE neurotoxin, alpha-latrotoxin, from black widow spider venom causes synaptic vesicle exocytosis and neurotransmitter release from presynaptic nerve terminals 1-4. Although the mechanism of action of alpha-latrotoxin is not known, it does require binding of alpha-latrotoxin to a high-affinity receptor on the presynaptic plasma membrane 5. The alpha-latrotoxin receptor seems to be exclusively at the presynaptic plasmamembrane 6. Here we report that the alpha-latrotoxin receptor specifically binds to a synaptic vesicle protein, synaptotagmin, and modulates its phosphorylation. Synaptotagmin is a synaptic vesicle-specific membrane protein that binds negatively charged phospholipids and contains two copies of a putative Ca2+-binding domain from protein kinase C (the C2-domain), suggesting a regulatory role in synaptic vesicle fusion 7,8. Our findings suggest that a physiological role of the alpha-latrotoxin receptor may be the docking of synaptic vesicles at the active zone. The direct interaction of the alpha-latrotoxin receptor with a synaptic vesicle protein also suggests a mechanism of action for this toxin in causing neurotransmitter release.	UNIV TEXAS,SW MED CTR,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; SHEMYAKIN BIOORGAN CHEM INST,MOSCOW 117871,USSR	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences			Davletov, Bazbek/ABA-8569-2021; Ushkaryov, Yuri/AAQ-2985-2020	Ushkaryov, Yuri/0000-0002-5712-8297; Davletov, Bazbek/0000-0003-4658-3275; Petrenko, Alexander/0000-0002-6689-6546				BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; CLARK AW, 1970, NATURE, V225, P703, DOI 10.1038/225703a0; FRONTALI N, 1976, J CELL BIOL, V68, P462, DOI 10.1083/jcb.68.3.462; KELLY RB, 1988, NEURON, V1, P431, DOI 10.1016/0896-6273(88)90174-2; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KNAUS P, 1990, NEURON, V5, P453, DOI 10.1016/0896-6273(90)90084-S; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MCMAHON HT, 1990, J NEUROCHEM, V55, P2039, DOI 10.1111/j.1471-4159.1990.tb05793.x; OKAMOTO M, 1971, SCIENCE, V172, P733, DOI 10.1126/science.172.3984.733; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PETRENKO AG, 1990, EMBO J, V9, P2023, DOI 10.1002/j.1460-2075.1990.tb08331.x; PUMPLIN DW, 1977, J PHYSIOL-LONDON, V273, P443, DOI 10.1113/jphysiol.1977.sp012103; ROSENTHAL L, 1989, PHARMACOL THERAPEUT, V42, P115, DOI 10.1016/0163-7258(89)90024-7; SCHEER H, 1985, EMBO J, V4, P323, DOI 10.1002/j.1460-2075.1985.tb03632.x; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TZENG MC, 1979, J NEUROCHEM, V33, P263, DOI 10.1111/j.1471-4159.1979.tb11728.x; VALTORTA F, 1984, J CELL BIOL, V99, P124, DOI 10.1083/jcb.99.1.124; WANG JKT, 1988, J NEUROSCI, V8, P281	20	228	228	1	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1991	353	6339					65	68		10.1038/353065a0	http://dx.doi.org/10.1038/353065a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1881448				2022-12-01	WOS:A1991GD80500058
J	POUVELLE, B; SPIEGEL, R; HSIAO, L; HOWARD, RJ; MORRIS, RL; THOMAS, AP; TARASCHI, TF				POUVELLE, B; SPIEGEL, R; HSIAO, L; HOWARD, RJ; MORRIS, RL; THOMAS, AP; TARASCHI, TF			DIRECT ACCESS TO SERUM MACROMOLECULES BY INTRAERYTHROCYTIC MALARIA PARASITES	NATURE			English	Article							FALCIPARUM-INFECTED ERYTHROCYTES; PLASMODIUM-FALCIPARUM; TRANSPORT; MEMBRANE; PROTEIN; CULTURE	TRAFFICKING pathways in malaria-infected erythrocytes are complex because the internal parasite is separated from the serum by the erythrocyte and parasitophorous vacuolar membranes 1. Intraerythrocytic Plasmodium falciparum parasites can endocytose dextrans, protein A and an IgG2a antibody. Here we show that these macromolecules do not cross the erythrocyte or parasitophorous vacuolar membranes, but rather gain direct access to the aqueous space surrounding the parasite through a parasitophorous duct. Evidence for this structure includes visualization of membranes that are continuous between the parasitophorous vacuolar and erythrocyte membranes, and surface labelling of the parasite with fluorescent macromolecules under conditions that block endocytosis. The parasite can internalize by fluid-phase endocytosis macromolecules from the aqueous compartment surrounding it. Thus, surface antigens on trophozoites and schizonts should be considered as targets for antibody-directed parasiticidal agents.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, DEPT PATHOL & CELL BIOL, 1020 LOCUST ST, PHILADELPHIA, PA 19107 USA; DNAX RES INST MOLEC & CELLULAR BIOL INC, PALO ALTO, CA 94304 USA	Jefferson University; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Thomas, Andrew/C-6755-2013	Thomas, Andrew/0000-0002-9026-7467				AIKAWA M, 1978, J CELL BIOL, V77, P72, DOI 10.1083/jcb.77.1.72; BARNWELL JW, 1990, BLOOD CELLS, V16, P379; ELFORD BC, 1985, MOL BIOCHEM PARASIT, V16, P43, DOI 10.1016/0166-6851(85)90048-9; GREEN TJ, 1985, AM J TROP MED HYG, V34, P24, DOI 10.4269/ajtmh.1985.34.24; GRELLIER P, 1991, J CELL BIOL, V112, P267, DOI 10.1083/jcb.112.2.267; HOWARD RJ, 1986, J CELL BIOL, V103, P1269, DOI 10.1083/jcb.103.4.1269; HOWARD RJ, 1987, J CELL BIOL, V104, P1269, DOI 10.1083/jcb.104.5.1269; HSIAO LL, 1991, BIOCHEM J, V274, P121, DOI 10.1042/bj2740121; HUNTER J A, 1991, Biophysical Journal, V59, p442A; JENSEN JB, 1982, SCIENCE, V216, P1230, DOI 10.1126/science.7043736; JEPSEN S, 1983, SCAND J IMMUNOL, V18, P567, DOI 10.1111/j.1365-3083.1983.tb00893.x; KUISMANEN E, 1989, METHOD CELL BIOL, V32, P257; RODRIGUEZ MH, 1986, NATURE, V324, P388, DOI 10.1038/324388a0; SWANSON JA, 1985, J CELL BIOL, V100, P851, DOI 10.1083/jcb.100.3.851; TAYLOR DW, 1987, MOL BIOCHEM PARASIT, V25, P165, DOI 10.1016/0166-6851(87)90005-3; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VANDERSCHAFT PH, 1987, BIOCHIM BIOPHYS ACTA, V901, P1, DOI 10.1016/0005-2736(87)90250-1	17	193	194	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 5	1991	353	6339					73	75		10.1038/353073a0	http://dx.doi.org/10.1038/353073a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1715521				2022-12-01	WOS:A1991GD80500061
J	POWELL, SK; CUNNINGHAM, BA; EDELMAN, GM; RODRIGUEZBOULAN, E				POWELL, SK; CUNNINGHAM, BA; EDELMAN, GM; RODRIGUEZBOULAN, E			TARGETING OF TRANSMEMBRANE AND GPI-ANCHORED FORMS OF N-CAM TO OPPOSITE DOMAINS OF A POLARIZED EPITHELIAL-CELL	NATURE			English	Article							ADHESION MOLECULE UVOMORULIN; MDCK CELLS; PROTEINS; COMPONENT; KIDNEY; CDNAS; LINE	THE calcium-independent neural cell adhesion molecule N-CAM is expressed transiently during development in many tissues, including epithelia 1. The three naturally occurring principal isoforms 2,3 of N-CAM differ in the way in which they associate with the membrane and in their cytoplasmic domains 4. These isoforms are generated by developmentally regulated alternative splicing of a single gene 4-6: the large cytoplasmic domain (ld) form (relative molecular mass 180,000 (M(r) 180K)) is specific for post-mitotic neurons; the 120K small cytoplasmic domain (ssd) and 140K small surface domain (sd) forms also occur on other cell types 7. One function of the different isoforms could be to specify cellular localization; for example, glycosyl phosphatidyl inositol (GPI)-membrane anchoring acts as a targeting signal for expression on the apical surface of polarized epithelial cells 8,9. Neurons and epithelial cells may use similar mechanisms for polarizing their plasma membrane proteins 10,11. We have therefore investigated the targeting of GPI-anchored (ssd N-CAM, 120K) and transmembrane forms of N-CAM (sd N-CAM, 140K; Id N-CAM, 180K) by comparing the expression of each after transfection of the appropriate complementary DNAs into polarized epithelial cells. We find that isoforms with alternative modes of membrane association are targeted to different surfaces of polarized epithelial cells: ssd N-CAM is expressed on the apical surface, whereas sd and ld N-CAM are expressed on the basolateral surface. These results suggest that the different isoforms of N-CAM determine their own diverse cellular destinations. They also support the hypothesis that the GPI anchor acts as an apical targeting signal in epithelia.	ROCKEFELLER UNIV,DEPT DEV & MOLEC BIOL,NEW YORK,NY 10021	Rockefeller University	POWELL, SK (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DEPT CELL BIOL & ANAT,1300 YORK AVE,NEW YORK,NY 10021, USA.							CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; CUNNINGHAM BA, 1990, MORPHOREGULATORY MOL; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; FLEMING TP, 1988, ANNU REV CELL BIOL, V4, P459, DOI 10.1146/annurev.cellbio.4.1.459; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HEMPERLY JJ, 1986, P NATL ACAD SCI USA, V83, P9822, DOI 10.1073/pnas.83.24.9822; KLEIN G, 1988, DEVELOPMENT, V102, P749; LEBIVIC A, 1990, J CELL BIOL, V110, P1533, DOI 10.1083/jcb.110.5.1533; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; LETOURNEAU PC, 1989, DEVELOPMENT, V105, P505; LISANTI MP, 1990, TRENDS BIOCHEM SCI, V15, P113, DOI 10.1016/0968-0004(90)90195-H; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; MATSUZAKI F, 1990, J CELL BIOL, V110, P1239, DOI 10.1083/jcb.110.4.1239; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; MEGE RM, 1988, P NATL ACAD SCI USA, V85, P7274, DOI 10.1073/pnas.85.19.7274; MOORE HPH, 1985, J CELL BIOL, V101, P1773, DOI 10.1083/jcb.101.5.1773; MURRAY BA, 1986, J CELL BIOL, V102, P189, DOI 10.1083/jcb.102.1.189; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; OWENS GC, 1987, P NATL ACAD SCI USA, V84, P294, DOI 10.1073/pnas.84.1.294; PERSOHN E, 1989, J COMP NEUROL, V288, P92, DOI 10.1002/cne.902880108; PIZZEY JA, 1989, J CELL BIOL, V109, P3465, DOI 10.1083/jcb.109.6.3465; POLLERBERG GE, 1987, CELL TISSUE RES, V250, P227, DOI 10.1007/BF00214676; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; THIERY JP, 1982, P NATL ACAD SCI-BIOL, V79, P6737, DOI 10.1073/pnas.79.21.6737	27	105	106	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1991	353	6339					76	77		10.1038/353076a0	http://dx.doi.org/10.1038/353076a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1831882				2022-12-01	WOS:A1991GD80500062
J	SAKAI, T; OHTANI, N; MCGEE, TL; ROBBINS, PD; DRYJA, TP				SAKAI, T; OHTANI, N; MCGEE, TL; ROBBINS, PD; DRYJA, TP			ONCOGENIC GERM-LINE MUTATIONS IN SP1 AND ATF SITES IN THE HUMAN RETINOBLASTOMA GENE	NATURE			English	Article							DNA-BINDING; REPORTER GENE; EXPRESSION; SEQUENCE; PROTEINS	THE transcription of a eukaryotic gene is a consequence of intricate interactions between members of a set of transcription factors 1. We describe here evidence indicating that at least two distinct DNA-binding factors play an important part in the transcription of the human retinoblastoma gene (Rb). One of the factors reacts with a sequence overlapping with a potential Sp1 recognition sequence in the promoter region of the gene, the other with a nearby ATF recognition sequence. We have identified two naturally occurring point mutations in these recognition sequences that cause hereditary retinoblastoma. The nuclear factors do not bind to the mutant sequences. We infer that these nuclear factors are necessary for the expression of the Rb gene and the suppression of cancer.	HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,DEPT OPHTHALMOL,BOSTON,MA 02114; UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh				Ohtani, Naoko/0000-0001-8934-0797				BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; MACKLIN MT, 1960, AM J HUM GENET, V12, P1; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; ORITA M, 1989, GENOMICS, V5, P871; SAMBROOK J, 1989, MOL CLONING LAB MANU, V3, P16; SASSONECORSI P, 1990, ONCOGENE, V5, P427	14	214	219	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1991	353	6339					83	90		10.1038/353083a0	http://dx.doi.org/10.1038/353083a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1881452				2022-12-01	WOS:A1991GD80500065
J	CARCILLO, JA; DAVIS, AL; ZARITSKY, A				CARCILLO, JA; DAVIS, AL; ZARITSKY, A			ROLE OF EARLY FLUID RESUSCITATION IN PEDIATRIC SEPTIC SHOCK	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NOREPINEPHRINE THERAPY; MYOCARDIAL DEPRESSION; CARDIAC DYSFUNCTION; CANINE MODEL; SEPSIS; CHILDREN	Objective. - To examine the association of the volume of fluid administered at 1 and 6 hours after presentation, with survival and the occurrence of the adult respiratory distress syndrome, cardiogenic pulmonary edema, and persistent hypovolemia during the resuscitation of children with septic shock. Setting and Patients. - All pediatric patients with septic shock presenting to the emergency department over a 6-year period and having a pulmonary artery catheter inserted by 6 hours after presentation were identified. Methods. - Patients were analyzed together and in three groups based on fluid volume in the first hour: group 1, less than 20 mL/kg; group 2,20 to 40 mL/kg; and group 3, more than 40 mL/kg. Adult respiratory distress syndrome was diagnosed by the presence of alveolar infiltrates, hypoxemia, and a pulmonary capillary wedge pressure of 15 mm Hg or less. Cardiogenic pulmonary edema was diagnosed similarly, except the pulmonary capillary wedge pressure was greater than 15 mm Hg. Hypovolemia was diagnosed by the presence of oliguria, hypotension, and a pulmonary capillary wedge pressure of 8 mm Hg or less 6 hours after presentation. Results. - We identified 34 patients (median age, 13.5 months). At 1 and 6 hours, respectively, group 1 (n = 14) received 11 +/- 6 and 71 +/- 29 mL/kg (mean +/- SD) of fluid; group 2 received 32 +/- 5 and 108 +/- 54 mL/kg of fluid; and group 3 received 69 +/- 19 and 117 +/- 29 mL/kg of fluid. Survival in group 3 (eight of nine patients) was significantly better than in group 1 (six of 14 patients) or group 2 (four of 11 patients). Adult respiratory distress syndrome developed in 11 patients (32%) and cardiogenic pulmonary edema developed in five patients (15%). Having adult respiratory distress syndrome was associated with increased mortality, but adult respiratory distress syndrome was not increased in any group. Similarly, cardiogenic pulmonary edema was not associated with the fluid volume received or with decreased survival. Hypovolemia occurred in six patients in group 1 and two patients in group 2; all eight subsequently died. Conclusion. - Rapid fluid resuscitation in excess of 40 mL/kg in the first hour following emergency department presentation was associated with improved survival, decreased occurrence of persistent hypovolemia, and no increase in the risk of cardiogenic pulmonary edema or adult respiratory distress syndrome in this group of pediatric patients with septic shock.	GEORGE WASHINGTON UNIV,CHILDRENS HOSP,NATL MED CTR,DEPT ANESTHESIOL & CRIT CARE MED,WASHINGTON,DC 20010	Children's National Health System; George Washington University								BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; BOUCEK MM, 1984, J PEDIATR-US, V105, P538, DOI 10.1016/S0022-3476(84)80416-3; CARROLL GC, 1982, AM J PHYSIOL, V243, pR131, DOI 10.1152/ajpregu.1982.243.1.R131; CHAMEIDES L, 1988, TXB PEDIATRIC ADV LI, P47; CHERNOW B, 1986, CIRC SHOCK, V18, P141; DESJARS P, 1987, CRIT CARE MED, V15, P134, DOI 10.1097/00003246-198702000-00011; KAUFMAN BS, 1984, CHEST, V85, P336, DOI 10.1378/chest.85.3.336; MEADOWS D, 1988, CRIT CARE MED, V16, P663, DOI 10.1097/00003246-198807000-00003; MONSALVE F, 1984, CRIT CARE MED, V12, P1021, DOI 10.1097/00003246-198412000-00003; NATANSON C, 1986, J CLIN INVEST, V78, P259, DOI 10.1172/JCI112559; NATANSON C, 1989, J CLIN INVEST, V83, P243, DOI 10.1172/JCI113866; PARKER MM, 1984, ANN INTERN MED, V100, P483, DOI 10.7326/0003-4819-100-4-483; POWELL KR, 1990, J PEDIATR-US, V117, P515, DOI 10.1016/S0022-3476(05)80682-1; RACKOW EC, 1987, CIRC SHOCK, V22, P11; REILLY JM, 1989, CHEST, V95, P1072, DOI 10.1378/chest.95.5.1072; ROTH BL, 1959, MOL CELLULAR MECHANI, P41; WEIL M, 1977, ANN CLIN RES, V9, P181; WEIL MH, 1978, AM J MED, V64, P920, DOI 10.1016/0002-9343(78)90444-8; WILES JB, 1980, CRIT CARE MED, V8, P55, DOI 10.1097/00003246-198002000-00001; WILSON RF, 1971, ANN SURG, V174, P939, DOI 10.1097/00000658-197112000-00009; [No title captured]; [No title captured]	22	247	255	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 4	1991	266	9					1242	1245		10.1001/jama.266.9.1242	http://dx.doi.org/10.1001/jama.266.9.1242			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC858	1870250				2022-12-01	WOS:A1991GC85800033
J	FISHBEIN, DJ				FISHBEIN, DJ			DO-DNA - ALCOHOLISM IN THE SOVIET-UNION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											FISHBEIN, DJ (corresponding author), UNIV MASSACHUSETTS,SCH MED,BOX 426,55 LAKE AVE N,WORCESTER,MA 01655, USA.							ADELMAN SA, IN PRESS IMPATIENT P; KIRN TF, 1987, JAMA-J AM MED ASSOC, V253, P883; KIRPICHENKO AA, 1989, PSYCHIATRY; ROBINS LN, 1984, ARCH GEN PSYCHIAT, V41, P949; SMITH H, 1989, NEW RUSSIANS; 1987, DIAGNOSTIC STATISTIC, P173	6	2	2	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 4	1991	266	9					1211	1212		10.1001/jama.266.9.1211	http://dx.doi.org/10.1001/jama.266.9.1211			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GC858	1870239				2022-12-01	WOS:A1991GC85800013
J	NEWMAN, LG; WALLER, J; PALESTRO, CJ; SCHWARTZ, M; KLEIN, MJ; HERMANN, G; HARRINGTON, E; HARRINGTON, M; ROMAN, SH; STAGNAROGREEN, A				NEWMAN, LG; WALLER, J; PALESTRO, CJ; SCHWARTZ, M; KLEIN, MJ; HERMANN, G; HARRINGTON, E; HARRINGTON, M; ROMAN, SH; STAGNAROGREEN, A			UNSUSPECTED OSTEOMYELITIS IN DIABETIC FOOT ULCERS - DIAGNOSIS AND MONITORING BY LEUKOCYTE SCANNING WITH INDIUM IN-111 OXYQUINOLINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOWER-EXTREMITY INFECTIONS; CONCISE COMMUNICATION; PEDAL OSTEOMYELITIS; CIPROFLOXACIN; MELLITUS; SCINTIGRAPHY; THERAPY; DISEASE; BONE	Objective. - The prevalence of osteomyelitis in diabetic foot ulcers is unknown. Early diagnosis of this infection is critical, as prompt antibiotic treatment decreases the rate of amputation. We therefore assessed the prevalence of osteomyelitis in 35 diabetic patients with 41 foot ulcers. We compared results of roentgenograms, leukocyte scans with indium in 111 oxyquinoline, and bone scans with the diagnostic criterion standards of bone histologic and culture findings. Leukocyte scans were repeated at 2- to 3-week intervals during antibiotic treatment. Design. - Cohort study Setting. - Institutional and private, ambulatory and hospitalized patients. Patients. - Consecutive sample of 54 diabetic patients. Thirty-five patients with 41 foot ulcers were included. Results. - As determined by bone biopsy and culture, osteomyelitis was found to underlie 28 (68%) of 41 diabetic foot ulcers. Only nine (32%) of the 28 cases were diagnosed clinically by the referring physician. Underscoring the clinically silent nature of osteomyelitis in these ulcers, 19 (68%) of 28 occurred in outpatients, 19 (68%) of 28 occurred in ulcers not exposing bone, and 18 (64%) of 28 had no evidence of inflammation on physical examination. All patients with ulcers that exposed bone had osteomyelitis. Of the imaging tests, the leukocyte scan had the highest sensitivity, 89%. In patients with osteomyelitis, the leukocyte scan image intensity decreased by 16 to 34 days of antibiotic treatment and normalized by 36 to 54 days. Conclusion. - The majority of diabetic foot ulcers have an underlying osteomyelitis that is clinically unsuspected. Leukocyte scans are highly sensitive for diagnosing osteomyelitis in diabetic foot ulcers and may be useful for monitoring the efficacy of antibiotic treatment. We recommend that diabetic patients with foot ulcers that expose bone should be treated for osteomyelitis. Diabetic patients with foot ulcers that do not expose bone should undergo leukocyte scanning, which eliminates the risk of bone biopsy in diagnosing osteomyelitis and allows for the diagnosis and treatment of this well-known but often silent precursor of lower extremity amputation.	MT SINAI MED CTR, DEPT SURG, DIV ORTHOPED SURG, NEW YORK, NY 10029 USA; MT SINAI MED CTR, DIV VASC SURG, NEW YORK, NY 10029 USA; MT SINAI MED CTR, DEPT NUCL MED, NEW YORK, NY 10029 USA; MT SINAI MED CTR, DEPT PATHOL, NEW YORK, NY 10029 USA; MT SINAI MED CTR, DEPT RADIOL, NEW YORK, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	NEWMAN, LG (corresponding author), MT SINAI MED CTR, DEPT MED, DIV ENDOCRINOL & METAB, BOX 1087, 1 GUSTAVE L LEVY PL, NEW YORK, NY 10029 USA.			Stagnaro-Green, Alex/0000-0003-2434-3852				ALAZRAKI N, 1985, AM J ROENTGENOL, V145, P767, DOI 10.2214/ajr.145.4.767; BAMBERGER DM, 1987, AM J MED, V83, P653, DOI 10.1016/0002-9343(87)90894-1; BEAM TR, 1988, 2ND INT S NEW QUIN G; EYMONTT MJ, 1981, RADIOLOGY, V140, P475, DOI 10.1148/radiology.140.2.6454901; FIERER J, 1979, REV INFECT DIS, V1, P210; GELFAND MJ, 1977, JAMA-J AM MED ASSOC, V237, P245, DOI 10.1001/jama.237.3.245; GREENBERG RN, 1987, ANTIMICROB AGENTS CH, V31, P151, DOI 10.1128/AAC.31.2.151; HOOGKAMPKORSTANJE JAA, 1989, J ANTIMICROB CHEMOTH, V23, P427, DOI 10.1093/jac/23.3.427; KEENAN AM, 1989, ARCH INTERN MED, V149, P2262, DOI 10.1001/archinte.149.10.2262; KOLYVAS E, 1978, CLIN NUCL MED, V3, P461, DOI 10.1097/00003072-197812000-00003; LESLIE C A, 1989, Comprehensive Therapy, V15, P23; MAURER AH, 1981, J NUCL MED, V22, P941; MAURER AH, 1986, RADIOLOGY, V161, P221, DOI 10.1148/radiology.161.1.3763871; MCCARTHY K, 1988, J NUCL MED, V29, P1015; NORRBY SR, 1989, SCAND J INFECT DIS, P74; PARK HM, 1982, J NUCL MED, V23, P569; PETERSON LR, 1989, AM J MED, V86, P801, DOI 10.1016/0002-9343(89)90476-2; RATOPOULOS V, 1982, AM J ROENTGENOL, V139, P1077; ROSENBLATT DS, 1989, CLIN DIABETES, V7, P85; SCHAUWECKER DS, 1988, J NUCL MED, V29, P1651; SCHER KS, 1988, SURGERY, V104, P661; SELDIN DW, 1985, J NUCL MED, V26, P988; SINHA S, 1972, MEDICINE, V51, P191, DOI 10.1097/00005792-197205000-00006; THAKUR ML, 1977, J NUCL MED, V18, P1022; WALDVOGEL FA, 1970, NEW ENGL J MED, V282, P316, DOI 10.1056/NEJM197002052820606; WALDVOGEL FA, 1989, REV INFECT DIS, V11, pS1259; WHEAT J, 1985, AM J MED, V78, P218, DOI 10.1016/0002-9343(85)90388-2; WHEAT LJ, 1986, ARCH INTERN MED, V146, P1935, DOI 10.1001/archinte.146.10.1935; 1980, NIH812284 PUBL, P5	29	250	251	2	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 4	1991	266	9					1246	1251		10.1001/jama.266.9.1246	http://dx.doi.org/10.1001/jama.266.9.1246			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC858	1908030				2022-12-01	WOS:A1991GC85800034
J	WHITE, DJ; CHANG, HG; BENACH, JL; BOSLER, EM; MELDRUM, SC; MEANS, RG; DEBBIE, JG; BIRKHEAD, GS; MORSE, DL				WHITE, DJ; CHANG, HG; BENACH, JL; BOSLER, EM; MELDRUM, SC; MEANS, RG; DEBBIE, JG; BIRKHEAD, GS; MORSE, DL			THE GEOGRAPHIC SPREAD AND TEMPORAL INCREASE OF THE LYME-DISEASE EPIDEMIC	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ERYTHEMA CHRONICUM MIGRANS; NEW-YORK; IXODES-DAMMINI; BORRELIA-BURGDORFERI; WESTCHESTER-COUNTY; UNITED-STATES; ENDEMIC AREA; TICK BITES; ARTHRITIS; FEATURES	Objective. - To describe the temporal and geographic progression of the Lyme disease epidemic in New York State from 1977 through 1989. Design. - Communicable disease surveillance system. Setting. - Statewide. Main Outcome Measures. - The progression of the epidemic was examined by analyzing trends in Lyme disease cases reported to the state surveillance system, town and county Lyme disease incidence rates, Lyme disease hospital discharge rates, and the distribution of Ixodes dammini ticks obtained from surveillance efforts and submitted for identification. Main Results. - The number of confirmed Lyme disease cases in New York has increased with concurrent increases in the number of hospital discharges. The number of counties endemic for Lyme disease increased from four to eight between 1985 and 1989. The number of counties with documented I dammini ticks increased from four in 1985 to 22 in 1989. Incidence of the disease also increased within known endemic counties. Conclusions. - Tick surveillance indicated that the range of I dammini has expanded annually into areas up to 384 km from the original known endemic areas of Long Island, NY, and Connecticut. Cumulative data from human surveillance resources document both temporal increases and geographic expansion of the Lyme disease epidemic in New York.			WHITE, DJ (corresponding author), NEW YORK STATE DEPT HLTH, BUR COMMUNICABLE DIS CONTROL, 651 CORNING TOWER, EMPIRE STATE PLAZA, ALBANY, NY 12237 USA.		Birkhead, Guthrie/AAG-9058-2019	Birkhead, Guthrie/0000-0002-6511-6560	NIAID NIH HHS [AI27044] Funding Source: Medline; NIAMS NIH HHS [AR40445] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI027044, R01AI027044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040445] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anderson J F, 1989, Conn Med, V53, P343; ANDERSON JF, 1987, J PARASITOL, V73, P419, DOI 10.2307/3282102; ANDERSON JF, 1986, INFECT IMMUN, V51, P394, DOI 10.1128/IAI.51.2.394-396.1986; BENACH J L, 1986, Zentralblatt fuer Bakteriologie Mikrobiologie und Hygiene Series A, V263, P477; BENACH JL, 1983, NEW ENGL J MED, V308, P740, DOI 10.1056/NEJM198303313081302; BENACH JL, 1988, ANN NY ACAD SCI, V539, P1; BIRKHEAD G, 1990, 4TH INT C LYM BORR S, P12; BIRKHEAD GS, 1990, 4TH INT C LYM BORR S, P67; BISHOPP FC, 1945, J PARASITOL, V31, P1, DOI 10.2307/3273061; BOSLER EM, 1984, YALE J BIOL MED, V57, P651; BOWEN GS, 1984, AM J EPIDEMIOL, V120, P387; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; Cartter M L, 1989, Conn Med, V53, P320; CIESIELSKI CA, 1988, ANN NY ACAD SCI, V539, P283, DOI 10.1111/j.1749-6632.1988.tb31862.x; Cooley R. A., 1945, NATION INST HEALTH BULL, V184, P1; COSTELLO CM, 1989, J INFECT DIS, V159, P136, DOI 10.1093/infdis/159.1.136; FALCO RC, 1989, AM J PUBLIC HEALTH, V79, P12, DOI 10.2105/AJPH.79.1.12; FALCO RC, 1988, AM J EPIDEMIOL, V127, P826, DOI 10.1093/oxfordjournals.aje.a114865; FISH D, 1990, J WILDLIFE DIS, V26, P339, DOI 10.7589/0090-3558-26.3.339; FISH D, 1990, 4TH INT C LYM BORR S, P50; HABICHT GS, 1987, SCI AM, V257, P78, DOI 10.1038/scientificamerican0787-78; HANRAHAN JP, 1984, J INFECT DIS, V150, P489, DOI 10.1093/infdis/150.4.489; HANRAHAN JP, 1984, YALE J BIOL MED, V57, P643; JAMNBACK H, 1969, STATE MUSEUM SCI SER, V19, P1; LASTAVICA CC, 1989, NEW ENGL J MED, V320, P133, DOI 10.1056/NEJM198901193200301; REIK L, 1979, MEDICINE, V58, P281, DOI 10.1097/00005792-197907000-00001; SMITH PF, 1988, ANN NY ACAD SCI, V539, P289, DOI 10.1111/j.1749-6632.1988.tb31863.x; SMITH RP, 1990, AM J PUBLIC HEALTH, V80, P333, DOI 10.2105/AJPH.80.3.333; SPIELMAN A, 1979, J MED ENTOMOL, V15, P218, DOI 10.1093/jmedent/15.3.218; STANEK G, 1987, LYME BORRELIOSIS, P1; STEERE AC, 1983, ANN INTERN MED, V99, P76, DOI 10.7326/0003-4819-99-1-76; STEERE AC, 1979, ANN INTERN MED, V90, P896, DOI 10.7326/0003-4819-90-6-896; STEERE AC, 1979, ANN INTERN MED, V91, P730, DOI 10.7326/0003-4819-91-5-730; STEERE AC, 1980, ANN INTERN MED, V93, P8, DOI 10.7326/0003-4819-93-1-8; STEERE AC, 1978, AM J EPIDEMIOL, V108, P312, DOI 10.1093/oxfordjournals.aje.a112625; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1986, J INFECT DIS, V154, P295, DOI 10.1093/infdis/154.2.295; STEERE AC, 1977, ANN INTERN MED, V86, P685, DOI 10.7326/0003-4819-86-6-685; STEERE AC, 1983, NEW ENGL J MED, V308, P733, DOI 10.1056/NEJM198303313081301; STEERE AC, 1977, ARTHRITIS RHEUM, V20, P7, DOI 10.1002/art.1780200102; STEERE AC, 1984, YALE J BIOL MED, V57, P445; Tsai T F, 1989, Conn Med, V53, P324; WALLIS RC, 1978, AM J EPIDEMIOL, V108, P322, DOI 10.1093/oxfordjournals.aje.a112626; WEINSTEIN A, 1989, NEW YORK STATE J MED, V89, P566; WEISBROD AR, 1989, APPL ENVIRON MICROB, V55, P1921, DOI 10.1128/AEM.55.8.1921-1924.1989; WILLIAMS CL, 1986, AM J PUBLIC HEALTH, V76, P62, DOI 10.2105/AJPH.76.1.62; 1985, AM HOSP ASS NEWSLETT, V2, P6; 1989, MMWR, V38, P668	48	96	96	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 4	1991	266	9					1230	1236		10.1001/jama.266.9.1230	http://dx.doi.org/10.1001/jama.266.9.1230			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC858	1870248				2022-12-01	WOS:A1991GC85800031
J	DALONZO, GE; BARST, RJ; AYRES, SM; BERGOFSKY, EH; BRUNDAGE, BH; DETRE, KM; FISHMAN, AP; GOLDRING, RM; GROVES, BM; KERNIS, JT; LEVY, PS; PIETRA, GG; REID, LM; REEVES, JT; RICH, S; VREIM, CE; WILLIAMS, GW; WU, M				DALONZO, GE; BARST, RJ; AYRES, SM; BERGOFSKY, EH; BRUNDAGE, BH; DETRE, KM; FISHMAN, AP; GOLDRING, RM; GROVES, BM; KERNIS, JT; LEVY, PS; PIETRA, GG; REID, LM; REEVES, JT; RICH, S; VREIM, CE; WILLIAMS, GW; WU, M			SURVIVAL IN PATIENTS WITH PRIMARY PULMONARY-HYPERTENSION - RESULTS FROM A NATIONAL PROSPECTIVE REGISTRY	ANNALS OF INTERNAL MEDICINE			English	Article						HYPERTENSION, PULMONARY; VENTRICULAR FUNCTION, RIGHT; ATRIAL FUNCTION, RIGHT; RAYNAUDS DISEASE; HEART-LUNG TRANSPLANTATION	UNUSUALLY LONG DURATION; NATURAL-HISTORY	Objective: To characterize mortality in persons diagnosed with primary pulmonary hypertension and to investigate factors associated with survival. Design: Registry with prospective follow-up. Setting: Thirty-two clinical centers in the United States participating in the Patient Registry for the Characterization of Primary Pulmonary Hypertension supported by the National Heart, Lung, and Blood Institute. Patients: Patients (194) diagnosed at clinical centers between 1 July 1981 and 31 December 1985 and followed through 8 August 1988. Measurements: At diagnosis, measurements of hemodynamic variables, pulmonary function, and gas exchange variables were taken in addition to information on demographic variables, medical history, and life-style. Patients were followed for survival at 6-month intervals. Main Results: The estimated median survival of these patients was 2.8 years (95% Cl, 1.9 to 3.7 years). Estimated single-year survival rates were as follows: at 1 year, 68% (Cl, 61% to 75%); at 3 years, 48% (Cl, 41% to 55%); and at 5 years, 34% (Cl, 24% to 44%). Variables associated with poor survival included a New York Heart Association (NYHA) functional class of III or IV, presence of Raynaud phenomenon, elevated mean right atrial pressure, elevated mean pulmonary artery pressure, decreased cardiac index, and decreased diffusing capacity for carbon monoxide (DL(CO)). Drug therapy at entry or discharge was not associated with survival duration. Conclusions: Mortality was most closely associated with right ventricular hemodynamic function and can be characterized by means of an equation using three variables: mean pulmonary artery pressure, mean right atrial pressure, and cardiac index. Such an equation, once validated prospectively, could be used as an adjunct in planning treatment strategies and allocating medical resources.	NHLBI, DIV LUNG DIS, WESTWOOD BLDG, ROOM 6A09, BETHESDA, MD 20892 USA; UNIV TEXAS, MED CTR, DIV PULM, HOUSTON, TX 77030 USA; BABYS HOSP S, NEW YORK, NY 10032 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, RICHMOND, VA 23298 USA; SUNY STONY BROOK, HLTH SCI CTR, DIV PULM CRIT CARE, STONY BROOK, NY 11794 USA; UNIV CALIF LOS ANGELES, LOS ANGELES CTY HARBOR MED CTR, TORRANCE, CA 90509 USA; UNIV PITTSBURGH, GRAD SCH PUBL HLTH, DEPT EPIDEMIOL, PITTSBURGH, PA 15261 USA; UNIV PENN, DEPT PHYS MED & REHABIL, PHILADELPHIA, PA 19104 USA; NYU, DEPT MED, NEW YORK, NY 10016 USA; UNIV HOSP DENVER, DIV CARDIOL, DENVER, CO 80262 USA; UNIV ILLINOIS, SCH PUBL HLTH, CHICAGO, IL 60680 USA; HOSP UNIV PENN, DEPT PATHOL & MED, PHILADELPHIA, PA 19104 USA; CHILDRENS HOSP MED CTR, MED CTR, DEPT PATHOL, BOSTON, MA 02115 USA; UNIV COLORADO, HLTH SCI CTR, CARDIOVASC PULM RES LAB, DENVER, CO 80262 USA; UNIV ILLINOIS, DEPT MED, CARDIOL SECT, CHICAGO, IL 60680 USA; CLEVELAND CLIN FDN, CLEVELAND, OH 44195 USA; NIH, DIV HEART LUNG & BLOOD INST, MATH & STAT BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Texas System; Virginia Commonwealth University; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Pennsylvania; New York University; University of Colorado System; University of Colorado Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Pennsylvania; Pennsylvania Medicine; Harvard University; Boston Children's Hospital; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Cleveland Clinic Foundation; National Institutes of Health (NIH) - USA				goldring, roberta/0000-0003-3319-4932	NHLBI NIH HHS [N01-HR-14000] Funding Source: Medline; DIVISION OF LUNG DISEASES [N01HR014000] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham M T, 1981, Indian Heart J, V33, P5; BOURDILLON PDV, 1976, BRIT HEART J, V38, P264; CHARTERS AD, 1970, BRIT HEART J, V32, P130; FUJII A, 1981, BRIT HEART J, V46, P574; FUSTER V, 1981, AM J CARDIOL, V47, P422, DOI 10.1016/0002-9149(81)90761-X; FUSTER V, 1984, CIRCULATION, V70, P580, DOI 10.1161/01.CIR.70.4.580; GLANVILLE AR, 1987, CHEST, V91, P675, DOI 10.1378/chest.91.5.675; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KANEMOTO N, 1979, JPN HEART J, V20, P395; KLEIGER RE, 1976, CHEST, V69, P143, DOI 10.1378/chest.69.2.143; LEE ET, 1980, STATISTICAL METHODS; MCCAFFREY R M, 1964, Obstet Gynecol Surv, V19, P567, DOI 10.1097/00006254-196408000-00001; NELSON DM, 1983, OBSTET GYNECOL, V62, pS58; OAKLEY C, 1968, LANCET, V1, P890; PIETRA GG, 1989, CIRCULATION, V80, P1198, DOI 10.1161/01.CIR.80.5.1198; RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216; RICH S, 1984, AM J MED, V76, P573, DOI 10.1016/0002-9343(84)90279-1; ROZKOVEC A, 1986, BRIT HEART J, V55, P449; SUAREZ LD, 1979, BRIT HEART J, V41, P702; TRELL E, 1973, ACTA MED SCAND, V193, P137; VOELKEL N, 1979, PULMONARY VASCULAR D, V14, P573; WALCOTT G, 1970, AM J MED, V49, P70, DOI 10.1016/S0002-9343(70)80115-2; WEIR EK, 1989, AM REV RESPIR DIS, V140, P1623, DOI 10.1164/ajrccm/140.6.1623; ZAHAVI I, 1984, ARCH INTERN MED, V144, P742, DOI 10.1001/archinte.144.4.742	24	2610	2735	0	70	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1991	115	5					343	349		10.7326/0003-4819-115-5-343	http://dx.doi.org/10.7326/0003-4819-115-5-343			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC065	1863023				2022-12-01	WOS:A1991GC06500002
J	KIYOSAWA, K; SODEYAMA, T; TANAKA, E; NAKANO, Y; FURUTA, S; NISHIOKA, K; PURCELL, RH; ALTER, HJ				KIYOSAWA, K; SODEYAMA, T; TANAKA, E; NAKANO, Y; FURUTA, S; NISHIOKA, K; PURCELL, RH; ALTER, HJ			HEPATITIS-C IN HOSPITAL EMPLOYEES WITH NEEDLESTICK INJURIES	ANNALS OF INTERNAL MEDICINE			English	Note						HEPATITIS VIRAL, NON-A, NON-B; HEPATITIS-C VIRUS; ACCIDENTS, OCCUPATIONAL; NEEDLESTICK INJURY; OCCUPATIONAL EXPOSURE	NON-A; B VIRUS	Of 357 needlestick accidents occurring at a university hospital between 1981 and 1989, 200 involved 196 health care workers who were then prospectively followed for 6 months; 110 of these 196 workers were exposed to blood from antibody to the hepatitis C virus (anti-HCV). Only 4 of these 110 exposed persons (4%; 95% CI, 1% to 9%) developed non-A, non-B hepatitis. Hepatitis was accompanied by anti-HCV seroconversion in 3 of these 4 persons. Three of the four were icteric, and each had a peak alanine aminotransferase level exceeding 8.5-mu-kat/L. There was no instance of anti-HCV seroconversion among the 106 recipients of an anti-HCV-positive needlestick who did not manifest biochemical or clinical evidence of hepatitis. This study documents that HCV-related non-A, non-B hepatitis can be transmitted infrequently by needlestick injury.	JAPANESE RED CROSS SOC, CENT BLOOD CTR, SHIBUYA KU, TOKYO 150, JAPAN; NIAID, HEPATITIS VIRUSES SECT, BETHESDA, MD 20892 USA; NIH, WARREN GRANT MAGNUSON CLIN CTR, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA	KIYOSAWA, K (corresponding author), SHINSHU UNIV, SCH MED, DEPT INTERNAL MED 2, 3-1-1 ASAHI, MATSUMOTO, NAGANO 390, JAPAN.							ALTER HJ, 1991, IN PRESS VIRAL HEPAT; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; EVERHART JE, 1990, ANN INTERN MED, V112, P544, DOI 10.7326/0003-4819-112-7-544; GIOVANNINI M, 1990, LANCET, V335, P1166, DOI 10.1016/0140-6736(90)91174-9; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MASUKO K, 1985, GASTROENTEROLOGY, V88, P151, DOI 10.1016/S0016-5085(85)80147-5; PONZETTO A, 1987, J INFECT DIS, V155, P72, DOI 10.1093/infdis/155.1.72; SHIKATA T, 1977, J INFECT DIS, V136, P571, DOI 10.1093/infdis/136.4.571; XEEFF LB, 1979, GASTROENTEROLOGY, V77, P161; YOSHIZAWA H, 1982, GASTROENTEROLOGY, V82, P502	10	299	302	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1991	115	5					367	369		10.7326/0003-4819-115-5-367	http://dx.doi.org/10.7326/0003-4819-115-5-367			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC065	1907441				2022-12-01	WOS:A1991GC06500006
J	SENIE, RT; ROSEN, PP; RHODES, P; LESSER, ML				SENIE, RT; ROSEN, PP; RHODES, P; LESSER, ML			TIMING OF BREAST-CANCER EXCISION DURING THE MENSTRUAL-CYCLE INFLUENCES DURATION OF DISEASE-FREE SURVIVAL	ANNALS OF INTERNAL MEDICINE			English	Article						BREAST NEOPLASMS; MENSTRUAL CYCLE; MASTECTOMY; NEOPLASM RECURRENCE, LOCAL; FOLLICULAR PHASE	PERIPHERAL-BLOOD; SURGICAL CURE; CARCINOMA; EPIDEMIOLOGY; WOMEN	Objective: To study disease-free survival at 10 years in relation to timing of breast tumor excision during the menstrual cycle. Design: A prospective study of consecutively treated patients with primary breast cancer. Setting: Memorial Sloan-Kettering Cancer Center, New York. Patients: Two hundred and eighty-three premenopausal patients treated by mastectomy and axillary dissection. Main Results: When the tumor was excised during the follicular phase, approximated by setting the putative day of ovulation on day 14 after the onset of last menses, a higher recurrence risk (43%) was observed compared with excision later in the menstrual cycle (29%, P = 0.02). The rate peaked among patients treated between days 7 and 14 and was lowest between days 20 and 30. Multivariate analysis using the Cox regression model to control for tumor size, nodal status, estrogen receptor status, adjuvant chemotherapy, and family history indicated that the hazard rate of breast cancer recurrence after excision during the follicular phase was 1.53 (95% Cl, 1.02 to 2.29). Stratification by nodal status indicated that the effect of phase was statistically significant only among patients with positive nodes (hazard ratio, 2.10; Cl, 1.19 to 3.70). Conclusions: Our results support the hypothesis that the risk for recurrence may be affected by the hormonal milieu of the menstrual cycle; these findings must be confirmed, however, by a prospective study in which cycle phase at time of tumor excision is biochemically documented.	MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA; CORNELL UNIV, N SHORE UNIV HOSP, COLL MED, MANHASSET, NY 11030 USA	Memorial Sloan Kettering Cancer Center; Cornell University; Northwell Health; North Shore University Hospital	SENIE, RT (corresponding author), CTR DIS CONTROL, 1600 CLIFTON RD, ATLANTA, GA 30333 USA.							AKSEL S, 1981, FERTIL STERIL, V36, P521; ANDERSON TJ, 1989, HUM PATHOL, V20, P1139, DOI 10.1016/S0046-8177(89)80003-6; AXELROD DM, 1988, CANCER INVEST, V6, P7, DOI 10.3109/07357908809077024; BADWE RA, 1991, LANCET, V337, P1261, DOI 10.1016/0140-6736(91)92927-T; Beatson GT, 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; BIEGLMAYER C, 1990, FERTIL STERIL, V53, P842; BROWN JB, 1989, INT J GYNECOL OBSTET, P111; CHIAZZE L, 1968, J AMER MED ASSOC, V203, P377, DOI 10.1001/jama.203.6.377; COX DR, 1972, J R STAT SOC B, V34, P187; GELBER RD, 1989, LANCET, V2, P1344; HEISE E, 1982, ONCOLOGY, V39, P340, DOI 10.1159/000225667; HRUSHESKY WJM, 1988, J NATL CANCER I, V80, P1232, DOI 10.1093/jnci/80.15.1232; HRUSHESKY WJM, 1989, LANCET, V2, P949; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LESSER ML, 1982, SURGERY, V91, P234; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; METCALF MG, 1983, NEW ZEAL MED J, V96, P645; POWLES TJ, 1989, LANCET, V2, P1343; RATAJCZAK HV, 1988, J EXP MED, V168, P73, DOI 10.1084/jem.168.1.73; ROSEN PP, 1982, CANCER, V50, P171, DOI 10.1002/1097-0142(19820701)50:1<171::AID-CNCR2820500132>3.0.CO;2-M; SENIE R T, 1990, Breast Cancer Research and Treatment, V16, P146; SENIE RT, 1981, AM J PUBLIC HEALTH, V71, P583, DOI 10.2105/AJPH.71.6.583; SENIE RT, 1980, CANCER, V46, P1705, DOI 10.1002/1097-0142(19801001)46:7<1705::AID-CNCR2820460734>3.0.CO;2-Q; SENIE RT, 1985, BREAST CANCER RES TR, V5, P301, DOI 10.1007/BF01806025; STRATTON JA, 1984, J CLIN LAB IMMUNOL, V15, P127; SULKE AN, 1985, BRIT MED J, V290, P884, DOI 10.1136/bmj.290.6472.884; TRELOAR AE, 1967, INT J FERTIL, V12, P77; VIGNON F, 1983, J CLIN ENDOCR METAB, V56, P1124, DOI 10.1210/jcem-56-6-1124; VILLE Y, 1990, BREAST CANCER RES TR, V16, P119, DOI 10.1007/BF01809296; VOGEL PM, 1981, AM J PATHOL, V104, P23; Vollman RF., 1977, MENSTRUAL CYCLE; WHITE D, 1982, BRIT J CANCER, V46, P611, DOI 10.1038/bjc.1982.245; 1989, CLIN GYNECOLOGIC END, P3	34	118	118	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1991	115	5					337	342		10.7326/0003-4819-115-5-337	http://dx.doi.org/10.7326/0003-4819-115-5-337			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC065	1863022				2022-12-01	WOS:A1991GC06500001
J	VINER, S; SZALAI, JP; HOFFSTEIN, V				VINER, S; SZALAI, JP; HOFFSTEIN, V			ARE HISTORY AND PHYSICAL-EXAMINATION A GOOD SCREENING-TEST FOR SLEEP-APNEA	ANNALS OF INTERNAL MEDICINE			English	Article							SNORERS	Objective: To determine whether presenting clinical history, pharyngeal examination, and the overall subjective impression of the clinician could serve as a sensitive screening test for sleep apnea. Design: Blinded comparison of history and physical examination with results of nocturnal polysomnography. Setting: Sleep clinic of a tertiary referral center. Patients: A total of 410 patients referred for suspected sleep apnea syndrome. Most patients reported snoring. Measurements: All patients were asked standard questions and given an examination relevant to the diagnosis of the sleep apnea syndrome, and all had full nocturnal polysomnography. Patients with more than ten episodes of apnea or hypopnea per hour of sleep were classified as having sleep apnea. Stepwise linear logistic regression was used to develop two predictive models of sleep apnea: one based on the presence of characteristic clinical features, age, sex, and body mass index; and one based on subjective clinical impression. Results: The prevalence of sleep apnea in our patients was 46%. Only age, body mass index, male sex, and snoring were found to be predictors of sleep apnea. The logistic rule discriminated between patients with and without sleep apnea (receiver operating characteristic [ROC] area, 0.77 [95% Cl, 0.73 to 0.82]). For patients with a predicted probability of apnea of less than 20%, the clinical model had 94% sensitivity and 28% specificity. Subjective impression alone identified correctly only 52% of patients with sleep apnea and had a specificity of 70%. Conclusions: In patients with a high predicted probability of the sleep apnea syndrome, subjective impression alone or any combination of clinical features cannot serve as a reliable screening test. However, in patients with a low predicted probability of sleep apnea, the model based on clinical data was sufficiently sensitive to permit about a 30% reduction in the number of unnecessary sleep studies.	ST MICHAELS HOSP, 30 BOND ST, TORONTO M5B 1W8, ONTARIO, CANADA; SUNNYBROOK HLTH SCI CTR, DEPT RES DESIGN BIOSTAT, TORONTO M4N 3M5, ONTARIO, CANADA; CALGARY GEN HOSP, BOW VALLY CTR, CALGARY T2E 0A1, ALBERTA, CANADA	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Calgary								[Anonymous], 1989, AM REV RESPIR DIS, V139, P559; BRADLEY TD, 1986, NEW ENGL J MED, V315, P1327, DOI 10.1056/NEJM198611203152105; CARSKADON MA, 1981, J GERONTOL, V36, P420, DOI 10.1093/geronj/36.4.420; GISLASON T, 1988, J CLIN EPIDEMIOL, V41, P571, DOI 10.1016/0895-4356(88)90061-3; Guilleminault C., 1978, SLEEP APNEAS SYNDROM, V1, P1; HAPONIK EF, 1984, AM J MED, V77, P671, DOI 10.1016/0002-9343(84)90361-9; HOFFSTEIN V, 1988, LANCET, V2, P992; Hosmer D, 2013, APPL LOGISTIC REGRES; IXON WJ, 1988, BMDP STATISTICAL SOF, P941; JEONG DU, 1989, CLIN EXP HYPERTENS A, V11, P1301, DOI 10.3109/10641968909038171; KALES A, 1985, J CHRON DIS, V38, P419, DOI 10.1016/0021-9681(85)90137-7; KAPUNIAI LE, 1988, SLEEP, V11, P430, DOI 10.1093/sleep/11.5.430; LAVIE P, 1983, SLEEP, V6, P312, DOI 10.1093/sleep/6.4.312; RIVLIN J, 1984, AM REV RESPIR DIS, V129, P355; SWETS JA, 1989, EVALUATION DIAGNOSTI; 1990, SAS P200 SAS I INC T, P175	16	210	220	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1991	115	5					356	359		10.7326/0003-4819-115-5-356	http://dx.doi.org/10.7326/0003-4819-115-5-356			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC065	1863025				2022-12-01	WOS:A1991GC06500004
J	CARTWRIGHT, KAV; JONES, DM; SMITH, AJ; STUART, JM; KACZMARSKI, EB; PALMER, SR				CARTWRIGHT, KAV; JONES, DM; SMITH, AJ; STUART, JM; KACZMARSKI, EB; PALMER, SR			INFLUENZA-A AND MENINGOCOCCAL DISEASE	LANCET			English	Article							NEISSERIA-MENINGITIDIS; INFECTIONS; EPIDEMIC; VIRUSES	There are several anecdotal accounts of the association between outbreaks of influenza and meningococcal disease. The exceptional increase in the number of cases of meningococcal infection 2 weeks after an influenza A outbreak in England and Wales during November and December, 1989, provided an opportunity to investigate the relation between the two events. Patients with meningococcal disease in December, 1989, were more likely than age-matched controls to show serological evidence of recent influenza A infection (odds ratio 3.9, 95% CI 1.2-13.9). The most likely explanation for the association is immune suppression induced by influenza A, though a lowering of mucosal resistance to meningococcal invasion may also be a factor. Public health authorities should be aware of the association and should be prepared to alert medical practitioners and the public to the increased risk of meningococcal disease when influenza A outbreaks occur.	WITHINGTON HOSP,PUBL HLTH LAB,MANCHESTER M20 8LR,LANCS,ENGLAND; ST LUKES HOSP,PUBL HLTH LAB,GUILDFORD,ENGLAND; GLOUCESTER HLTH AUTHOR,DEPT PUBL HLTH MED,GLOUCESTER,ENGLAND; COMMUNICABLE DIS SURVEILLANCE CTR WELSH UNIT,CARDIFF,WALES		CARTWRIGHT, KAV (corresponding author), GLOUCESTER ROYAL HOSP,PUBL HLTH LAB,GREAT WESTERN RD,GLOUCESTER GL1 3NN,ENGLAND.		Smith, Ashley/GZB-0298-2022					ABRAMSON JS, 1988, PERSPECT BIOL MED, V32, P63; ARTENSTEIN MS, 1967, J AMER MED ASSOC, V201, P1004; BLAKEBROUGH IS, 1982, J INFECT DIS, V146, P626, DOI 10.1093/infdis/146.5.626; CAMBRIDGE G, 1976, INFECT IMMUN, V13, P36, DOI 10.1128/IAI.13.1.36-43.1976; CAUGANT DA, 1986, P NATL ACAD SCI USA, V83, P4927, DOI 10.1073/pnas.83.13.4927; DEWALS P, 1983, J INFECTION, V6, P147, DOI 10.1016/S0163-4453(83)92756-1; EDWARDS EA, 1977, SCAND J INFECT DIS, V9, P105, DOI 10.3109/inf.1977.9.issue-2.09; FIJEN CAP, 1989, LANCET, V2, P585; Fleming D M, 1985, Health Trends, V17, P13; FLEMING DM, 1990, BRIT J GEN PRACT, V40, P495; FLEMING DM, 1988, J ROY COLL GEN PRACT, V38, P159; KLEINERMAN ES, 1975, LANCET, V2, P1063; LAL H B, 1963, J Indian Med Assoc, V40, P113; LARSON HE, 1976, LANCET, V1, P283, DOI 10.1016/S0140-6736(76)91407-0; MOORE PS, 1990, JAMA-J AM MED ASSOC, V264, P1271, DOI 10.1001/jama.264.10.1271; OLCEN P, 1979, SCAND J INFECT DIS, V11, P111, DOI 10.3109/inf.1979.11.issue-2.03; OXFORD JS, 1990, TOPLEY WILSONS PRINC, V4, P305; PALMER DF, 1975, ADV LABORATORY TECHN, P44; PARKER MT, 1979, J INFECT S2, V1, P9; PETHER JVS, 1982, LANCET, V1, P804; SCHUBIGER G, 1986, SCHWEIZ MED WSCHR, V116, P1172; SWEET C, 1990, TOPLEY WILSONS PRINC, V4, P105; YOUNG LS, 1972, NEW ENGL J MED, V287, P5, DOI 10.1056/NEJM197207062870102; 1990, IMMUNISATION INFECTI, P90; 1988, LANCET, V1, P95	25	159	160	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1991	338	8766					554	557		10.1016/0140-6736(91)91112-8	http://dx.doi.org/10.1016/0140-6736(91)91112-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD002	1678811				2022-12-01	WOS:A1991GD00200015
J	DOUGLAS, AS; RAWLES, JM; ALEXANDER, E; ALLAN, TM				DOUGLAS, AS; RAWLES, JM; ALEXANDER, E; ALLAN, TM			WINTER PRESSURE ON HOSPITAL MEDICAL BEDS	BRITISH MEDICAL JOURNAL			English	Article									UNIV ABERDEEN,SCH MED,WELLCOME RES LIB,ABERDEEN AB9 1FX,SCOTLAND; GRAMPIAN AREA HLTH BOARD,DEPT COMMUNITY MED,ABERDEEN,SCOTLAND	University of Aberdeen; University of Aberdeen	DOUGLAS, AS (corresponding author), UNIV ABERDEEN,SCH MED,DEPT MED & THERAPEUT,ABERDEEN AB9 2ZB,SCOTLAND.							DOUGLAS AS, 1991, LANCET, P1393; QUETELET MA, 1842, TREATISE MAN DEV HIS, P34; Sothern R., 1972, PHYSIOL TEACH, V1, P1	3	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1991	303	6801					508	509		10.1136/bmj.303.6801.508-a	http://dx.doi.org/10.1136/bmj.303.6801.508-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD804	1912863	Green Published, Bronze			2022-12-01	WOS:A1991GD80400020
J	FITZPATRICK, MM; SHAH, V; TROMPETER, RS; DILLON, MJ; BARRATT, TM				FITZPATRICK, MM; SHAH, V; TROMPETER, RS; DILLON, MJ; BARRATT, TM			LONG-TERM RENAL OUTCOME OF CHILDHOOD HEMOLYTIC UREMIC SYNDROME	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEMOLYTIC-UREMIC SYNDROME; PROGNOSTIC FEATURES; ESCHERICHIA-COLI	Objective - To evaluate the long term outcome of renal function in infants and children after diarrhoea associated haemolytic uraemic syndrome. Setting - The Hospital for Sick Children, Great Ormond Street, and the Royal Free Hospital, London. Subjects - 103 children with the syndrome who presented between 1966 and 1985; 88 attended for follow up investigations (40 male, 48 female) with a mean age 11.6 (range 5.2-22.6) years and a mean duration of follow up of 8.5 (range 5.1-21.3) years. Main outcome measures - Blood pressure, ratio of early morning urine albumin to creatinine concentration, glomerular filtration rate, and plasma renin activity. Results - The mean (SD) systolic blood pressure standard deviation score was 0.38 (0.67) and diastolic blood pressure SD score was 0.10 (0.76). The geometric mean ratio of overnight urine albumin to creatinine concentration was 1.27 (range 0.03-48.2), significantly higher than the value observed in 77 normal children (0.32 (0.05-1.95), p < 0.0001). Glomerular filtration rate estimated from the plasma clearance of chromium-51 EDTA was 95.1 (22.7) ml/min/1.73 m2 surface area, and 16 children had a rate of less-than-or-equal-to 80 ml/min/1.73 m2. Significant negative correlations were found between glomerular filtration rate and urinary albumin to creatinine ratio (r = -0.41, p < 0.0001) and glomerular filtration rate and systolic blood pressure SD score (r = -0.48, p < 0.0001). A significant positive correlation was found between urinary albumin to creatinine ratio and systolic blood pressure SD score (r = 0.25, p = 0.02). Conclusions - After an acute episode of diarrhoea associated haemolytic uraemic syndrome 31% (27/88) of children had an increased albumin excretion, 18% (16/88) had a reduced glomerular filtration rate and 10% (9/88) had both, in association with a higher systolic blood pressure, indicating considerable residual nephropathy in this group.	INST CHILD HLTH, MED LAB, LONDON WC1N 1EH, ENGLAND	University of London; University College London	FITZPATRICK, MM (corresponding author), INST CHILD HLTH, DEPT PAEDIAT NEPHROL, LONDON WC1N 1EH, ENGLAND.							[Anonymous], 1987, PEDIATRICS, V79, P1; CHANTLER C, 1972, ARCH DIS CHILD, V47, P613, DOI 10.1136/adc.47.254.613; COAD NAG, 1991, CLIN NEPHROL, V35, P10; DILLON MJ, 1975, J CLIN PATHOL, V28, P625, DOI 10.1136/jcp.28.8.625; DONCKERWOLCKE RA, 1979, PAEDIATRICIAN, V8, P378; GASSER C, 1955, Schweiz Med Wochenschr, V85, P905; GIANANTONIO CA, 1973, NEPHRON, V11, P174; GIBB DM, 1990, THESIS U BRISTOL BRI; HABIB R, 1982, ADV NEPHROL, V14, P109; KAPLAN BS, 1971, J PEDIATR-US, V78, P420, DOI 10.1016/S0022-3476(71)80221-4; KAPLAN BS, 1977, CLIN NEPHROL, V8, P495; KARMALI MA, 1983, LANCET, V1, P619, DOI 10.1016/s0140-6736(83)91795-6; LEVIN M, 1984, ARCH DIS CHILD, V59, P397, DOI 10.1136/adc.59.5.397; Levin M, 1989, Adv Pediatr Infect Dis, V4, P51; LOIRAT C, 1984, ACTA PAEDIATR SCAND, V73, P505, DOI 10.1111/j.1651-2227.1984.tb09962.x; LONDE S, 1985, PEDIATRICS, V76, P460; MARTIN DL, 1990, NEW ENGL J MED, V323, P1161, DOI 10.1056/NEJM199010253231703; MILFORD DV, 1990, ARCH DIS CHILD, V65, P716, DOI 10.1136/adc.65.7.716; MILFORD DV, 1991, J PEDIATR-US, V118, P191, DOI 10.1016/S0022-3476(05)80481-0; MUAKA PBK, 1981, EUR J PEDIATR, V136, P237; PERELSTEIN EM, 1990, ARCH DIS CHILD, V65, P728, DOI 10.1136/adc.65.7.728; SIENIAWSKA M, 1990, PEDIATR NEPHROL, V4, P213, DOI 10.1007/BF00857656; TROMPETER RS, 1983, ARCH DIS CHILD, V58, P101, DOI 10.1136/adc.58.2.101; VANDYCK M, 1988, CLIN NEPHROL, V29, P109; WALTERS MDS, 1989, PEDIATR NEPHROL, V3, P130, DOI 10.1007/BF00852893; WRIGHT BM, 1970, LANCET, V1, P337	26	83	84	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 31	1991	303	6801					489	492		10.1136/bmj.303.6801.489	http://dx.doi.org/10.1136/bmj.303.6801.489			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD804	1912857	Green Published, Bronze			2022-12-01	WOS:A1991GD80400014
J	GOSSEYE, S; VANOBBERGH, L; WEYNAND, B; SCHEIFF, JM; MOULIN, D; DEGOYET, JD; OTTE, JB				GOSSEYE, S; VANOBBERGH, L; WEYNAND, B; SCHEIFF, JM; MOULIN, D; DEGOYET, JD; OTTE, JB			PLATELET AGGREGATES IN SMALL LUNG VESSELS AND DEATH DURING LIVER-TRANSPLANTATION	LANCET			English	Article							SCREEN FILTRATION; BLOOD FILTRATION; PREVENTION; TRANSFUSION	10 children who died suddenly during liver transplantation were found at necropsy to have extensive obstruction of small lung vessels by platelet aggregates. In 7 of these patients pulmonary artery pressure changes before death were consistent with acute obstruction of the pulmonary vascular bed. Platelet aggregates were not strikingly increased in blood vessels in other tissues. No single obvious cause for these unusual histological findings could be identified, although the presence of intravascular catheters, perioperative blood and platelet concentrate transfusions, and cellular debris from the liver forced into the circulation during surgery might predispose to platelet aggregation.	CATHOLIC UNIV LOUVAIN,ST LUC UNIV HOSP,DEPT INTENS CARE,B-1200 BRUSSELS,BELGIUM; CATHOLIC UNIV LOUVAIN,ST LUC UNIV HOSP,DEPT PAEDIAT SURG,B-1200 BRUSSELS,BELGIUM; CATHOLIC UNIV LOUVAIN,ST LUC UNIV HOSP,DEPT PATHOL,B-1200 BRUSSELS,BELGIUM; CATHOLIC UNIV LOUVAIN,ST LUC UNIV HOSP,DEPT ANAESTHESIOL,B-1200 BRUSSELS,BELGIUM; CATHOLIC UNIV LOUVAIN,ST LUC UNIV HOSP,DEPT HAEMATOL,B-1200 BRUSSELS,BELGIUM	Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc			Weynand, Birgit/H-9587-2019; Goyet, Jean de Ville de/I-6913-2019; Goyet, Jean de Ville de/A-1708-2014	Goyet, Jean de Ville de/0000-0001-7681-6178; Goyet, Jean de Ville de/0000-0001-7681-6178				BARRETT J, 1978, ARCH SURG-CHICAGO, V113, P947; CARLIER M, 1987, TRANSPLANT P, V19, P3333; DERIAN CK, 1990, THROMB RES, V57, P393, DOI 10.1016/0049-3848(90)90255-B; DURTSCHI MB, 1979, AM J SURG, V138, P8, DOI 10.1016/0002-9610(79)90235-6; ELMER O, 1988, AM J SURG, V155, P289, DOI 10.1016/S0002-9610(88)80716-5; GRIFFITH EM, 1977, LANCET, V1, P1010; HARKER LA, 1977, ANN SURG, V186, P594, DOI 10.1097/00000658-197711000-00009; HOAR PF, 1978, ANESTHESIOLOGY, V48, P445, DOI 10.1097/00000542-197806000-00014; MCNAMARA JJ, 1978, SURG GYNECOL OBSTET, V147, P507; MILLER RD, 1990, ANESTHESIA, P1467; MOSELEY RV, 1970, ANN SURG, V171, P329, DOI 10.1097/00000658-197003000-00002; REUL GJ, 1973, ARCH SURG-CHICAGO, V106, P386; REUL GJ, 1974, CHEST, V66, P4, DOI 10.1378/chest.66.1.4; SNYDER EL, 1983, TRANSFUSION, V23, P460, DOI 10.1046/j.1537-2995.1983.23684074264.x	14	21	21	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1991	338	8766					532	534		10.1016/0140-6736(91)91099-G	http://dx.doi.org/10.1016/0140-6736(91)91099-G			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD002	1678799				2022-12-01	WOS:A1991GD00200003
J	HOEKMAN, K; VONBLOMBERGVANDERFLIER, BME; WAGSTAFF, J; DREXHAGE, HA; PINEDO, HM				HOEKMAN, K; VONBLOMBERGVANDERFLIER, BME; WAGSTAFF, J; DREXHAGE, HA; PINEDO, HM			REVERSIBLE THYROID-DYSFUNCTION DURING TREATMENT WITH GM-CSF	LANCET			English	Note							COLONY-STIMULATING FACTOR; ANTIGEN EXPRESSION; DENDRITIC CELLS; INDUCTION; INTERFERON; INVITRO; THERAPY	To investigate whether autoimmunity against thyroid antigens is induced or exacerbated by granulocyte-macrophage colony-stimulating factor, thyroid function and thyroid autoantibodies were studied in 14 patients with advanced breast cancer and 11 with soft-tissue sarcoma who received several cycles of doxorubicin and cyclophosphamide plus GM-CSF 250-mu-g/m2 intravenously daily for 10 days in every 21 day cycle. All patients had normal thyroid function before treatment. In 2 patients with pre-existing thyroid antibodies, thyroid dysfunction developed but disappeared after cessation of GM-CSF. No other autoimmune abnormalities appeared. Stimulation of antigen-presenting cells by GM-CSF may bring about this phenomenon.	FREE UNIV AMSTERDAM HOSP,DEPT MED ONCOL,DE BOELELAAN 1117,1007 MB AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT PATHOL,AMSTERDAM,NETHERLANDS; ERASMUS UNIV,DEPT IMMUNOL,3000 DR ROTTERDAM,NETHERLANDS	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Erasmus University Rotterdam								ATKINS MB, 1988, NEW ENGL J MED, V318, P1557, DOI 10.1056/NEJM198806163182401; BURMAN P, 1986, J CLIN ENDOCR METAB, V63, P1086, DOI 10.1210/jcem-63-5-1086; HAZENBERG BPC, 1989, BLOOD, V74, P2769, DOI 10.1182/blood.V74.8.2769.2769; KUNG AWC, 1990, J CLIN ENDOCR METAB, V71, P1230, DOI 10.1210/jcem-71-5-1230; LIESCHKE GJ, 1989, ANN INTERN MED, V110, P357, DOI 10.7326/0003-4819-110-5-357; MARKOWICZ S, 1990, J CLIN INVEST, V85, P955, DOI 10.1172/JCI114525; MARTIN A, 1990, ENDOCRINOLOGY, V127, P651, DOI 10.1210/endo-127-2-651; SMITH PD, 1990, J IMMUNOL, V144, P3829; VOORBY HAM, 1990, CLIN IMMUNOL IMMUNOP, V55, P9, DOI 10.1016/0090-1229(90)90065-X; WEETMAN AP, 1985, J CLIN ENDOCR METAB, V61, P817, DOI 10.1210/jcem-61-5-817	10	57	57	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1991	338	8766					541	542		10.1016/0140-6736(91)91103-2	http://dx.doi.org/10.1016/0140-6736(91)91103-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD002	1678803	Green Submitted			2022-12-01	WOS:A1991GD00200007
J	HOPPU, K; TIKANOJA, T; TAPANAINEN, P; REMES, M; SAARENPAAHEIKKILA, O; KOUVALAINEN, K				HOPPU, K; TIKANOJA, T; TAPANAINEN, P; REMES, M; SAARENPAAHEIKKILA, O; KOUVALAINEN, K			ACCIDENTAL ASTEMIZOLE OVERDOSE IN YOUNG-CHILDREN	LANCET			English	Note							TORSADE-DE-POINTES	6 cases of accidental astemizole poisoning in children have been reported to the Finnish Poison Information Center. The children were aged 1 year 7 months to 3 years 4 months and had taken doses of 2.5 to 16.7 mg/kg, at least twelve times that recommended. In 2 children the overdose was verified by measurement of drug concentrations. Despite measures to prevent drug absorption prolonged QT(c)-interval, a sign of cardiac toxicity, was found in all 5 children on whom an electrocardiogram was available for analysis, and severe ventricular arrhythmias developed in 1. Young children with accidental astemizole overdose should be carefully monitored in hospital. Similar precautions may be justified in cases of overdose with other selective H-1-histamine receptor antagonists.	UNIV KUOPIO,DEPT PAEDIAT,KUOPIO,FINLAND; UNIV OULU,DEPT PAEDIAT,SF-90100 OULU 10,FINLAND; UNIV TAMPERE,DEPT PAEDIAT,TAMPERE,FINLAND	University of Eastern Finland; University of Oulu; Tampere University	HOPPU, K (corresponding author), UNIV HELSINKI,CHILDRENS HOSP,DEPT PAEDIAT 2,SF-00290 HELSINKI 29,FINLAND.		Hoppu, Kalle/A-2811-2009	Hoppu, Kalle/0000-0001-6775-0453				Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; CRAFT TM, 1986, BRIT MED J, V292, P660, DOI 10.1136/bmj.292.6521.660; DAVIES AJ, 1989, BRIT MED J, V298, P325, DOI 10.1136/bmj.298.6669.325; GARSON A, 1990, PEDIATRIC ARRHYTHMIA, P427; MONAHAN BP, 1990, JAMA-J AM MED ASSOC, V264, P2788, DOI 10.1001/jama.264.21.2788; RICHARDS DM, 1984, DRUGS, V28, P38, DOI 10.2165/00003495-198428010-00003; SIMONS FER, 1988, LANCET, V2, P624; SNOOK J, 1988, BRIT J CLIN PRACT, V42, P257; STRATMANN HG, 1987, AM HEART J, V113, P1470, DOI 10.1016/0002-8703(87)90664-8; WOESTENBORGHS R, 1986, DRUG DEVELOP RES, V8, P63, DOI 10.1002/ddr.430080108	10	66	68	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1991	338	8766					538	540		10.1016/0140-6736(91)91101-Y	http://dx.doi.org/10.1016/0140-6736(91)91101-Y			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD002	1678801				2022-12-01	WOS:A1991GD00200005
J	MAHALANABIS, D				MAHALANABIS, D			BREAST-FEEDING AND VITAMIN-A-DEFICIENCY AMONG CHILDREN ATTENDING A DIARRHEA TREATMENT CENTER IN BANGLADESH - A CASE-CONTROL STUDY	BRITISH MEDICAL JOURNAL			English	Article							XEROPHTHALMIA; MORTALITY; MOTHERS; RISK	Objective - To determine the effect of breast feeding on the risk of xerophthalmia in children aged 6 months to 3 years attending a diarrhoea treatment centre in Bangladesh. Design - Case-control study based on stratified analysis (Mantel-Haenszel) and multivariate analysis (logistic regression) of data from a treatment centre based surveillance system. Setting - A large diarrhoea treatment centre in Dhaka, Bangladesh. Patients - 2687 children aged 6 months to 3 years representing a 4% systematic sample of all children in this age group treated yearly at the centre over three consecutive years. 66 of the children were cases of xerophthalmia (that is, they had Bitot's spots or corneal lesions or night blindness or night blindness plus conjunctival xerosis or any combination of these) and the remaining 2621 did not have signs or symptoms of vitamin A deficiency. This second group served as controls. Main outcome measure - Xerophthalmia and breast fed at onset of diarrhoea or presentation. Results - The odds ratio relating breast feeding to vitamin A deficiency after adjustment for a large number of confounding variables (0.26 (95% confidence interval 0.14 to 0.49); p < 0.001) reflected a 74% reduction in the risk of vitamin A deficiency among breast fed children. The estimated reduction of risk did not decline with age, and some 49% of children aged 24-35 months were still being breast fed. The odds ratio relating breast feeding to xerophthalmia in the third year of life (0.35 (95% confidence interval 0.35 to 0.86) reflected a 65% reduced risk of vitamin A deficiency. Other important risk factors or prognostic indicators for xerophthalmia as identified by multivariate analysis were recent measles, prolonged diarrhoea, severe protein energy malnutrition, and poor socioeconomic state. Conclusions - These results indicate that breast feeding was associated with a substantial reduction of the risk of vitamin A deficiency extending to the third year of life and support the recommendation that mothers in developing countries should be advised to breast feed for as long as possible.			MAHALANABIS, D (corresponding author), INT CTR DIARRHOEL DIS RES,DIV CLIN SCI,POB 128,DHAKA,BANGLADESH.							Becroft T C, 1967, Med J Aust, V2, P810; BRAKOHIAPA LA, 1988, LANCET, V2, P416; BROSS I, 1954, BIOMETRICS, V10, P478, DOI 10.2307/3001619; BROWN KH, 1982, AM J CLIN NUTR, V36, P878, DOI 10.1093/ajcn/36.5.878; COHEN N, 1985, SOC SCI MED, V21, P1269, DOI 10.1016/0277-9536(85)90276-X; DUALEH K A, 1989, Food and Nutrition Bulletin, V11, P43; GEBREMEDHIN M, 1976, AM J CLIN NUTR, V29, P441, DOI 10.1093/ajcn/29.4.441; HABTE D, 1989, 13 P NAT S INT VIT A, P7; MANTEL N, 1959, J NATL CANCER I, V22, P719; NEWELL DJ, 1963, BIOMETRICS, V19, P187, DOI 10.2307/2527585; ROY SK, 1984, J TROP MED HYG, V87, P11; ROY SK, 1989, VITAMIN A DEFICIENCY, P107; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P137; SINHA DP, 1973, LANCET, V2, P228; SOMMER A, 1986, LANCET, V1, P1169; SOMMER A, 1983, LANCET, V2, P585; SOMMER A, 1977, GUIDELINES ERADICATI, P1; STOLL BJ, 1985, J TROP PEDIATRICS, V31, P36, DOI 10.1093/tropej/31.1.36; STOLL BJ, 1982, BRIT MED J, V285, P1185, DOI 10.1136/bmj.285.6349.1185; TARWOTJO I, 1982, AM J CLIN NUTR, V35, P574, DOI 10.1093/ajcn/35.3.574; VANSTEENBERGEN WM, 1981, J TROP PEDIATRICS, V27, P155, DOI 10.1093/tropej/27.3.155; Vis H L, 1981, Assignment Child, V55-56, P183; WEST KP, 1986, AM J CLIN NUTR, V44, P690; 1985, BANGLADESH NATIONAL; 1976, WHO TECH REP SER, V590, P35	25	40	40	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1991	303	6801					493	496		10.1136/bmj.303.6801.493	http://dx.doi.org/10.1136/bmj.303.6801.493			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD804	1912858	Green Published, Bronze			2022-12-01	WOS:A1991GD80400015
J	MATSUBARA, Y; NARISAWA, K; TADA, K; IKEDA, H; YAO, YQ; DANKS, DM; GREEN, A; MCCABE, ERB				MATSUBARA, Y; NARISAWA, K; TADA, K; IKEDA, H; YAO, YQ; DANKS, DM; GREEN, A; MCCABE, ERB			PREVALENCE OF K329E MUTATION IN MEDIUM-CHAIN ACYL-COA DEHYDROGENASE GENE DETERMINED FROM GUTHRIE CARDS	LANCET			English	Article							DEFICIENCY; DIAGNOSIS	Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency is an autosomal recessive disorder that has been associated with sudden infant death syndrome and a condition resembling Reye's syndrome. The point mutation K329E is thought to be the commonest mutation causing MCAD deficiency in caucasian patients. The prevalence of this mutation was determined by use of dried blood spots on Guthrie cards obtained during neonatal screening programmes. 12 carriers were identified among 479 newborn babies in Britain, 5 among 353 in Australia, and 5 among 536 in North America but none among 500 in Japan. Since presymptomatic diagnosis and appropriate dietary management can prevent life-threatening episodes in MCAD deficiency, population-based DNA screening for this potentially fatal disorder might be justified in countries with a high frequency of this mutation.	TOHOKU UNIV,SCH MED,DEPT PEDIAT,SENDAI,MIYAGI 980,JAPAN; ROYAL CHILDRENS HOSP,MURDOCH INST,PARKVILLE,VIC 3052,AUSTRALIA; HOLLYMOOR HOSP,W MIDLANDS REG NEONATAL SCREENING LAB,BIRMINGHAM,ENGLAND; BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030	Tohoku University; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Baylor College of Medicine; Baylor College of Medicine	MATSUBARA, Y (corresponding author), TOHOKU UNIV,SCH MED,DEPT BIOCHEM GENET,1-1 SEIRYOMACHI,AOBA KU,SENDAI,MIYAGI 980,JAPAN.							BLAKEMORE AIF, 1991, LANCET, V337, P298, DOI 10.1016/0140-6736(91)90907-7; JINKS DC, 1989, HUM GENET, V81, P363, DOI 10.1007/BF00283692; KELLY DP, 1990, P NATL ACAD SCI USA, V87, P9236, DOI 10.1073/pnas.87.23.9236; MATSUBARA Y, 1990, LANCET, V335, P1589, DOI 10.1016/0140-6736(90)91413-5; MATSUBARA Y, 1990, BIOCHEM BIOPH RES CO, V171, P498, DOI 10.1016/0006-291X(90)91421-N; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; RINALDO P, 1988, NEW ENGL J MED, V319, P1308, DOI 10.1056/NEJM198811173192003; Roe C, 1989, METABOLIC BASIS INHE, P889; YOKOTA I, 1990, J CLIN INVEST, V86, P1000, DOI 10.1172/JCI114761; [No title captured]; 1986, LANCET, V2, P1073	11	105	106	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1991	338	8766					552	553		10.1016/0140-6736(91)91110-G	http://dx.doi.org/10.1016/0140-6736(91)91110-G			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD002	1678810				2022-12-01	WOS:A1991GD00200014
J	MEYNAAR, IA; VANTWOUT, JW; VANDENBROUCKE, JP; VANFURTH, R				MEYNAAR, IA; VANTWOUT, JW; VANDENBROUCKE, JP; VANFURTH, R			USE OF INFLUENZA VACCINE IN THE NETHERLANDS	BRITISH MEDICAL JOURNAL			English	Article									LEIDEN UNIV,DEPT INFECT DIS,HOSP BLDG 1,CS-P,POB 9600,2300 RC LEIDEN,NETHERLANDS; LEIDEN UNIV,DEPT CLIN EPIDEMIOL,2300 RC LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC			Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				FRANK JW, 1985, CAN MED ASSOC J, V132, P371; HOFSTRA ML, 1990, HUISARTS WET, V33, P429; MCKINNEY WP, 1989, AM J PUBLIC HEALTH, V79, P1422, DOI 10.2105/AJPH.79.10.1422; NICHOLSON KG, 1990, BRIT MED J, V301, P617, DOI 10.1136/bmj.301.6753.617; 1990, VACCINATIE TEGEN INF	5	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1991	303	6801					508	508		10.1136/bmj.303.6801.508	http://dx.doi.org/10.1136/bmj.303.6801.508			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD804	1912862	Bronze, Green Published			2022-12-01	WOS:A1991GD80400019
J	STANFORD, JL; GRANGE, JM; POZNIAK, A				STANFORD, JL; GRANGE, JM; POZNIAK, A			IS AFRICA LOST	LANCET			English	Editorial Material							PULMONARY TUBERCULOSIS; MYCOBACTERIUM-VACCAE; IMMUNOTHERAPY		ROYAL BROMPTON & NATL HEART HOSP,LONDON,ENGLAND; UNIV ZIMBABWE,DEPT MED,HARARE,ZIMBABWE	Imperial College London; University of Zimbabwe	STANFORD, JL (corresponding author), UNIV COLL & MIDDLESEX SCH MED,DEPT MED MICROBIOL,RIDING HOUSE ST,LONDON W1P 7LD,ENGLAND.							BAHR GM, 1990, TUBERCLE, V71, P259, DOI 10.1016/0041-3879(90)90038-A; BALASUBRAMANIAN R, 1990, TUBERCLE, V71, P253, DOI 10.1016/0041-3879(90)90037-9; Ferebee SH, 1969, ADV TUBERC RES, V17, P29; FESTENSTEIN F, 1991, J APPL BACTERIOL, V17, P19; MICHIHIKO S, 1989, LANCET, V1, P1206; Pozniak A, 1987, B INT UNION TUBERC L, V62, P39; ROOK GAW, 1981, TUBERCLE, V62, P63, DOI 10.1016/0041-3879(81)90038-6; ROOK GAW, 1991, TUBERCLE, V72, P13, DOI 10.1016/0041-3879(91)90019-O; SAIDI KG, 1989, INT J LEPROSY, V57, P45; STANFORD JL, 1991, APMIS, V99, P103, DOI 10.1111/j.1699-0463.1991.tb05127.x; STANFORD JL, 1990, TUBERCLE, V71, P87, DOI 10.1016/0041-3879(90)90002-P; 1988, AM REV RESPIR DIS, V137, P1147	12	54	55	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1991	338	8766					557	558		10.1016/0140-6736(91)91113-9	http://dx.doi.org/10.1016/0140-6736(91)91113-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD002	1678812				2022-12-01	WOS:A1991GD00200016
J	WATSON, EK; MAYALL, E; CHAPPLE, J; DALZIEL, M; HARRINGTON, K; WILLIAMS, C; WILLIAMSON, R				WATSON, EK; MAYALL, E; CHAPPLE, J; DALZIEL, M; HARRINGTON, K; WILLIAMS, C; WILLIAMSON, R			SCREENING FOR CARRIERS OF CYSTIC-FIBROSIS THROUGH PRIMARY HEALTH-CARE SERVICES	BRITISH MEDICAL JOURNAL			English	Article							IDENTIFICATION; GENE	Objective - To evaluate the uptake of cystic fibrosis carrier testing offered through primary health care services. Design - Carrier testing for cystic fibrosis was offered to patients of reproductive age through primary health care services. Setting - Three general practice surgeries and four family planning clinics in South West Hertfordshire District Health Authority. Subjects - Over 1000 patients aged 16-44 attending two general practices and four family planning clinics and a stratified random sample of patients aged 16-44 from one general practice's age-sex register. Results - When screening was offered opportunistically the uptake was 66% in general practice and 87% in family planning clinics. Ten per cent of those offered a screening appointment by letter took up the invitation. Of the screened population, 76% had previously heard of cystic fibrosis, 35% realised it is inherited, and 18% realised that carriers need not have any family history. If they found themselves in an "at risk" partnership 39% would consider not having children and 26% would consider terminating an affected pregnancy, but in each case most people were unsure how they would react. Conclusions - Most people offered a cystic fibrosis test opportunistically wish to be tested, and the responses of those tested indicate that knowledge of carrier state would be considered in future reproductive decisions.	SW HERTFORDSHIRE DIST HLTH AUTHOR,WATFORD WD1 8UB,ENGLAND		WATSON, EK (corresponding author), UNIV LONDON IMPERIAL COLL SCI & TECHNOL,ST MARYS HOSP,SCH MED,DEPT BIOCHEM & MOLEC GENET,LONDON W2 1PG,ENGLAND.							CALNAN M, 1986, SOC SCI MED, V22, P673, DOI 10.1016/0277-9536(86)90039-0; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; Cystic Fibrosis Genetic Anal Consortium, 1990, AM J HUM GENET, V47, P354; DODGE JA, 1988, LANCET, V2, P672; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LENCH N, 1988, LANCET, V1, P1356; MANT D, 1990, BRIT MED J, V300, P916, DOI 10.1136/bmj.300.6729.916; MODELL B, 1990, J MED GENET, V27, P475, DOI 10.1136/jmg.27.8.475; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SKRABANEK P, 1986, LANCET, V1, P143; THOMPSON NF, 1990, BRIT J GEN PRACT, V40, P16; WATSON EK, 1990, HUM GENET, V85, P435, DOI 10.1007/BF02428303; WATSON EK, 1991, BRIT J GEN PRACT, V41, P237; WILLIAMSON R, 1989, PRENATAL DIAG, V9, P727, DOI 10.1002/pd.1970091008; 1990, CYSTIC FIBROSIS ADUL	16	105	105	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1991	303	6801					504	507		10.1136/bmj.303.6801.504	http://dx.doi.org/10.1136/bmj.303.6801.504			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GD804	1912861	Green Published			2022-12-01	WOS:A1991GD80400018
J	WILLIAMS, CJ				WILLIAMS, CJ			CANCER	BRITISH MEDICAL JOURNAL			English	Article							MORTALITY				WILLIAMS, CJ (corresponding author), ROYAL S HANS HOSP,MED ONCOL UNIT,SOUTHAMPTON SO9 4PE,HANTS,ENGLAND.							ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; Doll R, 1981, THE CAUSES OF CANCER; FINK K, 1968, PUBLIC HLTH REP, V63, P479; GRAY JAM, 1991, BREAST CANCER SCREEN; GUZICK DS, 1978, AM J PUBLIC HEALTH, V68, P125, DOI 10.2105/AJPH.68.2.125; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; ROBERTS MM, 1989, BRIT MED J, V299, P1153, DOI 10.1136/bmj.299.6708.1153; RODGERS A, 1991, BRIT MED J, V302, P411, DOI 10.1136/bmj.302.6773.411-b; SKRABANEK P, 1985, LANCET, V2, P318; TUYNS AJ, 1977, B CANCER, V64, P45; WALD N, 1991, BRIT MED J, V302, P845, DOI 10.1136/bmj.302.6780.845; 1988, LANCET, V2, P41; 1991, HLTH NATION; 1987, TECHNICAL B AM COLLE, V105; 1982, TRENDS CANCER SURVIV	15	9	9	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1991	303	6801					516	517		10.1136/bmj.303.6801.516	http://dx.doi.org/10.1136/bmj.303.6801.516			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD804	1912867	Bronze, Green Published			2022-12-01	WOS:A1991GD80400024
J	CROW, JF				CROW, JF			WAS WRIGHT RIGHT	SCIENCE			English	Editorial Material											CROW, JF (corresponding author), UNIV WISCONSIN,DEPT GENET,MADISON,WI 53706, USA.							BARTON NH, IN PRESS EVOLUTION; CROW JF, 1990, EVOLUTION, V44, P233, DOI [10.2307/2409403, 10.1111/j.1558-5646.1990.tb05194.x]; Fisher R.A., 1930, GENETICAL THEORY NAT; Haldane J. B. S., 1959, DARWINS BIOL WORK SO, P101; Provine WilliamB., 1986, S WRIGHT EVOLUTIONAR; WADE MJ, 1991, SCIENCE, V253, P1015, DOI 10.1126/science.1887214; WRIGHT S, 1988, AM NAT, V131, P115, DOI 10.1086/284777; Wright S, 1931, GENETICS, V16, P0097	8	12	12	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1991	253	5023					973	973		10.1126/science.1887230	http://dx.doi.org/10.1126/science.1887230			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC982	1887230				2022-12-01	WOS:A1991GC98200032
